Clinical Trials in Vaccines

Rank NCT NumbTitle Acronym Status Study ResuConditions Interventi
1 NCT04110Nasal and Flu-M3 Active, notNo ResultsInfluenza|Vaccine Virus Shedding Biological:

2 NCT03057Active Sur FLU-05-IB CompletedNo ResultsInfluenza Vaccines Biological:
3 NCT02915Safety and Immunogen CompletedHas ResultInfluenza Biological:
4 NCT03493Safety and Immunogen Active, notNo ResultsVaricella Zoster Vaccine Biological:
5 NCT03390Immunogenicity and Sa CompletedNo ResultsInfluenza Biological:
6 NCT01718Safety and CENV3 Unknown sNo ResultsVaccine Overdose of Undetermined Biological:
7 NCT03315Flu Vaccine ResponseEnrolling bNo ResultsViral Vaccines Biological:
8 NCT03509ProspectivMENINGRENot yet recNo ResultsHematopoietic Stem Cell Transplan Biological:
9 NCT02388Safety and STRIVE CompletedNo ResultsStaphylococcal Vaccine Biological
10 NCT03587Response to RotavirusRecruiting No ResultsRotavirus|Diarrhea Biological:
11 NCT04235Intradermal, FractionNot yet recNo ResultsHPV Infection|HPV Vaccine Biological:
12 NCT03685Recombinant SubunitRecruiting No ResultsVaricella Zoster Vaccine Biological
13 NCT03148Study to E BIOMR Recruiting No ResultsRubella|Measles Biological
14 NCT02765Heterologous Effect ofUnknown sNo ResultsHeterologous Effects of Vaccines Biological:
15 NCT03246Systems BiEPIC-HIPC Recruiting No ResultsNewborn Vaccine Immunogenicity Biological:
16 NCT00478Safety and Immunogen CompletedNo ResultsProphylaxis of Avian Influenza Vacci Biological
17 NCT02105The Effect and Safety Unknown sNo ResultsImmunogenicity and Adverse Drug EfBiological:
18 NCT02842Immunogenicity and Sa CompletedHas ResultMeningitis|Meningococcal MeningitBiological
19 NCT02196Study to E MR CompletedNo ResultsRubella|Measles Biological:
20 NCT01719School Located AdoleCompletedNo ResultsSchool Located Vaccine Program Behavioral
21 NCT02709Personaliz PERCELLVAActive, notNo ResultsGlioblastoma Biological:
22 NCT03971Immune Responses Af Recruiting No ResultsJapanese Encephalitis Vaccine Biological:
23 NCT01122Randomized Single-BlCompletedNo ResultsPlague Vaccine Biological:
24 NCT02456Strengthening Physic CompletedNo ResultsHPV Immunization Status Behavioral
25 NCT01656A Prospective, Open CompletedHas ResultJapanese Encephalitis|Japanese Ence Biological:
26 NCT03603Influenza Vaccine Re Active, notNo ResultsInfluenza Drug: Flua
27 NCT02806Safety Study of Enter Unknown sNo ResultsEnterovirus 71 Vaccine Biological:
28 NCT01571Exploration of the Bi CompletedNo ResultsPoliomyelitis|Tropical Enteropathy Biological:
29 NCT01446Three Doses of HepatUnknown sNo ResultsVaccine Response Impaired Biological:
30 NCT00735Safety and Immunogeni CompletedNo ResultsSeasonal Influenza, Vaccine Biological:
31 NCT01716Acceptability of Fluz CompletedNo ResultsPatient Response to Fluzone ID Vaccine
32 NCT03327Early Flu Shots in SOTNot yet recNo ResultsInfluenza|Solid Organ Transplant Biological:
33 NCT01976Vaccine Therapy for TActive, notNo ResultsChronic Lymphocytic Leukemia (CLL)Biological
34 NCT01215Influenza Vaccine PosTerminate Has ResultHematopoietic Stem Cell Transplan Biological:
35 NCT03964A Study of MOSAICO Recruiting No ResultsHealthy Biological
36 NCT03674A Study Combining PeRecruiting No ResultsHepatocellular Carcinoma|Liver Canc Biological
37 NCT03395Public Health MessagCompletedNo ResultsVaccine Hesitancy Behavioral:
38 NCT00841Safety and Immunogen CompletedNo ResultsPrepandemic Influenza Vaccine Biological:
39 NCT03972Optimizing HPV Vaccin Active, notHas ResultVaccine Refusal Behavioral
40 NCT03654To Evaluate the Immun Active, notNo ResultsHepatitis A Vaccine Biological:
41 NCT03212HBV Vaccination in HIUnknown sNo ResultsHepatitis B Vaccination, HIV Biological:
42 NCT00560Safety of a Influenza CompletedHas ResultSeasonal Influenza|Vaccine Biological:
43 NCT04227Safety and Immune Res Active, notNo ResultsRespiratory Syncytial Virus InfectionBiological
44 NCT02851Tailoring of Vaccine CompletedNo ResultsChildhood Vaccinations Behavioral
45 NCT01344Study to Evaluate Saf CompletedHas ResultSeasonal Influenza Biological:
46 NCT04072Long-Term Immunogeni Not yet recNo ResultsEnterovirus 71 Human Biological:
47 NCT03330Safety andMV/VV/HeCompletedNo ResultsMeasles|Varicella|Hepatitis A Biological:
48 NCT02269A Phase I Clinical Tri CompletedNo ResultsInfluenza Biological:
49 NCT01151Safety and Immunogeni CompletedNo ResultsSeasonal Influenza Biological:
50 NCT03748Analysis of Antigen S Active, notNo ResultsImmunity, Cellular Drug: Infl
51 NCT02602Immunogenicity of a JCompletedNo ResultsJapanese Encephalitis Biological:
52 NCT01394Risk of Narcolepsy AsCompletedHas ResultNarcolepsy Biological
53 NCT01430Maternal Flu Vaccine CompletedNo ResultsInfluenza Biological:
54 NCT02153Immunogenicity of HCompletedHas ResultInfluenza Vaccine Biological:
55 NCT02628Investigating the Eff CompletedNo ResultsTyphoid Vaccine on Sleep Biological:
56 NCT01023Immunologic Response CompletedHas ResultInfluenza Biological:
57 NCT03133Phase II of Live Atte Unknown sNo ResultsEpidemic Parotitis,Mumps Biological
58 NCT03139High Dose vs. StandarActive, notNo ResultsInfluenza|Immunosuppression Biological:
59 NCT03287Flu2Text: F2T CompletedNo ResultsInfluenza|Vaccination Behavioral
60 NCT03263Non Inferiority Tria CompletedNo ResultsMeningococcal Vaccine Biological
61 NCT02229Evaluation of PrimingCompletedNo ResultsAvian Influenza Biological:
62 NCT03934MotivationMOTIVE Recruiting No ResultsVaccine Hesitancy Other: MOt
63 NCT02203A Randomized,ParallelCompletedHas ResultHepatitis B Biological:
64 NCT00918Safety and Immunogen CompletedNo ResultsInfluenza Disease Biological:
65 NCT01717Persistence of AntiboCompletedHas ResultMeningococcal Disease|Meningococc Biological
66 NCT01823Persistence of ImmunCompletedHas ResultMeningococcal Disease Biological
67 NCT00511Safety and Immunogen CompletedHas ResultSeasonal Influenza Vaccine Biological:
68 NCT01736The Immunogenicity aCompletedNo ResultsInfluenza Biological:
69 NCT03763Effectiveness of HPV Recruiting No ResultsUterine Cervical Dysplasia|PapillomBiological:
70 NCT01224School InflMCSkipp CompletedNo ResultsImmunizations|Vaccination|Influen Behavioral:
71 NCT01651Safety and Immunogeni CompletedHas ResultHuman Influenza Biological:
72 NCT02555Immunity Period AferActive, notNo ResultsYellow Fever Vaccine|Immunity Biological:
73 NCT01084Evaluation of the Sa CompletedNo ResultsDengue Virus Biological:
74 NCT02999The Phase IVa of InacUnknown sNo ResultsSafety of Inactivated EV71 Vaccine| Biological:
75 NCT03519Clinical Study on Co Recruiting No ResultsEnterovirus 71 Inactivated Vaccine Biological:
76 NCT00787Continued Safety andEnrolling bNo ResultsTularemia Biological:
77 NCT01906Persistence of ImmunCompletedNo ResultsInfluenza, Human|Immunisation ReaBiological:
78 NCT03301Efficacy, Safety, and CompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological:
79 NCT02133PCV7 in the Preventi CompletedNo ResultsStreptococcal Pneumonia|Nasophary Biological
80 NCT03694FLUAD vs. FLUZONE HD Recruiting No ResultsFlu Drug: Flua
81 NCT03851Pharmacist Impact onCompletedNo ResultsPneumococcal Pneumonia Behavioral
82 NCT01782Evaluating the Safet CompletedNo ResultsDengue Biological:
83 NCT03150Comparison Med-Jet H CompletedNo ResultsNeedle Phobia Biological:
84 NCT00764Double Blind, Safety CompletedNo ResultsBotulism Vaccine Biological:
85 NCT01564Dose of Hepatitis B CompletedNo ResultsVaccination; Complications, Reactio Biological:
86 NCT02093Immunogenocity andCompletedNo
Sa ResultsHealthy Biological:
87 NCT03460Safety and Immunogeni Active, notNo ResultsSafety Issues|Immunogenicity Biological:
88 NCT01451Safety and Immunogeni CompletedNo ResultsHealthy Biological:
89 NCT03654To EvaluateVITHA-C Active, notNo ResultsHepatitis A Vaccine Biological:
90 NCT02560Adjuvanted InfluenzaCompletedNo ResultsTransplantation|Influenza Vaccines Biological
91 NCT01663SMS Mobile Vaxtech CompletedHas ResultAdherence to Vaccination SchedulesBehavioral
92 NCT01072Auto-immun GRIPLUP CompletedNo ResultsSystemic Lupus Erythematosus (SLE)Drug: Vacc
93 NCT01640Safety and Immunogeni CompletedHas ResultInfluenza Biological:
94 NCT01519Cancer Vaccine TargetCompletedHas ResultNeoplasms|Malignant Solid Tumor Biological:
95 NCT01865Comparison of Immunog CompletedNo ResultsHepatitis A Biological:
96 NCT02808Personaliz PerCellVacActive, notNo ResultsGlioblastoma Biological:
97 NCT01776Safety and Immunogen CompletedHas ResultPandemic H5N1 Influenza Biological
98 NCT02708Safety Study of QuadrCompletedNo ResultsQuadrivalent Influenza Virus Vaccin Biological:
99 NCT02960ImiquimodIMIFLU CompletedNo ResultsInfluenza Vaccine Biological:
100 NCT01700Coadministration of MCompletedHas ResultMeasles Antibody Seroconversion|Ru Biological:
101 NCT02992Safety and Tolerabili Terminate No ResultsAdvanced Cancer Biological
103 NCT03116Yellow Fever Vaccine Recruiting No ResultsYellow Fever Vaccine|Yellow Fever Drug: Stama
104 NCT03001The Phase IVb of InacCompletedNo ResultsHand, Foot and Mouth Disease (HF Biological:
105 NCT00654Allogeneic Cellular V CompletedHas ResultNon-Small Cell Lung Cancer Drug: 1650
106 NCT01812Safety and Immunogen WithdrawnNo ResultsInfection, Viral, Enterovirus Biological
107 NCT02436A Study to Evaluate t CompletedNo ResultsH7N9 Influenza Vaccine Biological
108 NCT01446A Cohort Study to As CompletedNo ResultsHuman Papillomavirus|HIV-1 InfectiBiological:
109 NCT00522Safety and Immunogen CompletedNo ResultsInfluenza Biological:
110 NCT03405HBsAb Response AferUnknown sNo ResultsChronic Hepatitis B, HBsAg, HepatitiDrug: Comm
111 NCT01830The Safety, Immunogen Unknown sNo ResultsVaricella Biological:
112 NCT00433Safety, Tolerability CompletedHas ResultMeningococcal Disease Biological
113 NCT02154Phase 3 Study to EvalCompletedNo ResultsHealthy Biological:
114 NCT03077Study of an Investiga CompletedNo ResultsMeningitis|Meningococcal MeningitBiological
115 NCT03051Safety andVEE Active, notNo ResultsVenezuelan Equine EncephalomyelitiBiological:
116 NCT02083Evaluation of the Pro CompletedNo ResultsMalaria Biological
117 NCT01644Trial of Additional M Unknown sNo ResultsMeasles Vaccine Biological:
118 NCT02750Effectiven TheraVACCRecruiting No ResultsGenital Warts Biological:
119 NCT02710SynchronizSINC CompletedNo ResultsVaccination Behavioral:
120 NCT01973Safety and Immunogen CompletedHas ResultMeningococcal Disease Biological
121 NCT00736Efficacy and Safety ofCompletedHas ResultHelicobacter Pylori Infection Biological:
122 NCT01867Immunogenicity, SafetCompletedHas ResultInfluenza Biological:
123 NCT03914Immune Modulatory EDnrolling bNo ResultsDiffuse Intrinsic Pontine Glioma or Biological
124 NCT03267Engaging PEPICC-HPVUnknown sNo ResultsVaccine Decision Making Other: Vac
125 NCT02263Do Some Healthy Adult CompletedNo ResultsInfluenza Biological:
126 NCT01531Safety and Efficacy S CompletedNo ResultsShigella Biological:
127 NCT03933Immune Non-inferiorit Recruiting No ResultsTyphoid Biological:
128 NCT00103Vaccine Therapy in TreCompletedHas ResultLung Cancer Biological:
129 NCT02177Safety and Immunogen CompletedHas ResultRabies Infection Biological:
130 NCT01772Brief Influenza Vacc CompletedNo ResultsInfluenza|Infectious Disease|Pregn Other: Infl
131 NCT01910Systems Biology of I CompletedHas ResultInfluenza A Virus, H5N1 Subtype Biological
132 NCT03735AssessmentFluSHED-2CompletedNo ResultsInfluenza Vaccines Biological:
133 NCT01908Human Papilloma ViruCompletedNo ResultsPatient Compliance Behavioral
134 NCT03587Evaluation HOSPIVAC Recruiting No ResultsVaccination Biological:
135 NCT01897Immunogenicity and SCompletedHas ResultMeningococcal Meningitis|Meningoc Biological:
136 NCT00767Safety and Immunogen CompletedHas ResultShort Bowel Syndrome Biological:
137 NCT03581Immunogenicity of CoRecruiting No ResultsVaccine Reaction Biological:
138 NCT00518Immunogenicity of a CompletedNo ResultsInfluenza Biological:
139 NCT01717Evaluation of ImmunoCompletedNo ResultsHealthy Biological:
140 NCT02547Assessment of an OralCompletedNo ResultsSeasonal Influenza B Biological
142 NCT03793Neoadjuvan HER2VacciRecruiting No ResultsDCIS Biological
143 NCT01522Early Immune Response CompletedHas ResultInfluenza Virus Vaccine Biological:
144 NCT03430Yellow Fever Vaccine CompletedNo ResultsSystemic Lupus|Rheumatoid ArthritiBiological:
145 NCT03582Efficacy Evaluation foEnrolling bNo ResultsHand, Foot and Mouth Disease Biological:
146 NCT00848Safety and Immunogeni CompletedNo ResultsPre-pandemic Influenza Vaccine Biological:
148 NCT03294HPV Centralized R/R RActive, notNo ResultsVaccines Behavioral
149 NCT03743Kinetics o KIRV CompletedNo ResultsInfluenza|Influenza, Human|VaccineBiological:
150 NCT03756Influenza Vaccine as Recruiting No ResultsDepression|Healthy Biological:
151 NCT02514Pilot Stud KAVI-VZV- Unknown sNo ResultsHealthy Biological:
152 NCT01591A Study to Assess theCompletedHas ResultInfluenza, Human Biological:
153 NCT02603A Clinical Trial to Ev CompletedNo ResultsHepatitis E Biological:
154 NCT02153The Safety and Immun Unknown sNo ResultsRotavirus Biological:
155 NCT01535HPV Vaccine Accepta CompletedNo ResultsHPV Vaccine Attitudes|HPV Vaccine Intention
156 NCT01152Study to Evaluate Saf CompletedHas ResultSeasonal Influenza Biological:
157 NCT01195Safety Study of Four CompletedNo ResultsCytomegalovirus Biological:
158 NCT04094Study to A 4CMenB Recruiting No ResultsNeisseria Gonorrhoeae Infection Biological
159 NCT01119Vaccine Hyporesponse CompletedHas ResultVaccine Response Impaired Biological:
160 NCT02759Effectiveness Trial t Active, notNo ResultsHepatitis E Infection Drug: Heco
161 NCT01214Novartis Vaccine and CompletedHas ResultN. Meningitidis Carriage Biological
162 NCT02092Safety and Immunogen WithdrawnNo ResultsQ Fever Biological:
163 NCT01525Standard Dose VersusCompletedNo ResultsPediatric Solid Organ Transplant Pat Drug: High-
164 NCT03614Immunologic Response CompletedHas ResultInfluenza, Human|Immune ResponsBiological:
165 NCT02231The Immunogenicity an CompletedNo ResultsPoliomyelitis Biological:
166 NCT02270Safety and Immunogeni CompletedHas ResultInfections, Streptococcal|StreptococBiological:
167 NCT00498Safety and Immunogeni CompletedNo ResultsSeasonal Influenza|Vaccine Biological:
168 NCT02145A Trial Co iMAP2 CompletedNo ResultsResponses to Infant Immunisations Drug: Repe
169 NCT00841Safety, Tolerability CompletedHas ResultPandemic Influenza Disease Biological:
170 NCT02018Safety Study Of ChemActive, notNo ResultsBreast Cancer Biological
171 NCT03316Immunogenicity of Hep Unknown sNo ResultsHepatitis B Vaccine Biological:
172 NCT03391Immunogenicity and SCompletedNo ResultsInfluenza Biological:
173 NCT02264Vaccination of AdvanRecruiting No ResultsLung Neoplasms Biological
174 NCT03705CVD 38000: Study of Recruiting No ResultsTyphoid and/or Cholera VaccinationDrug: Vivo
175 NCT00856Evaluation of Persis CompletedHas ResultMeningococcal Meningitis Biological
176 NCT01453Study to Evaluate th CompletedHas ResultMeningococcal Disease|Meningococca Biological
177 NCT02111Immunogenicity and Sa CompletedNo ResultsHealthy Biological:
178 NCT00956Safety and Immunogeni CompletedNo ResultsInfluenza|Seasonal Influenza Biological:
179 NCT01640Immunogenicity and SCompletedNo ResultsPandemic Influenza Biological
180 NCT03771Serologic Response t Active, notNo ResultsChronic Lymphocytic Leukemia (CL Drug: Shing
181 NCT00893PR1 Vaccination in MTerminate Has ResultLeukemia|Myelodysplastic SyndromBiological:
182 NCT01640Safety and Immunogeni CompletedHas ResultHuman|Influenza Biological:
183 NCT01698Pertussis (Tdap) Vacc CompletedNo ResultsPertussis|Pregnancy Biological:
184 NCT01360Hepatitis A Vaccine CompletedNo ResultsResponse to Hepatitis A Vaccine Biological:
185 NCT01654Randomized Trial of HCompletedHas ResultInfluenza Biological:
186 NCT03368Immunogenicity of CoCompletedNo ResultsVaccine Response Impaired Biological
187 NCT02963Immunogenicity of Hep Unknown sNo ResultsHepatitis B Vaccine Biological:
188 NCT04162Safety and Immunogen Recruiting No ResultsRabies Biological
189 NCT02196Video to Promote HPVCompletedNo ResultsVaccine Acceptance|Social Accepta Other: Edu
190 NCT01376Vaccine Therapy in TrRecruiting No ResultsMalignant Solid Tumour|Breast CanBiological:
191 NCT01043Knowledge and Attit CompletedNo ResultsKnowledge|Attitude|Behavior Behavioral:
192 NCT01357Safety and Immunogeni CompletedNo ResultsInfluenza Biological:
193 NCT02991Immunogenicity of HeActive, notHas ResultHepatitis B Vaccine Biological:
194 NCT02956Efficacy and Safety o CompletedNo ResultsRabies Biological:
195 NCT01498Seasonal Influenza DNCompletedNo ResultsInfluenza Biological:
196 NCT01334Trial of Vaccine Ther Terminate No ResultsRecurrent Epithelial Ovarian Cancer Biological:
197 NCT03813Safety Study of Reco Active, notNo ResultsCondylomata Acuminata|Cervical C Biological
198 NCT01666Study Comp IMMUNE CompletedHas ResultCancer|Influenza Viral Infections Biological:
199 NCT03714Immunogenicity and SCompletedNo ResultsVaccine Biological:
201 NCT02433Evaluating the Safety CompletedNo ResultsDengue Biological
202 NCT03310Immunization Reminde CompletedNo ResultsImmunization; Infection Other: Alm
203 NCT04036A Phase 1/2 Clinical TRecruiting No ResultsWhooping Cough Biological
204 NCT01766Safety and Immunogeni CompletedHas ResultPandemic H5N1 Influenza Biological
205 NCT03098Trial of Si VPTII Active, notNo ResultsPneumococcal Vaccine Biological:
206 NCT01445Immunogenicity and SCompletedNo ResultsPregnancy Biological:
207 NCT03792Timeliness and Comple Not yet recNo ResultsVaccination Failure Behavioral
208 NCT01023Infectivity, Replicat CompletedHas ResultInfluenza Biological
209 NCT03548BCG Vaccina bcgscars Not yet recNo ResultsBCG Vaccination Reaction Biological:
211 NCT03392Active Sur FLU-06-IB CompletedNo ResultsInfluenza, Human|OrthomyxoviridaeBiological:
I
212 NCT00936Evaluation of MeningCompletedNo ResultsMeningococcal Sero-type C Infectio Biological:
213 NCT02888Safety and Immunogen Unknown sNo ResultsCervical Cancer Biological
214 NCT03501Multilevel Intervent Recruiting No ResultsPapillomavirus Vaccines Behavioral
215 NCT03931The Transparent SafetCompletedNo ResultsDiphtheria|Tetanus|Pertussis|HepatBiological:
216 NCT03475cAd3-Marburg Vaccine Active, notNo ResultsMarburg Virus Disease Biological
217 NCT04180Increasing Optimal UsEnrolling bNo ResultsHuman Papillomavirus Vaccines Other: Pra
218 NCT01977Safety of Hib Vaccine CompletedNo ResultsHealthy Biological:
219 NCT03303Phase I to Test a Ne CompletedNo ResultsPneumococcal Pneumonia|Pneumoni Biological:
220 NCT03701Durability HIPCVAX-0CompletedNo ResultsInfluenza A Subtype H5N1 Infection Biological:
221 NCT01857Safety of Two Trivale CompletedHas ResultInfluenza|Fever Biological:
222 NCT03558Clinical Trial on Per Recruiting No ResultsPancreatic Tumor Biological:
223 NCT03908Clinical Study of Pe Not yet recNo ResultsEsophageal Cancer|Non Small Cell Biological
224 NCT01055Effects of Age on Res CompletedHas Result2009 H1N1 Influenza Virus Biological
225 NCT00748Safety and Immunogeni CompletedNo ResultsSeasonal Influenza Biological
226 NCT03399Increasing HPV VaccinEnrolling bNo ResultsHPV Vaccines Behavioral:
227 NCT03042Trial of T cholangio Recruiting No ResultsCholangiocarcinoma Biological:
228 NCT01788Safety and Tolerabili CompletedHas ResultInfluenza Biological
229 NCT01483DecitabineAML WithdrawnNo ResultsAcute Myelogenous Leukemia Biological:
230 NCT03186PreTeenVax EvaluatioCompletedNo ResultsHuman Papilloma Virus Behavioral
231 NCT03393Immunogenicity and Sa CompletedNo ResultsHepatitis B Vaccines Biological:
232 NCT00306Comparison of Safety,CompletedHas ResultInfluenza Biological:
234 NCT00999Conjugate And PolysaUnknown sNo ResultsPneumococcal Vaccines|HIV|HIV InfBiological
235 NCT03725Immunogenicity of Fra Not yet recNo ResultsYellow Fever Biological
236 NCT01811Effect of H TIV_HIV_TCompletedNo ResultsInfluenza|HIV|Tuberculosis Biological:
237 NCT02049A Study of ICT-121 DeCompletedNo ResultsGlioblastoma Multiforme Biological:
238 NCT01042To Determine the SafCompletedNo ResultsHealthy Biological
239 NCT00569Vaccine Study for SurCompletedNo ResultsPancreatic Cancer Biological
240 NCT02615Enhancing a SustainaCompletedHas ResultHerpes Zoster|Pneumococcal InfectBehavioral
241 NCT03989Safety, ImmunogenicitRecruiting No ResultsMalaria Biological:
242 NCT03867FY15-14: TNDBR Not yet recNo ResultsTularemia Biological:
243 NCT01843A Phase I/II Trial of CompletedHas ResultDengue Biological:
244 NCT00992Immunogenicity, TolerCompletedNo ResultsPandemic Influenza Disease Biological
245 NCT01595A School Health CenteCompletedNo ResultsImmunization Program|School HealtBehavioral
246 NCT03903Efficacy Trial of a C Active, notNo ResultsHand, Foot and Mouth Disease Biological
247 NCT02477Study of Adsorption TCompletedNo ResultsPertussis Biological:
248 NCT02808Personaliz PerCellVacActive, notNo ResultsBrain Cancer|Neoplasm MetastasesBiological:
249 NCT00329Safety and Immunogen CompletedHas ResultMeningococcal Disease Biological
250 NCT00473Phase 1 Trial of Na-A Terminate No ResultsHookworm Infection Biological
251 NCT01668Trial of Additional M Unknown sNo ResultsMeasles Vaccine Biological:
252 NCT03578ImmunisingiMAP3 Recruiting No ResultsWhooping Cough|Maternal VaccineBiological:
E
253 NCT01096Immunogenicity Study Unknown sNo ResultsHuman Influenza Biological:
254 NCT00489Primary Vaccination CompletedHas ResultInfections, Streptococcal|Streptoc Biological:
255 NCT02549Efficacy & SNIFFLE-3 CompletedHas ResultInfluenza Vaccines Efficacy and Safe Drug: Live
256 NCT02348Safety and Immunogeni Active, notNo ResultsTriple Negative Breast Cancer|Tripl Biological
257 NCT01684Safety and Immunogeni CompletedNo ResultsChickenpox|Zoster Biological:
258 NCT01720High Dose Influenza VCompletedHas ResultInfluenza Biological:
259 NCT00630Efficacy Study of TwoCompletedHas ResultInfluenza Biological:
260 NCT01367Safety, Tolerability CompletedHas ResultMeningococcal Disease|Meningococc Biological
261 NCT00956Safety and Immunogen CompletedHas ResultSeasonal Influenza Biological:
262 NCT03300MUC1 Vaccine in PrevRecruiting No ResultsLung Carcinoma Other: Lab
263 NCT03801Improving HPV VaccinRecruiting No ResultsHPV Vaccinations Behavioral
264 NCT02806Safety and Immunogeni Unknown sNo ResultsQuadrivalent Influenza Virus Vaccin Biological:
265 NCT02924Centralized IIS-based Unknown sNo ResultsReminder System for Influenza Vacc Behavioral:
266 NCT01412Magnitude of the AntiCompletedHas ResultStreptococcal Infections|Gram-PositiBiological:
267 NCT01431A Health Belief ModeCompletedHas ResultHPV Vaccine Acceptability Behavioral:
268 NCT02001A Follow-up Study forCompletedNo ResultsHand, Foot and Mouth Disease Biological:
270 NCT00828Antibody Re IVS CompletedNo ResultsPulmonary Sarcoidosis Biological:
271 NCT03016Safety and Tolerabili Unknown sNo ResultsHerpes Zoster Biological:
272 NCT03083Immunity tHVP01 Active, notNo ResultsHepatitis B|Immunization; InfectionDrug: Hepat
273 NCT03140Persistenc PRISM Active, notNo ResultsEbola Virus Disease Biological:
274 NCT03476Immunogenicity and SCompletedNo ResultsMeningococcal Infections Biological
275 NCT03501Evaluation of Human Recruiting No ResultsChronic Lymphocytic Leukemia|Diff Biological:
276 NCT00943Sanofi H1N1 InfluenzaCompletedHas ResultInfluenza Biological:
277 NCT03474Study on Liquid BovinCompletedNo ResultsRotavirus Gastroenteritis Biological:
278 NCT03205Immunogenicity and Sa CompletedNo ResultsMeningitis|Meningococcal MeningitBiological
279 NCT01258Study to Assess SafetCompletedNo ResultsPhase 1 Safety Study of GelVac Nas Drug: GelV
280 NCT01272Safety and Immunogeni CompletedHas ResultInvasive Meningococcal Disease Biological
281 NCT03137School-locaSKIPP RCT CompletedNo ResultsChildhood Influenza Vaccination|SchOther: Sch
282 NCT01502Study to E HTNV/PUUCompletedNo ResultsHemorrhagic Fever With Renal Syn Biological
283 NCT02935Phase 3 TriTorlak-300CompletedHas ResultInfluenza Biological
284 NCT02596Immunogenicity and SCompletedNo ResultsPlague Biological:
285 NCT00264Study of the Safety a CompletedHas ResultInfluenza Disease; Flu Biological:
286 NCT02955Immunogenicity and Sa CompletedNo ResultsMeningitis|Meningococcal MeningitBiological
287 NCT01884Phase III, Study to E CompletedNo ResultsHepatitis B|Cirrhosis|Awaiting OrgaBiological:
288 NCT00734Safety and Immunogen CompletedHas ResultInterpandemic Influenza Biological:
289 NCT01945Influenza VIVVE:Pilot CompletedNo ResultsHeart Failure Drug: inact
290 NCT02876The Immuno FLU1 CompletedHas ResultInfluenza Biological:
291 NCT01989Study of Safety and I CompletedNo ResultsVaccine Response Biological
293 NCT02869Safety and Immunogen Unknown sNo ResultsACYW135 Meningococcal PolysacchaBiological
294 NCT01505Immune Mem IMAP-1 CompletedNo ResultsHealthy Volunteers Drug: quad
295 NCT00829Therapeutic TreatmenWithdrawnNo ResultsRecurrent Respiratory PapillomatosiBiological
296 NCT02819Cohort StuFLU-01-IB CompletedNo ResultsInfluenza Biological:
297 NCT01712Study of Intradermal CompletedHas ResultInfluenza Biological:
298 NCT01658Efficacy of Candidate CompletedNo ResultsMalaria Biological
299 NCT01343Innovative Tool to In CompletedHas ResultGARDASIL Vaccination Behavioral
300 NCT01510The ClinicaIPV CompletedNo ResultsPoliomyelitis Biological:
301 NCT02994Evaluation of the ImpRecruiting No ResultsHPV Vaccination Drug: HPV
302 NCT00997Evaluating an Ebola CompletedNo ResultsEbola Virus Disease|Marburg Virus Biological:
303 NCT03038A Randomise HBV003 Not yet recNo ResultsChronic Hepatitis b Biological:
304 NCT01001Clinical Trial of the P CompletedNo ResultsPlasmodium Falciparum Biological:
305 NCT00262Study of the Safety CompletedHas ResultPrevention of Meningococcal DiseasBiological
306 NCT03671Personalized Vaccine Recruiting No ResultsAdvanced Cancer|Metastatic CanceBiological:
307 NCT02313Prospective Cohort StCompletedNo ResultsInfluenza Biological:
309 NCT01559Comparative Study ofCompletedNo ResultsTetanus|Tetanus Vaccine Biological:
310 NCT02258Study of FluzoneÂ® Qu CompletedHas ResultInfluenza Biological
311 NCT01812Immunogenicity and SCompletedNo ResultsInfluenza|Human ImmunodeficiencyBiological:
312 NCT01311Indirect E FinIPcarr Unknown sHas ResultPneumococcal Infections Biological:
313 NCT01404Tolerability and ImmuCompletedNo ResultsInfluenza Biological:
314 NCT03609Phase 2 SaRVF Recruiting No ResultsRif Valley Fever Biological:
315 NCT02140Effectiveness, ImmunCompletedHas ResultMeningococcal Disease Biological
316 NCT03277Flu Vaccine ResponseRecruiting No ResultsRheumatologic Disorder|Inflammat Biological:
317 NCT01551The ClinicaIVV CompletedNo ResultsInfluenza Biological:
318 NCT01732Adolescent Vaccinati CompletedNo ResultsAdolescent Vaccination Status Behavioral:
319 NCT03384Vaccine to Prevent ReRecruiting No ResultsBreast Cancer Female|Breast Cancer,Biological
320 NCT04163Ovarian CaOLIVIA Recruiting No ResultsOvarian Cancer Drug: W_ov
321 NCT00310Persistence of AntiboCompletedNo ResultsPrevention of Meningococcal Infect Biological
322 NCT03540Evaluation of Influen CompletedNo ResultsSystemic Lupus|Sjogren's SyndromeBiological:
324 NCT01808Standard-dose VersusCompletedNo ResultsInfluenza, Human|Transplantation InBiological:
325 NCT01339Introducti ICVB CompletedNo ResultsCholera Biological
326 NCT02907Influenza Vaccine AttiCompletedNo ResultsVaccination|Influenza Behavioral
327 NCT03391Vaccinatio Papillon Recruiting No ResultsHPV - Anogenital Human Papilloma Vi Biological:
328 NCT00614Low Dose Vaccine Stud Terminate No ResultsPancreatic Cancer Biological
329 NCT01148Assessment of AntiboCompletedHas ResultMeningococcal Disease|Meningococc Biological
330 NCT02458Vaccine -diVenus Unknown sNo ResultsDiphtheria|Tetanus|Pertussis|Poliom Biological:
331 NCT01103Evaluating the Safet CompletedNo ResultsHIV Infections Biological
332 NCT03160Study on ImmunizatioCompletedNo ResultsMeasles|Mumps|Rubella|Adverse Ev Biological
333 NCT02567SMS Mobile SMSVaxGua CompletedNo ResultsAdherence to Vaccination SchedulesBehavioral
334 NCT01493Safety Study of HPV Terminate No ResultsHead and Neck Cancer Biological
335 NCT01180Intradermal Versus InCompletedNo ResultsInfluenza Vaccine Biological:
337 NCT02729Safety Study of RabieCompletedNo ResultsRabies Biological
338 NCT02211Biological Vaccine: WithdrawnNo ResultsHead and Neck Squamous Cell Carc Biological
339 NCT03659Immune Res VaccHemInRecruiting No ResultsVaccination|Hematopoietic Stem CelBiological
340 NCT04222FluPRINT Study: CharaRecruiting No ResultsImmunization Other: Flue
341 NCT03996Vaccinatio VEME Recruiting No ResultsAging|Age-Related ImmunodeficienDrug: Met
342 NCT02116Phase 2a Immunogenic Active, notNo ResultsHemorrhagic Fever With Renal Syn Biological
343 NCT01740Vaccine Acceptance CompletedNo ResultsPregnancy Behavioral
344 NCT01129Safety and Immunogeni CompletedNo ResultsSalmonella Biological:
345 NCT03231Comparative Immunoge Unknown sNo ResultsHepatitis A Biological:
346 NCT00978Safety and Efficacy o CompletedHas ResultH1N1 Influenza Virus Biological
347 NCT03104Genomics and Epigeno Active, notNo ResultsPneumonia|Aging Biological
348 NCT02019Phase Ib TrJ65 CompletedNo ResultsBreast Cancer|Ovarian Cancer Biological:
349 NCT01436Evaluating the Safet CompletedNo ResultsDengue Biological
350 NCT02275p53MVA Vaccine and CompletedNo
G ResultsRecurrent Ovarian Epithelial Cance Biological
351 NCT03591Shingrix Vaccine in PaRecruiting No ResultsInflammatory Bowel Diseases Biological
352 NCT01565Immunization Delivery CompletedNo ResultsImmunization Status Among ObstetriBehavioral
353 NCT01977The Safety and Immun CompletedNo ResultsHealthy Biological:
354 NCT01164Comparison of Flu VacCompletedNo ResultsInfluenza Biological:
355 NCT01443An Alternative BoosteCompletedNo ResultsInvasive Streptococcus PneumoniaeBiological
356 NCT01140Safety andPCIRNRT06CompletedNo ResultsInfluenza Biological:
357 NCT04255Nine-valent HPV VacciNot yet recNo ResultsHPV Positive Oropharyngeal Squamou Biological:
358 NCT02152Study of Evaluating CompletedNo ResultsHepatitis B Biological:
359 NCT00644Immunogenicity and Sa CompletedNo ResultsFLU Biological:
360 NCT02231Text Message VaccineCompletedNo ResultsVaccination Other: edu
361 NCT01000A Study to Evaluate CompletedHas ResultMeningococcal Disease Biological
362 NCT03460Vaccine CaRE-CAMP Recruiting No ResultsMeasles Vaccination|Oral Polio VaccBiological:
363 NCT01073Safety and Immune Re CompletedNo ResultsDengue Virus Biological:
364 NCT02762Influenza RCT-IVVE Recruiting No ResultsHeart Failure|Influenza Other: Ster
365 NCT01623MAS-1 AdjuCCTA #000WithdrawnNo ResultsInfluenza Vaccines|Aged Biological:
366 NCT01079Clinical Study to Eva CompletedNo ResultsInfluenza Biological
367 NCT02212A Study to Evaluate thCompletedHas ResultInfluenza, Human Biological:
368 NCT00450A Study to Evaluate CompletedHas ResultMeningococcal Infections|MeningocBiological
369 NCT01859Therapeutic Vaccine fActive, notHas ResultHIV|Therapeutic Vaccine Biological
370 NCT03219Immunologic Response Unknown sNo ResultsHepatitis B Biological:
371 NCT03199Neoantigen DNA VacciRecruiting No ResultsTriple Negative Breast Cancer|Tripl Drug: Durv
372 NCT02385Evaluation of Human Recruiting No ResultsInfluenza|Influenza Immunisation Biological:
373 NCT02898Robust Antibody and CompletedNo ResultsHepatitis B Vaccines Biological
374 NCT01960AdolescentAVIP CompletedNo ResultsEvaluating Attitudes Toward HPV VacDrug: HPV
375 NCT02842Immune Lot ConsistenCompletedNo ResultsMeningitis|Meningococcal MeningitBiological
376 NCT02710The Interaction Betw CompletedHas ResultNon-target Heterologous Effects of Biological:
377 NCT02908Safety and Immunogen CompletedHas ResultInfluenza Biological
378 NCT01665A Time-motion StudyCompletedHas ResultInfluenza|Vaccination Site ReactionsBiological:
379 NCT03278Phase IV Clinical Tri CompletedNo ResultsHand, Foot and Mouth Disease Biological:
381 NCT03730DC Vaccine in ColorecRecruiting No ResultsColorectal Cancer Biological:
382 NCT03165Fever Afer SimultaneCompletedHas ResultFever Afer Vaccination|Fever|FebriBiological:
383 NCT02186Evaluating the Safety CompletedNo ResultsWest Nile Virus Biological
384 NCT01982Reactogenicity, Safe CompletedHas ResultInfluenza Biological
385 NCT01636Immunogenicity and Sa CompletedNo ResultsHand, Foot and Mouth Disease Biological:
386 NCT00721Safety, Tolerability CompletedHas ResultMeningococcal Infections Biological
387 NCT01266WT-1 Analog Peptide CompletedNo ResultsAcute Myeloid Leukemia|Acute LymBiological
388 NCT00464Safety, and Immunogen CompletedHas ResultInfluenza Biological:
389 NCT02227Efficacy St SKIPP RCT CompletedNo ResultsChildhood Influenza Vaccination|SchOther: Scho
390 NCT00389Phase IV Trial to De CompletedHas ResultInfluenza Biological:
391 NCT03323Immune Responses inRecruiting No ResultsInfluenza Biological:
392 NCT02563Study of FluzoneÂ® Qu CompletedHas ResultInfluenza Biological
393 NCT00645A Phase I, Randomized CompletedNo ResultsInvasive Group B Streptococcus (GBSBiological:
394 NCT03627Non Inferiority Trial CompletedNo ResultsHepatitis B Infection Biological:
395 NCT01661Clinical Trial of Gr CompletedNo ResultsMeningitis Biological
396 NCT03807Trail of T TVATLC01 Not yet recNo ResultsLung Cancer Biological
397 NCT01974Study Response of 13CompletedHas ResultEnd Stage Renal Disease Biological
398 NCT03734A PragmatiPAIVED Recruiting No ResultsInfluenza|Influenza-like Illness Biological:
399 NCT02026Persistence of Varice Not yet recNo ResultsPersistence of Varicella Immunity Biological:
400 NCT02553A Study of the Safety CompletedNo ResultsInfluenza Biological:
401 NCT01273Safety and Immunogen CompletedNo ResultsStaphylococcal Infections|CandidiasBiological:
402 NCT02598Seasonal TrIVACFLU-S CompletedHas ResultInfluenza, Human Biological:
403 NCT02785Randomized TTbOPV CompletedNo ResultsPoliomyelitis Biological:
404 NCT01941Vaccine Therapy in H CompletedNo ResultsCytomegalovirus Infection|Healthy, Biological
405 NCT03615Safety, Tolerability CompletedNo ResultsMERS (Middle East Respiratory Syn Biological
407 NCT00735Study to Evaluate Saf CompletedNo ResultsInfluenza Biological:
408 NCT03614Typhoid Conjugate VaActive, notNo ResultsTyphoid Biological:
409 NCT02263Immunogenicity of HCompletedNo ResultsAutoimmune Disease|Juvenile Idiopa Biological
410 NCT03739Reactogenicity, Safe Not yet recNo ResultsVaccine Adverse Reaction Biological:
411 NCT01653A Phase I Clinical Tri CompletedNo ResultsHuman Papillomavirus Biological:
412 NCT01423Safety and Immunogen CompletedHas ResultMeningococcal Disease|Meningococc Biological
414 NCT01658Study of the Safety a CompletedNo ResultsInfluenza Biological
415 NCT02544Safety Study of Pneu Unknown sNo ResultsPneumococcal 13-valent Conjugate Biological
416 NCT04162Hepatitis B Vaccine inCompletedNo ResultsHepatitis B Vaccination Biological
417 NCT00944A Vaccine Study for HWithdrawnNo ResultsNeuroblastoma|RhabdomyosarcomaBiological
418 NCT01854Clinical Efficacy of T CompletedHas ResultInfluenza Biological:
419 NCT00501A Controll BCGov-01 CompletedNo ResultsCervical Cancer|Genital Warts Biological
420 NCT00854Safety and Efficacy S CompletedNo ResultsBreast Cancer Biological
421 NCT02981A Blind, Randomized aCompletedNo ResultsVaricella Biological:
422 NCT00919Safety of and Immun CompletedNo ResultsDengue Shock Syndrome|Dengue He Biological
423 NCT01349Immunization With a CompletedNo ResultsLung Cancer Biological
424 NCT03468Clinical Study of Pe Recruiting No ResultsAdvanced Esophageal Squamous CarBiological
425 NCT02002The Fifh-year Follow-CompletedNo ResultsHepatitis A Biological:
426 NCT01926PCV13 + Hep PCV13+HeUnknown sNo ResultsMeasurement of Immune ResponseBiological:
t
427 NCT04133Clinical Trial of the Recruiting No ResultsDengue Biological:
429 NCT01646A Phase 3 Trial Evalu CompletedHas ResultPneumococcal Vaccines|Pneumococc Biological
430 NCT01203The Immunogenicity aCompletedHas ResultHepatitis b Biological
431 NCT02479Type I-Polarized AutoActive, notNo ResultsBreast Cancer|Metastatic Breast Ca Biological:
432 NCT01100Tolerability and Safe CompletedNo ResultsInfluenza Biological:
433 NCT02752Immunogenicity and SCompletedNo ResultsMeningitis|Meningococcal MeningitBiological
434 NCT03408Lot-to-lot ConsistencyCompletedNo ResultsHepatitis B Vaccines Biological:
435 NCT03631Personalized Vaccine Recruiting No ResultsSmoldering Plasma Cell Myeloma Procedure:
436 NCT04111Safety and Immunogen Recruiting No ResultsHand, Foot and Mouth Disease Biological:
437 NCT03871Neoantigen-primed DC Not yet recNo ResultsCarcinoma, Non-Small Cell Lung|CarBiological
438 NCT01998A Study to Evaluate t CompletedHas ResultInfluenza Biological:
439 NCT00561Safety and Immunogen CompletedNo ResultsAvian Influenza Biological:
440 NCT01446Immune Response Indu CompletedHas ResultStreptococcal Infection|Gram-positivBiological:
441 NCT01761Protecting Pregnant CompletedNo ResultsInfluenza|Pertussis Behavioral
442 NCT04083Induction of Gut PermRecruiting No ResultsIntestinal Permeability|Inflammati Biological:
443 NCT02984PROMOtion PromovaC Recruiting No ResultsVaccination Promotion Behavioral:
444 NCT02302A Phase â…¢ Clinical CompletedNo ResultsH. Pylori Infection Biological:
445 NCT03467Role of Interferon-Î» CompletedNo ResultsVaccine Response Impaired|Allogene Biological:
446 NCT03739Efficacy of a Plant-de CompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological
447 NCT00384A Phase I/II Trial of CompletedHas ResultDengue Fever Biological:
448 NCT01507An Efficacy Trial in I CompletedNo ResultsHand, Foot and Mouth Disease Biological
449 NCT00944Peds Sanofi H1N1 Inf CompletedHas ResultInfluenza Biological
450 NCT01986Immunogenicity and SCompletedNo ResultsHealthy Biological
451 NCT00995Pilot Study of the RotCompletedNo ResultsIntestinal Failure|Rotavirus VaccinesBiological:
452 NCT03956Neoantigen Peptide Va Not yet recNo ResultsPancreas Cancer|Pancreatic Cancer|Biological
453 NCT01155Safety of VIP-H1N1 CompletedNo ResultsHIV Infection Biological:
454 NCT01695Response to Influenz Terminate No ResultsNeoplasms Biological:
455 NCT01373Study of a Novel Tetr CompletedHas ResultDengue|Dengue Fever|Dengue Hemo Biological:
456 NCT01776Safety and Immunogen CompletedHas ResultPandemic H5N1 Influenza Biological
457 NCT00519Immunogenicity and Sa CompletedNo ResultsInfluenza Disease Biological:
458 NCT01946Study of FluzoneÂ® Qu CompletedHas ResultInfluenza Biological:
459 NCT01010Tolerability and ImmuCompletedNo ResultsInfluenza Biological:
460 NCT01997Phase 1 StuIPV-004 CompletedNo ResultsPoliomyelitis Biological:
461 NCT00866Safety and Efficacy StTerminate No ResultsShigella Biological:
462 NCT03101Study of a Live Atten CompletedNo ResultsChikungunya Biological
463 NCT01575Evaluation of the HumCompletedHas ResultRotavirus Gastroenteritis Biological
464 NCT00382Safety and Immunogen CompletedNo ResultsInfluenza Biological
465 NCT04223Purified Inactivated Active, notNo ResultsJapanese Encephalitis Virus DiseaseBiological
466 NCT00607The EfficacIVCAD CompletedNo ResultsCoronary Artery Diseases|MyocardiaBiological:
467 NCT03777Safety and Immunogeni Active, notNo ResultsInfluenza Biological:
468 NCT03095Seasonal TrIVACFLUS- CompletedHas ResultInfluenza, Human Biological
469 NCT03630Immune Response and Recruiting No ResultsBreast Cancer|HER2-positive BreastBiological
470 NCT01046Antibody Titer AnalysUnknown sNo ResultsSerology Analysis|Novel H1N1 Influ Biological
471 NCT03240The Phase IVc of InacActive, notNo ResultsHand, Foot and Mouth Disease (HF Biological:
472 NCT01091A Study to Evaluate t CompletedNo ResultsRotavirus Gastroenteritis Biological
473 NCT01424A Phase 4, Placebo-C CompletedHas ResultMeningococcal Meningitis Biological
474 NCT04186Study to E EBOVAC3DRecruiting No ResultsEbola Virus Disease Biological
475 NCT02367A Clinical Trial for I CompletedNo ResultsEncephalitis Biological:
476 NCT02289Vaccine Against Escher CompletedNo ResultsE.Coli Infections Biological:
477 NCT02247Study of Safety and I Unknown sNo ResultsInfluenza Biological
478 NCT01026Study Evaluating Ant CompletedHas Result13-valent Pneumococcal Vaccine|I Biological
479 NCT02514Long-term Immunogeni CompletedNo ResultsEncephalitis, Japanese Biological:
480 NCT03898The EffectsFLU-TW Not yet recNo ResultsInfluenza Biological:
481 NCT01119Study on t MenAfriCaCompletedNo ResultsMeningitis Biological
482 NCT00645Pediatric Safety and CompletedHas ResultInfluenza Biological:
483 NCT03357Mix Vaccine for MetasCompletedNo ResultsMetastatic Sarcoma|Reaction - MixeBiological:
484 NCT03357Mix Vaccine for MetasCompletedNo ResultsMetastasis From Malignant Tumor ofBiological:
485 NCT01512Long Term Immunogeni Unknown sNo ResultsHPV|HIV Biological:
486 NCT02952Evaluating the Infect CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological:
487 NCT02194Oncoquest-L Vaccine N i ot yet recNo ResultsFollicular Lymphoma Biological:
488 NCT01928Randomized, Double Unknown
Bl sNo ResultsCervical High Grade Squamous Intrae
Biological
489 NCT03357Mix Vaccine for MetasCompletedNo ResultsMetastatic Colorectal Cancer|ReactiBiological:
490 NCT02286Immune Response toCompletedHas
R ResultDiarrhea Rotavirus Biological:
491 NCT01696Phase II Trial to Eva Active, notNo ResultsDengue Biological
492 NCT02569Investigating the Im Unknown sNo ResultsMeningococcal Infections Biological
493 NCT04152Effectiveness and Saf Recruiting No ResultsEbola Virus Disease Biological
494 NCT00488B Cell Response to a CompletedHas ResultMeningococcal Disease Biological
495 NCT03036Preventive Human Papi Recruiting No ResultsKidney Transplantation Other: Lab
496 NCT02233Immunogenicity, SafetCompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological:
497 NCT00242Safety andGRC28 CompletedNo ResultsInactivated Influenza Vaccine Biological:
498 NCT01368Comparison PCIRNRT09CompletedNo ResultsInfluenza Vaccine Biological:
500 NCT01444Study of Parenterally Unknown sNo ResultsInfluenza Biological:
501 NCT00297Study of the Safety CompletedNo ResultsMeningococcal Disease Biological
502 NCT00970Dendritic Cell (DC)-B Active, notNo ResultsCancer of Prostate|Cancer of the P Biological:
503 NCT00617Study to Evaluate theCompletedHas ResultInfluenza Biological:
506 NCT02673Safety and Efficacy CompletedNo ResultsHealthy Biological:
507 NCT02461Trial of High Dose vs CompletedHas ResultInflammatory Bowel Disease (IBD) Biological:
508 NCT00841An Hepatitis B VaccinCompletedNo ResultsHepatitis B Infection|Hepatitis C Inf Biological:
509 NCT00572Randomized Trial of ACompletedHas ResultHuman Papillomavirus Infection Biological
510 NCT01443Evaluating the Safet CompletedNo ResultsH5N1 Influenza Biological
511 NCT02158Freeze-dried Live Att CompletedHas ResultMeasles/Rubella Drug: Free
512 NCT01374Study of a Novel Tetr CompletedHas ResultDengue Fever|Dengue HemorrhagicBiological:
513 NCT02151Freeze-dried Live Att CompletedHas ResultMeasles/Rubella Drug: Free
514 NCT03979NonavalentNOVEL Not yet recNo ResultsNeoplasia Biological:
515 NCT01979A Phase 1 Ascending CompletedNo ResultsAnthrax Infection Biological:
516 NCT01488Immunogenicity and Sa CompletedHas ResultHealthy Biological:
517 NCT03746Immunogenicity and SRecruiting No ResultsDengue Fever Biological
518 NCT01027Extension Study Eval CompletedHas ResultMeningococcal Disease Biological
519 NCT01629Immunogenicity of A CompletedHas ResultTetanus|Diphtheria|Pertussis|Who Biological
520 NCT03063Entolimod, an AdjuvaActive, notNo ResultsSubstance Use Disorders Drug: Ento
521 NCT01676Seasonal Influenza HACompletedNo ResultsInfluenza Biological:
522 NCT02274Evaluating the Safety CompletedNo ResultsInfluenza A Virus, H7N9 Subtype Biological
523 NCT02140Safety Stu MUC-1 Unknown sNo ResultsEpithelial Cancers of the Lung, Brea Drug: Ad-s
524 NCT01346Safety, Tolerability, CompletedHas ResultInfluenza Disease Biological:
525 NCT03935Immunogenicity Study Active, notNo ResultsCondylomata Acuminata|Cervical C Biological
526 NCT01986Protectivity and SafetCompletedNo ResultsHealthy Biological
527 NCT00644Study to Evaluate theCompletedHas ResultInfluenza, Human Biological:
528 NCT01013Immunogenicity and Sa CompletedNo ResultsInfluenza Vaccines Biological:
529 NCT04091Evaluation of the Saf Not yet recNo ResultsEnterovirus Infections|Influenza Biological:
530 NCT01883AutologousADCVCTASEnrolling bNo ResultsSarcoma|Neoplasms, Connective and Biological:
531 NCT00322A Phase I/II Trial of CompletedHas ResultDengue Biological:
532 NCT01242Ross River Virus (RRVCompletedNo ResultsProphylaxis of Ross River Virus InfecBiological:
533 NCT02398Investigating MeningoActive, notNo ResultsMeningococcal Vaccines|Meningococca Biological
534 NCT03121Pharmacodynamic Open CompletedNo ResultsSeasonal Influenza Preventative Va Biological:
535 NCT01004A Clinical Trial of Sp CompletedNo ResultsInfluenza Biological:
536 NCT01876Dendritic Cell Vaccin CompletedHas ResultMetastatic Melanoma Biological:
538 NCT02919Immunogenicity and SUnknown sNo ResultsMeningitis|Meningococcal MeningitBiological
539 NCT00992Safety of and ImmuneCompletedHas ResultHIV Infections|H1N1 Influenza VirusBiological
540 NCT02567Immunogenicity and Sa CompletedNo ResultsHPV Vaccines Immunogenicity and SBiological
541 NCT02585A Study of a SeasonalCompletedHas ResultInfluenza, Human Biological:
542 NCT01947Immunogenicity and CompletedNo ResultsArthritis, Rheumatoid|Spondylarthrit Biological:
543 NCT02263Phase 3 Study to EvalCompletedHas ResultHealthy Biological:
544 NCT03962Research on Optimal N I ot yet recNo ResultsHepatitis B Vaccine Biological:
545 NCT00310Comparative Trial EvaCompletedNo ResultsInfluenza Biological:
546 NCT03373Effect of Extended D Unknown sNo ResultsCholera|Vibrio Cholerae Infection Biological:
547 NCT01761The Safety and Immuno CompletedNo ResultsHealthy Biological:
548 NCT00722Comparison Study of Terminate No ResultsMalignant Melanoma Stage IV Biological
549 NCT0109513 Valent Pneumococc CompletedNo ResultsPneumococcal Disease Biological
550 NCT01991Safety, Tolerability CompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological:
551 NCT03328Age and Response to Recruiting No ResultsInfluenza|Influenza Immunisation Biological:
552 NCT02858Conjugate Vaccine Aga Recruiting No ResultsSerogroup C Meningococcal MeningiBiological
553 NCT02914Evaluation of Immunog CompletedHas ResultInfections, Rotavirus|Rotavirus VaccBiological:
554 NCT01273Safety of an Inactiva CompletedNo ResultsInfection; Viral, Enterovirus Biological:
555 NCT03403Vaccine AttSPECIVAC Not yet recNo ResultsVaccine Practice Behavioral
556 NCT04051Immunogenicity and Sa Not yet recNo ResultsSafety Issues|Immunogenicity Biological
557 NCT01508A Clinical Trial to As CompletedNo ResultsHand, Foot and Mouth Disease|HerpBiological:
558 NCT01216Standard Versus High-CompletedHas ResultPediatric Patients With Acute Lymp Drug: High-
559 NCT02710A Phase III Clinical T CompletedNo ResultsInfluenza Biological:
560 NCT02109Safety of HVTN 097 CompletedNo ResultsHIV Infection Biological:
561 NCT00522Support Annual StrainCompletedNo ResultsInfluenza Disease Biological:
562 NCT01339A Phase 3B, Open Labe CompletedHas ResultMeningococcal Disease|Meningococc Biological
563 NCT01119Comparison FLUSECUOUnknown sNo ResultsHealthy Volunteers Biological:
564 NCT03947HPV-SAVE: 9-Valent HNot yet recNo ResultsAnal Intraepithelial Neoplasia|Ana Drug: 9-va
565 NCT03682EvaluationProPositiveRecruiting No ResultsHiv|Meningitis, Meningococcal|HIVBiological
566 NCT01654A Phase IIb, Open-La CompletedHas ResultPneumococcal Infection Biological
567 NCT00584Safety and Immunogeni CompletedHas ResultTularemia Biological:
568 NCT01877Study of Purified Ver CompletedNo ResultsRabies Biological:
569 NCT00674Comparison of GSK BiCompletedHas ResultInfections, Meningococcal Biological
570 NCT01123Evaluating the SafeneCompletedNo ResultsSeasonal Influenza Biological:
571 NCT02542Potential MechanismsCompletedHas ResultIntussusception|Rotavirus Infection Drug: Rota
572 NCT02454Phase I Tr NOA-16 CompletedNo ResultsGlioma Drug: IDH1
573 NCT03314Efficacy Trial of a Va Unknown sNo ResultsHerpes Zoster Biological:
574 NCT00310Safety and Immunogen CompletedHas ResultMeningococcal Meningitis Biological
575 NCT01386Ixiaro as Booster Af CompletedNo ResultsJapanese Encephalitis Biological
576 NCT02822Safety and Immunogen Unknown sNo ResultsFlu Biological
577 NCT00727Immunogeni HPV CompletedHas ResultInflammatory Bowel Disease Biological:
578 NCT01341Immunogenicity of Hep CompletedNo ResultsInflammatory Bowel Disease|Crohn's Biological:
579 NCT02109Phase I/II DescendingCompletedHas ResultEvaluation of a Rotavirus Vaccine Biological
580 NCT01792Dendritic Cell Vaccin CompletedNo ResultsMalignant Glioma Biological
581 NCT03516Reducing De REDIVAC-LCompletedNo ResultsCommunicable Disease Behavioral
582 NCT01581Studies of the ImmunCompletedNo ResultsHematopoietic Stem Cell TransplantBiological:
583 NCT00433Wilm's Tumor 1 (WT1)CompletedHas ResultMyelodysplastic Syndrome|Acute MDrug: WT1
584 NCT01285ReactogeniTL01 CompletedNo ResultsHIV Infections Biological
585 NCT01569A Protected Study of CompletedNo ResultsThe Efficacy of Inactivated EV71 Va Biological
586 NCT00366Study to Evaluate a 1 CompletedHas ResultVaccines, Pneumococcal Biological
587 NCT01239Swine Flu (Influenza CompletedNo ResultsInfluenza Drug: Seas
588 NCT00258Phase IV Trial to Col CompletedHas ResultInfluenza Biological:
589 NCT03654Immune Response and CompletedNo
R ResultsInfluenza Virus Vaccine Adverse ReaBiological:
591 NCT02425Safety and Immunogeni CompletedHas ResultDengue Fever Biological
592 NCT02015Study of Controlled HCompletedNo ResultsMalaria Biological:
593 NCT02948Infectivity, Safety a Terminate No ResultsRespiratory Syncytial Virus InfectionBiological:
594 NCT00570Feasibilit Piiitch CompletedHas ResultInfluenza Biological:
595 NCT03445Immunogenicity and Sa Unknown sNo ResultsInfluenza, Human Biological:
596 NCT02269The Immunogenicity aCompletedNo ResultsInfluenza Biological:
597 NCT02692A Study to Evaluate t CompletedNo ResultsHealthy Biological:
598 NCT01177Study of the Safety CompletedNo ResultsH1N1 Flu Biological
599 NCT01215Standard vs High-Dose CompletedHas ResultAdult Stem Cell Hematopoetic TransBiological:
600 NCT00158A Comparison of OneCompletedNo
V ResultsInfluenza Biological:
602 NCT01667Vaccine HeVHIP CompletedNo ResultsChildhood Vaccination Behavioral
603 NCT04083CytotoxicitCYF-8 Recruiting No ResultsHealthy|Cytotoxicity|Yellow Fever VDrug: Yell
604 NCT01067Single Center, Open LTerminate No ResultsRabies Other: No
605 NCT04183Immunogenicity & Safe CompletedNo ResultsCongenital Rubella Infection|Measl Biological:
606 NCT03525Therapeutic Vaccine Recruiting No ResultsProstate Cancer Biological:
608 NCT03058Two Doses of MultimeCompletedHas ResultInfluenza|Influenza Immunisation Biological
609 NCT01852Evaluating the Safety CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological:
610 NCT02429Effects of Persistent Terminate No ResultsHepatitis C Infection Drug: Rec
611 NCT01641Immunogenicity Study CompletedNo ResultsRabies Biological:
612 NCT01712A Phase I, Safety Stu CompletedNo ResultsThe Study Focused on the Safety of Biological
613 NCT01889Safety and Immunogen CompletedNo ResultsMeningitis, Meningococcal, SerogroBiological
614 NCT01609Seasonal Influenza DNCompletedNo ResultsInfluenza Biological:
615 NCT02657Safety and Efficacy o CompletedNo ResultsRabies Biological:
616 NCT02427Safety and Immunogeni Recruiting No ResultsTriple Negative Breast Cancer|Tripl Biological:
618 NCT03418HPV Anti-CHARE-40 Recruiting No ResultsCarcinoma, Squamous Cell|Head anDrug: HPV
619 NCT04108Safety Study of 15-V Recruiting No ResultsPneumonia, Pneumococcal Biological
620 NCT04019Dosage-Escalation St Recruiting No ResultsRabies|Rabies Immunisation Biological
621 NCT01430Study of FluzoneÂ® I CompletedHas ResultInfluenza Biological
622 NCT01209Safety and Immunogeni CompletedHas ResultSeasonal Influenza Biological:
623 NCT03888Bacille Calmette-GuÃ© Not yet recNo ResultsMultiple Sclerosis Drug: Baci
624 NCT03122Neoantigen DNA VacciRecruiting No ResultsPancreatic Cancer|Pancreas Cancer|Biological
625 NCT02061DC VaccineDCIS6 Unknown sNo ResultsBreast Cancer|DCIS Biological:
626 NCT01378A Safety and Immunog CompletedNo ResultsHIV-1 Infection Biological
627 NCT03908OptimisingOpTIMUMNot yet recNo ResultsPregnancy Related|Immunization; InBiological:
628 NCT03399Evaluation of MetabolUnknown sNo ResultsInfluenza Vaccine|Immune Response| Biological:
629 NCT02443VA-008 ACAM2000Â®Unknown
Va sNo ResultsSmallpox Vaccine Adverse Reaction Biological
630 NCT01616Zinc and/or ProbioticCompletedHas ResultImmunity to Oral Rotavirus Vaccine|Dietary Su
631 NCT01478A Phase 3b Study to CompletedHas ResultMeningococcal Disease|Meningococc Biological
632 NCT00734Safety and ReactogenCompletedNo ResultsHaemophilus Influenzae Type b Biological
633 NCT01529Safety and Dose RangiCompletedHas ResultPertussis|Whooping Cough|TetanusBiological:
634 NCT03168A Study on the Recomb CompletedNo ResultsHepatitis E Biological:
635 NCT02297Immune Response toUnknown
H sNo ResultsElderly Immune System Biological:
636 NCT01499Cohort Stud MUCOFLU CompletedNo ResultsCystic Fibrosis With Gastrointestina Biological:
637 NCT00637Immunogenicity and SCompletedHas ResultInfections, Papillomavirus|PapillomaBiological:
638 NCT03747EffectiveneIVIHPV1 Recruiting No ResultsHealthy Biological
639 NCT02325Search for BREMEAVACompletedNo ResultsMeasles|Rubella|Mumps Biological
640 NCT01662Safety and Immunogeni CompletedHas ResultRabies|Japanese Encephalitis Biological:
641 NCT019954-valent HPV Vaccine Unknown sNo ResultsRecurrent Respiratory PapillomatosiBiological:
642 NCT00254Yellow Fever Virus V CompletedNo ResultsViremia Biological:
643 NCT01978Immune and Hormone CompletedHas ResultHealthy Biological:
644 NCT03274Safety and Immunogen CompletedNo ResultsHand, Foot and Mouth Disease Biological:
645 NCT01258A Study of High-DoseCompletedHas ResultInfluenza Biological:
646 NCT00970Immunogenicity, SafeCompletedNo ResultsPandemic Influenza Biological
647 NCT03527Safety, Reactogenici Active, notNo ResultsTyphoid Biological:
648 NCT01396Study of a Live Atte CompletedHas ResultJapanese Encephalitis|Japanese Ence Biological:
649 NCT01007Immunogenicity and Sa CompletedNo ResultsInfluenza Biological
650 NCT02718Trial to Evaluate Saf CompletedNo ResultsEbola Virus Disease Biological:
651 NCT03165Clinical Study to Eva CompletedNo ResultsInfluenza, Human Biological
652 NCT04199Safety and Efficacy o Recruiting No ResultsHepatitis B Biological:
653 NCT00925AcceptabilGirasol CompletedHas ResultHuman Papillomavirus Infection Biological:
654 NCT01758Safety and Immunogeni CompletedNo ResultsHealthy Biological:
655 NCT02003Comparative CORE-HIV CompletedNo ResultsHepatitis B|HIV Biological:
656 NCT01205Immunogenicity of Flu CompletedHas ResultHIV|Cancer Biological
657 NCT02067Increasing Human PapCompletedNo ResultsHuman Papilloma Virus Infection Behavioral:
658 NCT03519Immunogenicity of thRecruiting No ResultsIdiopathic CD4 T Cell LymphocytopeBiological:
659 NCT01666Phase I/II Safety and CompletedNo ResultsHealthy Biological
660 NCT03592DC Vaccine in PancreaRecruiting No ResultsPancreatic Ductal Adenocarcinoma Drug: mDC
661 NCT02813Safety and Immunogeni Unknown sNo ResultsTetanus|Diphtheria|Whooping Cou Biological:
662 NCT03719Extended Dose IntervActive, notNo ResultsAdverse Reaction to Cholera Vaccin Biological:
663 NCT02285Protective Efficacy o CompletedHas ResultInfluenza Biological:
664 NCT01873Vaccine SoVSMRCT CompletedNo ResultsCommunicable Diseases Behavioral
665 NCT02040Safety and Immune Res CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological:
666 NCT01949The Immuno HAV CompletedNo ResultsHepatitis A Biological:
667 NCT00914Safety and Immunogen CompletedNo ResultsPandemic H5N1 Influenza Biological
668 NCT04188Safety and Immunogeni Not yet recNo ResultsHepatitis B Biological
669 NCT02003Immunogenicity and SCompletedNo ResultsMeningitis Biological:
670 NCT01579EvaluationBoost CompletedNo ResultsCholera Biological:
671 NCT02691Assess the Safety an CompletedNo ResultsInfluenza|Healthy Biological:
672 NCT00992Novartis H1N1 Vacci CompletedHas ResultInfluenza Biological:
673 NCT02533A Booster Dose of AdCompletedNo ResultsEbola Virus Disease Biological
675 NCT01470Immunogenicity, SafetCompletedNo ResultsDiphtheria|Tetanus|Pertussis|HepatBiological
676 NCT00744Study Eval CAPITA CompletedHas ResultPneumonia, Pneumococcal|Pneumoco Biological
677 NCT02555Phase 2 Study of TAK-CompletedHas ResultInfluenza Infection Biological:
678 NCT02139Persistency Study Af CompletedHas ResultMeningitis, Epiglottitis, Pneumonia Biological
679 NCT00311Study of the Safety, CompletedNo ResultsEncephalitis, Tick-Borne Biological:
680 NCT01744Vaccine Therapy in TrSuspendedNo ResultsRecurrent Melanoma|Stage IIIB Ski Biological
682 NCT03686The ImpactFLU2 Recruiting No ResultsInfluenza Biological:
683 NCT02543DC Vaccination in CMRecruiting No ResultsMyeloid Leukemia, Chronic Biological:
684 NCT02959Immunogenicity of HeUnknown sNo ResultsHepatitis B Vaccination Biological:
685 NCT02133A Post-marketing SafetCompletedNo ResultsInfluenza|Vaccination Adverse Event
686 NCT02718Complement ACDC Recruiting No ResultsMalignant Melanoma|Adjuvant DrugBiological:
687 NCT02819PRIMM Trial (Phone RCompletedNo ResultsImmunization Other: A c
688 NCT03950Increasing Vaccine U CompletedNo ResultsInfluenza|Tetanus|Diphtheria|Pert Other: Modi
689 NCT01003Studies of H1N1VAC CompletedHas ResultHealthy Biological:
690 NCT03300Ability of a Dendriti Terminate Has ResultMelanoma|Gastrointestinal Cancer|Biological:
691 NCT00848A Dose Ranging StudyCompletedNo ResultsInfluenza Biological
692 NCT02326A Phase I Clinical Tr CompletedNo ResultsEbola Virus Disease Biological:
693 NCT00963H1N1 Vaccine in Pre CompletedHas ResultInfluenza Biological:
694 NCT02548Dendritic PancVax Terminate No ResultsPancreatic Cancer Biological
695 NCT01995Safety and Immunogeni CompletedNo ResultsInfluenza A Virus, H7N9 Subtype Biological:
696 NCT02362Long-Term TARP VacciEnrolling bNo ResultsProstatic Neoplasms|Neoplasms of PBiological
697 NCT00678Phase 1 SaHOPS CompletedHas ResultMeningococcal Infection, Group B Biological
698 NCT03592Can an Educ PAPRICA Enrolling bNo ResultsHuman Papillomavirus Vaccination Behavioral
699 NCT02582Influenza Vaccine an CompletedNo ResultsInfluenza, Human|Pneumococcal InfBiological:
700 NCT01526A Study to Compare tCompletedHas ResultHuman Papillomavirus Other: HPV
701 NCT01092A Study of Japanese ECompletedHas ResultEncephalitis|Japanese Encephalitis Biological:
702 NCT00980Swine Flu (Novel Infl CompletedNo ResultsInfluenza Biological:
703 NCT01890Immunogenicity and Sa CompletedHas ResultMeningitis|Meningococcal InfectionBiological
704 NCT01273Safety of an Inactiva CompletedNo ResultsHand-foot-mouth Disease|Infection;Biological:
705 NCT02975MenB VacciMenBVacciCompletedNo ResultsMeningococcal Vaccine Other: Awa
706 NCT01250A Study of ComparingCompletedNo ResultsHealthy Biological: BCG Vaccin
707 NCT02961Live Enterovirus Vacc CompletedNo ResultsEnterovirus Infection|Type 1 DiabetBiological:
708 NCT02645Safety and Immunogen CompletedNo ResultsTyphoid Biological:
709 NCT01266Antiangiogenic PeptidUnknown sNo ResultsHepatocellular Carcinoma Biological:
710 NCT00329Immunogenicity and SCompletedHas ResultMeningococcal Disease|Meningococc Biological
711 NCT04110Patient Portal RemindActive, notNo ResultsInfluenza|Respiratory Tract Infectio Behavioral
712 NCT01729An Intervention Promo CompletedNo ResultsHuman Papilloma Virus-Related CervBehavioral
713 NCT01597A Study to Evaluate t CompletedHas ResultSystemic Lupus Erythematosus Biological
714 NCT02699Immunogenicity and Sa Active, notHas ResultMalaria|Malaria Vaccines Dietary Su
715 NCT01879Safety and Immunogen CompletedHas ResultHuman Influenza Biological:
716 NCT02971Amendment of rTSST-1 CompletedHas ResultToxic-Shock Syndrome|Sepsis Biological:
717 NCT00311Immunogenicity, SafetCompletedNo ResultsPrevention of Meningococcal Infect Biological
718 NCT02521A Study to M2-ABMGCompletedNo ResultsAdverse Event Following Immunisat Biological
719 NCT00893Inactivated Influenza CompletedNo ResultsInfluenza Biological:
720 NCT04089Long-term Immunogenic Not yet recNo ResultsLupus Erythematosus Diagnostic
721 NCT03137A Phase I Clinical Stu CompletedNo ResultsWhooping Cough Biological
722 NCT02511Comparison of VaccinCompletedHas ResultVaccine Efficacy Biological
723 NCT00922Safety and Immunogeni CompletedNo ResultsInfluenza A Biological:
724 NCT01184Randomized Trial of ACompletedHas ResultQuadrivalent HPV Vaccine|Human Pa Biological
725 NCT02824Immunogenicity and SCompletedHas ResultDengue Fever|Dengue HemorrhagicBiological
726 NCT00962Study of MMenOccy CompletedNo ResultsMeningococcal Meningitis, Serogro Drug: meni
727 NCT02330Phase 1 Study to AsseCompletedNo ResultsHealthy Biological:
728 NCT00657Immunogenicity, SafeCompletedHas ResultSerogroup B Meningococcal MeningiBiological
729 NCT00847Extension Study of V CompletedHas ResultMeningococcal Disease Biological
730 NCT01244Characterization of Enrolling bNo ResultsYellow Fever Vaccine
731 NCT01666Efficacy of Malaria V CompletedNo ResultsMalaria Biological
732 NCT01911Japanese Pediatric H CompletedNo ResultsInfluenza Biological:
733 NCT03300Improved NINVICTUS Terminate No ResultsInfluenza Drug: Seas
734 NCT00676Study Evaluating 13-vCompletedHas ResultVaccines, Pneumococcal Conjugate Biological
735 NCT03897Evaluating Immunogeni Recruiting No ResultsHepatitis B Biological:
738 NCT00992Safety of and ImmuneCompletedHas ResultHIV Infections|H1N1 Influenza VirusBiological
739 NCT02834A Dose RedDoRIS Active, notNo ResultsHuman Papilloma Virus Drug: biva
740 NCT03125Babies BorBEAR Men Active, notNo ResultsPrematurity|Vaccination|MeningocoBiological
741 NCT03438A Post Marketing SurvActive, notNo ResultsCervical Intraepithelial Neoplasia Other: Safe
743 NCT00934Direct and Indirect PrCompletedNo ResultsInfluenza Biological:
744 NCT01465A Study to DetermineCompletedNo ResultsInfluenza Biological
745 NCT03971Blood Donor CVD 500Recruiting No ResultsRisk Reduction Drug: Vivot
746 NCT04270Immunogeni 9-VPH-MVIRecruiting No ResultsHIV Infections|HPV Infection Biological
748 NCT00639A Study to Describe PCompletedHas ResultHealthy Biological:
750 NCT00964Study of Evaluation I CompletedNo ResultsAged Biological
751 NCT0143213-valent Pneumococca CompletedHas ResultPneumococcal Infections Biological
752 NCT03338Clinical Study of ImmuCompletedNo ResultsYellow Fever Vaccine
753 NCT02405Safety and Immunogen Active, notNo ResultsCondylomata Acuminata Biological
754 NCT00537Immunogenicity, SafetCompletedNo ResultsProphylaxis of Avian Influenza Biological:
755 NCT02236Immune Res HPV CompletedNo ResultsInfection Biological:
756 NCT01256Modified Vaccinia AnCompletedNo ResultsNasopharyngeal Neoplasms|Epstein-B Drug: MVA
757 NCT01507Safety Trial of MonovCompletedHas ResultInfluenza Biological
758 NCT00842Efficacy and Safety o CompletedHas ResultDengue Virus|Dengue Fever|Dengue Biological:
759 NCT02466Safety and Immunogen Recruiting No ResultsWestern Equine Encephalitis Biological
760 NCT01827Safety & ImmunogeniCompletedNo Results #NAME? Biological
761 NCT03894Study to Assess the Active, notNo ResultsRespiratory Disorders Biological
762 NCT01298Influenza A/H1N1/200CompletedNo ResultsDecreased Immunologic Activity [PEBiological
764 NCT00684Phase I Tr Auto TAG Active, notNo ResultsCarcinoma, Advanced Metastatic Biological
765 NCT00845Immunogenicity of a Sp CompletedHas ResultInfluenza|Orthomyxoviruses|MyxoviBiological:
766 NCT01254Evaluating the Safety CompletedNo ResultsParainfluenza Virus 3, Human Biological
767 NCT00323Immuno-Augmentation CompletedHas ResultLeukemia Drug: Sarg
768 NCT02526Immunogenicity of a CompletedHas ResultEncephalitis Biological:
769 NCT01024Immunogeni PREFLUVA CompletedNo ResultsInfluenza Biological
770 NCT00694Human Immune Respon Active, notNo ResultsYellow Fever Biological:
771 NCT00722Safety and Immune Re CompletedNo ResultsInfluenza|Virus Diseases Biological
772 NCT00709Mass Oral Cholera VacCompletedNo ResultsCholera|Diarrhea Biological
773 NCT02381Annual Study to InvesCompletedHas ResultInfluenza Biological:
774 NCT00388Study of Inactivated, CompletedHas ResultOrthomyxoviridae Infection|InfluenBiological:
775 NCT01034Immune Response toCompletedHas ResultInflammatory Bowel Disease|Uterine Biological
776 NCT04072A Clinical Study of a Active, notNo ResultsHerpes Zoster Biological:
777 NCT03885Presumptively Initiat Enrolling bNo ResultsPreventive Health Services (PREV H Behavioral
778 NCT01829Lung Cancer Vaccine CompletedNo ResultsLung Cancer Biological:
779 NCT01339Study of the Purified CompletedNo ResultsRabies|Rabies Virus Biological:
780 NCT00938Study to Evaluate theCompletedHas ResultInfluenza Biological
781 NCT02764Safety and Immunogen Recruiting No ResultsHepatitis|Hepatitis B|Liver Disease Biological
782 NCT01997A Case Cont ICICLE SuspendedNo ResultsInfluenza Vaccine Effectiveness
783 NCT00809Vaccination With GM-Active, notNo ResultsAcute Myeloid Leukemia|Chronic My Biological
784 NCT00870Clinical Tr DNA-Ad CompletedNo ResultsMalaria Biological:
785 NCT03598Randomized RIVER Enrolling bNo ResultsInfluenza Biological:
786 NCT02253Safety & Immunogenic CompletedNo ResultsImmune Response to MMR Vaccine Biological
788 NCT02820A Study of a Recombin CompletedNo ResultsStaphylococcus Aureus Infection Biological
789 NCT01622Adolescent VaccinatioCompletedNo ResultsAdolescent Vaccination Status Behavioral
790 NCT00841Safety and Efficacy S CompletedNo ResultsBreast Cancer Biological
792 NCT02727Cholera VaCVIS CompletedNo ResultsCholera Biological:
793 NCT02787INfluenza INVESTED Active, notNo ResultsHeart Failure|Myocardial Infarction Biological:
794 NCT00380Safety, Tolerability CompletedHas ResultPapillomavirus Infections Biological
795 NCT01047Sinovac, Pandemic InCompletedNo ResultsInfluenza Biological:
796 NCT03047Combination TherapyRecruiting No ResultsMetastatic Melanoma Drug: Nivo
797 NCT04146Safety Study of Live Active, notNo ResultsInfluenza Biological
798 NCT00572Safety Stu HPV-022 PUnknown sNo ResultsHuman Papillomavirus (HPV) VaccinBiological
799 NCT01774H5N1 Vaccine Study iCompletedNo ResultsInfluenza Biological:
800 NCT02084Vaccine Therapy in TrCompletedNo ResultsNeoplasms, Lung Biological:
801 NCT03970CVD 37000: ImmunityRecruiting
a No ResultsTyphoid Vaccination Drug: Vivot
802 NCT01635Immunogenicity of SACompletedNo ResultsHealthy Infants Biological:
803 NCT03694Flublok v. Standard DRecruiting No ResultsInfluenza|Pneumonia|Lower Respirat Biological:
804 NCT03286Comparison CODI Active, notNo ResultsPoliovirus Vaccine, Inactivated|Poli Biological:
805 NCT02141Plasmablast Trafficki CompletedHas ResultInfluenza Biological:
806 NCT03701Immune Response toTerminate
In No ResultsB-cell Malignancies Biological:
807 NCT03998Clinical Trial to Ass Not yet recNo ResultsRheumatic Fever Biological
809 NCT01551The Clinical Trial Pro CompletedNo ResultsInfluenza Biological:
810 NCT00366Study Evaluating a 13CompletedHas ResultVaccines, Pneumococcal Biological
811 NCT01267A Clinical Trial for I CompletedNo ResultsHand, Foot and Mouth Disease Biological
812 NCT03675The KEN SHE Study onActive, notNo ResultsPapillomavirus Infections Biological
813 NCT02654Safety and Immunogeni CompletedNo ResultsEastern Equine Encephalitis Biological:
814 NCT00348Study Comparing a DTCompletedHas ResultDiphtheria|Tetanus|Pertussis|Hepati Biological
815 NCT02063HER-2 PulsAdjuvant Active, notHas ResultBreast Cancer Biological:
816 NCT02758Promotion of InfluenzCompletedNo ResultsHuman Influenza Vaccination in HeaOther: Flu
817 NCT01649Yearly Licence Tolera CompletedNo ResultsInfluenza Drug: Fluva
818 NCT02865Trial To Test Safety Recruiting No ResultsCancer of Head and Neck|Cancer ofDrug: DPX-
819 NCT02251A Phase I Study Prim CompletedNo ResultsAvian Influenza|Immunisation Biological
820 NCT00862Alternate ADS CompletedHas ResultCervical Cancer|Genital Warts Biological:
821 NCT04203Improving IVVY Active, notNo ResultsVaccination Refusal Other: IVY
822 NCT00317Phase 1 Trial of a Ma CompletedHas ResultPlasmodium Falciparum Malaria Biological
823 NCT02741Safety and Immunogeni Recruiting No ResultsDengue Fever|Dengue HemorrhagicBiological
824 NCT01306The Effect MVEPI Unknown sNo ResultsMortality|Vaccines Biological:
825 NCT00616Safety and Immune Re CompletedHas ResultMeningococcal Infections Biological
826 NCT02003Immunogenicity and SCompletedNo ResultsMeningitis Biological
827 NCT01943Immunologic Mechanis CompletedHas ResultDengue|Dengue Fever|Dengue Hemo Biological
829 NCT02133A Clinical Trial to St CompletedNo ResultsRotavirus Gastroenteritis Biological
830 NCT03962Immunogenicity and Pe Not yet recNo ResultsHepatitis B Vaccine Biological:
831 NCT02490Diagnostic ImmunizatiUnknown sNo ResultsPrimary Immunodeficiency Biological:
832 NCT03402Mobile PhoMOPING Unknown sNo ResultsImmunization; Infection Behavioral
833 NCT03890Study of a Quadrival Recruiting No ResultsMeningococcal Infection (Healthy VoBiological
834 NCT00414A Study of 2 Doses ofCompletedHas ResultHepatitis B Biological:
835 NCT00880Study of Sanofi PasteCompletedHas ResultDengue Fever|Dengue HemorrhagicBiological:
836 NCT04072CommunityCPVAC Recruiting No ResultsHuman Papillomavirus Vaccines Behavioral
837 NCT02234Pilot StudyDRibble CompletedNo ResultsAdenocarcinoma of the Prostate Drug: Cycl
838 NCT00807Mammaglobin-A DNACompletedNo
V ResultsMetastatic Breast Cancer Biological
839 NCT02909Factors Associated WiCompletedNo ResultsInfluenza Vaccine, Influenza Other: No
840 NCT01431Seasonal Influenza VaCompletedNo ResultsSeasonal Influenza Vaccination Behavioral
841 NCT01359Study of Two Doses oCompletedHas ResultMeningitis|Meningococcal InfectionBiological
842 NCT02776A Single-blind Study Recruiting No ResultsHantaan Virus Biological
843 NCT03125Dose-Optimization TriCompletedNo ResultsNorovirus Gastroenteritis Biological
844 NCT01317Safety and Efficacy o CompletedNo ResultsSmallpox Drug: smal
845 NCT02115The Immunotherapy of CompletedNo ResultsNeoplasms, Lung Biological:
846 NCT02500The SafetyMER4101 Active, notNo ResultsInfluenza, Human Biological:
847 NCT02988Comparison of Laser A CompletedNo ResultsInfluenza in Human Biological:
848 NCT04041Ebola Sudan Chimpanz Active, notNo ResultsEbola Virus Biological
849 NCT01434Evaluating the Compar CompletedHas ResultMeningococcal Disease|Meningococc Biological
850 NCT03804Using "Decision Aids"Not yet recNo ResultsRotavirus Vaccines Other: Deci
851 NCT03391PolyPEPI10OBERTO Active, notNo ResultsColorectal Cancer Biological
852 NCT03572Preventive Effectiven CompletedNo ResultsHuman Influenza Biological:
853 NCT01111H1N1 Influenza VaccinCompletedHas ResultHIV Infections Biological:
854 NCT00703Ovarian Dendritic CellRecruiting No ResultsOvarian Cancer Biological:
855 NCT02692Safety and Immunogen CompletedNo ResultsMumps Biological:
856 NCT02547Vaccinatio VACINA Active, notNo ResultsRheumatoid Arthritis Biological
857 NCT01264Safe Admini SAFE CompletedHas ResultEgg Allergy Biological:
858 NCT03560CMV-MVA Triplex Vacc Recruiting No ResultsAccelerated Phase Chronic MyelogeBiological
859 NCT02074Safety Study of CanceCompletedNo ResultsNeoplasms, Pancreas Biological:
860 NCT03299Clinical Efficacy of Recruiting No ResultsTyphoid Biological
861 NCT01587DNA-based Influenza CompletedNo
V ResultsInfluenza, Human|OrthomyxoviridaeBiological
I
862 NCT01680A Randomized, Open-lCompletedHas ResultRabies Biological:
863 NCT00626Safety and Immune RCompletedHas ResultMeningococcal Infections Biologica
864 NCT00633Non-inferiority StudyCompletedHas ResultInfluenza Biological
865 NCT03682Andes Virus DNA Vacci Active, notNo ResultsHantavirus Pulmonary Infection|Im Biological
866 NCT03039Long-Term Immunogenic Active, notNo ResultsHealthy Volunteers|Norovirus Biological:
867 NCT01933Study of the Tdap Co CompletedHas ResultDiphtheria|Tetanus|Pertussis Biological
868 NCT01264Safety and Immunogeni CompletedNo ResultsHIV Infections Biological:
869 NCT01725Immunogenicity and SCompletedHas ResultMeningococcal Disease Biologica
870 NCT00734Safety of and ImmuneCompletedNo ResultsInfluenza|Virus Diseases Biological
871 NCT01461Quadrivalent HPV VacCompletedHas ResultHIV Infections Biological:
872 NCT03205Immunogenicity and SCompletedNo ResultsMeningitis, Meningococcal Biological
873 NCT02055Pilot Study: Gene ExpCompletedHas ResultHepatitis B Biological:
874 NCT01474Trivalent Influenza V CompletedNo ResultsCentral Nervous System Neoplasm Biological:
875 NCT02653Impact of Metabolic Terminate Has ResultImmune Deficiency|Metabolic Syn Biological:
876 NCT00746Safety andWinVax004CompletedHas ResultWest Nile Fever Biological
877 NCT01214Safety and Immunogen CompletedHas ResultMeningococcal Disease|Meningococc Biological
878 NCT01687Efficacy anSARCOVACCompletedNo ResultsSarcoidosis|Influenza Vaccine Drug: Seas
879 NCT02418Safety and Immunogeni CompletedNo ResultsMalaria|Plasmodium Falciparum Biological
880 NCT04051Immunogenicity and SActive, notNo ResultsVaccination Biological:
881 NCT01064A Study of Dengue Vac CompletedNo ResultsDengue Fever|Dengue HemorrhagicBiological:
882 NCT02038Immunogeni VRI01 CompletedNo ResultsHIV Infection Biological
883 NCT01148Evaluation of Menin CompletedHas ResultMeningococcal Meningitis Biological
884 NCT03988Neoepitope-based PerNot yet recNo ResultsPediatric Recurrent Brain Tumor Biological
885 NCT00815Immune Res HPV-kind CompletedNo ResultsJuvenile Idiopathic Arthritis|Syste Other: Hum
886 NCT03430Phase 1 NonOPV2M4aActive, notNo ResultsPoliomyelitis Biological:
887 NCT04142Tdap Vaccine Safety Recruiting No ResultsTetanus Biological:
888 NCT01390Study of Adolescent CompletedNo ResultsImmunization|Reminder Systems Other: Par
889 NCT02111Vaccine Therapy in TrActive, notNo ResultsFallopian Tube Clear Cell Adenocar Other: Labo
890 NCT01048The ClinicaIPV CompletedNo ResultsPoliomyelitis Biological:
891 NCT03346Study of Immune Resp Enrolling bNo ResultsInfluenza Vaccination Biological:
892 NCT02623Study of a Booster D CompletedHas ResultDengue Fever|Dengue HemorrhagicBiological
893 NCT01968Evaluating the Safety CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological:
894 NCT02583Pilot Study of the Im CompletedNo ResultsMeningococcal Serogroup B Biological:
895 NCT00343Comparison of DTaP-HCompletedHas ResultDiphtheria|Tetanus|Pertussis|HepatBiological:
896 NCT02937Zika Virus Z001 CompletedNo ResultsZika Biological:
897 NCT01945Sanofi Pasteur QuadriCompletedNo ResultsPregnancy|Influenza Biological:
898 NCT03023Gardasil 9 Vaccine in Recruiting No ResultsAllogeneic Hematopoietic Stem CellBiological
899 NCT02179DiphtheriaVacciPremUnknown sNo ResultsHib Immunisation in Very Preterm-bo Biological:
900 NCT03372Project IMPACT Immun CompletedNo ResultsInfluenza Biological
901 NCT00584Safety Evaluation of CompletedHas ResultQ Fever Biological
902 NCT01175Evaluation of the Saf CompletedNo ResultsInfluenza A Virus Infection Biological
903 NCT01246Effect of Age and Pri CompletedHas ResultInfluenza Biological:
904 NCT03445Increasing the Uptak CompletedNo ResultsImmunization Programs Other: Edu
905 NCT01273The Immunogenicity of CompletedNo ResultsHemodialysis Patients Biological:
906 NCT00402Open-Label Study of H CompletedHas ResultInfluenza Biological:
907 NCT03099Infectivity, Safety a CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological
908 NCT01290Turnover of Antigen Active, notNo ResultsYellow Fever Biological
909 NCT01911T Cell Responses to VCompletedHas ResultHerpes Zoster Biological:
910 NCT04122Immune Response toCompletedNo
I ResultsImmunology|Nephrology Biological:
911 NCT02451Study of a Single Dos CompletedHas ResultInfluenza Biological:
912 NCT02740Immunogenicity and SUnknown sNo ResultsHuman Papillomavirus Biological:
913 NCT00359Human Papillomavirus CompletedHas ResultInfections, Papillomavirus|PapillomaBiological:
914 NCT01388Simplifying the RabieCompletedHas ResultRabies Biological:
915 NCT00828Effects of PVA CompletedNo ResultsRheumatoid Arthritis|Spondylarthr Biological:
916 NCT02601Immunogenicity and Sa CompletedNo ResultsHepatitis A Biological:
917 NCT02509Staged PhaEBOVAC-SaCompletedNo ResultsEbola Virus Disease Biological
918 NCT02968Long Term Merck08 Active, notNo ResultsHuman Papillomavirus Biological
919 NCT00964CSL H1N1 Influenza VaWithdrawnNo ResultsInfluenza Biological:
920 NCT01069Open-label, UncontrolCompletedNo ResultsSwine-Origin Influenza A H1N1 VirusBiological:
921 NCT01019Efficacy and Safety o Unknown sNo ResultsInfluenza H1N1 Biological
922 NCT00994Safety, Im ETH-TVT CompletedNo ResultsMeningococcal Meningitis Biological
923 NCT03457OptimisingOPTIWIN Recruiting No ResultsObesity Biological:
924 NCT02602The Acceptability of CompletedNo ResultsVaccination
925 NCT01671Safety of Labeled DenCompletedNo ResultsColorectal Neoplasms|Colorectal CaBiological:
927 NCT00907Vaccination With GS CompletedHas ResultInfections, Streptococcal|Streptoc Biological
928 NCT01633Annual Study to InvesCompletedNo ResultsProphylaxis of Influenza Biological:
929 NCT03771Immunogenicity and Sa Active, notNo ResultsDengue Fever Biological
930 NCT01894Antibody Persistence,CompletedHas ResultMeningoccocal Disease|Meningococc Biological
931 NCT01014Clinical Trial of Reco Unknown sNo ResultsHepatitis E Biological:
932 NCT01707Prenatal Education A CompletedNo ResultsImmunization Behavioral
933 NCT03109Safety and Immunogeni CompletedNo ResultsSafety Issues Biological:
934 NCT00825Safety and Immunogeni CompletedHas ResultRabies Biological
935 NCT01000Rapid Evaluation of CompletedNo ResultsInfluenza Biological:
936 NCT00097Safety, Tolerability CompletedNo ResultsPneumonic Plague|Preventive Ther Biological:
937 NCT02010OptimizingOASIS CompletedNo ResultsIncrease in Use of Immunization RegOther: Rem
938 NCT01568Electronic MessagingCompletedNo ResultsPatient Compliance|Health Knowledge Procedure:
939 NCT00601Canadian Manufacture CompletedHas ResultDiphtheria|Tetanus Biological:
940 NCT01000Single-blind, Dose-ra CompletedNo ResultsSwine-Origin Influenza A H1N1 VirusBiological:
941 NCT01622Multiple Antigen-EngCompletedNo ResultsMelanoma Biological
942 NCT00888A Study to Assess theCompletedHas ResultInfluenza Biological:
943 NCT00316Safety and Immunogeni CompletedNo ResultsInfluenza Disease Biological:
944 NCT03962Immunogenicity and PNot yet recNo ResultsHepatitis B Vaccine Biological:
946 NCT02584Phase III Study on Ro CompletedNo ResultsRotavirus Gastroenteritis Biological
947 NCT03068Neoepitope-based PerNot yet recNo ResultsPediatric Brain Tumor Biological
948 NCT01688Jet Injecti JIFI CompletedHas ResultInfluenza, Human Biological:
949 NCT01245Safety, Tolerability, CompletedHas ResultHerpes Zoster|Varicella-zoster Vacc Biological:
950 NCT02712MMR and MMRV Vaccine Unknown sNo ResultsMeasles Biological
951 NCT01254An InterveHPV CompletedHas ResultCervical Cancer Behavioral:
952 NCT01147Active Immunotherapy CompletedNo ResultsColon Cancer|Lung Cancer|Breast CBiological
953 NCT01097Effect of H1N1ChildWithdrawnNo Results2009 H1N1 Influenza Biological
954 NCT01737Atopic Dermatitis Re CompletedHas ResultDermatitis, Atopic Biological:
955 NCT03071Measles-Rubella VaccUnknown sNo ResultsMeasles|Rubella|Rubella Syndrome,Biological
956 NCT02474Shedding, QLAIV CompletedHas ResultHuman Immunodeficiency Virus (HI Biological:
957 NCT00579Second Extension Stud CompletedHas ResultInfluenza Biological:
958 NCT01082ImmunizatiSPZ-Irrad CompletedNo ResultsMalaria Biological:
959 NCT00313Combined Modality TrCompletedNo ResultsMalignant Melanoma Stage IV Biological
960 NCT04083A Randomized, BlindeRecruiting No ResultsHPV Infection|HPV-Related Cervical Biological
961 NCT02993State Immunization I Active, notNo ResultsVaccine|Human Papiloma Virus VaccOther: Vac
962 NCT00946Study of Influenza VaCompletedNo ResultsInfluenza Biological:
963 NCT00244A Randomiz UFO VAX CompletedHas ResultMedication Adherence|Substance Abu Biological:
964 NCT03028Reactogenic VSI CompletedNo ResultsInfluenza, Human Biological:
966 NCT00436Interferon as a MucosCompletedHas ResultInfluenza Biological:
967 NCT00857MRKAd5 HIV-1 Gag Vac CompletedHas ResultHepatitis C Biological
968 NCT00984Safety Study of a PlanCompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological
969 NCT02256Safety and Immunogeni CompletedHas ResultProphylaxis: Influenza Biological:
970 NCT00938EvaluationMEL39 CompletedNo ResultsMelanoma Biological
971 NCT02640Safety of a MeningocoCompletedHas ResultMeningitis|Meningococcal MeningitBiological
972 NCT03104AssessmentFlushed CompletedNo ResultsInfluenza Vaccination|Influenza|VacBiological:
973 NCT03873Immunogenicity and SCompletedNo ResultsHand, Foot and Mouth Disease Biological
974 NCT01702Derivation of Tumor Terminate No ResultsGlioblastoma Biological
975 NCT00474A Study to Evaluate CompletedHas ResultMeningococcal Meningitis|Meningoc Biological
976 NCT00968Immunogenicity and SCompletedHas ResultInfluenza Biological:
977 NCT00853Group Study of the SaCompletedNo ResultsInfluenza|Virus Diseases Biological
978 NCT02761Centralized IIS-based CompletedNo ResultsReminder Systems|Influenza Vaccin Behavioral:
979 NCT03557Systems Biology of InRecruiting No ResultsRabies Human Biological
980 NCT02726Cardio-respiratory E CompletedHas ResultComplication Due to Immunization Drug: Advil
981 NCT04047Systems Biology of ZoRecruiting No ResultsZoster|Zoster Varicella|Shingles|ChBiological:
982 NCT03917Pfs230D1M-EPA/AS01Recruiting
Va No ResultsMalaria Biological
983 NCT01923TherapeutiVACCAIN-TCompletedNo ResultsAnal Intraepithelial Neoplasia|HIV Drug: HPV-
984 NCT00474Study Evaluating a 13CompletedHas ResultVaccines, Pneumococcal Biological
985 NCT00657A Phase I, Randomized CompletedNo ResultsInvasive Group B Streptococcus (GBSBiological
986 NCT03555A Phase 3 Lot-consisteCompletedNo ResultsVaricella Biological:
987 NCT00402Improving the Humoral CompletedNo ResultsLung Transplantation|Influenza VaccBiological:
988 NCT00885Evaluation of Respon CompletedHas ResultInfluenza Biological:
989 NCT01764A Phase 1 Dose EscalaCompletedHas ResultRotavirus Infection Biological:
990 NCT01002Influenza VaccinationUnknown sNo ResultsInfluenza Vaccine in Scleroderma Biological:
991 NCT01411Study of a Booster In CompletedHas ResultDengue|Dengue Hemorrhagic FeverBiological:
992 NCT01784Comparison of Purifi CompletedNo ResultsRabies Biological:
993 NCT02114Comparison of a Live Active, notNo ResultsShingles|Herpes Zoster Biological:
994 NCT01948Study of DTaP-IPV-Hep CompletedHas ResultDiphtheria|Tetanus|Whooping Cough| Biological
995 NCT01060Safety and Efficacy S CompletedNo ResultsDiarrhea Biological:
996 NCT01412Vaccine+HBIG VersusCompletedNo ResultsChronic Hepatitis B Drug: Vacc
997 NCT00516Single Group Study ofCompletedNo ResultsInfluenza|Virus Diseases Biological
998 NCT02151Impact of Influenza VCompletedNo ResultsInfluenza Behavioral
999 NCT02556Efficacy of an Oral, K CompletedNo ResultsDiarrhea Biological
1000 NCT02494A Phase III Clinical T Unknown sNo ResultsPneumonia Biological
1001 NCT03776VenezuelanVEEV Recruiting No ResultsEncephalitis|Encephalitis, Viral|In Biological:
1002 NCT01410Immunogenicity and SCompletedHas ResultBacterial Meningitis Biological
1003 NCT02747Efficacy, TIDES Active, notNo ResultsHealthy Volunteers Biological
1004 NCT02123Serologica PCV13HIV2CompletedNo ResultsHIV Infection|Pneumococcal Infecti Biological
1005 NCT03180Vaccines I COVAGREFRecruiting No ResultsTransplantation Biological
1006 NCT04265OptimizingOPTIMO Not yet recNo ResultsHPV Vaccination|HIV Infected Child Biological:
1007 NCT01008Sinovac, H1N1 Vaccine CompletedNo ResultsInfluenza Biological:
1008 NCT00943CSL H1N1 Influenza VaCompletedHas ResultInfluenza Biological:
1009 NCT02213Influenza VaccinationTerminate No ResultsCancer Biological:
1010 NCT00607The Efficacy of Influ CompletedNo ResultsCoronary Artery Diseases|MyocardiaBiological:
1011 NCT00872An ExtendeMAL059 Unknown sNo ResultsMalaria Biological
1012 NCT01306Influenza MatluHIV CompletedNo ResultsInfluenza Biological:
1013 NCT01879Safety and Immunogen CompletedHas ResultHuman Influenza Biological:
1014 NCT00580Study Comparing PrevCompletedNo ResultsVaccines, Pneumococcal|Vaccines, Biological
1015 NCT01033Immunogenicity and SCompletedNo ResultsHealthy Biological:
1016 NCT04171RetrospectVENUS Recruiting No ResultsCervix, Dysplasia|HPV Infection|HPVDrug: HPV
1017 NCT03832HPV VaccinHPV Recruiting No ResultsHuman Papillomavirus Vaccine Biological:
1018 NCT00906A Study of FMRESP CompletedNo ResultsCancer Biological:
1019 NCT03284Vaccination In PregnaUnknown sNo ResultsPregnancy Related|Vaccination Biological:
1020 NCT02529ADITEC FLU 2 STUDY: Active, notNo ResultsInfluenza Biological:
1021 NCT00778Immunogenicity and To CompletedNo ResultsInfluenza Biological:
1022 NCT01189A Clinical Study on T Unknown sNo ResultsChronic Hepatitis B Patients With H Biological
1023 NCT00915Safety and Immunogeni CompletedNo ResultsInfluenza Drug: CCS/C
1024 NCT01452Safety Surveillance CompletedNo ResultsMeningococcal Disease Biologica
1026 NCT01468Two Schedules of Hepat CompletedNo ResultsRenal Failure Biological:
1027 NCT00125Evaluation of the Vi CompletedNo ResultsTyphoid|Paratyphoid Fever Biological:
1028 NCT00988Safety andRBM99026CompletedNo ResultsChronic Hepatitis B Biological
1029 NCT02880Immunogeni JEV06 CompletedNo ResultsEncephalitis, Japanese|Measles|M Biological
1030 NCT01770Induction oMMRinOLTUnknown sNo ResultsMeasles Biological
1031 NCT00760A Study to Evaluate SCompletedNo ResultsVibrio Cholerae Biological:
1032 NCT01265WT-1 Analog Peptide CompletedNo ResultsMalignant Pleural Mesothelioma Biological
1033 NCT02711Safety of RUTIÂ® Vac Not yet recNo ResultsTuberculosis, Multidrug Resistant Biological
1034 NCT03410Vaccination Adjuved ACompletedNo ResultsHepatitis B|Hepatitis|Hepatitis, Vi Biological:
1035 NCT00559Safety, Tolerability, CompletedNo ResultsInfluenza Infection Biological
1036 NCT01407Tolerability and Imm CompletedNo ResultsNovel 2009 Influenza H1N1|Influen Biological:
1037 NCT00310Safety, Tolerability CompletedNo ResultsMeningococcal Infection Biological
1038 NCT01168Bivalent Norovirus VaCompletedHas ResultGastroenteritis Biological:
1039 NCT00482Safety andA001 CompletedNo ResultsHIV Infection Biological
1040 NCT01385Educational Interven CompletedNo ResultsVaccine Hesitancy Other: Vid
1042 NCT00911Bivalent Vaccine WithRecruiting No ResultsNeuroblastoma Biological:
1043 NCT02529NivolumabAVERT Active, notNo ResultsMalignant Glioma|Astrocytoma|Gli Drug: nivo
1044 NCT00460Phase II AMA-1 MalarCompletedHas ResultPlasmodium Falciparum Malaria Biological
1045 NCT01376Evaluating the Safety CompletedNo ResultsHIV Infections Biological
1046 NCT04015Neoantigen-based PerNot yet recNo ResultsGlioblastoma Biological
1047 NCT01764Pneumococc PPR02 CompletedNo ResultsAdverse Effects Drug: Pneu
1048 NCT02324Vaccines AVAST Unknown sNo ResultsTyphoid Fever|Enteric Fever Biological:
1049 NCT01954Antibody Response ofUnknown sNo ResultsJapanese Encephalitis Biological:
1050 NCT00175Optimizing Hepatitis CompletedNo ResultsHepatitis B Biological:
1051 NCT01150Phase II Tularemia V CompletedNo ResultsTularaemia Other: Plac
1052 NCT00444Study Evaluating 13-vCompletedHas ResultVaccines, Pneumococcal Biological
1053 NCT01034Field Trial Mothers'GiUnknown sNo ResultsInfluenza Human Biological:
1054 NCT00504Intradermal InfluenzaCompletedHas ResultInfluenza Biological:
1055 NCT00518A Study to Evaluate CompletedHas ResultMeningococcal Meningitis|Human Pap Biological
1057 NCT00963Sanofi H1N1 InfluenzaCompletedHas ResultInfluenza Drug: AS03
1058 NCT00808Primary Vaccination CompletedHas ResultInfections, Streptococcal Biological:
1059 NCT01732Study of a Quadrival CompletedNo ResultsMeningitis|Meningococcal MeningitBiological
1060 NCT03149Accelerated Vaccinat CompletedNo ResultsHepatitis B|Hemodialysis ComplicatDrug: Hepat
1061 NCT00230Inactivated Influenza CompletedNo ResultsInfluenza Biological
1062 NCT00923Trial of Two Versus T Active, notNo ResultsCervical Cancer|Cervical PrecanceroBiological:
1063 NCT01432Seasonal Influenza VaUnknown sNo ResultsInfluenza|Influenza Like Illness|SeveBiological:
1064 NCT00332Title: Recombinant PlCompletedNo ResultsHealthy Volunteers Biological:
1065 NCT03365A Phase â…£ Clinical TWithdrawnNo ResultsHepatitis E Biological:
1066 NCT04096Combination of PD-1 Recruiting No ResultsUterine Cervical Neoplasms|CervicaDrug: Sint
1067 NCT01482Safety Study of GroupCompletedNo ResultsMeningococcal Meningitis|Meningoc Biological:
1068 NCT01134Study of a Tetravalen CompletedHas ResultDengue Fever|Dengue HemorrhagicBiological:
1069 NCT03337Effectiveness of Targ CompletedNo ResultsHPV-Related Cervical Carcinoma Other: Edu
1070 NCT02281The Safety Research CompletedNo ResultsRabies|Healthy Biological:
1071 NCT01961Study of ASP7374, CelCompletedNo ResultsInfluenza|Vaccine Biological
1072 NCT02480Reactogenicity, Safet CompletedNo ResultsInfluenza Biological:
1073 NCT02613Safety and Immunogeni CompletedNo ResultsMalaria Biological:
1075 NCT00308Safety Study of CandiCompletedHas ResultMalaria Biological
1076 NCT01827Immunogenicity and Sa CompletedHas ResultHerpes Zoster Biological
1077 NCT02685Safety, Tolerability CompletedNo ResultsHealthy Biological
1078 NCT00561Phase IV Trial to Col CompletedHas ResultInfluenza Biological:
1079 NCT02580A Study to T2-ABMG CompletedNo ResultsPoliomyelitis Biological:
1080 NCT02482Baby Vaccine Study ( Active, notNo ResultsInfectious Diseases Biological
1081 NCT03796Assessing Barriers an CompletedNo ResultsImmunization Behavioral:
1082 NCT03462Safety and Immunogeni CompletedNo ResultsSafety Issues Biological:
1083 NCT01193Safety and Immunogen CompletedHas ResultStreptococcal Infections Biological:
1084 NCT01364Safety and ImmunogeCompletedNo ResultsMalaria Biological:
1085 NCT01187Study of CYD DengueCompletedHas ResultDengue|Dengue Hemorrhagic FeverBiological:
1086 NCT00500Chiron Corp HCV E1/ECompletedNo ResultsHepatitis C Biological
1087 NCT02771Study to Evaluate theActive, notNo ResultsHealthy Volunteer|HIV Vaccine Biological
1088 NCT01547Immunogenicity and SCompletedHas ResultBacterial Meningitis Biological
1089 NCT01030Booster and Catch-upCompletedHas ResultInfections, Streptococcal Biological
1090 NCT03460Evaluation of a RecomCompletedNo ResultsInfluenza, Human Biological:
1091 NCT00014Vaccine Therapy in TrTerminate No ResultsKidney Cancer Biological:
1092 NCT00665Pilot Trial of a WT-1 CompletedHas ResultLeukemia Biological
1093 NCT01489Preparedness Study -CompletedHas ResultSexual Transmission of Infection Biological:
1094 NCT03702Response to the SHING Recruiting No ResultsSafety and Tolerability|Compare SH Biological
1095 NCT02266System Alignment forCompletedHas ResultInfluenza|Infections, PneumococcalOther: Arm
1096 NCT01505Efficacy Study of Pne CompletedNo ResultsCrohn's Disease Drug: 23-v
1097 NCT04029Neovac 2 Bu NEOVAC2BNot yet recNo ResultsHepatitis B Biological:
1098 NCT01352A Global Phase 3 SafeCompletedHas ResultMeningitis, Meningococcal Biological:
1099 NCT02126Safety and Immunogen CompletedNo ResultsHookworm Infection|Hookworm DisBiological
1100 NCT03824High and Low ResourcEnrolling bNo ResultsHuman Papilloma Virus|Tdap - TetanBehavioral
1101 NCT02075Consistency, Immunog CompletedHas ResultHerpes Zoster Biological
1102 NCT02587Clinical Study to Eva CompletedNo ResultsInfluenza Biological
1103 NCT01376Phase I Dose Escalat WithdrawnNo ResultsSARS Drug: Alum
1104 NCT02173Safety and Immunogen CompletedHas ResultMeningococcal Disease Biological:
1106 NCT00373Study Comparing 13-vCompletedHas ResultVaccines, Pneumococcal Biological
1107 NCT01640MenPF-1 - A New Vacc Active, notNo ResultsSerogroup B Meningococcal DiseaseBiological
1108 NCT00094Safety of and ImmuneCompletedNo ResultsDengue Fever Biological
1109 NCT00119Safety and Immunogeni CompletedNo ResultsCholera Biological:
1110 NCT01992Phase 2, Observer-Bl CompletedHas ResultMeningococcal Disease Biologica
1111 NCT00697Immunogenicity and Sa CompletedNo ResultsHepatitis B Biological
1112 NCT00186A Study to Assess theRecruiting No ResultsParainfluenza|Respiratory Viral Infe Biological:
1113 NCT01867Salvage Ovarian FANGCompletedHas ResultStage III Ovarian Cancer|Stage IV O Biological
1114 NCT01964Clinical Study to Eva CompletedNo ResultsInfluenza Virus Biological:
1115 NCT01651Multivalent HPV (HumCompletedHas ResultGenital Warts|Anal Cancer|Anal IntrBiological
1116 NCT01928Dose-finding Study ofCompletedHas ResultH7N9 Influenza Biological
1117 NCT03853Efficacy of Intralesi Not yet recNo ResultsCondylomata Acuminata Biological
1118 NCT03020Kinetics of SLVP016 Terminate Has ResultInfluenza Biological:
1119 NCT01268A Study to Evaluate CompletedNo ResultsEnterovirus Infection Biological:
1120 NCT02649Influenza Virus Vacci CompletedHas ResultHealthy Participants Biological
1121 NCT00309Study to Evaluate th CompletedNo ResultsInfluenza Biological
1122 NCT01394Immunologic Response CompletedNo ResultsLymphoma|Multiple Myeloma|Myelop Biological
1123 NCT01554Clinical Trial of Inac CompletedNo ResultsInfluenza Biological:
1124 NCT02434Study of the Immunoge Unknown sNo ResultsInfluenza Biological
1125 NCT00890Autologousrcc Unknown sNo ResultsRenal Cell Cancer Biological:
1126 NCT02370AFIX to Im AFIX CompletedNo ResultsPapillomavirus Vaccines|AdolescentOther: AFI
1127 NCT00269Study to Evaluate a 1 CompletedNo ResultsVaccines, Pneumococcal Conjugate Biological
1128 NCT04270A Phase Ib Study of Not yet recNo ResultsRabies Biological
1129 NCT01898Modified Melanoma Va Recruiting No ResultsMalignant Melanoma Biological
1131 NCT02868Phase 1 Placebo-contrCompletedNo ResultsNorovirus Gastroenteritis Biological
1132 NCT00345Purified Rabies Vacci CompletedNo ResultsRabies Post-exposure Prophylaxis Biological:
1133 NCT04054Vaccine Response WitNot yet recNo ResultsBreast Carcinoma|Colorectal Aden Biological
1134 NCT01233Real-time Influenza VCompletedNo ResultsVaccine Safety Other: Tex
1135 NCT00799Vaccination of Patie Active, notNo ResultsOvarian Cancer|Primary Peritoneal Drug: GM-C
1136 NCT02062Study of Evaluating S CompletedNo ResultsPneumococcal Infection|Influenza Biological:
1137 NCT03637An Improvement Proje CompletedNo ResultsInfluenza Vaccination Other: Com
1138 NCT00714Immunogenicity and Sa CompletedHas ResultInfluenza Biological:
1139 NCT02475Serologic Assay ValidaCompletedHas ResultNorovirus|Healthy Participants Biological:
1140 NCT03183FLUAD vs. Fluzone Hi CompletedNo ResultsPain|Quality of Life|Injection Site Biological
1141 NCT03321Lot-to-lot ConsistencyCompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological:
1142 NCT00806Study to Evaluate th CompletedHas ResultMeningitis|Meningococcal InfectionBiological:
1143 NCT01825Improving Rotavirus CompletedNo ResultsHealthy Infants|Mothers Biological:
1144 NCT01824Transmissi TRAP-HPV Recruiting No ResultsHuman Papillomavirus Infection Biological:
1145 NCT01430Study of Sanofi PasteCompletedHas ResultMeningococcal Disease|Meningitis Biological
1146 NCT02457The SafetyCUTHIVTHCompletedNo ResultsHIV Biological
1147 NCT03031African-Canadian StudUnknown sNo ResultsEbola Biological
1148 NCT01318A Fmri Stu EPU057 CompletedNo ResultsNicotine Dependency|Smoking Biological:
1149 NCT01561Cholecalciferol and FlTerminate No ResultsHealthy, no Evidence of Disease Dietary Sup
1150 NCT02564Evaluating the Safet CompletedNo ResultsHemorrhagic Fever, Ebola Biological
1151 NCT02432Intensive Locoregion Active, notNo ResultsCancer of Ovary|Cancer of the Ova Biological:
1152 NCT03478AdherenceAVADI-1
t CompletedNo ResultsType 1 Diabetes Mellitus Biological:
1153 NCT01214Study of PENTAXIMâ„¢ CompletedNo ResultsDiphtheria|Tetanus|Pertussis|Polio Biological
1154 NCT03428TimelinessTICA CompletedNo ResultsVaccinations Behavioral
1155 NCT01065Vaccinatio MAIVAX CompletedNo ResultsAutoimmune Diseases Biological:
1156 NCT023473 Adjuvated ReducedCompletedNo
D ResultsPoliomyelitis Biological:
1157 NCT01941High-Dose Trivalent CompletedNo ResultsCentral Nervous System Neoplasm Biological:
1158 NCT00788Study of ChimeriVaxâ„CompletedHas ResultDengue Virus|Dengue Fever|Dengue Biological
1159 NCT00537Safety of and ImmuneCompletedNo ResultsWest Nile Fever Biological
1160 NCT00699Safety of a Herpes Si CompletedNo ResultsHerpes Simplex Biological
1161 NCT01427A Study of FluzoneÂ®CompletedHas ResultInfluenza Biological:
1162 NCT03797Mobile NudGEVaP Recruiting No ResultsImmunization Coverage Behavioral
1163 NCT02289A Clinical Trial on t CompletedNo ResultsEbola Vaccines Biological
1164 NCT01993Sanofi Pasteur's TdapCompletedNo ResultsDiphtheria|Tetanus|Pertussis Biological
1165 NCT03999Safety and Immunogen Recruiting No ResultsInfluenza A Biological
1166 NCT01761Clinical Tr TraNsgripeCompletedNo ResultsInfection in Solid Organ Transplant RBiological:
1167 NCT00961Evaluation of a SchooCompletedNo ResultsInfluenza|Influenza Vaccines Biological:
1168 NCT00500Study Evaluating a 13CompletedHas ResultVaccines, Pneumococcal Conjugate Biological
1169 NCT01154Study to Evaluate theCompletedNo ResultsSchistosomiasis Biological
1170 NCT00624Safety and Immunogen Terminate No ResultsCholera|Diarrhea|Vibrio Infections Biological:
1171 NCT00391Immunogenicity of Hig CompletedHas ResultOrthomyxoviridae Infection|InfluenBiological:
1172 NCT01944Impact andPPVP CompletedHas ResultStudy is Open to Seniors Age 50 or Behavioral
1173 NCT02287Meningococcal Quadri CompletedHas ResultMeningococcal Disease|Infections, Biological
1174 NCT02810Study of MeninigococCompletedNo ResultsMeningococcal Vaccines Biological
1176 NCT04236UltrasoundSIRVA CompletedNo ResultsShoulder Injury Related to Vaccine ADiagnostic
1177 NCT00131Typhoid Vi Vaccine EfCompletedNo ResultsTyphoid|Paratyphoid Fever Biological:
1179 NCT01800A Phase Ib Trial of CompletedNo ResultsNasopharyngeal Cancer|Epstein BarrDrug: MVA
1180 NCT03472Safety and Immunogen CompletedNo ResultsAvian Influenza|Influenza ImmunisaOther: Aqu
1181 NCT01550Study of a Tetravalen CompletedHas ResultDengue|Dengue Fever|Dengue Hemo Biological:
1182 NCT02890Evaluating LID Terminate Has ResultRespiratory Syncytial Virus InfectionBiological:
1183 NCT01110Tetravalent Chimeric CompletedNo ResultsDengue Drug: Place
1184 NCT03888Response tFLU-PG Recruiting No ResultsInfluenza Biological:
1185 NCT02684Evaluation of the Sa CompletedNo ResultsDengue Biological
1186 NCT02121A Phase I/IIa Study o CompletedNo ResultsInfluenza Biological:
1187 NCT02762Clinical Trial of Rec Unknown sNo ResultsAcquired Immunodeficiency Syndr Biological:
1188 NCT04017Application of a TBE- Active, notNo ResultsTick Borne Encephalitis Drug: FSM
1189 NCT01577Adolescent VaccinatioCompletedNo ResultsImmunization Rate Behavioral
1190 NCT02794Evaluating the Infect CompletedHas ResultRespiratory Syncytial Virus InfectionBiological:
1191 NCT02788Immunogenicity of Rec Enrolling bNo ResultsHealthy Volunteers Biological
1192 NCT04274HPV VaccinPPV Not yet recNo ResultsHPV|Immunization|Human PapillomBiological:
1193 NCT01042Vaccine Therapy and 1CompletedHas ResultMale Breast Cancer|Recurrent Breast Biological
1194 NCT02236Immunogenicity, SafetCompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological
1195 NCT02143A Phase IIILAIV ImmuCompletedNo ResultsLive Attenuated Influenza Vaccine Drug: Flue
1196 NCT01982Immune Persistence Af Unknown sNo ResultsChickenpox Biological:
1197 NCT02551HPV Vaccination: An CompletedHas ResultHuman Papilloma Virus Infection Ty Behavioral
1198 NCT01777Immunogenicity, ReacCompletedHas ResultInfections, Meningococcal Biological
1199 NCT01994Safety and Immunogen CompletedHas ResultMeningococcal Disease Biologica
1200 NCT00890Evaluation immunisatUnknown sNo ResultsTick Borne Encephalitis Biological
1201 NCT00139Immunogenicity Study CompletedNo ResultsHepatitis A Biological:
1202 NCT00101Universal Granulocyt CompletedHas ResultMelanoma (Skin) Biological
1203 NCT03680Reactogenicity and PrCompletedNo ResultsSafety Issues|Immunogenicity Biological
1204 NCT01512Immunogenicity and Sa Unknown sNo ResultsInfluenza Drug: Adim
1205 NCT02964A Trial on the Effica CompletedNo ResultsInfluenza Biological:
1206 NCT00886A Study to Evaluate I CompletedHas ResultHerpes Zoster Biological
1208 NCT01044Study of I Rabies-ID CompletedNo ResultsRabies Prevention|Rabies Exposure Biological:
1209 NCT01129Can we RedMALTA CompletedNo ResultsInvasive Meningococcal Disease Biological
1210 NCT01508Effectiveness of a Bi Unknown sNo ResultsCholera
1211 NCT00342Safety and Immunogen WithdrawnNo ResultsInfluenza Biological:
1212 NCT00311Safety and Immunogen CompletedNo ResultsPandemic Influenza Disease Biological
1213 NCT03354Multi-antigen CMV-Mod Recruiting No ResultsCytomegaloviral Infection|Hematopoi Other: Lab
1214 NCT03867Efficacy of Hepatitis Not yet recNo ResultsHepatitis B Vaccine Adverse Reaction
1215 NCT01223Polyvalent Vaccine-K CompletedHas ResultFallopian Tubes Cancer|Ovarian CanBiological
1216 NCT01906A Post-marketing SafetCompletedNo ResultsInfluenza|Vaccination Adverse Event
1217 NCT00981Rotavirus Vaccine ProCompletedHas ResultRotavirus Infections Biological:
1218 NCT02447A Study to Compare tCompletedHas ResultInfections, Streptococcal Biological
1219 NCT01044Study in Infants (6-1 CompletedNo ResultsHaemophilus Influenzae Type b (Hib)Biological:
1220 NCT01641Comparison of GlaxoSCompletedHas ResultInfections, Meningococcal Biological
1221 NCT00514Immunogenicity Study CompletedHas ResultDiphtheria|Tetanus|Pertussis|HepatiBiological
1222 NCT02835Mobile Health Interv CompletedNo ResultsHealthy Subject Other: Edu
1223 NCT03705ImmunizatiISAP Not yet recNo ResultsImmunization Behavioral
1224 NCT02485Analysis of Bone MarRecruiting No ResultsInfluenza|Influenza Immunisation Biological:
1225 NCT01821New Methods to Meas CompletedNo ResultsHepatitis B Drug: Hepat
1226 NCT04042Effect of Knowledge Not yet recNo ResultsImmunization; Infection|EducationaBehavioral:
1227 NCT01486Additional Measles VUnknown sNo ResultsMeasles Infection Biological:
1228 NCT01697Polio NID and RoutineCompletedNo ResultsPolio Behavioral:
1229 NCT02408Vaccine Responses inCompletedNo ResultsPertussis Biological:
1230 NCT03498Seroprevalence of BorCompletedNo ResultsPertussis|Pregnancy Related Biological:
1231 NCT01164Detoxified J5 Core G Terminate No ResultsBacterial Sepsis Biological
1232 NCT02742Safety and Immunogen CompletedNo ResultsCholera Biological:
1233 NCT03438Multi-antigen CMV-Mo WithdrawnNo ResultsAccelerated Phase Chronic MyelogeBiological
1234 NCT00920Safety and Immune RCompletedNo ResultsDengue Fever Biological
1235 NCT02872Open-LabelOLIVE CompletedHas ResultImmune Response Biological:
1236 NCT02378STRIVE (SieSTRIVE CompletedHas ResultHemorrhagic Fever, Ebola Biological
1237 NCT02157Vaccine Therapy in TrRecruiting No ResultsHER2/Neu Negative|Recurrent BreastBiological
1238 NCT00868Study of a PANFLUVACompletedHas ResultInfluenza|Healthy Biological:
1239 NCT00442Reduced Intensity SteActive, notNo ResultsChronic Lymphocytic Leukemia Biological
1240 NCT03736Resistance Exercise t Active, notNo ResultsInfluenza, Human Behavioral:
1241 NCT01855Safety and Immunogeni CompletedHas ResultProphylaxis of A/H3N2v Influenza Biological:
1243 NCT04078An EvaluatPAVE Not yet recNo Results13-valent Pneumococcal Vaccine|S Other: nas
1244 NCT01405Understanding TyphoiActive, notNo ResultsTyphoid Fever|Enteric Fever|TyphoiBiological:
1245 NCT01653Live Versus InactivateCompletedNo ResultsInfluenza Biological:
1246 NCT011732010-2011 Trivalent CompletedHas ResultInfluenza Biological:
1247 NCT00310H5N1 Vaccine IntramuCompletedNo ResultsInfluenza Biological:
1248 NCT02643Immunogeni MR+JE CompletedNo ResultsMeasles|Rubella|Japanese EncephalBiological:
1249 NCT03191Vaccine ExEnquÃªte VCompletedNo ResultsMultiple Sclerosis Other: Aut
1250 NCT02584Project IMPACT Immun CompletedNo ResultsInfluenza Biological
1252 NCT03971Immunogenicity and Sa CompletedNo ResultsAdverse Effect and Immunogenicity Biological:
1253 NCT00278Vaccine Therapy For PTerminate Has ResultLymphoproliferative Disorder Biological:
1254 NCT00514Non-Inferiority of M CompletedHas ResultInfections, Meningococcal Biological
1255 NCT01902Dendritic Cell Vaccin Terminate No ResultsGlioma|Brain Cancer|Brain Tumor|GBiological
1256 NCT00959A Study to DetermineCompletedHas ResultInfluenza Biological:
1257 NCT02572Immunity AIATDYFV CompletedNo ResultsYellow Fever
1258 NCT01096Blockade of PD-1 in Active, notNo ResultsAcute Myelogenous Leukemia|AMLBiological
1259 NCT03893AMPLIFYingAMPLIFY- Recruiting No ResultsMalignant Glioma Drug: IDH1
1260 NCT02661Long-term Safety Fol Active, notNo ResultsHemorrhagic Fever, Ebola Biological
1261 NCT01197Vaccine Therapy in CuActive, notNo ResultsProstate Cancer Biological:
1262 NCT02275Study to Investigate CompletedNo ResultsMultiple Sclerosis, Relapsing-RemittBiological:
1263 NCT00012Vaccine Therapy in TrCompletedNo ResultsMelanoma (Skin) Biological:
1264 NCT04236Safety Evaluation of CompletedNo ResultsMeningococcal Infections Biological
1265 NCT03897Safety & I VXA-NVV-1Recruiting No ResultsNorovirus Infection Biological
1266 NCT02728Safety, ReaHSRV CompletedNo ResultsRotavirus Gastroenteritis Biological:
1267 NCT00765Clinical Study of the CompletedHas ResultInfluenza Biological:
1268 NCT03574A Study Assessing 13 Recruiting No ResultsPneumococcal Infections|Pneumococ Biological:
1269 NCT04071A STUDY OF A RSV Recruiting No ResultsRespiratory Tract Infection Biological:
1270 NCT01158VA-006 Vaccinia Vacc CompletedHas ResultSmallpox Vaccine Adverse Reaction Biological
1271 NCT00883Influenza Vaccine in CompletedNo ResultsInfluenza With Pneumonia, InfluenzaBiological:
1272 NCT00369Safety Study Of Nasa Terminate No ResultsHIV Infections Biological
1273 NCT01319Flu Vaccine Against CompletedNo ResultsPneumonia|Laboratory Confirmed IBiological:
1274 NCT00205Influenza Vaccine in CompletedNo ResultsInfluenza Drug: Influ
1275 NCT03993Solid Organ Transpla Recruiting No ResultsKidney Transplant; Complications Biological
1276 NCT01406Safety of A Group A, CompletedNo ResultsHealthy Biological:
1277 NCT01617Clinical Study for Sa CompletedNo ResultsInfluenza Biological:
1278 NCT00309Evaluation of the ImmCompletedHas ResultInfections, Papillomavirus Biological:
1279 NCT02851Survivin Vaccine : M Recruiting No ResultsMultiple Myeloma Biological
1280 NCT00954A Study of Swine-origCompletedNo ResultsInfluenza|Swine-origin A/H1N1 Infl Biological:
1281 NCT00387Safety and Long-termCompletedNo ResultsTick Born Encephalitis Biological:
1282 NCT00667Safety and Immunogen CompletedHas ResultMeningococcal Meningitis Biological
1283 NCT03998Immunogenicity of ChRecruiting No ResultsCholera|Inflammatory Bowel DiseasBiological:
1284 NCT02898P3+ Intervention Pha Active, notNo ResultsVaccination Behavioral:
1285 NCT01959Safety, Reactogenici CompletedHas ResultInfluenza Biological:
1287 NCT04224Immunogeni PLAT Not yet recNo ResultsPreventive Immunization; MeningitiBiological
1288 NCT00310Immunogenicity, SafeCompletedNo ResultsPrevention of Meningococcal Infect Biological
1289 NCT03119Autologous Dendritic CompletedHas ResultHepatitis C, Chronic|Liver Diseases|Biological
1290 NCT03531Safety andVEE Not yet recNo ResultsVenezuelan Equine EncephalomyelitBiological:
1291 NCT00875Study of ChimeriVaxâ„CompletedHas ResultDengue Virus|Dengue Fever|Dengue Biological:
1292 NCT00755Safety and Immunogen CompletedNo ResultsInfluenza A Subtype H5N1 Infection Biological:
1294 NCT00677Safety and Immunogen CompletedNo ResultsTransplant Biological
1295 NCT01022Autologous Vaccine f CompletedNo ResultsLymphoma, Follicular Biological:
1296 NCT01018A Study to Evaluate CompletedHas ResultMeningococcal Disease|Meningococc Biological
1297 NCT03695Probiotic and InfluenzCompletedNo ResultsInfluenza-like Illness Biological
1298 NCT01582Assessment of Needle- Unknown sNo ResultsInfluenza Biological:
1299 NCT00772Study of Fluzone Vac CompletedHas ResultOrthomyxoviridae Infection|InfluenBiological:
1300 NCT03615A Study to Evaluate t CompletedNo ResultsPneumococcal Infections Biological:
1301 NCT03525Immunogenicity and SCompletedNo ResultsHealthy Volunteers Biological:
1302 NCT02040Study of Tetanus and CompletedNo ResultsPertussis|Tetanus|Diphtheria|Poliom Biological
1303 NCT01159Western EqWEE CompletedNo ResultsVirus Biological:
1304 NCT02960H3.3K27M Peptide Vac SuspendedNo ResultsDiffuse Intrinsic Pontine Glioma|Gl Biological
1305 NCT02661A Phase Ib Trial of a WithdrawnNo ResultsMalignant Pleural Mesothelioma ( Biological
1306 NCT00290Safety and Immunogen CompletedHas ResultDengue Biological
1307 NCT03207This Study Will Evalu CompletedHas ResultRotavirus Infection|Rotavirus VaccinBiological:
1308 NCT02428Text Message Reminde CompletedNo ResultsPregnancy
1309 NCT00130A Study to Evaluate SCompletedHas ResultHerpes Zoster Biological:
1310 NCT03561Safety Study of S.Fle CompletedNo ResultsDysentery|Dysentery, Bacillary Biological:
1311 NCT03268A Study to Evaluate t Unknown sNo ResultsEnterovirus Infections Biological:
1312 NCT00574Safety of and ImmuneCompletedNo ResultsHIV Infections Biological
1313 NCT00459The Use of Dendritic CompletedNo ResultsMultiple Myeloma Biological:
1314 NCT01871Rotarix Vaccine Effec CompletedNo ResultsRotavirus|Acute Gastroenteritis
V ResultImmunosuppression Biological:
1316 NCT00310Kinetics of B Cell Re CompletedNo ResultsPrevention of Meningococcal Infect Biological
1317 NCT01222A Post-marketing StudCompletedHas ResultInfluenza Biological:
1318 NCT03855Effectiveness of BoosRecruiting No ResultsHepatitis A|Human Immunodeficienc Drug: Vaqt
1319 NCT02250Randomized Study ofCompletedHas ResultImmune Response to Influenza Vaccin Biological:
1320 NCT02445Comparison of Immuniz CompletedNo ResultsHepatitis A|Hepatitis B Biological:
1321 NCT01908Induction PCV13inSI CompletedNo ResultsInflammatory Bowel Diseases|CrohnBiological
D
1322 NCT03527A Study to Evaluate t CompletedNo ResultsDysentery, Bacillary Biological
1323 NCT02115Phase II Trial to Eval WithdrawnNo ResultsHodgkin Lymphoma|Non-Hodgkin Biological
1324 NCT03300Safety and Immunogeni Active, notNo ResultsInfluenza|Vaccine Biological:
1325 NCT00710Impact of a Human PaCompletedHas ResultHIV Infection Biological:
1326 NCT00873Observational Study CompletedNo ResultsHealthy Biological:
1327 NCT00622Vaccination of Patien Terminate Has ResultBreast Cancer Biological:
1329 NCT00474A Study to Evaluate CompletedHas ResultMeningitis, Meningococcal Biological
1330 NCT01953Trial of PneumococcalActive, notNo ResultsPneumococcal Vaccines Biological
1331 NCT01328Zoster Vaccine Respons CompletedHas ResultImmune System Diseases Drug: Zost
1332 NCT01595Pancreatic Tumor CelActive, notNo ResultsPancreatic Cancer Drug: Cycl
1333 NCT03350Occupational ExposurRecruiting No ResultsPapillomavirus Vaccines Biological:
1334 NCT01027Primary and Booster CompletedHas ResultInfections, Streptococcal Biological
1335 NCT01706Provenge With or WitActive, notHas ResultProstate Cancer Biological:
1336 NCT00680Primary Vaccination CompletedHas ResultInfections, Streptococcal Biological:
1337 NCT03571A Safety And Immunog CompletedHas ResultPneumococcal Infections Biological
1338 NCT01006Safety and Immunogen CompletedNo ResultsBird Flu|Influenza Other: Plac
1339 NCT03718Combination HTNV a Not yet recNo ResultsHantaan Virus Disease, Puumala Vir Combinatio
1340 NCT01538Immunogenicity of InfUnknown sNo ResultsInfluenza Biological:
1341 NCT022803 Adjuvated ReducedCompletedNo
D ResultsImmunization, Booster Biological:
1342 NCT00808Safety and Immunogen CompletedNo ResultsHaemophilus Influenzae Type b Biological
1343 NCT03057HPV IIS Reminder/RecUnknown sNo ResultsReminder Systems Other: Vac
1344 NCT02592The Immunogenicity oCompletedHas ResultPneumococcal Pneumonia|InfluenzBiological
1345 NCT01465Influenza VaccinationUnknown sNo ResultsFibromyalgia Syndrome Biological
1346 NCT04059AntibodiesARIVA Enrolling bNo ResultsVaccine Response Impaired Biological:
1347 NCT00627Immunogenicity and R CompletedHas ResultAcellular Pertussis|Diphtheria|Poli Biological:
1348 NCT02459Safety andMVX13211CompletedNo ResultsInfection by Streptococcus Group B Biological
1349 NCT03965Recombinant InfluenzActive, notNo ResultsInfluenza|Influenza -Like Illness|In Biological
1350 NCT02369Immunogenicity and Re CompletedHas ResultInfluenza Biological:
1351 NCT00510Autologous Dendritic CompletedHas ResultHIV Infections Biological
1352 NCT01679Systems Biology of V CompletedNo ResultsSystems Biology|Early Gene|EV71 VBiological:
1353 NCT03652A Study to Investiga CompletedNo ResultsInfections, Meningococcal Biological
1354 NCT021654 Pillars Toolkit for CompletedHas ResultAdolescent HPV Vaccine|AdolescentBehavioral:
1355 NCT01720Study of the ImmuneRecruiting No ResultsNon-small Cell Lung Cancer (NSCLC)Biological:
1356 NCT02992The Effects of Increa CompletedNo ResultsRotavirus Infection|Vaccine Respon Biological:
1357 NCT01190Study of Japanese EncCompletedHas ResultJapanese Encephalitis|Varicella Biological:
1358 NCT03304The Feasibility of P CompletedNo ResultsPertussis Behavioral
1360 NCT00549A Single Centre Stud CompletedHas ResultInfections, Papillomavirus Biological
1361 NCT02678Safety and Immunogen Active, notNo ResultsDengue Biological:
1362 NCT01373AdCh63 ME-TRAP andCompletedNo
M ResultsMalaria Biological
1363 NCT02965A Safety Study of Liv CompletedNo ResultsVaricella Biological:
1364 NCT01173Delivery, Uptake and CompletedNo ResultsCervical Cancer Biological:
1365 NCT02057The Effect of AlendroCompletedNo ResultsHepatitis B Drug: Alen
1366 NCT02554Sanofi Pasteur QuadriCompletedNo ResultsPregnancy|Influenza Biological:
1367 NCT00430Safety & Immunogenic CompletedHas ResultInfluenza|Influenza Vaccines Biological
1368 NCT00384A Study of 2 Doses o CompletedHas ResultMeningococcal Meningitis|MeaslesBiological
1369 NCT0249213 Valent Pneumococca CompletedNo ResultsChronic Kidney Failure Biological
1370 NCT00231A Phase I Safety and CompletedNo ResultsInfluenza Biological:
1371 NCT02237Safety and Immune Res CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological:
1372 NCT01349Allogeneic GM-CSF VaCompletedHas ResultMultiple Myeloma Drug: Lena
1373 NCT01551Salvage Ovarian FAN CompletedHas ResultStage III Ovarian Cancer|Stage IV O Biological
1374 NCT01009ImmunizatiHIV-VAC CompletedHas ResultHIV INFECTIONS Biological:
1375 NCT02547Immune Responses Afe Recruiting No ResultsRabies Biological:
1376 NCT02089Study of SP306 GivenCompletedHas ResultTetanus|Diphtheria|Pertussis Biological:
1377 NCT01412Immunogenicity and SCompletedHas ResultInfluenza Biological
1378 NCT03591Dendritic Cell DKK1 Not yet recNo ResultsMonoclonal Gammopathy|SmolderBiological:
1379 NCT00695Safety and Immune Re CompletedNo ResultsHIV Infections Biological
1380 NCT01929Post-marketing SurveiCompletedHas ResultDiphtheria-Tetanus-acellular PertussBiological:
1381 NCT00895Immunogenicity and Sa CompletedNo ResultsInfluenza|Avian Influenza Biological:
1382 NCT02600Post-Marketing Observ CompletedNo ResultsHuman Influenza Biological:
1383 NCT00772Study of Reduced DosCompletedHas ResultMeningitis|Meningococcemia|Neisse Biological
1385 NCT03579Evaluation Of ClostridCompletedNo ResultsClostridium Difficile Associated DiseBiological:
1386 NCT03252mHealth-AsMINT Active, notNo ResultsImmunization Behavioral:
1387 NCT01846EvaluationMel59 CompletedNo ResultsMelanoma Biological
1388 NCT00476A Study to Test the E CompletedNo ResultsHepatitis B Virus Biological:
1389 NCT03039Immune Response toRecruiting
P No ResultsHIV Lipodystrophy|Aging Biological
1390 NCT01365Pilot Introduction of CompletedNo ResultsCholera
1391 NCT02432Vaccine Therapy and P Active, notNo ResultsAdult Solid Neoplasm|Bladder Carc Other: Lab
1393 NCT00584Safety andRVF CompletedHas ResultRif Valley Fever Biological
1394 NCT02675Vaccine Efficacy in Di CompletedNo ResultsInflammation Biological:
1395 NCT01559Diarrhea and BivalentCompletedNo ResultsSeroimmunity|Diarrhea|Polio Biological:
1396 NCT00662Safety andH-100-001CompletedNo ResultsInfluenza Biological:
1397 NCT04032HPV Vaccine IntervenRecruiting No ResultsHealthy Subject Other: Bes
1398 NCT00169Study of ImmunologicCompletedNo ResultsProphylaxis Pneumococcal Vaccine Biological
1399 NCT00892Evaluating Breast 37 CompletedNo ResultsBreast Neoplasms Biological
1400 NCT00133Pentavalent DTaP-HepCompletedNo ResultsDiphtheria|Hepatitis B|Poliomyeliti Biological
1401 NCT02750Peptide VaAZACTA Recruiting No ResultsMyelodysplastic Syndrome|Acute MBiological
1402 NCT02434A Study of Two DosesCompletedNo ResultsCholera Biological:
1403 NCT02709Consolidation TherapWithdrawnNo ResultsCancer|Hematologic Malignancies Biological
1404 NCT02285Platin-based Chemothe CompletedNo ResultsMelanoma Biological:
1405 NCT01711Tdap Vaccine in Pos CompletedHas ResultDiphtheria|Pertussis|Tetanus Biological
1406 NCT01492Lipopeptide ImmunisaCompletedNo ResultsHIV-1 Infection Biological
1407 NCT00475Study Evaluating 13-vCompletedHas ResultVaccines, Pneumococcal Conjugate Biological
1408 NCT03900A Study of Safety an Recruiting No ResultsHPV Infections Biological
1409 NCT01483Increasing Use of theCompletedHas ResultHerpes Zoster Other: Cho
1410 NCT03439Immunogenicity and SActive, notNo ResultsHerpes Zoster Biological
1411 NCT00956A Study of Inactivate CompletedNo ResultsInfluenza|Swine-origin A/H1N1 Infl Biological:
1412 NCT00079Safety, Tolerability CompletedNo ResultsSmallpox Biological
1413 NCT01767Study to Assess the SCompletedHas ResultHerpes Zoster Biological
1415 NCT01967Study of a QuadrivaleCompletedHas ResultInfluenza Biological:
1418 NCT01165Study to Evaluate GS CompletedHas ResultHerpes Zoster Biological
1419 NCT03768Nudging for VaccinatiCompletedNo ResultsInfluenza, Human|Vaccination; SepsBehavioral
1420 NCT01165Immunogenicity and SCompletedHas ResultInfections, Meningococcal Biological
1421 NCT01890Phase II Study of Ad Active, notNo ResultsMalignant Pleural Mesothelioma Biological
1422 NCT00964Protecting HPV CompletedNo ResultsCervical Cancer Drug: Lice
1423 NCT02364Evaluation of a Singl CompletedNo ResultsStaphylococcal Infections Biological
1424 NCT03144Mood and Influenza Va CompletedHas ResultVaccination; Infection Other: Posi
1425 NCT00694Evalution of Immunoge CompletedNo ResultsRabies|Japanese Encephalitis|Pre-EBiological:
1426 NCT02438Inactivated Influenz CompletedHas ResultInfluenza Biological:
1427 NCT00813Girls OnGuGirls OnGuCompletedHas ResultVaccination Behavioral
1428 NCT01436Study of Yellow FeverCompletedHas ResultDengue|Dengue Hemorrhagic Fever| Biological:
1429 NCT00534Immunogenicity Study CompletedHas ResultDiphtheria|Tetanus|Pertussis|HepatBiological:
1430 NCT00426Evaluation of Safety CompletedHas ResultInfections, Papillomavirus Biological:
1431 NCT03918Clostridium Difficile Recruiting No ResultsClostridium Difficile Associated DiseBiological:
1432 NCT00884Safety and Immunogeni CompletedNo ResultsInfluenza|Orthomyxoviridae Infecti Biological:
1433 NCT02151Evaluating the Safety CompletedNo ResultsInfluenza A Virus, H7N9 Subtype Biological:
1434 NCT01808Dendritic Cell (DC) V Active, notNo ResultsMalignant Glioma|Glioblastoma MulBiological
1435 NCT02615A Study of Type-1 PolWithdrawnNo ResultsMetastatic Colorectal Cancer Biological
1436 NCT03387HER2 Directed DendriRecruiting No ResultsBreast Cancer|Breast Cancer Female| Biological
1437 NCT04109Collection GRC00097CompletedNo ResultsInfluenza Biological
1438 NCT01044Study of Seasonal Inf CompletedNo ResultsInfluenza Biological:
1439 NCT01016Evaluation of Influe CompletedNo ResultsLymphoma|Multiple Myeloma|Influe Biological
1440 NCT01047A Study of V503, a 9 CompletedHas ResultCervical Cancers|Vulvar Cancers|VaBiological:
1441 NCT01150Safety and Immunogen CompletedHas ResultGroup B Streptococcus Biological:
1442 NCT02013Dose-EscalMTBVAC CompletedHas ResultTuberculosis|Healthy Biological:
1443 NCT03007Realization of the R CompletedNo ResultsCoverage Rate of Vaccination for InfBehavioral:
1444 NCT00760Intradermal Versus InCompletedNo ResultsInfluenza Virus|Influenza Vaccine Biological:
1445 NCT00197Long Term Follow-up CompletedHas ResultHepatitis B|Hepatitis A Biological:
1446 NCT01949A Study of Two DosesCompletedNo ResultsCholera Biological:
1447 NCT01827Comparison of Immune CompletedHas ResultInfluenza Biological:
1448 NCT01189IL15 Dendritic Cell VaCompletedNo ResultsMalignant Melanoma Stage III|Mali Biological:
1449 NCT03580A Study to DetermineRecruiting No ResultsMalaria,Falciparum Biological:
1450 NCT00737Introduction of an OrCompletedNo ResultsRotavirus Gastroenteritis Biological:
1451 NCT01631Re-licensing Study t CompletedHas ResultInfluenza Biological:
1452 NCT01797A Randomized, Control CompletedHas ResultInfluenza Biological:
1453 NCT01142Study to Assess Eff CompletedNo ResultsMalaria Biological
1454 NCT01131TBE-vaccine to Patie CompletedNo ResultsRheumatoid Arthritis|Exposed to T Biological:
1455 NCT01842Safety of H1N1 Influ CompletedNo ResultsVirus Diseases|Respiratory Tract In Biological:
1456 NCT03051HPV Vaccine Therapy Recruiting
i No ResultsHigh Grade Anal Canal Squamous Intr
Other: Lab
1457 NCT00131Introduction of the V CompletedNo ResultsTyphoid|Paratyphoid Fever Biological:
1458 NCT00389Trial to Collect Safe CompletedHas ResultInfluenza Biological:
1459 NCT03955VSMART (ViVSMART Recruiting No ResultsStress Behavioral
1460 NCT00678Primary Vaccination CCompletedHas ResultInfections, Streptococcal Biological:
1461 NCT00972Safety and Immunogeni CompletedHas ResultInfluenza Biological
1462 NCT02506Multi-antigen CMV-MV Active, notNo ResultsAccelerated Phase Chronic MyelogeOther: Lab
1463 NCT03942Study of BPZE1 IntranEnrolling bNo ResultsPertussis|Whooping Cough Combinatio
1464 NCT00812Influenza VaccinationCompletedHas ResultInfluenza Drug: Infl
1465 NCT03699A Randomized, Double- Recruiting No ResultsHIV Infections Biological
1466 NCT00989Clinical Trial to Eva WithdrawnNo ResultsInfluenza Biological:
1467 NCT00119A Efficacy Against Ot Terminate No ResultsHepatitis A Biological
1468 NCT02174Rotavirus vs. Sucrose Unknown sNo ResultsVaccination Pain Management Drug: Sucr
1469 NCT02061HER-2 PulsNeoadjuvaActive, notNo ResultsBreast Cancer Biological:
1470 NCT03284HPV VaccinCOVENANTRecruiting No ResultsAIDS-Related Human PapillomavirusOther:I Lab
1471 NCT02584A Phase â…£ Clinical CompletedNo ResultsHepatitis E|Hepatitis B Biological:
1472 NCT02623Influenza Vaccine Re Active, notNo ResultsInfluenza Biological:
1473 NCT01524Bridging Study for Kil CompletedNo ResultsVibrio Cholerae|Cholera Biological:
1474 NCT041132-year Follow-up AferCompletedNo ResultsPertussis Biological:
1475 NCT01557Comparative EffectiveCompletedNo ResultsImmunization Rates Behavioral
1476 NCT0196413vPnC Multidose Vial CompletedHas ResultPneumococcal Vaccines Biological
1477 NCT01086Cellular and HumoralCompletedNo ResultsInfluenza Biological
1478 NCT03521Safety, Tolerability a Active, notNo ResultsMalaria Biological
1479 NCT03713Clinical Trial for Me CompletedNo ResultsSigns and Symptoms Biological:
1480 NCT01069H1N1sw Vaccine in AdTerminate No ResultsImmunocompromised Biological
1481 NCT01444Study of the Booster CompletedHas ResultDiphtheria|Tetanus|Whooping Cough Biological
1482 NCT01713Vaccine Response AfCompletedNo ResultsIdiopathic Thrombocytopenic Purp Biological:
1483 NCT00434Immunogenicity, SafetCompletedNo ResultsInfluenza Biological:
1484 NCT01153Primary Vaccination SCompletedHas ResultInfections, Streptococcal|Streptoc Biological:
1485 NCT00473Safety of and ImmuneCompletedNo ResultsDengue Biological
1486 NCT02946Study to Assess the CompletedHas ResultInfections, Meningococcal Biological
1487 NCT03530Apnea in HospitalizedRecruiting No ResultsApnea|Apnea Neonatal|PrematuritBiological:
1488 NCT01193Study Evaluating a 1 CompletedHas Result13-valent Pneumococcal Vaccine|PrBiological
1489 NCT03966A Clinical Trial to E Enrolling bNo ResultsStaphylococcus Aureus Infection Biological:
1490 NCT02697Anti-Hep B AntibodiesCompletedNo ResultsHepatitis B Biological:
1491 NCT01141Trivalent Gangliosid CompletedHas ResultSarcoma Biological:
1492 NCT00771Study of Antibody ResCompletedHas ResultMeningitis|Meningococcemia Biological
1493 NCT01040Traveler's Diarrhea (TCompletedNo ResultsTraveler's Diarrhea Biological:
1494 NCT00347Descriptive, Open-labCompletedHas ResultTetanus|Diphtheria|Pertussis Biological:
1495 NCT01062A Study of DTaP//PRPCompletedNo ResultsDiphtheria|Tetanus|Pertussis|Haemo Biological
1496 NCT00757Efficacy of Influenza CompletedNo ResultsHIV|Influenza|Vaccination|HIV InfecBiological
1497 NCT02717Safety and Immunogen CompletedHas ResultPNC Vaccine|HIV-infected Pregnan Biological
1498 NCT03405Immunological Memory Unknown sNo ResultsImmunogenicity, Vaccine|Immunol Biological
1499 NCT03795A Shedding Study of ACompletedNo ResultsHealthy Biological:
1500 NCT03870DC Vaccines Targetin Not yet recNo ResultsCervical Intraepithelial Neoplasia Biological:
1501 NCT02669Efficacy and ImmunogenCompletedNo ResultsHealthy Volunteers Biological:
1502 NCT02666EvaluationPROMOVAActive, notNo ResultsMotivational Interviewing Behavioral:
1503 NCT01554Clinical Trial of the CompletedNo ResultsInfluenza Biological:
1504 NCT03784A Phase 2, Double-bliCompletedNo ResultsInfluenza Infection Biological:
1505 NCT02417A Phase â…£ Clinical TCompletedNo ResultsHepatitis E Biological:
1506 NCT01730Ad/HER2/Neu Dendriti CompletedNo ResultsBreast Neoplasms|Breast Cancer|AdBiological
1507 NCT02787Clinical and ImmunoloUnknown sNo ResultsPulmonary Disease, Chronic Obstru Biological
1508 NCT01101Does the HPV VaccineUnknown sNo ResultsCervical Cancer|Hpv|Warts Biological:
1509 NCT03878Phase II Clinical Tri Active, notNo ResultsHealthy Biological
1510 NCT00753Trial to Evaluate the CompletedHas ResultInfluenza Biological:
1511 NCT03056Immunogenicity of InCompletedNo ResultsInflammatory Bowel Diseases Biological:
1512 NCT03765Safety of GQM10 CompletedNo ResultsInfluenza Biological:
1513 NCT00118Safety of and ImmuneCompletedNo ResultsTick-Borne Encephalitis Biological
1514 NCT03237Safety of An Oral O1 CompletedNo ResultsSafety of the Oral O1 / O139 CholeraBiological:
1515 NCT04082MIDRIX4-LU MIDRIX4- Recruiting No ResultsNon-small Cell Lung Cancer MetastatBiological:
1516 NCT00440Study of RecombinantCompletedHas ResultHepatitis B Biological
1517 NCT01688Safety Study of an OrCompletedNo ResultsInfluenza Biological:
1518 NCT01632Vaccine Therapy in TreCompletedNo ResultsHER2-positive Breast Cancer|Male Br Biological
1519 NCT02046Safety and Immunogen CompletedHas ResultGBS Disease|Streptococcus AgalactiBiological:
1520 NCT02480Study to Evaluate theCompletedHas ResultInfluenza, Human Biological:
1521 NCT03859Clinical Trial to Eva CompletedNo ResultsSeasonal Influenza Biological:
1522 NCT02187Safety & EfEGF Terminate No ResultsCarcinoma, Non-Small-Cell Lung Biological:
1523 NCT03511Effectiveness of the Enrolling bNo ResultsHepatitis B
1524 NCT01983Antibody Persistence CompletedNo ResultsDiphtheria|Tetanus|Whooping Cough Biological:
1525 NCT02307Quadrivalent Influen CompletedNo ResultsInfluenza Biological
1527 NCT00870Efficacy of Bilhvax3 CompletedNo ResultsUrinary Schistosomiasis|Schistos Biological:
1528 NCT00697Consistency of 3 ConsCompletedNo ResultsHepatitis B Biological
1529 NCT01233Study of Alternative CompletedNo ResultsCholera|Diarrhoea|Vibrio Infection Biological:
1530 NCT02735Study to Evaluate Imm CompletedHas ResultHerpes Zoster Biological
1531 NCT02038Safety andNOR-107 CompletedHas ResultHealthy Volunteers|Norovirus, Prev Biological:
1532 NCT02104Clinical Trial for the CompletedNo ResultsHuman Influenza Biological:
1534 NCT00125Combined Vi VaccinatCompletedNo ResultsTyphoid|Paratyphoid Fever Biological:
1535 NCT01299A Trial To Assess The CompletedHas ResultMeningococcal Vaccine Biological:
1536 NCT02382A Clinical Mel61 Recruiting No ResultsMelanoma Drug: dabr
1537 NCT02952ZIKA Vaccine in NaiveCompletedNo ResultsZika Virus Infection Drug: Salin
1538 NCT02134The Influe SLVP025 CompletedHas ResultCytomegalovirus Infections|InfluenzBiological
1539 NCT04228A Study of 2-dose Va Not yet recNo ResultsEbola Biological
1540 NCT01322Vaccine Therapy in TrActive, notNo ResultsStage III Ovarian Epithelial Cancer Biological
1541 NCT01346Study of 7-valent Pn Unknown sNo ResultsIdiopathic Nephrotic Syndrome Biological
1542 NCT04188Effect of Selenium SuCompletedNo ResultsSelenium Supplementation|InfluenzDietary Su
1543 NCT00836Ipilimumab +/- VaccinCompletedHas ResultPancreatic Cancer Drug: Ipil
1544 NCT02678Multi-center Phase I/Active, notNo ResultsMetastatic Melanoma Drug: TLPL
1545 NCT00926SerologicalInjHepAVarUnknown sNo ResultsVaricella|Hepatitis A Biological:
1546 NCT01705Safety of One Dose o WithdrawnNo ResultsMeningococcal Disease Biological
1547 NCT01511Phase IV Clinical Trial CompletedNo ResultsHuman Influenza Biological:
1548 NCT02511Pertussis MAMA CompletedNo ResultsPertussis Drug: Infan
1549 NCT04032A PHASE 2B PLACEBORecruiting No ResultsRespiratory Tract Infection Biological:
1550 NCT01593Understanding the ImCompletedNo ResultsMeningitis|Meningococcal Disease|Biological
1551 NCT02283Phase I Trial to Asse CompletedNo ResultsHemorrhagic Fever, Ebola Biological
1553 NCT02268VAccinationVACC-HeFTCompletedNo ResultsChronic Heart Failure Biological:
1554 NCT00419Immunogenicity of OnCompletedNo ResultsCholera|Diarrhea|Vibrio Infections Biological:
1555 NCT01691Study of FluzoneÂ® I CompletedHas ResultInfluenza Biological
1556 NCT01548Evaluate the Safety o Unknown sNo ResultsHuman Papillomavirus Biological:
1557 NCT00532Non-Inferiority of Va CompletedHas ResultInfluenza Biological
1558 NCT01191Vaccine Therapy in TrCompletedNo ResultsRecurrent Colon Cancer|Recurrent Ga Other: lab
1559 NCT01810Safety and Immunogen WithdrawnNo ResultsInfluenza, Human|HIV|Malaria|TetaBiological:
1560 NCT03089South AustB Part of ItCompletedNo ResultsMeningococcal Disease Biological
1561 NCT04144A Vaccine (H2NVAC) BRecruiting No ResultsDuctal Breast Carcinoma In Situ|HE Biological
1562 NCT03833The Efficacy of Influ Active, notNo ResultsJuvenile Idiopathic Arthritis Biological:
1563 NCT01580Phase I/IIa Trial of F CompletedNo ResultsOvarian Cancer|Endometrial Cancer| Biological
1564 NCT01461A Clinical Trial to CompletedHas ResultVaccines|Meningococcal Vaccines Biological:
1565 NCT04107A Study to LEISH3 Not yet recNo ResultsPost-kala-azar Dermal LeishmaniasisBiological
1566 NCT01799Combination of gp96-WithdrawnNo ResultsNon-Small Cell Lung Cancer|Non-smBiological
1567 NCT00689Study Evaluating A 1 CompletedHas ResultPneumococcal Vaccine Biological
1568 NCT02907Influenza Vaccine RanCompletedNo ResultsVaccination|Influenza Behavioral
1569 NCT03629A Study of CMV Vaccin Recruiting No ResultsCytomegalovirus (CMV) Infection|KiBiological:
1570 NCT03135A Trial to Describe t Recruiting No ResultsMeningococcal Vaccine Biological
1571 NCT02207A Study to Evaluate CompletedHas ResultInfluenza Biological:
1572 NCT04054To Evaluate the ImmuCompletedNo ResultsVaccination|Reaction - Vaccine Biological
1573 NCT00797Immunogenicity and SCompletedHas ResultDiphtheria|Tetanus|Pertussis|Poliom Biological:
1574 NCT01402Targeting PncHR CompletedNo ResultsPneumococcal Pneumonia Biological
1575 NCT03443A Study to Test if a Active, notNo ResultsRespiratory Disorders Biological
P ResultsAsthma Biological
1577 NCT04199Safety and Immunogen Not yet recNo ResultsNipah Virus Infection Biological:
1578 NCT01972Phase I Study of Ad5 CompletedNo ResultsColon Cancer Biological
1579 NCT02095Antibody Persistence CompletedNo ResultsHealthy Biological:
1580 NCT04060Triplex Vaccine in Pr Recruiting No ResultsAccelerated Phase Chronic Myelog Drug: Lete
1581 NCT02719A Dose Ranging SafetCompletedHas ResultInfluenza Biological
1582 NCT00700A Study of the Safety,CompletedNo ResultsInfluenza Biological:
1584 NCT03755A Study of An AdjuvaNot yet recNo ResultsH7N9 Influenza Biological
1585 NCT01094A Study of the CDX-1 Terminate No ResultsBladder Cancer Biological
1586 NCT03898Response tIIV-LN Not yet recNo ResultsInfluenza Biological:
1587 NCT00420Vaccine MaintenanceTerminate No ResultsCarcinoma, Non-Small-Cell Lung Biological
1588 NCT02340rTSST-1 VarrTSST-1 CompletedHas ResultToxic Shock Syndrome|Vaccination; Biological:
1589 NCT01075Immunogenicity of Pne Unknown sNo ResultsAtaxia Telangiectasia Biological
1590 NCT04049DNA Vaccination Aga Recruiting No ResultsRelapsed Neuroblastoma Biological
1591 NCT02193IDH1 PeptiRESIST Active, notNo ResultsBrain Cancer|Brain Neoplasm, PrimaBiological
1592 NCT02149GAPVAC Phase I Trial CompletedNo ResultsGlioblastoma Drug: APVA
1593 NCT02558HPV Vaccination: Eva CompletedNo ResultsHuman Papilloma Virus Infection Ty Behavioral
1594 NCT01439Safety and Immunogeni CompletedHas ResultTetanus|Diphtheria|Pertussis|Who Biological:
1596 NCT02477Long-term Immunogeni CompletedNo ResultsSystemic Lupus Erythematosus Biological:
1598 NCT03085A Phase I Study of Q CompletedNo ResultsHPV Infections Biological:
1599 NCT02746Immunogenicity and Sa CompletedNo ResultsHealthy Volunteers Drug: Sing
1600 NCT02558Pneumonia Vaccine inCompletedNo ResultsPneumococcal Infection Biological
1601 NCT00192Trial to Co FluMist CompletedNo ResultsInfluenza Biological:
1602 NCT00133Inactivated Influenz CompletedNo ResultsInfluenza Biological
1603 NCT02904Evaluate Safety of Co CompletedNo ResultsSafety, Pentavalent Vaccine Biological:
1604 NCT01827The Protection Effec CompletedNo ResultsRabies Vaccine Allergy Biological:
1605 NCT02408Varicella Zoster Vacc Terminate No ResultsPsoriasis Drug: Varic
1606 NCT02538Safety and EffectiveneActive, notNo ResultsRheumatoid Arthritis|Inflammatory Biological
Ar
1607 NCT00652Immunogenicity, EfficUnknown sNo ResultsMalaria Biological
1608 NCT01224Study to Compare SelCompletedNo ResultsInfluenza Biological:
1609 NCT01916Differences in Respo CompletedNo ResultsHIV|Acquired Immunodeficiency Sy Drug: Seaso
1610 NCT03525Study of Safety, Tol Active, notNo ResultsHuman Papilloma Virus|Hiv|Organ TBiological:
1611 NCT02867Safety Study of ACYWCompletedNo ResultsMeningococcal Biological
1612 NCT00641Safety of and ImmuneCompletedNo ResultsParainfluenza|Virus Diseases Biological
1613 NCT01274A Multi-center, Obse CompletedHas ResultMeningococcal Disease|Meningococc Biological
1614 NCT01777Safety and Immunogen CompletedHas ResultHerpes Zoster Biological
1615 NCT03376Allogeneic Myeloma G Recruiting No ResultsMultiple Myeloma Biological
1616 NCT02154Systems BioVAX-002 CompletedHas ResultInfluenza Drug: IIV
1617 NCT00927Safety Surveillance CompletedNo ResultsSmallpox Biological
1618 NCT04082Immune Response folRecruiting No ResultsDiphtheria-Tetanus-acellular Pertussis Vaccines
1619 NCT01008Clinical Trial to Eva CompletedNo ResultsHIV Infections Biological
1620 NCT01052Safety and Immunogeni CompletedNo ResultsInfluenza, Avian Biological:
1621 NCT03480Messenger RNA (mRNA) Terminate No ResultsMelanoma|Colon Cancer|Gastrointes Biological
1622 NCT02526Pertussis MutliboostCompletedNo ResultsPertussis|Meningitis|Preventive Im Biological
1623 NCT00344Evaluation of the Im CompletedHas ResultInfections, Papillomavirus Biological
1624 NCT01331Systems Biology of ZoCompletedHas ResultShingles Biological
1625 NCT01150Clinical Trial to Asse CompletedNo ResultsJapanese Encephalitis Biological:
1626 NCT00617Immunogenicity and Sa CompletedHas ResultDengue Fever|Dengue HemorrhagicBiological
1627 NCT03982Immunologic Response CompletedNo ResultsInfluenza, Human|Immune ResponsBiological:
1628 NCT00505Prospective Trial of Active, notNo ResultsChildhood Cancer|Multiple Disease Biological:
1629 NCT04176A Study to Test GlaxoRecruiting No ResultsHerpes Zoster Biological
1630 NCT02549Neo-adjuvant EvaluatRecruiting No ResultsOligodendroglioma|Astrocytoma, GrBiological
1631 NCT02176A Phase I/ CSC CompletedNo ResultsNeoplasms,Colorectal Biological:
1632 NCT00589Analysis of the Mech CompletedNo ResultsHealthy Biological
1633 NCT01345Study to Evaluate Imm CompletedHas ResultMalaria|Malaria Vaccines Biological:
1634 NCT00950Long-term Follow-up CompletedHas ResultInfections, Streptococcal Biological
1635 NCT00944Safety, Tolerability CompletedHas ResultMeningococcal Disease|Meningococc Biological
1636 NCT01195Immunogenicity and SCompletedNo ResultsInfluenza Biological
1637 NCT01262Vitamin D Supplement Active, notNo ResultsImmunosenescence|Shingles Biological:
1638 NCT03604Increasing RAVE Active, notNo ResultsHuman Papilloma Virus Behavioral:
1639 NCT02027Single Dos SCVB CompletedNo ResultsCholera Biological:
1640 NCT00863Human Papillomavirus WithdrawnNo ResultsHuman Papilloma Virus-Related Car Biological:
1641 NCT03753TITRE III: Influenza Enrolling bNo ResultsInfluenza Biological:
1642 NCT02288Safety and Immunogen CompletedNo ResultsSafety, Immunogenicity Biological:
1643 NCT04027Comparison of Immunog Not yet recNo ResultsPolio Biological:
1644 NCT01069Safety and ReactogeniCompletedNo ResultsShigellosis Biological:
1645 NCT01025Study in Toddlers (12 CompletedNo ResultsHaemophilus Influenzae Type b (Hib)Biological:
1646 NCT00307Influenza VaccinationCompletedNo ResultsLymphoma Biological:
1647 NCT01995Randomized RELATIVESCompletedNo ResultsInfluenza
1648 NCT00562A Study of CSL's IVV CompletedHas ResultInfluenza Biological:
1649 NCT01933Efficacy and Safety ofUnknown sNo ResultsChronic Kidney Disease|Hepatitis B Biological:
1650 NCT03853Clinical Trial to Eva CompletedNo ResultsSeasonal Influenza Biological:
1651 NCT02830Dose-Ranging Trial ofCompletedNo ResultsRespiratory Syncytial Virus (RSV) Biological:
D ResultDengue|Dengue Fever|Dengue Hemor Biological:
1653 NCT02482Vaccine EnMARVSmARecruiting No ResultsMelanoma Biological:
1654 NCT00993Immunogenicity and Sa CompletedHas ResultDengue|Dengue Hemorrhagic FeverBiological:
1655 NCT01146FluAlert: Influenza VaCompletedNo ResultsInfluenza Other: Prov
1657 NCT01126Understanding the PeCompletedNo ResultsHealthy Procedure:
1659 NCT00948Study of Purified Ver CompletedNo ResultsRabies Biological:
1660 NCT00480Safety, ImmunogeniciCompletedNo ResultsTB Biological
1661 NCT01571A Study to 2009-0165CompletedNo ResultsHIV Infection Drug: Vacc
1662 NCT02099Safety & I HIV-CORE CompletedNo ResultsAIDS Biological
1663 NCT03724Blood Donor CVD 900Recruiting No ResultsCholera Vaccination Drug: Vaxc
1664 NCT01138The Immunogenicity of CompletedNo ResultsHIV Infections|Varicella-Zoster VirusBiological:
1665 NCT02918AssessmentPINC WithdrawnNo ResultsVaccination|Immunization Biological:
1666 NCT02868Pharmacists as Immun Active, notNo ResultsHealthy Biological:
1667 NCT03193Impact of Hepatitis BCompletedNo ResultsHBV Biological:
1668 NCT00911Immunogenicity and Sa CompletedNo ResultsSystemic Lupus Erythematosus Drug: huma
1669 NCT01817Immunogenicity and Sa CompletedNo ResultsChickenpox Biological:
1670 NCT00311Evaluation of Long-T CompletedNo ResultsEncephalitis, Tick-Borne Biological:
1671 NCT01135Pneumococcal Conjuga CompletedNo ResultsHIV Biological
1672 NCT03748Herd Immun HIIVU Active, notNo ResultsInfluenza, Human Other: Lett
1673 NCT02178Safety and Effectivit CompletedNo ResultsNeoplasms,Ovarian Biological:
1674 NCT02710Immunogenicity Study Active, notNo ResultsCondylomata Acuminata Biological:
1675 NCT01567Lot-to-lot Consistenc CompletedHas ResultJapanese Encephalitis Biological:
1676 NCT00956A Study of Swine-ori CompletedNo ResultsInfluenza|Swine-origin A/H1N1 Infl Biological:
1677 NCT01896A Phase 2, Multicent CompletedNo ResultsMetastatic Pancreatic Adenocarcin Drug: Ipil
1678 NCT00739Response to HepatitisTerminate No ResultsCeliac Disease Biological:
1679 NCT01459A Study to Evaluate SCompletedNo ResultsInfluenza Biological:
1680 NCT01119Immunological PersisCompletedHas ResultInfections, Streptococcal Biological
1681 NCT01444A Randomize NSCLC Terminate No ResultsCarcinoma, Non-Small-Cell Lung Biological
1682 NCT04073Safety and Immunogen Not yet recNo ResultsDiphtheria|Tetanus|Pertussis|HepatiBiological
1683 NCT04101B Cell and Antibody RNot yet recNo ResultsInfluenza Drug: Fluz
1684 NCT01534Evaluating the Safet CompletedNo ResultsInfluenza A Subtype H7N7 Infection Biological
1685 NCT02992Study of a Tetravalen Active, notNo ResultsDengue Fever|Dengue HemorrhagicBiological:
1686 NCT03713A Study to Assess th Recruiting No ResultsRabies Biological
1687 NCT03246Centralized IIS-based CompletedNo ResultsReminder Systems|Influenza Vaccin Behavioral
1688 NCT01827Phase II Trial to As CompletedHas ResultSmallpox Biological
1689 NCT00521Study Evaluating 13 VCompletedHas ResultInfluenza Biological
1690 NCT00620Safety and Immunogeni CompletedHas ResultInfluenza Biological
1691 NCT02919Safety and Efficacy CompletedNo ResultsHuman Immunodeficiency Virus Biological
1692 NCT01735Efficacy and ImmunogActive, notNo ResultsCervical Intraepithelial Neoplasia|C Biological:
1693 NCT03673Effect of Influenza V Recruiting No ResultsInfluenza|Influenza Immunisation Biological:
1694 NCT00304Post-marketing Evalu CompletedHas ResultPertussis|Diphtheria|Tetanus|Poliom Biological:
1695 NCT03336Protectivity and Safe CompletedNo ResultsSafety Issues Biological:
1696 NCT03141Comparison of Heterol Active, notNo ResultsDengue Virus Biological
1697 NCT02704Sequential OptimizatiCompletedNo ResultsMalaria Biological:
1698 NCT01452Safety of MenACWY-CCompletedNo ResultsMeningococcal Disease Biologica
1699 NCT01147Phase I Study of ETECCompletedNo ResultsGastroenteritis Escherichia Coli Biological:
1700 NCT01306Influenza MatluHIV CompletedNo ResultsInfluenza Biological:
1701 NCT03265HPV VaccinVACCIN-H CompletedNo ResultsHuman Papillomavirus Infection Other: Sel
1702 NCT01573H5N1 Vaccination WitCompletedNo ResultsInfluenza Drug: ASO3
1704 NCT00020Vaccine Therapy in T Terminate No ResultsLeukemia Biological:
1705 NCT01011A Study of the Effica CompletedHas ResultCutaneous Leishmaniasis Biological
1706 NCT01254Study of a Tetravalen CompletedHas ResultDengue Fever|Dengue HemorrhagicBiological:
1707 NCT00380Efficacy of RTS,S/AS0 CompletedHas ResultMalaria Biological:
1708 NCT04001Tunatar daIRISS Recruiting No ResultsLow Immunization Uptake Other: Com
1709 NCT00969Multisite CTA-CD CompletedHas ResultCocaine Dependence Drug: TA-C
1710 NCT00342Safety, ImmunogenicitCompletedHas ResultTyphoid Fever Biological:
1711 NCT00894A Study of Safety, T CompletedNo ResultsHIV-1 Infection Biological
1712 NCT01098Vaccine Hesitancy: A SCompletedNo ResultsVaccine Hesitancy|Vaccine Refusal Other: web-based su
1713 NCT02819Study to E FLU-02-IB CompletedNo ResultsInfluenza Biological:
1714 NCT03355Evaluation of Conditi Active, notNo ResultsImmunization; Infection Other: Con
1715 NCT00386Study to Evaluate ReaCompletedNo ResultsInfluenza Biological:
1716 NCT01893Evaluating the Safety Recruiting No ResultsRespiratory Syncytial Virus InfectionBiological:
1717 NCT01577Evaluate t VACINFL20Unknown sNo ResultsPregnancy|Investigation or Care i Biological:
1718 NCT03546Safety and Immunogen CompletedHas ResultPapillomavirus Infections|Uterine Biological
1719 NCT03869Immunogeni MEQ00063Recruiting No ResultsHealthy Volunteers (Meningococcal B I iological
1720 NCT01381Evaluation of Immunog CompletedHas ResultInfections, Papillomavirus Biological:
1721 NCT00289Randomized Controlled CompletedNo ResultsDiarrhea|Cholera|Vibrio Infections Biological:
1722 NCT02649AutologousMESODEC Recruiting No ResultsMalignant Pleural Mesothelioma Biological:
1723 NCT00643Vaccine ThACTIVATe CompletedHas ResultMalignant Neoplasms of Brain Biological
1724 NCT03537Immunogenicity and SRecruiting No ResultsMeningococcal Infections Biological
1725 NCT00294H5 Vaccine Alone or CompletedNo ResultsInfluenza Biological:
1726 NCT03909Clinical Trial of Ent CompletedNo ResultsHand, Foot and Mouth Disease Biological
1727 NCT03163Immune Response Foll CompletedHas ResultInfluenza Biological:
1728 NCT02146Study on EffectivenesUnknown sNo ResultsVaricella Biological:
1729 NCT00458Safety of and ImmuneCompletedNo ResultsDengue Hemorrhagic Fever Biological
1730 NCT01232Systems Biology of TriCompletedHas ResultInfluenza Biological:
1731 NCT01375ExplorationPROVIDE CompletedNo ResultsRotavirus Diarrhea|Vaccine Virus S Biological:
1732 NCT01022Efficacy SaMICIVAX CompletedNo ResultsInflammatory Bowel Disease (IBD) Drug: Vacc
1733 NCT03032A First in Human StudyCompletedNo ResultsHealthy Biological:
1734 NCT01509EuroNeut41: Safety &CompletedNo ResultsHIV Biological:
1735 NCT01767Phase-3 Study of ASP7 CompletedNo ResultsInfluenza Biological
1736 NCT00368Safety, ImmunogenicityCompletedHas ResultShigellosis Biological:
1737 NCT01125Immunogenicity and SCompletedNo ResultsHaemophilus Influenzae Type b (Hib)Biological
1738 NCT00828Measles VaSMC4692 Unknown sNo ResultsNon-Small Cell Lung Cancer|MeasleBiological:
1739 NCT02889Safety, Three BatchesUnknown sNo ResultsHand Foot and Mouth Disease Biological:
1740 NCT02540Safety and Immunogen CompletedHas ResultHepatitis B Biological
1741 NCT02015Phase 1 Safety Study Unknown sNo ResultsInfluenza Biological
1742 NCT02083A Phase I VAC058 CompletedNo ResultsMalaria Biologica
1743 NCT01896Study of a Candidate CompletedNo ResultsClostridium Difficile Infection Biological:
1744 NCT01751Safety and Immunogeni CompletedHas ResultHerpes Zoster Biological
1745 NCT00988A Study of Influenza CompletedHas ResultInfluenza Biological:
1746 NCT01811Oral CholerROCV CompletedNo ResultsCholera Biological:
1747 NCT03969Safety of RIV4 Versu Recruiting No ResultsSafety|Adverse Event Following Im Biological:
1748 NCT01365Immunogenicity and SCompletedHas ResultRabies Biological:
1749 NCT02586H7N9 Boost in HealthCompletedNo ResultsInfluenza Biological
1750 NCT00439Higher Dose Intrader CompletedHas ResultInfluenza Biological
1751 NCT00735A Study to DetermineCompletedHas ResultInfluenza Biological:
1752 NCT01262Study of Reduced-antiCompletedNo ResultsDiphteria, Tetanus and Pertussis Biological:
1753 NCT00604Safety of and ImmuneCompletedHas ResultHIV Infections|Sexually Transmitted Biological
1754 NCT00536Efficacy anVAC-ADN CompletedNo ResultsChronic Hepatitis B Biological
1755 NCT02987Pilot StudySLVP023 CompletedHas ResultInfluenza Biological:
1756 NCT04239A Phase Ib Study of Not yet recNo ResultsTuberculosis Biological:
1757 NCT04096Virtual Reality for th Not yet recNo ResultsVirtual Reality|Vaccination|Pain|NuOther: Virt
1758 NCT02200A Clinical EV71 CompletedNo ResultsEnterovirus 71 Human Biological
1759 NCT00831Study of DTaP-IPV-HeCompletedHas ResultDiphtheria|Tetanus|Pertussis|Haemo Biological
1760 NCT01827WT1 Analog Peptide VActive, notNo ResultsMultiple Myeloma|Minimal ResidualBiological
1761 NCT01666Infliximab IBD Influe CompletedNo ResultsInflammatory Bowel Disease Biological:
1762 NCT02914A Study to Evaluate t CompletedHas ResultInfluenza, Human Biological:
1763 NCT00551Study of Inactivated, CompletedHas ResultInfluenza|Myxovirus Infection Biological:
1764 NCT01689Study of Tetanus ToxoCompletedHas ResultPertussis|Tetanus|Diphtheria Biological:
1765 NCT00241Vaccine Efficacy Agai CompletedHas ResultInfections, Rotavirus Biological:
1766 NCT01194Study of Live, Attenu Terminate Has ResultInfluenza Biological:
1767 NCT01606Vaccine Therapy and CompletedNo ResultsRecurrent Breast Carcinoma|Recurren Drug: Cycl
1768 NCT02534Immunogenicity, SafetActive, notHas ResultMeningococcal B Disease Biological:
1769 NCT04204Immune Equivalence Not Be yet recNo ResultsTyphoid Biological:
1770 NCT01859Safety of NSNIFFLE CompletedNo ResultsEgg Hypersensitivity Biological:
1771 NCT00595Long Term PersistenceCompletedHas ResultJapanese Encephalitis Biological:
1772 NCT02714Impact of Helminth I Unknown sNo ResultsMaternal Infection Affecting NewboOther: Eff
1774 NCT03141Vvax001 Cancer Vaccin CompletedNo ResultsCIN 2/3|Cervical Cancer Biological
1775 NCT03312Effects of SLVP033 Active, notNo ResultsInfluenza|Hepatitis A|Typhoid|HealBiological:
1776 NCT01096Mother - Da MDI CompletedNo ResultsCervical Cancer Biological:
1777 NCT02624Immunogenicity and Sa Unknown sNo ResultsLate Complication From Kidney TranDrug: Quad
1778 NCT01771Training Study to ChaCompletedNo ResultsHealthy Biological:
1779 NCT00344A Study to Evaluate thCompletedHas ResultHealthy Biological:
1780 NCT02993Immunogenicity and SActive, notNo ResultsDengue Fever|Dengue HemorrhagicBiological
1781 NCT02826Adjuvant PVX-410 Vacc Active, notNo ResultsBreast Cancer Biological
1782 NCT01943The Role of Pre-exist CompletedNo ResultsYellow Fever|Encephalitis, JapaneseBiological:
1783 NCT00546Clinical Trial to Stud CompletedHas ResultLatent Tuberculosis Infection|TubercBiological:
1785 NCT01481Study of a QuadrivaleCompletedNo ResultsInfluenza Biological:
1786 NCT01089A Study of the Immuno CompletedNo ResultsInfluenza|Swine-origin A/H1N1 Infl Biological:
1787 NCT04077Senescent Immunity iRecruiting No ResultsFlu Vaccine
1789 NCT02538The Role oRota-biomCompletedNo ResultsRotavirus Infections|Intestinal Bac Biological
1790 NCT02358Attitudes Toward HumCompletedNo ResultsHuman Papillomavirus Vaccines|InflBehavioral
1791 NCT01171Study to Assess the ECompletedHas ResultInfections, Rotavirus Biological:
H ResultHepatitis B Biological:
1793 NCT02333Safety and Efficacy o CompletedNo ResultsLung Neoplasms Biological
1794 NCT04015Safety and Immunogen Recruiting No ResultsZika|Chikungunya Biological
1795 NCT00370Safety and Immunogen CompletedHas ResultInfections, Streptococcal Biological:
1796 NCT02385A Phase I/IMel62; 6P Active, notHas ResultMelanoma Drug: Ipil
1797 NCT03922Evaluation of Safety, Recruiting No ResultsPolio Biological:
1798 NCT02511TBE (Tick-borne Enceph CompletedHas ResultVaccine Responsiveness in Allergy|VBiological:
1799 NCT03512Trial to Evaluate the Active, notNo ResultsPneumococcal Infections Biological:
1800 NCT01492Vaccine Therapy in PrActive, notNo ResultsCancer Survivor|Prevention of HumaBiological:
1801 NCT00995Trial of Yellow Fever CompletedHas ResultYellow Fever Biological:
1802 NCT01053A Study to Assess th CompletedNo ResultsGroup B Streptococcus (GBS) DiseasBiological:
1803 NCT02692A Phase III Clinical T CompletedHas ResultHaemophilus Influenza Biological:
1804 NCT01930Purified Vero Rabies CompletedNo ResultsRabies Biological
1805 NCT01580Phase 3 Study of A G CompletedNo ResultsMeningitis|Influenza Biological:
1807 NCT01954Study to Evaluate th CompletedHas ResultHerpes Zoster Biological
1808 NCT00334Study of 2 Doses of HCompletedNo ResultsInfections, Rotavirus Biological:
1809 NCT03579Study of Proscavax VaNot yet recNo ResultsProstate Cancer Biological:
1810 NCT01433Combination Immunot CompletedHas ResultLung Cancer|Adenocarcinoma Biological:
1811 NCT01654Safety and Immunogeni CompletedNo ResultsInfluenza Biological
1812 NCT02804A Clinical Trial to E CompletedNo ResultsStaphylococcus Aureus Infection Biological
1813 NCT00483Study of the Safety CompletedHas ResultMeningococcal Meningitis|MeaslesBiological
1814 NCT03879Survivin Long PeptideRecruiting No ResultsLung Atypical Carcinoid Tumor|LungBiological
1815 NCT03412Bcl-XL_42-CAF09b VacRecruiting No ResultsProstate Cancer Biological
1816 NCT00440Hepatitis B Vaccine P CompletedHas ResultHepatitis B Virus Infection Biological
1817 NCT03583A Trial to Evaluate t Recruiting No ResultsEbola Disease|Immunisation Biological
1818 NCT03442Quality ImprovementActive, notNo ResultsHuman Papillomavirus Infection Other: Ass
1819 NCT01416Immunogenicity and SCompletedHas ResultInfluenza Biological
1820 NCT02655Tropical In TROPICS1 CompletedNo ResultsInfluenza, Human Biological:
1821 NCT04059Non- InferiNIFTY Not yet recNo ResultsYellow Fever Biological:
1822 NCT00363To Assess Immunogenic CompletedHas ResultInfections, Rotavirus Biological:
1823 NCT01003A Study of the Safety CompletedNo ResultsMalaria Biological
1824 NCT01218Study of QuadrivalenCompletedHas ResultInfluenza Biological:
1826 NCT00793Immunization of Pati Terminate No ResultsNon Small Cell Lung Cancer (NSCLC)Biological
1827 NCT03553H3N2 M2SR in PediatrActive, notNo ResultsInfluenza|Influenza Immunisation Biological
1828 NCT02893Post-authorisation PaCompletedHas ResultInfluenza, Human Other: Vacc
1829 NCT03000Web App Technology Recruiting
f No ResultsHuman Papillomavirus Virus|HPV Behavioral
1830 NCT04154HPV Vaccination Amon CompletedNo ResultsCervical Cancer|Healthy Diet Behavioral
1831 NCT01422Flu Vaccine Study in Unknown sNo ResultsDuchenne Muscular Dystrophy|Spina Biological:
1832 NCT02332Phase I/II: Decitabi Terminate Has ResultGliomas|Medulloblastoma|Neuroect Biological:
1833 NCT01320Reverse Genetic H9N2CompletedNo ResultsInfluenza Biological
1834 NCT00382A Study in Infants to CompletedNo ResultsInfections, Rotavirus Biological:
1835 NCT01408Immunogenic JE0153 CompletedHas ResultEncephalitis, Japanese B Biological:
1836 NCT01053Study of Swine-OriginCompletedNo ResultsInfluenza|Pandemic Influenza|Influ Biological
1837 NCT02054Adjuvant Tumor LysatSuspendedNo ResultsThoracic Sarcomas|Thorasic Cancer Biological
1838 NCT02017A Phase 1, Dose EscalCompletedHas ResultShigellosis Biological
1839 NCT00378Efficacy Trial of Tw CompletedNo ResultsOtitis Media|Pneumococcal InfectioBiological
1841 NCT01139Safety of a Live Atte CompletedNo ResultsHuman Parainfluenza Virus 2 Biological
1842 NCT01806Text ReminTRIO CompletedHas ResultHuman Papilloma Virus Other: Tex
1843 NCT02455Safety Study of a Dis Recruiting No ResultsCocaine Dependence Biological
1844 NCT00966Rapid Evaluation of S WithdrawnNo ResultsInfluenza Drug: Fluv
1845 NCT01830A Trial to Assess the CompletedHas ResultMeningococcal Vaccine Biological:
1846 NCT01255Evaluation of the Sa CompletedNo ResultsMetapneumovirus Biological
1847 NCT03887Quality ImprovementRecruiting
S No ResultsHuman Papillomavirus Infection Other: VAC
1848 NCT00440A Phase I TTMUVA-01Terminate No ResultsTuberculosis Biological
1849 NCT01342Humoral and Cell MedCompletedNo ResultsSeasonal Influenza;|Influenza;|Infl Biological:
1850 NCT00461A Phase 2 Study to E CompletedHas ResultInfluenza Vaccine Biological:
1851 NCT01512A Phase II, Safety an CompletedNo ResultsThe Study Focused on the Safety of Biological:
1852 NCT01698Optimizing Influenza Unknown sNo ResultsInfluenza Biological:
1853 NCT02737A Study of WT1 VacciActive, notNo ResultsOvarian Cancer|Fallopian Tube|PrimBiological
1854 NCT00918Study Evaluating 13-vCompletedHas ResultPneumococcal Conjugate Vaccine Biological
1855 NCT03566A Study to Assess theCompletedNo ResultsHealthy Biological:
1856 NCT00314Safety Study of ChimeCompletedHas ResultEncephalitis|Japanese Encephalitis Biological:
1857 NCT01098Drug Use InvestigatioCompletedNo ResultsSwine-Origin Influenza A H1N1 VirusBiological:
1858 NCT01444Study of an Investiga CompletedNo ResultsPneumococcal Infections|Pneumoc Biological
1859 NCT02687Safety, Tolerability a CompletedNo ResultsMalaria Biological
1860 NCT00657Safety and Immunogeni CompletedHas ResultHepatitis B Biological:
1861 NCT01181Post-Partum Immunizat CompletedHas ResultInfluenza Other: Plac
1862 NCT00735Study of ChimeriVaxâ„CompletedHas ResultJapanese Encephalitis|Hepatitis A Biological:
1863 NCT01793Evaluation EVATAT Unknown sNo ResultsAIDS Biological:
1864 NCT01537Phase I Safety Trial CompletedHas ResultPneumococcal Vaccines Other: Pla
1865 NCT03196Preliminary Study on CompletedNo ResultsInfluenza A Biological:
1866 NCT01487Efficacy and Safety o Unknown sNo ResultsChronic Hepatitis B Biological
1867 NCT03503Safety, Tolerability, Not yet recNo ResultsMalaria Biological
1868 NCT01026Extension Study Eval CompletedHas ResultMeningococcal Disease Biological
1869 NCT00617H9 Priming Study in HCompletedNo ResultsInfluenza Biological:
1870 NCT00680Human Papillomavirus CompletedNo ResultsHPV Behavioral
1871 NCT02826Study to Evaluate Saf CompletedNo ResultsCytomegalovirus Infections Drug: VBI-
1872 NCT00621Immunogenicity and Sa CompletedHas ResultJapanese Encephalitis|Hepatitis A Biological:
1873 NCT03145Immunisation HistoryCompletedNo ResultsImmunization; Infection Other: Coll
1874 NCT02444A Trial In ELVIS CompletedNo ResultsInnate Immune Response Drug: BCG
1875 NCT00299CMV Glycoprotein B Va Unknown sNo ResultsCytomegalovirus Infections Biological
1876 NCT01233Tdap Vaccination for CompletedNo ResultsPertussis|Vaccination Other: Sur
1877 NCT03669CT18 Infant InfluenzaRecruiting No ResultsInfluenza Biological:
1878 NCT01682Immunogenicity, SafetCompletedHas ResultMeningococcal Disease|Infections, Biologica
1879 NCT01042Dendritic Cells (DC) Terminate Has ResultMetastatic Melanoma Biological:
1880 NCT03402Impact of EVaxAll Recruiting No ResultsHaemopoietic Stem Cell TransplantatDrug: 4th
1881 NCT01254A Study of the Safety CompletedHas ResultPapillomavirus Infections Biological:
1882 NCT02311Duration of Immune RCompletedNo ResultsRheumatoid Arthritis Biological:
1884 NCT00707Pertussis Vaccine in CompletedNo ResultsDiphtheria|Pertussis|Tetanus Drug: Place
1885 NCT00127Immunogenicity and SCompletedNo ResultsMeasles|Rubella|Mumps|Varicella Biological
1886 NCT03059DC/AML Fusion Cell VRecruiting No ResultsAcute Myelogenous Leukemia Biological
1887 NCT00143Pneumonia Vaccine inCompletedNo ResultsBone Marrow Transplant Biological
1889 NCT00524Vaccine Therapy in TrUnknown sNo ResultsBreast Cancer Biological
1890 NCT01218Evaluation of PandemCompletedNo ResultsImmunocompromised Patients|Safety Biological
1891 NCT00455Safety Assessment ofCompletedNo ResultsLeukemia, Myeloid, Chronic Biological:
1892 NCT00977Evaluating Mel 51 Terminate No ResultsMelanoma Biological
1894 NCT02377Making Effective Hu CompletedNo ResultsHuman Papillomavirus Behavioral:
1895 NCT00224Study to Compare SafCompletedNo ResultsHerpes Simplex Biological
1896 NCT03462Evaluating the Live-A Active, notNo ResultsEbola Virus Disease Biological
1897 NCT03987Usability of HPV Vac CompletedNo ResultsHuman Papilloma Virus (HPV) Behavioral
1898 NCT01001Rapid Evaluation of PCompletedNo ResultsH1N1/2009 Influenza Biological:
1899 NCT02031Immunogenicity of InCompletedNo ResultsHIV
1900 NCT01311Study of AdacelÂ® VacCompletedHas ResultTetanus|Diphtheria|Pertussis Biological
1902 NCT00981A Study of ChimeriVaxCompletedHas ResultEncephalitis|Japanese Encephalitis Biological:
1903 NCT01391A Safety Study of Ina CompletedNo ResultsThe Study Focused on the Safety of Biological:
1904 NCT03489The Effect FPCV Recruiting No ResultsPneumococcal Infection|StreptococcBiological
1905 NCT01967Safety and Efficacy ofUnknown sNo ResultsInfluenza, Human Drug: Inta
1906 NCT00708Study Evaluating 13-VCompletedHas ResultVaccines, Pneumococcal Biological
1907 NCT00424Safety of RecombinanUnknown sNo ResultsMalaria Biological
1908 NCT01887Study of a Candidate Terminate
Cl Has ResultClostridium Difficile Infection Biological:
1909 NCT00688Study Evaluating A 1 CompletedHas ResultVaccines|Pneumococcal Conjugate VBiological
1910 NCT01215Study of Sanofi PasteuCompletedNo ResultsInfluenza Biological:
1911 NCT03251Immunologic Response Recruiting No ResultsCholera Drug: Vaxc
1912 NCT00848Safety, Tolerability, CompletedNo ResultsInfluenza Biological:
1913 NCT00127Immunogenicity and SCompletedNo ResultsMumps|Varicella|Rubella|Measles Biological
1914 NCT01011Study of Influenza VaCompletedHas ResultInfluenza Biological:
1915 NCT03804Immune Dam ALTIBPCO Recruiting No ResultsChronic Obstructive Pulmonary DiseOther: Anti
1916 NCT00694PSMA and TARP Peptide CompletedHas ResultProstate Cancer Biological:
1917 NCT03278Post-authorisation PaCompletedHas ResultInfluenza, Human Other: Enh
1919 NCT03758Comparison DC-HIV04 Recruiting No ResultsHIV Infections Biological
1920 NCT00814Safety of the HIV Vac CompletedNo ResultsAIDS Biological:
1921 NCT04080Functional LAIV Recruiting No ResultsInfluenza, Human Biological:
1922 NCT00090Vaccine Treatment foTerminate No ResultsBreast Cancer Biological:
1923 NCT01436TIV and High Dose TIVCompletedHas ResultInfluenza Biological:
1924 NCT03526An Immunogenicity and CompletedNo ResultsPoliomyelitis Biological:
1925 NCT00356Randomized, Double CompletedNo
Bl ResultsInfluenza Biological:
1926 NCT00267Synthetic Vaccine in CompletedHas ResultChronic Myeloid Leukemia|MinimalBiological:
1927 NCT00353Accelerated ImmunizaCompletedHas ResultCytomegalovirus Infections Biological
1928 NCT00289Safety and Effectiven CompletedHas ResultProstate Cancer Biological:
1929 NCT02231Safety, Tolerability CompletedNo ResultsHealthy Adult Immune Responses toBiological
1931 NCT00968Study to Evaluate Imm CompletedHas ResultInfluenza Biological
1933 NCT02132Dose Escalation, RandCompletedNo ResultsMalaria|Plasmodium Falciparum MaBiological:
1934 NCT02038Randomized, Open-lab CompletedNo ResultsSmallpox Biologica
1935 NCT01054Examining the Role oCompletedNo ResultsHIV Infections Biological
1936 NCT00249Safety andC001 CompletedNo ResultsHIV Infection Biological
1937 NCT03848Impact on HOPE9 Not yet recNo ResultsCervical Intraepithelial Neoplasia Biological:
1938 NCT02564Safety, Tolerability CompletedNo ResultsHemorrhagic Fever, Ebola Biological
1939 NCT00127Safety, Tolerability, CompletedHas ResultClostridium Infections Biological:
1940 NCT00792Vaccination Course CompletedHas ResultInfections, Streptococcal Biological
1941 NCT00655Safety and Immunogen CompletedNo ResultsActive Immunization Biological:
1942 NCT01694Bacille Calmette GuÃ© CompletedHas ResultProspective|Single-blind|Clinical|TrBiological:
1943 NCT00656Conjugate Pneumococca CompletedNo ResultsAtaxia Telangiectasia (AT) Drug: Conj
1944 NCT00680H5N1 (Clade 2) VaccinCompletedNo ResultsInfluenza Biological
1945 NCT00395The Safety and Immun CompletedNo ResultsTuberculosis|HIV Infections Biological
1946 NCT02134Vaccine Therapy in T Active, notHas ResultColorectal Adenoma|Colorectal AdeOther: Lab
1948 NCT02409Study Comparing DTP-H Terminate No ResultsImmune Response to DTP-HB-Hib VaBiological:
1949 NCT01110Study of a Birth DoseWithdrawnNo ResultsInfections, Rotavirus Biological:
1950 NCT00731Immuno & Reacto of CompletedNo
TF ResultsInfluenza Biological:
1951 NCT00464Wyeth Study To EvaluCompletedHas ResultPneumococcal Vaccines Biological
1952 NCT02612A Safety and ImmunoCompletedHas ResultAvian Influenza Biological
1953 NCT02561A Study To Investigat Active, notHas ResultClostridium Difficile Associated DiseBiological:
1954 NCT03932Efficacy Study With QIActive, notNo ResultsInfluenza, Human Biological:
1955 NCT03926Safety Study of Live CompletedNo ResultsInfluenza Biological
1956 NCT02502Safety and Immunogen Unknown sNo ResultsCholera Biological:
1957 NCT03954A Safety Study of 2 F Active, notNo ResultsInfections, Rotavirus Biological:
1959 NCT01040Observational Safety CompletedNo ResultsPandemic Influenza A (H1N1)|A NewOther: Non
1960 NCT02034Evaluate a New ShigelCompletedNo ResultsShigellosis Biological
1961 NCT04117Pooled Mutant KRAS-T Not yet recNo ResultsColorectal Cancer|Pancreatic CanceDrug: KRAS
1962 NCT00214Safety, Tolerability, CompletedHas ResultClostridium Infections Biological:
1963 NCT01310Immune Response Stud CompletedNo ResultsInfluenza Vaccine Allergy|Cell Mediated React
1964 NCT02568Recombinant Human Active,
Pa notNo ResultsHealthy Subject Other: Lab
1965 NCT00513Vaccine Therapy and Unknown sNo ResultsMyelodysplastic Syndromes Biological
1966 NCT02255Clinical Study to Eva CompletedNo ResultsInfluenza Biological:
1967 NCT02215A Clinical Trial of t CompletedNo ResultsMalaria Biological:
1968 NCT01199Immunogenicity of RoCompletedNo ResultsRotavirus Gastroenteritis Biological:
1969 NCT01014Study to Evaluate theTerminate Has ResultInfluenza Biological
1970 NCT02783Safety andTdap/IIV CompletedHas ResultPregnancy Biological:
1971 NCT00776Influenza VaccinationCompletedNo ResultsHemodialysis|Renal TransplantationBiological:
1972 NCT01151Safety and Efficacy o Unknown sNo ResultsRheumatoid Arthritis|SpondyloarthrBiological
1974 NCT00262Kinetic of Immune MeUnknown sNo ResultsMeningococcal Disease; MeningococBiological
1975 NCT01189Cell MediaCMI CompletedHas ResultImmunity to Influenza Vaccine Biological:
1976 NCT01241Decitabine Followed CompletedNo ResultsNeuroblastoma|Ewings Sarcoma|OsBiological:
1977 NCT02136Post-License Safety EvCompletedNo ResultsInfluenza|Adverse Drug Event
1978 NCT04199Efficacy Against Oral Not yet recNo ResultsPapillomavirus Infections Biological:
1979 NCT01755Study to Evaluate theCompletedHas ResultTuberculosis|Tuberculosis Vaccines Biological:
1980 NCT01980Effect of Tocilizumab Unknown sNo ResultsRheumatoid Arthritis|Cellular Imm Biological:
1981 NCT01880Phase I, Open-Label SUnknown sNo ResultsCervical Intraepithelial Neoplasia Biological:
1982 NCT00956A Clinical Trial With CompletedNo ResultsInfluenza Biological:
1983 NCT01233Opting In vs Opting OCompletedNo ResultsInfluenza Vaccination Other: Opt
1984 NCT01472Impact of Rotavirus VUnknown sNo ResultsViral Gastroenteritis Due to Rotavirus|Gastroen
1985 NCT00478Human Papillomavirus CompletedNo ResultsInfections, Papillomavirus Biological
1986 NCT00987Safety Study of SeasonCompletedNo ResultsHealthy Adults Device: Lec
1987 NCT03550Study to Evaluate theActive, notNo ResultsPneumococcal Infections Biological:
1988 NCT00216Twinrix Alternative S Unknown sNo ResultsAntibody Response Afer Vaccinatio Biological:
1989 NCT01252Immunogenicity and In CompletedNo ResultsHepatitis A Biological:
1990 NCT03107Bioarray f StikoSero Unknown sNo ResultsImmunization; Infection Procedure:
1991 NCT00391Study of Inactivated, CompletedHas ResultOrthomyxoviridae Infection|InfluenBiological:
1992 NCT03473A Safety and Immunoge CompletedNo ResultsAntiviral Prophylaxis|Respiratory SynOther: Pla
1993 NCT01123Safety and Immunogeni CompletedHas ResultTyphoid Fever Biological
1994 NCT01339Improving the ImmunTerminate Has ResultBreast Cancer|Colon Cancer|BladdeDrug: Glyco
1995 NCT03102Evaluating the Infect CompletedHas ResultRespiratory Syncytial Virus InfectionBiological
1996 NCT02943A Second Dose of Meas Recruiting No ResultsChild Mortality|Child Morbidity Biological:
1997 NCT00652Immunogenicity of GSCompletedHas ResultInfluenza Biological
1998 NCT01146TextFluenza: Using T CompletedHas ResultInfluenza Other: Tex
1999 NCT01815High-Dose Influenza Active, notNo ResultsInfluenza Biological:
2000 NCT02228Study of a Single Dos CompletedHas ResultInfluenza Biological:
2001 NCT01521Prevenar Special Use-CompletedHas ResultPneumococcal Vaccine|StreptococcBiological:
2002 NCT00992H1N1 Vaccine at Two CompletedHas
D ResultInfluenza Biological:
2004 NCT00783Phase 1 Study of a H5CompletedNo ResultsInfluenza|Pandemic Influenza Biological:
2005 NCT00965Study to Evaluate Saf CompletedNo ResultsAlzheimer's Disease Biological:
2006 NCT00840Immunogenicity, SafetCompletedNo ResultsEncephalitis, Tick-Borne Biological:
2007 NCT03060A Study to Assess th Active, notNo ResultsHIV-1 Biological
2008 NCT00307Trivalent Baculoviru CompletedNo ResultsInfluenza Biological: Trivalent
2009 NCT00565LT Vaccine Patch Self CompletedHas ResultPrevention of Travelers' Diarrhea Biological:
2010 NCT01056Safety and Efficacy o CompletedNo ResultsSmallpox Drug: smal
2011 NCT01502Evaluation TVDV CompletedNo ResultsDengue Disease|Dengue Fever Biological
2012 NCT02892A Phase I Clinical Tr CompletedNo ResultsPneumococcal Infections Biological
2013 NCT00795Effects of Vaccinati CompletedNo ResultsAstrocytoma|Oligo-Astrocytoma|GlBiological
2014 NCT01481Evaluation of an Infl Unknown sNo ResultsInfluenza Behavioral
2015 NCT00366Safety of and ImmuneCompletedNo ResultsParamyxoviridae Infections|Virus DiBiological:
2016 NCT03090ClostridiumClover Active, notNo ResultsClostridium Difficile Infection Biological:
2017 NCT00487Vaccination for the T Active, notNo ResultsFollicular Lymphoma Biological:
2018 NCT00937Safety and Immunogen CompletedHas ResultMeningococcal Meningitis|Meningoc Biological:
2019 NCT00993A Study to Assess th CompletedNo ResultsInfluenza Biologica
2020 NCT02697Trial of a Social Ma Active, notNo ResultsHPV Vaccination Behavioral
2021 NCT04091A Study to Evaluate t Recruiting No ResultsHerpes Zoster Biological
2022 NCT01991Humoral and Cellular CompletedNo ResultsTick Borne Encephalitis Biological:
2023 NCT01823Safety Study of BPX-2CompletedNo ResultsCastrate Resistent Prostate Cancer Biological
2025 NCT00796Vaccination of HIV-1 ICompletedNo ResultsHIV Biological:
2026 NCT01446Study of Investigatio CompletedNo ResultsPneumonia|Pneumococcal InfectionBiological
2027 NCT02466Study of Nivolumab i WithdrawnNo ResultsLung Cancer|Adenocarcinoma of thDrug: Nivo
2028 NCT00971Safety, ImmunogeniciCompletedHas ResultInfluenza Biological
2029 NCT02450Evaluating the Safety CompletedNo ResultsDengue Biological:
2030 NCT00415Safety of and ImmuneWithdrawnNo ResultsHIV Infections Biological
2031 NCT03541Safety and Immunogeni Active, notNo ResultsPertussis|Pertussis Immunisation Biological
2032 NCT01092Long-term Follow-up CoompletedNo ResultsAIDS Procedure:
2033 NCT03597EvaluationSAUVAC CompletedNo ResultsImmunocompromised Patients and Non-immunosu
2034 NCT01263Pneumococcal Vaccina CompletedNo ResultsRecurrent Acute Otitis Media Biological:
2035 NCT01286Immune Response Afe CompletedHas ResultHIV|Rabies Biological:
2036 NCT01432Study of Gardasil in Active, notHas ResultHuman Papillomavirus Biological:
2037 NCT02193Randomized, Controlle CompletedNo ResultsRotavirus Vaccine Biological:
2040 NCT00861EvaluationFinIP CompletedNo ResultsInfections, Streptococcal Biological:
2041 NCT03816Immunogenicity and Sa Active, notNo ResultsInfluenza Biological
2042 NCT04220Measles Vaccination Recruiting No ResultsMeasles Vaccine|Hospital Admission|Biological:
2043 NCT03964Study to Assess ImmuRecruiting No ResultsMeningococcal Meningitis Biological
2044 NCT00715Evaluation of VaccinaCompletedNo ResultsHuman Papilloma Virus (HPV)|Tetanus Other: Remi
2046 NCT01002Rapid Evaluation of CompletedNo ResultsHIV Infections|H1N1 Influenza Biological:
2047 NCT03886Subunit Vaccine AgainNot yet recNo ResultsRheumatoid Arthritis|Healthy ContrBiological:
2048 NCT00619Study of Immunogenic CompletedHas ResultDiphtheria|Polio|Pertussis|HepatitiBiological
2049 NCT01974PregText: Feasibility CompletedHas ResultPregnancy Behavioral
2050 NCT01157Yearly Strain Variati CompletedNo ResultsInfluenza|Seasonal Influenza Biological:
2052 NCT01542A Comparison of the CompletedHas ResultHealthy Biological
2053 NCT01984Study of a DNA-basedCompletedNo ResultsVenezuelan Equine Encephalitis ViruBiological
2054 NCT03341Mobile Phone SMS Mes Unknown sNo ResultsTuberculosis|Polio|Diphtheria|Pert Behavioral
2055 NCT00609Evaluate Safety and CompletedHas ResultInfections, Streptococcal|Streptoc Biological
2056 NCT00853Immune Res REPLAY CompletedHas ResultInvasive Pneumococcal Disease Biological
2057 NCT00839Impact on Carriage, CompletedNo ResultsInfections, Streptococcal Biological:
2058 NCT01784A Phase I/IUV1/hTERTActive, notNo ResultsProstate Cancer Biological
2059 NCT00980Study to Assess the I CompletedHas ResultInfluenza Biological
2060 NCT00384Study to Evaluate a 1 CompletedHas ResultVaccines, Pneumococcal Biological:
2061 NCT00486Expanded CharacterizCompletedNo ResultsHIV Infections Biological
2062 NCT01491Safety of PENTAXIMÂ® CompletedNo ResultsDiphtheria|Tetanus|Pertussis|Polio Biological
2063 NCT00974Phase I STEBVax in HeCompletedNo ResultsToxic Shock Syndrome StaphylococcaDrug: Alum
2064 NCT03794A Study of Personali Active, notNo ResultsNon Small Cell Lung Cancer|Colore Procedure:
2065 NCT00874HLA-A2-Restricted Gl CompletedNo ResultsAstrocytoma|Oligoastrocytoma|Oli Biological:
2066 NCT00358Phase I Pediatric FMPCompletedHas ResultPlasmodium Falciparum Malaria Biological
2067 NCT00707Evaluation of PneumoCompletedNo ResultsInfections, Streptococcal Biological
2068 NCT01375Safety Study of a Rot CompletedNo ResultsDiarrhea|Vomit|Fever|Nausea|IrritaDrug: Rota
2069 NCT01456Immunogenicity of Gar Unknown sNo ResultsHuman Papillomavirus Biological:
2072 NCT02362Multi-Epitope TARP PeRecruiting No ResultsProstatic Neoplasms|Prostate CanceBiological
2073 NCT04078MIDRIXNEO- MIDRIXNE Recruiting No ResultsNon-small Cell Lung Cancer Biological:
2074 NCT01263Clinical Trial of Rec CompletedNo ResultsCervical Cancer Biological
2075 NCT01259Hepatitis HVS CompletedNo ResultsHepatitis B Biological:
2076 NCT01991Immunogenicity, SafetyCompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological
2077 NCT02733A Phase III Study of Active, notNo ResultsHuman Papilloma Virus Infection TypBiological
2078 NCT00869Safety and RVF Active, notNo ResultsRif Valley Fever Biological:
2079 NCT02654Evaluating the Safety CompletedNo ResultsHIV Infections Biological:
2080 NCT00774Regulation of Mucos CompletedNo ResultsMeningococcal Infections Biological
2081 NCT01018An Evaluation Of ThreCompletedNo ResultsBacterial Infections|Staphylococcal Biological
2082 NCT03132Immunogenic YF-HIV Recruiting No ResultsHIV Infections Biological
2083 NCT00375A Safety and ImmunolCompletedNo ResultsInfluenza Biological:
2084 NCT03445Increasing Healthca WithdrawnNo ResultsMeningitis|HPV - Anogenital HumanBehavioral
2085 NCT04188A Clinical Trial to E Recruiting No ResultsNorwalk Gastroenteritis|Norovirus IBiological:
2086 NCT00908Early Immune Respons CompletedNo ResultsHIV Infections Biological
2087 NCT00101Universal Granulocyt Active, notHas ResultLymphoma Drug: Cycl
2088 NCT03700Investigating the Ef Active, notNo ResultsInfluenza, Vaccination Behavioral
2089 NCT00092Evaluation of the Saf CompletedHas ResultHealthy Biological:
2090 NCT03633Safety, Tolerability, Recruiting No ResultsCutaneous Melanoma|Non-small Cell Biological
2091 NCT03295Clinical Study of Me CompletedNo ResultsMeningitis, Meningococcal Biological
2092 NCT01889A Phase I Study to E CompletedNo ResultsHIV Biologica
2093 NCT01107Early Rabi I49P1 CompletedNo ResultsRabies Prevention Biological:
2094 NCT00454Vaccine Therapy and Unknown sNo ResultsLeukemia Biological
2095 NCT02600Personalized Peptide Active, notNo ResultsColorectal Adenocarcinoma|Pancreat Drug: Imiq
2096 NCT01737Enhancing Influenza VCompletedNo ResultsInfluenza Vaccination in Seniors Drug: resi
2097 NCT01320Study to Evaluate theCompletedNo ResultsHIV Biological:
2098 NCT02485Evaluation of a New ECompletedHas ResultEbola Virus Disease Biological
2099 NCT00844p53 SyntheISA-P53-CTCompletedNo ResultsOvarian Cancer Drug: P53-
2100 NCT01177A Study of DTaP-IPV-HCompletedHas ResultDiphtheria|Tetanus|Whooping Cough Biological
2101 NCT00094Safety of and ImmuneCompletedNo ResultsWest Nile Fever Encephalitis Biological
2102 NCT01859SMS Reminders to Imp Unknown sNo ResultsVaccination Failure Behavioral
2103 NCT00911Booster Vaccination CompletedHas ResultInfections, Streptococcal Biological:
2105 NCT02085Effects of BCG on I CompletedNo ResultsSepsis Biological:
2106 NCT03311Evaluation of Immunog CompletedHas ResultDiphtheria-Tetanus-acellular PertussBiological:
2107 NCT01202Two-site Intradermal CompletedNo ResultsInfluenza Biological:
2108 NCT03920Flavivirus FlaviPrimeNot yet recNo ResultsJapanese Encephalitis Biological
2109 NCT00322A Study of an Investi CompletedHas ResultHerpes Zoster Biological:
2110 NCT03759Increasing Human PapActive, notNo ResultsHuman Papilloma Virus Behavioral
2111 NCT02917A Study to Evaluate t CompletedNo ResultsInfluenza, Human Biological
2112 NCT00170Phase II Study of RanCompletedNo ResultsPrevention of Bacillus Anthracis (AntBiological:
2114 NCT00850AutologousDRibble CompletedNo ResultsNon Small Cell Lung Cancer Biological:
2115 NCT03554Typhoid Conjugate VaRecruiting No ResultsEnteric Fever|Typhoid Fever|Salmone Biological
2116 NCT00892Immunogenicity & SafCompletedHas ResultMeasles|Varicella|Mumps|Rubella Biological:
2117 NCT00677A ProspectiMI-MA182CompletedHas ResultInfluenza Biological:
2118 NCT03966Improving the SchoolNot yet recNo ResultsVaccine Adverse Reaction|Vaccinati Other: Mul
2119 NCT01686IntradermalIDIPV CompletedHas ResultPolio Immunity Drug: IPOL
2120 NCT01989Booster Vaccination CompletedNo ResultsRecurrent Melanoma|Stage IA Skin Biological
2121 NCT00308Safety of and ImmuneCompletedNo ResultsParamyxoviridae Infections|Virus DiBiological:
2122 NCT00084Vaccine Therapy Comb CompletedHas ResultPancreatic Cancer Biological:
2123 NCT00452Study Evaluating 13- CompletedHas ResultPneumococcal Infections Biological
2124 NCT00974Study to Evaluate Pe CompletedHas ResultInfections, Meningococcal Procedure:
2125 NCT01561A Study to Evaluate t CompletedNo ResultsInfluenza Biological:
2126 NCT01341Proof-of-C MSP3-POCCompletedNo ResultsMalaria Biological
2127 NCT02823Safety and Immunogen CompletedNo ResultsCholera Biological
2128 NCT03420Study to Evaluate Saf CompletedNo ResultsMalaria|Malaria,Falciparum Biological
2129 NCT04024Establishi NSABP FB-Recruiting No ResultsTriple-negative Breast Cancer Biological
2130 NCT02175Role of BCG as BoosteCompletedNo ResultsBCG Vaccination Biological:
2131 NCT03656Non-specific Effects Enrolling bNo ResultsInfluenza-like Illness|Upper Respir Biological:
2132 NCT03209Edtech-HPVEdtech-HPRecruiting No ResultsParents Behavioral
2133 NCT01101Observational Safety CompletedNo ResultsInfluenza A (H1N1) Other: This
2134 NCT04028Ebola Vaccine Trial Recruiting No ResultsEbola Virus Disease Drug: Ad2
2135 NCT03929A Study of 2-dose Va Active, notNo ResultsEbola Virus Disease Biological
2136 NCT01514The Safety and Immun CompletedNo ResultsInfluenza Biological:
2137 NCT01497Safety of Tuberculos CompletedNo ResultsTuberculosis Biological
2138 NCT02610Anti-Hep B AntibodieCompletedNo ResultsHepatitis B Biological
2139 NCT00554Comparative Study ofCompletedNo ResultsInfluenza Biological:
2140 NCT04075 A Phase â… Clinical Trial
Recruiting
of Recombinant
No Results
Hepatitis
HepatitisB BVaccine (Hansenula Polymorpha,
Biological:
10Î¼g)
2141 NCT00152Pneumonia Vaccine inUnknown sNo ResultsTransplant Biological
2142 NCT00698Safety Evaluation of CompletedNo ResultsProphylaxis for Herpes Simplex Biological
2143 NCT03598PolyImmune PIVOT-RCCNot yet recNo ResultsRenal Cell Carcinoma Drug: Durv
2144 NCT04078Shigella CVD 30000: SNot yet recNo ResultsShigella Biological:
2146 NCT00417Inactivated Influenza Unknown sNo ResultsInfluenza Biological:
2147 NCT02979Immunogenicity and SCompletedNo ResultsDengue Fever|Dengue HemorrhagicBiological
2148 NCT00545Revaccination With I CompletedHas ResultInfluenza|Influenza, Human Biological
2149 NCT01751LEISH-F3 + GLA-SE anCompletedNo ResultsLeishmaniasis Biological:
2150 NCT02145Efficacy anROSE Active, notNo ResultsSevere Rotavirus Gastroenteritis Biological:
2151 NCT01159Giving ImmGIVE CompletedNo ResultsHPV Vaccines Behavioral
2152 NCT02723Evaluate Safety of G CompletedNo ResultsInfluenza, Human Biological:
2153 NCT01831Responses to InfluenzCompletedHas ResultMELAS Syndrome Biological:
2154 NCT02840Safety and Immunogen CompletedNo ResultsPrevention of Zika Infection|Zika-S Biological
2155 NCT01323Consistency of Immuno CompletedHas ResultMalaria Biological
2156 NCT00349Study of the Ability oCompletedNo ResultsInfluenza Biological
2157 NCT01249The Safety Evaluatio CompletedHas ResultInfections, Papillomavirus Biological
2158 NCT00973Safety and Immunogeni CompletedHas ResultNovel 2009 Influenza H1N1 Biological
2159 NCT03934Evaluating the Safety Active, notNo ResultsHIV Infections Biological
2160 NCT00170Safety, Tolerability CompletedNo ResultsBacillus Anthracis (Anthrax) Biological:
2161 NCT02878Safety Study of Meni Unknown sNo ResultsMeningitis, Meningococcal Biological
2162 NCT00371Adenovirus Vaccine f CompletedNo ResultsPlasmodium Falciparum Infection Drug: Plac
2163 NCT02406Phase III Trial to Eva Active, notNo ResultsDengue Biological
2164 NCT01248Safety and Immunogen CompletedHas ResultTetanus|Poliomyelitis|Hepatitis B|HBiological
2165 NCT03875Post-VaccinBioCol-VIRNot yet recNo ResultsVaccination|Immune Response
2166 NCT02768Immunogenicity of a Q CompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological:
2167 NCT01881Safety and Immunogen Unknown sNo ResultsAcquired Immunodeficiency Syndr Biological:
2168 NCT00996Single-blind, Dose-ra CompletedNo ResultsInfluenza Biological:
2169 NCT02562A Bridging Study of a CompletedNo ResultsCervical Intraepithelial Neoplasia|C Procedure:
2170 NCT00485A Study to Evaluate CompletedHas ResultInfections, Papillomavirus Biological
2171 NCT02428Immunogenicity and Sa CompletedNo ResultsDiphtheria|Tetanus|Pertussis|Polio Biological
2172 NCT01400Imiquimod/Brain Tumor SuspendedNo ResultsDiffuse Intrinsic Pontine Glioma Biological
2173 NCT03415Hepatitis B Vaccine f CompletedNo ResultsHepatitis B Biological
2174 NCT01441PD-1 Alone or With De Terminate Has ResultRenal Cell Carcinoma Drug: CT-0
2175 NCT01000Immunogenicity and SCompletedNo ResultsH1N1 Pandemic Flu
2177 NCT00998A Long-Term Study ofCompletedNo ResultsSmallpox
2178 NCT00741Prospective Trial of CompletedHas ResultBreast Cancer|Lung Cancer|Prostat Biological:
2179 NCT02609ImmunizatiImmuSMACompletedNo ResultsPharmacy|Immunization|Vaccines Behavioral
2180 NCT01773Inactivated Split Viru CompletedNo ResultsInfluenza Biological:
2181 NCT00452Study Evaluating 13-vCompletedHas ResultPneumococcal Infections Biological
2182 NCT04232Inactivated Polioviru Not yet recNo ResultsPolio Biological:
2183 NCT03502The Effect LAIV/EHPCCompletedNo ResultsPneumonia|Influenza, Human Biological:
2184 NCT00444Immunogenicity and SCompletedHas ResultNeisseria Meningitidis|Meningococca Biological
2185 NCT00844Study to Evaluate ImpCompletedHas ResultInfluenza Biological
2186 NCT01474Zostavax in Systemic CompletedNo ResultsSystemic Lupus Erythematosus Drug: Zost
2187 NCT01508Intradermal Trivalent CompletedNo ResultsChronic Illness Biological
2188 NCT01033Recombinant Attenuat CompletedNo ResultsPneumonia Biological
2189 NCT03628An Evaluation of Tai CompletedHas ResultHuman Papilloma Virus Vaccines|AttBehavioral:
2190 NCT00393Hepatitis B Vaccine CompletedHas ResultHepatitis B Biological
2191 NCT01052A Study to Assess th CompletedNo ResultsGroup B Streptococcus (GBS) DiseasBiological:
2192 NCT02628Immunogenicity and Sa Active, notNo ResultsDengue Fever|Dengue HemorrhagicBiological
2193 NCT01248FluMist in FluEMIST CompletedNo ResultsEgg Allergy|Eligible for Vaccination Biological:
2194 NCT00412Determining Long-TerCompletedHas ResultEncephalitis, Japanese B Biological:
2195 NCT00730Safety and Immunogeni CompletedNo ResultsTuberculosis (TB) Biological
2196 NCT00310Immunogenicity and SCompletedHas ResultMeningococcal Meningitis Biological
2197 NCT03780MMR at 6 Months TriRecruiting No ResultsMeales-mumps-rubella Vaccine Biological
2198 NCT02640Cog-VACCIN Cog-VACCICompletedNo ResultsVascular Cognitive Impairment no Behavioral
2199 NCT00989Study to Evaluate Imm CompletedHas ResultInfluenza Biological:
2200 NCT03160Study of Biomarkers Unknown sNo ResultsPrevention of Influenza Drug: Seas
2201 NCT00772Evaluation of the Saf CompletedHas ResultInfluenza Biological:
2202 NCT01313A Clinical Trial for I CompletedNo ResultsHand, Foot, and Mouth Disease|Ente Biological
2203 NCT01866Immune Response ToEnrolling
I bNo ResultsTonsillitis, Hypertrophy Drug: FLU
2204 NCT04142Study to Assess the Recruiting No ResultsMeningococcal Infection (Healthy VoBiological
2205 NCT00902Immune Responses Ind CompletedHas ResultImmune Response Biological:
2206 NCT02045Study to Evaluate Im CompletedHas ResultHerpes Zoster Biological
2207 NCT00478Vaccine Therapy in T Terminate Has ResultLymphoma Biological
2208 NCT04090pTVG-HP DNA VaccineRecruiting No ResultsCastration-resistant Prostate Cance Biological
2209 NCT01284Parent-son-provider CompletedNo ResultsHuman Papillomavirus Vaccination
2210 NCT01298The Study of Immunoge Unknown sNo ResultsChronic Kidney Disease, Stage IV (S Biological
2211 NCT01226Immunogenicity and SCompletedNo ResultsHaemophilus Influenzae Type b (Hib)Biological:
2212 NCT03744A Clinical Trial of A Not yet recNo ResultsInfluenza Biological:
2213 NCT03590Regimen OptimizationCompletedNo ResultsMalaria Biological:
2215 NCT00232Study Comparing Immun CompletedNo ResultsInfluenza Biological:
2216 NCT03121Personalized Tumor VRecruiting No ResultsFollicular Lymphoma Biological
2217 NCT04084Study to Evaluate th Recruiting No ResultsMeningococcal Infection (Healthy VoBiological
2218 NCT03554A Study to Evaluate t Active, notNo ResultsPoliomyelitis Biological:
2220 NCT01373Leukemic Dendritic CeCompletedNo ResultsAcute Myeloid Leukemia (AML)|Leuke Biological
2221 NCT03422Evaluating the Infect Recruiting No ResultsRespiratory Syncytial Virus InfectionBiological:
2223 NCT03666Patient Portal - Flu R CompletedNo ResultsInfluenza|Respiratory Tract Infectio Behavioral
2224 NCT00877Evaluation of Long-t CompletedHas ResultInfections, Papillomavirus|PapillomaProcedure:
2225 NCT00602Low Cost Interventio CompletedNo ResultsChildhood Immunization Completio Other: Red
2226 NCT00396A Study to Explore thCompletedHas ResultInfections, Rotavirus Biological:
2227 NCT01209Vaccine Therapy in P CompletedNo ResultsAnal Cancer|Nonneoplastic Conditi Biological
2228 NCT03483A Phase II Dose-rangiActive, notNo ResultsRotavirus Infections Biological:
2231 NCT01431Trial With AutologousCompletedNo ResultsStage II Breast Cancer|Stage III BreaBiological:
2232 NCT02601Safety and Immunogen Active, notNo ResultsRespiratory Syncytial Virus InfectionBiological
2233 NCT01276Effectiveness of SMS Unknown sNo ResultsHPV Vaccines Behavioral
2234 NCT00392Immunogeni CSISP-MENCompletedHas ResultMeningococcal Infection Biological
2235 NCT01399Shigella Sonnei OSPCWithdrawnNo ResultsShigellosis Drug: CP
2236 NCT00386Study to Evaluate ReaCompletedNo ResultsInfluenza Biological:
2237 NCT04242Phase 2 Shigella VaccNot yet recNo ResultsImmunisation|Shigella Infection Other: Plac
2238 NCT01183The Safety and Immun CompletedNo ResultsVirus Disease|DNA Virus Infections|Biological:
2239 NCT00349FMP2.1/AS02A: Rabies CompletedHas ResultMalaria|Plasmodium Falciparum MaBiological
2240 NCT02383QUILT-3.011 Phase 2 Active, notNo ResultsChordoma Other: GI-
2242 NCT03948Feasibility of Imple Recruiting No ResultsImmunisation Anxiety Related ReactOther: Mul
2243 NCT00993Travelers' Diarrhea (TCompletedNo ResultsTravelers' Diarrhea Biological:
2244 NCT00726Aldesleukin With or CompletedHas ResultStage IV Melanoma Biological:
2245 NCT04100Phase I Cli PICTON Not yet recNo ResultsPneumococcal Infections|StreptococBiological
2246 NCT00240H5 Booster Afer a T CompletedNo ResultsInfluenza Biological:
2247 NCT03789Reactogenicity, Safet Active, notNo ResultsSafety Issues Biological:
2248 NCT02690Extension Study to EvCompletedHas ResultBacterial Infection Due to StreptocoBiological:
2249 NCT01838Improving INSPIRE CompletedNo ResultsAdolescent Immunization Behavioral:
2250 NCT01126Combination HepatitiUnknown sNo ResultsHepatitis B Biological:
2251 NCT01375Effect of Vaccination CompletedNo ResultsSquamous Papilloma of the Larynx Biological:
2252 NCT02052MulticenteSPLENEVA Active, notNo ResultsSplenectomized Patients Biological
2253 NCT03722Monovalent mOPV1 Recruiting No ResultsPoliomyelitis Biological
2255 NCT00697Evaluation of ImmunoCompletedNo ResultsProphylaxis Herpes Simplex Biological
2256 NCT03296Efficacy of CONDYVACRecruiting No ResultsGenital Warts Biological:
2257 NCT00660Trial of Autologous, Unknown sNo ResultsAdenocarcinoma of the Ovary Biological
2258 NCT01087Brief Interventions t Unknown sNo ResultsHuman Papillomavirus Infection Behavioral
2259 NCT02992Malaria VaRTSS CompletedHas ResultMalaria Vaccine Biological
2260 NCT00623Study to Determine aCompletedHas ResultInfluenza Biological:
2262 NCT04209Safety and Immunogen CompletedNo ResultsHepatitis B Biological:
2263 NCT01072Evaluation of the Saf CompletedNo ResultsDengue Biological
2264 NCT00459Safety of and ImmuneCompletedHas ResultHIV Infections|Meningitis Biological
2265 NCT02252Rotavirus RotaNeo CompletedNo ResultsGastroenteritis
2266 NCT01770Age-Specific Strategi CompletedNo ResultsChildhood Vaccination Behavioral:
2267 NCT03069InnovativePNEUMOVRecruiting No ResultsInvasive Pneumococcal Infection Biological
2268 NCT01146Annual Study to InvesCompletedNo ResultsInfluenza Biological:
2269 NCT01096Trial to Evaluate the CompletedHas ResultInfluenza Biological
2271 NCT00500Study Evaluating SafeCompletedHas ResultPneumococcal Infections Biological
2272 NCT01063Adult Safety Study ofCompletedNo ResultsInfluenza Biological:
2273 NCT00996Pivotal, Multicenter CompletedHas ResultInfluenza Biological
2274 NCT01288Cytokine Production aCompletedNo ResultsImmunity; Defect Due to Antibody or Cell Me
2275 NCT03600Safety of LAIV4 in Ch Recruiting No ResultsAsthma in Children|Vaccine Advers Biological:
2278 NCT01711Study to Evaluate Im CompletedHas ResultInfluenza Biological:
2279 NCT01600ZOSTAVAXâ„¢ (ZosterActive, notNo ResultsHerpes Zoster|Shingles Biological
2280 NCT04097Factors InfFIVA Recruiting No ResultsFlu, Human Behavioral:
2281 NCT00466COMPAS (Clinical Oti CompletedHas ResultInfections, Streptococcal Biological:
2282 NCT02117A Study To Investigat CompletedHas ResultClostridium Difficile Associated DiseBiological:
2283 NCT01578Immune Responses toCompletedHas ResultInfluenza Biological
2284 NCT04185Immunogenicity and SNot yet recNo ResultsRotavirus Gastroenteritis Biological
2285 NCT01504Phase 1/2 Lyme VacciCompletedNo ResultsProphylaxis of Lyme Borreliosis Biological
2286 NCT00423Immunogenicity of GlCompletedHas ResultInfections, Papillomavirus|PapillomaBiological:
2287 NCT01803Dendritic Cell Vacci Active, notNo ResultsSarcoma|Sof Tissue Sarcoma|BoneBiological
2288 NCT00034Study of gp75 VaccineCompletedNo ResultsMalignant Melanoma Biological
2289 NCT02948Safety and Immunogen Active, notNo ResultsHealthy Volunteers Biological
2290 NCT01180Evaluation of SeasonaCompletedNo ResultsSeasonal Influenza Biological:
2291 NCT01608Study of a Single Dos CompletedHas ResultSalmonella Infections|Typhoid FeverBiological:
2292 NCT01130A Pilot Study of Glio Recruiting No ResultsNewly Diagnosed Pediatric Pontine Biological:
2293 NCT03384Multi-Targeted Reco Active, notHas ResultNeoplasms|Prostate Cancer|Lung CBiological
2294 NCT00317Vaccination With AutActive, notNo ResultsBreast Cancer Biological:
2296 NCT01435Safety Study of a Me CompletedNo ResultsMelanoma Biological
2297 NCT01403CollaboratiCollabFlu CompletedNo ResultsInfluenza|Collaboration Behavioral:
2298 NCT00652Evaluation of ImmunoCompletedHas ResultInfections, Papillomavirus Biological
2299 NCT01852Exploratio PCV13 CompletedHas ResultMultiple Myeloma Biological:
2300 NCT01049Dose Sparing Intrade CompletedNo ResultsInfluenza Infection Biological
2301 NCT04080Influenza VaccinationRecruiting No ResultsPlasma Cell Neoplasm Biological:
2302 NCT00985Immunization of Chil CompletedHas ResultInfections, Streptococcal Biological
2303 NCT01789A Phase I/IUV1-hTERTActive, notNo ResultsNon-small Cell Lung Cancer Biological
2304 NCT02189Phase â…£ Clinical T CompletedNo ResultsHepatitis E Biological:
2305 NCT02366Trial of the Safety a CompletedNo ResultsHIV Biological
2306 NCT00464Non-Inferiority of M CompletedHas ResultInfections, Meningococcal Biological
2308 NCT03183Intralesional Measle Unknown sNo ResultsCommon Wart|Plantar Wart Drug: Meas
2309 NCT00558A Pilot St NANOVAX CompletedNo ResultsInfluenza, Human Biological: Flu Vacci
2310 NCT00170Comparison of DeliverCompletedNo ResultsInfluenza Biological: Trivalent
2311 NCT02166Immune Response toTerminate
He No ResultsHepatitis B Vaccination Biological
2312 NCT02408VRC 208: Dose, Safet CompletedNo ResultsHealthy Adult Immune Responses toBiological
2314 NCT00496Safety,Tolerability a CompletedHas ResultGastroenteritis|Rotavirus Biological:
2315 NCT00928Study Comparing a TdCompletedNo ResultsHealthy Biological
2316 NCT00758Influenza VaccinationUnknown sNo ResultsInfluenza|Acquired Immune DeficieBiological
2317 NCT03458Yellow Fever ImmuneCompletedNo ResultsHealthy Drug: Yell
2318 NCT01381PPSV23 Pneumococcal CompletedNo ResultsChronic Obstructive Pulmonary DiseBiological
2319 NCT01037Observational Study oCompletedNo ResultsNovel Influenza A (H1N1)|A New FluOther: Non
2320 NCT01669Adjuvanting Viral Ve CompletedNo ResultsMalaria|Matrix M Biological
2321 NCT03206Immuno-persistence SCompletedNo ResultsCervical Intraepithelial Neoplasia|C Procedure:
2322 NCT00971Cyclophosphamide and CompletedHas ResultBreast Cancer Biological
2323 NCT02567Post-authorisation SaCompletedNo ResultsInfluenza Other: Vacc
2324 NCT03835Trial to Evaluate the Active, notNo ResultsPneumococcal Disease Biological
2325 NCT00452Evaluation of Long-TeCompletedNo ResultsEncephalitis, Tick-Borne Procedure:
2326 NCT03966Effectiveness of CAR Recruiting No ResultsVaccination; Complications|Vaccine Other: Mul
2327 NCT01466A Phase 3b, RandomizCompletedHas ResultMeningococcal Disease|Meningococc Biological
2328 NCT00517Study to T FUTURE CompletedNo ResultsCervical Cancer|Genital Warts Biological
2329 NCT01570Combination Immunot CompletedNo ResultsBreast Cancer Drug: Herc
2330 NCT00756Evaluation of Pneumoc CompletedNo ResultsInfections, Streptococcal Biological
2331 NCT00377Demonstrate the Supe CompletedNo ResultsInfluenza Biological:
2332 NCT03671A Post-marketing SurvRecruiting No ResultsNeoplasms, Rectal Other: Safe
2333 NCT02071Safety, Tolerability, CompletedNo ResultsInfluenza A Drug: Vacc
2334 NCT02274Immunogeni DREVAC Unknown sNo ResultsInvasive Pneumococcal Infections|SiBiological
2335 NCT01506Immunogenicity and SCompletedHas ResultRubella|Varicella|Measles|Mumps Biological:
2336 NCT01399A Phase II Clinical Tr CompletedNo ResultsImmunogenicity|Safety Biological
2337 NCT01000Rapid Evaluation of PCompletedNo ResultsInfluenza|H1N1 2009 Influenza Biological:
2338 NCT02067Safety Stu CJCV1-01 CompletedHas ResultCampylobacter Infection Biological
2339 NCT03854Hepatitis B Virus VaccRecruiting No ResultsViral Hepatitis B|Immunization; InfeDrug: Enge
2340 NCT00291A Study to Compare th CompletedNo ResultsHepatitis B Biological
2341 NCT00128Safety and Immunogeni CompletedNo ResultsCholera Biological:
2342 NCT03360Vaccine Therapy in TrRecruiting No ResultsGiant Cell Glioblastoma|Recurrent Other: Lab
2343 NCT00664Flu VaccinaFLUVACS-I CompletedNo ResultsHeart Failure Biological:
2344 NCT00098Study to Evaluate theCompletedNo ResultsRECOMBINANT BOTULINUM VACCINBiological:
2345 NCT01815Immunogenicity and Sa CompletedNo ResultsJapanese Encephalitis|Chickenpox Biological:
2346 NCT01662Vaccine Health Litera CompletedHas ResultInfluenza Other: Tex
2347 NCT00385Study to Evaluate th CompletedHas ResultInfluenza Biological
2348 NCT00370Safety and Immunogen CompletedNo ResultsInfections, Streptococcal Biological
2349 NCT03296Bacillus CaACTIVATE Active, notNo ResultsInfection|Hospitalization|Mortality Biological:
2350 NCT00085DC Vaccine CombinedCompletedHas ResultKidney Cancer Biological:
2351 NCT01991Study of Immunogenic CompletedNo ResultsMeasles|Mumps|Rubella|Varicella Biological
2353 NCT01188Study of Japanese EnCompletedHas ResultJapanese Encephalitis|Measles|MuBiological:
2354 NCT01644Clinical Trial Assess CompletedHas ResultInfluenza Prophylaxis Device: Str
2355 NCT00779Efficacy, ImmunogenicCompletedHas ResultInfections, Papillomavirus Biological
2356 NCT02398Conventional VaccineCompletedNo ResultsHuman Influenza Biological:
2357 NCT00901ACE527 Safety and I CompletedNo ResultsEnterotoxigenic E. Coli (ETEC) Infect Biological:
2358 NCT00051Development of a NeCompletedNo ResultsHIV Infections Biological:
2359 NCT02601PfSPZ Vaccine: Dose CompletedNo ResultsMalaria Biological
2360 NCT00707Safety and Immunogeni CompletedHas ResultTuberculosis Biological:
2361 NCT00778Clinical Study in Chi CompletedHas ResultInfluenza Biological:
2362 NCT01379A Study to Evaluate t CompletedHas ResultInfluenza Biological
2363 NCT01278Trial of Vaccine The CompletedNo ResultsMalignant Melanoma Biological
2365 NCT00625Study to E Sched2 CompletedNo ResultsMeningococcal Infections|Pneumoco Biological: NeisVacC
2366 NCT00387Study Evaluating SafeCompletedNo ResultsHealthy Biological
2367 NCT00320Compare Immunogenicit CompletedNo ResultsDiphtheria|Hepatitis B|PoliomyelitisBiological
2368 NCT03685HEPLISAV-B Hepatitis Recruiting No ResultsHepatitis|Safety and Tolerability Biological:
2369 NCT04083Intra-dermal With TopRecruiting No ResultsInflammatory Bowel Diseases|Hepati Biological:
2370 NCT01264CombinatioMEL53 CompletedNo ResultsMelanoma Biological
2371 NCT01861Modified Melanoma Va Unknown sNo ResultsHigh Risk HLA-A2+ Melanoma|Metast Biological
2372 NCT00674Phase IV InterchangeaCompletedNo ResultsDiphtheria|Tetanus|Pertussis|HepatBiological:
2373 NCT00082Vaccine Therapy WithCompletedHas ResultBreast Cancer Biological:
2374 NCT02636Nelipepimut-S Plus GM Active, notNo ResultsDuctal Breast Carcinoma In Situ Other: Lab
2375 NCT02382Two-dose Schedule ofUnknown sNo ResultsHuman Papilloma Virus Biological
2376 NCT02797Study of the Long TerUnknown sNo ResultsHepatitis B Vaccines Other: Dete
2377 NCT04024Study to Assess the I Recruiting No ResultsInfluenza (Healthy Volunteers) Biological
2378 NCT00943Sanofi Pasteur, TIV + CompletedHas ResultInfluenza Biological:
2379 NCT00307Assess the Immunogen CompletedNo ResultsInfections, Streptococcal|Streptoc Biological
2380 NCT00545Study of a ADVAX-EP CompletedNo ResultsHIV Infections Device: Tri
2381 NCT01942Adult Influenza Vacc CompletedNo ResultsInfluenza Vaccination Behavioral
2382 NCT00703A Phase I/ CHESAT Active, notNo ResultsNeuroblastoma Biological:
2383 NCT03264Safety and Effectiven CompletedHas ResultHealthy Drug: HRIG
2384 NCT00356Study in Adolescents CompletedHas ResultInfections, Meningococcal Biological
2386 NCT01159Comparison of Engerix Unknown sNo ResultsCeliac Disease Biological:
2387 NCT03953Increasing HPV VaccinNot yet recNo ResultsHuman Papilloma Virus|HPV VaccinaBiological:
2389 NCT01746Immunogenicity and SCompletedHas ResultInfections, Streptococcal|Streptoc Biological:
2390 NCT01475Sequential InactivatedCompletedNo ResultsPolio|Poliomyelitis Biological:
2393 NCT00558Alpha-type-1 DendritiCompletedNo ResultsMetastatic Colorectal Cancer Biological
2394 NCT02693A Study to Evaluate t Unknown sNo ResultsHepatitis B, Chronic Biological
2395 NCT01067Safety and Immunogeni CompletedHas ResultDiarrhea Biological:
2396 NCT02266Exploring LAIV CompletedNo ResultsAcquired Immune Deficiency SyndroBiological:
2397 NCT02419Mature Dendritic CellWithdrawnNo ResultsCarcinoma, Non-Small-Cell-Lung|Non Procedure:
2398 NCT01421Safety and Immunogeni CompletedNo ResultsInfection, Viral, Enterovirus Biological
2399 NCT01251Hepatitis B ChallengeCompletedHas ResultHepatitis B Biological:
2400 NCT00800Immunogenicity Study CompletedNo ResultsInfluenza Biological:
2401 NCT03699Reducing tSTOP-FLU Recruiting No ResultsInfluenza|Organ Transplantation Biological:
2402 NCT01973Vaccinatio ABSIDE Recruiting No ResultsMalignant Melanoma of Skin Stage IOther: arm
2403 NCT02094DTaP-IPV-Hep B-PRP~T CompletedNo ResultsDiphtheria|Tetanus|Pertussis|Haemop Biological
2404 NCT00294Study to Evaluate theCompletedHas ResultInfections, Papillomavirus|PapillomaBiological:
2405 NCT02002A Study of BAM CompletedNo ResultsBCG Infection|Reaction - Vaccine| Biological
2406 NCT01536Sirolimus and VaccineActive, notNo ResultsRecurrent Fallopian Tube Cancer|Recu Biological
2407 NCT04266Phase I Tr PANDA-VANot yet recNo ResultsSquamous Cell Lung Cancer|Squamou Biological
2408 NCT02964A Phase â…£ Clinical TCompletedHas ResultHepatitis E Biological:
2409 NCT00538Evaluation of Safety CompletedHas ResultInfluenza Biological:
2410 NCT04248DNAJB1-PRKACA Fusion Not yet recNo ResultsFibrolamellar Hepatocellular Carcin Drug: DNAJ
2411 NCT00798Heterosubtypic Immun CompletedNo ResultsInfluenza Biological:
2412 NCT03998Diphtheria Vaccinati CompletedNo ResultsDiphtheria|Inflammatory Bowel Dis Biological:
2413 NCT02079Study Immunogenicity CompletedNo ResultsPneumococcal Infections Biological:
2414 NCT00822Influenza Vaccinatio CompletedNo ResultsInfluenza Drug: Influ
2415 NCT00383Study of Inactivated, CompletedNo ResultsOrthomyxoviridae Infection|InfluenBiological:
2416 NCT01061Safety and Immunogeni Unknown sNo ResultsRotavirus Gastroenteritis Biological
2417 NCT02732Hepatitis B Vaccinati CompletedNo ResultsHepatitis B Biological
2418 NCT00620Probiotics to EnhanceCompletedNo ResultsHealthy Dietary Su
2419 NCT00712Cytomegalovirus VacciCompletedNo ResultsPrecancerous/Nonmalignant ConditBiological
2420 NCT03729Immunological ToleraRecruiting No ResultsRabies Biological:
2421 NCT00441Safety and Efficacy S CompletedHas ResultJapanese Encephalitis Biological:
2422 NCT03448Safety of 4Fluart Int Unknown sNo ResultsInfluenza Biological:
2423 NCT02079Effectiveness of the CompletedNo ResultsPneumonia|Acute Respiratory DiseaBiological
2424 NCT02526Safety and Immunogeni CompletedNo ResultsHerpes Zoster Biological:
2425 NCT00940Toll-like Receptor (T CompletedNo ResultsMelanoma Biological:
2427 NCT00804Database Surveillanc CompletedNo ResultsDiphtheria|Tetanus|Pertussis|HaemBiological:
2428 NCT00471Safety and Immunogen CompletedNo ResultsMelanoma (Skin)|Intraocular Mela Biological
2429 NCT02722Trial of Heat Shock P Recruiting No ResultsGlioblastoma Multiforme|Astrocyt Biological
2430 NCT02748MTX Discontinuation CompletedHas ResultArthritis, Rheumatoid Drug: Meth
2431 NCT00981Direct and Indirect B CompletedNo ResultsInfluenza Virus Infection|Influenza-lBiological:
2432 NCT02267Phase 1 Trial of EbolaCompletedNo ResultsEbola Virus Disease|Hemorrhagic FeBiological
2433 NCT04220Inactivated PoliomyelCompletedNo ResultsPoliomyelitis Biological:
2434 NCT01026Rotavirus GastroenterCompletedNo ResultsRotavirus Gastroenteritis
2435 NCT02284Adult Influenza Vacci CompletedNo ResultsInfluenza Behavioral
2436 NCT01967An Open Label Study Recruiting No ResultsHealthy Biological
2437 NCT01201A Study to Evaluate t CompletedNo ResultsInfluenza Infection Biological
2438 NCT02200Influenza Immunizati Recruiting No ResultsInfluenza|Immunization|Older AdulBiological:
2439 NCT00519Long-term PersistenceCompletedHas ResultHepatitis B Vaccine Biological:
2441 NCT00427Study Comparing a 13CompletedHas ResultPneumococcal Infections Biological
2443 NCT04066A CombinatPrEPVacc Not yet recNo ResultsHIV Infections Biological
2444 NCT00360Partially-blind (Obse CompletedHas ResultMalaria Biological
2445 NCT03133Evaluation of the Eff Recruiting No ResultsInfluenza, Human Biological:
2446 NCT01461A Clinical Trial to S CompletedHas ResultVaccines|Meningococcal Vaccines Biological:
2447 NCT03981Salmonella Conjugates Recruiting No ResultsRisk Reduction Biological:
2448 NCT00799Safety Study of GSK CompletedHas ResultInfections, Papillomavirus Biological:
2449 NCT03228Immune Responses and Recruiting No ResultsRabies Procedure:
2450 NCT02937In the Era of the HPV Recruiting No ResultsHSIL, High-Grade Squamous Intraepithelial Les
2451 NCT00028Vaccine Therapy WithCompletedNo ResultsAdenocarcinoma of the Colon|Adenoc Biological
2452 NCT01729Vaccine Therapy in TrTerminate No ResultsHER2-positive Breast Cancer|Male BBiological
2453 NCT03893Immunity and Safety Not yet recNo ResultsHand, Foot and Mouth Disease Biological:
2455 NCT01773Immunizatio IPiCC CompletedNo ResultsUp-to-date Immunization Status for B Cehavioral:
2456 NCT02314Placebo Controlled, DCompletedHas ResultEbola Virus Biological
2457 NCT00772Phase I Randomized, TPerminate Has ResultClostridium Difficile Infection|ClostrBiological:
2458 NCT01382H5N1 Vaccine Study iCompletedNo ResultsH5N1 Influenza Biological:
2459 NCT00945Study of the Influenz CompletedNo ResultsInfluenza Biological:
2460 NCT02515Safety Stu Mel64;PATActive, notNo ResultsMelanoma Biological
2461 NCT02957Immunogeni RETAIN Active, notNo ResultsInfluenza, Human Biological:
2463 NCT02780Vaccine ThWOKVAC Active, notNo ResultsHER2/Neu Negative|No Evidence ofOther: Di Lab
2464 NCT00566Efficacy Study of an I CompletedNo ResultsInfluenza Biological:
2465 NCT00865Safety and Effective Terminate Has ResultHIV Infections Biological
2466 NCT00698Immunogenicity and SCompletedNo ResultsHepatitis B Biological
2467 NCT00973Norwalk Vaccine StudCompletedNo ResultsAcute Gastroenteritis|Norwalk VirusBiological:
2468 NCT01080Safety and Efficacy S CompletedHas ResultDysentery|Shigella|Diarrhea Biological:
2469 NCT00432A Study to Evaluate I CompletedHas ResultInfections, Rotavirus|Rotavirus VaccBiological:
2470 NCT00399Trastuzumab, CyclophCompletedNo ResultsBreast Neoplasms Biological
2471 NCT00552Immunogenicity and Sa CompletedHas ResultInfections, Papillomavirus Biological:
2472 NCT00900Impact of 7vPCV Unknown sNo ResultsStreptococcus Pneumoniae Biological
2473 NCT00920Safety & Immunogenic CompletedHas ResultHerpes Zoster Biological:
2474 NCT02665Safety Study of Freez Unknown sNo ResultsInfluenza Biological:
2475 NCT03429Maximizing HPV Vaccin Not yet recNo ResultsHuman Papillomavirus (HPV) VaccinBehavioral
2476 NCT00835Evaluation of GlaxoSmCompletedHas ResultTetanus|Acellular Pertussis|DiphtheBiological:
2477 NCT02882Adjuvanted InfluenzaActive, notNo ResultsInfluenza|Influenza-like Illness Biological:
2478 NCT02979Study to Evaluate theCompletedHas ResultHerpes Zoster Biological
2479 NCT02052Study to Assess the I CompletedHas ResultHerpes Zoster Biological
2480 NCT01664From Innovation to SoCompletedHas ResultInfluenza Behavioral:
2481 NCT01014Evaluate the Safety a CompletedNo ResultsInfluenza Biological:
2482 NCT00057A New Anthrax VaccinCompletedNo ResultsAnthrax Biological: Anthrax|Bi
2483 NCT02242Study to Evaluate th CompletedHas ResultInfluenza Biological:
2484 NCT00516Vaccine TheNSCLC Terminate No ResultsNon-small-cell Lung Cancer (NSCLC) Biological
S
2485 NCT01026EBA-175 RII-NG MalarCompletedNo ResultsPlasmodium Falciparum Malaria Drug: Plac
2486 NCT00296H5 Vaccine Alone or W CompletedNo ResultsInfluenza Drug: Alum
2487 NCT00405A Pilot Study of TumoCompletedNo ResultsSarcoma|Neuroblastoma|Wilm's T Biological:
2488 NCT00706Immune Responses toCompletedHas ResultHIV Infections Biological
2489 NCT00126Evaluate 4 Different CompletedNo ResultsInfections, Meningococcal Biological
2490 NCT01381Dose Escalation Trial CompletedNo ResultsPlague Biological:
2491 NCT03807Chikungunya Vaccine Recruiting No ResultsChikungunya Virus Infection Biological
2493 NCT02531A Study to Describe tCompletedHas ResultMENINGOCOCCAL INFECTION Biological:
2494 NCT03581A Study in Healthy AdCompletedNo ResultsInfluenza Biological
2495 NCT03373Vaccination for Child Recruiting No ResultsVaccination|Hematologic MalignancBiological:
2497 NCT00492Immunity AgVZVinOLTxUnknown sNo ResultsLiver Disease|Immunosuppression|V Biological:
2498 NCT00530Idiotypic VFLIDVAX20Recruiting No ResultsFollicular Lymphoma|First Relapse/ Biological:
2499 NCT00980Immunogenicity, SafeCompletedNo ResultsInfluenza|Virus Diseases Biological
2500 NCT01609Norovirus Bivalent-VaCompletedHas ResultPrevention From Norovirus InfectionBiological:
2501 NCT01909Combination Vaccine CompletedNo
I ResultsCarcinoma, Non-Small-Cell Lung Drug: Cycl
2502 NCT01345Persistence Of Antib CompletedHas ResultMeningococcal Disease Biologica
2503 NCT00481Immunogenicity and SCompletedHas ResultHuman Papillomavirus (HPV) Infecti Biological:
2504 NCT00742Immunogenicity and Sa CompletedHas ResultInfluenza Biological
2505 NCT00784Phase II Study of AlloTerminate Has ResultBreast Cancer Biological:
2506 NCT00455Influenza Vaccine in CompletedNo ResultsInfluenza|Infant, Premature Biological: Trivalent
2507 NCT00702Safety and Efficacy S Terminate Has ResultHypertension|Cardiovascular Disea Biological
2508 NCT00213Safety and Immunogen Unknown sNo ResultsOrgan Transplant|ImmunosuppressiBiological
2509 NCT01701Safety, Tolerability, CompletedHas ResultBotulism Biological:
2510 NCT01442Study of a Single Dos CompletedHas ResultMeningitis|Meningococcal InfectionBiological
2511 NCT02771Influence of BCG on Unknown sNo ResultsWhooping Cough Biological:
2512 NCT02274DTaP-IPV/Hib VaccineCompletedNo ResultsTetanus|Diphtheria|Pertussis|Poliom Biological
2513 NCT02860High Dose Flu Vaccin Recruiting No ResultsHematopoietic Cell Transplantation Biological:
2514 NCT01277Comparison of GSK Bio CompletedNo ResultsTetanus|Diphtheria|Acellular PertusBiological:
2515 NCT01377A Dose-escalating StuCompletedNo ResultsDiarrhea|Fever|Nausea|Vomit|IrritaBiological:
2516 NCT00138Control of CEI CompletedHas ResultInfluenza Biological:
2517 NCT01056The ClinicaSabin IPV CompletedNo ResultsPoliomyelitis Biological:
2518 NCT01240Study of QuadrivalenCompletedHas ResultInfluenza Biological:
2519 NCT00548Safety and Immunogeni Unknown sNo ResultsCholera|Diarrhea|Vibrio Infections Biological:
2521 NCT00219Neonatal Immunizati CompletedNo ResultsPneumonia|Meningitis|Otitis Medi Biological
2522 NCT02956Personaliz SKLB1608 Recruiting No ResultsCarcinoma, Non-Small-Cell Lung Biological:
2523 NCT01063Study of I FLU-HOP Unknown sNo ResultsInfluenza A Virus, H1N1 Subtype Biological
2524 NCT00671Trial of Melaxin Canc Terminate Has ResultMelanoma Biological
2525 NCT02743A Phase I Trial to Ev CompletedNo ResultsYellow Fever Drug: ISA-
2526 NCT03057The Treatment of Adva Not yet recNo ResultsCarcinoma, Non-Small-Cell Lung Biological:
2527 NCT03002Tailoring of Vaccine- CompletedNo ResultsHuman Papillomavirus Behavioral
2528 NCT00727Vaccine Therapy WithActive, notHas ResultPancreatic Cancer Biological
2529 NCT02528MiHA-loade PSCT19 Recruiting No ResultsHematological Malignancies Biological
2530 NCT00871Feasibility Study of Terminate Has ResultTetanus|Poliomyelitis|Neisseria MenBiological
2531 NCT03600Cellular Immune RespRecruiting No ResultsTyphoid Fever Patients and Healthy Biological:
2532 NCT00824Study Evaluating 13- CompletedHas ResultPneumococcal Vaccines Biological
2533 NCT02101Immune Response ofCompletedNo
In ResultsInfluenza, Human Biological:
2535 NCT00426GM-CSF Vaccinations CompletedNo ResultsMyelodysplastic Syndrome RAEB-I orBiological
2536 NCT01974Study to Evaluate Im CompletedHas ResultInfluenza Biological:
2537 NCT00561Immunogenicity and Sa CompletedHas ResultPrevention of : Herpes-Zoster Biological:
2538 NCT00600Immunogenicity and Sa CompletedNo ResultsTuberculosis (TB) Biological:
2539 NCT01441A Phase I Safety and Terminate No ResultsHIV Infection Biological:
2540 NCT00333Immunogenicity, SafetCompletedNo ResultsInfluenza Biological:
2541 NCT00610Immunogenicity & Reac CompletedHas ResultAcellular Pertussis|Tetanus|DiphtheBiological:
2542 NCT02411A Phase I Study of a Active, notNo ResultsProstate Cancer Biological:
2543 NCT02035IVAC MUTANOME Phase CompletedNo ResultsMelanoma Biologica
2544 NCT00971Evaluation of the Im CompletedHas ResultInfluenza Biological:
2545 NCT03630Safety andMET33 Recruiting No ResultsHealthy Volunteers (Meningococcal B I iological:
2546 NCT03042Vaccination With PD-Active, notNo ResultsMultiple Myeloma Biological:
2547 NCT00120Study of Na-ASP-2 HuCompletedNo ResultsHookworm Infection Biological
2548 NCT03982A Study of an Ad26.RSActive, notNo ResultsRespiratory Syncytial Viruses|RespirBiological:
2549 NCT02151Î±DC1 Vaccine + ChemCompletedHas ResultMalignant Neoplasm of Pancreas Met Biological:
2550 NCT01102Effectiveness of HepaCompletedNo ResultsHepatitis Biological:
2551 NCT02010Phase I Study of a DeActive, notNo ResultsGlioblastoma|Glioblastoma Multif Biological:
2552 NCT02532Long-term BR-JELITE CompletedNo ResultsJapanese Encephalitis Biological:
2553 NCT00626The Use of Dendritic CompletedNo ResultsMetastatic Melanoma Biological
2554 NCT01459Evaluating the Safety CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological
2555 NCT01218A Study to Evaluate thCompletedHas ResultInfluenza Biological:
2556 NCT00050Expanded Dryvax Dilut CompletedNo ResultsSmallpox Biological:
2557 NCT00952A Study of Different CompletedHas ResultInfluenza|Swine-origin A/H1N1 Infl Biological
2558 NCT04001Vaccinatio VIP-ACS Recruiting No ResultsAcute Coronary Syndrome Biological
2559 NCT02537Developing a Self-pe Active, notNo ResultsHuman Papillomavirus Vaccines Behavioral:
2560 NCT03802Pneumococcal Conjuga Recruiting No ResultsRenal Transplantation|Aging Drug: 23 v
2561 NCT03025Safety andVIPV-07 CompletedNo ResultsPoliomyelitis Biological:
2562 NCT01165Study to Evaluate Eff CompletedHas ResultHerpes Zoster Biological
2563 NCT03822A Clinical Trial to E CompletedNo ResultsPoliomyelitis Biological
2564 NCT00458Vaccination of Patien Active, notHas ResultRenal Cancer Biological
2566 NCT00300Vaccine Treatment f CompletedNo ResultsMalignant Melanoma Biological
2567 NCT00345Immunogenicity and SCompletedHas ResultInfections, Streptococcal Biological:
2568 NCT01831Safety and Immunogeni CompletedNo ResultsPoliomyelitis Biological:
2569 NCT02535Developing a Self-perEnrolling bNo ResultsHuman Papillomavirus Vaccines Behavioral
2570 NCT00271Fractional Dose TetraCompletedNo ResultsInfections, Meningococcal|MeningitBiological
2571 NCT00613Safety and Immunogeni CompletedNo ResultsHelicobacter Pylori|Gastritis|Gast Biological:
2572 NCT02947Effect of I IVF-FluVacEnrolling bNo ResultsInfertility Biological:
2573 NCT01088A Trial of Boost Vacci Recruiting No ResultsPancreatic Cancer Biological
2574 NCT02087HPV (Human VACCAIN-PCompletedNo ResultsAIN|HIV Biological:
2575 NCT03822A Clinical Trial to E CompletedNo ResultsPoliomyelitis Biological
2576 NCT00783Influenza Vaccinatio CompletedNo ResultsImmunosuppression Biological:
2577 NCT02416A Study to Assess SafCompletedNo ResultsEbola Viral Disease Biological
2578 NCT03296The Phase IVd of InacUnknown sNo ResultsHand, Foot and Mouth Disease (HF Biological:
2579 NCT00950Observational Study CompletedNo ResultsInfluenza|Pandemic Influenza Biological: H1N1 Pand
2580 NCT04166Research TSPLEMENGNot yet recNo ResultsSplenectomy Biological
2581 NCT01960An Alternate Dosing SCompletedHas ResultDiarrhea|Gastroenteritis Biological:
2582 NCT02444ZOSTAVAX in Persons Active, notHas ResultShingles Drug: ZOS
2583 NCT02713Hepatitis B VaccinatioCompletedNo ResultsHepatitis B Biological
2584 NCT00694Vaccination With LethCompletedNo ResultsGlioma Biological
2586 NCT00196Human Papilloma ViruCompletedHas ResultInfections, Papillomavirus Biological:
2587 NCT03559Patient-individualize Recruiting No ResultsPrimary/Relapsed Acute LymphoblastBiological
2588 NCT01192Comparison PRIME CompletedNo ResultsMeningococcal Meningitis Biological
2589 NCT02405Safety and Feasibilit Recruiting No ResultsHPV16 Associated Cervical Cancer Biological:
2590 NCT04230Limits of the Social CompletedNo ResultsInfluenza Vaccine|Behavioral InterveBehavioral
2591 NCT00958A Clinical Trial of CS CompletedHas ResultInfluenza Biological:
2592 NCT00441Study of Modified Pr CompletedHas ResultHaemophilus Influenzae Type B|Hepa Biological
2593 NCT00404Lot Consistency StudyCompletedHas ResultDiphtheria|Tetanus|Pertussis|Hepati Biological
2594 NCT00573Multipeptide VaccineCompletedNo ResultsBreast Neoplasm|Breast Cancer|CanBiological:
2595 NCT01267Booster Study of Comb CompletedNo ResultsDiphtheria|Pertussis|Tetanus Biological:
2596 NCT00252Safety and Immunogen CompletedNo ResultsHIV Infection Biological
2597 NCT02946Effect of DE-FluVac Enrolling bNo ResultsInfertility|Recurrent Miscarriage Biological:
2598 NCT02676A Study of the Safet CompletedHas ResultShigella Sonnei Infection Biological
2599 NCT02111Safety of NSNIFFLE-2 CompletedNo ResultsEgg Hypersensitivity Drug: Admin
2600 NCT04239GVAX Plus CheckpointRecruiting No ResultsNeuroblastoma|Pediatric Solid TumProcedure:
2601 NCT02726Pneumococcal Post-Va Unknown sNo ResultsSmokers, Elderly, Asthma, COPD, RecBiological:
2602 NCT03038Safety, ImmunogenicitWithdrawnNo ResultsShigella Sonnei Dysenteries Biological:
2603 NCT00048NeuroblastCYCHE2 CompletedNo ResultsNeuroblastoma Biological
2604 NCT03023T-cell And General I CompletedHas ResultInfluenza Biological:
2605 NCT02128Study of t CervISA CompletedNo ResultsCervical Cancer Drug: ISA1
2606 NCT00928Safety Surveillance CompletedNo ResultsSmallpox
2607 NCT01557A Clinical PMV-001 CompletedHas ResultProphylaxis for the Measles Infectio Biological
2608 NCT01045Safety and Immunogeni WithdrawnNo ResultsInfluenza Biological
2609 NCT00977Phase 1 Study of the WithdrawnNo ResultsMalaria|Malaria Vaccines|PlasmodiBiological
2610 NCT00730A Study to Assess theTerminate Has ResultHuman Papillomavirus Infection Lead Biological:
2611 NCT03547Immunogenicity and SRecruiting No ResultsMeningococcal Infections Biological
2612 NCT03590Influenza VaccinationCompletedNo ResultsInfluenza|Solid Carcinoma Biological:
2613 NCT02690Cross-vaccination St CompletedNo ResultsHerpes Zoster Biological
2614 NCT00128Vaccine To Prevent CerCompletedHas ResultCervical Cancer|Precancerous CondiBiological:
2615 NCT00407Efficacy Study of T CeCompletedNo ResultsHIV Infections Biological:
2616 NCT00408Efficacy of Combine CompletedNo ResultsMalaria|Malaria, Falciparum Biological
2617 NCT03572A Study to Evaluate t Recruiting No ResultsRespiratory Tract Infection Biological:
2618 NCT02309Lenalidomide in ImprCompletedNo ResultsMonoclonal B-Cell Lymphocytosis|SOther: Lab
2619 NCT01450Safety and Immunogen CompletedNo ResultsMalaria Biological
2620 NCT00490Phase 1-2 of a CpG-ACompletedHas ResultLymphoma, Mantle-Cell Biological
2621 NCT00718Immunogenicity and Sa CompletedNo ResultsInfluenza|Orthomyxoviridae Infecti Biological:
2623 NCT03617Safety andGRC90 CompletedHas ResultInfluenza Biological
2624 NCT01266Safety and Immunogen CompletedHas ResultRotavirus Infection Biological:
2625 NCT01403Study to InTERIVA CompletedHas ResultMultiple Sclerosis Drug: terif
2626 NCT01949Safety AndP27A CompletedNo ResultsMalaria Biological
2627 NCT00250Evaluation of the Im CompletedHas ResultInfections, Papillomavirus|PapillomaBiological:
2628 NCT03012Multi-epitope Folate Recruiting No ResultsBilateral Breast Carcinoma|Stage IB Drug: Cycl
2629 NCT03955Using BootRADVax Enrolling bNo ResultsPrimary Prevention Behavioral
2630 NCT03960Assessing the Effecti Recruiting No ResultsDengue Biological
2631 NCT01769MeFirst: A Tailored I CompletedNo ResultsHuman Papillomavirus-Related Car Behavioral:
2632 NCT03281A Study to Test if t Active, notNo ResultsRespiratory Disorders Biological
2633 NCT01258Tumor Cell Vaccines Terminate No ResultsMesolthelioma|Esophageal Cancer Drug: Celeb
2634 NCT01706Evaluation of a 3-dos CompletedNo ResultsClostridium Difficile Associated DiseBiological:
2636 NCT00849A Study of Safety, To CompletedHas ResultHIV-1|HIV Infections Other: Com
2637 NCT01386Immune Res HIPAVAC CompletedNo ResultsHIV|Human Papillomavirus Biological:
2638 NCT00828Effectiveness of a V CompletedNo ResultsInfluenza Vaccine|Papillomavirus InfOther: Vac
2640 NCT03223Safety and Immunogeni Recruiting No ResultsGlioblastoma Drug: Poly-
2641 NCT01262Safety and Immunogen CompletedHas ResultTuberculosis Biological:
2642 NCT02106Safety and Immunogen CompletedHas ResultInfections, Meningococcal Biological
2644 NCT00715The Long-term AntiboCompletedHas ResultInfections, Meningococcal Biological
2645 NCT02661Safety and Immunogeni CompletedNo ResultsNorovirus Biological:
2646 NCT03042Vaccine AgV6 Recruiting No ResultsAtherosclerosis Biological:
2647 NCT00397Evaluate Safety & Im CompletedHas ResultInfluenza Biological:
2649 NCT02891A Safety Trial to Tes CompletedNo ResultsEbola Disease|Marburg Disease Biological:
2650 NCT03610Safety, Reactogenici Recruiting No ResultsHuman Papillomavirus Infections Biological
2652 NCT00831Study of DTaP-IPV-H CompletedHas ResultDiphtheria|Tetanus|Pertussis|Haemo Biological
2653 NCT01359A Study To Assess th CompletedHas ResultRheumatoid Arthritis Drug: CP-6
2655 NCT01000Response tRIFLUVAC CompletedNo ResultsMamma Carcinoma|Heart Failure Biological:
2656 NCT01914Study of t HPVXneutrUnknown sNo ResultsInfection With Human PapillomaviruBiological:
2657 NCT00488Single Group Study ofCompletedNo ResultsInfluenza|Virus Diseases Biological
2658 NCT00248Safety and Immunogen CompletedHas ResultMeningitis, Meningococcal, SerogroBiological
2659 NCT03821Trail To Evaluate the Recruiting No ResultsPoliomyelitis Biological
2660 NCT02415Typhoid Vac IMPACT Recruiting No ResultsCognitive Side Effects of Cancer Th Biological
2661 NCT01987T-cell And General ImCompletedHas ResultInfluenza Biological:
2662 NCT01192Allogeneic ATOMIC Active, notNo ResultsNeuroblastoma Biological
2663 NCT00148Allogeneic Tumor CellWithdrawnNo ResultsMetastatic Solid Tumors Biological:
2664 NCT00958A Clinical Trial of CS CompletedHas ResultInfluenza Biological:
2665 NCT01107Study to Assess the SCompletedNo ResultsInfections, Rotavirus Biological:
2666 NCT00596Longterm Immunogenic CompletedHas ResultJapanese Encephalitis Biological:
2667 NCT02546Use of a Patient EducCompletedNo ResultsHuman Papilloma Virus Infection Ty Other: TH
2668 NCT03798Immunogenicity of HeRecruiting No ResultsInflammatory Bowel Diseases|CrohnBiological:
2669 NCT00617Safety and Immunogen CompletedNo ResultsNeisseria Meningitidis (Bacterial M Biological
2670 NCT01248Influenza and Text M CompletedNo ResultsPregnancy Other: inf
2671 NCT00168Early Two-dose Measle CompletedNo ResultsMeasles Biological:
2672 NCT03061Safety and Efficacy CompletedNo ResultsInfluenza Virus Vaccine Adverse ReaBiological:
2673 NCT00849A Worldwide, Phase ICompletedNo ResultsHIV-1|HIV Infections Biological
2674 NCT00194Vaccine Therapy in TrActive, notNo ResultsHER2/Neu Positive|HLA-A2 Positive BCiological
2675 NCT02883Evaluating the Safety Terminate No ResultsInfluenza Biological:
2676 NCT02491A Phase 3 Clinical Tri CompletedNo ResultsRabies Biological:
2677 NCT03676Evaluate the Safety CompletedNo ResultsCervical Cancers|Vulvar Cancer|VagBiological
2678 NCT00943Sanofi H1N1 + TIV - ACompletedHas ResultInfluenza Biological:
2679 NCT01428Immunogenicity and SCompletedNo ResultsGroup A, C Polysaccharide MeningitBiological:
2680 NCT01568Post-marketing ClinicaCompletedNo ResultsHuman Influenza Biological:
2681 NCT03476Tenofovir Disoproxil Recruiting No ResultsHepatitis B Infection|Congenital MaDrug: Tenof
2682 NCT03549A Study to Evaluate Not yet recNo ResultsPneumococcal Infection Biological:
2683 NCT02724MMR Vaccination Amo CompletedNo ResultsHIV Biological
2684 NCT02145EducationaHPV CompletedHas ResultHPV Vaccination Status Behavioral:
2685 NCT00030Vaccine Therapy in TrCompletedHas ResultBreast Cancer Biological
2687 NCT03604The Immuno BMS-1886Recruiting No ResultsHerpes Zoster|Inflammatory DiseaseBiological:
2688 NCT00539Immunology and Safet CompletedHas ResultMeningitis|Meningococcemia Biological
2689 NCT03946CombinatioVolATIL Not yet recNo ResultsSquamous Cell Carcinoma of the HeBiological
2690 NCT00965Therapeutic Cocaine CompletedHas ResultCocaine Dependence Biological:
2691 NCT00323Phase II Feasibility CompletedHas ResultGlioblastoma Multiforme Biological
2692 NCT01685Immunogenicity of F CompletedHas ResultSolid Organ Transplant Recipient ( Biological:
2693 NCT00380Offering Influenza a Unknown sNo ResultsHigh Risk for Serious Influenza|Hig Biological:
2694 NCT01939Immunogenicity and Sa Active, notNo ResultsInfections, Meningococcal Biological
2695 NCT04147Personalized DC VacciRecruiting No ResultsGastric Cancer|Hepatocellular Carc Biological
2696 NCT01988Study of Safety and ECompletedNo ResultsMalaria Biological
2697 NCT01008Safety and Immune Re WithdrawnNo ResultsInfluenza Biological:
2698 NCT00144VaxTeen Hepatitis B VCompletedNo ResultsHepatitis Biological:
2699 NCT03433A Study to Investiga CompletedNo ResultsMeningitis, Meningococcal Biological
2700 NCT00896Evaluation of a Boos CompletedHas ResultInfections, Streptococcal Biological
2701 NCT00729Study of Two Doses ofCompletedNo ResultsInfections, Rotavirus Biological:
2702 NCT00491A Study of the ImmunCompletedNo ResultsInfluenza|Orthomyxoviridae Infecti Biological:
2703 NCT03910Sm-TSP-2 SchistosomiRecruiting No ResultsSchistosomiasis|Schistosoma MansoBiological
2704 NCT041023-year Follow-up AferCompletedNo ResultsPertussis Biological:
2705 NCT01404Safety of HaemophiluCompletedNo ResultsHaemophilus Influenzae Type B InfeBiological
2706 NCT00936Safety, Tolerability CompletedNo ResultsInfluenza Biological
2707 NCT00030Vaccine Therapy in TrTerminate No ResultsUnspecified Adult Solid Tumor, ProtoBiological
2708 NCT02383Yellow FevMTX_YF Unknown sNo ResultsRheumatic|Dermatologic Disorders Biological:
2709 NCT02665Reducing DREDIVAC CompletedNo ResultsCommunicable Diseases Behavioral:
2710 NCT02218Evaluation of the ImmCompletedHas ResultInfluenza Biological:
2711 NCT00379B-19 Parvovirus VacciTerminate No ResultsParvovirus B19 Infection Biological
2712 NCT00693Safety and Immunogen CompletedNo ResultsInfections, Papillomavirus Biological
2713 NCT0072836-Month Post-marketi CompletedHas ResultMeningitis|Meningococcal Disease Biological:
2714 NCT03629Safety and ProtectiveActive, notNo ResultsCervical Intraepithelial Neoplasia Biological:
2715 NCT00133gB/MF59 Vaccine in PCompletedNo ResultsCytomegalovirus Infections Biological
2716 NCT02249Clinical Efficacy of CompletedNo ResultsChronic Hepatitis B Drug: ABX2
2717 NCT01686Efficacy St WIDEA Recruiting No ResultsAcute Myeloid Leukemia Biological:
2718 NCT00147Immunogenicity of Boo Unknown sNo ResultsLiver Transplantation|Hepatitis B Biological:
2719 NCT00744Hepatitis BHAVIT CompletedNo ResultsHepatitis B Other: Ince
2720 NCT01031Clinical Trial to Com CompletedNo ResultsH1N1 Influenza Virus|Invasive Solid Biological
2721 NCT03703Phase III Study of Li Not yet recNo ResultsDiarrhea|Diarrhea Rotavirus Biological:
2722 NCT00379Study to Assess the SCompletedNo ResultsTetanus|Haemophilus Influenzae Typ Biological:
2723 NCT00812Dose Ranging Study to CompletedNo ResultsInfluenza Biological
2724 NCT00623Evaluate Tolerability Terminate No ResultsHIV Infections Biological
2725 NCT02499Vaccine Therapy and Recruiting No ResultsHormone-Resistant Prostate Cancer|Biological
2726 NCT00343A Study of the ImmunCompletedNo ResultsInfluenza|Orthomyxoviridae Infecti Biological:
2727 NCT03529A Study to Describe tActive, notNo ResultsRespiratory Tract Infections Biological:
2728 NCT00905Influenza Vaccine in CompletedHas ResultInfluenza Biological:
2729 NCT01911A Phase 3b, Single-CeCompletedHas ResultPrevention of the Meningococcal DiBiologica
2730 NCT01444Study of an Investiga CompletedNo ResultsPneumococcal Infections|Streptoc Biological
2731 NCT00291Compare the ImmuneCompletedNo
Re ResultsHepatitis B Biological
2732 NCT02077Vaccination With PepCompletedNo ResultsMalignant Melanoma With MetastasBiological:
2733 NCT02285Safety and Immunogen CompletedNo ResultsPneumococcal Infectious Diseases Biological
2734 NCT03226Vaccinatio RENALVax-WithdrawnNo ResultsCarcinoma, Renal Cell|Vaccination| Radiation:
2735 NCT01006Vaccination Against Unknown sNo ResultsInfluenza|Rheumatic Diseases Biological
2736 NCT00849Two-Arm Study of a DN CompletedHas ResultProstate Cancer Biological
2737 NCT02259Î³-irradiated BCG to CompletedHas ResultInnate Immune Response Biological:
2738 NCT01021Safety of and ImmuneCompletedNo ResultsParamyxoviridae Infections|Virus DiDrug: rHPI
2739 NCT00866Safety and Efficacy C Terminate No ResultsShigella Biological:
2740 NCT02522Development of an InCompletedNo ResultsInfluenza Biological
2741 NCT03111Monocytic ExpressionCompletedNo ResultsSickle Cell Disease Biological:
2742 NCT01301Vaccination Against PUnknown sNo ResultsRheumatoid Arthritis Biological:
2743 NCT00316Human Papillomavirus CompletedHas ResultInfections, Papillomavirus Biological
2744 NCT01509Safety Study of InactiCompletedNo ResultsShigellosis Biological:
2745 NCT00199NY-ESO-1 Plasmid DNCompletedNo ResultsProstate Cancer|Bladder Cancer|NoBiological
2746 NCT01207Cluster RCT - Evaluat Unknown sNo ResultsInfluenza Behavioral
2747 NCT00150Project UNITY - HIV RCompletedNo ResultsHIV Infections|Hepatitis B Behavioral
2748 NCT02986Study to Assess the CompletedHas ResultInfections, Meningococcal Biological
2749 NCT00836Safety andPAPSI CompletedHas ResultAsthma Biological
2750 NCT02544PDE5 Inhibition Via T Active, notNo ResultsHead and Neck Squamous Cell Carc Drug: Tada
2752 NCT00126Immunogenicity and SCompletedNo ResultsMumps|Rubella|Measles|Varicella Biological
2753 NCT01484Laboratory Study of LCompletedNo ResultsHIV-1 Infection|H1N1|Influenza|FluBiological:
2754 NCT02740Evaluating the 2-dos Unknown sNo ResultsHuman Papillomavirus|Cervical IntraBiological
2755 NCT01428Safety andGCHT01 Active, notNo ResultsHIV Infections Biological:
2756 NCT00254Melanoma Vaccine WiCompletedHas ResultMelanoma Drug: Leup
2757 NCT03123Gardasil Administrati WithdrawnNo ResultsVaccine Administration Rates Behavioral
2758 NCT01009The Effect of Fact Ve CompletedHas ResultInfluenza Vaccination Behavioral
2759 NCT00538ComparativFLUVACS CompletedHas ResultInfluenza Biological:
2760 NCT01028PCV10 ReacPRISM Unknown sNo ResultsPneumococcal Pneumonia Biological:
2761 NCT03028Adaptive Immune Resp Terminate Has ResultInfluenza Biological:
2762 NCT02223Therapy for Progress WithdrawnNo ResultsCancer|Hematologic Malignancies Biological
2763 NCT02543A Study of the ImmunCompletedHas ResultHealthy Drug: Ixek
2764 NCT03747HPV Message TestingEnrolling bNo ResultsVaccine|Human Papilloma Virus Other: Soc
2765 NCT03220VAXCHORA Pediatric Active, notNo ResultsCholera Vaccination Reaction Biological
2766 NCT00363A Study to Demonstrat CompletedNo ResultsInfluenza Biological:
2767 NCT02432Comparison CIzQIDS CompletedNo ResultsImmunization|DTaP Vaccine|HepatitBehavioral
2768 NCT01160A Study to Evaluate t CompletedNo ResultsInfections, Staphylococcal Biological
2769 NCT02589Zambia Si SiVET CompletedNo ResultsHigh Risk for HIV Biological:
2770 NCT02370The Effect of Previo Recruiting No ResultsChronic Kidney Diseases Biological:
2771 NCT02518Khushi Baby (KB): NovUnknown sNo ResultsDTP Vaccine Series Completion Device: NF
2772 NCT03916Safety and Immunogeni Recruiting No ResultsRespiratory Syncytial Virus (RSV) Biological
2773 NCT02491A Study to Assess theCompletedHas ResultRespiratory Synctial Virus Infections Biological
2774 NCT01148Safety and Immunogeni CompletedHas ResultMalaria Biological:
2775 NCT02238Effect of MOSAIC CompletedNo ResultsInfection Biological
2776 NCT04143Immunogeni MET55 Recruiting No ResultsHealthy Volunteers (Meningococcal B I iological
2777 NCT01841Safety and Immunogen CompletedNo ResultsInfluenza Due to Influenza A Virus Biological:
2778 NCT02817DTaP-IPV-HB-PRP-T Com CompletedNo ResultsDiphtheria|Tetanus|Pertussis|HepatBiological
2779 NCT01032Immunogenicity, SafetCompletedNo ResultsH1N1 Influenza Virus|Human Immunod Biological:
2780 NCT02387Immunogenicity and To CompletedNo ResultsHuman Influenza Biological:
2781 NCT01544Examining AFIX CompletedNo ResultsAdolescent Health Services|ImmuniOther: Ass
2782 NCT00955Study to Evaluate Pe CompletedHas ResultInfections, Meningococcal Biological
2783 NCT02576Safety and Efficacy S Unknown sNo ResultsHuman Papillomavirus|High-Grade Sq Biological:
2784 NCT02142Clinical Tolerance to CompletedNo ResultsEgg Allergy
2785 NCT03020Immunogenicity and SCompletedNo ResultsInfluenza, Human Biological
2786 NCT00696Safety and Immunogen CompletedNo ResultsHepatitis B Biological
2787 NCT01635A Phase 1/2b Study ofCompletedNo ResultsMalaria Biological
2788 NCT03709SDH of HPV Vaccine CompletedNo ResultsHuman Papilloma Virus
2791 NCT01389Study of SP059 GivenCompletedNo ResultsPoliomyelitis|Polio Biological:
2792 NCT00317Safety Study of a VaccCompletedNo ResultsHepatitis B|Diphtheria|Whole Cell Biological:
2793 NCT00317Safety Study of a VaccCompletedNo ResultsDiphtheria|Hepatitis B|Whole Cell Biological:
2794 NCT01282Influenza Vaccine Saf CompletedNo ResultsInfluenza
2795 NCT00635An Open-Label, Singl CompletedHas ResultHPV Infections Biological
2797 NCT00513Human Papillomavirus CompletedHas ResultInfection|Precancerous Condition Biological:
2798 NCT00698Evaluation of Safety CompletedNo ResultsHerpes Simplex Biological
2799 NCT02873RSV-MVA-BN Vaccine CompletedNo
P ResultsRespiratory Syncytial Virus InfectionBiological
2800 NCT00390Study in Adolescents/CompletedNo ResultsInfections, Meningococcal Biological
2802 NCT04090A Study to Test GlaxoActive, notNo ResultsRespiratory Syncytial Virus InfectionBiological
2803 NCT01173Persistence of RabiesUnknown sNo ResultsRabies Biological
2804 NCT00996Nicotine Vaccination CompletedHas ResultNicotine Dependence Biological:
2805 NCT03548Study To Describe TheActive, notNo ResultsVaccines Biological
2806 NCT00254Descriptive, Post-marCompletedHas ResultMeningitis|Meningococcal Disease Biological:
2807 NCT00422Immunogenicity and SCompletedHas ResultMeningococcal Meningitis|MeaslesBiological
2808 NCT03438Flucelvax (TIVc or QI Active, notNo ResultsInfluenza, Human|Pregnancy|Birth Biological:
2809 NCT04038Financing Strategies oRecruiting No ResultsInfluenza Vaccines|Influenza, HumaOther: No
2810 NCT00270Safety, Tolerability CompletedHas ResultHIV Infections Biological:
2811 NCT00389Vaccine Therapy in T Active, notNo ResultsPancreatic Cancer Biological:
2812 NCT00961Safety of and ImmuneCompletedNo ResultsHIV Infections Biological:
2813 NCT00249Determining Safety a CompletedNo ResultsEncephalitis, Japanese B Biological:
2814 NCT01642Safety and Immunogeni CompletedHas ResultMeningitis|Meningococcal Disease Biological
2815 NCT02937To Look or Not to LooUnknown sNo ResultsVaccination Behavioral
2816 NCT03170Randomized ControlleUnknown sNo ResultsMEASLES DISEASE Biological:
2817 NCT00976Multi-Year Study of Terminate Has ResultInfluenza Biological:
2818 NCT03089A Study to Evaluate CompletedHas ResultDysentery, Bacillary Biological
2819 NCT01209Vaccine Therapy in T Active, notNo ResultsLymphoplasmacytic Lymphoma Biological
2820 NCT00373Trial of pDNA CMV VaCompletedNo ResultsCytomegalovirus Infection Biological
2822 NCT03674A Study to Evaluate DCompletedNo ResultsRespiratory Syncytial Virus InfectionBiological
2823 NCT01266Persistence and BoostCompletedHas ResultInfections, Meningococcal Biological
2824 NCT01224Safety and Immunogeni CompletedHas ResultDengue Fever Biological:
2825 NCT00840Immunotherapy UsingCompletedNo ResultsLeukemia Drug: lena
2826 NCT01369Shigella Sonnel O-SP CompletedNo ResultsImmunogenicity|Shigellosis Biological
2827 NCT00428Vaccine Therapy in T Terminate Has ResultLeukemia Biological:
2828 NCT00928Trial for MEL36 CompletedNo ResultsMelanoma Drug: low-
2829 NCT04033Safety andMV-ZIKA-RRecruiting No ResultsZika Virus Infection Biological
2830 NCT03227Evaluating the Infect Active, notNo ResultsRespiratory Syncytial Virus InfectionBiological:
2831 NCT03170A Phase 1/2, Randomiz CompletedHas ResultGroup B Streptococcal Infections Biological:
2832 NCT04120A HIV Vaccine Trial i Not yet recNo ResultsHIV-1-infection Biological:
2833 NCT01002Cell Immunity Respons Unknown sNo ResultsRheumatoid Arthritis Biological:
2834 NCT00835A Study of 2 Doses o CompletedHas ResultHepatitis A Virus Infection Biological:
2835 NCT00005Vaccine Therapy Plus CompletedNo ResultsProstate Cancer Biological: MUC1-KLH
2837 NCT01669Study in Healthy AdulCompletedHas ResultTuberculosis Biological:
2838 NCT00321Study to Evaluate an CompletedHas ResultInfluenza Biological:
2839 NCT00496An Immunogenicity an CompletedHas ResultPapillomavirus Infections Biological
2840 NCT03213A Study to EVA-VRS01Unknown sNo ResultsRespiratory Syncytial Virus InfectionBiological
2841 NCT01172ComparativVAX128-01CompletedNo ResultsInfluenza Biological:
2842 NCT00695A Trial to Test the R CompletedHas ResultInfluenza Biological
2843 NCT00583Phase II S APP21 Active, notNo ResultsRecurrent Prostate Cancer Biological
2844 NCT02535Investigat SONIC Unknown sNo ResultsImmune System Diseases|Chronic KiBiological
2845 NCT02692Response and Clearanc WithdrawnNo ResultsVaricella|Transplants Biological:
2846 NCT00370Phase 1 Trial of CMV CompletedNo ResultsCytomegalovirus Infection Biological
2847 NCT02802iVAC-CLL01: Patient-inRecruiting No ResultsLeukemia, Chronic Lymphatic Biological
2848 NCT01693EffectiveneXo_Gripe CompletedNo ResultsInfluenza|Acute Respiratory Infecti Biological:
2849 NCT03255EvaluationGamTBvacCompletedNo ResultsTuberculosis Biological
2850 NCT02337Phase 1 Trial of Inact CompletedNo ResultsWest Nile Viral Infection Biological
2851 NCT02712Bexseroâ„¢and Routine CompletedNo ResultsMeningococcal Infections Biological
2852 NCT00731Safety and VAART CompletedNo ResultsArthritis, Juvenile Rheumatoid Biological
2853 NCT01317Safety and Immunogen CompletedHas ResultRicin Biological:
2854 NCT02344Study of Egg-derived CompletedNo ResultsInfluenza, Human Biological:
2855 NCT00792The Hepatitis B Vacc CompletedHas ResultHepatitis B Biological:
2856 NCT02316Strategies for the Pr CompletedNo ResultsHIV/AIDS and Infections Biological:
2857 NCT01619Safety andPCV1103 Unknown sNo ResultsPneumonia|Meningitis|BacteraemiaBiological:
2858 NCT01018Adenovirus Type 35 BCompletedNo ResultsMalaria Biological
2859 NCT02960mHealth InterventionCompletedNo ResultsHealthy Subject Other: Inf
2860 NCT00258Primary & Booster ImCompletedNo ResultsHaemophilus Influenzae Type b|NeisBiological
2861 NCT00457A Trial to Evaluate t CompletedHas ResultPertussis|Tetanus|Diphtheria Biological
2862 NCT00128Prevention of GBS CoCompletedHas ResultBeta Haemolytic Streptococcal InfecBiological:
2864 NCT00743Study Evaluating the CompletedHas ResultPneumococcal Disease|13-valent P Biological
2865 NCT02808An HPV Vaccine Provid CompletedNo ResultsHuman Papillomavirus|Uterine CervBehavioral:
2866 NCT03919Protectivity and Safe Recruiting No ResultsImmunogenicity Biological:
2867 NCT03031The Influence of the CompletedNo ResultsRotavirus
2868 NCT01821The Post-Marketing SCompletedNo ResultsRabies Vaccine Allergy|Vaccination Biological:
2869 NCT01689Post-licensure Safety CompletedHas ResultMeningitis|Meningococcal InfectionBiological
2870 NCT03854Healthy, Immunized Active, notNo ResultsVaccine Hesitancy|Communicable DiBehavioral
2871 NCT02569Impact of Boostrixâ„¢CompletedNo ResultsDiphtheria|Acellular Pertussis|Teta Other: Per
2872 NCT01371A Phase IIA Trial to CompletedNo ResultsHIV Infections Biological
2873 NCT01588Vaccine Therapy in PrActive, notNo ResultsAccelerated Phase Chronic MyelogeBiological
2874 NCT01067Safety and Immunogeni CompletedNo ResultsRecurrent Vulvovaginal Candidiasis Biological
2875 NCT00943A Study of V503 (A Mu Active, notHas ResultCervical Cancers|Vulvar Cancer|VagBiological:
2876 NCT02753Safety and ReactogeniCompletedHas ResultRespiratory Syncytial Virus InfectionBiological
2877 NCT03023Tissue-specific RespoTerminate Has ResultInfluenza Biological:
2878 NCT03596Evaluating the Infect Recruiting No ResultsRSV Infection Biological
2879 NCT00604Immunogenicity and Sa CompletedNo ResultsPoliomyelitis Biological:
2880 NCT02933Immunogenicity of InActive, notNo ResultsInfluenza Procedure:
2881 NCT00717Safety and Immunogeni CompletedNo ResultsRoss River Virus Disease (RRVD) Biological:
2882 NCT03609The STOP-HSTOP-HPV Recruiting No ResultsVaccination|Immunization Behavioral
2883 NCT00849Safety Study of GSK BCompletedHas ResultInfections, Papillomavirus Biological
2884 NCT03497Marketability of a Te Recruiting No ResultsHuman Papilloma Virus Behavioral
2885 NCT00325Non-Inferiority StudyCompletedNo ResultsHealthy Biological:
2886 NCT02646Safety and Immunogeni Unknown sNo ResultsHealthy Biological
2887 NCT03560HIV-1-Gag Conserved-E Active, notNo ResultsHIV Infections Biological
2888 NCT02692Safety and BCG-EHMICompletedNo ResultsMalaria|Plasmodium Falciparum Biological:
2889 NCT02955A Phase 1, Randomized CompletedNo ResultsPneumococcal Infections Biological:
2890 NCT00529Evaluate Safety & Imm CompletedHas ResultInfluenza Biological:
2891 NCT00758Co-administration of CompletedHas ResultInfections, Meningococcal Biological
2892 NCT00546Safety, Reactogenicit CompletedNo ResultsInfluenza Biological
2893 NCT00080Effectiveness of and CompletedNo ResultsHIV Infections Biological
2894 NCT00942A Study to Assess th CompletedNo ResultsInfluenza Biologica
2895 NCT02643SerologicalIPV CompletedNo ResultsPoliomyelitis Biological:
2896 NCT02936Standard VIV-RA Active, notNo ResultsRheumatoid Arthritis Biological:
2897 NCT00423A Phase I Study of th CompletedNo ResultsTuberculosis Biological
2898 NCT02590Effects of Chronic Vi Terminate Has ResultHepatitis C Drug: Zoste
2899 NCT00492Immunogenicity and SCompletedHas ResultInfections, Papillomavirus Biological
2900 NCT03958A Study to Describe Recruiting No ResultsTetanus Immunisation Diphtheria ImBiological:
2901 NCT00722Vaccine Therapy in PrCompletedNo ResultsNonneoplastic Condition Biological
2902 NCT01421H1N1 Vaccine Safety Unknown sNo ResultsH1N1 Influenza
2903 NCT01511Safety Trial of Live CompletedHas ResultInfluenza|Avian Influenza Biological:
2904 NCT00090An Investigational St CompletedHas ResultCondylomata Acuminata Biological:
2905 NCT03726Comparative EffectiveEnrolling bNo ResultsHuman Papillomavirus Infection Behavioral
2906 NCT02142Safety and Immunogeni CompletedHas ResultNorovirus Prevention Biological:
2908 NCT02493B7.1/IL-2 Leukaemia Not yet recNo ResultsLeukemia, Myeloid, Acute|MyelodysBiological:
2909 NCT00480Efficacy, Safety, Rea CompletedHas ResultInfections, Rotavirus|Rotavirus VaccBiological:
2910 NCT01489Chikungunya Virus Vac CompletedHas ResultViral Vaccines|Chikungunya Fever|CBiological
2911 NCT00488Study Evaluating 7-VaCompletedHas ResultPneumococcal Infections Biological:
2912 NCT03039Vaccination ComplianCompletedNo ResultsVaccine Compliance Other: Obs
2913 NCT03318Co-Administration of CompletedNo ResultsAvian Influenza|Influenza|Influenz Drug: AS03|
2914 NCT00205Study Evaluating PneuCompletedHas ResultHealthy Subjects|Pneumococcal InfeBiological
2915 NCT03497Assess the Safety & Active, notNo ResultsInfluenza A Virus, H5N1 Subtype Biological
2916 NCT00481Immunogenicity, SafetCompletedHas ResultPandemic|Avian Influenza Biological
2917 NCT00880Autologous Vaccinati Active, notNo ResultsBreast Cancer Biological:
2918 NCT01748Vaccine Therapy and CompletedNo ResultsRecurrent Melanoma|Stage IIA Mel Drug: Mont
2919 NCT00370A Phase II Trial of a CompletedHas ResultDengue Biological
2920 NCT02956A Study to Rank DiffeCompletedHas ResultRespiratory Syncytial Virus InfectionBiological
2921 NCT01307Systems Biology of CompletedHas ResultPneumococcal Infection Biological
2922 NCT00445Study Evaluating PersCompletedNo ResultsHepatitis B Biological:
2923 NCT03180Enhancing Health CarCompletedHas ResultVaccination Behavioral
2925 NCT01416A Systematic Review oCompletedNo ResultsInfluenza Biological:
2926 NCT00383Comparison of AdjuvaCompletedNo ResultsHepatitis B Biological:
2927 NCT01403Effects of the Oral C CompletedHas ResultPneumonia Biological
2928 NCT02531EnterotoxigETVAX/dmLCompletedHas ResultEscherichia Coli Diarrhea Biological
2929 NCT00026A Study of Dryvax VacCompletedNo ResultsSmallpox Biological: Dryvax vac
2930 NCT01678Imiquimod and TumorActive, notNo ResultsHigh Risk WHO Grade II Glioma|RecBiological
2931 NCT00396Th1 Response to InfluTerminate No ResultsInfluenza Drug: Place
2932 NCT01970A Phase I Study With Active, notNo ResultsMelanoma Biological:
2933 NCT00771Immunogenicity & SafCompletedHas ResultInfluenza Biological
2934 NCT00480Consistency Study of CompletedNo ResultsHepatitis B Biological:
2935 NCT02831Study on thIAMI Recruiting No ResultsMyocardial Infarction|Influenza, Hu Biological:
2936 NCT00754Evaluate the Safety a CompletedNo ResultsInfluenza Biological:
2937 NCT00746A Phase II Study of Unknown sNo ResultsMelanoma Biological
2938 NCT03312Sanofi 2017 H7N9 WitCompletedNo ResultsAvian Influenza|Influenza ImmunisaDrug: AS03
2939 NCT03308Safety and Immunogen CompletedHas ResultInfluenza|Flu Biological:
2940 NCT00708The Effect of Extend CompletedNo ResultsVaccination Behavioral:
2942 NCT03162Efficacy, ImmunogenicCompletedHas ResultMalaria Biological
2943 NCT01909Evaluating the Safet WithdrawnNo ResultsHIV Infections Biological
2944 NCT02860A Study to Evaluate SCompletedNo ResultsHealthy Biological
2945 NCT02554Fasting-mimicking D WithdrawnNo ResultsImmunosenescence Biological:
2946 NCT01199Text Message Reminde CompletedNo ResultsVaccination Other: Tex
2947 NCT02141Safety and Immunogen CompletedHas ResultMeningococcal Disease Biologica
2948 NCT00261Safety Stu MANON-0CompletedNo ResultsHealthy Volunteers|HIV Infection Biological
2949 NCT00492Study Evaluating Saf CompletedHas ResultPneumococcal Infections Biological
2950 NCT00063Safety of an HIV VaccCompletedNo ResultsHIV Infections Biological
2951 NCT01204Safety & Immunogenic CompletedHas ResultInfections, Streptococcal Biological
2952 NCT01022Vaccine Responses toCompletedNo ResultsHIV Infection|Rheumatic Disease|CaBiological
2953 NCT03546Sero-conversion StudyEnrolling bNo ResultsPoliomyelitis Biological:
2954 NCT03313A Trial To Evaluate A CompletedNo ResultsPneumococcal Infections Biological:
2955 NCT02447Vaccinating Children Active, notNo ResultsAcute Lymphoblastic Leukemia Biological
2956 NCT00538Evaluate Safety and I CompletedHas ResultInfluenza Biological:
2957 NCT01680Influenza ImmunizatioCompletedNo ResultsInfluenza Biological:
2958 NCT00107Safety of Recombinant CompletedNo ResultsHIV Infections Biological
2959 NCT02859Safety, Tolerability a CompletedNo ResultsMalaria Biological:
2960 NCT02040Immunogenicity of 3+CompletedNo ResultsInfectious Disease Biological
2961 NCT00541Partially Blind Study CompletedHas ResultInfections, Papillomavirus Biological:
2962 NCT02133B-cell Immunity to In CompletedHas ResultInfluenza Biological
2964 NCT03084A Study to Assess theRecruiting No ResultsMalaria Biological
2965 NCT01453Phase II FANGâ„¢ in Terminate Has ResultAdvanced Melanoma Biological:
2966 NCT03166Personalized TherapeWithdrawnNo ResultsNon Small Cell Lung Cancer|NSCLC|N Drug: Pemb
2967 NCT01111Evaluation of PandemCompletedNo ResultsInfluenza Biological
2968 NCT02360Safety, Reactogenicit CompletedHas ResultRespiratory Syncytial Virus InfectionBiological
2969 NCT03689Arginase-1 Peptide VaRecruiting No ResultsNon Small Cell Lung Cancer|Urothe Biological
2970 NCT01366Safety, ImmunogenicitCompletedHas ResultMalaria Biological:
2971 NCT01674Study of Immune Respo CompletedNo ResultsInfluenza, Human Biological
2972 NCT01153Immunization of Chil CompletedHas ResultInfections, Streptococcal Biological
2973 NCT00310A Safety Study to AssCompletedNo ResultsHSV-2 Biological
2974 NCT03602Study of B ROTAVAC Active, notNo ResultsDiarrhea|Diarrhea Rotavirus Biological
2975 NCT02728Dendritic Cell/Myelo Active, notNo ResultsMultiple Myeloma Procedure:
2976 NCT02247RSV F Vaccine MaternCompletedNo ResultsRespiratory Syncytial Virus InfectionDrug: Salin
2977 NCT00109Safety, Tolerability WithdrawnNo ResultsVenezuelan Equine Encephalitis Biological:
2978 NCT00439Dose Escalation StudyUnknown sNo ResultsDiarrhea Biological:
2981 NCT00125Recombinant CMV gBCompletedNo ResultsCytomegalovirus Infections Biological
2982 NCT00652Co-administration of CompletedHas ResultInfections, Streptococcal Biological
2983 NCT00036Vaccine Therapy Plus CompletedNo ResultsProstate Cancer Biological
2984 NCT00711Phase 3 Study of a H5CompletedNo ResultsInfluenza Biological:
2985 NCT00683Post-Marketing StudyCompletedHas ResultVaccines, Pneumococcal Conjugate Biological
2986 NCT02788Safety, Tolerability Active, notNo ResultsHealthy Biological
2987 NCT03587Study to Assess Pote CompletedHas ResultMeningitis, Meningococcal Biological
2988 NCT01267Peptide Vaccination i Unknown sNo ResultsEsophageal Cancer Biological:
2989 NCT03589Study on the Safety Active, notNo ResultsClostridium Difficile Immunisation Biological
2990 NCT03884Response toLAIV-TTB Not yet recNo ResultsInfluenza Biological:
2991 NCT03729Impact of HIV-1 and Recruiting No ResultsHIV-1-infection|Human Immunodefic Biological:
2992 NCT00231A Study of an Investi CompletedHas ResultHerpes Zoster Biological
2993 NCT00562Immune Res ITAP CompletedNo ResultsHIV Infections Biological
2994 NCT02632Influenza Vaccine in CompletedNo ResultsInfluenza, Human Biological:
2995 NCT01813Immunogenicity of Ina CompletedNo ResultsPoliomyelitis Biological:
2996 NCT02637Sequential Versus Si Recruiting No ResultsPneumococcal Infections Drug: PCV
2997 NCT03286An RCT Promoting HPUnknown sNo ResultsHealth Behavior Behavioral
2998 NCT03020Phase I Study to Eva CompletedNo ResultsCrimean-Congo Hemorrhagic Fever Biological
2999 NCT00705Vaccine Therapy of P CompletedNo ResultsProstate Cancer Biological
3000 NCT00921Safety of VAX102 VaccCompletedNo ResultsInfluenza Biological:
3001 NCT03088Genetic anSLVP028 CompletedNo ResultsInfluenza|Healthy Biological
3002 NCT02014Safety and Immunogen Terminate No ResultsInfluenza Biological
3003 NCT00503Vaccine Therapy in TrCompletedNo ResultsLung Cancer Biological
3004 NCT03142Does Timeliness of DTCompletedNo ResultsAtopic Dermatitis Biological:
3005 NCT00280H5 Adult - Chiron StuCompletedNo ResultsInfluenza Biological
3006 NCT03152Study to Check the EfRecruiting No ResultsPrevention of TB Recurrence Biological
3007 NCT00760Evaluation of Safety CompletedHas ResultInfluenza Biological:
3008 NCT00304Vaccine Therapy in TreCompletedHas ResultBreast Cancer Biological:
3009 NCT02858A Study to Assess theCompletedHas ResultDiphtheria|Tetanus|Pertussis|HepatBiological:
3010 NCT01239Antibody Persistence CompletedHas ResultMeningitis|Meningococcal MeningitBiological
3011 NCT02174Phase 1 Clinical Tri CompletedNo ResultsMalaria Biological
3012 NCT00042Study of ReactogeniciCompletedNo ResultsSmallpox Biological: Cell-Cult
3013 NCT00830Safety of a Second DoCompletedNo ResultsVaricella Biological:
3014 NCT00466Phase 2 Study of SafeCompletedNo ResultsSmallpox Drug: MVA
3015 NCT00258Immunogenicity and SCompletedHas ResultDiphtheria|Tetanus|Pertussis Biological:
3016 NCT02862Second Stage:Open-lab CompletedHas ResultChronic Hepatitis B Biological:
3017 NCT03032Safety andVIPV-06 CompletedNo ResultsPoliomyelitis Biological:
3018 NCT01086Safety and Immunogeni CompletedNo ResultsHerpes Zoster Biological
3020 NCT02519Study to Evaluate Imm CompletedHas ResultHerpes Zoster Biological
3022 NCT01457Immunogenicity and R CompletedNo ResultsHepatitis B|Acellular Pertussis|Hae Biological:
3023 NCT01003Study to Evaluate Saf Terminate Has ResultInfluenza Biological:
3024 NCT02027Clinical Tr FLUVAC EVUnknown sNo ResultsInfluenza-like Illness Other: nas
3025 NCT00107Effectiveness of Two CompletedHas ResultHepatitis B Biological:
3026 NCT03281Five-year Immune Pers CompletedNo ResultsHand, Foot and Mouth Disease
3027 NCT01304Safety of Synbiotics aCompletedNo ResultsInfluenza Biological:
3028 NCT03181Evaluating HVTN 119 Active, notNo ResultsHIV Infections Biological
3029 NCT01390Vaccination of High RCompletedHas ResultStage IV Breast Cancer Biological
3030 NCT02296Effect of HPV Vaccin CompletedNo ResultsCervical Cancer Biological:
3032 NCT02385PCV10 ImmunogenicitCompletedNo ResultsStreptococcus Pneumoniae Biological
3033 NCT00888Safety andTGC14F CompletedNo ResultsHuman Immunodeficiency Virus Infec Biological
3034 NCT00115Eldery High Dose TIV CompletedNo ResultsInfluenza Biological: Trivalent
3035 NCT01067Blockade of PD-1 in CActive, notNo ResultsMultiple Myeloma Drug: CT-01
3036 NCT03597A Study of Immunogen Enrolling bNo ResultsPoliomyelitis Biological:
3038 NCT03370A Phase 4 Post-marketCompletedHas ResultPandemic Influenza Prevention Biological:
3039 NCT00471Vaccine Therapy in TrCompletedNo ResultsIntraocular Melanoma|Malignant C Biological
3040 NCT00465Primary Study to DemCompletedHas ResultInfections, Meningococcal Biological
3041 NCT014273-year ImmunogenicitUnknown sNo ResultsAnogenital Human Papilloma Virus Infection
3042 NCT02751QUILT-3.013: Study o Active, notNo ResultsCancer Biological:
3044 NCT01307Vaccine Therapy WithTerminate Has ResultRecurrent Melanoma|Stage IV Skin Biological
3045 NCT02548A Study to Evaluate t CompletedHas ResultVirus Diseases Biological
3046 NCT01934Study to Evaluate th CompletedHas ResultInfections, Meningococcal Biological
3047 NCT02269Vaccine Treatment forCompletedHas ResultEbola Virus Biological
3048 NCT01457Comparison of Immuno CompletedNo ResultsHepatitis B|Poliomyelitis|Diphtheri Biological
3049 NCT00514A Post-marketing SafeCompletedNo ResultsPoliomyelitis Biological:
3050 NCT02924Effect of MMOSAIC-2 CompletedNo ResultsInfection Biological
3051 NCT03101Live Attenuated Influ CompletedHas ResultInfluenza Biological:
3052 NCT01129Rates of Pertussis Di CompletedNo ResultsPertussis Biological:
3053 NCT00508Study Evaluating the CompletedHas ResultPneumococcal Infections Biological
3054 NCT01191Peptide Vaccination Terminate No ResultsMetastatic Melanoma Drug: Vacc
3055 NCT03961AmsterdamACTHIVE-0Recruiting No ResultsHIV-1-infection Biological
3056 NCT01767Study to Evaluate Saf CompletedNo ResultsPneumococcal Disease Biological
3057 NCT00964Flu Vaccine in PrevenCompletedNo ResultsChronic Myeloproliferative Disor Biological
3058 NCT02296Vaccination ResponseTerminate No ResultsIndividuality|Asthma|Immune SysteBiological:
3059 NCT01866The Safety and Immuno Unknown sNo ResultsVaricella Biological:
3060 NCT04269The Effect of Inflam Not yet recNo ResultsYellow Fever Biological:
3061 NCT01341AdolescentREACH Unknown sNo ResultsHepatitis B Biological:
3062 NCT02861Phase II S MV-CHIK-2CompletedNo ResultsChikungunya Virus Infection Biological:
3063 NCT01908Automated SMS Reminde Unknown sNo ResultsVaccination Failure Behavioral
3064 NCT01175Immunization of Chi CompletedHas ResultInfections, Streptococcal Biological:
3066 NCT00094MDX-010 Antibody, MCompletedHas ResultMelanoma|Metastases Drug: MDX-
3067 NCT02058Phase 1A/1PSA Active, notNo ResultsProstate Cancer Biological
3069 NCT03014Immunotherapy Vaccin CompletedNo ResultsBreastcancer Drug: GP2
3070 NCT00466The Effect of Rituxim Terminate No ResultsRheumatoid Arthritis Biological:
3071 NCT01024Phase 1/2a Trial of P Terminate Has ResultMalaria Biological
3072 NCT001293 Formulations of Hi CompletedHas ResultHaemophilus Influenzae Type b|NeisBiological:
3073 NCT02451Safety and Immunogeni CompletedNo ResultsPneumococcal Infections Biological:
3074 NCT00413Safety and Efficacy o CompletedNo ResultsHIV Infections Biological
3075 NCT01282Patient-donor Vaccin Terminate Has ResultTransplant-Related Cancer Biological:
3076 NCT00463Boosterability of Liv CompletedNo ResultsJapanese Encephalitis Biological:
3077 NCT00415Safety/ImmMP-12 CompletedHas ResultRif Valley Fever Biological
3078 NCT03848Analyzing Childhood RTerminate No ResultsPancreatic Cancer Drug: Gemc
3079 NCT02538Intradermal Rabies I CompletedNo ResultsIntradermal (ID) Vaccination Device Device: Na
3080 NCT01450AdCh63 ME-TRAP andCompletedNo
M ResultsMalaria Biologica
3082 NCT00125HVTN Protocol 204 - ACompletedNo ResultsHIV Infections Biological
3083 NCT02005Study of IMOVAX POLICompletedHas ResultPoliomyelitis|Polio Biological
3084 NCT01813Study of the ImmunogCompletedNo ResultsChronic Hepatitis B Drug: HBsA
3085 NCT02598Safety, Tolerability CompletedNo ResultsHemorrhagic Fever, Ebola Biological
3086 NCT00978Transfected Dendriti CompletedNo ResultsBreast Cancer|Malignant Melanom Biological:
3087 NCT01226Influenza Vaccine ChaCompletedNo ResultsInfluenza Biological:
3088 NCT01094Efficacy of Recombin Active, notNo ResultsNasopharyngeal Cancer|Epstein-Barr Biological:
3089 NCT01357Evaluation of the LonCompletedHas ResultInfections, Cytomegalovirus Procedure:
3090 NCT00614Safety and Tolerabili WithdrawnNo ResultsHIV Infections Biological:
3091 NCT03371AST-VAC2 Vaccine in PRecruiting No ResultsNon-small Cell Lung Cancer in the A Biological
3092 NCT01885Dendritic Cell Vaccin Active, notNo ResultsColorectal Cancer Biological:
3093 NCT00534Effectiveness, Safety CompletedHas ResultInfections, Papillomavirus Biological:
3094 NCT01215Safety and Immunogen CompletedNo ResultsHIV Infections Biological
3095 NCT03481Treatment of Castrat Active, notNo ResultsProstatic Neoplasms|Prostatic Canc Biological
3096 NCT00320Safety of and ImmuneCompletedNo ResultsMalaria Biological
3097 NCT02904Mobile andM-SIMI CompletedNo ResultsMeasles Behavioral
3098 NCT00345Study to Evaluate th CompletedHas ResultInfections, Papillomavirus Biological
3099 NCT00775Influenza Vaccine RevCompletedHas ResultInfluenza|Orthomyxovirus InfectionBiological:
3100 NCT00831Study of Safety and CompletedHas ResultInfluenza Biological:
3101 NCT02177Immunogenicity and SWithdrawnNo ResultsInfluenza Biological
3102 NCT00371Influenza VaccinationCompletedNo ResultsCoronary Artery Disease Biological:
3103 NCT03430Safety of a Single Do CompletedNo ResultsInfluenza|Flu Biological:
3104 NCT00940A Clinical Trial of CS CompletedHas ResultInfluenza Caused by the Novel Influ Biological:
3105 NCT00381Prevention, Randomize CompletedHas ResultHealthy Biological
3106 NCT02124Concomitant AdministCompletedHas ResultPREVENTION OF INVASIVE PNEUMOBiological
3107 NCT00345Annual Study to InvesWithdrawnNo ResultsHealthy Volunteers Biological:
3108 NCT02510Neoepitope-based PerTerminate No ResultsGlioblastoma Multiforme|AstrocytoBiological
3109 NCT03008Phase I, Randomized,Active, notNo ResultsZika Virus Infection Other: Plac
3110 NCT01441Experimental PfSPZ VCompletedNo ResultsMalaria|Prevention and Control|Ac Biological:
3111 NCT00376Immunogenicity and SCompletedNo ResultsAcellular Pertussis|Tetanus|DiphtheBiological:
3112 NCT03038Recombinan FLU007 CompletedNo ResultsInfluenza, Avian Biological
3113 NCT02386ID Recombinant RicinWithdrawnNo ResultsRicin Poisoning Biological:
3114 NCT00703Study of Inactivated, CompletedNo ResultsInfluenza|Orthomyxoviridae Infecti Biological:
3115 NCT01437Efficiency of the HepaUnknown sNo ResultsHIV Biological:
3116 NCT02465Phase 2a ID93 + GLA-SCompletedHas ResultPulmonary Tuberculosis Other: Pla
3117 NCT00806Antibody Response toCompletedHas ResultChronic Kidney Disease Drug: Gard
3118 NCT00272Safety and Effectiven CompletedNo ResultsHIV Infections Biological:
3119 NCT00361Vaccine Therapy in T Terminate Has ResultMyelodysplastic Syndromes Biological
3121 NCT03384CIRN Pnuemococcal Co Active, notNo ResultsInvasive Pneumococcal Disease, ProBiological
3122 NCT00325Acetaminophen Before CompletedHas ResultFever Drug: Acet
3123 NCT01519Study of a Single Dos CompletedHas ResultMeningitis|Meningococcal MeningitBiological
3124 NCT00540Study to Evaluate an CompletedHas ResultInfluenza Biological:
3125 NCT00972A Pilot Study of Vacc CompletedNo ResultsProstatic Neoplasms|Prostate SpecifBiological:
3127 NCT00061Safety of and ImmuneUnknown sNo ResultsHIV Infections Biological:
3128 NCT03383CMV-MVA Triplex Vac.CompletedNo ResultsLymphoma|Multiple Myeloma Biological
3129 NCT00172Antibody Response aUnknown sNo ResultsHepatitis B|Vaccine Biological: Hepatitis
3130 NCT00031Phase II Study of a B CompletedNo ResultsKidney Cancer Biological:
3131 NCT02705Consolidation TherapyWithdrawnNo ResultsCancer|Metastatic Solid Malignanci Biological
3133 NCT02266Placebo- Controlled SCompletedNo ResultsRespiratory Syncytial Virus (RSV) Biological:
3134 NCT01868SOP ToolkiSOP CompletedHas ResultAdult Influenza Vaccinations|Adult Behavioral:
3135 NCT02173Immunogenicity and Sa CompletedNo ResultsVaricella Biological:
3136 NCT00601Vaccine Therapy, TretCompletedHas ResultLung Cancer Biological
3137 NCT01705Safety and Immunogen CompletedNo ResultsAIDS Biological:
3139 NCT00506Evaluate ReactogenicCompletedHas ResultInfluenza Biological
3140 NCT00317Assess the Immune Res CompletedNo ResultsDiphtheria; Haemophilus InfluenzaeBiological
T
3141 NCT00667Vaccine Therapy in PrCompletedHas ResultCervical Cancer|Nonneoplastic CondBiological
3142 NCT00307Safety & Immunogenic CompletedHas ResultInfections, Streptococcal Biological:
3143 NCT01199Effect of Treatment WCompletedHas ResultRelapsing Multiple Sclerosis Drug: Fingo
3144 NCT03192A Study to Evaluate WithdrawnNo ResultsVirus Diseases Biological:
3145 NCT01030Immunogenicity of OfCompletedNo ResultsPapilloma Viral Infection
3146 NCT00141Response to Booster D CompletedNo ResultsHepatitis Biological: hepatitis
3147 NCT00982Safety andPedVacc00CompletedNo ResultsHIV-1|HIV Infections Biological
3148 NCT02547A Study to Evaluate t CompletedHas ResultRespiratory Disorders Biological
3149 NCT04062A Study to Evaluate t Recruiting No ResultsVirus Diseases Biological
3150 NCT00260Broad Spectrum HPV CompletedNo ResultsHPV|Cervical Cancer|PremalignancyBiological
3151 NCT00445Lenalidomide and VacCompletedHas ResultMultiple Myeloma and Plasma Cell Biological
3152 NCT02918A Phase 2 Influenza ACompletedNo ResultsInfluenza Biological:
3154 NCT00877Safety, Long Term Im Unknown sNo ResultsDiphtheria|Tetanus|Pertussis|HepatBiological:
3155 NCT00345Safety of Hib-MenCY-T CompletedHas ResultHaemophilus Influenzae Type b|NeisBiological:
3156 NCT02236Interactive, Health L CompletedNo ResultsHuman Papillomavirus Behavioral
3157 NCT01195Trial to Evaluate Saf Terminate Has ResultInfluenza Biological:
3158 NCT00224Safety Study of Herp CompletedHas ResultHerpes Simplex Biological:
3159 NCT00158Assess Safety & ReactCompletedNo ResultsHaemophilus Influenzae Type b DiseBiological:
3160 NCT04026Study of GlaxoSmithKlRecruiting No ResultsClostridium Infections Biological:
3161 NCT00982Safety and Immunogen CompletedNo ResultsPost Kala Azar Dermal LeishmaniasisBiological:
3162 NCT01982Group B StreptococcuCompletedNo ResultsImmunisation During Pregnancy|Group B Stre
3163 NCT01651Humoral and Cellular CompletedNo ResultsPostcancer Fatigue|Chronic Fatigue Biological:
3164 NCT01922Challenge Study of a CompletedNo ResultsEnteritis; Escherichia Coli, EnterotoxBiological
3165 NCT01356Dose-Ranging Study oCompletedNo ResultsCervical Intraepithelial Neoplasia|C Biological:
3166 NCT02427A Study to Evaluate CompletedHas ResultHuman Influenza Biological:
3167 NCT00617Safety and Immunogen CompletedNo ResultsDiphtheria|Tetanus|Pertussis|HepatBiological:
3168 NCT03152Avelumab Pl AVEVAC Active, notNo ResultsColorectal Carcinoma Drug: Ave
3169 NCT02575A Clinical Trial to E CompletedNo ResultsEbola Disease Biological:
3170 NCT00325Safety of DTPa-IPV/HiCompletedHas ResultHaemophilus Influenzae Type b|Dipht Biological
3171 NCT04247Anti-PD-L1/TGF- <= TNot yet recNo ResultsHead and Neck Cancer|Head and N Drug: M782
3172 NCT00599Safety and Tolerabili CompletedNo ResultsHealthy Biological:
3173 NCT01489"Prime BooEVAD Terminate No ResultsCommon Variable ImmunodeficiencBiological:
3174 NCT04074Safety and Immunogeni Active, notNo ResultsInfluenza, Human Biological:
3175 NCT03813Safety andCPS135 Recruiting No ResultsMalaria,Falciparum|Controlled Huma Biological:
3176 NCT02721Safety and Immunogen Active, notNo ResultsSolid Tumors Biological
3177 NCT00622Pneumococcal Conjuga CompletedNo ResultsHIV Infections|Streptococcus Pneu Biological
3178 NCT01984Testing th AIMHi CompletedNo ResultsVaccine Preventable Diseases|MeniOther: Poi
3179 NCT00871Study to Evaluate GSKCompletedHas ResultNeisseria Meningitidis|HaemophilusBiological
3180 NCT00023Antibody Production Recruiting No ResultsPrimary Immune Deficiency Biological:
3181 NCT02213H7N9 Mix and MatchCompletedNo
W ResultsAvian Influenza Drug: MF59
3182 NCT00401Comparison of a DTaPCompletedHas ResultHepatitis B|Polio|Diphtheria|Pertu Biological
3183 NCT00004Vaccine Therapy Plus CompletedNo ResultsProstate Cancer Biological: MUC-2-KL
3184 NCT02146A Safety and Immunoge CompletedNo ResultsAllergic Rhinitis Biological
3185 NCT00581Study Evaluating PrevCompletedNo ResultsVaccines, Pneumococcal Conjugate Biological
3186 NCT01049A Study of a QuadrivaCompletedNo ResultsMeningitis|Meningococcal InfectionBiological
3187 NCT01710CervicovagCRC306 CompletedNo ResultsTick-Borne Encephalitis Drug: Tico
3188 NCT01939ProtectionT1DM CompletedNo ResultsType 1 Diabetes Mellitus Biological
3189 NCT00773Study of the MUC1 PeCompletedHas ResultRisk for Colorectal Cancer Biological:
3190 NCT00001Vaccine Therapy WithTerminate Has ResultRenal Cell Carcinoma Biological:
3191 NCT02568A Study to Assess theCompletedNo ResultsHepatitis C Infection Biological
3192 NCT00346Annual Study to InvesCompletedNo ResultsHealthy Volunteers Biological:
3193 NCT04023Promoting HPV VaccinCompletedNo ResultsHuman Papilloma Virus Behavioral:
3194 NCT00611Safety Stu VACCILUP CompletedNo ResultsLupus Erythematosus, Systemic Biological
3195 NCT01838Regulatory Post-Marke CompletedNo ResultsHepatitis A
3196 NCT03158Immunogenicity and TCompletedHas ResultCervical Cancer|Vulvar Cancer|VagiBiological:
3197 NCT00508Co-Administration of CompletedHas ResultInfections, Meningococcal Biological
3198 NCT02736Immunogenicity and SUnknown sNo ResultsDiseases Caused by Streptococcus Biological
3199 NCT01604Additional 6-Month SCompletedNo ResultsProphylaxis of Ross River Virus InfecBiological:
3200 NCT01061Trial of Bi-shRNA-fu CompletedNo ResultsEwings Sarcoma|Non Small Cell LunBiological:
3201 NCT00311Cell-Mediated ImmunCompletedNo ResultsInfluenza Biological: Influenza
3202 NCT02223Meningococcal Quadri CompletedHas ResultMeningococcal Disease|Pregnancy|IBiological
3203 NCT01770A Phase 2 Safety and CompletedHas ResultAnthrax Biological:
3204 NCT01721Comparison of Two Me CompletedNo ResultsConsequences of Immunization Me Procedure:
3205 NCT00981Study of Live Attenu CompletedHas ResultJapanese Encephalitis Biological:
3206 NCT00772Study of the Effect CompletedHas ResultDiphtheria|Tetanus|Haemophilus InfBiological
3207 NCT03072International Multic Active, notNo ResultsEbola Virus Disease|Prevention Biological
3208 NCT01092Gardasil Vaccination iCompletedHas ResultGardasil Vaccine|Stem Cell Transpl Biological:
3209 NCT00751Traveler's Diarrhea ( CompletedHas ResultPrevention of Travelers' Diarrhea Biological:
3210 NCT00574Idiotype Vaccine Fol CompletedNo ResultsLymphoma Biological:
3211 NCT00463Live Atten JEV03 CompletedHas ResultJapanese Encephalitis Biological:
3212 NCT00282US-licensed Combined CompletedHas ResultAcellular Pertussis|Tetanus|DiphtheBiological
3213 NCT00305Vaccine Therapy, Cyc CompletedHas ResultPancreatic Cancer Drug: Cetu
3215 NCT02089Cancer Stem Cells VacCompletedNo ResultsNeoplasms, Liver Biological:
3216 NCT00533Primary Vaccination CompletedHas ResultInfections, Rotavirus Biological:
3217 NCT01362Study of Quinvaxem fo CompletedHas ResultDiphtheria|Pertussis|Tetanus|HepatBiological
3218 NCT01356Effective Study of Liv CompletedNo ResultsPsoriasis Drug: live
3219 NCT00546Follow-up Study to E CompletedHas ResultInfections, Papillomavirus Biological:
3220 NCT02723A Long-term Follow-up Active, notNo ResultsHerpes Zoster Biological
3221 NCT00316Immunogenicity & Safe CompletedNo ResultsDiphtheria|Acellular Pertussis|Teta Biological
3222 NCT04013Measles Vaccination CompletedNo ResultsMeasles Behavioral:
3223 NCT01896Hepatitis BInfanrix CompletedNo ResultsMeningococcal Disease|Pneumococcal Biological:
3224 NCT01250Safety and Immunogen CompletedNo ResultsHealthy Biological:
3225 NCT01206Evaluation of the Eff CompletedNo ResultsInfluenza Caused by the 2009 H1N1 Other: Fol
3227 NCT01781Immunogeni SOT13 CompletedNo ResultsKidney Transplantation|Liver TranspBiological
3228 NCT03927Safety and Immunogen Not yet recNo ResultsInfluenza Biological:
3229 NCT01702Prevalence-based HeaCompletedNo ResultsHuman Papillomavirus Infection Other: Pre
3230 NCT00169Pneumococcal Adult-CompletedNo ResultsPneumonia Biological
3231 NCT03673Safety of MET41 Recruiting No ResultsHealthy Volunteers (Meningococcal B I iological
3232 NCT02481A Single-center, OpenUnknown sNo ResultsMeningococcal Meningitis Biological
3233 NCT01215Safety and Tolerabil CompletedHas ResultPneumococcal Infections Biological
3234 NCT01519Use of an Electronic CompletedHas ResultHerpes Zoster Disease Other: An i
3235 NCT02126Phase I/II MEL60 Active, notNo ResultsMelanoma|Metastatic Melanoma| Biological
3236 NCT01702Consistency Study of CompletedHas ResultRubella|Measles|Mumps Biological:
3237 NCT00169Vaccination of Childr CompletedNo ResultsAllogeneic Haematopoietic Stem CellBiological
3238 NCT02338Safety and Efficacy S CompletedNo ResultsProstatic Neoplasms Biological
3239 NCT01926Safety, Tolerability, CompletedHas ResultVulvovaginal Candidiasis Biological:
3240 NCT00196Evaluate 4 Different CompletedNo ResultsInfections, Meningococcal Biological:
3241 NCT00696Study Comparing Immu CompletedNo ResultsHepatitis B Biological
3242 NCT03132EpidemioloPICARVAC CompletedNo ResultsVaccination|Elderly Other: Anal
3243 NCT00660Safety and Immunogen CompletedNo ResultsPandemic Influenza Vaccine|PrevenBiological
3244 NCT00137Safety of the IntramuCompletedNo ResultsInfluenza Procedure:
3245 NCT02091Safety and Immunogen CompletedNo ResultsInfluenza, Human Biological:
3246 NCT04224A Clinical Trial to E Not yet recNo ResultsHIV Infections Biological
3247 NCT00216Study of the ProtectivUnknown sNo ResultsInfluenza Biological:
3248 NCT01734A Booster Dose of InaCompletedNo ResultsEV71-associated Disease Biological
3249 NCT02812DOSE HPV: Developmen CompletedNo ResultsBehavior Behavioral
3250 NCT02831Immunogenicity, SafetCompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological:
3251 NCT00940Safety and Immunogeni Unknown sNo ResultsKidney Transplant Biological:
3252 NCT01218Efficacy and Safety o CompletedHas ResultAIDS Biological
3253 NCT01424Safety and Immunogeni Terminate Has ResultTuberculosis Biological:
3255 NCT00624Assessment of AntiboCompletedNo ResultsInfections, Streptococcal Biological
3256 NCT00049Chemotherapy Followed CompletedNo ResultsLung Cancer Biological
3257 NCT00053Effect of Dose, Safet CompletedHas ResultSmallpox Biological:
3258 NCT00291Assess Immune Respon CompletedNo ResultsDiphtheria|Tetanus|Pertussis|Hepati Biological
3260 NCT00169Assess the Immunogeni CompletedNo ResultsRotavirus Gastroenteritis Biological:
3261 NCT01957Vaccine Therapy and Active, notNo ResultsGiant Cell Glioblastoma|Glioblasto Other: Lab
3262 NCT00321Study to DemonstrateCompletedHas ResultInfluenza Biological:
3263 NCT00443Characterisation of CompletedNo ResultsMalaria Biological
3264 NCT00337Follow up of Thai AduCompletedHas ResultHIV-1
3265 NCT00954Reducing Pain in Fou CompletedNo ResultsPain From Immunization Behavioral:
3266 NCT01032Post Authorization SaCompletedNo ResultsInfluenza|Swine-Origin A/H1N1 Influenza Viru
3267 NCT01966A Safety and Immunog CompletedNo ResultsAllergic Rhinoconjunctivitis Biological
3268 NCT01379Safety and ImmunogeCompletedNo ResultsMalaria Biological
3269 NCT00291A Study to Compare th CompletedNo ResultsHepatitis B Biological
3270 NCT01573Herpes ZosVZV-ZostavCompletedNo ResultsHerpes Zoster Biological:
3271 NCT00568Study of Two Formulat CompletedHas ResultVaricella Biological:
3272 NCT00579Multivalent ConjugateCompletedNo ResultsProstate|Cancer Biological:
3273 NCT03619Pneumococcal Vaccina Enrolling bNo ResultsMultiple Myeloma|Pneumococcal InBiological
3274 NCT03617Vaccinatio Mel-65 Recruiting No ResultsMelanoma Biological
3275 NCT00388Assess GSK BiologicalCompletedNo ResultsRubella|Mumps|Measles Biological:
3276 NCT02996VRC 320: A Phase I, RCompletedNo ResultsPrevention of Zika Infection|Zika-S Biological
3277 NCT00197Long Term F/U StudieCompletedNo ResultsHepatitis B|Hepatitis A Biological
3278 NCT04201Safety, ImmunogeniciRecruiting No ResultsMalaria, Vivax Biological
3279 NCT00683Dendritic Cells (Whit CompletedNo ResultsMelanoma Drug: cycl
3280 NCT00780Safety And Blood Col CompletedNo ResultsMeningitis, Meningococcal Biological
3281 NCT00809Vaccination With AutActive, notNo ResultsMelanoma Biological:
3282 NCT00443Meningococ MNB3 CompletedNo ResultsNeisseria Meningitidis Serogroup B Biological
3283 NCT00938A Clinical Trial of CS CompletedHas ResultInfluenza Caused by the Novel Influ Biological:
3284 NCT00596Study of I CLLIFVAC Terminate No ResultsChronic Lymphocytic Leukemia Drug: Imiq
3285 NCT00955A Study To Examine Se CompletedNo ResultsPneumonia Other: Pre
3286 NCT01109Extended Follow-Up of CompletedNo ResultsHIV Infections
3287 NCT01031Vaccine StuTBEV Terminate Has ResultTick-Borne Encephalitis|EncephalitisBiological
3288 NCT01817Hepatitis B Vaccine i CompletedHas ResultChronic Hepatitis B Biological:
3289 NCT00325Assess the Safety & RCompletedHas ResultDiphtheria|Tetanus|Poliomyelitis|AcBiological
3290 NCT00307A Lot-to-lot Consiste CompletedNo ResultsInfections, Streptococcal Biological
3291 NCT00706Vaccine Therapy in T WithdrawnNo ResultsBreast Cancer Biological
3292 NCT00436Safety and Immunogen CompletedHas ResultMalaria Biological:
3293 NCT00847Trastuzumab, Cyclopho CompletedHas ResultBreast Cancer Biological
3294 NCT00238Controlling Acute or CompletedNo ResultsHIV Infections Drug: Patie
3295 NCT00873A ProspectMI-MA205CompletedHas ResultHealthy Biological:
3296 NCT00333Thai Prophylactic HIVTerminate No ResultsHIV Biological
3298 NCT00085Vaccine Therapy in TrCompletedNo ResultsCiliary Body and Choroid MelanomaBiological
3299 NCT02338Safety and Efficacy S CompletedNo ResultsBreast Neoplasms Biological
3300 NCT00121Health SMART (StressCompletedNo ResultsPsychological Stress Behavioral
3301 NCT00477M-Vax + Low Dose IntNot yet recNo ResultsMelanoma Biological
3302 NCT00463Pneumococcal Vaccine CompletedHas ResultHepatitis B|Acellular Pertussis|Te Biological:
3304 NCT03774Immunity Duration ofActive, notNo ResultsRabies Biological
3305 NCT00710Investigating the MortUnknown sNo ResultsInfant, Newborn|Healthy Biological:
3306 NCT02080Target Ant BMGF1 CompletedNo ResultsMalaria Biological
3307 NCT02401Factors Associated WCompletedNo ResultsAging Biological:
3308 NCT00092Study of an Investiga CompletedHas ResultCervical Cancer|Genital Warts Biological:
3309 NCT02501Reactogenicity, Safet CompletedNo ResultsTuberculosis Biological:
3310 NCT01933Self-AdminiSNIF CompletedHas ResultInfluenza Drug: FluM
3311 NCT01152A Safety and Immunolo CompletedNo ResultsBreast Cancer Biological
3312 NCT02338Safety and Efficacy S CompletedNo ResultsLiver Neoplasms Biological
3313 NCT01892Text MessaTXT4FLUJACompletedNo ResultsInfluenza Other: Tex
3315 NCT00383Evaluate Safety & Imm CompletedNo ResultsInfections, Rotavirus Biological:
3316 NCT01584Clinical Trial of a T Unknown sNo ResultsCancer.|Melanoma.|Ovarian Cancer.Biological
3317 NCT02241RNActiveÂ® Rabies VaCompletedNo ResultsRabies Biological
3318 NCT02490Pertussis PIFA CompletedNo ResultsFood Allergy
3319 NCT02338Safety and Efficacy S CompletedNo ResultsPancreatic Neoplasms Biological
3320 NCT01656Phase I Safety and ImCompletedNo ResultsPreventive Avian Flu Biological: Avian Flu
3321 NCT03028Innate and Acquired CompletedHas ResultInfluenza Biological:
3322 NCT00861Immunogenicity of GSCompletedHas ResultRubella|Mumps|Measles|Measles-M Biological:
3323 NCT00226Evaluate Vaccine Aga CompletedHas ResultVaricella|Chickenpox Vaccines Biological:
3324 NCT00514Immunogenicity and Sa CompletedNo ResultsDiphtheria|Tetanus|Pertussis|Polio Drug: Boost
3325 NCT02121Cross-reactTy21a-ASCUnknown sNo ResultsHealthy Biological:
3326 NCT02797Educational InterventCompletedHas ResultHPV Vaccination Decision Quality Behavioral:
3327 NCT00449Assess Consistency o CompletedNo ResultsInfluenza Biological:
3328 NCT01961Epacadostat and VacciCompletedHas ResultMucosal Melanoma|Recurrent Melano Drug: Epac
3329 NCT00402Dendritic Cell VaccineCompletedNo ResultsHIV Infections Biological:
3330 NCT01374H1N1 Vaccine in Pregn Terminate No ResultsVaccine Exposure During Pregnancy
3331 NCT02745A Combined Cell TherWithdrawnNo ResultsNeuroblastoma|Neoplasms, Nerve TProcedure:
3332 NCT00777Study of a Booster DoCompletedHas ResultMeningitis|Meningococcemia Biological
3333 NCT02508A Pilot Study ComparTerminate Has ResultHuman Papilloma Virus, Male Behavioral
3334 NCT02977IMVAMUNEÂ® Smallpox Recruiting No ResultsMonkeypox Virus Infection Biologica
3335 NCT03239Vaccinatio VEPSC Active, notNo ResultsInfectious Disease|Pneumonia, Bacte Behavioral
3336 NCT00137Comparison of Immune CompletedNo ResultsPoliomyelitis Biological:
3337 NCT01719Reactogenicity, Safet CompletedHas ResultInfluenza Biological
3338 NCT01805RSV001 - A New Vaccin CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological:
3339 NCT01675A Phase I Study to Ev CompletedNo ResultsBird Flu|Avian Influenza|Influenza Biological:
3340 NCT02171Influenza A/H5N1 Vacc CompletedHas ResultInfluenza A Subtype H5N1 Infection Biological
3341 NCT01010A Double-Dose SafetyCompletedNo ResultsInfluenza Biological
3342 NCT00137Immunogenicity & SafCompletedNo ResultsInfections, Meningococcal Biological
3343 NCT00613Study of a Multi-Ant Terminate Has ResultMelanoma|Cancer Biological:
3344 NCT03313Trial to Evaluate the CompletedHas ResultPneumococcal Infections Biological:
3345 NCT00310Persistence of ImmunCompletedNo ResultsPrevention of Meningococcal Infect Procedure
3346 NCT00808A Study Evaluating S CompletedHas ResultMeningitis, Meningococcal Biological
3347 NCT00000A Double-Blind PlacebCompletedNo ResultsHIV Infections|Pneumococcal InfectBiological
3348 NCT01829Safety Study of ChAd CompletedNo ResultsTuberculosis Biological
3349 NCT00119Effect of MeningococCompletedNo ResultsMeningitis Biological
3350 NCT00751Vaccines and Dietary TOerminate Has ResultUlcerative Colitis Biological:
3351 NCT01842Vaccine Therapy and CompletedNo ResultsAdult Acute Myeloid Leukemia in ReBiological
3352 NCT00289Assess the Immunogeni CompletedNo ResultsInfections, Rotavirus Biological:
3353 NCT01657H5-VLP + GLA-AF Vacci CompletedNo ResultsInfluenza A Subtype H5N1 Infection Biological
3354 NCT00089Vaccine Therapy in TrCompletedNo ResultsIntraocular Melanoma|Melanoma (SBiological
3355 NCT00161Comparison of the SaCompletedNo ResultsInfluenza Biological: Vero Cell-
3356 NCT03180Scientific Evaluation Recruiting No ResultsCervical Cancer|Cervical HPV Infect Biological:
3357 NCT03688Class II Invariant Ch Recruiting No ResultsHepatitis C Biological
3358 NCT01290Safety Study of RespirCompletedNo ResultsRespiratory Syncytial Virus InfectionBiological:
3359 NCT00453Lot Consistency, ImmCompletedHas ResultInfections, Meningococcal Biological
3361 NCT03746Maternal Immunizati Recruiting No ResultsMeningitis|Meningococcal Biological
3362 NCT01280Improving PETNic002CompletedHas ResultNicotine Dependence Biological
3363 NCT02200A Study of NeuroVaxâ„ Unknown sNo ResultsMultiple Sclerosis Biological
3364 NCT00346To Evaluate 2 Doses oCompletedNo ResultsRotavirus Infections Biological:
3365 NCT00466Vaccine ThCML0206 CompletedHas ResultLeukemia Biological
3366 NCT01755Immunogenicity and Sa CompletedHas ResultInfections, Meningococcal Biological
3367 NCT01843A Phase I AdBa WithdrawnNo ResultsHealthy|Malaria Biological:
3369 NCT00316Human Papilloma ViruCompletedHas ResultCervical Intraepithelial Neoplasia|P Biological:
3370 NCT02921H7N9 Vaccination WitCompletedNo ResultsAvian Influenza|H1N1 Influenza|Inf Drug: AS03
3371 NCT00111Study to Evaluate theCompletedNo ResultsLeishmaniasis, Cutaneous Biological:
3372 NCT02339Observation Study anUnknown sNo ResultsDog Bite Biological:
3373 NCT01764Assessing Fever RatesCompletedNo ResultsFever Other: text
3374 NCT03606A Study to Evaluate t Recruiting No ResultsRespiratory Syncytial Virus Biological:
3375 NCT01288Vitamin D BCG-25-D CompletedNo ResultsTuberculosis Dietary Su
3376 NCT03945Flublok or Fluzone WActive, notNo ResultsInfluenza|Influenza Immunisation Biological
3377 NCT02797SF2a-TT15 Conjugate CompletedNo ResultsShigellosis|Bacillary Dysentery Biological:
3378 NCT01447Study to Assess the ECompletedNo ResultsStaphylococcal Infections|Yeast InfeBiological
3379 NCT03163Safety and ProtectiveCompletedNo ResultsMalaria Biological
3380 NCT00239A Trial of a Walter R CompletedHas ResultDengue Biological:
3381 NCT02699Observational Safety CompletedNo ResultsMeningitis|Meningococcal MeningitBiological
3382 NCT00092Cervical I FUTURE II CompletedHas ResultCervical Cancer|Genital Warts Biological:
3383 NCT01938H7N9 Mix and MatchCompletedNo ResultsInfluenza Biological
3384 NCT00693Safety and Immune Re CompletedHas ResultInfluenza Biological:
3385 NCT03387Evaluating the Infect Recruiting No ResultsRSV Infection Biological
3386 NCT00960Tumor and Vaccine SitActive, notNo ResultsMelanoma Drug: gp10
3387 NCT00861Adjuvant Therapy of CompletedNo ResultsMelanoma Drug: Pegy
3388 NCT04123Development of a LivCompletedNo ResultsDiarrhoeal Disease Biological:
3389 NCT00383Lot-to-Lot ConsistencyCompletedNo ResultsOrthomyxoviridae Infection|InfluenBiological:
3390 NCT03191A Study to Evaluate t WithdrawnNo ResultsRespiratory Syncytial Virus InfectionBiological
3391 NCT00427Study in Children to CompletedHas ResultInfections, Meningococcal Biological
3392 NCT02097Dose-Finding Study oCompletedHas ResultPneumonia, Pneumococcal Biological:
3393 NCT02589Improving Influenza Unknown sNo ResultsInfluenza Other: ele
3394 NCT02184Safety and Immunogen CompletedHas ResultMeasles; Mumps; Rubella Biological:
3395 NCT00547Pneumococcal Vaccine CompletedHas ResultInfections, Streptococcal Biological:
3396 NCT02374Immunogeni RABVAX CompletedNo ResultsRabies Drug: Rabi
3397 NCT00502Evaluate Safety & Im CompletedHas ResultInfluenza Biological
3398 NCT02302Safety and Immunogeni CompletedNo ResultsDengue Fever Biological
3399 NCT02242Screening of VolunteerRecruiting No ResultsVaccines|Antiviral Agents|Immunologic Factors|
3400 NCT03510Video-Assisted Counse Recruiting No ResultsHuman Papillomavirus Infection Behavioral
3401 NCT02663Safety and Immunogeni CompletedNo ResultsPlasmodium Falciparum Infection Drug: Arte
3402 NCT01216Local Modulation of Terminate No ResultsMetastatic Melanoma Biological
3403 NCT03777Study To Describe TheCompletedNo ResultsVaccines Biological
3404 NCT00111Study to Evaluate theCompletedNo ResultsLeishmaniasis, Mucocutaneous Biological:
3405 NCT01527Pneumococcal Conjuga Active, notNo ResultsInfection in Solid Organ Transplant RBiological
3406 NCT03697A Study ExBERT Active, notNo ResultsPertussis Biological
3407 NCT01353Open-label Study to CompletedNo ResultsHealthy Biological
3408 NCT03185TSA-DC Vaccine in TreUnknown sNo ResultsTumor Gastric|Tumor, Colorectal Biological
3409 NCT02317Evaluation of the Saf CompletedNo ResultsDengue Biological
3410 NCT00117Study of the HIV gp12CompletedNo ResultsHIV Infections Biological
3411 NCT00000An HIV Vaccine PrepaCompletedNo ResultsHIV Infections Behavioral: Vaccine
3412 NCT00322Modified Process Hepa CompletedNo ResultsHepatitis B|Hepatocellular Carcino Biological
3413 NCT00623A Phase 1 Study of MCompletedHas ResultMelanoma|Sarcoma|Gastrointestinal Biological:
3414 NCT01396Text Reminders for ImCompletedNo ResultsChild Immunizations Behavioral
3416 NCT01527A Study to Evaluate t CompletedHas ResultHerpes Zoster Biological:
3418 NCT01443Evaluating the Safet WithdrawnNo ResultsPneumococcal Infections|HIV InfectBiological:
3419 NCT01340Immunogenicity and SCompletedHas ResultMeningococcal Infection Biological
3420 NCT02044A Phase I/IIa Study o CompletedNo ResultsPlasmodium Falciparum Malaria Biological
3421 NCT03562Vaccine ReECZTRA 5 Active, notNo ResultsAtopic Dermatitis Drug: Tral
3422 NCT00903Trial to Evaluate Saf CompletedNo ResultsSeasonal Influenza Biological:
3423 NCT01191Cellular and Molecul CompletedNo ResultsHealthy Volunteers|Influenza
3424 NCT00390Study to Evaluate theCompletedHas ResultInfections, Streptococcal Biological
3425 NCT00386Needle-free Jet Injec CompletedNo ResultsInfluenza Biological:
3426 NCT02990Complementary StudyUnknown
o sNo ResultsYellow Fever
3427 NCT01676A Phase I Clinical Tr WithdrawnNo ResultsHealthy Biological:
3428 NCT02336A Phase I/II Trial o Active, notNo ResultsBreast Cancer Biological
3429 NCT00576Surgical ReGliadel WaCompletedNo ResultsMalignant Glioma Biological:
3430 NCT00420Long-term Efficacy anCompletedHas ResultInfections, Rotavirus Biological:
3431 NCT00913Bevacizumab, Autologo Terminate Has ResultMetastatic Renal Cell Carcinoma Biological:
3432 NCT01171Immunogenicity and SCompletedHas ResultTetanus|Diphtheria|Haemophilus Infl Biological:
3433 NCT01548Effects of Short-term Unknown sNo ResultsHepatitis B|Vaccination Failure Drug: Ator
3434 NCT00051Evaluation of the Saf CompletedNo ResultsHIV Infections Biological
3435 NCT01418Safety of and ImmuneCompletedNo ResultsHIV Seronegativity|HIV Preventive VBiological
3436 NCT02285Assessing the Effect CompletedHas ResultMeningococcal Disease Biological
3437 NCT03969A Study to Assess th Not yet recNo ResultsLeishmaniasis, Cutaneous Biological
3441 NCT01393Evaluation of Long-teEnrolling bNo ResultsUterine Cervical Cancer Procedure:
3443 NCT00383Development of Immun Terminate Has ResultInfectious Diseases|Influenza|AvianBiological
3444 NCT03147Observational Study DCompletedNo ResultsWhooping Cough|Pertussis
3445 NCT00043Safety of an HIV DNA CompletedNo ResultsHIV Infections Biological: pGA2/JS2
3446 NCT03029IGFBP-2 Vaccine and CSuspendedNo ResultsStage III Fallopian Tube Cancer|StagDrug: Carb
3447 NCT00390Does the Order in WhCompletedNo ResultsPain Drug: Pent
3448 NCT03169A Clinical Study to Ev CompletedNo ResultsPoliomyelitis Biological:
3449 NCT00662Study of the Safety, CompletedNo ResultsDiphtheria|Tetanus|Whooping CougBiological:
3450 NCT02485A Study to Evaluate t CompletedHas ResultVirus Diseases Biological
3451 NCT00679The Effectiveness of CompletedNo ResultsVaricella (Chickenpox)|Chickenpox VProcedure:
3453 NCT00498Safety and Effectiven WithdrawnNo ResultsHIV Infections Biological
3454 NCT02957Safety and Immunogen CompletedNo ResultsInfluenza A Virus, H7N9 Subtype Biological
3455 NCT0203413-valent Pneumococca CompletedHas ResultPrevention of Pneumonia and InvasiBiological
3456 NCT01806Intranasal AD4-H5-VTCompletedNo ResultsHealthy Volunteer Biological
3457 NCT02950A Study Combining NeRecruiting No ResultsKidney Cancer Drug: NeoV
3458 NCT03382Study to Assess the CompletedNo ResultsChikungunya Biological
3459 NCT04224Vaccine CoVACGREN CompletedNo ResultsPrimary SjÃ¶gren Syndrome Other: Que
3460 NCT00703Rabies Immunization CompletedNo ResultsRabies Biological: Rabies vac
3461 NCT03880Efficacy of Candidat Active, notNo ResultsInfluenza Biological
3462 NCT02145PXVX0200 (CVD103-Hg CompletedNo ResultsCholera Biological
3464 NCT02279Open Rando HYPOPNE Unknown sNo ResultsPneumococcal Infection Biological
3465 NCT00869Phase 2 Trial of Ther CompletedHas ResultChronic Hepatitis B Biological
3466 NCT035892013/2017 H7N9 PrimActive, notNo ResultsAvian Influenza|Influenza ImmunisaBiological
3467 NCT03379Use of SMS and InterCompletedNo ResultsImmunization; Infection|SMS Other: SMS
3468 NCT01024Evaluation of PandemCompletedNo ResultsInfluenza Caused by the Novel A(H1N Other: Fol
3470 NCT01520HPV Vaccine EffectivenCompletedNo ResultsHPV16 Anitbody Levels Post Vaccination|HPV18
3471 NCT03547A Phase I Trial to E Active, notNo ResultsHIV/AIDS Biological
3472 NCT00583Phase II S APP22 Active, notNo ResultsHormone Refractory Prostate CanceBiologica
3474 NCT00282Safety Study of MVA STerminate No ResultsHIV Infections|Smallpox Biological
3475 NCT01440A Study of Immunogeni CompletedHas ResultInfluenza Biologica
3476 NCT01250A Trial Evaluating a CompletedHas ResultHealthy Subjects Biological:
3477 NCT00944Preparing fCATSA Unknown sNo ResultsHIV Infection|HIV Infections
3478 NCT03314Phase 3 Safety and ImCompletedNo ResultsInfluenza, Human Biological:
3479 NCT04164Live Attenuated Influ Not yet recNo ResultsInfluenza Drug: Flum
3480 NCT01313Tumor Cell Vaccine f CompletedNo ResultsSarcoma|Melanoma|Epithelial Malig Drug: Cycl
3481 NCT00279Vaccination Study of CompletedNo ResultsRheumatoid Arthritis Drug: Teta
3482 NCT02354Clinical Trial of Ebo CompletedNo ResultsHemorrhagic Fever, Ebola Biological
3483 NCT00561Vaccine Therapy in T CompletedNo ResultsLymphoma Biological
3484 NCT00479Annual Study to InvesCompletedNo ResultsHealthy Volunteers Biological:
3485 NCT00976A/H1N1 Immunogenicit CompletedNo ResultsInfluenza|Pandemic Influenza Biological:
3486 NCT02425Safety Stu Mel63; C Terminate No ResultsMelanoma Biological
3487 NCT03337An Observational StudCompletedNo ResultsHIV Infections Other: Obs
3488 NCT01461Safety Stu HIVIS06 CompletedNo ResultsHealthy Volunteers Biological:
3489 NCT02864RSV-MVA-BN Vaccine Withdrawn
Ph No ResultsRespiratory Syncytial Virus InfectionBiological
3490 NCT01146Adefovir Plus VaccinaCompletedHas ResultHepatitis B|Liver Transplantation Drug: Adefo
3492 NCT02608A Study to Evaluate thCompletedNo ResultsRespiratory Syncytial Virus (RSV) Biological:
3493 NCT00137Study of Immunogenici CompletedNo ResultsInfections, Rotavirus Biological:
3494 NCT02901Long-term PersistenceCompletedHas ResultHepatitis B Vaccine Biological:
3495 NCT01224A Study EvaLIfT CompletedNo ResultsInfluenza Biological:
3496 NCT00612Vaccine Therapy in TrCompletedNo ResultsBrain and Central Nervous System T Biological:
3497 NCT02097Vaccination ResponseCompletedHas ResultRelapsing Forms of Multiple SclerosiDrug: dime
3498 NCT02583Clinical Study to Eva CompletedHas ResultInfluenza Biological
3499 NCT00761Study Evaluating 13- CompletedHas ResultHealthy Subjects Biological
3500 NCT00715A Phase I Cancer VaccUnknown sNo ResultsMetastatic Breast Cancer Biological:
3501 NCT00004Vaccine Therapy in TrCompletedNo ResultsBreast Cancer Biological
a ResultsHIV Infections Biological
3503 NCT02477Safety and Immunogeni CompletedNo ResultsSystemic Lupus Erythematosus Biological:
3504 NCT03459Efficacy of FendrixÂ® Recruiting No ResultsLiver Disease Chronic|Hepatitis B ViBiological:
3505 NCT01143Pilot Study of Allog CompletedNo ResultsLung Cancer|Esophageal Cancer|MaBiological
3506 NCT01196A Study to Evaluate t CompletedHas ResultInfluenza Biological
3507 NCT02967Influenza Vaccine FeaCompletedHas ResultAsthmatic Drug: ccIIV
3508 NCT01086Safety and Transfluva CompletedNo ResultsRenal Transplant Recipients|ImmunBiological
3509 NCT01733Study to Assess the I CompletedNo ResultsInfections, Rotavirus|Rotavirus VaccOther: Data
3510 NCT00456Complementary Testin CompletedHas ResultInfections, Papillomavirus Biological:
3511 NCT03186Influenza HA Ferritin CompletedNo ResultsInfluenza Biological
3513 NCT00969Comparison of GSK Me CompletedHas ResultVaricella|Rubella|Mumps|Measles Biological:
3514 NCT02827Association of Host GCompletedNo ResultsDengue Fever|Dengue Haemorrhagic Fever
3515 NCT01190Safety Evaluation of CompletedHas ResultInfections, Papillomavirus Biological
3516 NCT01178Non-specific ResponsUnknown sNo ResultsInfluenza H1N1
3517 NCT01047Immunogenicity and Sa CompletedHas ResultEncephalitis Biological:
3518 NCT02503TherapeutiTBCOX2 Active, notNo ResultsTuberculosis Drug: etori
3519 NCT00015Vaccine Therapy Plus CompletedNo ResultsProstate Cancer Biological:
3520 NCT00464Effect of Probiotic o CompletedNo ResultsCholera Biological:
3521 NCT02058Immunogenicity and SCompletedHas ResultRubella|Mumps|Measles Biological
3522 NCT00975Novel Influenza A/H1N CompletedNo ResultsVirus Diseases|Respiratory Tract Di Biological:
3523 NCT03606Therapeutic VaccinatiRecruiting No ResultsHIV-1-infection Biological
3524 NCT01204Dendritic Cell Vaccin Active, notNo ResultsGlioma|Anaplastic Astrocytoma|AnaBiological
3526 NCT00315Immunogenicity of DCompletedHas ResultHepatitis B|Polio|Diphtheria|PertusBiological
3527 NCT00604Immunogenicity Study CompletedHas ResultJapanese Encephalitis Biological:
3528 NCT00148Antibody Responses tCompletedNo ResultsHIV Infections Biological
3529 NCT00192Phase II Study to Inv CompletedNo ResultsInfluenza Biological:
3530 NCT01336The Long-term Immuno CompletedNo ResultsInfluenza Biological:
3531 NCT02243Mail OutreMOTIVATECompletedNo ResultsInfluenza, Human|Influenza|HumanBehavioral
3532 NCT02179Safety and Tolerabil CompletedNo ResultsLung Cancer|Breast Cancer|Prostat Biological
3533 NCT02116Safety, Tolerability, CompletedNo ResultsPneumococcal Infections|PneumoniBiological
3534 NCT00524Challenge Dose of Hep CompletedHas ResultHepatitis B Biological:
3536 NCT02240A Study to Assess Ne CompletedNo ResultsEbola|Ebola Zaire Biological
3537 NCT00800Study of the Safety Terminate No ResultsTuberculosis Biological
3538 NCT00164Pneumococcal Conjuga CompletedNo ResultsPneumococcal Infections Biological:
3539 NCT03688Enhanced Safety Surve CompletedNo ResultsInfluenza, Human Other: Pas
3540 NCT02153Vaccine Plus Booster CompletedHas ResultProstate Cancer|Prostatic NeoplasmBiological
3541 NCT00776Study of Immune Respo CompletedNo ResultsInfluenza|Orthomyxovirus InfectionBiological:
3542 NCT00492Dendritic Dendritic WithdrawnNo ResultsSquamous Cell Carcinoma of Head Biological:
3543 NCT02529An Exploratory Safet CompletedNo ResultsHigh Grade Cervical Intraepithelial Biological
3544 NCT02052A Study To Investigat CompletedNo ResultsClostridium Difficile Biological:
3545 NCT00351Immunogenicity/SafetCompletedNo ResultsMeasles|Mumps|Rubella|Varicella Biological
3546 NCT01545Evaluation of a Vacci CompletedHas ResultInfections, Streptococcal Biological
3547 NCT01782AcceptabiliPopCorn CompletedNo ResultsHepatitis B Other: Data
3548 NCT01001Does Seasonal InfluenCompletedHas ResultInfluenza Biological:
3550 NCT01439An Efficacy Study of CompletedHas ResultInfluenza Biological:
3552 NCT04053Clinic Trial to Evalu Recruiting No ResultsVaccination Biological:
3553 NCT00791Vaccine Therapy in TrCompletedHas ResultHER2-positive Breast Cancer|Male BBiological
3554 NCT03313SaniVac Trial - Sanit Recruiting No ResultsRotavirus Infections|Environmental Other: Sani
3555 NCT03762Combined IPPS-BOOSTActive, notNo ResultsRheumatoid Arthritis|Systemic LupuBiological
3556 NCT00603Phase I Safety and ImCompletedNo ResultsInfluenza Infection Biological:
3557 NCT00551A Study to Evaluate CompletedNo ResultsCervical Cancer|Vulvar Cancer|VagiBiological
3558 NCT00389Safety Study of MVA SWithdrawnNo ResultsSmallpox|Atopic Dermatitis Biological
3559 NCT02560Safety and Immunogen Unknown sNo ResultsHaemophilus Influenzae Type b InfeBiological:
3560 NCT00969Study to Evaluate Imm CompletedHas ResultInfections, Rotavirus|Rotavirus VaccBiological:
3561 NCT00698Comparing Immunogeni CompletedNo ResultsHepatitis B Biological
3562 NCT02022Safety, Tolerability a CompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological:
3563 NCT03425Randomized, Placebo-c CompletedNo ResultsZika Virus|Zika Virus Infection Biological:
3564 NCT02566Study of HSHIVERINGCompletedHas ResultInfluenza|Multiple Myeloma|WaldeBiological:
3565 NCT02353Oral Water HydrationCompletedNo ResultsPresyncope|Syncope Other: Ora
3566 NCT01712Safety and Immunogen CompletedNo ResultsHIV Biological
3567 NCT00155Rapid Vaccination of Unknown sNo ResultsInfluenza Biological
3568 NCT00306Safety Study of PandeCompletedHas ResultInfluenza|Influenza Vaccines Biological
3569 NCT04087An Immunogenic Perso Recruiting No ResultsCancer Biological
3570 NCT00344Safety and Immunogen CompletedHas ResultInfections, Streptococcal Biological:
3571 NCT01713Testing Educational Ma Unknown sNo ResultsImmunization Behavioral
3572 NCT00053Dose Study of ACAM20 CompletedHas ResultSmallpox Biological
3573 NCT03582Phase II Clinical Tria Not yet recNo ResultsFibromyalgia Biological:
3574 NCT01479Efficacy a PRESENT CompletedNo ResultsBreast Cancer With Low to IntermedBiological
3575 NCT00697Safety and Immunogen CompletedNo ResultsHepatitis B Biological
3576 NCT00197Immune Response & CompletedHas
Sa ResultHepatitis A Biological:
3577 NCT00319A Safety and Efficacy CompletedHas ResultJapanese Encephalitis Biological:
3578 NCT03999Long-Term Safety andRecruiting No ResultsDengue Fever Biological:
3579 NCT03201A Long Term Follow-up Active, notNo ResultsRespiratory Disorders Biological
3580 NCT01890Immunotherapy WithCompletedNo
C ResultsStage III Colon Cancer Biological
3581 NCT00033Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological
3582 NCT00222Influenza VaccinationCompletedNo ResultsAnticoagulants|Influenza Vaccines Drug: Influ
3583 NCT02218A Phase I SMENSCH CompletedNo ResultsHealthy Biological
3584 NCT02315Safety, Tolerability Active, notNo ResultsHealthy Biological
3585 NCT02014Safety andAMA1-DiCCompletedNo ResultsMalaria, Falciparum Biological
3586 NCT01095A Phase I Safety StudCompletedNo ResultsOvarian Neoplasms|Breast Neoplas Biological:
3587 NCT02852Evaluating the Immu CompletedNo ResultsHIV Infections Biological
3588 NCT00005Vaccine Therapy in TrTerminate No ResultsAdenocarcinoma of the Prostate|RecBiological:
3589 NCT03968Undetectable IgE as Recruiting No ResultsImmune Deficiency Biological:
3590 NCT02308Safety and Immunogeni CompletedHas ResultPneumococcal Disease Biological
3591 NCT01231Safety and Immunogen CompletedHas ResultMalaria Biological:
3592 NCT02376OPV Transmissibility CompletedNo ResultsPolio Other: Cont
3593 NCT02107Safety and Immunogen CompletedNo ResultsInfluenza, Human|Flu, Human|Flu, ABiological:
3594 NCT02531Phase 1 Study of dmLT Active, notNo ResultsGastroenteritis Escherichia Coli Other: Pla
3595 NCT02075Immunogeni CUT*HIVA Unknown sNo ResultsHIV Biological
3596 NCT02421Study of Varying Inj CompletedNo ResultsDengue Biological
3597 NCT00474Safety & Immunogenic CompletedHas ResultInfections, Meningococcal Biological
3598 NCT02624A Study to DetermineCompletedNo ResultsRespiratory Syncytial Virus InfectionBiological:
3599 NCT00434Dose-ranging Study toCompletedHas ResultAIDS|HIV Infections Biological
3600 NCT01326Therapeutic HepatitisCompletedHas ResultChronic Hepatitis B Biological
3601 NCT00196Study to Evaluate MeCompletedNo ResultsInfections, Meningococcal Biological:
3602 NCT00327Safety and Immune Re CompletedNo ResultsProphylactic Pneumococcal Disease Biological
3603 NCT02621HBV Vaccine in Renal CompletedNo ResultsRenal Failure Biological
3604 NCT01896HPV Vaccination in SpTerminate Has ResultPRD (Paediatric Rheumatological Disease)|IBD
3605 NCT01616Immunogenicity and SCompletedHas ResultInfections, Streptococcal Biological
3606 NCT01334WT1 Immuni WIN CompletedNo ResultsLeukaemia (Acute)|Leukaemia (ChroBiologica
3607 NCT02654Vaccination ResponseRecruiting No ResultsIndividuality|Healthy|Asthma|ImmuBiological
3608 NCT01251Immunogenicity and SCompletedNo ResultsInfectious Disease by Haemophilus IBiological:
3609 NCT04009VAC071: A Study to ARecruiting No ResultsMalaria, Vivax Biological
3610 NCT00105Vaccine Treatment foCompletedNo ResultsProstate Cancer Biological
3611 NCT00693Dose-Comparison Stud CompletedNo ResultsInfections, Papillomavirus Biological
3612 NCT00139Study of 2 Doses of HCompletedNo ResultsInfections, Rotavirus Biological:
3614 NCT00277Safety Study of HBV DCompletedNo ResultsChronic Hepatitis B Biological
3615 NCT01077GARDASILâ„ VIP CompletedHas ResultHuman Papillomavirus Infections
3616 NCT02280Safety and Immunogeni CompletedHas ResultEbola Viruses Other: Pla
3617 NCT00283Half vs Full Dose Infl CompletedNo ResultsInfluenza Biological:
3618 NCT04183PCV13 in Non-pregn CompletedNo ResultsPneumococcal Infections Biological
3619 NCT02362A Study to Assess th CompletedNo ResultsHepatitis C Infection|HIV Infection Biological
3620 NCT00740Impact of SIVANHOE CompletedNo ResultsRotavirus Gastroenteritis Biological:
3621 NCT00197Comparison of Monodo CompletedNo ResultsHepatitis B Biological:
3622 NCT00111Study of an HIV PreveCompletedNo ResultsHIV Infections Biological
3623 NCT01708Safety and Immunogeni CompletedNo ResultsPoliomyelitis Drug: IPV|
3624 NCT01106Study to Evaluate th CompletedHas ResultHaemophilus Influenzae Type b|TetaBiological:
3625 NCT00755Annual Study for SeruCompletedHas ResultInfluenza|Orthomyxoviridae Infecti Biological:
3626 NCT01860Vouchers to Promote CompletedNo ResultsWhooping Cough Other: Full
3627 NCT00168Immunology of Non-spe CompletedNo ResultsMeasles|Diphtheria|Tetanus|PertusBiological:
3628 NCT04130VAC077: Safety and I Recruiting No ResultsMalaria,Falciparum Biological
3629 NCT02725Clostridium Difficile CompletedNo ResultsClostridium Difficile Associated DiseBiological:
3630 NCT02173Safety and Efficacy S Unknown sNo ResultsBacterial Vaginosis Biological:
3631 NCT00004Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: recombina
3632 NCT00962Measles, Mumps, andCompletedNo ResultsMeasles|Mumps|Rubella Biological
3633 NCT02415A Laboratory EvaluatiCompletedHas ResultImmunologic Tests Other: Ser
3635 NCT02771Safety and Efficacy Unknown sNo ResultsGlioma Biological:
3636 NCT01310Monovalent H5N1 Vacc CompletedHas ResultInfluenza Biological:
3637 NCT03266The Immune Response CompletedNo
t ResultsInfluenza Drug: Vaxi
3638 NCT01169EP1300 Polyepitope DCompletedNo ResultsPlasmodium Falciparum Malaria Drug: Plac
3639 NCT02985A Prospective Study Recruiting No ResultsNon-Alcoholic Fatty Liver Disease|HBiological:
3640 NCT03161GVAX Pancreas VaccinRecruiting No ResultsPancreatic Cancer Drug: Cycl
3641 NCT00274Safety Study of HSV2 CompletedNo ResultsHSV-2 Biological
3642 NCT01209Acceptability and FeaUnknown sNo ResultsCervical Cancer Behavioral
3643 NCT00519Safety, Reactogenici CompletedNo ResultsPandemic Influenza Biological
3644 NCT02169Hepatitis B Booster S CompletedHas ResultHepatitis B Biological:
3645 NCT03399Safety and ImmunogeRecruiting No ResultsMERS (Middle East Respiratory Syn Biological
3646 NCT00197Liposomal Based IntraCompletedNo ResultsInfluenza Biological:
3647 NCT00169A Study in Children WCompletedNo ResultsStreptococcal Infections Biological
3648 NCT01296Population Versus PraCompletedNo ResultsHealth Services Research|ComparatiBehavioral:
Y ResultAtopic Dermatitis Biological
3650 NCT01900Study of a Booster D CompletedHas ResultJapanese Encephalitis Biological
3651 NCT01443Experimental AD4-H5-CompletedNo ResultsH5N1 Influenza Biological:
3653 NCT00799Men's Beliefs About CompletedHas ResultAnus Neoplasms
3654 NCT00401Influenza Vaccine Po CompletedNo ResultsInfluenza|Vaccine|Pregnancy
3656 NCT02385IM Recombinant RicinWithdrawnNo ResultsRicin Poisoning Biological:
3657 NCT02296A Study to Find Out i Unknown sNo ResultsEbola Virus Disease Biological
3658 NCT00414Phase I Study of Saf CompletedNo ResultsMalaria Drug: AMA1
3659 NCT00766High Dose Influenza WithdrawnNo ResultsInfluenza Biological:
3660 NCT00514Vaccine Therapy in TrUnknown sNo ResultsProstate Cancer Biological
3661 NCT02412Intestinal and HumoraCompletedNo ResultsPoliomyelitis Biological:
3662 NCT00866Efficacy of GSK Biolo CompletedHas ResultMalaria Biological:
3663 NCT00814Vaccine Therapy in TrTerminate Has ResultProstate Cancer Biological:
3664 NCT04025Systems Analyses of Recruiting No ResultsHealthy Volunteer Biological:
3665 NCT04006A Study to Test GlaxoRecruiting No ResultsHerpes Zoster Biological
3666 NCT01585A MultipepMEL58 CompletedNo ResultsMelanoma Biological
3667 NCT00301Vaccine Therapy and Active, notNo ResultsLeukemia Biological
3668 NCT01035Study of GSK BiologicCompletedHas ResultInfluenza Biological:
3669 NCT01942VACcinatioVACIMRA Active, notNo ResultsRheumatoid Arthritis Biological
3670 NCT03027A Study to DetermineRecruiting No ResultsCrohn Disease|Mycobacterium Avium Biological
3671 NCT00074S0310: Vaccine Therap Terminate No ResultsLung Cancer Biological:
3672 NCT04157Th-1 DendrDECIST Not yet recNo ResultsPancreatic Adenocarcinoma|PancreaBiological
3673 NCT00698Comparing Immunogeni CompletedNo ResultsHepatitis B Biological
P ResultsPneumococcal Infection Biological:
3675 NCT01444Study of Two InvestigCompletedNo ResultsPneumococcal Infections|Streptoc Biological
3676 NCT02103Intradermal InfluenzaCompletedNo ResultsInfluenza Viral Infections Drug: Imiq
3677 NCT01531Hepatitis HBV VIP Unknown sNo ResultsInflammatory Bowel Disease Biological:
3678 NCT04258A TRIAL TO EVALUAT Not yet recNo ResultsGroup B Streptococcal Infections Biological
3679 NCT01479Evaluating the Immune CompletedNo ResultsHIV Infections Biological:
3680 NCT02562Trial for Safety and CompletedHas ResultChikungunya Virus Infection Biological
3681 NCT00980Study to Evaluate 13 CompletedHas ResultVaccines, Pneumococcal Conjugate Biological:
3682 NCT01536Safety, Tolerability CompletedHas ResultMeasles|Mumps|Rubella|Varicella Biological
3683 NCT00741Safety and Immunogen CompletedNo ResultsCholera|Vibrio Infections|Diarrhea Biological
3684 NCT03367Evaluate Immunogenic Enrolling bNo ResultsRotavirus Infections Biological
3685 NCT00601Evaluation of Menin CompletedHas ResultMeningococcal Disease Biological
3686 NCT03589rCSP/AP10-602 [GLA-LRecruiting No ResultsPlasmodium Falciparum Infection Other: AP1
3688 NCT04071Immunogenicity and SNot yet recNo ResultsImmunogenicity|Safety Biological:
3689 NCT03769Immunogenicity and Sa Active, notNo ResultsLyme Borreliosis Biological:
3690 NCT02425Depletion HIV-CORE0Unknown sNo ResultsHIV Biological
3691 NCT03879VRC 313: A Trivalent VActive, notNo ResultsVenezuelan Equine Encephalitis|West Biologica
3692 NCT01762Field Application of CompletedNo ResultsOther Specified Effects of Reduced Drug: Shan
3693 NCT02504Can Earlie BCGR SuspendedNo ResultsInfant Mortality|BCG Biological
3694 NCT00338Safety and Immunogen CompletedNo ResultsHepatitis A Biological
3696 NCT01310Comparison of the EffCompletedHas ResultInfluenza Biological:
3697 NCT01424Adjuvanted InfluenzaUnknown sNo ResultsInfluenza
3698 NCT01232A Study to Assess th CompletedNo ResultsMultiple Myeloma Biological
3699 NCT00792Immunogenicity and Sa CompletedHas ResultVaricella Biological:
3700 NCT01981Post-licensure Safety CompletedHas ResultJapanese Encephalitis Biological:
3701 NCT01086An Open-Label, Random CompletedNo ResultsInfluenza A Virus, H5N1 Subtype Biological
3702 NCT02814Clinical Trial of the Recruiting No ResultsToxic Shock Syndrome Biological:
3703 NCT00851A Trial to Evaluate A CompletedNo ResultsHIV|HIV Infections Biological
3704 NCT04051Dual Vaccine Trial in Recruiting No ResultsPolycythemia Vera|Essential Throm Drug: PD-L
3705 NCT00859Dose Finding Study ofCompletedNo ResultsProstate Cancer Biological
3706 NCT02419Trial to Evaluate the CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological
3707 NCT03626A Clinical GESIDA100Active, notNo ResultsHIV Infections Biological
3708 NCT00880Safety and Immune Res CompletedHas ResultHIV Infection|Rotavirus Infection Biological:
3709 NCT03735Specialized Immune Ce Not yet recNo ResultsStage II Fallopian Tube Cancer AJCC Biological:
3710 NCT02240Vaccinatio Vaccimil CompletedNo ResultsRA|SLE|Vasculitis|Scleroderma|Sj Biological:
3711 NCT03645Clinical Study of a P Recruiting No ResultsPancreatic Cancer|Pancreatic Carci Biological
3712 NCT01398Cyclin B1 Peptide-PulWithdrawnNo ResultsNon-small Cell Lung Cancer Biological:
3713 NCT00458Treatment PRIMAL CompletedNo ResultsChronic Lymphocytic Leukemia (CLL)Biological
3714 NCT00924An Open Label PhaseCompletedNo
I ResultsProstate Cancer|Breast Cancer|Lun Biological
3715 NCT03404Assessment of FamilyCompletedNo ResultsContraception|Contraceptive UsageBehavioral:
3716 NCT02927A Challenge Study to CompletedNo ResultsMalaria Biological
3717 NCT03674A Study To Evaluate Recruiting No ResultsNon-Small Cell Lung Cancer|Triple-nBiological
3718 NCT00122Human Papilloma Virus CompletedHas ResultInfections, Papillomavirus Biological:
3719 NCT00109V221 Concomitant UsCompletedHas ResultMeasles|Mumps|Rubella|Varicella Biological
3720 NCT00298DNP-Modified Autolog Terminate No ResultsNon-Small Cell Lung Cancer - ComplBiological
3721 NCT02777A Study to Evaluate t CompletedNo ResultsEnterovirus Infections Biological:
3722 NCT02972A Study of NASIMMUActive, notNo ResultsInfluenza Biological
3723 NCT00162A Novel Vaccine for WithdrawnNo ResultsMultiple Myeloma|Tumors Biological
3724 NCT00341Malaria Vaccine in ChCompletedNo ResultsMalaria Drug: AMA1-C1/Alhydr
3725 NCT00452Study to Assess SafetCompletedNo ResultsDiphtheria|Acellular Pertussis|Teta Biological:
3726 NCT01467Vaccine EffectivenessCompletedHas ResultRotavirus Infections|Gastroenteriti Other: No
3727 NCT01309Immunogenicity and Sa CompletedHas ResultPoliomyelitis|Tetanus|Acellular Per Biological:
3728 NCT02847Fractional fIPV CompletedNo ResultsPoliomyelitis Biological:
3729 NCT00533SARS Coronavirus VacWithdrawnNo ResultsCoronavirus (SARS-CoV) Drug: Alum
3730 NCT00697Immunogenicity & Rea CompletedNo ResultsHepatitis B Biological
3731 NCT01585Safety and Immunogen CompletedNo ResultsCholera Biological
3732 NCT00039Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological:
3733 NCT00318Safety Study of an AdCompletedNo ResultsInfluenza Biological:
3734 NCT00513Phase Ib T PMAL03 CompletedNo ResultsFalciparum Malaria Biological:
3735 NCT00784Zanamivir VStop-Flu-2 CompletedHas ResultInfluenza Biological:
3736 NCT01453Safety and Immunogen CompletedHas ResultAcellular Pertussis|Hepatitis B|Hae Biological
3737 NCT00127Dose Ranging Study oCompletedHas ResultHaemophilus Influenzae Type b|NeisBiological
3738 NCT00005Vaccine Therapy in TrCompletedNo ResultsLiver Cancer Biological
3739 NCT00310PneuMum: Pneumococca Unknown sNo ResultsMiddle Ear Effusion|Tympanic Memb Biological
3740 NCT00798Study Evaluating SafeTerminate Has ResultMeningitis, Meningococcal Biological
3741 NCT03294Centralized ReminderCompletedNo ResultsInfluenza, Human|OrthomyxoviridaeBehavioral:
I
3742 NCT02325A Safety and Immunog CompletedNo ResultsHealthy Biological
3744 NCT01353Immunogenicity and Sa CompletedHas ResultPoliomyelitis|Tetanus|Acellular Per Biological:
3745 NCT02543A Study of a Vaccine CompletedHas ResultPneumonia Biological
3746 NCT03599The STOP-HSTOP-HPV CompletedNo ResultsImmunization|Vaccination Behavioral
3747 NCT01764Clinical Tr FLUVAC EVUnknown sNo ResultsAdult Hospitalized Other: nas
3748 NCT00090A Study to Evaluate CompletedHas ResultHealthy Adult Female Participants| Biological
3749 NCT00574Study Evaluating 13- CompletedHas ResultVaccines, Pneumococcal Conjugate Biological
3750 NCT03532Neoantigen DNA VacciRecruiting No ResultsMetastatic Hormone-Sensitive ProstBiological
3751 NCT00837GI-4000 With Adoptive WithdrawnNo ResultsPancreatic Cancer Other: Scre
3752 NCT01019Studies of Immune ReCompletedNo ResultsCholera|Typhoid Drug: Plac
3753 NCT00093Vaccine Therapy WithCompletedNo ResultsBreast Cancer Biological
3754 NCT00849Study to Assess the Terminate No ResultsHaemophilus Influenzae|Streptoco Biological
3755 NCT01852Effectiveness of Infl CompletedNo ResultsAsthma|Chronic Obstructive PulmonBehavioral
3756 NCT00303Immunogenicity Study CompletedHas ResultDiphtheria|Tetanus|Pertussis|Poliom Biological
3757 NCT03557Testing a Novel Dair CompletedNo ResultsImmunodeficiency Dietary Su
3758 NCT00485Shigella Flexneri 2a CompletedHas ResultShigellosis Biological:
3759 NCT00442Safety and Immunogen CompletedHas ResultWest Nile Fever Biological
3760 NCT00730Study of ChimeriVaxâ„CompletedNo ResultsDengue|Dengue Fever|Dengue Hemo Biological:
3761 NCT01940Phase 3, R rBV A/B WithdrawnNo ResultsBotulism Biological:
3762 NCT00062Safety of an Oral HIV Unknown sNo ResultsHIV Infections Biological
3763 NCT00806Phase 1 Norwalk VaccCompletedNo ResultsNorovirus Drug: Adju
3764 NCT00814Primary Vaccination CompletedHas ResultInfections, Streptococcal|Streptoc Biological
3765 NCT01942H7N9 Mix and MatchCompletedNo ResultsInfluenza Drug: AS03
3766 NCT00836Study to Collect Sera CompletedHas ResultInfluenza Biological:
3767 NCT00323Study of a Booster D CompletedNo ResultsNeisseria Meningitidis|HaemophilusBiological
3768 NCT03671Immunogenicity and SCompletedNo ResultsPoliomyelitis Biological:
3769 NCT02032A Study to Character CompletedNo ResultsHepatitis B Biological:
3770 NCT00099Safety of and ImmuneUnknown sNo ResultsHIV Infections|Pneumococcal InfectBiological
3771 NCT01787Improving Pneumococca CompletedHas ResultCommunity Acquired Pneumonia Other: Foc
3772 NCT00373Vaccine Therapy, PaclTerminate No ResultsFallopian Tube Cancer|Ovarian CancBiological
3773 NCT02294Study of the ImmuneCompletedNo ResultsMultiple Myeloma|Myeloma, Multiple|Myelom
3774 NCT03947A Study of GC3107(BCG Not yet recNo ResultsBCG Vaccination Reaction|TuberculoBiological:
3775 NCT01351Safety and ImmunogeCompletedNo ResultsMalaria Biologica
3776 NCT03416Evaluation of the Eff CompletedNo ResultsDengue Biological
3777 NCT00119CDC Anthrax Vaccine CompletedNo
Cl ResultsHealthy Biological
3778 NCT00710Influenza TITRE CompletedHas ResultInfluenza Biological:
3779 NCT00730Assessment of Three CompletedNo ResultsPlasmodium Falciparum Malaria Biological
3780 NCT03510Safety, ImmunogenicitActive, notNo ResultsMalaria Biological
3782 NCT00161Study of NeisVac-C VaCompletedNo ResultsMeningitis, Meningococcal Biological: Group C
3783 NCT00130EvaluationSHIELD-2 Terminate No ResultsStaphylococcal Infections|Chronic KBiological:
3784 NCT03929A Study of Safety, To Active, notNo ResultsPapillomavirus Infections Biological
3785 NCT00468A Study of Two DosesCompletedHas ResultDengue Fever|Dengue HemorrhagicOther: Plac
3786 NCT00169Long Term Immunogenic CompletedNo ResultsHepatitis B|Vaccination Biological:
3787 NCT00705Vaccine ThMel48 CompletedNo ResultsIntraocular Melanoma|Malignant C Biological
3788 NCT01480Safety, Tolerability, CompletedHas ResultBacterial Infections|Virus Diseases Biological:
3789 NCT03363Study to Investigate Unknown sNo ResultsTuberculosis Biological
3790 NCT01207Prevenar (PCV-7) PostCompletedHas ResultHealthy Children Afer Vaccination Other: Non
3792 NCT02563Seasonal Influenza VaUnknown sNo ResultsChronic Obstructive Pulmonary DiseBiological:
3793 NCT01707To DetermiOCV CompletedNo ResultsPrevention Harmful Effects Biological:
3794 NCT01355Vaccine Therapy in CoCompletedNo ResultsHER2-positive Breast Cancer|Male Br Biological
3795 NCT00851Broad Spectrum HPV CompletedHas
V ResultHuman Papilloma Virus|Cervical CanBiological
3796 NCT00536The Effects of Tysabr CompletedHas ResultMultiple Sclerosis Biological:
3797 NCT03277A Study to DetermineCompletedNo ResultsHuman Volunteers Biologica
3798 NCT00739Interventions to Incr CompletedHas ResultHepatitis B Virus Behavioral
3799 NCT02593Safety and Immunogeni CompletedNo ResultsRespiratory Syncytial Virus (RSV) Biological:
3800 NCT00556Phase IV Clinical Trial CompletedNo ResultsInfluenza Biological:
3801 NCT00859ACE393-103 ACE393-10Unknown sNo ResultsCampylobacter Infection Biological:
3802 NCT00336The Safety and Immuno Unknown sNo ResultsPertussis Biological
3803 NCT01215A Study of Pneumococ CompletedHas ResultPneumococcal Infections Biological
3804 NCT01005Safety and Immunogen CompletedHas ResultHealthy Biological:
3805 NCT03765Trial To Evaluate Th Recruiting No ResultsGroup B Streptococcus Infections Biological:
3806 NCT00707Safety Study of HBV-0CompletedNo ResultsWest Nile Virus Disease Biological
3807 NCT00857OPT-821 With or Witho CompletedHas ResultStage IA Fallopian Tube Cancer|StagOther: Lab
3808 NCT00024Chemotherapy, VaccinCompletedNo ResultsMultiple Myeloma Biological
3809 NCT03707An Efficacy Study of CompletedNo ResultsMalaria Biological
3810 NCT02451A Study to Evaluate CompletedNo ResultsMeningococcal Disease Biologica
3811 NCT03369A Clinical Trail Of A Active, notNo ResultsH7N9 Influenza Biological
3812 NCT01317H5N1 Mix and MatchCompletedNo ResultsInfluenza Drug: AS03
3813 NCT04142Dose-rangin VYF01 Recruiting No ResultsYellow Fever (Healthy Volunteers) Biological:
3814 NCT01084Investigation of the CompletedNo ResultsHIV-1 Biological
3815 NCT00698Humoral and CellularCompletedNo ResultsProphylaxis Herpes Simplex Biological
3816 NCT00046Safety and Immunolog CompletedNo ResultsBreast Neoplasms Drug: THERATOPEÂ® v
3817 NCT01644Safety Study of ChimeCompletedHas ResultEscherichia Coli Infection Biological
3818 NCT00091Safety of and ImmuneCompletedNo ResultsHIV Infections|Influenza Biological: Cold-adapt
3819 NCT02662The Epidem ERVS Active, notNo ResultsRotavirus Infection
3820 NCT00996Immunogenicity and SCompletedHas ResultInfections, Papillomavirus Biological
3821 NCT00398Vaccine Therapy and CompletedHas ResultLeukemia|Lung Cancer|Malignant Me Biological
3822 NCT01361Humoral Response toCompletedNo
T ResultsTick-borne Encephalitis Biological
3823 NCT00428Banking of Chronic L CompletedNo ResultsChronic Lymphocytic Leukemia Procedure:
3824 NCT03276Efficacy, Safety and Active, notNo ResultsMalaria Biological:
3825 NCT03189A Study To Evaluate CompletedNo ResultsMeningococcal ACWY Disease Biological
3826 NCT00001Use of a Varicella-Zo CompletedNo ResultsHIV Infections|Chickenpox Biological: Varicella V
3827 NCT00133A/H5N1 Vaccine in HeCompletedNo ResultsInfluenza Biological
3828 NCT00263A Study of Safety, Re CompletedHas ResultInfections, Rotavirus Biological:
3829 NCT00320Phase II Study of Pan CompletedNo ResultsInfluenza Biological:
3831 NCT00201Evaluation of the Sa Terminate Has ResultCytomegalovirus Infections Biological
3832 NCT03344Immunogenicity and Sa CompletedNo ResultsInfluenza|Flu Biological:
3833 NCT03483Trial of a Chikunguny Active, notNo ResultsChikungunya Virus Infection Biological
3834 NCT03409Evaluating the Safety Active, notNo ResultsHIV Infections Biological:
3835 NCT04166A Phase II RaC-Ad Not yet recNo ResultsHead Neck Tumors|NeuroendocrineBiological:
3836 NCT00109Safety, Tolerability, CompletedNo ResultsShingles Biological:
3837 NCT03382Study to Evaluate Saf Recruiting No ResultsGlioblastoma Multiforme Biological:
3838 NCT01518Atopic Dermatitis ResCompletedNo ResultsAtopic Dermatitis Drug: Fluzo
3839 NCT01730Studying Cell ImmuneCompletedNo ResultsNormal Physiology
3840 NCT01633Poliovirus Vaccine Tri CompletedNo ResultsHealthy Infants Biological:
3841 NCT00483Immunogenicity and SCompletedNo ResultsHepatitis A Biological:
3842 NCT00395Comparison of the Imm CompletedNo ResultsInfluenza Biological:
3843 NCT00647Effect of GP-INFA Terminate No ResultsInfluenza Infection Drug: vacc
3844 NCT02204Safety and Immune Re Recruiting No ResultsBreast Cancer|Breast Carcinoma|MaBiological
3845 NCT00845Human Leukocyte Anti CompletedNo ResultsGastric Cancer Biological:
3846 NCT00125Vaccination of Patien CompletedNo ResultsMelanoma|Neoplasm Metastasis Biological:
3847 NCT00136Study of a Pandemic CompletedNo ResultsInfluenza Biological:
3848 NCT01426The YellowEP46 NOV CompletedNo ResultsHIV Infection|Yellow Fever Biological:
3849 NCT02704Optimal Timing of Zost CompletedNo ResultsShingles Biological:
3850 NCT01966The Safety and Immuno CompletedHas ResultHIV Infections Biological
3851 NCT00605Safety and Tolerabili CompletedHas ResultJapanese Encephalitis Biological:
3852 NCT00347Safety Study of an In CompletedNo ResultsInfluenza (Pandemic) Biological
3854 NCT00073Vaccine Treatment foCompletedNo ResultsNon-small Cell Carcinoma|Adenoca Biological:
3855 NCT03552QUILT-2.025 NANT Neo Recruiting No ResultsColorectal Cancer|Breast Cancer|H Biological
3856 NCT02287VSV-ZEBOVVSV-ZEBOVCompletedNo ResultsEbolavirus Disease Biological
3857 NCT00457ComparingPNEUMO CompletedHas ResultPulmonary Disease, Chronic ObstrucBiological
3858 NCT00007Shingles P SPS CompletedNo ResultsHerpes Zoster|Postherpetic NeuralgBiological:
3859 NCT03806Malaria VaMVPE Active, notNo ResultsMalaria,Falciparum|Feasibility|SafeBiological
3860 NCT00962Safety and Immunogen CompletedHas ResultHIV Infections|Pneumococcal InfectBiological
3862 NCT03760Trial to Evaluate th CompletedNo ResultsPneumococcal Disease Biological
3863 NCT00121Vaccine Therapy in PrCompletedHas ResultCervical Cancer|Precancerous CondiBiological
3864 NCT01709RSV-F Vaccine and InfCompletedNo ResultsRespiratory Syncytial Virus (RSV) Biological:
3865 NCT02276One-visit Multi-site Unknown sNo ResultsRabies Pre-exposure Prophylaxis Biological:
3866 NCT01650Safety andMVA(TB)02CompletedNo ResultsTuberculosis|HIV Biological
3867 NCT01459Understanding Immuni CompletedNo ResultsAntibody Persistance Afer Booster Other: Ven
3868 NCT01707Response tRituxivac CompletedNo ResultsNon-Hodgkin Lymphoma (NHL) Biological:
3869 NCT01277Study to Assess ImmuCompletedHas ResultInfections, Papillomavirus Biological
3870 NCT01739Live Attenuated ETECCompletedHas ResultDiarrhea Biological:
3871 NCT00435Study to Evaluate Sa CompletedNo ResultsInfections, Cytomegalovirus Biological
3872 NCT01681Immunogenicity and SCompletedHas ResultMeasles|Mumps|Rubella Biological:
3873 NCT02500Persistence of Prote CompletedNo ResultsMeningococcal Meningitis|Meningoc Biological
3874 NCT00240Ontogeny of MeaslesUnknown sNo ResultsMeasles Biological
3875 NCT01318Surveillance for AdveCompletedHas ResultInfluenza|Vaccines Adverse Reaction
3876 NCT00290Assess if Immune Resp CompletedNo ResultsHaemophilus Influenzae Type b|Diph
Biological
3877 NCT00287A Safety and Efficacy CompletedHas ResultHepatitis Biological:
3878 NCT00100Trial of rPA-102 Vacc CompletedNo ResultsAnthrax Biological:
3879 NCT02473Pilot Trial of HER-2/ No longer aNo ResultsMetastatic Cancer Biological: HER-2/ne
3880 NCT00109Vaccine Therapy in TrCompletedNo ResultsAdenocarcinoma of the Prostate|RecBiological
3881 NCT01051Safety and Efficacy o CompletedNo ResultsInfluenza Biological:
3882 NCT03918EvaluationVACCIPRE Recruiting No ResultsPremature Birth Other: Que
3883 NCT00879Study Evaluating SafeCompletedHas ResultMeningitis, Meningococcal Biological:
3884 NCT03239Promoting ProFluGP CompletedNo ResultsHealth Behavior|Vaccination|Influ Other: Adv
3885 NCT01707Routes of FLUWAY CompletedNo ResultsInfluenza Biological
3886 NCT02357Antibodies and Memory WithdrawnNo ResultsHIV|Pneumococcal Infections Other: Eva
3887 NCT00798A Phase I Study of QuCompletedNo ResultsHuman Immunodeficiency Virus|Huma Biological:
3888 NCT00718Immunogenicity and Sa CompletedHas ResultInfluenza Vaccines Biological:
3889 NCT02293Phase II S BVX006 CompletedNo ResultsInfluenza Biological
3890 NCT00804Humoral and Cellular CompletedNo ResultsTick-borne Encephalitis Biological:
3891 NCT01818A Phase I Study of CompletedNo ResultsSeasonal Influenza Biological
3892 NCT02983Analysis on AEFI SurveCompletedNo ResultsVaricocele Biological:
3893 NCT00397GMZ2-Aluminum Hydro Unknown sNo ResultsMalaria Biological
3894 NCT00578Immunogenicity and SCompletedHas ResultVaricella|Rubella|Mumps|Measles Biological
3895 NCT00947Evaluation of Long-t CompletedHas ResultInfections, Papillomavirus Procedure:
3896 NCT00614Immuno,Safety of GSKCompletedHas ResultInfections, Meningococcal Biological
3897 NCT01578Evaluating the Safet CompletedNo ResultsHIV Infections Biological:
3898 NCT02199Immunogenicity and SCompletedNo ResultsMeningitis|Meningococcal MeningitBiological
3899 NCT01254Antibody Production FCompletedNo ResultsOrgan Transplantation Biological
3900 NCT01335Safety Surveillance A CompletedNo ResultsJapanese Encephalitis Biological:
3901 NCT00890A Study to Assess theCompletedNo ResultsMalaria Biological
3902 NCT00190Immunogeni HEPAVAC CompletedNo ResultsHIV Infection Drug: grou
3903 NCT01738Phase Three Clinical Unknown sNo ResultsRandomized|Double-blind|Placebo Biological:
3905 NCT01145Docetaxel and PredniTerminate Has ResultHormone-Resistant Prostate Cancer Drug: Doce
3906 NCT02318New Study - HumoralUnknown
R sNo ResultsTick-borne Encephalitis Biological
3907 NCT01403A Follow-On Study Wit CompletedNo ResultsHealthy Biological:
3908 NCT03552Immunogenicity and SCompletedNo ResultsTetanus|Diphtheria|Pneumococcal IBiological:
3909 NCT02410Evaluation Lipo-MERI Recruiting No ResultsMelanoma Biological:
3910 NCT02287Personalized NeoAnt Active, notNo ResultsGlioblastoma Radiation:
3911 NCT01398Cellular and Humoral CompletedNo ResultsHumoral and Cellular Immune Resp Biological:
3912 NCT03630Response oRIPS Not yet recNo ResultsPTEN Hamartoma Tumor Syndrome Biological:
3913 NCT03865A Study to Evaluate t Recruiting No ResultsEnterovirus 71 Infection Biological:
3914 NCT00104Vaccine Therapy in TreCompletedNo ResultsMelanoma (Skin) Biological
3915 NCT01734Efficacy anMV130 CompletedNo ResultsBronchospasm; Bronchiolitis|BronchBiological:
3916 NCT00674Study of Cancer Pept CompletedNo ResultsBreast Cancer Biological
3917 NCT00121Study to Evaluate theCompletedNo ResultsCutaneous Leishmaniasis Biological:
3918 NCT00929Extension Study of t CompletedHas ResultInfections, Papillomavirus Procedure:
3919 NCT01667Safety and Immunogen CompletedNo ResultsGenital Herpes Simplex Type 2 Biological
3920 NCT00287Comparison of SafetyCompletedNo ResultsPertussis|Diphtheria|Tetanus|Polio Biological:
3921 NCT01924Lenalidomide as Immu Terminate Has ResultHematologic Disorder Drug: Lena
3922 NCT00003Vaccine Therapy in T CompletedHas ResultMelanoma (Skin) Biological:
3923 NCT00197A Study to Evaluate SCompletedNo ResultsPlasmodium Falciparum Biological
3924 NCT00489A Research Study to TCompletedNo ResultsHepatitis B Infection Biological:
3925 NCT00038A Phase I/II Trial of Terminate No ResultsLeukemia, Lymphocytic, Chronic Biological:
3926 NCT03294The Aim of This StudyActive, notNo ResultsVirus Diseases Biological:
3927 NCT00161TBE Antibody PersisteCompletedNo ResultsEncephalitis, Tick-Borne Biological:
3928 NCT02907Evaluation of Immunog CompletedHas ResultRotavirus Biological:
3929 NCT03715Personaliz NeoPepVacRecruiting No ResultsMalignant Melanoma, Metastatic|Non Drug: EVA
3930 NCT00340Experimental VaccineCompletedNo ResultsPlasmodium Falciparum Malaria|VacDrug: MSP1(42)-FVO
3931 NCT00766Vaccination-DendriticCompletedHas ResultMalignant Glioma Biological:
3932 NCT00239PPV: Pneumococcal Po CompletedNo ResultsAging Biological
3933 NCT02118Study of BK1301 (DTaP CompletedHas ResultDiphtheria|Tetanus|Pertussis Biological
3934 NCT01266HLA-A*0201 RestricteUnknown sNo ResultsPancreatic Cancer Biological
3935 NCT00352Immunogenicity & SafCompletedNo ResultsPoliomyelitis|Tetanus|Acellular PertBiological
3936 NCT03943GARDASIL 9: 3 Dose vRecruiting No ResultsImmunization|Efficacy|Human PapilBiological:
3937 NCT04009Evaluating the Safet Recruiting No ResultsMosquito-Borne Infectious DiseasesBiological
3938 NCT01262Impact of GSK BiologiCompletedHas ResultInfections, Streptococcal Biological
3939 NCT02012Mechanisms of ImpairActive, notNo ResultsHIV|Pneumococcal Infections|PneuBiological:
3940 NCT02492Study of a Single Pri CompletedHas ResultJapanese Encephalitis Biological:
3941 NCT02377Immunogenicity and SCompletedHas ResultDiphtheria-Tetanus-acellular PertussBiological:
3942 NCT00834Phase I/II Clinical T CompletedNo ResultsMultiple Myeloma Biological:
3943 NCT00196Human Papilloma ViruCompletedNo ResultsInfections, Papillomavirus Biological
3944 NCT00139A Study to Compare th CompletedNo ResultsHepatitis A Biological:
3945 NCT03828Trial to Evaluate th CompletedNo ResultsPneumococcal Disease Biological
3946 NCT00654Study of the DTaP-IP CompletedHas ResultDiphtheria|Tetanus|Pertussis|Hepati Biological
3947 NCT01141HIV-1 PeptiHIV-BIS CompletedHas ResultAids, Cdc Group I Biological
3948 NCT00921Comparative Safety an CompletedHas ResultInfluenza Biological
3949 NCT01230Study of Different ForCompletedNo ResultsClostridium Difficile Infection|Diarr Biological:
3950 NCT00345Dendritic Cell Vaccin CompletedHas ResultProstate Cancer Biological:
3951 NCT02139Dose-finding, Safety CompletedNo ResultsCervical Intraepithelial Neoplasia Biological:
3952 NCT00699Evaluation of Immunog CompletedNo ResultsHepatitis B Biological
3953 NCT04022The Prospective CohoNot yet recNo ResultsCancer of Cervix|Vaccinia Biological:
3954 NCT01995CT7, MAGE-A3, and WT Active, notNo ResultsMultiple Myeloma Biological
3955 NCT03003Vaccination of Patien Not yet recNo ResultsNeoplasms by Site|Metastatic Canc Drug: Mont
3957 NCT00771HIV Testing & Womens CompletedHas ResultHIV Behavioral
3958 NCT02593Folate Receptor AlphaActive, notNo ResultsBreast Cancer Biological
3959 NCT00772Study of a ClostridiumCompletedNo ResultsDiarrhea|Clostridium Difficile Infect Biological:
3960 NCT02982Human Mese HERA Recruiting No ResultsAging Frailty Biological
3961 NCT00121Safety Study to Evalu CompletedNo ResultsCutaneous Leishmaniasis Biological:
3962 NCT02362Influenza VaccinationCompletedNo ResultsInfluenza
3963 NCT00850Three-Dose Regimen CompletedNo ResultsHIV|HIV Infections Biological
3964 NCT00370Prophylactic AntipyreCompletedNo ResultsInfections, Rotavirus Biological:
3966 NCT037382017 A/H7N9 IIV RevaActive, notNo ResultsAvian Influenza|Influenza ImmunisaBiological
3967 NCT04177Evaluating a Caregiv CompletedNo ResultsDiphtheria|Tetanus|Pertussis|Polio Behavioral
3968 NCT00092Study to Evaluate Fr CompletedNo ResultsMeasles|Mumps|Rubella|Varicella Biological:
3969 NCT01641Primary Vaccination W CompletedHas ResultInfections, Streptococcal Biological:
3970 NCT00404Improving Influenza CompletedNo ResultsInfluenza Behavioral:
3971 NCT02747Qualitative, Qualitat Active, notNo ResultsAstrocytoma|Glioma|OligodendrogBiological:
3972 NCT00979Safety, ImmunogenicitCompletedHas ResultInfluenza Biological
3973 NCT01312A Clinical Trial of A Active, notNo ResultsOvarian Cancer|Fallopian Tube CancBiological
3974 NCT01604Treatment TAIL Terminate No ResultsB-cell Chronic Lymphocytic LeukemiBiological
3976 NCT00195Study Evaluating VaccCompletedNo ResultsHIV Infections Biological
3977 NCT04041Nous-209 Genetic Vacc Recruiting No ResultsSolid Tumor, Adult Biological
3978 NCT03028Phase I Trial of Meas CompletedNo ResultsChikungunya Virus Infection Other: Pla
3979 NCT03485A Clinical Study to E CompletedNo ResultsDengue Biological:
3980 NCT01626The Effect of Milk C CompletedNo ResultsThe Effect of Milk Components on the Response to Pneumo
3981 NCT02198Effect of Influenza Va CompletedNo ResultsPatient With Influenza Like Illness Biological:
3983 NCT01657Safety, Reactogenicit CompletedNo ResultsRespiratory Disorders Biological
3984 NCT00370Study of a Pandemic ICompletedNo ResultsInfluenza Biological
3985 NCT02388Safety and Tolerabilit CompletedNo ResultsShigellosis Biological:
3986 NCT00562Study Evaluating 13- CompletedHas ResultHealthy Biological
3987 NCT00211Evaluation of ManufaCompletedNo ResultsStaphylococcal Infections|Chronic KBiological:
3988 NCT01425Evaluating P13UK CompletedNo ResultsStreptococcus Pneumoniae
3989 NCT01983Long-Term Study of Ho CompletedHas ResultDengue|Dengue Fever|Dengue Hemorrhagic F
3990 NCT02843Combined CI YNTAX Unknown sNo ResultsComplication of Transplant Biological:
3991 NCT02876Partnershi PREVAC Active, notNo ResultsEbola Virus Disease Biological
3992 NCT03926Safety andCHLM-02 Not yet recNo ResultsTrachoma Biological
3993 NCT02627Safety, ImmunogenicitCompletedNo ResultsMalaria Biological
3994 NCT01105Antibody Persistence CompletedNo ResultsDiphtheria|Tetanus|Whooping Cough|Hepatitis
3995 NCT00314A Safety and Efficacy CompletedHas ResultJapanese Encephalitis Biological:
3996 NCT00999Study Measuring the CSompletedNo ResultsInfluenza Biological:
3997 NCT00325Immune Responses toCompletedNo ResultsSmallpox Vaccine
3998 NCT03450A Pivotal Trial to Ass Active, notNo ResultsInfluenza Biological:
3999 NCT00307Study to Evaluate theCompletedNo ResultsStreptococcus Pneumoniae VaccinesBiological
4000 NCT02376Safety andEV06 CompletedNo ResultsHIV/AIDS Biological
4001 NCT03017Reactogenicity, Safet CompletedNo ResultsTuberculosis Biological:
4002 NCT02375Immunosene IVVI Terminate No ResultsChronic Renal Disease Biological
4003 NCT00534Safety, ImmunogenicitCompletedNo ResultsHepatitis A Biological:
4004 NCT00029A Study of Patients WCompletedNo ResultsHIV Infections Other: Observation
4005 NCT02041Investigation of the CompletedHas ResultPlasma Cell Disorder Drug: Lena
4006 NCT00000A Multicenter, Random CompletedNo ResultsHIV Infections Biological: TBC-3B Va
4007 NCT01924DC Vaccine CombinedUnknown
W sNo ResultsRenal Cell Carcinoma Biological:
4008 NCT01066Vaccinatio RICH-3 CompletedNo ResultsHIV Biological:
4009 NCT00972Evaluation of the Im CompletedHas ResultAIDS Biological:
4010 NCT01309Trial of Ad FANG OvarActive, notNo ResultsOvarian Cancer Biological:
4011 NCT00970Immunogenicity and Sa CompletedHas ResultTetanus|Diphtheria|Haemophilus Infl Biological
4012 NCT04064Safety, Tolerability, Recruiting No ResultsZika Virus Biological
4013 NCT00350A Phase II Trial of a CompletedHas ResultDengue Biological:
4014 NCT03611Evaluation of the Saf CompletedNo ResultsZika Virus Biological:
4015 NCT01954Study Evaluating Aer CompletedNo ResultsTuberculosis Biological
4016 NCT00376Study of a Pandemic ICompletedNo ResultsInfluenza Biological
4017 NCT00260Study of Inactivated PCompletedNo ResultsLevel of Immunity Against PoliovirusBiological:
4018 NCT03179High vs. Standard DosRecruiting No ResultsHematopoietic Cell Transplantation Biological:
4019 NCT04023Observational Study Not yet recNo ResultsDengue Virus Infection Drug: CYD-
4020 NCT02915Evaluating the Safet Active, notNo ResultsHIV Infections Biological
4021 NCT03160A Study to Assess th Terminate No ResultsAdenoviral Infection Biological
4022 NCT03606Nab-Paclitaxel and DuNot yet recNo ResultsAnatomic Stage IV Breast Cancer AJ Drug: Carb
4023 NCT01886Causes of Rotavirus VCompletedHas ResultDiarrhoea
4024 NCT02075A Study to Evaluate t CompletedHas ResultRespiratory Disorders Biological
4025 NCT01436Staged Phase I/II HepaCompletedHas ResultHepatitis C Biological
4026 NCT03599Adjuvanted InfluenzaActive, notNo ResultsInfluenza|Influenza-like Illness|Inf Biological:
4027 NCT03682Safety/Efficacy Study Active, notNo ResultsAvian Influenza|Influenza ImmunisaBiological
4028 NCT00347Safety and Immunogen CompletedNo ResultsPlasmodium Falciparum Malaria Biological
4029 NCT01584Adenovirus Vaccine PWithdrawnNo ResultsAdenovirus
4031 NCT00000A Study of the Safety CompletedNo ResultsHIV Infections Biological: Varicella V
4032 NCT03460Dynamics of the Immu CompletedNo ResultsPneumonia, Pneumococcal Biological
4033 NCT03368Long-term Immunogen CompletedHas ResultInfection, Human ImmunodeficiencyProcedure:
4034 NCT00311St. Jude Open Label HCompletedNo ResultsInfluenza Biological:
4035 NCT02594Safety, To CM04-101WithdrawnNo ResultsCongenital Cytomegalovirus InfectioDrug: CyMV
4037 NCT01324Safety, Tolerability CompletedHas ResultStaphylococcal Infections Biological
4038 NCT02329VZV VaccinVZIDST CompletedNo ResultsVaricella Zoster Infection Biological:
4039 NCT00493Study to Evaluate th CompletedNo ResultsChronic Plaque Psoriasis Drug: alef
4040 NCT03128Evaluation of Immunog WithdrawnNo ResultsDiphtheria|Acellular Pertussis|HaemBiological:
4042 NCT00875Safety Study of GSK BCompletedHas ResultInfections, Rotavirus Other: Hea
4043 NCT00462Phase 3 Immunogenicit CompletedNo ResultsInfluenza Biological:
4044 NCT00445Phase I Hepatitis C V CompletedNo ResultsChronic Hepatitis C Biological
4045 NCT01177Effectiveness Study ofCompletedNo ResultsInfections, Rotavirus|Rotavirus VaccProcedure:
4046 NCT01314KAP/WTP an HPV Unknown sNo ResultsHuman Papillomavirus
4047 NCT01513The Safety, Tolerabil CompletedHas ResultPneumococcal Infections Biological
4048 NCT00431Safety and ImmunogeUnknown sNo ResultsMalaria Biological
4049 NCT00103Safety and Immunogen Unknown sNo ResultsSmallpox Biological
4050 NCT00874Exploratory Trial to CompletedHas ResultMeningococcal Infections|MeningocBiological
4051 NCT02587Study of Tetanus ToxoCompletedNo ResultsTetanus|Diphtheria|Pertussis|Who Biological:
4052 NCT03518BARDA Secu B-SAFE Active, notNo ResultsAnthrax Biological:
4053 NCT00276Study Evaluating PrevCompletedNo ResultsPneumococcal Infections Biological:
4054 NCT00631Safety and Immunogen CompletedNo ResultsMeningitis|Meningococcal InfectionBiological
4055 NCT01289Immune Res Expand ID Unknown sNo ResultsImmune Response Procedure:
4056 NCT01900Persistence of AntiboCompletedHas ResultInfections, Meningococcal Procedure:
4057 NCT03820EBOVAC-Salone ExtenRecruiting No ResultsEbola Virus Disease Other: Fol
4058 NCT01041Safety and Immunogeni CompletedHas ResultEncephalitis Biological:
4059 NCT00419Influenza Vaccinatio CompletedNo ResultsInfluenza Biological:
4060 NCT00582Safety andVEE C-84 Active, notNo ResultsVenezuelan Equine EncephalomyelitBiological:
4061 NCT00774Immune Response ofCompletedHas
H ResultHepatitis B Biological
4062 NCT01181Phase 1b Influenza VaCompletedNo ResultsInfluenza Biological:
4063 NCT01414Pneumococc PCVFU CompletedNo ResultsImmune Tolerance Biological:
4065 NCT01317H5N1 Mix and MatchCompletedNo ResultsInfluenza Other: Pho
4066 NCT03662Clinical Study of a P Active, notNo ResultsAdvanced Malignant Solid Tumor Biological
4067 NCT00982Study of Live AttenuaCompletedHas ResultJapanese Encephalitis|Yellow Fever Biological:
4068 NCT00697Immunogenicity & Rea CompletedNo ResultsHepatitis B Biological:
4069 NCT00000A Phase I Safety and CompletedNo ResultsHIV Infections Biological: rgp120/H
4070 NCT01678A Study to Evaluate t CompletedNo ResultsRespiratory Disorders Biological
4071 NCT02396Vaccine Therapy in R Recruiting No ResultsAccelerated Phase Chronic MyelogeBiological
4072 NCT00075Safety and Efficacy S CompletedNo ResultsMalaria Biological
4073 NCT02787Safety of Chlamydia CompletedNo ResultsChlamydia Trachomatis Biological
4074 NCT04109Early Antibiotic Ther Recruiting No ResultsVaccination Reaction Drug: ABT
4075 NCT03930Pregnancy,PAIR Enrolling bNo ResultsArsenic--Toxicology|Immunologic DiBiological:
4076 NCT02237Phase I Study on VEGFUnknown sNo ResultsMetastatic Cancer Biological
4077 NCT01181Safety of Tuberculos CompletedNo ResultsTuberculosis Biological
4078 NCT03341Immunogenicity and SCompletedHas ResultDengue Biological:
4079 NCT03728Immunogenicity FromActive, notNo ResultsAnti-HPV Antibody Levels|Cervical Biological:
4080 NCT00374MUC1 Vaccine in ConjCompletedNo ResultsProstate Cancer Drug: MUC
4081 NCT01082Efficacy a TANGO Terminate No ResultsHuman Papillomavirus Infection Biological:
4082 NCT01432Pneumococcal Adult KCompletedNo ResultsPneumococcal Disease Biological:
4083 NCT00515Vaccination Plus Ont Unknown sNo ResultsMelanoma Drug: 4-pe
4084 NCT02374Phase I Tri VSVÎ”G-ZE CompletedNo ResultsEbola Viruses Biological
4086 NCT00307Multicentre Booster &CompletedNo ResultsAcellular Pertussis|Tetanus|Hepatit Biological
4087 NCT00825Safety Study of CSL L CompletedHas ResultInfluenza Biological:
4088 NCT00294Study Evaluating Tre CompletedNo ResultsVaccines, Pneumococcal|Infant|FevBiological:
4090 NCT00574Study Evaluating the CompletedHas ResultPneumococcal Vaccines Biological
4091 NCT02998Trial of Pe PERIOP-04Recruiting No ResultsAbdominal Cancer Drug: Ciali
4092 NCT04238A Study to Evaluate t Recruiting No ResultsTetanus|Diphtheria|Whooping Cou Biological:
4093 NCT03451Postpartum HPV VaccRecruiting No ResultsHPV-Related Malignancy Drug: Gard
4094 NCT00625A Phase I/II Study to CompletedNo ResultsRenal Cell Carcinoma Biological:
4095 NCT00698Comparison of SafetyCompletedNo ResultsHepatitis B Biological
4096 NCT01416Phase 1 Study of a CaCompletedNo ResultsOvarian Cancer|Fallopian Tube CancBiological
4097 NCT02908Promoting Flu VaccinUnknown sNo ResultsNot Condition-specific Behavioral
4098 NCT00943Yearly Strain Variati CompletedNo ResultsInfluenza|Seasonal Influenza Biological:
4099 NCT01761Pilot Text Message foCompletedNo ResultsInfluenza Behavioral
4100 NCT02140An Open Label Randomi Terminate No ResultsProstate Carcinoma Biological:
4101 NCT02915A Study to Evaluate EUnknown sNo ResultsInfluenza, Human Biological:
4102 NCT00243Peptide-pulsed vs. RNCompletedNo ResultsMelanoma Stage III or IV Biological:
4103 NCT04208A Multilevel ApproachCompletedNo ResultsHuman Papilloma Virus Other: pos
4104 NCT00071Vaccine Therapy in TrTerminate No ResultsMale Breast Cancer|Recurrent BreasBiological
4105 NCT03350Duration oDOPPIO Active, notNo ResultsCKD (Chronic Kidney Disease) Stage 5D|Pneum
4106 NCT02291REMUNE HIV/AIDS Vacci Unknown sNo ResultsHIV/AIDS Biological
4107 NCT00006Half-Dose Flu VaccineCompletedNo ResultsInfluenza Biological: Approved i
4108 NCT01303A Case-conVES WithdrawnNo ResultsMeningococcal Disease
4109 NCT00318Efficacy of NicVAX i CompletedNo ResultsSmoking Cessation Biological:
4110 NCT01600Facilitating Completi CompletedNo ResultsAdolescent Immunizations Among Clinic Popul
4111 NCT02077Representat RAVVIH CompletedNo ResultsHIV Other: Que
4113 NCT02114Dose Ranging Safety aCompletedNo ResultsGenital Herpes Simplex Type 2 Biological
4114 NCT00355Study of MenactraÂ®CompletedHas ResultMeningococcal Meningitis|Tetanus|D Biological:
4115 NCT03523Effect of Systemic In Recruiting No ResultsMajor Depressive Disorder Biological:
4116 NCT02729Dose-escalMTBVAC-PCompletedNo ResultsTuberculosis Biological
4117 NCT00230Hepatitis B Vaccinati CompletedNo ResultsHIV Infections|Hepatitis B Biological
4118 NCT02757A Post-marketing, ObsCompletedHas ResultDiphtheria Biological:
4119 NCT00001A Phase I Trial of HIV CompletedNo ResultsHIV Infections Biological: HIV-1 C4-
4120 NCT00140To Test 2 Doses of GSCompletedNo ResultsInfections, Rotavirus Biological:
4121 NCT02883Childhood Influenza ICompletedNo ResultsInfluenza, Human Other: Inte
4122 NCT00542Impact of Immunosupp CompletedNo ResultsInflammatory Bowel Disease (IBD)| Other: blo
4123 NCT02991Immunogeni YEFE Recruiting No ResultsYellow Fever Biological:
4124 NCT01729Phase II/III Clinical Unknown sNo ResultsCutaneous Melanoma Biological
4126 NCT00901Understanding the ImCompletedNo ResultsMeningitis|Septicemia Biological
4127 NCT00385Evaluate Protective E CompletedNo ResultsInfections, Rotavirus Biological:
4128 NCT00697Immunogenicity and R CompletedNo ResultsHepatitis B Biological
4129 NCT02124Evaluation of the LonWithdrawnNo ResultsHepatitis A Procedure:
4130 NCT02938Vaccination of Triple Recruiting No ResultsBreast Neoplasms Biological
4131 NCT00169Human Papilloma ViruCompletedNo ResultsInfections, Papillomavirus Biological
4132 NCT00595Rapid Immunization St CompletedHas ResultJapanese Encephalitis Biological:
4133 NCT00002A Phase I/II Safety CompletedNo ResultsHIV Infections Biological: HIV-1 Pe
4134 NCT02934Impact of HPV VaccinCompletedNo ResultsCervical Intraepithelial Neoplasia| Procedure:
4135 NCT03437Study to Assess the CompletedNo ResultsInfluenza Biological
4136 NCT00004Vaccine Therapy Plus CompletedNo ResultsAccelerated Phase Chronic MyelogeBiological
4137 NCT01463Music Therapy as ProCompletedNo ResultsImmunization Behavioral
4138 NCT02471Effect of ROVE CompletedNo ResultsObesity Drug: Pneu
4139 NCT02686Immunogenicity of a TCompletedNo ResultsInfluenza|End Stage Renal Failure|CBiological:
4140 NCT00857A Study to Evaluate CompletedHas ResultSmallpox Biologica
4141 NCT01846Booster DoRVEc CompletedHas ResultRicin Poisoning Biological
4142 NCT03973Effectiveness of MateCompletedNo ResultsWhooping Cough Other: Not
4143 NCT01392Study Assessing the ECompletedHas ResultPneumococcal Vaccines Biological
4145 NCT02135Evaluation of the LonWithdrawnNo ResultsHepatitis B|Hepatitis A Procedure:
4146 NCT04072Demonstration Project Recruiting No ResultsHepatitis B Virus|Health Care AssociBiological:
4147 NCT01556Safety andMAL019 CompletedNo ResultsMalaria, Falciparum Biological
4148 NCT01905Study to Evaluate theCompletedNo ResultsInfections, Respiratory Syncytial Vir Biological
4149 NCT01200Trial Evaluating a 13 CompletedHas ResultHealthy Subjects Biological:
4150 NCT02545A Clinical Study to E Active, notNo ResultsVirus Diseases Biological
4151 NCT00941The Effect of HPV VacCompletedHas ResultHIV Positive|Anal Condylomata|AnalDrug: Sali
4152 NCT00905HSPPC-96 VHeatShockCompletedNo ResultsBrain and Central Nervous System T Biological
4153 NCT00937Dendritic Cell Vaccin CompletedNo ResultsLymphoma|Multiple Myeloma and PBiological:
4154 NCT04201Pembrolizumab and aRecruiting
V No ResultsRecurrent Glioblastoma Biological:
4155 NCT028972-week dc 2 wk MTX Unknown sNo ResultsRheumatoid Arthritis|Influenza|MeDrug: Meth
4156 NCT00450153Sm-EDTMP With or CompletedHas ResultProstate Cancer Radiation:
4157 NCT01545Safety of LAIV CompletedNo ResultsHealthy|Influenza Biological:
4158 NCT00693Vaccine Therapy and O WithdrawnNo ResultsFallopian Tube Cancer|Ovarian CancBiological
4159 NCT03850Phase IIa Trial of PD Recruiting No ResultsSmoldering Multiple Myeloma Biological:
4160 NCT04127Study of P VRV12 Recruiting No ResultsRabies (Healthy Volunteers) Biological:
4161 NCT01861Seroprevalence of Hep CompletedNo ResultsHepatitis B|Immune Response|SeroBiological:
4162 NCT00371Immunogenicity of 7-CompletedNo ResultsPneumonia|Meningitis|Invasive Pn Biological
4163 NCT00496Prophylactic Antipyr CompletedHas ResultInfections, Streptococcal Biological
4164 NCT00580Injection Of AJCC Sta CompletedNo ResultsMelanoma Biological
4165 NCT00022Vaccine Therapy in PrCompletedNo ResultsInfection|Leukemia Biological: trivalent
4167 NCT01543Peptide Vaccine and Terminate No ResultsMalignant Melanoma Drug: Che
4168 NCT00140Vaccination Priming aCompletedNo ResultsProstate Cancer Biological: Immunothe
4169 NCT00984A Study to Assess SafCompletedNo ResultsMalaria Biological
4170 NCT03192Optimal Timing of ZosCompletedNo ResultsHerpes Zoster Biological:
4171 NCT00616Vaccine Therapy in TrCompletedNo ResultsProstate Cancer Biological:
4172 NCT01017Safety and Immune Re Unknown sNo ResultsHIV-1 Infection|Cancer|ImmunosupOther: sero
4173 NCT01782Dose-finding and Saf CompletedNo ResultsMeningococcal Disease Biological
4174 NCT04131HPV DNA Vaccine ViaNot E yet recNo ResultsHuman Papillomavirus Type 16|Cervica Drug: pNG
4175 NCT01963A Study to Assess theCompletedNo ResultsPain|Vaccination Adverse Event Device: Int
4176 NCT00430Evaluation of Safety, CompletedNo ResultsEpstein Barr Virus (EBV) Infection Biological:
4177 NCT00003PSA Vaccine Therapy C i ompletedNo ResultsProstate Cancer Biological: fowlpox vi
4178 NCT00076Safety and Effectiven CompletedNo ResultsHIV Infections|HIV Seronegativity Biological
4179 NCT02897Community and Physic Active, notNo ResultsPapillomavirus Infections|Health B Other: Sur
4180 NCT00698Vaccination of AJCC SCompletedNo ResultsMelanoma|Skin Biological
4182 NCT04131Vaccination Trial of Active, notNo ResultsEquine Encephalitis Biological
4183 NCT00400Phase Ia Malaria VaccTerminate No ResultsFalciparum Malaria Biological:
4184 NCT00811Safety Study of GSK BCompletedHas ResultInfections, Papillomavirus Biological:
4185 NCT00529A Phase I/ CEA(6D)VRCompletedNo ResultsColorectal Cancer|Breast Cancer|L Biological
4186 NCT01937A Hospital IIAP Unknown sNo ResultsPostpartum Women Behavioral:
4187 NCT00518Study of NY-ESO-1 IS CompletedHas ResultMelanoma Biological
4188 NCT04063Immunogeni IM and ID Recruiting No ResultsPoliomyelitis Biological:
4189 NCT01386Immune Responses toCompletedNo ResultsHIV Negative|Adaptive Immunity|I Biological
4190 NCT02301Maternal Tdap ImmunCompletedNo ResultsPertussis|Whooping Cough Biological:
4191 NCT00139A Study to Test 2 DosCompletedNo ResultsInfections, Rotavirus Biological:
4192 NCT00392NMRC-M3V-Ad-PfCA Active,
Vacc notNo ResultsPlasmodium Falciparum Biologica
4193 NCT01627Safety and Immunogen CompletedHas ResultInfections, Papillomavirus Biological:
4194 NCT00374Safety and Immunogen CompletedNo ResultsMalaria, Falciparum|Malaria Biological:
4195 NCT00005Chemotherapy Plus Va Active, notNo ResultsMantle Cell Lymphoma|Lymphoma,Drug:
M EPOC
4196 NCT03041Study of Safety and CompletedNo ResultsSchistosomiasis Biological
4197 NCT01763Immunogenicity and Re Unknown sNo ResultsImmunogenicity|Reactogenicity Biological:
4198 NCT00140Dose Escalation and ECompletedNo ResultsProstate Cancer Biological: Immunothe
4199 NCT02532A Clinical Trial to CompletedNo ResultsMalaria Biological
4200 NCT01219IDO PeptidIDOvaccineCompletedNo ResultsNSCLC|Lung Cancer Biological:
4201 NCT00365Study of Human PapillCompletedHas ResultHPV 16 Infection Biological
4203 NCT00056Determining an EffectCompletedNo ResultsHIV Infections Biological:
4204 NCT02741Impact of Patient Ed CompletedNo ResultsInfluenza, Human Behavioral:
4205 NCT01248Unimolecular Pentaval CompletedNo ResultsFallopian Tubes|Ovarian Cancer|PerBiological
4206 NCT03820Vaccination CoverageRecruiting
a No ResultsDiabetes|Chronic Kidney Disease|Allergy|Cysti
4207 NCT00270Safety of Peptide VacCompletedNo ResultsMyelodysplastic Syndrome (MDS) Drug: WT1
4208 NCT01978Effectiveness of Rota WithdrawnNo ResultsInfections, Rotavirus Procedure:
4209 NCT00461Influence of Persist CompletedNo ResultsImmune Senescence Biological
4210 NCT00187Evaluate Tolerability CompletedNo ResultsHuman Immunodeficiency Virus|HIVBiological
4211 NCT00333Immune Memory Evalua CompletedNo ResultsInfections, Streptococcal Biological
4212 NCT01222Vaccine Therapy, TemCompletedNo ResultsBrain and Central Nervous System T Biological
4213 NCT02015Altruistically Framed CompletedNo ResultsParental Vaccine Intentions for TheirBehavioral:
4214 NCT00148Immune Response and CompletedHas ResultTetanus|Acellular Pertussis|DiphtheBiological:
4215 NCT04264Safety and Immunogeni CompletedNo ResultsPolio Biological:
4216 NCT00587Dose-Escala DES CompletedNo ResultsMultiple Sclerosis, Relapsing-RemittBiological:
4217 NCT03330Immunogeni PIVOT Active, notNo ResultsInfluenza, Human Biological:
4218 NCT00047HIV-1 Vaccine Test in CompletedNo ResultsHIV Seronegativity|AIDS Vaccines Drug: VRC-HIVDNA00
4219 NCT02941OptimisingORVAC Recruiting No ResultsViral Gastroenteritis Due to RotaviruDrug: Rota
4220 NCT03092Dendritic Cell Vacci Recruiting No ResultsMelanoma Biological
4221 NCT01031A Pilot Study to Eva CompletedNo ResultsEND STAGE RENAL DISEASE Biological
4222 NCT02926A Study to Evaluate t CompletedNo ResultsHealthy Biological
4223 NCT01263Safety, Tolerability CompletedHas ResultBacillus Anthracis (Anthrax) Infectio Biological
4224 NCT01841Immunogeni IPV002AB Unknown sNo ResultsPolio Biological:
4225 NCT00452A Phase Ib MSP3LSP Unknown sNo ResultsMalaria Biological:
4226 NCT00777Study of MenactraÂ®CompletedHas ResultMeningitis|Meningococcemia|Pertus Biological
4227 NCT00223HIV Vaccine Trial in T CompletedHas ResultHIV Infection Biological
4228 NCT01701Study of a HCV004 CompletedNo ResultsHepatitis C Biologica
4229 NCT00661Comparison of GSK134 CompletedHas ResultInfections, Meningococcal Biological
4230 NCT01396Safety Surveillance o CompletedHas ResultPneumococcal Disease Biological:
4231 NCT03055Study in Healthy VoluCompletedNo ResultsMosquito-Borne Disease Biological:
4232 NCT00478Ovarian Cancer and I CompletedNo ResultsOvarian Cancer Biological: The curren
4233 NCT01687MulticentePRIMAVERUnknown sNo ResultsTransplantation|Systemic Lupus Er Biological:
4234 NCT03422Neoantigen-based PerSuspendedNo ResultsGlioblastoma Biological
4235 NCT04133The Immunogenicity an Recruiting No ResultsSeasonal Influenza|Hand, Foot and Biological:
4236 NCT00503TBE Antibody PersisteCompletedNo ResultsEncephalitis, Tick-Borne Biological:
4237 NCT00501Gardasil Vaccination Unknown sNo ResultsPapillomavirus Infections Biological: human pap
4238 NCT00103Trial to Evaluate the CompletedNo ResultsPrevention of Anthrax Infection Biological:
4239 NCT00223Double-blind, Randomi CompletedNo ResultsMalaria, Falciparum Biological
4240 NCT00961Trial for Vaccine The Terminate No ResultsMetastatic Malignant Melanoma Biological:
4241 NCT00769PET-CT Scan Pro000002CompletedNo ResultsImmune Response to Influenza VaccBiological:
4242 NCT00227S0348 Vaccine Therapy WithdrawnNo ResultsBreast Cancer Drug: recombinant mo
4243 NCT03183Immunogenicity and Pe WithdrawnNo ResultsHepatitis A Biological:
4244 NCT01278A Safety Study of IMOCompletedNo ResultsPolio|Poliomyelitis Biological:
4245 NCT01139One Year Antibody PeCompletedHas ResultMeningococcal Disease Biologica
4246 NCT00834Dendritic CCRG 05-0CompletedNo ResultsAcute Myeloid Leukemia (AML) Biological:
4247 NCT01046Post-marketing SurveiTerminate No ResultsInfections, Streptococcal Biological:
4248 NCT00311Open Label EvaluationCompletedNo ResultsInfluenza Biological: Inactivat
4249 NCT03053Impact of ExplanationUnknown sNo ResultsNewborn Morbidity Other: Ora
4250 NCT03519Pertussis Immunizati Recruiting No ResultsImmunization; Infection|Pertussis| Biological:
4251 NCT02464An Information-MotivCompletedNo ResultsHuman Papillomavirus Infection Behavioral
4252 NCT01114Study of GSK BiologicCompletedHas ResultInfluenza Biological:
4253 NCT00289Assess Feasibility of CompletedNo ResultsHepatitis B Biological
4254 NCT00345To Evaluate Immunogen CompletedNo ResultsInfections, Rotavirus Biological:
4255 NCT02839A Study to Evaluate SCompletedHas ResultAvian Influenza Biological:
4256 NCT00851Live Zoster Vaccine inCompletedHas ResultHerpes Zoster|HIV Infections Biological
4257 NCT02508Study AsseAFF012 CompletedNo ResultsHypercholesterolemia Biological
4258 NCT04210Study of Shenzhen Qua Recruiting No ResultsInfluenza Biological:
4259 NCT00700Immune Responses ToCompletedNo ResultsMelanoma Biological:
4260 NCT00290Safety of Purified MeCompletedHas ResultInfections, Meningococcal Biological
4261 NCT03010Study Assessing the CompletedNo ResultsLyme Borreliosis, Nervous System Biological
4262 NCT00091SGN-00101 Vaccine inCompletedNo ResultsAtypical Squamous Cells of UndeterBiological
4264 NCT01307Survey of Predictors Unknown sNo ResultsHuman Papillomavirus|Cervical Cancer
4265 NCT00751Immunogenic ISS T-002 CompletedNo ResultsHIV Infections Biological:
4266 NCT03806Phase 2a Clinical Tri Active, notNo ResultsTuberculosis Biological
4267 NCT00757Safety and Immunogen WithdrawnNo ResultsRotavirus Infections Biological
4268 NCT02040Phase II/II KAMRAB-0Unknown sNo ResultsRabies Drug: Acti
4269 NCT02463Immunogenicity of a Unknown sNo ResultsPneumococcal Infection|ANCA-associated Vascu
4270 NCT03643Ex Vivo EvaANTISTAPHRecruiting No ResultsStaphylococcus Aureus Biological:
4272 NCT01506Zostavax in Rheumatoi Unknown sNo ResultsRheumatoid Arthritis|Varicella ZosteDrug: Zosta
4273 NCT03533Preventing Post-VacciCompletedHas ResultSyncope, Vasovagal Device: Bu
4274 NCT00002Vaccine Therapy in T CompletedNo ResultsRefractory Multiple Myeloma|StageBiological
4275 NCT01000Consistency & Immunog CompletedHas ResultHaemophilus Influenzae Type b Biological:
4276 NCT00866A Study for Evaluatio WithdrawnNo ResultsInfluenza Biological:
4277 NCT02911Open Study of the DuCompletedNo ResultsHemorrhagic Fever, Ebola Procedure:
4278 NCT00255Safety and Immune Re CompletedHas ResultDiphtheria|Polio|Pertussis Biological
4279 NCT008857-valent P PCV Unknown sNo ResultsInvasive Pneumococcal Disease Biological
4280 NCT00280Safety and Immunogeni CompletedNo ResultsRotavirus Infections Biological
4281 NCT00518Efficacy, ImmunogenicTerminate Has ResultStaphylococcus Aureus|Bacteremia|Biological:
4282 NCT01244Immunogenicity, SafetCompletedNo ResultsVirus Diseases|RNA Virus Infections|Biological
4283 NCT04148A Safety a IN NE-rPA Recruiting No ResultsAnthrax Biological:
4284 NCT00870An Immunog Tdap BoostUnknown sNo ResultsTetanus|Diphtheria|Pertussis Biological:
4285 NCT00524Immunogenicity and Re CompletedHas ResultDose Schedule Study Biological:
4286 NCT00677Cell-mediated Immune CompletedNo ResultsKidney Transplant
4287 NCT01336Safety and Immunogen CompletedNo ResultsShigella Infection Other: Pla
4288 NCT01055Basic and Clinical ResUnknown sNo ResultsVirus Diseases|Respiratory Tract Di Biological:
4290 NCT02334SVN53-67/M57-KLH Pep Recruiting No ResultsPartial Response of Multiple Myelo Biological
4291 NCT02658Trial to Ev PRIMALVA CompletedNo ResultsMalaria Biological:
4292 NCT00470Vaccine Therapy and Q CompletedNo ResultsBreast Cancer Biological
4293 NCT02358A Vaccine Trial for L Recruiting No ResultsLow Grade Glioma Biological
4294 NCT02700Enhancing Anti--Teta SuspendedNo ResultsPlasma Cell Myeloma Drug: Melp
4296 NCT03196NK Cell MeFlu vaccineActive, notNo ResultsPregnancy Related|Influenza, HumaOther: Ther
4297 NCT00307Safety and Efficacy S CompletedNo ResultsProphylaxis Invasive Pneumococcal Biological
4298 NCT03096Respiratory Syncytial Recruiting No ResultsRespiratory Syncytial Virus (RSV)|M Other: Que
4299 NCT00187Evaluation of the SafeCompletedNo ResultsHIV Infection|Human Immunodeficie Biological:
4300 NCT00002Papilloma Virus VacciUnknown sNo ResultsPrecancerous Condition Biological: autologou
4301 NCT02924A Study of Varliluma Recruiting No ResultsGlioma|Malignant Glioma|AstrocytoBiological:
4302 NCT01247Clinical Investigatio Unknown sNo ResultsAnaphylaxis|Allergy|Oculorespiratory Syndrome
4303 NCT03914Expanded Access Neoa TemporarilyNo ResultsSolid Tumor, Adult Biological: Neoantige
4304 NCT00789Cohort Study of VolunTerminate No ResultsHIV Infection|HIV Seronegativity
4306 NCT03590Safety and Immunogen CompletedNo ResultsChikungunya Fever Biological
4307 NCT01331Safety andTHERAVACUnknown sNo ResultsMelanoma Biological:
4308 NCT00000A Phase II, ComparatiCompletedNo ResultsHIV Infections|Measles Biological:
4309 NCT02764TPIV200/huFR-1 (A Mu Active, notNo ResultsOvarian Cancer Biological
4310 NCT01021Immunogenicity and Sa CompletedHas ResultPoliomyelitis|Poliomyelitis Vaccines Biological:
4311 NCT00327Study to Evaluate theCompletedNo ResultsInfections, Streptococcal Biological
Se ResultsInfluenza, Human|Human Immunodeficiency Vir
4313 NCT00002A Phase I, Observer-BCompletedNo ResultsHIV Infections|HIV Seronegativity Biological: HIV p24/
4314 NCT00130Concomitant Use andCompletedHas ResultRotavirus Infections|GastroenteritisBiological:
4315 NCT00316Persistence of AntiboCompletedNo ResultsPrevention of Meningococcal Infect Biological
4316 NCT00133Influenza Vaccine in PCompletedNo ResultsInfluenza Biological: Trivalent
4317 NCT03202Duration of IPV Prim Active, notNo ResultsPoliomyelitis Biological:
4318 NCT00434Safety and Immunogen CompletedHas ResultHerpes Zoster Biological
4319 NCT00115A/H5N1in Adult - AveCompletedNo ResultsInfluenza Biological: Influenza
4320 NCT01530Single-step Antigen L CompletedNo ResultsMelanoma Biological:
4321 NCT04126Study of Safety, Reac Recruiting No ResultsRespiratory Syncytial Virus InfectionBiological
4322 NCT00654Safety and Immunogen CompletedNo ResultsEscherichia Coli Infections Drug: Cipr
4323 NCT03806Phase 1 Clinical Tria Active, notNo ResultsTuberculosis Biological
4324 NCT03856A Message Framing InNot yet recNo ResultsCervical Cancer|Anal Cancer|PenileBehavioral
4325 NCT01601A Study of Two InjectUnknown sNo ResultsHealthy Infants|Immunization|Pai Behavioral:
4326 NCT01295Study of Long Term I CompletedHas ResultHerpes Zoster Procedure:
4327 NCT00258Evaluation of Take anCompletedNo ResultsSmallpox|Poxvirus Infection Biological: Smallpox v
4328 NCT02225MF59-adjuvanted InflCompletedNo ResultsInfluenza, Human|Pneumococcal InfBiological
4329 NCT03814Dose, Safety, Tolerab Recruiting No ResultsInfluenza Biological
4330 NCT02894A Study of Leish2a CompletedNo ResultsLeishmaniasis, Cutaneous Drug: ChA
4331 NCT01859Study to Evaluate theCompletedHas ResultInfluenza|Healthy Biological:
4332 NCT00786Immunogenicity and SCompletedHas ResultSystemic Lupus Erythematosus Biological:
4333 NCT00437A Phase I Study of OvCompletedNo ResultsEpithelial Ovarian, Tubal or Periton Biological:
4334 NCT03359Atezolizumab Given inRecruiting No ResultsUrothelial/Bladder Cancer, Nos Drug: Atez
4335 NCT00985Immunogenicity and Sa CompletedNo ResultsChronic Kidney Disease Biological:
4336 NCT03723Persistence of IPV I Not yet recNo ResultsPoliomyelitis Biological:
4337 NCT01073A Study of V503 VaccCompletedHas ResultPapillomavirus Infections Biological
4338 NCT03041Immunological Memory Unknown sNo ResultsHIV Infection Biological
4339 NCT01071HIV Vaccine Study in HCompletedNo ResultsHIV Infections Biological:
4340 NCT00740Safety and Immunogen CompletedNo ResultsDengue Virus|Dengue Fever|Dengue Biological:
4341 NCT02404A Safety and ImmuneCompletedNo ResultsHIV Infection Biological
4342 NCT01376Safety and Immunogen CompletedNo ResultsHand, Foot and Mouth Disease Biological
4343 NCT00285Cytomegalovirus (CMV CompletedNo ResultsAcute Lymphoblastic Leukemia|Ch Biological
4344 NCT01102A Second Study of Ni CompletedNo ResultsSmoking Cessation Biological:
4345 NCT00146Post-marketing SafetyCompletedNo ResultsHepatitis B|Poliomyelitis|DiphtheriaBiological:
4346 NCT01695IPV in ModMIPV CompletedNo ResultsImmunity to Polio Vaccines in MalnoBiological:
4347 NCT00195Study Evaluating VaccTerminate No ResultsHIV Infections Biological:
4348 NCT03636Respiratory Syncytial Active, notNo ResultsRespiratory Syncytial Virus InfectionBiological:
4349 NCT01032Immunogenicity, SafetCompletedNo ResultsH1N1 Influenza Virus|Chronic PulmoBiological:
4350 NCT02052Safety of Sublingual CompletedNo ResultsGastroenteritis Escherichia Coli Biological
4351 NCT01794Improving ImmProve CompletedNo ResultsImprove Childhood Immunization RaOther: Prov
4353 NCT03332Comparative Tests of CompletedNo ResultsInfluenza, Human Behavioral:
4354 NCT00153Immunogenicity and R CompletedNo ResultsPneumococcal Infections Biological
4355 NCT01496Maternal I MI GIFT CompletedNo ResultsPregnancy|Influenza
4356 NCT02305Safety and Blood DonCompletedHas ResultMeningitis, Meningococcal, SerogroBiological
4357 NCT02839Study of Co-administ CompletedNo ResultsHookworm Disease|Hookworm InfecBiological:
4358 NCT02911Open Study of the DuCompletedNo ResultsEbola Hemorrhagic Fever Procedure:
4359 NCT03026 A Phase â…AEC/BCO2CompletedNo
Study of the RecombinantResults
Mycobacterium
Tuberculosis Tuberculosis Vaccine Freeze-dried
Biological:
4360 NCT00289Safety and Immunogeni CompletedNo ResultsInfluenza Biological: Inactivate
4361 NCT00670Trial CompB-BOOST CompletedNo ResultsHepatitis B|HIV Infection Biological
4362 NCT02551A Study to Investiga WithdrawnNo ResultsGrowth and Development Dietary Su
4363 NCT02825Homeopathi HVT Unknown sNo ResultsHealthy Volunteers Biological
4364 NCT00831Safety and Efficacy T CompletedNo ResultsHormonal Refractory Prostate CanceBiological
4365 NCT00005Vaccine Therapy in T CompletedNo ResultsMelanoma Biological: dendritic
4366 NCT00891Persistence of AntiboCompletedHas ResultNeisseria Meningitidis|HaemophilusBiological
4367 NCT01857Efficacy, Safety and CompletedHas ResultMalaria Biological
4368 NCT00995A Study With PeptideUnknown sNo ResultsEsophageal Cancer Biological:
4369 NCT00480Trial CompaVIHVAC-B CompletedNo ResultsHIV Infections Biological
4370 NCT00006Vaccine Therapy Foll Terminate Has ResultLymphoma Biological
4371 NCT03514Acquired I ACQUIVASNot yet recNo ResultsSystemic Vasculitis Biological
4372 NCT01532Pilot StudyBreast 41 Terminate No ResultsBreast Cancer Biological:
4373 NCT00022Vaccine Therapy in T Unknown sNo ResultsMelanoma (Skin) Biological: recombin
4374 NCT01709Safety and Immunogeni CompletedNo ResultsPoliomyelitis Drug: IPV|
4375 NCT00377Active Immunization Terminate No ResultsPrimary Advanced Carcinoma of theBiological
4376 NCT03355A Follow-up Extensio CompletedHas ResultCervical Intraepithelial Neoplasia Procedure:
4377 NCT00316Safety and Immunogen CompletedHas ResultHIV Infections Biologica
4378 NCT00006Vaccine Therapy and CompletedNo ResultsRecurrent Melanoma|Stage IV Mel Biological
4379 NCT01152A Test of the Effectiv CompletedNo ResultsProcedural Pain Device: De
4380 NCT03827Safety Study of HepatRecruiting No ResultsHepatitis E|Immunisation Biological
4381 NCT03989Immunogeni SPICE Recruiting No ResultsMelanoma|Non Small Cell Lung Cancer
4382 NCT00548Immunogenicity & Rea CompletedHas ResultAcellular Pertussis|Tetanus|DiphtheBiological:
4383 NCT00664Study of Different Fo CompletedNo ResultsInfluenza|Orthomyxoviridae Infecti Biological:
4384 NCT01846B Memory Cell Respon Unknown sNo ResultsAsplenia|Î²-thalassemia Major Biological
4385 NCT00158Immune Response Post CompletedHas ResultHepatitis B Biological:
4386 NCT02545A Study to Evaluate t Active, notHas ResultMultiple Sclerosis, Relapsing-RemittBiological:
4387 NCT00168Non-Specific Effects CompletedNo ResultsMeasles Biological:
4388 NCT00716Safety and Pharmacod Terminate No ResultsMelanoma Biological
4389 NCT03599The STOP-HSTOP-HPV Active, notNo ResultsImmunization|Vaccination Behavioral
4390 NCT03486Safety, Tolerability, Active, notNo ResultsCytomegalovirus Infections Biological
4392 NCT03307ID HBV Vaccination WCompletedNo ResultsHepatitis B Biological
4393 NCT00836NicVAX/Placebo as anCompletedNo ResultsSmoking Cessation|Smoking|TobaccBiological:
4394 NCT01385Strategies for EnhancCompletedNo ResultsMucosal Immunity Drug: Fluz
4395 NCT00814Evaluation of Non-ty CompletedHas ResultStreptococcus Pneumoniae|Haemoph Biological
4396 NCT03591"Persistence of NeutraRecruiting No ResultsHIV Infections|Yellow Fever VaccineDiagnostic
4397 NCT03855A Study to EPI-MAL-0Recruiting No ResultsMalaria Procedure:
4398 NCT00637ReactogeniSG06RS02 Terminate No ResultsHIV Infections|Acquired Immune DeBiological
4399 NCT03632Immunogeni MET52 Recruiting No ResultsMeningococcal Infection Biological
4400 NCT03197Phase 3 Study of 10- Active, notHas ResultPneumonia, Pneumococcal Biological:
4401 NCT00345Safety of Hib-MenCY-T CompletedHas ResultHaemophilus Influenzae Type b|NeisBiological:
4402 NCT00312Phase I/II Trial of a CompletedHas ResultMalaria|Plasmodium Falciparum MaBiological
4403 NCT02919Vaccinatio COREVAX-1Active, notNo ResultsStage IV Colorectal Cancer|Curative Biological
4404 NCT00290Evaluation of the ImmCompletedHas ResultTetanus|Acellular Pertussis|DiphtheBiological
4405 NCT01938Home AdministrationCompletedHas ResultInfluenza Biological:
4406 NCT03493A Study to Evaluate Active, notNo ResultsPrevention of HPV Types 16- and 18-r Biological:
4407 NCT03016A Study to Evaluate I WithdrawnNo ResultsPoliomyelitis Biological:
4408 NCT00450Vaccine Therapy WithCompletedHas ResultProstate Cancer Drug: Sarg
4409 NCT03158Study to EvFluMist CompletedHas ResultInfluenza|Healthy Biological
4410 NCT00412A Phase I Study of S CompletedNo ResultsHIV Infections Biological:
4411 NCT02473Study to EvFluMist CompletedHas ResultInfluenza|Healthy Biological:
4412 NCT01731The Effica ICHAT CompletedNo ResultsCompletion of Three Dose Series of Other: Tel
4413 NCT01673Decitabine, Vaccine TCompletedNo ResultsRecurrent Fallopian Tube Cancer|Rec Drug: deci
4414 NCT02291Immunogenicity of IntCompletedNo ResultsPoliomyelitis Biological
4415 NCT02559Safety and Immunogen CompletedNo ResultsRabies Biological
4416 NCT02963A Phase 1, First-in-h CompletedNo ResultsZika Virus Infection Biological:
4417 NCT01995An Individualized AntWithdrawnNo ResultsHepatocellular Carcinoma Biological:
4418 NCT02290InactivatedIIJI CompletedHas ResultInfluenza, Human Biological:
4419 NCT00498Dose Ranging Study to CompletedNo ResultsTyphoid Fever Biological:
4420 NCT00307Double-blind Study oCompletedNo ResultsMalaria Biological
4421 NCT01291Dendritic Cell Vaccin Unknown sNo ResultsGlioblastoma|Renal Cell Carcinoma Biological:
4422 NCT03815VAccinatioADVANCE Recruiting No ResultsIntermediate Risk Prostate Cancer|CBiological
4424 NCT02871Adjuvanted InactivateUnknown sNo ResultsInfluenza Biological:
4425 NCT00052Vaccine Therapy for Unknown sNo ResultsMalignant Melanoma Biological: CancerVa
4426 NCT00052Vaccine Therapy for PUnknown sNo ResultsMalignant Melanoma Biological: CancerVa
4427 NCT03453The Role oSLVP030 CompletedNo ResultsInfluenza|Healthy Biological:
4428 NCT01374VA-005 Clinical OutcoUnknown sNo ResultsComplication of Smallpox VaccinatioBiological:
4429 NCT00810Study of Maternal Hep Terminate No ResultsHepatitis C
4430 NCT00349Safety and Immunogeni CompletedNo ResultsInfluenza Biological: Whole vir
4431 NCT00095Investigation of V520Terminate Has ResultAIDS|HIV Infections Biological
4432 NCT00343Experimental VaccineCompletedNo ResultsPlasmodium Falciparum Malaria Biological: AMA1-C1|
4433 NCT00001Study of a Flu VaccineCompletedNo ResultsInfluenza Biological: Influenza
4434 NCT00045S0122: Combination CTerminate No ResultsLung Cancer Biological
4435 NCT00293GP96 Heat Shock Prote CompletedNo ResultsBrain and Central Nervous System T Biological
4436 NCT01176Vaccine Combining Mu Active, notNo ResultsMelanoma (Skin) Biological
4437 NCT03970Alternative Schedule Active, notNo ResultsLyme Borreliosis Biological:
4438 NCT03609The STOP-HSTOP-HPV Recruiting No ResultsImmunization|Vaccination Behavioral
4439 NCT02743Study to EvFluMist CompletedHas ResultInfluenza|Healthy Biological
4440 NCT00353To Evaluate Safety & CompletedHas ResultInfections, Rotavirus Biological:
4441 NCT01586Pakistan S SIAD CompletedNo ResultsPolio Drug: mOP
4442 NCT02141Immunogenicity, React CompletedNo ResultsRotavirus Biological:
4443 NCT02921Childhood Influenza ICompletedNo ResultsInfluenza, Human Other: Inte
4444 NCT01578Single-centVSG-2011-CompletedNo ResultsHealthy Biological
4445 NCT00921Study to Investigate CompletedNo ResultsInfluenza Biological
4446 NCT00134Study of 2 Doses of OCompletedNo ResultsInfections, Rotavirus Biological:
4447 NCT00397Safety and Immunogen CompletedHas ResultTuberculosis Biological
4448 NCT02639Safety and ImmunogeCompletedHas ResultInfections, Meningococcal Biological
4449 NCT03609The STOP-HSTOP_HPVRecruiting No ResultsImmunization|Vaccination Behavioral
4450 NCT01505Randomized FANG-CLMTerminate Has ResultColon Cancer Biological:
4451 NCT03693Virtual Reality vs. S Recruiting No ResultsVaccination Device: Vir
4452 NCT02239PA83-FhCMB Plant-Der CompletedNo ResultsAnthrax Biological
4453 NCT01546Sanariaâ„¢ PfSPZ ChaCompletedNo ResultsMalaria Biological
4454 NCT01132Autologous OC-DC Vac CompletedNo ResultsChemotherapy|Tumor|Ovarian CanBiological
4455 NCT02589Safety and ImmunogeCompletedNo ResultsHIV Biological
4456 NCT02927RSV Investigational V Active, notNo ResultsRespiratory Syncytial Virus InfectionBiological
4457 NCT01927Phase 1 ID93 + GLA-SECompletedNo ResultsPulmonary Tuberculosis Biological
4458 NCT03599The STOP-HSTOP-HPV Recruiting No ResultsImmunization|Vaccination Behavioral
4459 NCT04223Incidence of Influen Recruiting No ResultsInfluenza|Vaccination|Attitude of HDiagnostic
4460 NCT01144A Trial to Evaluate CompletedHas ResultSmallpox Biological
4461 NCT01140Dermal HIVVac09 CompletedNo ResultsHIV-1 Biological
4462 NCT01090Study of GlaxoSmithKlCompletedHas ResultTetanus|Hepatitis B|Haemophilus Inf Biological
4463 NCT02772DNA Vaccine TherapyActive,
i notNo ResultsChronic Hepatitis|Hepatitis C Infect Biological
4464 NCT00443RotaTeqÂ® and Mening CompletedHas ResultMeningitis, Meningococcal|Rotavirus Biological
4466 NCT01739A Phase I/IIa Sporoz CompletedNo ResultsPlasmodium Falciparum Malaria Biological
4467 NCT02996Safety, Tolerability CompletedNo ResultsAutosomal-dominant Hyper-IgE Sy Drug: NDV
4468 NCT00257Trial of Autologous, CompletedNo ResultsMelanoma Biological
4469 NCT00197Immunogenicity and SCompletedHas ResultHepatitis A Biological:
4470 NCT00108Survivin Peptide VaccUnknown sNo ResultsMalignant Melanoma|Pancreatic Can Biological:
4471 NCT01978Immunogenicity, SafeCompletedHas ResultNeisseria Meningitidis|HaemophilusBiological
4472 NCT00210Healthy Adult VolunteCompletedNo ResultsShigella Infection Biological:
4473 NCT00140Prime-Boost Dose SchCompletedNo ResultsProstate Cancer Biological: Immunothe
4474 NCT01210Immunogenicity and SCompletedNo ResultsMeningococcal Disease|Meningococc Biological
4475 NCT01282Long-Term Study on SCompletedNo ResultsChronic Kidney Disease Biological:
4476 NCT00534Vaccine Therapy in PaTerminate Has ResultLung Cancer Biological
4477 NCT02643Immunogenicity of Mo CompletedNo ResultsPoliomyelitis Biological
4478 NCT00140Prime-Boost Dose SchCompletedNo ResultsProstate Cancer Biological: Immunothe
4481 NCT04093Polarized Dendritic C Not yet recNo ResultsHLA-A2 Positive Cells Present|Refr Biological:
4482 NCT03540Distraction and Vibra CompletedNo ResultsPain Due to Childhood Vaccination Device: Buz
4483 NCT02662mHealth tomimi Unknown sNo ResultsMeasles Other: SMS
4484 NCT00091Study of t BiovaxID Unknown sNo ResultsNon-Hodgkins Lymphoma Biological
4485 NCT00788Vaccine Therapy WithRecruiting No ResultsCervical Cancer|Precancerous CondBiological
4486 NCT00002A Comparative PhaseCompletedNo
I ResultsHIV Infections Biological: Smallpox
4487 NCT01040A Study to Assess theCompletedHas ResultDiphtheria|Tetanus|Pertussis Biological:
4488 NCT01925Effects of PneumococCompletedNo ResultsNasopharyngeal Carriage of Streptococcus Pn
4489 NCT03942Modified Immune Cells Recruiting No ResultsStage III Hepatocellular Carcinoma Radiation:
4490 NCT03681EMaBS TB Vaccine St Recruiting No ResultsSafety|Immunogenicity Biological
4491 NCT00266Vaccine Therapy, TrasCompletedHas ResultBreast Cancer Biological:
4492 NCT00005Evaluation of the SafeTerminate No ResultsKidney Transplant Recipients Biological:
4493 NCT00584Safety andEEE CompletedHas ResultEastern Equine Encephalitis Biological:
4494 NCT00109A Combined Tdap Vacc CompletedNo ResultsDiphtheria|Tetanus|Acellular PertusBiological: Combined d
4495 NCT00323Long-Term Follow-up CompletedHas
o ResultMalaria Biological
4496 NCT00009Vaccine Therapy WithTerminate No ResultsUnspecified Adult Solid Tumor, ProtoBiological
4497 NCT03145Immunogenicity and Sa CompletedNo ResultsRabies Virus Biological:
4498 NCT02463Residual Anti-pneumoCompletedNo ResultsPneumococcal Infection|ANCA-associated Vascu
4499 NCT04010A Trial to Assess the Recruiting No ResultsRotavirus Infection of Children Biological:
4500 NCT02616Study to Evaluate theCompletedNo ResultsHIV Drug: MVA.
4501 NCT02178Trial to I TB036 CompletedNo ResultsTuberculosis Biological
4502 NCT00184Continuation BoosterTerminate No ResultsMelanoma Biological: Montanide
4503 NCT01144Immunogenicity and CompletedHas ResultInfections, Meningococcal Biological:
4504 NCT00053Dose Safety, Tolerabi Terminate No ResultsSmallpox Biological:
4505 NCT02215Immunogenicity and SCompletedNo ResultsInfluenza|Streptococcus Pneumoni Biological:
4506 NCT04103Substance P as a BiomCompletedNo ResultsImmunisation Anxiety Related ReactDietary Su
4507 NCT00296Memory for Flu FactsCompletedNo ResultsInfluenza Vaccines Behavioral
4508 NCT04143Intradermal InfluenzaRecruiting No ResultsInfluenza Biological
4509 NCT00192Trial to In CAIVT CompletedNo ResultsInfluenza Biological:
4510 NCT01448T Cell Vaccination in CompletedNo ResultsMultiple Sclerosis Biological:
4511 NCT00161Comparison of the SaCompletedNo ResultsInfluenza Biological: Vero Cell-
4512 NCT00479Phase 1 Safety Study CompletedNo ResultsAIDS Vaccines|HIV Infections|HIV-1 Drug: VRC
4513 NCT01147Vaccine Therapy in TrCompletedNo ResultsGastric Cancer|Head and Neck CancBiological
4514 NCT03564D2560C00015 FluMistCompletedHas ResultInfluenza|Healthy Biological:
4515 NCT01040Novel Influenza A/H1N Unknown sNo ResultsInfluenza|Swine-origin A/H1N1 Infl Biological: 7.5ug H1N
4516 NCT00261Vaccine for RecurrentCompletedNo ResultsRecurrent Urinary Tract Infections Biological:
4517 NCT00753A Study of V934/V935CompletedHas ResultNon-Small Cell Lung Carcinoma|BreBiological:
4518 NCT01653BioThraxÂ® (Anthrax)Active, notNo ResultsPregnancy Complications|Pregnanc Biological:
4519 NCT00192A Phase II,FluMist CompletedNo ResultsInfluenza Biological:
4520 NCT01531A Study Assessing 13 CompletedNo ResultsPneumococcal Infection Biological
4521 NCT00337Human Papillomavirus CompletedHas ResultPapillomavirus Type 16/18 Infection|Biological:
4522 NCT02401A Phase I Trial to Eva CompletedNo ResultsEbola Virus Disease Biological
4523 NCT02093Safety Profile Follow CompletedNo ResultsHealthy
4525 NCT01878The Treatment With HUnknown sNo ResultsChronic Hepatitis B Drug: Drug
4526 NCT01287Safety and Immunogeni CompletedNo ResultsDiphtheria|Tetanus|Poliomyelitis|PeBiological:
4527 NCT00819Safety Stu FLU-A CompletedHas ResultInfluenza Biological:
4528 NCT01511Study to Investigate CompletedHas ResultHealthy Biological:
4529 NCT01235TIV Infant/TITRE IIB Unknown sNo ResultsInfluenza Biological:
4530 NCT00265The Effectiveness of CompletedNo ResultsInfluenza Vaccines
4531 NCT00314Study Evaluating the CompletedNo ResultsMeningitis, Meningococcal Biological
4532 NCT00683A Phase I Clinical Tri CompletedNo ResultsOvarian Cancer|Peritoneal Cancer Biological:
4533 NCT00192Trial to As FluMist CompletedNo ResultsHealthy Biological:
4534 NCT00683Human Leukocyte Anti Terminate Has ResultPancreatic Cancer|Pancreas NeoplaBiological
4535 NCT013042010/2011 Trivalent ICompletedNo ResultsInfluenza Biological:
4536 NCT02339Effect of Raxibacuma CompletedHas ResultInfections, Bacterial Biological
4537 NCT03691Immunogenicity and SRecruiting No ResultsHealthy Volunteers (Meningococcal B I iological
4538 NCT00377CS DNA MVA Trial in WithdrawnNo ResultsPlasmodium Falciparum Malaria Biological: MVA-CSO
4539 NCT02471Laboratory EvaluationRecruiting No ResultsMalaria
4540 NCT02570A Safety and ImmuneCompletedHas
S ResultChicken-pox Illness (Varicella Virus Biological:
4541 NCT00263Assessment of GSK Bio CompletedNo ResultsAcellular Pertussis|Diphtheria|Teta Biological:
4542 NCT02409An Individualized AntCompletedNo ResultsAdvanced Adult Hepatocellular Car Biological:
4543 NCT00730Phase 1 Safety and ImCompletedNo ResultsInfluenza Biological
4545 NCT03594Safety and Immune Res CompletedNo ResultsInfluenza Biological:
4547 NCT00316A Phase II Study on CompletedHas ResultAtopic Dermatitis Biologica
4548 NCT02126Identifoca PNEUMOVUnknown sNo ResultsPneumococcal Diseases Drug: pneu
4549 NCT01262Improving Immunogenic CompletedHas ResultHIV Infection Biological:
4550 NCT03287MYPHISMO: MYPHISM Not yet recNo ResultsColorectal Cancer|Adenoid Cystic C Drug: TetM
4551 NCT01229A Study to Evaluate t CompletedHas ResultHerpes Zoster Biological
4553 NCT00312Phase I/II Trial of a CompletedHas ResultPlasmodium Falciparum Malaria Biological
4554 NCT01289Modified Dose and Sch Unknown sNo ResultsHIV Infection Biological
4555 NCT02447Duration of ProtectioCompletedNo ResultsDiphtheria|Acellular Pertussis|Teta Biological:
4556 NCT00129Comparison of GSKBioCompletedHas ResultHaemophilus Influenzae Type b|NeisBiological:
4557 NCT02453Study of BPZE1 (High CompletedHas ResultPertussis|Whooping Cough Biological
4558 NCT03307Evaluation SKIPP CompletedNo ResultsChildhood Influenza Vaccination|SchOther: Text
4559 NCT002570804 GCC: MAGE-A3/H CompletedNo ResultsSquamous Cell Carcinoma of the HeBiological
4560 NCT03879Autologous DendriticRecruiting No ResultsChildhood Glioblastoma Drug: deple
4561 NCT02565The Effect of Influen Recruiting No ResultsSystemic Inflammatory Response Biological:
4562 NCT04224Consistency Study forCompletedNo ResultsPoliomyelitis Biological:
4563 NCT00303V710 First-In-Man (F CompletedHas ResultStaphylococcal Infections Biological
4565 NCT02901Observational Study CompletedNo ResultsParotid Gland Infection|Fever
4566 NCT03814A Study to Assess theActive, notNo ResultsRespiratory Syncytial Virus InfectionBiological
4567 NCT04206An Exploratory Open-L Not yet recNo ResultsHPV Infection Drug: Gard
4568 NCT01854Peptide VaPERFORMAWithdrawnNo ResultsGlioblastoma Biological
4569 NCT02591Immunogenicity and SCompletedHas ResultMeningitis|Meningococcal MeningitBiological
4570 NCT00000Phase I Safety and I CompletedNo ResultsHIV Infections Biological: HIVAC-1e|
4571 NCT03903Immunobridging Study Active, notNo ResultsPapillomavirus Infections Biological:
4572 NCT02009ICI-VPH: I ICI-VPH Active, notNo ResultsHuman Papillomavirus Infections Biological
4573 NCT01899An Incitat IMPROVEDCompletedNo ResultsPneumococcal Infections
4574 NCT00000A Multicenter, RandoCompletedNo ResultsHIV Infections Biological: MN rgp120
4575 NCT01623A ChallengeVAC045 CompletedNo ResultsPlasmodium Falciparum Malaria Biological
4576 NCT00217Vaccine Therapy, GM-C CompletedNo ResultsAdult Solid Neoplasm Biological
4577 NCT01067TIV Infant TITRE II Unknown sNo ResultsInfluenza Biological:
4578 NCT00469Vaccine Therapy WithTerminate No ResultsLeukemia|Multiple Myeloma and PlBiological:
4579 NCT00003Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: dendritic
4580 NCT02098Chemoproph BMGF2b CompletedNo ResultsMalaria Biological:
4581 NCT00099Immunization AgainstCompletedNo ResultsCutaneous T-cell Lymphoma|Sezary Biological:
4582 NCT00776Vaccine for PreventionCompletedNo ResultsInfluenza, Human Drug: Mono
4583 NCT00004Vaccine Therapy in T CompletedNo ResultsKidney Cancer Biological: dendritic
4584 NCT00362Comparison of DTaP-ICompletedHas ResultHepatitis B|Polio|Diphtheria|Pertu Biological
4585 NCT03266AntitetanusVAT65 CompletedNo ResultsTetanus Other: Que
4586 NCT02639Screening of Healthy Recruiting No ResultsMalaria
4587 NCT00337T and B Cell ResponseCompletedNo ResultsInfluenza
4588 NCT02334A Comparison of Matu Active, notNo ResultsMelanoma Biological:
4589 NCT00000A Phase I RandomizedCompletedNo ResultsHIV Infections Biological: HIVAC-1e|
4590 NCT03893Safety, Tolerability a CompletedNo ResultsPrevention of Influenza Biological:
4591 NCT01335Safety StudH5N1 CompletedNo ResultsAvian Influenza|Bird Flu Biological:
4592 NCT02742Impact of Pneumococc CompletedNo ResultsAcute Otitis Media|Otitis Media Other: Data
4593 NCT01308Immunother LAG-3/IMPTerminate No ResultsMelanoma Biological:
4594 NCT02902Glycan Att Gastrovim Unknown sNo ResultsGastroenteritis|Acute GastroenteritiBiological:
4595 NCT01352A Trial to B1971016 CompletedHas ResultHealthy Biological
4596 NCT01353Hepatitis A VaccinatioCompletedNo ResultsHepatitis A
4597 NCT00520Broad Spectrum HPV CompletedNo
( ResultsCervical Cancer|Vulvar Cancer|VagiBiological
4598 NCT02994txt2protect2p CompletedNo ResultsHuman Papillomavirus Behavioral
4599 NCT02212Trial to Assess Immu CompletedHas ResultInfections, Meningococcal Biological
4600 NCT00594Comparison of Three CompletedHas ResultJapanese Encephalitis Biological:
4601 NCT01982Vaccine Therapy and IWithdrawnNo ResultsRecurrent Fallopian Tube Cancer|Recu Biological
4602 NCT00834Prevention of HumanCompletedHas ResultHPV Infections Biological
4603 NCT02133AccountablACO/PH CompletedNo ResultsImmunization Reminder System Other: Cen
4604 NCT01947Pneumococc PneuVAC CompletedNo ResultsCrohns Disease Biological
4605 NCT02337Phase 1 Clinical Tria Recruiting No ResultsTuberculosis Biological
4606 NCT01305A Phase IIIROTAVAC Unknown sNo ResultsViral Gastroenteritis Due to RotaviruBiological:
4607 NCT00061Evaluation of Transg CompletedNo ResultsProstatic Neoplasms Biological: Transgeni
4608 NCT02255Anti-pneum PneumoMIActive, notNo ResultsInfections, Pneumococcal|Bowel DisBiological
4609 NCT03331PreventionHCP Unknown sNo ResultsRespiratory Tract Disease|Influenza Biological:
4610 NCT04056A Study to DetermineRecruiting No ResultsShigellosis Biological:
4611 NCT02640Effect of Morning vs. CompletedNo ResultsPremature Birth|Intermittent Hypo Biological:
4612 NCT03382Safety, Reactogenici Active, notNo ResultsCytomegalovirus Infection Biological
4613 NCT03849Safety, Reactogenicit CompletedNo ResultsInfluenza Biological:
4614 NCT00246One Year Study to EvaCompletedNo ResultsPlague Biological:
4615 NCT00019Vaccine Therapy in TrCompletedNo ResultsLung Cancer Biological:
4616 NCT00091Vaccine Therapy in TrCompletedHas ResultOvarian Cancer|Primary Peritoneal Biological:
4617 NCT01673Evaluating Immune ReTerminate Has ResultInfluenza Drug: Live
4618 NCT00937Safety and Reactogenic CompletedHas ResultPoliomyelitis Biological:
4619 NCT04214EvaluationEVAPOR Not yet recNo ResultsPneumococcal Infections|Lymphoma, Biological:
4620 NCT00289Safety and Immunogen CompletedHas ResultHaemophilus Influenzae Type b|NeisBiological:
4621 NCT00703H5N1 Priming and Boo CompletedHas ResultInfluenza Biological
4622 NCT01951Safety and Efficacy S CompletedNo ResultsExposure to Hepatitis B Virus Drug: HBsA
4623 NCT00751Immunogenicity & SafCompletedHas ResultMeasles|Varicella|Mumps|Rubella Biological:
4624 NCT00437MVA Post-Event: AdmiCompletedNo ResultsSmallpox Drug: Plac
4625 NCT00106Comparison of Three CompletedHas
H ResultHIV Infection|Hepatitis B Biological
4626 NCT01457A Study to Assess Im CompletedNo ResultsInfluenza Biological:
4627 NCT03824A Study to Evaluate t CompletedNo ResultsMalaria Biological
4628 NCT03658Phase 2 Dose and ForCompletedNo ResultsInfluenza, Human Biological
4629 NCT02207An Extension to StudyCompletedHas ResultMalaria Procedure:
4630 NCT02962A Randomised, Double- CompletedHas ResultInfluenza Biological:
4631 NCT01707A Safety and Immunog CompletedNo ResultsAllergic Rhinoconjunctivitis Biological
4632 NCT02446Combined Study - PhaCompletedHas ResultInfections, Meningococcal Biological
4633 NCT01562Study to Evaluate LonCompletedHas ResultTick Borne Encephalitis Other: Blo
4634 NCT00487Phase 1 Study of the CompletedNo ResultsMalaria Drug: AMA
4635 NCT00986MUC1 Vaccine for TripCompletedNo ResultsBreast Cancer|Inflammatory Breast B Ciological
4636 NCT02153Safety and Immunogeni CompletedHas ResultNorovirus Biological:
4638 NCT01783ImmunizatiMMV WithdrawnNo ResultsMalaria, Falciparum Drug: Azit
4639 NCT00988Dendritic Cells(DC)-B CompletedNo ResultsMultiple Myeloma|Plasmocytoma Biological:
4640 NCT04264Safety and Immunogeni CompletedNo ResultsPolio Biological:
4641 NCT00100Vaccine Therapy in T Terminate No ResultsLeukemia Drug: autologous tumo
4642 NCT02504Speed of Injection anUnknown sNo ResultsRoutine Infant Immunizations|Pai Other: Fas
4643 NCT00089Vaccine Therapy WithCompletedNo ResultsCiliary Body and Choroid MelanomaBiological
4644 NCT02983Pertussis PERILIC Recruiting No ResultsBordetella Pertussis, Whooping CouProcedure:
4645 NCT02129CDX-1401 and Poly-ICActive, notNo ResultsCutaneous Melanoma|Mucosal Melan Biological
4646 NCT00106Safety Study of NY-ESCompletedNo ResultsNeoplasms Biological:
4647 NCT02693DC Vaccine CombinedUnknown sNo ResultsEsophagus Cancer Biological:
4648 NCT00255Vaccine Treatment forCompletedNo ResultsPancreatic Cancer Biological
a ResultsHIV Infections Biological
4650 NCT00263Comparison of GSK BiCompletedNo ResultsDiphtheria|Acellular Pertussis|Teta Biological:
4651 NCT04251GNOS-PV02 PersonaliNot yet recNo ResultsHCC Biological
4652 NCT00959A/H1N1 Immunogenicit CompletedNo ResultsInfluenza|Pandemic Influenza Biological:
4653 NCT00192Study to Evaluate theCompletedNo ResultsInfluenza Biological:
4654 NCT04232Dose-Finding Trial t Recruiting No ResultsCytomegalovirus Infection Biological
4655 NCT00780Feasibility of Autolo WithdrawnNo ResultsColorectal Neoplasms|Anal, Colon, Biological
4656 NCT00697Safety, ImmunogeniciCompletedNo ResultsHepatitis B Biological
4657 NCT00393Determining Responses CompletedNo ResultsHIV Infections|Hepatitis C Biological:
4658 NCT04138A Study of a Vaccine Recruiting No ResultsRespiratory Syncytial Virus InfectionBiological
4659 NCT00824Study Eval PILOT CompletedHas ResultPneumococcal Conjugate Vaccine Biological
4660 NCT00369Efficacy and Safety o CompletedNo ResultsSmokers Biological
4661 NCT00004Vaccine Therapy in T CompletedNo ResultsLeukemia Biological: QS21|Biolo
4662 NCT00805Study to Compare theCompletedHas ResultHepatitis B Biological:
4663 NCT03143Seasonal MRTSS-SMC Active, notNo ResultsMalaria,Falciparum|Children, Only Biological
4664 NCT03642Trial to Evaluate the CompletedNo ResultsPneumococcal Infections Biological
4665 NCT02257Post-authorization SaUnknown sNo ResultsDiphtheria|Tetanus|Pertussis|Hepatitis B|Hae
4666 NCT00607Safety and Efficacy o CompletedHas ResultSmallpox Biological:
4667 NCT02011Safety of Two Doses oCompletedNo ResultsHepatitis A|Hepatitis A Virus Biological:
4668 NCT02260Revaccination With CompletedHas ResultPneumococcal Infection Biologica
4669 NCT01163A Study of the Effec CompletedHas ResultRheumatoid Arthritis Biological
4670 NCT00596Concomitant VaccinatCompletedHas ResultJapanese Encephalitis Biological
4671 NCT04170A Clinical Trial to Recruiting No ResultsMiddle East Respiratory Syndrome CBiological
4672 NCT02206H7 Influenza Prime-BCompletedNo ResultsInfluenza Biological
4673 NCT01677Safety, Tolerability CompletedNo ResultsInfluenza A Biological:
4674 NCT03563QUILT-3.088: NANT PaWithdrawnNo ResultsMetastatic Pancreatic Cancer Drug: Gemc
4675 NCT01627Immunogenicity and Sa CompletedHas ResultHepatitis B Biological:
4676 NCT02277A Phase-I, Dose Esca WithdrawnNo ResultsOvarian, Fallopian Tube and Periton Biological
4677 NCT00532A Phase 1 EP1090 Unknown sNo ResultsHIV Infections Biological
4678 NCT01284Safety, ImmunogenicitCompletedNo ResultsHDL|Drug Safety Biological
4679 NCT00019Vaccine Therapy in TrCompletedNo ResultsRecurrent Colon Cancer|Extensive StDrug: Detox-B adjuvan
4680 NCT00003Vaccine Therapy in T CompletedHas ResultRecurrent Melanoma|Stage IA MelaBiological
4681 NCT00339Safety of and ImmuneCompletedHas ResultHIV Infections|Sexually Transmitted Biological
4682 NCT00546Study Evaluating The CompletedHas ResultPneumococcal Infections Biological
4683 NCT04120Phase 3 Pivotal Trial Active, notNo ResultsInfluenza, Human Biological:
4684 NCT02472A Study to Evaluate t CompletedNo ResultsRespiratory Syncytial Virus Biological
4685 NCT01553Immunogenicity and SCompletedHas ResultNeisseria Meningitidis|Bacterial Inf Biological
4686 NCT03541Passive Enhanced SafeCompletedNo ResultsYellow Fever Biological:
4687 NCT00355Study to Compare Boo CompletedNo ResultsInfant|Healthy Biological
4688 NCT00346Safety and Immunogeni CompletedHas ResultAcellular Pertussis|Diphtheria|Teta Biological
4689 NCT03653Human Papilloma ViruNot yet recNo ResultsMucoviscidosis Other: Sel
4690 NCT02220Does the Fecal MicroCompletedNo ResultsRotavirus Infections|Reaction - Vaccine Nos|Int
4691 NCT02390Vaccination in Prosta CompletedNo ResultsProstate Cancer Biological
4692 NCT02002ADXS 11-001 VaccinatiRecruiting No ResultsHead and Neck Cancer|Squamous Cel Biological
4693 NCT02148Immune Responses toCompletedHas ResultPregnancy Biological:
4694 NCT01883A Safety and Efficac CompletedNo ResultsPlasmodium Falciparum Malaria Biological
4695 NCT00496Safety,Tolerability a CompletedNo ResultsVaricella Biological:
4696 NCT04161Study of PersonalizedRecruiting No ResultsPancreatic Cancer Drug: Atez
4697 NCT00247Impact of HIV on MeaCompletedNo ResultsHIV Infection|Measles|Children Biological: standard-t
4698 NCT00092Immunogenicity BridgCompletedNo ResultsCervical Cancer|Genital Warts Biological:
4699 NCT04144Safety and Immunogen Recruiting No ResultsHuman Metapneumovirus and Human Biological
4700 NCT01766Safety of One Dose o CompletedHas ResultMeningococcal Disease Biologica
4701 NCT01901The ParentPARENT Active, notNo ResultsHealthy|Human Papilloma Virus InfeOther: edu
4702 NCT00120Lamivudine and TheraTerminate No ResultsHepatitis B Drug: Lami
4703 NCT00808Assessing MA181 CompletedHas ResultHealthy Biological:
4704 NCT03406Combination Immunoth Recruiting No ResultsSmall Cell Lung Cancer|Lung CancerDrug: Nivo
4705 NCT01096Follow-up of Immunoge Unknown sNo ResultsInfluenza
4706 NCT02368Ebola CVD-Mali #200CompletedNo ResultsEbola Virus Disease|Hemorrhagic FeBiological
4707 NCT03093Effect of Rabies Imm CompletedNo ResultsRabies Biological:
4708 NCT00655Effectiveness of HumaCompletedNo ResultsRotavirus Severe Gastroenteritis Other: Coll
4709 NCT03294Cognitive, Emotional CompletedNo ResultsHealthy Biological:
4711 NCT00625A Study to DIPS CompletedNo ResultsHaemophilus Infections
4712 NCT00539Immunogenicity, SafetyCompletedNo ResultsInfluenza Biological:
4713 NCT03878Safety and Immunogen Recruiting No ResultsHealthy Volunteer Biological
4714 NCT00292Immunization With NY CompletedNo ResultsProstate Cancer Biological
4715 NCT01049Preventative MisconcCompletedNo ResultsHIV|HIV Infections Behavioral
4716 NCT01086A Study of Meningococ CompletedHas ResultMeningococcal Infection|MeningitisBiological
4717 NCT03190Study of CRS-207, Ni Recruiting No ResultsPancreatic Cancer Drug: Cycl
4718 NCT01817Trial of RNActiveÂ®-DTerminate No ResultsProstate Cancer Biological:
4719 NCT03870Evaluation of an Inf Recruiting No ResultsTuberculosis|Diphtheria|Tetanus|PeBehavioral:
4720 NCT00469Phase Ib TrMSP3TN Unknown sNo ResultsMalaria Biological:
4721 NCT02389A T Cell-based HIV VaRecruiting No ResultsHIV Other: HIV
4722 NCT00057HerpeVac Trial for CompletedHas ResultHerpes Simplex Infection Biological:
4723 NCT01386CT-011 and p53 GenetWithdrawnNo ResultsBreast Cancer|Colon Cancer|PancreBiological
4724 NCT00107Vaccine Therapy in T CompletedNo ResultsBrain and Central Nervous System T Biological:
4725 NCT03968Parent Targeted InterCompletedNo ResultsProcedural Pain Behavioral
4726 NCT01113A Clinical Trial of C CompletedHas ResultInfluenza Biological
4727 NCT01567Study of DC VaccinatiRecruiting No ResultsGlioma|Glioblastoma Multiforme|NProcedure:
4728 NCT01049A Safety a THYB-03 CompletedNo ResultsTuberculosis Biological:
4729 NCT03829Neonatal Va NeoVac2S Not yet recNo ResultsHepatitis B Other: Hum
4730 NCT03548A Double-Blind PlacebRecruiting No ResultsGastroenteritis Escherichia Coli|Im Other: Pla
4731 NCT00984Persistence of ImmuniCompletedHas ResultHepatitis B Biological:
4732 NCT02628Protecting PROPEL Active, notNo ResultsPneumonia Biological
4733 NCT00868MTD Study of VaccineCompletedNo ResultsCastrate Resistant Prostate Cancer Biological
4734 NCT00606Immunogenicity of the CompletedNo ResultsInfluenza|Orthomyxoviridae Infecti Biological:
4735 NCT00231Inactivated Influenza CompletedNo ResultsInfluenza Biological: Fluzone
4736 NCT00002Safety and Effects of CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: APL 400-0
4738 NCT00076A Study of LIPO-5 an CompletedNo ResultsHIV Infections Biological
4739 NCT03219A Pilot Study of a P Not yet recNo ResultsLymphocytic Leukemia Drug: Neo
4740 NCT00189Take Rate, Immunogeni CompletedNo ResultsSmallpox Biological:
4741 NCT02957Parental Views RelateCompletedNo ResultsHealthy Children
4742 NCT00240Revaccination With SCompletedNo ResultsInfluenza Biological: Influenz
4743 NCT00396BCG Vaccination Deli CompletedNo ResultsTuberculosis Biological
4744 NCT00170Elderly Influenza Va CompletedNo ResultsInfluenza
4745 NCT00017Vaccine Therapy in TrWithdrawnNo ResultsBreast Cancer|Gastric Cancer|Lung Biological
4746 NCT01045Trial of A aMILs Active, notHas ResultMultiple Myeloma Biological
4747 NCT00996Post-AuthoH1N1 PASSCompletedNo ResultsInfluenza Other: Safe
4748 NCT03346Integrating a Health CompletedNo ResultsHuman Papilloma Virus|Cervical Ca Behavioral
4749 NCT01250Vaccine Therapy and CompletedNo ResultsAnaplastic Astrocytoma|Anaplastic Other: Lab
4750 NCT03953A Study Exploring theCompletedNo ResultsHealthy Biological:
4751 NCT02505Efficacy of HBV Vacci CompletedNo ResultsChronic Hepatitis B Drug: Enge
4752 NCT01127Vaccinatio KS2422-vaCompletedNo ResultsMetastatic Breast Cancer Biological:
4753 NCT02080Investigating the Im CompletedNo ResultsMeningitis Biological
4754 NCT02943Reduced PC PCV1+1 CompletedNo ResultsPneumonia|Meningitis Biological
4755 NCT02451Neoadjuvant/Adjuvant Recruiting No ResultsPancreatic Cancer Drug: Cycl
4756 NCT01682ADITEC FLU STUDY: Un CompletedNo ResultsInfluenza Biological:
4757 NCT00963Safety & Immunogenic CompletedHas ResultHIV Infections|Pneumococcal InfectBiological
4758 NCT02479Measuring the ImpactCompletedNo ResultsHIV Other: HIV
4759 NCT00700Antibody Persistence CompletedHas ResultMeningitis|Meningococcemia Biological
4760 NCT02564A Controlled Study toUnknown sNo ResultsHealthy Biological:
4761 NCT00001A Pilot Study of Auto CompletedHas ResultEwing's Sarcoma|Rhabdomyosarco Biological:
4762 NCT02364A Phase I SMAGTRIVAActive, notNo ResultsBreast Neoplasms Drug: MAG
4763 NCT00005Safety of the CandidaCompletedNo ResultsHIV Infections Drug: Interleukin-12|
4764 NCT01847IPV Clinica IPV CompletedNo ResultsPoliomyelitis Drug: IPV
4765 NCT00427Phase I Study of AMACompletedNo ResultsMalaria Biological
4766 NCT02062Early Versus Delayed CompletedHas ResultHIV Exposure|HIV Infection Biological:
4767 NCT00071Safety of and ImmuneCompletedNo ResultsHIV Infections Biological: VRC-HIV
4768 NCT00197Comparative Study inCompletedNo ResultsHepatitis A Biological:
4769 NCT01807Safety, ImmunogenicitCompletedNo ResultsVaccination Adverse Events|VaccinatBiological:
4770 NCT01137Immunogenicity and SCompletedNo ResultsRabies Biological
4771 NCT01311Transcutaneous Immun CompletedNo ResultsHealthy Volunteers Biological
4772 NCT01839Concomitant AdministCompletedNo ResultsNeisseria Meningitidis|Bacterial Inf Biological
4773 NCT00057Evaluation of a DiabeCompletedNo ResultsInsulin-dependent Diabetes MellitusBiological:
4774 NCT00135Study to Evaluate GlaCompletedNo ResultsInfections, Meningococcal Biological
4775 NCT02633Persistence of Bacter CompletedHas ResultMeningitis|Meningococcal MeningitBiological
4776 NCT00996Immunogenicity of NoActive, notNo ResultsInfluenza|HIV Infections
4777 NCT00666Pilot StudyMIRB #862Unknown sNo ResultsAnal Cancer|HIV Infections Biological:
4778 NCT00521Impaired Immunity inUnknown sNo ResultsNeoplasms Other: Imm
4779 NCT00943Minor HistocompatibilTerminate No ResultsPreleukemia|Myeloproliferative Di Drug: Flud
4780 NCT03455Evaluation of NDV-3ACompletedNo ResultsStaphylococcus Aureus Biological:
4781 NCT03571Assessment of FamilyCompletedNo ResultsContraception|Contraceptive UsageBehavioral
4782 NCT00158Immune Memory FollCompletedNo ResultsHib Disease|Hepatitis B|Pertussis|PBiological:
4783 NCT00981Safety andPedVacc00Unknown sNo ResultsHIV-1|HIV Infections Biological
4784 NCT00679Immunogenicity, SafetCompletedHas ResultTyphoid Biological:
4785 NCT00091Vaccine Therapy in TreUnknown sNo ResultsColorectal Cancer Biological
4786 NCT00138Comparison of InactivCompletedNo ResultsInfluenza Biological: FluMist|Bi
4787 NCT00005Vaccine Therapy Plus CompletedNo ResultsBreast Cancer|Lung Cancer|OvarianBiological: HER-2/neu
4788 NCT01341Tumor Cell Vaccines Terminate No ResultsSarcoma|Melanoma|Epithelial Malig Biological
4789 NCT00920Safety and ReactogeniCompletedHas ResultPoliomyelitis Biological:
4790 NCT01738Safety Study of MeaslWithdrawnNo ResultsMumps|Rubella|Measles|Varicella Biological:
4791 NCT02492SA4Ag Safety, TolerabCompletedHas ResultStaphylococcal Infections Biological:
4792 NCT03722Phase 1 Clinical Trial Active, notNo ResultsPulmonary TB Biological:
4794 NCT03621GlaxoSmithKline's (G Recruiting No ResultsInfections, Meningococcal Biological:
4795 NCT03870Influenza VaccinationCompletedNo ResultsDiabetes Behavioral:
4796 NCT00535A Study of an Invest CompletedHas ResultHerpes Zoster|Herpes Zoster-relate Biological:
4797 NCT00197Immunogenicity & SafCompletedHas ResultHepatitis A Biological
4798 NCT00689Efficacy Study of HP CompletedNo ResultsInfections, Papillomavirus Biological:
4799 NCT03909Pertussis Vaccinatio Recruiting No ResultsPertussis Biological:
4800 NCT03632A Study to Evaluate Recruiting No ResultsBreast Cancer|HER2+ Breast CancerBiological
4801 NCT02446Evaluation of Antibo CompletedHas ResultInfections, Meningococcal Biologica
4802 NCT02853A Study of AV0328 AdCompletedNo ResultsPNAG-expressing Pathogenic MicrobBiological:
4803 NCT00213The Safety of Oka VariUnknown sNo ResultsOrgan Transplantation|ImmunosuppBiological:
4804 NCT00750Evaluation of ReactogCompletedHas ResultInfections, Rotavirus Biological:
4805 NCT00197Response osched1 CompletedNo ResultsPneumococcal Infections|Meningoco Biological
4806 NCT00698Vaccination of Prost CompletedNo ResultsProstate Cancer Biological
4807 NCT00318Safety Study of Four CompletedHas ResultInfluenza Biological:
4808 NCT00169Immune Memory of DTP CompletedHas ResultWhole Cell Pertussis|Diphtheria|HeBiological:
4809 NCT01061Immunogenicity, SafeCompletedNo ResultsHaemophilus Influenzae Type b Biological:
4810 NCT02071Phase 1 LEISH-F3 + SLCompletedNo ResultsVisceral Leishmaniasis Biological:
4811 NCT00257Immune System Functio CompletedNo ResultsHIV Infections Biological:
4812 NCT01637A Randomized ControlCompletedNo ResultsMothers of Newborn Infants Behavioral:
4813 NCT01622Effectiveness of H1N1Unknown sNo ResultsInfluenza|Pneumonia
4814 NCT00923Wilm's Tumor 1 ProteiCompletedHas ResultLeukemia, Acute Myelogenous (AMLDrug: WT1
4815 NCT03302Phase 1 LEP-F1 + GLA-CompletedNo ResultsLeprosy Biological:
4816 NCT03554QUILT-3.05TNBC WithdrawnNo ResultsTriple Negative Breast Cancer (TNBCDrug: Leuc
In ResultsTransplant
4818 NCT00436Vaccine Therapy WithActive, notNo ResultsHER2-positive Breast Cancer|Stage IBiological
4819 NCT03068Comparison of Three Recruiting No ResultsInfluenza Biological:
4820 NCT00614Responses to Immuniz CompletedNo ResultsAtopic Dermatitis Biological:
4821 NCT01915Study of the Safety o CompletedNo ResultsHealthy Volunteers Biological
4822 NCT00002A Study of GENEVAX-H CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: APL 400-0
4823 NCT01227Study of OTSGC-A24 VUnknown sNo ResultsGastric Cancer Biological
4824 NCT01246Long Term Immunity aCompletedHas ResultJapanese Encephalitis Procedure:
4825 NCT00962Reactogenicity, ImmuWithdrawnNo ResultsChronic Lymphocytic Leukemia Biological:
4826 NCT00126Study in Children to CompletedNo ResultsInfections, Meningococcal Biological
4827 NCT03395Efficiency GlioVax Recruiting No ResultsGlioblastoma Biological:
4828 NCT01079Safety Study of AdjuvCompletedHas ResultMelanoma Biological:
4829 NCT00939Prevalence of HookwoCompletedHas ResultHookworm Infection Biological:
4830 NCT00440A Phase 1/2 Clinical TCompletedNo ResultsInfluenza Biological:
4831 NCT00027An Investigational C CompletedNo ResultsHIV Infections Biological: Combinat
4832 NCT00319Immunogenicity and Sa CompletedNo ResultsPertussis|Diphtheria|Poliomyelitis| Biological
4833 NCT04087 Phase â… aPâ…
Clinical
CTPVTrial
Notofyet
Pneumococcal
recNo ResultsVaccine
Pneumonia|Respiratory Tract Disease
Biological
4834 NCT03535Characteri BVAC CompletedNo ResultsHepatitis B Biological:
4835 NCT03383Safety Profile Follow CompletedNo ResultsHealthy|Pregnant
4836 NCT00133FLU-VACS Comparative CompletedNo ResultsInfluenza Biological:
4838 NCT02745Nutrition, NOVEL CompletedNo ResultsSmall Intestine Bacterial Overgrowth
4839 NCT00056HIV Vaccine DesignedCompletedNo ResultsHIV Infections Biological:
4840 NCT01504Immune Response and WithdrawnNo ResultsNon-small Cell Lung Cancer Biological:
4841 NCT00539Safety and ReactogeniCompletedHas ResultInfluenza Biological:
4842 NCT01913A Non-inferiority Tr CompletedHas Result18-42 Year Old Healthy Vaccinia-naÃBiological
4844 NCT00458Vaccination With Dend Active, notNo ResultsMultiple Myeloma Biological:
4845 NCT00505A Phase III, Open-LabCompletedNo ResultsInfluenza Biological:
4846 NCT02344Partnership for ReseaActive, notHas ResultEbola Virus Biological
4847 NCT03299PEP-CMV inPRiME Active, notNo ResultsRecurrent Medulloblastoma|RecurreDrug: PEP
4848 NCT01777AcceptabiliPRALINE CompletedNo ResultsHepatitis B Other: Data
4849 NCT00105Simplified Consent forCompletedNo ResultsAdolescent Behavior
4850 NCT00712Immune Responses inCompletedHas ResultPertussis|Tetanus|Diphtheria Biological
4851 NCT00000Active Immunization oCompletedNo ResultsHIV Infections Biological: gp160 Va
4852 NCT01159Human Papillomavirus CompletedNo ResultsHuman Papillomavirus|Infection
4853 NCT00385A Study to DetermineCompletedNo ResultsMalaria Biological
4854 NCT01304Immunogenicity and TCompletedHas ResultHuman Papillomavirus Biological
4855 NCT02618Follow-up Study to A CompletedNo ResultsParkinson's Disease Biological
4856 NCT03199RV001V, a RhoC AnticCompletedNo ResultsProstate Cancer Biological
4857 NCT00412Study to Assess SafetCompletedHas ResultTetanus|Diphtheria|Acellular PertusBiological:
4858 NCT00343Cyclophosphamide and WithdrawnNo ResultsLeukemia Biological
4859 NCT01195Safety and Immunogeni CompletedNo ResultsEnd Stage Renal Disease Biological:
4860 NCT01892Pneumococcal Vaccine CompletedNo ResultsChronic Lymphocytic Leukemia Drug: Prev
4861 NCT01898DCs Vaccine Combined Unknown sNo ResultsHigh-risk Sof Tissue Sarcoma Biological:
4862 NCT03902Safety and Immunogeni CompletedNo ResultsPolio and Post-Polio Syndrome Biological
4863 NCT00871Immunogenicity and Sa CompletedHas ResultAcellular Pertussis|Tetanus|DiphtheBiological:
4864 NCT00289Study of Safety, ImmuCompletedHas ResultMalaria Biological
4865 NCT00776Autologous SCT Follow Terminate Has ResultSmall Cell Lung Cancer Biological
4866 NCT00415Proteinase 3 PR1 Pe Terminate Has ResultLeukemia Biological
4867 NCT01605Trial for M PEBS-POC1Unknown sNo ResultsMalaria Biological
4868 NCT02276Evaluation of Long T CompletedNo ResultsCervical Cancer|Anogenital Warts Biological:
4869 NCT00114Anthrax Vaccine ClinicCompletedNo ResultsAnthrax Drug: Anthrax Vaccin
4870 NCT01434Initial Study of Mala CompletedNo ResultsMalaria Biological:
4871 NCT02864Evaluation of a Pilot CompletedNo ResultsCholera|Diarrhea
4872 NCT00023S0114 Vaccine Therapy Terminate No ResultsBrain Tumors|Gastric Cancer|OvariaBiological
4873 NCT03853Study on t VACTEVIH Recruiting No ResultsHIV Infections Diagnostic
4874 NCT03970VAC 072-An Efficacy Recruiting No ResultsMalaria Biological
4875 NCT00000A Study to Test the S CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: HIV p24/
4876 NCT00829Pneumococcal Vaccina CompletedNo ResultsInflammatory Bowel Disease|Crohn Biological
D
4878 NCT00470Vaccine Therapy and R CompletedNo ResultsMelanoma (Skin) Drug: resi
4879 NCT02866Safety of SNIFFLE-4 CompletedHas ResultAsthma Drug: Admin
4880 NCT03467A Study to Evaluate CompletedNo ResultsPneumococcal Infection Biological:
4881 NCT02285MG1 Maraba I214 Active, notNo ResultsAdvanced/Metastatic Solid TumoursBiological
4882 NCT03442Afluria Pregnancy RegRecruiting No ResultsInfluenza, Human|Pregnancy|Birth Biological:
4884 NCT00148Safety & Activity of CompletedNo ResultsNeoplasms, Prostate Biological
4885 NCT00669Cost-Effectiveness AnaUnknown sNo ResultsGastroenteritis|Rotavirus Vaccines|Cost-Effect
4886 NCT02621Immunogenicity and Sa CompletedNo ResultsInfluenza, Human Biological:
4887 NCT00091Safety of and ImmuneCompletedNo ResultsHIV Infections Biological: VRC-HIVA
4888 NCT00003HER-2/Neu Vaccine Plu CompletedNo ResultsBreast Cancer|Lung Cancer|OvarianBiological: HER-2/neu
4889 NCT01382Safety Study of Reco CompletedNo ResultsEscherichia Coli Infection Biological:
4890 NCT00586Safety and Immunogeni CompletedHas ResultInfections, Papillomavirus Biological:
4891 NCT01219Ex Vivo-Expanded HER2 WithdrawnNo ResultsHER2-positive Breast Cancer|Male BBiological
4892 NCT00134Hib-MenCY-TT Vaccine CompletedHas ResultNeisseria Meningitidis|HaemophilusBiological
4893 NCT02114A Study to Compare ICompletedHas ResultPapilloma Viral Infection Biological
4894 NCT01457Immunogenicity and R CompletedNo ResultsHepatitis B|Diphtheria|HaemophilusBiological:
4895 NCT01258Seasonal FlFluad Tx CompletedNo ResultsImmunocompromised|TransplantedBiological:
4896 NCT02366A Study to Assess theCompletedNo ResultsInfluenza|Vaccine Biological
4897 NCT02917Hepatitis A Vaccine Recruiting No ResultsAutoimmune Rheumatologic DiseasBiological:
4898 NCT01484Phase 1 LEISH-F3 VaccCompletedNo ResultsLeishmaniasis Biological:
4899 NCT04137Study to Evaluate theRecruiting No ResultsInfluenza (Healthy Volunteers) Biological:
4900 NCT03293Evaluation of the Saf CompletedNo ResultsInfluenza Biological:
4901 NCT00186Vaccine Therapy for MCompletedNo ResultsMultiple Myeloma Biological:
4902 NCT02621Study of Egg-derived CompletedNo ResultsInfluenza, Human Biological:
4903 NCT00197Evaluation of the Im CompletedNo ResultsStreptococcus Pneumoniae Biological
4904 NCT02360Combination TherapyCompletedNo
W ResultsHepatitis B, Chronic Drug: Entec
4905 NCT00348Immunogenicity and SCompletedNo ResultsPoliomyelitis|Polio Biological:
4906 NCT04168A Phase 1/Phase 2 StRecruiting No ResultsPneumonia, Pneumococcal Drug: pPCV
4907 NCT00126Vaccine Therapy in T Unknown sNo ResultsMelanoma (Skin) Biological:
4908 NCT00000Active Immunization CompletedNo ResultsHIV Infections|Pregnancy|HIV SeronBiological: gp160 Va
4909 NCT03309Fifeen-year ImmunolEnrolling bNo ResultsHuman Papillomavirus|Cervical Cancer
4910 NCT02991A Study to Evaluate PCompletedNo ResultsVirus Diseases Procedure:
4911 NCT00889Phase I Study of the CompletedNo ResultsMalaria Drug: BSAM
4912 NCT00085Vaccine Therapy in TrUnknown sNo ResultsMelanoma (Skin) Biological:
4914 NCT00653A Study to Quantify CompletedNo ResultsTuberculosis Biological:
4915 NCT01926Immunogenicity and Sa CompletedHas ResultRotavirus Disease Biological:
4916 NCT00343Vaccine Therapy in TrCompletedNo ResultsHER2-positive Breast Cancer|Male Br Biological
4917 NCT03647QUILT-3.091 NANT Cho WithdrawnNo ResultsChordoma|Unresectable Malignant Biological
4918 NCT00753Human Leukocyte Anti CompletedNo ResultsEsophageal Cancer Biological
4919 NCT01256Antibody Levels AgainUnknown sNo ResultsOrgan Transplantation
4920 NCT03639A Study of a Persona Recruiting No ResultsNon Small Cell Lung Cancer|Colore Biological
4921 NCT02996Zika-Vaccine Dose FinCompletedNo ResultsZika Virus Biological
4922 NCT00113Vaccine and AntibodyCompletedNo ResultsProstatic Neoplasms Biological
4923 NCT00914Lyophilized IMVAMUNCompletedNo ResultsSmallpox Biological
4924 NCT00656A Randomized Phase CompletedNo
II ResultsRabies Biological
4925 NCT00359Long-Term Antibody Pe CompletedHas ResultNeisseria Meningitidis|HaemophilusBiological
4926 NCT00116Vaccination in the Pe CompletedNo ResultsAcute Myelogenous Leukemia Biological: GVAX leuk
4927 NCT01603Immune Response in CompletedHas
A ResultEfficacy of the New CPRV Biological
4928 NCT02688DC Vaccine CombinedUnknown sNo ResultsSmall- Cell Lung Cancer Biological:
4929 NCT01064Safety StudEl-porCEA Unknown sNo ResultsColorectal Cancer Biological
4930 NCT02382Persistency Study Af CompletedHas ResultPertussis Biological:
4931 NCT03283Panblok H7 Vaccine CompletedHas ResultInfluenza, Human Biological:
4932 NCT03679Dendritic Cell/AML FuRecruiting No ResultsAcute Myelogenous Leukemia Drug: decit
4933 NCT00259Immunogenicity and SCompletedNo ResultsDiphtheria|Tetanus|Polio|Pertussis Biological:
4934 NCT00068Analysis of Immune RCompletedNo ResultsAcquired Immunodeficiency Syndrome|HIV Infections
4935 NCT01698Low GradeEVACC-B Unknown sNo ResultsIndolent Lymphoproliferative DisordBiological
4936 NCT03844Study to A M&M Recruiting No ResultsHIV-1 Infection Biological
4937 NCT01896A Phase III Study to CompletedNo ResultsHealthy Infants Biological:
4938 NCT00535Safety and Immunogen CompletedNo ResultsPandemic Influenza|Prevention Biological
4939 NCT04192Safety and Immune Re Recruiting No ResultsInfluenza Biological:
4940 NCT01700Predictors PPIR CompletedNo ResultsInnate Immune Response Other: Bre
4941 NCT00582Prostatic Acid PhosphCompletedNo ResultsProstate Cancer Biological
4942 NCT01006Efficacy & Safety of CompletedNo ResultsGlioblastoma Multiforme Biological:
4943 NCT01704RSV-F Vaccine Dose CompletedNo ResultsRespiratory Syncytial Virus (RSV) Biological
4944 NCT03848Safety, Tolerability, Active, notNo ResultsPneumococcal Infections Biological
4945 NCT00291Safety and Immunogen CompletedNo ResultsTuberculosis (TB) Biological
4946 NCT03026Safety and Immunogen CompletedNo ResultsRespiratory Syncytial Viruses Biological
4947 NCT00439A Clinical CMV CompletedNo ResultsCytomegalovirus Infections Biological:
4948 NCT03965Study of Purified Ve Recruiting No ResultsRabies (Healthy Volunteers) Biological
4949 NCT02276HER2-PeptiHER2 CompletedNo ResultsGastric Cancer|Breast Cancer Drug: Cycl
4950 NCT00020Vaccine Therapy in TrCompletedNo ResultsLung Cancer|Adult Sof Tissue Sar Drug: interleukin-2|
4951 NCT03799Anti-Schistosomiasis CompletedNo ResultsSchistosomiasis Biological
4952 NCT00812A Study for Evaluatio CompletedHas ResultInfluenza Biological
4953 NCT01158This is a Study to As CompletedNo ResultsJapanese Encephalitis Biological
4954 NCT00467Safety and Immunogeni CompletedHas ResultTetanus|Diphtheria|Pertussis Biological:
4955 NCT01418Safety Evaluation of CompletedHas ResultInfections, Papillomavirus Biological
4956 NCT00862DC Vaccine Therapy Co Unknown sNo ResultsRenal Cell Carcinoma Biological:
4957 NCT00534Study to Evaluate theCompletedHas ResultShingles Biological:
4958 NCT00013Pneumococcal Vaccine CompletedNo ResultsHIV Infections|Hepatitis B|Measles Biological: Diphtheri
4959 NCT02298B-Cell HemHMvax-RegEnrolling bNo ResultsMonoclonal Gammopathy of Undetermined Sig
4960 NCT00186Efficacy Study of ComCompletedNo ResultsHepatitis B Biological:
4961 NCT03342Immunogenicity and Sa CompletedNo ResultsDengue Biological:
4962 NCT01375A Comparability StudyCompletedNo ResultsSmoking Biological:
4963 NCT04086Influenza VAGA Recruiting No ResultsAsthma in Children|Influenza Vaccine|Immuni
4964 NCT03741Safety of Rabivax-S f CompletedNo ResultsRabies Vaccine Adverse Reaction Biological:
4965 NCT00356Persistence of the ImCompletedNo ResultsHepatitis B Biological:
4966 NCT00145Immunization With thTerminate No ResultsMalignant Melanoma Biological
4967 NCT02030Safety and Efficacy TrCompletedNo ResultsGenital Herpes Simplex Type 2 Biological
4968 NCT03762Multiple MMAPSS Not yet recNo ResultsMultiple Myeloma Biological
4969 NCT00335Persistence of the ImCompletedNo ResultsHepatitis B Biological:
4971 NCT02082Immunogenicity and Sa WithdrawnNo ResultsInfections, Papillomavirus Biological:
4972 NCT00258Vaccine Trial for Cle Active, notNo ResultsSarcoma, Clear Cell|Sarcoma, AlveoBiological
4973 NCT00515Vaccination of MelanCompletedNo ResultsMelanoma Biological
4974 NCT00192A Prospective, RandomiCompletedNo ResultsHealthy Biological:
4975 NCT00220T-Cell Vaccination in Unknown sNo ResultsMultiple Sclerosis Biological:
4976 NCT03388Pertussis PERILIC-IC Recruiting No ResultsBordetella Pertussis, Whooping CouProcedure:
4977 NCT03362PVX-410 Vaccine PlusRecruiting No ResultsTriple Negative Breast Cancer|MetasDrug: Pemb
4978 NCT00162Allogeneic Tumor CellWithdrawnNo ResultsChronic Myeloid Leukemia Biological:
4979 NCT00192Trial to Investigate CompletedNo ResultsInfluenza Biological:
4980 NCT02767Safety and Immunogeni CompletedNo ResultsHIV Infection Biological
4981 NCT00089Vaccine Treatment ofTerminate Has ResultKidney Cancer Drug: 117-
4982 NCT01702A Two-doseDPIV-002 CompletedNo ResultsDengue Fever Biological
4983 NCT01207A Randomize OIDA CompletedNo ResultsInfluenza Behavioral
4984 NCT00488Peptide Vaccinations CompletedHas ResultMyelodysplastic Syndrome (MDS)|ABiological
4985 NCT00635Safety and Immunogeni CompletedHas ResultPoliomyelitis|Diphtheria|Tetanus|AcBiological:
4986 NCT03896Safety, ImmunogenicitRecruiting No ResultsMalaria,Falciparum Biological
4987 NCT01133A Model for Implemen Unknown sNo ResultsGenital Human Papilloma Virus InfecDrug: Garda
4988 NCT03507Non-integrated Costs CompletedNo ResultsControl - No Incentive for Flu VaccinBehavioral:
4989 NCT00312Concomitant Use of HCompletedHas ResultHepatitis A Virus Biological
4990 NCT02415Influenza Challenge Terminate Has ResultMAJOR DEPRESSIVE DISORDER Biological
4991 NCT00535ZOSTAVAXâ„¢ AdminiCompletedHas ResultHerpes Zoster|Pneumococcal InfectBiological
4992 NCT02232Immunologic Response Recruiting No ResultsAsplenia Biological
4993 NCT03233Simulation-Based StreUnknown sNo ResultsStress, Psychological Behavioral
4994 NCT01136Clinical Trial to Inv CompletedNo ResultsLatent Tuberculosis Infection|TubercBiological
4995 NCT01027Dose EscalaCONVERT Unknown sNo ResultsChronic Hepatitis B Drug: CYT1
4996 NCT04017Multi-Level Communic CompletedNo ResultsHPV-associated Cancer Behavioral
4997 NCT00120Follow-up Study of GSCompletedNo ResultsInfections, Papillomavirus Biological
4998 NCT04113Surveillan CYD00082 Not yet recNo ResultsDengue Fever
4999 NCT03111Multi-component Inter Recruiting No ResultsHuman Papillomavirus (HPV) Behavioral
5000 NCT01019Immunogenicity and SCompletedNo ResultsInfectious Disease by Haemophilus IBiological:
5001 NCT03722Immunogenicity TrialActive, notNo ResultsInfluenza Biological:
5002 NCT02564Effect of A MALRAB CompletedNo ResultsRabies Drug: Chlo
5003 NCT00925A Study of Transgeni Unknown sNo ResultsStage IIIB Skin Melanoma|Stage III Biological
5004 NCT03208A Study to Compare LCompletedNo ResultsDiphtheria|Tetanus|Pertussis|Poliom Biological
5005 NCT00003Vaccine Therapy in T CompletedNo ResultsLeukemia|Myelodysplastic SyndromBiological: ras pepti
5006 NCT01513A Phase Il ISS T-003 CompletedNo ResultsHIV Infections Biological:
5007 NCT00561Safety Study of Multi CompletedNo ResultsEsophageal Cancer Biological
5008 NCT00436Vaccine Therapy and CompletedNo ResultsMelanoma (Skin) Biological:
5009 NCT02571HSV529 Vaccine in HSCompletedNo ResultsHerpes Simplex Virus 2 Biological
5010 NCT00368Immunogenicity and Sa Terminate No ResultsPneumococcal Infections Biological
5011 NCT03310Immunogenicity and SCompletedNo ResultsHealthy Biological:
5013 NCT04222Safety and HSV15 Recruiting No ResultsGenital Herpes Biological
5014 NCT02814Study to E ALIZE CompletedHas ResultAsthma Drug: Benr
5015 NCT00910A Test of t Buzzy Unknown sNo ResultsPain Device: Bu
5016 NCT03167Effects of Lactobacil CompletedNo ResultsInfluenza Vaccination|Immune RespDietary Su
5017 NCT04072A Personalized NeoA Not yet recNo ResultsMelanoma (Skin) Drug: Pept
5018 NCT03866A Study to Evaluate t Recruiting No ResultsHepatitis B, Chronic Biological
5019 NCT04064Clinical Study to Eva CompletedNo ResultsTuberculosis|BCG Vaccination Device: BC
5020 NCT02972An HIV Vacc EHVAT01 Terminate No ResultsHIV-1-infection Biological
5021 NCT00317Immunogenicity & Safe CompletedNo ResultsDiphtheria|Hepatitis B|HaemophilusBiological
5022 NCT02775Safety and Immunogen CompletedNo ResultsPoliomyelitis Biological
5023 NCT00121AIDS Vaccine Study CCompletedNo ResultsHIV Infections Biological:
5024 NCT02526Cisplatin- VICORYX-2CompletedNo ResultsHPV-induced Cancers Biological
5025 NCT00489Persistence Study of CompletedHas ResultAcellular Pertussis|Tetanus|DiphtheProcedure:
5026 NCT01734DC Vaccination for P CompletedNo ResultsAcute Myeloid Leukemia Biological:
5027 NCT01502Safety Stu DENV-1 PI CompletedNo ResultsDengue Fever Biological:
5028 NCT00156MMR and Varicella VaCompletedNo ResultsChickenpox|Rubella|Rubeola|Mumps
5029 NCT03992A Phase 2 WRAIR Not yet recNo ResultsChikungunya Biological
5030 NCT03423Lot-to-lot Consistenc CompletedNo ResultsDengue Fever Biological:
5031 NCT01405Partnering With MediCompletedNo ResultsInfant and Young Child Feeding Behavioral
5032 NCT01989A Randomized Trial oTerminate No ResultsEarly Neonatal Mortality Biological:
5033 NCT03204Safety of VJECEVAX-2CompletedNo ResultsJapanese Encephalitis Biological:
5034 NCT02503Evaluation of the Saf CompletedHas ResultPrevention of Ebola Infection Biological:
5035 NCT01349A Study to Evaluate t CompletedHas ResultHepatitis A Biological:
5036 NCT03702ImmunisatiITCHHI CompletedNo ResultsNecator Americanus Infection Biological
5037 NCT03885Study to EvPNEU-PLA Active, notNo ResultsPneumococcal Infections Biological:
5038 NCT00001A Phase I, MulticenteCompletedNo ResultsHIV Infections Biological: gp160 Va
5039 NCT00019Vaccine Therapy Plus CompletedNo ResultsBreast Cancer|Ovarian Cancer Biological:
5040 NCT00953A Study of V260 in H CompletedHas ResultRotavirus Gastroenteritis Biological:
5041 NCT03050Standard of Care Alo Active, notNo ResultsColorectal Tumors|Colorectal Neop Drug: Avel
5042 NCT00131Bacillus Calmette-Gu CompletedNo ResultsMalaria Biological:
5043 NCT00425Assess Efficacy, ImmuCompletedNo ResultsInfections, Rotavirus Biological:
5044 NCT01003A Study of the ImmunWithdrawnNo ResultsRotavirus Gastroenteritis|Diphtheri Biological
5045 NCT01984Vaccination Status, K CompletedNo ResultsInflammatory Bowel Disease Other: Sur
5046 NCT03343Safety, ImmunogenicitActive, notNo ResultsVirus, Zika|Zika Virus Disease|FlavivDrug: Place
5047 NCT03110VRC 705: ADNA CompletedNo ResultsZika Virus|Zika Virus Infection|VirusBiologica
5048 NCT03334An Exploratory Study CompletedNo ResultsHealthy Biological
5049 NCT00653A Phase I Study to A CompletedNo ResultsTuberculosis Biological
5050 NCT03666PreventingPREST Active, notNo ResultsPreventing Stroke in Sickle Cell Ana Biological:
5051 NCT02955CIMAvax Vaccine, NivRecruiting No ResultsAdvanced Head and Neck SquamousOther: Ce Lab
5052 NCT00851A Study of a Bivalent CompletedNo ResultsInfluenza Biological
5053 NCT00003Vaccine Therapy Plus CompletedNo ResultsBreast Cancer Biological: GM2-KLH v
5054 NCT00050Effects of Therapeuti CompletedNo ResultsHIV Infections Biological: Therapeut
5055 NCT03332Phase 1b Study of a CUnknown sNo ResultsEpithelial Ovarian Cancer|Fallopian Biological
5056 NCT00764Influenza Vaccine in CompletedNo ResultsInfluenza|HIV Biological:
5057 NCT03956Flu and MoFor-ME Not yet recNo ResultsVaccination|Infection Other: Stan
5058 NCT00290Evaluate the Immunoge CompletedNo ResultsInfections, Papillomavirus Biological
5059 NCT00343Immuno & Safety Study CompletedHas ResultHepatitis B Biological:
5060 NCT02267Study of HSHIVERINGCompletedNo ResultsInfluenza|Gammopathy Drug: Fluz
5061 NCT01741Study to DeGARDASIL CompletedHas ResultSystemic Lupus Erythematosus Drug: Garda
5062 NCT01462Immunogenicity and SCompletedHas ResultInfections, Papillomavirus Biological:
5063 NCT01031Immunogenicity and SCompletedNo ResultsDiphtheria|Tetanus|Pertussis|Poliom Biological
5064 NCT00048Vaccine and Chemothe Terminate Has ResultBreast Neoplasms|Metastases, NeoBiological
5065 NCT00792Direct and Indirect B CompletedNo ResultsInfluenza Virus Infection Biological:
5066 NCT00344AMA1-C1/Alhydrogel CompletedNo ResultsPlasmodium Falciparum Malaria Biological
5068 NCT00168Vitamin A SupplementUnknown sNo ResultsMortality|Morbidity Drug: Vita
5069 NCT01946T Cell Transfer With Unknown sNo ResultsMelanoma Drug: Cyclo
5070 NCT00772Antibody Responses Fo Terminate Has ResultMeningitis|Meningococcemia Biological
5071 NCT00294Evaluation of the Saf Unknown sNo ResultsInfluenza Biological
5072 NCT00088Vaccine Therapy, TrasTerminate Has ResultBreast Cancer Biological:
5073 NCT03220Efficacy of DOLVAX Unknown sNo ResultsIntravenous Injections|Vaccination Device: Bu
5074 NCT02004Safety and ECLIPSE CompletedHas Result2nd-line, 3rd-line and Greater MetasBiological
5075 NCT02624H5N8 Mix and MatchCompletedNo
W ResultsAvian Influenza|Influenza Drug: AS03
5076 NCT00197Examine Safety and I CompletedHas ResultMalaria Biological
5077 NCT01109Mucosal R MICH CompletedNo ResultsKidney Transplantation|Immunity Biological:
5078 NCT00037Survival in a RandomiCompletedNo ResultsCarcinoma, Small Cell Lung Biological:
5079 NCT001339-valent CRM 197 Pn CompletedNo ResultsPneumococcal Infection Drug: Plac
5080 NCT01197Utilization of Human Unknown sNo ResultsHuman Papillomavirus (HPV) Other: Survey
5081 NCT02807Do NSAIDSNLP CompletedNo ResultsImmune System and Related DisordeDrug: Ibup
5082 NCT01174Pneumococc PREVIX_C CompletedNo ResultsOtitis Media Drug: Synf
5083 NCT01323A Trial to Assess the CompletedHas ResultMeningococcal Vaccine|rLP2086|Rep Biological:
5084 NCT00002A Phase I Trial of AP CompletedNo ResultsHIV Infections Biological: APL 400-0
5085 NCT00087Vaccine Therapy in T Terminate No ResultsRecurrent Melanoma|Stage IV Mel Biological
5086 NCT00197Post-marketing StudyCompletedNo ResultsInfluenza Biological:
5087 NCT01349Immunogenicity and SCompletedNo ResultsHepatitis B Biological:
5088 NCT00192Trial to Investigate CompletedNo ResultsInfluenza Biological:
5089 NCT03164Phase 1/2 Study of Recruiting No ResultsMetastatic Non-small Cell Lung Can Drug: Durv
5090 NCT01813Safety Study of Live CompletedHas ResultDiarrhea Biological
5091 NCT02006Pilot Study to Assess CompletedNo ResultsSystemic Lupus Erythematosus (SLE)
5092 NCT00005Vaccine Therapy and SCompletedNo ResultsLung Cancer Biological: ras pepti
5093 NCT02052This Study Aims to DeCompletedHas ResultHepatitis B Biological:
5094 NCT03275A Study to Evaluate t Active, notNo ResultsInfluenza, Human Biological
5095 NCT04044ReappraisaROMA Recruiting No ResultsSomatic Symptom Disorder Behavioral
5096 NCT00192Trial to Assess Safet CompletedNo ResultsInfluenza Biological:
5097 NCT00582Safety andVEE TC-83 Active, notNo ResultsVenezuelan Equine EncephalomyelitBiological:
5098 NCT03020B-cell Immunity to In CompletedHas ResultInfluenza Biological:
5099 NCT04180Human Papi HPV-CIR Not yet recNo ResultsSystemic Lupus Erythematosus|IdiopOther: sel
5100 NCT00929A Safety anTHYB-02 CompletedNo ResultsTuberculosis Biological
5101 NCT00858VRC 307: A Double-BliCompletedNo ResultsInfluenza, Human Drug: VRC-
5102 NCT00868Direct Tumor InjectioTerminate No ResultsMetastatic Pancreatic Cancer Biological:
5103 NCT01449Immunogenicity and Sa CompletedHas ResultAcellular Pertussis|Tetanus|Diphth Biological:
5104 NCT03095Pneumococcal Vaccina CompletedNo ResultsThalassemia|Pneumococcal InfectioDietary Su
5105 NCT03023Protective MechanismCompletedHas ResultInfluenza Biological:
5106 NCT00001Active Specific Immu CompletedNo ResultsB Cell Lymphoma|Follicular Lymp Drug: Id-KLH Vaccin
5107 NCT00420To Assess Safety, Rea CompletedHas ResultInfections, Rotavirus Biological:
5108 NCT00985Safety & Immunogenic CompletedHas ResultInfections, Streptococcal Biological
5109 NCT03819Study With Lu AF2051Terminate No ResultsAlzheimer Disease Drug: Lu A
5110 NCT02806Pneumococci and HibCompletedNo ResultsMeningitis Biological:
5111 NCT00070Vaccine Therapy in TrCompletedNo ResultsBladder Cancer Biological: BCG vacci
5112 NCT00006Vaccine Therapy Plus CompletedNo ResultsColorectal Cancer|Pancreatic CanceBiological: QS21|Biol
5113 NCT00030Vaccine Therapy in T CompletedNo ResultsLeukemia Biological: recombina
5114 NCT00258Immunogenicity Study CompletedNo ResultsOrthomyxoviridae Infections|Influe Biological:
5115 NCT00284A Study of Safety an CompletedNo ResultsProphylaxis Against Plasmodium Fal Biological
5116 NCT00118Vaccine Therapy WithCompletedNo ResultsMelanoma (Skin) Biological
5117 NCT00923Therapy to Treat Ew CompletedHas ResultNeuroblastoma|Sarcoma|Rhabdomyos Drug: Tumo
5118 NCT02224Cyclophosphamide, TA Terminate No ResultsProgressive Solid Malignancies|RefrBiological
5119 NCT01633Canadian Rotavirus S Recruiting No ResultsViral Gastroenteritis Due to Rotavirus
5120 NCT01738Immunogenicity and Sa CompletedHas ResultTetanus|Acellular Pertussis|DiphtheBiological:
5121 NCT03284Safety andHVTN107 CompletedNo ResultsHIV Infections Biological
5122 NCT01582TBE Seropersistence upCompletedNo ResultsTick-borne Encephalitis (TBE) Biological
5123 NCT00030Vaccine Therapy in TrCompletedNo ResultsProstate Cancer Biological: PSA prost
5124 NCT00093Vaccine Therapy in TreWithdrawnNo ResultsLiver Cancer Biological: alpha fet
5125 NCT00240Follow-up Study 16-2CompletedHas ResultHepatitis B Biological:
5126 NCT00611Study of a New FormuCompletedHas ResultPoliomyelitis|Acellular Pertussis|Te Biological:
5127 NCT00938Reactogenicity and SaCompletedHas ResultInfections, Rotavirus Biological:
5128 NCT03391Evaluation of the Eff CompletedNo ResultsHIV/AIDS Biological
5129 NCT00708Randomized Phase II C TompletedNo ResultsRabies Biological:
5130 NCT00001A Phase I, Multicent CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: gp160 Va
5131 NCT00020Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: NY-ESO-1
5132 NCT01115PostpartumPPFP-IZ CompletedNo ResultsContraception Behavioral
5133 NCT01307Long Term Follow-up CompletedNo ResultsHepatitis A Biological:
5134 NCT01777ComparativMMR CompletedNo ResultsMeasles|Mumps|Rubella Biological
5135 NCT02658A Multicenter, Double-Unknown sNo ResultsInfluenza Biological:
5136 NCT00326CVD 909 Vi Prime BooCompletedNo ResultsTyphoid Fever Biological:
5137 NCT00096Vaccine Therapy in TrCompletedNo ResultsKidney Cancer Biological
5138 NCT01592Impact on Quality of CompletedNo ResultsInfections, Rotavirus Other: Data
5139 NCT00454Study of Long-term An CompletedHas ResultHaemophilus Influenzae Type b|NeisBiological:
5140 NCT00833A Pilot Stu PARC002 CompletedHas ResultHIV-1 Infection|HIV Infections Biological:
5141 NCT01269Immunomodu OUSCOX2 CompletedNo ResultsHIV Drug: Etori
5142 NCT00612Anti-MART-1 F5 Cells Terminate Has ResultMetastatic Melanoma|Skin Cancer Biological
5143 NCT00142Hepatitis B Vaccine CompletedNo ResultsHIV Infection|Hepatitis B
5144 NCT02946The PertADO Geneva CompletedNo
T ResultsPertussis Biological
5145 NCT00442Response oCMVflu CompletedNo ResultsInfluenza Biological:
5146 NCT00145Immunization With 8 SuspendedNo ResultsMalignant Melanoma Biological
5147 NCT01599Phase 1 ID93 + GLA-SECompletedNo ResultsPulmonary Tuberculosis Biological:
5148 NCT00076Safety of the EnvPro CompletedNo ResultsHIV Infections Biological: EnvPro
5149 NCT02280Alternate ADS CompletedNo ResultsCervical Cancer|Genital Warts Biological:
5150 NCT00879Immunogenicity and R CompletedNo ResultsDiphtheria|Poliomyelitis|Hepatitis BBiological:
5151 NCT00313Immunogenicity and SCompletedNo ResultsMeasles|Mumps|Rubella|HepatitisBiological
5152 NCT00199Study of NY-ESO-1 IS CompletedNo ResultsMelanoma Biological
5153 NCT00313Safety of DTaP-IPV-H CompletedHas ResultDiphtheria|Tetanus|Pertussis|Haemo Biological
5154 NCT00019Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: aldesleuki
5155 NCT03260Pneumococcal Vaccine Recruiting No ResultsAsthma Biological
5156 NCT00027Vaccine Therapy and STerminate No ResultsSarcoma Biological: NY-ESO-1
5157 NCT01369Making Decisions Ab CompletedNo ResultsMeasles|Mumps|Rubella|MMR Vacc Other: Beh
5158 NCT00643Study of a Tetravalen CompletedHas ResultMeningitis|Meningococcal InfectionBiological
5160 NCT02485A Pilot Study to Asse CompletedNo ResultsProstate Cancer Other: Blo
5161 NCT01522Vaccine Therapy WithCompletedNo ResultsAnaplastic Astrocytoma|Anaplastic Biological
5162 NCT00038Vaccinia Virus VaccineCompletedNo ResultsSmallpox Biological: Wetvax (A
5163 NCT00000A Phase I, Multicent CompletedNo ResultsHIV Infections Biological: rgp120/HI
5164 NCT03956Safety and Tolerabili CompletedNo ResultsTyphoid Fever Biological
5165 NCT00352Immunogenicity, SafeCompletedNo ResultsMumps|Rubella|Measles|Varicella Biological
5166 NCT00006Vaccine Therapy in TrCompletedNo ResultsFallopian Tube Cancer|Ovarian CancBiological: MUC1-KLH
5167 NCT02100Antibody Persistence WithdrawnNo ResultsInfections, Papillomavirus Procedure:
5168 NCT02653Long-term Follow-up Active, notNo ResultsCervical Cancer|Vulvar Cancer|VagiBiological
5169 NCT02933Immune Durability AfActive, notNo ResultsImmune Response|Vaccination|Durability
5170 NCT00069Vaccine Therapy and CompletedNo ResultsBrain and Central Nervous System Biological: sargramos
5171 NCT03282Evaluate S JECEVAX-3CompletedNo ResultsJapanese Encephalitis Biological:
5172 NCT00353Immunogenicity, SafeCompletedNo ResultsVaricella|Rubella|Measles|Mumps Biological
5173 NCT02239TDENV PIV and LAV DCompletedNo ResultsDengue Biological
5174 NCT00617To Immunize PatientsCompletedHas ResultSmall Cell Lung Cancer Drug: Pacli
5175 NCT01529Reducing Children's DCompletedNo ResultsChildren's Distress During Flu Vaccination
5176 NCT03206Atezolizumab, Guadeci SuspendedNo ResultsPlatinum-Resistant Fallopian Tube Drug: Atez
5177 NCT00867Extended Follow-Up oActive, notNo ResultsCervical Cancer|Human Papillomavirus|Anal C
5178 NCT00757Assessment of ClinicaCompletedNo ResultsInfections, Rotavirus Biological:
5179 NCT00092Consistency Lots Vac CompletedHas ResultRotavirus Infections Biological:
5180 NCT00050APSV in Vaccinia NaivCompletedNo ResultsSmallpox Biological: Aventis P
5181 NCT00814Immunogenicity of AdCompletedNo ResultsInfluenza Biological:
5182 NCT02275Safety of UV1 Vaccin Active, notNo ResultsMalignant Melanoma Drug: Ipil
5183 NCT02499Follow-up of PregnanTerminate Has ResultMiscarriage|Stillbirth|Cholera Biological:
5184 NCT03020B-cell Immunity to In CompletedHas ResultInfluenza Biological:
5185 NCT00365Dose-Ranging Study oCompletedHas ResultPapillomavirus Infections|Genital D Biological
5186 NCT02289Safety Study of Vx006CompletedNo ResultsSolid Tumor Drug: Vx-0
5187 NCT02181A Phase Ia Clinical CompletedNo ResultsMalaria|Plasmodium Falciparum Biological
5188 NCT00334Vaccine Therapy in T CompletedNo ResultsIntraocular Melanoma|Melanoma (SBiological:
5189 NCT03953A Study of a PersonalRecruiting No ResultsNon Small Cell Lung Cancer|ColorecBiological
5190 NCT03618Evaluating HIV-1 NeutActive, notNo ResultsHIV Infections|Systemic Lupus Eryt Biological
5191 NCT01525A Clinical Study to CompletedNo ResultsMetastatic Renal Cell Carcinoma Biological:
5192 NCT02708Screening fSHOT CompletedHas ResultPreventive Health Services Behavioral
5193 NCT01684RBL001/RBL0 MERIT CompletedNo ResultsMelanoma Biological
5194 NCT03303A Study to Evaluate t Active, notNo ResultsRespiratory Syncytial Viruses|RespiraBiological
5195 NCT00189Dose-finding Study t CompletedNo ResultsSmallpox Biologica
5196 NCT02193Safety and Immunogen CompletedHas ResultDengue Fever Drug: TDV
5197 NCT00513Assess Reacto- and I CompletedHas ResultInfections, Streptococcal Biological:
5198 NCT00496Safety, Tolerability CompletedNo ResultsPneumococcal Infection Biological:
5199 NCT02766A Clinical Study CompCompletedNo ResultsImmune Response to Oral Polio VaccBiological:
5200 NCT00779Evaluation of ReactogCompletedHas ResultInfections, Rotavirus Biological:
5201 NCT00260Immunogenicity and SCompletedNo ResultsRabies Biological:
5203 NCT02692Natural Dendritic Cel CompletedNo ResultsProstatic Neoplasms|Immunotherapy Biological
5204 NCT00050Studies of Influenza CompletedNo ResultsHIV Infections Drug: Inter
5205 NCT00543Broad Spectrum HPV CompletedHas
( ResultCervical Cancer|Vulvar Cancer|VagiBiological
5206 NCT01803Post-marketing SafetyWithdrawnNo ResultsImmunisation Against Streptococcu Other: Synf
5207 NCT00007Monoclonal AntibodyUnknown
T sNo ResultsColorectal Cancer Biological: BCG vacci
5208 NCT02243GVAX Pancreas VaccinCompletedHas ResultPreviously Treated Metastatic Aden Biological
5209 NCT01668A Phase II Trial to CompletedNo ResultsSmallpox Biological
5210 NCT01593Volunteer Screening foRecruiting No ResultsNormal Physiology
5211 NCT00669Vaccine Therapy and Active, notNo ResultsPancreatic Acinar Cell Carcinoma|PaBiological:
5212 NCT03840Safety and Immunogen CompletedNo ResultsCytomegalovirus Infections Biological
5213 NCT04067Velocity 2: An AnthraxRecruiting No ResultsAnthrax Drug: Cipr
5214 NCT03472Special Access Pro CompletedNo ResultsVaccination Biologica
5215 NCT00374Experimental VaccineCompletedNo ResultsEbola Hemorrhagic Fever|Ebola Virus Drug: VRC
5216 NCT00990Interchangeability of CompletedNo ResultsInfant Immunizations Biological:
5217 NCT03807Group B StMVX0002 Active, notNo ResultsGroup B Strep Infection Biological
5218 NCT01298A Study to Assess th CompletedHas ResultPneumococcal Disease Procedure:
5219 NCT02833Sirolimus and VaccineWithdrawnNo ResultsRecurrent Fallopian Tube Carcinoma| Other: Lab
5220 NCT00406Study to Assess the SCompletedNo ResultsTetanus|Diphtheria|Acellular PertusBiological:
5221 NCT02117Safety and Immunogen CompletedHas ResultHealthy Biological:
5222 NCT02515Evaluating New Formu CompletedNo ResultsGenital Herpes Simplex Type 2 Biological
5223 NCT00316A Randomized, Double CompletedHas ResultSmallpox Biological
5224 NCT01461Promoting Human Papi CompletedNo ResultsHuman Papilloma Virus Behavioral
5225 NCT01935Efficacy Study of Vx0 CompletedNo ResultsNon-small Cell Lung Cancer MetastatDrug: Vx-0
5226 NCT00731Reacto & Immunogenic CompletedNo ResultsInfluenza Biological:
5227 NCT00005Vaccine Plus Interle CompletedNo ResultsRecurrent Melanoma|Stage IV Mel Biological
5228 NCT01915Study to Analyze the CompletedNo ResultsInfections, Rotavirus Other: Data
5229 NCT00089Vaccine Therapy WithCompletedNo ResultsMelanoma (Skin) Biological: incomplet
5230 NCT00002Tumor Cell Vaccine inCompletedNo ResultsUnspecified Adult Solid Tumor, ProtoBiological: filgrasti
5231 NCT00605Ebola and Marburg ViCompletedNo ResultsEbola Vaccines|Marburg Virus DiseaDrug: VRC
5232 NCT03659Post-Approval Safety Not yet recNo ResultsCervical Cancer Biological:
5233 NCT00161Dose-finding Study t CompletedNo ResultsTick-borne Encephalitis Biological: Tick-borne
5234 NCT01403Peptide-based GliomaTerminate No ResultsGlioblastoma Drug: Cycl
5235 NCT03381Peptide Vaccination Active, notNo ResultsFollicular Lymphoma Biological:
5236 NCT02238Safety and Tolerabili CompletedNo ResultsRabies Biological
5237 NCT01810NY-ESO-1 Vaccine in Terminate Has ResultUnresectable or Metastatic Melano Biological
5238 NCT02111Safety StudIPV005 CompletedNo ResultsPolio Biological:
5239 NCT00161Dose-finding Study t CompletedNo ResultsTick-borne Encephalitis Biological: Tick-borne
5240 NCT01273Evaluation of UniversUnknown sNo ResultsGastrointestinal Diseases
5241 NCT02618A "NegativeMS-tolDC Recruiting No ResultsMultiple Sclerosis Biological:
5242 NCT00289Long-Term Immune Per CompletedHas ResultHepatitis B|Hepatitis A Biological:
5243 NCT00731A Phase I Study of a CompletedNo ResultsTuberculosis Biological
5244 NCT00503A Phase IV Study to ECompletedNo ResultsVaccination Biological
5245 NCT01342Immunochemoradiother CompletedNo ResultsLocally Advanced Pancreatic Adeno Biological:
5246 NCT01953iC9-GD2-CAVEGAS Active, notNo ResultsOsteosarcoma|Neuroblastoma Genetic: G
5247 NCT00478Dendritic CDC-Ova CompletedNo ResultsOvarian Cancer|Fallopian Tube CancBiological
5248 NCT02942Safety and Immunogen Active, notNo ResultsMalaria Biological
5249 NCT02323Isolated AnANRSHBEPCompletedNo ResultsHIV Infection|Hepatitis B Other: blo
5250 NCT01094Study of a Novel TherCompletedNo ResultsHepatitis C Biological
5251 NCT01908To Develop, Implement Active, notNo ResultsPolio|Polio Sero Conversion|Polio Behavioral
5252 NCT00273Immunogeni PCV-7 CompletedNo ResultsPneumococcal Infections|Streptococcus Pneumo
5253 NCT02392Evaluating the Clini CompletedNo ResultsDengue Biological
5254 NCT01333Hepatitis B Antibody CompletedHas ResultHepatitis B Biological:
5255 NCT00479Pneumococcal RefereCompletedNo ResultsPneumococcal Infections Biological
5257 NCT02689Safety, Tolerability Terminate No ResultsHPV 16- and/or HPV 18-Infected WoDrug: GTL0
5258 NCT04121ChAdOx1 85 TB039 Recruiting No ResultsMycobacterium Tuberculosis, ProtecBiological
5259 NCT01266Vaccine Therapy in TrUnknown sNo ResultsCervical Adenocarcinoma|Cervical Biological
5260 NCT00879High Dose IMVAMUNEÂ® CompletedNo ResultsVariola Major (Smallpox) Biological
5261 NCT00528Safety and Effectiven CompletedNo ResultsHIV Infections Biological:
5263 NCT03729Prevention of DiarrheCompletedNo ResultsDiarrhea Biological:
5264 NCT00697Comparison of Immuno CompletedNo ResultsHepatitis B Biological
5265 NCT02159Pilot Study of Interf Terminate Has ResultCancer Drug: Inter
5266 NCT00125Study to Evaluate theCompletedNo ResultsHealthy|Influenza Biological:
5267 NCT01621Immunogenicity and SCompletedHas ResultMeasles-Mumps-Rubella Biological:
5268 NCT03698Safety andQHD04 CompletedNo ResultsInfluenza Biological
5269 NCT02229Vaccination of High REnrolling bNo ResultsBreast Neoplasms Biological
5270 NCT02997Safety andHVTN111 CompletedNo ResultsHIV Infections Biological
5271 NCT01984A Phase III Study of CompletedHas ResultHuman Papillomavirus Infection Biological:
5272 NCT03439DNA Plasmid-encoding Recruiting No ResultsHuman Papillomavirus-16 Positive|HBiological
5273 NCT00214Immunological Conseq CompletedNo ResultsObstructive Sleep Apnea Biological:
5274 NCT02567Vaccination Impact AgCompletedNo ResultsAcute Otitis Media|Pneumonia Other: Data
5275 NCT02596Phase 2 Clinical Tria Unknown sNo ResultsCervical Intraepithelial Neoplasia Biological:
5276 NCT00935Dendritic Cell Based WithdrawnNo ResultsBreast Cancer Biological:
5277 NCT03676Tolerability and ImmuActive, notNo ResultsBotulism Biological:
5278 NCT01651Assessment of the SerCompletedNo ResultsPresence of Materials From PCV-1 Procedure:
5279 NCT01870Randomized Clinical Unknown sNo ResultsPoliomyelitis Biological:
5280 NCT00409Cancer Vacc START CompletedHas ResultNon-small Cell Lung Cancer Biological
5281 NCT01467FeverText: Assessing CompletedHas ResultFever
5282 NCT01701Influenza A Vaccine ( CompletedNo ResultsInfluenza A Biological:
5283 NCT02453Immune-Related TraffRecruiting No ResultsVaccine Response Impaired Other: low
5284 NCT02027Vitamin A, Stool MicrCompletedNo ResultsVitamin A Deficiency
5285 NCT01151Safety andHIV-CORE CompletedNo ResultsHIV-1 Infections Biological
5286 NCT01927Evaluating the Safety WithdrawnNo ResultsHIV Infections Biological
5288 NCT00325Study To Evaluate theCompletedNo ResultsHealthy Drug: FluM
5289 NCT02900Influenza Vaccinatio CompletedNo ResultsPulmonary Disease, Chronic ObstrucOther: Infl
5290 NCT02153Study to Evaluate theCompletedNo ResultsHepatitis B Procedure:
5291 NCT00140Safety and Immunogen CompletedNo ResultsNeoplasms, Breast Biological:
5292 NCT00269TY800 Dose EscalatioCompletedNo ResultsTyphoid and Paratyphoid Fevers Biological
5293 NCT00973VRC 308: An Open-Lab CompletedNo ResultsInfluenza A Virus, H1N1 Subtype|NoBiological
5294 NCT01867Enzalutamide With orActive, notNo ResultsProstate Cancer Biological
5295 NCT00023Vaccine Therapy in TrCompletedNo ResultsLung Cancer Biological: autologou
5296 NCT01903A Study to Evaluate SCompletedNo ResultsAllogeneic Hematopoietic Cell TransBiological
5297 NCT00877A Double-Dose SafetyCompletedHas ResultHealthy Biological
5298 NCT00146Safety and Immunogen CompletedNo ResultsTuberculosis (TB) Biological
5299 NCT01598Safety Stu REALISTIC:Terminate No ResultsHPV-16 +ve Oropharyngeal Carcino Biological
5300 NCT00595Comparison of Three CompletedHas ResultJapanese Encephalitis Biological:
5301 NCT01117Human Papillomavirus CompletedNo ResultsHuman Papillomavirus
5302 NCT00121Malaria Candidate VaCompletedNo ResultsMalaria Biological:
5303 NCT00089A Cancer Vaccine (CGCompletedNo ResultsLung Cancer|Carcinoma, Non-Small-Biological: CG8123|
5304 NCT00289Long-Term Immune Per CompletedHas ResultHepatitis B|Hepatitis A Biological
5305 NCT01631Re-licensing Study t CompletedHas ResultInfluenza Biological:
5306 NCT01095Evaluating Heterolog CompletedNo ResultsHIV Infections Biological:
5307 NCT02013Safety and Immunogen CompletedHas ResultMalaria Biological
5308 NCT03023The Human Mucosal ICompletedHas ResultInfluenza Biological:
5309 NCT02680Assess the Safety & CompletedNo ResultsA/Vietnam/H5N1 Influenza Virus Biological
5310 NCT03929Neoantigen Vaccine PNot yet recNo ResultsMelanoma Drug: Nivo
5311 NCT01057Evaluation of VaccinaCompletedHas ResultImmunization Status|Well Child CareOther: Aut
5312 NCT03176Non-specifiNOVAC Active, notNo ResultsVaccine Reaction|Anemia|Malaria,FOther: Ven
5313 NCT00000A Phase I Safety and CompletedNo ResultsHIV Infections Biological: P3C541b
5314 NCT02252A Safety and Efficac CompletedNo ResultsPlasmodium Falciparum Malaria Biological
5315 NCT00229Racial Disparities in CompletedNo ResultsPneumococcal Disease Prevention Behavioral:
5316 NCT00387Study Evaluating Saf CompletedHas ResultHealthy Biological:
5317 NCT01368Effective Analgesia D CompletedNo ResultsPain
5318 NCT01130Novel InterIMIRC1003Terminate No ResultsHIV-1 Infection Biological
5319 NCT01659Study of MenactraÂ®CompletedHas ResultMeningitis|Meningococcal InfectionBiological
5320 NCT02370Study to Evaluate theCompletedNo ResultsEbola Biological
5322 NCT03375A Study of MG1111 inUnknown sNo ResultsHealthy Children Drug: Varic
5323 NCT03838Immunogenicity and SCompletedNo ResultsStreptococcal Pneumonia|HIV/AIDSBiological:
5324 NCT01527Safety, Tolerability, CompletedHas ResultHerpes Zoster|Shingles Biological:
5325 NCT01735Using PneuPREV-IX_B Active, notNo ResultsOtitis Media|Febrile Illness|Cough|LBiological:
5326 NCT02411Safety andGX-188E Unknown sNo ResultsCervical Intraepithelial Neoplasia 3 Biological:
5327 NCT00196Safety & Immunogenic CompletedHas ResultInfections, Meningococcal Biological
5328 NCT04130Study of Safety and Recruiting No ResultsMERS (Middle East Respiratory Sy Biological
5329 NCT00001A Phase I, MulticenteCompletedNo ResultsHIV Infections Biological: gp160 Vac
5330 NCT01966SGI-110 in CombinatiActive, notNo ResultsMetastatic Colorectal Cancer Drug: CY|B
5331 NCT03694Adolescent MenACWY Recruiting No ResultsMeningococcal Disease, Invasive Biologica
5332 NCT00586A Randomized Study tCompletedHas ResultInfluenza Vaccines Biological:
5333 NCT01265A Clinical ASET CompletedNo ResultsStage IV Renal Cell Cancer Biological
5334 NCT00287Induction and ExpansiCompletedNo ResultsHIV Infections Biological
5335 NCT00296Immunogenicity of Two CompletedNo ResultsOrthomyxoviridae Infection|InfluenBiological: Inactivated
5336 NCT02434A Pilot Study CompariRecruiting No ResultsHIV|Communicable Diseases|Hepatit Drug: Enge
5337 NCT00231Human Papilloma ViruCompletedHas ResultInfections, Papillomavirus Biological
5338 NCT00258Descriptive, Post-marCompletedHas ResultPertussis Biological:
5339 NCT01635Vaccine for Patients Unknown sNo ResultsAdult Diffuse Astrocytoma|Adult M Biological:
5340 NCT00161Immunogenicity and SCompletedNo ResultsEncephalitis, Tick-borne Biological: Tick-Borne
5341 NCT04144Recombinan FBP00001 Recruiting No ResultsInfluenza Biological:
5342 NCT03361A Pilot Study of a Pe Not yet recNo ResultsFollicular Lymphoma Drug: Ritu
5343 NCT00001A Phase I Study of th CompletedNo ResultsHIV Infections Biological: rgp120/HIV
5344 NCT00363Immune Response in CompletedNo
P ResultsBreast Cancer Biological
5345 NCT00076Safety of and ImmuneCompletedNo ResultsHIV Infections Biological: HIV CTL
5346 NCT00429Assess Efficacy, ImmuCompletedNo ResultsHepatitis B Biological:
5347 NCT00565Safety, Reactogenici CompletedNo ResultsVariola Major (Smallpox) Drug: Plac
5348 NCT02543A Study to Evaluate CompletedNo ResultsHealthy Biological
5349 NCT00560Revaccination With CompletedHas ResultPneumococcal Infection Biological
5350 NCT00363Interferon and GM-CSCompletedHas ResultLeukemia Biological:
5352 NCT00593Influenza Vaccine in CompletedNo ResultsInfluenza|Pregnancy
5353 NCT03153Comparison BetweenUnknown
T sNo ResultsGenital Wart Biological:
5354 NCT01897Efficacy anDC Unknown sNo ResultsPancreatic Cancer Procedure:
5355 NCT02523Placebo Controlled StUnknown sNo ResultsSafety Markers of Adjuvanted InflueBiological:
5356 NCT00019Vaccine Therapy Plus CompletedNo ResultsColorectal Cancer|Endometrial CancBiological: aldesleuk
5357 NCT01549Phase I/IIa Dose-escalCompletedNo ResultsHIV-1 Infection Biological:
5358 NCT02956A ComparisRabiesMabCompletedHas ResultHuman Rabies Biological
5359 NCT01198Immunogenicity and SCompletedHas ResultInfections, Rotavirus Biological:
5360 NCT01070A Study of a New Cand CompletedNo ResultsHepatitis C Biologica
5361 NCT02649Adjuvant DADDIT-GLI Recruiting No ResultsGlioblastoma Multiforme of Brain Biological
5362 NCT03127QUILT-3.040: ETBX-011 CompletedNo ResultsThyroid Cancer|Colon Cancer|OvariBiological:
5363 NCT03014H5N8 Mix and MatchCompletedNo ResultsAvian Influenza Drug: AS03
5364 NCT00610Anti-gp100 Cells Plu Terminate Has ResultMetastatic Melanoma|Skin Cancer Drug: cycl
5365 NCT01994ImmunizatiIMRAS CompletedNo ResultsMalaria Biological:
5366 NCT00004Vaccine Therapy Plus CompletedNo ResultsMelanoma (Skin) Biological: liposomal
5367 NCT00821Randomized, Double CBompletedNo ResultsTumors Drug: NY-E
5368 NCT00427A Phase I Study of t CompletedNo ResultsTuberculosis Biological
5369 NCT00382Dose-Escalating Trial CompletedNo ResultsInfluenza Biological
5370 NCT02647Safety andPAMVAC CompletedNo ResultsMalaria, Antepartum Biological
5371 NCT01069Safety Study of Pept CompletedNo ResultsNon-small Cell Lung Cancer Biological
5372 NCT00240Study to Evaluate theCompletedNo ResultsInfluenza Biological
5373 NCT00095Vaccine Therapy in TrTerminate No ResultsBreast Cancer|Unspecified Adult SolBiological
5374 NCT01031Trial to As DG002 CompletedNo ResultsPlasmodium Falciparum Malaria Biological
5375 NCT00381Vaccine Therapy, IncoCompletedNo ResultsNonneoplastic Condition Biological
5376 NCT01419A Study to Assess theCompletedNo ResultsInfluenza|Healthy Biological
5377 NCT01718Phase 1/2a Study of CompletedNo ResultsSmoldering Multiple Myeloma Biological:
5378 NCT00202Efficacy of Anti-TuberCompletedNo ResultsMultiple Sclerosis Biological:
5379 NCT01099A Study in Healthy AdCompletedNo ResultsImmunologic Tests Procedure:
5380 NCT01104A Clinical Study to As CompletedHas ResultHealthy Biological
5381 NCT03328Impact of HPVAC Recruiting No ResultsHPV Vaccination|Pap Smear|Cervical Cancer|C
5382 NCT00170Pneumococcal Vaccinat CompletedNo ResultsPneumococcal Infections Biological
5383 NCT01660Multi-peptide VaccineCompletedNo ResultsMetastatic Breast Cancer Biological:
5384 NCT00480A Study of MVA85A, iCompletedNo ResultsHIV Infections|TB Biological
5385 NCT01081Safety andFase1B CompletedNo ResultsMalaria, Vivax Drug: Pept
5386 NCT01867Testing Pfs25-EPA/AlhCompletedNo ResultsMalaria Biological:
5387 NCT04271Safety, ImmunogenicitNot yet recNo ResultsMalaria,Falciparum Biological
5388 NCT04199Use of Stress Inocula Not yet recNo ResultsStress Behavioral:
5389 NCT03563QUILT 3.071: NANT CoActive, notNo ResultsColorectal Cancer Metastatic|mCRCBiological
5390 NCT01788Combining Entertainme CompletedNo ResultsInfluenza Other: Vi
5391 NCT0219623-valent PolysaccharCompletedNo ResultsJuvenile Idiopathic Arthritis Biological:
5392 NCT00446Analgesic Properties CompletedNo ResultsProcedural Pain Other: Admi
5393 NCT00189Safety, Tolerability CompletedNo ResultsDermatitis, Atopic|Hay Fever Biologica
5394 NCT02605Hepatitis B in Cystic Enrolling bNo ResultsCystic Fibrosis|Hepatitis A|Hepatiti Biological:
5395 NCT00492Month 30 & 42 ExtensCompletedHas ResultHerpes Zoster Procedure:
5396 NCT00435Safety and Efficacy o CompletedHas ResultHepatitis B Biological:
5397 NCT02212The Effect of Prophyl CompletedNo ResultsFever Other: Ace
5398 NCT00297Study Evaluating the CompletedNo ResultsMeningitis, Meningococcal Biological
5399 NCT00945A Study to MI-CP215 CompletedHas ResultHealthy Biological
5400 NCT00587ICC-1132 - Candidate CompletedNo ResultsPlasmodium Falciparum Malaria Biological:
5401 NCT00100Safety of and ImmuneCompletedNo ResultsHIV Infections|Hepatitis B Drug: CpG7
5402 NCT00027Safety and Immune Re CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: ALVAC(2
5403 NCT03683EXTENSIONExt EBUG CompletedNo ResultsVaccination Failure Behavioral:
5404 NCT00104Vaccine Therapy and Terminate No ResultsLymphoma Biological
5405 NCT00099Phase I Study of a Va CompletedNo ResultsHealthy Procedure: Blood Tes
5406 NCT00491Safety and Immunogen CompletedNo ResultsInfluenza|Orthomyxoviridae InfectioBiological:
5407 NCT03341Trial to Evaluate the Recruiting No ResultsMalaria Biological
5408 NCT01677A Study of VaccinatioCompletedNo ResultsPancreatic Adenocarcinoma Non-resBiological:
5409 NCT00153Study to Eliminate HibCompletedNo ResultsHaemophilus Influenzae Type B|CarrBiological
5410 NCT01540Trial of a Falciparum CompletedNo ResultsMalaria Biological
5411 NCT00297Post-marketing SafetyCompletedNo ResultsDiphtheria|Tetanus|Acellular PertusBiological:
5412 NCT02775Gene-Modif NYM CompletedNo ResultsAdult Solid Neoplasm|Childhood SoBiological
5413 NCT00204Vaccination With TumCompletedNo ResultsMalignant Melanoma Biological
5414 NCT01188First Adult Safety Tri CompletedNo ResultsPertussis Biological:
5415 NCT00952Influenza Vaccine in Terminate No ResultsBrain and Central Nervous System Other: cyt
5416 NCT00122GVAX in Advanced PrUnknown sNo ResultsProstate Cancer Biological
5417 NCT00697Evaluation of Immunog CompletedNo ResultsHepatitis B Biological
5418 NCT01003A Safety a THYB-01 CompletedNo ResultsTuberculosis Biological
5419 NCT01037Novartis Pandemic InCompletedNo ResultsInfluenza Other: Non
5420 NCT01922Vaccine Therapy WithUnknown sNo ResultsHER2/Neu Positive|Recurrent BreastBiological
5421 NCT03568Personalized ImmunoRecruiting No ResultsAdvanced Cancer Drug: pers
5422 NCT00228TCV -01-002: T-Cell V Unknown sNo ResultsMultiple Sclerosis Biological:
5423 NCT01988Safety of a Booster D CompletedHas ResultDiphtheria|Tetanus|Acellular PertusBiological:
5424 NCT00045Vaccine Therapy WithCompletedNo ResultsProstate Cancer Biological: recombina
5425 NCT01814Vaccine Therapy WithActive, notHas ResultRecurrent Glioblastoma|Recurrent Biological
5426 NCT01895Safety and Efficacy C CompletedNo ResultsCholera Biological
5427 NCT00071Vaccine Therapy UsingCompletedHas ResultMelanoma (Skin) Biological
5428 NCT00019Vaccine Therapy WithCompletedNo ResultsMelanoma (Skin) Biological: aldesleuki
5429 NCT01512Clinical Tr Bilhvax1a CompletedNo ResultsSchistosomiasis|Bilharziasis|UrinaryBiological
5430 NCT00005Vaccine Therapy in TrUnknown sNo ResultsMelanoma (Skin) Biological
5431 NCT01985The Impact of a ShortUnknown sNo ResultsPrematurity|RSV|Influenza|Upper Res Behavioral:
5432 NCT00891Study to Evaluate Sa CompletedNo ResultsMeasles Biological: MVA-mBN8
5433 NCT00415Safety and Immunogeni CompletedNo ResultsInfluenza|Orthomyxoviridae Infecti Biological:
5434 NCT03281An Ancillary Study Pr Active, notNo ResultsMalaria
5435 NCT00051Screening HIV-InfecteCompletedNo ResultsHIV Infection
5436 NCT01146Vaccinatio CD lam Unknown sNo ResultsAcute Myelogenous Leukemia Other: cell
5437 NCT01182Duration of Long-ter CompletedNo ResultsHepatitis B
5438 NCT01312Autologous T-Cells C Unknown sNo ResultsOvarian Carcinoma|Fallopian Tube CBiological
5440 NCT00001Vaccination of Folli CompletedNo ResultsB Cell Lymphoma|Follicular Lymp Drug: Id-KLH Vaccine
5441 NCT00470Vaccine Therapy and G CompletedNo ResultsMelanoma (Skin) Biological
5442 NCT00946A Study to MI-CP217 CompletedHas ResultInfluenza Biological:
5443 NCT03033Integrating Primary &CompletedNo ResultsHPV-Related Carcinoma Behavioral:
5444 NCT02935A Safety, IPCAVD-01Active, notNo ResultsHealthy Biological
5445 NCT00003Vaccine Therapy in T CompletedNo ResultsBreast Cancer Biological: Detox-B
5446 NCT00406Long-term Follow-up CompletedNo ResultsRubella|Varicella|Mumps|Measles Biological:
5447 NCT00385Proteomic Profiling foCompletedNo ResultsInfluenza Biological: FluMist
5448 NCT01302Safety, Tolerability CompletedNo ResultsFlu Biological:
5449 NCT00089Candidate HIV VaccinCompletedNo ResultsHIV Infections Drug: VRC-HIVDNA01
5450 NCT01666A Two-doseDPIV-001 CompletedHas ResultDengue Fever Biological
5451 NCT00019Vaccine Therapy WithCompletedNo ResultsMelanoma (Skin) Biological: aldesleuki
5452 NCT01206IMPAACT P1 HPV CompletedNo ResultsPapilloma Virus, Human
5453 NCT00121Malaria Infection Dia CompletedNo ResultsMalaria Biological
5454 NCT03092IPV-102 Safety, Toler Terminate Has ResultPoliomyelitis Biological:
5455 NCT00654Study of the Safety a CompletedNo ResultsTB Biological:
5456 NCT00709Pandemic Influenza PCompletedNo ResultsInfluenza Biological:
Va ResultsAtopic Dermatitis
5458 NCT00290Study to Test the Eff CompletedHas ResultLung Cancer, Non-Small Cell Biological
5459 NCT00128Vaccine Therapy in T Unknown sNo ResultsMelanoma (Skin) Biological
5460 NCT01069Safety Study of Pepti CompletedNo ResultsSmall Cell Lung Cancer Biological
5461 NCT00189Effect of MNOES CompletedNo ResultsStreptococcus Pneumoniae Infectio Biological:
5462 NCT00524Trial to Describe the CompletedHas ResultInfluenza Biological:
5463 NCT01697Gene and Vaccine TheActive, notNo ResultsMalignant Neoplasm Biological
5464 NCT00019Vaccine Therapy WithCompletedNo ResultsColorectal Cancer Biological:
5465 NCT03098PREVAIL VI: Identific CompletedNo ResultsEbola Virus Disease
5466 NCT00029A Study to Prepare foCompletedNo ResultsHIV Infections
5467 NCT00031Screening Protocol foCompletedNo ResultsHIV Seronegativity|HIV Infections
5468 NCT02905A Safety and Efficac CompletedNo ResultsMalaria Biological
5469 NCT01420Bacille Calmette-GuÃCompletedNo ResultsAsthma|Eczema|Food Hypersensitivity
5470 NCT00798Adenovirus CCL-21 TrCompletedNo ResultsMelanoma (Skin) Biological:
5471 NCT01245Immunogenicity and Sa CompletedHas ResultAcellular Pertussis|Poliomyelitis|T Biological
5472 NCT00037Vaccine Therapy WithUnknown sNo ResultsMelanoma (Skin) Biological: MAGE-10.A
5473 NCT00098Study of the Feasibil CompletedNo ResultsNon-Small-Cell Lung Carcinoma|Lu Biological
5474 NCT02864Postmarketing SurveilActive, notNo ResultsMeningitis|Meningococcal MeningitBiological
5475 NCT02993MelanomaMIND-DC
P Active, notNo ResultsMelanoma (Skin) Biological:
5476 NCT00001Phase I Study of APL CompletedNo ResultsAcquired Immunodeficiency Syndrom Biological: APL 400-0
5477 NCT00197Long-Term Follow-UpCompletedHas
S ResultHepatitis B|Hepatitis A Biological:
5478 NCT00004Vaccine Therapy in TrCompletedNo ResultsProstate Cancer Biological: recombina
5479 NCT02147A Study to Assess Im CompletedHas ResultRheumatoid Arthritis Drug: Tofa
5480 NCT00594Immunogenicity and SCompletedNo ResultsStreptococcus Pneumoniae Biological
5481 NCT00329Year 3 Extension for CompletedHas ResultInfections, Rotavirus Biological:
5482 NCT00640Vaccine Therapy in TreCompletedNo ResultsBreast Cancer Biological
5483 NCT00598Antibody and Safety CompletedNo ResultsSmoking Biological
5484 NCT04270Cancer Peptides Plus Not yet recNo ResultsBreast Cancer Biological:
5485 NCT01922Investigat UKHVCSpoCompletedNo ResultsHIV Biological
5486 NCT01556ZOSTAVAXâ„¢ Safety aCompletedHas ResultHerpes Zoster|Shingles Biological:
5487 NCT01248Post Marketing SurveiCompletedNo ResultsInfections, Streptococcal Other: Synf
5488 NCT020396-year Antibody Check CompletedNo ResultsPost Other Specified Vaccination EncOther: Blo
5489 NCT03091S1602: Different Stra Recruiting No ResultsStage 0 Bladder Urothelial CarcinomBiological
5490 NCT03667Integrating Community CompletedNo ResultsRabies in Animals|Worms; IntestineOther: int
5491 NCT00666A Study to DetermineCompletedNo
t ResultsMalaria Biological
5492 NCT02170Vaccine Therapy BeforTerminate Has ResultRecurrent Renal Cell Carcinoma|Stage Other: Lab
5493 NCT02934Shigella WRSS1 VaccinCompletedNo ResultsDiarrhea Biological
5494 NCT00009HIV-1 Vaccine Test in CompletedNo ResultsHealthy|HIV Seronegativity Drug: VRC4302
5495 NCT01692A Study Evaluating 13CompletedNo ResultsPneumococcal Infection Biological
5496 NCT00003Vaccine Therapy Compa Terminate No ResultsMelanoma (Skin) Biological: BCG vacci
5497 NCT02263A Pilot Study to Asse CompletedHas ResultInfluenza Biological:
5498 NCT00993Assessing the Use of CompletedHas ResultRheumatoid Arthritis Other: Pla
5499 NCT00101Vaccine Therapy and IUnknown sNo ResultsNeuroblastoma|Sarcoma Biological: aldesleuk
5500 NCT02837Safety andHSV-2 CompletedNo ResultsHerpes Genitalis Biological
5501 NCT00054An Open Label Study CoompletedNo ResultsCarcinoma, Non-Small-Cell Lung|L Biological: EP2101
5502 NCT00277Salmonella Typhi Vi OCompletedNo ResultsTyphoid Fever Drug: BB IND 6989
5503 NCT00551A Study to Test the SaCompletedNo ResultsBacterial Infections; Virus Diseases Biological:
5504 NCT00889Higher Infused LymphCompletedNo ResultsLymphoma
5505 NCT00089Vaccine Therapy in TrCompletedNo ResultsIntraocular Melanoma|Melanoma (SBiological: incomplet
S ResultInflammatory Bowel Disease Drug: Vedol
5507 NCT00003Vaccine Therapy, InteCompletedNo ResultsBreast Cancer|Esophageal Cancer|Ga Biological: ALVAC-CEA
5508 NCT00004A Study to See WhethCompletedNo ResultsHIV Infections|HIV Seronegativity Biological: gp160 M
5509 NCT00948Vaccine Bi DCVaccineCompletedNo ResultsMetastatic Melanoma Biological:
5510 NCT00004Tumor Vaccine and IntCompletedNo ResultsRecurrent Ovarian Epithelial Cancer Biological
5511 NCT00019Vaccine Therapy and B CompletedNo ResultsBreast Cancer|Cervical Cancer|ColoBiological: aldesleuk
5512 NCT00678Histocompatibility LeTerminate No ResultsBreast Cancer Biological
5513 NCT01369Study of Single Dose CompletedNo ResultsInfluenza, Human Biological
S ResultShingles Drug: Zoste
5515 NCT00054Safety of and ImmuneCompletedNo ResultsHIV Infections Biological: EP HIV-10
5516 NCT01146Further Investigation CompletedNo ResultsInfluenza Biological
5517 NCT00021Vaccine Therapy in TrCompletedNo ResultsMelanoma (Skin)|Unspecified AdultBiological:
S aldesleuk
5518 NCT01245Combination Immunot CompletedNo ResultsMyeloma Biological
5519 NCT01974Phase I Safety Study CompletedNo ResultsHepatocellular Carcinoma Biological
5520 NCT03285A Study to Evaluate t Unknown sNo ResultsInfluenza Vaccine Biological:
5521 NCT00112Vaccine Therapy in PatCompletedHas ResultFallopian Tube Cancer|Ovarian CancBiological:
5523 NCT00603DCVax-L Vaccination WithdrawnNo ResultsOvarian Cancer|Primary Peritoneal Biological:
5524 NCT00694Pandemic Influenza PCompletedNo ResultsInfluenza Biological:
5525 NCT00001p53 Vaccine for Ovar Terminate No ResultsOvarian Neoplasm Biological:
5526 NCT04134A Phase 1 Open LabelRecruiting No ResultsSolid Metastatic Tumor Biological
5527 NCT00161Safety and Immunogen CompletedNo ResultsEncephalitis, Tick-borne Biological: Tick-Borne
5528 NCT00995Characterization of CompletedNo ResultsHealthy Volunteers
5529 NCT01728Impact of SC vs IM A CompletedHas ResultDengue Fever Biological:
5530 NCT00079Vaccine Plus Montanid CompletedNo ResultsBreast Cancer Biological: incomplet
5531 NCT00081Evaluation and TreatmCompletedNo ResultsVaccinia Drug: NP-016 Vaccine
5532 NCT01584Adjuvanted InfluenzaCompletedNo ResultsInfluenza
5533 NCT00803Vaccine Therapy in StaCompletedHas ResultFallopian Tube Cancer|Ovarian CancBiological
5534 NCT02874Vaccinatio VAX-PD CompletedNo ResultsParkinson's Disease Behavioral
5535 NCT00000Hepatitis B Vaccine CliCompletedNo ResultsHepatitis B|Hepatitis, Viral, Human|Biological: hepatitis
5536 NCT02844Evaluation of Vaccin CompletedNo ResultsPrevention of Meningococcus C InfeOther: Men
5537 NCT02293A Phase II Randomised Active, notNo ResultsProstate Cancer Biological
5538 NCT01915Trial of RNActiveÂ®-DTerminate No ResultsNon-Small Cell Lung Carcinoma Biological:
5539 NCT01579Study of t LucaVax Unknown sNo ResultsInoperable Stage III Non-small Cell Drug: GV10
5540 NCT02367A DatabaseH1N1-014 CompletedNo ResultsMultiple Sclerosis Other: Exp
5541 NCT00637Intratumoral Dendrit WithdrawnNo ResultsLymphoma Biological:
5542 NCT00004Vaccine Therapy in T CompletedNo ResultsUnspecified Adult Solid Tumor, ProtoBiological: MVA-MUC1
5543 NCT00000A Study of the Effect CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: ALVAC(2
5544 NCT01847PNEUMOCELL PNEUMOCE CompletedNo ResultsIgG Deficiency Biological:
5545 NCT00595Effect of a Booster D CompletedHas ResultJapanese Encephalitis Biological:
5546 NCT00390Single-Blind, Control CompletedNo ResultsHIV Infections Biologica
5547 NCT01069Safety Study of Pept CompletedNo ResultsNon-Small Cell Lung Cancer Biological
5548 NCT00912Pilot StudyMEL37 CompletedNo ResultsMelanoma Biological
5549 NCT02811ObservatioHPVfollowCompletedNo ResultsHuman Papillomavirus Virus Other: ven
5550 NCT02925A Study to Assess th CompletedHas ResultMalaria Biological
5551 NCT00490Study to C EV03/ANR CompletedNo ResultsHIV Infections Biological
5552 NCT00254Assessment of the ImCompletedNo ResultsDiphtheria|Tetanus|Polio|Pertussis Biological:
5553 NCT01574A Vaccine TVTNSCLC Terminate No ResultsNon-Small Cell Lung Cancer (NSCLC)Biological:
5554 NCT02600A Study to Assess th CompletedNo ResultsMalaria Biological
5555 NCT02712DAR-901 TB DAR-PIA Active, notNo ResultsTuberculosis Biological:
5556 NCT00509Safety andLSA-3-rec CompletedNo ResultsHealthy Biological:
5557 NCT00624Gemcitabine With Pept SuspendedNo ResultsBile Duct Cancer Biological
5558 NCT03921Safety andPNEU-WAYRecruiting No ResultsPneumococcal Infections Biological
5559 NCT00025Influenza Vaccine in CompletedNo ResultsHIV Infection
5560 NCT00003Vaccine Therapy in TreTerminate No ResultsOvarian Cancer Biological: BCG vacci
5561 NCT00648Phase I StuCDX1307-0CompletedNo ResultsBreast Cancer|Colorectal Cancer|PaBiological
5562 NCT00091Vaccine Therapy, CheCompletedNo ResultsLung Cancer Biological: recombin
5563 NCT00300Phase I Study of WestCompletedNo ResultsWest Nile Fever Drug: VRC-WNVDNA0
5564 NCT00003VaccinationSILVA CompletedNo ResultsLung Cancer Biological: BCG vacci
5565 NCT02572A Study to Assess th CompletedHas ResultMalaria Biological:
5566 NCT00919The DuratiKLL2 CompletedNo ResultsChronic Lymphocytic Leukemia (CLL)Biological
5567 NCT02912Post-marketing StudyRecruiting No ResultsRabies Drug: Kam
5568 NCT00425Gemcitabine and Capec CompletedNo ResultsPancreatic Cancer Biological
5569 NCT00027Vaccination Against HTerminate No ResultsBreast Neoplasms Biological: Heat Shoc
5570 NCT00021Vaccine Therapy in TrCompletedNo ResultsHead and Neck Cancer|Metastatic CBiological: recombin
5571 NCT03952Sanaria PfSPZ ChallenRecruiting No ResultsMalaria Drug: Chlo
5572 NCT00150Utilization of Oral S CompletedNo ResultsPain|Procedural Pain Behavioral
5573 NCT02153Serologic Response toCompletedNo ResultsInfections, Rotavirus Procedure:
5574 NCT03131Effectiveness of Alco Unknown sNo ResultsSkin Infection Drug: Alco
5575 NCT00128Trivalent, Live, Cold CompletedNo ResultsInfluenza Drug: Liqu
5576 NCT00001Active Immunization CompletedNo ResultsHIV Infections|Pregnancy Biological: rgp120/H
5577 NCT00345Study to Evaluate theCompletedNo ResultsHealthy Biological
5578 NCT02508Safety, Tolerability, CompletedNo ResultsTuberculosis Other: AP1
5579 NCT00385Immunogenicity, SafetCompletedHas ResultAcellular Pertussis|Diphtheria|Teta Biological:
5580 NCT01379Reducing IRID Terminate No ResultsPain Behavioral
5581 NCT00508A Phase 1/2A Study toTerminate Has ResultHealthy Biological
5582 NCT02496Phase I Safety and ImCompletedNo ResultsHepatitis B Biological
5583 NCT01590Assessment of HBV VaUnknown sNo ResultsHepatitis b Vaccine
5584 NCT00221Effectiveness of Infl CompletedNo ResultsInfluenza Biological:
5585 NCT00258Persistence of Antib CompletedHas ResultMeningitis|Meningococcal InfectionBiological:
5586 NCT00601Vaccine Therapy in TrCompletedNo ResultsLung Cancer Biological:
5587 NCT00168Long-term Follow-up CompletedNo ResultsMeasles Biological:
5588 NCT00004Vaccine Therapy in TrCompletedNo ResultsProstate Cancer Biological: PSA RNA-p
5589 NCT01577Immunogeni PCV13-BobCompletedNo ResultsPneumococcal Infections Biological:
5590 NCT00054An Open Label Study CoompletedNo ResultsColonic Neoplasms|Colorectal NeopBiological: EP2101
5591 NCT00289Long-term Immune Pers CompletedHas ResultHepatitis B|Hepatitis A Biological:
5592 NCT00595Intussusception SurveCompletedNo ResultsIntussusception (IS)|Rotavirus VacciOther: Hosp
5593 NCT00192Trial to Assess Safet CompletedNo ResultsInfluenza Biological:
5594 NCT02295Fever and Wheezing Ev CompletedNo ResultsFever|Wheezing Behavioral
5595 NCT00006A Study of the Safety CompletedNo ResultsHIV Infections Biological: ALVAC(2)
5596 NCT00192Trial of the Safety, T CompletedNo ResultsInfluenza Biological:
5597 NCT01755A Trial to Assess the CompletedNo ResultsInfluenza Biological:
5598 NCT02798Trial to Evaluate Saf CompletedNo ResultsCytomegalovirus Infection Biological
5599 NCT02316Dose-Confirmation, Im CompletedHas ResultClostridium Difficile Biological:
5600 NCT00548Tâˆ’Cell Turnover Fo CompletedNo ResultsTuberculosis Biological
5601 NCT02646Phase 2b Challenge SCompletedNo ResultsShigellosis Biological:
5602 NCT00291Long-Term Immune Pers CompletedHas ResultHepatitis A Biological:
5603 NCT00289Long-Term Immune Pers CompletedHas ResultHepatitis A Biological:
5604 NCT02953Testing if BCG (Bacil Unknown sNo ResultsInnate Immunity|Bacille Calmette- Biological:
5605 NCT01410A Feasibility and Saf CompletedNo ResultsMetastatic Pancreatic Cancer Drug: vacc.
5606 NCT04111Phase 2A Study of AdNot yet recNo ResultsPancreatic Ductal Adenocarcinoma Biological
5607 NCT02422Immunogenicity and Sa CompletedHas ResultAcellular Pertussis|Tetanus|PoliomyBiological:
5608 NCT00146Should Low Birth Weig CompletedNo ResultsTuberculosis Biological:
5609 NCT03927Immunother I-ATTAC Recruiting No ResultsGlioblastoma Biological
5610 NCT02141CommunityCAPolista CompletedNo ResultsPneumonia|Streptococcus Pneumo Biological:
5611 NCT03615Cytomegalo ATTAC-P Active, notNo ResultsGlioblastoma|Malignant Glioma|Medu Biological
5612 NCT02326PRIME: Pilot Study EvCompletedNo ResultsBladder Cancer Drug: Baci
5613 NCT00001Active Immunization CompletedNo ResultsGraf vs Host Disease|Multiple Mye Drug: Myeloma Immun
5614 NCT00001Active Immunization WithdrawnNo ResultsHIV Infections|Pregnancy|HIV SeronBiological: MF59|Biol
5615 NCT00001A Study of the Effec CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: ALVAC-H
5616 NCT00082Invaplex 50 Vaccine CompletedNo ResultsDiarrhea Biological:
5617 NCT01623A Phase I Study to D CompletedNo ResultsInfluenza Biologica
5618 NCT00712Single Der GIHU004 CompletedHas ResultHIV Infection Biological
5619 NCT00001A Phase I MulticenterCompletedNo ResultsHIV Infections Biological: rgp120/HI
5620 NCT01723A Study To Assess TheCompletedHas ResultAllergic Rhinitis Biological:
5621 NCT03803A Single Ascending DoRecruiting No ResultsHealthy Volunteers|Pneumococcal DBiological
5622 NCT00505Phase I Sa ISST-001 CompletedNo ResultsHIV Infections Biological:
5623 NCT00068HER-2 Protein Vaccin CompletedNo ResultsBreast Cancer Biological: HER-2/neu
5624 NCT00649Assessment of the Ef CompletedNo ResultsRheumatoid Arthritis Biological
5625 NCT00197The Immediate and LoCompletedNo ResultsHaemophilus Influenzae Type b Biological: Hib conjug
5626 NCT00877Hutterite Influenza P CompletedNo ResultsInfluenza Biological:
5627 NCT00240LT F-up Study 16-20 CompletedHas ResultHepatitis B Biological:
5628 NCT01095A Study of AdCh63 CompletedNo ResultsMalaria Biologica
5629 NCT00045HIV-1 Vaccine Test in WithdrawnNo ResultsHealthy Drug: VCR-HIVDNA00
5630 NCT00211StaphVAX Immunogenic CompletedNo ResultsStaphylococcal Infections|Joint ProsBiological:
5631 NCT00104Vaccine Therapy in TrUnknown sNo ResultsLung Cancer Biological:
5632 NCT01768Study To DB1971042 CompletedHas ResultMeningitis, Meningococcal, SerogroBiological:
5633 NCT00003Vaccine Therapy Plus CompletedHas ResultMelanoma (Skin) Biological:
5634 NCT00002Effectiveness of an H CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: MN rgp12
5635 NCT00586Primary & Booster StuCompletedHas ResultHaemophilus Influenzae Type b|NeisBiological:
5636 NCT00107Vaccine Therapy in TrCompletedNo ResultsBreast Cancer Biological: therapeut
5637 NCT01385Safety and Immunogen CompletedHas ResultHookworm Infection|Hookworm DisBiological
5638 NCT00082Combination Study WCompletedNo ResultsSmallpox Biological:
5639 NCT03897An Efficacy Study of Recruiting No ResultsMelanoma Biological
5640 NCT00027Study Using VaccinatiCompletedNo ResultsLeukemia,Myeloid, Chronic|Leukemia Biological: Heat Shoc
5641 NCT03239A Study to Evaluate I CompletedNo ResultsPoliomyelitis Biological:
5642 NCT03105FASTER-TlaFASTER Unknown sNo ResultsCervical Intraepithelial Neoplasia| Biological
5643 NCT03180Efficacy of FLU-v in CompletedHas ResultInfluenza Biological
5644 NCT02950Safety and Effectiven WithdrawnNo ResultsInfluenza, Human Biological:
5645 NCT01502Safety andRotavin-MCompletedNo ResultsDiarrhea|Fever|Nausea|Vomit|IrritaBiological:
5646 NCT04180Safety and Efficacy CompletedNo ResultsMelanoma|Kidney Cancer Biological:
5647 NCT00457Safety and Immunogeni CompletedNo ResultsPandemic Influenza|Influenza A ViruBiological:
5648 NCT04268A Trial For The Study Not yet recNo ResultsVaccine Reaction Drug: FMP
5649 NCT00001A Phase I Study of t CompletedNo ResultsHIV Infections Biological: rgp120/HI
5650 NCT04206GP96 Heat Shock Prote Not yet recNo ResultsLiver Cancer Biological:
5651 NCT00617Maternal Immunization CompletedNo ResultsOtitis Media Biological
5652 NCT04160Immunotherapy WithRecruiting No ResultsMerkel Cell Carcinoma|Cutaneous Biological:
5653 NCT00004Phase III Randomized,CompletedNo ResultsPertussis Biological: whole-cell
5654 NCT01861Phase 1/II C-015-404CompletedNo ResultsTuberculosis Biological
5655 NCT02570A Cohort Study to DetCompletedNo ResultsDengue Procedure:
5657 NCT01065Experimental Therapeu CompletedNo ResultsSolid Tumors Stage II, Stage III a Biological:
5658 NCT00684Evaluation of ImmuneCompletedHas ResultHepatitis A|Hepatitis B Biological:
5659 NCT00027Vaccine Therapy in TrCompletedNo ResultsBreast Cancer|Colorectal Cancer|GaBiological
5660 NCT00705Effect of Levamisole CompletedNo ResultsRenal Dialysis Drug: Leva
5662 NCT02206Assessing Human-to-Mo CompletedNo ResultsMalaria
5663 NCT01368Safety of Lactobacill CompletedNo ResultsHealthy|Elderly Biological
5664 NCT02496Dendritic DEND/TIA Recruiting No ResultsSarcoma|Central Nervous System T Biological
5665 NCT03147Immunogenicity and Sa CompletedNo ResultsPolio Biological:
5666 NCT01759A Trial to Assess the CompletedNo ResultsInfluenza Biological:
5667 NCT02100A Study of Live Oral CompletedNo ResultsCholera Biological
5668 NCT01989Sargramostim, VaccinCompletedHas ResultIris Melanoma|Medium/Large Size POther: Lab
5669 NCT00656Study of Colon GVAX CompletedNo ResultsColorectal Cancer|Metastatic CanceBiological
5670 NCT00445Autologous Dendritic CompletedNo ResultsType 1 Diabetes Biological:
5671 NCT01239Vaccine Therapy WithCompletedNo ResultsCutaneous B-cell Non-Hodgkin LympBiological
5672 NCT02434Cross Sectional StudyCompletedNo ResultsInflammatory Bowel Disease (IBD) Procedure:
5673 NCT02532MVA85A Aerosol vs Int Terminate No ResultsTuberculosis Biological
5674 NCT00411V501 ImmunogenicityCompletedHas ResultHPV Infections Biological
5675 NCT00142Mother's Gif Project CompletedNo ResultsPneumococcal Infections Biological
5676 NCT00000A Phase I/II Trial of CompletedNo ResultsHIV Infections Biological: rgp120/H
5677 NCT01259Safety Study of Multi CompletedNo ResultsMetastatic Breast Cancer Biologica
5678 NCT01863Safety Stu GeniusVacCompletedNo ResultsMelanoma|Tumor Vaccines|Effects Biological
5679 NCT03783Dose, Safety, Tolera Active, notNo ResultsHuman Immunodeficiency Virus PreBiological
5680 NCT02756A Safety a FLSC-001 CompletedNo ResultsHIV Infection Biological
5681 NCT01176Multiple Class I Pep Active, notNo ResultsMelanoma (Skin) Biological
5682 NCT02298A Study to Evaluate thCompletedHas ResultRespiratory Syncytial Virus (RSV) Biological
5683 NCT00337Concomitant Use of GCompletedHas ResultNeoplasms, Glandular and Epitheli Biological
5684 NCT01844UCLA-Amity Parolee CompletedNo ResultsHepatitis B|Hepatitis C|HIV|Drug AdBehavioral
5685 NCT03900Evaluating INSPIRE Recruiting No ResultsInvasive Pneumococcal Disease|Pneumonia
5686 NCT01765Phase 1b Study InvesCompletedHas ResultHealthy Volunteers Biological
5687 NCT02070Gene-Modified T CellsTerminate No ResultsUnspecified Adult Solid Tumor, ProtoDrug: cycl
5688 NCT00106Vaccine to Prevent WeCompletedNo ResultsHealthy|West Nile Fever|Healthy V Drug: VRC-WNVDNA0
5689 NCT01893Re-licensing Study t CompletedNo ResultsInfluenza Biological:
5690 NCT00004Phase III Randomized,CompletedNo ResultsPertussis Biological: diphtheria
5691 NCT00056Therapeutic HIV VaccCompletedNo ResultsHIV Infections Biological
5692 NCT00108Vaccine Treatment forCompletedNo ResultsHealthy Drug: VRC-HIVADV01
5693 NCT03463The Safety of Boostr Active, notNo ResultsWhooping Cough
5694 NCT00072Experimental Ebola VaCompletedNo ResultsHemorrhagic Fever, Ebola|Healthy Drug: VRC-EBODNA01
5695 NCT01696A Neoadjuvant Study CompletedHas ResultProstate Cancer Adenocarcinoma in Drug: dega
5696 NCT00623Phase I Safety Study CompletedNo ResultsHIV Infections Biological: MVA-mBN
5697 NCT00088PANVAC-V and PANVAC- CompletedHas ResultAdenocarcinoma|Colorectal Cancer|Biological
5698 NCT00019Vaccine Therapy in TrCompletedNo ResultsAnal Cancer|Cervical Cancer|EsophBiological: human pap
5699 NCT00681Histocompatibility LeCompletedNo ResultsEsophageal Cancer Biological
5700 NCT00128Denileukin Difitox F CompletedNo ResultsBreast Cancer|Colorectal Cancer|Lun Biological:
5701 NCT00681Histocompatibility LeCompletedNo ResultsGastric Cancer Biological
5702 NCT00681Histocompatibility LeCompletedNo ResultsEsophageal Cancer Biological
5703 NCT00677Histocompatibility LeTerminate No ResultsBreast Cancer Biological
5704 NCT00127A Study of V110 a Pn CompletedNo ResultsHealthy|Pneumococcal Infections Biological
5705 NCT02615A Clinical CTHBVACAUnknown sNo ResultsChronic Hepatitis B Biological
5706 NCT01206The Effect of Time-Sl CompletedNo ResultsSeasonal Influenza Behavioral
5707 NCT01082Melanoma Vaccine inUnknown sNo ResultsMelanoma (Skin) Biological
5708 NCT00108Tumor RNA TransfecteCompletedNo ResultsProstate Cancer Biological: Tumor RNA
5709 NCT02933Study of Oncoimmunom Recruiting No ResultsOvarian Cancer Biologica
5710 NCT00429Safety/Efficacy Trial CompletedNo ResultsHealthy Biological
5711 NCT00603Study to Show That thCompletedNo ResultsHepatitis B|Hepatitis A Biological:
5712 NCT00000A Phase I, Multicent CompletedNo ResultsHIV Infections Biological: rgp120/H
5713 NCT01967Safety and Immunogen CompletedHas ResultLatent Tuberculosis|Latent Tubercu Biological:
5714 NCT04167Impact of IMPACT Recruiting No ResultsHuman Papillomavirus Infection Other: biol
5715 NCT02451Prenatal InflammatioRecruiting No ResultsPregnancy Biological:
5716 NCT00001A Phase I Safety and CompletedNo ResultsHIV Infections Biological: ALVAC-HI
5717 NCT01012H1N1v Vaccination ofCompletedNo ResultsH1N1v Influenza Biological:
5718 NCT00000Safety and Effectiven CompletedNo ResultsHIV Infections Biological: ALVAC(2)
5719 NCT00499Stem Cell Transplant, CompletedNo ResultsMultiple Myeloma and Plasma Cell Biological
5720 NCT00327Primary & Booster StuCompletedNo ResultsNeisseria Meningitidis|HaemophilusBiological:
5721 NCT03926Safety and Immunogen CompletedNo ResultsTyphoid Fever Biological:
5722 NCT03049Dose, Safety, Tolerab CompletedNo ResultsRespiratory Syncytial Virus Drug: VRC
5723 NCT00197Immunogenicity of a CompletedNo ResultsStreptococcus Pneumoniae Biological: 9 valent
5724 NCT01165Lopinavir and Ritona WithdrawnNo ResultsHodgkin Lymphoma|Stage I Adult HDrug: lopi
5725 NCT01218NeisVac-C Single PrimCompletedNo ResultsNeisseria Meningitidis Biological
5726 NCT03877VELOCITY: An AnthraxActive, notNo ResultsAnthrax Biological:
5727 NCT02808Vaccineâ€Related Pa CompletedNo ResultsPain Other: Man
5728 NCT01579Evaluation of Buffer CompletedNo ResultsPolio Other: Buff
5729 NCT01617Ovarian CaCAN-003X CompletedHas ResultEpithelial Ovarian Cancer Biological:
5730 NCT00486Open-Label Safety StuCompletedNo ResultsVisceral Leishmaniasis|Post-kala-az Biological
5731 NCT01354A Pharmacovigilance CompletedNo ResultsAdverse Drug Reactions
5732 NCT01553SchistosomSchistoVA CompletedNo ResultsSchistosomiasis|Anemia|Underweight|Stunting|Intestinal
5733 NCT00027Vaccine Therapy and Unknown sNo ResultsColorectal Cancer Biological: ALVAC-CEA
5734 NCT00090Phase 1 meCS6 + LT(RWithdrawnNo ResultsDiarrhea Biological
5735 NCT03565Pneumococc VACIRiSS Recruiting No ResultsSepsis Biological
5736 NCT00176Tumor-Pulsed DendritTerminate No ResultsMetastatic Colorectal Cancer Drug: Inter
5737 NCT00109A Measles, Mumps, an CompletedNo ResultsMeasles Biological
5738 NCT01272Vaccination With PepCompletedNo ResultsRelapsed Multiple Myeloma Biological:
5739 NCT00319Post-licensure, Modi CompletedHas ResultPertussis|Tetanus|Diphtheria Biological
5740 NCT02081Repeat BCG Vaccinatio Recruiting No ResultsDiabetes Mellitus, Type One|DiabetBiological:
5742 NCT00710Safety, Tolerability a CompletedNo ResultsMild Essential Hypertension|ModeraBiological
5743 NCT00306A Study to Evaluate CompletedNo ResultsInfections, Papillomavirus Biological
5744 NCT00125Does Extra-High DoseCompletedNo ResultsPeritoneal Dialysis|Renal Disease, E Biological:
5745 NCT01292Edible Hepatitis B Va WithdrawnNo ResultsHealthy, no Evidence of Disease Biological
5746 NCT00170Trivalent rHA Dose EscCompletedNo ResultsInfluenza Biological: rHAO Triva
5747 NCT01086Immunogenicity and Sa CompletedHas ResultTetanus|Poliomyelitis|Acellular Per Biological:
5748 NCT03169QUILT-3.050: NANT CoWithdrawnNo ResultsColorectal Cancer Biological
5749 NCT01296Study of a New MVA Va CompletedNo ResultsHepatitis C Infection Biological
5750 NCT00932Seroimmuni Sero 2007 Unknown sNo ResultsDiphtheria|Tetanus|Pertussis|Polio|Haemophi
5751 NCT01194A BCG Challenge Mode CompletedNo ResultsTuberculosis Biological:
5752 NCT00937Human Papilloma ViruCompletedNo ResultsHuman Papillomavirus Other: Ther
5753 NCT00602Phase II Study of ImmCompletedNo ResultsChronic Hepatitis C Biological:
5754 NCT02948Cohort Event MonitorActive, notNo ResultsDengue Fever|Dengue Hemorrhagic Fever
5755 NCT00136Study of Vaccination CompletedNo ResultsAcute Myelogenous Leukemia|Myelo Biological:
5756 NCT00906RNActiveÂ®-Derived TTerminate Has ResultHormone Refractory Prostate CanceBiological
5757 NCT00633Study of TA-NIC to AsCompletedNo ResultsSmoking Biological:
5758 NCT00514Feasibility Study of Terminate No ResultsLeukemia Biological:
5759 NCT01189Observational Study CompletedNo ResultsAlzheimer's Disease Biological:
5760 NCT03463A First-In-Human StudRecruiting No ResultsHepatitis B, Chronic Biological
5761 NCT03889Effect of Age and Fit Recruiting No ResultsAging|Inflammation Biological:
5762 NCT00714PneuMum:PneuMumCompletedNo
P ResultsMiddle Ear Effusion|Tympanic Memb Biological
5763 NCT00581Primary CaPCAIR CompletedHas ResultAdolescent Immunizations|PreventiOther: out
5764 NCT03782Dendritic Cell (DC)/ Recruiting No ResultsMultiple Myeloma Drug: Nivo
5766 NCT00001A Phase I Safety and CompletedNo ResultsHIV Infections Biological: APL 400-
5767 NCT00002A Study of AIDSVAX BCompletedNo ResultsHIV Infections Biological: MN rgp12
5768 NCT00092A Study of An ApprovCompletedNo ResultsMeasles|Mumps|Rubella|Varicella Biological
5769 NCT02933Postmarketing SurveilCompletedNo ResultsJapanese Encephalitis
5770 NCT02452Peptide-specific Vacc Unknown sNo ResultsRecurrent Prostate Cancer Biological
5771 NCT00573Safety and CHASE Active, notNo ResultsArthritis Other: Blo
5772 NCT01093Safety/Tolerability, CompletedNo ResultsAlzheimer's Disease Biological
5773 NCT01294Immunogenicity and R CompletedNo ResultsAcellular Pertussis|Tetanus|DiphtheBiological:
5774 NCT01945Complement C2 Active, notNo ResultsComplement Mediated Bacterial Killing in Heal
5775 NCT00003Vaccine Therapy in TrCompletedNo ResultsCervical Cancer Biological: human pap
5776 NCT01417Safety and Efficacy CompletedHas ResultMetastatic Pancreatic Cancer Biological
5777 NCT00197Immunogenicity and R CompletedNo ResultsNeisseria Meningitidis Biological: Meningoc
5778 NCT01351Lenalidomide and VacActive, notNo ResultsAnn Arbor Stage I Small Lymphocyt Other: Lab
5779 NCT01304A Study of HPV-003 CompletedNo ResultsCervical Intraepithelial Neoplasia Biological
5780 NCT00341Assessment of BiologiTerminate No ResultsMalaria
5781 NCT00453Immunogenicity and SCompletedNo ResultsDiphtheria|Tetanus|Haemophilus InfBiological:
5782 NCT04116First-in-HuROSALIE Not yet recNo ResultsGlioblastoma, Adult Biological
5783 NCT02300Rollover Trial for Pl CompletedNo ResultsGenital Herpes Simplex Type 2 Biological
5784 NCT03048InflammatiK01 Recruiting No ResultsPosttraumatic Stress Disorder Biological:
5785 NCT00408Safety Study of AvianCompletedNo ResultsInfluenza A Virus, H5N1 Subtype|In Drug: VRC
5786 NCT01446Dendritic Cell Vaccin CompletedNo ResultsProstatic Neoplasms Biological:
5787 NCT01802Emla-Cream as Pain RRecruiting No ResultsChildren|Pain Drug: Eml
5788 NCT00001A Phase II Clinical T CompletedNo ResultsHIV Infections Biological: rgp120/H
5790 NCT01995Safety and Immunogen CompletedNo ResultsStreptococcus Pneumoniae Biological
5791 NCT00329Evaluate Immune Respo CompletedNo ResultsHepatitis B Biological: Hepatitis
5792 NCT00709Phase I Study of HIV CompletedNo ResultsHIV Infections Drug: VRC
5793 NCT00092Safety, Tolerability CompletedNo ResultsMeasles|Mumps|Rubella|Varicella Biological
5794 NCT01441Expression of Th9 CelUnknown sNo ResultsHepatitis B
5795 NCT03271Impact of Rotavirus VaCompletedNo ResultsGastroenteritis Other: No
5796 NCT01147Evaluation of Boostri CompletedHas ResultAcellular Pertussis|Tetanus|DiphtheBiological:
5797 NCT01455The Effect of ProximitCompletedNo ResultsInfluenza|Human Other: Fun
5798 NCT00544Immunogenicity, Antib Terminate No ResultsAcellular Pertussis|Tetanus|DiphtheBiological
5799 NCT00006Chemotherapy, Stem CompletedHas
C ResultMultiple Myeloma Drug: Myel
5800 NCT00228Safety Study of Trit CompletedHas ResultWhole Cell Pertussis|Tetanus|HepatBiological
5801 NCT00138Responses of PrematuTerminate No ResultsMeasles|Mumps|Rubella|Varicella
5802 NCT00335Pharma-Pen (Formerly WithdrawnNo ResultsInfluenza Device: Auto-injector
5803 NCT00102HIV-1 Vaccine BoosteCompletedNo ResultsHealthy|HIV Infections Biological: VRC-HIV
5804 NCT04106DURvalumab DURANCE Not yet recNo ResultsBladder Cancer Drug: Durv
5805 NCT00429Safety/Efficacy Trial CompletedNo ResultsHealthy Biological
5806 NCT03293Study of the Safety, CompletedNo ResultsFlu, Human Biological
5807 NCT02452Autologous OC-L VaccCompletedNo ResultsPrimary Ovarian Cancer|Fallopian T Biological:
5808 NCT02465Effectiveness of Tri Unknown sNo ResultsInfluenza Viral Infections
5809 NCT00294Long-term Impact of CompletedNo ResultsPneumococcal Infections
5810 NCT01682Study to Analyze the CompletedNo ResultsInfections, Rotavirus Other: Data
5811 NCT01159Antigenic CompetitionCompletedNo ResultsHIV Infections Biological:
5812 NCT02286Effects of Oxygen Tre CompletedNo ResultsMyocardial Infarction|InflammationBiological
5813 NCT00124Intranasal RecombinaWithdrawnNo ResultsDiarrhea Biological:
5814 NCT00488Study Evaluating Str CompletedNo ResultsPneumococcal Infections Biological: Pneumoco
5815 NCT00518Follow-up Study to EvCompletedHas ResultInfections, Papillomavirus Procedure:
5816 NCT00436Implementing Hospital CompletedNo ResultsIntussusception|LRTI-related Post NOther: Not
5817 NCT01825Comparison of the SafCompletedHas ResultInfluenza Biological:
5818 NCT02895Bedside Inoculation ofWithdrawnNo ResultsAscites|Peritonitis Other: Cul
5819 NCT00192Trial to Compare the SCompletedNo ResultsAsthma Biological:
5820 NCT00306Safety and Immunogen CompletedNo ResultsMalignant Melanoma Biological: CYT004-
5821 NCT00083Safety and Immunogen CompletedNo ResultsHealthy|HIV Infections Drug: VRC-HIVADV01
5822 NCT00965Efficacy of Dendritic Unknown sNo ResultsAcute Myeloid Leukemia|Chronic MBiological:
5823 NCT00217Trial To Assess Safety CompletedNo ResultsInfluenza Biological:
5824 NCT00701Study to Evaluate Saf CompletedNo ResultsHypertension Biological
5825 NCT03270Phase 1a/bIMX-02 CompletedNo ResultsHelicobacter Pylori Infected Subject Biological:
5826 NCT02006Screening for Silent ACompletedNo ResultsAtrial Fibrillation Device: `M
5827 NCT00242Randomized ControlleUnknown sNo ResultsTuberculosis Biological:
5828 NCT01278Trial of Vaccine Ther CompletedNo ResultsProstate Cancer Biological: Dendritic
5829 NCT00003Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: ALVAC-hB
5830 NCT00170Young Adult Influenz CompletedNo ResultsInfluenza Biological: FluzoneÂ®
5831 NCT01723Peptide Vaccinations Terminate No ResultsMetastatic Melanoma Biological:
5832 NCT00306Safety and Immunogen CompletedNo ResultsMelanoma Biological: CYT004-
5833 NCT00078Peptide Vaccine to P CompletedNo ResultsNasopharyngeal Neoplasms Drug: EBV-LMP-2
5834 NCT00576Tumor Lysate Pulsed CompletedNo ResultsGlioblastoma Biological
5835 NCT00597Determine Toxicity a CompletedHas ResultMelanoma Biological
5836 NCT00138Mercury Levels in Pr CompletedNo ResultsMercury Levels
5837 NCT02818Universal UCPVax Recruiting No ResultsMetastatic Non-small Cell Lung CancDrug: UCP
5838 NCT00118Vaccine Therapy WithCompletedNo ResultsMelanoma (Skin) Biological
5839 NCT04099Phase I Cli PICTHC Not yet recNo ResultsDiphtheria|Tetanus|Pertussis Biological
5840 NCT03480A Study to Evaluate CompletedNo ResultsPneumococcal Infections Biological
5841 NCT00189Study on Safety, Tole CompletedNo ResultsSmallpox Biological: MVA-BN
5842 NCT01011Staphylococcus Aureus CompletedHas ResultStaphylococcus Aureus Biological:
5843 NCT03169QUILT-3.044: NANT No WithdrawnNo ResultsNon-small Cell Lung Cancer Biological
5844 NCT00677Histocompatibility LeTerminate No ResultsColorectal Cancer|Colon Cancer|RecBiological
5846 NCT00681Histocompatibility LeCompletedNo ResultsGastric Cancer Biological
5847 NCT03387QUILT-3.070:PancreatActive, notNo ResultsPancreatic Cancer Drug: Aldo
5848 NCT00116Vaccination in the Pe CompletedNo ResultsMultiple Myeloma Biological
5849 NCT01867Efficacy and Safety o CompletedNo ResultsAnthrax Biological
5850 NCT00087RNA-Loaded DendriticCompletedNo ResultsRenal Cell Carcinoma Biological
5851 NCT00776Immunogenicity of a CompletedHas ResultJapanese Encephalitis Biological:
5852 NCT00092Study of an Investiga CompletedNo ResultsDiphtheria|Tetanus|Pertussis|Hepati Biological:
5853 NCT01920Phase I/II Trial of I CompletedNo ResultsCNS Tumor, Adult Biological
5854 NCT03713Impact of Metormin Recruiting No ResultsAging|Vaccine Response Impaired Drug: Met
5855 NCT03947A Study to DetermineNot yet recNo ResultsMalaria,Falciparum Biological
5856 NCT00269Persistence of Antib CompletedHas ResultMeningitis|Meningococcal InfectionBiological
5857 NCT02985Studies of the Safety CompletedNo ResultsPoliomyelitis Biological
5858 NCT00192Trial to Compare the SCompletedNo ResultsHealthy Biological:
5859 NCT00192Trial to Compare the SCompletedNo ResultsRespiratory Tract Infections Biological:
5860 NCT00203Study of CAP1-6D in CompletedHas ResultPancreatic Adenocarcinoma Biological
5861 NCT03723Rapid Injection TechnCompletedNo ResultsPain Other: Rap
5862 NCT03745Cohort Study of Heal Active, notNo ResultsMonkeypox Other: Blo
5863 NCT00398Vaccine Therapy in TreCompletedHas ResultIntraocular Melanoma|Melanoma (SBiological
5864 NCT03188Immunogenicity of a STerminate No ResultsDiphtheria-Tetanus-Acellular PertussOther: Blo
5865 NCT02094A Phase 3 Lot to Lot CompletedNo ResultsCholera Biological
5866 NCT03169QUILT-3.047: NANT HWithdrawnNo ResultsHead and Neck Squamous Cell Carc Biological
5867 NCT00674Histocompatibility LeUnknown sNo ResultsNon Small Cell Lung Cancer Biological
5868 NCT02115Safety and Protectiv CompletedNo ResultsMalaria|Plasmodium Falciparum MaBiological:
5869 NCT00673Histocompatibility LeUnknown sNo ResultsNon Small Cell Lung Cancer Biological
5870 NCT00086Vaccine Therapy in T Unknown sNo ResultsMelanoma (Skin) Biological
5871 NCT00449TG4040 in Patients WWithdrawnNo ResultsHepatitis C Drug: Plac
5872 NCT00426Safety of HEPLISAVâ„¢CompletedNo ResultsHepatitis B Biological
5873 NCT00639Vaccine ThATTAC Active, notNo ResultsMalignant Neoplasms of Brain Biological:
5874 NCT00111Evaluating the Effect CompletedNo ResultsRheumatoid Arthritis Drug: Anak
5875 NCT00299NY-ESO-1 Protein WitCompletedNo ResultsTumors Biological
5876 NCT03444the Combination of GRecruiting No ResultsCervical Cancer Drug: GX-1
5877 NCT02096Microbiolog MicrobioloCompletedNo ResultsOtitis Media in Children
5878 NCT03801Influence of Inflamm CompletedNo ResultsHealthy Infants Biological:
5879 NCT02301Phase IIB TL + YCWP Active, notNo ResultsMelanoma Drug: TLPL
5880 NCT03197QUILT-3.051: NANT Ov WithdrawnNo ResultsOvarian Cancer Biological
5881 NCT00350Investigation of V52 Terminate Has ResultHIV Infections Biological
5882 NCT00189Safety, Tolerability CompletedNo ResultsHIV Infections Biologica
5883 NCT02547Safety, Tolerability, CompletedHas ResultPneumococcal Infections Biological:
5884 NCT01063Rabies Immune PlasmCompletedNo ResultsRabies Biological:
5885 NCT01249Safety and Immunogeni CompletedNo ResultsDiphtheria|Tetanus|Pertussis|Poliom Biological:
5886 NCT00995Efficacy and Safety CompletedNo ResultsSmoking Behavior|Smoking Lapse BBiological:
5887 NCT00054Vaccine Therapy in PrCompletedNo ResultsCervical Cancer|Cervical Intraepith Biological
5888 NCT00008Evaluation of Two TypCompletedNo ResultsBacterial Infections|Group B Strept Biological: GBS III-TT
5890 NCT00006Effectiveness of AIDS CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: MN rgp12
5891 NCT01385Distributi HPV-canceUnknown sNo ResultsCervical Cancer
5892 NCT04128Study of Safety and Recruiting No ResultsMERS (Middle East Respiratory Sy Drug: BVR
5893 NCT01021Primary and SecondarUnknown sNo ResultsHPV Infections|Precancerous DiseasBiological:
5894 NCT00326Study in Toddlers to CompletedHas ResultHaemophilus Influenzae Type b|NeisBiological:
5895 NCT02582A Study to M3-ABMGCompletedHas ResultPoliomyelitis Biological
5896 NCT00237Safety of GlaxoSmithKCompletedNo ResultsHepatitis A Biological: Hepatitis
5897 NCT00962The Pandemic Stress V Terminate No ResultsPsychological Stress Behavioral
5898 NCT02213Impact of VaccinationTerminate No ResultsFood Hypersensitivity Procedure:
5899 NCT00137Early Versus Delayed CompletedNo ResultsPneumococcal Infections Biological
5900 NCT00005PSA-Based Vaccine and CompletedNo ResultsProstate Cancer|Prostate NeoplasmDrug: rV-PSA|Drug: r
5901 NCT00988Therapeutic VaccinatiCompletedHas ResultHPV16 Positive|Cervical IntraepithelBiological:
5902 NCT01137ZOSTAVAXÂ® in RenalCompletedNo ResultsHerpes Zoster Biological:
5903 NCT01256Health Management CompletedNo
Tr ResultsNo Conditions Behavioral
5904 NCT00001A Phase I, Multicent CompletedNo ResultsHIV Infections Biological: Aluminum
5905 NCT00321Phase I Study of VaccCompletedNo ResultsHIV Infections Drug: VRC-HIVDNA01
5906 NCT01086Epidemiologic Study CompletedNo ResultsPneumonia, Pneumococcal|VaccineProcedure:
5907 NCT00109"Prime-Boost" Vaccine CompletedNo ResultsHIV Infections Drug: VRC-HIVDNA01
5908 NCT00001A Phase I, Multicent CompletedNo ResultsHIV Infections Biological: Aluminum
5909 NCT01302AutologousTriMix-Ipi CompletedNo ResultsMalignant Melanoma Stage III|Mali Biological
5910 NCT00192Trial to Investigate V CompletedNo ResultsInfluenza Biological:
5911 NCT01341Safety, Tolerability, CompletedHas ResultBacterial Infections|Virus Diseases Biological
5912 NCT00703Safety and Immunogen Unknown sNo ResultsMalaria Biological
5913 NCT00092A Study of Gardasil ( CompletedHas ResultHuman|Papillomavirus Infections Biological
5914 NCT00028Novel Adjuvants for CompletedNo ResultsMelanoma Biological: MDX-CTL
5915 NCT00508Safety and Efficacy o CompletedNo ResultsHepatitis B Disease Biological
5916 NCT04179A Study to Qualify anCompletedNo ResultsHepatitis B Biological:
5917 NCT00005Vaccine Therapy in T Unknown sNo ResultsProstate Cancer Biological: PSA prosta
5918 NCT00331The Effect of Bacill Unknown sNo ResultsHIV Infections Biological
5919 NCT00112Safety Study to Eval CompletedHas ResultCancer Biological:
5920 NCT01538Phase II Study of Gra CompletedNo ResultsGrass Pollen Allergy Biological
5921 NCT00516ETEC LogistTrek CompletedNo ResultsDiarrhea Biological:
5922 NCT00336Safety and Immunogen CompletedNo ResultsSmallpox Biological:
5923 NCT00000A Multicenter, Random WithdrawnNo ResultsHIV Infections
5924 NCT00071Vaccine Therapy and CompletedNo ResultsLymphoma Biological
5925 NCT01422Immunization With PlCompletedNo ResultsMalaria|Plasmodium Falciparum Drug: Chlo
5926 NCT01944Phase I/II Study of V Terminate No ResultsMelanoma Biological:
5928 NCT00303Vaccine Therapy WithTerminate No ResultsRecurrent Melanoma|Stage IV Mel Drug: cycl
5929 NCT03136QUILT-3.039: NANT PaActive, notNo ResultsPancreatic Cancer Drug: Cycl
5930 NCT02715Influence of Dietary Recruiting No ResultsCardiovascular Diseases Biological
5931 NCT00839A Study of ProQuadâ„Terminate Has ResultMeasles|Mumps|Rubella|Varicella Biological
5932 NCT03400Comparing MorbidityRecruiting
a No ResultsHeterologous Immunity|Infant MorbiBiological
5933 NCT00366To Evaluate Immunoge CompletedNo ResultsHepatitis B Biological:
5934 NCT00192Trial to Investigate I CompletedNo ResultsInfluenza Biological:
5935 NCT00092Dose Confirmation EfCompletedHas ResultRotavirus Infections Biological:
5936 NCT00134Rituximab and CyclopCompletedHas ResultLymphoma Biological
5937 NCT00923Trial of an RNActiveÂCompletedNo ResultsNon Small Cell Lung Cancer Biological
5938 NCT00071Study to Evaluate theCompletedNo ResultsStaphylococcal Infections|Kidney FaiBiological:
5939 NCT02958Phase I StuSynGEM Unknown sNo ResultsRespiratory Syncytial Viral InfectionsBiological
5940 NCT00006Immune Responses inCompletedNo ResultsHIV Infections Biological: ALVAC(2)
5941 NCT03331A Study of PCV Active, notNo ResultsStreptococcal Pneumonia Other: Pro
5942 NCT00195Study Investigating A CompletedNo ResultsPneumococcal Infections Biological: Prevenar
5943 NCT01964Evaluating the Safety WithdrawnNo ResultsHIV Infections Biological
5944 NCT00632Combination of Chemo Unknown sNo ResultsEsophageal Cancer Biological:
5945 NCT03188Safety and Efficacy o CompletedNo ResultsImmunization Biological
5946 NCT03606Gambia PerGaPs Recruiting No ResultsPertussis Biological:
5947 NCT01128Postlicensure ObservaCompletedHas ResultPneumococcal Disease Other: No
5948 NCT01304A Follow-up Study to CompletedNo ResultsSmoking Cessation|Nicotine Depen Biological:
5949 NCT01193A Study To6114A1-40CompletedHas ResultPneumococcal Infections Biological:
5950 NCT00263Safety, Reactogenici CompletedNo ResultsHaemophilus Influenzae Type b|NeisBiological
5951 NCT03895A Study to Evaluate CompletedNo ResultsHealthy Volunteers Drug: Bim
5952 NCT01357Study to Assess if Q CompletedHas ResultDiphtheria|Pertussis|Tetanus|HepatBiological
5953 NCT03614Clinic Trial to Evalu CompletedNo ResultsPoliomyelitis Biological:
5954 NCT01952GVAX for Colorectal Recruiting No ResultsColorectal Cancer Biological
5955 NCT00011Vaccine (ALVAC-HIV vCompletedNo ResultsHIV Infections Biological: ALVAC(2
5956 NCT01379Study of TAK-816 in HCompletedNo ResultsImmunization Biological
5957 NCT02909Effect of Drinking F CompletedNo ResultsInfluenza Dietary Su
5958 NCT00953A Study of MVA85A inCompletedHas ResultTuberculosis Biological
5959 NCT01015Cancer Vacc INSPIRE Terminate Has ResultNon-Small Cell Lung Cancer Biological
5960 NCT04035A Phase 1 Safety StudRecruiting No ResultsPrevention of Dengue Fever Biological:
5961 NCT00003Vaccine Therapy in T CompletedNo ResultsBreast Cancer Biological: BCG vacci
5962 NCT00002Vaccine Therapy in T Unknown sNo ResultsMelanoma (Skin) Biological: sargramos
5963 NCT01568Post-marketing SurveiCompletedNo ResultsAcellular Pertussis|Diphtheria|Teta Other: Infa
5964 NCT00601Virological Response CompletedNo ResultsChronic Hepatitis C Biological:
5965 NCT00005Effectiveness of Givi CompletedNo ResultsHIV Infections Biological: ALVAC(2)
5967 NCT00843A Pilot Study Assessi Terminate Has ResultMetastatic Pancreatic Carcinoma Radiation:
5968 NCT00192Trial to Determine theCompletedNo ResultsInfluenza Biological
5969 NCT03161Providing Additional CompletedNo ResultsEbola Virus Disease Biological
5970 NCT03014Autologous Dendritic WithdrawnNo ResultsGiant Cell Glioblastoma|GliosarcomBiological
5971 NCT00524Assessment of the Rea CompletedNo ResultsPertussis|Diphtheria Biological:
5972 NCT03110TDENV PIV and LAV DWithdrawnNo ResultsDengue Biological
5973 NCT04105Breast Cancer NeoantiRecruiting No ResultsBreast Cancer|Triple Negative BreasBiological:
5974 NCT01456Immune Responses toActive, notNo ResultsMelanoma Biological:
5975 NCT01348Study With Dendritic Unknown sNo ResultsColorectal Carcinoma|Hepatic MetasDrug: Dendr
5976 NCT03699Freeze-Dried MVA-BNÂ Active, notNo ResultsSmallpox Biological
5977 NCT03329QUILT-3.060: NANT PaActive, notNo ResultsPancreatic Cancer Biological
5978 NCT01885AFF008E: ObservationCompletedNo ResultsParkinson's Disease
5979 NCT02188Safety and ReactogeniUnknown sNo ResultsFlu Biological:
5980 NCT03100Prevention of HumanRecruiting
P No ResultsPaediatric Kidney or Liver Transplantation|Chr
5981 NCT03197QUILT-3.048: NANT UrWithdrawnNo ResultsUrothelial Carcinoma Biological
5982 NCT00063Anthrax-rPA: Safety, CompletedNo ResultsAnthrax Biological: Recombin
5983 NCT03387QUILT-3.067: NANT TrActive, notNo ResultsTriple Negative Breast Cancer Drug: Aldo
5984 NCT01049Impact of Maraviroc Terminate No ResultsHIV Infections Drug: Mara
5985 NCT01207The Effect of a Plann CompletedNo ResultsSeasonal Influenza Behavioral
5986 NCT01505Safety and Immunogen CompletedHas ResultHerpes Zoster|Shingles Biological:
5987 NCT00465A Study of 2 Doses o CompletedNo ResultsTuberculosis Biological
5988 NCT00718Lentivirus RFUSIN2- Unknown sNo ResultsLeukemia, Myeloid, Acute Biological
5989 NCT03169QUILT-3.052: NANT NWithdrawnNo ResultsNon Hodgkin Lymphoma Biological
5990 NCT04112Measuring the HealthEnrolling bNo ResultsHealthy Controls Other: Blo
5991 NCT00316Immuno & Safety Stud Terminate No ResultsHaemophilus Influenzae Type b|Diph Biological:
5992 NCT04128Shingrix in Renal TranNot yet recNo ResultsKidney Transplant Recipient ResponsBiological:
5993 NCT00682Peptide Vaccination i Unknown sNo ResultsEsophageal Cancer Biological:
5994 NCT00995VRC 309: A Multi-CentCompletedNo ResultsInfluenza, Human Biological
5995 NCT03859Trial of Antibody Re Recruiting No ResultsHealthy Participants Biological
5996 NCT04176Entolimod on Immunos Recruiting No ResultsHealthy Drug: Ento
5997 NCT02296A Phase I RandomizedCompletedNo ResultsRespiratory Synctial Virus Biological:
5998 NCT01875Bacterial Pneumonia CompletedHas ResultCommunity Acquired Pneumonia Behavioral
5999 NCT00935Study of Peptide Vac CompletedNo ResultsTumors, Central Nervous System Biological
6000 NCT03497Seroprevale SPT-001 CompletedNo ResultsLeptospirosis
6001 NCT01544Efficacy of Pain Neur Unknown sNo ResultsPain, Chronic|Whiplash Injury Behavioral
6002 NCT00929Messenger Ribonucleic Terminate No ResultsUveal Melanoma Biological:
6003 NCT03938Investigation of Seri Recruiting No ResultsDrug-Related Side Effects and Adverse Reactio
6004 NCT02018Increased MBC WithdrawnNo ResultsMetastatic Breast Cancer Biological:
6005 NCT01486VXM01 Phase I Dose Es CompletedNo ResultsStage IV Pancreatic Cancer Biological
6006 NCT03435Safety and Immunogen CompletedNo ResultsMalaria,Falciparum Biological
6007 NCT01153Human Telomerase Rev WithdrawnNo ResultsMetastatic Prostate Cancer Biological
6008 NCT02886A Study of PVX-410, aRecruiting No ResultsSmoldering Multiple Myeloma Drug: Hilt
6009 NCT00019Vaccine Therapy in TrCompletedNo ResultsStage IV Melanoma|Stage III Mela Drug: dendritic cell
6010 NCT03563QUILT-3.072: NANT He WithdrawnNo ResultsHepatocellular Carcinoma Non-resecBiological
6011 NCT00020Vaccine Therapy Plus CompletedNo
I ResultsLymphoma Biological: aldesleuki
6012 NCT02455SurVaxM Vaccine TherActive, notNo ResultsGlioblastoma|Gliosarcoma Other: Lab
6013 NCT00562Immunogenicity and STerminate No ResultsHealthy Subjects Biological
6014 NCT03167QUILT-3.046: NANT MWithdrawnNo ResultsMelanoma Biological
6015 NCT01878Randomized m-SIMU CompletedNo ResultsDiphtheria|Tetanus|Pertussis|HepatOther: SMS
6016 NCT01690Natural Dendritic Cel CompletedNo ResultsMelanoma Biological
6017 NCT03549A Study AsLac-3 Recruiting No ResultsMeningitis, Meningococcal Biological:
6018 NCT03167QUILT-3.045: NANT Me WithdrawnNo ResultsMerkel Cell Carcinoma Biological
6019 NCT01897Phase I/II Study of V CompletedNo ResultsCancer of the Prostate Biological:
6020 NCT01923In-Situ Therapeutic C WithdrawnNo ResultsHepatocellular Carcinoma Biological:
6021 NCT03387QUILT-3.090: NANT SqActive, notNo ResultsSquamous Cell Carcinoma Drug: Aldo
6022 NCT00068VRC 300: Screening ofCompletedNo ResultsHealthy
6023 NCT00066Vaccine Therapy in TrCompletedNo ResultsFallopian Tube Cancer|Ovarian CancBiological: NY-ESO-1
6024 NCT03333A Double-blind RandoCompletedNo ResultsHealthy Volunteers Biological
6025 NCT00730AcceptanceHPV AccepCompletedNo ResultsHuman Papilloma Virus|HPV|Post Partum
6027 NCT03546PembrolizuMESOVAX Not yet recNo ResultsMesothelioma, Malignant|PD-L1 Neg Drug: Pemb
6028 NCT01986Safety, Tolerability, CompletedNo ResultsCytomegalovirus Infections Biological
6029 NCT00022Vaccine Therapy in TrCompletedNo ResultsLiver Cancer Biological:
6030 NCT00720Reduction of ImmunizCompletedNo ResultsPain Behavioral:
6031 NCT01157Study of VMP001 andCompletedHas ResultMalaria|Plasmodium Vivax Biological:
6032 NCT02760Lay HealthLHWAA CompletedNo ResultsLiver Neoplasms|Hepatitis B Behavioral:
6033 NCT01559Immune Response in Withdrawn
I No ResultsJapanese Encephalitis Biological:
6034 NCT02309Phase I-II Vaccinatio Terminate No ResultsHepatitis C, Chronic Biological
6035 NCT01086Crossover Vaccinatio CompletedNo ResultsCervical Neoplasia|HPV Infections
6036 NCT04246Phase 1/2 Trial of I Not yet recNo ResultsBreast Cancer|Gastric Cancer|Canc Biological
6037 NCT01133Effectiveness of Rota CompletedNo ResultsDiarrhea
6038 NCT00228Carcinoembryonic Anti CompletedNo ResultsColorectal Cancer|Liver Metastases Biological:
6039 NCT00677Histocompatibility LeTerminate No ResultsColorectal Cancer|Colon Cancer|RecBiologica
6040 NCT02097Study of ThE+VIP CompletedNo ResultsHepatitis B, Chronic Biological:
6041 NCT02518Ibrutinib as an Immu Active, notNo ResultsChronic Lymphocytic Leukemia|SmaBiological
6042 NCT02426Nivolumab and HPV-16 Active, notNo ResultsSolid Tumors Biological
6043 NCT03893Safety, Tol PNEU-PEDActive, notNo ResultsPneumococcal Infections|PneumocoBiological
6044 NCT03827Trial of PalloV-CC in Recruiting No ResultsColon Cancer Biological:
6045 NCT01346Study of DTap-IPV CoCompletedHas ResultTetanus|Diphtheria|Pertussis|MeaslBiological:
6046 NCT01234Asthma, Missed Immun Terminate No ResultsAtopic Dermatitis|Vitamin D Deficiency|Asthma
6047 NCT03586QUILT-3.080: NANT PaActive, notNo ResultsPancreatic Cancer Drug: Aldo
6048 NCT01998Safety and HNC CompletedNo ResultsCancer of Head and Neck|SquamousBiological:
6049 NCT00021Effects of Immunizati WithdrawnNo ResultsHIV Infections Biological: HIV-1 Im
6050 NCT02960Assessment of Immuno Terminate No ResultsCommon Variable Immune Deficiency Biological:
6051 NCT00245AutologousTERMS CompletedNo ResultsRelapsing-Remitting Multiple SclerosBiological:
6052 NCT01978Phase 1b Maintenance CompletedNo ResultsSolid Tumors Biological
6053 NCT00802Study of DAPTACELÂ®CompletedHas ResultDiphtheria|Tetanus|Pertussis|Polio Biological:
6054 NCT00090Study of MAGE-A3 anCompletedHas ResultMultiple Myeloma Biologica
6055 NCT01289Surveillance for Adv CompletedHas ResultNovel Influenza A/H1N1
6056 NCT00979Study of the Immunore CompletedNo ResultsRenal Cell Carcinoma|GIST Biological:
6057 NCT00575Safety Study of GBS CompletedNo ResultsGuillain-Barre Syndrome
6058 NCT01052Safety Study of a Li CompletedNo ResultsMelanoma Biological
6059 NCT00672Immunotherapy of Mel CompletedNo ResultsMetastatic Melanoma|Absence of CBiological
6060 NCT01094Study to Evaluate theCompletedHas ResultPoliomyelitis Biological:
6061 NCT00270Safety and Immune Re CompletedNo ResultsHIV Drug: VRC-HIVDNA01
6062 NCT00317A Study to Assess AntCompletedNo ResultsHaemophilus Influenzae Type b|TetaBiological
6063 NCT00791Anti-VEGFR Vaccine TCompletedNo ResultsNeovascular Maculopathy|Age RelaBiological
6064 NCT02465Vaccine ThATTAC-II Recruiting No ResultsGlioblastoma Multiforme|Glioblas Biological
6065 NCT04055A Trial to Evaluate t Recruiting No ResultsLassa Virus Infection Biological
6066 NCT00000A Study to Test If Gi CompletedNo ResultsHIV Infections Biological: Tetanus T
6067 NCT00686A Study to Evaluate t CompletedHas ResultHealthy Biological
6068 NCT02864Treatment of High-GraRecruiting No ResultsCervical Intraepithelial Neoplasia|CeDrug: 9-va
6069 NCT00212Combination VaccinatCompletedHas ResultHIV Infections Biological
6070 NCT03203A Safety and Efficac CompletedNo ResultsMalaria Biological
6071 NCT02544Markers of T Cell SupCompletedNo ResultsMalaria
6073 NCT02313A Safety and Immunog CompletedNo ResultsHealthy Biological
6074 NCT03673Phase 1a Study to Ev Recruiting No ResultsSolid Tumor, Adult Biological
6075 NCT03493Phase I/II Study of Recruiting No ResultsMetastatic Prostate Cancer|Prosta Biological
6076 NCT03998Efficacy, ImmunogeniActive, notNo ResultsPapillomavirus Infections Drug: V503
6077 NCT03688DC MigratiDERIVe SuspendedNo ResultsGlioblastoma Biological
6078 NCT00689The Effect of PharmacCompletedNo ResultsHerpes Zoster Other: Per
Va ResultsChickenpox|Herpes Zoster
6081 NCT02376A Study to Assess th CompletedNo ResultsHealthy Biological
6082 NCT01438Extension Study of H CompletedHas ResultTyphoid Fever Biological
6084 NCT00936Study of HBV-001 D1 CompletedNo ResultsDengue Fever Biological
6085 NCT03029Phase 2 Study of PemRecruiting No ResultsAdvanced Cancer|Ovarian Cancer|PrDrug: Pemb
6087 NCT02075Evaluation of Safety CompletedHas ResultTuberculosis Biological
6088 NCT01171Effectiveness of Flu Terminate No ResultsInfluenza Other: Rou
6089 NCT04040Using a Targeted Can Recruiting No ResultsMesothelioma|Pleural Mesothelio Biological
6090 NCT02366DC MigratiELEVATE Active, notNo ResultsGlioblastoma|Astrocytoma, Grade IVBiological
6091 NCT01926Phase II CaLymvac-1 CompletedNo ResultsFollicular Lymphoma Biological
6092 NCT03651The Study of the Saf CompletedNo ResultsInfluenza A Virus Infection|Influen Biological
6093 NCT00704Gene-Modified Lympho Terminate Has ResultKidney Cancer|Melanoma (Skin)|UnspBiological:
6094 NCT01236ExperimentEHMI9 CompletedNo ResultsPlasmodium Falciparum Malaria Drug: Chlo
6095 NCT00168Vitamin A With BCG VCompletedNo ResultsMortality|Morbidity Drug: Vita
6096 NCT04016Safety, To PNEU-PED-Recruiting No ResultsPneumococcal Infections Drug: V114
6097 NCT00861In-Situ Therapeutic CompletedNo ResultsMetastatic Cancer Biological
6098 NCT01850Safety Study of AADvaCompletedNo ResultsAlzheimer Disease Biological
6099 NCT03538UV1 Vaccine With Pem Recruiting No ResultsMalignant Melanoma Drug: UV1
6100 NCT02559Influenza Immunity inActive, notNo ResultsInfluenza Biological:
6101 NCT00775PENNVAX-B With or Wit CompletedNo ResultsHIV Infection Biological
6102 NCT00332Assess ImmunogenicitCompletedNo ResultsHepatitis B|Whole Cell Pertussis|T Biological
6103 NCT03845Mucosal and SystemicRecruiting No ResultsInfluenza Biological
6104 NCT03663OptimisingDNAVAC00CompletedNo ResultsHIV-1-infection Biological
6105 NCT00949Measuring ResponsesCompletedNo ResultsSexually Transmitted Diseases, Viral Biological
6106 NCT00740Malaria Vaccine for CCompletedNo ResultsMalaria|Malaria Infection Drug: AMA1
6107 NCT00986ProQuad Dose SelectCompletedHas ResultMeasles|Mumps|Rubella|Varicella Biological
6108 NCT00514Impact of the WHO RTerminate No ResultsMortality|Morbidity Biological:
6109 NCT01556Phase 1 Study of ONT-CompletedNo ResultsSolid Tumors Biological
6110 NCT01906MelbourneMIS BAIR Active, notNo ResultsAllergy|Eczema|Respiratory Tract InBiological:
6111 NCT00324Cyclophosphamide and CompletedNo ResultsMelanoma (Skin) Biological
6112 NCT00006Vaccine Therapy and G Unknown sNo ResultsMalignant Mesothelioma Biological: PA-1-STK
6113 NCT00054Vaccine Therapy and ICompletedNo ResultsMelanoma (Skin) Biological: aldesleuk
6114 NCT00289Effect of Risk Factor CompletedHas ResultHepatitis B|Hepatitis A Biological
6115 NCT03035Viaskin Pertussis VaccUnknown sNo ResultsWhooping Cough Biological:
6116 NCT00114Experimental VaccineCompletedNo ResultsMalaria Drug: AMA1/Alhydrog
6117 NCT00258Immune Responses toTerminate No ResultsMeasles|Mumps|Rubella|Varicella Biological: MMR-II|Bi
6118 NCT01008Antibody Production FUnknown sNo ResultsH1N1 Influenza
6119 NCT00003Vaccine Therapy Plus CompletedNo ResultsMelanoma (Skin) Biological: QS21|Biol
6120 NCT01517Sentinel SuSOS-VE01 CompletedNo ResultsInfluenza
6121 NCT02323A Study of DPX-SurvivUnknown sNo ResultsDiffuse Large B-Cell Lymphoma Biological
6122 NCT01302C11 AMT Positron EmiWithdrawnNo ResultsBreast Cancer Biological
6123 NCT00002Surgery and Vaccine TCompletedNo ResultsCervical Cancer Biological
6124 NCT03970Safety, ImmunogenicitRecruiting No ResultsNon Small Cell Lung Cancer Biological
6125 NCT00326Hepatitis A Vaccine, CompletedHas ResultHepatitis A|Measles|Mumps|RubelBiological
6126 NCT01303A Re-licensing Study CompletedHas ResultInfluenza Biological:
6128 NCT02968Pivotal Ph HVTN702 Active, notNo ResultsHIV Infections Biological
6130 NCT01957Phase II S RHEIA-VACCompletedNo ResultsGenital Infection Viral|HUMAN PA Biological:
6132 NCT00001Vaccination for MiddlCompletedNo ResultsOtitis Media Biological: Nontypea
6133 NCT00404Vaccine Therapy in T CompletedNo ResultsHead and Neck Cancer Biological:
6134 NCT02616A Phase 1 Study To E Recruiting No ResultsProstatic Neoplasms Biological
6135 NCT00005Vaccine Therapy in TrTerminate No ResultsIntraocular Melanoma|Melanoma (SBiological: MART-1 an
6136 NCT00004Vaccine Therapy WithUnknown sNo ResultsMelanoma (Skin) Biological: aldesleuk
6137 NCT00060Sequential VaccinatioCompletedHas ResultProstatic Neoplasms Drug: Rec
6138 NCT02573Safety, Tolerability CompletedHas ResultPneumococcal Infections Biological:
6139 NCT03110A Phase Ib Study of t CompletedNo ResultsSchistosomiasis Biological:
6140 NCT01081Phase I/II Study To T CompletedNo ResultsGlioma|High Grade Astrocytoma|GlBiological:
6141 NCT00072Neoadjuvant IntravesTerminate No ResultsBladder Adenocarcinoma|Bladder Squ Biological
6142 NCT00001Phase I Protocol for CompletedNo ResultsAcquired Immunodeficiency Syndrom Drug: PCLUS 3-18 MN
6143 NCT01006Comparison of DiffereCompletedNo ResultsPain|Anxiety Drug: Lipo
6144 NCT01477Study of a Dengue VacCompletedNo ResultsDengue Biological
6145 NCT02447Integrating Family P Unknown sNo ResultsContraception Behavioral
6146 NCT00386Safety and Immunogeni CompletedNo ResultsHIV Infections Biologica
6147 NCT02978Folate Receptor Alph Active, notNo ResultsPlatinum Sensitive Ovarian Cancer| Biological
6148 NCT00001Immunization of HLA CompletedNo ResultsMelanoma|Neoplasm Metastasis Biological: Immunodo
6149 NCT00696A Study to Test the CompletedHas ResultHerpes Zoster Biological
6150 NCT02114Effects of BCG on In CompletedNo ResultsInfluenza Virus Infection|Trained I Other: Pla
6151 NCT00553Pertussis Maternal I Unknown sNo ResultsPregnant Women Biological:
6152 NCT02375A LeukapheC-021-402CompletedNo ResultsTuberculosis Biological:
6153 NCT03784Nivolumab,da VINci Recruiting No ResultsGastric Cancer Drug: OTS
6154 NCT03049Trial23 - RandomizedActive, notNo ResultsCervical Intraepithelial Neoplasia (C Device: Co
6155 NCT00001Effect of Vaccination WithdrawnNo ResultsHIV Infections Biological: Influenza
6156 NCT00460Immunogenicity and SCompletedNo ResultsEncephalitis, Tick-Borne Biological:
6157 NCT03635Safety, Tolerability Active, notNo ResultsChikungunya Virus Infection Biological:
6158 NCT03576Study Confirming A HCompletedNo ResultsEnterotoxigenic Escherichia Coli Inf Biological
6159 NCT00006Safety and Effectiven CompletedNo ResultsHIV Infections Biological: ALVAC(2)
6160 NCT00291Immune Response & CSompletedHas ResultInfections, Meningococcal Biological
6161 NCT01106An Extension Study t CompletedNo ResultsTick Borne Encephalitis (TBE) Other: Ser
6162 NCT02648Study With CY, PembrRecruiting No ResultsPancreatic Cancer Drug: Cycl
6163 NCT00052Vaccine Therapy Plus CompletedNo ResultsBreast Cancer Biological: recombin
6164 NCT02334Study of the Safety CompletedNo ResultsMalaria Biological
6165 NCT00240Long Term Follow-Up CompletedHas
S ResultHepatitis B Procedure:
6166 NCT00616Interferon-gamma or CompletedNo ResultsMultiple Myeloma and Plasma Cell Biological
6167 NCT01058Phase I RindopepimutTerminate No ResultsBrain Cancer|Brain Stem Tumors|PoBiological
6168 NCT00033Vaccine Therapy in TrCompletedNo ResultsColorectal Cancer|Metastatic CanceBiological
6169 NCT01128Study Estimating the CompletedNo ResultsInvasive Pneumococcal Disease Other: No
6170 NCT00984Frozen ProQuad Admin CompletedHas ResultMeasles|Mumps|Rubella|Varicella Biological
6171 NCT01083EstablishmChallengeIICompletedNo ResultsMalaria, Vivax Biological
6172 NCT00003Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: gp100 ant
6173 NCT01437Regulatory Post-MarkCompletedHas ResultDiphtheria|Tetanus|Pertussis|Poliom Biological
6174 NCT01883CMV Glycoprotein B (CompletedNo ResultsViraemia
6175 NCT01113Dose-Escalation StudCompletedNo ResultsTuberculosis Biological:
6176 NCT01783Study of Vaccination Terminate No ResultsMelanoma Drug: Poly
6177 NCT00000A Phase I/II Double- CompletedNo ResultsHIV Infections Drug: Ritonavir|Biol
6178 NCT01229Effect of Zinc Supple CompletedNo ResultsPoliomyelitis Drug: Zinc
6179 NCT00006Vaccine Therapy FolloTerminate No ResultsMelanoma (Skin) Biological: MART-1 an
6180 NCT04056A Phase IV Study to ANot yet recNo ResultsHepatitis B|Diphtheria|HaemophilusBiological:
6181 NCT00081Vaccine Therapy and R CompletedNo ResultsLiver Neoplasms Drug: rV-CEA(6D)/TR
6182 NCT00000Safety and Effectiven WithdrawnNo ResultsHIV Infections|HIV Seronegativity Biological: Aluminum
6183 NCT00343Study to Compare PedCompletedNo ResultsDiphtheria|Tetanus|Pertussis|Polio Biological
6184 NCT00956Reactogenic HPV CSP01CompletedNo ResultsHPV Infections Biological:
6185 NCT01323Immunogenicity and Sa CompletedHas ResultPoliomyelitis Biological:
6186 NCT04193V114 and Acute Otit Not yet recNo ResultsAcute Otitis Media (AOM) Biological:
6187 NCT01478Safety and PharmacoCompletedNo ResultsSmoking Cessation Biological:
6188 NCT00626Chemothera ZAP IT CompletedNo ResultsMalignant Neoplasms of Brain Biological
6189 NCT01055Efficacy o HCVac CompletedNo ResultsChronic Hepatitis C Infection Drug: pegyl
6190 NCT00031Vaccine Therapy and CompletedNo ResultsIntraocular Melanoma|Melanoma (SBiological: MART-1 an
6191 NCT01339Vaccine Therapy Foll CompletedNo ResultsRecurrent Melanoma|Stage IV Mel Drug: cycl
6192 NCT02380Heterologous Effects CompletedNo ResultsTuberculosis Drug: BCG
6193 NCT00003Vaccine Therapy WithCompletedNo ResultsIntraocular Melanoma|Melanoma (SBiological: gp100 ant
6194 NCT00179Docetaxel Alone or inCompletedHas ResultBreast Cancer Drug: Doce
6195 NCT01816Phase Ia Study of C CompletedNo ResultsMalaria|Plasmodium Vivax Biological
6196 NCT01879Phase I Trial Evalua CompletedNo ResultsTuberculosis (TB) Biological
6197 NCT03148Safety and Pharmacod CompletedNo ResultsSmoking Cessation Biological:
6198 NCT00295LMB-2 Immunotoxin an CompletedNo ResultsMelanoma (Skin)|Non-melanomatou Biological
6199 NCT03493A Sourcing Study to Recruiting No ResultsMeningitis, Meningococcal Biological
6200 NCT01048Health SMART (StressCompletedNo ResultsBreast Cancer Behavioral
6201 NCT00912Booster Trial to 07- CompletedNo ResultsInfluenza Biological
6202 NCT00450Immunogenicity AfeCompletedNo ResultsVaccination
6203 NCT00006Vaccine Therapy WithCompletedNo ResultsMelanoma (Skin) Biological: MART-1 an
6204 NCT00890A Study of AdCh63 MCompletedNo ResultsMalaria Biological
6205 NCT02821Hespecta VaccinationUnknown sNo ResultsTumors or Premalignant Lesions Biological:
6206 NCT00479A Phase 2 Study of ImCompletedNo ResultsInfluenza Biological:
6207 NCT00203Effect of Public Sect Unknown sNo ResultsTuberculosis Behavioral
6208 NCT00340Improving the Effica CompletedNo ResultsHealthy Volunteer|HV Drug: AMA1-C1/Alhyd
6209 NCT00001A Phase I Study of g CompletedNo ResultsMelanoma Biological: gp100 h
6210 NCT00735V710 Clinical Study CompletedHas ResultStaphylococcal Infection Biological:
6211 NCT00295PpPfs25/ISA51 and ScCompletedNo ResultsPlasmodium Falciparum|Plasmodium Drug: PpPfs25/ISA51
6212 NCT01218ImmunizatiZonMw1 CompletedNo ResultsPlasmodium Falciparum Malaria Drug: Chlo
6213 NCT03449PreventionPAEAN Not yet recNo ResultsChronic Obstructive Pulmonary Dis Dietary Su
6214 NCT00273Evaluation of the Im CompletedHas ResultHigh-Risk Melanoma Drug: gp10
6215 NCT01015Open-label Safety andCompletedHas ResultVaccine Biological
6216 NCT00375Sporozoite Challenge CompletedNo ResultsMalaria, Falciparum|Malaria Biological:
6217 NCT01296An Open-label Study CompletedNo ResultsClostridium Difficile Infection Biological:
6218 NCT01323Immunogenicity and Sa CompletedHas ResultAcellular Pertussis|Poliomyelitis|D Biological:
6219 NCT00108A Phase II Study of CompletedHas ResultRecurrent Prostate Carcinoma|StageDrug: Bica
6220 NCT02335A Phase 1 FLU003 CompletedNo ResultsInfluenza Biological
6221 NCT03000Novel Isotope DilutioCompletedNo ResultsHealthy Infants|Infants With an Inf Biological:
6222 NCT00244Randomized Study ofCompletedNo
N ResultsMortality|Hospitalization|Adverse EBiologica
6223 NCT00126Revaccination of YounTerminate No ResultsMalaria Biological:
6224 NCT02046Clinic-bas StepUp CompletedHas ResultCervical Cancer Behavioral
6225 NCT00923Radiation, ChemotherCompletedHas ResultMelanoma|Skin Cancer Drug: MART
6226 NCT01890Assessing Contacts' CompletedNo ResultsPertussis Other: Web
6227 NCT02915Eschar InveEXIST Recruiting No ResultsScrub Typhus Other: Non
6228 NCT02008Follow-up Study to AsTerminate No ResultsAlzheimerÂ´s Disease Biological
6229 NCT00085Gene-Modified WhiteCompletedNo ResultsMelanoma (Skin) Biological: aldesleuk
6230 NCT00651Safety and ImmunogeCompletedNo ResultsMalignant Melanoma Biological: CYT004-M
6231 NCT00736Study to Evaluate theCompletedNo ResultsSmokers Biological:
6232 NCT00133ACAM 3000 MVA at Ha CompletedHas ResultSmallpox Biological:
6234 NCT00817Vitamin A and MaternCompletedNo ResultsInfluenza Dietary Su
6235 NCT01624A Study to GC1109 SuspendedNo ResultsAnthrax Biological:
6236 NCT03222Effectiveness of Dist CompletedNo ResultsPain Other: Dis
6237 NCT00072Immunization With gpCompletedNo ResultsMelanoma (Skin) Biological: aldesleuk
6238 NCT01830Explore AcAEFI Unknown sNo ResultsAdverse Reaction to Drug Other: sen
6239 NCT00282A Study to SIERRA CompletedHas ResultRheumatoid Arthritis Drug: Ritu
6240 NCT02003PrevalenceImpress Unknown sNo ResultsHuman Papillomavirus
6241 NCT02775Comparison VARI-IMM Recruiting No ResultsPregnancy Biological:
6242 NCT03239Evaluation of ImmunoCompletedHas ResultVaricella Biological
6243 NCT03460Targeting Cognitive I CompletedNo ResultsMajor Depressive Disorder Behavioral
6244 NCT02180A Lot-to-Lot ConsistenWithdrawnNo ResultsHerpes Zoster Biological:
6245 NCT0203118-monthsFUNDAMACompletedNo ResultsAlzheimer's Disease Drug: AAD
6246 NCT00546ZOSTAVAXâ„¢ in PatieCompletedHas ResultHerpes Zoster Biological:
6247 NCT00890Vaccine Therapy in TrCompletedNo ResultsRecurrent Central Nervous System Biological
6248 NCT00855Surveillance Program Active, notNo ResultsHaemophilus Infections|Diphtheria|Biological:
6249 NCT03871Peptide-baPICOP-GLORecruiting No ResultsColon Neoplasm|Colon Adenocarcino Diagnostic
6250 NCT02487DC Vaccine Therapy Co Not yet recNo ResultsRenal Neoplasma Biological:
6251 NCT00052Investigational Vacci CompletedNo ResultsTuberculosis|HIV Infections Biological:
6252 NCT00001Safety and Immunogen CompletedNo ResultsCutaneous Leishmaniasis Biological: Combinati
6253 NCT01652Effect of a PROBIMMCompletedNo ResultsEnhancement of Protective AntibodyDietary Su
6254 NCT00489Phase I Open-Label S CompletedNo ResultsInfluenza A Virus, H5N1 Subtype|In Drug: VRC
6255 NCT00847Augmentation of Dendr CompletedNo ResultsMelanoma Drug: Dacli
6256 NCT03443Cytomegalo CMV Not yet recNo ResultsCmv Congenital|CMV Viremia Diagnostic
6257 NCT00088Vaccine Therapy and STerminate No ResultsExtensive Stage Small Cell Lung Can Drug: reco
6258 NCT01178Pharmacoeconomic As CompletedNo ResultsSmoking Cessation Biological:
6259 NCT03547A Trial of Periopera Recruiting No ResultsMetastatic Colorectal Cancer Drug: mFOL
6260 NCT00893Autologous Dendritic CompletedNo ResultsBrain Tumors Drug: DC/A
6261 NCT01839Spanish Mixed HEXA/CompletedHas ResultNeisseria Meningitidis|Bacterial Inf Biological:
6262 NCT01426Id-KLH Vaccine + T CelCompletedNo ResultsMultiple Myeloma Biological
6263 NCT00771Androgen Ablation ThWithdrawnNo ResultsProstate Cancer Biological
6264 NCT00007Safety and Effectiven CompletedNo ResultsHIV Infections Biological: ALVAC-HI
6265 NCT00089GVAXÂ® Vaccine for PTerminate No ResultsProstate Cancer Biological
6266 NCT04193B-Enhancem BEe-HIVe Not yet recNo ResultsHIV Infection|Hepatitis B Biological
6267 NCT01066A Study on the SafetyCompletedNo ResultsMelanoma Biological:
6268 NCT00359Influenza Vaccinatio Terminate No ResultsInfluenza Disease Biological
6269 NCT01946Clinical ImmunizationCompletedNo ResultsFever Other: Ace
6270 NCT00317Study to Asses DTPw-CompletedHas ResultInfections, Meningococcal Biological
6271 NCT00873Open-Label Study AssCompletedNo ResultsPneumococcal Infections Biological:
6272 NCT03250Early DetecFluClinic CompletedNo ResultsAortic Stenosis
6273 NCT03939Peptide Vaccination Recruiting No ResultsChronic Lymphocytic Leukemia Combinatio
6274 NCT01397A Study to Assess theCompletedNo ResultsMalaria Biological
6275 NCT01402To Evaluate the Effec CompletedNo ResultsBacterial Infections Biological:
6276 NCT01405Safety and Immunogeni CompletedNo ResultsHepatitis A Biological:
6277 NCT00091Cyclophosphamide and CompletedNo ResultsMelanoma (Skin) Biological:
6278 NCT02897A Personal Cancer VaActive, notNo ResultsUrinary Bladder Cancer|Bladder Tu Biological
6279 NCT01333Safety and Immunogen CompletedNo ResultsHealthy Adult Volunteers Biological
6280 NCT00626Basilixima REGULATe CompletedNo ResultsMalignant Neoplasms Brain Biological:
6281 NCT00501Safety and Efficacy CompletedNo ResultsHepatitis B Drug: Clevu
6282 NCT01405A Study of DNA VaccinCompletedNo ResultsHealthy Biological
6283 NCT00485A Safety and Immunolo CompletedNo ResultsBreast Cancer Biological
6284 NCT00197Dendritic Cell Based CompletedNo ResultsAdvanced Melanoma Biological:
6285 NCT02477Assessment of Commun Unknown sNo ResultsVaccine Virus Shedding Biological:
6286 NCT03567Arresting VAVERT-HBVActive, notNo ResultsHepatitis B|Vertical Transmission of Drug: Teno
6287 NCT00655Antiangiogenic PeptidCompletedNo ResultsPancreatic Cancer Biological
6288 NCT00922Trial on the Safety CompletedNo ResultsTuberculosis Biological
6289 NCT00227Assess the Non-infer CompletedNo ResultsInfections, Meningococcal Biological
I ResultsSolid Organ Transplantation|Chronic Kidney Disease
6291 NCT00000Vaccination With Tet Terminate No ResultsCancer Biological:
6292 NCT01247Trial With Telomeras CompletedNo ResultsMalignant Melanoma Biological: GV1001
6293 NCT00289Concomitant Use of He CompletedHas ResultHepatitis A Virus Biological
6294 NCT01592Phase II Study of S-4 Unknown sNo ResultsCarcinoma, Non-Small-Cell Lung Drug: S-48
6295 NCT01885LAIV (FlumistÂ®) AdmiUnknown sNo ResultsCystic Fibrosis Biological:
6296 NCT03778Development of ChildRecruiting No ResultsInfluenza, Human Biological:
6297 NCT01666Clinical Efficacy of SuspendedNo ResultsPregnancy; Fetomaternal HemorrhaBiological
6298 NCT00243Dendritic Cell Vacci CompletedNo ResultsMelanoma Stage III or IV Biological:
6299 NCT01413Randomized Trial With CompletedNo ResultsColorectal Neoplasms Drug: Dend
6300 NCT03175Biological (A-051) CompletedNo ResultsTuberculosis Biological
6301 NCT02368Gene Expression ProfiCompletedNo ResultsHealthy Biological:
6302 NCT02816Safety and Immunogen CompletedNo ResultsJapanese Encephalitis Biological:
6303 NCT01062Re-examination StudyCompletedHas ResultVaricella Biological
6304 NCT00006Vaccine Therapy Plus CompletedNo ResultsLung Cancer Biological: monoclona
6305 NCT03619Evaluating HIVACAR Not yet recNo ResultsHIV Infections Other: Boo
6306 NCT02405DC Vaccination for PoActive, notNo ResultsAcute Myeloid Leukemia Biological
6307 NCT02738Safety, To 3 Star Active, notNo ResultsDown Syndrome Biological:
6308 NCT03004Protection From InfluUnknown sNo ResultsInfluenza Biological:
6309 NCT02655A Study of Anthrax V CompletedNo ResultsAnthrax Biological
6310 NCT00895Efficacy and Safety S Unknown sNo ResultsProstate Cancer Biological
6311 NCT04054Evaluation of the Saf Recruiting No ResultsVaccination Biological:
6312 NCT03789Vaccination With Flt3Recruiting No ResultsNon-Hodgkin's Lymphoma|MetastatiDrug: Pemb
In ResultsHIV Infections
6314 NCT02992Phase 3 Study of BK13CompletedNo ResultsImmunization; Infection Biological
6315 NCT02391Phase 4 Study To AsseCompletedNo ResultsTyphoid Fever Biological:
6316 NCT01461Vaccination Against MCompletedNo ResultsColorectal Cancer Biological:
6317 NCT00096A Phase I Feasibility CompletedNo ResultsProstatic Neoplasms Drug: Recombinant V
6318 NCT03172Efficacy of Na-GST-1 Recruiting No ResultsHookworm Infections Biological
6319 NCT02858Safety and Protectiv CompletedNo ResultsMalaria Drug: atov
6320 NCT02991Oral VaccinCDVAX Terminate No ResultsClostridium Difficile Infection Biological
6321 NCT00083Study of Tumor AntigeCompletedNo ResultsMultiple Myeloma Drug: Dexa
6322 NCT04002Immunother Dendr2 Terminate No ResultsGlioblastoma Biological:
6323 NCT01773GVAX vs. Placebo for Recruiting No ResultsMyelodysplastic Syndrome|Acute MBiological
6324 NCT02186Proof Of C POC_VAX-ICompletedNo ResultsHepatitis B Device: VA
6325 NCT02556ImmunizatiDSATH Active, notNo ResultsLiver Transplantation|Graf Failure Biological
6326 NCT00820IDA (Immun IDA-Adult CompletedNo ResultsAtopic Dermatitis Biological
6327 NCT00372Study on the Immunoge CompletedHas ResultInfluenza Biological
6328 NCT04187A Novel ThSpencer Not yet recNo ResultsAdrenocortical Carcinoma|Pheoch Biological
6329 NCT00635Novel Peptide Vaccin CompletedNo ResultsBladder Cancer Biologica
6330 NCT03806Maintenanc TEDOPAM Recruiting No ResultsPancreatic Ductal Adenocarcinoma|Drug: FOLF
6331 NCT02451A Phase I Study to A Unknown sNo ResultsEbola Virus Disease Biological
6332 NCT00767The Impact of the Hum Active, notNo ResultsChronic Kidney Disease|Dialysis Drug: Human Papillom
6333 NCT01933Study of Immune Resp Active, notNo ResultsHIV Infections Biological
6334 NCT03276Immunization To PrevRecruiting No ResultsPneumococcal Infections|COPD
6335 NCT03961Comparison ARPEP Recruiting No ResultsRabies Biological:
6336 NCT00329Study of the Influenc CompletedNo ResultsHIV Biological:
6337 NCT03797VAC069: A Study of BlRecruiting No ResultsMalaria, Vivax Biological:
6338 NCT00383Study Comparing the CompletedHas ResultInfluenza Biological:
6339 NCT02057A Study of NeuroVaxâ„ Unknown sNo ResultsSecondary Progress Multiple SclerosiBiological:
6340 NCT00749Dose-Escalation StudCompletedNo ResultsTuberculosis|Healthy Biological
6341 NCT02458Controlled Double Bl CompletedNo ResultsMalaria Biological
6343 NCT00679A Study of MVA85A inCompletedNo ResultsTuberculosis Biological
6344 NCT03404Dose Escalating StudyActive, notNo ResultsDiarrhea Biological:
6345 NCT03982Maternal AMAMA Recruiting No ResultsPertussis|Vaccination|Pregnancy|BrBiological:
6346 NCT03951Characterization of Recruiting No ResultsImmune Hepatitis Behavioral
6347 NCT00161Prevention of Respir CompletedNo ResultsRecurrent Upper and Lower Respirato Biological:
6348 NCT00963Vaccine Therapy in T CompletedNo ResultsLeukemia Biological:
6349 NCT00856Vaccinatio HIVDCVac CompletedNo ResultsHIV Infections Biological:
6350 NCT03896Phase 3 Study of 10- Active, notNo ResultsPneumonia, Pneumococcal Biological:
6351 NCT02115A Study to Evaluate t CompletedHas ResultRespiratory Syncytial Virus (RSV) Biological
6352 NCT00976TherapeutiEraMune0CompletedHas ResultHIV Infection Biological:
6353 NCT00001A Pilot Study of TumoCompletedNo ResultsEwing's Sarcoma|Rhabdomyosarco Drug: EF-1 Peptide|D
6354 NCT03620A Study to Evaluate Active, notNo ResultsPneumococcal Infections Biological:
6355 NCT00700Dose Comparison Stud CompletedHas ResultMeningitis|Meningococcal InfectionBiological
6356 NCT00004Vaccine Therapy Plus CompletedNo ResultsLymphoma Biological: keyhole l
6357 NCT01068Ovarian Cancer VaccinCompletedHas ResultEpithelial Ovarian Cancer Biological:
6358 NCT00020Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: aldesleuk
6359 NCT02576Safety and Tolerabili CompletedHas ResultAnogenital Human Papilloma Virus Biological:
6360 NCT00153Multiepitope PeptideUnknown sNo ResultsMetastatic Melanoma Biological
6361 NCT00019Vaccine Therapy in TrCompletedNo ResultsMelanoma (Skin) Biological: aldesleuk
6362 NCT00005Vaccine Therapy in TrCompletedNo ResultsMelanoma (Skin) Biological: OVA BiP p
6363 NCT03644Study to Determine ifActive, notNo ResultsCancer Other: Non
6364 NCT03113P53MVA and Pembroliz Recruiting No ResultsPD-L1 Positive|Recurrent Fallopia Other: Lab
6365 NCT00133UMD rPA Regimen Tria Terminate No ResultsBacillus Anthracis (Anthrax) Biological: Anthrax v
6366 NCT00616Characterization of T CompletedNo ResultsYellow Fever
6367 NCT00003Immunotherapy in TreTerminate No ResultsBreast Cancer Biological
6369 NCT02063Safety StudCSC CompletedNo ResultsNeoplasms, Breast
6370 NCT00357Ipilimumab With or WWithdrawnNo ResultsMelanoma (Skin) Biological
6371 NCT01479Study to Evaluate Sa CompletedNo ResultsTuberculosis Biological
6372 NCT02961Evaluation of PCV SchNot yet recNo ResultsPneumonia, Pneumococcal Biological
6373 NCT00019Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: MART-1 an
6374 NCT03401Risk Factors for Allo- WithdrawnNo ResultsSickle Cell Disease Other: Medi
6375 NCT03361ControlledCHIVAS Active, notNo ResultsStreptococcus Pyogenes Pharyngitis|Biological
6376 NCT00228Cyclophosphamide orCompletedNo
D ResultsHER2-positive Breast Cancer|RecurrDrug: ex v
6377 NCT01546Study of a MAVIS Active, notNo ResultsMelanoma Biological
6378 NCT02360Study to Evalutate LoCompletedNo ResultsInfection Drug: Hant
6379 NCT03392Safety, Reactogenici CompletedNo ResultsHuman Metapneumovirus and Human Biological
6380 NCT00589Vaccine Therapy and Unknown sNo ResultsHead and Neck Cancer Biological
6381 NCT03000Human Papi HYPER2 Active, notNo ResultsHuman Papillomavirus|Human Papillomavirus I
6382 NCT02078Safety and Efficacy S CompletedNo ResultsAdult Brain Glioblastoma|Glioblast Biological:
6383 NCT00002Vaccine Therapy and CompletedNo ResultsMelanoma (Skin) Biological
6384 NCT02543Evaluation MV140 Recruiting No ResultsUrinary Tract Infection Bacterial Biological
6385 NCT03431Immunogenicity of OnCompletedNo ResultsHuman Papillomavirus Vaccines Biological:
6386 NCT00168Vitamin A SupplementUnknown sNo ResultsInfant Mortality|Morbidity Drug: Vita
6387 NCT00016Vaccine Therapy in TrCompletedNo ResultsColorectal Cancer Biological: BCG vacci
6388 NCT02203Dose Escalation StudyCompletedNo ResultsMelanoma Biological
6389 NCT01300Human PapillomaviruUnknown sNo ResultsHPV Infection|HIV Infection|Syphilis
6390 NCT00633Multiple-Vaccine TherCompletedNo ResultsNon Small Cell Lung Cancer Biological
6391 NCT00218Safety and Effectiven CompletedNo ResultsSmoking Cessation|Tobacco Use CesBiological:
6392 NCT00022Vaccine Therapy WithCompletedNo ResultsMelanoma (Skin) Biological: aldesleuk
6393 NCT02464Open-Label Study of CompletedNo ResultsEbola Vaccine Biological
6394 NCT01236Impact of Rotavirus VaCompletedNo ResultsRotavirus Gastroenteritis|GastroenteOther: Dat
6395 NCT02663Evaluation of Safety Recruiting No ResultsInfluenza, Human Other: Data
6396 NCT01677Study of Yili Lactof CompletedNo ResultsImmunization|Human Influenza|C Dietary Su
6397 NCT00007Safety and Immune Re CompletedNo ResultsHIV Infections Biological: ALVAC(2)
6398 NCT01544V501 Safety and Effi CompletedHas ResultCervical Cancer|Cervical Intraepith Biological:
6399 NCT00908A/H5N1/LT Dose RangCompletedHas ResultPandemic Influenza Biological:
6400 NCT00849Study of the Effect o CompletedNo ResultsRespiratory Tract Infections Drug: Lacto
6401 NCT01565EvaluationExten MenCompletedNo ResultsVaccination With MenbVac Biological
6402 NCT00003Vaccine Therapy WithCompletedNo ResultsMelanoma (Skin) Biological: gp100 ant
6403 NCT02955Evaluation of the Saf CompletedNo ResultsInfluenza Biological:
6404 NCT01842EvaluationMV130 Active, notNo ResultsChronic Obstructive Pulmonary Dis Biological
6405 NCT00258Safety of Imovax Poli CompletedNo ResultsPoliomyelitis Biological: Inactivate
6406 NCT01639Chemo-immu CHIP CompletedNo ResultsRecurrent Ovarian Cancer Drug: Inter
6407 NCT00722Autologous and AllogRecruiting No ResultsColorectal Cancer|Ovarian Cancer| Biological: Autologou
6408 NCT00400Safety of REPEVAXÂ®CompletedNo ResultsHealthy Adult Biological
6409 NCT00036Vaccine Therapy in T Terminate No ResultsIntraocular Melanoma Biological: MART-1 an
6410 NCT01171Vaccination With Dend CompletedNo ResultsBrain Tumor|Glioblastoma|Medull Biological:
6411 NCT00142NY-ESO-1 Protein VacCompletedNo ResultsMalignant Melanoma Biological
6412 NCT01153Immunogenicity & Safe CompletedHas ResultInfluenza Biological:
6413 NCT00004Vaccine Therapy Plus CompletedNo ResultsLung Cancer Biological: QS21|Biol
6414 NCT00059Peptide Vaccination fCompletedHas ResultMelanoma Drug: Glyc
6415 NCT03755A Study to Evaluate SRecruiting No ResultsPeanut Allergy Drug: ASP0
6416 NCT03332SequentialNPGV Unknown sNo ResultsChronic Hepatitis b Drug: Ente
6417 NCT01143Vax Facts Human PapilCompletedHas ResultHuman Papillomavirus|Prevention Behavioral
6418 NCT02714Standard OAB-SOP CompletedNo ResultsHuman Papilloma Virus Infection Other: Firs
6419 NCT00621Vaccine Therapy and WithdrawnNo ResultsBrain and Central Nervous System Biological
6421 NCT01159Trial of a CSET 1437CompletedNo ResultsNon Small Cell Lung Cancer Biological:
6422 NCT00325Concomitant Use of GCompletedHas ResultNeoplasms, Glandular and Epitheli Biological
6423 NCT00012Vaccine Therapy in TrTerminate No ResultsColorectal Cancer|Esophageal CanceBiological
6424 NCT01634Safety of CIN3 CompletedNo ResultsCervical Intraepithelial Neoplasia 3 Genetic: G
6425 NCT01058Phase II Study of Luc CompletedNo ResultsLung Neoplasm|Carcinoma, BronchoBiological:
6426 NCT00411Persistence of HepatiCompletedNo ResultsHepatitis B Biological:
6427 NCT00498A Safety and Efficacy Terminate No ResultsHepatitis B Biological
6428 NCT02063Phase I Trial of DAR- CompletedNo ResultsTuberculosis Biological:
6429 NCT00091Interleukin-7 and VacCompletedNo ResultsMelanoma (Skin) Biological: MART-1 an
6430 NCT00964Safety Study of GSK BCompletedHas ResultHaemophilus Influenzae Type b|Acell Biological:
6431 NCT01697A Phase II TaMoVac IICompletedNo ResultsVaccines|HIV|Safety|ImmunogeniciBiological
6432 NCT02413Leukapheresis SampliCompletedNo ResultsTuberculosis Biological:
6433 NCT01001Long-term Follow-up CoompletedHas ResultEncephalitis|Japanese Encephalitis Other: Blo
6434 NCT00846Safe Study of DendritCompletedNo ResultsGlioblastoma|Brain Tumor Biological:
6435 NCT01877A Study to HELIOS Active, notHas ResultCytomegalovirus (CMV)-Positive ReciBiological
6436 NCT01974A Study to Evaluate t Active, notNo ResultsKidney Transplantation CytomegalovBiological
6438 NCT01924Tonsillar C Tons2 Unknown sNo ResultsHealthy Biological:
6439 NCT01931Study of Boosting St Active, notNo ResultsHIV Infections Biological
6440 NCT00960Study of Tecemotide (CompletedHas ResultNon-small Cell Lung Cancer Biological
6441 NCT00293Safety and Efficacy ofCompletedNo ResultsHypersensitivity Biological
6442 NCT00652Effect of an Allergen CompletedNo ResultsPerennial Allergic Rhinoconjunctivit Biological: CYT005-A
6443 NCT00258Rituximab, Vaccine T Unknown sNo ResultsLymphoma Biological
6445 NCT02851A Study to Evaluate SCompletedNo ResultsPeanut Allergy Drug: ASP0
6446 NCT02811PRIME FollPRIMEfoll CompletedNo ResultsMeningococcal Disease Other: ven
6447 NCT00382A Clinical Trial to Ev CompletedHas ResultRespiratory Tract Diseases Biological
6448 NCT03383Immune Res IMMUNEOActive, notNo ResultsHIV Infections|Neonatal Infection|LOther: RN
6449 NCT04197TPIV100 and Sargramos Not yet recNo ResultsBreast Adenocarcinoma|Stage II Brea
Biological
6450 NCT01570To Identify HLA-A110Unknown sNo ResultsAnonymous Donors at Blood Donation Center
6451 NCT02352A Multicenter, Double- CompletedNo ResultsInfluenza Biological:
6452 NCT00098Vaccine Therapy in TrTerminate No ResultsLung Cancer Drug: autologous tumo
6453 NCT00089Vaccine Therapy and Terminate No ResultsLymphoma Biological
6454 NCT02609Safety, Tolerability CompletedNo ResultsMyasthenia Gravis Biological
6455 NCT00862Persistence of Bacter CompletedHas ResultMeningococcal Infections|MeningitiBiological
6456 NCT00487Procurement of Follicu CompletedNo ResultsNon-Hodgkin's Lymphoma Procedure:
6457 NCT00680The Psychoneuroimmu CompletedHas ResultPrimary Insomnia
6458 NCT03508Study of Airway Infl Not yet recNo ResultsHealthy Volunteers|Rhinovirus Biological
6459 NCT00003Vaccine Therapy in TreCompletedNo ResultsLung Cancer|Malignant Mesothelio Biological: lung tum
6460 NCT01728Controlled Human Mal CompletedNo ResultsMalaria|Plasmodium Falciparum Biological:
6461 NCT02501A Phase II Clinical T WithdrawnNo ResultsUterine Cervical Neoplasms Biological
6462 NCT00019flt3L With or WithoutCompletedNo ResultsStage IV Melanoma|Stage IV Renal Drug: flt3 ligand|Dr
6463 NCT00713Non-Pharmacologic Int CompletedNo ResultsPain|Analgesia Procedure:
6464 NCT00058A Dose-escalation VacCompletedNo ResultsNeoplasms, Breast Biological
6465 NCT00019Vaccine Therapy in T CompletedNo ResultsStage II Multiple Myeloma|Stage II Drug: autologous tum
6467 NCT03334Adoptive Ce ACTION Recruiting No ResultsMalignant Glioma|High Grade Glio Biological
6468 NCT01782Proteome-based Immu Enrolling bNo ResultsNeoplasm Metastasis Biological:
6469 NCT01782Proteome-based Immu Enrolling bNo ResultsNeoplasm Metastasis Biological:
6470 NCT01759Proteome-based PersEnrolling bNo ResultsGlioblastoma Biological:
6471 NCT00019Aldesleukin With or CompletedHas ResultRecurrent Melanoma|Stage IIIA Ski Biological
6472 NCT00112Immunotherapy of Me CompletedNo ResultsMelanoma Biological
6473 NCT01228Rabies Virus Neutrali CompletedNo ResultsRabies Biological:
6474 NCT00975ProQuadâ„¢ Versus MCompletedHas ResultMeasles|Mumps|Rubella|Varicella Biological
6475 NCT00124Safety and Efficacy o CompletedNo ResultsHepatitis C Biological:
6476 NCT03597A Personal Cancer V Active, notNo ResultsMetastatic Melanoma Biological
6477 NCT02712This Study Will Evalu CompletedHas ResultHepatitis A Vaccine Other: Blo
6478 NCT02981Study of GVAX (With CompletedHas ResultMetastatic Colorectal Cancer Drug: CY|B
6479 NCT00733Tolerability and ImmuSuspendedNo ResultsHPV Infections Biological
6480 NCT02958Placebo Controlled EvCompletedHas ResultHerpes Zoster|Fibrosis Biological:
6481 NCT00686An Open-Label PhaseCompletedHas ResultSmallpox Biological
6482 NCT01732A Phase 2, MulticenteUnknown sNo ResultsInfectious Disease Biological:
6483 NCT00219Immunogeni MANON 02CompletedNo ResultsHIV Infection Biological
6484 NCT03888Knowledge and AttituCompletedNo ResultsHPV-Related Cervical Carcinoma Behavioral
6485 NCT00091Fludarabine FollowedCompletedNo ResultsMelanoma (Skin) Biological
6486 NCT00111Study to Evaluate th CompletedNo ResultsInfluenza Biological:
6487 NCT00926Hepatitis BHBV CompletedNo ResultsHepatitis B|Hepatitis C|HIV|HIV Inf Behavioral
6488 NCT01826Improving Parental S CompletedNo ResultsAcute Pain Behavioral
6489 NCT00211Evaluation of Consis CompletedNo ResultsStaphylococcal Infections Biological:
6490 NCT00192Trial to Determine theCompletedNo ResultsHealthy Biological:
6491 NCT02949Stress Inoculation ThrCompletedNo ResultsStress, Psychological|Stress, Physio Behavioral:
6492 NCT00255Immunogenicity and Sa CompletedNo ResultsDiphtheria|Tetanus|Poliomyelitis|HBiological:
6493 NCT00100Fluarix ImmunogenicitCompletedNo ResultsInfluenza Biological: Fluarix
6494 NCT01225Novel Peptide VaccinaUnknown sNo ResultsProstate Cancer Biological
6495 NCT00801Equivalence of the ReCompletedNo ResultsAtopic Dermatitis Drug: tacr
6496 NCT01111Child Pneumococcal SCompletedNo ResultsPneumococcal Disease Other: no
6497 NCT00386Long Term ProtectionCompletedNo ResultsTyphoid Fever
6498 NCT04115A Phase II, RandomizeRecruiting No ResultsGBM Biological:
6499 NCT00460Safety and Immunogen CompletedNo ResultsTuberculosis Biological
6500 NCT01017Safety and Immunogeni CompletedHas ResultTuberculosis|HIV Infections Biological
6501 NCT00001Prediction and Testin CompletedNo ResultsHIV Infections|Healthy
6502 NCT04113The Effects of Health CompletedNo ResultsHealth Education Behavioral
6503 NCT01715Assess the Risk of So CompletedNo ResultsInfluenza Other: Data
6504 NCT03143Evaluate t FluMist CompletedHas ResultInfluenza|Healthy Biological:
6505 NCT01528Humoral and Cellular CompletedNo ResultsOther Condition That May be a Focus Biological:
6506 NCT00080Vaccine Treatment in CompletedNo ResultsMelanoma Drug: IL-2|Drug: gp1
6507 NCT00378V501 Efficacy Study CompletedHas ResultHPV Infections Biological
6508 NCT02146Nasopharyngeal CarriCompletedHas ResultPneumococcal Disease
6509 NCT01281Study To Evaluate Lo Unknown sNo ResultsGiving a Vaccination in Three MonthOther: vac
6510 NCT02773PfSPZ Challenge in HeCompletedNo ResultsPlasmodium Falciparum Infection Drug: Chlo
6511 NCT00046Phase I Trial of Small CompletedNo ResultsHealthy Drug: Modified Vacci
6512 NCT01568Follow-up Study to E Terminate No ResultsAlzheimer's Disease
6513 NCT02383Immunodeficiency in Active,
C notNo ResultsCartilage-hair Hypoplasia Biological:
6514 NCT02999Personalized and Ce Recruiting No ResultsHead and Neck Squamous Cell Carc Other: MV
6515 NCT00161Follow-up Study on thCompletedNo ResultsMeningococcal Meninigitis, Serogroup C
6516 NCT00676Phase III STOP CompletedNo ResultsLung Neoplasm|Carcinoma Non-small Biological
6517 NCT00676Safety StudpeptidevacCompletedNo ResultsMetastatic Tumors Biological
6518 NCT01119Study of Pre-clearancCompletedNo ResultsTuberculosis Biological:
6519 NCT03603VGX-3100 and Electrop Recruiting No ResultsAnal Intraepithelial Neoplasia|High Device: El
6520 NCT00332ITV Extension Study CompletedNo ResultsHIV Biological:
6521 NCT02133Immunotherapy of TuUnknown sNo ResultsLiver Cancer|Pancreatic Adenocarc Biological:
6522 NCT00871Immunogenicity and SCompletedHas ResultTetanus|Acellular Pertussis|DiphtheBiological
6523 NCT00706A Safety anAVX502-00CompletedNo ResultsInfluenza Biological:
6524 NCT00860A Study to MI-CP185 CompletedHas ResultHealthy or Stable Underlying ChroniBiological
6525 NCT01066PRIMAGE (P PRIMAGE Unknown sNo ResultsInfluenza Dietary Su
6526 NCT01353Immune Response ofUnknown
In sNo ResultsAllergy Biological
6527 NCT00961Vaccination of MelanTerminate No ResultsMelanoma Biological:
6528 NCT00161Safety Study in Volu CompletedNo ResultsEncephalitis, Tick-borne Biological: Tick-Borne
6529 NCT00834A Phase II Study of Active, notNo ResultsNasopharyngeal Carcinoma Biological:
6530 NCT02653Impact of Immune Cha Unknown sNo ResultsMajor Depression Biological:
6531 NCT00362Study of PR5I, a Ped CompletedNo ResultsDiphtheria|Pertussis|Polio|HepatitiBiological
6532 NCT00529Phase I Sa ISSP-001 CompletedNo ResultsHIV Infections Biological:
6533 NCT00204Intradermal VaccinatiCompletedNo ResultsMalignant Melanoma Biological
6534 NCT00161FSME IMMUN NEW Follo CompletedNo ResultsEncephalitis, Tick-borne Biological: Tick-Borne
6535 NCT02320MART-1 Antigen WithCompletedNo ResultsStage IIA Skin Melanoma|Stage IIB Biological
6536 NCT01491Immunogenicity and SCompletedHas ResultAnthrax Biological:
6538 NCT00560Safety Study of ProQ CompletedHas ResultMeasles|Mumps|Rubella|Varicella Biological
6539 NCT00000A Phase I MulticenterCompletedNo ResultsHIV Infections Biological: gp160 Vac
6540 NCT02977ImmunizatiISI-JX Recruiting No ResultsMetastatic Tumor|Advanced TumorBiological
6541 NCT00442Dendritic Cells in Lu CompletedNo ResultsNon Small Cell Lung Cancer Biological
6542 NCT00121Safety of IntradermalCompletedNo ResultsHIV Infections|HIV Seronegativity Biological:
6543 NCT00005Comparison of Immune CompletedNo ResultsActive Immunity|Healthy|Stem Cell Transplantation
6544 NCT01025Study Eval AB PERSIS CompletedHas ResultHealthy Other: Blo
6545 NCT00138Herpevac Neonatal S Terminate No ResultsHerpes Simplex
6546 NCT01344Human Imm HIVBLD CompletedNo ResultsHIV Infection
6547 NCT00669Immunization With AFTerminate No ResultsHepatocellular Carcinoma|Hepatoma| Drug: AFP
6549 NCT00000A Phase I Safety and CompletedNo ResultsHIV Infections Biological: HIV-1 Pep
6551 NCT01290Study To Test the Saf CompletedNo ResultsGrade IV Glioma|Grade IV Astrocyt Biological:
6552 NCT00365Immunization of DiseTerminate No ResultsMelanoma Biological
6553 NCT00053Phase I/II Trial of M CompletedNo ResultsHealthy Drug: Modified Vacci
6554 NCT00338Lymphodepletion PlusRecruiting No ResultsMelanoma Biological:
6555 NCT01174Trial of ID-Specific Terminate Has ResultMyeloma Biological
6556 NCT00013HIV Candidate VaccineUnknown sNo ResultsHIV Infections|HIV Seronegativity Biological: ALVAC-H
6557 NCT00511Open-Label Study of CompletedHas ResultHepatitis B Biological
6558 NCT01463Modified Process Hepa CompletedHas ResultHepatitis B Biological
6559 NCT00639Antiangiogenic PeptidUnknown sNo ResultsPancreatic Cancer Biological
6560 NCT00886Hepatitis B Vaccinati CompletedNo ResultsHIV Infections Biological:
6561 NCT03502A Study to Evaluate Active, notNo ResultsHealthy Biological
6562 NCT00090Rotavirus Efficacy andCompletedHas ResultRotavirus Infections Biological
6563 NCT03006Epacadostat, PembrolRecruiting No ResultsMetastatic Pancreatic Adenocarcin Drug: Epac
6564 NCT02469A Study of ASP4070 toCompletedNo ResultsCedar Pollinosis Drug: ASP4
6565 NCT03826Safety, Tolerability CompletedNo ResultsInfluenza Biological
6566 NCT03600pTVG-HP and Nivoluma Recruiting No ResultsProstate Cancer Biological
6567 NCT01105Human Papilloma ViruCompletedNo ResultsHPV
6568 NCT01491PVSRIPO foPVSRIPO Active, notHas ResultGBM|Glioblastoma|Glioma|MalignaBiological
6569 NCT00850Safety and ImmunogeCompletedHas ResultMeningococcal Infections|MeningitiBiological
6570 NCT00545Immunogenicity and Sa CompletedNo ResultsInfluenza|Orthomyxoviridae Infecti Biological:
6571 NCT02216Follow-up AFF008A CompletedNo ResultsParkinson's Disease Biological
6572 NCT01393A Study to Evaluate t CompletedNo ResultsHealthy|Immunogenicity of ASP737Biological
6573 NCT00142Immunologic MemoryCompletedNo ResultsHIV Infections Biological:
6574 NCT03524Effect of ERIG Inject Recruiting No ResultsRabies Biological:
6575 NCT01509Prevenar13 Post MarkCompletedHas ResultHealthy Biological
6576 NCT00683Human Leukocyte Anti Unknown sNo ResultsPancreatic Cancer|Pancreas NeoplaBiological
6577 NCT00124Comparison of DendriCompletedNo ResultsMelanoma Drug: KLH;
6578 NCT00622Gemcitabine With AntCompletedNo ResultsPancreatic Cancer Biological
6579 NCT00311Dendritic Cell Vaccin CompletedNo ResultsColorectal Neoplasms Biological: MelCance
6580 NCT03380A Personal Cancer VaActive, notNo ResultsCarcinoma, Non-Small-Cell Lung|L Biological
6581 NCT03204Safety and Immunogen Active, notNo ResultsHIV Biological
6582 NCT02508A Study to Evaluate t Terminate Has ResultRespiratory Syncytial Virus Biological
6583 NCT00306Incidence of Influenz CompletedNo ResultsInfluenza Biological: Fluarix
6584 NCT01863Tolerability and ImmuCompletedNo ResultsSeasonal Influenza Biological:
6585 NCT00002Vaccine Therapy, CheCompletedNo ResultsPancreatic Cancer Biological: allogenei
6586 NCT00645The Influence of ProbUnknown sNo ResultsImmunity|Measles|Mumps|RubellaDietary Sup
6587 NCT03175QUILT-3.049: NANT TrWithdrawnNo ResultsTriple Negative Breast Cancer Biological
6588 NCT00510Personalized Active Terminate No ResultsNon-Hodgkin's Lymphoma Drug: autologous imm
6589 NCT00819CpG 7909/MontanideCompletedNo
I ResultsNY-ESO-1-expressing Tumors Biological
6590 NCT03911Treatment and Vacci Recruiting No ResultsAtypical Pneumonia Drug: Doxy
6591 NCT00093Vaccine Therapy WithUnknown sNo ResultsKidney Cancer Biological
6592 NCT00001Immunization of Pati CompletedNo ResultsMelanoma|Neoplasm Metastasis Drug: GP100 peptide|
6593 NCT03165Open LabelV3-P Recruiting No ResultsPancreatic Cancer Non-resectable Biological:
6594 NCT02062Evaluation of ImmunoCompletedHas ResultVaricella Biological
6595 NCT02927Immunogenicity and SUnknown sNo ResultsPneumococcal Infections Biological
6596 NCT02967A Campaign-based IDCompletedNo
f ResultsPoliomyelitis Device: ID
6597 NCT02888iHIVARNA Cl iHIVARNA-Terminate Has ResultHIV Infections Biological:
6598 NCT01213Prevention of Varicel WithdrawnNo ResultsHerpes Zoster Biological:
6599 NCT01865A Phase I/IIa AERAS-4CompletedHas ResultLatent Tuberculosis Bacteriology a Biological
6600 NCT00000A Phase I MulticenterCompletedNo ResultsHIV Infections Biological: gp160 Va
6601 NCT04239Propositive (Protecti Not yet recNo ResultsHIV/AIDS|Meningococcal Disease Diagnostic
6603 NCT01896Pilot StudyFib-P-2012CompletedNo ResultsImmunosenescence Dietary Su
6604 NCT00163Immunogenicity and SCompletedNo ResultsEncephalitis, Tick-borne Biological: Formaldeh
6605 NCT01533Exploratory Study on CompletedNo ResultsMajor Depressive Disorder Biological:
6606 NCT02201Immunogenicity and SUnknown sNo ResultsPneumococcal Infections Biological
6607 NCT03704Immunogenicity and SNot yet recNo ResultsInfluenza Biological:
6608 NCT03804ConvertingCBCV Not yet recNo ResultsBreast Cancer Radiation:
6609 NCT03343Antiviral Prophylaxis Recruiting No ResultsHepatitis B|Pregnancy Drug: Anti-
6610 NCT00197Lot-to-lot Consistenc CompletedNo ResultsTetanus|Hepatitis B|Haemophilus InBiological
6611 NCT00559Phase I/II DTIC-melv CompletedNo ResultsMelanoma Biological
6612 NCT02998Study to Assess the CompletedHas ResultInfluenza, Human Biological
6613 NCT00833Protective PIP-02 CompletedNo ResultsKidney Transplant|Immunology|Immunosuppr
6614 NCT02210Study of Dupilumab (CompletedNo ResultsAtopic Dermatitis Drug: Dupi
6616 NCT00000A Study to Evaluate t CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: Salmonel
6617 NCT00346DNA Vaccine for RagwCompletedNo ResultsSeasonal Allergic Rhinitis Drug: AIC
6619 NCT04235Improving ICARIA Not yet recNo ResultsChild Mortality Drug: Azit
6620 NCT02772Dendritic Cell-Based Unknown sNo ResultsGlioblastoma Multiforme|Glioblast Biological:
6621 NCT01960RSV F Dose-Ranging CompletedNo ResultsRespiratory Syncytial Virus InfectionBiological
6622 NCT02606Early Versus Late BCGRecruiting No ResultsSevere Illness|Septicaemia|Diarrho Biological:
6623 NCT02148FluarixÂ®/ FluLavalÂ®CompletedNo ResultsInfluenza Other: Data
6624 NCT02649Prostvac in Patients Active, notNo ResultsProstate Cancer Biological
6625 NCT02007Open-labelB-cell ther Unknown sNo ResultsAcute Myeloid Leukemia|Acute LymBiological
6626 NCT04096Uromune in Treating Recruiting No ResultsRecurrent Uti Biological
6627 NCT03153Pilot Study With CY, Recruiting No ResultsPancreatic Cancer Drug: Cyc
6628 NCT00197Study Comparing the CompletedNo ResultsInfluenza Biological:
6629 NCT00437Tetanus ImmunizationTerminate No ResultsTetanus Drug: Teta
6630 NCT02574myDC/pDC in Stage IIUnknown sNo ResultsMelanoma Drug: A: m
6631 NCT03121Safety Study of NBP60CompletedNo ResultsVaricella Zoster|Immunization; InfecBiological
6632 NCT01138Evaluation of AntibodCompletedHas ResultHepatitis B Biological:
6633 NCT00192Trial to Assess the Sa CompletedNo ResultsHealthy Biological:
6634 NCT00020Vaccine Therapy Plus CompletedNo ResultsProstate Cancer Biological: aldesleuk
6635 NCT00641Varicella Vaccination CompletedNo ResultsAsthma Drug: budes
6636 NCT00985Safety, Tolerability, CompletedHas ResultMeasles|Mumps|Rubella|Varicella Biological
6637 NCT00197Dendritic Cell Based CompletedNo ResultsAdvanced Renal Cell Carcinoma Biological:
6638 NCT01741AlloStimÂ® In-Situ VaWithdrawnNo ResultsMetastatic Colorectal Cancer Biological:
6639 NCT00304Humoral Determinants CompletedNo ResultsPneumonia|Pneumococcal Infections Biological
6640 NCT03820Safety, Tolerability, Active, notNo ResultsHerpes Zoster|Varicella Zoster Biological:
6641 NCT00510A Study of Active I CompletedNo ResultsAcute Myelogenous Leukemia Biological
6642 NCT02452Pilot Study to Evalu WithdrawnNo ResultsMelanoma Drug: ipil
6643 NCT00611BLYS and IFN in SLE CompletedNo ResultsSystemic Lupus Erythematosus Biological
6644 NCT00432Immunogenicity and SCompletedHas ResultVaricella|Measles|Mumps|Rubella|Di Biological
6645 NCT02780PfSPZ Challenge in N CompletedNo ResultsPlasmodium Falciparum Infection Biological:
6646 NCT00001Safety of and ImmuneCompletedNo ResultsHIV Infections Biological: rgp120/H
6647 NCT01270Post-Marketing SafetyCompletedHas ResultMeningitis|Meningococcal Disease Biological
6650 NCT00001Studies of In Vitro B CompletedNo ResultsHealthy
6651 NCT00116Active Specific Intr CompletedNo ResultsMelanoma Genetic: I
6652 NCT00809Collection and Banki CompletedNo ResultsMyelodysplastic Syndrome|Acute MOther: Coll
6653 NCT00551A Study of the Safety CompletedNo ResultsBacterial Infections; Virus Diseases Biological
6654 NCT03776Safety and Tolerabili CompletedNo ResultsTreatment of Acute Yellow Fever ViruBiological
6655 NCT00812Phase 1B StFDA-OPD CompletedNo ResultsHealthy Biological:
6656 NCT00004The Effects of Anti-H CompletedNo ResultsHIV Infections Biological:
6657 NCT04034A Double-blind RandoRecruiting No ResultsHealthy Volunteers Biological
6658 NCT03096Investigation of a TheRecruiting No ResultsCancer|Neoplasms Biological:
6659 NCT01265IMA901 in Patients ReCompletedNo ResultsMetastatic Renal Cell Carcinoma Drug: Suni
6660 NCT00616Phase 1 Study of NY-ECompletedHas ResultEpithelial Ovarian Cancer|Fallopian Biological
6661 NCT02209TDAP SafetTdap CompletedNo ResultsPertussis Biological:
6663 NCT01244A Study of the Safety CompletedNo ResultsPoliomyelitis|Polio Biological:
6664 NCT04152BCG Revaccination ofRecruiting No ResultsTuberculosis Biological:
6665 NCT01582Investigation of the CompletedNo ResultsCardiovascular Function Biological
6666 NCT01672A Study to Assess theCompletedNo ResultsSmoking|Vaccines Biological:
6667 NCT01612Safety andPSC25 CompletedHas ResultInfluenza Biological:
6668 NCT01153Post-marketing Safet CompletedNo ResultsInfections, Papillomavirus Other: Data
6669 NCT01337Safety, Tolerability CompletedHas ResultBacterial Infections|Virus Diseases Biological
6670 NCT00002Cyclophosphamide Plu CompletedNo ResultsBreast Cancer|Colorectal Cancer|K Biological
6671 NCT03465Dengue Serostatus StActive, notNo ResultsDengue|Severe Dengue|Dengue Fever|Virologi
6672 NCT01127DCVax Plus Poly ICLC CompletedNo ResultsHIV-1 Infection|HIV Infection|Healt Drug: DCVa
6673 NCT00000A Phase I Trial To E CompletedNo ResultsHIV Infections Biological: HIV-1 Pep
6674 NCT00000A Phase I MulticenterCompletedNo ResultsHIV Infections Biological: Hepatitis
6675 NCT03566CALR Exon 9 Mutant PActive, notNo ResultsMyeloproliferative Neoplasm, UnclaBiological
6676 NCT00000A Phase I/II Dose Esc CompletedNo ResultsHIV Infections Biological: gp160 Va
6677 NCT04160Persuasion in MedicinEnrolling bNo ResultsFlu, Human|Influenza, Human Behavioral:
6678 NCT01199Blood-borne InfectionCompletedHas ResultViral Hepatitis B|Contraception|Breas
Behavioral
6679 NCT00572A Study to Evaluate CompletedHas ResultStaphylococcus Aureus Infection Biological
6680 NCT02798A Study to Evaluate PCompletedHas ResultHepatitis B Biological:
6681 NCT03046Burden of COPDCAP Unknown sNo ResultsCOPD|Pneumonia|Pneumococcal VaBiological
6682 NCT01195Gastroenteritis From Terminate Has ResultPediatric Gastroenteritis Biological:
6683 NCT03307A Study of 2 Differe Recruiting No ResultsHuman Immunodeficiency Virus Biological
6684 NCT03407A Study to PIN2 CompletedNo ResultsImmunization; Infection Other: nas
6685 NCT02149A Study of NeuroVaxâ„ Unknown sNo ResultsMultiple Sclerosis Biological
6686 NCT01511Serological Response CompletedNo ResultsRotavirus Infection|Evidence of PCVProcedure:
6687 NCT02297Phase II T HER3+ Active, notNo ResultsBreast Cancer Biological
6688 NCT00641Peptide Vaccine and CompletedNo ResultsColorectal Cancer Biological
6689 NCT01462Immune Therapy of HCompletedNo ResultsHPV-induced Cancers Biological
6690 NCT00709A Study of CDX-1307,CompletedNo ResultsBreast Cancer|Colorectal Cancer|PaBiological
6691 NCT02476Study of Na-APR-1 (MCompletedNo ResultsHookworm Infection|Hookworm DisBiological
6692 NCT01445Safety and Dose FindiCompletedNo ResultsGrass Pollen Allergy Biological
6693 NCT03536Dose-Defining Safety Recruiting No ResultsTuberculosis Biological
6694 NCT00393Xenogeneic HER2/Neu Active, notNo ResultsBreast Cancer Biological
6695 NCT03203IMA970A Plus CV8102CompletedNo
i ResultsHepatocellular Carcinoma Drug: IMA
6696 NCT00004Biological Therapy in CompletedNo ResultsBreast Cancer|Colorectal Cancer|ExBiological
6697 NCT00617Effects of FLAIR CompletedNo ResultsAllergic Rhinitis Other: live
6698 NCT00509GV 1001 Immunotherap CompletedNo ResultsCarcinoma, Non-Small-Cell Lung Biological
6699 NCT01472Effects of Bortezomi CompletedNo ResultsMultiple Myeloma Procedure:
6700 NCT02879Oncolytic MG1-MAGEA Active, notNo ResultsNon-Small Cell Lung Cancer Biological
6701 NCT01341Phase II PAP Plus GMActive, notNo ResultsProstate Cancer Biological
6702 NCT01094Study of Tecemotide CompletedHas ResultMultiple Myeloma Biological
6703 NCT00750Study to Monitor the CompletedHas ResultInfluenza Biological:
6704 NCT00211StaphVAX in CardiovasCompletedNo ResultsStaphylococcal Infections|CardiovasBiological:
6705 NCT02799A Feasibili FS-ESCUD Unknown sNo ResultsCompliance
6706 NCT00211StaphVAX Immunogenic CompletedNo ResultsStaphylococcal Infections Biological:
6707 NCT03474Prevalence of HPV InfCompletedNo ResultsHPV - Anogenital Human Papilloma Virus Infec
6708 NCT03146Maintenance Dose Stu Terminate Has ResultGenital Herpes|HSV-2 Infection Biological
6709 NCT00133Docetaxel in CombinaTerminate No ResultsProstate Cancer Biological
6710 NCT00103Vaccine Therapy in TrCompletedHas ResultColorectal Cancer|Metastatic CanceBiological:
6711 NCT00550ZOSTAVAXâ„¢ Safety SCompletedHas ResultHerpes Zoster Biological:
6712 NCT02837ComparingCoheaHr- CompletedNo ResultsCervical Cancer Other: ques
6713 NCT02097The Effect StatVax CompletedNo ResultsHealthy Controls Drug: Ator
6714 NCT03396Brain StemBRAVO Recruiting No ResultsDiffuse Intrinsic Pontine Glioma (D Biological
6715 NCT03881Improving Well-BeingRecruiting No ResultsStress, Psychological Behavioral
6716 NCT01987Phase III Study to Ev CompletedNo ResultsInfluenza Biological
6717 NCT03697Efficacy a ADVANCE-IRecruiting No ResultsAcute Myeloid Leukemia in Remissi Biological
6718 NCT00874Peptide Vaccine TargeCompletedNo ResultsNon Small Cell Lung Cancer Biological
6719 NCT03700ImovaxÂ® RVAJ00001 Active, notNo ResultsHealthy Volunteers (Rabies ImmunizBiological
6720 NCT00949Increasing Family P CompletedNo ResultsPostpartum Period Other: Pre
6721 NCT00000A Phase I/II Study of CompletedNo ResultsHIV Infections Biological: gp160 Va
6722 NCT00280Dendritic Cell-based CompletedNo ResultsMalignant Pleural Mesothelioma Biological:
6723 NCT01311Hepatitis B Virus (HB Unknown sNo ResultsHealthy Volunteers Biological:
6724 NCT01585Exposure oChallengeIICompletedNo ResultsMalaria Biological:
6725 NCT01607A Study for Evaluatio CompletedHas ResultInfluenza Biological:
6726 NCT00513Phase I Study to Inve CompletedNo ResultsChronic Hepatitis B Genetic: a
6727 NCT00894Tick-Borne EncephalitCompletedHas ResultEncephalitis, Tick-Borne Biological
6728 NCT00779PROvenge PTROTECT CompletedHas ResultProstate Cancer Other: Cont
6729 NCT03867To Assess the Safety, Recruiting No ResultsMalaria,Falciparum Biological
6730 NCT03623E GFR TKI EPICAL Recruiting No ResultsCarcinoma, Non-Small-Cell Lung Drug: EGFR
6731 NCT02092Safety andREDUC CompletedHas ResultHIV I Infection Drug: Romi
6732 NCT02380AlloStimÂ® Immunothe CompletedNo ResultsColorectal Cancer Metastatic Biological:
6733 NCT01116An Assessme ADXS11-00Terminate No ResultsCervical Intraepithelial Neoplasia Biological
6734 NCT00000A Phase I Safety and CompletedNo ResultsHIV Infections Biological: HIV-1 C4-
6735 NCT01577Safety of GSK Biologi CompletedHas ResultAcellular Pertussis|Haemophilus InfBiological:
6736 NCT00324GM-CSF With or Withou SuspendedNo ResultsLymphoma Drug: auto
6737 NCT01694Impact of Nunavik2 Unknown sNo ResultsAcute Upper Respiratory Infection|Acute Lower
6738 NCT00138Pilot Study Freeze an CompletedNo ResultsDiphtheria|Hepatitis B|Pertussis|Poliomyelitis|Tetanus
6739 NCT01999A Study of the ImmunCompletedNo ResultsHepatitis B Biological
6740 NCT00988A Study of V503 GiveCompletedHas ResultHuman Papillomavirus Infection Biological
6741 NCT00843MulticentePneumococUnknown sNo ResultsPneumococcal Disease Biological
6742 NCT03556Open LabelV3-OVA Recruiting No ResultsOvarian Cancer Biological:
6743 NCT00767A Randomiz MEDI-559 CompletedNo ResultsHealthy Biological
6744 NCT03159Safety and Immunogeni WithdrawnNo ResultsPulmonary Tuberculoses|High Risk FDrug: GX-7
6745 NCT00036Idiotype Vaccine fo Unknown sNo ResultsLymphoma, Low-Grade Biological: FavId (Id
6746 NCT03018Radiation Therapy P Recruiting No ResultsGlioblastoma Drug: Pemb
6747 NCT01272Impact of Prevnar 13 CompletedNo ResultsAcute Otitis Media|Mastoiditis
6748 NCT00004Monoclonal AntibodyCompletedNo
T ResultsMelanoma (Skin) Biological
6749 NCT01967Phase I Study of Saf CompletedNo ResultsAstrocytic Tumors|Glioblastoma MuBiological:
6750 NCT02391Study to Evaluate th CompletedNo ResultsTuberculosis Biological
6751 NCT02769ID AdministID-ADAP CompletedNo ResultsIPV Device: We
6753 NCT02289A Study to Evaluate CompletedHas ResultRespiratory Syncytial Virus (RSV) Biological:
6754 NCT00000A Phase I Multicente CompletedNo ResultsHIV Infections Biological: HIVAC-1e|
6755 NCT03351Effect of ADELEWP1CompletedNo ResultsImmune System Disorders Biological:
6756 NCT00939Efficacy and Safety S Unknown sNo ResultsChronic Hepatitis B, Gestation Drug: Telb
6757 NCT02225Evaluation of the Saf CompletedHas ResultPneumococcal Infections Biological
6758 NCT01054EvaluationEFFIVAC CompletedNo ResultsVaccination
6759 NCT02804Gene-virusGENEVIR WithdrawnNo ResultsType 1 Diabetes Genetic: En
6760 NCT00258V260 Study: ConcomitCompletedHas ResultRotavirus Disease Biological:
6761 NCT00017Combination Chemothe Unknown sNo ResultsLymphoma Biological: autologo
6762 NCT00092Cervical Intraepithel CompletedHas ResultCervical Cancer|Genital Warts Biological
6763 NCT03114The Evaluation of Im CompletedNo ResultsVaricella Biological:
6764 NCT03114Immunogenicity and SCompletedNo ResultsVaricella Biological:
6765 NCT03565A Study to Evaluate t Recruiting No ResultsPneumococcal Infections Biological
6766 NCT00011ALVAC-HIV vCP1452 CompletedNo ResultsHIV Infections|HIV Seronegativity Biological
6767 NCT01289Immune Responses Af CompletedNo ResultsHealthy
6768 NCT01389Study to Evaluate th CompletedNo ResultsInfluenza Biological:
6769 NCT02429Adjuvant AUroRCC Unknown sNo ResultsRenal Cell Cancer|Advanced Renal CBiological
6770 NCT03035Dendritic Cell Thera Recruiting No ResultsAggressive Non-Hodgkin Lymphoma| Procedure:
6771 NCT01488Tenofovir in Late PregCompletedNo ResultsHepatitis B Infection|Chronic Infect Drug: TDF
6772 NCT01199Effect of Prevnar 13 oCompletedHas ResultOtitis Media Procedure:
6773 NCT00004Vaccine Therapy Plus CompletedNo ResultsLymphoma Biological: keyhole
6774 NCT01862Efficacy and Tolerabi CompletedHas ResultAnogenital Human Papilloma Virus Biological:
6775 NCT03950Lot-to-Lot PNEU-TRUActive, notNo ResultsPneumococcal Infections Drug: V114
6776 NCT01881CYT107 Afer VaccineCompletedHas ResultCastration Levels of Testosterone|C Biological
6777 NCT01362Immunogenicity and SCompletedHas ResultDiphtheria|Tetanus|Acellular PertusBiological:
6778 NCT00031The Effectiveness of CompletedNo ResultsHIV Infections Biological: gp160 MN
6779 NCT01976In Situ Vaccine for Recruiting No ResultsLow-Grade B-cell Lymphoma Drug: rhuF
6780 NCT01923Safety and Immunolog CompletedNo ResultsHIV Infections Biological:
6781 NCT01611Donor-DeriTAR CompletedNo ResultsAcute Lymphoblastic Leukemia|Ac Biological:
6782 NCT02464Trial to E PSC26 CompletedHas ResultInfluenza Biological:
6783 NCT00006Vaccinia Immune Globu WithdrawnNo ResultsHealthy|Communicable Diseases Drug: Vaccinia Immu
6785 NCT02600Efficacy Trial of a Br CompletedNo ResultsIncrease HPV Vaccination Uptake|DeBehavioral:
6786 NCT01066Improvemen HEPADIAL CompletedNo ResultsChronic Renal Failure|Humoral Immu Procedure:
6787 NCT00014Chemotherapy and Vacc CompletedNo ResultsBrain and Central Nervous System T Biological: aldesleuk
6788 NCT01457Immunogenicity and SCompletedNo ResultsHepatitis B|Diphtheria|HaemophilusBiological:
6789 NCT03258Utomilumab and ISA10 Active, notNo ResultsMalignant Neoplasms of Ill-defined Drug: Utom
6790 NCT02376Phase 1 Study of MGDCompletedNo ResultsHealthy Subjects Drug: MGD0
6791 NCT00063Vitamin A SupplementUnknown sNo ResultsInfant, Premature Drug: Vita
6792 NCT00079Lymphocyte-Depleting CompletedNo ResultsMelanoma (Skin) Biological
6793 NCT00569Immune ReconstitutioCompletedHas ResultLymphoma|Multiple Myeloma and Pl Biological:
6794 NCT00608HIV and Hepatitis Ca CompletedNo ResultsHepatitis, Viral, Human|HIV InfectioBehavioral:
6795 NCT00971A Pilot Study of Pre-ECompletedNo ResultsHIV Infections Drug: FTC/
6796 NCT00306Annual Study for FluarCompletedNo ResultsInfluenza Biological:
6797 NCT00473Non-inferiority of G CompletedHas ResultWhole Cell Pertussis|Haemophilus IBiological:
6798 NCT01326Vaccine ImRe-MATCHActive, notNo ResultsMedulloblastoma|NeuroectodermalBiological
6799 NCT03392CombinatioInSituVac1Recruiting No ResultsHigh Grade Glioma|Glioblastoma|GlCombinatio
6800 NCT01753Ciprofloxacin BioThraCompletedHas ResultAnthrax Biological:
6802 NCT00153WT1 Peptid VaccinatiUnknown sNo ResultsWT1 Expressing Carcinoma Biological
6803 NCT00807Intraseasonal Short- CompletedNo ResultsAllergy Biological:
6804 NCT01451Cellular Immunity in Unknown sNo ResultsHepatitis B Biological:
6805 NCT00160Adoptive Cell Transf SuspendedNo ResultsMelanoma Biological
6806 NCT01162Study to Evaluate theCompletedNo ResultsInfections, Rotavirus Biological:
6807 NCT02933MTBVAC Stu A-050 Recruiting No ResultsTuberculosis Biological
6808 NCT01086Study to Evaluate theCompletedNo ResultsInfections, Rotavirus Biological:
6809 NCT03950Safety andPNEU-AGEActive, notNo ResultsPneumococcal Infections Biological:
6810 NCT00135Study to Evaluate Gl CompletedNo ResultsInfections, Meningococcal Biological
6811 NCT02625Effectiveness of and CompletedNo ResultsTravel Medicine Other: Pha
6812 NCT01160Study to Evaluate th Terminate Has ResultInfluenza Biological
6813 NCT00153WT1 Peptide VaccinatUnknown sNo ResultsAcute Myeloid Leukemia|MyelodyspBiological
6814 NCT02389Phase IIb IIb-healthyCompletedNo ResultsTuberculosis Biological
6815 NCT00785Immune Res RAG-1/2 WithdrawnNo ResultsHIV Infections Biological:
6816 NCT02256Open LabelHCC Enrolling bNo ResultsHCC|Liver Cirrhosis Biological:
6817 NCT02787DC1s-CTL Cellular TheUnknown sNo ResultsRenal Cell Carcinoma Biological:
6818 NCT03884HIV and STIs Clinical Active, notNo ResultsHIV Infections|Sexual Behavior|RiskOther: Det
6819 NCT00488Safety and Local TolerCompletedNo ResultsPneumococcal Infections Biological: pneumoco
6820 NCT01040A Study to Pneucast CompletedNo ResultsPneumococcal Disease
6821 NCT01142Study of VGX-3400X, H CompletedNo ResultsHealthy Biological
6822 NCT01082Study of PEHIV-001 CompletedNo ResultsHIV-1 Infection|HIV Infections Biological
6823 NCT01147Safety StudMIAMINK CompletedHas ResultLiver Cirrhosis|Hepatocellular Carc Biological:
6824 NCT02758Study Assessing TolerWithdrawnNo ResultsParkinson's Disease Biological
6825 NCT00305Umbilical Cord Blood CompletedHas ResultType 1 Diabetes Mellitus Procedure:
6826 NCT03408Clinical T Ad4HIV CompletedNo ResultsHuman Immunodeficiency Virus Biological
6827 NCT01621EvaluationExten EffivCompletedNo ResultsNeisseria Meningitidis Biological
6828 NCT00377Study on the IncidencCompletedHas ResultInfluenza Biological:
6829 NCT02429PolysacchaPARS Unknown sNo ResultsSpecific Polysaccharide Antibody DeBiological
6830 NCT00157Safety Study of TecemCompletedHas ResultCarcinoma, Non-Small-Cell Lung|Lu Biological
6831 NCT01339Epidemiological, ObseCompletedNo ResultsInfections, Rotavirus Procedure:
6832 NCT00778Study Assessing Safe CompletedNo ResultsHealthy Biological:
6833 NCT04265Single Ascending DosNot yet recNo ResultsHealthy Volunteers Biological
6834 NCT02390Open-label, Phase I/ Unknown sNo ResultsHIV Biological:
6835 NCT00852A Study EvaMUC1 CompletedNo ResultsProstate Cancer Biological
6836 NCT04119Randomized, Double-b Not yet recNo ResultsMERS (Middle East Respiratory Syn Biological
6837 NCT02700Vaccine Therapy in T Recruiting No ResultsMetastatic Malignant Peripheral Ne Procedure:
6838 NCT01149Evaluation of a New VCompletedHas ResultMelanoma Biological
6839 NCT01683Safety Study of Tube CompletedNo ResultsTuberculosis Biological
6840 NCT00020Vaccine Therapy in TrCompletedNo ResultsExtraocular Extension Melanoma|ReDrug: gp100 antigen|
6841 NCT03692A Study to Evaluate t Active, notNo ResultsPneumococcal Infections Biological:
6842 NCT00327Cytotoxicity Induced Unknown sNo ResultsCarcinoma, Hepatocellular Biological: DC vaccine
6843 NCT00456Safety and Immunogen CompletedNo ResultsTuberculosis Biological
6844 NCT02374A Surveillance Study Recruiting No ResultsMalaria Procedure:
6845 NCT03207Microneedle Patch Stu CompletedNo ResultsVaccination|Skin Absorption Device: Mi
6846 NCT00042Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: D1/3-MAGE
6847 NCT03120Phase 1 Trial of PAN- CompletedNo ResultsProstate Cancer Biological
6848 NCT00808Safety and Immunogeni CompletedNo ResultsCrohn's Disease Biological:
6849 NCT03415Using Rapid Cycle RanRecruiting No ResultsClinical Decision Support Other: Curr
6850 NCT02207Influence of HyaluronCompletedHas ResultPoisoning by BCG Vaccine Drug: Hyal
6851 NCT02495A Study to Assess Eb CompletedNo ResultsEbola Virus Disease Biological
6852 NCT01091A Study to LAIV CompletedHas ResultHealthy or Stable Chronic Illness Biological
6853 NCT00112Immunotherapy of Sta CompletedNo ResultsMelanoma Biological
6854 NCT00019Vaccine Therapy WithCompletedNo ResultsStage IV Melanoma|Recurrent Mel Drug: gp100 antigen|D
6855 NCT00005Vaccine Therapy in T CompletedHas ResultProstate Cancer Biological:
6856 NCT00203Study of MAGE-3/MelCompletedNo ResultsMetastatic Melanoma Drug: MAGE
6857 NCT00203Trial of G250 Peptide Terminate No ResultsMetastatic Renal Cell Carcinoma Drug: G250
6858 NCT00003Vaccine Therapy in TreCompletedNo ResultsPancreatic Cancer Biological: vitespen
6859 NCT02557T-cell Diversity Follo CompletedNo ResultsInfluenza Biological:
6860 NCT00126Clinical Trial Studyi Terminate No ResultsKidney Cancer|Renal Cell Carcinom Biological
6861 NCT01039Assessment of SafetyUnknown sNo ResultsHealthy Biological
6862 NCT02754A Toll-like Receptor WithdrawnNo ResultsGlioblastoma|Glioma Drug: Beva
6863 NCT03101A Dose-finding Study CompletedNo ResultsRhinitis, Allergic, Seasonal Drug: ASP4
6864 NCT00001A Study on the Rate oCompletedNo ResultsHIV Infections Biological: Hepatitis
6865 NCT00003Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: MART-1 an
6866 NCT00595Open LabelOLTERMS Terminate Has ResultMultiple Sclerosis, Relapsing-RemittBiological:
6867 NCT04061Sero-epideSTORY Not yet recNo ResultsSerogroup C Meningococcal MeningiProcedure:
6868 NCT00005Vaccine Therapy in TrCompletedNo ResultsSarcoma Biological: vitespen
6869 NCT02317Immunotherapy of Gas Unknown sNo ResultsGastric Carcinoma Biological:
6870 NCT03189Assessing the Impact Recruiting No ResultsMaternal Health|Child Health|VacciBehavioral
6871 NCT00068Vaccine Therapy in TrCompletedNo ResultsBrain and Central Nervous System T Biological:
6872 NCT01133Improved Prevention Unknown
o sNo ResultsLiver Fibrosis Biological:
6873 NCT00005Vaccine Therapy in TrCompletedNo ResultsKidney Cancer Biological: therapeut
6874 NCT00017Vaccine Therapy in T Unknown sNo ResultsMelanoma (Skin) Biological: filgrastim
6875 NCT00001A Pilot Study of ImmuTerminate No ResultsHIV Infections Drug: Allogenic Dendri
6876 NCT00010Vaccine Therapy in TrTerminate No ResultsProstate Cancer Biological: therapeuti
6877 NCT01024Safety and Immunogen Terminate No ResultsHIV-1 Biological
6878 NCT00568Immunobiology of DiaTerminate Has ResultTuberculosis|Diabetes Mellitus Biological:
6879 NCT00680Patients With Mouse CompletedNo ResultsMelanoma Biological
6880 NCT00450Vaccine Therapy WithCompletedHas ResultRecurrent Plasma Cell Myeloma|RefDrug: Cycl
6881 NCT01933Burden of Invasive GrCompletedNo ResultsInvasive Group B Streptococcal Disease
6882 NCT00985A Study of ProQuad inCompletedHas ResultMeasles|Mumps|Rubella|Varicella Biological
6883 NCT04024NeoVax With Nivoluma Not yet recNo ResultsOvarian Cancer Drug: Nivo
6884 NCT00057Vaccine Therapy in TrCompletedNo ResultsUnspecified Adult Solid Tumor, ProtoBiological:
6885 NCT00482DTaP and APIA CompletedNo ResultsProlonged Apnea|Prolonged BradycBiological:
6886 NCT00010Vaccine Therapy in TrUnknown sNo ResultsMelanoma (Skin) Biological: MART-1 an
6887 NCT00032Vaccine Therapy and CompletedNo ResultsIntraocular Melanoma|Melanoma (SBiological: gp100 ant
6888 NCT03619Conditioni CSIDE Recruiting No ResultsSCID Drug: Busu
6889 NCT00726A Pilot Study, EvaluatTerminate Has ResultMetastatic Pancreatic Cancer Drug: Onta
6890 NCT01074ROTATEQ ReexaminatiCompletedHas ResultGastroenteritis Rotavirus
6891 NCT01996Understanding PneumCompletedNo ResultsMeningitis|Septicaemia|Pneumonia
6892 NCT03542Standard OABSOP-FolActive, notNo ResultsHuman Papilloma Virus Infection Device: Fir
6893 NCT00020Vaccine Therapy Plus CompletedNo ResultsEsophageal Cancer|Gastric Cancer Biological
6894 NCT00163Study to Investigate CompletedNo ResultsEncephalitis, Tick-borne Biological: Formaldeh
6895 NCT00008Vaccine Therapy in TrCompletedNo ResultsPancreatic Cancer Biological
6896 NCT01354Safety and Immunogen CompletedNo ResultsHealthy Adult Volunteers Biological:
6897 NCT02280Prevention of HPV in CompletedNo ResultsHuman Papillomavirus|Cervix CanceBehavioral
6898 NCT01062GARDASIL ReexaminatCompletedHas ResultHuman Papillomavirus (HPV) Infection
6899 NCT03102Understanding PneumRecruiting No ResultsStreptococcus Pneumoniae Infectio Diagnostic
6900 NCT00003Vaccine Therapy in TrCompletedNo ResultsBreast Cancer Biological: rV-DF3/M
T ResultsLung Cancer Biological: BCG vacci
6904 NCT00688Safety and Immune RCompletedNo ResultsAdvanced Melanoma|Stage III and Biological
6905 NCT02543A Study to Evaluate CompletedNo ResultsHealthy Biological
6906 NCT00509Vaccine Therapy in T CompletedNo ResultsCancer Biological
6907 NCT00679A Phase I SRisVac02 CompletedNo ResultsHIV Infections Biological
6908 NCT00785IMA910 PluIMA910-10CompletedNo ResultsColorectal Carcinoma Drug: Endo
6909 NCT02887Study of GLS-5700 in CompletedNo ResultsHealthy|Zika Biological:
6910 NCT00003Vaccine Therapy in T CompletedNo ResultsMelanoma (Skin) Biological: aldesleuki
6911 NCT02172A Study of INO-3112 D CompletedNo ResultsCervical Cancer Biological:
6912 NCT01734Study to Identify Fac CompletedHas ResultPregnancy, Newborn Health
6913 NCT02795Clinical Study of Re CompletedNo ResultsTuberculosis Biological:
6914 NCT02361To Evaluate the Effec CompletedNo ResultsBacterial Infections Biological:
6915 NCT03625Study to Evaluate IndRecruiting No ResultsHepatitis B Biological:
6916 NCT01338The Change of the TetCompletedNo ResultsTetanus
6917 NCT03500A Study to Evaluate SCompletedHas ResultHealthy Biological:
6918 NCT01355GARDASILâ„¢ Post Mark Terminate No ResultsPapillomavirus Infections
6919 NCT01262Evaluation of Influen CompletedNo ResultsInfluenza
6920 NCT01687Biological Efficacy S CompletedNo ResultsHerpes Simplex Type II Drug: Herp
6921 NCT01008Phase I Oncovir Poly CompletedNo ResultsMelanoma Drug: CP 87
6922 NCT00844Low-dose Challenge M CompletedNo ResultsDiarrhea Biological:
6923 NCT00002Interferon Alfa With Unknown sNo ResultsMelanoma (Skin) Biological: Detox-B a
6924 NCT03014Safety, Tolerability, CompletedNo ResultsZika Virus Biological
6925 NCT02100Safety and Efficacy o Unknown sNo ResultsCervical Intraepithelial Neoplasia 3 Biological:
6926 NCT00159Adoptive ImmunotherWithdrawnNo ResultsCMV Disease Biological
6927 NCT02853Evaluation of Immunog CompletedHas ResultDiphtheria|Hepatitis B|Acellular Pe Biological:
6928 NCT01862Collection of Biologi Terminate No ResultsMalaria
6929 NCT00451Hepatitis VHEPVACHI Unknown sNo ResultsHIV Infections|Hepatitis A|HepatitisBiological:
V ResultsFallopian Tube Cancer|Ovarian CancBiological: abagovom
6931 NCT00084Monoclonal AntibodyCompletedNo ResultsIntraocular Melanoma|Melanoma (SBiological
6932 NCT00166V260 Registration S CompletedHas ResultRotavirus Biological:
6933 NCT00050Safety/Efficacy of a CompletedNo ResultsCarcinoma, Renal Cell Drug: Allogeneic DCs
6934 NCT01878Pilot Study of BC-819CompletedNo ResultsTransitional Cell Carcinoma of BladdDrug: BC-8
6935 NCT00078PROSTVACÂ®-VF/TRICOM CompletedNo ResultsProstate Cancer Biological: PROSTVA
6936 NCT02707Anti-oxLDL IgM AntiboUnknown sNo ResultsLipid Metabolism, Inborn Errors Biological:
6937 NCT01213Dendritic GBM-Vax CompletedNo ResultsGlioblastoma Multiforme Drug: Triv
6938 NCT03168Trial to Evaluate the CompletedNo ResultsPlasmodium Falciparum Infection Biological
6939 NCT00828BLP25 Liposome VacciActive, notHas ResultLung Cancer Biological
6940 NCT01847Evaluation of the LonCompletedHas ResultHepatitis B Biological:
6941 NCT01895Effect of COMARIS CompletedNo ResultsAnkylosing Spondylitis Drug: Ada
6942 NCT01234Study of IMF-001 in CompletedNo ResultsSolid Tumor Biological:
6943 NCT00083A Study of TroVax VacCompletedNo ResultsCarcinoma, Renal Cell Biological:
6944 NCT00908Post Market SurveillaCompletedHas ResultDiphtheria|Acellular Pertussis|Teta Biological:
6945 NCT02116Anti-BiophaABI-RA Unknown sNo ResultsRheumatoid Arthritis|Juvenile IdiopaProcedure:
6946 NCT02535Seasonal THelios CompletedNo ResultsChronic Obstructive Pulmonary Disease (COPD
6947 NCT02316RNA-Immun TNBC-MERActive, notNo ResultsBreast Cancer (Triple Negative Brea Biological
6948 NCT00306Safety and Immunogen CompletedNo ResultsMalignant Melanoma Biological: CYT004-
6949 NCT04211Maternal Therapy With Recruiting No ResultsHepatitis B, Chronic|Pregnancy RelaDrug: Teno
6950 NCT03869Dose Escalating Stud Active, notNo ResultsDiarrhea Biological
6951 NCT01567Post-Licensure Study CompletedNo ResultsHuman Papilloma Virus Infection
6952 NCT00397Study Evaluating Sin CompletedHas ResultAlzheimer Disease Drug: bap
6953 NCT03803Dengue EffectivenessRecruiting No ResultsDengue|Severe Dengue|Virologically Confirm
6954 NCT02624Study Comparing AlloWithdrawnNo ResultsSquamous Cell Carcinoma Head andBiological:
6955 NCT00197Dendritic Cell Based Terminate No ResultsMetastatic Breast Cancer Biological:
6956 NCT02103An Evaluation of a C CompletedNo ResultsDialysis|Healthy Subjects|CytomegalDrug: ASP0
6957 NCT00325Study to Evaluate Saf CompletedNo ResultsCarcinoma, Renal Cell Biological: TroVaxÂ®
6958 NCT00693A Study to Assess th CompletedNo ResultsHepatitis B Biological
6959 NCT00090CP-675,206 (CTLA4-BlCompletedNo ResultsMelanoma (Skin) Biological
6960 NCT02688Safety and Efficacy Unknown sNo ResultsNon-Small-Cell Lung Cancer With B Biological:
6961 NCT00879Cellular ImmunotheraUnknown sNo ResultsBreast Cancer Biological:
6962 NCT01360Preventing the SpreadCompletedNo ResultsMalaria
6963 NCT02870Human Chal ETECvacWRecruiting No ResultsDiarrhea, Infantile Biological
6964 NCT02961Multi Interventional Active, notNo ResultsChronic Infection|HIV Drug: Marav
6965 NCT03548Dendritic DEN-STEMRecruiting No ResultsGlioblastoma Biological
6966 NCT00025Monoclonal AntibodyCompletedNo ResultsIntraocular Melanoma|Melanoma (SBiological: MART-1 an
6967 NCT00005Effectiveness of Trea Unknown sNo ResultsHIV Infections Drug: Lamivudine/Zid
6968 NCT00006Tumor Lysate Pulsed-CompletedNo ResultsLymphoma, Non-Hodgkin Biological: tumor-puls
6969 NCT00863Assessing Antibody RUnknown sNo ResultsLymphoma Biological:
6970 NCT00005Safety and Effectiven CompletedNo ResultsHIV Infections Biological: HIV-1 Im
6971 NCT02164To Evaluate the Effic CompletedNo ResultsPrevention Harmful Effects Biological:
6972 NCT00068Human Immune Respo CompletedNo ResultsSmallpox Biological: Dryvax
6973 NCT00303SIGA-246 to Treat SmWithdrawnNo ResultsVaccinia Drug: Vaccine: SIGA-
6974 NCT02687Safety andProQuadÂ CompletedNo ResultsRENAL INSUFFICIENCY, CHRONIC|LI Biological
6975 NCT01569A Phase II SKOPOS Unknown sNo ResultsMalignant|Pleural|Mesothelioma Biological
6976 NCT00367Evaluation of ReproduCompletedHas ResultMALARIA|FEVER|Sweating Fever|ChOther: 41
6977 NCT01084Probiotic, Prebiotic Unknown sNo ResultsDietary Intervention Dietary Su
6978 NCT01961A Study to Evaluate CompletedNo ResultsInfluenza|Vaccine Biological
6979 NCT01269Effects of Sulforaph CompletedNo ResultsSmoking Dietary Su
6980 NCT02864Peptide TaPERFORMAActive, notNo ResultsGlioblastoma|Glioblastoma Multifo Drug: 5-da
6981 NCT00000A Phase I Study to Ev CompletedNo ResultsHIV Infections|HIV Seronegativity Biological
6982 NCT01931METHORIVA METHORIVCompletedNo ResultsInfants Likely to Present Febrile Convulsions
6983 NCT00815Cytomegalovirus Cel CompletedNo ResultsCytomegalovirus Infections
6984 NCT00026Safety/ImmunogenicitCompletedNo ResultsHIV Infections Biological: ALVAC(2
6985 NCT03721ENCAPSID ESNCAPSID Recruiting No ResultsImmune Deficiency
6986 NCT01591Safety Study of Depi Terminate No ResultsAllergic Rhinitis|Rhinoconjunctivit Biological
6987 NCT03067Investigat TYGER Active, notNo ResultsSalmonella Typhi Infection Other: Salm
6988 NCT02718VXM01 Phase I Pilot SCompletedNo ResultsGlioblastoma Drug: VXM
6989 NCT01949Safety and Efficacy S CompletedNo ResultsNon-small Cell Lung Cancer Biological
6990 NCT00365Broad Spectrum HPV Withdrawn
Va No ResultsCervical Cancer|Condylomata AcumBiological:
6991 NCT00875Evaluation of Antibo CompletedHas ResultHepatitis B|Hepatitis A Procedure:
6992 NCT00157Phase 2b RandomizedCompletedHas ResultLung Neoplasms|Carcinoma, Non-Sma Biological
6993 NCT01950Safety and Efficacy S CompletedNo ResultsNon-small Cell Lung Cancer Biological
6994 NCT00401Rubella Susceptibili CompletedNo ResultsRubella|Vaccine
6996 NCT01508Epidemiology of RotavCompletedNo ResultsRotavirus Gastroenteritis
6997 NCT03158Zika Case Definition CompletedNo ResultsZika Virus Disease
6998 NCT01440IL-12 GeneMCC CompletedHas ResultMerkel Cell Carcinoma Biological
6999 NCT02694Trial of R TRAKC18 Unknown sNo ResultsPain|Development Procedure:
7000 NCT01795Vitamin B12 SupplemCompletedNo ResultsNutritional Anemia in Mothers.|NutrDietary Su
7001 NCT00300Safety and Efficacy o CompletedNo ResultsPancreas Cancer Biological
7002 NCT03911Phase II S PVX-2 Recruiting No ResultsASC-US|ASC-H Atypical Squamous Cel Biological
7003 NCT01109Safety Study of a Hu CompletedNo ResultsHuman Metapneumovirus Biological
7004 NCT00753Immunogenicity and Sa CompletedHas ResultHepatitis B|Tetanus|Poliomyelitis|DBiological:
7005 NCT00606Safety and Efficacy o CompletedHas ResultGenotype 1 Chronic Hepatitis C Drug: GI-5
7006 NCT02062Efficacy, Safety, and CompletedHas ResultRotavirus Gastroenteritis Biological:
7007 NCT03913Study of T PVX-6 Active, notNo ResultsASC-US|LSIL Biological
7008 NCT00342Surveillance of StreptCompletedNo ResultsGroup A Beta Hemolytic Streptococcal (GAS) Infection
7009 NCT00082Trial to Compare the Terminate No ResultsRenal Cell Carcinoma Biological: autologo
7010 NCT02649Docetaxel and PROSTVA Active, notNo ResultsProstate Cancer|Prostate NeoplasmsBiological
7011 NCT00766Intermittent Preventi CompletedNo ResultsMalaria Drug: Sulf
7013 NCT01777Development of Read-o CompletedHas ResultHepatitis B Biological
7014 NCT00221Increasing Infant PrevTerminate No ResultsHealthy Behavioral
7015 NCT00264GAS Epi Study to Meas CompletedNo ResultsStreptococcus Group A
7017 NCT02561A Study to Evaluate t CompletedNo ResultsRespiratory Syncytial Viruses|RespiraBiological
7018 NCT03576Evaluate Tolerability Recruiting No ResultsCytomegalovirus Infections|PreventaBiological:
7019 NCT02503The HPV-SAHPV-SAVE Enrolling bNo ResultsAnal Dysplasia|Human PapillomavirDevice: Th
7020 NCT00876To Study the Effect O CompletedNo ResultsLeishmaniasis, Visceral Drug: Amph
7021 NCT01583Post Authorisation SafCompletedNo ResultsDiphtheria, Tetanus and Pertussis
7022 NCT02112Study to Assess SeropCompletedNo ResultsHepatitis A|Viral Hepatitis Vaccines Other: Data
7023 NCT01374NASVAC PhasNASVAC Unknown sNo ResultsChronic Hepatitis B Biological
7024 NCT00924Safety, Tolerability CompletedNo ResultsType 2 Diabetes Mellitus Drug: CYT0
7025 NCT00711Repeated DGIEU006 CompletedNo ResultsHIV Infection Biological:
7026 NCT04210Study to Assess the SNot yet recNo ResultsPrevention of Herpes Zoster (HZ) Drug: Trea
7027 NCT01795Immunotherapy for RRecruiting No ResultsEpendymoma Biological
7028 NCT00001Autologous T-Cell TraCompletedNo ResultsBreast Neoplasm|Neoplasm MetastaProcedure: Autologous
7029 NCT01308Costa Rica Epidemiol SuspendedNo ResultsStreptococcus Pneumoniae Procedure:
7030 NCT00002Surgery and BCG in TrCompletedNo ResultsBladder Cancer Biological:
7031 NCT00706Anti-MART-1 F5 Lymph Terminate Has ResultMelanoma Biological
7032 NCT02420A Study fo C-013-404CompletedNo ResultsTuberculosis Biological:
7034 NCT02551Evaluate the Safety, CompletedHas ResultAlzheimer's Disease Biological
7035 NCT02795A Study of IMU-131(HRecruiting No ResultsGastrointestinal Neoplasms|Adeno Biological:
7036 NCT00633Peptide Vaccine FocusUnknown sNo ResultsBladder Cancer Biologica
7037 NCT00408Recombinant MeaslesCompletedHas
V ResultOvarian Cancer|Primary Peritoneal Biological
7038 NCT00653Effectiveness of Rota CompletedNo ResultsInfections, Rotavirus Other: No
7039 NCT01935Nutritional SupplemeCompletedNo ResultsImmunosenescence|Sarcopenia Dietary Su
7040 NCT00500Safety, Tolerability, CompletedNo ResultsEssential Hypertension Biological: CYT006-A
7041 NCT04042SBRT as a Vaccinatio Recruiting No ResultsMetastatic Melanoma Drug: Nivo
7042 NCT01644Phase 1 Study of Ant CompletedNo ResultsAdvanced Cancer Drug: Coho
7043 NCT00081A Safety and Effectiv CompletedNo ResultsLymphoma, Follicular|Lymphoma, SDrug: autologous hu
7044 NCT01378A Study to Evaluate CompletedNo ResultsTuberculosis Biological:
7045 NCT03349Safety and Tolerabili Active, notNo ResultsSafety Issues Biological
7046 NCT01553Effectiveness Study oCompletedNo ResultsCondyloma|Genital Warts
7047 NCT02097Substudy of Protocol CompletedNo ResultsTuberculosis
7048 NCT00047Monoclonal AntibodyCompletedNo ResultsLymphoma Biological:
7049 NCT03116Immunogenicity and SCompletedNo ResultsHerpes Zoster Biological:
7050 NCT04135A Controll Lac5-NasalRecruiting No ResultsMeningitis, Bacterial Biological:
7051 NCT01503Effectiveness of ParenUnknown sNo ResultsPain Behavioral
7052 NCT00133Proteomic Profiling foCompletedNo ResultsInfluenza Biological: Trivalent sp
7053 NCT03373Na-GST-1/Alhydrogel CompletedNo ResultsHookworm Infection|Hookworm DisBiological
7054 NCT00822Safety and Immunogen CompletedHas ResultHealthy Biological
7055 NCT03676CommunityCHAT Recruiting No ResultsChildhood Mortality Drug: Azit
7057 NCT00495Brief Cognitive-BehavCompletedNo ResultsPost-Traumatic Stress Disorder Behavioral:
7058 NCT01051Safety andSELECTED CompletedHas ResultRelapsing-Remitting Multiple SclerosBiological:
7059 NCT02015Study of Bacillus Ca CompletedHas ResultBladder Cancer Biological:
7060 NCT02809Study of GLS-5700 in CompletedNo ResultsHealthy Biological:
7061 NCT00898Prebiotics and Immu CompletedNo ResultsImmune Function Dietary Su
7062 NCT04114Study of R BRaVac Recruiting No ResultsProstate Cancer Recurrent Biological
7063 NCT00603Development of a SkiCompletedHas ResultHookworm Infection|Allergy Biological:
7064 NCT00541Weekly Vaccination WSuspendedNo ResultsDry Age Related Macular DegeneratDrug: Copa
7065 NCT03630Challenge NadA-Lac4Recruiting No ResultsMeningitis, Bacterial|Neisseria InfecBiological:
7066 NCT00772Retrospective Survey CompletedHas ResultDiphtheria|Pertussis|Haemophilus Infection|T
7067 NCT00696Immunogenicity and Sa CompletedHas ResultAcellular Pertussis|Diphtheria|Teta Biological:
7068 NCT03843Evaluation of the Saf Recruiting No ResultsVaricella Biological
7069 NCT00576Immunotherapy for Pa CompletedNo ResultsBrain Stem Glioma|Glioblastoma Biological:
7070 NCT00001A Study to Monitor t CompletedNo ResultsHIV Infections
7071 NCT02388Study to Evaluate theTerminate No ResultsAlzheimer Disease Drug: Lu A
7072 NCT01321Sleep DisruMOMS CompletedHas ResultPregnancy|Postpartum Period|SleepBehavioral
7073 NCT00192Trial to Assess the S CompletedNo ResultsInfluenza Biological:
7074 NCT02423In Situ, Au Poly-ICLC Recruiting No ResultsMelanoma|Head and Neck Cancer|Biological:
7075 NCT01995A Prospective, EpidemActive, notHas ResultRespiratory Syncyctial Virus Vaccine Procedure:
7076 NCT02099Antibody Levels AssocWithdrawnNo ResultsInvasive Group B Streptococcus Disease
7077 NCT01706Burden of RespiratoryCompletedNo ResultsRespiratory Syncyctial Virus Vaccine Other: Data
7078 NCT00204Treatment for Chroni Terminate No ResultsMajor Depressive Disorder Behavioral:
7079 NCT02712A Roll-overISST-003EFCompletedNo ResultsHIV Infections Other: No
7080 NCT02432IntratumorMERECA CompletedNo ResultsRenal Cell Carcinoma, Metastatic Biological:
7081 NCT01340A Study of V419 GiveCompletedHas ResultBacterial Infections|Virus Diseases Biological
7082 NCT02643A Phase 1/2 Study of Recruiting No ResultsHead and Neck Squamous Cell Carc Drug: Durv
7083 NCT02267Study AssesAFF011 CompletedNo ResultsParkinson Disease|NeurodegeneratiBiological
7084 NCT01435Study of Late Boost SActive, notNo ResultsHIV Infections Biological
7085 NCT02270Study AsseAFF009 CompletedNo ResultsMultiple System Atrophy|NeurodegeBiological
7086 NCT00476Immunogenicity and Re CompletedNo ResultsInfluenza Biological
7087 NCT02440Grass Poll SCITelderlyCompletedNo ResultsAllergy Drug: Pure
7088 NCT00581Study Evaluating the CompletedNo ResultsHealthy Biological:
7089 NCT02096Study to Determine thCompletedHas ResultPoliomyelitis|Diphtheria|Haemophilu Biological:
7090 NCT00316Effectiveness of the CompletedHas ResultHIV Infections|Schizophrenia|Schiz Drug: Twin
7091 NCT01856QUILT-3.006 for RecuActive, notNo ResultsMedullary Thyroid Cancer (MTC) Biological
7092 NCT00836A Study of the Safet Terminate Has ResultRotavirus Biological
7093 NCT04075Study of UB-312 in HeRecruiting No ResultsParkinson Disease|Parkinsonism Biological:
7094 NCT01335CHRONVAC-C Study Fol Unknown sNo ResultsChronic Hepatitis C Drug: Chro
7095 NCT01103Effects of High Cut-o Unknown sNo ResultsEnd-stage Kidney Disease|CD4 T CelDevice: P
7096 NCT03338Suicide Pl IGTM-101 Unknown sNo ResultsMelanoma Biological
7097 NCT03478Safety and PharmacokCompletedHas ResultHealthy Adult Immune Responses toBiologica
7098 NCT00136Response to GSK BiolCompletedHas ResultWhole Cell Pertussis|Haemophilus IBiological
7099 NCT01641Assessment of the ImCompletedHas ResultBacillus Anthracis (Anthrax) Biological:
7100 NCT02503Trial of Antigen PulseNot yet recNo ResultsMetastatic Colorectal Cancer Biological
7101 NCT00711Long-term Safety andCompletedNo ResultsAlzheimer's Disease
7102 NCT00469Vanderbilt VPES CompletedHas ResultPertussis Drug: Antib
7103 NCT00801Primary Tumor Harvest Active, notNo ResultsOvarian Cancer|Peritoneal Cancer|FProcedure:
7104 NCT01924Gardasil I GINI CompletedNo ResultsHPV Seroconversion
7105 NCT00741Dose-escalGHB-CS03 CompletedNo ResultsInfluenza Biological
7106 NCT02336Research InRIVER Active, notHas ResultHIV Drug: Comb
7107 NCT02568Infant Immunity Compa CompletedNo ResultsInfant Immunity Response and ImmuProcedure:
7108 NCT00231Trial Evaluating Safe CompletedNo ResultsGenital Herpes Drug: AG-
7109 NCT02159Sipuleucel-T With or CompletedHas ResultHormone-Resistant Prostate Cancer|Other: Lab
7110 NCT01137Post Marketing SurveCompletedHas ResultDiphtheria|Tetanus|Pertussis Biological
7111 NCT00362Developing World St CompletedHas ResultVomiting|Diarrhea|Fever Biological:
7112 NCT03563A Study to Assess Fr CompletedNo ResultsHerpes Zoster Other: Enco
7113 NCT01077A Study to Evaluate CompletedHas ResultVaricella|Herpes Zoster
7114 NCT03619Twinrix Pregnancy Reg CompletedHas ResultHepatitis Other: Data
7115 NCT02413A Phase I, Open LabelCompletedNo ResultsHIV-infection Biological
7116 NCT02597Bacterial Compositio CompletedNo ResultsInfluenza Biological:
7117 NCT01177Study to Evaluate theCompletedNo ResultsRotavirus Gastroenteritis Procedure:
7118 NCT01750To Evaluate the Effec CompletedNo ResultsProphylaxis Against Influenza Biological:
7119 NCT03849Reducing CompetitiveNot yet recNo ResultsSports Injury|Stress Reaction|Perf Behavioral
7120 NCT00138T-cell Response-Flu RiCompletedNo ResultsInfluenza Biological: Commercial
7121 NCT00152The Community Effecti Unknown sNo ResultsMalaria, Falciparum|Anemia Drug: Sulf
7122 NCT00138Influenza Immunity ACompletedNo ResultsInfluenza Biological: FluMist|Bi
7123 NCT00002Biological Therapy in CompletedNo ResultsProstate Cancer Biological: aldesleuk
7124 NCT01151Efficacy Against TB CompletedHas ResultTuberculosis|HIV Infections Biological
7125 NCT00224Phase I Trial Evaluati CompletedNo ResultsHealthy Japanese Male Adults Biological:
7126 NCT00672A Phase I WT-1 Terminate No ResultsAcute Myelogenous Leukemia (AML)| Biological
7127 NCT03891Confirmatory Study ofActive, notNo ResultsTetanus|Diphtheria|Pertussis|Poliom Biological:
7128 NCT01774Immunotherapy StudyTerminate No ResultsNon-small Cell Lung Cancer|ProgresDrug: Doce
7129 NCT02253Efficacy of Antiviral Unknown sNo ResultsImmune Globulin, Prophylaxis, TelbuDrug: telb
7130 NCT02447Trial of Tw BCGSTRAI CompletedNo ResultsMorbidity|Bacille Calmette-GuÃ©riBiological:
7131 NCT02067Demonstrate the Lot-tCompletedNo ResultsPrevention of Influenza Drug: GC FL
7132 NCT00952Study to Assess dHERCompletedNo ResultsMetastatic Breast Cancer Biological
7133 NCT00531Testing a PIndivo at CompletedNo ResultsInfluenza Other: Hea
7134 NCT01419GP2013 in ASSIST_FL CompletedNo ResultsFollicular Lymphoma Biological:
7135 NCT02934Study of RuImmRubVaCompletedNo ResultsPregnancy Biological:
7136 NCT01026Safety, Immune and Terminate No ResultsStage III Melanoma|Stage IV Mela Biological
7137 NCT00000A Phase II Safety an CompletedNo ResultsHIV Infections Biological: MN rgp12
7138 NCT01435Observational Study oCompletedNo ResultsInfections, Rotavirus Other: Data
7139 NCT00265Efficacy and Safety CompletedNo ResultsTuberculosis Biological
7140 NCT02014A Study to DetermineCompletedHas ResultPertussis|Pertussis Vaccines Procedure:
7141 NCT00341Efficacy and Safety CompletedNo ResultsTuberculosis Biological
7142 NCT00227Study Evaluating PrevCompletedNo ResultsInvasive Pneumococcal Disease Drug: Pneumococcal 7
7143 NCT00322Long-term PersistenceCompletedHas ResultHaemophilus Influenzae Type b|NeisBiological:
7144 NCT02195Efficacy and Safety S CompletedNo ResultsCervical Intraepithelial Neoplasia Drug: BLS
7145 NCT00111Intermittent Preventi CompletedNo ResultsMalaria|Anemia Drug: sulf
7146 NCT01734A Phase III Clinical CompletedHas ResultPneumococcal Disease Biological
7147 NCT03241MyChart inMyIBD CompletedNo ResultsInflammatory Bowel Diseases Behavioral
7148 NCT00958Alcohol UsNIAAA CompletedNo ResultsHepatitis C Behavioral
7149 NCT01350Skin Test Study of B CompletedNo ResultsHypersensitivity Biological
7150 NCT01363Surveillance of RotaviUnknown sNo ResultsGastroenteritis|Rotavirus Infections
7151 NCT00122Study of HIV-1 Rgp-1 Terminate No ResultsHIV Infections Biological:
7152 NCT02304Safety, Tolerability CompletedNo ResultsHealthy Biological
7153 NCT00263Study to Evaluate th CompletedNo ResultsHealthy Biological
7154 NCT00213The Effect of Needle CompletedNo ResultsInfluenza Device: 22
7155 NCT01526A Phase I Study To EvCompletedNo ResultsHER2+ Cancer Biological
7156 NCT00711Long-term Safety andCompletedNo ResultsAlzheimer's Disease
7157 NCT00918AntiretroviPHPC-02 CompletedNo ResultsHIV Infection Biological
7158 NCT01357Observational FollowTerminate No ResultsAlzheimerÂ´s Disease
7159 NCT00197Administration of AutCompletedNo ResultsBreast Neoplasms Biological
7160 NCT02035Immunotherapy StudyActive, notNo ResultsMetastatic Renal Cell Carcinoma|Met Biological
7161 NCT00063Dressing PreparationsCompletedNo ResultsSmallpox Biological: Wetvax (A
7162 NCT01622Immunogenicity and SCompletedNo ResultsRabies Biological
7163 NCT04234Patient Navigation 2. Not yet recNo ResultsCancer Behavioral:
7164 NCT00929Immunogenicity & Safe CompletedHas ResultInfluenza Biological:
7165 NCT01380MAGE-A3 Protein + ASCompletedHas ResultMultiple Myeloma Biological
7166 NCT00313Dendritic Cell Vaccin CompletedNo ResultsIntraocular Melanoma|Melanoma (SBiological:
7167 NCT03728The ImpactINFLAMMARecruiting No ResultsRSV Infection Biological
7168 NCT02065An Open-Label, PhaseCompletedNo ResultsHigh-risk HPV Infection and Biopsy- Biological
7169 NCT01551Post-marketing SurveiWithdrawnNo ResultsHuman Papillomavirus Infection Other: Cerv
7170 NCT01988Dynamics oDyPAVIR CompletedNo ResultsInfection by Human Papilloma VirusOther: Vari
7171 NCT01391Immunogenicity and SCompletedHas ResultHerpes Zoster Biological
7172 NCT01943Evaluation of the Per CompletedHas ResultInjections, Intradermal Device: ID
7173 NCT03817Non-vaccina ANOVAC BCompletedNo ResultsAdult Patients Drug Users|Substitu Other: Que
7174 NCT00471Pneumoniae Epidemio CompletedNo ResultsPneumococcal Disease
7175 NCT03072Pembrolizumab in RecCompletedNo ResultsMedullary Thyroid Cancer (MTC) Drug: Pem
7176 NCT02074A Phase I Study to E CompletedNo ResultsTuberculosis Biological
7177 NCT00532A/H5N1 Dose RangingCompletedNo ResultsPandemic Influenza Biological
7178 NCT00000A Placebo-Controlled,CompletedNo ResultsHIV Infections Biological: rgp120/H
7179 NCT01339National Trends in OtCompletedNo ResultsOtitis Media|Myringotomy Tube InsOther: no
7180 NCT00523IMA901 in IMA901-20CompletedNo ResultsRenal Cell Carcinoma Drug: Endo
7181 NCT00000A Phase I Clinical Tr CompletedNo ResultsHIV Infections Biological: rgp120/HI
7182 NCT01456Safety of Active Imm Unknown sNo ResultsOvarian Epithelial Cancer Biological:
7183 NCT04209Project Wellness GDMRecruiting No ResultsDiabetes, Gestational Behavioral:
7184 NCT00966Manicaland Cash Trans CompletedHas ResultVaccination|Education|Birth RegistrOther: Cond
7185 NCT04169Persistence of ProtectNot yet recNo ResultsHerpes Zoster Biological:
7186 NCT00254Immunogenicity and Sa CompletedNo ResultsDiphtheria|Tetanus|Haemophilus InfBiological:
7187 NCT03113AutologousBC-LDC Unknown sNo ResultsBreast Cancer Biological
7188 NCT01436Phase 3 St PrTK03 Recruiting No ResultsProstate Cancer Biological:
7189 NCT00493Safety and CP149 CompletedHas ResultRespiratory Viral Infections|Respira Biological
7190 NCT01817SystematicDESYRE Recruiting No ResultsRenal Transplantation Procedure:
7191 NCT01395ACAM2000Â® Myoperic CompletedNo ResultsMyocarditis|Pericarditis
7192 NCT03512Study to Evaluate H56Recruiting No ResultsTuberculosis, Pulmonary Biological:
7193 NCT01489Subcutaneous Immunot CompletedHas ResultAllergic Rhinoconjunctivitis Biological
7194 NCT03761Galinpepimut-S in CoRecruiting No ResultsAcute Myelogenous Leukemia|Ovarian Biological
7195 NCT00259Effect of TroVax in P CompletedNo ResultsColorectal Neoplasms Biological:
7196 NCT03767Trial of Neoadjuvant Recruiting No ResultsLocally Advanced Pancreatic Ducta Radiation:
7197 NCT00003Monoclonal AntibodyCompletedNo ResultsNeuroblastoma|Sarcoma Biological: BCG vacci
7198 NCT03721Evaluate the Safety, Active, notNo ResultsHealthy Biological:
7199 NCT01576Efficacy, Safety and CompletedHas ResultCryopyrin-associated Periodic Syn Biological
7200 NCT00000A Phase I Safety and CompletedNo ResultsHIV Infections Biological: HIV-1 Pe
7201 NCT03665PembrolizuIMA950-10Recruiting No ResultsGlioblastoma Multiforme|GlioblastoDrug: IMA9
7202 NCT03120Immunogenicity and SCompletedNo ResultsHerpes Zoster Biological:
7203 NCT00157Human Papillomavirus CompletedHas ResultPapillomavirus Infections Biological:
7204 NCT03040Efficacy of B7A BSIgG CompletedHas ResultHealthy Volunteer Biological
7205 NCT01874Serological Study in CompletedNo ResultsMumps|Rubella|Measles Biological
7207 NCT01214Assessment of the NaUnknown sNo ResultsAcute Otitis Media
7208 NCT02544SDF1 PlasmSTOP-PAD Unknown sNo ResultsPeripheral Arterial Disease Biological:
7209 NCT00189An Evaluation of ImmCompletedNo ResultsHIV Infection Biological
7210 NCT03618This is a Kingfisher Active, notNo ResultsHPV-Associated Cancers Biological
7211 NCT01473Intranasal Modified CompletedNo ResultsHIV Infection Biological:
7212 NCT00046Chemotherapy and Per CompletedNo ResultsInfection|Multiple Myeloma and Pl Biological: filgrasti
7213 NCT00041Rituxan Plus FavId ( Unknown sNo ResultsNon-Hodgkin's Lymphoma Biological: Id-KLH
7214 NCT01254Novel Peptide VaccinaCompletedNo ResultsRenal Cell Carcinoma Biological:
7215 NCT03585Utilizing All Health CompletedNo ResultsContraceptive Usage|Postpartum FaBehavioral
7216 NCT02058Immune Reconstitution CompletedNo ResultsMeasles Drug: Meas
7217 NCT01591Safety Study of FluM Terminate No ResultsInfluenza, Human Drug: Poly
7218 NCT00002A Phase I Safety and CompletedNo ResultsHIV Infections Biological: P3C541b
7219 NCT02998Racotumomab in Patie Recruiting No ResultsNeuroblastoma Drug: Rac
7220 NCT03869PreventingPREVENIR-Recruiting No ResultsHIV-1 Drug: Lami
7221 NCT00925STRIDE - S STRIDE Terminate Has ResultBreast Cancer Biological
7222 NCT01610Human Rabies Immuno CompletedNo ResultsRabies Biological
7223 NCT02140Exploratory Clinical CompletedNo ResultsHaemophilus Influenza Type b Biological
7224 NCT02900SurveillancRotavirus Unknown sNo ResultsGastroenteritis Biological:
7225 NCT02074Phase III Study of In CompletedHas ResultHealthy Volunteers|Haemophilus InfBiological:
7226 NCT02118Observation ISST-002 E CompletedNo ResultsHIV Infection Other: No
7227 NCT03832Assessing the ImmunNot yet recNo ResultsAdvanced Cancer Biological
7228 NCT00118Assessment of the Con CompletedNo ResultsType I Hypersensitivity Biological
7229 NCT03461Safety and Immunogen Recruiting No ResultsMild Cognitive Impairment|AlzheimBiological:
7230 NCT00150Rituximab in the TreaCompletedNo ResultsGravesÂ´ Disease|Thyroid Associat Drug: Meth
7231 NCT01109Streptococcus Pneumo CompletedHas ResultNasopharyngeal Carriage of S. Pneumoniae
7232 NCT01029ObservatioISS OBS T- CompletedNo ResultsHIV Infections
7233 NCT02192Investigating Enteric Active, notNo ResultsTyphoid Fever|Paratyphoid Fever Biological:
7234 NCT00822Study to Test the Sa CompletedHas ResultVaricella Biological:
7235 NCT00575Study to Investigate CompletedNo ResultsPerennial Allergy to House Dust Mit Drug: CYT
7236 NCT00775Immune ReconstitutioTerminate Has ResultAcquired Immune Deficiency Syndr Drug: Lopi
7237 NCT02562DSM265 Prophylaxis CompletedNo ResultsHealthy Drug: DSM2
7238 NCT00275A Study to Evaluate Terminate Has ResultHodgkin Disease|Lymphoma, Non-HDrug: Leup
7239 NCT01697The Impact of IntraveCompletedNo ResultsBladder Cancer Drug: Gemc
7240 NCT03064PICR-b NasPICRcarria Recruiting No ResultsStreptococcus Pneumoniae Biological:
7241 NCT04203A Clinical ECG-CHMINot yet recNo ResultsPlasmodium Falciparum Drug: atov
7242 NCT03870PreventionPROMISE-ERecruiting No ResultsHIV-1 Drug: Lami
7243 NCT01330HPV PrevalOromouthCompletedNo ResultsChronic Tonsillitis
7244 NCT00820Cholera Toxin B Subu CompletedNo ResultsInfection Biological:
7245 NCT02987A Study to Evaluate t CompletedHas ResultPneumococcal Infections Biological:
7246 NCT02686A Study to GIST CompletedNo ResultsGastrointestinal Stromal Tumor Biological:
7247 NCT00607Determination of DosiCompletedNo ResultsType 1 Diabetes Mellitus Biological:
7248 NCT02079Immune Function in OUnknown sNo ResultsInflammatory Bowel Disease
7249 NCT03905DCVAC/OvCa VITALIA Not yet recNo ResultsOvarian Cancer|Fallopian Tube CancBiological
7250 NCT00681ZostavaxÂ® at MinimuCompletedHas ResultHerpes Zoster Biological
7251 NCT02012Study of the ImmunogCompletedNo ResultsVirus Diseases|Hepatitis B Biological
7252 NCT00241Immune Responses toCompletedNo ResultsImmunity, Cellular|Hypersensitivity Biological:
7253 NCT00910Study of GF5 Active, notNo ResultsMetastatic Melanoma Biological
7254 NCT02696Phase 1 Study of GR CompletedNo ResultsMelanoma Biological
T ResultsCarcinoma, Non-Small-Cell Lung Biological
7256 NCT01184Study Of VGX-3400, HCompletedNo ResultsHealthy Biological
7257 NCT00563Phase I/IIa Dose Ran Unknown sNo ResultsChronic Hepatitis C Virus Infection Drug: CHR
7258 NCT03731A Study to Evaluate t Active, notNo ResultsPneumococcal Infections Biological:
7259 NCT01745Maternal An iTAP CompletedNo ResultsHepatitis B Chronic Infection|Pregn Drug: teno
7260 NCT02367Dose-escalation PhaseCompletedNo ResultsVaricella (Chicken Pox) Biological
7261 NCT03773MG1-MAGEA3 Pelican Not yet recNo ResultsMetastatic Melanoma|Squamous Cel Drug: Ad-
7262 NCT03721A Phase 1/2a Study oRecruiting No ResultsHIV/AIDS Biological
7263 NCT03714A Study of IO103 in MRecruiting No ResultsBasal Cell Carcinoma Biological:
7264 NCT04031Safety, Tol PNEU-PED-Active, notNo ResultsPneumococcal Infections Drug: Rota
7265 NCT03650Long-term Safety, TolRecruiting No ResultsRelapsing Multiple Sclerosis Biological
7266 NCT02258Flucelvax Pregnancy RWithdrawnNo ResultsPregnant Women, Influenza Biological:
7267 NCT04112Study to E HIPNOS Recruiting No ResultsAllergy to Himenoptera Venom Biological
7268 NCT01621Human Safe Capsaicin CompletedNo ResultsCOPD Biological:
7269 NCT01742Comparative Study ofCompletedHas ResultTuberculosis Device: Bi
7270 NCT01423Common Safety Follow Terminate Has ResultNon-Small Cell Lung Cancer|Multip Biological
7271 NCT03548A Study to DIRECT-01 Recruiting No ResultsLocally Advanced or Metastatic Soli Biological
7272 NCT02556Transcriptomics SignaUnknown sNo ResultsHealthy
7273 NCT02054Safety, Tolerability CompletedNo ResultsHIV Infection Biological
7274 NCT02661A Trial of CDX-1401 i WithdrawnNo ResultsNon Small Cell Lung Cancer|AdvancDrug: Pemb
7275 NCT00480A Study of the Immuno CompletedNo ResultsTB Biological:
7276 NCT02326PROSTVAC (PSA-TRICOM) Active, notNo ResultsStage I Prostate Adenocarcinoma AJOther: Lab
7277 NCT02642The Effect LPS-FluenzCompletedHas ResultInnate Immune Response|Immune TBiological
7278 NCT00418Efficacy M MIMOSA Terminate Has ResultOvarian Cancer Biological
7279 NCT01507TecemotideSPRINT CompletedHas ResultRectal Cancer Biological
7280 NCT02323Human Papi CIN3+plus CompletedNo ResultsCervical Cancer
7281 NCT03405Transfusion in Sickle Recruiting No ResultsSickle Cell Disease Procedure:
7282 NCT02944Gemcitabine HydrochlWithdrawnNo ResultsInfiltrating Bladder Urothelial Carc Drug: Cisp
7283 NCT02436Use of Text MessagesUnknown sNo ResultsAsthma Behavioral
7284 NCT00937Gynaecological Follo CompletedHas ResultInfections, Papillomavirus Other: Gyn
7285 NCT02670Phase I, Open Label DCompletedNo ResultsHealthy Biological:
7286 NCT02468Influenza Challenge SCompletedNo ResultsInfluenza Drug: VIS4
7287 NCT00196HIV Immune and Virolo Terminate No ResultsHIV Infection Drug: IL-2|
7288 NCT01675Safety and Efficacy o CompletedNo ResultsMalignant Pleural Mesothelioma Biological
7289 NCT01359Performance and Safet CompletedHas ResultInjections, Intradermal Device: PA
7290 NCT00001A Phase I Study of ReCompletedNo ResultsProstatic Neoplasms Biological: PROSTVAC
7291 NCT02576A Study to Assess Im CompletedHas ResultKidney Transplantation Biological
7292 NCT02450DSM265 Chemoprophyl CompletedNo ResultsFalciparum Malaria Drug: DSM2
7293 NCT02119Malaria CliGS Recruiting No ResultsMalaria
7294 NCT01540Post-licensure DepartCompletedNo ResultsSmallpox
7295 NCT03655pDNA Intralesional C Recruiting No ResultsCutaneous Melanoma, Stage III|CutBiological:
7296 NCT02378Safety and Immunogen CompletedHas ResultTuberculosis Biological:
7297 NCT03349DPX-SurvivSPiReL Recruiting No ResultsAdult Diffuse Large Cell Lymphoma|Biological
7298 NCT00931A Pilot Study of Pre-ECompletedNo ResultsHIV Infection Drug: FTC/
7299 NCT02555Placebo Controlled S Unknown sNo ResultsPrevention of Infections With BordetBiological:
7300 NCT02072A Protocol to Collect CompletedNo ResultsMeningococcal Biological
7301 NCT03083Cellular ImmunotheraActive, notNo ResultsMyelodysplastic Syndromes|Acute Biological
7302 NCT02025Efficacy of MISS CompletedNo ResultsSevere Sepsis|Septic Shock|Immun Drug: Mw,
7303 NCT02570Recruiting to Clinical CompletedNo ResultsParental Consent|Newborn|VaccinaBehavioral:
7304 NCT00509Mass-DrugMDATRANSCompletedNo ResultsMalaria, Falciparum Drug: Sulp
7305 NCT02262Immune Benefits of W CompletedNo ResultsElderly People Dietary Sup
7306 NCT03197EUpertstrain 4 Study o CompletedNo ResultsBordetella Pertussis, Whooping CouOther: Str
7307 NCT02010A Phase 1/2 Study of Terminate Has ResultBladder Cancer Biological:
7308 NCT00040Vaccine Study of MVATerminate No ResultsProstatic Neoplasms Biological: MVA-MUC
7309 NCT02176Oral Aurano Goldrake WithdrawnNo ResultsHIV Drug: Aura
7310 NCT00192Trial to Evaluate th CompletedNo ResultsInfluenza Biological:
7311 NCT01132VRC 900: Evaluation oRecruiting No ResultsImmune System
7312 NCT03419Study to AsB Part Of ItRecruiting No ResultsNeisseria Meningitidis
7313 NCT02746Influenza Challenge SCompletedNo ResultsInfluenza Biological:
7314 NCT04116A Phase 1 Study of H Recruiting No ResultsAdvanced Solid Tumor Biological
7315 NCT00850Peanut Allergy VaccinCompletedNo ResultsFood Hypersensitivity|HypersensitivBiological:
7316 NCT01399AssessmentFL-82 CompletedNo ResultsVitamin D Deficiency Dietary Su
7317 NCT03934HEPLISAV-BÂ® in AdulRecruiting No ResultsEnd Stage Renal Disease on Dialysis Drug: HEPL
7318 NCT01413Efficacy a LAPC-BC-8Terminate Has ResultPancreas, Adenocarcinoma Biological:
7319 NCT02487Evaluation of Free Ai CompletedNo ResultsInfluenza Other: Fre
7320 NCT00984A Pilot Study for Col CompletedNo ResultsInfluenza A Virus Infection|Swine Fl Biological:
7321 NCT00241A Video-Based HCV Cu CompletedNo ResultsHepatitis C|Opiate Dependence Behavioral
7322 NCT03722Epidemiology of Conge CompletedNo ResultsCytomegalovirus Congenital|Hearing Loss|Neu
7323 NCT01563Confirmatory Phase IICompletedNo ResultsPseudomonas Aeruginosa Infection Biological:
7324 NCT02363Gardasil I GINI Enrolling bNo ResultsHIV Biological:
7325 NCT00625Sex-Differential Heal Unknown sNo ResultsMortality|Morbidity|Growth|Neonat Biological
7326 NCT02441Interactio MAL-ED Unknown sNo ResultsDiarrhea|Malnutrition|Stunting|Wasting|Im
7327 NCT01858Tadalafil and Lenali CompletedNo ResultsMultiple Myeloma Biological
7328 NCT02901A Study of the Inter Unknown sNo ResultsChronic Hepatitis B Biological:
7329 NCT01024Observation ISS OBS P- CompletedNo ResultsHealthy Subjects
7330 NCT03205A Clinical Trial of Active, notNo ResultsHIV Infections Biological
7331 NCT03083Gardasil Knowledge CompletedNo ResultsHPV Other: Gard
7332 NCT01868Challenge Model for CompletedNo ResultsTuberculosis Biological:
7333 NCT03021Afya Credi AFYA Unknown sNo ResultsMaternal and Child Health Other: Cond
7334 NCT00444ZOSTAVAX(R) Local Reg CompletedNo ResultsVaricella Virus Infection Biological:
7335 NCT00002Gene Therapy in TreaCompletedNo ResultsNeuroblastoma Biological: gene-modi
7336 NCT03066SV-BR-1-GM in Metasta CompletedNo ResultsBreastcancer|Breast Neoplasm Biological
7337 NCT01003Safety Study of a Rec CompletedNo ResultsEsophageal Cancer Biological:
7338 NCT02088A Clinical Challenge CompletedNo ResultsTuberculosis Drug: BCG
7339 NCT01296Open-label, Randomize CompletedHas ResultJapanese Encephalitis Biological:
7340 NCT03890Assessment of PoliovRecruiting No ResultsPoliomyelitis Biological:
7341 NCT02100Understanding ParatyUnknown sNo ResultsEnteric Fever Caused by Salmonella Biological:
7342 NCT00499Paclitaxel, Cyclophos CompletedHas ResultBreast Cancer Biological
7343 NCT02707Perturbing of HIV Re Recruiting No ResultsAIDS|HIV Biological
7344 NCT04086Phase 2a Respiratory Recruiting No ResultsRespiratory Syncytial Viruses Biological
7345 NCT01313Electronic Medical R CompletedNo ResultsEMR Reminders to Improve Rates o Other: EM
7346 NCT01983Dendritic Cells Plus Recruiting No ResultsUveal Melanoma Biological
7347 NCT02051Induction of Donor-SpNo longer aNo ResultsRenal Failure Biological: Biologica
7348 NCT00004BCG Plus Interferon ACompletedNo ResultsBladder Cancer Biological: BCG vacci
7349 NCT03873RevaccinatSPLENEVACRecruiting No ResultsSplenectomised Patients Biological
7350 NCT00428Clinical IGSP-CHOP B CompletedNo ResultsInfluenza
7351 NCT00088PANVACâ„¢-VF Vaccine Unknown sNo ResultsPancreatic Cancer Biological: PANVACâ„
7352 NCT03303ASYMPTOMA AsymptoleiRecruiting No ResultsLeishmaniasis, Cutaneous Procedure:
7353 NCT00810A Trial of IMPI CompletedNo ResultsTuberculous Pericarditis Drug: Pred
7354 NCT01159Evaluation of a New ATerminate No ResultsLung Cancer, Non-Small Cell Biological
7355 NCT00508Study Evaluating Ser CompletedNo ResultsHealthy Procedure:
7356 NCT01521Effect of the Consum CompletedNo ResultsHealthy Free-living Elderly Other: 1-Fermented Da
7357 NCT00058Treating High Risk L CompletedNo ResultsLeukemia Biological:
7358 NCT00133Assessment of the Con CompletedNo ResultsType I Hypersensitivity Biological
7359 NCT01255Study on Dynamic Cha CompletedNo ResultsHand, Foot and Mouth Disease|Anti-EV71|Ant
7360 NCT00669 Phaseâ… /â…¡ Study ofUnknown
URLC10-177
sNo Results
and TTK-567
Esophageal
Peptide
Cancer
Vaccine Combined With
Biological
CpG7909 in Patients W
7361 NCT01599Influenza Burden AsseCompletedNo ResultsInfluenza Other: Data
7362 NCT01435Dose RangeCIN-002 CompletedNo ResultsNorovirus Infections Biological:
7363 NCT02898Immune Res SERO7LEP Unknown sNo ResultsLeptospirosis Other: coh
7364 NCT01074Human Inna UBC-INNATCompletedNo ResultsBacterial Infections Biological:
7365 NCT03282REO13 Melanoma WitWithdrawnNo ResultsMelanoma|Cancer of Skin Biological
I ResultsHIV Infections Biological
7367 NCT00138New Challenge Pool oCompletedNo ResultsGastroenteritis Norovirus Drug: Plac
7368 NCT01810Prevention of HepatitCompletedNo ResultsHepatitis B
7369 NCT00100Anti-HIV Treatment InCompletedNo ResultsHIV Infections Behavioral
7370 NCT02337A Phase I Study of th CompletedNo ResultsSchistosomiasis Other: Pla
7371 NCT00849Study of Repeat Intr Terminate Has ResultChronic Lymphocytic Leukemia|SmaBiological:
7372 NCT02823TG4010 and Nivolumab Active, notNo ResultsRecurrent Non-Small Cell Lung CarciBiological
7373 NCT04182Safety and Immunogen Recruiting No ResultsHand, Foot and Mouth Disease Biological
7374 NCT01225AD01 Follow up Extens CompletedNo ResultsAlzheimerÂ´s Disease
7375 NCT01701MicrobioloMICA CompletedNo ResultsChronic Obstructive Pulmonary Disease (COPD
7376 NCT03767EpidemioloMTBVAC-EP Recruiting No ResultsTuberculosis Diagnostic
7377 NCT00115Delivery of Preventiv CompletedNo ResultsPreventive Services|Immunizations Other: Prac
7378 NCT01875Enzalutamide in CombActive, notNo ResultsProstate Cancer Biological
7379 NCT03668A Study to Evaluate t Terminate No ResultsAlzheimer's Disease Drug: Lu A
7380 NCT00671Inoculating Celiac D CompletedNo ResultsCeliac Disease Biological
7381 NCT00000A Phase I Clinical T CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: MTP-PE/M
7382 NCT00113A Study to Evaluate t CompletedHas ResultHealthy Biological:
7383 NCT01949Safety and Efficacy S CompletedNo ResultsSolid Tumors Biological
7384 NCT01385A Study of Intraderm CompletedHas ResultHerpes Zoster Biological
7385 NCT00568Radiofrequency TheraCompletedNo ResultsMelanoma (Skin) Biological
7386 NCT00445Safety Study of TroVaCompletedNo ResultsCarcinoma, Renal Cell Biological
7387 NCT02546A Study in Healthy AdCompletedNo ResultsHealthy Biological:
7388 NCT00305Molecular EpidemioloCompletedNo ResultsStreptococcus Group A
7389 NCT03258Vitamin B12 Suppleme Recruiting No ResultsEarly Pregnancy Dietary Su
7390 NCT01373Oral Lenalidomide and CompletedHas ResultBladder Cancer Drug: Baci
7391 NCT03090MAMAS: Men MAMAS Unknown sNo ResultsHuman Immunodeficiency Virus|Herp Behavioral
7392 NCT02249CompetitivLactamica CompletedNo ResultsNeisseria Lactamica Biological:
7393 NCT02251Epidemiology Study ofRecruiting No ResultsMalaria Procedure:
7394 NCT03727Transfusion of D+ BloCompletedNo ResultsBlood Transfusion Associated Adver Other: Blo
7395 NCT04212Dendritic DECENDO Recruiting No ResultsEndometrial Cancer Biological:
7396 NCT01115Efficacy of Allergen I CompletedNo ResultsRhinitis, Allergic, Perennial Biological:
7397 NCT00003Immunotherapy in TreCompletedNo ResultsColorectal Cancer|Metastatic CanceBiological: carcinoe
7398 NCT03572Open LabelV3-MOMMRecruiting No ResultsBreast Cancer Biologica
7399 NCT01973Hepatitis B Seroepid Unknown sNo ResultsHepatitis B
7400 NCT01136Blood and Plasma Colle CompletedNo ResultsInfluenza A Virus Infection Biological:
7401 NCT02960Safety, PK and Antivi CompletedNo ResultsHIV Infection Biological
7402 NCT00421Pilot Study of GenotyCompletedNo ResultsInfluenza
7403 NCT02553Study to Evaluate theActive, notNo ResultsHealthy Biological:
7404 NCT02522A Study to PIN CompletedNo ResultsNasal Carriage of Pneumococci Other: nas
7405 NCT0387510E8.4/iMab BispecifiRecruiting No ResultsHIV-1-infection Biological
7406 NCT00168Different Doses of V CompletedNo ResultsMortality|Morbidity Drug: Vita
7407 NCT00959Safety, Tolerability, CompletedHas ResultAlzheimer's Disease Biological
7408 NCT01563Number of Rotavirus C ( ompletedNo ResultsInfections, Rotavirus Other: Data
7409 NCT00241A Video-Based HCV Cur CompletedNo ResultsHepatitis C|Opiate Dependence Procedure:
7410 NCT00453Imiquimod and Laser CompletedNo
T ResultsMelanoma (Skin)|Metastatic CancerDrug: imiq
7411 NCT01083Impact of PCV on Dis CompletedNo ResultsPneumococcal Nasopharyngeal Colonization|I
7412 NCT01935A Clinical Trial on H Unknown sNo ResultsChronic Hepatitis B Biological
7413 NCT00529Effects of Recombina CompletedHas ResultType 1 Diabetes Mellitus Drug: GAD
7414 NCT02445Safety and Immunogeni Active, notNo ResultsShigellosis|Bacillary Dysentery Biological:
7415 NCT02785Study of DPX-SurvivacActive, notNo ResultsRecurrent Epithelial Ovarian Cancer Other: DPX
7416 NCT01037Long-term PersistenceCompletedHas ResultHepatitis A|Hepatitis B Procedure:
7417 NCT04145AImmune - Artificial Recruiting No ResultsNon Small Cell Lung Cancer|NeoepiBiological:
7418 NCT03531An Extension Study ofTerminate No ResultsAlzheimer's Disease Biological
7419 NCT02541CharacterizCORAL CompletedNo ResultsDiarrhea|Gastroenteritis|Bacterial IBiological:
7420 NCT03983SurveillancSIIP Recruiting No ResultsPneumococcal Infections
7421 NCT03821A Phase I/II Clinical Recruiting No ResultsHead and Neck Cancer Biological:
7422 NCT02755A Study of Protectiv Recruiting No ResultsRespiratory Syncytial Virus Infectio Biological
7423 NCT03507Safety and Immunogeni CompletedNo ResultsHealthy Biological
7424 NCT02439A Study of CombinatiActive, notNo ResultsNon-small Cell Lung Cancer Biological
7425 NCT02640Safety of 4CMenB Ex CompletedNo ResultsInfections, Meningococcal Biological
7426 NCT02118Iron and PrIro'n'Pre CompletedNo ResultsAnemia|Iron Deficiency|Diarrhea|Ma Dietary Su
7427 NCT02797StrengtheniSRC CompletedNo ResultsAntepartum Hemorrhage|PostpartuOther: Mat
7428 NCT03564Examining BioactivityRecruiting No ResultsInvasive Breast Cancer Biological
7429 NCT01302Efficacy, Safety and CompletedHas ResultCryopyrin-associated Periodic Syn Drug: ACZ
7430 NCT03883Efficacy of MVA-NP+ Active, notNo ResultsInfluenza Biological
7431 NCT01240Immunotherapy WithCompletedNo ResultsAdvanced Non-small Cell Lung CancBiological
7432 NCT03206Safety and Efficacy o Unknown sNo ResultsCervical Intraepithelial Neoplasia 3 Biological
7433 NCT00535Studying Stored Sampl CompletedNo ResultsProstate Cancer Procedure:
7434 NCT01171Autologous DendriticCompletedNo ResultsProstatic Cancer Biological:
7435 NCT03110Cancer/TesrVV-740CTWithdrawnNo ResultsBreast Carcinoma Biological
7436 NCT00032Dryvax Dilution-Prev CompletedNo ResultsSmallpox Biological: Dryvax
7437 NCT01023A Study to Assess DV-CompletedNo ResultsHepatitis B, Chronic Drug: DV-6
7438 NCT02965Specific Immunotherap Unknown sNo ResultsAllergic Rhinitis|Allergic Asthma|GraDevice: In
7439 NCT00154Comparison of the HuUnknown sNo ResultsCervical Cancer
7440 NCT00112Immunotherapy of HLA CompletedNo ResultsMelanoma Biological:
7441 NCT00050Natural History of An Recruiting No ResultsAnthrax|Bacillus Infections
7442 NCT00548The Immune ImFIT CompletedNo ResultsImmune Response Behavioral:
7443 NCT01500Malaria ChITV CompletedNo ResultsMalaria Biological
7444 NCT00948Effects of follow-on CompletedNo ResultsInfant Dietary Su
7445 NCT00574A Study to Investigat CompletedHas ResultPerennial Allergic Rhinoconjunctivit Drug: CYT0
7446 NCT01583Efficacy of Newborn CompletedNo ResultsVitamin A Deficiency Dietary Su
7447 NCT01460Immunotherapy WithUnknown sNo ResultsNSCLC|Lung Cancer, Non-small Cell Biological
7448 NCT01485Streptococcus PneumUnknown sNo ResultsNursery Procedure:
7449 NCT00382Prehospital ScreeningCompletedNo ResultsAll Conditions Procedure:
7450 NCT02269A Phase3 Study to EvaCompletedHas ResultHealthy Japanese Children Age 7 Ye Drug: MED
7451 NCT02109A Phase I C-011-404CompletedNo ResultsTuberculosis Biological
7452 NCT02947Study to Assess SafetCompletedNo ResultsHealthy Volunteer Drug: Fima
7453 NCT00479Study Evaluating SafeCompletedHas ResultAlzheimer Disease Biological
7454 NCT00352BCG With or WithoutTerminate
G No ResultsBladder Cancer Biological:
7455 NCT01497Efficacy Study of DiabCompletedNo ResultsDiabetes Mellitus, Type 2 Behavioral:
7456 NCT02019Effects of Tobacco Pr CompletedNo ResultsInfluenza, Human|Smoking|Respirato Biological:
7457 NCT03944Bubble Continuous Pos Recruiting No ResultsPneumonia Device: Bu
7458 NCT03588Study of E SEEM Active, notNo ResultsMalnutrition, Child|Enteropathy|VaOther: Nut
I ResultsHealthy Biological:
7460 NCT03328Combination Study oRecruiting No ResultsBreast Cancer Female|Breast Neop Biological
7461 NCT01712Re-boostinRe-boost CompletedHas ResultHIV-1 Infection Biological:
7462 NCT01425Study to A Mel55 CompletedHas ResultMelanoma Biological
7463 NCT00003AD 32 With or Without CompletedNo ResultsBladder Cancer Biological: BCG vacci
7464 NCT01322Outcomes of Pandemic Unknown sNo ResultsInfluenza
7465 NCT03396Hepatitis BHBVTR Recruiting No ResultsHepatitis B Diagnostic
7466 NCT02878Effect of Schistosomi CompletedNo ResultsSchistosomiasis Mansoni|HIV Drug: Praz
7467 NCT00447REVAXISÂ® Versus DTCompletedNo
P ResultsDiphtheria|Tetanus|Poliomyelitis Biological: REVAXISÂ®
7468 NCT01000Antibody Persistence CompletedHas ResultHepatitis A|Hepatitis B Procedure:
7469 NCT02078A(H7N9) VLP AntigenCompletedNo ResultsInfluenza (Pandemic) Biological
7470 NCT00284Incidence of Group A CompletedNo
S ResultsStreptococcus Group A
7471 NCT01198Study of AERAS-402 inCompletedHas ResultTuberculosis Biological
7472 NCT00778Splenic Function AfeUnknown sNo ResultsOverwhelming Post-Splenectomy Infection
7473 NCT01072Immunotherapy StudyCompletedNo ResultsPancreatic Cancer Biological
7474 NCT01897A(H7N9) VLP Antigen CompletedNo ResultsAvian Influenza Biological:
7475 NCT02747ForgIng NeFINDIT Active, notNo ResultsPrediabetes Behavioral
7476 NCT03118Human ImHIP Enrolling bNo ResultsHealthy Other: Bio
7477 NCT03756Understanding RSV: SRecruiting No ResultsRespiratory Syncytial Virus (RSV) Diagnostic
7478 NCT00551Oregovomab With or Withdrawn
Wi No ResultsFallopian Tube Carcinoma|Primary PDrug: Cycl
7479 NCT00058Therapeutic VaccinatiCompletedNo ResultsHIV Infections Biological: Dendritic
7480 NCT03750VXM01 Plus Avelumab Recruiting No ResultsRecurrent Glioblastoma Biological
7481 NCT00413Long-Term Effectiven CompletedHas ResultArthritis, Rheumatoid Drug: CP-6
7482 NCT02866Safety and Tolerabili Recruiting No ResultsUterine Cervical Neoplasms Drug: BVAC
7483 NCT00423Safety and Immune RCompletedNo ResultsOvarian|Melanoma|Renal|Prostate|C Biologica
7484 NCT00464A Study of V950 in P CompletedHas ResultAlzheimer Disease Biological
7485 NCT00039Monoclonal AntibodyTerminate No ResultsAdult Acute Myeloid Leukemia WithBiological:
7486 NCT02531A Study to Evaluate t CompletedHas ResultPneumococcal Infections Biological
7487 NCT00807Health Care Decision CompletedNo ResultsCervical Cancer
7488 NCT00001A Phase I Safety and CompletedNo ResultsHIV Infections Biological: HIV p17/
7489 NCT01753Dendritic Cell Activa Active, notNo ResultsMelanoma Biological
7490 NCT01617Evaluate B BacteriophUnknown sNo ResultsPrimary Immune Deficiency DiseaseBiological
7491 NCT01767ApplicationOPTISCREECompletedHas ResultHepatitis B|Liver Cirrhosis|Carcino Other: ELIS
7492 NCT01779Vitamin A SupplementUnknown sNo ResultsAtopy|Asthma|Eczema|Food Allergy
7493 NCT03014Prevenar13 Drug UseCompletedHas
I ResultAdult Not Younger Than 65 Years
7494 NCT01823ExperimentEHRVI CompletedNo ResultsCommon Cold Other: pla
7495 NCT00524Safety andBIgGII CompletedNo ResultsTravelers' Diarrhea Biological:
7496 NCT02366REMUNE +RAISEA Unknown sNo ResultsHIV Biological:
7497 NCT02528NICU ParenNICU PEP Active, notNo ResultsLanguage Development|Premature Other: Kno
7498 NCT03315Combination Immunoth Recruiting No ResultsProstate Cancer Biological
7499 NCT00258Safety and Immunogen CompletedHas ResultDiphtheria|Tetanus|Pertussis Biological
7500 NCT00569A Post Marking StudyCompletedNo ResultsHealthy Biological:
7501 NCT04109PreliminaryDiVHeB Not yet recNo ResultsHepatitis B|Healthy|Diagnoses DiseDiagnostic
7503 NCT02484Respiratory Syncytial CompletedNo ResultsUpper Respiratory Tract Infection Biological:
7504 NCT01543Duration of hSBA RespCompletedNo ResultsMeningococcal Infection Procedure:
7505 NCT02405Immunotherapy and SB Terminate No ResultsPancreatic Cancer|Pancreatic Carci Drug: mFOL
7506 NCT03596The ProtecMIRRE CompletedNo ResultsDiarrhea Biological:
7507 NCT01117Clinical- and ImmunolCompletedNo ResultsAlzheimer's Disease Biological:
7508 NCT03454ControlledCHMI-tranCompletedNo ResultsMalaria,Falciparum|Gametocytes|Co Drug: Pipe
7509 NCT04108The ChoosiCHErIsH Enrolling bNo ResultsPediatric Obesity Behavioral:
7510 NCT00001A Multicenter, RandoCompletedNo ResultsHIV Infections Biological: APL 400-
7511 NCT02996Safety and Efficacy ofCompletedNo ResultsPlasmodium Falciparum Infection Drug: Arte
7512 NCT01887Varicella-r VARICOMPCompletedNo ResultsChickenpox
7513 NCT02836ControlledCHMI-tranCompletedNo ResultsMalaria Drug: Sulf
7514 NCT02096BoostrixÂ® PregnancyCompletedNo ResultsPertussis Other: Data
7515 NCT01574Seroepidemiologic StuCompletedNo ResultsHepatitis B
7516 NCT02841Old Red BloORBIT CompletedNo ResultsDisorder Related to Renal Transplantation|Tra
7517 NCT00001A Phase I, Multicent CompletedNo ResultsHIV Infections Biological: MN rgp12
7518 NCT02119Prevenar (13v) InfantCompletedHas ResultInfants Drug: Prev
7519 NCT00566Activated White BlooCompletedHas ResultMultiple Myeloma and Plasma Cell Biological
7520 NCT03412Effect of Antibiotics Unknown sNo ResultsForeskin HIV Susceptibility Drug: Oral
7521 NCT02093Evaluation on Immunog CompletedNo ResultsHealthy Biological:
7522 NCT03975Sexual RiskPREP Recruiting No ResultsHIV Infection|Prep Prescription|VacBehavioral
7523 NCT02372Assessment of a DengCompletedNo ResultsDengue Biological
7524 NCT00488Safety And Efficacy S WithdrawnNo ResultsHuman Immunodeficiency Virus Drug: CP-6
7525 NCT02122Research for ImmunotCompletedNo ResultsGlioma Biological:
7526 NCT00002Radiation Therapy, ChCompletedNo ResultsBladder Cancer Biological: BCG vacci
7527 NCT00067Apheresis and SpecimRecruiting No ResultsSample Collection
7528 NCT00984Residence Time of Bi CompletedNo ResultsSemen Exposure
7529 NCT01192"COhort StCOFLUPRECompletedNo ResultsInfluenza|Pregnancy
7530 NCT00952A Study to MI-CP206 CompletedHas ResultHealthy or Stable Underlying ChroniBiological
7531 NCT00713Cohort Study of HIV-1CompletedNo ResultsHIV Infections
7532 NCT00001A Phase I, RandomizeCompletedNo ResultsHIV Infections Biological: Aluminum
7533 NCT01520Influenza Burden Ass CompletedNo ResultsInfluenza Other: Data
7534 NCT04177Evaluating the Safet Recruiting No ResultsHIV Infections Biological
7535 NCT00234Study Evaluating PrevCompletedNo ResultsPneumococcal Disease
7536 NCT02933PROSTVAC in Combina Recruiting No ResultsProstate Cancer Biological
7537 NCT01937A Phase 1, RandomizeUnknown sNo ResultsHIV Infections Biological
7538 NCT03350A ScreeninMEP Recruiting No ResultsClostridium Difficile Infection Other: Mic
7539 NCT04237Chronic HBV InfectionRecruiting No ResultsHepatitis B, Chronic|Pregnancy RelaDrug: Teno
7540 NCT02506Neoadjuvant PROSTVAC Active, notNo ResultsProstatic Neoplasms Biological
7541 NCT03406Use of MobICT-CCS CompletedNo ResultsHealth|Pregnancy|Infant|Nutrition|Behavioral
7542 NCT01476Effect of NNVAS Unknown sNo ResultsVitamin A Deficiency Dietary Sup
7543 NCT00000A Phase I ComparativeCompletedNo ResultsHIV Infections Biological: Aluminum
7544 NCT03520Synovate Study for SyTerminate No ResultsSynovial Sarcoma|Cancer|Sof Tiss Biological
7545 NCT03633Defining t Lac-7 CompletedNo ResultsMeningitis, Bacterial Biological:
7546 NCT00354Phase I Study of IMP3CompletedNo ResultsHealthy Biological:
7547 NCT00075SGN-00101 Immunothera CompletedNo ResultsCervical Cancer|Precancerous CondiBiological:
7548 NCT01985Postmarketing Safety CompletedNo ResultsObservation Safety
7549 NCT00031Plasmapheresis of AnCompletedNo ResultsAnthrax Drug: Anthrax Immun
7550 NCT00927E. Coli 83972 InducedCompletedNo ResultsUrinary Tract Infection Biological:
7551 NCT01187Drug Use InvestigatioCompletedNo ResultsInfections, Papillomavirus Biological:
7552 NCT03265DNA Plasmid Encoding Recruiting No ResultsLeukemia, Lymphocytic, Chronic, B-CBiological:
7553 NCT00374A Study on Immunologi CompletedNo ResultsImmunity|Diarrhea|Respiratory TracDrug: Zinc,
7554 NCT00855Activated ArIL-2(LAK) CompletedNo ResultsMetastatic Breast Cancer|MalignantProcedure:
7555 NCT04212Frameshif Peptides oRecruiting No ResultsNeurofibromatosis Type 1 Genetic: F
7556 NCT03174A 24-month AIDA Active, notNo ResultsPrimary Progressive Nonfluent AphaDrug: AAD
7557 NCT00718Phase III Placebo-co CompletedHas ResultRotavirus|Gastroenteritis Biological:
7558 NCT01375Screening Volunteers Recruiting
f No ResultsScreening
7559 NCT02440A Study to Evaluate t CompletedNo ResultsHealthy Participants Biological
7560 NCT03222Trial to Assess the E Terminate No ResultsNeisseria Gonorrhoeae Drug: 1 mg/
7561 NCT03313Safety, To KEYNOTE-6Recruiting No ResultsSolid Tumors Biological
7562 NCT00001Effects on the Immune CompletedNo ResultsHIV Infections Biological: Tetanus T
7563 NCT00013Immune Therapies and CompletedNo ResultsHIV Infections Biological
7564 NCT01200Assessment of AlteraCompletedNo ResultsPregnancy Immune Function
7565 NCT02043Stopping Postpartum CompletedNo ResultsVitamin A Deficiency Dietary Su
7567 NCT02012Efficacy St CUN-OMALCompletedNo ResultsCholinergic Urticaria Biological:
7568 NCT00001A Pilot Study of the CompletedNo ResultsHIV Infections
7569 NCT02572A Phase I Study to E CompletedNo ResultsPneumococcal Infection Biological:
7570 NCT00912EvaluationMEL38 CompletedNo ResultsMelanoma Drug: GM-C
7573 NCT01600A Study of the Immuno CompletedHas ResultRotavirus Gastroenteritis Biological
7574 NCT03510Impact of Weekly Admi Recruiting No ResultsHealthy Volunteers Drug: Vemli
7575 NCT03948PrevalencePrevalgeo CompletedNo ResultsGeophagia Other: Que
7577 NCT00006Effectiveness of Add Terminate No ResultsHIV Infections Biological: HIV-1 Im
7578 NCT01838Phase I Study of Int Terminate Has ResultMetastatic Melanoma Biological
7579 NCT01299Community Awareness, CompletedNo ResultsUterine Cervical Cancer
7580 NCT02261Antigen-specific Can CompletedNo ResultsPancreatic Cancer, Resected Biological:
7581 NCT00000A Randomized, PlacebCompletedNo ResultsHIV Infections Biological: MF59|Biol
7582 NCT02533Cancer Immune Therap CompletedNo ResultsChildhood Solid Tumor Biological
7583 NCT02868Asymptomat AFP CompletedNo ResultsInfluenza Biological
7584 NCT01386Screening for LID ClinRecruiting No ResultsZika|Influenza
7585 NCT00387Efficacy and Safety Terminate No ResultsRhinitis, Allergic, Seasonal Biological
7586 NCT02471BehavioralBREATHE Active, notNo ResultsAttitude to Health|Pollution Relate Behavioral:
7587 NCT01245GARDASILâ„¢ Study inCompletedHas ResultPapillomavirus Infections Biological
7588 NCT00142Electronic Health RecCompletedNo ResultsInfluenza Device: El
7589 NCT03564Nutritiona MumtaLWRecruiting No ResultsUndernutrition Dietary Su
7590 NCT02574Pilot Study of Vigil CompletedNo ResultsMelanoma Recurrent|Malignant M Biological
7591 NCT01881The Safety and Effica WithdrawnNo ResultsType One Diabetes Drug: Dia
7592 NCT04180A Study of HB-201 AloRecruiting No ResultsHPV-Related Squamous Cell Carcin Drug: HB-2
7593 NCT02443Evaluation of PaternaCompletedNo ResultsHepatitis B Infection
7594 NCT00677The Effect FIAVS CompletedNo ResultsAllergens, House Dust Mites Biological
7595 NCT01473On Demand IPERGAY CompletedNo ResultsHIV Infection Drug: Truv
7596 NCT04173Safety and Pharmacoki Recruiting No ResultsHIV-1-infection Biological
7597 NCT03046Gastroenter GE Recruiting No ResultsGastroenteritis Diagnostic
7598 NCT01078Dose FindiGHB-CS07 CompletedNo ResultsInfluenza, Human Biological
7599 NCT00740Thermal Analgesia i Unknown sNo ResultsPain Other: suc
7600 NCT02654LoewenKIDS LoewenKIDActive, notNo ResultsInfectious Diseases Other: No
7601 NCT00174Safety Study of Passi Unknown sNo ResultsAlzheimer's Disease Drug: AAB
7602 NCT01876Towards HIULTRASTO CompletedNo ResultsChronic HIV-1 Infection Other: Anti
7603 NCT00222Qidong Hepatitis B InCompletedNo ResultsHepatitis B|Liver Neoplasms|Liver DBiological: Hep-V Vax
7604 NCT03590Strong Afr SAAF-STEPCompletedNo ResultsAdolescent Alcohol Use Behavioral
7605 NCT00724Randomized GHBCS-01 CompletedNo ResultsSeasonal Human Influenza Biological
7606 NCT03459Access to CohMSM-PRecruiting No ResultsHIV/AIDS Drug: HIV
7607 NCT02037Safety, Tolerability CompletedHas ResultStreptococcus Pneumoniae Infectio Biological:
7608 NCT01637Telbivudine Therapy CompletedNo ResultsHBV Drug: Telb
7609 NCT01420Sipuleucel-T, CT-011 Terminate Has ResultProstatic Neoplasms Drug: CT-0
7610 NCT02849Evaluation Interest Active, notNo ResultsUveal Melanoma Biological:
7611 NCT03864Impact of Steady StatRecruiting No ResultsHealthy Volunteers Drug: Tybos
7612 NCT02310Cvac as Maintenance WithdrawnNo ResultsPancreatic Carcinoma Stage I|PancreBiological:
7613 NCT01546Antibody Persistence CompletedNo ResultsDiphtheria|Tetanus|Poliomyelitis Biological:
7614 NCT00002A Study of Thalidomi CompletedNo ResultsHIV Infections Drug: Thalidomide
7615 NCT00000A Phase I Clinical Tr CompletedNo ResultsHIV Infections|HIV Seronegativity Biological: Env 2-3
7616 NCT01285Impact of IMIEPAP CompletedNo ResultsCommunity-acquired Pneumonia|Hea Other: Mul
7617 NCT03276Autologous Micro-fraCompletedNo ResultsDiabetic Foot Device: Li
7618 NCT04212Evaluating the Safety Not yet recNo ResultsHIV Infections Biological
7619 NCT04084Study of SQZ-PBMC-HP Recruiting No ResultsAdult Solid Tumor Biological
7620 NCT03425Safety and BVAC-B Recruiting No ResultsStomach Neoplasms Biological:
7621 NCT01214Problem SoProject SolCompletedNo ResultsMaternal Depression Behavioral
7622 NCT02871Pilot Study of a Phar Active, notNo ResultsBreast Cancer|Lung Cancer|GI CancOther: Pha
7623 NCT03721Poly-ICLC (Hiltonol) Recruiting No ResultsSolid Cancer Biological
7624 NCT03657Trial of C C134-HSV-Recruiting No ResultsGlioblastoma Multiforme of Brain|ABiological:
7625 NCT00431Epstein-Barr Virus-S CompletedNo ResultsNasopharyngeal Carcinoma Biological:
7626 NCT01900Progress oEXPEDITIOTerminate Has ResultAlzheimer's Disease Drug: Sola
7627 NCT00679Risk ReducSPREK! Active, notNo ResultsCoronary Heart Disease Behavioral:
7628 NCT00709Reduced Intensity TotCompletedHas ResultNon-Hodgkin's Lymphoma|LeukemiaBiological
7629 NCT00904Effect of EXPEDITIOCompletedNo ResultsAlzheimer's Disease Drug: LY20
7630 NCT02768Randomized Controlled Active, notNo ResultsProstate Cancer Biological
7631 NCT01160Seroprevalence StudyCompletedNo ResultsViral Hepatitis Vaccines|Hepatitis A Other: Ser
7632 NCT03606Etiology a OSPIS Recruiting No ResultsPneumonia Other: The
7633 NCT03866Prospective ObservatiRecruiting No ResultsHIV Infections|HIV-1-infection|Risk Behavioral
7634 NCT03754Impact of MAINTAINRecruiting No ResultsArthritis, Rheumatoid Behavioral
7635 NCT02739ControlledCHMI-SIKARecruiting No ResultsMalaria Biological
7636 NCT02001Malaria in Early Life CompletedNo ResultsPlasmodium Falciparum Malaria|Pl Drug: dihy
7637 NCT03262Neoadjuvant HiltonolÂ Recruiting No ResultsProstate Cancer Biological:
7638 NCT00199A Pilot Study of NY-E CompletedNo ResultsCancer|Neoplasm Biological
7639 NCT03353A Study Evaluating t Active, notNo ResultsNSCLC Biological
7640 NCT03325Safety, Tolerability, CompletedNo ResultsChikungunya Virus Biological
7641 NCT00768Study Eval Carriage CompletedNo ResultsHealthy Subjects
7642 NCT03023Study of Hepalatide(LCompletedNo ResultsHepatitis Bï¼Œ Chronic Drug: Hepa
7643 NCT00844A RetrospecIPD in saudUnknown sNo ResultsPneumococcal Infection Biological: serotypes
7644 NCT03020Low Birth Weight Fol Unknown sNo ResultsNon Specific Effects of Vaccine|Bacillus-Cal
7645 NCT03619A Study to GPP Recruiting No ResultsGeneralized Pustular Psoriasis Drug: ANB
7646 NCT02735The CorrelaCORTIS Active, notNo ResultsTuberculosis Drug: Ison
7647 NCT03490Durvalumab and "Boos Recruiting No ResultsAdenocarcinoma of the Pancreas Drug: Durv
7648 NCT02612Safety and Pharmacoki CompletedNo ResultsHepatitis Bï¼Œ Chronic Drug: Hepa
7649 NCT00309Prevention of UrinaryCompletedNo ResultsUrinary Tract Infections Procedure:
7650 NCT01715Effects of Plant Stan CompletedNo ResultsAsthma|Allergy Dietary Su
7651 NCT03721Evaluation of Infecti CompletedHas ResultNorovirus Infection Biological:
7652 NCT02885Durvalumab Panc-Durv WithdrawnNo ResultsMetastatic Pancreas Cancer Drug: Durv
7653 NCT00617Celiac Disease PrevenUnknown sNo ResultsCeliac Disease Other: Opt
7654 NCT01910PerioperatiPAOPUFAGUnknown sNo ResultsGastric Cancer Drug: omeg
7655 NCT03119Quality of EVADREP CompletedNo ResultsNew-borns Screening|Sickle Cell Di Other: No
7656 NCT00702Seroprevalence of Hep Unknown sNo ResultsHepatitis B
7657 NCT01761Immunogenic ICC H1 CompletedNo ResultsSeasonal Influenza Biological:
7658 NCT01568Tolerability and Safe CompletedNo ResultsParkinson's Disease Biological
7659 NCT01698Immunogeni ICC H5 CompletedNo ResultsAvian Influenza Biological:
7660 NCT00858Effect of ADIT CompletedNo ResultsImmune Function Behavioral:
7661 NCT03450Immunogeni TEBICA CompletedNo ResultsBreast Cancer Female Biological:
7662 NCT02543Effectiveness of KAE6Terminate No ResultsPlasmodium Falciparum Malaria Drug: KAE6
7663 NCT00001The Use of Bacteriop CompletedNo ResultsHIV Infections
7664 NCT00503Study Of RV-39 In Pa Terminate Has ResultAsthma Drug: flut
7665 NCT00007Photodynamic Therapy CompletedNo ResultsMelanoma (Skin) Biological: Detox-B a
7666 NCT04213Improving AdherenceRecruiting No ResultsRabies|Rabies Human|Rabies Virus O I ther: Rab
7667 NCT01627Comparison TIP3 CompletedNo ResultsMalaria Other: NF
7668 NCT04206Trial to Evaluate CIS4 Recruiting No ResultsMalaria Biologica
7669 NCT01188Fourth Dose of Human CompletedNo ResultsHuman Papillomavirus (HPV) Biological
7670 NCT02707Pilot Trial VORVAX Terminate No ResultsHIV-1 Infection Drug: Vori
7671 NCT02288Evaluation of a NovelCompletedNo ResultsMalaria|Anaemia Other: Oly
7672 NCT00685Phase I of Human Papi CompletedNo ResultsPapillomavirus Infections Biological
7673 NCT04044H1N1v Virus ChallengActive, notNo ResultsInfluenza Biological
7674 NCT00090Effect of Rituximab CompletedNo ResultsNon-Hodgkin's Lymphoma Drug: ritu
7675 NCT02149Controlled Human Mala CompletedNo ResultsMalaria Other: NF1
7676 NCT02643GPS (Givin GPS CompletedHas ResultPremature Birth of Newborn|Famil Behavioral
7677 NCT01421The NIH UNI Study: UTerminate No ResultsArgininosuccinic Aciduria|Carbamoyl-Phosphate Synthase
7678 NCT01490Dose Range Finding StCompletedNo ResultsAllergic Rhinoconjunctivitis Drug: Place
7679 NCT04196MethotrexaMTX Not yet recNo ResultsChronic Inflammatory Bowel Disease
7680 NCT02237Effect of PlasmodiumCompletedNo ResultsPlasmodium Falciparum Malaria|MaBiological:
7681 NCT01394Biological Standardiz CompletedNo ResultsAllergy to Grass Pollen Biological:
7682 NCT03473Transvaginal Ultraso Active, notNo ResultsInfertility, Female Procedure:
7683 NCT00185Phase I Intratumoral Terminate No ResultsLiver Cancer Biological:
7684 NCT02759Long-term PersistenceCompletedHas ResultHepatitis B|Pertussis Other: Blo
7685 NCT04117Study to CoEXPECT-2 Recruiting No ResultsE. Coli Infection
7686 NCT01012Study to Evaluate theCompletedNo ResultsHealthy Volunteers Drug: Hilto
7687 NCT02146Expanded A DCVax-L E Available No ResultsGBM|Glioblastoma Multiforme Biological: DCVax-L
7688 NCT02888Intensive ICUSPID Unknown sNo ResultsPrimary Immune Deficiency DisordeOther: Int
7689 NCT00023BCG With or WithoutCompletedNo ResultsBladder Cancer Biological: BCG vacc
7690 NCT01836Immunother PILLAR Terminate No ResultsPancreatic Cancer|Pancreatic Carc Drug: FOLF
7691 NCT02726Bihar Family Health InCompletedNo ResultsMaternal and Child Health Behavioral
7692 NCT00382A Study to Evaluate t CompletedNo ResultsPlaque Psoriasis Drug: Rapt
7693 NCT00991Redirected High AffinCompletedNo ResultsHIV Infections Biological:
7694 NCT03730Humoral Immunodefici Recruiting No ResultsSecondary Immune Deficiency DisorDrug: Hize
7695 NCT00448Stopping Up STUFFY CompletedNo ResultsRespiratory Tract Infections|CommoBehavioral
7696 NCT02414A Study to C-010-402CompletedHas ResultTuberculosis Biological
7697 NCT04059DevelopingTIMING Recruiting No ResultsGroup B Streptococcus Procedure:
7698 NCT02556Evaluation of the Saf CompletedNo ResultsSyringe Device: Sta
7699 NCT01496Tecemotide (L-BLP25)CompletedHas ResultProstate Cancer Radiation:
7700 NCT02431A Pilot Study to Eva CompletedNo ResultsIntracranial Tumors|Glioblastoma Other: PBR
7701 NCT01383EvaluationBFC Unknown sNo ResultsMalnutrition in Pregnancy|Other DisBehavioral:
7702 NCT01397The Effects of GLA o CompletedNo ResultsHealthy Volunteers Drug: GLA-
7703 NCT00553Cyclophosphamide, Rad Unknown sNo ResultsBreast Cancer|Colorectal Cancer|GaDrug: cycl
7704 NCT02504Markers of T Cell SupCompletedNo ResultsMalaria
7705 NCT01299Polyinosinic-PolycytidCompletedNo ResultsHealthy Volunteers Drug: Poly
7706 NCT02430A Study to C-012-402CompletedNo ResultsTuberculosis Biological
7707 NCT03415Effect of Implementa CompletedNo ResultsHepatitis C and B VIRUS Screening, Behavioral
7708 NCT01940Experimental Infecti Recruiting No ResultsHookworm Infection Biological
7709 NCT03627RESCEU Study: DefininRecruiting No ResultsRSV Infection|Respiratory Syncytial Other: No
7710 NCT03911HSV G207 in ChildrenRecruiting No ResultsNeoplasms, Brain|Glioblastoma MulBiological:
7711 NCT02995Safety DemonstrationCompletedNo ResultsAllergic Reaction to Nickel Device: Gol
7713 NCT00062Safety and Immunogen Unknown sNo ResultsNon-Small Cell Lung Cancer Biological: Recombin
7714 NCT00480A Study of the Immuno CompletedNo ResultsTB Biological:
7715 NCT03999A Clinical FLYBITE CompletedNo ResultsLeishmaniasis, Cutaneous|Insect BitOther: Sand
7716 NCT00797QuantiferoQUANTIPSCompletedNo ResultsTuberculosis Procedure:
7717 NCT02017Procurement of BloodUnknown sNo ResultsChronic Hepatitis B
7718 NCT01223A Study, Combination,CompletedNo ResultsCarcinoma Drug: LTX-
7719 NCT01807Sipuleucel-T With or CompletedNo ResultsAdenocarcinoma of the Prostate|Bon Biological:
7720 NCT01660Re-exposurTIP4 CompletedNo ResultsMalaria, Falciparum Biological
7721 NCT01676An Open-lab Î²-SPECIFICWithdrawnNo ResultsSystemic Juvenile Idiopathic Arthriti Drug: ACZ
7722 NCT00077Monoclonal AntibodyCompletedNo ResultsMelanoma (Skin) Biological:
7723 NCT00633Tolerability and Safe CompletedNo ResultsAlzheimer's Disease Biological
7724 NCT00130A Trial of IRS CompletedNo ResultsTuberculosis Drug: Isoni
7725 NCT02261A New Reagent AssayCompletedNo
E ResultsSickle Cell Disease Other: Blo
7726 NCT01938Evaluation of the Pro CompletedNo ResultsInfluenza Biological:
7727 NCT00495Tolerability and Safe CompletedNo ResultsAlzheimer's Disease Biological
7728 NCT01893Vitamin D SupplemenTerminate No ResultsD Vitamin Deficiency Patients Drug: Vita
7729 NCT02947Global Genomic and Pr Unknown sNo ResultsTyphoid Fever
V ResultsHIV-1 Infection Drug: Vacc
7731 NCT03947Phase 1b/2a Trial to Not yet recNo ResultsLeprosy Biological:
7732 NCT01596A/H5N1 Virus-Like PaCompletedNo ResultsInfluenza (Pandemic) Biological
7733 NCT01594A/H5N1 Virus-Like PaCompletedNo ResultsInfluenza (Pandemic) Biological
7734 NCT04065Study of Tenofovir Al Recruiting No ResultsHepatitis B Virus|Mother to Child T Drug: Teno
7735 NCT01780The NIH MINI Study: Recruiting No ResultsUCD|MMA|Acidemias|Fatty Acid Oxidation Def
7736 NCT01340Study of AERAS 422 i CompletedNo ResultsTuberculosis Drug: AERA
7737 NCT01324Safety and Tolerabili CompletedNo ResultsIntradermal Electroporation Drug: EMLA
7738 NCT02481A Clinical Trial of P Recruiting No ResultsCervical Intraepithelial Neoplasia Biological
7739 NCT04001Therapy for High-RiskRecruiting No ResultsHPV Positive Oropharyngeal Squam Drug: MED
7740 NCT03496Susceptibi CHMI-GamCompletedNo ResultsMalaria Other: PfS
7741 NCT02793Provenge Followed byWithdrawnNo ResultsProstate Cancer Biological:
7742 NCT00716PathophysiLBP003 Terminate No ResultsHealthy|Immunosuppressed Biological:
7743 NCT02793Docetaxel Followed bWithdrawnNo ResultsProstate Cancer Drug: Docet
7744 NCT00168Different Doses of Vi CompletedNo ResultsMortality|Morbidity Drug: Vita
7745 NCT00031Increasing HAART-IndCompletedNo ResultsHIV Infections Drug: Abacavir sulfat
7746 NCT00279The Role of Peptide-l CompletedNo ResultsMetastatic Melanoma Procedure
7747 NCT00003Cisplatin, Interferon CompletedNo ResultsMalignant Mesothelioma Biological: recombina
7748 NCT02261Immune Fun TDAP2 CompletedNo ResultsSarcopenia|Aging|Immune Functio Biological
7749 NCT00230The MOM Program atCompletedNo
t ResultsChild Development Behavioral
7750 NCT03334Identificat bNAb Active, notNo ResultsHIV/AIDS
7751 NCT01163Seroepidemiology of U J nknown sNo ResultsJapanese Encephalitis
7752 NCT02591PreventingPReSuTINeUnknown sNo ResultsUTI|Neurogenic Bladder Drug: Uro
7753 NCT01704A Study of CNTO 3157CompletedNo ResultsHealthy Volunteers and Asthma Drug: CNTO
7754 NCT03975Cervical Cytology - D Not yet recNo ResultsCervical Carcinoma|Cervical DysplasOther: SMS
7755 NCT04085Immunotherapy Based Recruiting No ResultsCancer Biological:
7756 NCT03353Adaptive Ca ACT CompletedNo ResultsDevelopment; Delayed, Mental|Anxiety|Situatio
7757 NCT02163Study of HPV Specifi CompletedNo ResultsHead and Neck Squamous Cell CancBiological
7758 NCT01057MeditationMEPARI CompletedNo ResultsAcute Respiratory Infection Behavioral
7759 NCT01383Identification of Pot CompletedNo ResultsCat Allergy Biological:
7760 NCT01487Prevaccination Study Unknown sNo ResultsHuman Papilloma Virus|Cervical Cancer|Cervica
7761 NCT00224LymphocytiCLONTAK WithdrawnNo ResultsCHRONIC LYMPHOCYTIC B-LEUKEMIBiological
7762 NCT00736Knowledge and Percep WithdrawnNo ResultsCervical Cancer|Precancerous CondiOther: sur
7763 NCT03131Dose Escalation and Unknown sNo ResultsCancer Biological:
7764 NCT02069Drug Use InvestigatioCompletedNo ResultsInfluenza Biological:
7765 NCT00006Studies of HIV-1 InfecCompletedNo ResultsHIV Infections|HIV Seronegativity
7766 NCT03400Autologous DendriticActive, notNo ResultsNewly Diagnosed Glioblastoma Biological
7767 NCT00006Long-Term Effects of CompletedNo ResultsHIV Infections|HIV Seronegativity
7768 NCT02071Enhancemen Poly-ICLC CompletedHas ResultHIV-1 Infected Adults With Chronic HDrug: Arm
7769 NCT02669Cellular ImmunotheraUnknown sNo ResultsNon Small Cell Lung Cancer Biological
7770 NCT00008Effectiveness of Earl WithdrawnNo ResultsHIV Infections Biological: Tetanus
7771 NCT00100RSV Challenge in HealCompletedNo ResultsRespiratory Infections, Acute|RespirDrug: RSV challenge m
7772 NCT02241Immunotherapy in Sub CompletedNo ResultsAerodigestive Precancerous Lesions Biological
7773 NCT00960A Long Term ExtensioTerminate Has ResultAlzheimer Disease Biological
7774 NCT00407Role of Antimicrobial CompletedNo ResultsAtopic Dermatitis
7775 NCT01788HPV in Adolescents CompletedNo ResultsHPV Infection|Cervical/Anal Dysplasia
7776 NCT00250V930 First in Man (F CompletedNo ResultsCancers Expressing HER-2 and/or C Biological: V930
7777 NCT02240Phase I St BBMPI03 Unknown sNo ResultsAcute Myelogenous Leukemia (AMLDrug: Sarg
7778 NCT01443Longitudinal Pattern Unknown sNo ResultsStreptococcus Pneumoniae Nasopharyngeal Ca
7779 NCT02193MVX-ONCO-1 in Patien Recruiting No ResultsSolid Tumor|Cancer Other: Tre
7780 NCT01689Phase II Randomized Terminate Has ResultMetastatic Melanoma Drug: Ipil
7781 NCT00155The Development of Unknown sNo ResultsCervical Cancer
7782 NCT01715Study of I MUCOVACTerminate No ResultsHIV Infected Women|Healthy WomeProcedure:
7783 NCT01159Surveillance Study t CompletedNo ResultsAcute Hepatitis A|Hepatitis Procedure:
7784 NCT00307Adenovirus Encoding CompletedNo ResultsMetastatic Breast Cancer|RecurrentBiological:
7785 NCT01641Tolerability, ImmunogCompletedNo ResultsHepatitis B, Chronic Genetic: H
7786 NCT02820A Phase I DENDR-ST CompletedNo Resultsde Novo Glioblastoma Biological:
7787 NCT01280A Study of ICT-107 I CompletedHas ResultGlioblastoma Multiforme Biological:
7788 NCT02995Tenofovir in Early Pr Recruiting No ResultsHepatitis B Drug: Teno
7789 NCT01567Phase II Trial With S CompletedHas ResultAllergic Rhinoconjunctivitis Biological:
7790 NCT01298Case-control Study o CompletedNo ResultsA/H1N1 Influenza|Swine Flu
7791 NCT01498A Study of ReACT CompletedNo ResultsGlioblastoma|Small Cell Glioblast Drug: Beva
7792 NCT03421Intravesical Ty21a fo Recruiting No ResultsNon Muscle Invasive Bladder CancerBiological:
7793 NCT00000A Study of HIV in NewCompletedNo ResultsHIV Infections
7794 NCT02536Intestinal INCA Unknown sNo ResultsMicrobiota|Eczema|Atopy
7795 NCT01160Pilot Study to Estima CompletedNo ResultsMalaria, Falciparum|Plasmodium Falciparum
7796 NCT01917A Comparison of the CompletedNo ResultsDiphtheria|Pertussis|Tetanus|HepatBiological:
7798 NCT01498BCG Modulation of thCompletedNo ResultsBladder Cancer Biological
7799 NCT00301Study on Preventing CompletedNo ResultsAnaemia in Children Drug: Ferr
7800 NCT00523Exploratory Study in CompletedNo ResultsInfections, Streptococcal Procedure:
7801 NCT03664DV2-HBV-27 HBV-27 Recruiting No ResultsPregnant Biological:
7802 NCT02234Improving IECDZ CompletedNo ResultsStunting|Child Development Behavioral
7803 NCT00670Chemotherapy Followe Terminate Has ResultMetastatic Melanoma|Metastatic ReBiological
7804 NCT03162The Safety and Antit Active, notNo ResultsCancer of Ovary|Neoplasms, Ovarian Biological
7805 NCT03621RESCEU Study, DefininActive, notNo ResultsRSV Infection|Respiratory Syncytial Virus Infec
7806 NCT00162Her-2/NeuAdHERe CompletedNo ResultsMetastatic Breast Cancer Biological:
7807 NCT03138Safety andPbVac CompletedNo ResultsMalaria,Falciparum|Plasmodium FalBiological
7808 NCT00965Mechanisms MOSAIC CompletedNo ResultsInfluenza
7809 NCT01042How Our Immune SystCompletedNo ResultsOvarian Cancer
7810 NCT00329Safety and Tolerabili CompletedNo ResultsCancer Biological:
7811 NCT00395Bronchitis BREATH Terminate Has ResultCOPD|Emphysema Behavioral
7812 NCT01477Sipuleucel-T ManufacCompletedHas ResultCancer of Prostate|Cancer of the P Biological:
7813 NCT01024ObservatioISS OBS T- CompletedNo ResultsHIV Infection
7814 NCT02888Carriage of StreptocoUnknown sNo ResultsStreptococcus Pneumoniae|Nasopha Other: Nas
7815 NCT01338Sipuleucel-mCRPC Terminate Has ResultProstate Cancer Biological:
7816 NCT03869Expansion of a DenguCompletedNo ResultsDengue Biological
7817 NCT01353DN24-02 as Adjuvant Terminate Has ResultUrothelial Carcinoma Biological
7818 NCT00419Inpatient Influenza SuCompletedNo ResultsInfluenza
7819 NCT02948EvaluationVOYAGE Active, notNo ResultsAsthma Drug: Dupi
7820 NCT03403A First-In-Human StudCompletedNo ResultsHealthy Drug: JNJ-
7821 NCT00471Normal Immunological Recruiting No ResultsMalaria
7822 NCT00451Follow-Up Study of SuRecruiting No ResultsProstate Cancer|Liver Cancer|Breast Cancer|
7823 NCT01697A Phase II Trial of T Active, notNo ResultsHead and Neck Squamous Cell Carc Drug: Tada
7824 NCT01322A Longitudinal SystemRecruiting No ResultsMalaria
7825 NCT00901Open Label Study of SCompletedHas ResultProstate Cancer Biological:
7826 NCT00715To Evaluate SipuleuceCompletedHas ResultProstate Cancer Biological:
7827 NCT03262MMF for HIV ReservoiActive, notNo ResultsHuman Immunodeficiency Virus I InfDrug: Myco
7828 NCT00421A Study to Evaluate aCompletedNo ResultsRespiratory Syncytial Virus (RSV) Biological
7829 NCT02153Longitudinal AnalysisTerminate No ResultsMalaria
7830 NCT00000A Phase II Study of L CompletedNo ResultsHIV Infections Drug: Aldesleukin
7831 NCT00629A Safety T BNIT-PR-0 CompletedNo ResultsAndrogen-insensitive Prostate Canc Biological
7832 NCT03462Complications in Chi Not yet recNo ResultsBeta-thalassemia Other: Demo
7833 NCT00675Safety Study of CADI Terminate No ResultsStage III or Stage IV Melanoma Biological:
7834 NCT02355Assessing AMRIC CompletedNo ResultsCardiovascular Disease|Cancer Other: Ins
7835 NCT02525Characterisation of CompletedHas ResultInfluenza Other: Infe
7836 NCT01922RSV Observational St CompletedNo ResultsRespiratory Syncytial Virus InfectionProcedure:
7837 NCT02816Dose-Finding Study ofCompletedHas ResultHealthy Biological:
7838 NCT04087Study to CoEXPECT-1 Recruiting No ResultsE.Coli Infections
7839 NCT00340Immune Responses toCompletedNo ResultsMycobacterium Tuberculosis
7840 NCT03819A Study of Three Diff Recruiting No ResultsHealthy Biological:
7841 NCT01312The Antiviral TherapyUnknown sNo ResultsHepatitis B Virus Infection, Pregnan Drug: antiv
7842 NCT02208Genetically Modified Recruiting No ResultsMalignant Glioma|Refractory Brain Biological
7843 NCT00776Effect of Early Skin CompletedHas ResultBreasteeding Other: skin
7844 NCT00500Blood Collection for CompletedNo ResultsHealthy Procedure:
7845 NCT04197Study on t BIOGN1 Recruiting No ResultsSuspected Damage to Fetus From BiOther: clin
7846 NCT03552sEphB4-HSA in Treati Not yet recNo ResultsRecurrent Bladder Carcinoma|Bladde Other: Pha
7847 NCT02122Implementation of a CompletedNo ResultsHIV|Chlamydia|Gonorrhea|Syphilis|Behavioral
7848 NCT03358A Prospective,Observa Recruiting No ResultsHepatitis B, Chronic
7849 NCT03550Hospital-based SurveiCompletedNo ResultsRotavirus Gastroenteritis, Young Taiwanese Chi
7850 NCT04214Chimeric Antigen Rece Not yet recNo ResultsRecurrent Glioblastoma|Recurrent Biological
7851 NCT00338Safety and Efficacy ofApproved fNo ResultsVaricella Drug: VariZIGâ„¢
7852 NCT01826Autologous Dendritic Active, notNo ResultsClear Cell Renal Cell Carcinoma|RecBiological:
7853 NCT03831A Study of INO-A002 Recruiting No ResultsHealthy Volunteers Biological
7854 NCT00901Lebanese ILIPSP Unknown sNo ResultsPneumonia|Meningitis|Sepsis|Bacteremia
7855 NCT00485A Phase II Study of E Terminate No ResultsRenal Cell Carcinoma Biological:
7856 NCT01194TroVaxÂ® In Subjects Terminate No ResultsHormone Refractory Prostate CanceDrug: Doce
7857 NCT04106Single Ascending DoseCompletedHas ResultInfluenza Biological:
7858 NCT02052Study of IDO Inhibit CompletedNo ResultsGlioblastoma Multiforme|Glioma|GDrug: Indo
7859 NCT01638Identification of Corr Unknown sNo ResultsDysentery Other: Lab
7860 NCT01890Study to Analyze the CompletedNo ResultsDiphtheria|Acellular Pertussis|Teta Other: Retr
7861 NCT00952Dose-finding Study o CompletedNo ResultsHealthy Drug: poly
7862 NCT00508Assessing the Effecti CompletedNo ResultsCardiovascular Diseases Other: Usu
7863 NCT02853Measuremen KAWASAKIUnknown sNo ResultsKawasaki Disease Other: lab
7864 NCT00118Shingles: Immune EffeCompletedNo ResultsAging|Herpes Zoster Behavioral:
7865 NCT00277Treatment of Autisti CompletedNo ResultsAutism|Food Allergies Procedure:
7866 NCT03490Intervention to ReducRecruiting No ResultsDiaper Dermatitis|Urinary Tract In Other: Dia
7867 NCT01261Modulation of Immune Unknown sNo ResultsAdjuvant Chemotherapy|Colon CanDietary Su
7868 NCT00935Host Dendritic Cells i Unknown sNo ResultsRelapsed Non-Hodgkin's Lymphoma| Biological
7869 NCT00103Use of ACA 125 in Pa CompletedNo ResultsOvarian Cancer|Fallopian Tube Neo Biological
7870 NCT03882Stromal Vascular Fra Recruiting No ResultsChronic Wounds Drug: Antri
7871 NCT01545Study of t AnoPalAnoCompletedNo ResultsWhooping Cough|Malaria|Malnutrition
7872 NCT01645Prevalence of HepatitiWithdrawnNo ResultsHepatitis B
7873 NCT02448A Multicenter Study Recruiting No ResultsStage II Colon Cancer Biological
7874 NCT03553Identifying Young Inf CompletedNo ResultsHerpes Zoster|Inflammatory Bowel Diseases|Cr
7875 NCT00034Study of Anti-HIV TheCompletedNo ResultsHIV Infections Drug: Lopinavir/Rito
7876 NCT00854Efficacy Study of TKc Unknown sNo ResultsAdvanced Colorectal Cancer Biological:
D ResultsAllergy|Rhinoconjunctivitis Biological
7878 NCT02856Effects of Basic Infe Unknown sNo ResultsInfection Control Training Other: Tra
7879 NCT03274Non-inferioaCTIVE Unknown sNo ResultsTravel and Motion Other: Nur
7880 NCT02714Safety and Effect of Active, notNo ResultsSolid Organ Cancers Biological
7881 NCT03969Study to Assess the ERecruiting No ResultsInfluenza Drug: Balo
7882 NCT00155Immunotherapy of Recu Unknown sNo ResultsCervical Cancer Biological
7883 NCT02527Effect of Bacterial V CompletedNo ResultsBacterial Vaginosis|HIV Infections Drug: Metr
7884 NCT00458Phase II S ACT III CompletedNo ResultsMalignant Glioma Drug: CDX
7885 NCT02873Safety and Efficacy S Active, notNo ResultsSquamous Cell Carcinoma of the OraDrug: GL-0
7886 NCT03162Safety and Efficacy Active, notNo ResultsHead and Neck Cancer|Human PapilDrug: MED
7887 NCT01747Surveillance of Hospi Unknown sNo ResultsPneumonia, Bacterial|Pneumonia, Viral|Meningi
7888 NCT03201ARTEMIS Pe ARTEMIS CompletedNo ResultsPeanut Allergy Biological
7889 NCT02473Optimal Human DoseCompletedNo
f ResultsGastroenteritis Norovirus Biological:
7890 NCT02454Safety and PK of MBXCompletedNo ResultsCytomegalovirus Infection Drug: MBX
7891 NCT04164Testing the Addition Recruiting No ResultsBladder Urothelial Carcinoma In Sit Drug: Gemc
7892 NCT02478Transmissi TransFLUasCompletedNo ResultsHuman Influenza Other: Infl
7893 NCT02909Performance of the HB CompletedNo ResultsHepatitis B Biological:
7894 NCT02056ATG VersusPREDICT-DTerminate No ResultsKidney Transplantation Drug: Anti
7895 NCT00685Safety of Cat-PAD in CCompletedNo ResultsCat Allergy Biological:
7896 NCT00291Safety and Immunogen CompletedNo ResultsEsophageal Cancer|Lung Cancer|St Drug: CHP
7897 NCT03377Study of C VAC068 Active, notNo ResultsMalaria, Vivax Other: Pla
7898 NCT01033Cat-PAD Exposure Ch CompletedNo ResultsCat Allergy Biological:
7899 NCT01198ToleroMune RagweedCompletedNo ResultsRagweed Allergy Biological
7901 NCT02345Trial of pIL-12 Elect Terminate Has ResultHead and Neck Squamous Cell Carc Biological
7902 NCT02498A Study of DSP-7888 CompletedNo ResultsAcute Myeloid Leukemia|Myelodyspl Drug: DSP-
7903 NCT03650A Large-scale Resear Not yet recNo ResultsGlioma of Brain Biological
7904 NCT01503Intrapleural Measles Active, notNo ResultsRecurrent Malignant Mesothelioma|Biological
7905 NCT00729Effectiveness of Cat-PCompletedNo ResultsCat Allergy Biological:
7906 NCT01502Trial of p IL-12MEL CompletedHas ResultMelanoma Biological
7907 NCT01024ObservatioISS OBS T- CompletedNo ResultsHIV Infection
7908 NCT03821Study to EvARES Recruiting No ResultsRhinitis, Allergic|RhinoconjunctivitisBiological
7909 NCT03910Intravenous FosfomycRecruiting No ResultsBacterial Infection|Multiple-drug R Drug: Fosf
7910 NCT03794The Effect of Inhale Recruiting No ResultsCOPD Drug: Steri
7911 NCT03205Neo-MASCT Immunoth Unknown sNo ResultsNSCLC Stage IV Biological
7912 NCT02117A Phase 2 Study of V Terminate Has ResultNon Small Cell Lung Cancer Drug: Viag
7913 NCT01218Prospective Surveilla CompletedNo ResultsDengue Fever|Fever
7914 NCT01389Post Partum MaternalCompletedNo ResultsEarly Postpartum and Newborn CareOther: Int
7915 NCT03053Immune Res IRECT-01 Active, notNo ResultsHead and Neck Squamous Cell Carcinoma
7916 NCT02387Study to Evaluate AntCompletedNo ResultsRespiratory Syncytial Virus InfectionDrug: Plac
7917 NCT02779Phase I, Dose Escalat CompletedNo ResultsBotulism Biological
7918 NCT01002OseltamiviOPTIMO CompletedNo ResultsMorbid Obesity Other: Pati
7919 NCT03645Two Different Distrac CompletedNo ResultsVenipuncture Site Reaction|ProceduDevice: Vi
7920 NCT04168Safety and Efficacy ofCompletedNo ResultsHepatitis B Virus (HBV) Biological
7921 NCT00456Invasive Infections i CompletedNo ResultsThalassemia|Sickle Cell Anemia Procedure: Historical
7922 NCT04163Talimogene LaherpareRecruiting No ResultsLocally Advanced Skin Squamous CeBiological
7923 NCT03325Dendritic Cell Thera Recruiting No ResultsStage III Cutaneous Melanoma AJCCProcedure:
7924 NCT02232Liver Canc Hepko-V5 Recruiting No ResultsHepatocellular Carcinoma|HCC|LiveBiological:
7925 NCT00336Trial of In INITII Active, notNo ResultsType 1 Diabetes Biological:
7926 NCT00081Intratumoral PV701 i Terminate No ResultsRecurrent Salivary Gland Cancer|ReBiological:
7927 NCT00867Safety of Cat-PAD to TCompletedNo ResultsCat Allergy Biological:
7928 NCT03399Stereotactic Body Ra Recruiting No ResultsMalignant Mesothelioma (MPM) Drug: Avel
7929 NCT03068Expanded A CDX-110 No longer aNo ResultsRecurrent GBM Biological: rindopepi
7930 NCT02367Phase 1/2 Study of TACompletedHas ResultInfluenza Infection Drug: TAK-
7931 NCT00757Re-exposure of EHMI-CompletedNo ResultsP. Falciparum Malaria Biological:
7932 NCT03550Immunother V3-Cervix Recruiting No ResultsCervical Cancer Biological:
7933 NCT01383Identification of Pot CompletedNo ResultsCat Allergy Biological:
7934 NCT01480Phase III ACT IV CompletedNo ResultsGlioblastoma|Small Cell Glioblasto Drug: Rind
7935 NCT03089Methodological StudyCompletedNo ResultsHypersensitivity Other: Hom
7936 NCT03896Single-Dose Study to Recruiting No ResultsRenal Impairment|Tuberculosis Drug: PA-8
7937 NCT03035Multiple Ascending DCompletedHas ResultHelminthic Infection Drug: Oxfe
7938 NCT03064Understanding HIV Sus CompletedNo ResultsHIV Infections Biological:
7939 NCT03618Anemia and InflammaCompletedNo ResultsIron Deficiency Anemia|Inflammati Biological:
7940 NCT03549Impact of Aluminum Recruiting No ResultsInsemination, Artificial Other: sam
7941 NCT01322A Pilot Trial of GI-4 Terminate Has ResultColon Cancer Drug: chem
7942 NCT03318T-Cell Infusion, Alde Recruiting No ResultsCOL6A3 Positive|HLA-A*0201 PositiBiological
7943 NCT04032Evaluate the Efficacy Not yet recNo ResultsBenign Prostatic Hyperplasia (BPH) Drug: GV10
7944 NCT02187An Efficac ORAL STRACompletedHas ResultRhematoid Arthritis Drug: Tofa
7945 NCT03179Cervix Image Sharing Active, notNo ResultsCervical Cancer|Cervical Abnormalities
7946 NCT03099Multidisciplinary Tea Unknown sNo ResultsRheumatoid Arthritis|Multidiscipli Other: Visit
7947 NCT03358DEC-205/NY-ESO-1 Fus Recruiting No ResultsAcute Myeloid Leukemia|Blasts 30 Biological
7948 NCT01730ImmunoTEP iTEPsein CompletedNo ResultsHER2 Negative Breast Carcinoma Ex Drug: TF2
7949 NCT02234Phase I Trial Evaluat CompletedHas ResultNeurocysticercosis Drug: Oxfe
7950 NCT00494Different ApproachesCompletedNo ResultsMalaria Parasitaemia|Birth Weight Other: del
7951 NCT00637A Study in Elderly Su CompletedNo ResultsInfections, Streptococcal Procedure:
7952 NCT03552World Mosquito Pro Recruiting No ResultsArbovirus Infections Other: Blo
7953 NCT01769A First-in UWI-02 CompletedHas ResultHealthy Volunteers Biological
7954 NCT03916V-Boost ImGBM Recruiting No ResultsGlioblastoma Multiforme|Glioma ofBiological:
7955 NCT02016Development of Immun CompletedNo ResultsOvarian Serous Adenocarcinoma|Undi Procedure:
D ResultsRhinitis, Allergic, Seasonal|ConjunctBiological
7957 NCT02292ToleroMune Grass FolCompletedNo ResultsRhinoconjunctivitis|Grass Allergy
7958 NCT03903Herpes Zoster: Risk F CompletedNo ResultsHerpes Zoster Other: retr
7959 NCT00387Investigation of Effi SuspendedNo ResultsType I Hypersensitivity Biological
7960 NCT01923ToleroMune Grass FolCompletedNo ResultsGrass Allergy|Rhinoconjunctivitis
7961 NCT00522Remote Sim RSMI CompletedNo ResultsDIabetes Other: rem
7962 NCT02710rAAVrh74.MHCK7.DYSF. CompletedNo ResultsDysferlinopathy Drug: rAA
7963 NCT00019Interleukin-2 Plus Ac CompletedNo ResultsUnspecified Adult Solid Tumor, ProtoBiological: aldesleuk
7964 NCT02486Transdermal Patch CVD CompletedHas ResultPeer Review, Research Drug: Dura
7965 NCT02849A Trial With Subcuta CompletedNo ResultsRhinoconjuntivitis Biological:
7966 NCT01385ToleroMune Grass ExpCompletedNo ResultsGrass Allergy|Rhinoconjunctivitis Biological
7967 NCT02371Transdermal Patch CVD CompletedHas ResultSmoking Drug: Nico
7968 NCT00109Dose-Escalation StudyUnknown sNo ResultsCarcinoma, Transitional Cell|Bladd Biological:
7969 NCT00110Investigation of Effi CompletedNo ResultsType I Hypersensitivity Biologica
7970 NCT01864The Effects of GLA ( CompletedNo ResultsHealthy Volunteers Biological
7971 NCT01819HomeTech Healthy LifCompletedNo ResultsOverweight Behavioral
7972 NCT00878Safety of ToleroMuneCompletedNo ResultsAllergy Biological
7973 NCT01753Mercury Versus Auto CompletedNo ResultsHealthy Volunteers
7974 NCT00264Hospital Based IncideCompletedNo ResultsStreptococcus Group A
7975 NCT04046Phase 1b SKISIMA-01Recruiting No ResultsColorectal Cancer|MSS|Stage IV ColDrug: ATP1
7976 NCT01166Safety and Tolerabili CompletedNo ResultsAllergy Biological
7977 NCT00056Assess Inc rhAT CompletedHas ResultAntithrombin Deficiency, CongenitalBiological
7978 NCT01579Phase II I CTCL Terminate Has ResultCutaneous T Cell Lymphomas (CTCL)Biological
7979 NCT03014A Systems Biology ApRecruiting No ResultsPlasmodium Falciparum Infection Biological:
7980 NCT01349The Development of aCompletedNo ResultsRespiratory Syncytial Virus InfectionBiological
7981 NCT03436Local HyperHPV Enrolling bNo ResultsCervical Intraepithelial Neoplasia| Device: Lo
7982 NCT03989Arm 2: Intratumoral Not yet recNo ResultsAdvanced Melanoma Biological
7983 NCT04144Predictors PRSVH Not yet recNo ResultsSyncytial Virus Respiratory InfectionOther: Not
7984 NCT01190Gynaecological Follo CompletedHas ResultInfections, Papillomavirus Procedure:
7985 NCT02019Study to Assess the BCompletedNo ResultsInfluenza Other: Data
7986 NCT00518Study Evaluating the CompletedNo ResultsHealthy Procedure:
7987 NCT03014Efficacy and Safety o CompletedNo ResultsGlabellar Frown Lines Biological:
7988 NCT03014Efficacy and Safety o CompletedNo ResultsGlabellar Frown Lines Biological:
7989 NCT03600Brain Fitness APP for Enrolling bNo ResultsMemory Problems Other: Brai
7990 NCT00325Follow-up Investigati CompletedNo ResultsType I Hypersensitivity Biologica
7991 NCT02511A Two-part Phase IIb A T ctive, notNo ResultsEwing's Sarcoma Biological
7992 NCT02393Feasibility of TelephoCompletedNo ResultsNo Specific Condition Other: Tel
7993 NCT03553Spatial Repellents forCompletedNo ResultsArbovirus Infections Other: tra
7994 NCT00508Malaria Incidence in CompletedNo ResultsMalaria Infection|Malaria Incidence|Anemia
7995 NCT00001Study of Immune Resp CompletedNo ResultsImmunoproliferative Disorder Drug: Bacteriophage
7996 NCT04262Injections GADinLADNot yet recNo ResultsLatent Autoimmune Diabetes in AduDrug: reco
7997 NCT03131Intratumoral Gene MeActive, notNo ResultsLung Cancer Biological:
7998 NCT03566Pilot Study for Evalu Enrolling bNo ResultsGastrointestinal Disease Device: Cr
7999 NCT03776Safety and Tolerabilit Recruiting No ResultsTreatment of Acute Zika Virus InfectBiological
8000 NCT03443Safety and Tolerabili CompletedNo ResultsTreatment of Acute Zika Virus InfectDrug: Tyzi
8001 NCT00840A Study to Examine t CompletedNo ResultsHIV|HIV Infections
8002 NCT03629Inducing I IIQ-2 Not yet recNo ResultsHiv Drug: ASA
8003 NCT04263UCPVax PluOptim-UCPNot yet recNo ResultsStage IV Non-small Cell Lung CancerProcedure:
8004 NCT01097The Effect of Probiot Unknown sNo ResultsHPV-related Cytological AbnormalitiDietary Su
8005 NCT01422Human Papi HYPER CompletedHas ResultHuman Papillomavirus
8006 NCT01769Evaluating EMIT CompletedNo ResultsInfluenza Virus Infection Transmission in Huma
8007 NCT02800Super Selective Intra Recruiting No ResultsGlioblastoma|Anaplastic Astrocyto Drug: Intra
8008 NCT02238Sepsis-Ass SAPFIRE Recruiting No ResultsSepsis
8009 NCT03377Impact of PharmaMDActive, notNo ResultsDiabetes Mellitus, Type 2 Behavioral
8010 NCT010184D Image-guided Adap CompletedNo ResultsLung Cancer Procedure:
8011 NCT02166DEC-205/NY-ESO-1 Fusi Recruiting No ResultsFallopian Tube Carcinoma|Ovarian Biological
8012 NCT00393Malaria TransmissionCompletedNo ResultsPlasmodium Falciparum Malaria
8013 NCT01327Ciliary Neurotrophic FCompletedNo ResultsIdiopathic Juxtafoveal TelangiectasiaBiological:
8014 NCT01447ToleroMune House DuCompletedNo ResultsRhinoconjunctivitis Biological
8015 NCT03076Safety, Tolerability, CompletedNo ResultsInfluenza Biological
8016 NCT03587Brain Fitness APP fo Enrolling bNo ResultsMild Cognitive Impairment|AlzheimOther: Brai
8017 NCT01740CTLA-4 Blockade and Terminate Has ResultMelanoma Drug: Cyc
8018 NCT00731Generation of DendritUnknown sNo ResultsNormal Full-Term Deliveries Procedure:
8019 NCT03052Human Papi MUCOHPVCompletedNo ResultsCystic Fibrosis Procedure:
8020 NCT01997IntrapleuraMpeTK01 Active, notNo ResultsMalignant Pleural Effusion|Lung C Biological:
8021 NCT00360Safety Study of 7 Bo CompletedNo ResultsHealthy Biological:
8022 NCT03565VRC 610: Phase I Saf SuspendedNo ResultsHealthy Adult Immune Response Biological
8023 NCT01744Effect of EPICC Unknown sNo ResultsPneumonia Other: Int
8024 NCT02937Tenofovir TA-PROHMActive, notNo ResultsHepatitis B Chronic Infection|Pregn Drug: Teno
8025 NCT00760Surveillance of Influ CompletedNo ResultsInfluenza Type A|Influenza Type B Other: Nas
8026 NCT03895Connors Protocol fo Enrolling bNo ResultsHealthy Volunteer Samples
8027 NCT00795Preoperative IntratumUnknown sNo ResultsPancreatic Cancer Biological:
8028 NCT00832Longitudinal Study o CompletedNo ResultsDysbacteriosis Drug: Cipro
8029 NCT00161Investigation of the CompletedNo ResultsTick-borne Encephalitis Biological: FSME-IM
8030 NCT02111Phase III VIABLE Active, notNo ResultsMetastatic Castrate Resistant ProstaBiological
8031 NCT00744Malaria Challenge WiCompletedNo ResultsPlasmodium Falciparum Infection Biological:
8032 NCT04216Best Practice Study o Active, notNo ResultsDiabetes Mellitus, Type 2|Primary CProcedure:
8033 NCT03641Defining Skin ImmunitCompletedNo ResultsZika|Dengue|Malaria|Chikungunya|Other: Vec
8034 NCT00023HIV and Genital Her CompletedNo ResultsHIV Infections|Herpes Genitalis|HIV Seronegativity|Syphi
8035 NCT02049Investigat ARCAGE-NCompletedNo ResultsHead and Neck Cancer
8036 NCT03327Western AuPrEPIT-WAActive, notNo ResultsHIV Prevention Drug: Tenof
8037 NCT03004Safety of Single and CompletedNo ResultsGlabellar Frown Lines Biological:
8038 NCT03407STI Care Model to Re CompletedNo ResultsHIV Prevention|Sexually Transmitte Diagnostic
8039 NCT02730PH 1 Study to Evalua Recruiting No ResultsAcute Myelogenous Leukemia|B-cellBiological
8040 NCT00401Immunity to Human CCompletedNo ResultsCholera
8041 NCT00138Human Immunity to M Unknown sNo ResultsPlasmodium Falciparum Malaria
8042 NCT03985Sexual andANRS 1238Recruiting No ResultsHIV Infections|Viral Hepatitis B|Se Other: Com
8043 NCT03084CD8 Reactivity to MicTerminate No ResultsImmune Modulation|Tuberculosis|Leprosy|Per
8044 NCT02143Effect of Liver and CompletedNo ResultsPlasmodium Vivax Infection|Plasmod Drug: Prim
8045 NCT00629Dissemination of Cer Terminate No ResultsCervical Cancer Behavioral
8046 NCT02788Safety, Tolerability, CompletedHas ResultMiddle East Respiratory Syndrome CBiological
8047 NCT01734Environmental Risk FaRecruiting No ResultsDermatomyositis|Adult Polymyositis|Inclusion
8048 NCT02630Feasibilit HVTN 914 CompletedNo ResultsHIV Infections|Acquired ImmunodefiProcedure:
8049 NCT01008Safety of ToleroMuneCompletedNo ResultsAllergy Biological
8050 NCT02511Long-term Observation Recruiting No ResultsPost Influenza
8051 NCT00589Phase 2a SBrTK02 CompletedNo ResultsMalignant Glioma|Glioblastoma MulBiological:
8052 NCT02594Influenza A H3N2 Hum CompletedNo ResultsDetermine Minimally to ModeratelyOther: Liv
8053 NCT00377Prospective Study of Unknown sNo ResultsDengue
8054 NCT00436Streptococcal InfectioCompletedNo ResultsStreptococcus Group A
8055 NCT00138Correlates of Protect CompletedNo ResultsMalaria
8056 NCT01598Use of RacotumomabCompletedNo
i ResultsNeuroblastoma|Ewing's Sarcoma|WDrug: rac
8057 NCT01065Medication Histories Terminate No ResultsMedication Reconciliation|Emerge Other: Med
8058 NCT00307Rheumatic Heart DiseCompletedNo ResultsStreptococcus Group A
8059 NCT01387Trial to As TOAST CompletedHas ResultAntiretroviral Treatment Outcomes Drug: Tenof
8060 NCT01002Comparison TIP1 CompletedNo ResultsPlasmodium Falciparum|Malaria Biological
8061 NCT001433TC or No 3TC for HI SuspendedNo ResultsHIV Infections Drug: Lami
8062 NCT00894The Study ARI CompletedNo ResultsChildhood Pneumonia|Pneumococcal Carriage
8063 NCT01168Host and Parasite FacRecruiting No ResultsMalaria
8064 NCT03909Emission Patterns of RRecruiting No ResultsRSV Infection|Aerosol Disease
8065 NCT02130Study to Evaluate Saf Active, notNo ResultsRespiratory System Agents|Anti-Ast Drug: benr
8066 NCT00432Immunogenicity and SCompletedNo ResultsMeasles|Mumps|Varicella Biological: M-M-Râ„
8067 NCT01971Evaluation of Anti-HeCompletedHas ResultInfluenza Biological
8068 NCT01311Study of HANRS CO1 CompletedNo ResultsHIV Infections Procedure: surgical
8069 NCT01543Respiratory Disease CompletedNo ResultsChronic Obstructive Pulmonary DiseOther: RT
8070 NCT00167Reducing the Effects CompletedNo ResultsMalaria Drug: sulf
8071 NCT00069Resistance to HIV Inf Unknown sNo ResultsHIV Infections
8072 NCT02298Complement InhibitioCompletedHas ResultThrombocytopenia|Alloimmune Plate Drug: Ecul
8073 NCT00906Safety TriaSTAT CompletedHas ResultEnd-Stage Renal Disease|Kidney FaiBiological:
8074 NCT03369RCT of Efficacy of AmRecruiting No ResultsTreatment Failure|Lethargy|AlteredDrug: Amoxi
8075 NCT03426The Gut-Brain Study Recruiting No ResultsAutism Spectrum Disorder (ASD)|Gas Biological
8076 NCT01861Pneumococcal Carriage CompletedNo ResultsLower Respiratory Tract Infections
8077 NCT00837Anti-TNF Agents for tCompletedHas ResultRheumatoid Arthritis Drug: Etan
8078 NCT00340HLA-B35 Alleles and WithdrawnNo ResultsHIV-1|AIDS
8079 NCT02301The Effect of Anti-vi Unknown sNo Resultsthe Safety of Anti-viral Drugs Used Drug: Lami
8080 NCT03083Sanaria PfSPZ Challe CompletedNo ResultsMalaria Drug: Chlo
8081 NCT00151Thymic Tolerance in PTerminate No ResultsHeart Transplantation Procedure:
8082 NCT02090Development of Human CompletedNo ResultsAllergic Rhinitis|Asthma|Latent TubOther: TLR
8083 NCT03607Adalimumab Microneed Active, notNo ResultsPain|Injection Site Biological
8084 NCT00923Biology Studies of H Enrolling bNo ResultsAcute Lymphoblastic Leukemia|Myelodyspla
8085 NCT00131Safety and Efficacy o Active, notNo ResultsHIV Infection Genetic: V
8086 NCT00158Kilimanjaro IPTi Drug CompletedNo ResultsMalaria Drug: sulp
8087 NCT00695Long Term Follow UpRecruiting No ResultsSevere Combined ImmunodeficiencyProcedure:
8088 NCT00867TCAD vs. Monotherapy CompletedHas ResultInfluenza Drug: TCAD
8089 NCT00950Nurse TeleNATCHOS CompletedHas ResultType 1 Diabetes|Type 2 Diabetes Behavioral
8090 NCT03468123I Radiolabeled 3 CompletedNo ResultsHuman Immunodeficiency Virus Combinatio
8091 NCT01757The Clinic GBS CompletedNo ResultsStreptococcus Agalactiae (Streptococcus Group
8092 NCT00424Comparison of the Qua WithdrawnNo ResultsChronic Liver Disease|TB Procedure:
8093 NCT01853A Study to PEARL CompletedHas ResultLung Cancer, Non-Small Cell Biological
8094 NCT01265Malaria Surveillance CompletedNo ResultsMalaria
8095 NCT01911Genetic SusceptibilityActive, notNo ResultsInvasive Streptococcal Infection|Invasive Grou
8096 NCT01269Prospective EvaluatioCompletedNo ResultsBronchial Hyperreactivity|Infant, P Other: Met
8097 NCT02313Phase 1/2 Study of TACompletedHas ResultInfluenza Infection Drug: Subc
8098 NCT02511Sanaria PfSPZ Challe CompletedNo ResultsMalaria Drug: Chlo
8099 NCT04090Effects of MOCOGSENot yet recNo ResultsMultiple Sclerosis Diagnostic
Re ResultsHealthy
8101 NCT02514A Phase II Study Usi Active, notNo ResultsHematopoietic Neoplasms|Tumors of Drug: Ibru
8102 NCT00006Active Immunotherapy Unknown sNo ResultsRenal Cell Carcinoma Biological: DC RCC-R
8103 NCT01550Pilot ImmunotherapyCompletedNo ResultsMalignant Glioma of Brain Drug: IGF-
8104 NCT01800Milk IngredMIRAGE CompletedNo ResultsBacterial Infection|Diarrhea|GastroeDietary Su
8105 NCT01279MontelukasMAC Unknown sNo ResultsPersistent Cough|Whooping Cough Drug: Mont
8106 NCT01390Role of Human Milk Ba CompletedNo ResultsRespiratory Infections Dietary Su
8107 NCT01048Campylobacter Jejun Unknown sNo ResultsCampylobacter Infections Biological
8108 NCT02014Safety and ReactogeniCompletedNo ResultsInfluenza A Other: 1:1
H ResultsHepatitis C
8110 NCT02107Phase II Study of DCVCompletedNo ResultsProstate Cancer Biological
8111 NCT04114Tenofovir iPK-TDF Not yet recNo ResultsHepatitis B|Tenofovir|Pregnancy Drug: Teno
8112 NCT00427Fluorouracil, Semust CompletedNo ResultsColorectal Cancer Biological: BCG vacci
8113 NCT00911Host Factors in Invas Terminate No ResultsStaphylococcal Aureus Infection|Recurrent Staphylococcal
8114 NCT01534Identificat TETRA CompletedNo ResultsHepatitis C
8115 NCT00571Parental Permission aCompletedNo ResultsAdolescents
8116 NCT00537Characterization of A Recruiting No ResultsHIV Infections Drug: Dolu
8117 NCT01225The Effect PRETEC CompletedNo ResultsGastroenteritis|Bacterial Infection| Dietary Su
8118 NCT00923Pilot Study of Lipos CompletedHas ResultSarcoma, Kaposi Drug: Lipo
8119 NCT00005Genetics of Hepatitis CompletedNo ResultsHepatitis C|Liver Disease
8120 NCT02028Efficacy of OndangapiTerminate No ResultsVomiting|Gastroenteritis Drug: Ond
8121 NCT00947Safety and Efficacy S CompletedNo ResultsHealthy Drug: PUR0
8122 NCT01150Evaluating Modes of WithdrawnNo ResultsInfluenza Behavioral
8123 NCT02500Telephone-based SmoCompletedNo ResultsNicotine Dependence Behavioral
8124 NCT02868AssessmentEMIRATH Recruiting No ResultsAcute Respiratory Infection Other: Nas
8125 NCT03916Registry a CREST Active, notNo ResultsAsthma|Pediatric ALL|School HealthOther: Hom
8126 NCT01358Study to Evaluate AntCompletedHas ResultTetanus|Poliomyelitis|HaemophilusProcedure:
I
8127 NCT01709The Effect PROTETEC CompletedNo ResultsGastroenteritis|Bacterial Infection| Dietary Su
8128 NCT02992AtezolizumSABR-PDL1Recruiting No ResultsPatients With Metastatic Tumours Drug: Anti
8129 NCT03550Open LabeV3-myomaRecruiting No ResultsMyoma;Uterus|Fibroid Uterus|Lei Biological
8130 NCT01286Oseltamivir Infant In CompletedNo ResultsInfluenza, Human
8131 NCT00341Studies of the Natur CompletedNo ResultsAutoimmune/Connective Tissue Diseases|Idiop
8132 NCT01019TherapeutiERAMUNE-CompletedNo ResultsHIV-1 Infection Drug: ART
8133 NCT01019ExplorationMUCOVIR CompletedNo ResultsHIV-1 Infection Procedure:
8134 NCT01697The Combined Use ofUnknown
I sNo ResultsMalaria Other: Ind
8135 NCT00001Prevention of RSV InfCompletedNo ResultsRespiratory Syncytial Virus InfectionDrug: RSV Polyclonal
8136 NCT03995Integrated Care Deli Not yet recNo ResultsHIV Behavioral:
8137 NCT00246Effect of Tai Chi Vs. CompletedNo ResultsCancer|Cancer Survivor Procedure:
8138 NCT00339Collection and Distri Enrolling bNo ResultsHealthy Donors
8139 NCT00272Study Testing the Bio CompletedNo ResultsRenal Cell Carcinoma Biological
8140 NCT00891Probiotic Ingestion anCompletedNo ResultsIsoagglutinin-Mediated Hemolysis|Pr Dietary Su
8141 NCT00311Use TST and QFT-RD1Unknown
T sNo ResultsTuberculosis|Latent Tuberculosis|TuDrug: tuber
8142 NCT00772Immune Parameters iCompletedNo ResultsMalaria
8143 NCT01078Observational SurveilCompletedHas ResultHuman Papillomavirus Infection
8144 NCT02123Hawaii PatHI-PRAISE CompletedHas ResultDiabetes Mellitus Behavioral:
8145 NCT03942A New Approach to Ce Not yet recNo ResultsHealthy
8146 NCT03909Oral AzithrSANTE Not yet recNo ResultsStillbirths and Infant Mortality Drug: Azit
8147 NCT00001Observation of HIV-InCompletedNo ResultsHIV Infection
8148 NCT03251A Dose Escalation an Recruiting No ResultsCancer|Tumors|Neoplasm|MalignaDrug: BMS-
8149 NCT03861Re-evaluatACORG-HLNot yet recNo ResultsOrgan Transplantation Other: DNA
8150 NCT00058PreventionEUCLID CompletedNo ResultsEpstein-Barr Virus Infections|Lympho Biological:
8151 NCT02718Study to Evaluate Saf CompletedNo ResultsThrombocytopenia Drug: UCB
8152 NCT03113Repeated Subcutaneou CompletedNo ResultsAlzheimer's Disease Drug: ABva
8153 NCT01053A Randomis PEPpIE Unknown sNo ResultsInfluenza Drug: Tami
8154 NCT00217A Pilot Study of Ale CompletedHas ResultMyelodysplastic Syndromes Drug: Ale
8155 NCT03871Abatacept HLA-A29 Recruiting No ResultsEye Diseases|Uveitis Drug: Abat
8156 NCT03088ParticipantPERTH Terminate No ResultsIntervention Study Behavioral
8157 NCT03985Non-immersive VirtuaNot yet recNo ResultsProcedural Pain Other: Dist
8158 NCT03561Team-Based Goals and CompletedNo ResultsHealthy Behavioral
8159 NCT04250Chemoprophylactic AcNot yet recNo ResultsHealthy Drug: M571
8160 NCT01636Special Drug Use InveCompletedNo ResultsInfections, Rotavirus Biological:
M ResultsLatent Tuberculosis
8162 NCT00640A ProspectPIPET C WithdrawnNo ResultsPandemic Influenza
8163 NCT01494Pediatric PharmaJetCompletedNo ResultsFunctionality and Performance of Device
8164 NCT00640A ProspectPIPET B WithdrawnNo ResultsPandemic Influenza
8165 NCT01479Study on the IncidencCompletedNo ResultsIntussusception Other: Data
8166 NCT00857Intermittent Preventi CompletedNo ResultsAnaemia|Malaria Drug: Sulf
8167 NCT00498Study Evaluating ACCCompletedHas ResultAlzheimer Disease Biological
8168 NCT02346Impact of AKINVAV CompletedNo ResultsUterine Cervical Dysplasia|PapillomaDrug: AV2|
8169 NCT02328Compass - Compass
R Active, notNo ResultsCancer of the Cervix|Cervical IntraeDevice: Mo
8170 NCT02877Interest of HepScreenCompletedNo ResultsSolid Tumor Other: hepa
8171 NCT00955Long Term Extension C S ompletedNo ResultsAlzheimer Disease Drug: ACC
8172 NCT00112AAB-001 in Patients CompletedNo ResultsAlzheimer's Disease Drug: bapi
8173 NCT02495Phase 2 Study of MPDWithdrawnNo ResultsNon-Small Cell Lung Cancer Drug: CDX
8174 NCT00001Investigation of the Recruiting No ResultsT-cell Lymphoma|B-Cell Lymphoma|ATL|Myel
8175 NCT00203International Adopti CompletedNo ResultsStress Behavioral
8176 NCT02541Using Covered Stent Unknown sNo ResultsLiver Disease Device: th
8177 NCT02946Kinetics a PAPCLEAR Recruiting No ResultsHPV Genital Infection (Primary CondOther: vag
8178 NCT01040Immunogenicity and SCompletedNo ResultsRheumatoid Arthritis Biological:
8179 NCT01175Trends Over Time (199 CompletedNo ResultsDiarrhoea|Gastroenteritis Other: Dat
8180 NCT02540Detection BALISTIC CompletedNo ResultsChronic Obstructive Pulmonary Disease (COPD
8181 NCT02936Assessing ACCESS Active, notNo ResultsCancer Other: Med
8182 NCT00161Irradiated Donor Lymp CompletedNo ResultsCancer Biological:
8183 NCT01774Effectiveness of an CompletedNo ResultsPrevention of Mother-to-child Transm Behavioral
8184 NCT00297Using Informatics to CompletedNo ResultsElderly; Renal Insufficiency Procedure:
8185 NCT01399Restricted IntravenouCompletedNo ResultsSurgery|Perioperative Care|Immun Behavioral
8186 NCT03100Phase Ib/IIORION-01 Recruiting No ResultsEpithelial Ovarian Cancer Drug: Niv
8187 NCT03206Treatment B-NHL 201Recruiting No ResultsMature B-cell Non-Hodgkin Lymph Drug: Ritu
8188 NCT01623Eisenmenge ES-QuERI CompletedNo ResultsPulmonary Arterial Hypertension Other: Sub
8189 NCT02757CD8+ T Cell Therapy aActive, notNo ResultsColorectal Adenocarcinoma|Metastat Biological
8190 NCT03304Community DynamicsRecruiting No ResultsMalaria
8191 NCT00209IPTi in Mozambican InUnknown sNo ResultsMalaria Drug: Sulf
8192 NCT01018Arabinoxylan Rice BraCompletedNo ResultsHepatocellular Carcinoma|HepatitisProcedure:
8193 NCT00935Clinical T Pvivax CompletedNo ResultsPlasmodium Vivax Malaria Biological:
8194 NCT01171Trends Over Time (199 CompletedNo ResultsGastroenteritis Other: Epi
8195 NCT00367Clarithromycin v Cipr CompletedNo ResultsPulmonary Diseases Drug: Addi
8196 NCT00263Effects of ThymectomCompletedNo ResultsThymectomy and Cardiothoracic SurBehavioral
8197 NCT03856A Clinical Trial in H Active, notNo ResultsHIV Infections Biological
8198 NCT01129Diabetes VDiViD Terminate No ResultsDiabetes, Type I|Enterovirus Infec Drug: GAD-
8199 NCT03168Radiation and Immune Recruiting No ResultsNon Small Cell Lung Cancer MetastatDrug: Ipil
8200 NCT01193Molecular MOLOS CompletedNo ResultsOsteoarticular Infections Procedure:
8201 NCT03122Evaluating HVTN 120 CompletedNo ResultsHIV Infections Biological
8202 NCT02989Inter-preg inter-act Recruiting No ResultsObesity|Pregnancy Behavioral
8203 NCT00674Newborn ViVA CompletedNo ResultsVitamin A Deficiency Dietary Su
8204 NCT03152CAN008 Biomarker CD9 Unknown sNo ResultsGlioblastoma
8205 NCT00800Dose Finding Study WCompletedNo ResultsRhinoconjunctivitis|Allergies Drug: CYT
8206 NCT03195Chemoprotective ActWithdrawnNo ResultsMalaria,Falciparum Drug: MM
8207 NCT01315Interest o COMEDRACompletedNo ResultsRheumatoid Arthritis Behavioral
8208 NCT00945PreventioniLiNS-DOSECompletedNo ResultsMalnutrition Dietary Su
8209 NCT03043Phase 1b Study PVSRIRecruiting No ResultsMalignant Glioma|Anaplastic Astro Biological
8210 NCT02066A Phase I RandomizedCompletedNo ResultsTuberculosis Biological
8211 NCT02148Improving Identificat CompletedNo ResultsSocial Harms in Substance Users in HIV Trials
8212 NCT02215GBS Sero-co V98_28OBCompletedNo ResultsInvasive Group B Streptococcus Disease
8213 NCT01259Llama Antibody, RotavCompletedNo ResultsMale Children|6-24 Months Old With Drug: VHH
8214 NCT00692Impact of HIV-TB Unknown sNo ResultsLatent Tuberculosis Infection|HIV Infections|T
8215 NCT03352NasoShieldNasoShieldActive, notNo ResultsHealthy Volunteers Biological:
8216 NCT01704Vacc-4x + LIMID CompletedHas ResultHIV-1 Infection Drug: Lena
8217 NCT04139ObservatioBioSTaR Recruiting No ResultsRheumatoid Arthritis|SpondyloarthriOther: Ther
8218 NCT01235Dendritic Cell (DC) A Unknown sNo ResultsMalignant Glioma Biological:
8219 NCT02676Validation of Patholo Unknown sNo ResultsMycoses
8220 NCT03325Phase 2a Study to EvaCompletedNo ResultsAnemia of Chronic Kidney Disease Biological
8221 NCT01717Genital HPV InfectionCompletedNo ResultsHuman Papillomavirus Infections
8222 NCT02540Comparison of CovereCompletedNo ResultsCirrhosis Device: co
8223 NCT00299SP Resistance and Fa WithdrawnNo ResultsPlasmodium Falciparum Malaria Drug: sulfadoxine/py
8224 NCT02660Effect of OC459 on t Unknown sNo ResultsAsthma|Rhinovirus|Picornaviridae Drug: OC45
8225 NCT00186Gene Modified AllogeCompletedNo ResultsNeuroblastoma Drug: Inter
8226 NCT02836Shared Med SMV CompletedNo ResultsDiabetes Mellitus Type 2 Behavioral:
8227 NCT00899Microsphere-DelivereCompletedNo ResultsHead and Neck Cancer Biological
8228 NCT03280Transition to College Unknown sNo ResultsInterpretation Bias Modification|S Behavioral
8229 NCT01210FLU-FIT Program at K CompletedNo ResultsColorectal Cancer Screening Behavioral
8230 NCT02620Primary In Pre-POINTCompletedNo ResultsType 1 Diabetes Drug: Huma
8231 NCT04173Main Trial MT-SECFLORecruiting No ResultsFecal Microbiota Transplantation|CeOther: Fec
8232 NCT01012EMD 640 744 in Monta CompletedNo ResultsAdvanced Solid Tumors Biological
8233 NCT01213A Multifac HELEN II CompletedNo ResultsHeart Failure Behavioral
8234 NCT01213Home Based HFHELENI CompletedNo ResultsHeart Failure Behavioral
8235 NCT00138Funguria in HospitalizCompletedNo ResultsCandidiasis
8236 NCT01238Long Term Extension Terminate Has ResultAlzheimer's Disease Biological
8237 NCT00457Preclinical Study To Active, notNo ResultsAdrenocortical Carcinoma|Cushing's Syndrom
8238 NCT02422Pretomanid in AdultsRecruiting No ResultsTuberculosis Drug: PA-8
8239 NCT04252A Common Elements-ba Recruiting No ResultsMaternal Distress|Perinatal Depre Behavioral
8240 NCT01359Study to AsISS OBS T- CompletedNo ResultsHIV Infection
8241 NCT03548Safety and Efficacy o Active, notNo ResultsClostridial Infection|Dysbiosis|Prob Procedure:
8242 NCT01626A Study to Evaluate WithdrawnNo ResultsVaricella Biological
8243 NCT01309Study of I PRIMUS Terminate No ResultsColorectal Cancer Biological
8244 NCT00428Colombia ELEAP II Terminate No ResultsPneumonia|Meningitis|Bacteremia|Other: Surv
8245 NCT00001Studies of the ImmunCompletedNo ResultsImmunologic Deficiency Syndromes|Neoplasms
8246 NCT03922Surveillance of Zika- Recruiting No ResultsMicrocephaly|Congenital Infection Diagnostic
8247 NCT03113PreventionANRS-PREVActive, notNo ResultsHIV Infections Drug: PrEP
8248 NCT00302A Study to Evaluate t Terminate No ResultsB-Cell Chronic Lymphocytic LeukemiBiological
8249 NCT02812Burden of Invasive GrUnknown sNo ResultsInvasive Group B Streptococcal Disease
8250 NCT00432Safety Study of a Ref CompletedNo ResultsVaricella|Measles|Mumps|Rubella Biological: VARIVAXÂ
8251 NCT03517Evaluation of a HomeCompletedNo ResultsHIV Infections|HIV/AIDS|DepressionBehaviora
8252 NCT02388Treatment With OmaliCompletedHas ResultAsthma Drug: omali
8253 NCT03118Maraviroc on HIV-1 InWithdrawnNo ResultsHIV-1-infection Other: For
8254 NCT02640The ImpactPx-Lixi CompletedNo ResultsDiabetes Afer Total PancreatectomyDrug: Lixi
8255 NCT00058Treatment CLIMAT CompletedNo ResultsChronic Lymphocytic B-Leukemia Biological:
8256 NCT00577Docetaxel and Immuno Terminate Has ResultProstate Cancer Drug: Doce
8257 NCT03144Safety and Tolerabili CompletedNo ResultsHuman Papillomavirus Drug: GX-I
8258 NCT02234The SwedisSHP SuspendedNo ResultsHaving Ever Injected Drugs Behavioral:
8259 NCT01730Bacterial COMBAT CompletedNo ResultsMeningitis, Bacterial
8260 NCT00980Bone Tissue EngineerCompletedHas ResultTooth Loss Procedure:
8261 NCT00578Identification of Pre CompletedNo ResultsProstate Cancer
8262 NCT03074Insecticid REACT Unknown sNo ResultsMalaria Device: Ins
8263 NCT01914Immunological MechaUnknown sNo ResultsAllergy Desensitization
8264 NCT00240Use of COLD-fX to PreCompletedNo ResultsRespiratory Tract Infection Dietary Su
8265 NCT02709Safety and Efficacy o CompletedHas ResultBacterial Vaginosis Drug: 5% M
8266 NCT00043Post Marketing SurveiCompletedNo ResultsOsteopetrosis Drug: Actimmune Reg
8267 NCT01953Study Assessing Risk CompletedNo ResultsInfections, Papillomavirus Other: Data
8268 NCT01749CIK Treatment for HCCompletedNo ResultsCarcinoma, Hepatocellular Biological:
8269 NCT02633Analgecine for the Tr CompletedNo ResultsNeuropathic Pain Biological:
8270 NCT03931Efficacy of NNP Not yet recNo ResultsMalaria|Anemia Other: Bed
8271 NCT00161Safety Study of FSMECompletedNo ResultsTick-borne Encephalitis Biological: FSME-IM
8272 NCT03491Emission Patterns of Not yet recNo ResultsPathogen Transmission
8273 NCT01211The FLU-FOBT Program CompletedNo ResultsColorectal Cancer Behavioral
8274 NCT00238Busulfan, Melphalan,CompletedHas ResultLymphoma Biological
8275 NCT02000FluLavalÂ® Quadrival WithdrawnNo ResultsInfluenza Other: Data
8276 NCT00859Effects of 801 CompletedNo ResultsCeliac Disease
8277 NCT02773Human Challenge Mode CompletedHas ResultHealthy Volunteer Biological:
8278 NCT01443The Relevance of PerfCompletedNo ResultsFebrile Convulsions
8279 NCT03816Modelling EAVI2020_Recruiting No ResultsHIV-1-infection Biological
8280 NCT02312Belgian CroBE-C@TS Unknown sNo ResultsHematopoietic Stem Cell Transplantation|Hemat
8281 NCT04247Effects of Prior Expo Not yet recNo ResultsCommunication Research Other: Expo
8282 NCT03014Untersuchung Zur ErfCompletedNo ResultsRhinitis, Allergic, Seasonal Other: Qual
8283 NCT03796Phenotypic4BLMS Not yet recNo ResultsMultiple Sclerosis
8284 NCT01766Atorvastatin for HAA CompletedHas ResultAcquired Immune Deficiency SyndroOther: ator
8285 NCT01459Comparison DoDoPi CompletedNo ResultsHIV/AIDS|Tuberculosis|Diabetes MelOther: Doo
8286 NCT02899Genotyping of HumanUnknown
P sNo ResultsNeonatal Thrombocytopenia Isoimmu Biological:
8287 NCT02579Revaccination With PCompletedNo ResultsAllergic Rhinitis
8288 NCT03607Impact of DIAFEVER Recruiting No ResultsFever Without Source Diagnostic
8289 NCT01338The DeveloPERCAPS CompletedNo ResultsCervical Intraepithelial Neoplasia| Biological:
8290 NCT01969A Phase I SASCT WithdrawnNo ResultsEwing Sarcoma Biological
8291 NCT02049Preconception Women's CompletedNo ResultsPreconception Care|Women's HealtOther: Pre
8292 NCT03674Evaluation of Safety, Recruiting No ResultsHCV Infection Biological:
8293 NCT04238Safety, To TB31F Recruiting No ResultsMalaria,Falciparum Biological:
8294 NCT03977Maternal Antiviral Tr CompletedNo ResultsHepatitis B Drug: nucl
8295 NCT03289Effectiven Net-PBO Active, notNo ResultsInsecticide Resistance Drug: syner
8296 NCT02280Efficacy of Rifaximin CompletedHas ResultDysentery|Diarrhea|Enteric Campylo Biological:
8297 NCT03578HPV-E6-Specific Anti-Recruiting No ResultsCervical Cancer|Head and Neck SquDrug: HPV E
8298 NCT02190An Efficacy and Safet CompletedNo ResultsFibrodysplasia Ossificans Progressiv Drug: Palo
8299 NCT03168Synbiotic SAIMES CompletedNo ResultsHealthy Dietary Su
8300 NCT04062Immunophenotype ofRecruiting
R No ResultsAge Associated Immune Deficiency|E Other: no
8301 NCT03542First-void Urine SampRecruiting No ResultsCervical Cancer Device: Col
8302 NCT02611Medi-Port Pilot RandoCompletedNo ResultsActively Undergoing Cancer Treatmen Device: Me
8303 NCT01058Safety of IFNa Kinoid CompletedNo ResultsSystemic Lupus Erythematosus Biological:
8304 NCT02979An Open-Label Extensi Active, notNo ResultsFibrodysplasia Ossificans Progressiv Drug: Palo
8305 NCT03468The Safety of Anti-v CompletedNo ResultsHepatitis B, Chronic Drug: Telb
8306 NCT02322A Natural History Stu Active, notNo ResultsFibrodysplasia Ossificans Progressiva
8307 NCT02521In-Home Evaluation ofSuspendedNo ResultsFibrodysplasia Ossificans Progressiv Drug: Palo
8308 NCT03188AfyaJamii (Parenting CompletedNo ResultsPregnancy Related|Group, Peer Behavioral:
8309 NCT02910Clinical Response to Enrolling bNo ResultsAsthma|Allergic Rhinitis Biological
8310 NCT00204Local Treatment of MCompletedNo ResultsMalignant Melanoma Drug: rM2
8311 NCT01221Eculizumab Therapy fCompletedHas ResultDense Deposit Disease|Membranopro Drug: Ecul
8312 NCT01429Interferon ADRN-01 CompletedNo ResultsAtopic Dermatitis|Eczema Herpeticum|Herpes
8313 NCT02375A Phase I C-037-456CompletedHas ResultTuberculosis Biological:
8314 NCT01905Post-marketing SafetyCompletedNo ResultsInfections, Papillomavirus Other: Data
8315 NCT01966CD34+ (Non-Malignant) Recruiting No ResultsBone Marrow Failure Syndrome|Seve Biological:
8316 NCT03844Targeting CONFRONTRecruiting No ResultsHead and Neck Cancer Drug: Avel
8317 NCT01602Immunity to Measles Unknown
V sNo ResultsMeasles
8318 NCT00521Phase 2 Study of Intr CompletedHas ResultMelanoma Drug: PV-1
8319 NCT04245Multimodality Treatme Not yet recNo ResultsNon-small Cell Lung Cancer|NSCLC Drug: Durv
8320 NCT01472A Study of eX-FLU CompletedNo ResultsInfluenza Behavioral
8321 NCT02189Polio End-game StrateCompletedNo ResultsPoliomyelitis Biological:
8322 NCT00231The MOM MOM Pr ProgCompletedHas ResultChild Development Behavioral
8323 NCT00333A Study of Plasma-DeCompletedNo ResultsHealthy Volunteers Drug: Huma
8324 NCT00333Pharmacokinetic (PK)CompletedNo ResultsHealthy Volunteers|Chemical Terro Drug: Huma
8325 NCT00823Immune Status of Elde CompletedNo ResultsAging Other: Bloo
8326 NCT01694Understanding and Dis CompletedNo ResultsPreventive Screening|Prostate CancBehavioral
8327 NCT04165Study of P B8011006 Recruiting No ResultsNon-muscle Invasive Bladder Cance Drug: PF-0
8328 NCT00490Interventi M-FLU CompletedNo ResultsInfluenza Behavioral
8329 NCT02107Phase II Study of DCVCompletedNo ResultsProstate Cancer Biological:
8330 NCT02800Change in Child-feed CompletedNo ResultsHealth Education, Community|Diet,Behavioral
F
8331 NCT02081The Investigation of CompletedNo ResultsChildhood Infections
8332 NCT02519A ProspectPHIRST-SA Unknown sNo ResultsInfective Organism Causing Respiratory Diseas
8333 NCT00713Tramadol Versus Fenta CompletedNo ResultsPain|Neonatal Infections|Analgesia Drug: Fent
8334 NCT01190Epidemiology Study ofCompletedNo ResultsMalaria Procedure:
8335 NCT00782Integrating Well-WomUnknown sNo ResultsPrimary Care Other: Cen
8336 NCT00453Efficacy of Sulfadoxi Terminate No ResultsMalaria Drug: Sulf
8337 NCT03026Effect of Milk Protei CompletedNo ResultsImmunosenescence|Inflammation Dietary Su
8338 NCT02524PrevalenceAMPAMAVICompletedNo ResultsHuman Papillomavirus (HPV)|Medicall Other: Sys
8339 NCT01058Reproducibility of MaCompletedNo ResultsHealthy Biological:
8340 NCT03022QUILT-3.032: A MulticRecruiting No ResultsBladder Cancer Drug: ALT-
8341 NCT01616R-FACT Stud R-FACT Unknown sNo ResultsHemolysis
8342 NCT03388Challenge Infection oCompletedNo ResultsUpper Respiratory Tract Infections Biological:
8343 NCT00623Seasonal IntermittentCompletedNo ResultsMalaria Drug: Seas
8344 NCT00234Health-e-Access Telem CompletedNo ResultsCommon Childhood Illnesses|Non-eOther: Hea
8345 NCT00926Neonatal Pain- and DiUnknown sNo ResultsPain
8346 NCT03857Treatment T-GaiD Active, notNo ResultsDravet Syndrome|Severe MyoclonicDiagnostic
E T
8347 NCT00085PEG-Interferon Alfa-2Terminate No ResultsFallopian Tube Cancer|Ovarian CancBiological:
8348 NCT03191Immunologi RUTIVAC-1Recruiting No ResultsHigh-Risk Non-Muscle-Invasive BladDrug: RUTI
8349 NCT01775IgA NephroNIDOCIGA CompletedNo ResultsIgA Nephropathy Other: bloo
8350 NCT02508Personalized Immunoth CompletedNo ResultsInfection|Immune Deficiency|HypoBiological
8351 NCT00346Analysis of the ImmunCompletedNo ResultsMalaria
8352 NCT02281Evaluate the Response Active, notNo ResultsBladder Cancer|High Risk SuperficiaBiological
8353 NCT01042Profiling o LymphoscrCompletedNo ResultsType 1 Diabetes Other: Blo
8354 NCT02273Pain Perception of ChUnknown sNo ResultsPain Device: Bu
8355 NCT02200Impact of Providing FCompletedHas ResultInfant's Tooth Brushing Other: Inf
8356 NCT01542Effect of ProBoost CompletedNo ResultsInflammation Dietary Su
8357 NCT00930Infections in Pediatri Unknown sNo ResultsInfections
8358 NCT01556Multi-Drug DesensitizTerminate Has ResultHeart Transplantation Drug: Bort
8359 NCT03912Investigating ImmuneRecruiting No ResultsTuberculosis Biological
8360 NCT03967Developing Low-Cost Recruiting No ResultsChild Malnutrition Other: Mat
8361 NCT00610Phase II Study With I Unknown sNo ResultsRenal Cell Carcinoma|Melanoma|Car Biological:
8362 NCT02027Phase I Tri VGX-6150-CompletedNo ResultsHepatitis C, Chronic Biological
8363 NCT03922Navigatin NNM2 Recruiting No ResultsPostpartum Health|Breasteeding|Co Behavioral
8364 NCT04003Using a Humanoid Rob Recruiting No ResultsChildhood Cancer Behavioral
8365 NCT01124The Factors Affecting CompletedNo ResultsHealthy Subjects|Health Care Providers
8366 NCT01227Amyloid Imaging AndCompletedHas ResultAlzheimer's Disease Biological
8367 NCT02901Phase 2 Durvalumab (Recruiting No ResultsCarcinoma in Situ of Bladder|Bladd Drug: Durv
8368 NCT01073Adjuvant Cisplatin Pl CompletedNo ResultsCholangiocellular Carcinoma Drug: Cisp
8369 NCT01557Study of R Mel-Ipi-Rx Terminate No ResultsMalignant Melanoma Drug: Ipil
8370 NCT01500Comparison of the EffCompletedNo ResultsPollen Allergy Biological:
8371 NCT03496Predicting Hospitaliz CompletedNo ResultsRheumatoid Arthritis|Spondyloarthrit Drug: Biol
8372 NCT02041Assessment of VAC-3SUnknown sNo ResultsHIV Biological:
8373 NCT03612An mHealth PPFP Not yet recNo ResultsContraception Behavior Behavioral
8374 NCT00351Examining Factors ThaCompletedNo ResultsHIV Infections
8375 NCT01284First Line Comparati WithdrawnNo ResultsBladder Cancer Biological
8376 NCT03571A Nationwide Italian CompletedNo ResultsSplenectomy; Status
8377 NCT04067Homemade Yogurt Sup Not yet recNo ResultsChild Malnutrition Behavioral
8378 NCT02558Administration of a L CompletedNo ResultsNosocomial Infection Dietary Su
8379 NCT03907Using Comm CHNCHW Recruiting No ResultsPregnant Women|Home Visits Other: Hom
8380 NCT01062Cellular Immune Respo WithdrawnNo ResultsHepatitis C, Chronic|Liver Diseases|Virus Diseases
8381 NCT02009School-BasSTART-IPT CompletedNo ResultsMalaria Drug: Dihy
8382 NCT02529Web-based Preconcept CompletedNo ResultsReproductive Health Behavioral
8383 NCT03174Immunomodulatory Eff CompletedNo ResultsRecurrent Pregnancy Loss Drug: IVIg
8384 NCT02431Phase I Study of INO-CompletedNo ResultsHepatitis B Biological
8385 NCT00777Study of S ZU-SkinSITCompletedNo ResultsAllergic Rhinoconjunctivitis Drug: Patc
8386 NCT04050Malaria Bi MBC Recruiting No ResultsMalaria
8387 NCT00231Age of Exposure and ICompletedNo ResultsMalaria Drug: Sulf
8388 NCT03473Primary Care CKD RegCompletedNo ResultsHypertension|Chronic Kidney DiseaOther: CKD
8389 NCT01027Integrating Cancer CoCompletedNo ResultsCancer Behavioral
8390 NCT00694Study of My STCC Unknown sNo ResultsBladder Cancer Biological
8391 NCT01486Respiratory Viral Inf CompletedNo ResultsAcute Viral Respiratory Tract Diseases
8392 NCT03387Efficacy A TES2016 CompletedNo ResultsUncomplicated Malaria Drug: Arte
8393 NCT02111Evaluating the AsthmaCompletedHas ResultAsthma Biological:
8394 NCT03345Safety, Tolerability, Active, notNo ResultsInfluenza Biological
8395 NCT02363Can Text Reminders I CompletedNo ResultsCervical Carcinoma|Cervical DysplasOther: Neu
8396 NCT03425Elvitegravir/Cobicist Active, notNo ResultsChronic Hepatitis B in HIV Patient| Drug: Elvit
8397 NCT01859"Anticipatory Guidan CompletedNo ResultsHealth Knowledge, Attitudes, Pract Behavioral:
8398 NCT02643Effect of Different P CompletedNo ResultsHypersensitivity Biological
8399 NCT00555Efficacy Study of Earl CompletedHas ResultInfluenza Drug: Osel
8400 NCT01331Comparison IKSIT CompletedNo ResultsHealthy Behavioral:
8401 NCT01773MACCE in Hospitaliz Recruiting No ResultsCommunity-acquired Pneumonia
8402 NCT03157Oral Probiotic Admin CompletedNo ResultsAsthma Dietary Su
8403 NCT03236A Direct o ADVANCE Recruiting No ResultsHepatitis C Drug: Zepat
8404 NCT04089SouthEast A SEAe Active, notNo ResultsEncephalitis Diagnostic
8405 NCT00214Can Screening PeopleUnknown sNo ResultsTuberculosis Procedure: Screening
8406 NCT04264Baseline InvestigationCompletedNo ResultsHepatitis B
8407 NCT02329Efficacy of JIKI CompletedNo ResultsEbola Virus Disease Drug: Favip
8408 NCT03690Genetic FaCHIKGENE Recruiting No ResultsChikungunya Fever Other: Qual
8409 NCT00589An Interactive PrevenCompletedNo ResultsPrevention Behavioral:
8410 NCT02612Taenia Sol CYSTISTOPRecruiting No ResultsTaenia Solium Infection Drug: Mass
8411 NCT02491Immunotherapy Combi Active, notNo ResultsBreast Cancer Biological
8412 NCT01025Desensitization With Terminate Has ResultDesensitization Drug: Bel
8413 NCT00148Creation of Bone MarWithdrawnNo ResultsMyelodysplastic Syndromes|MyelofiDevice: DB
8414 NCT01173Smoking Cessation InCompletedHas ResultSmoking Cessation|Tobacco Use CesOther: Smo
8415 NCT03190Expanded Quantitative Recruiting No ResultsUrinary Tract Infections Diagnostic
8416 NCT01997Safety and Efficacy o CompletedHas ResultRefractory Generalized Myasthenia Biological
8417 NCT03260Phase Ib/II of TG400 Recruiting No ResultsHead and Neck Squamous Cell Carc Biological
8418 NCT02049An Open-label ExtensiActive, notNo ResultsRheumatoid Arthritis Drug: ABT-
8419 NCT01771Optimization of ContrCompletedNo ResultsMalaria Biological:
8420 NCT00847Host-pathog OMVac Unknown sNo ResultsOtitis Media Other: que
8421 NCT00932Effect of Educational Unknown sNo ResultsPulmonary Disease, Chronic ObstrucBehavioral
8422 NCT02653IGRA and M TBTubercolRecruiting No ResultsTuberculosis, Pulmonary|InterferonOther: IGR
8423 NCT02244Improving AdolCHICACompletedNo ResultsSexually Transmitted Diseases|DeprBehavioral
8424 NCT00815Autologous Cytokine C I ompletedNo ResultsChronic Myeloid Leukemia Biological:
8425 NCT00814Pilot Study of a Ralt CompletedHas ResultAcquired Immune Deficiency Syndr Drug: Ralt
8426 NCT01086Rituximab for Autoi CompletedNo ResultsAutoimmune Disease Drug: Ritu
8427 NCT00367Pulmonary Hypertensio CompletedNo ResultsSecondary Pulmonary Arterial Hypertension|Sickle Cell
8428 NCT01280Effects of Maternal Unknown sNo ResultsDepression|Pregnancy
8429 NCT00786Cookstove Replacemen CompletedNo ResultsAcute Lower Respiratory Illness Other: Imp
8430 NCT01773Mechanisms of InterpCompletedNo ResultsRhinovirus Infection in Asthma Other: Rhin
8431 NCT00002An Expanded Access O CompletedNo ResultsHIV Infections Biological: HIV-1 Im
8432 NCT00002An Expanded Access O CompletedNo ResultsHIV Infections Biological: HIV-1 Im
8433 NCT02155Modulation of Immune CompletedHas ResultHIV-1 Infection Drug: Aspi
8434 NCT00934Epidemiology of InfecUnknown sNo ResultsInfections
8435 NCT02697Family InclFINEBRAINCompletedNo ResultsBrain Stimulation Behavioral
8436 NCT03296Phages DynMETAKIDS Terminate No ResultsHuman Gut Microbiome DevelopmeOther: coll
8437 NCT01159Mechanisms of Rhinov Unknown sNo ResultsRhinovirus Infection in Asthma Other: Rhin
8438 NCT00536Role of Zinc in Recur CompletedNo ResultsAcute Respiratory Infections Drug: Zinc
8439 NCT012702009 H1N1 PandemicWithdrawn
an No ResultsInfluenza
8440 NCT02048Long-term Effects of CompletedNo ResultsType 2 Diabetes|Obesity|Metabolic Syndrome
8441 NCT03413NosocomialNOSOGRIPNot yet recNo ResultsHospital-Acquired Infection|Influen Other: Que
8442 NCT00519Health InteAsk CompletedNo ResultsVision Impairment|Hearing ImpairmBehavioral
8443 NCT00275Interferon Alpha 2b PlCompletedNo ResultsChronic Hepatitis B Drug: inter
8444 NCT00541Diagnosis oThrasherI Unknown sNo ResultsLatent Tuberculosis Infection|Tuberculosis|HIV Infections
8445 NCT00521Study of TrovaxÂ® PluTerminate No ResultsProstatic Neoplasms Biological
8446 NCT03339French TraMDR bacteCompletedNo ResultsTravel Medicine Other: Que
8447 NCT02086Phase I Cl L19-IL2 CompletedNo ResultsSolid Tumour Drug: L19-
8448 NCT03332Clinical Study on Tri Unknown sNo ResultsProgression-Free-Survival|RecurrencOther: Tra
8449 NCT00712Evaluation of the PubUnknown sNo ResultsMalaria Drug: sulf
8450 NCT00002Phase I Safety Study CompletedNo ResultsHIV Infections Drug: Anti-HIV Immu
8451 NCT00001The Safety and Effec CompletedNo ResultsHIV Infections Drug: F105 Monoclon
8452 NCT03774Evaluation of the Ma CompletedNo ResultsKnowledge, Attitudes, Practice|GendBehavioral
8453 NCT01338Pilot Study of Leupr Active, notHas ResultMyelodysplastic Syndrome|Acute L Procedure:
8454 NCT04261The OPTIMIZE Study: Not O yet recNo ResultsPregnancy Related Behavioral
8455 NCT02389A Phase IbOZ/DSMCoCompletedNo ResultsMalaria Drug: DSM
8456 NCT02143Lysine Trial in Adults CompletedNo ResultsDiarrhea Dietary Su
8457 NCT00091Rituximab to Treat St CompletedNo ResultsStiff Person Syndrome Drug: Ritu
8458 NCT02522EvaluationCOLDPREVCompletedNo ResultsCommon Cold Device: Co
8459 NCT00026Research in Skin Inf CompletedNo ResultsPsoriasis
8460 NCT00001Lymphocyte Re-infusiCompletedHas ResultMelanoma|Neoplasm Metastasis Drug: gp10
8461 NCT00001Gene Transfer TherapCompletedNo ResultsSevere Combined Immunodeficienc Drug: ADA PBSC|Drug:
8462 NCT03910Prevalence of Latent Not yet recNo ResultsLatent Tuberculosis Drug: Tuber
8463 NCT02479EvaluationCOLDPREVICompletedNo ResultsCommon Cold Device: Co
8464 NCT03838BiotherapiERIBIO Not yet recNo ResultsRheumatoid Arthritis|SpondyloarthriOther: The
8465 NCT02269A Phase 3 Open-labelCompletedHas ResultHealthy Japanese Children Age 2 YeaDrug: MED
8466 NCT01916Randomized ControlleActive, notNo ResultsOperable Breast Cancer Drug: 0.5%
8467 NCT01892A Randomized ControlTerminate Has ResultNeuromyelitis Optica|NeuromyelitisDrug: Ecul
8468 NCT01624Controlled Human Mal CompletedNo ResultsMalaria Biological:
8469 NCT01149RO4929097 And Exemes Terminate No ResultsEstrogen Receptor Positive|HER2/NeDrug: Exem
8470 NCT00055Study of Families WitRecruiting No ResultsRheumatic Diseases|Rheumatoid Arthritis|Syst
8471 NCT00018Gene Transfer TherapCompletedNo ResultsSevere Combined Immunodeficienc Drug: CD34+ cells tra
8472 NCT01317Endothelial Function Unknown sNo ResultsHypertension, Pulmonary|Pulmonary Device: En
8473 NCT001205-Year Safety Study oCompletedHas ResultAtopic Dermatitis Drug: Pime
8474 NCT03840Experimental Human Recruiting
I No ResultsGonococcal Infection Drug: Cefi
8475 NCT01563Number of Rotavirus C ( ompletedNo ResultsInfections, Rotavirus Other: Data
8476 NCT01045The Role oAntiCardAgTerminate No ResultsAging|Inflammation Drug: fluva
8477 NCT02395Dendritic MesoCanceUnknown sNo ResultsMesothelioma Biological
8478 NCT03656A Safety Study For P Active, notNo ResultsSeizures|Urticaria and Angioedema|Apnea|Fe
8479 NCT03932Clinical Study on the Recruiting No ResultsPregnancy Other: IVF
8480 NCT01284Amyloid ImACCTION CompletedNo ResultsAlzheimer's Disease Biological:
8481 NCT02223Two CenterCC4 CompletedNo ResultsColorectal Cancer Biological
8482 NCT02936Lyon Cohort of MaterRecruiting No ResultsToxoplasmosis, Congenital
8483 NCT01834Post Market SurveillaCompletedHas ResultPneumococcal Disease Biological:
8484 NCT01465A Study to Evaluate CCompletedNo ResultsHealthy Drug: CDX-
8485 NCT03136Complex Mu EIRA Unknown sNo ResultsHealth Behavior|Health Promotion|Behavioral:
8486 NCT00078Treatment CLIPA CompletedNo ResultsLeukemia|Leukemia, B-Cell, ChronicBiological:
8487 NCT03416Transforming Care and CompletedNo ResultsSocial Stress Other: Scr
8488 NCT01107EffectiveneINSPIRA CompletedHas ResultRespiratory Syncytial Virus InfectionBiological:
8489 NCT00001Phase I Study to Eval CompletedNo ResultsHIV Infection Biological: HIV-1 Im
8490 NCT01385Observatiopre U7-53 Unknown sNo ResultsDuchenne Muscular Dystrophy
8491 NCT00816District-ba NF Nutriti CompletedNo ResultsMalnutrition Behavioral
8492 NCT02855Efficiency BIOSAFE CompletedNo ResultsRheumatoid Arthritis (RA)|Spondyloa Other: Nur
8493 NCT00227Study Evaluating PneuCompletedNo ResultsPneumococcal Meningitis
8494 NCT00195Study of Streptococc CompletedNo ResultsOtitis Media|Otitis Media With Eff Drug: Prevenar
8495 NCT00543Dose Escalation StudyTerminate No ResultsChronic Lymphocytic Leukemia|SmalDrug: Lena
8496 NCT01175Impact of Vitamin D RCompletedHas ResultVitamin D Deficiency|End-stage RenDrug: Chole
8497 NCT01418Characterization of InCompletedNo ResultsInfluenza-like Illness
8498 NCT03915AddressingRheum-iC Enrolling bNo ResultsSystemic Lupus Erythematosus Behavioral
8499 NCT03961A Family-based Inter Not yet recNo ResultsCervical Cancer|Healthy Women Behavioral:
8500 NCT03856High-quali ACHIEVE Recruiting No ResultsCOPD|HIV/AIDS Behavioral:
8501 NCT00626A Post Marketing EvalCompletedHas ResultAsthma|Wheezing|ImmunosuppresDrug: No I
8502 NCT03215Cross SectiAMBASS CompletedNo ResultsChronic Hepatitis b Diagnostic
8503 NCT02558Regional VAVFN CompletedNo ResultsAny Condition Treated in Primary CaOther: Pri
8504 NCT02672A New Micro Swim-upUnknown sNo ResultsMicroswimup Procedure Efficacy
8505 NCT03247Getting Ahead for Ca Recruiting No ResultsCancer Prevention Behavioral:
8506 NCT01536Safety Stu MonoPepTCompletedNo ResultsType 1 Diabetes Drug: Pro i
8507 NCT00189Immune Dysfunction Ci ompletedHas ResultAsthma Drug: Xolai
8508 NCT00679A Study of How MK-07 Terminate Has ResultPeripheral Vascular Diseases Drug: MK-0
8509 NCT03894NASCITA ItaNASCITA Recruiting No ResultsSocial Determinants of Health|Heal Other: No i
8510 NCT02696Safety and Pharmacoki Terminate Has ResultViral Infection Drug: UV-4
8511 NCT03477The Efficacy of Intra- Not yet recNo ResultsWarts Drug: Bleo
8512 NCT00434Campylobacter JejuniUnknown sNo ResultsCampylobacter Infections Biological
8513 NCT02302TP10 Use in Patients WithdrawnNo ResultsDense Deposit Disease Drug: TP10
8514 NCT01694Clinical Safety and P Unknown sNo ResultsMalignant Solid Tumors Biological
8515 NCT01510Phase 1 Trial of Ipil Terminate No ResultsProstate Cancer Drug: GVAX
8516 NCT00000Trial to Reduce Alloi CompletedNo ResultsBlood Platelets|Hematologic DiseasProcedure: platelet t
8517 NCT04245Home Testing of RespiActive, notNo ResultsInfluenza -Like Illness|Influenza A|Influenza Ty
8518 NCT01671Comparison of BacterCompletedNo ResultsMethicillin-Resistant Staphylococcus Aureus
8519 NCT01668PACT for InSMI-PACT CompletedNo ResultsSchizophrenia Spectrum & Other PsyOther: Pat
8520 NCT02891InspiratoryRESCOM Recruiting No ResultsSpinal Cord Injuries|Pneumonia Procedure:
8521 NCT03265A Phase II A-043 WithdrawnNo ResultsTuberculosis Infection Biological
8522 NCT01730Neisseria MeningitidiCompletedNo ResultsStreptococcus Pneumoniae|NeisseriOther: Dat
8523 NCT03991EvaluationSUpErCDZ Recruiting No ResultsEarly Childhood Development Other: SMA
8524 NCT00003Biological Therapy in CompletedNo ResultsBrain and Central Nervous System T Biological: autologo
8525 NCT02366Hepatitis B and HepatActive, notNo ResultsHepatitis B|Hepatitis C|Carcinoma, Hepatocell
8526 NCT02249Nutrition ENECTAc Unknown sNo ResultsGrowth Retardation|Malnutrition Behavioral
8527 NCT03815What is the Incidenc Recruiting No ResultsInvasive Pneumococcal Disease, RecOther: Ref
8528 NCT02111A Phase 1/2 Study of CompletedHas ResultInfluenza Drug: TAK-
8529 NCT02979Understanding ExcretiCompletedNo ResultsZika Virus Other: Sem
8530 NCT04254Mobile Application foNot yet recNo ResultsInflammatory Bowel Diseases Device: Per
8531 NCT01195CD19-CAR CI D19TPALLTerminate No ResultsAcute Lymphoblastic Leukemia Genetic: do
8532 NCT02284Animal-assisted TheraCompletedNo ResultsSurgery Behavioral:
8533 NCT01987Using Smartphones inCompletedNo ResultsSelf-efficacy
8534 NCT03804Risk and Benefit Info Enrolling bNo ResultsHeart Failure Other: Ref
8535 NCT04204Assessment of Wearab Recruiting No ResultsInfluenza A H3N2 Device: Lu
8536 NCT03892GynecologiIMPACT CompletedNo ResultsCystic Fibrosis Other: Self
8537 NCT00004Biological Therapy FoCompletedNo ResultsMelanoma (Skin) Biological: aldesleuk
8538 NCT02457HSV G207 Alone or Wit Recruiting No ResultsSupratentorial Neoplasms, Maligna Biological:
8539 NCT03536Asili Evaluation in t CompletedNo ResultsDiarrhea|Cough|Fever|MalnutritionBehavioral
8540 NCT03207BiomarkersPRESAGE Enrolling bNo ResultsInfluenza A Biological:
8541 NCT01977EffectiveneLUCOMAI CompletedNo ResultsMalnutrition Behavioral
8542 NCT02838Identification and Ch CompletedHas ResultInfections, Streptococcal Other: BAL
8543 NCT02583Evaluating the Safety Active, notHas ResultTuberculosis|HIV Infections Drug: Beda
8544 NCT02228A Study of CC1C Terminate No ResultsColorectal Cancer Biological
8545 NCT01000Diabetes Group VisitsCompletedNo ResultsDiabetes
8546 NCT00564Dose-Finding Study ofCompletedNo ResultsTravelers' Diarrhea Biological:
8547 NCT00564Dose-Finding Study oCompletedNo ResultsTravelers' Diarrhea Biological:
8548 NCT04218The Factors Affecting Not yet recNo ResultsAtopic Dermatitis
8549 NCT01388Pharmacokinetics of CompletedNo ResultsPrematurity of Fetus Drug: Osel
8550 NCT01509Impact of a MultidiscUnknown sNo ResultsStage 5 Chronic Kidney Disease Other: Mult
8551 NCT01910Characterisation of T CompletedNo ResultsDermatitis Other: KLH
8552 NCT00377Stress Management Th CompletedNo ResultsCancer|Psychological Stress|UnspeciOther: Sel
8553 NCT00576Genomic ToVM CompletedNo ResultsHealthy
8554 NCT01308Management of Soil-tr Unknown sNo ResultsHelminthiasis|Strongyloides StercoraDrug: Iver
8555 NCT01391Study to Evaluate theCompletedHas ResultDengue Other: Dat
8556 NCT02392Evaluation LLML Unknown sNo ResultsMalaria Biological:
8557 NCT04179Bacillus Calmette-Gu Recruiting No ResultsNon-Muscle Invasive Bladder CanceDrug: Baci
8558 NCT04149A Study CoCheckMateRecruiting No ResultsBladder Cancer Drug: nivo
8559 NCT01314The Effect of a Dewo CompletedNo ResultsMalnutrition|Intestinal Diseases, ParDrug: Mebe
8560 NCT00578Bone Marro SCALLOP Terminate No ResultsSickle Cell Disease|Hemoglobin SC Drug: Busu
8561 NCT03711Efficacy and Safety Recruiting No ResultsHigh-risk Non-muscle Invasive Blad Biological
8562 NCT03081A Prelimin immunotheCompletedNo ResultsUnexplained Recurrent Miscarriage aProcedure
8563 NCT04099Pain & Agi PACIFIC Not yet recNo ResultsOsteo Arthritis Knee Behavioral
8564 NCT01819Phase I/II ALLO-WT1CompletedNo ResultsAcute Myeloid Leukemia|Chronic MBiological
8565 NCT02104Postpartum Empowerme CompletedNo ResultsMaternal and Newborn Health Behavioral
8566 NCT02507Antisense102: Pilot Active, notNo ResultsMalignant Glioma|Neoplasms Drug: IGF-
8567 NCT02451Reducing So WECARE01Active, notNo ResultsAsthma|Obesity|Health Care UtilizaBehavioral
8568 NCT00402ProQuadÂ® IntramuscCompletedHas ResultMeasles|Mumps|Rubella|Varicella Biological
8569 NCT03929Mindful Mo Y-U Recruiting No ResultsPhysical Inactivty|Wellbeing|Mindf Behavioral
8570 NCT03511Reducing ARACEFIT Recruiting No ResultsCytomegalovirus Congenital Behavioral
8571 NCT03653A Communit EW-D Recruiting No ResultsPhysical Disability Behavioral
8572 NCT01506SublingualSLIT CompletedNo ResultsAllergic Rhinitis Biological:
8573 NCT03114Mindful Movement for CompletedNo ResultsPhysical Inactivity Other: Min
8574 NCT01713Impact of Insecticide Unknown sNo ResultsMalaria, Falciparum Other: Indo
8575 NCT00794Bacillus C Sutent CompletedHas ResultUrinary Tract Urothelial Carcinoma Drug: Sunit
8576 NCT00725Evaluation of a New CompletedHas ResultLeukaemia, Myelocytic, Acute Biological
8577 NCT00002A Multicenter, DoubleCompletedNo ResultsHIV Infections Biological: HIV-1 Im
8578 NCT00006Interleukin-2 Plus A CompletedNo ResultsHIV Infections Biological: Diphtheri
8579 NCT01059Transdermal AbsorptiCompletedNo ResultsToxicity Drug: tra
8580 NCT03086CED With Irinotecan LRecruiting No ResultsDiffuse Intrinsic Pontine Glioma Drug: Conv
8581 NCT03955Impact of Pedestrian Recruiting No ResultsHead of Household Other: Foo
8582 NCT04154Implementing HPV DNA Not yet recNo ResultsTransgenderism|Cervical Cancer|HuDiagnostic
8583 NCT04237Primary CarPCCE Active, notNo ResultsBehavioral Economics|Primary HealBehavioral
8584 NCT02713Early Liter ELPI CompletedHas ResultChild Development Behavioral
8585 NCT01241Dendritic PMR-MM-0CompletedNo ResultsMalignant (Pleural) Mesothelioma Biological:
8586 NCT02661Dose FindinMM09 Recruiting No ResultsRhinitis|Rhinoconjunctivitis Biological
8587 NCT02654Dose FindinMG56 Unknown sNo ResultsRhinitis|Rhinoconjunctivitis Biological
8588 NCT00752Study Evaluating ACCCompletedHas ResultAlzheimer Disease Biological
8589 NCT00647A Study to Test V930 CompletedNo ResultsCancer Biological:
8590 NCT00727Pennsylvania Abusiv CompletedNo ResultsInjury|Traumatic Brain Injury|Child Behavioral
8591 NCT03384A Study to Evaluate t Recruiting No ResultsLeprosy, Multibacillary Drug: Beda
8592 NCT02858E7 TCR T Cells for H Recruiting No ResultsPapillomavirus Infections|Cervical Biological
8593 NCT01552NutributteNPPU CompletedNo ResultsUndernutrition Dietary Su
8594 NCT01326Human Facto SAFE-C CompletedNo ResultsPrimary Health Care|Aged|Clinical Other: Pat
8595 NCT02509Repeat IverRIMDAMALCompletedHas ResultMalaria|Lymphatic Filariasis Drug: Iver
8596 NCT02270Study of ONT-10 and CompletedNo ResultsAdvanced Breast Carcinoma|AdvancBiological
8597 NCT02107Phase II Study of DC CompletedNo ResultsProstate Cancer Biological
8598 NCT03368Evaluation of Integra CompletedNo ResultsPolio Other: Mat
8599 NCT02422Comparative AutoantiEnrolling bNo ResultsAutoimmune Diseases|Lupus Erythematosus,
8600 NCT01410Integrated Stepped CaCompletedNo ResultsLiver Diseases, Alcoholic|Alcoholis Other: Int
8601 NCT03554Study of Activated CyRecruiting No ResultsAdvanced Gastric Cancer Biological
8602 NCT03540Study of Activated CyRecruiting No ResultsAdvanced Kidney Cancer Biological
8603 NCT03524Study of Activated CyRecruiting No ResultsAdvanced Colorectal Cancer Biological
8604 NCT03524Study of Activated CyRecruiting No ResultsAdvanced Breast Cancer Biological
8605 NCT03509Study of Activated CyRecruiting No ResultsAdvanced Pancreatic Cancer Biological
8606 NCT03501Study of Activated CyRecruiting No ResultsAdvanced Lung Cancer Biological
8607 NCT03484Study of Activated CyRecruiting No ResultsAdvanced Liver Cancer Biological
8608 NCT03237Assessment of Knowled CompletedNo ResultsKnowledge, Attitudes, Practice
8609 NCT01175Gene Therapy for X-l Unknown sNo ResultsX-linked Severe Combined Immunode Genetic: Si
8610 NCT00623Ghana Newb Newhints CompletedNo ResultsNeonatal Mortality Behavioral
8611 NCT02139Patient-Centered Car CompletedNo ResultsHepatitis B|Hepatitis C|Liver DiseasBehavioral
8612 NCT03780EXperimentEXPECD4 Active, notNo ResultsMajor Depressive Disorder Behavioral
8613 NCT03709Exercise in MethamphRecruiting No ResultsMethamphetamine Abuse Behavioral
8614 NCT00672Prevention, Randomize CompletedNo ResultsTraveler's Diarrhea Biological:
8615 NCT00896Study of GSK2132231A CompletedHas ResultMelanoma Biological
8616 NCT00245A Phase II Trial of C CompletedNo ResultsMetastatic Pancreatic Cancer|NonreBiological
8617 NCT00435Efficacy o BIgGI CompletedNo ResultsDiarrhea Biological:
8618 NCT00118Different Doses of Ty CompletedNo ResultsType I Hypersensitivity Biological
8619 NCT01129Gene Transfer for SevActive, notNo ResultsSevere Combined Immunodeficienc Biological:
8620 NCT02654Study of OATALANTE Recruiting No ResultsNon Small Cell Lung Cancer Drug: OSE2
8621 NCT02625Safety & Immunogenici CompletedNo ResultsProstatic Neoplasms, Castration-ResiBiological
8622 NCT02592Safety & Immunogenic Terminate No ResultsCarcinoma, Non-Small-Cell Lung Biological
8623 NCT00001Mechanisms of Aller CompletedNo ResultsAsthma|Hypersensitivity
8624 NCT00448Cigarette Smoke and Su CompletedNo ResultsHealthy
8625 NCT00751Phase 1b SBrTK01 CompletedNo ResultsMalignant Glioma|Glioblastoma MulBiological:
8626 NCT01540Controlled Human Mala CompletedNo ResultsMalaria Biological:
8627 NCT01767Site Selection for Int CompletedNo ResultsIntracutaneous Drug Delivery Device: Inj
8628 NCT00730Dose RespoPRO CompletedNo ResultsImmune System Dietary Su
8629 NCT01431Sequencing of Sipule CompletedHas ResultProstatic Neoplasm|Prostate Cance Biological:
8630 NCT03905Dose-finding Study ofRecruiting No ResultsScabies Drug: Moxi
8631 NCT03117Safe-SCOPESafe-SCOPCompletedNo ResultsQuality Assurance of Patient Safety Other: Che
8632 NCT01211Integrated vs SequentCompletedHas ResultPTSD|Substance Addiction Behavioral
8633 NCT02274Improving MedicationCompletedNo ResultsDiabetes Mellitus|Medication AdheBehavioral
8634 NCT04267A Study of the Effica Not yet recNo ResultsNon-small Cell Lung Cancer (NSCLC)Drug: Ate
8635 NCT02857A Medical Home-Based Recruiting No ResultsChild Abuse Behavioral
8636 NCT01487Concurrent vs. Sequen CompletedHas ResultProstate Cancer Metastatic|Hormone Biological:
8637 NCT03289A Study of RO7198457 Recruiting No ResultsMelanoma|Non-Small Cell Lung CancDrug: RO7
8638 NCT00000A Phase I/II Study of CompletedNo ResultsHIV Infections Drug: Anti-HIV Immu
8639 NCT00795Safety and Tolerabili CompletedNo ResultsAlzheimer's Disease Biological
8640 NCT01502Educational InterventCompletedNo ResultsDental Caries Behavioral
8641 NCT01097Safety, Tolerability CompletedNo ResultsAlzheimer's Disease Biological
8642 NCT03554Comparative EffectiveActive, notNo ResultsLGBT Health|Cultural Competency|EBehavioral:
8643 NCT01023To Investigate the Sa CompletedNo ResultsAlzheimer Disease Biological
8644 NCT00956To Investigate the Sa CompletedNo ResultsAlzheimer Disease Biological
8645 NCT02903Multi-site SMS CompletedNo ResultsObesity Behavioral
8646 NCT00733Safety and Tolerabili CompletedNo ResultsAlzheimer Disease Biological
8647 NCT01460Azacitidine (AZA) in CompletedNo ResultsLeukemia Drug: Azaci
8648 NCT03346Effect of PhotodymamRecruiting No ResultsHalitosis Other: Ton
8649 NCT03093Impact of a Hospital CompletedNo ResultsAsthma Other: Pha
8650 NCT02820Knowledge and Percep CompletedNo ResultsKnowledge Maternal-Child Health Services
8651 NCT01661Desensitis NaCeD CompletedHas ResultCeliac Disease Biological
8652 NCT00065ProvengeÂ® (SipuleucCompletedHas ResultProstate Cancer Biological:
8653 NCT01207Prognostic SSADREPA CompletedNo ResultsAnemia; Drepanocytic Procedure:
8654 NCT02007Photodynamic Therapy Unknown sNo ResultsHalitosis Other: PDT
8655 NCT03891A Clinical IMPACT-TBNot yet recNo ResultsTuberculosis Drug: Imati
8656 NCT01087Improving Diabetes CUnknown sNo ResultsDiabetes Mellitus Behavioral
8657 NCT02459Culturally-adapted DiaActive, notNo ResultsPrediabetic State|Metabolic SyndroBehavioral
8658 NCT01785Moderate Acute Malnu CompletedNo ResultsMalnutrition Other: Int
8659 NCT02417PostpartumPACER CompletedNo ResultsHIV Other: Com
8660 NCT02485IRIS Regist IRISRegistrRecruiting No ResultsEye Diseases Procedure:
8661 NCT03462Promoting Patient EngCompletedNo ResultsHealth Knowledge, Attitudes, Practi Other: Heal
8662 NCT02885Prevalence, Strain Ci CompletedNo ResultsInfluenza, Human Other: Data
8663 NCT02957Improving South AfricActive, notNo ResultsHIV|Partner Violence|Malnutrition Behavioral
8664 NCT02643Tolerability and Pha CompletedNo ResultsChemotherapy-induced Neutropeni Biological
8665 NCT02323Point of Care SusceptiCompletedNo ResultsUrinary Tract Infections Device: FLE
8666 NCT02301Step it Up: An Exerci CompletedNo ResultsMultiple Sclerosis Behavioral:
8667 NCT03249Preventing Obesity i Unknown sNo ResultsPregnancy|Overweight|Obesity Behavioral
8668 NCT01280Staying ActSTAR CompletedHas ResultOsteoarthritis, Knee|Hypertension Behavioral
8669 NCT00659Immunogenicity Study CompletedHas ResultHIV I Infection Drug: Vacc
8670 NCT02435Web System Asthma WithdrawnNo ResultsAsthma Behavioral
8671 NCT01848Living Well Project f CompletedHas ResultAcquired Immunodeficiency SyndroBehavioral
8672 NCT04149Attractive Targeted SuNot yet recNo ResultsVector Transmission Device: Att
8673 NCT00359Effect of MontelukastCompletedHas ResultAsthma Drug: mont
8674 NCT02457Mobile -SoM-SAKHI Active, notNo ResultsUnder Nutrition Other: Mob
8675 NCT01897Human Papi HPVandPreUnknown sNo ResultsHPV-infection in Pregnant Women
8676 NCT03292The Effect and SafetyEnrolling bNo ResultsHeart Transplantation Drug: Thym
8677 NCT02245The Effect PROMIS-BFCompletedNo ResultsChild Acute Malnutrition Dietary Sup
8678 NCT00000A Placebo-Controlled,CompletedNo ResultsHIV Infections Biological: MTP-PE/M
8679 NCT04066Integrated Disease MNot yet recNo ResultsHeart Failure Other: Int
8680 NCT01104Dengue SerDengSeropUnknown sNo ResultsBlood Donors|Dengue Other: Biol
8681 NCT03644Children's Deep NeckCompletedNo ResultsDeep Neck Infections
8682 NCT04229GPS Compared With Recruiting No ResultsAcute Myeloid Leukemia Biological
8683 NCT02002The Use ofGABA Active, notNo ResultsType I Diabetes Drug: Plac
8684 NCT02030RCT of Brief UniversaCompletedNo ResultsChild Behavior Disorders|Parenting Behavioral:
8685 NCT03169Gene Study for InfantNot yet recNo ResultsStudy Genetic Basis of Infantile Ons Genetic: H
8686 NCT03928Evaluating the Safety Active, notNo ResultsHIV Infections Biological
8687 NCT03194Healthy AdHAT Active, notNo ResultsPregnancy Prevention|Life Skill De Behavioral
8688 NCT02490Effectiveness of Vide CompletedNo ResultsPregnancy|Weight Gain Behavioral
8689 NCT00136Prevention of PerinatUnknown sNo ResultsInfant, Newborn, Diseases|Sepsis|Pu Drug: Chlo
8690 NCT03037Statin Adj STAR Not yet recNo ResultsHIV Infection Drug: ART,
8691 NCT02604Identification and Tr CompletedNo ResultsThrombotic Microangiopathy|DisordDrug: ecul
8692 NCT03482Crowdsourcing to ProCompletedNo ResultsHepatitis|Hepatitis B|Hepatitis C Behavioral
8693 NCT03341Placebo-Controlled TriRecruiting No ResultsLower Respiratory Tract Infection Drug: Azit
8694 NCT00988Sugammadex Hypersens CompletedHas ResultHypersensitivity Drug: Plac
8695 NCT0257924 MonthsADAMANTCompletedNo ResultsAlzheimer's Disease Biological
8696 NCT01740Study to Evaluate Eff CompletedNo ResultsThalassemia Major Biological:
8697 NCT00381A Study of ZYC300 AdCompletedNo ResultsBreast Cancer|Ovarian Cancer|ProsDrug: Cycl
8698 NCT04078EvaluationAS UMJ/SMNot yet recNo ResultsSexually Transmitted Diseases
8699 NCT00001A Comprehensive ClinRecruiting No ResultsLyme Disease
8700 NCT01894Mobile PhoMobile WACompletedNo ResultsMaternal Health|Neonatal Health|FBehavioral
8701 NCT03928The Response to Intr Not yet recNo ResultsCutaneous Metastatic Melanoma Biological:
8702 NCT03799AtezolizumALBAN Recruiting No ResultsBladder Cancer Drug: BCG|
8703 NCT03790SequentialMITOBCG Not yet recNo ResultsBladder Cancer Drug: Mito
8704 NCT03664ElectromotFB10 Recruiting No ResultsBladder Cancer Drug: BCG
8705 NCT03528AssessmentPOTOMACRecruiting No ResultsNon-muscle-invasive Bladder CanceBiological
8706 NCT03335MitomycinRITE-USA Recruiting No ResultsBladder Cancer|Bladder Neoplasm|Bl Combinatio
8707 NCT03317ADAPT-BLADDER: Mode Recruiting No ResultsUrothelial Carcinoma|Bladder Canc Drug: Durv
8708 NCT02948Adding MitBCG+MMCRecruiting No ResultsBladder Cancer Biological
8709 NCT02808Pembrolizumab and BC Recruiting No ResultsRecurrent Bladder Carcinoma|StageBiological
8710 NCT02311Phase I Mitomycin CoCompletedNo ResultsUrinary Bladder Neoplasm Drug: Mito
8711 NCT02254SHTC - EURSHTC-EUROWithdrawnNo ResultsUrinary Bladder Neoplasms|UrologiDevice: Sy
8712 NCT02202Sequential Intravesic Terminate Has ResultBladder Carcinoma Device: In
8713 NCT00471Nasopharyngeal Stre CompletedHas ResultStreptococcus Pneumoniae Infections
8714 NCT04107Using Electronic MedActive, notNo ResultsQuality of Health Care|HIV/AIDS|EleBehavioral
8716 NCT03910Dried Blood Spot TestRecruiting No ResultsCytomegalovirus Infection Device: DBS
8717 NCT01625A Study of ALT-801 inUnknown sNo ResultsNon-muscle Invasive Bladder Cance Biological
8718 NCT02279Neonatal Package Stud CompletedNo ResultsNeonatal Infections Drug: Chlo
8719 NCT01442SequentialBCG/EMD CompletedNo ResultsBladder Cancer Biological
8720 NCT01316IntravesicaBladder CaCompletedNo ResultsCarcinoma in Situ|Bladder Cancer Drug: Valr
8721 NCT00974Mitomycin C Versus Ba Terminate Has ResultBladder Cancer Drug: Mito
8722 NCT01230Topical MetronidazoleCompletedHas ResultBacterial Vaginosis|Candidiasis|Tri Drug: Neo-
8723 NCT02979EvaluationM2SFlu CompletedNo ResultsInfluenza|Otitis Media|Lower Resp Tr Procedure:
8724 NCT00384Hyperthermia Treatme Terminate No ResultsUrinary Bladder Diseases|Urinary Device: Sy
8725 NCT00330Combined Use of BCGCompletedNo ResultsCarcinoma of Urinary Bladder, Superf Drug: Bacil
8726 NCT03511A PragmatiSMART Recruiting No ResultsHiv|Adolescent Behavior|Sex, Safe Behavioral
8727 NCT03698Reduce Stigma and I Recruiting No ResultsHIV Behaviora
8728 NCT01290Post-marketing StudyTerminate No ResultsInfections, Papillomavirus Other: Data
8729 NCT03932Fever AferFATB Recruiting No ResultsTick-Bite; Fever|Tick Fever|Tick-Bor Other: The
8730 NCT00547Phase I/II Intratumo CompletedNo ResultsPancreatic Cancer Drug: Gemc
8731 NCT03161Impact of SUSTAIN1 CompletedNo ResultsMaternal Death Affecting Fetus or NBehavioral
8732 NCT01335Clinical Study of TU CompletedHas ResultHIV Infections Biological
8733 NCT01927TherapeutiTPE CompletedNo ResultsMyasthenia Gravis Other: Ski
8734 NCT01144Clinical St THYMON-1CompletedHas ResultHIV Infections Biological:
8735 NCT01489A Study to DetermineTerminate Has ResultAutoimmune Disorders Biological
8736 NCT04260Study of P VERSATILE Not yet recNo ResultsMetastatic Head and Neck Cancer|RCombinati
8737 NCT01143Hepatitis CHEPTIDES CompletedHas ResultHepatitis C|Depression Other: Dep
8738 NCT01677Study of Yili Mei Yi CompletedNo ResultsImmunization|Human Influenza|Com Dietary Sup
8739 NCT03614A Study of PEPNI Recruiting No ResultsRespiratory Syncytial Virus InfectionProcedure:
8740 NCT02470Evaluation of Safety Active, notNo ResultsStage IV Non-small Cell Lung CancerBiological
8741 NCT03996Harm Reduc seguiPrEP Recruiting No ResultsHIV/AIDS|HIV Infections|Sexually T Behavioral:
8742 NCT01992Assessment of EfficacWithdrawnNo ResultsInfluenza Biological
8743 NCT02105Phase II Study of DC CompletedNo ResultsProstate Cancer|Prostate Cancer MeBiological
8744 NCT04166Bangladesh MSNP: Soc Recruiting No ResultsStunting|Undernutrition Other: Con
8745 NCT02555Single Ascending DoseTerminate No ResultsHealthy Biological
8746 NCT01321Rotavirus Burden andUnknown sNo ResultsGastroenteritis|Dehydration
8747 NCT01314Impact of ECoEnv CompletedNo ResultsSpondylarthritis|Primary Systemic Vasculitis
8748 NCT01050MedlinePlus Health PrCompletedNo ResultsAcne Vulgaris|Allergic Rhinitis|An Other: heal
8749 NCT03425Diaper Distribution i WithdrawnNo ResultsDiaper Rash|UTI|Depressive Sympt Other: Dia
8750 NCT01830RegulatoryRTCAS CompletedNo ResultsGrass Pollen Allergy|Specific Immunotherapy
8751 NCT02103Effect of LIME Active, notNo ResultsHealth of Formula-fed Children|Infan Dietary Su
8752 NCT02647 Salud al DÃa: EngagingCompletedNo
Latino Parents
Results
in Pediatric
PrimaryPrimary
Health Care Behavioral: Salud al DÃa
8753 NCT04117Prevalence of HPV-assNot yet recNo ResultsHuman Papilloma Virus Infection|P Diagnostic
8754 NCT02808Liver Injur LISHBV Not yet recNo ResultsLiver Injury|Hepatitis B Virus Infecti Other: HBV
8755 NCT02157Connecting Healthy WCompletedHas ResultContraception|Sexually TransmittedBehavioral
8756 NCT03837A Clinical Study to E Recruiting No ResultsWiskott-Aldrich Syndrome Genetic: O
8757 NCT00004Biological Therapy FoCompletedNo ResultsBrain and Central Nervous System T Biological: aldesleuk
8758 NCT02374COMorbiditCOMEDSPACompletedNo ResultsAxial Spondyloarthritis Behavioral
8759 NCT03725The PATH HPATH Recruiting No ResultsNeonatal Abstinence Syndrome Behavioral
8760 NCT03984Sexual He SHE-WOMNot yet recNo ResultsCervical Cancer|Breast Cancer|ContBehaviora
8761 NCT04033Group AnteGRAND Recruiting No ResultsAntenatal Care Behavioral
8762 NCT01406Durham Connects RCTActive, notNo ResultsUnspecified Child Maltreatment, Su Other: Du
8763 NCT01706Sero-prevalence of A CompletedNo ResultsPertussis Procedure:
8764 NCT00832Routine FeGENIFERH CompletedNo ResultsRhesus Negative Pregnant Women Genetic: G
8765 NCT00000A Study to Compare th CompletedNo ResultsHIV Infections Drug: Indinavir sulfa
8766 NCT03900Paediatric PI-POC Recruiting No ResultsMeningitis|Pediatric Infectious DiseDiagnostic
8767 NCT00769Emergency Use of Don Unknown sNo ResultsCancer Biological
8768 NCT01793Rare DiseasCoRDS Recruiting No ResultsRare Disorders|Undiagnosed Disorders|Disorde
8769 NCT04185BangladeshHFP MSNPRecruiting No ResultsStunting|Undernutrition Other: HFP
8770 NCT01836A Study to Find the CompletedHas ResultMalaria Drug: KAE
8771 NCT00421Effect of Information CompletedNo ResultsDelivery of Services to Rural PopulatBehavioral
8772 NCT02387Efficacy of MINDFULNCompletedNo ResultsBurnout Syndrome Behavioral:
8773 NCT04182HS#2017-3512, Adapti Not yet recNo ResultsLLIN, PBO LLIN, IRS, Larviciding Other: Regu
8774 NCT03800Effects of Nutritional Not yet recNo ResultsEscherichia Coli Infections Drug: "Mut
8775 NCT01553Mobile Diabetes EducCompletedNo ResultsDiabetes Mellitus Behavioral
8776 NCT01031Study to Identify and WithdrawnNo ResultsInfections, Streptococcal Procedure:
8777 NCT02906Platelet Ki PLATCAT Unknown sNo ResultsThrombopenia|Central Venous CathProcedure:
8778 NCT00664Atacicept iAugust III CompletedHas ResultRheumatoid Arthritis Biological
8779 NCT02550LIFE Leipzi LIFE-Child Recruiting No ResultsChildhood Obesity
8780 NCT01621Clinical Study of WT CompletedHas ResultCancer Biological
8781 NCT03657DCVAC/OvCa Afer StaActive, notNo ResultsOvarian Cancer Recurrent Biological
8782 NCT01876Targeted ScAHI CompletedNo ResultsHIV Behavioral:
8783 NCT00848Clinical St THYMON-0CompletedHas ResultHIV Infections Other: Pla
8784 NCT03574QUILT-2.024: Phase 2WithdrawnNo ResultsNon Small Cell Lung Cancer Drug: Nab-
8785 NCT02042A Phase I Study to E CompletedNo ResultsHIV Biological
8786 NCT03689Evidence Generation Recruiting No ResultsStunting|Low Birth Weight|Anemia Dietary Su
8787 NCT03495Vigil + Ir VITA Recruiting No ResultsEwing Sarcoma|Ewing Family of TumBiological
8788 NCT01515Gene TheraTIGET-WASActive, notNo ResultsWiskott-Aldrich Syndrome (WAS) Genetic: O
8789 NCT03700A Clinical FamilyStreRecruiting No ResultsSocial Determinants of Health|Chil Behavioral
8790 NCT02460Immunotherapy Combin Active, notNo ResultsNon-small Cell Lung Cancer|ProgresDrug: Doce
8791 NCT02107Efficacy of DCVAC/OvC Terminate No ResultsEpithelial Ovarian Carcinoma Biological
8792 NCT01322A Randomiz Prospect CompletedHas ResultProstate Cancer Metastatic Biological
8793 NCT01147Asthma Con ACEM CompletedNo ResultsPersistent Asthma|Elderly Drug: Comb
8794 NCT01545Chemokine-Modulatory Terminate No ResultsColorectal Cancer|Colorectal Carci Drug: Che
8795 NCT00723Temodal (Temozolomid CompletedHas ResultGlioblastoma|Glioma|Astrocytoma Drug: Temo
8796 NCT03149A Study of WIZARD 2 Active, notNo ResultsGlioblastoma Drug: DSP-
8797 NCT03707Safety, Tolerability CompletedNo ResultsMalaria Drug: P218
8798 NCT00948A Study of CDX-1401 CompletedNo ResultsAdvanced Malignancies Biological
8799 NCT03594CommunityCoMIC Active, notNo ResultsChildhood Diarrhea|Childhood Pne Behavioral
8800 NCT03311A Study of DSP-7888 Recruiting No ResultsNeoplasms|Melanoma|Non Small Cell Drug: DSP-
8801 NCT03364GPPAD-POInT (GlobalRecruiting
P No ResultsDiabetes Mellitus, Type 1 Drug: Oral
8803 NCT02677SequentialLymvac-2 Recruiting No ResultsFollicular Lymphoma Radiation:
8804 NCT00638AdV-tk ThePaTK01 CompletedNo ResultsPancreatic Adenocarcinoma|PancreaBiological:
8805 NCT01138Study of a DNA ImmuTerminate No ResultsMalignant Melanoma Biological:
8806 NCT00365External Beam RadiatiCompletedHas ResultSof Tissue Sarcoma Biological
8807 NCT04172A Study of Erdafitini Not yet recNo ResultsUrinary Bladder Neoplasms Drug: Erdaf
8808 NCT03392Evaluation of Safe Sl CompletedNo ResultsSudden Infant Death Device: St
8809 NCT03995Efficacy and Safety Recruiting No ResultsWHIM Syndrome Drug: Mavo
8810 NCT03796JAK1 Inhib JADE TEENRecruiting No ResultsAtopic Dermatitis Drug: Plac
8811 NCT04019Effects of Early Com Recruiting No ResultsChild Development Other: Nur
8812 NCT00045Study of a GBM Unknown sNo ResultsGlioblastoma Multiforme|Glioblas Drug: Dend
8813 NCT00050Phase II Trial of All CompletedNo ResultsHead and Neck Cancer|Squamous Cel Genetic: Allovectin-7
8814 NCT02847Study to E LILAC CompletedNo ResultsSystemic Lupus Erythematosus|ActiDrug: BIIB
8815 NCT00044Phase II Trial of All CompletedNo ResultsMelanoma|Metastatic Melanoma|Ma Genetic: Allovectin-7
8816 NCT03477A New Biom BIODRAFT Recruiting No ResultsHeart Transplant Rejection Diagnostic
8817 NCT03921Decision Support for Recruiting No ResultsChronic Renal Disease Radiation:
8818 NCT02304Care Coordination forUnknown sNo ResultsExperiences With Health Care Coordination
8819 NCT02064Patients Treated for Active, notNo ResultsWiskott-Aldrich Syndrome
8820 NCT00529A Randomized Controll CompletedNo ResultsHIV Infections Behavioral
8821 NCT01756Assessment of CR8020 CompletedNo ResultsInfluenza Biological
8822 NCT01685Evaluation of ComputCompletedNo ResultsPrimary Care Patients With Chronic Other: Max
8823 NCT01406Assessment of CR6261 CompletedNo ResultsInfluenza Biological
8824 NCT02816Housing PrescriptionsActive, notNo ResultsHousing Instability|High EmergencyBehavioral
8825 NCT02686ProspectivePRESAGE Active, notNo ResultsRheumatoid Arthritis
8826 NCT01920Platelet Rich Plasma vEnrolling bNo ResultsHip Osteoarthritis Biological:
8827 NCT04165Multicenter Study of CompletedNo ResultsTetanus
8828 NCT01947Doula Home Visiting Active, notNo ResultsBreast Feeding|Parenting|Child De Behavioral
8829 NCT00001Twins Study of Gene TCompletedNo ResultsAcquired Immunodeficiency Syndrom Drug: Syngeneic Lymp
8830 NCT02554Novel Mechanisms and Recruiting No ResultsComplication of Prematurity|ImmunOther: Adj
8831 NCT01616Arthritis AFEP+10 KCompletedNo ResultsArthritis|Diabetes|Hypertension|PrBehavioral
8832 NCT03130AntibioticsABCD CompletedNo ResultsDiarrhea Drug: Azit
8833 NCT01556Evaluation NEOCORD Terminate No ResultsOmphalitis Other: Cord
8834 NCT03058OEIS Outcome Data Re Recruiting No ResultsPeripheral Arterial Disease
8835 NCT02233Effect of Iron/Zinc-B CompletedNo ResultsIron Deficiency|Zinc Deficiency Other: FeZ
8836 NCT03947Evaluation of a PatienNot yet recNo ResultsDiabetes Mellitus, Type 2 Other: My
8837 NCT03697Safety and Efficacy S Terminate No ResultsUrinary Tract Infection Drug: Fosf
8838 NCT02216Effect of C HCV CompletedNo ResultsChronic Hepatitis C Drug: Pegin
8839 NCT02957Evolocumab PregnancRecruiting No ResultsHypercholesterolemia; ASCVD; PregDrug: evo
8840 NCT02963ErythrocytPITT Recruiting No ResultsCardiac Surgery Other: SVO
8841 NCT04087The UniverUZ-CHS-BCActive, notNo ResultsHIV Infections|Immune Activation|COther: HIV
8842 NCT03379PraluentÂ® (AlirocumRecruiting No ResultsHypercholesterolemia Drug: ALI
8844 NCT02139An Open-label, SingleCompletedNo ResultsRabies Biological:
8845 NCT00951Feasibility Study of CompletedNo ResultsHIV Infections Behavioral:
8846 NCT03983Plant Stan PLANTASTIRecruiting No ResultsAsthma, Allergic|Cardiovascular Dis Dietary Sup
8847 NCT00002A Randomized, Multice CompletedNo ResultsCryptosporidiosis|HIV Infections Drug: Cryptosporidi
8848 NCT03087A Retrospective and WithdrawnNo ResultsWHIM Syndrome Other: No
8849 NCT02891Trial to Evaluate Be CompletedNo ResultsPneumonia Drug: Amox
8850 NCT00429Perinatal HypothermiUnknown sNo ResultsHypothermia|Morbidity|Mortality Device: th
8851 NCT01072Study to Identify and Terminate No ResultsAcute Otitis Media Procedure:
8852 NCT01160Study to CharacterizeWithdrawnNo ResultsInfections, Streptococcal Procedure:
8853 NCT04008Study of InHOSPIGRIPCompletedNo ResultsInfluenza Virus Infection Other: Retr
8854 NCT01204Study to Identify and CompletedNo ResultsInfections, Streptococcal Procedure:
8855 NCT00442Study to Investigate CompletedNo ResultsFalciparum Malaria Procedure:
8856 NCT01561A Study to Investigat CompletedNo ResultsInfluenza Virus Drug: VX-7
8857 NCT01292Safety Stu TMB-108 CompletedNo ResultsPrevention of Infection With HIV-1 Biological:
8858 NCT04264Is the Preoperative P Enrolling bNo ResultsSickle Cell Disease
8859 NCT03265ExpressingNEO Active, notNo ResultsColon Cancer Metastatic|Head and Biological
8860 NCT00682DaclizumabTAXI CompletedNo ResultsRenal Transplantation Drug: Thym
8861 NCT01313Gemcitabine and CT-0Terminate Has ResultPancreatic Neoplasms|Cancer of th Biological
8862 NCT02910Cost-effec COST Active, notNo ResultsMalaria Other: Acte
8863 NCT03643Impact of 2SMD-transNot yet recNo ResultsMyelodysplastic Syndromes|Transf Other: Tra
8864 NCT01984Treatment Hiltonol Terminate Has ResultMelanoma|Squamous Cell Carcinoma Drug:
o Poly-
8865 NCT02826Abnormal Fe MAGIC CompletedNo ResultsCrohn's Disease|Genetic PredispositOther: bio
8866 NCT00960Randomized SHINE CompletedNo ResultsObesity Behavioral
8867 NCT01516Phase 2a EBA Trial o CompletedNo ResultsTuberculosis Drug: AZD5
8869 NCT03132Vitamin D SupplemenUnknown sNo ResultsVitamin D Status Dietary Su
8870 NCT01836Keep It UpKIU! CompletedHas ResultHIV|Gonorrhea|Chlamydia Behavioral
8871 NCT02128Epidemiology of Chron CompletedNo ResultsChronic Obstructive Pulmonary Disease|Chroni
8872 NCT02054Immunotherapy StudyActive, notNo ResultsStage IV Melanoma|Metastatic Me Drug: Hyp
8873 NCT00279TEDDY - The EnvironmActive, notNo ResultsType 1 Diabetes Mellitus
8874 NCT02208Newborn Kit to Save LCompletedNo ResultsNeurodevelopment|Neonatal Mortal Device: Ne
8875 NCT03626Safety and Pharmacoki CompletedHas ResultOrgan Transplant Rejection|PsoriasiDrug: Sust
8876 NCT04236Tuberculosis InfectionRecruiting No ResultsTuberculosis Infection Other: TB i
8877 NCT04075Feasibility of a Self Recruiting No ResultsChildhood Cancer Survivors Behavioral
8878 NCT04075A Study of OcrelizumaRecruiting No ResultsMultiple Sclerosis Drug: Ocre
8879 NCT03460Clinical F French-hMActive, notNo ResultsLower Resp Tract Infection|Human Metapneumo
8880 NCT03308An Efficac FOCUS CompletedHas ResultMigraine Prophylaxis Drug: Fre
8881 NCT03389Assessemen ONCOVIR Recruiting No ResultsRespiratory Tract Viral Infection Diagnostic
8882 NCT02043Outcome atPEDIACAMUnknown sNo ResultsHIV
8883 NCT01824SHINE SanitSHINE CompletedNo ResultsGrowth; Stunting, Nutritional|AnemBehavioral
8884 NCT01827Safety and Efficacy ofCompletedHas ResultStaphylococcal Infection Drug: Mupi
8885 NCT00001A Pilot Study to Obta CompletedNo ResultsCytomegalovirus Retinitis|HIV InfectDrug: Globulin, Immu
8886 NCT00000A Phase III Randomiz CompletedNo ResultsHIV Infections|Pregnancy Drug: Anti-HIV Immu
8887 NCT00000A Double-Blind, PlaceCompletedNo ResultsHIV Infections Drug: Globulin, Immu
8888 NCT00000A Phase I Study of A CompletedNo ResultsHIV Infections Drug: Zidovudine|Dru
8889 NCT00000A Phase I Study of t CompletedNo ResultsHIV Infections|Pregnancy Drug: CD4-IgG
8890 NCT00730Uncomplicated Skin aCompletedHas ResultStaphylococcal Infection Drug: Trim
8891 NCT04099Lifestyle, STANIS Recruiting No ResultsMedication Adherence Behavioral:
8892 NCT02860Safety and Early Eff Not yet recNo ResultsSevere Combined Immunodeficienc Biological:
8893 NCT03131Realize theREAL Active, notNo ResultsChronic Obstructive Pulmonary Disease COPD
8894 NCT02003Cardiovascular Risk a CompletedNo ResultsProstate Cancer
8895 NCT00272Effect of Zinc and V CompletedNo ResultsDiarrhea|Pneumonia|Acute Respirato Drug: Zinc
8896 NCT01031Study to Identify and CompletedNo ResultsAcute Otitis Media Procedure:
8897 NCT00778Study of Milk Allergy CompletedHas ResultFood Hypersensitivity|Milk Hypersen Biological:
8898 NCT01266Effects of PREP CompletedNo ResultsHealth Behavior Behavioral:
8899 NCT01852Reversing Tissue Fibr CompletedNo ResultsHIV Infection|HIV Infections Drug: Losa
8900 NCT03573Decreasing Stunting CompletedNo ResultsDepression, Postpartum|MalnutritioOther: Car
8901 NCT01202A Retrospective SurveCompletedNo ResultsNosocomial Rotavirus GastroenteritiOther: Dat
8902 NCT03162Clinical Trial of Effi CompletedHas ResultAcute Upper Respiratory Infections Drug: Anafe
8903 NCT03424Underreporting of OcCompletedNo ResultsHealth Professional Other: Surv
8904 NCT02716Phase 1 Study of Tre Terminate Has ResultMultiple Myeloma Drug: Trem
8905 NCT01470A Open-Label Study OCompletedHas ResultCrohn's Disease Drug: CP-6
8906 NCT02587ImmunoTEP iTEP ColonCompletedNo ResultsMetastatic Colorectal Cancer Drug: TF2
8907 NCT00350Study of the Clinical CompletedNo ResultsClostridium Infections Biological
8908 NCT00849A Study of Safety an Terminate Has ResultMelanoma Biological
8909 NCT00130Tuberculosis Treatmen CompletedHas ResultTuberculosis Drug: Etha
8910 NCT03301Clinical Trial of Anaf CompletedNo ResultsPreventive Medicine Drug: Anaf
8911 NCT00995The Women's HIV Sero CompletedNo ResultsHIV Infections
8912 NCT03229A Pilot St HPV Unknown sNo ResultsHPV Infection Other: Clu
8913 NCT03326Community-based Inter Recruiting No ResultsExercise|Physical Activity|AccidentaBehavioral:
8914 NCT03568Protecting PHOENIx Recruiting No ResultsTuberculosis, MDR Drug: Dela
8915 NCT02821Using Biomarkers to Recruiting No ResultsPulmonary Tuberculosis Procedure:
8916 NCT03947iMEA : ComiMEA Recruiting No ResultsProlapse Genital Other: bio
8917 NCT03354The Bronchi BeneFIT CompletedNo ResultsBronchiolitis Behavioral
8918 NCT02720Safety and Efficacy Recruiting No ResultsHIV Infections Drug: Cabo
8919 NCT03039Clinical Trial of Effi CompletedNo ResultsAcute Respiratory Viral Infections Drug: Ergo
8920 NCT01648Program ofPICCOPD+ CompletedNo ResultsChronic Obstructive Pulmonary DiseBehavioral
8921 NCT04171Enhancing ENAT Not yet recNo ResultsLow Birthweight|Preterm Birth|Mater Drug: Azit
8922 NCT01804Clinical Trial of Clini CompletedHas ResultInfluenza Drug: Ergo
8923 NCT03487Medical CaMESSAGESRecruiting No ResultsType 2 Diabetes Mellitus Other: Dia
8924 NCT03967Repeat IveRIMDAMALRecruiting No ResultsMalaria Drug: Iver
8925 NCT03395NNITS-Nitazoxanide foRecruiting No ResultsGastroenteritis Norovirus Drug: Nita
8926 NCT03037INTERCEPTRedeS
B Recruiting No ResultsAnemia Device: IN
8927 NCT03164Evaluating the Safety Recruiting No ResultsHIV Infections Drug: Oral
8928 NCT00211A Study of Risk Facto CompletedNo ResultsPure Red-cell Aplasia Drug: No i
8929 NCT02038A Study To Assess Th CompletedHas ResultDiabetes Mellitus, Type 1 Drug: Plac
8930 NCT02541Efficacy OfEOLIA CompletedNo ResultsAllergic Asthma Biological
8931 NCT02410TBTC StudyS31/A5349Active, notNo ResultsTuberculosis Drug: rifa
8932 NCT01765Clinical Trial of Safe CompletedNo ResultsAcute Upper Respiratory Tract InfectDrug: Ergo
8933 NCT01052Safety and IRC002 CompletedHas ResultInfluenza A|Influenza B Biological
8934 NCT03975Comparative AnalysisCompletedHas ResultRheumatoid Arthritis
8935 NCT03925Creation ofCoSImmGERecruiting No ResultsImmune System and Related DisordeProcedure:
8936 NCT00942A Study to PREDICT CompletedHas ResultMelanoma Biological
8937 NCT00824Developmen DPA Unknown sNo ResultsDiabetes Type 2 Other: Com
8938 NCT04230Estimating the MalariNot yet recNo ResultsMalaria Other: Stan
8939 NCT04157Estimating the MalariRecruiting No ResultsMalaria Other: Stan
8940 NCT02737An Investigational I Recruiting No ResultsAdvanced Cancer Drug: BMS
8941 NCT03919RSV Study in Adults 6CompletedNo ResultsRSV Infection Other: Cha
8942 NCT00796A Phase III Study to Terminate Has ResultMelanoma Drug: GSK
8943 NCT02783Pathogen RPREPAReS CompletedNo ResultsThrombocytopenia Device: Pa
8944 NCT02203Using Baby Books to CompletedNo ResultsCondition 1 - Educational Conditio Behavioral
8945 NCT02844Study Eval RITEPRALLWithdrawnNo ResultsCD22+ Relapsed/Refractory B-ALL Drug: 90Y-
8946 NCT01125MillenniumMVP CompletedNo ResultsChild Survival Other: Hea
8947 NCT02064An Open Label, Pilot Active, notNo ResultsLong-standing Type 1 Diabetes MelliDevice: Bet
8948 NCT02151Phase 1 Single-ascendCompletedHas ResultHealthy Volunteer Biological
8949 NCT02577Testing a EPRALLO WithdrawnNo ResultsLymphocyte B CD22 Positive Acute Drug: 90Y-
8950 NCT02363Using Stable Isotope CompletedNo ResultsVitamin A Deficiency Dietary Su
8951 NCT00952Pharmacokinetic Study CompletedHas ResultHemophilia A Biological:
8952 NCT01051Evaluation of a New CompletedHas ResultLeukaemia, Myelocytic, Acute Biological
8953 NCT01239Supplement iLiNS-DYA CompletedNo ResultsInfant Malnutrition|Malnutrition in Dietary Su
8954 NCT01045MOMCare:MOMCareCompletedNo
C ResultsDepression Behaviora
8955 NCT03451Phase I/II Study of A Recruiting No ResultsRefractory or Relapsed Solid Tumo Drug: Ave
8956 NCT03971Impact of Serious PediEnrolling bNo ResultsFamily Members of: Newborns Extremely Premat
8957 NCT02951Study Evaluating the EActive, notHas ResultInfection, Human ImmunodeficiencyDrug: Cabot
8958 NCT02037The ImpactSMS CompletedNo ResultsShort Message Service|Text MessagBehavioral
8959 NCT01719Influenza Virus Chall Unknown sNo ResultsInfluenza Biological:
8960 NCT01094Hyperthermia and Mito Unknown sNo ResultsBladder Cancer Biological
8961 NCT03382A Study of PC786 to ECompletedNo ResultsRespiratory Syncytial Virus InfectionDrug: PC78
8962 NCT02938Study to Evaluate theActive, notHas ResultHIV Infections Drug: Cabot
8963 NCT01424Safety and Efficacy T CompletedHas ResultMultidrug-resistant Tuberculosis Drug: Dela
8964 NCT04235Physical RePRIME-KneNot yet recNo ResultsResilience|Aging
8965 NCT00212International ImmuneTerminate No ResultsHemophilia A With Inhibitors Drug: Fact
8966 NCT01977Task Shari AFFIRM-SACompletedNo ResultsModerate Depression|Clinical Depr Behavioral
8967 NCT01892Improving Preterm OuCompletedNo ResultsDepression|Child Development Behavioral
8968 NCT00263Safety and PerformanCompletedNo ResultsThrombocytopenia Device: Pa
8969 NCT00339Interleukin-1 Recept CompletedNo ResultsSystemic-Onset Juvenile Idiopathic ADrug: Anak
8970 NCT03459Study to E ReCePI Recruiting No ResultsAnemia Device: IN
8971 NCT03751Bordetella Periscope Recruiting No ResultsWhooping Cough Biological:
8972 NCT01723A Long-Term Safety ECompletedHas ResultAlzheimer's Disease Drug: Cre
8973 NCT02263Treatment THERA Terminate No ResultsRefractory Hemochromatosis Rheu Drug: Anak
8974 NCT04121PreventionPIANO Not yet recNo ResultsPneumonia Other: On-l
8975 NCT03026Effect of a Mentor-baNot yet recNo ResultsMetastatic Breastcancer Behavioral:
8976 NCT03482Impact of SINTEGR-C Active, notNo ResultsCOPD Behavioral
8977 NCT02755Introducin IPCP-KenyaUnknown sNo ResultsHIV Drug: Truv
8978 NCT01821Wired Mothers - Use CompletedNo ResultsPregnancy|Maternal Health|NewboDevice: Wi
8979 NCT03976Evaluation Well-child CompletedNo ResultsWell-child Care Other: Trai
8980 NCT01852Autologous TransplanCompletedNo ResultsADA-SCID Genetic: I
8981 NCT04234Eosinophil-eo-Drive Not yet recNo ResultsCOPD Exacerbation Drug: 5 da
8982 NCT03439A Study of ARRY-3717Recruiting No ResultsDilated Cardiomyopathy|Lamin A/C Drug: ARRY
8983 NCT020343-part Study to Evalu CompletedNo ResultsHealthy Volunteers Drug: CC-2
8984 NCT02177Clinical Benefit, Saf Not yet recNo ResultsInfections, Bacterial Biological:
8985 NCT02302Trial to Ev TRULIGHT CompletedNo ResultsHIV Drug: tripl
8986 NCT0370317.12.INF HAPPY TU Recruiting No ResultsHealthy Infants Other: Ther
8987 NCT01816Treatment DATIPO CompletedNo ResultsProsthesis-related Infections Other: dura
8988 NCT00774Abatacept ACCESS CompletedHas ResultLupus Nephritis|Lupus Erythematosu Drug: abat
8989 NCT03715Financial Incentives Enrolling bNo ResultsDelivery of Health Care Behavioral:
8990 NCT03299Efficacy, Safety and Active, notNo ResultsHIV Infections Drug: Cabot
8991 NCT03394Technology to ImprovActive, notNo ResultsDiabetes Mellitus, Type 2 Other: dia
8992 NCT00216Evaluation of the HeaCompletedNo ResultsChild Abuse Behavioral
8993 NCT03849TCRÎ±Î²-depleted ProgRecruiting No ResultsAcute Lymphoblastic Leukemia (AL Drug: Cycl
8994 NCT03498Reintegration of Chil CompletedNo ResultsParenting Behavioral
8995 NCT02986PVSRIPO in RecurrentRecruiting No ResultsMalignant Glioma Biological
8996 NCT01213Evaluation of a New CompletedHas ResultMelanoma Biological
8997 NCT03594Maintenance (vs. Chan Not yet recNo ResultsNegative Therapy Expectation Behavioral:
8998 NCT00952Prevalence of Nasopha CompletedHas ResultStreptococcus Pneumoniae Infectio Other: Nas
8999 NCT01550Study of HydroxychlorCompletedHas ResultMetastatic Renal Cell Carcinoma Drug: Hydr
9000 NCT03707Mechanisms of Immun Not yet recNo ResultsImmune Deficiency
9001 NCT02467Project 4B: Lower ExtCompletedNo ResultsSepsis Device: Mu
9002 NCT00480GSK1572932A Antigen- Terminate Has ResultLung Cancer, Non-Small Cell Biological
Liverpool United Ki London United Ki London United Ki London United Ki
9003 NCT03478Strimvelis Registry Enrolling bNo ResultsImmunologic Deficiency SyndromesGenetic: St
9004 NCT03737Immunoglobulin Repla Not yet recNo ResultsBronchiectasis|Immunoglobulin Subc
Drug: Cuvit
9005 NCT02165Get Ready GREAT CompletedHas ResultHIV Behavioral:
9006 NCT03538Autologous Gene TherRecruiting No ResultsSevere Combined Immunodeficienc Drug: APro
9007 NCT03830Mil Familias Cohort Enrolling bNo ResultsType2 Diabetes Mellitus|Cardiovascular Diseas
9008 NCT02169Development of a NatUnknown sNo ResultsPregnancy|Premature Birth|Infant, Behavioral
9009 NCT02713A Phase 2 Study of a WithdrawnNo ResultsInfluenza Prevention Drug: TAK-
9010 NCT02655Study of thCOPD1722Recruiting No ResultsPulmonary Disease, Chronic Obstruct Other: Sam
9011 NCT02800KOrea COpd KOCOSS Recruiting No ResultsCOPD
9012 NCT04268Community-Based, CliNot yet recNo ResultsDrug Use Disorders|Hepatitis C|Ha Other: Com
9013 NCT01372Nurse-family Partner CompletedNo ResultsDomestic Violence Behavioral:
9014 NCT03554Efficacy of Three NoveRecruiting No ResultsMalaria|Anaemia Other: Chl
9015 NCT04121NorwegianNOR-MS Recruiting No ResultsRelapsing Multiple Sclerosis|MultiplBiological:
9016 NCT04059EvaluationEMPATHY Recruiting No ResultsHypoparathyroidism|Hypoparathyroidism Post
9017 NCT00962Study EvaluCLIPPER CompletedHas ResultArthritis, Juvenile Idiopathic Drug: Etan
9018 NCT03524Home Hospital for Sud Recruiting No ResultsInfection|Heart Failure|COPD|Asthm
Other: Hom
9019 NCT03203Hospital-Level Care atCompletedNo ResultsInfection|Heart Failure|COPD|Asthm Other: Home
9020 NCT03178Post-Acute Physician CompletedNo ResultsA Patient Discharged From an Acute-Other: Hom
9021 NCT02864Hospitalization at H CompletedNo ResultsPneumonia|Heart Failure|Cellulitis|UOther: Hom
9022 NCT00569Study With Candida ACompletedHas ResultWarts|HPV Drug: Cand
9023 NCT02343COPE With COPD TriaCompletedNo ResultsChronic Obstructive Pulmonary DiseOther: Ca
9024 NCT04016Diabetes Pu DiabPuebl Recruiting No ResultsType2 Diabetes Behavioral
9025 NCT01512Gene TransLVXSCID-NRecruiting No ResultsSevere Combined ImmunodeficiencyGenetic: C
Outcome M Sponsor/CoGender Age Phases EnrollmentFunded ByStudy TypeStudy DesiOther IDs
Number ofImperial C All 18 Years toNot
30 Years
ApplicÂ (Adult)40 Other InterventioInterventi 18/LO/090
Solicited a Butantan InAll 6 Months to 59 Years Â (Child,533Adult)
Other ObservatioObservatioFLU-05-IB
PercentageSanofi Pas All 6 Months toPhase
35 Months
4 Â 1950
(Child)
Industry InterventioAllocation GRC88|U11
Cellular imDeepali KuAll 50 Years and
Phase
older
4 Â (Adult, 51Older
Other
Adult) InterventioAllocation UHN-Shingr
Primary ImMahidol UnAll 18 Years toPhase
49 Years
2|PhÂ (Adult)
945 Other InterventioAllocation Tri Fluvac
Safety and National LiAll 18 Years toPhase
55 Years
1|PhÂ (Adult)50 Other InterventioAllocation NRC
Neutralizi University All 18 Years and
Phase
older
Other
Adult) InterventioInterventi 826207
% of patienAssistance All 18 Years and
Notolder
Applic
Â (Adult, 40Older
Other
Adult) InterventioInterventi K180302J
Subjects inPfizer All 18 Years toPhase
85 Years
2 Â (Adult,
3449Older
Industry
Adult)InterventioAllocation B3451002|
The rotavirOxford UniAll 8 Weeks toPhase
9 Weeks
4 Â (Child)
1000 Other InterventioInterventi 21EN
HPV antibod University All 27 Years toPhase
45 Years
4 Â (Adult)40 Other InterventioAllocation STUDY000
Humoral imUniversity All 18 Years and
Phase
older
Other
Adult) InterventioInterventi UHNTID00
Immunogenic The Immuno All 11 MonthsPhase
to 11 Months
2|Ph Â 432 (Child)
Other InterventioAllocation ASCLIN 00
Number ofClifford
i C All 30 Years toNot
100Applic
Years Â (Adult,
450 Older
OtherAdult)InterventioAllocation H0015460
Molecular Bs oston ChiAll up to 1 DayNot
Â (Child)
Applic 890 Other InterventioAllocation IRB-P0002
Cell-mediaNovartis V All 18 Years toPhase
65 Years
2 Â (Adult,58Older
Industry
Adult)InterventioAllocation V87P3
The dynamiNational C All 18 Years and
Phase
older
4 Â (Adult,200Older
Other
Adult) InterventioAllocation A-BR-101-
PercentageSanofi Pas All 56 Years and
Phase
older
Industry
Adult) InterventioAllocation MET49
Safety and The Immuno Male 18 Years toPhase
49 Years
1 Â (Adult)30 Other InterventioInterventi ASCLIN 00
The likelih University All 10 Years toNot
18 Years
ApplicÂ (Child,
2000 Adult)
Other|U.S.InterventioAllocation 08-0204
Incidence oGuangdongAll 18 Years toPhase
65 Years
1 Â (Adult,10Older
Other|Indu
Adult)InterventioInterventi Ag-mRNA-D
JEV antibodMedical UnAll 18 Years and
Phase
older
Other|Indu
Adult) InterventioAllocation IXIARO-bo
To measureDynPort VaAll 18 Years toPhase
55 Years
2 Â (Adult) 402 Industry InterventioAllocation rF1V-02b
The percenUniversity All 9 Years andNot
older
Applic
Â (Child,
93582
Adult,
Other|U.S.InterventioAllocation
Older Adult) 13-2785
Change of Indian Ins All 18 Years toPhase
50 Years
4 Â (Adult)17 Other InterventioInterventi JEV SA14-1
Innate cel Mayo ClinicAll 65 Years and
Phase
older
4 Â (Older243 Adult)
Other|NIHInterventioAllocation 17-010601
The rate ofBeijing ChaAll 6 Months toPhase
35 Months
4 Â20000
(Child)
Other InterventioInterventi cycdc2016
Vaccine imm InternationAll 42 Days to Phase
49 Days1 Â (Child)372 Other InterventioAllocation POLIO ROT
seroconvers Sormland CAll 18 Years and
Phase
older
Other
Adult) InterventioAllocation Rombo - 2
Evaluation Novartis V All 18 Years and
Phase
older
Industry
Adult) InterventioAllocation V44P12S|2
Overall patTouro Unive All 18 Years to 64 Years Â (Adult)249 Other|InduObservatioObservatioM0611
Vaccine imm University All 18 Years and older Â (Adult,150 Older
Other
Adult) ObservatioObservatio17-5960
Incidence XEME Bioph All 18 Years and
Phase
older
Industry|NInterventioInterventi
Adult) NU 13H05|
Number ofMasonic CaAll 6 Months and
Not older
ApplicÂ (Child,68Adult,
OtherOlder InterventioAllocation
Adult) 2010NTLS
Vaccine Ef Janssen VaAll 18 Years toPhase
60 Years
3 Â (Adult)
3800 Industry InterventioAllocation CR108604|
Safety of Chinese PLAll 18 Years and
Phase
older
Other
Adult) InterventioAllocation LKSM001
Vaccine HeUniversity All 18 Years and
Notolder
Applic
Â (Adult,883Older
Other
Adult) InterventioAllocation H2016:390
EvaluationNovartis V All 18 Years and
Phase
older
Industry
Adult) InterventioAllocation V87P11|20
To DetermiUniversity All 18 Years and
Notolder
Applic
Â (Adult,
1021 Older
Other|NIHInterventioAllocation
Adult) HUM00155
SeroconverBoryung PhAll 16 Years and
Phase
older
3 Â (Child,253Adult,
Industry
Older Adult)
InterventioAllocation BR-HAV-CT
Immunologi Chiang MaiAll 18 Years and
Phase
older
Other
Adult) InterventioAllocation 4565
Number ofNovartis V All 18 Years and
Phase
older
4 Â (Adult,
1398 Older
Industry
Solicited a Meissa VaccAll 18 Years toPhase
40 Years
1 Â (Adult)20 Industry InterventioAllocation MV-003
Overall chaEmory UnivAll 18 Years toNot
50 Years
ApplicÂ (Adult)
850 Other InterventioAllocation IRB000872
PercentageNovartis V All 65 Years andPhase
older
2 Â (Older Adult)
63 Industry InterventioInterventi V70_32S|2
Serum neutrMedigen Va All 2 Years to 9 Years Â (Child) 312 Industry ObservatioObservatioFU-EV-21e
Number ofUniversity All 18 Weeks to Phase
19 Months
4 Â (Child)
278 Other InterventioAllocation MV/VV/He
to evaluateJiangsu ProAll 18 Years toPhase
49 Years
1 Â (Adult)110 Other|InduInterventioInterventi JSVCT019
To evaluateNovartis V All 18 Years andPhase
older
2 Â (Adult,138
Older
Industry
Adult) InterventioAllocation V71_19S
DetermineWashington All 18 Years toEarly
50 Years
PhasÂ (Adult)11 Other InterventioInterventi 2.02E+08
Changing inChulalongkAll 1 Year to 5Not
YearsApplic
Â (Child) 50 Other|InduInterventioInterventi IRB456/56
Incidence Hopital duAll 6 Months and older Â (Child,24 Adult,
Other|Indu
Older ObservatioObservatioNarco-H1N
Adult)
Number ofUniversity Female Child, AdulPhase 4 4193 Other InterventioAllocation HP-000495
GeometricPATH|InstitAll 18 Years toPhase
51 Years
2 Â (Adult)43 Other InterventioAllocation LAIV-H5N2
Acute (nighUniversity All 18 Years toNot
40 Years
ApplicÂ (Adult)16 Other InterventioAllocation MSD-IDREC
DeterminatUniversity All 18 Years andNotolder
Applic
Â (Adult,107
Older
Other
Adult) InterventioInterventi URMC 09-
Positive coChinese AcAll 8 Months to Phase
24 Months
2 Â 1080
(Child)
Other InterventioAllocation 2015L0019
Vaccine ImmUniversity All 18 Years andPhase
older
3 Â (Adult,173
Older
Other
Adult) InterventioAllocation UHNTID00
PercentageColumbia UAll 6 Months to Not8 Years
ApplicÂ (Child)
2086 Other|NIHInterventioAllocation AAAR4101
AssessmentInternatio All 18 Years toPhase
45 Years
2|PhÂ (Adult)88 Other InterventioAllocation PR-17068
ProportionMahidol UnAll 18 Years toPhase
49 Years
2 Â (Adult)60 Other InterventioInterventi GPO Avian
The percentCedarville All up to 6 Years Â (Child) 347 Other ObservatioObservatioIRB #997
Immunogeni Peking UniAll 18 Years toPhase
25 Years
4 Â (Adult)353 Other|InduInterventioAllocation HepB-2014
Evaluation Novartis V All 18 Years andPhase
older
2 Â (Adult,130
Older
Industry
Adult) InterventioAllocation V71_10S|2
PercentageNovartis V All 48 MonthsPhase
to 60 Months
3 Â 805
(Child)
Industry InterventioAllocation V72P12E2|
PercentageNovartis V All 7 Years to 15
Phase
Years
4 Â (Child)465 Industry InterventioAllocation V59P20E1
GeometricNovartis
M V All 18 Years andPhase
older
3 Â (Adult,135
Older
Industry
Adult) InterventioInterventi V58P1S|20
HemagglutinSinovac BioAll 6 Months to Phase
85 Years
Industry
OlderInterventioInterventi
Adult) PRO-INF-4
OccurrenceMahidol UnFemale 25 Years to 53 Years Â (Adult)964 Other ObservatioObservatioHPV 021|2
Seasonal inMonroe Cou All 4 Years to 13
NotYears
Applic
Â (Child)
25366 Other InterventioAllocation 439262
older
2 Â (Older Adult)
Immune res The Immuno All 9 Months to Phase
50 Years
4 Â (Child,
4761Adult)
Other InterventioInterventi ASCLIN 00
Frequency National
o InAll 18 Years toPhase
50 Years
1 Â (Adult)18 NIH InterventioAllocation CIR 253
Incidence Chinese AcAll 6 Months to Phase
71 Months
4 Â20770
(Child)
Other InterventioInterventi CY2016KM
Antibody poShandong PAll 6 Months to Phase
12 Months
4 Â 1944
(Child)
Other InterventioAllocation Shandong
Number forU.S. Army All 18 Years toPhase
65 Years
2 Â (Adult,
1000Older
U.S. Fed
Adult)InterventioInterventi A-15207.a|
change froCenters fo All 12 Years toNot
60 Years
ApplicÂ (Child,
207Adult)
Other InterventioInterventi BJCDCWJ2
Time of ocMedicago All 18 Years toPhase
64 Years
3 Â (Adult)
10137 Industry InterventioAllocation CP-PRO-QV
Carriage R Centers fo All 2 Years to 5Not
Years
Applic
Â (Child)3281 Other InterventioAllocation BJCDCWJ2
Non-inferi David H. C All 65 Years andPhase
older
4 Â (Older500
Adult)
Other|U.S.InterventioAllocation 10-27-29|
Change in vVirginia C All 19 Years toNot
64 Years
ApplicÂ (Adult)
431 Other InterventioInterventi HM200142
Frequency National InAll 18 Years toPhase
50 Years
Local and sbrian.wardAll 18 Years toPhase
49 Years
4 Â (Adult)80 Other InterventioAllocation RI-MUHC:
The primaryDynPort VaAll 18 Years toPhase
55 Years
2 Â (Adult)440 Industry InterventioAllocation:rBV A/B-02
SeroconversWu Jiang|BAll 1 Year to 65Not
Years
Applic
Â (Child, 537
Adult,
Other
Older Adult)
InterventioAllocation BJCDCWJ2
To asses thPT Bio Far All 6 Months to Phase
11 Years
2|PhÂ (Child)
405 Industry InterventioInterventi Influenza
Local reac PT Bio Far All 6 Months to Phase
40 Years
2 Â (Child,600Adult)
Industry InterventioAllocation Typhoid 0
To evaluat Jiangsu ProAll 2 Years to 70
Phase
Years
3 Â (Child,
1200
Adult,
Other|Indu
Older Adult)
InterventioAllocation 20080808
SeroconverBoryung PhAll 12 MonthsPhase
to 23 Months
3 Â 119
(Child)
Industry InterventioAllocation BR- HAV-CT
Rates of s University All 18 Years andPhase
older4 Â (Adult, 73
Older
Other
Adult) InterventioAllocation 15-9503
CompletionUniversity All 1 Month to 12 Months Â (Child)321 Other ObservatioObservatio12-1144|O
The express AssistanceAll 18 Years andPhase
Older
Other
Adult) InterventioAllocation P090104
older3 Â (Adult,126
Older
Industry
Adult) InterventioInterventi V58_32S|2
Number ofNational
P CaAll 18 Years toPhase
100 Years
1 Â (Adult, 34 Older
NIH Adult) InterventioInterventi 120056|12
concentratiSinovac BioAll 16 Years toPhase
25 Years
4 Â (Child,239
Adult)
Industry InterventioAllocation PRO-HA-40
65 Years
1 Â (Adult,10Older
Other|Indu
Adult)InterventioInterventi Ag-mRNA-C
PercentageNovartis V All 18 Years toPhase
64 Years
2 Â (Adult)979 Industry|UInterventioAllocation V89_04
The rate ofBeijing ChaAll 3 Years to 60
Phase
Years1 Â (Child, Adult)
40 Other InterventioAllocation cycdc2015
Response tUniversity All 18 Years andPhase
Older
Other
PercentagePATH All 9 Months to Phase
11 Months
4 Â (Child)
482 Other InterventioAllocation HS677
Incidence Agenus IncAll 18 Years andPhase
older1 Â (Adult, Older
3 Industry
Adult) InterventioInterventi C-600-01
older3 Â (Adult,
2654
Older
Industry
Adult) InterventioAllocation V58P4
the adapti Singapore All 30 Years toPhase
50 Years
2 Â (Adult)70 Other InterventioAllocation YF-Statin-0
The effect Chinese AcAll 6 Months to Phase
71 Months
4 Â40724
(Child)
Other InterventioInterventi 2016-012-
Number ofEdward HirAll 18 Years andPhase
Older
Other
Adult) InterventioInterventi CTN-0505|
NeutralizatSinovac BioAll 6 Months to Phase
11 Months
2 Â (Child)
0 Industry InterventioAllocation EV71-1001-
Safety of Medigen Va All 20 Years toPhase
60 Years
1|Ph
Â (Adult)
200 Industry InterventioAllocation CT-MV-21
immune res Kenya MediAll 9 Years to 14 Years Â (Child)179 Other|InduObservatioObservatio(MISP)IISP
Antibody rNovartis V All 65 Years andPhase
older2 Â (Older Adult)
56 Industry InterventioAllocation V70P5S|20
HBsAb leveMahidol UnAll 18 Years toPhase
80 Years
3 Â (Adult,97Older
OtherAdult)InterventioAllocation 13/2560(E
Incidence oBeijing CenAll 4 Years to 12
Phase
Years4 Â (Child)
50000 Other InterventioAllocation BJCDPC-8
PercentageNovartis V All 6 Months to Phase
8 Months
2 Â (Child)
60 Industry InterventioAllocation V72P9|Eud
Solicited l Il-Yang PhaAll 18 Years andPhase
Older
Industry
Adult) InterventioInterventi IY_IFEZ_A
Antibody tSanofi Pas All 2 Years to 9Phase
Years3Â (Child) 999 Industry InterventioAllocation MET35|U11
Safety: Oc U.S. Army All 18 Years toPhase
65 Years
U.S. Fed
Adult)InterventioInterventi S-13-04|I
Protective Malaria VaAll 18 Years toPhase
45 Years
2 Â (Adult)32 Other InterventioAllocation:2304-493-
Mortality|Bandim Hea All 4 Months to Phase
6 Months
4 Â (Child)
3750 Other InterventioAllocation OPTIMUNIS
Change in University Female 16 Years andPhase
older3 Â (Child, Adult,
75 Other
Older Adult)
InterventioAllocation Merck-MIS
Under-immu Columbia UAll up to 17 Years
Not ÂApplic
(Child) 15348 Other|U.S.InterventioAllocation AAAP6516|
17 Years
3 Â (Child)264 Industry InterventioAllocation V72_42|20
The Effica Novartis V All 18 Years toPhase
40 Years
1 Â (Adult)63 Industry InterventioAllocation V99P2|200
HemagglutiNovartis|NAll 50 Years andPhase
older4 Â (Adult,
2902
Older
Industry
Adult) InterventioAllocation V71_22
Safety of Shenzhen G All 6 Months to Phase
80 Years
1 Â (Child, 10Adult,
OtherOlderInterventioInterventi
Adult) GIMI-IRB-
Vaccine AdUniversity All 26 Years andNotolder
Applic
Â (Adult,
1800
Older
Other|Indu
Adult) InterventioAllocation UNewMexi
Systemic aMount SinaAll 18 Years toPhase
69 Years
4 Â (Adult,11Older
OtherAdult)InterventioAllocation 14-0808
Number ofUniversity All 18 Years toPhase
45 Years
1 Â (Adult)26 Other InterventioAllocation HP-000497
SeroconverInternationAll 6 Months to Phase
45 Years
3 Â (Child,
1800Adult)
Other|InduInterventioAllocation IVI T003
Number ofEdward HirAll 18 Years toPhase
80 Years
2 Â (Adult,32Older
Other|NIHInterventioInterventi
Adult) CDR000041
PercentageNovartis|NAll 1 Year and Phase
older Â3 (Child, Adult,
885 Industry
Older Adult)
InterventioAllocation V49_30|20
The proport The UniverFemale 18 Years andNotolder
Applic
Â (Adult,321
Older
Other
Adult) InterventioAllocation PIV-INT-1
Change in National InAll 21 Years toPhase
45 Years
2 Â (Adult)50 NIH|OtherInterventioAllocation DAIT HIPC
Kinetics ofImperial C All 6 Years to 16
Phase
Years4 Â (Child) 12 Other InterventioInterventi 18SM4658|
Vaccine AdEast CaroliAll 9 Years to 17
NotYears
Applic
Â (Child)522 Other InterventioInterventi Merck-509
Change in Centre HosAll 65 Years andNotolder
Applic
Â (Older402
Adult)
Other InterventioAllocation CHM-2017-
SeroresponJN-InternaAll 18 Years toPhase
55 Years
2 Â (Adult)525 Industry InterventioAllocation JN-NM-002
Safety and Children's All 6 Weeks toPhase
18 Months
1 Â (Child)
8 Other|InduInterventioAllocation Merck IISP
Anti-polio Internatio All 1 Year to 3Phase
Years Â3 (Child) 579 Other|U.S.InterventioAllocation PR-17120
evaluate thNovartis V All 18 Years toPhase
84 Years
Industry
Adult)InterventioAllocation V78P5S|20
To monitorInstituto NFemale 9 Years to 24
Phase
Years4 Â (Child,
2000
Adult)
Other InterventioAllocation 883
Safety and Vaxart All 18 Years toPhase
49 Years
1 Â (Adult)54 Industry InterventioAllocation VXA03-001
Number ofMahidol UnAll 18 Years toPhase
49 Years
1|Ph
Â (Adult)
340 Other InterventioAllocation GPO Tri Fl
Adverse Eve Mayo CliniFemale 18 Years and
Phase
older1|Ph
Â (Adult, 43
Older
Other
Adult) InterventioInterventi 16-01056
Levels of Johns HopkAll 18 Years toNot
50 Years
ApplicÂ (Adult)20 Other InterventioAllocation CIR 281
Number ofUniversity
p All 2 Years to 60
NotYears
Applic
Â (Child,600
Adult)
Other InterventioAllocation VFAReuma
Odds ratio Jiangsu ProAll 6 Months toPhase
35 Months
4 Â40000
(Child)
Other|InduInterventioInterventi JSVCT048
EvaluationNovartis V All 18 Years toPhase
60 Years
Evaluation Novartis|NAll 18 Years and
Phase
Older
Industry
Initiation University All 11 Years toNot
14 Years
ApplicÂ (Child)
37003 Other|NIHInterventioAllocation 17-001559
SeroconverVanderbiltAll 18 Years to 45 Years Â (Adult)10 Other ObservatioObservatio 181619
Positive a University All 18 Years toPhase
60 Years
4 Â (Adult)75 Other InterventioAllocation 2.02E+09
Change in University Female 18 Years toPhase
50 Years
4 Â (Adult)45 Other InterventioAllocation KAVI-VZV-
The PercenSeqirus All 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation CSLCT-ASU
OccurrenceJiangsu ProAll 16 Years toPhase
65 Years
Other|Indu
Older InterventioAllocation
Adult) JSVCT025
the occurr Sichuan CeAll 8 Months toPhase
9 Months
4 Â (Child)
2800 Other|InduInterventioAllocation cnbg-001
HPV vaccinIndiana UnMale 18 Years to 26 Years Â (Adult)
2000 Other|InduObservatioObservatioYMSM HPV v
PercentageNovartis V All 65 Years and
Phase
Safety CMV Resear Male 30 Years toPhase
50 Years
1 Â (Adult)36 Other InterventioInterventi 1
The changeUniversity All 18 Years toPhase
25 Years
4 Â (Adult)15 Other InterventioInterventi 19-1145
Antibody TiMerck ShaAll 25 Years and older Â (Adult,174Older
Industry
Adult) ObservatioObservatio0000-131|
Effectiven NorwegianFemale 16 Years toPhase
39 Years
4 Â (Child,
19460Adult)
24 Years
3 Â (Adult)
2968 Industry InterventioAllocation V72_29
Change in IU.S. Army All 18 Years and
Phase
0 U.S.Adult)
Fed InterventioInterventi S-11-19|F
Safety profVanderbiltAll 3 Years to 17
Phase
Years1 Â (Child) 38 Other|InduInterventioAllocation 111069 - I
DetermininRichard Zi All 4 Years to 20
Phase
Years4 Â (Child,166
Adult)
Other|U.S.InterventioAllocation PRO18050
Comparison Chinese AcAll 2 Months toPhase
4 Months
2|Ph Â (Child)
1200 Other InterventioAllocation Yangjingsi
ConcentratGlaxoSmithFemale 18 Years toPhase
40 Years
2 Â (Adult)
1053 Industry InterventioAllocation 205220|V9
evaluate thNovartis|NAll 18 Years and
Phase
Older
Industry
PT immunog Public HealAll 16 Years toPhase
45 Years
4 Â (Child,366
Adult)
Other InterventioAllocation iMAP2
Number ofNovartis|NAll 18 Years and
Phase
older3 Â (Adult,
3647
Older
Industry
Safety of Baylor ReseFemale 18 Years toPhase
80 Years
1|Ph
Â (Adult,10Older
Anti-HBs s Suping Wan All 19 Years toPhase
70 Years
OtherAdult)InterventioAllocation 2012ZX100
GeometricSanofi
M Pas All 6 Months toPhase
17 Years
3 Â (Child)301 Industry InterventioAllocation GQM0001
Number ofUniversity All 18 Years and
Phase
older1|Ph
Â (Adult,150
Older
Other
PercentageUniversity All 18 Years and
Phase
Older
Other
Adult) InterventioAllocation HP-000815
18 Years
3 Â (Child,389
Adult)
Industry InterventioAllocation V59P13E1
GeometricNovartis V All 18 Years toPhase
64 Years
3 Â (Adult)252 Industry InterventioAllocation V59_53|20
Solicited l Il-Yang PhaMale 20 Years toPhase
55 Years
1 Â (Adult)44 Industry InterventioAllocation IY_IFEZ_10
Immunogenic Novartis|NAll 18 Years and
Phase
Older
Industry
Immunogenic AdimmuneAll 20 Years toPhase
60 Years
1|Ph
Â (Adult)39 Industry InterventioInterventi FLUW001A
A four-fol University All 50 Years and
Early
older
Phas
Â (Adult, 33
Older
Other
Patient Im M.D. AnderAll 18 Years and
Phase
older
2 Â (Adult, 12
Older
Other|Indu
Phase
older
3 Â (Adult,126
Older
Industry
Does vacciUniversite Female 18 Years toPhase
40 Years
4 Â (Adult)99 Other InterventioAllocation cev001|20
seroconvers Lars RomboAll 18 Years and
Phase
older
2 Â (Adult, 68
Older
Other
Adult) InterventioInterventi EU 2009-0
Non-inferi University All 65 Years and
Phase
older
4 Â (Older205Adult)
Other|InduInterventioAllocation PRO10110
SeroconverAlba MariaAll 12 MonthsPhase
to 24 Months
4 Â 851
(Child)
Other|U.S.InterventioAllocation PAHO-2014
Anti-HBs s Suping Wan All 18 Years toPhase
70 Years
Safety and University All 18 Years toPhase
65 Years
1 Â (Adult,18Older
OtherAdult)InterventioAllocation RAB001
HPV Vaccina Children's All 11 Years and
Notolder
Applic
Â (Child,110
Adult,
Other
Older Adult)
InterventioAllocation IRB 14-01
Type and du Pravin KauAll 18 Years and
Phase
older
1 Â (Adult,100
Older
Other
Adult) InterventioAllocation OSU-09138
Incorrect UniversidaFemale 18 Years toPhase
30 Years
4 Â (Adult)200 Other InterventioAllocation HPV vaccin
To evaluateNovartis V All 18 Years and
Phase
older
2 Â (Adult,125
Older
Industry
Number and Shanxi MedAll 18 Years toPhase
70 Years
Titer leve Yisheng Bi All 21 Years toPhase
65 Years
Industry
Adult)InterventioAllocation RV001-II
Frequency National
o I All 18 Years toPhase
70 Years
NIH|Indust
Adult)InterventioAllocation VRC 701
Frequency Oslo UniverFemale 18 Years toPhase
75 Years
1|PhÂ (Adult, 5Older
OtherAdult)InterventioInterventi DC-006
Solicited l Xiamen UniAll 18 Years toPhase
45 Years
1 Â (Adult)24 Other|InduInterventioAllocation HPV-PRO-0
The Geomet Saad JamshAll 18 Years toPhase
64 Years
2 Â (Adult)105 Other|InduInterventioAllocation CIC 1336-B
seroconverJiangsu Pr All 3 Months toPhase
5 Years
3 Â (Child)
1950 Other InterventioAllocation JSVCT028
Phase
older
2 Â (Adult,126
Older
Industry
50 Years
Increase i Interactiv All up to 3 Months
Not Applic
Â (Child) 1445 Other InterventioAllocation 027562-74
methods ofGamaleya R All 18 Years toPhase
40 Years
1|PhÂ (Adult)50 Other InterventioAllocation GamLPV-0
The PercenNovartis V All 65 Years and
Phase
older
2 Â (Older
1393Adult)
Industry|UInterventioAllocation V89_13
Carriage o Kim MulholAll 2 Months toPhase
10 Weeks
2|Ph Â (Child)
2501 Other InterventioAllocation HREC3602
Elevation oHospital UnFemale 18 Years toPhase
38 Years
2 Â (Adult)204 Other InterventioAllocation EN11-009
Age specifiLifespan HAll 1 Month to 24 Months Â (Child)
1800 Other ObservatioObservatio 2
32 Years
4 Â (Adult)20 Other InterventioInterventi URMC 09-
number ofAssiut
c UnivAll 6 Months toNot5 Years
ApplicÂ (Child)
100 Other InterventioInterventi bcgvaccina
To evaluateNovartis V All 6 Months toPhase
35 Months
2 Â (Child)
281 Industry InterventioAllocation V70P2|200
number ofButantan
p InAll 18 Years to 130 Years Â (Adult,
403 Older
OtherAdult)ObservatioObservatioFLU-06-IB
To evaluateUniversity All 12 MonthsPhase
to 13 Months
4 Â 452
(Child)
Other InterventioAllocation H07-02175
Evaluate t Beijing ChaAll 9 Years to 30
Phase
Years
1 Â (Child,135
Adult)
Other InterventioAllocation cycdc2016
Rates of H Mayo ClinicAll 11 Years toNot
12 Years
ApplicÂ (Child)
Percent of Vabiotech|All 6 Weeks toNot
12 Weeks
Applic Â (Child)
222 Industry InterventioInterventi VABIOTECH
To evaluateNational InAll 18 Years toPhase
50 Years
1 Â (Adult)40 NIH|OtherInterventioAllocation RV 507|WR
Initiation Washington All 9 Years andNot
older
Applic
Â (Child,
10900
Adult,
Older Adult) 201911030
Incidence rPT Bio Far All 18 Years toPhase
40 Years
1 Â (Adult)25 Industry InterventioInterventi Hib 0110
Incidence LimmaTechAll 60 Years toPhase
70 Years
1 Â (Adult,72Older
Industry
Adult)InterventioAllocation Pneumo1
Number ofEmory
p UniveAll Child, AdulPhase 4 12 Other|NIHInterventioAllocation IRB001008
Number OfNovartis V All 4 Years to 17
Phase
Years
3 Â (Child)
2055 Industry InterventioAllocation V58_31|U1
Overall ti Changhai HAll 20 Years toPhase
75 Years
1 Â (Adult,60Older
OtherAdult)InterventioAllocation ChanghaiH
Number ofStemirna Th All 18 Years toNot
75 Years
ApplicÂ (Adult,24Older
Industry|OInterventioInterventi
Adult) STZD-1801
Phase
older
1|Ph
Â (Adult, 34
Older
Adult) URMC 09-
older
2 Â (Adult,133
Older
Industry
Age-appropr Vanderbilt All 18 Years andNotolder
Applic
Â (Adult,355
Older
Adult) 171793|1R
Changes inImmunitorAll Child, AdulPhase 1|Ph 20 Industry InterventioInterventi 3
Number ofGlaxoSmithAll 18 Years andPhase
older
3 Â (Adult, 50
Older
Industry
Tolerance University All 18 Years toPhase
75 Years
1 Â (Adult, 0Older
Other Adult)InterventioAllocation 13.0376
Initiation Emory Unive All 11 Years toNot
12 Years
ApplicÂ (Child)
168 Other|NIHInterventioAllocation IRB000903
SeroprotecVBI VaccineAll 18 Years andPhase
older
3 Â (Adult,
1609
Older
Industry
Adult) InterventioAllocation Sci-B-Vac-
Number ofNovartis
S VaAll 18 Years andPhase
older
3 Â (Adult,
2235
Older
Industry|OInterventioAllocation
Adult) V58P4E1|E
Compare thUniversity Female 18 Years toPhase
39 Years
4 Â (Adult)150 Other InterventioInterventi MatFlu_HI
Antibody reHospital UnAll 18 Years andPhase
older
3 Â (Adult,220
Older
Other
Adult) InterventioAllocation Maria Pen
Immune res Centers fo All 9 Months to Phase
23 Months
4 Â 1788
(Child)
U.S. Fed|OInterventioAllocation 2017-197
humoral ant University All 18 Years toPhase
55 Years
4 Â (Adult)301 Other InterventioInterventi TIV_HIV_T
Safety andPrecision LAll 18 Years andPhase
older
1 Â (Adult, 20
Older
Industry
Adult) InterventioInterventi ICT-121 DC
Safety and Internatio All 12 MonthsPhase
to 45 Years
2 Â (Child,
330 Other
Adult) InterventioAllocation PR-09047
The primary NewLink Ge All 18 Years andPhase
older
2 Â (Adult, 73
Older
Industry
Adult) InterventioAllocation NLG0205|
Number ofAuburn UniAll 18 Years andNotolder
Applic
Â (Adult,120
Older
Other|Indu
Adult) InterventioAllocation MISP5338
Incidence oNational InFemale 18 Years toPhase
38 Years
2 Â (Adult)900 NIH InterventioAllocation 999919113
Number ofU.S.e Army All 18 Years toPhase
65 Years
U.S. Fed
Adult)InterventioInterventi S-15-23|F
PercentageU.S. Army All 6 Years to 9Phase
Years1|Ph
Â (Child) 7 U.S. Fed|I InterventioInterventi A-13227|G
To evaluateNovartis V All 18 MonthsPhase
and older
Industry
OlderInterventioAllocation
Adult) V111_04
Change froUniversity All Child, AdulNot Applic 3417 Other InterventioAllocation 11-1041
The effica Sinovac BioAll 6 Months to Phase
71 Months
4 Â15500
(Child)
Industry InterventioAllocation PRO-EV71-
Immunogenic Jiangsu Pr All 3 Months to Phase
5 Months
3 Â (Child)
65 Years
1 Â (Adult,10Older
Other|Indu
Adult)InterventioInterventi Ag-mRNA-C
Phase
Years
3 Â (Child)
1500 Industry InterventioAllocation V59P10
To determiAlbert B. All 18 Years toPhase
45 Years
1 Â (Adult) 9 Other InterventioAllocation SVI-06-02
6 Months
4 Â (Child)
4050 Other InterventioAllocation OPTIMUNI
Fold-diffe St George'sAll 3 Years to 4 Years Â (Child) 85 Other ObservatioObservatio 17.0269
Assess the Chinese AcAll 20 Years to 50 Years Â (Adult)20 Other|InduObservatioObservatioImmunity_
Antibody CGlaxoSmithAll 6 Weeks toPhase
12 Weeks
3 Â (Child)230 Industry InterventioAllocation 109661|20
Vaccine Ef Imperial C All 2 Years to 18
Phase
Years
4 Â (Child,276
Adult)
Other InterventioAllocation 15SM2801|
Safety of Washington Female 18 Years andPhase
older
1 Â (Adult, 18
Older
Other
Adult) InterventioInterventi 2.02E+08
To evaluateBeijing CenAll 1 Year to 12Phase
Years4Â (Child)1200 Other InterventioAllocation BJCDPC-2
Total All-c Insight Th All 65 Years andPhase
older
4 Â (Older
2957
Adult)
Other InterventioAllocation GRC75-HD
Number ofNovartis V All 18 Years toPhase
49 Years
3 Â (Adult)
18 Years
Industry InterventioAllocation V102_02E1
PercentageNovartis|NAll 65 Years andPhase
older
2 Â (Older Adult)
Immunogeni National CaAll 55 Years toPhase
80 Years
1 Â (Adult,50Older
NIH Adult)InterventioInterventi NCI-2017-
Clinic HPV University All 11 Years toNot
17 Years
ApplicÂ (Child)
300 Other InterventioInterventi 1330087
Evaluate seBeijing ChaAll 3 Years to 60
Phase
Years
3 Â (Child,
2400
Adult)
Number ofUniversity All 6 Months to Not18Applic
Years Â 100000
(Child, Adult)
GeometricNovartis V Female 18 Years toPhase
40 Years
2 Â (Adult)270 Industry InterventioAllocation V98_05
Change From University Male 18 Years toPhase
25 Years
4 Â (Adult)90 Other InterventioAllocation 11083108|
The incide Sinovac BioAll 6 Months to 35 Months Â10077 (Child)
Industry ObservatioObservatioPRO-EV71-
The PercenSeqirus All 18 Years andPhase
older
4 Â (Adult,120
Older
Industry
Serologic RShahid BehAll 20 Years to 60 Years Â (Adult)49 Other ObservatioObservatioSBMU 87-0
Number ofHaEmek
p Med
All 50 Years and
Phase
older
4 Â (Adult,250
Older
Other
Adult) InterventioAllocation 142-016-E
Antibody reUniversity All 40 Years toPhase
80 Years
4 Â (Adult,16Older
Other|Indu
Adult)InterventioAllocation H17-00175
Humoral ImUniversity All 18 Years to 65 Years Â (Adult,126Older
OtherAdult)ObservatioObservatioOVG2016/
Antibody tSanofi Pas All 46 MonthsPhase
to 61 Months
3 Â (Child)
91 Industry InterventioInterventi MET62|201
PercentageEmory UnivAll 18 Years and
Phase
older
1 Â (Adult,100
Older
Other
Adult) InterventioInterventi IRB001010
Number ofNational InAll 18 Years and
Phase
older
2 Â (Adult,406
Older
NIHAdult) InterventioAllocation 09-0053|N
Immunogeni Serum InstiAll 6 Weeks toPhase
8 Weeks
2|PhÂ (Child)
1500 Industry InterventioAllocation ROTA:06
Levels of Sanofi Pas All 12 MonthsPhase
to 23 Months
2 Â 200
(Child)
Industry InterventioAllocation MET54|201
The primarOlogy BiosAll 18 Years toPhase
49 Years
1 Â (Adult) 7 Industry InterventioAllocation 2009-GEL-
25 Years
Industry InterventioAllocation V102_03|2
Influenza vUniversity All Child, AdulNot Applic 17650 Other|U.S.InterventioAllocation 5R18HS021
Change fromU.S. Army All 18 Years toPhase
49 Years
1 Â (Adult)31 U.S. Fed|I InterventioAllocation A-17088|W
Number ofInstitute All 18 Years toPhase
65 Years
OtherAdult)InterventioAllocation Torlak-300
To evaluateJiangsu ProAll 18 Years toPhase
55 Years
2 Â (Adult)240 Other|InduInterventioAllocation JSVCT017
49 Years
2 Â (Adult)613 Industry|OInterventioAllocation V58P5
PercentageSanofi Pas All 12 MonthsPhase
to 23 Months
3 Â 918
(Child)
Industry InterventioAllocation MET51|U11
Post-vaccinFundaciÃ³nAll 18 Years toPhase
65 Years
OtherAdult)InterventioAllocation HEPATOTR
Phase
older
2 Â (Older Adult)
64 Industry InterventioInterventi V70P7S|20
Feasibilit McMaster AUll 18 Years and
Phase
older
4 Â (Adult,107
Older
Other
Adult) InterventioAllocation RCT IVVE Pi
Change in Emory UnivAll 20 Years toPhase
30 Years
4 Â (Adult)20 Other InterventioAllocation IRB000901
To evaluat National InAll 18 Years toPhase
49 Years
1 Â (Adult)62 NIH|IndustInterventioAllocation 140011|14
Evaluation Novartis V All 18 Years and
Phase
older
2 Â (Adult,143
Older
Industry
Evaluate seBeijing ChaAll 2 Years to 50
Phase
Years
3 Â (Child,
1200
Adult)
To examineEmory Unive Female 18 Years to 30 Years Â (Adult)203 Other|NIHObservatioTime PerspIRB000461
Comparison University All 18 Years toEarly
80 Years
PhasÂ (Adult, 0Older
OtherAdult)InterventioInterventi 1124197
Safety asseButantan InAll 18 Years and older Â (Adult, 63 Older
Other
Adult) ObservatioObservatioFLU-01-IB
GeometricSanofi
M Pas All 18 Years toPhase
64 Years
3 Â (Adult)
3360 Industry InterventioAllocation QID01|U11
Vaccine Ef University Male 18 Years toPhase
50 Years
2 Â (Adult)120 Other InterventioAllocation VAC047
On-time CoPlanned PaFemale 19 Years toNot
26 Years
ApplicÂ (Adult)
365 Other|InduInterventioAllocation PPFA-Merc
The study oChinese AcAll 60 Days to Phase
90 Days3 Â (Child)
1200 Other InterventioAllocation IMBCAMS-
ProportionYale UniverFemale 15 Years toNot
26 Years
ApplicÂ (Child,35
Adult)
Other InterventioAllocation 2E+09
Safety of ENational InAll 18 Years toPhase
50 Years
1 Â (Adult)108 NIH InterventioAllocation RV 247
Safety ass Vaxine Pty All 18 Years and
Phase
older
1|Ph
Â (Adult, 40
Older
Adult) HBV003
To determinSanaria IncAll 18 Years toPhase
50 Years
1 Â (Adult)80 Industry|OInterventioAllocation Sanaria.2
Number ofNovartis V All 12 MonthsPhase
to 10 Years
2 Â (Child)
Treatment-rCapital MeAll 18 Years toEarly
75 Years
PhasÂ (Adult,10Older
OtherAdult)InterventioInterventi TCL DC Vac
Vaccine ImButantan InAll 18 Years and older Â (Adult,120 Older
Other
Safety andNovartis V All 18 Years and
Phase
older
2 Â (Adult,125
Older
Industry
Protective Epicentre Female 14 Years toNot
49 Years
ApplicÂ (Child,
2129 Adult)
Other InterventioAllocation Epicentre/
Phase
older
4 Â (Adult,208
Older
Industry
Adult) InterventioAllocation GRC55|U11
Immunogeni University Female 18 Years toPhase
39 Years
4 Â (Adult)105 Other InterventioInterventi MatFlu_HI
Carriage DArto PalmuAll 3 Years to 7 Years Â (Child)2341 Other|InduObservatioObservatioTHL/1843/
Post vaccinFluart InnoAll 18 Years and
Phase
older
4 Â (Adult,121
Older
Industry
Adult) InterventioAllocation FluvalAB-
Number ofU.S. Army All 18 Years toPhase
65 Years
U.S. Fed
Adult)InterventioInterventi S-16-12
18 Years
2 Â (Child, 305Adult)
Industry InterventioAllocation V102_16
Influenza hStony Brook All 3 Years to 22
Phase
Years
2 Â (Child, Adult)
To evaluateChinese AcAll 36 MonthsPhase
and older
OtherOlderInterventioAllocation
Adult) IMBCAMS-
New immuni University All 18 Years and
Notolder
Applic
Â (Adult,
3783
Older
Adult) 12-0378
Immunogeni H. Lee MofAll 18 Years and
Phase
older
Adult) MCC-1911
Change from University Female Child, AdulPhase 1 10 Other|InduInterventioInterventi OLIVIA-UM
PersistenceNovartis V All 12 MonthsPhase
to 13 Months
4 Â (Child)
33 Industry InterventioAllocation M14P5E1|I
Number ofUniversity All 9 Years andPhase
older4Â (Child, Adult,
300 Other
Older Adult)
InterventioAllocation H3N2Vacci
Antibody rNovartis V All 18 Years and
Phase
older
Industry
Number ofInova
p HealAll 18 Years toPhase
70 Years
4 Â (Adult,62Older
OtherAdult)InterventioAllocation IFH201320
Number ofInternatio All 1 Year and Not
older
Applic
Â (Child,
240000
Adult,Other
Older Adult)
InterventioAllocation PR-10061
Number ofColumbia UAll 6 Months and
Not older
ApplicÂ (Child,
400Adult,
Adult) AAAQ9636
Rate of se Centre Hosp Female 15 Years toPhase
40 Years
Other InterventioAllocation CE/17-12-
The primary NewLink Ge All 18 Years and
Phase
older
2 Â (Adult, Older
9 Industry
19 Years
2|PhÂ (Child,
817Adult)
Vaccine re Boryung PhAll 7 Weeks toPhase
10 Weeks
3 Â (Child) 476 Industry InterventioAllocation BR-DTPP-C
Local and National InAll 18 Years toPhase
50 Years
1 Â (Adult)24 NIH InterventioAllocation Ad26.ENVA
Immunogeni Centers forAll 18 MonthsPhase
to 6 Years
4 Â (Child) 873 Other|InduInterventioAllocation BJCDCWJ2
CompletionUniversity All 6 Weeks toNot
6 Months
Applic Â (Child)
720 Other|NIHInterventioAllocation 14-2170|1
Number ofSidney KimAll 18 Years toPhase
75 Years
1 Â (Adult, 2Older
Other|NIH|
Adult)InterventioAllocation J11129|P5
Seroconvers University All 18 Years toNot
59 Years
ApplicÂ (Adult)
229 Other InterventioAllocation KUOA-02
Number ofSanofi Pas All 6 Months toPhase
8 Years
4 Â (Child)60 Industry InterventioAllocation GRC49|U11
Safety of r Institute o All 5 Years andNot
older
Applic
Â (Child, Adult,
120 Other|Indu
Older Adult)
InterventioInterventi VX-2015.0
ImmunizatiRobert FerAll 18 Years and
Phase
older
1 Â (Adult, Older
0 Other|Indu
proportionHospices CAll 18 Years and
Notolder
Applic
Â (Adult,100
Older
Other|Indu
Adult) InterventioInterventi 69HCL17_0
To assess tUniversity All 48 MonthsNotto 72
Applic
Months Â (Child)
40 Other InterventioAllocation FluPRINT
Change in UConn HeaAll 65 Years and
Phase
older
1 Â (Older Adult)
40 Other InterventioAllocation 19-205-2|
SeroconverU.S. Army All 18 Years toPhase
49 Years
2 Â (Adult) 132 U.S. Fed|I InterventioAllocation S-14-01|2
Influenza vEmory UnivFemale 18 Years toNot
50 Years
ApplicÂ (Adult)
To assess tUniversity All 18 Years toPhase
45 Years
1 Â (Adult)51 Other|NIHInterventioAllocation HP-000450
To verify t China Nati All 18 MonthsPhase
to 24 Months
4 Â 300
(Child)
Industry|OInterventioAllocation 911100001
PercentageNational InAll 12 Years and
Phase
older
NIHOlder Adult)
InterventioAllocation DAIT-AAIB-
Pneumococc The JacksoAll 65 Years and
Notolder
Applic
Â (Older Adult)
40 Other InterventioAllocation 16-071J-1
Primary vaCOL GeorgeAll 18 Years and
Phase
older
1|Ph
Â (Adult, 39
Older
U.S.Adult)
Fed|OInterventioAllocation 2013-0139
Safety of National InAll 18 Years toPhase
50 Years
1 Â (Adult) 112 NIH InterventioAllocation CIR 279
Recommende City of HopFemale 18 Years and
Phase
older
Adult) 13373|NCI
Change in Boston Med All 50 Years and
Phase
older
Other
Adult) InterventioAllocation H-37673
Change in tUniversity Female 15 Years and
Notolder
Applic
Â (Child,
97087
Adult,
Older Adult) 11-1149|U
Incidence PT Bio Far All 6 Weeks toPhase
11 Weeks
1 Â (Child) 30 Industry InterventioInterventi Penta 0111
Incidence oNational InAll 6 Months toPhase
35 Months
1 Â (Child)
243 NIH InterventioAllocation 09-0018|N
ProportionUniversity All 12 MonthsPhase
to 13 Months
3 Â 178
(Child)
Other InterventioAllocation OVG 2011/
To evaluat University All 20 Years toPhase
59 Years
2 Â (Adult) 324 Other|InduInterventioAllocation H10-01356
Number ofWeill
p MedicMale 20 Years toPhase
50 Years
3 Â (Adult) 500 Other|NIHInterventioAllocation 19-110210
Number ofJiangsu
s ProAll up to 75 Years
PhaseÂ 3(Child, Adult,
1537Older
Other|Indu
Adult)InterventioAllocation JSEPI-003
To evaluateNovartis V All 16 MonthsPhase
to 48 Months
2 Â (Child)
89 Industry InterventioAllocation V70P2E1
PercentageColumbia UAll 11 Years andNotolder
Applic
Â (Child,416
Adult,
Other|Indu
Older Adult)
InterventioAllocation AAAM3756
PercentageNovartis V All 55 Days to Phase
89 Days3 Â (Child)529 Industry InterventioAllocation V59_33
CompositeBandim Hea All up to 59 Months
Phase 4Â (Child)28000 Other InterventioAllocation RE-CAMP
ImmunogenicNational InAll 18 Years toPhase
50 Years
1 Â (Adult)18 NIH InterventioAllocation CIR 254|#
Adverse caMcMaster AUll 18 Years andPhase
older
4 Â (Adult,
5000
Older
Other
Adult) InterventioAllocation RCT-IVVE 2
safety|immUS Departm All 65 Years andPhase
older
1|Ph
Â (Older Adult)
0 U.S. Fed|OInterventioAllocation CLIN-07-11
Antibody anOpera CROAll 18 Years toPhase
60 Years
4 Â (Adult) 7 Other InterventioInterventi V111_06TP
The FrequenSeqirus All 5 Years to 8Phase
Years4Â (Child) 402 Industry InterventioAllocation CSLCT-USF
Lot to Lot Novartis V All 11 Years toPhase
55 Years
3 Â (Child,
3539Adult)
Industry InterventioAllocation V59P13
The Rate ofNational InAll 18 Years toPhase
65 Years
1 Â (Adult,33Older
NIH|Indust
Adult)InterventioAllocation 130141|13
Immunologi Chiang MaiAll 18 Years toPhase
25 Years
4 Â (Adult)80 Other InterventioAllocation 4564
older
1 Â (Adult, 24
Older
Other|Indu
PercentageNational InAll 18 Years toPhase
49 Years
4 Â (Adult)70 NIH InterventioInterventi 14-0071|H
Antibody toShandong PAll 22 Years toPhase
60 Years
4 Â (Adult)300 Other InterventioAllocation HCV-001
Parents' wiUniversity All 11 Years to 18 Years Â (Child,
1509Adult)
Other|InduObservatioObservatio13-2889
GeometricSanofi Pas All 10 Years toPhase
55 Years
3 Â (Child,
3344Adult)
Effect on Medical ReAll 16 Weeks to Not22Applic
Weeks Â (Child)
302 Other InterventioAllocation SCC 1085
Number ofSanofi Pas All 3 Years andPhase
180 Industry
Older Adult)
InterventioAllocation GRC71|U11
Time to AdmBrenda ColAll 18 Years toPhase
69 Years
Other|Indu
Adult)InterventioAllocation SP1203
The seroconSinovac BioAll 6 Months to Phase
35 Months
4 Â (Child)
120 Industry|OInterventioAllocation PRO-EV71-
50 Years
Changes inUniversity All 18 Years andPhase
older
1 Â (Adult, 12
Older
Other
Adult) InterventioInterventi UPCC 1621
Number ofDuke
P UniveAll 12 MonthsPhase
to 16 Months
4 Â 221
(Child)
Other|U.S.InterventioAllocation Pro000824
65 Years
1 Â (Adult,28Older
NIH Adult)InterventioAllocation CIR 290|W
PercentagePATH|MinisAll 18 Years toPhase
40 Years
The GMT ofSinovac BioAll 6 Months to Phase
5 Years
3 Â (Child)
1400 Industry InterventioAllocation PRO-EV71-
89 Days2 Â (Child)
To assess tSellas Life All 18 Years andPhase
older
2 Â (Adult, 22
Older
Industry
PercentageNovartis|NAll 3 Years to 64
Phase
Years
3 Â (Child,
1893
Adult)
Industry InterventioAllocation V71P5|IND
Influenza vUniversity All 4 Years to 19
NotYears
Applic
Â (Child,
20461Adult)
Other InterventioAllocation 5R18HS02
PercentageSanofi Pas All 18 Years andPhase
older
4 Â (Adult,116
Older
Industry
Adult) InterventioAllocation GRC35
Humoral immNational InAll 18 Years to 64 Years Â (Adult)150 Other ObservatioObservatioFinFLU_H
older
4 Â (Adult,208
Older
Industry
To evaluateNovartis V Female 18 Years toPhase
40 Years
1 Â (Adult)130 Industry InterventioAllocation V98P2
1. The testInternatio All 20 Years toPhase
45 Years
2|PhÂ (Adult)
Safety|Imm Hualan BiolAll 2 Years andPhase
900 Industry
Older Adult)
InterventioAllocation Hualanbio-
Disease-freWenxiang W All 18 Years toPhase
70 Years
1|PhÂ (Adult,30Older
OtherAdult)InterventioInterventi TVATLC01
Change FroMichigan StAll 50 Years andPhase
older
4 Â (Adult, 25
Older
Other|Indu
Adult) InterventioInterventi WI170883
LaboratoryHenry M. JAll 18 Years andPhase
older
4 Â (Adult,
10650Older
Other|NIH|
Adult) InterventioAllocation IDCRP-120
DetermineUniversity
t All 18 Years toPhase
80 Years
Adult) 13-1380
Number ofSanofi
p Pas All 65 Years andPhase
older
Industry InterventioAllocation QHD01|U11
The primaryNovaDigm AllT 18 Years toPhase
50 Years
1 Â (Adult)40 Industry|OInterventioAllocation NDV-3-001
45 Years
1 Â (Adult)60 Industry|OInterventioAllocation IVACFLU-S-
ProportionGuangxi ZhAll 60 Days to Phase
90 Days3 Â (Child)600 Other|InduInterventioAllocation Tiantan-2
Successful City of HopAll 18 Years toPhase
60 Years
1 Â (Adult)24 Other|NIHInterventioInterventi 08173|NCI
OccurrenceMarylyn AdAll 18 Years toPhase
55 Years
1 Â (Adult)26 Other InterventioAllocation UKE-DZIF1
Number ofNovartis V All 6 Months to Phase
71 Months
3 Â (Child)
Safety as Novartis V All 18 Years toPhase
39 Years
Safety of University All 9 Months to Phase
23 Months
2 Â (Child)
250 Other InterventioAllocation HP-000810
Immunogeni The UniverAll up to 18 Years
PhaseÂ 3(Child, Adult)
55 Other InterventioInterventi 2007/028
Number ofResearch I All 18 Years toPhase
49 Years
safety|clinUniversity Female 18 Years toPhase
50 Years
1 Â (Adult)52 Other|NIHInterventioInterventi 130662|R
Human Seru Novartis|NAll 11 Years toPhase
17 Years
3 Â (Child)344 Industry InterventioAllocation V72_41
17 Years
2|Ph
Â (Child)
Safety|Imm VaxInnate All 18 Years toPhase
49 Years
1 Â (Adult)275 Industry InterventioInterventi VAX161-01
Evaluate t Beijing ChaAll 2 Months andPhaseolder
Adult) cycdc2015
Hepatitis BUniversity All 65 Years andEarly
older
PhasÂ (Older Adult)
The primary Penn StateAll 1 Year to 70Phase
Years1Â (Child, Adult,
0 Other
Older Adult)
InterventioInterventi IRB 30761
PercentagePATH|InstiAll 24 MonthsPhase
to 71 Months
3 Â1761
(Child)
Other|U.S.InterventioAllocation LAIV-SEN-0
Primary ObSimon Dobs Female 9 Years to 26
Phase
Adult)
The primarCOL GeorgeAll 18 Years andPhase
older1|Ph
Â (Adult, 95
Older
U.S.Adult)
Fed InterventioAllocation 03-20012
The incide Sinovac (DaAll 1 Year to 12Phase
Years3Â (Child)5997 Industry InterventioAllocation PRO-VZV-3
Immunogeni National InAll 18 Years toPhase
50 Years
Confirm the Memorial SAll 18 Years andPhase
Older
Adult) 08-095
Number ofChanghai HAll 18 Years toNot
75 Years
Other|Indu
Adult)InterventioInterventi CHO-0100
The geomet Sinovac BioAll 18 Months to 35 Months Â 332 (Child)
Industry ObservatioObservatioPRO-HA-401
Immune reHelsinki UnAll 50 Years andPhase
Older
Other
Adult) InterventioAllocation PCV13 adul
ProportionNational TaAll 50 Years toPhase
70 Years
OtherAdult)InterventioAllocation 20171218
Safety|Imm Hualan BiolAll 2 Years andPhase
360 Industry
Older Adult)
InterventioInterventi Hualanbio-
Serotype-sPfizer All 65 Years andPhase
older3 Â (Older764Adult)
Industry InterventioAllocation B1851088
Immunogeni Jiangsu Pr All 16 Years andPhase
older2|Ph
Â (Child,
1091
Adult,
Other|Indu
Older Adult)
InterventioAllocation KT0003
Number ofJoseph BaaAll 18 Years andPhase
Older
Other
Adult) InterventioInterventi CASE3113|
Incidence oFluart InnoAll 6 Months to Not36Applic
Months Â (Child)
10 Industry InterventioAllocation FLUVAL P-
older3 Â (Child,810
Adult,
Industry
Older Adult)
InterventioAllocation MET56|U11
To demonstVBI VaccineAll 18 Years toPhase
45 Years
3 Â (Adult)
2837 Industry InterventioAllocation Sci-B-Vac-
Feasibility M.D. AnderAll 18 Years andEarly
older
PhasÂ (Adult, 30
Older
Adult) 2018-0345
The serocoSinovac BioAll 8 Months andPhaseolder
Older Adult) EV71-SN-2
Incidence Shenzhen PAll 18 Years toPhase
70 Years
1 Â (Adult,30Older
OtherAdult)InterventioInterventi ShenzhenP
Number ofNovartis V All 3 Years to 17
Phase
Years3 Â (Child)430 Industry InterventioAllocation V58P15|20
Number and Novartis V All 18 Years toPhase
60 Years
2 Â (Adult)47 Industry InterventioAllocation V87P1E1|2
GeometricNovartis|NFemale 18 Years toPhase
40 Years
Receipt of Emory UnivFemale 18 Years toNot
50 Years
ApplicÂ (Adult)
330 Other|U.S.InterventioAllocation IRB000602
Change in USDA, West Female 18 Years toEarly
49 Years
PhasÂ (Adult)15 U.S. Fed InterventioInterventi FL109
VaccinationUniversitÃ Female 18 Years andNotolder
Applic
Â (Adult,
1600
Older
Other
The occurre Jiangsu ProAll 6 Years to 15
Phase
Years3 Â (Child)
4464 Other InterventioAllocation TMMUHP0
Peripheral University All 18 Years and older Â (Adult,200 Older
Other
Adult) ObservatioObservatio2014-141;
OccurrenceMedicago All 65 Years andPhase
older3 Â (Older
12793
Adult)
Industry InterventioAllocation CP-PRO-QV
Number ofU.S. Army All 6 Years to 10
Phase
Years1|Ph
Â (Child) 7 U.S. Fed|I InterventioInterventi WRAIR 104
The incide Sinovac BioAll 6 Months to Phase
35 Months
3 Â10077
(Child)
Industry InterventioAllocation PRO-EV71-
Number ofNational InAll 6 Months to Phase
17 Years
2 Â (Child)583 NIH InterventioAllocation 09-0054
Protectivi PT Bio Far All 6 Weeks toPhase
11 Weeks
2 Â (Child)220 Industry InterventioAllocation Penta 0211
The safety Seattle Ch All 6 Weeks toPhase
14 Weeks
4 Â (Child) 15 Other|NIHInterventioInterventi RS_Rota_va
Safety of Washington All 18 Years and
Phase
Older
Adult) 201908124
proportionOswaldo CrAll 18 Years toPhase
59 Years
2 Â (Adult)450 Other InterventioAllocation VIP-H1N1
Optimal ti Washington All 18 Years and
Phase
Older
Adult) 2.01E+08
Number ofSanofi Pas All 2 Years to 14
Phase
Years3 Â (Child)
10275 Industry InterventioAllocation CYD14|UTN
The PercenNovartis V All 6 Months toPhase
17 Years
2 Â (Child)662 Industry|UInterventioAllocation V89_11
Compare imm Novartis V All 18 Years toPhase
60 Years
Number ofSanofi Pas All 18 Years and
Phase
Older
Industry
Post vaccinFluart InnoAll 18 Years and
Notolder
Applic
Â (Adult,355
Older
Industry
Adult) InterventioAllocation FLUVAL P-
the safety University All 18 Years toPhase
45 Years
1 Â (Adult)120 Other InterventioAllocation 2013/914|
To evaluateUniversity All 18 Years toPhase
45 Years
Incidence Themis BioAll 21 Years toPhase
50 Years
2 Â (Adult)34 Industry|UInterventioAllocation MV-CHIK-2
Immunoglob PATH|Noguc All 42 Days to Phase
55 Days4 Â (Child)456 Other|U.S.InterventioAllocation GHANA-HR
CPMP criter Novartis V All 18 Years toPhase
60 Years
2 Â (Adult)40 Industry InterventioAllocation V87P2|Eud
Safety monChinese AcAll 6 Months toPhase
23 Months
3 Â 1050
(Child)
CardiovascShahid BehAll 25 Years and
Phase
older2|Ph
Â (Adult,300
Older
Other
Adult) InterventioAllocation SBMU- 86-
GeometricButantan
M InAll 18 Years toPhase
69 Years
Other
Adult)InterventioAllocation FLU-07-IB
Number and Institute o All 18 Years toPhase
60 Years
2|Ph
Â (Adult)
889 Industry|OInterventioAllocation IVACFLU-S
Rate of HEH. Lee MoffAll 18 Years and
Phase
Older
Other
Adult) InterventioInterventi MCC-1965
This study National TaAll 6 Months to 18 Years Â (Child, 50Adult)
Other ObservatioObservatio200912031
Evaluate thChinese AcAll 6 Months toPhase
71 Months
4 Â (Child)
800 Other InterventioInterventi 2017-003-
Severity a Shantha BiMale 18 Years toPhase
55 Years
1 Â (Adult)20 Industry InterventioAllocation SBL/BRVTV
PercentageNovartis|NAll 11 Years toPhase
18 Years
4 Â (Child,801
Adult)
Binding anUniversite All 18 Years and
Phase
Older
Other|Indu
Adult) InterventioAllocation VAC52150E
positive seJiangsu Pr All 6 Months toPhase
11 Months
3 Â (Child)
Number ofGlycoVaxy Female 18 Years toPhase 70 Years
Industry
Adult)InterventioAllocation GVXN EC-4
Injection s VaxInnate All 65 Years toPhase
75 Years
1|Ph
Â (Older200
Adult)
Industry InterventioAllocation VAX2012Q-
Serotype-sPfizer All 3 Years andPhase
263 Industry
Older Adult)
InterventioAllocation 6096A1-30
Long-term PATH|InterAll 43 MonthsPhase
to 51 Months
4 Â 561
(Child)
Other InterventioInterventi JEV07 - PR
HAI titers Stanford Un All 2 Years to 20
Phase
40 Other|NIHInterventioAllocation 50200|5U1
Meningococ London SchAll Child, AdulPhase 4 33000 Other InterventioInterventi LSHTM_56
GeometricNovartis|NAll
M 3 Years to 17
Phase
Years2|Ph
Â (Child)
3604 Industry InterventioAllocation V58P12|Eu
Relief deg Fuda CanceAll 40 Years toPhase
70 Years
1|Ph
Â (Adult,30Older
Other
Adult)InterventioAllocation sarcoma M
70 Years
1|Ph
Â (Adult,30Older
Other
Adult)InterventioAllocation kidney can
type specifUniversity All 13 Years toPhase
27 Years
3 Â (Child,100
Adult)
Other InterventioAllocation HLS04/201
Grades of National InAll 6 Months toPhase
24 Months
1 Â (Child)
33 NIH InterventioAllocation CIR 311
Overall tumXEME BiopAll 18 Years and
Phase
Older
Industry
Adult) InterventioInterventi X13-21008
Cervical H University Female 18 Years and Phase
Older
Other|Indu
Adult) InterventioAllocation QHPV-RTC
70 Years
1|Ph
Â (Adult,30Older
Other
Adult)InterventioAllocation colorectal
Number/Per PATH|CentrAll 9 Months toPhase
11 Months
4 Â (Child)
600 Other InterventioAllocation PATH-RVI-
Safety|Imm Butantan Institute|Banco
All 18 Years
Nacional
toPhase
59deYears
Desenvolvimento
2 Â (Adult)300 Other
Economico
InterventioAllocation
e Social|FundaÃ§Ã£o
DEN-01-IB
de Amparo Ã Pesquisa do
Breadth ofUCSF BenioAll 18 Years toPhase
65 Years
4 Â (Adult,18Older
Other
Adult)InterventioInterventi Childrens
Numbers and London SchAll 1 Year and Phase
older Â3 (Child,
500000
Adult,Other|Indu
Older Adult)
InterventioInterventi DRC-EB-00
Summary of Novartis V All 56 Days to Phase
83 Days2 Â (Child)216 Industry InterventioAllocation V59P16|20
Human papil National CaAll 18 Years toPhase
49 Years
2 Â (Adult)180 NIH InterventioInterventi NCI-2017-
Immunogeni Medicago All 18 Years toPhase
49 Years
2 Â (Adult)300 Industry InterventioAllocation CP-Q13VLP
To demonstSeattle ChiAll 42 Days to Phase
84 Days
2|Ph
Â (Child)
1375 Other|InduInterventioAllocation 5065501
HAI respons University All 65 Years and
Phase
older
HemagglutiCenter for All 18 Years toPhase
34 Years
4 Â (Adult)292 Other InterventioAllocation PRO-INF-B
Safety in eIsconova AAll 65 Years toPhase
75 Years
1 Â (Older 110Adult)
Industry InterventioAllocation ISC-Influe
Safety, tol Novartis V All 11 Years toPhase
18 Years
Ability to Roswell ParMale 18 Years and
Phase
older
2 Â (Adult, 15
Older
Other
49 Years
3 Â (Adult)
Ratios of Seqirus|NoAll 6 Months toPhase
48 Months
1|Ph Â (Child)
50 Years
PercentageBiomat USA All 18 Years toPhase
69 Years
Adult) GB-0115
Measure An University All 18 Years toPhase
64 Years
4 Â (Adult)81 Other InterventioAllocation 2015-0813|
complianceNational I All 18 Years and
Phase
older
3 Â (Adult,
1260Older
NIHAdult) InterventioAllocation DESPR DA0
GeometricUniversity Female 18 Years toNot
23 Years
ApplicÂ (Adult)
200 Other|InduInterventioAllocation 32090
Characteri National InAll 22 Years toPhase
54 Years
Number ofTakeda All Child, Adult, Older Ad 3331 Industry ObservatioObservatio247-012|Ja
Phase
Years
3 Â (Child)
20869 Industry InterventioAllocation CYD15|UTN
Number ofTakeda All Child, Adult, Older Ad 3493 Industry ObservatioObservatio247-011|Ja
Incidence oImperial C Female 18 Years toPhase
55 Years
3 Â (Adult)
1000 Other InterventioAllocation C/39/2018
The safety PaxVax, IncAll 18 Years toPhase
40 Years
1 Â (Adult)120 Industry InterventioAllocation PXVX-PA-1
Passive HaInternationAll 20 Years toPhase
49 Years
1 Â (Adult)40 Other InterventioAllocation FM-01 V1
GeometricTakeda All 18 Years toPhase
60 Years
2 Â (Adult)40 Industry InterventioInterventi DEN-210
Persistenc Novartis V All 40 MonthsPhase
to 62 Months
2 Â 163
(Child)
Industry InterventioAllocation V72P6E1|E
Number ofSanofi Pas All 11 Years toPhase
12 Years
4 Â (Child)423 Industry InterventioAllocation Td551|U11
Adverse evBaylor Col Male 18 Years toEarly
40 Years
PhasÂ (Adult)40 Other InterventioAllocation H-39354
Incidence oNational I All 18 Years toPhase
70 Years
NIH|Indust
Adult)InterventioAllocation VRC 703
70 Years
1 Â (Adult,24Older
NIH Adult)InterventioInterventi URMC 14-
AssessmentSingapore CAll 21 Years and
Phase
older
1 Â (Adult, 24
Older
Other|Indu
Adult) InterventioInterventi MUC-1
Comparison Novartis V All 6 Months toPhase
72 Months
3 Â 6104
(Child)
Anti-HPV 6,Xiamen UniFemale 18 Years toPhase
45 Years
Protectivi PT Bio Far All 6 Weeks toPhase
11 Weeks
3 Â (Child)600 Industry InterventioAllocation Penta 0312
Number ofNovartis|NAll 6 Months toPhase
71 Months
3 Â 4902
(Child)
Industry InterventioAllocation V70P5|Eud
To assess tAbbott BiolAll 61 Years and
Phase
older
2 Â (Adult,622
Older
Industry
Adult) InterventioAllocation S203.2.00
SeroconverChina Nati All 6 Months toPhase
11 Months
4 Â 1134
(Child)
Industry|OInterventioAllocation EV71-Flu-
Achieving aN.N. PetroAll 18 Years and
Phase
older
1|Ph
Â (Adult, 48
Older
Other
Adult) InterventioInterventi MC-01-201
ReactogeniU.S. Army All 12 MonthsPhase
to 15 Months
1|Ph Â (Child)
51 U.S. Fed|I InterventioAllocation WRAIR 824
Immune resp Ology BiosAll 16 Years and
Phase
older
3 Â (Child,
1968Adult,
Industry
Older Adult)
To charact University All 18 Years toNot
60 Years
ApplicÂ (Adult)15 Other InterventioInterventi OVG 2014/
PD: LocatioVaxart Male 18 Years toPhase
49 Years
1 Â (Adult) 8 Industry InterventioAllocation VXA02-RLT
Evaluate i Sinovac BioAll 60 Years and
Phase
older
4 Â (Adult,100
Older
Industry
Adult) InterventioInterventi PRO-PanFl
Immune Res Walter J. SAll 18 Years and
Phase
older
2 Â (Adult, 15
Older
Adult) 12-048|R0
GeometricNovartis V All 65 Years and
Phase
older
3 Â (Older
7109Adult)
PercentageBeijing Zh All 2 Months toPhase
5 Months
1|Ph Â (Child)
360 Industry|OInterventioAllocation 85201602
The Number National I Female 18 Years toPhase
39 Years
2 Â (Adult)130 NIH InterventioAllocation P1086|108
Comparison Laval UniveAll 9 Years to 10
Phase
Years
3 Â (Child)376 Other InterventioAllocation HPV 2355
45 Years
1 Â (Adult)60 Other|U.S.InterventioAllocation TORLAK-10
Immunogenic University All 18 Years and older Â (Adult,645 Older
Other
Adult) ObservatioObservatioCS_2013_0
Solicited L Il-Yang PhaAll 6 Months to Phase
18 Years
Industry InterventioAllocation IY_IFEZ_C
Anti-HBs SShanxi MedAll 18 Years toPhase
70 Years
Requirement Novartis|No All 60 Years andPhase
older
3 Â (Adult,600
Older
Adult) M70P1|Part
Change in Johns HopkAll 1 Year and Phase
120 Other
Older Adult)
InterventioAllocation IRB000080
Incidence rBeijing CenAll 2 Months to Phase
12 Months
4 Â (Child)
680 Other InterventioAllocation BJCDPC-4
Induction Baylor ReseAll 21 Years toPhase
75 Years
2 Â (Adult, 9Older
OtherAdult)InterventioAllocation Baylor IRB
To assess University All 39 MonthsPhase
to 46 Months
4 Â 100
(Child)
Other InterventioAllocation 2009/04
Safety|Imm Medicago All 18 Years toPhase
49 Years
1|Ph
Â (Adult)
120 Industry InterventioAllocation CP-Q12VLP
Frequency National InAll 9 Years to 99
Phase
Years
4 Â (Child,240
Adult,
NIHOlder Adult)
InterventioInterventi 16-0101|H
Measure seThe Immuno All 3 Months to Phase
19 Years
2|PhÂ (Child,
1644Adult)
Other InterventioAllocation ASCLIN 00
Anti-Rota GlaxoSmithAll 6 Weeks toPhase
12 Weeks
3 Â (Child)
1612 Industry InterventioAllocation 115461|20
To evaluateSinovac BioAll 18 Years toPhase
49 Years
1 Â (Adult)36 Industry InterventioAllocation EV71-1001-
ProportionsAssistanceAll Child, Adult, Older Ad 3350 Other ObservatioObservatioNI16019
Immunogeni PT Bio Far All 6 Months to Phase
60 Years
3 Â (Child,
3071Adult)
the incide Jiangsu ProAll 6 Months to Phase
35 Months
3 Â10245
(Child)
Other|InduInterventioAllocation JSVCT010
Local ReacVanderbiltAll 3 Years to 17
Phase
Years
1 Â (Child) 50 Other InterventioAllocation VICC PED
the 95% con Jiangsu ProAll 3 Years andPhase
older3Â (Child,3664
Adult,
Other|Indu
Older Adult)
InterventioAllocation JSVCT031
Frequency HIVo VaccinAll 18 Years toPhase
40 Years
1 Â (Adult)202 Other InterventioAllocation HVTN 097
Evaluate thNovartis V All 18 Years toPhase
64 Years
10 Years
3 Â (Child)
Number ofNational
s CeAll 18 Years toPhase
60 Years
4 Â (Adult)85 Other InterventioAllocation FLUSECURE
The proport University Male 18 Years andPhase
older
1 Â (Adult,206
Older
Other|Indu
Change in St George'sAll 10 Years toPhase
45 Years
4 Â (Child,55 Adult)
Other InterventioInterventi 17.0177
Number ofNational InAll 55 Years toPhase
74 Years
NIH Adult)InterventioAllocation 11-0034|H
Safety: Ad U.S. Army All 17 Years toPhase
65 Years
U.S. Fed
Older InterventioInterventi
Adult) A-12775|F
Number ofSanofi
p Pas All 18 Years toPhase
64 Years
2 Â (Adult)342 Industry InterventioAllocation VRV04|U11
Number ofGlaxoSmithAll 2 Years to 10
Phase
Years
Using the sNovartis V All 1 Year to 45Phase
Years2Â (Child, Adult)
The Effect Children's All 42 Days to Phase
90 Days4 Â (Child)144 Other|U.S.InterventioAllocation 2015-2754
safety and National C All 18 Years andPhase
older
1 Â (Adult, 39
Older
Other
Adult) InterventioInterventi NCT-2013-
The incide Jiangsu Pr All 40 Years andPhase
older
3 Â (Adult,
30000Older
Other
Adult) InterventioAllocation CS-HZ-201
to 59 Months
2 Â 623
(Child)
Industry InterventioAllocation V59P7|EUD
Antibody tiHelsinki UnAll 18 Years andPhase
older
3 Â (Adult,120
Older
Other
Adult) InterventioAllocation 382/E7/07
Frequency FluGen IncAll 18 Years toPhase
49 Years
1 Â (Adult)96 Industry InterventioAllocation H3N2-V00
Antibody TBoston ChiFemale 9 Years to 26
NotYears
Applic
Â (Child, Adult)
53 Other|InduInterventioAllocation 07-09-034
antibody tiAsan MedicAll 18 Years toPhase
40 Years
Number ofPATH All 6 Weeks toPhase
35 Months
1|Ph Â (Child)
204 Other InterventioAllocation VAC-013
safety of aCedars-SinAll 18 Years andPhase
older
1 Â (Adult, 71
Older
Other
Vaccines r Kaiser Per All 1 Month toNot 11 Applic
Months Â (Child)
250 Other InterventioAllocation 1R01HD07
Change froUniversity All 5 Years to 70 Years Â (Child, Adult,
12 Other
Older Adult)
ObservatioObservatioUCSF Proto
Cellular I National HeAll 18 Years toPhase
85 Years
2 Â (Adult, 4Older
NIH Adult)InterventioInterventi 070091|07
Frequency St George' Female 18 Years toPhase
45 Years
1 Â (Adult) 8 Other InterventioInterventi 2010-0227
Evaluate thChinese AcAll 6 Months to Phase
71 Months
3 Â12000
(Child)
Other InterventioAllocation EV71-KMB1
PercentageWyeth is nAll 42 Days to Phase
98 Days3 Â (Child)613 Industry InterventioAllocation 6096A1-00
Persistenc University All 17 Months to 14 Years Â (Child)
560 Other ObservatioObservatio2010/03
GeometricSanofi Pas All 6 Months to Phase
36 Months
4 Â (Child)
30 Industry InterventioAllocation GRC26
Immune res Saarland UnAll 16 Years andPhase
45 Other
Older Adult)
InterventioAllocation Impfrain
GeometricNovartis
M V All 18 Years toPhase
60 Years
3 Â (Adult)
1200 Industry InterventioAllocation V58P9|EUD
45 Years
2 Â (Adult)351 Industry InterventioAllocation DEN-205|U
45 Years
1 Â (Adult)141 NIH InterventioAllocation 140035|14
Grades of National InAll 6 Months to Phase
24 Months
1 Â (Child)
Influenza Duke UniveFemale 18 Years andNotolder
Applic
Â (Adult,544
Older
Adult) Pro000049
SeroconverIl-Yang PhaAll 3 Years to 18
Phase
Adult)
Industry InterventioAllocation IF4CH03
The immunog Sinovac BioAll 6 Months andPhase
older
Industry
Adult) PRO-INF-4
Safety and CHA Vaccine All 20 Years toPhase
50 Years
1|PhÂ (Adult)75 Industry InterventioAllocation CVI-HBV-0
To assess tFraunhoferAll 18 Years toPhase
50 Years
1 Â (Adult)80 Industry|UInterventioAllocation WRAIR 175
Patients ExVanderbiltAll 18 Years andPhase
Older
Other
Adult) InterventioAllocation VICC BMT
Comparison Kaiser Per All 5 Years to 8Not
Years
Applic
Â (Child) 280 Other|U.S.InterventioInterventi CDC Protoc
Safety Hualan BiolAll 2 Years andPhase
60 Industry
Older Adult)
InterventioInterventi Hualanbio-
Parental V Kaiser Per All Child, AdulNot Applic 491 Other InterventioAllocation 250147
Incidence oUniversity All 18 Years toPhase
60 Years
4 Â (Adult)80 Other InterventioInterventi YFV_001
Rabies viruNovartis V All Child, Adult, Older Ad 200 Industry ObservatioObservatioM49P8E1
Protectivi PT Bio Far All 9 Months to Phase
12 Months
2|Ph Â (Child)
540 Industry InterventioAllocation MR-BF 031
Number ofThe p First Male 18 Years toPhase
70 Years
Other|Indu
Adult)InterventioAllocation 2018-007
Older
Industry
Mean Perce National InAll 18 Years toPhase
49 Years
2 Â (Adult)120 NIH InterventioAllocation 14-0112|H
Frequency National
a InAll 6 Months to Phase
24 Months
1 Â (Child)
HBV vaccinRockefellerAll 18 Years toPhase
62 Years
4 Â (Adult) 6 Other|NIHInterventioAllocation CRI-0844|
Rabies Neut Queen Saov All 18 Years toNot
60 Years
ApplicÂ (Adult)75 Other InterventioAllocation RC5502
Evaluate t Chinese AcAll 8 Months to Phase
59 Years
Other InterventioAllocation FMumps-K
Evaluate t The Immuno All 18 Years toPhase
50 Years
1 Â (Adult)60 Other InterventioAllocation ASCLIN / 0
Incidence oNational I All 6 Years to 17
Phase
Years1 Â (Child) 75 NIH|IndustInterventioAllocation VRC 702
Identificat Yisheng Bi All 21 Years toPhase
65 Years
1 Â (Adult,37Older
Adult) RV001-I
Older
Other
17 Years
2 Â (Child)524 Industry InterventioAllocation V59P6|BB-
Dose LimitiUniversity All 18 Years andPhase
older1|Ph
Â (Adult, 44
Older
Other|Indu
Adult) InterventioAllocation RHMCAN098
Adverse evBeijing Zh All 6 Weeks and Phase
80 Industry|OInterventioInterventi
Older Adult) 2.02E+08
49 Years
older4 Â (Older300
Adult)
Industry InterventioAllocation GRC48|U 1
Comparison Novartis V All 3 Years to 17
Phase
Years3 Â (Child)
cumulativeS. Andrea All 18 Years andPhase
Older
Other
Adult) InterventioAllocation BCG-RIS-0
Safety of Washington All 18 Years andPhase
Older
Adult) 201708105
Blood Pre Abramson FCemale 18 Years andPhase
older1|Ph
Â (Adult, 58
Older
Other
Adult) InterventioAllocation 807010|15
Safety in a GeoVax, InAll 18 Years toPhase
50 Years
1 Â (Adult) 9 Industry|OInterventioInterventi GV-TH-01
Pertussis sSt George' Female 16 Years andPhase
Adult,
Other
Older Adult)
InterventioAllocation 2018.03
Humoral i Tan Tock S All 65 Years to 100 Years Â (Older240Adult)
Other ObservatioObservatioDSRB 2016
Safety as Cangene Co All 18 Years toPhase
65 Years
4 Â (Adult,
3000Older
Industry
Adult)InterventioInterventi VA-008
Number/Per PATH|ChristAll 5 Weeks toPhase
16 Weeks
4 Â (Child)620 Other InterventioAllocation CMC ZP 20
65 Years
3 Â (Adult,18Older
Industry
Adult)InterventioAllocation V72_37
Rates of loNovartis V All 2 Months to Phase
20 Months
1 Â (Child)
40 Industry InterventioAllocation M37P1
The Number Novartis V All 18 Years toPhase
40 Years
Anti-HEV aXiamen InnAll 18 Years andPhase
Older
Industry
Adult) InterventioAllocation PRO-HE-00
Number ofHealth Sci All 20 Years andPhase
Older
Other
Adult) InterventioAllocation NIH R01
immunogenic Assistance All 6 Months andPhaseolder
4 Â (Child,439
Adult,
OtherOlder InterventioInterventi
Adult) P 100201|
Number ofGlaxoSmithFemale 20 Years toPhase
25 Years
3 Â (Adult)152 Industry InterventioAllocation 111567|20
HPV infectiInternationFemale 13 Years toNot
15 Years
ApplicÂ (Child)
18000 Other InterventioAllocation IVI HPV1
PrevalenceAssistanceAll 18 Years toPhase
36 Years
65 Years
Industry
Adult)InterventioAllocation V49_23|20
Papilloma National I All 1 Year to 17Phase
Years3Â (Child) 20 Other|InduInterventioInterventi 50934
Compare thEmory UnivAll 18 Years toPhase
40 Years
1 Â (Adult)80 Other|InduInterventioAllocation IRB000459
Change in LJohns HopkFemale 18 Years toPhase
39 Years
4 Â (Adult)103 Other|U.S.InterventioInterventi CIR 292|2
The seropos Sinovac Bi All 6 Months to Phase
6 Months
4 Â (Child)
780 Industry|OInterventioAllocation PRO-EV71-
64 Years
2 Â (Adult)300 Industry InterventioAllocation FIM09|UTN
To identif Novartis V All 18 Years andPhase
Older
Industry
Adult) InterventioAllocation V110_03|2
Safety endInternationAll 6 Months to Phase
23 Months
2 Â (Child)
285 Other|InduInterventioAllocation IVI T002
to 24 Months
3 Â 274
(Child)
Industry InterventioAllocation JEC12|U11
The primary AdimmuneAll 1 Year to 17Not
Years
Applic
Â (Child) 183 Industry InterventioAllocation FLU09002
Incidence Profectus All 18 Years toPhase
60 Years
1 Â (Adult)38 Industry|UInterventioAllocation rVSV-EBOV
Efficacy: A Seqirus All 2 Years to 17
Phase
Years4 Â (Child)
4514 Industry InterventioAllocation V130_12|2
Safety of Baylor ReseAll 18 Years andPhase
Older
Other
Adult) InterventioInterventi IND 18850
Antibody RJohns HopkFemale 18 Years toPhase
26 Years
4 Â (Adult)200 Other|InduInterventioAllocation Merck IIS
Incidence rBeijing CenAll 3 Years andPhase
Adult,
Other
Older Adult)
InterventioAllocation BJCDPC-3
Serologic UniversidaAll 18 Years andPhase
Older
Other|Indu
Adult) InterventioAllocation 45/2012
Rate of Se St. Jude ChAll 3 Years to 21
Phase
85 Other InterventioAllocation FLUHD
HPV VaccinUniversity All 9 Years to 70
NotYears
Applic
Â (Child,
53414
Adult,
Other
Older Adult)
InterventioAllocation R01CA1545
ProportionNational InAll 18 Years toPhase
60 Years
2 Â (Adult)100 NIH InterventioInterventi 180092|18
Systemic r Mahidol UnAll 9 Years to 65
Phase
Years1|Ph
Â (Child,363
Adult,
Other
Older Adult)
InterventioAllocation GPO FLU V
Safety andUniversity All 18 Years andPhase
Older
Other
Participan Green CrosAll 19 Years toPhase
64 Years
1|Ph
Â (Adult)
220 Industry InterventioAllocation GC3111_P1
VibriocidalJohns HopkAll 1 Year and Phase
181 Other
Older Adult)
Number ofProtein Sc All 50 Years andPhase
older3 Â (Adult,
9003
Older
Industry
Adult) InterventioAllocation PSC12
Days underKaiser Per Female 18 Years toNot
60 Years
ApplicÂ (Adult)
1675 Other|U.S.InterventioAllocation 1R01HS021
Frequency National
o InAll 6 Months to Phase
24 Months
1 Â (Child)
changes ofChinese AcAll 18 MonthsPhase
to 65 Years
4 Â 35000
(Child,Other
Adult, Older
Adult) qiangming
Day 43 posNovartis V All 18 Years andPhase
Older
Industry
Number ofPT Bio Far All 10 Years toPhase
40 Years
1 Â (Child,100
Adult)
Industry InterventioAllocation Hep B 011
PercentageBeijing MinAll 2 Years to 30
Phase
Years3 Â (Child,
1260
Adult)
Industry InterventioAllocation 2012L0264
Immunogeni Sachin DesaAll 6 Years andPhase
426 Other
Older Adult)
InterventioAllocation CR-WC-11
For each vaBiondVax PAll 18 Years toPhase
60 Years
2 Â (Adult)224 Industry|OInterventioAllocation BVX-007
Number ofNational InFemale 18 Years toPhase
39 Years
2 Â (Adult)84 NIH InterventioAllocation 09-0072|N
60 Years
1 Â (Adult)110 Other|InduInterventioAllocation JSVCT020-
1.GeometriNovartis V All 18 Years andPhase
older3 Â (Adult,
2680
Older
Industry
SeroprotecNovartis V All 42 Days to Phase
64 Days3 Â (Child)175 Industry InterventioInterventi V66_05
Number ofPfizer All 65 Years andPhase
older
4 Â (Older
84496
Adult)
Industry InterventioAllocation 6115A1-30
SeroconverTakeda All 20 Years toPhase
49 Years
2 Â (Adult)400 Industry InterventioAllocation TAK-850/C
GeometricNovartis V All 5 Years to 6Phase
Years3Â (Child) 426 Industry InterventioAllocation V37_07E2
Immunogenic Novartis|NAll 1 Year to 10Phase
Years4Â (Child) 300 Industry InterventioAllocation M48P3|91
MTD of recRoswell ParAll 18 Years andPhase
older
1 Â (Adult, Older
9 Other|NIHInterventioInterventi
Adult) I 215912|
The primary AdimmuneAll 18 Years andNotolder
Applic
Â (Adult,292
Older
Industry
Adult) InterventioAllocation FLU09001
The proport Emory UnivAll 42 Years toPhase
71 Years
1 Â (Adult,60Older
OtherAdult)InterventioAllocation IRB001064
DC toxicityCharite UniAll 18 Years toPhase
80 Years
OtherAdult)InterventioInterventi CSTI571AD
Anti-HBs s Shanxi MedAll 18 Years toPhase
70 Years
the rate ofCenters forAll 3 Years and older Â (Child,166240
Adult,
Other|Indu
Older Adult)
ObservatioObservatioBJCDCWJ2
Relapse-freIstituto Sc All 18 Years andPhase
older
2 Â (Adult,120
Older
Other
Adult) InterventioAllocation IRST172.0
ImmunizatiChildren's All up to 1 WeekNotÂApplic
(Child) 600 Other InterventioAllocation 15-012572
Percent of Atlanta VAAll Child, AdulNot Applic 67000 U.S. Fed|OInterventioAllocation AtlantaVA
Number ofUniversity All 19 Years toNot
70 Years
ApplicÂ (Adult,
255Older
OtherAdult)InterventioInterventi H1N1VAC-2
PercentageNational CaAll 18 Years toPhase
70 Years
2 Â (Adult, 1Older
AssessmentNovartis|NAll 6 Months to Phase
35 Months
1 Â (Child)
60 Years
1 Â (Adult)120 Other|InduInterventioAllocation JSVCT020
39 Years
Safety and Baylor ReseAll 18 Years andPhase
older
1 Â (Adult, Older
7 Other
49 Years
1 Â (Adult)48 NIH|OtherInterventioAllocation URMC 13-
To assess National CaMale 18 Years toPhase
99 Years
1 Â (Adult, 8Older
Bactericid U.S. Army All 18 Years toPhase
45 Years
1 Â (Adult)36 U.S. Fed InterventioAllocation WRAIR 139
Assessing cInternatio All Child, AdulNot Applic 300 Other InterventioAllocation PP201704-
SeroconverKorea UnivAll 65 Years andPhase
older
4 Â (Older224
Adult)
Other InterventioAllocation INFLUENZ
Number ofLake Cumbe All 12 Years toNot
20 Years
ApplicÂ (Child,
935Adult)
Other|InduInterventioInterventi LCDHD-12-
Number ofSanofi Pas All 9 Months to Phase
18 Months
3 Â (Child)
300 Industry InterventioAllocation JEC07|UTN
PercentageUniversity All 6 Months to Phase
12 Years
2 Â (Child)
1000 Other InterventioAllocation 2009/08 H
PercentageSanofi Pas All 9 Months to Phase
17 Months
3 Â (Child)
300 Industry InterventioInterventi MTA70|U11
To evaluateSinovac BioAll 6 Months to Phase
11 Years
1 Â (Child)132 Industry InterventioAllocation EV71-1001
Vaccine upUniversity All 16 Years toNot
99 Years
ApplicÂ (Child,
1326Adult,
Adult) IRB201601
Biological: BCG VaccinGreen SignAll up to 14 Years
Phase
Â 3(Child) 120 Industry InterventioAllocation BCGV/034/
Appearance Tampere Un All up to 2 Months
PhaseÂ1 (Child) 315 Other InterventioAllocation 98203M Kn
Safety endInternationAll 2 Years to 45
Phase
Years
1 Â (Child,144
Adult)
Toxicities FukushimaAll 20 Years toPhase
80 Years
1 Â (Adult, 9Older
25 Years
3 Â (Child,
1072Adult)
Industry InterventioAllocation V59P11|20
Receipt of University All 4 Months andNot older
ApplicÂ (Child,
480000Adult,
Adult) R01AI1350
1 Dose CovUniversity Female 11 Years toNot
18 Years
ApplicÂ (Child,
831Adult)
Other InterventioAllocation PP100047
Number ofHuman Geno All 18 Years andPhase
older
4 Â (Adult, 79
Older
Industry
Adult) InterventioAllocation 115470|HG
Anti-Circu GlaxoSmithAll 6 Months to Phase
6 Years
3 Â (Child)759 Industry InterventioAllocation 200596
older
2 Â (Older Adult)
63 Industry InterventioAllocation V70_44S|2
Number ofBiomedizinAll 18 Years toPhase
64 Years
1 Â (Adult)23 Industry|OInterventioAllocation BioMed071
Demonstrat Novartis V All 7 Weeks toPhase
16 Weeks
3 Â (Child)257 Industry InterventioAllocation M14P6|Imp
Safety: inc Fidec CorpAll 6 Weeks toPhase
5 Years
4 Â (Child)164 Other InterventioInterventi M2-ABMG
Total effec PATH|InstiAll 6 Months to Phase
10 Years
4 Â (Child)
10000 Other|InduInterventioAllocation TIV-SEN-01
Humoral imTuen Mun A Hll 18 Years and older Â (Adult, 90Older
Other
Adult) ObservatioObservatioNTWC/REC
safety and Gamaleya R All 18 Years toPhase
40 Years
1 Â (Adult)36 Other InterventioAllocation GamLPV-0
Humoral ImMedical UnAll 18 Years toPhase
60 Years
4 Â (Adult) 116 Other InterventioAllocation RV_FSME_1
49 Years
1 Â (Adult)25 NIH InterventioInterventi URMC 10-
Immunogeni University Male 18 Years toNot
26 Years
ApplicÂ (Adult)
220 Other|InduInterventioAllocation IISP#3820
50 Years
2 Â (Child, 118
Adult)
Industry InterventioAllocation CYD63|U11
ProportionProf. Eliza All 18 Years toPhase
65 Years
2 Â (Adult,38Older
Other|Indu
Adult)InterventioInterventi MenOccy|I
Solicited l Il-Yang PhaMale 20 Years toPhase
55 Years
1 Â (Adult) 100 Industry InterventioAllocation IY_IFEZ_10
The Geomet Novartis V All 55 Days to Phase
89 Days
3 Â (Child)3630 Industry InterventioAllocation V72P13|EU
PercentageNovartis V All 365 Days toPhase
394 Days
3 Â (Child)2249 Industry InterventioAllocation V72P13E1|
DetermineEmory Unive All 18 Years and older Â (Adult,300Older
Other|NIHObservatioObservatioIRB000028
Adult)
Vaccine Ef University Male 18 Years toPhase
50 Years
2 Â (Adult) 120 Other InterventioAllocation VAC046
Co-PrimaryOlogy BiosAll 6 Months toPhase
17 Years
3 Â (Child) 60 Industry InterventioInterventi 811202
Number ofVaccitech
d All 65 Years and
Phase
older
Industry|OInterventioAllocation FLU007 IN
PercentageWyeth is nAll up to 54 Days
Phase
Â (Child)
3 354 Industry InterventioAllocation 6096A1-01
ProportionUniversity All up to 45 Years
600 Other|InduInterventioAllocation 18-2793
to 14 Months
4 Â 173
(Child)
Industry InterventioAllocation GRC29
Immunogeni AdimmuneAll 18 Years and
Phase
older
4 Â (Adult,130
Older
Industry
Adult) InterventioInterventi FLU12T13A
The Number National I All 4 Years to 25
Phase
Years
2 Â (Child,155
Adult)
NIH InterventioInterventi P1088|108
non-inferi London Scho Female 9 Years to 14
Phase
Years
3 Â (Child)930 Other|NIHInterventioAllocation MITU-002
hSBA GMT|h St George' All 7 Weeks toPhase
11 Weeks
4 Â (Child) 132 Other|InduInterventioAllocation 16.0247|2
Number ofGlaxoSmithFemale 9 Years to 45 Years Â (Child,3017
Adult)
Industry ObservatioObservatio 207350
To identif Novartis V All 18 Years and
Phase
older
3 Â (Adult,660
Older
Industry
LaboratoryWayne SullAll Child, AdulPhase 4 4598 Other|U.S.InterventioAllocation F09042200
Safety of University All 50 Years and
Phase
older
1 Â (Adult, 24
Older
Other
Adult) InterventioAllocation Flu003
Phase
older
4 Â (Adult,150
Older
Other
Adult) InterventioInterventi HP-000400
AntibodiesUniversity Female 18 Years and
Phase
older
4 Â (Adult,158
Older
Other
Adult) InterventioInterventi 9-VPH-MVI
To identif Novartis V All 6 Months toPhase
17 Years
3 Â (Child) 752 Industry InterventioAllocation V110_04|2
Influenza MedImmunAll 6 Months and older Â (Child,
147494Adult,
Industry
Older ObservatioTime
Adult) PerspMI-MA156
To identif Novartis V All 6 Months toPhase
17 Years
3 Â (Child) 778 Industry InterventioAllocation V111_03|2
Evaluate t Ewha Woma All 2 Years to 90
Phase
Years
4 Â (Child, Adult,
70 Other
Older Adult)
InterventioInterventi EU-KF-050
Serotype-SPfizer All 50 Years and
Phase
older
3 Â (Adult,324
Older
Industry
Adult) InterventioAllocation B1851048|
Number ofThe Immuno Male 18 Years and older Â (Adult,374Older
Other
Adult) ObservatioObservatioASCLIN 00
Measure ad Jun Zhang|All 18 Years toPhase
55 Years
1 Â (Adult) 144 Other|InduInterventioAllocation HPV-PRO-0
safety and Novartis V All 6 Months toPhase
17 Years
2 Â (Child) 471 Industry InterventioAllocation V87P6|200
Presence ofUniversity Male 35 Years toPhase
45 Years
4 Â (Adult)30 Other InterventioInterventi 2010/0707
To determin Chinese UnAll 18 Years and
Phase
older
1 Â (Adult, 18
Older
Other
Adult) InterventioInterventi VAC002
Number ofPATH|InstitAll 18 Years toPhase
49 Years
1 Â (Adult)48 Other|InduInterventioAllocation IVAC-mH1N
Phase
Years
2 Â (Child)4002 Industry InterventioAllocation CYD23|201
65 Years
U.S. Fed
Adult)InterventioAllocation S-13-06
Safety of PX'Therap Female 18 Years toPhase
55 Years
1 Â (Adult)24 Industry|OInterventioAllocation EN41CT1.1
Anti-PD, a GlaxoSmithAll 50 Years toPhase
80 Years
Industry
to determiErasme UniAll 18 Years and
Phase
older
4 Â (Adult,185
Older
Other
Adult) InterventioInterventi Etude 200
PercentageNovartis V All 2 Months toPhase
6 Months
2 Â (Child)
To determiMary CrowlAll 18 Years and
Phase
older
1 Â (Adult, 50
Older
Other
Adult) InterventioAllocation MCMRC #0
Summary of Sanofi All 18 Years toPhase
49 Years
2 Â (Adult) 729 Industry InterventioAllocation GCE03
Frequency National
o InAll 6 Months toPhase
36 Months
1 Â (Child)
28 NIH InterventioAllocation P1096|117
Number ofM.D. AnderAll Child, AdulPhase 2 39 Other|InduInterventioAllocation 2003-0605
Change FroSiriraj Hos All 1 Year to 5Phase
Years Â4 (Child) 50 Other|InduInterventioInterventi JEC26-EXT
Immunogenic Institut N Female 18 Years toPhase
45 Years
2 Â (Adult) 110 Other|InduInterventioInterventi C09-33|20
1. Isolatio Emory Unive All 18 Years toNot
70 Years
Adult) IRB000095
40 Years
1 Â (Adult)22 NIH|OtherInterventioAllocation CIR 247
Receipt of InternationAll 2 Years andNot
older
Applic
Â (Child,
51151
Adult,
Other
Older Adult)
InterventioInterventi DK - 02
the Serum Abbott All 18 Years and
Phase
older3 Â (Adult,120Older
Industry
Adult) InterventioInterventi INFL3014
Number ofSanofi All 65 Years and
Phase
older2 Â (Older817 Adult)
Industry InterventioAllocation FID04
Twelve Mon Mayo CliniFemale 9 Years to 26
Phase
15 Other|InduInterventioInterventi 09-000485
ReactogeniShanghai InAll 40 Years and
Phase
older1|Ph
Â (Adult,522Older
Industry
Adult) InterventioAllocation 2017L04524-â… /â…¡
Child's ImmUniversity All up to 2 Months
Not Applic
Â (Child) 600 Other|NIHInterventioAllocation 17-1274|1
Immunologi Edward Hirs All 21 Years and
Phase
5 Other
Adult) InterventioInterventi BG1006
Information Sanofi Pas All 10 Years and
Phase
older3 Â (Child,816Adult,
Industry
Older Adult)
InterventioAllocation VRV08|U11
Serum Haem GlaxoSmithAll 65 Years and
Phase
older3 Â (Older726 Adult)
Industry InterventioAllocation 112662
Number ofShenzhen KAll up to 24 Hours
PhaseÂ 4(Child) 5000 Industry|OInterventioInterventi KT0012
Identificat MedImmune All 2 Years to 17 Years Â (Child)
8760 Industry ObservatioObservatioMA-VA-MED
To assess tDana-FarbeAll 18 Years and
Phase
older1 Â (Adult, 33Older
Adult) 08-160
50 Years
1|Ph
Â (Adult)82 U.S. Fed InterventioAllocation WRAIR 155
Post-vaccinMarshfieldAll 18 Years toPhase
64 Years
4 Â (Adult) 350 Other|U.S.InterventioAllocation MCL10218
Seropositi Serum InstiAll 15 MonthsPhase
to 18 Months
4 Â 341(Child)
Industry|OInterventioAllocation MMR-01/12
Number ofPATHP VacciAll 24 MonthsPhase
to 59 Months
2 Â 309(Child)
Other InterventioAllocation LAIV-BD-01
OccurrenceJiangsu Pr All 18 Years toEarly
65 Years
Other|Indu
Adult)InterventioAllocation JSVCT027a
Utilization University All 18 Years and
Notolder
Applic
Â (Adult, 42Older
Other
The primary COL GeorgeAll 18 Years and
Phase
older1|Ph
Â (Adult,100Older
U.S.Adult)
Fed InterventioAllocation 00-2005|
GeometricNovartis V All 4 Years to 18
Phase
Years3 Â (Child,
2333 Adult)
Number ofInternatio
p All 1 Year to 14 Years Â (Child)
75170 Other ObservatioObservatioPR-15091
All-Cause Brigham anAll 18 Years and
Phase
older4 Â (Adult,
5388 Older
Adult) 2015P001
PercentageMerck ShaFemale 9 Years to 15
Phase
Years3 Â (Child)110 Industry InterventioInterventi V501-029|
Evaluate imSinovac BioAll 6 Months toPhase
35 Months
4 Â (Child)
310 Industry InterventioAllocation PRO-PanFl
Number and Inge MarieAll 18 Years and
Phase
older1|Ph
Â (Adult, 50Older
Other
Adult) InterventioInterventi MM1636
Reactions Codagenix,All 18 Years toPhase
45 Years
1 Â (Adult)33 Industry InterventioAllocation CODA01-0
To assess tNational InFemale 25 Years toNot
40 Years
ApplicÂ (Adult)222 Other InterventioAllocation 111040 (HP
Co-PrimaryOlogy BiosAll 65 Years and
Phase
91 Industry InterventioInterventi 811201
The primarFuda CanceAll 20 Years toPhase
80 Years
1|Ph
Â (Adult,40Older
OtherAdult)InterventioAllocation CLL-001|2
Phase
older4 Â (Adult,260Older
Other
Immunogenic Internatio All 10 MonthsPhase
to 12 Months
4 Â1000(Child)
Other InterventioAllocation PR-11050
Number ofKaiser Per All 18 Years to 64 Years Â 1600000
(Adult) Other|InduObservatioObservatioCN-18-317
sero-converAga Khan UAll 14 Weeks toPhase
10 Months
4 Â (Child)
500 Other InterventioAllocation 4624-Ped-
Number ofStanford Un All 8 Years to 34
Phase
86 Other|NIHInterventioAllocation SU-21987-
Seroconvers Gilead Sci All 18 Years and older Â (Adult, Older2 Industry
Adult) ObservatioObservatioGS-US-313
Solicited Butantan I All 18 Years toPhase
45 Years
1 Â (Adult)48 Other InterventioAllocation EGA-01-IB
To evaluateNovartis|NAll 6 Months toPhase
59 Months
2 Â (Child)
To evaluateChinese AcAll 6 Months toPhase
35 Months
3 Â 1200
(Child)
Other InterventioAllocation IMBCAMS-
105 Days
3 Â (Child)605 Industry InterventioAllocation 6096A1-50
to evaluateJiangsu ProAll 5 Years to 22
Phase
Years
1 Â (Child,100
Adult)
Persistent University Female 15 Years toPhase
20 Years
4 Â (Child,
2250 Adult)
Other InterventioAllocation STUDY000
65 Years
U.S. Fed
Adult)InterventioInterventi A-14568.a
Number ofSanofi Pas All 42 Days to Phase
50 Days3 Â (Child)
2133 Industry InterventioAllocation AL201
Rate of Tr H. Lee MofFemale 18 Years and
Phase
older
1 Â (Adult, 15
Older
Other
Influenza vService de All 18 Years toNot
65 Years
ApplicÂ (Adult,
379Older
OtherAdult)InterventioAllocation MDP-2016-
AssessmentFluart InnoAll 18 Years and
Phase
older
4 Â (Adult,120
Older
Industry
Adult) InterventioInterventi Fluval AB-
Number ofDana-FarbeAll 18 Years and
Phase
older
1|Ph
Â (Adult, 44
Older
Other
GeometricNational
m InAll 18 Years toPhase
47 Years
1 Â (Adult)62 NIH InterventioAllocation 13-0087
Pain Follo Duke UniveFemale 9 Years to 18
Phase
Years
4 Â (Child, Adult)
72 Other|U.S.InterventioAllocation Pro000143
CombinationVanderbiltAll Child, AdulNot Applic 8 Other InterventioAllocation 190032
OccurrenceU.S. Army All 12 MonthsPhase
to 47 Months
1 Â 135
(Child)
U.S. Fed|OInterventioAllocation WRAIR 103
Number ofSanofi
50 Years
2 Â (Adult)150 Industry InterventioAllocation CYD50|U11
Mortality|Bandim Hea All 9 Months toPhase
35 Months
4 Â 3500
(Child)Other InterventioAllocation MV-EPI
PercentagesNovartis V All 2 Years to 10
Phase
Years
3 Â (Child)
PercentageBeijing MinAll 2 Months toPhase
6 Years
3 Â (Child)
2195 Industry InterventioAllocation 2013L0104
45 Years
2 Â (Adult)90 Industry|UInterventioAllocation CYD56|U11
112 Days
occurrenceSerum InstiAll 6 Weeks toPhase
8 Weeks
3 Â (Child)
7500 Industry|OInterventioAllocation ROTA:03/1
70 Years
Rabies neutChulalongkAll 12 MonthsPhase
to 60 Years
4 Â (Child,
40 Other
Adult) InterventioInterventi RabiesPID
ImmunizatiUniversiti All Child, AdulNot Applic 1813 Other InterventioAllocation MOPING/V
Antibody tSanofi Pas All 12 MonthsPhase
to 23 Months
3 Â 675
(Child)
Industry InterventioAllocation MEQ00065|
The PercenMerck ShaAll 2 Months toPhase
2 Months
3 Â (Child)
1718 Industry InterventioAllocation V232-057|
PercentageSanofi Pas All 2 Years to 45
Phase
Years
2 Â (Child,
1198
Adult)
Industry InterventioAllocation CYD28|201
HPV vaccineArizona St All 9 Years to 18
NotYears
Applic
Â (Child, Adult)
90 Other|NIHInterventioAllocation STUDY000
Safety Ass UbiVac|ProMale Child, AdulPhase 1 3 Industry|OInterventioInterventi 14-116B
Evaluate s Washington Female 18 Years and
Phase
older
1 Â (Adult, 15
Older
Other
Adult) InterventioInterventi 06-0298 /
Number ofKing's
p Col All 18 Years and older Â (Adult,270Older
Other
Adult) ObservatioObservatio16/LO/100
seasonal inUniversity All 24 MonthsNotto 60Applic
Months Â3618
(Child)
Other|U.S.InterventioAllocation 5U01IP000
GeometricSanofi Pas All 12 MonthsPhase
to 18 Months
3 Â 123
(Child)
Industry InterventioAllocation MTA73|U11
Hantaan VaU.S. Army All 18 Years toPhase
49 Years
1 Â (Adult)27 U.S. Fed InterventioAllocation S-15-40|W
Evaluate thVaxart All 19 Years toPhase
49 Years
1 Â (Adult)66 Industry InterventioAllocation VXA-G11-1
Pocket for Seoul Nati All 32 Years toPhase
60 Years
3 Â (Adult)145 Other|InduInterventioInterventi CJ_SPX_303
80 Years
OtherAdult)InterventioAllocation CLN-001|2
Number ofNova
P Immun All 18 Years and
Phase
older
1 Â (Adult,102
Older
Industry
Adult) InterventioAllocation MPE002
Haemagglut Pantec BioAll 18 Years toPhase
30 Years
1 Â (Adult)20 Industry|OInterventioAllocation PCT-007
50 Years
1 Â (Adult)40 NIH|OtherInterventioAllocation RV 508|WR
GeometricNovartis|NAll 12 MonthsPhase
to 23 Months
2 Â 992
(Child)
Decisional Taipei MedAll 20 Years toNot
80 Years
ApplicÂ (Adult,
180Older
OtherAdult)InterventioAllocation 108HHC-0
Incidence Treos Bio All 18 Years toPhase
75 Years
Adult) OBERTO 10
PreventiveResearch InAll 18 Years and
Phase
older
3 Â (Adult,
2000
Older
Other
Adult) InterventioInterventi VSI-III-01/
Safety|Imm University All 18 Years and
Phase
older
4 Â (Adult,120
Older
Other
Adult) InterventioInterventi Upenn HIV
To determinLoyola UnivFemale 18 Years and
Phase
older
2 Â (Adult, 36
Older
Other
The serocoSinovac (DaAll 8 Months toPhase
18 Months
3 Â 1150
(Child)
Industry InterventioAllocation PRO-MUMP
Humoral res University All 18 Years toNot
85 Years
Other|Indu
Adult)InterventioAllocation 9419
CategoricalUniversity All 6 Months toNot24Applic
Years Â (Child,
31Adult)
Other InterventioAllocation HUM 0003
Feasibilit City of HopAll 18 Years toPhase
80 Years
2 Â (Adult,36Older
Adult) 18007|NCI
75 Years
OtherAdult)InterventioAllocation CLP-001|2
Efficacy o University All 9 Months toPhase
12 Years
3 Â (Child)
Safety andUniversity All 65 Years and
Phase
older
1 Â (Older Adult)
50 Other|InduInterventioAllocation B2011:131
Non-inferi Novartis V All 6 Years andPhase
644 Industry
Older Adult)
InterventioAllocation V49_24
1 Year
3 Â (Child)1630 Industry InterventioAllocation V59P21|BB
Phase
older
OccurrenceNational InAll 18 Years toPhase
49 Years
GeometricTakeda All 18 Years and
Phase
older
2 Â (Adult,528
Older
Industry
Adult) InterventioInterventi NOR-213|2
Phase
Years
1 Â (Child, Adult)
40 Industry InterventioAllocation Td527|U11
Safety of InternationAll 18 Years toPhase
40 Years
1 Â (Adult) 147 Other|InduInterventioAllocation IAVI B002
198 Industry
Older Adult)
InterventioInterventi V59_50
49 Years
Time to th National InAll 27 Years and
Phase
older
3 Â (Adult,575
Older
NIHAdult) InterventioAllocation A5298|117
Antibody tiSanofi Pas All 12 MonthsPhase
to 23 Months
3 Â1183
(Child)
Number ofRockefellerAll
D 18 Years toNot
60 Years
ApplicÂ (Adult)10 Other InterventioInterventi BRO-0828
Efficacy of Wake ForestAll 18 Years and older Â (Adult, 38Older
Adult)
Antibody RRockefellerAll 18 Years toNot
65 Years
OtherAdult)InterventioAllocation UAN-0891
GeometricSanofi Pas All 50 Years and
Phase
older
2 Â (Adult,479
Older
Industry
Adult) InterventioAllocation H-244-004
89 Days
Humoral imAssistance All 18 Years toPhase
65 Years
OtherAdult)InterventioAllocation P110115
Number ofSanaria IncMale 18 Years toPhase
35 Years
1 Â (Adult)33 Industry|OInterventioAllocation EGSPZV1
Seroconvers China NatioAll 60 Days to Phase
89 Days
4 Â (Child)360 Industry|OInterventioAllocation ChinaNBG
To provideSanofi All 12 MonthsPhase
to 15 Months
2 Â 210
(Child)
Industry InterventioAllocation CYD08|UTN
Evaluation French NatAll 21 Years toPhase
50 Years
1|PhÂ (Adult)92 Other InterventioAllocation 2012-0024
to 63 Months
3 Â 433
(Child)
Safety andWashington All up to 39 Years
10 Other InterventioInterventi 19-x190
the immunog N.M. WulffFemale 12 Years toPhase
18 Years
4 Â (Child, 135
Adult)
Other InterventioInterventi NL26.113.
safety - SAPierre Van All 18 Years toPhase
50 Years
1 Â (Adult)30 Other|U.S.InterventioAllocation UAM4a
AEs occurriGCAM Inc.All 18 Years toPhase
63 Years
2|PhÂ (Adult)
100 Industry InterventioInterventi GCAM-TET-
receipt of Boston ChiFemale 13 Years toNot
17 Years
ApplicÂ (Child)
420 Other InterventioAllocation 10-01-002
Incidence oMayo ClinicFemale 18 Years and
Early
older
PhasÂ (Adult, 19
Older
Adult) MC1361|NC
To evaluateChinese AcAll 60 Days to Phase
90 Days
1 Â (Child)130 Other InterventioAllocation imbcams-0
Influenza nUniversity All 18 Years and
Phase
older
4 Â (Adult, 75
Older
Other
22 Years
2 Â (Child, 251
Adult)
Frequency National
a InAll 6 Months toPhase
24 Months
1 Â (Child)
Immune res Canadian IAll 17 Years toPhase
25 Years
4 Â (Child, 120
Adult)
Other InterventioAllocation CT11
50 Days
3 Â (Child)379 Industry InterventioAllocation AL203
Incidence, Kathryn St All 18 Years toPhase
50 Years
1 Â (Adult)36 Other|U.S.InterventioAllocation 2016P0002
Number ofSanofi Pas Female 18 Years and older Â (Adult,244Older
Industry
Adult) ObservatioObservatioQIV08|U11
Antibody rM.D. AnderAll 18 Years and
Phase
older
4 Â (Adult, 48
Older
Adult) 2016-0714
Hib antiboCentral HosAll up to 6 Months
PhaseÂ4 (Child) 160 Other InterventioAllocation 2013-A013
Change in American PAll 18 Years and older Â (Adult, 6234
Older
Other
Adult) ObservatioObservatio 18
The AdversU.S. Army All 17 Years toPhase
65 Years
2 Â (Child,10 Adult,
U.S. Fed
Adult) A-13480|F
Frequency National
42 Years
1 Â (Adult)20 NIH InterventioInterventi URMC 10-
Number ofUniversity All 2 Years to 9Phase
Years4Â (Child) 34 Other|NIHInterventioAllocation URMC10-00
Difference Tan Tock S All 65 Years andNotolder
Applic
Â (Older8837
Adult)
Other InterventioAllocation DSRB 2017
vaccine effShiraz UnivAll 18 Years toPhase
80 Years
2|PhÂ (Adult,
130Older
OccurrenceNational InAll 2 Years to 10
Phase
Years
1|Ph
Â (Child) 35 NIH InterventioAllocation 06-0072
Grades of sNational InAll 6 Months to Phase
24 Months
1 Â (Child)
Tracking o Sri EdupugaAll 18 Years toNot
45 Years
ApplicÂ (Adult)50 Other|NIHInterventioAllocation IRB000464
Number ofStanford Un All 40 Years andPhase
older
4 Â (Adult, 54
Older
Adult) SU-19385|
measuremen Mahidol UnAll Child, AdulNot Applic 60 Other InterventioAllocation 07-59-14
GeometricSanofi Pas All 6 Months andPhase
older
Industry
Adult) QIV06|U11
The neutralShanghai ZFemale 9 Years to 45
Phase
Years
2 Â (Child,
1200
Adult)
Industry InterventioAllocation 311-HPV-1
25 Years
2 Â (Adult)383 Industry InterventioAllocation 108052 (F
Number ofInstitute o All 18 Years toPhase
47 Years
3 Â (Adult)500 Other InterventioAllocation ITMC0211|
Serologica Region SkaAll 18 Years andPhase
older
4 Â (Adult,505
Older
Other
Adult) InterventioInterventi EU-nr 200
Changes ofJiangsu Pr All 18 MonthsPhase
to 65 Years
4 Â 13500
(Child,Other
Adult, Older
Adult) JSEPI-004
Stage 1: N Janssen VaAll 1 Year and Phase
older Â3 (Child, 1023
Adult,Industry|OInterventioAllocation
Older Adult) CR107372|
B memory University
a Female 17 Years toPhase
35 Years
Other|InduInterventioAllocation H16-00700
Safety: occNational InAll 18 Years toPhase
99 Years
2 Â (Adult, 0Older
NIH Adult)InterventioAllocation 09-0060|N01AI80007C
SeroprotectNovartis V All 61 Years andPhase
older
4 Â (Adult,100
Older
Industry
ProportionTel-Aviv S All 18 Years toNot
65 Years
ApplicÂ (Adult,
200Older
OtherAdult)InterventioInterventi TASMC-09-
To evaluateArmauer Ha All 2 Years to 29
Phase
Years
2 Â (Child,412
Adult)
Other InterventioInterventi AHRI/WHO/
Immunogeni Women's an Female 18 Years and older Â (Adult,150Older
Other|Indu
Adult) ObservatioObservatioHREC/17/
AcceptabilUniversity Female 18 Years to 26 Years Â (Adult)600 Other|NIHObservatioObservatio14-2178|5
Adverse evePawel KalinAll 18 Years andPhase
older
1 Â (Adult, Older
6 Other|NIHInterventioAllocation
Adult) 10-052|R0
CHMP criteNovartis|NAll 65 Years andPhase
older
2 Â (Older Adult)
50 Industry InterventioAllocation V70P3S|Eu
Vaccine PnGlaxoSmithAll 46 MonthsPhase
to 50 Months
3 Â (Child)
Antihemagg Abbott BioAll 18 Years andPhase
older
3 Â (Adult,120
Older
Industry
Adult) InterventioInterventi M13-567|2
60 Years
3 Â (Adult)200 Industry InterventioInterventi DEN-307
to 12 Years
3 Â (Child)
851 Industry InterventioAllocation V72_28E1|
Rate of conXiamen UnivAll 16 Years toPhase
65 Years
3 Â (Child,
112604 Adult,
Other|Indu
Adult) Pro-HE-00
Utilizatio University Female 16 Years andPhase
older
3 Â (Child,197
Adult,
Other
Older Adult)
InterventioAllocation 12-0134-E
Local reac PT Bio Far All 2 Years to 40
Phase
Years
1 Â (Child,100
Adult)
Rabies Vir Novartis V All 18 Years toPhase
50 Years
3 Â (Adult)825 Industry InterventioAllocation M49P8
Safety andUniversity All 6 Months to Phase
35 Months
4 Â (Child)
167 Other InterventioInterventi H09-02749
To evaluateDynPort VaAll 18 Years toPhase
40 Years
1 Â (Adult)40 Industry InterventioAllocation rF1V-01
NYSIIS rep University All Child, AdulNot Applic 31 Other|U.S.InterventioAllocation 5U01IP000
Increase i East Carol All 18 Years toEarly
26 Years
PhasÂ (Adult)
283 Other|InduInterventioAllocation MISP-3963
PercentageSanofi Pas All 11 Years toPhase
60 Years
4 Â (Child,
3651Adult)
Industry InterventioAllocation TDC01
SeroprotectNovartis V All 6 Months to Phase
19 Years
2|PhÂ (Child,
123Adult)
Safety|ImmuLisa H. ButAll 18 Years andPhase
older
1 Â (Adult, 35
Older
Adult) 09-021|1P
older
4 Â (Adult,120
Older
Industry
Adult) InterventioAllocation CSLCT-NHF
older
2 Â (Adult,100
Older
Industry
Adult) InterventioAllocation V71P3S|Eu
70 Years
8 Years
Rotavirus Serum InstiAll 6 Weeks toPhase
8 Weeks
3 Â (Child)
1500 Industry|OInterventioAllocation ROTA: 04 /
Safety and Washington All up to 21 Years
Phase
Â 1(Child, Adult)
10 Other InterventioInterventi 2.02E+08
Anti Influ PharmaJet,All 18 Years toPhase
64 Years
4 Â (Adult)
1250 Industry InterventioAllocation PJ-501-12-
GeometricMerck SharAll 50 Years andPhase
older
3 Â (Adult,600
Older
Adult) V211-029
Short termCHU de Que All 11 Months to 22 Months Â5808 (Child)
Other|InduObservatioObservatio 200783
The ReceipBoston Med Female 11 Years toNot15 Years
ApplicÂ (Child)
200 Other InterventioAllocation H26306
The primary Etubics CoAll 21 Years toPhase
75 Years
Adult) ETBX-011
The primarUniversity All 4 Years to 9Phase
Years4Â (Child) 0 Other|NIHInterventioAllocation URMC 09-
SeroprotecNational InFemale 18 Years toNot 64 Years
ApplicÂ (Adult)
368 NIH|OtherInterventioAllocation DAIT ADRN
SeroconverCenters fo All 6 Months to Phase
11 Months
4 Â (Child)
620 U.S. Fed|OInterventioAllocation CDC
Number ofUniversity
P All 2 Years to 25
Phase
Years
2 Â (Child,101
Adult)
Other|InduInterventioAllocation 13-1752
Number ofNovartis|NAll 18 Years andPhase
older
3 Â (Adult,
1522
Older
Industry
Adult) InterventioAllocation V58P4E2|2
Three group Malaria Vaccine
All and Drug
18 Years
Development
toPhase
45 Years
1|Ph
Center|National
Â (Adult)27 Other|NIH|
Heart, ILung,
nterventioAllocation
and Blood Institute
MVDC-2008
(NHLBI)|Asoclinic Inmuno
Safety and Baylor ReseAll 21 Years toPhase
75 Years
OtherAdult)InterventioInterventi Baylor IRB
AE of localNational VaFemale 9 Years to 45 Phase
Years
1 Â (Child, Adult)
90 Industry|OInterventioAllocation GXIRB2019
17 Years
ApplicÂ (Child)
94000 Other|NIHInterventioAllocation 15-1560|1
To provideSanofi Pas All 18 Years andPhase
older
2 Â (Adult,130
Older
Industry
Adult) InterventioAllocation GRT86
Vaccine SeUniversity All 14 Years toNot
29 Years
ApplicÂ (Child,
546Adult)
Other|NIHInterventioAllocation NIDA-1747
PercentageResearch InAll 18 Years toPhase
50 Years
1 Â (Adult)44 Other InterventioAllocation VSI-I-01/2
antibody tiNovartis|NAll 18 Years andPhase
older
3 Â (Adult,125
Older
Industry
Adult) InterventioAllocation V44P10S|E
Antibody RNational InAll 18 Years toPhase
40 Years
Number ofMerck ShaAll 18 Years toPhase
55 Years
1 Â (Adult)17 Industry InterventioAllocation V520-022|
Safety wil Medicago All 18 Years toPhase
60 Years
1 Â (Adult)48 Industry InterventioAllocation Medicago
Immunologi Novartis V All 18 Years toPhase
49 Years
3 Â (Adult)
Safety of t Craig L SlinAll 18 Years toPhase
85 Years
2 Â (Adult,51Older
55 Years
virus shed Public HeaAll 6 Years to 13
Phase
Years
4 Â (Child)373 Other InterventioAllocation Flushed
The serocon Sinovac Bi All 6 Months to Phase
35 Months
4 Â (Child)
300 Industry|OInterventioAllocation EV71-SD-2
number ofDartmouth- All 18 Years andPhase
older
1 Â (Adult, Older
1 Other
Adult) InterventioInterventi W12209
65 Years
3 Â (Adult,
2831Older
Industry
Adult)InterventioAllocation V59P17
older
2 Â (Adult,168
Older
Industry
49 Years
Number ofUniversity
s All 6 Months to Not
18Applic
Years Â (Child,
56549Adult)
Antibody TiEmory UnivAll 18 Years toPhase
49 Years
The ChangeSt. Justine All 7 Weeks and Phase
older
2 Â (Child, Adult,
56 Other
Older Adult)
Change in Emory Unive All 50 Years andPhase
older
2 Â (Adult, 60
Older
Adult) IRB001058
Safety and National InAll 1 Year to 99Phase
Years2Â (Child,2380
Adult,
NIH
Older Adult)
Safety/ toxAcademisch Male 18 Years andPhase
older
1|Ph
Â (Adult, 40
Older
Other|Indu
Adult) InterventioInterventi NL42802.0
To evaluateNovartis V Female 18 Years toPhase40 Years
The post-i Sinovac (DaAll 1 Year to 3Phase
Years Â3 (Child) 1197 Industry InterventioAllocation PRO-VZV-3
HIA titers University All 16 Years andPhase
older
4 Â (Child, Adult,
50 Other
Older Adult)
InterventioAllocation 06-0380-A
Summary of Sanofi Pas All 6 Months to Phase
11 Months
3 Â (Child)
Maximum PATHSe All 18 Years toPhase
45 Years
1 Â (Adult)48 Other InterventioAllocation VAC 009
The number Tel-Aviv S All 16 Years toPhase
90 Years
Adult) 0344-09
12 Months
3 Â (Child)
720 Industry InterventioAllocation CYD33|U11
Number ofSanofi
64 Years
2 Â (Adult)408 Industry InterventioAllocation VRV02|U11
Changes inUniversity All 50 Years toPhase
85 Years
Other|Indu
PercentageSanofi Pas All 6 Weeks toPhase
8 Weeks
3 Â (Child)177 Industry InterventioInterventi A3L33|U11
Severe diarTD VaccineAll 18 Years toPhase
50 Years
2 Â (Adult)70 Industry|OInterventioAllocation ACE527-10
remaining Govind BalAll up to 1 DayNotÂ (Child)
Applic 259 Other InterventioAllocation LHMC-1
Safety, de National InAll 18 Years toPhase
49 Years
1 Â (Adult)22 NIH|OtherInterventioAllocation CIR 241|W
Influenza VThe ClevelaFemale Child, AdulNot Applic 105 Other InterventioAllocation 13-1157
Time to fir U.S. Army All 6 Months to Phase
18 Months
3 Â (Child)
356 U.S. Fed|OInterventioAllocation HSRRB A-7
ProportionJiangsu ProAll 42 Days to Phase
77 Days3 Â (Child)
1200 Other|InduInterventioAllocation JSVCT022
Number ofSRI InternaAll 18 Years toPhase
50 Years
1 Â (Adult)90 Industry|UInterventioAllocation SRI-VEEV-0
Phase
Years
3 Â (Child,341
Adult)
Vaccine Ef Takeda All 4 Years to 16
Phase
Years
3 Â (Child)
20100 Industry InterventioAllocation DEN-301|U
Serologica University All 18 Years toPhase
65 Years
3 Â (Adult,50Older
OtherAdult)InterventioInterventi 2011-0045
Immunogeni Hospices CiAll up to 17 Years
Not ÂApplic
(Child) 341 Other InterventioInterventi 69HCL17_0
AnamnesticFred HutchAll 9 Years to 13
Phase
Years
4 Â (Child)100 Other|NIHInterventioAllocation RG100706
Study the Sinovac BioAll 18 Years toPhase
60 Years
4 Â (Adult)150 Industry InterventioAllocation PRO-PanFl
Number ofNational InAll 18 Years andPhase
older
2 Â (Adult,408
Older
SeroprotecSeoul Nati All 20 Years andNotolder
Applic
Â (Adult, 97
Older
Other|Indu
Adult) InterventioAllocation 1407-057-
Influenza i Shahid BehAll 25 Years andPhase
older
2|Ph
Â (Adult,360
Older
Other
Adult) InterventioAllocation SBMU- 86-
Long term Kf EMRI-WellAll 19 Months to 35 Months Â 450 (Child)
Other|InduObservatioObservatioSSC 1512
The number University Female 18 Years toPhase
39 Years
3 Â (Adult)
2116 Other InterventioAllocation Maternal_
older
2 Â (Adult,126
Older
Industry
To compareWyeth is nAll 2 Years to 9Phase
Years4Â (Child) 101 Industry InterventioAllocation 0887X-101
Three co-pStatens SerAll 18 Years andPhase
older
3 Â (Adult,802
Older
Other
Adult) InterventioAllocation VTdaP-01
Recurrence| Hospital S Female 18 Years to 100 Years Â (Adult,
508 Older
Other|Indu
Adult)
ObservatioObservatioISM-19062
AntibodiesLondon SchFemale 4 Years to 26
Phase
Years
3 Â (Child,
1720
Adult)
Other|InduInterventioAllocation SCC 1597
The primarSt. Jude ChAll 2 Years to 21
Phase
Years
1 Â (Child, Adult)
56 Other InterventioAllocation FMRESP
Gene expreSt George'sFemale Child, Adult, Older Ad 30 Other ObservatioObservatio 17.006
Early geneUniversity All 13 MonthsPhase
to 65 Years
2 Â (Child,
120 Other|Indu
Adult, Older
InterventioInterventi
Adult) OVG 2015/
Post-vaccinFluart InnoAll 18 Years andNotolder
Applic
Â (Adult,234
Older
Industry
The changeThe 458 HoAll 18 Years toPhase
65 Years
2 Â (Adult,33Older
OtherAdult)InterventioAllocation 71007.02
Immunogenic NasVax LtdAll 65 Years andPhase
older
Industry InterventioAllocation NX09-4
Timing relaNovartis V All 2 Years to 10 Years Â (Child)393 Industry ObservatioObservatioV59_54OB
older
3 Â (Adult,126
Older
Industry
Hepatitis Tehran UniAll 25 Years toNot
70 Years
Total proteInternatio All 2 Years andPhase
older4Â (Child,
37673
Adult,
Other|Indu
Older Adult)
InterventioAllocation T-17
Safety and Institut N All 18 Years toPhase
60 Years
1 Â (Adult)10 Other InterventioInterventi INSERM R
Measles sePATH|Resea All 9 Months to Phase
9 Months
4 Â (Child)
628 Other InterventioAllocation JEV06 (862
serologic Klara M. P All 12 MonthsPhase
to 20 Years
4 Â (Child,
90 Other
Adult) InterventioInterventi MMR in ped
ProportionInternationAll 1 Year to 40Phase
Years4Â (Child, 200
Adult)
Other|InduInterventioInterventi CH-WC-02
To assess tSellas Lif All 18 Years andPhase
older
2 Â (Adult, 31
Older
Industry|UInterventioAllocation
Adult) 10-134
Clinical sa Archivel F All 18 Years andPhase
older
2 Â (Adult, 27
Older
Adult) 2.02E+08
Protective FundaciÃ³nAll 18 Years toPhase
64 Years
4 Â (Adult)67 Other InterventioInterventi IBS-VACAN
Measures oNovartis|NAll 18 Years toPhase
40 Years
Incidence oFluart InnoAll 3 Years to 18
NotYears
Applic
Â (Child, Adult)
58 Industry InterventioAllocation FLUVAL P-
Determinati Novartis|NAll 32 MonthsPhase
to 40 Months
4 Â 241
(Child)
Industry InterventioAllocation M14P1E1|I
Number ofTakeda All 18 Years toPhase
85 Years
Industry
Adult)InterventioAllocation LV03-104|
50 Years
1 Â (Adult)80 Other|InduInterventioAllocation A001
Change in pVanderbilt All 18 Years toNot
60 Years
ApplicÂ (Adult)
155 Other InterventioAllocation VA 1111
8 Years
To determin Memorial SAll up to 21 Years
PhaseÂ 1|Ph
(Child, Adult)
296 Other InterventioInterventi 05-075
The safety Gary ArcheAll 18 Years toPhase
80 Years
1 Â (Adult, 7Older
Other|Indu
Adult)InterventioAllocation Pro000652
Number ofU.S. Army All 1 Year to 6Phase
Years Â2 (Child) 400 U.S. Fed|NInterventioAllocation 07-0003|U
Frequency National
55 Years
1 Â (Adult)36 NIH|OtherInterventioAllocation HVTN 088|
Safety andWashington All 18 Years and
Phase
older
1 Â (Adult, Older
6 Other
Adult) InterventioInterventi 18-x324
Safety andInternatio All 6 Weeks toPhase
50 Years
Other|InduInterventioAllocation PR-11023|
Clinically University All 18 Years toPhase
60 Years
2 Â (Adult)112 Other InterventioAllocation OVG 2014/
NeutralizinKhon KaenAll 72 MonthsPhase
to 80 Months
4 Â (Child)
88 Other InterventioInterventi JEC24
A single apUniversity All 19 Years toPhase
60 Years
1|PhÂ (Adult)39 Other InterventioAllocation C05-0027
Safety: inc National InAll 18 Years toPhase
45 Years
GeometricWyeth is nAll 42 Days to Phase
98 Days3 Â (Child)
1712 Industry InterventioAllocation 6096A1-30
Field Trial Children's Female 15 Years toPhase
45 Years
3 Â (Child,
3000Adult)
Other InterventioAllocation Mothers'Gif
SeroprotecPATH|VA Pu All 65 Years and
Phase
older
2 Â (Older257
Adult)
Other|U.S.InterventioAllocation ID/RD01
18 Years
3 Â (Child,
1620Adult)
HemagglutiJanssen VaAll 60 Years and
Phase
older
2 Â (Adult,180
Older
Industry
Adult) InterventioAllocation CR108403
Number ofNational InAll 18 Years and
Phase
older
2 Â (Adult,789
Older
NIHAdult) InterventioAllocation 09-0058
ConcentratGlaxoSmithAll 6 Weeks toPhase
12 Weeks
Phase
older
2 Â (Adult,300
Older
Industry
Adult) InterventioAllocation MET44|U11
Hepatitis BBenha UnivAll 19 Years and
Notolder
Applic
Â (Adult,114
Older
Other|Indu
Adult) InterventioAllocation BN-0517
GeometricNational
m InAll 65 Years and
Phase
older
1|Ph
Â (Older261
Adult)
NIH InterventioAllocation 04-076
GeometricDr R. Sank Female 10 Years toPhase
18 Years
4 Â (Child,
20000Adult)
Other InterventioAllocation BMGF48979
LaboratoryCenters fo All 6 Months to 10 Years Â (Child)
10000 U.S. Fed|OObservatioObservatioCDC-NCIRD
To select DynPort VaAll 18 Years toPhase
55 Years
2 Â (Adult)400 Industry InterventioAllocation:rF1V-02(a)
SeroconverXiamen InnAll 18 Years toPhase
50 Years
4 Â (Adult) 0 Industry|OInterventioAllocation PRO-HE-01
Objective Buhai Wang Female 18 Years and
Phase
older
2 Â (Adult, 20
Older
Other|Indu
Adult) InterventioInterventi WBH-7209
Adverse R JN-InternaAll 18 Years toPhase
50 Years
1 Â (Adult)60 Industry InterventioAllocation JN-NM-001
Post-Dose Sanofi Pas All 18 Years toPhase
60 Years
HPV vaccinUniversity Female 12 Years toNot
26 Years
ApplicÂ (Child,
256Adult)
evaluate thBeijing CenAll 10 Years toPhase
60 Years
Other|InduInterventioAllocation BJCDCP-10
seroconvers UMN Pharm All 20 Years toPhase
64 Years
3 Â (Adult)900 Industry InterventioAllocation 7374-CL-0
ImmediateResearch InAll 18 Years toPhase
49 Years
Incidence aSanaria In All 6 Months toPhase
45 Years
Industry|OInterventioAllocation BSPZV2
GMT antibo University All 18 Years toPhase
50 Years
1 Â (Adult)175 Other|InduInterventioAllocation UHL10763
55 Years
1 Â (Adult)40 U.S. Fed|NInterventioAllocation WRAIR 102
Number ofGlaxoSmithAll 50 Years and
Phase
older
3 Â (Adult, 96
Older
Industry
Adult) InterventioInterventi 116796|20
Titer to H Janssen VaAll 18 Years toPhase
50 Years
1 Â (Adult)36 Industry InterventioAllocation CR108068
35 Months
4 Â (Child)
To evaluateFidec CorpAll 5 Weeks toPhase
5 Years
4 Â (Child)154 Other InterventioInterventi T2-ABMG
Pneumococc University All 8 Weeks toPhase
12 Weeks
2 Â (Child)189 Other InterventioAllocation OVG2015/
Number ofAuburn UniAll 19 Years andNotolder
Applic
Â (Adult, 52
Older
Adult) 1R36HS026
Solicited PT Bio Far All up to 40 Years
Phase
Â 1(Child, Adult)
100 Industry InterventioAllocation RV 0117
The PercenNovartis V Female 18 Years toPhase
40 Years
1|PhÂ (Adult)
380 Industry InterventioAllocation V98_08|MC
Vaccine SaUniversity All 18 Years toPhase
50 Years
Phase
Years
2 Â (Child)150 Industry InterventioAllocation CYD30|UTN
Evaluate t National InAll 18 Years toPhase
45 Years
1 Â (Adult)60 NIH InterventioAllocation 01-002|11
To evaluat PaxVax, IncAll 18 Years toPhase
49 Years
1 Â (Adult)60 Industry|NInterventioAllocation HVTN 110
Phase
Years
3 Â (Child,180
Adult,
Industry
Older Adult)
ConcentratGlaxoSmithAll 9 Months to Phase
18 Months
3 Â (Child)
282 Industry InterventioAllocation 112909
SeroconverLaboratori All 3 Years to 17
Phase
Years
3 Â (Child)
1556 Industry|OInterventioAllocation LIO-04-16
ConversionCaladrius BAll 16 Years andPhase
older
1|Ph
Â (Child, Adult,
9 Industry
Older Adult)
InterventioInterventi CDR000006
Number ofH. Lee MofAll 18 Years andNotolder
Applic
Â (Adult, 16
Older
Other|Indu
Human Papi H. Lee MofFemale 16 Years toNot
24 Years
ApplicÂ (Child,
406Adult)
Other|InduInterventioAllocation MCC-16685
Response to National HeAll 18 Years toPhase
99 Years
Reliant MeUniversity All 18 Years andNotolder
Applic
Â (Adult,
30000
Older
Other|Indu
Adult) InterventioAllocation 9713747|H
Serologica Kyunghee U All 18 Years andPhase
older
4 Â (Adult,197
Older
Other
Adult) InterventioAllocation CD vaccina
ProportionInstitut P Female 15 Years toNot
55 Years
ApplicÂ (Child,
8500Adult)
Industry|OInterventioAllocation 2017-083
PercentagePfizer All 10 Years toPhase
25 Years
3 Â (Child,
5715Adult)
Industry InterventioAllocation B1971014|
Vaccine-reBaylor Col All 18 Years toPhase
50 Years
1 Â (Adult)32 Other InterventioAllocation HV-001|60
HPV vaccina Children's All 18 Years andNotolder
Applic
Â (Adult,225
Older
Other
Adult) InterventioAllocation Childrens
older
3 Â (Adult,651
Older
Industry
Time to fir Seqirus All 65 Years andPhase
older
3 Â (Older6798
Adult)
40 Years
1 Â (Adult) 0 NIH InterventioAllocation 09-0100
PercentageGlaxoSmithAll 55 Days to Phase
89 Days3 Â (Child)225 Industry InterventioAllocation 205249|V7
The PercenSeqirus All 18 Years toPhase
59 Years
4 Â (Adult)120 Industry InterventioInterventi CSLCT-TIV
PercentagePfizer All 42 Days to Phase
Safety|Imm University All 18 Years toPhase
50 Years
1 Â (Adult)52 Other InterventioAllocation 2011/06
50 Years
1 Â (Adult)28 NIH|OtherInterventioAllocation CIR 189|H.
adverse evInternationAll 12 MonthsPhase
to 40 Years
2 Â (Child,
200 Other|Indu
Adult) InterventioAllocation C-8-ph2
1. Percent Novartis V All 10 Years toPhase
25 Years
Anti-HBs anGlaxoSmithAll 18 Years andPhase
older
3 Â (Adult, 93
Older
Industry
To determin St. Jude ChAll 12 MonthsPhase
to 6 Years
1 Â (Child) 54 Other InterventioInterventi SENDAI
Time to Pr Gradalis, InAll 18 Years andPhase
older
2 Â (Adult, Older
1 Industry
Adult) InterventioInterventi CL-PTL 110
RT-PCR-conf Seqirus|NoAll 6 Months to Phase
72 Months
3 Â10647
(Child)
GeometricMerck ShaAll 16 Years toPhase
26 Years
3 Â (Child,
2520Adult)
Industry InterventioAllocation V503-003|
64 Years
Cure rate Assiut UnivAll 3 Years to 50
Phase
Years
3 Â (Child, Adult)
45 Other InterventioAllocation MMR vaccin
Number ofStanford Un All 24 MonthsPhase
to 35 Months
4 Â (Child)
6 Other|NIHInterventioInterventi SU-15086|
Primary enNational HeAll 20 Years toPhase
60 Years
1 Â (Adult)60 Other InterventioAllocation QCR-10013
PercentageSt. Jude ChAll 2 Years to 8Phase
Years2Â (Child) 87 Other InterventioAllocation FLUVIT
To evaluat GlaxoSmithAll 18 Years toPhase
60 Years
1 Â (Adult)400 Industry InterventioAllocation 106750
To assess aFondazioneAll 18 Years and older Â (Adult,124Older
Other
Adult) ObservatioObservatioINT 72/09
Number ofHualan BiolAll 6 Months andPhase
older
Industry
Adult) Hualanbio-
SeroconverVaxInnate All 18 Years toPhase
64 Years
2 Â (Adult)450 Industry|UInterventioAllocation VAX2012Q-
immunologicHadassah M All 15 Years toPhase
70 Years
1|PhÂ (Child,13
Adult,
Adult) RCC- vac-s
HPV vaccinUniversity All Child, AdulNot Applic 223 Other InterventioAllocation 13-3599|7
Demonstrat Wyeth is nAll 65 Years andPhase
older
2 Â (Older915
Adult)
Safety pro University All 1 Year to 45Phase
48 Other InterventioAllocation RAB002
grade 2-4 Hadassah M All Child, AdulPhase 1|Ph 50 Other InterventioInterventi 0419-12-H
GeometricResearch InAll 18 Years toPhase
100 Years
2 Â (Adult,300 Older
OtherAdult)InterventioAllocation VSI-II-01/
Incidence Vaxart All 18 Years toPhase
49 Years
serum bacteNovartis V All 10 Years toPhase
60 Years
Industry InterventioAllocation M49P7
Phase 1: SaNational CaAll 60 Years andPhase
older
1 Â (Adult, 80
Older
NIH|OtherInterventioAllocation
Adult) 190134|19
Number ofColumbia UAll 18 Years and older Â (Adult,400 Older
Other|U.S.ObservatioTime
Adult) PerspAAAD1619
To determiBeth Israe Female 18 Years andPhase
older
2 Â (Adult, 23
Older
Adult) 07-380
Immunogeni Jiangsu ProAll 3 Years to 65
Phase
Years
4 Â (Child,
2225
Adult,
Other|Indu
Older Adult)
InterventioAllocation JSEPI-002
Vaccinatio University All Child, AdulNot Applic 8438 Other InterventioAllocation RRK6479
Serum Haem GlaxoSmithAll 18 Years toPhase
60 Years
49 Years
2 Â (Adult)50 Industry InterventioInterventi NOR-210|U
Injection-SDuke UniveAll 65 Years andPhase
older
4 Â (Older778
Adult)
49 Years
3 Â (Adult)
1200 Industry InterventioAllocation CP-PRO-QV
PercentageNovartis|NAll 55 Days to Phase
89 Days3 Â (Child)
Immunogeni Internatio All 1 Month toPhase
45 Years
Other|U.S.InterventioAllocation PR-09070
The primaryMcGill UnivAll 18 Years toPhase
45 Years
4 Â (Adult)
1000 Other InterventioAllocation CIHR-MOP-
Number ofSanofi Pas All 2 Years to 6Phase
Years4Â (Child) 666 Industry InterventioAllocation MPS01|U11
Grade 3 orImperial C All 18 Years toPhase
45 Years
1|PhÂ (Adult)30 Other InterventioAllocation 14SM2037
Measure nu Dalhousie All 13 Years toPhase
65 Years
Other|Indu
Adult) CT1401-B
FMRI|ReacMaastrichtMale 25 Years toPhase
40 Years
1|PhÂ (Adult)38 Other InterventioAllocation CCMO3191
Effect of Roswell ParAll 18 Years toNot
64 Years
ApplicÂ (Adult)
211 Other|NIHInterventioAllocation I 203111|
50 Years
Change in tRoswell PaFemale 18 Years andPhase
older
1|Ph
Â (Adult, 13
Older
Other|Indu
Adult) InterventioAllocation 11-128|5P
AdherenceJesÃºs MorAll 18 Years and older Â (Adult,300 Older
Other
Adult) ObservatioObservatioC-127
Non-inferioSanofi All 56 Days to Phase
70 Days3 Â (Child)370 Industry InterventioAllocation E2I49|U11
TimelinessJohns HopkAll up to 24 Months
Not Applic
Â (Child)2065 Other InterventioAllocation IRB001613
Protection Assistance All 18 Years andPhase
older
4 Â (Adult,234
Older
Other
Adult) InterventioInterventi P 090901
For each ofStatens SerAll 42 Days to Phase
49 Days2 Â (Child)824 Other|InduInterventioAllocation VIPV-05|2
EstimationWake Forest All 18 Years andPhase
older
1 Â (Adult, 28
Older
Adult) IRB000248
Phase
Years
2 Â (Child)300 Industry InterventioAllocation CYD24|201
50 Years
To compareGlaxoSmithAll 18 Years toPhase
45 Years
3 Â (Adult)
2491 Industry InterventioAllocation 208141/01
OccurrencesSanofi Pas All 65 Years andPhase
older
4 Â (Older
31989
Adult)
Industry InterventioAllocation FIM12|U11
Full on ti Swiss TropiFemale Child, AdulNot Applic 200 Other InterventioAllocation GHS-ERC00
Solicited Centre HosAll 18 Years toPhase
65 Years
1|PhÂ (Adult,
120Older
Other|Indu
Adult)InterventioAllocation cAd3-EBOZ
Phase
Years
3 Â (Child,
1440
Adult)
Industry InterventioAllocation Td528|U11
Bris10 - F FluGen IncAll 18 Years toPhase
49 Years
1 Â (Adult)250 Industry InterventioAllocation FLUGEN-H
SeroconversFundaciÃ³nAll 16 Years andPhase
older
3 Â (Child,499
Adult,
Other
Older Adult)
InterventioAllocation TraNsgripe
Influenza aCenters fo All 6 Years to 16
Phase
Years
4 Â (Child)
7854 Other InterventioAllocation DOH97-DC
Pneumococc Wyeth is nAll 65 Years andPhase
older
3 Â (Older105
Adult)
Safety of Oswaldo CrAll 18 Years toPhase
49 Years
1 Â (Adult)20 Other InterventioInterventi sm14-CT00
proportionInternatio All 9 Months to Phase
12 Months
2 Â (Child)
74 Other|InduInterventioAllocation CHPR-01
GeometricSanofi Pas All 65 Years andPhase
older
3 Â (Older
3851
Adult)
Industry InterventioAllocation FIM05
KnowledgeThomas JefAll 50 Years andPhase
older
4 Â (Adult,203
Older
Other
Adult) InterventioInterventi Merck IISP
Number ofGlaxoSmithAll 2 Months to 23 Months Â (Child)
144 Industry ObservatioObservatio205534|V
reactogenicPATH All 18 Years toPhase
45 Years
1 Â (Adult)60 Other InterventioAllocation VAC-046
8 Years
PathologicUniversity All 18 Years and older Â (Adult, 30Older
Other
Adult) ObservatioObservatioSIRVA
vaccine effInternatio All 5 Years to 60
Phase
Years
4 Â (Child,
96468
Adult)
Other|U.S.InterventioAllocation T3
older
4 Â (Adult,120
Older
Industry
Immune res Cancer ResAll 18 Years andPhase
older
1 Â (Adult, 22
Older
Other
Adult) InterventioPrimary PuCRUKD/13
GeometricNational InAll 18 Years toPhase
49 Years
45 Years
2 Â (Adult)189 Industry InterventioAllocation CYD47|UTN
24 Months
1 Â (Child)
17 NIH InterventioAllocation IMPAACT 2
45 Years
Plasma HAIStanford Un Female 18 Years toPhase
49 Years
4 Â (Adult)50 Other|NIHInterventioInterventi 50163|5U1
50 Years
Solicited a Green CrosAll 19 Years toPhase
65 Years
Industry
Adult)InterventioAllocation GC3110A_
Occurrence, Centers forAll 18 Years toPhase
60 Years
1 Â (Adult)36 Other InterventioAllocation CDCPChina
Humoral imMedical UnAll 18 Years toPhase
60 Years
4 Â (Adult)73 Other InterventioInterventi TBE_obesit
Percent of University All 11 Years toNot
17 Years
ApplicÂ (Child)
34581 Other|U.S.InterventioAllocation 10-1209|U
24 Months
1 Â (Child)
Comparison National InAll 18 Years andPhase
older
2 Â (Adult, 78
Older
NIHAdult) InterventioAllocation 160053|16
Immunogenic Johns HopkFemale 15 Years toPhase
45 Years
Other|InduInterventioInterventi IRB002279
Phase 1 - H. Lee MoffAll 18 Years andPhase
older
1|Ph
Â (Adult, 44
Older
Adult) NCI-8461|
Immunogeni Medicago All 50 Years andPhase
older
2 Â (Adult,450
Older
Industry
Adult) InterventioAllocation CP-Q13VLP
Immune res Public HealAll 5 Years to 10
Phase
Years
4 Â (Child)300 Other InterventioInterventi LAIV Immu
Immune prot ChangchunAll 1 Year to 6Phase
Years Â4 (Child) 350 Industry|OInterventioIntervention Model:
First Dose RegenstrieAll 11 Years toNot
14 Years
ApplicÂ (Child)
647 Other|InduInterventioAllocation Merck - 14
Number ofGlaxoSmithAll 84 MonthsPhase
to 95 Months
3 Â 156
(Child)
Industry InterventioAllocation 116727|20
Number ofNovartis V All 12 MonthsPhase
to 15 Months
2 Â 202
(Child)
achievemen Elisabethi All 19 Years toPhase
65 Years
2 Â (Adult,99Older
Other|Indu
Adult)InterventioAllocation ASOKLIF 0
concentratiCenters fo All up to 6 Months
PhaseÂ4 (Child) 248 U.S. Fed|OInterventioAllocation CDC-NCID-
Number ofH. Lee MoffAll 18 Years andPhase
older
2 Â (Adult, 43
Older
Adult) MCC-13639
Number ofPT Bio Far All 9 Months to Phase
47 Months
4 Â (Child)
590 Industry InterventioAllocation PMS-MR-0
Change of N a ational C All 18 Years andPhase
older
4 Â (Adult,300
Older
Other
Adult) InterventioAllocation BR-100-08
PercentageChangchunAll 3 Years to 17
Phase
Years
3 Â (Child)
9000 Industry|OInterventioAllocation F20160728
Number ofMerck ShaAll 60 Years andPhase
older
1 Â (Adult,120
Older
Industry
Adult) InterventioAllocation V212-003|
Titers for GlaxoSmithAll 60 Years andPhase
older
2 Â (Adult,150
Older
Industry
ProportionCenters fo All 18 Years andNotolder
Applic
Â (Adult,130
Older
U.S.Adult)
Fed InterventioAllocation CDC-NCEZI
GeometricUniversity All 2 Months to Phase
3 Months
4 Â (Child)
404 Other|InduInterventioAllocation 2008_06
Vaccine proInternatio All 1 Year and older Â (Child, Adult,
240 Other
Older Adult)
ObservatioObservatioCR-WC-10
older
2 Â (Adult, Older
0 Industry
CPMP criter Novartis|NAll 18 Years andPhase
older
2 Â (Adult,520
Older
Industry
Adult) InterventioAllocation V87P1|Eud
Optimal doCity of HopAll 1 Year to 21Phase
Years1|Ph
Â (Child, Adult)
80 Other|NIHInterventioInterventi 17236|NCI
The proport Children's All 6 Years to 12 Years Â (Child)
1500 Other ObservatioObservatio2019-09
Number ofMemorial SFemale 18 Years andNotolder
Applic
Â (Adult, 22
Older
Other|Indu
the rate ofCenters forAll 60 Years and older Â (Adult,
536812
Older
Other|Indu
Adult) ObservatioObservatioBJCDCWJ2
Number ofButantan
P InMale 18 Years toPhase
40 Years
1 Â (Adult)80 Other InterventioAllocation 1242/06
Antibody CGlaxoSmithAll 42 Days to Phase
76 Days3 Â (Child)320 Industry InterventioAllocation 200799
Anti-PRP anNovartis V All 6 Months to Phase
12 Months
3 Â (Child)
Number ofGlaxoSmithAll 1 Year to 17Phase
Years3Â (Child) 86 Industry InterventioAllocation 115524|20
Number ofSanofi Pas All 12 MonthsPhase
to 18 Months
3 Â1843
(Child)
Industry InterventioAllocation AL204
AcceptabilOhio StateMale 18 Years toNot
25 Years
ApplicÂ (Adult)
150 Other|NIHInterventioAllocation OSU-15234
ProportionLifespan HAll 6 Weeks toNot12 Months
Applic Â (Child)
1800 Other InterventioAllocation OPP11826
Number ofNational
i InAll 18 Years toPhase
49 Years
Part 2- To University All 18 Years toPhase
60 Years
4 Â (Adult)21 Other InterventioInterventi OVG 2012/
Number ofHarvard
p ScFemale Child, AdulNot Applic 400 Other InterventioAllocation TBDNA
7 Months
4 Â (Child)Other InterventioAllocation MVurban
age appropAga Khan UAll 3 Months to Not
14Applic
Months Â 4560
(Child)
Other InterventioAllocation 1952-Ped-
kinetics of Universite Female 18 Years toPhase
40 Years
4 Â (Adult)370 Other InterventioAllocation cev002
PercentageMahidol UnFemale 18 Years andEarly
older
Phas
Â (Adult,129
Older
Other
Adult) InterventioAllocation SI 089/201
Clinical meNational InAll 18 Years toPhase
50 Years
1 Â (Adult)20 NIH InterventioAllocation 04-086|N0
Number ofInternationAll 1 Year to 45Phase
Adult)
Other InterventioAllocation PR-15076
Cytomegalo City of Ho All 18 Years andPhase
older
2 Â (Adult, Older
0 Other
DetermineNational InAll 18 Years toPhase
50 Years
HI Titers, MarshfieldAll 65 Years toNot
74 Years
ApplicÂ (Older
179
Adult)
Other|U.S.InterventioAllocation MCL10416
LaboratoryCenters fo All 18 Years andPhase
older
2|Ph
Â (Adult,
8651
Older
U.S.Adult)
Fed|OInterventioAllocation CDC-NCIRD
Immunologi University All 18 Years andPhase
older
1 Â (Adult, 30
Older
Other|U.S.InterventioInterventi
Adult) 9140|NCI-
Solicted A Rebecca CoAll 19 Years toPhase
50 Years
1 Â (Adult)60 Other InterventioAllocation PANFLUVAC
To assess tDana-FarbeAll 18 Years andPhase
older
1 Â (Adult, 40
Older
Other
Cell mediaUniversity All 65 Years andNotolder
Applic
Â (Older Adult)
Number ofNovartis V All 3 Years to 92
Phase
Years
1 Â (Child,627
Adult,
Industry
Older Adult)
Vaccine-ty University All 15 Months to 40 Years Â (Child,
5900 Other
Adult) ObservatioObservatio5270|OPP
Diagnosis oUniversity All 18 Years toPhase
60 Years
2 Â (Adult)99 Other InterventioAllocation OVG 2011/
Laboratory-McMaster AUll Child, AdulPhase 4 4611 Other InterventioAllocation RC1-27412
39 Years
40 Years
SeroconverCenters fo All 8 Months to Phase
9 Months
4 Â (Child)
1043 Other|U.S.InterventioAllocation 201518
PercentageHospices CiAll 18 Years and older Â (Adult,335Older
Other
Adult) ObservatioObservatio69HCL17_0
Number and American PAll 18 Years and older Â (Adult,1080
Older
Other
older
2 Â (Older Adult)
60 Industry InterventioAllocation V70P4S|Eu
To evaluateJiangsu Pr All 10 Years toPhase
60 Years
3 Â (Child,
1800 Adult)
Other InterventioAllocation JSVCT041
Efficacy of Sidney KimAll Child, AdulPhase 1 23 Other|NIHInterventioAllocation J0216|P30
Phase
Years
3 Â (Child)
Rate of ToxEdward ZigAll 1 Year to 29Phase
GeometricSeqirus All 6 Months to Phase
17 Years
3 Â (Child)
1474 Industry InterventioAllocation CSLCT-USF
Access theThe Immuno All Child, Adult, Older Ad 440 Other ObservatioObservatioASCLIN 00
Toxicity|I Beth Israe All 18 Years andPhase
older
2 Â (Adult, 63
Older
Other|NIH|
safety and German Can All 18 Years andPhase
older
1 Â (Adult, 60
Older
Other
Adult) InterventioAllocation NCT-2016-
PercentageJanssen VaAll up to 71 Years
677Older
Adult) CR108112|
Time to treOslo UniverMale 18 Years toPhase
75 Years
1|Ph
Â (Adult,30Older
Other Adult)InterventioInterventi DC-005
Specific a Dr. med. MAll 18 Years to 70 Years Â (Adult,226Older
Other Adult)ObservatioObservatioUMR-MS20
To determiCaladrius BAll 16 Years and
Phase
older1|Ph
Â (Child, Adult,
56 Industry
Older Adult)
InterventioAllocation CDR000006
Incidence oWalvax BioAll 2 Months toPhase
55 Years
Industry InterventioAllocation 8.15E+09
Rate of So Vaxart All 18 Years toPhase
49 Years
1 Â (Adult)86 Industry InterventioAllocation VXA-NVV-1
Any adverse MSD Wellco All 6 Weeks toPhase
45 Years
1|Ph
Â (Child,
100Adult)
Industry InterventioAllocation HL/RVV/CT
The Geomet GlaxoSmithAll 18 Years and
Phase
Older
Industry
Serotype-sPfizer All 42 Days to Phase
5 Years3 Â (Child)656 Industry InterventioAllocation B1851178
PercentagePfizer Female 18 Years toPhase
49 Years
2 Â (Adult)710 Industry InterventioAllocation C3671004
Percent of Cangene Co All 18 Years toPhase
65 Years
3 Â (Adult,25Older
Industry|UInterventioInterventi
Adult) VA-006
DetermineUniversity
t All 6 Months toPhase
5 Years
4 Â (Child)412 Other InterventioAllocation Paediatric
To determiSt George' All 18 Years toPhase
45 Years
1 Â (Adult)31 Other|InduInterventioAllocation 2005-0059
Clinical pn Internatio All 6 Months toPhase
23 Months
3 Â 3508
(Child)
Other|U.S.InterventioAllocation PR-09054|
Antibody reUniversity All 18 Years and
Notolder
Applic
Â (Adult,152
Older
Other
Change in Emory UnivAll 50 Years and
Phase
Older
Other
Adult) InterventioAllocation IRB001092
The adverse Jiangsu ProAll 6 Months toPhase
5 Years
1 Â (Child)40 Other InterventioAllocation JSVCT006
Incidence Crucell Ho All 18 Years toPhase
50 Years
1 Â (Adult)84 Industry InterventioAllocation INF-V-A01
Number ofGlaxoSmithMale 10 Years toPhase
18 Years
2 Â (Child,270
Adult)
Industry InterventioAllocation 580299/01
Rate of Co H. Lee MoffAll 18 Years and
Early
older
PhasÂ (Adult, 20
Older
Other
To provideSanofi Pas All 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation GPF07|UTN
immunogenic Novartis V All 15 Years toPhase
68 Years
4 Â (Child,323
Adult,
Industry
Adult) V48P7E1
8 Months
3 Â (Child)
Achieving Medical UnAll 6 Years to 18
NotYears
Applic
Â (Child, Adult)
80 Other InterventioInterventi Dembinski
Number ofEmory Unive Female 18 Years toNot
50 Years
ApplicÂ (Adult)
Number ofProtein Sc All 6 Years to 17
Phase
Years
3 Â (Child)219 Industry InterventioAllocation PSC08
Hemagglutin Shanghai InAll 6 Months toPhase
36 Months
2 Â (Child)
312 Industry InterventioAllocation SIBP-2009-
SeroresponBrigham anAll 18 Years and
Phase
Older
Other
Adult) InterventioAllocation 2019P0036
antibody r Novartis|NAll 11 Weeks toPhase
15 Weeks
3 Â (Child)
150 Industry InterventioAllocation M14P3|Imp
Number ofRussian AcAll 18 Years toPhase
65 Years
1|Ph
Â (Adult,10Older
Other Adult)InterventioInterventi IFCI-04/10
PercentageU.S. Army All 18 Years toPhase
65 Years
U.S. Fed
Adult)InterventioAllocation S-13-05
GeometricSanofi
M Pas All 2 Years to 45
Phase
Years
2 Â (Child,180
Adult)
Industry InterventioAllocation CYD22|201
To assess tAltimmune,All 19 Years toPhase
49 Years
1 Â (Adult)48 Industry InterventioAllocation H-0701-2|
PercentageNational InAll 18 Years and
Phase
Older
NIHAdult) InterventioAllocation 12-0011|H
The primary University All 18 Years toPhase
35 Years
3 Â (Adult)50 Other InterventioInterventi 7350
ProportionIcon Gene All 18 Years and
Phase
Older
Industry
Adult) InterventioInterventi PMP0025-
23 Years
2 Â (Child,155
Adult)
The precenIndonesia All 60 Years toPhase
90 Years
Other Adult)InterventioAllocation Vaccine20
Immunogeni University All 42 Years toPhase
60 Years
2|Ph
Â (Adult)
300 Other InterventioAllocation CAPPesq 0
64 Years
3 Â (Adult)
4292 Industry InterventioAllocation FID31
PercentageMerck ShaAll 50 Years and
Phase
older3 Â (Adult,
1200
Older
Industry
Adult) InterventioAllocation V114-021
PercentageTakeda All 18 Years toPhase
60 Years
3 Â (Adult)900 Industry InterventioAllocation DEN-314|2
SeroprotectSanofi Pas All 11 Years toPhase
14 Years
2 Â (Child)277 Industry InterventioAllocation TD9809
Subjects R U.S. Army All 18 Years toPhase
55 Years
1 Â (Adult)20 U.S. Fed InterventioInterventi A-15812|U
Number ofUniversity All 3 Years to 21
Phase
Years
1 Â (Child, Adult)
29 Other InterventioAllocation PNOC 007|
ProportionUniversity All 18 Years and
Phase
0 Other
Adult) InterventioAllocation IRB14-151
Systemic aU.S. Army All 18 Years toPhase
50 Years
1 Â (Adult)22 U.S. Fed InterventioAllocation NMRC 2004
Number ofGlaxoSmithAll 6 Weeks toPhase
12 Weeks
3 Â (Child)
PrevalenceSt. MichaelFemale 18 Years and older Â (Adult,317Older
Other
GeometricMerck ShaAll 50 Years and
Phase
Older
Industry
OccurrenceBeijing Zhi All 3 Months and
Phaseolder
1 Â (Child,180
Adult,
Industry
Adult) 2.02E+08
Serum neutr EnimmuneAll 2 Months toPhase
6 Years
2 Â (Child)140 Industry InterventioAllocation EV-BR1501
Signs and sNational InAll 18 Years toPhase
45 Years
1 Â (Adult)48 NIH|OtherInterventioAllocation HVTN 073/
To assess tBeth Israe All 18 Years and
Phase
Older
Other
The Vaccine Children's All up to 5 Years Â (Child) 2268 Other|InduObservatioObservatio 111725
Influenza Emory UnivAll 18 Years toNot
89 Years
To establisNovartis|NAll 8 Weeks toPhase
11 Weeks
4 Â (Child) 75 Industry InterventioAllocation M14P5|Imp
Number ofNovartis V All 65 Years and
Phase
older4 Â (Older767
Adult)
Serologica National TaAll Child, AdulPhase 4 170 Other InterventioAllocation 20160807
HemagglutiMarshfieldAll 5 Years to 17
Phase
Years4 Â (Child)131 Other|U.S.InterventioAllocation 5U01IP000
The Post-i Sinovac BioAll 18 MonthsPhase
to 24 Months
4 Â 301
(Child)
Industry InterventioAllocation PRO-HAB-4
serologic Klara M. P All 18 Years toPhase
99 Years
OtherAdult)InterventioAllocation PCV13 in S
Number ofGlaxoSmithAll 18 Years toPhase
50 Years
2 Â (Adult)71 Industry InterventioAllocation 205626|H0
Immune resp David Rizz All 18 Years and
Phase
0 Other
Adult) InterventioAllocation Pro000425
OccurrencePATH|IcahnAll 18 Years toPhase
39 Years
1 Â (Adult)65 Other|InduInterventioAllocation CVIA 057 (
HPV-6 AntiUniversity Female 16 Years toPhase
23 Years
Other InterventioAllocation ATN 064
The percent University All 41 Months to 7 Years Â (Child) 28 Other ObservatioObservatioOVG 2008/
Number ofBeth Israe Female 18 Years and
Phase
older1|Ph
Â (Adult, Older
8 Other|U.S.InterventioAllocation
Adult) 03-221|NC
Phase
Older
Industry
2 Months
3 Â (Child)
proportionMurdoch Ch All 60 Days to Phase
74 Days2|Ph
Â (Child)
1400 Other|InduInterventioAllocation 09/19|566
Change FroMcMaster All 80 Years and older Â (Older241 Adult)
Number ofSidney KimAll 18 Years toNot
76 Years
OtherAdult)InterventioAllocation J1179|NA_
# of partic Eastern Vi All 27 Years toPhase
69 Years
Other|Indu
Adult)InterventioInterventi 17-09-FB-
ConcentratGlaxoSmithAll 90 Days to Phase
118 Days
Number ofUniversity Male 18 Years and
Phase
Older
Other|Indu
Adult) InterventioAllocation CO11816|A
12 Weeks
PercentagePfizer All 6 Years to 64
Phase
Adult)
Industry InterventioInterventi B1851172|
Safety, de PaxVax, IncAll 18 Years toPhase
40 Years
1 Â (Adult)166 Industry InterventioAllocation PXVX-H5-1
Summary of U.S. Army All 18 Years toPhase
49 Years
1 Â (Adult)72 U.S. Fed InterventioAllocation S-15-39
Antibody tiCenters forMale 18 Years toPhase
60 Years
4 Â (Adult)480 U.S. Fed|OInterventioAllocation CDC-NCIR
Booster effStatens Se All 10 Years toPhase
15 Years
1|Ph
Â (Child)
240 Other|InduInterventioAllocation VIPV-04|2
Immunogeni Novartis V All 2 Months toPhase
4 Months
3 Â (Child)
916 Industry InterventioAllocation M37P2
17 Years
ApplicÂ (Child)
The Number Kameda Me All 65 Years and
Phase
older4 Â (Older162
Adult)
Other|InduInterventioAllocation 15-041-16
proportionTel-Aviv S All 18 Years toNot
90 Years
OtherAdult)InterventioAllocation 0332-11-T
Influenza University All 18 Years and older Â (Adult,150Older
Other
Adult) ObservatioObservatioARIVA_me1
to 20 Months
2 Â 403
(Child)
Safety; reaMinervax Female 18 Years toPhase
40 Years
1 Â (Adult)240 Other InterventioAllocation 2014-0045
DifferencesInsight Th All 18 Years toPhase
120 Years
Other|Indu
Adult)
InterventioAllocation INSI-20190
Humoral ImGlaxoSmithAll 18 Years andPhase
older
Industry
Safety and Sharon Ridd All 18 Years andPhase
older
1|Ph
Â (Adult, 11Older
Adult) Riddler 0
Genomic siJiangsu ProAll 2 Years to 5Phase
Years2Â (Child) 72 Other|InduInterventioAllocation JSVCT012
Human Seru GlaxoSmithAll 18 Years toPhase
40 Years
2 Â (Adult) 996 Industry InterventioAllocation 205343|V5
Change in University All 11 Years toNot
17 Years
ApplicÂ (Child)22 Other|InduInterventioAllocation PRO13070
ImmunologOlivera FinAll 18 Years andPhase
older
1|Ph
Â (Adult, 30Older
Other
Adult) InterventioAllocation 11-094|90
ProportionUniversity All up to 15 Weeks
PhaseÂ4 (Child) 220 Other InterventioAllocation CHRMS 17-
to 42 Months
3 Â 454
(Child)
Industry InterventioAllocation JEC15|UTN
Rate of imm University All 18 Years toNot
100Applic
Years Â (Adult,
644 Older
OtherAdult) InterventioAllocation 6007232
older
Industry
Number ofGlaxoSmithFemale 15 Years toPhase 45 Years
ProportionNational I All 12 MonthsPhase
to 50 Years
2 Â (Child,
192 NIH|OtherInterventioAllocation
Adult) PR-15097|
Safety of University Male 2 Years to 50
Phase
Years
1 Â (Child, Adult)
52 Other InterventioAllocation VAC041
The incidenSinovac (DaAll 1 Year to 49Phase
Adult)
Industry InterventioAllocation PRO-VZV-1
Vaccine covLondon SchoolFemale
of Hygiene
9 Years
andand
Tropical
Phase
older4ÂMedicine|National
(Child,5532
Adult,
Other
Older
Institute
Adult)
for Medical Research,
MITU-001
Tanzania|Ocean Road Can
Safety/AdvMassachuse All 40 Years toPhase
70 Years
1 Â (Adult,28Older
OtherAdult)InterventioAllocation 2014-P-00
Number ofSanofi Pas Female 18 Years and older Â (Adult, 87 Older
Industry
Adult) ObservatioObservatioQID02|U11
60 Years
2 Â (Adult) 512 Industry InterventioAllocation 107495|20
PercentageSanofi Pas All 249 Days toPhase
305 Days
3 Â (Child)1128 Industry InterventioAllocation MTA44
Antibody rAZ Sint-JanAll 50 Years andPhase
older
Other|Indu
Adult) InterventioAllocation WS211344
AssessmentNational InAll 12 MonthsPhase
to 35 Months
1 Â (Child)
56 NIH InterventioAllocation 04-101
Frequency National
24 Months
1 Â (Child)
Response CSidney KimAll 18 Years andPhase
older
Other|Indu
Adult) InterventioInterventi J1115|NA_
Time to Pr Gradalis, InAll 18 Years andPhase
older
2 Â (Adult, Older
5 Industry
Numbers ofGitte Kron All 18 Years toPhase
60 Years
1 Â (Adult)11 Other InterventioAllocation EudraCT 2
Rabies neutQueen Saov All 18 Years toNot
60 Years
ApplicÂ (Adult)40 Other InterventioAllocation 495/2015
12 Years
3 Â (Child) 534 Industry InterventioAllocation Td536 (EF
GeometricCrucell Ho All 18 Years andPhase
older
Industry
Adult) InterventioAllocation ADD-V-A00
Number ofCasep Compr All 18 Years andEarly
older
Phas
Â (Adult, 18Older
Other
Adult) InterventioInterventi CASE1A16
50 Years
1 Â (Adult)48 NIH InterventioAllocation Ad5HVR48.
Number ofGlaxoSmithAll 10 Years and older Â (Child,682 Adult,
Industry
Older Adult)
ObservatioObservatio 115374
Number ofOlogy
s BiosAll 18 Years toPhase
59 Years
1|PhÂ (Adult)
Number ofProtein Sc All 18 Years and older Â (Adult,
254648 Older
Industry|OObservatioObservatioPSC13
Adult)
GeometricSanofi Pas All 3 Years to 5Phase
Years2Â (Child) 173 Industry InterventioAllocation MTA17
10 Weeks
3 Â (Child) 489 Industry InterventioAllocation 111634
Toxin A- anPfizer All 65 Years toPhase
85 Years
Timely vacDuke Univer Female 16 Years and Notolder
Applic
Â (Child,412Adult,
Older Adult) D0271|1R
Safety|Imm Craig L SlinAll 18 Years andPhase
older
Other
HBV DNA inThe HIV NeAll 18 Years toNot
70 Years
ApplicÂ (Adult,
200Older
OtherAdult)InterventioAllocation HIV-NAT 0
Antibody rMedical Uni All 21 Years toEarly
65 Years
OtherAdult)InterventioAllocation MUSC vacci
To determin InternationAll 12 Months and older Â (Child,
31552Adult,
Other|Indu
OlderObservatioObservatioCR-WC-03
Adult)
Tolerabilit City of HopAll 18 Years andPhase
older
Adult) 15002|NCI
50 Years
1 Â (Adult)60 NIH InterventioAllocation Ad26.ENVA
Safety: Al U.S. Army All 17 Years andPhase
older
U.S.Older
Fed Adult)
InterventioInterventi A-12592|F
Change in H Tulane UnivAll 18 Years and older Â (Adult,164 Older
Other
The proport Centers fo All 6 Weeks toNot11 Months
Applic Â (Child)
699 U.S. Fed|OInterventioAllocation CDC-458-G
Comparison Colby Pha All 18 Years toPhase
49 Years
1 Â (Adult)128 Industry InterventioAllocation H-100-001
Human papi Ohio StateMale 18 Years toPhase
25 Years
3 Â (Adult)
Antibody cGlaxoSmithAll 31 MonthsPhase
to 57 Months
3 Â 100
(Child)
To evaluateCraig L Sli All 18 Years and
Phase
Adult) 12911|R2
To assess tNational InAll up to 5 Days
Phase
Â (Child)
2 5 NIH InterventioAllocation 03-062
Incidence Inge HÃ¸ghAll 18 Years and
Phase
Older
Other
Adult) InterventioInterventi AZACTA
Number ofSanofi
p Pas All 1 Year and Phase
336 Industry
Older Adult)
InterventioAllocation SHC03|U11
Number ofKiromic,
a InAll 18 Years and
Phase
older1|Ph
Â (Adult, Older
0 Industry
Adult) InterventioInterventi KiroVAX001
Immunogenic Radboud Un All 18 Years toPhase
70 Years
2 Â (Adult,54Older
OtherAdult)InterventioAllocation NL32381.0
GeometricNational InFemale 18 Years toPhase
45 Years
Plasma HIVFrench NatAll 18 Years toPhase
59 Years
PercentageShanghai ZFemale 9 Years to 45
Phase
90 Industry InterventioAllocation 312-HPV-2
Answers toNYU LangoAll 60 Years and
Notolder
Applic
Â (Adult,170
Older
Other|Indu
Phase
Older
Industry
Immunogeni Sanofi Pas All 3 Years to 17
Phase
Years2 Â (Child)303 Industry InterventioAllocation GPF08|UTN
Safety|Imm Sanofi Pas All 18 Years toPhase
31 Years
Vaccine ReGlaxoSmithAll 18 Years and
Phase
Older
Industry
Humoral ImGlaxoSmithAll 3 Years to 17
Phase
Years3 Â (Child)245 Industry InterventioInterventi 113638|20
GeometricSanofi
M Pas All 9 Years to 17
Phase
Years3 Â (Child)100 Industry InterventioInterventi GQM09|U1
Titers for GlaxoSmithAll 18 MonthsPhase
to 47 Months
2 Â 599
(Child)
Phase
Older
Industry
Efficiency: Adriaan BaAll Child, AdulNot Applic 200 Other InterventioAllocation ABarbarou
25 Years
2 Â (Child,
1013
Adult)
1-Year ProgM.D. AnderAll 18 Years and
Phase
Older
Adult) 2011-0289
DetermineMurdoch
t Ch
Female 12 Years toPhase
26 Years
3 Â (Child,240
Adult)
Other InterventioInterventi RCH CA270
Number ofPfizer
s All 18 Years toPhase
64 Years
1 Â (Adult)100 Industry InterventioInterventi B3451015
Mood Outco University All 65 Years toNot
85 Years
ApplicÂ (Older106
Adult)
Rabies viruNovartis|NAll 12 MonthsPhase
to 18 Months
2 Â 200
(Child)
Industry InterventioAllocation M49P2
OccurrenceMark PrausAll 18 Years toPhase
49 Years
1 Â (Adult)100 Other InterventioAllocation 2015 TIV-
GARDASIL EVmory UnivFemale 13 Years toPhase
18 Years
3 Â (Child,216
Adult)
Other|InduInterventioAllocation IRB000155
to 13 Months
3 Â 792
(Child)
Summary of Sanofi Pas All 15 MonthsPhase
to 18 Months
3 Â 362
(Child)
Industry InterventioAllocation AL205
18 Years
3 Â (Child,751
Adult)
C difficile Pfizer All 50 Years and
Phase
older3 Â (Adult,
1960
Older
Industry
Adult) InterventioAllocation B5091019
To provide Sanofi Pas All 6 Months toPhase
17 Years
2 Â (Child)350 Industry InterventioAllocation GPA12
Measuremen National InAll 18 Years toPhase
49 Years
Number ofMacarena A Dll 13 Years toPhase
99 Years
Adult) 20120750
overall su Pawel KalinAll 18 Years and
Phase
0 Other
Expansion H. Lee MofAll 18 Years and
Early
older
PhasÂ (Adult, 30
Older
Adult) MCC-1933
Number ofSanofi Pas All 6 Months and
Phaseolder
Industry
Adult) GRC00097|
antibody tiArmed ForcAll 18 Years toNot
49 Years
ApplicÂ (Adult)26 Other InterventioAllocation WRAIR1525
SeroconverUniversity All 20 Years toPhase
65 Years
3 Â (Adult,42Older
OtherAdult)InterventioAllocation 09-0780-C
PercentageMerck ShaFemale 12 Years toPhase
26 Years
PercentageNovartis V Female 18 Years toPhase
40 Years
Number ofBiofabri, S All 18 Years toPhase
45 Years
1 Â (Adult)36 Industry|OInterventioAllocation MTBVAC-0
Influenza VUniversity Female 18 Years and older Â (Adult,236Older
Other
Adult) ObservatioObservatiohomwo 01
Seroconvers University All 18 Years toNot
75 Years
Anti-hepatGlaxoSmithAll 3 Years to 13
Phase
Years
3 Â (Child)276 Industry InterventioAllocation 208127/132
Number ofSanofi
p Pas All 1 Year and Phase
336 Industry
Older Adult)
InterventioAllocation SHC02|U11
Number ofStanford Un All 18 Years toPhase
100 Years
Adult) SU-031920
Immune res Baylor ReseAll 21 Years toPhase
75 Years
Adult) 009-273|R
To evaluateUniversity All 5 Months to Phase
45 Years
1|PhÂ (Child,
91Adult)
Other InterventioAllocation VAC073
Primary stuInternatio All 6 Weeks toPhase
20 Weeks
4 Â (Child)
4550 Other InterventioAllocation 2007-024
SeroprotecCrucell Ho All 18 Years andNotolder
Applic
Â (Adult,110
Older
Industry
PercentagePATH|Johns All 24 MonthsPhase
to 59 Months
3 Â1761
(Child)
Other|U.S.InterventioAllocation LAIV-CE-01
Safety andUniversity All 18 Years toPhase
50 Years
1|PhÂ (Adult)52 Other InterventioAllocation VAC039
SeroconverSormland CAll 18 Years andPhase
older
2 Â (Adult, 68
Older
Other
Adverse PrJiangsu Pr Female 18 Years toPhase
35 Years
4 Â (Adult)122 Other InterventioInterventi JSEPI-001
Time to re Fred HutchAll 27 Years toPhase
69 Years
Adult) 9790|NCI-
Logistic fe Internatio All 5 Years to 18
Phase
Years
4 Â (Child,
100742
Adult)
Other|InduInterventioAllocation T-14
GeometricSanofi Pas All 6 Months to Phase
36 Months
4 Â (Child)
HemagglutiUniversity Female 50 Years andPhase
older
4 Â (Adult,160
Older
Other
10 Weeks
Antibody RNovartis V All 3 Years to 8Phase
Years2|Ph
Â (Child)1357 Industry InterventioAllocation V112_02
CMV events City of Ho All 18 Years toPhase
75 Years
Adult) 14295|NCI
Immunogeni ILiAD Biot All 18 Years toPhase
50 Years
2 Â (Adult)300 Industry InterventioAllocation IB-200P
Number ofAkron ChildAll 18 Years andPhase
older
4 Â (Adult,336
Older
Other
ProportionInternationAll 18 Years toPhase
50 Years
1 Â (Adult)60 Other|InduInterventioAllocation IAVI W001
reactogenicInstituto NAll 18 Years toPhase
60 Years
2 Â (Adult) 0 Other InterventioAllocation CI:863, No
To demonstr GlaxoSmithAll 6 Weeks toPhase
27 Months
3 Â (Child)
Distress Anna TaddiAll 2 Months to Phase
6 Months
3 Â (Child)
Participat H. Lee MoffFemale 18 Years andPhase
older
1 Â (Adult, Older
7 Other
OccurrenceAIDS MaligFemale 25 Years andPhase
older
3 Â (Adult,536
Older
Other|NIH|
Adult) InterventioAllocation AMC-099|
Adverse reXiamen InnAll 18 Years andPhase
older
4 Â (Adult,602
Older
Industry
Analysis o NorthwesteAll 18 Years toPhase
89 Years
OtherAdult)InterventioAllocation STU00201
ProportionInternatio All 1 Year and Phase
216 Other|Indu
Older Adult)
Anti-PT GMT Mahidol UnAll Child, Adult, Older Ad 180 Other ObservatioObservatioTDA202 2 y
1) Change University All 19 MonthsNot to 5Applic
Years Â (Child)
68000 Other|U.S.InterventioAllocation 11-1480|P
70 Days3 Â (Child)500 Industry InterventioAllocation B4671001|
Reactogenic National InAll 18 Years toPhase
64 Years
1 Â (Adult)95 NIH InterventioAllocation 08-0059|U
ProportionSanaria In All 1 Year to 12Phase
Years2Â (Child) 200 Industry|OInterventioAllocation LaSPZV1
Adverse evCenter for All 12 MonthsPhase
to 45 Years
3 Â (Child,
756 Other
Adult) InterventioAllocation MRVAC VX.
The adjuvan HepNet StuAll 18 Years toPhase
60 Years
to 24 Months
3 Â1106
(Child)
Industry InterventioAllocation A3L27|U11
The number Neufeld, E All 18 MonthsNot to 18
Applic
Years Â (Child,
10 Other
Adult) InterventioInterventi CHB 04-10
Adverse evNovartis|NAll 18 Years andPhase
older
3 Â (Adult,
4400
Older
Industry
12 Weeks
To determiNational InAll 18 Years toPhase
50 Years
PercentageGlaxoSmithAll 12 Years toPhase
20 Years
2 Â (Child,604
Adult)
Industry InterventioAllocation 205613|V1
OccurrenceDuke Univer All 6 Weeks and Phase
older
4 Â (Child,300
Adult,
Older Adult) Pro000880
OccurrenceJiangsu Pr All 18 Years toPhase
70 Years
Other|Indu
Adult)InterventioAllocation JSVCT049
Levels of aSanofi Pas All 9 Years to 10
Phase
Years
3 Â (Child)150 Industry InterventioAllocation A3L49|U11
ProgressionMabVax The All 16 Years andPhase
older
2 Â (Child,136
Adult,
Industry
Older Adult)
InterventioAllocation MV-0109D
Incidence Intercell U All 18 Years toPhase
64 Years
2 Â (Adult)723 Industry InterventioAllocation ELT209|Eu
69 Years
4 Â (Child,545
Adult,
Industry
Adult) TD518
Immunogeni Sanofi All 60 Days to Phase
89 Days3 Â (Child)
1056 Industry InterventioAllocation C5A06|UTN
First episo University All 18 Years toPhase
55 Years
4 Â (Adult)507 Other InterventioAllocation CHRU02 (Et
Number ofWestat|Eun Female Child, AdulPhase 2 347 Other|NIHInterventioAllocation NICHD P10
immunoglob Aghia SophiAll 2 Months to 15 Months Â (Child)60 Other ObservatioObservatioisppd2018
PercentageJanssen VaAll 18 Years andPhase
older
1 Â (Adult, 24
Older
Industry
Adult) InterventioInterventi CR108554|
Incidence Shenzhen PFemale 18 Years toPhase
70 Years
1 Â (Adult,80Older
OtherAdult)InterventioInterventi ShenzhenP
49 Years
2 Â (Adult)
4176 Industry InterventioAllocation NOR-211|U
VaccinationUniversitÃ All 18 Years andNotolder
Applic
Â (Adult,
2719
Older
Other
Number ofHualan BiolAll 6 Months to Phase
36 Months
3 Â (Child)
810 Industry InterventioAllocation Hualanbio-i
GeometricAdvagene BAll 20 Years toPhase
70 Years
Industry
Adult)InterventioAllocation 1.07E+09
Adverse reXiamen InnAll 18 Years andPhase
older
4 Â (Adult,600
Older
Adult) PRO-HE-00
Fraction ofNational CaAll 18 Years toPhase
99 Years
1 Â (Adult,33Older
NIH Adult)InterventioAllocation 130016|13
The number Mikhael PeAll 18 Years toPhase
80 Years
Other|Indu
Adult)InterventioAllocation 1.15E+11
Seroconvers Medstar HeAll 9 Years to 17
Phase
Years
4 Â (Child) 60 Other|InduInterventioAllocation GardasilM
level of I Gamaleya R All 18 Years toPhase
49 Years
2 Â (Adult)180 Other InterventioAllocation 01-GamTBv
older
3 Â (Older
43695
Adult)
Rate of im Boston Med All 18 Years to 75 Years Â (Adult,173Older
OtherAdult)ObservatioObservatioH-35669
Number ofSanofi
p Pas All 6 Months andPhase
older
3 Â (Child,230
Adult,
Industry
Adult) GQM10|U1
50 Years
ProportionJiangsu Pr All 16 Years toPhase
60 Years
Other InterventioAllocation JSVCT023
Toxicity as University All 18 Years andPhase
older
1 Â (Adult, Older
6 Other
Adult) InterventioInterventi MIDRIX4-
The Number Merck ShaAll 50 Years andPhase
older
3 Â (Adult,540
Older
Industry
Safety of Vaxart All 18 Years toPhase
49 Years
ProportionMayo CliniAll 18 Years andPhase
older
1 Â (Adult, 22
Older
Other|Indu
Adult) InterventioInterventi MC1136|NC
ConcentratGlaxoSmithFemale 18 Years toPhase
40 Years
2 Â (Adult)75 Industry InterventioAllocation 205235|V9
SeroconverIl-Yang PhaAll 19 Years toPhase
64 Years
1|Ph
Â (Adult)84 Industry InterventioAllocation IY_IFEZ_Q
The lower Sinovac BioAll 6 Months to Phase
35 Months
3 Â 2340
(Child)
Industry InterventioAllocation PRO-QINF-
Overall SurBioven EurAll 18 Years andPhase
older
3 Â (Adult,106
Older
Industry
Adult) InterventioAllocation BV-NSCLC-
to assess t National HeAll 4 Years to 75 Years Â (Child,350
Adult,
NIHOlder Adult)
ObservatioObservatio999918085
to 54 Months
3 Â 558
(Child)
Immunogeni Novavax|De All 18 Years toPhase
49 Years
2 Â (Adult)400 Industry|UInterventioAllocation FLU-SIQ-2
The primarAdimmuneAll 18 Years andPhase
older
4 Â (Adult,120
Older
Industry
Adult) InterventioInterventi FLU10T11A
A significa Institut N All 6 Years to 9Phase
Years3Â (Child) 250 Other InterventioAllocation BT05-01|2
Anti-HBs anGlaxoSmithAll 15 Years toPhase
50 Years
3 Â (Child,951
Adult)
ProportionInternationAll 1 Year and Phase
386 Other|Indu
Older Adult)
Anti-glyco GlaxoSmithAll 68 Years andPhase
older
3 Â (Older Adult)
70 Industry InterventioInterventi 204926|20
64 Years
2 Â (Adult)420 Industry InterventioAllocation NOR-107|2
PercentageButantan Institute|FundaÃ§Ã£o
All 18 Years toPhase
de
59 Amparo
Years
4 Â (Adult)
Ã Pesquisa
195 Otherdo Estado
de SÃ£o Paulo FLU-03-IB
50 Years
Total proteInternatio All 2 Years to 16
Phase
Years
4 Â (Child)
27231 Other|InduInterventioAllocation T-7
18 Years
2 Â (Child,
1714Adult)
Adverse evCraig L Sli All 18 Years andPhase
older
1|Ph
Â (Adult, 50
Older
Adult) 17700|R0
Comparison National InAll 18 Years toPhase
49 Years
Number ofStanford Un All 60 Years andPhase
older
4 Â (Adult, 78
Older
Adult) SU-25199|
Binding AnJanssen VaAll 18 Years toPhase
50 Years
3 Â (Adult)741 Industry InterventioAllocation CR108694|
Safety as University Female 18 Years and Phase
older
1 Â (Adult, 22
Older
Adult) 7396|NCI-
Pneumococc National a All 2 Years to 20
Phase
Years
4 Â (Child, Adult)
50 Other InterventioAllocation NKU 70496
The producHuazhong A Ull 18 Years toNot
55 Years
ApplicÂ (Adult)60 Other InterventioAllocation ENT-SELEN
DetermineSidney KimAll 18 Years andPhase
older
1 Â (Adult, 30
Older
Other
Adult) InterventioAllocation J0834|BMS
Graded StaCancer InsiAll 18 Years andPhase
older
1|Ph
Â (Adult, 45
Older
Industry
ImmunogenicUniversity All 13 MonthsPhase
to 30 Months
2|Ph Â 600 (Child)
Other InterventioAllocation CAPPesq 0
All adverseNovartis V All 2 Years and older Â (Child, Adult,
0 Industry
Older Adult)
Observational V59_45OB
Safety stu Hualan BiolAll 3 Years andPhase
Adult,
Industry
Older Adult)
Titers of mUniversite All up to 40 Years Â (Child, Adult)
232 Other ObservatioObservatiocev003
PercentagePfizer Female 18 Years toPhase
49 Years
phenotypeUniversity All 30 Years toPhase
70 Years
4 Â (Adult,20Older
OtherAdult)InterventioAllocation OVG 2012/
The number UniversitÃ All 18 Years toPhase
55 Years
1 Â (Adult)30 Other InterventioInterventi UKE-DZIF2
50 Years
SeroconversUniversity All 18 Years andPhase
older
4 Â (Adult, 42
Older
Other
ProportionInternationAll 1 Year to 40Phase
Adult)
Other|InduInterventioAllocation C-8IR
older
4 Â (Adult,200
Older
Industry
Adult) InterventioAllocation GRC50|U 1
Occurrence,Shanghai ZFemale 9 Years to 45 Phase
Years
1 Â (Child,160
Adult)
Industry InterventioAllocation 311-HPV-1
Haemagglut GlaxoSmithAll 65 Years andPhase
older
2 Â (Older1596
Adult)
Safety andCity of HopAll 18 Years andPhase
older
1 Â (Adult, 12
Older
Adult) 10105|NCI
ProportionCenters fo Female 13 Years toPhase49 Years
2|PhÂ (Child, Adult)
0 U.S. Fed InterventioAllocation CDC-NCIRD
PrevalenceUniversity All 14 Years andPhase
older
4 Â (Child,
34489Adult,
Other
Older Adult)
InterventioAllocation HREC/16/
Adverse eveMayo ClinicFemale 18 Years and Phase
older
1 Â (Adult, 43
Older
Adult) MC1713|NC
ComparingUniversity All 3 Years to 18
Early
Years
Phas
Â (Child, Adult)
62 Other InterventioAllocation MS Pecs-Pa
Safety and COL GeorgeFemale 18 Years and Phase
older
1|Ph
Â (Adult, 51
Older
U.S.Adult)
Fed InterventioAllocation 05-20025/
GeometricPfizer All 10 Years toPhase
12 Years
2 Â (Child)
2648 Industry InterventioAllocation B1971015|
To assess University All 12 Years toPhase
50 Years
Other InterventioAllocation LEISH3
Number ofEckhard PoAll 18 Years andPhase
older
1 Â (Adult, Older
0 Other
Number ofColumbia UMale 18 Years andNotolder
Applic
Â (Adult,222
Older
Other
Adult) InterventioAllocation AAAR0289
Incidence Hookipa BiAll 18 Years toPhase
99 Years
Industry
Adult)InterventioAllocation H-100-002
25 Years
3 Â (Child,
1590Adult)
Number ofGlaxoSmithAll 6 Months to Phase
49 Years
3 Â (Child,
1886Adult)
SeroconversChina Nati All 60 Days to Phase
89 Days4 Â (Child)604 Industry|OInterventioAllocation sIPV-2018
Number ofSanofi All 6 Years to 8Phase
Years3Â (Child) 132 Industry InterventioInterventi TD525
ExpressionHelsinki UnAll 18 Years toPhase
64 Years
4 Â (Adult)42 Other InterventioAllocation 411/E5/02
Number ofGlaxoSmith
80 Years
Industry
Change in Rohit Dive All 19 Years toPhase
20 Years
Rate of locProfectus BAll 18 Years toPhase
49 Years
1 Â (Adult)274 Industry|OInterventioAllocation CVIA 077;
Adverse evSidney KimAll 18 Years andPhase
older
1 Â (Adult, 10
Older
Other
Adult) InterventioInterventi 13S.462|S
GeomotericPT Bio Far All 18 MonthsPhase
to 24 Months
2|Ph Â 399 (Child)
Industry InterventioInterventi Booster Pe
Clinically City of HopAll 18 Years andPhase
older
2 Â (Adult,128
Older
Adult) 19065|NCI
Humoral ImGlaxoSmithAll 6 Months to Phase
35 Months
2 Â (Child)
Safety of Seqirus All 6 Months to Phase
8 Years
3 Â (Child)298 Industry InterventioAllocation CSLCT-FLU-
ReactogeniSeqirus|NoAll 65 Years andPhase
older
1 Â (Older196
Adult)
Industry InterventioAllocation V133_01EX
Number ofShanghai InAll 12 Years andPhase
older
2 Â (Child,560
Adult,
Industry
Older Adult)
InterventioAllocation 2016L0990
2 year Rec Celldex Th All 18 Years andPhase
older
2 Â (Adult, Older
3 Industry
Adult) InterventioInterventi CDX1307-0
HAI titer Stanford Un All 20 Years toPhase
75 Years
4 Â (Adult,50Older
Adult) 50328
To determin NewLink Ge All 18 Years andPhase
older
2 Â (Adult, Older
6 Industry
64 Years
1 Â (Adult)46 Industry|OInterventioAllocation BioMed07
Primary end Sheba Medi All 2 Years to 25 Years Â (Child, Adult)
20 Other ObservatioObservatioSHEBA-09-
Adverse evBelarusianAll 1 Year to 20Early
Years
Phas
Â (Child, Adult)
12 Other InterventioInterventi BelarusianP
The percenGary ArcheAll 18 Years andPhase
older
1 Â (Adult, 24
Older
Other
Adult) InterventioInterventi Pro000547
Safety pro immatics BAll 18 Years andPhase
older
1 Â (Adult, 16
Older
Adult) GAPVAC-10
Rate of ph RegenstrieAll 11 Years toNot
17 Years
ApplicÂ (Child)
1305 Other|InduInterventioAllocation Merck 21
64 Years
4 Â (Adult)
Immunogeni Crucell Ho All 18 Years andPhase
older
3 Â (Adult,440
Older
Industry
Neutralizi Tuen Mun FHemale 18 Years to 35 Years Â (Adult)84 Other ObservatioObservatioNTWC/CRE
50 Years
Systemic anShanghai BFemale 9 Years to 45
Phase
Years
1 Â (Child, Adult)
90 Industry InterventioAllocation 4-HPV-100
Change froUniversity All 65 Years andPhase
older
1|Ph
Â (Older Adult)
39 Other InterventioAllocation VaccinÃ¢g
Antibody rUniversity All 50 Years toEarly
65 Years
Adult) R01AG045
The first e MedImmune All 60 Years andPhase
older
3 Â (Adult,
3009
Older
Industry
Adult) InterventioAllocation D153-P516
The frequen National InAll 18 Years toPhase
34 Years
1|PhÂ (Adult)96 NIH InterventioAllocation 04-019
Frequency Institute
a o All 8 Weeks toNot10 Weeks
Applic Â (Child)
330 Other InterventioInterventi VX.2016.0
Observation Beijing CenAll Child, AdulPhase 4 37 Other InterventioInterventi BJCDPC-6
Varicella Innovaderm All 50 Years andPhase
older
4 Â (Adult, Older
3 Other|Indu
Adult) InterventioAllocation Inno-6041
Immunogenic University All 50 Years andPhase
older
2 Â (Adult,617
Older
Other
Adult) InterventioAllocation VERVE-UM
Number ofAfrican MaAll 12 MonthsPhase
to 48 Months
2 Â 378
(Child)
Other InterventioAllocation MSP3_ML_
Immunogeni Dalhousie All 18 Years toPhase
60 Years
4 Â (Adult)276 Other|InduInterventioAllocation SP1002
In group a Emory UnivAll 18 Years andNotolder
Applic
Â (Adult, 63
Older
Other
Antibody tiUniversita All 18 Years toPhase
55 Years
3 Â (Adult)270 Other InterventioAllocation 503-IC
The rate o Beijing ChaAll 2 Years to 50
Phase
Years
1 Â (Child, Adult)
60 Other InterventioAllocation cycdc2016
Frequency National InAll 6 Months to Phase
49 Years
NIH|OtherInterventioAllocation CIR 248
55 Years
older
3 Â (Adult, 60
Older
Industry
2-year pro Sidney KimAll 18 Years andPhase
older
2 Â (Adult, 54
Older
Other|Indu
Adult) InterventioAllocation J16118|IR
Number ofEmory UnivAll 18 Years toNot
40 Years
ApplicÂ (Adult)33 Other InterventioAllocation IRB000742
To provideEmergent BAll 17 Years and older Â (Child,
897227
Adult,
Industry
Older Adult)
ObservatioObservatioH-406-005
Immune res Hillel Yaff Female 18 Years to 45 Years Â (Adult)40 Other ObservatioObservatio0079-19-
To evaluateFrench NatAll 18 Years andPhase
older
2 Â (Adult,306
Older
Other|Indu
Frequency Ology
a BiosAll 6 Months to Phase
17 Years
1|PhÂ (Child)
Response rNational CaAll 18 Years toPhase
70 Years
PercentagePublic HeaAll 13 Years toPhase
17 Years
4 Â (Child)400 Other InterventioAllocation Multiboost
35 Years
Number ofEmory Unive All 25 Years toNot
79 Years
Adult) IRB000502
immunogen Boryung PhAll 12 MonthsPhase
to 23 Months
3 Â 205
(Child)
Industry|OInterventioAllocation KD287-BR-
PercentageSanofi All 18 Years toPhase
45 Years
2 Â (Adult)260 Industry InterventioAllocation CYD12
DetermininRichard Zi All 4 Years to 21
Phase
Years
4 Â (Child,220
Adult)
Other|U.S.InterventioAllocation STUDY1904
To prospectMemorial SAll 2 Years to 18
Phase
Years
2 Â (Child, Adult)
Evaluation GlaxoSmithAll 18 Years andPhase
older
3 Â (Adult, 86
Older
Industry
Safety - i University All 18 Years andPhase
older
1 Â (Adult, 30
Older
Other
Adult) InterventioAllocation 15-17692|
The number Fuda CanceAll 18 Years toPhase
80 Years
OtherAdult)InterventioAllocation CLC-001
Assess IgGMayo CliniAll 20 Years toPhase
70 Years
PercentageGlaxoSmithAll 8 Weeks toPhase
12 Weeks
Antibody CGlaxoSmithAll 31 MonthsPhase
to 44 Months
3 Â 466
(Child)
to 24 Months
2|Ph Â1588 (Child)
PercentageUMN Pharm All 21 Years toPhase
41 Years
2 Â (Adult)87 Industry InterventioAllocation JPIP501-01
VZV-specifUniversity All 60 Years andPhase
older
1 Â (Adult, 33
Older
Other|NIH|
Adult) InterventioInterventi 10-0189|K
HPV vaccinOregon Hea All 18 Years toNot
89 Years
ApplicÂ (Adult,
22000Older
Number ofInternatio
p All 1 Year and Phase
older Â3 (Child,
204438
Adult,Other
Older Adult)
AcceptabiliPublic HealFemale 18 Years to 45 Years Â (Adult)450 Other ObservatioObservatioGAT.1246-
SeroprotecBritish Co All 10 Years toPhase
13 Years
4 Â (Child)80 Other InterventioInterventi H18-02607
Evaluate t Beijing CenAll 10 Years toPhase
60 Years
3 Â (Child,
1200Adult)
Other|InduInterventioAllocation BJCDCP-11
SeroconverInstituto All 2 Months to Phase
2 Months
2 Â (Child)
360 Other InterventioAllocation fIPV-CISPO
Safety andGlycoVaxy All 18 Years toPhase
50 Years
1 Â (Adult)40 Industry InterventioAllocation SD 133
Anti-PRP anNovartis V All 12 MonthsPhase
to 18 Months
3 Â 846
(Child)
Industry InterventioAllocation M37P2E1
ImmunogenicM.D. AnderAll 18 Years andPhase
older
2 Â (Adult, 28
Older
Adult) 2004-0340
Vaccine UpDalhousie All 3 Years to 14 Years Â (Child)902 Other ObservatioObservatioPCIRN PD0
CSL's IVV Seqirus All 18 Years toPhase
64 Years
4 Â (Adult)
anti-HepatTel-Aviv S All 18 Years andPhase
older
3 Â (Adult,100
Older
Other
Adult) InterventioAllocation TLVMC1.20
The lower Sinovac BioAll 3 Years andPhase
Adult,
Industry
Older Adult)
InterventioAllocation PRO-QINF-
Systemic ReVaxart All 18 Years toPhase
49 Years
1 Â (Adult)66 Industry InterventioAllocation VXA-RSV-1
45 Years
Measuremen Gary DooliAll 18 Years toPhase
66 Years
1 Â (Adult, 3Older
OtherAdult)InterventioInterventi Mel-2012-
Phase
Years
2 Â (Child)600 Industry InterventioAllocation CYD13|UTN
influenza Columbia UAll 6 Months to Not75Applic
Years Â (Child,
6145Adult,
Older Adult) AAAE4956|
Number ofUniversity Female 18 Years toPhase
39 Years
3 Â (Adult)800 Other InterventioAllocation MatluHIV
PercentageUniversity All 3 Years to 9 Years Â (Child) 240 Other ObservatioObservatioOVG 2009/
Antibody rNovartis V All 18 Years andPhase
older
3 Â (Adult,126
Older
Industry
To provide Sanofi Pas All 18 Years toPhase
60 Years
2 Â (Adult)384 Industry InterventioAllocation VRV01|UTN
Dose selecUniversity All 2 Months to Phase
3 Months
1 Â (Child)
214 Other InterventioAllocation TB012
primary saHospital ClAll 18 Years andPhase
older
1 Â (Adult, 30
Older
Other
Adult) InterventioAllocation RisVac 03
Vaccine SaUniversity All 18 Years toPhase
50 Years
1|PhÂ (Adult)72 Other|InduInterventioAllocation HIV-CORE
PercentageUniversity All 18 Years toPhase
64 Years
4 Â (Adult)200 Other InterventioInterventi HP-000823
ProportionThe HIV NeAll 1 Year to 15Phase
Years4Â (Child) 60 Other InterventioAllocation HIV-NAT 1
pneumococPublic HeaAll 2 Months toPhase
2 Months
4 Â (Child)
0 Other InterventioAllocation PINC trial
EffectiveneCanadian IAll 18 Years and
Phase
older4 Â (Adult,
2384
Older
Other|Indu
Adult) InterventioInterventi CT12
productionZagazig UniAll 18 Years toNot
70 Years
ApplicÂ (Adult,
220Older
Other
antibody tiTuen Mun FHemale up to 35 Years
100 Other InterventioInterventi NTWC/CRE
SeroconverChangchunAll 1 Year to 3Phase
Years Â4 (Child) 368 Other InterventioIntervention Model:
Long-term Novartis|NAll
a 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation V48P2E3|4
immunogen The HIV NeAll 2 Months toNot9 Years
ApplicÂ (Child)90 Other InterventioAllocation HIV-NAT 1
Vaccine upNational I All 65 Years and
Notolder
Applic
Â (Older
48125
Adult)
The primarFuda CanceFemale 18 Years toPhase
75 Years
1|Ph
Â (Adult,40Older
Other
Adult)InterventioAllocation CLO-001|2
Anti-HPV 6Jun Zhang|All 18 Years toPhase
55 Years
Number/Per PATH All 10 MonthsPhase
to 12 Months
4 Â 818
(Child)
Other InterventioAllocation JEV05 (VAC
Immunogeni Sanofi Pas All 6 Months toPhase
35 Months
2 Â (Child)
401 Industry InterventioAllocation GPF09|UTN
Overall Su Sidney KimAll 18 Years and
Phase
Older
Other
Adult) InterventioAllocation J13108|NA
1. The primShaare ZedAll 1 Year and Not
older
Applic
Â (Child, Adult,
210 Other
Older Adult)
InterventioAllocation 15363.ct.il
Measures oFluart InnoAll 18 Years and
Notolder
Applic
Â (Adult,
1206
Older
Industry
ConcentratGlaxoSmithAll 18 MonthsPhase
to 21 Months
3 Â 238
(Child)
Overall SurBioven EurAll 20 Years toPhase
65 Years
3 Â (Adult, Older
Industry
Adult)InterventioMasking: NBV-NSCLC-
seroprotecLG Chem All 6 Weeks toPhase
8 Weeks2 Â (Child)336 Industry InterventioAllocation LG-VDCL00
HemagglutiUniversity All 18 Years toPhase
80 Years
4 Â (Adult,50Older
Other
Adult)InterventioAllocation IRB-30000
50 Years
1 Â (Adult)45 NIH InterventioAllocation URMC 11-
Antibody co Sanofi Pas All 9 Years to 60
Phase
Adult)
Primary enCureVac A All 18 Years toPhase
40 Years
1 Â (Adult)52 Industry InterventioAllocation CV-7202-1
Receipt of University All 6 Months toNot17Applic
Years Â (Child)
25531 Other InterventioAllocation 15-0570_2
40 Years
59 Years
3 Â (Adult)
To Demonst Novartis V All 18 Years and
Phase
Older
Industry
Number ofJanssen VaAll 18 Years toPhase
50 Years
1|Ph
Â (Adult)27 Industry InterventioAllocation CR108161
Number ofXiamen UniFemale 18 Years toPhase
45 Years
3 Â (Adult)
7372 Other|InduInterventioAllocation HPV-PRO-0
Cellular f National InAll 3 Months toPhase
15 Years
4 Â (Child)220 NIH InterventioAllocation 18-0009|H
14 Years
4 Â (Child)215 Industry InterventioAllocation TRI05
PercentagePT Bio Far All 6 Months toPhase
40 Years
Industry InterventioAllocation QIV 0217
Number ofU.S.S Army All 18 Years toPhase
42 Years
Number orSanaria In All 18 Years toPhase
45 Years
1 Â (Adult)45 Industry|OInterventioAllocation MAVACHE|
Relative in Novartis V All 11 Years to 21 Years Â (Child,
55397
Adult)
Industry ObservatioObservatioV59_34OB
Safety of dNational InAll 18 Years toPhase
45 Years
Humoral imm University Female 18 Years toPhase
39 Years
2|Ph
Â (Adult)
194 Other InterventioAllocation Maternal_
Realizatio Hospices CiFemale 11 Years to 18 Years Â (Child,74Adult)
Other ObservatioObservatio69HCL17_0
GMT of neut National InAll 18 Years toPhase
49 Years
Phase
Older
Industry
Rate Of SuDana-Farber All Child, AdulEarly Phas 9 Other|NIHInterventioInterventi 00-053|P0
Date of Cli IDRI All 18 Years toPhase
70 Years
2 Â (Adult,45Older
Other
Adult)InterventioAllocation IDRI-LCVTC
PercentageSanofi All 2 Years to 11
Phase
Years3 Â (Child)250 Industry InterventioAllocation CYD32|UTN
Frequency GlaxoSmithAll 5 Months toPhase
17 Months
2 Â (Child)
Difference Johns HopkAll Child, AdulNot Applic 21 Other InterventioAllocation IRB000087
Cocaine AbBaylor Col All 18 Years toPhase
55 Years
2 Â (Adult)300 Other|NIH| InterventioAllocation R01DA025
Number ofEunice KenAll Child, AdulPhase 2 301 NIH InterventioAllocation 99999905
Safety andMerck ShaAll 18 Years and
Phase
Older
Industry
Other: web-based su Children's All Child, Adult, Older Ad 1000 Other ObservatioObservatio09 10-218
Adverse eveButantan InAll 18 Years and older Â (Adult,120Older
Other
ProportionInteractiv All up to 23 Months
Not Applic
Â (Child)11197 Other InterventioAllocation IRD-IRB_2
EvaluationGlaxoSmithAll 67 Years and
Phase
Frequency National
a InAll 4 Months toPhase
59 Months
1 Â (Child)
Immunogeni Instituto NFemale 18 Years toPhase
39 Years
2|Ph
Â (Adult)
240 Other InterventioAllocation CI 1059_1
SeroconversMerck ShaAll 9 Years to 26
Phase
Adult)
Industry InterventioInterventi V503-017|
Antibody tiSanofi Pas All 56 Years and
Phase
Older
Industry
Adult) InterventioInterventi MEQ00063
Number ofGlaxoSmithFemale 9 Years to 25
Phase
Years3 Â (Child,
1447
Adult)
culture-proInternationAll 12 MonthsPhase
and older
3 Â (Child,
69329Adult,
Other|Indu
Adult) C8phIII
Phase
older1|Ph
Â (Adult, 20
Older
Other
Adult) InterventioInterventi CCRG13-00
Humoral anJohn SampsAll 18 Years and
Phase
Older
Adult) Pro00004
Level of a Sanofi Pas All 42 Days to Phase
89 Days3 Â (Child)
2475 Industry InterventioAllocation MET42
GMT and freNational InAll 65 Years and
Phase
older1|Ph
Â (Older600
Adult)
The seroconSinovac BioAll 6 Months toPhase
71 Months
3 Â (Child)
900 Industry InterventioAllocation PRO-EV71-
HAI AntiboAltimmune,All 18 Years toPhase
50 Years
4 Â (Adult)20 Industry|OInterventioInterventi ALT-FLZ-40
SeroconverShanghai MAll 1 Year to 7Phase
Years Â4 (Child) 1200 Other|InduInterventioAllocation SH2012VA
Number, sevNational InAll 18 Years toPhase
50 Years
Efficacy, Emory UnivAll 25 Years and
Notolder
Applic
Â (Adult, 66
Older
Other
Presence ofUniversity All up to 7 Days
Phase
Â (Child)
3 700 Other|U.S.InterventioAllocation PROVIDE
SeroconversAssistance All 18 Years toPhase
64 Years
3 Â (Adult)228 Other|InduInterventioAllocation P 070165
45 Years
â€¢ SafetyPX'Therap Female 18 Years toPhase
55 Years
1 Â (Adult)48 Industry|OInterventioAllocation 2010-0236
seroconversUMN Pharm All 65 Years and
Phase
older3 Â (Older1020
Adult)
Industry InterventioAllocation 7374-CL-0
Number ofEunice KenAll 1 Year to 4Phase
Years Â3 (Child) 2799 NIH|OtherInterventioAllocation 99990000
Anti-PRP anNovartis V All 13 MonthsPhase
to 59 Months
3 Â 700
(Child)
To assess pSoroka UniAll 18 Years toPhase
80 Years
1|Ph
Â (Adult,15Older
Other
Adult)InterventioAllocation sor469208c
Evaluate thBeijing ChaAll 6 Months toPhase
71 Months
4 Â20900
(Child)
Subjects WMaastrichtAll 18 Years toPhase
59 Years
1 Â (Adult)34 Other InterventioAllocation HBnr01|20
40 Years
1 Â (Adult)316 Industry InterventioAllocation VAX2012Q
Safety of University All up to 16 Weeks
PhaseÂ1 (Child) 65 Other InterventioAllocation VAC058
75 Years
1|Ph
Â (Adult,
102Older
Industry
Adult)InterventioAllocation CDI19 (DF
Phase
Older
Industry
Number ofSanofi
P Pas All 6 Months and
Phase
older
2 Â (Child,600
Adult,
Industry
Adult) GRC43|UTN
ProportionInternatio All 1 Year and Not
older
Applic
Â (Child,60000
Adult,Other
Older Adult)
Adverse biDuke UniveFemale 18 Years and
Phase
Older
Adult) Pro001017
GeometricNovartis V All 18 Years and
Phase
Older
Industry
Percent achNational InAll 19 Years toPhase
50 Years
2 Â (Adult)27 NIH InterventioAllocation 13-0044|D
49 Years
1|Ph
Â (Adult)
GeometricSeqirus All 65 Years and
Phase
Adult)
Industry InterventioAllocation CSLCT-USF
ImmunogenicGlaxoSmithAll 18 Years and
Phase
Older
Industry
PercentageNational InFemale 13 Years toPhase
45 Years
2 Â (Child,319
Adult)
NIH InterventioAllocation A5240|103
Primary endFrench NatAll 18 Years toPhase
75 Years
1|Ph
Â (Adult,70Older
Other
30 Years
4 Â (Adult)10 Other|NIHInterventioInterventi SU-24167|
The number Anhui Zhif All 18 Years toPhase
45 Years
1 Â (Adult)30 Industry InterventioAllocation AEC/BCO2-â… b-healthy
Compare theCardenal HAll 3 Years to 14
NotYears
Applic
Â (Child) 30 Other InterventioAllocation CardenalH
To evaluat Medigen Va All 2 Months toPhase
12 Years
2 Â (Child)366 Industry InterventioAllocation CT-EV-21
71 Days
3 Â (Child)263 Industry InterventioAllocation A3L17
Antigen-speSellas Life All 18 Years and
Notolder
Applic
Â (Adult, 22
Older
Industry
Serologic University All 9 Years to 60
NotYears
Applic
Â (Child,137
Adult)
Other|InduInterventioAllocation REMICADE
The GeometrSeqirus All 6 Months toPhase
59 Months
3 Â 2250
(Child)
Industry InterventioAllocation CSLCT-QIV-
GeometricSanofi All 18 Years and
Phase
older
2 Â (Adult,
2098Older
Industry
Adult) InterventioAllocation FID29
12 Years
1|PhÂ (Child)43 Industry InterventioInterventi Td540|U11
10 Weeks
3 Â (Child)
Humoral I University All 24 MonthsPhase
to 35 Months
4 Â (Child)
ProportionMayo ClinicFemale 18 Years and
Phase
older
1 Â (Adult, 24
Older
Adult) MC1015|NC
PercentagePfizer All 12 MonthsPhase
to 24 Months
2 Â 398
(Child)
GeometricInternation
M All 6 Months toPhase
45 Years
3 Â (Child,
1800Adult)
Incidence oImperial C All 2 Years to 17 Years Â (Child)282 Other ObservatioObservatioRHM CHI 0
Long Term Valneva AuAll 18 Years and
Phase
older
3 Â (Adult,349
Older
Industry
Adult) InterventioInterventi IC51-305
Difference Centre de Female 18 Years and older Â (Adult,323Older
Other
Adult) ObservatioObservatioHelmVacc_I
Phase
Years
Immunogeni University Female 18 Years and
Phase
older
1 Â (Adult, 12
Older
Other
Adult) InterventioInterventi Vvax001-U
hemagglutinStanford Un All 18 Years and
Phase
older
4 Â (Adult, 54
Older
Adult) 40216|R01
DetermineJhpiego|MFemale
t 9 Years to 13
NotYears
Applic
Â (Child)
8000 Other|InduInterventioInterventi 36448
Immunogeni The HospitFemale 12 Years toPhase
19 Years
Other|InduInterventioAllocation 1E+09
Change froUniversity All 18 Years toNot
45 Years
ApplicÂ (Adult)24 Other|InduInterventioAllocation CRC305B
PercentageMedImmunAll 6 Months toPhase
59 Months
2 Â (Child)
200 Industry InterventioAllocation MI-CP129
Antibody leSanofi Pas All 9 Years to 13
Phase
Years
3 Â (Child)528 Industry InterventioAllocation CYD67|U11
Dose LimitMassachuse Female 18 Years and
Phase
older
1 Â (Adult, 22
Older
Other|Indu
Difference Singapore All 21 Years toPhase
50 Years
2 Â (Adult)84 Other InterventioAllocation EID-JE/YF-
VAS Pain ScGermans Tri Male 18 Years toPhase
40 Years
1 Â (Adult)24 Other|InduInterventioAllocation FA/MI/01|
HemagglutinGlaxoSmithAll 19 Years toPhase
40 Years
Phase
Years
3 Â (Child,
1701
Adult)
Industry InterventioAllocation GQM04|U11
To provideSanofi Pas All 18 Years toPhase
60 Years
2 Â (Adult)202 Industry InterventioAllocation GPF18|201
HemagglutinVanderbiltAll 65 Years to 125 Years Â (Older
100Adult)
Other ObservatioObservatiosingle cell
CHMP criteNovartis|NAll 18 Years and
Phase
older
2 Â (Adult,100
Older
Industry
Height of Academisch Male 18 Years toNot
35 Years
ApplicÂ (Adult)63 Other|U.S.InterventioAllocation NL 52510.
WillingnessIndiana UniFemale 18 Years and
Phase
older
3 Â (Adult,
1165Older
Other
16 Weeks
3 Â (Child)
Number ofGlaxoSmith
P All 20 Years toPhase
21 Years
4 Â (Adult)76 Industry InterventioInterventi 108984
efficacy a Fuda CanceAll 18 Years toPhase
80 Years
OtherAdult)InterventioAllocation FudaCH
50 Years
1 Â (Adult)57 Other InterventioAllocation ZIKA001
to 18 Months
3 Â1200
(Child)
Safety (Ad Craig L SlinAll 18 Years and
Phase
older
1|Ph
Â (Adult, Older
3 Other
frequency Uo niversity All 18 Years toPhase
45 Years
1 Â (Adult)30 Other InterventioAllocation CHRMS 19-
Humoral TBMedical UnAll 18 Years toPhase
60 Years
4 Â (Adult)119 Other InterventioAllocation TBE_1.1
98 Days
2 Â (Child)460 Industry InterventioAllocation B7471003
PrevalenceUniversity All 9 Years to 26
Phase
Years2 Â (Child,
1499
Adult)
Other|NIH| InterventioInterventi UAB-F1412
The IncideGE HealthcAll 18 Years toPhase
49 Years
1 Â (Adult)60 Industry InterventioAllocation X-100-001
Antibody (Novartis V Female 20 Years toPhase
42 Years
1 Â (Adult)95 Industry InterventioAllocation V98P2E1
Number ofJiangsu Pr All 3 Months toPhase
5 Years
3 Â (Child)
1992 Other|InduInterventioAllocation PRO-20130
Number Subj Sanofi Pas All 2 Years to 17
Phase
Years2 Â (Child)342 Industry InterventioAllocation VRV06|U11
The serocon Jiangsu ProAll 3 Months toPhase
5 Months
3 Â (Child)
9 Months
1|Ph Â (Child)
Phase
Older
Industry
Demonstrat GlaxoSmithAll 6 Weeks toPhase
16 Weeks
Prostate c OncBioMun Male 18 Years and
Phase
Older
Other
Adult) InterventioAllocation O17-11110
Phase I: R H. Lee MofAll 18 Years and
Phase
older1|Ph
Â (Adult, 73
Older
Other
Adult) InterventioAllocation MCC-1643
To evaluat Beijing CenAll 6 Months and
Phaseolder
4 Â (Child,900
Adult,
Adult) BJCDPC-1
OccurrenceJiangsu Pr All 18 Years toPhase
65 Years
Other|Indu
Adult)InterventioAllocation JSVCT027
12 Months
3 Â 1378
(Child)
Industry InterventioAllocation MTA48
Incidence Roswell PaAll 18 Years and
Phase
Older
Adult) I 79518|N
Number and Herlev HosMale 18 Years and
Phase
Older
Other
Adult) InterventioAllocation UR1534
The Number Merck ShaAll 18 Years and
Phase
Older
Industry
Frequency National
45 Years
HPV vaccinUniversity All Child, AdulNot Applic 264 Other|U.S.InterventioAllocation 18-0146a|
64 Years
SeroprotectTan Tock S All 65 Years and
Phase
older4 Â (Older200
Adult)
Other InterventioAllocation 2015/0104
The proporUniversity All 9 Months toPhase
60 Years
Other|InduInterventioAllocation OxTREC Re
12 Weeks
3 Â (Child)
Safety of University All 18 Years toPhase
50 Years
1|Ph
Â (Adult)16 Other InterventioAllocation VAC037
GeometricSanofi
M Pas All 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation QIV03|UTN
Rate of HeIl-Yang PhaAll 19 Years and
Phase
older3 Â (Adult,
1794
Older
Industry
Adult) InterventioAllocation IY_IFEZ_Q
Safety and Theresa Wh All 18 Years and
Phase
1 Other|Indu
Frequency National
o InAll 9 Years to 17
Phase
Years1 Â (Child) 43 NIH InterventioAllocation 17-0012
Number ofGlaxoSmithAll 6 Months and older Â (Child,
19334Adult,
Industry|OObservatioObservatio
Older Adult) 202056
Vaccine In Klein BuenAll 11 Years and
Notolder
Applic
Â (Child,900
Adult,
Older Adult) 1R01CA210
HPV vaccinUniversity Female 18 Years and
Notolder
Applic
Â (Adult,634
Older
Other
Adult) InterventioAllocation IRB-12050
Immunogeni Children's All 3 Years to 35
NotYears
Applic
Â (Child, Adult)
Tolerabilit University All 2 Years to 25
Phase
Years1|Ph
Â (Child, Adult)
1 Other InterventioInterventi 14.0855
Number ofOlogy BiosAll 18 Years toPhase
49 Years
1|Ph
Â (Adult)
Demonstrate GlaxoSmithAll 11 Weeks toPhase
17 Weeks
3 Â (Child)
SeroconverMahidol UnAll 1 Year to 3Phase
Years Â3 (Child) 152 Other InterventioInterventi JE0153
To provideSanofi Pas All 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation GPF14|UTN
ImmunologNational CaAll 18 Years and
Phase
older1|Ph
Â (Adult, 21
Older
Number ofGSK Vaccine All 18 Years toPhase
45 Years
1 Â (Adult)50 Industry InterventioAllocation H03_01TP
Culture-coNational I All 6 Weeks toPhase
12 Weeks
3 Â (Child)
3075 Other|InduInterventioAllocation KTL69-0|P
SeroprotecNovartis|NAll 6 Months toPhase
35 Months
4 Â (Child)
270 Industry InterventioAllocation M71P1|EUD
Safety, as National InAll 6 Months toPhase
49 Years
NIH InterventioAllocation CIR 258
PercentageUniversity All 11 Years toNot
18 Years
ApplicÂ (Child,
3812Adult)
Other InterventioAllocation 056103-00
Urine cocaWeill MedicAll 21 Years toPhase
69 Years
1 Â (Adult,30Older
OtherAdult)InterventioAllocation 1.21E+10
Assess theUniversity All 20 Years toPhase
65 Years
OtherAdult)InterventioAllocation H07-01465
18 Years
3 Â (Child,
3596
Adult)
Frequency National InAll 6 Months toPhase
49 Years
HPV vaccinUniversity All Child, AdulNot Applic 6 Other|U.S.InterventioAllocation 18-0146b|
To evaluateSt George' All 18 Years toPhase
55 Years
1 Â (Adult) 9 Other|InduInterventioAllocation TMUVA-01|
Cell mediatNovartis V All 6 Months toPhase
36 Months
2 Â (Child)
84 Industry InterventioAllocation V70_34|20
PercentageMedImmunAll 12 MonthsPhase
to 35 Months
2 Â 101
(Child)
Industry InterventioAllocation MI-CP128
Evaluate thChinese AcAll 6 Months toPhase
5 Years
2 Â (Child)660 Other InterventioAllocation EV71-KMB1
Antibody TiStony BrooAll 18 Years and
Phase
Older
Other
Dose limitiMemorial SFemale 18 Years and
Phase
Older
Other
GeometricPfizer All 6 Years to 17
Phase
Years3 Â (Child)158 Industry InterventioAllocation 6096A1-30
Number ofJanssen VaAll 39 Days to Phase
59 Days2 Â (Child)302 Industry InterventioAllocation CR108472
Phase
older3 Â (Adult,
2004
Older
Industry
Evaluate clNovartis V All Child, Adult, Older Ad 556 Industry ObservatioObservatioV110_11
The occurre Sanofi All 18 Years toPhase
50 Years
1 Â (Adult)63 Industry InterventioAllocation PPR01
Part 1 - In Sanaria IncAll 5 Months toPhase
9 Years
1|Ph
Â (Child)
337 Industry|OInterventioAllocation KEMRI/SER
Number ofGlaxoSmithAll Child, AdulPhase 4 29 Industry InterventioAllocation 110071
Number ofNational
P InFemale 18 Years toPhase
49 Years
Number ofSanofi Pas All 12 MonthsPhase
to 18 Months
3 Â1200
(Child)
Industry InterventioAllocation JEC02
Optimal vac BIOSANTECH All 18 Years toPhase
64 Years
1|Ph
Â (Adult)50 Industry|OInterventioAllocation EVATAT
Unsolicite PATH VacciAll 18 Years toPhase
40 Years
587 subjectHualan BiolAll 3 Years to 50
Phase
Adult)
Industry InterventioAllocation 2015L0005
HBV DNA su Fuqiang YaAll 18 Years toPhase
65 Years
OtherAdult)InterventioAllocation 2011005S
The number Sanaria In Male 18 Years toPhase
55 Years
2 Â (Adult)420 Industry|OInterventioAllocation IDSPZV1
Persistenc Novartis V All 40 MonthsPhase
to 62 Months
2 Â 120
(Child)
Industry InterventioAllocation V72P9E1|E
59 Years
completedSyracuse
v UAll 11 Years and
Phase
Adult,
Other
Older Adult)
InterventioInterventi IISP ID# 3
OccurrenceVBI VaccineAll 18 Years toPhase
40 Years
1 Â (Adult)128 Industry|OInterventioAllocation VBI-1501
Number ofSanofi
P Pas All 12 MonthsPhase
to 5 Years
2 Â (Child)300 Industry InterventioAllocation JEC01
The primary University All Child, Adult, Older Ad 166 Other ObservatioObservatioOVG 2012/
Cytokine coMurdoch Ch All up to 3 Days
NotÂ Applic
(Child) 185 Other InterventioAllocation VAC/01 ELV
safety|immUniversity All 18 Years and
Phase
Older
Adult) 04-107|R0
Maternal TYale Unive All 18 Years to 64 Years Â (Adult)102 Other ObservatioObservatio 1.01E+09
Serum hema Canadian IAll 6 Months toPhase
23 Months
2 Â (Child)
180 Other InterventioAllocation CT18
Non-inferi GlaxoSmithAll 2 Years to 10
Phase
Years3 Â (Child)715 Industry InterventioAllocation 205238|V5
Delayed TyJohn Kirkwo All 18 Years and
Phase
Older
Adult) UPCI 01-1
antibody r University All 18 Years and
Phase
Older
Other
Adult) InterventioAllocation 38RC17.19
PercentageMerck ShaFemale 9 Years to 15
Phase
Years3 Â (Child)100 Industry InterventioInterventi V503-008
Initial ImmBassett HeAll 40 Years toPhase
75 Years
4 Â (Adult,87Older
PostvaccinaSeqirus All 18 Years and
Phase
older3 Â (Adult,
3484
Older
Industry
Adult) InterventioAllocation CSLCT-QIV-
Incidence oNational InAll up to 45 Years
80 NIH InterventioAllocation 05-0048|H
Antibody leGlaxoSmithAll 11 MonthsPhase
to 13 Months
3 Â (Child)
ProgressionDana-FarbeAll 18 Years and
Phase
Older
Other|Indu
Immunogenic University All 16 Years and
Phase
70 OtherOlder Adult)
InterventioAllocation 02-0182-C|
60 Years
3 Â (Adult)300 Industry InterventioAllocation GQM07|U1
Disease re San AntoniAll 18 Years and
Phase
Older
U.S.Adult)
Fed|I InterventioAllocation CDR00005
Antibody tiButantan I All 6 Months to 90 Years Â (Child,
1152Adult,
OtherOlderObservatioObservatioBUTVAC-Inf
Adult)
To assess Tehran UniAll 18 Years toPhase
65 Years
1 Â (Adult,12Older
OtherAdult)InterventioAllocation 418-A-220
Safety: To Craig L SlinAll 18 Years and
Phase
older
1 Â (Adult, 11
Older
Other
Safety, as National InAll 18 Years toPhase
50 Years
6 month %University All Child, AdulNot Applic 30 Other|InduInterventioAllocation 14-1873
Anti-gD antGlaxoSmithFemale 10 Years toPhase
17 Years
3 Â (Child)
50 Years
99 Years
ApplicÂ (Adult,
325Older
OccurrenceDavid ScheAll 6 Months toPhase
59 Years
4 Â (Child,
156Adult)
DetermineUniversity All 6 Months to 25 Years Â (Child,33Adult)
Other|NIHObservatioObservatio20090858|
11 Years
4 Â (Child)
49 Years
Number ofSanofi All 18 Years toPhase
54 Years
2 Â (Adult)
202 Industry InterventioAllocation H-040-005
Evaluate thLongding LAll 6 Months toPhase
49 Years
1 Â (Child,
288Adult)
Other InterventioAllocation EV71-KMB1
Immunogeni London SchAll 6 Weeks toPhase
8 Weeks
4 Â (Child)
2100 Other InterventioAllocation QA1075
Change from The UniverAll 65 Years and
Phase
older
4 Â (Older100
Adult)
Other InterventioAllocation UW 12339
Local and African MaMale 18 Years toPhase
45 Years
1 Â (Adult)40 Other InterventioAllocation GMZ2_2_0
Number ofSanofi Pas All 50 Years and
Phase
older
3 Â (Adult,
9302
Older
Industry
Information Sanofi Pas All 18 Years and
Phase
older
4 Â (Adult,240
Older
Industry
Adult) InterventioAllocation GID33|U11
PercentageEmory UnivAll 18 Years toPhase
49 Years
2 Â (Adult)50 Other InterventioInterventi IRB000970
AssessmentSeqirus|NoAll 65 Years and
Phase
older
1 Â (Older450
Adult)
Industry InterventioAllocation V104P3|20
to 21 Months
3 Â 944
(Child)
64 Years
2 Â (Adult)
1250 Industry InterventioAllocation FID33|UTN
Rate and eCentre HosAll 40 Years to 65 Years Â (Adult,44Older
OtherAdult)ObservatioObservatioALTIBPCO|
OccurrenceH. Lee MoffMale 18 Years and
Notolder
Applic
Â (Adult, 29
Older
Adult) MCC-15262
Weekly IncGlaxoSmithAll 6 Months and older Â (Child,
23939 Adult,
Industry|OObservatioObservatio
Older Adult) 207781
Number ofGlaxoSmithAll 6 Months toPhase
17 Years
Safety and Sharon Ridd All 18 Years toPhase
65 Years
1 Â (Adult,40Older
Adult) DAIDS-ES
55 Years
Outcome Mea University All 18 Years toPhase
50 Years
1|PhÂ (Adult) 5 Other InterventioInterventi IRB-30000
To determin NewLink Ge All 18 Years and
Phase
older
1|Ph
Â (Adult, Older
3 Industry
64 Years
2 Â (Adult)
The serocoSinovac BioAll 60 Days to Phase
90 Days3 Â (Child)
1200 Industry InterventioAllocation PRO-sIPV-
To evaluateSinovac BioAll 18 Years toPhase
60 Years
1 Â (Adult)
120 Industry|OInterventioAllocation PRO-PanFl
Response: M.D. AnderAll 18 Years and
Phase
older
2 Â (Adult, 11
Older
Other|Indu
Cellular I National HeAll 18 Years toPhase
80 Years
2 Â (Adult,38Older
Adverse EvRockefellerMale 18 Years and
Phase
older
1|Ph
Â (Adult, 24
Older
Other
Adult) InterventioAllocation RDA 0466
Solicited s National InAll 18 Years toPhase
65 Years
1 Â (Adult,
143Older
60 Years
4 Â (Adult)
Phase
older
3 Â (Adult,240
Older
Industry
35 Months
2 Â (Child)
Safety andSanaria IncMale 18 Years toPhase
35 Years
1 Â (Adult)67 Industry|OInterventioAllocation BSPZV1
To assess Bavarian NAll 18 Years toPhase
45 Years
2 Â (Adult)87 Industry InterventioAllocation POX-MVA-
MagnitudeNational
50 Years
1 Â (Adult) 8 NIH InterventioAllocation HVTN 082|
Safety of Internatio All 18 Years toPhase
60 Years
1 Â (Adult)45 Other InterventioAllocation IAVI C001
evaluation AlessandroFemale 18 Years toPhase 64 Years
3 Â (Adult)
1220 Other InterventioAllocation HOPE9 STU
Number ofJanssen VaAll 4 Years to 70
Phase
Years
2 Â (Child,
1075Adult,
Older Adult) CR107249|
Number ofSanofi
55 Years
Antibody GGlaxoSmithAll 36 MonthsPhase
to 46 Months
3 Â 172
(Child)
SimultaneouStatens SerAll up to 49 Days
Phase
Â (Child)
3 817 Other InterventioAllocation VIPV-03
All-cause Lone GraffAll up to 7 DaysPhase
Â (Child)
4 4262 Other InterventioAllocation EudraCT20
Immunogeni Institute All 2 Years andPhase
30 Other
Older Adult)
InterventioPrimary Pu04MI07
Immune res National InAll 19 Years toPhase
99 Years
1|PhÂ (Adult,
517Older
NIH Adult)InterventioAllocation 07-0022
Data on adUniversity All 18 Years toPhase
50 Years
1 Â (Adult)20 Other InterventioAllocation TB010
Change in National CaAll 40 Years toPhase
70 Years
NIH Adult)InterventioAllocation NCI-2014-
Safety of vNational I All 18 Years toPhase
40 Years
1 Â (Adult)36 NIH|Other| InterventioAllocation HVTN 067|
PercentageSerum InstiAll 6 Weeks toPhase
8 Weeks
4 Â (Child)211 Industry|OInterventioAllocation Penta-01/
Immunogeni GlaxoSmithAll up to 5 DaysPhase
Â (Child)
2 0 Industry InterventioAllocation 112980
GMT of theGlaxoSmithAll 6 Months to Phase
6 Years
Number and Institute All 18 Years toPhase
60 Years
2|PhÂ (Adult)
930 Industry|OInterventioAllocation IVACFLU-A
Day 1, 8 anPfizer All 65 Years toPhase
85 Years
Efficacy EnSeqirus All 6 Months to Phase
47 Months
3 Â 3830
(Child)
Number ofCodagenix,All 18 Years toPhase
45 Years
1 Â (Adult)125 Industry InterventioAllocation CODA01-0
Immunogeni InternationAll 1 Year to 40Phase
Adult)
Other|InduInterventioAllocation IVI-CHOVI
PercentagesGlaxoSmithAll 6 Weeks toPhase
12 Weeks
3 Â (Child)
60 Years
To quantifyNovartis V All 6 Months and older Â (Child,7284 Adult,
Industry
Older ObservatioObservatioV111_09O
Adult)
Number ofGSK Vaccine All 18 Years toPhase
45 Years
100 Years
Other|Indu
Adult)
InterventioInterventi J1994|IRB
Number ofSanofi All 65 Years andPhase
older
1 Â (Older Adult)
48 Industry InterventioAllocation H-030-009
the dynamiCenters fo All 12 Years to 60 Years Â (Child,207Adult)
Other ObservatioObservatioBJCDCWJ2
Persistenc National CaAll 9 Years to 11
Phase
Years
2 Â (Child)200 NIH InterventioInterventi NCI-2015-
Immunologi The VaccinAll 18 Years andPhase
older
2 Â (Adult, 30
Older
Industry
Adult) InterventioMasking: NCDR000055
Evaluate anSeqirus All 12 MonthsPhase
to 84 Months
3 Â 607
(Child)
Incidence aSanaria In All 18 Years toPhase
45 Years
1 Â (Adult)67 Industry|UInterventioAllocation WRAIR #20
SeropositivPATH All 6 Weeks toPhase
18 Weeks
4 Â (Child)
1140 Other InterventioAllocation PATH HS53
Haemagglut GlaxoSmithAll 3 Years to 9Phase
Years3Â (Child) 60 Industry InterventioAllocation 113810
PercentageDuke Univer Female 18 Years toPhase45 Years
4 Â (Adult)81 Other|U.S.InterventioAllocation Pro000711
SeroprotectUniversita All 18 Years andPhase
older
4 Â (Adult,407
Older
Other
Adult) InterventioInterventi ML2394
Safety (advUniversity All
of Sao Paulo|FundaÃ§Ã£o
Child, AdulPhasede 4 Amparo5000Ã Pesquisa
Other doInterventioAllocation
Estado de SÃ£o PauloCEDMAC-H
older
3 Â (Adult,312
Older
Industry
To measureChiron CorAll 13 Years toPhase
15 Years
4 Â (Child)264 Industry InterventioAllocation M14P2
Cellular I VanderbiltAll 65 Years andNotolder
Applic
Â (Older105Adult)
Other|U.S.InterventioAllocation 080925|5U
Tolerance University All 1 Year to 24Phase
occurence Sichuan CeAll 3 Years and older Â (Child,
400000
Adult,
Other|Indu
Older Adult)
ObservatioObservatiocnbg-002
Incidence Merck ShaMale 20 Years toPhase
45 Years
3 Â (Adult)
Incident R GlaxoSmithAll 18 Years toPhase
50 Years
2 Â (Adult)
Cellular r Tel-Aviv S All 18 Years andPhase
Older
Other
Adult) InterventioAllocation TASMC-13-
Number ofHealthBanks Female 18 Years toPhase
45 Years
1 Â (Adult)15 Industry InterventioInterventi HBPEKVPI0
Evaluate i Sinovac BioAll 3 Years andPhase
Adult,
Industry
Older Adult)
InterventioAllocation PRO-PanFl
VaccinationThe Univers Female 18 Years andNotolder
Applic
Â (Adult,280
Older
Other
Adult) InterventioAllocation HSC-MS-10
Change in pAssociate All up to 6 Years Â (Child) 1200 Other|InduObservatioObservatio 38070
OccurrenceGlaxoSmithFemale 18 Years toPhase
25 Years
1 Â (Adult)
Adverse eveUniversity All 18 Years toPhase
49 Years
98 Days 2 Â (Child)489 Industry InterventioAllocation C3571002
Anti-HBs aIDEWE Occu All 18 Years andPhase
Older
Other|Indu
Adult) InterventioAllocation IDEWE-301
ImmunogenicSinovac BioAll 18 MonthsPhase
to 5 Years
4 Â (Child)
303 Industry InterventioAllocation PRO-HA-40
Serum samp Jena UniverAll 18 Years and older Â (Adult,900 Older
Other
Adult) ObservatioObservatioStikoSero
GeometricSanofi
M All 6 Months to Phase
8 Years
2 Â (Child)
520 Industry InterventioAllocation FID07
45 Years
Number ofNovartis All 18 Years toPhase
40 Years
Evaluate a National CaAll 60 Years toPhase
100 Years
2 Â (Adult,1 Older
NIH Adult) InterventioAllocation 110146|11
24 Months
1 Â (Child)
Mortality|Bandim Hea All 18 MonthsNot to 24
Applic
Months Â8500
(Child)
Other InterventioAllocation MV18Mont
61 Years
3 Â (Adult)
Influenza Columbia UAll 6 Months to Not50Applic
Years Â (Child,
30537Adult)
Other InterventioAllocation AAAF0137
HospitalizaInsight Th All 65 Years andPhase
older4 Â (Older823
Adult)
Other InterventioAllocation GRC75-EXT
GeometricSanofi
M Pas All 6 Months andPhaseolder
4 Â (Child,
602Adult,
Industry
Adult) FST01|U11
Number ofPfizer All 2 Months to 2 Years Â (Child)1143 Industry ObservatioObservatio0887X1-44
64 Years
2 Â (Adult)
Titers for GlaxoSmithAll 18 Years toPhase
60 Years
2 Â (Adult)
Number ofOlogy
45 Years
1 Â (Adult)
To evaluateUnited BioAll 50 Years toPhase
80 Years
1 Â (Adult,19Older
Adult) UBI Protoc
SeropositivPfizer All 1 Year to 11Phase
Years3Â (Child) 302 Industry InterventioAllocation 700801|EU
Vaccine Ef Janssen VaFemale 18 Years toPhase
35 Years
Biological: Trivalent National InAll 18 Years andPhase
Older
GMTs AferIntercell U All 18 Years toPhase
64 Years
2 Â (Adult)
160 Industry InterventioAllocation ELT203
Pocket for Seoul Nati All 19 Years toPhase
60 Years
3 Â (Adult)88 Other|InduInterventioInterventi CJ_SPX_302
50 Years
1 Â (Adult)40 U.S. Fed|I InterventioAllocation S-11-0007
Solicited LG Life Sci All 19 Years toPhase
50 Years
1 Â (Adult)63 Industry InterventioAllocation LG-VECL00
Induction Ian F. Poll All 18 Years andEarly
older
PhasÂ (Adult, 13
Older
Other|Indu
Adult) InterventioAllocation 07-057|R2
Influenza University All Child, AdulNot Applic 6 Other InterventioAllocation 1.25E+08
Frequency National InAll 6 Months to Phase
49 Years
NIH|OtherInterventioAllocation CIR 231|W
First primaPfizer All 50 Years andPhase
older3 Â (Adult,
17525Older
Industry
To determinDana-FarbeAll 35 Years andPhase
Older
Other
89 Days 2 Â (Child)
45 Years
2 Â (Adult)27 Other InterventioAllocation Flu002
Number ofMemorial SAll 21 Years and older Â (Adult,181 Older
Other
older3 Â (Adult,
1426
Older
Industry
Outcome of Medical UnAll 18 Years andPhase
Older
Other
Adult) InterventioAllocation EudraCT_2
Number ofBellicum
P PMale 18 Years andPhase
Older
Industry
Adult) InterventioInterventi BP-PC-002
Frequency National
50 Years
2 Â (Adult)
299 NIH InterventioAllocation HVTN 205|
To evaluateBaylor ReseAll 18 Years andPhase
Older
Other
Number and Sanofi Pas All 6 Weeks toPhase
50 Years
1 Â (Child,
280Adult)
Industry InterventioAllocation PPR02|U11
Phase I: ReH. Lee MoffAll 18 Years andPhase
older1|Ph
Â (Adult, Older
0 Other
35 Months
2 Â (Child)
Virus neutrNational I All 18 Years toPhase
50 Years
1 Â (Adult)20 NIH|IndustInterventioAllocation CIR 301
Safety and National InAll 18 Years toPhase
50 Years
2 Â (Adult) 0 NIH|OtherInterventioAllocation IAVI V002|10419
49 Years
OccurrenceGlaxoSmithAll 18 Years toPhase
55 Years
1 Â (Adult)
EvaluationGroupe Hosp All 18 Years and older Â (Adult, 80 Older
Other
Adult) ObservatioObservatioSAUVAC
Possible r Lund UniveAll up to 6 Months
Not Applic
Â (Child) 109 Other InterventioAllocation LU62601
60 Years
ApplicÂ (Adult)33 Other InterventioInterventi RC5303
PercentageH. Lee MofMale 27 Years toPhase
45 Years
2 Â (Adult)
150 Other|InduInterventioInterventi MCC-1659
General SyNational I All 6 Weeks toPhase
10 Weeks
3 Â (Child)
1498 Other|InduInterventioAllocation Rota/CeNS
Number ofOlogy
45 Years
1|Ph
Â (Adult)
Safety andNational InAll 18 Years toPhase
50 Years
OccurrenceGlaxoSmithAll 6 Weeks toPhase
18 Months
3 Â 41188
(Child)Industry InterventioAllocation 111442
Fold rise i National InAll 18 Years toPhase
60 Years
Non-acciden Bandim Hea All 9 Months to Phase
59 Months
4 Â 5400
(Child)
Other InterventioAllocation 053/CNES/
SeroresponSerum InstiAll 2 Years to 29
Phase
Years3 Â (Child,
1800
Adult)
Industry|OInterventioAllocation ACYWX-03|
1) the per University All 11 Years toNot
18 Years
ApplicÂ (Child,
4807Adult)
Other|U.S.InterventioAllocation 07-0763|U
50 Years
OccurrenceUniversity All 20 Years toPhase
59 Years
4 Â (Adult)
150 Other|InduInterventioAllocation H09-02820
the differeRegion SkaAll 18 Years andPhase
Older
Other
Adult) InterventioAllocation VACCIMIL-
to 18 Months
3 Â 254
(Child)
Industry InterventioAllocation A3L22
Number ofColumbia UFemale 18 Years andNotolder
Applic
Â (Adult,166
Older
Adult) AAAM4906
To assess Baxter HeaAll 18 Years andPhase
Older
Industry
Seroconvers Ology BiosAll 50 Years andPhase
older3 Â (Adult,
3195
Older
Industry
45 Years
1 Â (Adult)
140 Industry InterventioAllocation INV-DEN-1
The natureIchor MediAll 18 Years toPhase
49 Years
1 Â (Adult)42 Industry|UInterventioAllocation IMS-VEEV-
The primarAga Khan UAll up to 14 Days
NotÂApplic
(Child) 3850 Other InterventioAllocation 4320-Ped_
to 18 Months
3 Â 245
(Child)
PercentageWyeth is nAll 5 Years to 8Phase
Years3Â (Child) 89 Industry InterventioAllocation 6096A1-30
18 Months
3 Â (Child)
AssessmentUltimovacsMale 18 Years andPhase
older1|Ph
Â (Adult, 21
Older
Industry
GeometricGlaxoSmith
M All 3 Years to 17
Phase
Years3 Â (Child)
98 Days 3 Â (Child)286 Industry InterventioAllocation 6096A1-00
Relatedness National InAll 18 Years toPhase
50 Years
DescriptionSanofi Pas All 60 Days to Phase
74 Days 4 Â (Child)900 Industry InterventioInterventi E2I60|U11
Data descriNational InAll 18 Years toPhase
40 Years
Group 1 onlGritstone OAll 18 Years and older Â (Adult,140 Older
Industry
Adult) ObservatioObservatioGO-003
Both immuno Ian F. Poll All 18 Years andEarly
older
PhasÂ (Adult, 10
Older
Adult) 08-135|1R
OccurrenceU.S. Army All 1 Year to 6Phase
Years Â1 (Child) 100 U.S. Fed|NInterventioAllocation 05-0146|U
40 Years
1 Â (Adult)
Safety of National I All 18 Years toPhase
40 Years
1 Â (Adult)29 Other InterventioInterventi Rotavin01
Antibody tLaval UniveFemale 12 Years toPhase
14 Years
3 Â (Child)
416 Other InterventioAllocation 122.05.01
Solicited a Green CrosAll 19 Years toPhase
65 Years
Industry
Adult)InterventioAllocation GC3106_P1
Vaccine ReGlaxoSmithAll 56 Years andPhase
older
3 Â (Adult,400
Older
Industry
Difference National CaMale 18 Years toPhase
99 Years
2 Â (Adult,75Older
Safety and University All 18 Years andPhase
older
1 Â (Adult, Older
6 Other
Adult) InterventioInterventi MIDRIXNE
Measure inj Xiamen UniFemale 18 Years toPhase
55 Years
1 Â (Adult)38 Other|InduInterventioInterventi HPV-PRO-0
Vaccine Ef Yale Unive All 18 Years andPhase
older
4 Â (Adult,595
Older
Adult) 00050117
Immunogen Medicago|S All 18 Years toPhase
60 Years
2 Â (Adult)390 Industry|OInterventioAllocation CP-H5VLP-
Cervical in Shanghai ZFemale 18 Years toPhase
30 Years
3 Â (Adult)
12000 Industry|OInterventioAllocation 311-HPV-1
PRNT80 â‰¥ U.S. Army All 18 Years toPhase
65 Years
U.S. Fed
Adult)InterventioInterventi A-15322|F
Frequency National
50 Years
1 Â (Adult)14 NIH InterventioAllocation HVTN 112|
Tâˆ’cell pr University All 16 Years toPhase
40 Years
2 Â (Child, Adult)
9 Other|InduInterventioAllocation SysVac01 -
The primary Pfizer All 18 Years toPhase
85 Years
Industry
Adult)InterventioAllocation 6123K1-10
Immunogeni Oswaldo CrAll 18 Years toPhase
59 Years
Safety, tol PowderMeAll 18 Years toPhase
50 Years
1 Â (Adult)189 Industry InterventioAllocation PM FLS-00
Change in Ann & Robe Male 18 Years toNot
26 Years
ApplicÂ (Adult) 0 Other InterventioAllocation PA18162
AE of localNational VAll 6 Months to Phase
59 Years
Industry|OInterventioAllocation CXSL17000
Blood concNational InAll 18 Years to 50 Years Â (Adult)47 NIH ObservatioObservatioHVTN 908|
Rate of Im H. Lee MofAll 18 Years andPhase
older
2 Â (Adult, 43
Older
Other|NIH|
Influenza vThe Univers All 18 Years andNotolder
Applic
Â (Adult,
22584Older
Other
Adult) InterventioAllocation SenderoFl
older
3 Â (Adult,695
Older
Industry
Incidence Genocea BiAll 18 Years andPhase
older
1|Ph
Â (Adult, 99
Older
Industry
Adult) InterventioAllocation GEN-009-1
Severe sol Serum InstiAll 12 MonthsPhase
to 16 Months
2 Â 375
(Child)
Industry|OInterventioAllocation ACYWX-002
safety and RockefellerAll 18 Years toPhase
62 Years
1 Â (Adult)14 Other InterventioAllocation SSC-0803
rabies viruProvincial All 5 Years to 8Phase
Years3Â (Child) 703 Other InterventioAllocation I49P1
Overall su The VaccinAll 18 Years andPhase
older
3 Â (Adult,244
Older
Industry
Adult) InterventioAllocation CDR000051
ProportionM.D. AnderAll 18 Years andPhase
older
1 Â (Adult, 60
Older
Adult) 2014-1029
ReactogeniUniversity All 65 Years toPhase
75 Years
Occurrence, Institut Pa All 18 Years toPhase
27 Years
1 Â (Adult)36 Industry InterventioAllocation MV1-F4-CT
50 Years
1 Â (Adult)40 Other InterventioAllocation EBL06
Clinical r University Female 18 Years andPhase
older
2 Â (Adult, 19
Older
Other|Indu
Adult) InterventioInterventi ISA-P53-C
GeometricSanofi Pas All 55 Days to Phase
65 Days3 Â (Child)
1375 Industry InterventioAllocation A3L24|UTN
50 Years
To assess tAga Khan UAll up to 18 Weeks
Not Applic
Â (Child) 300 Other InterventioAllocation 2013/3110
to 18 Months
3 Â 450
(Child)
50 Years
To determin Radboud Un Male 18 Years toPhase
35 Years
2|PhÂ (Adult)20 Other InterventioAllocation BCG-LPS
448 Industry
Older Adult)
InterventioAllocation 201532|20
immunogeni Queen Saov All 60 Years toNot
100Applic
Years Â (Adult,
180 Older
OtherAdult)InterventioAllocation TIC 5301
Primary: PlUniversity All 18 Years toNot
70 Years
ApplicÂ (Adult, 6Older
OtherAdult)InterventioAllocation UoL001462
Vaccine-reMerck ShaAll 50 Years andPhase
older
3 Â (Adult,101
Older
Industry
HPV VaccinUniversity Female Child, AdulNot Applic 3 Other InterventioAllocation 48789
PercentageGreen CrosAll 65 Years andPhase
older
Industry InterventioInterventi GC3110A_
Safety of PharmAthen All 18 Years toPhase
55 Years
2 Â (Adult)415 Industry|NInterventioAllocation 05-0003|Q
Humoral imGlaxoSmithAll 18 Years toPhase
64 Years
Vaccine-in ProvidenceAll 18 Years andPhase
older
1 Â (Adult, Older
Adult) 06-76|1R2
blood cult Stanford UAll 6 Months to 16 Years Â (Child)
40000 Other|U.S.ObservatioObservatioIRB-39627
to 21 Months
2 Â 501
(Child)
Number ofMedImmunAll 18 Years toPhase
49 Years
4 Â (Adult) 300 Industry InterventioAllocation MI-MA182
Student feUniversity All 11 Years andNotolder
Applic
Â (Child,
1400
Adult,
Other
Older Adult)
Post BoosteEastern Vi All 18 Years toPhase
90 Years
Other|Indu
Adult)InterventioAllocation Doris Duke
PercentageNational CaAll Child, AdulPhase 1 30 NIH InterventioInterventi NCI-2013-
Frequency National
36 Months
1 Â (Child)
45 NIH|OtherInterventioAllocation CIR 215|CI
Overall SurSidney KimAll 18 Years andPhase
older
Adult) J9988|R01
PercentageWyeth is nAll 7 Months to Phase
5 Years
3 Â (Child) 355 Industry InterventioAllocation 6096A1-30
17 Years
Immunogenic Novavax|De All 18 Years toPhase
64 Years
2 Â (Adult) 500 Industry|UInterventioAllocation NVX 778.S
Number ofVac4All|UnAll 12 MonthsPhase
to 48 Months
2 Â 800
(Child)
Industry|OInterventioAllocation MMVDU-0
Number ofInternatio All 1 Year to 45Phase
Years1|Ph
Â (Child, 840
Adult)
Other|InduInterventioAllocation PR-16021
Safety of PSanaria IncAll 18 Years toPhase
45 Years
1 Â (Adult)21 Industry|OInterventioAllocation BSPZV3a
Recommende Antigen ExFemale 18 Years andPhase
older
Adult) NSABP FB-
anti-salmon Radboud Un All 18 Years andNotolder
Applic
Â (Adult, 30
Older
Other
Adult) InterventioAllocation BCG-TFV1
Number ofRoss UniverAll Child, AdulPhase 4 430 Other|InduInterventioAllocation 18-04-FL
Vaccinatio Memorial SAll 21 Years toNot
84 Years
ApplicÂ (Adult,
800Older
Safety of FNovartis V All 6 Months and older Â (Child,
135469 Adult,
Industry
Older ObservatioObservatioV111_05
Adult)
The total MRC/UVRIAll U 18 Years andPhase
older
Other|Indu
Adult) InterventioInterventi MUL/PK/0
PercentageJanssen VaAll 4 Months to Phase
11 Months
2 Â (Child)
108 Industry|OInterventioAllocation CR108617|
The primary AdimmuneFemale 18 Years andPhase
older
Industry
Adult) InterventioInterventi FLU11T12P
50 Years
Levels of aSanofi Pas All 12 MonthsNot to 18
Applic
Months Â 122 (Child)
Immunogenic Sanofi Pas All 65 Years andPhase
older
Industry InterventioAllocation FID01C
The overallSinovac BioAll up to 49 Years
144 Industry InterventioAllocation PRO-HB-10
Antibody tiUniversity All 16 Years andPhase
older
Other
Older Adult)
InterventioAllocation 04-0450-A
To compareGlaxoSmithAll 18 Years andPhase
older
3 Â (Adult,7460
Older
Industry
Safety of Washington All 18 Years andPhase
older
Other|Indu
Adult) InterventioAllocation 18-x172
Protective University All 18 Years toPhase
45 Years
2 Â (Adult) 102 Other InterventioAllocation HP-000862
Safety, as National InAll 18 Years andPhase
older
Adult) CIR 211 (S
The primary Centers fo All 18 Years andPhase
older
1|Ph
Â (Adult, 55
Older
U.S.Adult)
Fed InterventioInterventi CDC-NCIRD
Antibody leSanofi Pas Female 9 Years to 14
Phase
Years
3 Â (Child)480 Industry InterventioAllocation CYD71|U11
60 Years
The number National InAll 18 Years toPhase
49 Years
Laboratory-Epicentre|All 6 Weeks toPhase
2 Years
3 Â (Child)6586 Other|InduInterventioAllocation R822388
Rate of HPV Children's Female 11 Years toNot
17 Years
ApplicÂ (Child)
23675 Other|U.S.InterventioAllocation 09-00-735
Safety of GInstitute o All 3 Years andPhase
120 Other|Indu
Older Adult)
InterventioInterventi VX-2015.0
Clinical Sa Stanford UAll 13 Years toPhase
65 Years
Older Adult) SU-18615|
35 Years
Anti-Circu GlaxoSmithAll 5 Months to Phase
17 Months
3 Â (Child)
Efficacy of PowderMeAll 18 Years toPhase
50 Years
1 Â (Adult) 105 Industry InterventioAllocation PM FLS-00
Number ofGlaxoSmithFemale 26 Years andPhase
older
Industry
Phase
Years
50 Years
55 Years
2 Â (Adult)226 Industry|NInterventioAllocation 05-0002|P
OccurrenceBeijing Zh All 3 Months andPhaseolder
1 Â (Child,200
Adult,
Older Adult) 2.02E+08
45 Years
Efficacy (i Butantan InAll 24 MonthsPhase
to 59 Years
3 Â 16944
(Child,Other
Adult) InterventioAllocation DEN-03-IB
Number ofGlaxoSmithAll 60 Days to Phase
90 Days 2 Â (Child)721 Industry InterventioAllocation 113948
Change in AssistanceAll 18 Years and older Â (Adult, 1200
Older
Other
Adult) ObservatioObservatioK170603J
64 Years
2 Â (Adult)900 Industry InterventioAllocation CP-Q14VLP
Occurrence, Centers forAll 18 Years toPhase
50 Years
1 Â (Adult)56 Other InterventioAllocation CDCPChina
SeroprotectNovartis V All 29 Years toPhase
60 Years
2|Ph
Â (Adult)
Anti-HPV16Jun Zhang|Female 9 Years to 26
Phase
Adult)
Other|InduInterventioAllocation HPV-PRO-0
25 Years
3 Â (Child,225
Adult)
91 Days 3 Â (Child)354 Industry InterventioInterventi A3L35|U11
Dose-limit Masonic CaAll 3 Years andPhase
8 Other
Older Adult)
InterventioInterventi 2009LS13
Immunogeni MaastrichtAll 18 Years toPhase
59 Years
2 Â (Adult)133 Other InterventioAllocation HBnr02|20
Number ofBeth IsraelAll 18 Years andPhase
Older
Adult) 11-178|P5
This study St. Jude ChAll 6 Months to 21 Years Â (Child, 104Adult)
Other ObservatioObservatioSOVAC
60 Years
To provide Sanofi All 18 Years to 25 Years Â (Adult) 147 Industry ObservatioObservatioVVL05
DetermineMemorial SAll 65 Years andPhase
older2 Â (Older126
Adult)
VaccinationPharmacy Q All 19 Years andNotolder
Applic
Â (Adult,
22301Older
Other
Hemagglutin Baxter HeaAll 18 Years andPhase
older3 Â (Adult,
1928
Older
Industry
72 Days 3 Â (Child)708 Industry InterventioAllocation 6096A1-01
Number ofPATHS All 18 Years toPhase
45 Years
1 Â (Adult)80 Other InterventioAllocation CVIA 065
Detection Liverpool All 18 Years toPhase
50 Years
19 Years
3 Â (Child,450
Adult)
Rates of C Children's All 4 Years to 18
NotYears
Applic
Â (Child,
4455
Adult)
Other InterventioAllocation CHLA-08-0
Cell-mediaOklahoma AMll 50 Years toPhase
75 Years
1 Â (Adult,20Older
OtherAdult)InterventioAllocation OMRF 11-4
SeroconverThe UniverAll 21 Years andNotolder
Applic
Â (Adult, 93
Older
Other
Adult) InterventioAllocation HKU-2012-
Safety (advArizona StaAll 18 Years toPhase
40 Years
1 Â (Adult)60 Other InterventioAllocation 09-RASV-S
Intention Indiana UniFemale 18 Years andNotolder
Applic
Â (Adult,908
Older
Other
Adult) InterventioAllocation 1.81E+09
Antibody RMerck ShaAll 4 Years to 8Phase
Years3Â (Child)1478 Industry InterventioAllocation V232-058|
Antibody (Novartis|NFemale 20 Years toPhase
42 Years
1 Â (Adult)50 Industry InterventioInterventi V98P1E1
NeutralizinSanofi Pas All 9 Years to 50
Phase
Years2 Â (Child,
1050
Adult)
To estimateWalter ReeAll 6 Months andPhaseolder
1|Ph
Â (Child,17
Adult,
U.S. Fed|OInterventioAllocation
Older Adult) 357349
Measles Ser PATH All 20 MonthsPhase
to 36 Months
3 Â 519
(Child)
Other InterventioAllocation JEV02
40 Years
1 Â (Adult)12 Industry InterventioAllocation 692342/00
PercentageNovartis V All 6 Months to Phase
12 Months
2 Â (Child)
Humoral imRigshospit All 5 Months to Phase
7 Months
4 Â (Child)
6500 Other InterventioAllocation LGS.MMR.0
the MontreBeijing Fri All 50 Years andNotolder
Applic
Â (Adult, 60
Older
Other
64 Years
Frequency University All 24 Years toPhase
54 Years
4 Â (Adult)20 Other InterventioInterventi BioVacSafe
Older
Industry
Number ofJiangsu
p ProAll 6 Months to Phase
60 Months
1 Â (Child)
evaluation University All 2 Years to 59
NotYears
Applic
Â (Child,300
Adult)
Other InterventioInterventi LAIV-tonsi
ProportionSanofi Pas All 59 Years andPhase
Older
Industry
Adult) InterventioAllocation MEQ00066
T Cell Res University All 18 Years and
Notolder
Applic
Â (Adult,193
Older
Other
Adult) InterventioAllocation H 13000
Phase
older
3 Â (Adult,865
Older
Industry
Immunologi Sidney KimAll 18 Years toPhase
120 Years
1|PhÂ (Adult,1 Older
Adult) J06143 CD
ProgressioUniversity Male 18 Years and
Phase
older
2 Â (Adult, 60
Older
Other|Indu
Adult) InterventioAllocation UW18037|
Decision RIndiana UnAll 13 Years to 17 Years Â (Child)62 Other|InduObservational Merck IISP
Titers of n ChulalongkAll 18 Years to 26 Years Â (Adult)60 Other ObservatioObservatio2011/02_M
Anti-PRP (pNovartis V All 365 Days toPhase
569 Days
3 Â (Child)660 Industry InterventioAllocation V37_07E1
Number ofShanghai InAll 3 Years andPhase
Adult,
Industry
Older Adult)
Incidence aSanaria In All 18 Years toPhase
45 Years
1 Â (Adult)104 Industry|OInterventioAllocation EGSPZV3
ProtectionNational InAll 18 Years toPhase
50 Years
Rate of sigID BiomediAll 50 Years and
Phase
older
3 Â (Adult,900
Older
Industry
Adult) InterventioAllocation IDB707-10
Feasibilit Washington All 18 Years and
Phase
older
1 Â (Adult, 20
Older
Other
26 Years
Serious AdFidec CorpAll 6 Weeks toPhase
5 Years
2 Â (Child)
1023 Other InterventioAllocation M5 ABMG
Evaluate thAdimmuneAll 3 Years to 17
Phase
Years
3 Â (Child)174 Industry InterventioAllocation ADIMQIS2
Safety/FeaDCPrime BAll 18 Years toPhase
80 Years
Industry
Adult)InterventioAllocation DCOne-1
Grades of National InAll 6 Months toPhase
24 Months
1 Â (Child)
Local reac National InAll 18 Years toPhase
40 Years
1 Â (Adult)18 NIH InterventioInterventi RV 156A|1
Receipt of University All 4 Months and
Not older
ApplicÂ (Child,
343087 Adult,
24 Years
Industry InterventioInterventi 111375|20
The study University All up to 365 Days
Not Applic
Â (Child) 1506 Other InterventioAllocation X05071300
Presence oGlaxoSmithAll 6 Weeks toPhase
14 Weeks
Any incidenAIDS MaligMale 13 Years toPhase
26 Years
Other|NIH| InterventioInterventi AMC-072|
CumulativeMurdoch Ch All up to 18 Weeks
PhaseÂ2 (Child) 688 Other InterventioAllocation MCRI-RV3-
50 Years
Evaluation Protein Sc All 18 Years toPhase
49 Years
2|PhÂ (Adult)
459 Industry InterventioAllocation PSC01
pathologicClinica UniAll 18 Years toPhase
75 Years
2 Â (Adult,29Older
Adult) DEND/CM
Frequency National
o InAll 6 Months toPhase
60 Months
1 Â (Child)
Percent of University Female 18 Years toNot
26 Years
ApplicÂ (Adult)
200 Other|InduInterventioAllocation HP-000470
Serum BactCentro Supe All 14 MonthsPhase
to 19 Months
4 Â 389
(Child)
Other InterventioAllocation CSISP-VAC
Vaccine SafEunice KenAll 18 Years toPhase
49 Years
1 Â (Adult) 0 NIH InterventioAllocation 999911214
EvaluationGlaxoSmithAll 18 Years toPhase
65 Years
Industry
49 Years
The immuno Jiangsu Pr All up to 24 Hours
PhaseÂ 3(Child) 1740 Other InterventioAllocation JSVCT008
Safety andU.S. Army All 18 Years toPhase
55 Years
1 Â (Adult)60 U.S. Fed|NInterventioAllocation 04-031|N0
ProportionNantCell, I All 18 Years toPhase
100 Years
Industry|NInterventioAllocation
Adult) QUILT-3.01
Phase
older
4 Â (Adult,121
Older
Industry
percent coUniversity All 13 Years and
Notolder
Applic
Â (Child,260
Adult,
Other
Older Adult)
Incidence Intercell U All 18 Years toPhase
64 Years
3 Â (Adult)
2036 Industry InterventioAllocation ELT301|Eu
Median Time Masonic CaAll 18 Years and
Phase
older
2 Â (Adult, 21
Older
Other
Adult) InterventioAllocation 2006LS04
Safety ite CanSino BiAll 6 Weeks andPhase
older
1 Â (Child,237
Adult,
Older Adult) CS-CTP-PC
65 Years
Number ofVA PharmaAll 18 Years toPhase
60 Years
1 Â (Adult)54 Industry InterventioAllocation UIV-I-01/2
PercentageGlaxoSmithFemale 22 Years toPhase
46 Years
Part I - Pa University All 11 Years toNot
70 Years
ApplicÂ (Child,
597Adult,
Other|Indu
Adult) 13-0026-P
Protective Mount SinaAll 18 Years toPhase
69 Years
4 Â (Adult,30Older
OtherAdult)InterventioAllocation MSH 09-02
occurrenceRuth TacheAll 18 Years and
Phase
older
3 Â (Adult, 51
Older
Other
Adult) InterventioInterventi UHKT-RLP/
ProportionAssistance All 18 Years toPhase
75 Years
2 Â (Adult,70Older
OtherAdult)InterventioInterventi P120131|2
Vaccine resCenters fo All 35 Days to Phase
41 Days
4 Â (Child)
1256 U.S. Fed|OInterventioAllocation PR-18045
Titers for GlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,
4659
Older
Industry
40 Years
Relapse freAssistance All 18 Years and
Phase
older
3 Â (Adult,300
Older
Other
Cell-mediaAVAX TechnFemale 18 Years and
Phase
older
1|Ph
Â (Adult, 34
Older
Industry
Adult) InterventioAllocation A/100/050
Gardasil i Indiana UnAll 11 Years toNot
15 Years
ApplicÂ (Child)
55 Years
2 Â (Adult) 193 Other InterventioAllocation BAKMAL16
CategoricaSanofi Pas All 18 Years toPhase
49 Years
2 Â (Adult) 110 Industry InterventioAllocation FID30
Immunogeni Novartis|NAll 18 Years and
Phase
older
2|Ph
Â (Adult,
2719
Older
Industry
SeroconverVBI VaccineAll 18 Years toPhase
45 Years
3 Â (Adult) 100 Industry InterventioAllocation 38-13-040
50 Years
1 Â (Adult) 141 NIH|OtherInterventioAllocation CIR 268
Number ofNational InAll 2 Years to 24
Phase
Years
1|Ph
Â (Child,384
Adult)
NIH|OtherInterventioAllocation P1065|103
Number ofUniversity All 8 Weeks to 15 Weeks Â (Child) 20 Other ObservatioObservatioOVG 2014/
new immuni University All 7 Months toNot19Applic
Months Â10175
(Child)
Other|U.S.InterventioAllocation U01IP0000
Immunogenic AssistanceAll 18 Years and
Phase
older
2 Â (Adult,120
Older
Other
Adult) InterventioAllocation P150964|2
HI titers a Abbott BiolAll 18 Years and
Phase
older
3 Â (Adult,121
Older
Industry
35 Months
1 Â (Child)
Haemagglut GlaxoSmithAll 18 Years and
Phase
older
2 Â (Adult,
2007
Older
Industry
PercentagePfizer All 68 Years and
Phase
older
3 Â (Older1053
Adult)
Industry InterventioInterventi 6115A1-30
To assess Ology BiosAll 18 Years toPhase
59 Years
Antibody RNovartis V All 6 Months toPhase
35 Months
2|Ph Â (Child)
Developmen Columbia UAll 60 Years to 80 Years Â (Adult,26Older
Other|Indu
Adult)ObservatioObservatioAAAE1779
Comparison VanderbiltAll 5 Years to 11
Phase
Years
4 Â (Child)300 Other|U.S.InterventioAllocation 181211|20
MEASURESFluart InnoAll 18 Years and
Notolder
Applic
Â (Adult,256
Older
Industry
The Geomet Seqirus All 5 Years to 17
Phase
Years
3 Â (Child)
2278 Industry InterventioAllocation CSLCT-QIV-
35 Months
3 Â (Child)
Incidence Merck ShaAll 50 Years and older Â (Adult,
30000Older
Industry|OObservatioObservatioV211-024|
Adult)
Flu vaccinaAgrupament All Child, AdulNot Applic 401 Other InterventioInterventi FIVA_2019
16 Weeks
3 Â (Child)
85 Years
Industry
Flu AntibodNational InAll 18 Years toPhase
45 Years
1|PhÂ (Adult)43 NIH InterventioAllocation 120103|12
Serum immu PT Bio Far All up to 5 Days
Phase
Â (Child)
3 1000 Industry InterventioAllocation RV 0319
Antibody reBaxalta noAll 18 Years toPhase
70 Years
1|PhÂ (Adult,
1630Older
Industry
Titers of GlaxoSmithFemale 18 Years toPhase
45 Years
3 Â (Adult)
Number ofMacarena A Dll 1 Year to 100
Phase
Years
1 Â (Child, 19
Adult,
Other
Older Adult)
Evaluate thEli Lilly All 18 Years and
Phase
older
1 Â (Adult, 31
Older
Adult) CP09-0001
PercentageTakeda All 4 Years to 16
Phase
Years
2 Â (Child)200 Industry InterventioInterventi DEN-313|U
To evaluat Dalhousie All 12 MonthsPhase
to 59 Months
2 Â 200
(Child)
Other|InduInterventioInterventi PCIRN RT-0
200 Industry
Older Adult)
InterventioInterventi TYP31 (SF
Safety|GlioIan F. Poll All 12 MonthsNotto 21
Applic
Years Â (Child,
60 Other
Adult) InterventioInterventi PRO08030
Number ofNational CaAll 18 Years toPhase
100 Years
To determin Dana-FarbeAll 18 Years and
Phase
older
1 Â (Adult, 20
Older
Other
40 Years
1 Â (Adult)31 NIH InterventioAllocation RV 156|10468
Number ofSidney KimAll 18 Years and
Phase
older
1 Â (Adult, 21
Older
Other
Adult) InterventioAllocation J1112
Evaluate thUniversity All 6 Months toNot18Applic
Years Â 117175
(Child, Adult)
Other|U.S.InterventioAllocation 10-0589|1
Phase
Years
Number ofH. Lee MoffAll 18 Years and
Notolder
Applic
Â (Adult, Older
8 Other
Seroconvers The UniverAll 21 Years and
Notolder
Applic
Â (Adult,262
Older
Other
Change in hEmory UnivAll 18 Years and
Phase
older
4 Â (Adult,180
Older
Other|Indu
to 21 Months
3 Â 218
(Child)
AssessmentUltimovacsAll 18 Years and
Phase
older
1|Ph
Â (Adult, 18
Older
Adult) 2012-0018
Number ofJun Zhang|All 16 Years and
Phase
older
4 Â (Child,601
Adult,
Other|Indu
Older Adult)
InterventioAllocation PRO-HE-05
Safety andInternationAll 18 Years toPhase
40 Years
1 Â (Adult)22 Other InterventioAllocation rcAd001/IA
17 Years
3 Â (Child)
Safety dataNational InAll 18 Years toPhase
45 Years
1 Â (Adult)27 NIH InterventioAllocation HVTN 073E
Cure rate| Assiut UnivAll Child, AdulPhase 4 30 Other InterventioAllocation MMRVCRY
Biological: Flu Vacci NanoPass TAll 18 Years toNot
40 Years
ApplicÂ (Adult)
180 Industry InterventioAllocation NP39|Eudr
Biological: Trivalent National InAll 18 Years toPhase
64 Years
2 Â (Adult)
change of Seoul NatioAll 20 Years toNot
25 Years
ApplicÂ (Adult) 9 Other InterventioInterventi HBV_VAX_
Local and sNational InAll 18 Years toPhase
66 Years
Frequency National InAll 18 Years and
Phase
older
1 Â (Adult, 30
Older
Adult) CIR 211 (S
The PercenMerck ShaAll 6 Weeks toPhase
12 Weeks
3 Â (Child)110 Industry InterventioAllocation V260-021|
Anti-tetanuSanofi Pas All 18 Years and
Phase
older
3 Â (Adult, 52
Older
Industry
Adult) InterventioAllocation RPV02C
anti influe Hadassah MAll 18 Years toNot
70 Years
ApplicÂ (Adult,
100Older
OtherAdult)InterventioAllocation azw6gmHH
Feasibilit RockefellerAll 18 Years to 59 Years Â (Adult) 6 Other|NIHObservatioObservatioBRO-0905|
the incide Far Easter All 18 Years toPhase
65 Years
4 Â (Adult,38Older
OtherAdult)InterventioAllocation FEMH-97-C
To quantifyNovartis V All 6 Months and older Â (Child,
4028 Adult,
Industry
Older ObservatioObservatioV110_07O
Adult)
50 Years
Anti-HPV16Jun Zhang|Female 10 Years to 28 Years Â (Child,
940Adult)
Other|InduObservatioObservatioHPV-PRO-0
Toxicity a Sidney KimAll 18 Years toPhase
120 Years
Adult) J0947|P30
Number ofGlaxoSmith
p All 6 Months and older Â (Child,
11530 Adult,
Industry|OObservational
Older Adult) 202055
Phase
older
1) To invesNovartis|NAll 6 Years to 16
Phase
Years
4 Â (Child)235 Industry InterventioAllocation V48P4E3
Student feUniversity All 11 Years and
Notolder
Applic
Â (Child,
7800Adult,
Other
Older Adult)
GeometricNovartis|NAll 18 Years toPhase
60 Years
Quadrivalen Merck ShaFemale 16 Years toPhase
23 Years
3 Â (Child,
1877 Adult)
Disease-freGeorge E. Female 18 Years and
Phase
older
2 Â (Adult,275
Older
Industry
85 Years
To demonstr GlaxoSmithAll 18 Years and
Phase
older
2 Â (Adult,
3350Older
Industry
Number ofGlaxoSmithAll 9 Years to 25 Years Â (Child,
1710Adult)
Safety|Ef Immune Tar All 18 Years toPhase
45 Years
1|PhÂ (Adult)
111 Industry InterventioAllocation FP-01.1_C
the proportAssistance All 18 Years and
Phase
older
2 Â (Adult,165
Older
Other
Adult) InterventioAllocation AOM10028
to 15 Months
3 Â 716
(Child)
The GMT ofJiangsu ProAll 6 Months toPhase
36 Months
2 Â 1200
(Child)
OccurrenceDavid ScheiAll 20 Years toPhase
59 Years
4 Â (Adult)309 Other InterventioAllocation H09-02811
Safety: Pr U.S. Army All 18 Years toPhase
50 Years
1 Â (Adult)48 U.S. Fed InterventioAllocation S-13-09|N
Vaccine effNational TaMale 20 Years and
Phase
older
4 Â (Adult,575
Older
Other
Anti-HBs anHenogen|GAll 15 Years and
Phase
Adult,
Industry
Older Adult)
InterventioAllocation HN018/HBV
Adverse evInternatio All 18 Years toPhase
40 Years
2 Â (Adult)150 Other InterventioAllocation C-12
Incidence oMayo ClinicAll 18 Years and
Early
older
PhasÂ (Adult, 20
Older
Adult) MC1772|NC
Total DeathLa Fundacio All 21 Years toPhase
90 Years
OtherAdult)InterventioAllocation DDI (976)
To evaluateDynPort VaAll 18 Years toPhase
40 Years
1 Â (Adult)44 Industry InterventioAllocation rBV A/B-01
Seroconvers ChangchunAll 1 Year to 3Phase
Years Â4 (Child) 497 Other InterventioAllocation: Non-Rand
Receipt of Columbia UAll 6 Months toNot9 Years
ApplicÂ (Child)
660 Other InterventioAllocation AAAJ9354
Phase
Older
Industry
Post vacc: GlaxoSmithAll 12 MonthsPhase
to 14 Months
3 Â 390
(Child)
Time to fir Hellenic InAll 65 Years and
Phase
older4 Â (Older200
Adult)
Other InterventioAllocation ACTIVATE
Clinical R Dartmouth- All 18 Years and
Phase
Older
Adult) D0238|R0
Immunogeni The Immuno All 12 MonthsPhase
to 18 Months
3 Â1560
(Child)
Other|InduInterventioAllocation ASCLIN/00
GeometricSanofi Pas All 65 Years and
Phase
older3 Â (Older
2670
Adult)
Industry InterventioAllocation QHD00013|
to 18 Months
3 Â 542
(Child)
Industry InterventioAllocation JEC04|UTN
59 Years
4 Â (Adult)83 Industry InterventioAllocation PJ-500-07
25 Years
3 Â (Adult)
The proport Korea UnivAll 18 Years toPhase
60 Years
4 Â (Adult)88 Other InterventioAllocation FLUHIV
Adverse EvTD VaccineAll 18 Years toPhase
50 Years
Tolerabilit National InAll 18 Years toPhase
32 Years
1 Â (Adult)24 NIH InterventioAllocation P01AI0451
Incidence Sanaria In All 18 Years toPhase
50 Years
2 Â (Adult)92 Industry|UInterventioAllocation NMRC.2015
50 Years
36 Months
2 Â (Child)
Haemagglut GlaxoSmithAll 3 Years to 17
Phase
Years3 Â (Child)520 Industry InterventioAllocation 115115
DeterminatOslo UniverAll 18 Years and
Phase
older1|Ph
Â (Adult, 31
Older
Other
Adult) InterventioAllocation DC malign
HI titers a Abbott BiolAll 18 Years and
Phase
Older
Industry
Biological: NeisVacC Public HealAll 7 Weeks toPhase
12 Weeks
4 Â (Child)130 Other InterventioAllocation Sched2|Eu
Local and sWyeth is nAll 18 MonthsPhase
to 36 Months
1 Â (Child)
One monthGlaxoSmith
a All 11 Weeks toPhase
17 Weeks
3 Â (Child)
HEPLISAV-BNational HeAll 18 Years toPhase
99 Years
Sero-protecThe UniverAll 18 Years and
Phase
older2|Ph
Â (Adult,100
Older
Other
Adult) InterventioAllocation IBDHepBVa
Safety: To University All 18 Years and
Phase
4 Other
Number ofHadassah
a M
All Child, AdulPhase 2|Ph 50 Other InterventioInterventi 0419-12-
SeroprotectShantha BiAll 6 Weeks toPhase
8 Weeks4 Â (Child)144 Industry InterventioAllocation SBL/DTPwH
120 Years
1|PhÂ (Adult,
24 Older
Adult) 371-02|M
Change in National CaFemale 18 Years and
Phase
Older
NIHAdult) InterventioAllocation NCI-2015-
Immunogeni UniversidaAll 10 Years toPhase
11 Years
3 Â (Child)500 Other|InduInterventioAllocation 091-2014
Number ofSherief
i AbAll 20 Years to 22 Years Â (Adult)200 Other ObservatioObservatioHBV vaccin
GeometricSanofi
M Pas All 60 Years and
Phase
older3 Â (Adult,
1540
Older
Industry
Adult) InterventioAllocation QHD00011|
Number ofNational InAll 6 Months toPhase
17 Years
2 Â (Child)531 NIH InterventioAllocation 09-0047|N
1 month poGlaxoSmithAll 8 Weeks toPhase
16 Weeks
To evaluateRockefelle All 18 Years toPhase
60 Years
1 Â (Adult)40 Other|InduInterventioAllocation DHO-0614
TimelinessColumbia UAll 18 Years and
Notolder
Applic
Â (Adult,
7250
Older
Other
Adult) InterventioAllocation AAAK5058
Evaluate t Baylor Col All Child, AdulPhase 1|Ph 7 Other InterventioInterventi 22053-CHE
Non-inferioBio ProducAll 18 Years toPhase
75 Years
2|Ph
Â (Adult,
162Older
OtherAdult)InterventioAllocation RIG01
Vaccine ReGlaxoSmithAll 11 Years toPhase
55 Years
2 Â (Child,500
Adult)
50 Years
Comparison Shaare ZedAll 1 Year to 20Not
Years
Applic
Â (Child, 210
Adult)
Other InterventioAllocation 15364.ct.il
HPV vaccinCedars-SinaAll 11 Years toEarly
13 Years
PhasÂ (Child) 3 Other InterventioAllocation Pro54249
OccurrenceNational InAll 6 Months to Phase
17 Years
2 Â (Child)270 NIH InterventioAllocation 12-0016|H
ConcentratGlaxoSmithAll 2 Years to 17
Phase
Years
3 Â (Child) 52 Industry InterventioAllocation 115884|20
NeutralizinSanofi Pas All 2 Months to Phase
2 Months
4 Â (Child)
456 Industry InterventioAllocation IPV30|U11
older
1|Ph
Â (Older175
Adult)
Industry|OInterventioAllocation QHD00008|
Grade IV aAlphaVax, IAll 18 Years toPhase
50 Years
1 Â (Adult)96 Industry|OInterventioAllocation HVTN 059
The primary Pawel KalinAll 18 Years toPhase
80 Years
1 Â (Adult,15Older
Safety andCHA Vaccine All 19 Years toPhase
60 Years
1|PhÂ (Adult)36 Industry InterventioAllocation CVI-HBV-0
Characteri Intercell U All 18 Years toPhase
64 Years
2 Â (Adult)600 Industry InterventioAllocation ELT208
DifferentiaSheffield All 18 Years toPhase
49 Years
2 Â (Adult)28 Other InterventioInterventi STH18166
Immunologi Washington All 18 Years andEarly
older
Phas
Â (Adult, Older
0 Other
Adult) InterventioInterventi 15-x043
NeutralizatSinovac BioAll 6 Months to Phase
35 Months
2 Â (Child)
540 Industry InterventioAllocation EV71-1001-
PercentageMerck ShaAll 50 Years andPhase
older
3 Â (Adult,204
Older
Industry
Adult) InterventioAllocation V232-059-
To demonstr Ology BiosAll 18 Years toPhase
49 Years
3 Â (Adult)
Vaccine re Oriol Manue All 18 Years andPhase
older
2|Ph
Â (Adult,780
Older
Other
Safety, tol Istituto Sc All 18 Years toPhase
70 Years
2 Â (Adult,24Older
OtherAdult)InterventioAllocation IRST172.0
Number ofSanofi Pas All 1 Month toPhase
6 Months
older
3 Â (Adult,
5752
Older
Industry
MenC-speci University All up to 7 DaysPhase
Â (Child)
4 28 Other InterventioAllocation OVG-2013/
Safety of Roswell ParFemale 18 Years andPhase
older
1 Â (Adult, Older
7 Other|NIH|
Adult) InterventioInterventi I 199911|
Safety of UNC LinebeAll 18 Years andPhase
older
1 Â (Adult, Older
6 Other
Adult) InterventioInterventi LCCC1804
Number ofXiamen InnAll 30 Years andPhase
older
4 Â (Adult,475
Older
Industry
older
2 Â (Adult,133
Older
Industry
Number ofSidney
p KimAll 12 Years toPhase
100 Years
1 Â (Child, 12Adult,
Other|Indu
OlderInterventioInterventi
Adult) J19140|IR
NeutralisinUniversity All 18 Years andPhase
older
1 Â (Adult,292
Older
Adult) UHL10548
Achieving Medical UnAll 11 Years toNot
18 Years
ApplicÂ (Child,46
Adult)
Other InterventioInterventi Dembinski
Serotype-sSK Chemical All 50 Years andPhase
older
3 Â (Adult,767
Older
Industry
Adult) InterventioAllocation NBP606_PC
VaccinationUniversity All 6 Months andNot older
ApplicÂ (Child,
140Adult,
Adult) 1
To provide Sanofi Pas All 60 Years andPhase
older
3 Â (Adult,
3707
Older
Industry
Adult) InterventioAllocation GID17
The frequen Shantha BiAll 6 Weeks toPhase
8 Weeks
1|PhÂ (Child)90 Industry InterventioAllocation SBL/BRV-T
ProportionChiang MaiAll 18 Years toPhase
60 Years
4 Â (Adult)16 Other InterventioAllocation Research I
To measureTufs MediAll 18 Years toPhase
49 Years
1 Â (Adult)52 Other|InduInterventioAllocation 7142
Safety andCity of HopAll 18 Years toPhase
65 Years
1 Â (Adult,46Older
Adult) CDR00005
Rabies specQueen Saov All 20 Years toNot
60 Years
ApplicÂ (Adult)60 Other InterventioAllocation QSMI-IRB
Number ofSanofi All 9 Months to Phase
10 Years
2 Â (Child) 96 Industry InterventioAllocation H-040-004
PercentageFluart Inn All 18 Years toPhase
59 Years
1 Â (Adult)36 Industry|OInterventioAllocation 4Fluart-H-
Radiologic Naval HealAll Child, AdulPhase 4 152723 U.S. Fed InterventioAllocation DAMD17-00
Evaluate thBeijing ChaAll 50 Years toPhase
80 Years
1|PhÂ (Adult,
440Older
OtherAdult)InterventioAllocation cycdc2015
Toxicity of Radboud Un All 18 Years toPhase
70 Years
Information Sanofi Pas All 18 Years andPhase
older
3 Â (Adult,129
Older
Industry
Adult) InterventioAllocation GID34|200
A summarySanofi
o Pas Male 6 Weeks to 24 Months Â 62538(Child)Industry ObservatioObservatioM5A11
Evaluate thIchor MediAll 18 Years andPhase
older
1 Â (Adult, 24
Older
Adult) 07-003
The rollin Ann & Robe All 3 Years to 21
Phase
Years
1 Â (Child, Adult)
Satisfacto Seoul NatioAll 18 Years andPhase
Older
Other
Adult) InterventioAllocation SNUH-IMJ-
Clinical in The UniverAll Child, AdulPhase 4 6300 Other InterventioAllocation BJC004.6
50 Years
1 Â (Adult)91 Other|NIH| InterventioAllocation HP-000615
Safety monChinese AcAll 2 Months to Phase
3 Months
4 Â 49731
(Child)Other InterventioInterventi 20170416
Rotavirus vLifespan|MAll 2 Months to 5 Years Â (Child) 803 Other|InduObservatioObservatioHCH-001
influenza Columbia UAll 18 Years andNotolder
Applic
Â (Adult,
4026
Older
Other
The degreeRockefellerAll 18 Years toNot
80 Years
ApplicÂ (Adult,
140Older
OtherAdult)InterventioAllocation TWA-0804
HI antibodyGreen CrosAll 18 Years andPhase
Older
Industry
Adult) InterventioAllocation GC1116|ìž„ìƒì œë„ê³¼ - 649
Presence oJohns HopkAll 76 Years andNotolder
Applic
Â (Older525
Adult)
Other InterventioInterventi NA_00092
Number ofGlaxoSmithAll 7 Years to 8Phase
Older
Industry
Adult) InterventioAllocation GRT90|200
Serotype-sPfizer All 18 Years toPhase
64 Years
3 Â (Adult)
40 Years
2 Â (Adult)88 Industry InterventioAllocation H01_04TP|
Incident HIMRC/UVRIAll U 18 Years toPhase
40 Years
2 Â (Adult)
1668 Other|InduInterventioAllocation PV1
17 Months
2 Â (Child)
Mean frequUniversity All 9 Years andNot
older
Applic
Â (Child, Adult,
8 Other
Older Adult)
InterventioInterventi RSRB00065
GeometricPfizer All 11 Years toPhase
17 Years
2 Â (Child)
2499 Industry InterventioAllocation:B1971011|
45 Years
Older
Industry
65 Years
OtherAdult)InterventioAllocation Jan-17
Overall pr Sunnybrook Female 18 Years and older Â (Adult,100Older
Other|Indu
Maximum National
to CaAll 18 Years andPhase
Older
NIHAdult) InterventioInterventi NCI-2012-
Quantifica University All 19 Years andPhase
Adult) 7905|NCI-
ConsistencJiangsu ProAll 6 Months to Phase
35 Months
4 Â 3000
(Child)
Other|InduInterventioAllocation JSVCT048-
Post at lea GlaxoSmithAll 6 Weeks toPhase
16 Weeks
3 Â (Child)
Children enUniversity All Child, AdulNot Applic 107 Other|U.S.InterventioAllocation IP000500|R
PercentageMerck SharAll 18 Years toPhase
60 Years
1 Â (Adult)513 Industry|UInterventioAllocation V920-004|
55 Years
Number ofOlogy BiosAll 18 Years toPhase
59 Years
2|PhÂ (Adult)
Older
Industry
Adult) InterventioAllocation GID29
Adverse evCraig L Sli All 18 Years andPhase
older1|Ph
Â (Adult, 22
Older
Adult) 18174|R0
Difference The UniverAll 70 Years toPhase
79 Years
Other|U.S.InterventioAllocation YHT004.5
Frequency National
a InAll 18 Years toPhase
50 Years
Incidence University All 18 Years andPhase
Older
Adult) 9626|NCI-
Number ofBaxter
s HeaAll 18 Years toPhase
49 Years
3 Â (Adult)
Participan National InMale 18 Years toPhase
50 Years
2 Â (Adult)
2504 NIH|OtherInterventioAllocation HVTN 505|
Adult,
Industry
Older Adult)
InterventioAllocation 208129/03
50 Years
1|PhÂ (Adult)98 Industry InterventioAllocation LV01-103|
40 Years
1|PhÂ (Adult)30 U.S. Fed|OInterventioAllocation A-15647|0
10 Weeks
Safety will Sidney KimAll 18 Years andPhase
Older
Adult) J05118|RA
25 Years
Decrease co German-JorAll 2 Months to Phase
2 Years
1|PhÂ (Child)
377 Other|InduInterventioAllocation 0887X1-46
Older
Industry
Evaluate thBeijing ChaAll 3 Years andPhase
80 Other
Older Adult)
InterventioAllocation cycdc2015
Reach - FeaUniversity All 18 Years toNot
99 Years
ApplicÂ (Adult,
1296Older
Adult) IRB201701
Phase
older
3 Â (Older 1332
Adult)
HospitalizaInsight Th All 65 Years and
Phase
older
Other|InduInterventioAllocation INSI-20160
Change in GlaxoSmithAll 50 Years and
Phase
older
3 Â (Adult,404
Older
Industry
Phase
older
3 Â (Adult,935
Older
Industry
Primary OuUniversity All 6 Months toNot18Applic
Years Â (Child,
87665Adult)
Other InterventioAllocation 1U01IP000
Adverse EvNovavax All 60 Years and
Phase
older
2 Â (Adult,467
Older
Industry
Adult) InterventioAllocation NVX755.20
Biological: Anthrax|BiDynPort VaAll 18 Years toPhase
40 Years
1 Â (Adult)70 Industry InterventioAllocation rPA-EC-02|
Haemagglut GlaxoSmithAll 6 Months toPhase
35 Months
3 Â 2432
(Child)
Survival|AsBioven SdnAll 18 Years and
Phase
older
2|Ph
Â (Adult,230
Older
Industry
Adult) InterventioAllocation CT 07-03
Number ofNational
s InAll 18 Years toPhase
40 Years
Adverse eve National InAll 18 Years toPhase
49 Years
1|PhÂ (Adult)
To estimat University All up to 30 Years
16 Other InterventioInterventi UMCC 2005
Immunoglob US Departm All 18 Years and
Notolder
Applic
Â (Adult,107
Older
U.S.Adult)
Fed|OInterventioAllocation INDA-002-
19 Years
2 Â (Child, 125
Adult)
Incidence National InAll 18 Years toPhase
45 Years
1 Â (Adult)48 NIH InterventioAllocation 08-0066|Pa
Frequency Themis BioAll 21 Years toPhase
65 Years
2 Â (Adult,60Older
Adult) MV-CHIK-2
25 Years
to 10 Years
2 Â (Child)
HemagglutiNational InAll 18 Years toPhase
49 Years
1 Â (Adult)20 NIH InterventioInterventi 16-003
Number ofChildren's All up to 18 Years
Not ÂApplic
(Child, Adult)
300 Other InterventioAllocation CCGChina-
OccurrenceGlaxoSmithAll 12 MonthsPhase
to 23 Months
1 Â (Child)
Safety of University All up to 18 Years
PhaseÂ 2|Ph
(Child, Adult)
80 Other InterventioInterventi VZVinOLTx
PercentageClinica UniAll 18 Years toPhase
65 Years
OtherAdult)InterventioAllocation CUN-90-20
Number ofUMN Pharm All 20 Years toPhase
40 Years
2 Â (Adult)90 Industry InterventioAllocation JPIP501-01
49 Years
1|PhÂ (Adult)
132 Industry InterventioAllocation LV03-105|
Identify t UbiVac|NatAll 18 Years and
Phase
older
2 Â (Adult, 12
Older
Adult) UbiVac DP
to 45 Months
3 Â 205
(Child)
25 Years
3 Â (Child, 676
Adult)
Haemagglut GlaxoSmithAll 20 Years toPhase
64 Years
2 Â (Adult) 100 Industry InterventioAllocation 111756
Disease ReMasonic CaFemale 18 Years and
Phase
older
2 Â (Adult, 14
Older
Other
Adult) InterventioInterventi 2007LS09
Biological: Trivalent University All 6 Months to 17 Months Â (Child)66 Other ObservatioObservatioURRSRB15
Change FroBTG InternAll 35 Years toPhase
70 Years
2 Â (Adult,20Older
Other|Indu
Adult)InterventioAllocation PR002-CLN
GeometricThe Hospita All 2 Months toPhase
18 Years
Four-Fold California All 18 Years toPhase
69 Years
2 Â (Adult,45Older
OtherAdult)InterventioInterventi rBV A/B-CL
55 Years
2 Â (Child, 834
Adult)
Industry InterventioInterventi MTA77|U11
Antibody rRadboud Un Female 18 Years toPhase
55 Years
4 Â (Adult)75 Other InterventioAllocation BCG-DKTP
68 Months
3 Â (Child)
424 Industry InterventioAllocation J2I02 (EF
Immunogenic VanderbiltAll 3 Years to 17
Phase
Years
2 Â (Child)200 Other|NIHInterventioAllocation VICC PED
Immunogeni GlaxoSmithAll 15 Years and
Phase
older
3 Â (Child,806
Adult,
Industry
Older Adult)
To assess i National I All 6 Weeks toPhase
12 Weeks
2 Â (Child) 200 Other InterventioAllocation Rotavin02|
MAARI Rate Baylor CollAll 4 Years to 18
Phase
Years
4 Â (Child,
29255
Adult)
Other|InduInterventioAllocation BCM H-218
To evaluateChinese AcAll 60 Days to Phase
90 Days
2 Â (Child)500 Other InterventioAllocation imbcams-0
GeometricSanofi
M Pas All 6 Months toPhase
8 Years
3 Â (Child)4363 Industry InterventioAllocation QIV04|UTN
Safety: proInternationAll 10 Weeks toPhase
11 Months
2 Â (Child)
300 Other|InduInterventioAllocation CH-WC-01
50 Years
Immunogeni Papua NewAll up to 3 DaysPhase
Â (Child)
2 318 Other InterventioAllocation 071613/Z/
Number ofSichuan UnAll 18 Years toPhase
90 Years
1 Â (Adult,20Older
OtherAdult)InterventioInterventi SKLB1608
Evaluation Institut N All 20 Years andPhase
older
4 Â (Adult,147
Older
Other
Adult) InterventioInterventi FLU-HOP
Safety as Prisma HeaAll 18 Years andPhase
older
1|Ph
Â (Adult, Older
3 Other|Indu
Adult) InterventioInterventi CC/ORI 07
45 Years
ProgressionSecond AffiAll 18 Years toPhase
80 Years
1 Â (Adult,30Older
OtherAdult)InterventioInterventi pl001
Overall chaEmory UnivAll 18 Years andNotolder
Applic
Â (Adult,
1320
Older
Other
Safety as Sidney KimAll 18 Years toPhase
120 Years
Adult) J0810|P30
EvaluationRadboud Un All 18 Years andPhase
older
1|Ph
Â (Adult, 10
Older
Other
Adult) InterventioInterventi PSCT19
Anti-PRP AGlaxoSmithAll 8 Weeks toPhase
16 Weeks
MAIT cells Internatio All 1 Year to 59Phase
30 Other InterventioInterventi PR-17082
GeometricPfizer All 140 Days toPhase
392 Days
Immunologi Mahidol UnAll 60 Years andPhase
older
4 Â (Adult,221
Older
Other
Adult) InterventioAllocation Elderly Flu
PercentageMedImmune All 18 Years toPhase
49 Years
4 Â (Adult)303 Industry InterventioAllocation CD-VA-FluM
Feasibility Dana-FarbeAll 18 Years andNotolder
Applic
Â (Adult, 24
Older
Other
35 Months
2 Â (Child)
GeometricMerck ShaAll 70 Years andPhase
older
3 Â (Older759
Adult)
40 Years
Safety and Barbara Ensoli,
All MD|Novartis
18 YearsVaccines|Istituto
toPhase
55 Years
1 Â (Adult)
Superiore
11 Other|Indu
di SanitÃ
InterventioAllocation ISS P-002
64 Years
3 Â (Adult)
1359 NIH InterventioAllocation 06-0016|C
24 Years
Number and University Male 18 Years andPhase
older
1 Â (Adult, 40
Older
Other
Adult) InterventioAllocation UW14072|2
Safety and Biontech RAll 18 Years toPhase
99 Years
1 Â (Adult,15Older
Industry
Adult)InterventioInterventi RB_0004-0
GeometricGlaxoSmithAll 61 Years andPhase
older
3 Â (Adult,145
Older
Industry
Antibody tiSanofi Pas All 2 Months to Phase
12 Months
3 Â (Child)
525 Industry InterventioAllocation MET33|U11
Incidence Lene MeldgAll 18 Years andPhase
older
1 Â (Adult, 10
Older
Other
Adult) InterventioInterventi MY0001|20
Safety and Baylor Col All 18 Years toPhase
45 Years
1 Â (Adult)36 Other InterventioAllocation SVI-04-01
PercentageJanssen VaAll 65 Years andPhase
older
2 Â (Older
6675
Adult)
Industry InterventioAllocation CR108634
Recommende David BartlAll 18 Years andPhase
older
1|Ph
Â (Adult, 64
Older
Adult) 12-110|5P
the proporNational TaMale 18 Years toNot
40 Years
ApplicÂ (Adult)
Assess safeCedars-SinAll 18 Years andPhase
older
1 Â (Adult, 39
Older
Other
To assess tBoryung PhAll 6 Years to 7Phase
Years4Â (Child) 94 Industry InterventioInterventi BR-KD-287
To assess Beth Israe All 18 Years andPhase
older
1|Ph
Â (Adult, 20
Older
Other|Indu
Adult) InterventioInterventi 2001P0011
SummarizeNational
t InAll 6 Months to Phase
49 Years
Years3Â (Child)5220 Industry InterventioAllocation 114541
70 Years
Number ofSanofi
P Pas All 6 Months to Phase
9 Years
2 Â (Child)474 Industry InterventioAllocation FUF15|UTN
Major CardiHospital IsAll 18 Years andPhase
older
3 Â (Adult,
9200
Older
Other
Adult) InterventioAllocation VIP-ACS tri
Survey Ite University All 18 Years andNotolder
Applic
Â (Adult,160
Older
Adult) 1R01CA178
anti-pneumVA Office All 35 Years toEarly
75 Years
PhasÂ (Adult,
275Older
U.S. Fed
Adult)InterventioAllocation INFB-019-
Seroconvers Statens SerAll 54 Days to Phase
75 Days3 Â (Child)800 Other|InduInterventioAllocation VIPV-07
older
3 Â (Adult,
16165
Older
Industry
The differeSinovac BioAll 60 Days to Phase
90 Days3 Â (Child)240 Industry InterventioAllocation PRO-sIPV-3
Number ofBeth Israe All 18 Years andPhase
older
1|Ph
Â (Adult, 38
Older
Adult) 04-117
Titers for GlaxoSmithAll 6 Months to Phase
17 Years
3 Â (Child)
To assess NewLink Ge All 18 Years andPhase
older
1|Ph
Â (Adult, Older
6 Industry
60 Months
3 Â (Child)
Change in Fidec CorpAll 5 Weeks and Phase
older
4 Â (Child,
1420
Adult,
HPV vaccinUniversity All 18 Years andNotolder
Applic
Â (Adult, 95
Older
Adult) 1R01CA178
To measureEpicentre|All 2 Years to 20
Phase
Years
4 Â (Child,720
Adult)
Other InterventioAllocation MB-04-ME
Safety meaNovartis V All 18 Years toPhase
40 Years
1 Â (Adult)113 Industry InterventioAllocation HPP002
Clinical P Center for Female 21 Years toPhase
38 Years
Disease freSidney KimAll 18 Years andPhase
older
2 Â (Adult, 72
Older
Other
Adult) InterventioAllocation J09100|NA
CumulativeProf. Jan Male 18 Years andPhase
older
4 Â (Adult,126
Older
Other
Adult) InterventioAllocation NL45200.0
The differeSinovac BioAll 60 Days to Phase
90 Days3 Â (Child)240 Industry InterventioAllocation PRO-sIPV-3
Immunogenic University All 18 Years andPhase
older
4 Â (Adult,304
Older
Other|Indu
Adult) InterventioAllocation KEK No 805
65 Years
Adult) CR107227|
Evaluate thChinese AcAll 8 Months to Phase
9 Months
4 Â (Child)
Biological: H1N1 PandOlogy BiosAll 2 Months and older Â (Child, 3216Adult,
Industry
Older ObservatioObservatio
Adult) 820901
75 Years
3 Â (Adult,84Older
Other|Indu
Adult)InterventioAllocation P170938J
G1 Serum-n Dennis CleAll up to 83 Days
Phase
Â (Child)
4 66 Other|InduInterventioAllocation Pro000490
MeasuringLouis Stok All 50 Years andPhase
older
4 Â (Adult, 22
Older
U.S.Adult)
Fed|OInterventioAllocation Canaday Zo
ProportionChiang MaiAll 18 Years andPhase
older
4 Â (Adult,154
Older
Other
Adult) InterventioAllocation Research I
To determin Massachuse All 18 Years andPhase
older
1 Â (Adult, 11
Older
Other
Evaluate i Novartis V All 18 MonthsPhase
to 96 Months
3 Â 197
(Child)
Industry InterventioAllocation V70P5E1|2
55 Years
Primary end University All 1 Year to 30Phase
Years1|Ph
Â (Child, Adult)
30 Other InterventioInterventi IVAC-ALL-
Response tPublic HeaAll 14 Years toPhase
21 Years
2|PhÂ (Child,91
Adult)
Other InterventioAllocation PRIME
Safety andSidney KimFemale 18 Years toPhase
100 Years
Adult) J1553|IRB
Vaccine uptSB IstanbuAll 18 Years toNot
90 Years
ApplicÂ (Adult,
244Older
OtherAdult)InterventioAllocation 855 - 21/1
Seroconvers Seqirus All 6 Months to Phase
9 Years
2 Â (Child)473 Industry InterventioAllocation CSLCT-CAL-
The Number Merck ShaAll 40 Days to Phase
80 Days3 Â (Child)546 Industry InterventioAllocation V121-019|
Equivalence Sanofi Pas All 2 Months andPhase
older
3 Â (Child,
1189Adult,
Industry
Adult) A3L11
Safety|Imm University All 18 Years andPhase
older
1 Â (Adult, 11
Older
Other
OccurrenceGlaxoSmithAll 18 Years andPhase
older
3 Â (Adult,550
Older
Industry
safety and Internatio All 18 Years toPhase
40 Years
1 Â (Adult)48 Other InterventioAllocation IAVI C002
Clinical P Center for Female 21 Years toPhase
45 Years
45 Years
2 Â (Adult)74 Industry InterventioAllocation 205494|H0
Incidence oImperial C All 2 Years to 17
Phase
Years
4 Â (Child)779 Other InterventioInterventi RHM CHI 0
The number Dana-FarbeAll 1 Year and Phase
26 Other
Older Adult)
InterventioInterventi 19-680
Change froNational J All 19 Years toNot
80 Years
ApplicÂ (Adult,
140Older
OtherAdult)InterventioAllocation HS-2953
solicited r PATH All 18 Years toPhase
45 Years
2 Â (Adult) 0 Other InterventioAllocation VAC-047
Patients whMalcolm BrAll up to 64 Years
Phase
Â 1(Child, Adult)
13 Other InterventioAllocation H8354|HI
Number ofStanford Un All 1 Year to 8Phase
Years Â4 (Child) 20 Other|NIHInterventioInterventi SU-17219-
HPV-specifiISA PharmaFemale 18 Years andPhase
older
1|Ph
Â (Adult, 93
Older
Adult) ISA-HPV-0
The percenEmergent BAll 17 Years and older Â (Child,14108
Adult,
Industry
Older Adult)
Incidence Serum InstiMale 18 Years toPhase
45 Years
1 Â (Adult)60 Industry|OInterventioAllocation PMV-001|C
Booster huGlaxoSmithAll 18 Years andPhase
older
2 Â (Adult, Older
0 Industry|OInterventioAllocation
Adult) 112576
Antibody|TEunice KenAll 18 Years toPhase
49 Years
1 Â (Adult) 0 NIH InterventioAllocation 090213|09
Number ofGlaxoSmithFemale 10 Years and
Phase
Adult,
Industry
Older Adult)
InterventioInterventi 108160|20
Antibody tSanofi Pas All 42 Days to Phase
89 Days3 Â (Child)
SeroprotecSeoul Nati All 20 Years and
Notolder
Applic
Â (Adult,143
Older
Other|Indu
Adult) InterventioAllocation 1806-088-
Occurrence,GlaxoSmithAll 50 Years and
Phase
older3 Â (Adult,
8686
Older
Industry
25 Years
3 Â (Adult)
7466 Industry InterventioAllocation CDR000044
CD4 T cell Soroka UniAll 18 Years toPhase
60 Years
2 Â (Adult)40 Other InterventioAllocation sor444006c
Vaccine effUniversity All 18 Years toPhase
50 Years
1|Ph
Â (Adult)30 Other|InduInterventioAllocation VAC030|MR
85 Years
2 Â (Older 312
Adult)
Industry InterventioAllocation C3671002|
Rate of re Mayo ClinicAll 18 Years and
Phase
Older
Adult) MC138E|NC
Safety ass University All 18 Years toPhase
50 Years
Freedom FrRonald Levy All 21 Years toPhase
70 Years
2 Â (Adult,59Older
Adult) IRB-05089
ImmunogenicSanofi Pas All 18 Years and
Phase
Older
Industry
Number ofCrucell Ho All 18 Years toPhase
49 Years
Number ofSanofi Pas All 6 Months and
Phaseolder
4 Â (Child,240
Adult,
Industry
Adult) GRC90|U11
Number ofNational InAll 6 Weeks toPhase
14 Weeks
4 Â (Child)
PercentageSanofi All 18 Years toPhase
59 Years
2 Â (Adult)128 Industry InterventioAllocation PDY11684|
To evaluat Centre HospAll 18 Years toPhase
45 Years
1 Â (Adult)56 Other InterventioAllocation P27A_1_1
25 Years
Disease-freAcademic aFemale 18 Years and
Phase
Older
Adult) RU011501I
17 Years
ApplicÂ (Child)
6000 Other|U.S.InterventioAllocation 18-1588
Dengue sym Albert B. All 9 Years to 44 Years Â (Child,
2130
Adult)
Other ObservatioObservatioDNG10042
DetermineUniversity
t Female 18 Years toNot
26 Years
ApplicÂ (Adult)
661 Other InterventioAllocation HUM00069
Rate of moGlaxoSmithAll 40 Years toPhase
80 Years
Industry
Tabulation National CaAll 18 Years toPhase
99 Years
1 Â (Adult,44Older
Number subjPfizer All 50 Years toPhase
85 Years
Industry
Adult)InterventioAllocation B5091001
OccurrenceNational InAll 12 MonthsPhase
to 50 Years
2 Â (Child,
266 NIH
Adult) InterventioAllocation WRAIR 204
45 Years
GeometricUniversity All 18 Years and
Phase
Older
Other
Adult) InterventioAllocation LTN0001
Implementa Duke UniveFemale 12 Years to 26 Years Â (Child,
3988Adult)
Other|U.S.Observational Pro000110
Phase
older3 Â (Older
14819Adult)
Dose-limitiAdilia Hor All 18 Years and
Phase
Older
Other|Indu
Adult) InterventioInterventi GCO 17-05
59 Years
Human Seru GlaxoSmithAll 85 Days to Phase
119 Days
3 Â (Child)750 Industry InterventioAllocation 205240|V7
Phase
older2 Â (Older363
Adult)
30 Years
2 Â (Child,818
Adult)
PercentageTakeda All 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation NOR-204|U
Immunother ImmunitorAll 18 Years and
Phase
Older
Adult) V6
Phase
Older
Industry
SeroconverProtein Sc All 18 Years toPhase
49 Years
3 Â (Adult)
1350 Industry|OInterventioAllocation PSC16
45 Years
PercentageJanssen VaFemale 18 Years toPhase
60 Years
1|Ph
Â (Adult)66 Industry InterventioAllocation CR108458|
Number ofOlogy
46 Years
PercentageSanofi Pas All 50 Days to Phase
70 Days2 Â (Child)624 Industry InterventioAllocation A3L02
Phase
Older
Industry
Adult) InterventioAllocation A3921129
100 Years
Adult) SU-17219-
Adequate riSt. AntoniuAll 18 Years andNotolder
Applic
Â (Adult, 50
Older
Other
Adult) InterventioAllocation RIFLUVAC|v
comparingUniversity
o Female 9 Years to 13
Phase
Years
4 Â (Child) 12 Other InterventioAllocation 2013/422|
Safety, de National InAll 18 Years toPhase
49 Years
Safety: Se U.S. Army All 18 Years toPhase
45 Years
Positive ra Chinese AcAll 24 MonthsPhase
to 48 Months
3 Â1165
(Child)
Change in lOhio StateFemale 40 Years toNot
80 Years
ApplicÂ (Adult,
180Older
OtherAdult)InterventioAllocation OSU-13194
PhaseYears
Older Adult) SU-17219-
Number ofBaylor Col All Child, AdulPhase 1|Ph 11 Other InterventioInterventi H-26652-A
InvestigateHadassah M All 18 Years andPhase
older
1|Ph
Â (Adult,100
Older
Other
Adult) InterventioAllocation 100798-HM
Seroconvers Seqirus All 18 Years andPhase
older
2 Â (Adult,
1313Older
Industry
Adult) InterventioAllocation CSLCT-CAL-
16 Weeks
PercentageValneva AuAll 18 Years and older Â (Adult,3258Older
Industry
Adult) ObservatioObservatioIC51-303
Outcome Me RegenstrieAll 11 Years toEarly
17 Years
PhasÂ (Child)
1306 Other|InduInterventioAllocation Merck - 20
Change in University All 50 Years toPhase
70 Years
4 Â (Adult,30Older
Number ofPfizer All 12 MonthsPhase
to 18 Months
3 Â 330
(Child)
To assess tUniversity Female 14 Years toNot
50 Years
ApplicÂ (Child,
216Adult)
Other InterventioAllocation PRO09100
Vaccine ef Bandim Hea All 4 Months to Phase
6 Months
4 Â (Child)
5879 Other|InduInterventioAllocation RUF-91134
Number ofAdvocate
p HAll 18 Years and older Â (Adult, 28 Older
Other
Safety andMerck SharAll 18 Years toPhase
50 Years
1 Â (Adult)360 Industry|OInterventioAllocation V520-018|
Immune res University Female 19 Years andPhase
older
1|Ph
Â (Adult, 26
Older
Adult) 6304|NCI-
Frequency National InAll 6 Years to 26
Phase
Years
1 Â (Child, Adult)
1 NIH InterventioAllocation URMC 16-
Positive seJiangsu Pr All 10 Years toPhase
60 Years
3 Â (Child,
1200 Adult)
Number ofShanghai BFemale 9 Years to 45
Phase
Years
1 Â (Child, Adult)
90 Industry|OInterventioAllocation 9-HPV-100
Number ofNational
P InAll 18 Years andPhase
older
2 Â (Adult,805
Older
The serocon Jiangsu ProAll 6 Months to Phase
5 Years
3 Â (Child)
Number ofHualan BiolAll 3 Years andNotolder
Applic
Â (Child, Adult,
600 Industry
Older Adult)
AssessmentNew DiscovFemale 20 Years toPhase
35 Years
4 Â (Adult)280 Industry InterventioAllocation US-G10-P6
Solicited LG Chem All 19 Years toPhase
50 Years
1 Â (Adult)60 Industry InterventioAllocation LG-VECL00
ProportionChiang MaiAll 20 Years toPhase
59 Years
4 Â (Adult)632 Other InterventioAllocation Research I
75 Years
ApplicÂ (Adult,
1294Older
OtherAdult)InterventioAllocation 14-0402|P
Safety Memorial SAll 18 Years toNot
120Applic
Years Â (Adult,
14 Older
Adult) 01-019|MS
Titers of GlaxoSmithAll 18 Years toPhase
59 Years
Change in Kevin WintAll 50 Years andPhase
older
2 Â (Adult, 50
Older
Other|Indu
Objective rCentre HosAll 18 Years toPhase
75 Years
2 Â (Adult,47Older
Other|Indu
Adult)InterventioInterventi P/2019/41
Cocaine InNew York St All 21 Years toPhase
45 Years
2 Â (Adult)15 Other InterventioAllocation #3980|NID
Tumor-specDartmouth- All 18 Years andPhase
older
2 Â (Adult, 11
Older
Other
Adult) InterventioInterventi D0536
Phase
Years
2 Â (Child, Adult)
AcceptanceLouisiana All 18 Years andPhase
older
2 Â (Adult, Older
Adult) 5800
Immunogeni Pfizer All 12 MonthsPhase
to 14 Months
3 Â 877
(Child)
Industry InterventioAllocation MENACWY-T
Disease-freSichuan UnAll 18 Years toPhase
100 Years
OtherAdult)InterventioInterventi SI2019175
Assess theNational InAll 18 Years toPhase
35 Years
1 Â (Adult)296 NIH|Other| InterventioAllocation 999914010
64 Years
anti-HBs coCenters fo All 13 Years toPhase
16 Years
4 Â (Child)60 U.S. Fed|OInterventioAllocation CDC-NCID-
40 Years
2 Â (Child,
1709 Adult)
41 Years
ProportionGlaxoSmithAll 6 Weeks toPhase
12 Weeks
To provide Sanofi Pas All 18 Years and
Phase
older
2 Â (Adult,130
Older
Industry
Safety and Baylor Col All 18 Years toPhase
45 Years
1|PhÂ (Adult)
290 Other InterventioAllocation TSP-18-03
Comparison Mahidol UnAll Child, Adult, Older Ad 181 Other ObservatioObservatioTDA202 3 y
Number ofNovartis V All 2 Months toPhase
5 Years
Safety: Th Colby Pha All 65 Years and
Phase
older
2 Â (Older472
Adult)
Industry InterventioAllocation H-100-002
PercentageNational CaAll 18 Years and
Phase
older
1 Â (Adult, 42
Older
Quantitati University All 18 Years to 60 Years Â (Adult)30 Other ObservatioObservatioCS_2014_0
The child' Kaiser Per Female 18 Years and
Notolder
Applic
Â (Adult,824
Older
Other
Adult) InterventioAllocation 1R01HD079
Humoral ImGlaxoSmithAll 50 Years and
Phase
older
3 Â (Adult,357
Older
Industry
Number and National InAll 18 Years toPhase
45 Years
1|PhÂ (Adult)43 NIH InterventioAllocation 05-0078
Solicited a GlaxoSmithFemale 18 Years toPhase
30 Years
Summary of Sanofi Pas All Child, Adult, Older Ad 1421 Industry ObservatioObservatioMTA38
Phase
older
4 Â (Adult,
6051
Older
Industry
Efficacy: National InFemale 12 Years toPhase
17 Years
2 Â (Child)409 NIH InterventioAllocation 04-039
PercentageAbivax S.A.All 18 Years toPhase
65 Years
2|PhÂ (Adult,
261Older
Industry
Adult)InterventioAllocation ABX203-00
Overall surZwi Bernem All 18 Years and
Phase
older
2 Â (Adult,130
Older
Other
Adult) InterventioAllocation CCRG12-00
Persistenc National T All Child, AdulNot Applic 31 Other InterventioAllocation 931205
Determine,Kirby Insti All 16 Years and
Notolder
Applic
Â (Child,204
Adult,
Other
Older Adult)
InterventioAllocation X08-0161
The primary Chiltern PeAll 2 Years to 70
Phase
Years
3 Â (Child, Adult,
59 Industry
Older Adult)
InterventioAllocation V111_15TP
GeometricCenter for All 60 Days to Phase
91 Days
3 Â (Child)825 Other InterventioAllocation CVIA 068
OccurrenceGlaxoSmithAll 90 Days to Phase
120 Days
immunogenic Seqirus|NoAll 18 Years toPhase
40 Years
1|PhÂ (Adult)
To evaluateSt. Jude ChAll 18 Years toPhase
35 Years
1 Â (Adult) 3 Other InterventioInterventi DVP-I
Incidence University Male 18 Years and
Phase
older
1|Ph
Â (Adult, 72
Older
Other
Adult) InterventioAllocation UW15014|
Phase
older
2 Â (Adult,120
Older
Industry
Adult) InterventioInterventi GRT63
85 Years
2 Â (Adult,
1235Older
Industry
Adult)InterventioAllocation C3671001|
39 Years
65 Years
3 Â (Adult,13Older
Industry
Adult)InterventioAllocation V72_59|20
Number and Sanofi Pas All 18 Years toPhase
50 Years
Anti-HBs seHenogen|GAll 15 Years and
Phase
older
3 Â (Child,257
Adult,
Industry
Older Adult)
Number ofHerlev HosAll 18 Years toPhase
80 Years
1 Â (Adult,10Older
Other
Adult)InterventioAllocation MM1304
the rate o Walvax BioAll 2 Years andPhase
Adult,
Older Adult) Walvax-01
Overall Re Istituto Sc All 19 Years and
Phase
older
2 Â (Adult, Older
0 Other
Adult) InterventioInterventi IRST189.0
Primary End Tel-Aviv S All 18 Years toPhase
65 Years
Other
Number ofUniversity Male 18 Years and
Phase
older
2 Â (Adult, 17
Older
Adult) CO08802|H
Cytokine PRadboud Un All 18 Years toNot
55 Years
ApplicÂ (Adult)15 Other InterventioInterventi NL45427.0
Frequency National InAll 6 Months toPhase
36 Months
1 Â (Child)
12 NIH|OtherInterventioAllocation CIR 255
To measureUniversity All 18 Years toPhase
45 Years
2 Â (Adult)20 Other InterventioInterventi HP-0004071
Reduction H i vivo|GlaxAll 18 Years toPhase
45 Years
1|PhÂ (Adult)
174 Industry InterventioAllocation IDB 004 ID
Intracellu Francis Co All Child, AdulNot Applic 102 Other InterventioAllocation CHUB-HO1 s
Immunogenic Tel-Aviv S All 18 Years toPhase
64 Years
25 Years
2 Â (Adult)
Safety|Imm PATH All 18 Years toPhase
45 Years
estimate t Ludwig InsAll 18 Years andPhase
older
1 Â (Adult, 15
Older
Other
Interventi Ottawa HosAll 18 Years andNotolder
Applic
Â (Adult, 46
Older
Other
Adult) InterventioAllocation Guide Clus
- an HIV ri New York BFemale 18 Years andNotolder
Applic
Â (Adult,400
Older
Other
Adult) InterventioAllocation IRB 406-0
55 Years
Immunogeni Johann WolAll 2 Years to 5Phase
Years4Â (Child) 70 Other InterventioAllocation PAPSI.FFM
Phase 1 - NDonald T. All 18 Years andPhase
older
1 Â (Adult, 16
Older
Other
Safety of Pawel KalinAll 18 Years andPhase
older
1 Â (Adult, 22
Older
Adult) 03-118|PC
to 21 Months
4 Â1439
(Child)
The short InternationAll 6 Months to 25 Years Â (Child,149Adult)
Other|NIHObservatioObservatioIMPAACT P
HPV-16 andShanghai ZFemale 9 Years to 24
Phase
Years
2 Â (Child,900
Adult)
Industry|OInterventioAllocation 311-HPV-1
â€¢ To evalGeneCure B All 18 Years toPhase
60 Years
1 Â (Adult)30 Industry InterventioAllocation A010
Number ofM.D. AnderAll 18 Years andPhase
older
2 Â (Adult, 98
Older
Other
Increase HSt. Louis UFemale 9 Years to 26
NotYears
Applic
Â (Child, Adult)
Influenza NorthwesteAll 50 Years andNotolder
Applic
Â (Adult,125
Older
Adult) Fact vers
LaboratoryUniversity All 18 Years toPhase
49 Years
4 Â (Adult)
1952 Other|InduInterventioAllocation FLUVACS
Serotype-sKEMRI-WellAll 12 MonthsPhase
to 59 Months
4 Â 600
(Child)
Other|InduInterventioAllocation SSC 1635
49 Years
4 Â (Adult)10 Other|NIHInterventioAllocation SU-31434-
Number ofKiromic, InAll 18 Years andPhase
older
1|Ph
Â (Adult, Older
0 Industry
PercentageEli Lilly a All 18 Years toPhase
65 Years
1 Â (Adult,84Older
Industry
Adult)InterventioAllocation 16202|I1F
Changes inDartmouth- All Child, AdulNot Applic 1200 Other|NIHInterventioAllocation D18180|3P
Cohort 1 (1PaxVax, IncAll 2 Years to 17
Phase
Years
4 Â (Child)595 Industry InterventioAllocation PXVX-VC-2
occurrenceGlaxoSmithAll 18 Years toPhase
64 Years
4 Â (Adult)
relative ri Children's All 3 Months to Not18Applic
Months Â 2186
(Child)
Other|InduInterventioAllocation ChildrensR
40 Years
Number ofEmory UnivFemale 18 Years toPhase
40 Years
1|PhÂ (Adult)
immunogeni Lakehead UAll 18 Years andPhase
older
4 Â (Adult,138
Older
Other
Adult) InterventioAllocation RP-232-08
20% increaKhushi BabAll 42 Days to Not
6 Months
ApplicÂ (Child)
Frequency National
25 Months
1|Ph Â (Child)
45 Years
17 Months
3 Â (Child)
Change in cNIZO FoodAll 18 Years toNot
50 Years
ApplicÂ (Adult)42 Other|InduInterventioAllocation NL49042.0
Antibody tSanofi Pas All 2 Years andPhase
Adult,
Industry
Older Adult)
InterventioAllocation MET55|U11
Phase II s Mahidol UnAll 18 Years toPhase
49 Years
2 Â (Adult)150 Other InterventioAllocation GPO AVIAN
Number ofSanofi Pas All 5 Weeks toPhase
8 Weeks
GeometricChiltern PeAll 18 Years toPhase
60 Years
3 Â (Adult)154 Industry InterventioAllocation V111_14TP
Immunogenic Fluart InnoAll 3 Years to 18
Phase
Years
3 Â (Child,120
Adult)
Industry InterventioInterventi FABNovo-H
Change in University All Child, AdulNot Applic 91 Other InterventioAllocation 2011-3
to 23 Months
3 Â 342
(Child)
Absence ofTHEVAX Gen Female 18 Years toPhase
55 Years
2 Â (Adult)10 Industry InterventioAllocation VAX 02-01
AnaphylactiSt. Justin All 2 Years to 17 Years Â (Child)124 Other ObservatioObservatioFluMist24
HI[hemagglSK Chemical All 6 Months to Phase
35 Months
3 Â (Child)
171 Industry InterventioAllocation NBP607-QI
Occurrence, GlaxoSmithAll 15 Years andPhase
older
3 Â (Child,
1303
Adult,
Industry
Older Adult)
Time to fir University All 5 Months to Phase
17 Months
1|Ph Â (Child)
HPV VaccinDuke UniveAll Child, Adult, Older Ad 32 Other ObservatioObservatioPro001007
Number ofSanofi
P Pas All 18 Years andPhase
older
4 Â (Adult,120
Older
Industry
Adult) InterventioInterventi GRC41
Safety andNovavax|InAll 18 Years toPhase
64 Years
2 Â (Adult)
4560 Industry|OInterventioAllocation NVX 754 H
A descriptiSanofi Pas All 3 Months toPhase
68 Months
3 Â (Child)
74 Industry InterventioAllocation IPV35 (EF
OccurrenceGlaxoSmithAll 56 Days to Phase
83 Days
OccurrenceGlaxoSmithAll up to 3 Days
Phase
Â (Child)
3 500 Industry InterventioAllocation 759346/00
AssessmentDalhousie All 18 Years to 69 Years Â (Adult,
1143Older
OtherAdult)ObservatioObservatio 114142
Measure SeMerck ShaFemale 9 Years to 26
Phase
Years
1 Â (Child, Adult)
100 Years
Adult) SU-17219-
OccurrenceAIDS MaligMale 18 Years and
Phase
older
2 Â (Adult,112
Older
Other|NIH|
Adult) InterventioAllocation AMC-052|
40 Years
Plaque RedBavarian NAll 55 Years and
Phase
older
2 Â (Adult,420
Older
Industry
Adult) InterventioAllocation RSV-MVA-0
Meningococc GlaxoSmithAll 15 Years toPhase
19 Years
Industry InterventioAllocation 108595 Mt
64 Years
80 Years
1 Â (Adult,40Older
Industry
Rabies antiPeking UnivAll 20 Years toPhase
60 Years
4 Â (Adult)160 Other InterventioInterventi PKUPH-ER-
Mean of thYale Unive All 18 Years toPhase
50 Years
2 Â (Adult)14 Other|InduInterventioInterventi 08040036
Incidence Pfizer All 42 Days to Phase
72 Days
4 Â (Child)299 Industry InterventioAllocation B4671004|
Summary of Sanofi Pas All Child, Adult, Older Ad 62626 Industry ObservatioObservatioMTA30
Measles, MSanofi Pas All 9 Months toPhase
12 Months
3 Â 1664
(Child)
Safety ObjeSeqirus Female Child, Adult, Older Ad 660 Industry ObservatioObservatioV130_11O
economic bu Peking UniAll 6 Months and older Â (Child,
11500 Adult,
OtherOlder ObservatioObservatioIRB000010
Adult)
Percent of National InAll 18 Years toPhase
50 Years
1|Ph
Â (Adult)28 NIH|OtherInterventioAllocation A5176|101
Safety as mSidney KimAll 18 Years toPhase
120 Years
Adult) J0619|P30
Local and sHIV VaccineAll 18 Years toPhase
45 Years
1 Â (Adult)80 Other|NIHInterventioAllocation HVTN 078|
SeroconverPATH All 8 Months toPhase
11 Months
3 Â (Child)
600 Other InterventioAllocation JEV01
55 Years
3 Â (Child,300
Adult)
Pain|Fear|R University All 18 Years and
Phase
older
3 Â (Adult,160
Older
Other
ProportionPostgraduaAll Child, AdulNot Applic 120 Other InterventioAllocation LM/PED/0
Efficacy of Sanofi All 65 Years and
Phase
older
3 Â (Older
9172
Adult)
Industry InterventioAllocation FIM07|UTN
ConcentratGlaxoSmithAll 22 Years toPhase
50 Years
Maximum M.D.tol AnderAll 18 Years and
Phase
older
1 Â (Adult, 12
Older
Adult) 2009-0465
CMV-specifUniversity All 18 Years toPhase
45 Years
1 Â (Adult)16 Other|InduInterventioAllocation Jacobson V
To assess tAbbott BiolAll 18 Years toPhase
64 Years
2 Â (Adult)
1270 Industry InterventioAllocation S203.2.004
45 Years
Phase
Years
Number ofInviragen All 18 Years toPhase
45 Years
1 Â (Adult)96 Industry InterventioAllocation INV-DEN-1
Maximum H. To Lee MofAll 18 Years and
Phase
older
1 Â (Adult, 22
Older
Other|Indu
Vaccine safEunice KenAll 18 Years toPhase
49 Years
Number ofOHSU Knigh All 18 Years and
Phase
older
2 Â (Adult, Older
Adult) CDR00005
To evaluat University All 18 Years toPhase
85 Years
2 Â (Adult,41Older
Frequency Themis Bi All 18 Years toPhase
55 Years
1 Â (Adult)48 Industry InterventioAllocation MV-ZIKA-R
Grades of sNational InAll 6 Months toPhase
24 Months
1 Â (Child)
49 Years
Area underFrench NatAll 18 Years toPhase
65 Years
2 Â (Adult,69Older
OtherAdult)InterventioAllocation EHVA T02/
Cell immunTel-Aviv S All 18 Years toPhase
90 Years
4 Â (Adult,90Older
OtherAdult)InterventioAllocation TASMC-09-
Hepatitis Merck ShaAll 12 MonthsPhase
to 23 Months
3 Â (Child)
Biological: MUC1-KLHMemorial SMale 18 Years andPhase
Older
Adult) 99-040|MS
60 Years
ConcentratGlaxoSmithAll 18 Years toPhase
50 Years
2 Â (Adult)20 Industry|OInterventioInterventi 116777|20
Titers for GlaxoSmithAll 60 Years andPhase
older2 Â (Adult,
1220
Older
Industry
GeometricMerck ShaAll 9 Years to 45
Phase
Years
3 Â (Child,600
Adult)
Number ofPontificia
s Universidad
Male 18
Catolica
Years to
dePhase
50
Chile|ComisiÃ³n
Years
1 Â (Adult)24 Nacional
Other de InvestigaciÃ³n
CientÃfica
15-216|rB
y TecnolÃ³gica|Millennium
Safety|Imm VaxInnate All 18 Years andPhase
Older
Industry
Adult) InterventioAllocation VAX128-01
64 Years
PSA doubliDavid M LuMale 18 Years toPhase
90 Years
2 Â (Adult,70Older
Adult) 201705743
ProportionUniversity All 65 Years and older Â (Older Adult)
43 Other ObservatioObservatioRG_14-216
clearance University All 6 Months to 21 Years Â (Child,0Adult)
Other ObservatioObservatio15-2042
CMV-specifUniversity All 18 Years toPhase
45 Years
1 Â (Adult)10 Other|InduInterventioAllocation Jacobson V
Induction oUniversity All 18 Years andPhase
Older
Other
Adult) InterventioAllocation iVAC-CLL01
LaboratoryButantan InAll 6 Years to 18
Phase
Years
4 Â (Child,
1742
Adult)
Other InterventioAllocation BUTANTAN
The number Gamaleya R All 18 Years toPhase
49 Years
1 Â (Adult)60 Other InterventioAllocation GamTBvac
49 Years
Fever|SysteCHU de Que All 2 Months to 14 Months Â 4535 (Child)
Other|InduObservatioObservatio 1224
JIA diseas N.M. WulffAll 4 Years to 9Phase
Years4Â (Child) 140 Other InterventioAllocation VAART|ISR
50 Years
1 Â (Adult)30 U.S. Fed InterventioAllocation S-10-0002,
GeometricSK Chemical All 19 Years andPhase
older3 Â (Adult,
1155
Older
Industry
Adult) InterventioAllocation NBP607_Fl
Hepatitis National T All 18 Years toNot
23 Years
ApplicÂ (Adult)
Hepatitis Fred HutchAll 18 Years andPhase
Older
Other
Adult) InterventioAllocation U010
ProportionPapua NewAll up to 35 Days
Phase
Â (Child)
3 200 Other InterventioAllocation PCV1103
45 Years
Receipt of Ohio StateAll 18 Years toNot
25 Years
ApplicÂ (Adult)
1 m afer tGlaxoSmithAll 6 Weeks toPhase
12 Weeks
3 Â (Child)478 Industry InterventioAllocation 103974 (pr
GeometricSanofi All 65 Years andPhase
Adult)
Industry InterventioAllocation TD515
The Time tNational InFemale 18 Years toPhase 40 Years
Persistenc Pfizer All Child, AdulPhase 3 243 Industry InterventioAllocation MENACWY-T
5 Years3 Â (Child)373 Industry InterventioAllocation 6096A1-30
Number ofMeharry Me All 9 Years andNot
older
Applic
Â (Child, Adult,
806 Other
Older Adult)
InterventioAllocation U54CA153
PercentagePT Bio Far All 10 Years toPhase
40 Years
2|PhÂ (Child,
536Adult)
Industry InterventioAllocation Hep B 021
differencesAcademisch All 6 Weeks to 3 Years Â (Child) 88 Other|U.S.ObservatioObservatioAIGHD-CSP
Incidence Beijing CenAll Child, AdulPhase 4 10500 Other InterventioAllocation BJCDPC-5
Rates of S Sanofi Pas All 9 Months to 23 Months Â (Child)
116 Industry ObservatioObservatioMTA57|U 1
Intention Milton S. All 18 Years andNotolder
Applic
Â (Adult,148
Older
Other|Indu
Adult) InterventioAllocation Study0000
OccurrenceGlaxoSmithAll up to 12 Months Â (Child) 1 Industry ObservatioObservatio 201521
Safety (locInternationAll 18 Years toPhase
60 Years
2 Â (Adult)115 Other InterventioAllocation IAVI 010
Safety bas City of HopAll 18 Years toPhase
75 Years
1 Â (Adult,36Older
Adult) 12022|NCI
Systemic anPevion BioFemale 18 Years toPhase 45 Years
1 Â (Adult)48 Industry InterventioAllocation PCAN001
Phase
Years
3 Â (Child,
3074
Adult)
Number ofGlaxoSmithFemale 18 Years toPhase 45 Years
49 Years
4 Â (Adult) 3 Other|NIHInterventioAllocation SU-33722|
59 Months
1 Â (Child)
The non-infSanofi Pas All 42 Days to Phase
50 Days2 Â (Child)236 Industry InterventioAllocation IPV25
Change in Insight Th All 65 Years and
Notolder
Applic
Â (Older200Adult)
Other|InduInterventioAllocation INSI-20160
Rates of suOlogy BiosAll 18 Years toPhase
40 Years
1|PhÂ (Adult)
Change in tUniversity All 11 Years toNot
17 Years
ApplicÂ (Child)24 Other|NIHInterventioInterventi 6R01CA20
Phase
older
3 Â (Adult,
1239Older
Industry
HPV VaccinReal PrevenFemale 18 Years toNot
26 Years
ApplicÂ (Adult)
360 Industry|OInterventioAllocation R44DP006
HI titers 4 Solvay PhaAll 3 Years andPhase
900 Industry
Older Adult)
InterventioAllocation S201.3.121
Number ofPATH All 6 Weeks toPhase
45 Years
1|PhÂ (Child,
609Adult)
Other InterventioAllocation VAC-041
65 Years
NIH Adult)InterventioAllocation ACTG A536
Frequency Radboud Un All 18 Years toPhase
35 Years
2 Â (Adult)20 Other InterventioAllocation BCG-EHMI|
49 Years
1 Â (Adult)66 Industry InterventioAllocation B7471001
Phase
older
3 Â (Adult,
1252Older
Industry
Anti-pneum GlaxoSmithAll 12 MonthsPhase
to 23 Months
3 Â 363
(Child)
40 Years
1|PhÂ (Adult)
Analytical National InAll 18 Years toPhase
55 Years
2 Â (Adult)114 NIH InterventioAllocation A5197|100
To assess University All 18 Years and
Phase
older
1 Â (Adult, 58
Older
Other
Adult) InterventioAllocation Flu001
SeroconverCenters fo All 2 Months to 6 Months Â (Child)
Seroconvers McGill UnivAll 18 Years and
Phase
older
4 Â (Adult,280
Older
Other
Adult) InterventioAllocation MP-37-201
Local and sUniversity All 18 Years toPhase
45 Years
Serum ZostRockefellerAll 50 Years toNot
60 Years
ApplicÂ (Adult)14 Other|NIHInterventioAllocation OJE-0890|
15 Years
3 Â (Child)100 Industry InterventioInterventi 110168
21 Years
1 Â (Adult)90 Industry InterventioAllocation NGB00005|
Successful City of HopAll 18 Years toPhase
55 Years
1 Â (Adult)68 Other|NIHInterventioAllocation City of H
Adverse EffInternatio All 6 Months and older Â (Child,
800000 Adult,
Other|Indu
Older ObservatioObservatioICID-2011
Adult)
Number ofPATH|Minist All 18 Years toPhase
49 Years
Base StudyMerck ShaMale 16 Years toPhase
26 Years
3 Â (Child,
4065 Adult)
HPV vaccinUniversity All 11 Years toNot
17 Years
ApplicÂ (Child)
17000 Other InterventioAllocation PCS-2017C
49 Years
2 Â (Adult)454 Industry InterventioAllocation NOR-201|U
Safety (lo National InAll 18 Years toPhase
50 Years
Vaccine-relKing's Col All 18 Years and
Phase
older
1 Â (Adult, 10
Older
Other
14 Weeks
50 Years
ConcentratWyeth is nAll 90 Days to Phase
120 Days
1 Â (Child)800 Industry InterventioAllocation 0887X-101
complianceJaye ShykeFemale 14 Years to 55 Years Â (Child,99Adult)
Other ObservatioObservatio 27919
GeometricNational
64 Years
98 Days1|Ph
Â (Child)249 Industry InterventioAllocation 6096A1-00
Number ofBiomedical
l All 18 Years toPhase
49 Years
2 Â (Adult)720 U.S. Fed InterventioAllocation BP-I-16-00
Number Sub Novartis|NAll 18 Years toPhase
40 Years
Phase
older
1 Â (Adult, Older
8 Other
Immune res Mayo ClinicAll 18 Years and
Early
older
Phas
Â (Adult, 30
Older
Adult) MC0972|NC
Incidence U.S. Army All 20 Years toPhase
25 Years
2 Â (Adult)120 U.S. Fed|I InterventioAllocation WRAIR 128
45 Years
Number ofEmory Unive All 25 Years toNot
89 Years
Adult) IRB000479
Anti-HBs aHenogen All 16 Years and
Phase
older
3 Â (Child,102
Adult,
Industry
Older Adult)
ImmunizatiJohns Hopki All up to 24 Months
Not Applic
Â (Child) 608 Other|NIHInterventioAllocation IRB000862
Phase
older
3 Â (Adult,265
Older
Industry
Incidence oGlaxoSmithAll Child, Adult, Older Ad 1 Industry Observational 115997
Anti-HBs s GlaxoSmithAll 15 Years and
Phase
Adult,
Industry
Older Adult)
Number ofYubari Kib All Child, AdulNot Applic 199 Other InterventioAllocation 803121
Number and PATH|Scand All 6 Months toPhase
45 Years
1|PhÂ (Child,
475Adult)
Other|InduInterventioAllocation VAC 014
Biological: Dryvax vacNational InAll 18 Years toPhase
32 Years
2 Â (Adult) NIH InterventioMasking: DDMID 01-632
Dose limitiFrank Lieb All 18 Years and
Early
older
PhasÂ (Adult, 27
Older
Other
Immunogenic National InAll 21 Years and
Phase
Older
Number ofPatrick
p Ot All 18 Years and
Phase
Older
Other
64 Years
Anti-HBs seHenogen All 18 Years toPhase
40 Years
3 Â (Adult)450 Industry InterventioAllocation HN016/HB
The number Ole FroberAll 18 Years and
Phase
older4 Â (Adult,
4400
Older
Other|Indu
Adult) InterventioAllocation IAMI-2014
To assess tNovavax All 18 Years toPhase
49 Years
2 Â (Adult)317 Industry InterventioAllocation NVX 755.2
To conductOchsner HeAll 19 Years and
Phase
Older
Other|Indu
Adult) InterventioAllocation USA-MCI-0
GeometricNational
99 Years
Number ofSanofi
P Pas All 6 Months and
Phaseolder
4 Â (Child,240
Adult,
Industry
Adult) GRC73|U11
symptom rep University All 18 Years and
Notolder
Applic
Â (Adult,100
Older
Other
Adult) InterventioAllocation KPKF001
Phase
Years3 Â (Child)210 Industry InterventioInterventi 113528
55 Years
2 Â (Adult)154 Industry|OInterventioAllocation 205081
Grade 3 orNational InAll 18 Years toPhase
24 Years
1 Â (Adult) 0 NIH InterventioAllocation P1082|10776
Number ofJanssen VacAll 18 Years toPhase
50 Years
1 Â (Adult)72 Industry|NInterventioAllocation CR108144|
Anti-Influ University All 50 Years toPhase
75 Years
2 Â (Adult, 0Older
OtherAdult)InterventioAllocation HS-16-004
Receipt of Columbia UAll 9 Months toNot50Applic
Years Â (Child,
2586Adult)
Other InterventioAllocation AAAF4263
Phase
Years3 Â (Child)239 Industry InterventioAllocation V72_62|20
Clinical lo Objectif R Male 18 Years toPhase
45 Years
1 Â (Adult)38 Other InterventioAllocation ORVACS 00
TIV ComparPfizer All 65 Years and
Phase
older3 Â (Older
1185
Adult)
Grade IV aAlphaVax, IAll 18 Years toPhase
60 Years
1 Â (Adult)48 Industry|OInterventioAllocation HVTN 040
14 Weeks
Antibody reUniversity All 6 Months and
Phaseolder
4 Â (Child,
1141Adult,
Adult) CER-09-23
Seroconvers Centers fo All 2 Months toPhase
18 Months
4 Â (Child)
85 Years
Industry
Adult)InterventioAllocation C3571001
ProportionCanadian IAll 3 Years to 18
Phase
Adult)
Other InterventioAllocation SI02
Phase
Laboratory-University All 6 Months toPhase
10 Years
4 Â (Child)
18163 Other|U.S.InterventioAllocation 13-0210|U
Developmen National I All 18 Years toPhase
24 Years
1 Â (Adult)20 NIH InterventioInterventi P1059|10051|PACTG P1059
Incidence aSanaria In All 6 Months toPhase
65 Years
Older Adult) EGSPZV2
Serologica The UniverAll 6 Weeks toPhase
9 Weeks4 Â (Child)100 Other InterventioAllocation UW 09-024
Titers of GlaxoSmithFemale 9 Years to 25
Phase
Adult)
PhaseYears
Anti-glyco GlaxoSmithAll 65 Years and
Phase
older3 Â (Older430
Adult)
Incidence University All 18 Years toPhase
50 Years
Enzyme-LinGradalis, InAll 18 Years and
Phase
Older
Industry
Safety andWashington All 18 Years and
Phase
0 Other|Indu
Adult) InterventioAllocation 18-x429
the proportButantan InAll 18 Years toPhase
50 Years
1 Â (Adult)266 Other InterventioAllocation BUTVAC - I
45 Years
Adverse evHerlev HosAll 18 Years and
Phase
Older
Other
Adult) InterventioInterventi AA1809
50 Years
2 Â (Adult)67 Industry|OInterventioAllocation 114460
Area underNational InAll 18 Years toPhase
42 Years
1 Â (Adult)36 NIH|OtherInterventioAllocation:URMC 12-
to 21 Months
3 Â 105
(Child)
50 Years
1 Â (Adult)42 Industry InterventioAllocation PM HSD-00
GeometricCentre for All 6 Weeks toPhase
8 Weeks
2|PhÂ (Child)
450 Other|InduInterventioAllocation CVIA 066
Complete RNational HAll 18 Years toPhase
70 Years
Adult) BMTCTN14
Counts andNovavax Female 18 Years toPhase
40 Years
2 Â (Adult)50 Industry InterventioAllocation RSV-M-203
Incidence aDynPort VaAll 18 Years toPhase
40 Years
1 Â (Adult) 0 Industry InterventioAllocation VEE-01
ReactogeniBharat BioAll 8 Weeks toPhase
20 Weeks
1|PhÂ (Child)
540 Industry|OInterventioAllocation BBIL/ROTA
To evaluat HIV VaccinAll 18 Years toPhase
50 Years
1 Â (Adult)96 Other InterventioAllocation HVTN 096
50 Years
1 Â (Adult)48 NIH|IndustInterventioAllocation HVTN 094|
Time to CMRobert PasFemale 14 Years toPhase
40 Years
Other|NIH| InterventioAllocation 99-038|U0
12 Weeks
safety|res Memorial SMale 18 Years andPhase
older
1 Â (Adult, Older
Adult) 01-140|P3
Frequency Ology
a BiosAll 18 Years andPhase
older
3 Â (Adult,
3583
Older
Industry
Number ofWyeth is nAll Child, Adult, Older Ad 3366 Industry ObservatioObservatio0887X-102
Local And SJanssen VaAll 18 Years toPhase
50 Years
1|Ph
Â (Adult)
201 Industry InterventioAllocation CR108152
25 Years
overall su University All 20 Years toPhase
80 Years
2 Â (Adult,60Older
OtherAdult)InterventioInterventi YMU-03
Frequency National InFemale 18 Years toPhase
39 Years
Plasma HAIStanford Un All 2 Years to 49
Phase
Years
4 Â (Child, Adult)
50 Other|NIHInterventioInterventi 50122|5U1
DetermineVA EasternAll 21 Years toPhase
75 Years
U.S. Fed
Varicella- Merck ShaAll 50 Years andPhase
older
3 Â (Adult,763
Older
Industry
Numbers ofUniversity All 18 Years andPhase
older
1|Ph
Â (Adult, 97
Older
Other
Anti-influ University All 18 Years to 55 Years Â (Adult)57 Other ObservatioObservatioKent001|A
SeroconverCenters fo All 6 Weeks toPhase
7 Weeks
3 Â (Child)
1206 U.S. Fed|OInterventioAllocation ICDDRB-RR
Immune res Jena UniverAll 60 Years andPhase
older
4 Â (Adult,132
Older
Other
Adult) InterventioAllocation EudraCT 2
Uptake of tChinese UnMale 18 Years andNotolder
Applic
Â (Adult,624
Older
Other
Adult) InterventioAllocation HMRF1314
Safety of The ScientAll 18 Years toPhase
55 Years
1 Â (Adult)60 Other|InduInterventioAllocation MON116.4
Is to inves Memorial SMale 18 Years andPhase
older
1 Â (Adult, 14
Older
Other
Immune reVaxInnate All 18 Years toPhase
49 Years
1 Â (Adult)80 Industry InterventioAllocation VAX102-07
Hemagglutin Stanford UnAll 12 Years toPhase
49 Years
Other|NIHInterventioAllocation 31050|2U1
Cellular i University All 18 Years andPhase
older
1 Â (Adult, Older
3 Other
Adult) InterventioAllocation FLU006|20
Safety|Imm University All 18 Years andPhase
older
1 Â (Adult, 19
Older
Other
Adult) InterventioAllocation 20020225|
Atopic derm Bandim Hea All 24 Months to 24 Months 1027559
Â (Child)
Other ObservatioObservatioDTaP-Delay
GeometricNational
64 Years
1|Ph
Â (Adult)
PercentageSerum InstiAll 18 Years toPhase
65 Years
2|Ph
Â (Adult,
2000Older
Industry
Adult)InterventioAllocation VPM1002-I
older
3 Â (Adult,526
Older
Industry
The Number University All 18 Years andPhase
older
1 Â (Adult, 12
Older
Adult) 11992|UVA
19 Months
3 Â (Child)
Number ofSanofi All 56 Years andPhase
older
2 Â (Adult,139
Older
Industry
Adult) InterventioAllocation MTA75|U11
50 Years
1 Â (Adult)39 U.S. Fed|OInterventioAllocation S-14-02
Biological: Cell-Cult DynPort VaAll 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation SMPX-001
To provide Sanofi Pas All 4 Years to 6Phase
Years4Â (Child) 122 Industry InterventioInterventi VBK12
55 Years
PercentageSanofi Pas All 6 Years to 8Phase
Years3Â (Child) 115 Industry InterventioAllocation TD521
The ProporChongqingAll 18 Years toPhase
65 Years
Adult) 71006.01-
Seroconvers Statens Se All 6 Weeks toPhase
9 Months
3 Â (Child)
1002 Other|InduInterventioAllocation VIPV-06
Solicited GlaxoSmithAll 18 Years toPhase
69 Years
1 Â (Adult,20Older
Industry
Adult)InterventioInterventi 113819
older
3 Â (Adult,882
Older
Industry
70 Years
1 Â (Adult,28Older
NIH Adult)InterventioAllocation CIR 310
Immunogeni GlaxoSmithAll 12 Weeks to Phase
16 Weeks
3 Â (Child)
80 Industry InterventioInterventi 217744/06
12 Weeks
Measure ofInstitut N All 18 Years andNotolder
Applic
Â (Adult,
2000
Older
Other|Indu
Adult) InterventioInterventi C13-47|20
Qualitativ University All 12 Years toPhase
17 Years
2 Â (Child)123 Other|NIHInterventioAllocation ATN 025
The seropos Sinovac BioAll 6 Months to 35 Months Â (Child)
343 Industry ObservatioObservatioPRO-EV71-
number ofMayo CliniAll 65 Years andPhase
older
1 Â (Older Adult)
Frequency National
50 Years
Number ofUniversity
P Female 18 Years andPhase
older
1 Â (Adult, Older
6 Other|U.S.InterventioAllocation
Adult) 110396
number ofCancer
H Prev
Female 25 Years toPhase
25 Years
4 Â (Adult)832 Other InterventioAllocation F11J09000
17 Years
2 Â (Child)60 Industry|OInterventioAllocation 112898
Non-inferi University All 6 Weeks toPhase
8 Weeks
4 Â (Child)304 Other InterventioAllocation 2015/01
Safety: proInternationAll 18 Years toPhase
50 Years
2 Â (Adult)91 Other|InduInterventioAllocation IAVI A002
Biological: Trivalent National InAll 65 Years andPhase
older
2 Â (Older414
Adult)
First Stage Beth Israe All 18 Years andPhase
older
2 Â (Adult, 35
Older
Adult) 09-061
Seroconvers Centers fo All 2 Months to Phase
18 Months
4 Â (Child)
older
3 Â (Adult,
5075
Older
Industry
SeroprotecTakeda All 20 Years toPhase
49 Years
4 Â (Adult)55 Industry InterventioInterventi BLB-750/C
Safety|Imm Ahmad TarhiAll 18 Years andPhase
older
1 Â (Adult, 22
Older
Adult) 04-173|NC
Meningococ GlaxoSmithAll 11 Years toPhase
17 Years
Guangxi CeAll 9 Years to 45 Years Â (Child,300
Adult)
Other ObservatioObservatioV501-030-
Determinati NantBioSciAll 18 Years andPhase
older
1 Â (Adult, Older
3 Industry
Adult) InterventioInterventi QUILT-3.01
safety|immMemorial SMale 18 Years andPhase
older
1 Â (Adult, 34
Older
Adult) 99-062|P3
Frequency National CaAll 18 Years andPhase
older
2 Â (Adult, 10
Older
Persistenc Pfizer All 17 Years toPhase
66 Years
Industry
Adult) MENACWY-T
Number ofMerck SharAll 18 Years toPhase
50 Years
1 Â (Adult)39 Industry|UInterventioAllocation V920-001|
Immunogeni GlaxoSmithAll 8 Weeks toPhase
15 Weeks
OccurrenceGlaxoSmithAll 2 Months to 6 Years Â (Child) 349 Industry ObservatioObservatio 108344
Change in cNIZO FoodAll 18 Years toNot
50 Years
ApplicÂ (Adult)
108 Other|InduInterventioAllocation NL56906.0
Serum AntiSt. Louis All 18 Years toPhase
49 Years
OccurrenceSanofi Pas All up to 59 Months Â (Child)1195 Industry ObservatioObservatioM5A16|UTN
98 Days3 Â (Child)
To determiCliniques uAll 18 Years andPhase
older
1|Ph
Â (Adult, Older
2 Other
Adult) InterventioInterventi Luc 10-002
Adverse evAcademisch All 18 Years toPhase
50 Years
1 Â (Adult)24 Other InterventioAllocation NL69161.0
Occurrence, GlaxoSmithAll 18 Years toPhase
45 Years
Humoral anCity of HopAll 18 Years to 120 Years Â (Adult,
459 Older
Other|NIHObservatioObservatio06157|P3
Adult)
Integrated Michigan SAll 18 Years to 80 Years Â (Adult, 1Older
OtherAdult)ObservatioObservatio14-848FM
Antibody tiBeijing CenAll 1 Year to 12Phase
Years4Â (Child)1800 Other InterventioAllocation BJCDPC-9
Peak Neutra University All 18 Years toPhase
60 Years
1|PhÂ (Adult)46 Other|NIHInterventioInterventi IDIM-2018
anti-HBSAgBaylor Col All 16 Years toPhase
19 Years
4 Â (Child,
400 Adult)
Other|U.S.InterventioAllocation H-26257
Immunogeni Themis Bi All 18 Years toPhase
55 Years
2 Â (Adult)
263 Industry InterventioAllocation MV-CHIK-2
Improvemen Aga Khan UAll up to 14 Days
NotÂApplic
(Child) 300 Other InterventioAllocation EM-2013-I
23 Months
3 Â (Child)
55 Years
1 Â (Adult)62 NIH InterventioAllocation A5281|108
Overall Su Bristol-My All 18 Years andPhase
older3 Â (Adult,
1783
Older
Industry
Adult) InterventioAllocation MDX010-2
Dose LimitOncBioMune Male 18 Years andPhase
Older
Adult) O11-10678
HI antibodSinovac BioAll 12 Years toPhase
17 Years
2 Â (Child) Industry|OInterventioAllocation PRO-sPanFlu-2001
Treatment-Cancer InsiFemale 18 Years andPhase
Older
Industry
Adult) InterventioAllocation C.2008.14
Efficacy of Tel-Aviv S All 18 Years toNot
85 Years
OtherAdult)InterventioAllocation TASMC-05-
OccurrenceSeattle ChiAll 18 Years toPhase
50 Years
1|PhÂ (Adult) 6 Other InterventioAllocation WR 1584
12 Weeks
2 Â (Child)
The serocoSinovac BioAll 2 Years andPhase
Adult,Industry
Older Adult)
InterventioAllocation PRO-PPV-3
AcquisitionNational InAll 18 Years toPhase
35 Years
2 Â (Adult)
801 NIH|OtherInterventioAllocation HVTN 503
T-cell ImmuSidney KimAll 18 Years andPhase
Older
Other|NIHInterventioAllocation:J10140|P0
Adult)
The proport PATH All 2 Years to 5Phase
Years3Â (Child) 306 Other InterventioAllocation JEV04|HS3
Safety as U.S. Army All 18 Years toPhase
50 Years
2 Â (Adult)20 U.S. Fed InterventioInterventi FY04-33, L
Change in Albert Ein All 18 Years toPhase
100 Years
2 Â (Adult,9 Older
Number ofUniversity
A All 18 Years toPhase
50 Years
1 Â (Adult)66 Other InterventioAllocation VIC-NANO-
Safety of University All 10 Weeks to Phase
12 Months
1 Â (Child)
50 Years
1 Â (Adult)
50 Years
2 Â (Adult)
Years4Â (Child) 60 Industry InterventioInterventi IPV46 (EF
Immunogeni Genexine, All 20 Years toNot
60 Years
ApplicÂ (Adult) 6 Industry InterventioInterventi HB110E_PI
70 Years
2 Â (Adult,
578Older
Adult) CR108062|
to evaluat Inge MarieAll 18 Years andPhase
Older
Other
Adult) InterventioInterventi AA 0914
Adverse EvPepTcell Li Male 18 Years toPhase
45 Years
1 Â (Adult)32 Industry InterventioAllocation FLU-v-002
Clinical Be Chinese UnAll 18 Years andPhase
Older
Other
Adult) InterventioInterventi VAC003
ConcentratGlaxoSmithMale 18 Years toNot
45 Years
ApplicÂ (Adult)47 Industry InterventioAllocation 115429|20
Suspected National InAll 6 Years to 23
Phase
Years1|Ph
Â (Child, Adult)
0 NIH|OtherInterventioAllocation P1049|10165|IMPAACT
Treatment Cancer
e ResAll 18 Years andPhase
Older
Other
Adult) InterventioAllocation CRUKD/17
Safety andRadboud Un All 18 Years toPhase
75 Years
OtherAdult)InterventioAllocation EudraCT 2
15 Years
4 Â (Child)
Number ofInternationAll 18 Years toPhase
50 Years
1 Â (Adult)
218 Other|NIHInterventioAllocation IAVI B003/
overall sa National CaMale 18 Years toPhase
99 Years
1 Â (Adult, 5Older
50 Years
1 Â (Adult)60 NIH|OtherInterventioAllocation CIR 212|N
Measles vaJohns HopkAll 18 Years andNotolder
Applic
Â (Adult,537
Older
Other
Adult) InterventioAllocation KEMRI SER
35 Years
3 Â (Adult)
older2 Â (Older807
Adult)
Industry InterventioAllocation FID21
35 Months
4 Â (Child)
60 Years
cardiovascInstitute All 30 Years toPhase
80 Years
2|PhÂ (Adult,
658Older
Other|Indu
Adult)InterventioAllocation IK-NP-0021
OccurrenceSanofi Pas All 6 Months andPhase
older
1 Â (Child,
101 Adult,
Industry
Adult) FSQ01|U11
Haemaggluti Seqirus All 6 Months to Phase
8 Years
2 Â (Child)
370 Industry InterventioAllocation CSLCT-CAL-
89 Days2 Â (Child)147 Industry InterventioAllocation V72P6
Serotype-sPfizer All 50 Years and
Phase
older
4 Â (Adult,882
Older
Industry
Adult) InterventioAllocation:B1851138
Immunogeni Solvay PhaAll 18 Years and
Phase
older
3 Â (Adult,120
Older
Industry
Safety and Washington All 18 Years and
Phase
older
1 Â (Adult, Older
1 Other
49 Years
The primaryNational InAll 18 Years toPhase
45 Years
1 Â (Adult)64 NIH|OtherInterventioAllocation 110257|11
Antibody coGlaxoSmithAll 8 Weeks toPhase
12 Weeks
SeroconverVaxine Pty All 18 Years and
Phase
older
1 Â (Adult,150
Older
Adult) FLU007
50 Years
1 Â (Adult) 0 U.S. Fed InterventioAllocation S-14-05|F
57 Years
2 Â (Adult)
1150 Industry InterventioAllocation GID02
HBV immunizTel-Aviv SoAll 18 Years and
Notolder
Applic
Â (Adult,100
Older
Other|Indu
Adult) InterventioInterventi TASMC-11-
Number ofIDRI|Wellco All 18 Years toPhase
60 Years
2 Â (Adult)60 Other InterventioAllocation IDRI-TBVPX
PercentageJohns HopkFemale 9 Years to 21
NotYears
Applic
Â (Child, Adult)
67 Other|InduInterventioAllocation NA_00020
Quantitati National InAll 18 Years and
Phase
older
2 Â (Adult, 48
Older
NIHAdult) InterventioAllocation A5220|10148|ACTG A5
HematologiSidney KimAll 18 Years and
Early
older
Phas
Â (Adult, Older
Adult) J05115|P3
Adjusted GGlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,237
Older
Industry
Immunogeni University All 2 Months toPhase
2 Months
2|Ph Â (Child)
248 Other InterventioAllocation H17-02645
Fever >=38Kaiser Per All 6 Weeks toPhase
9 Months
3 Â (Child)374 Other|U.S.InterventioAllocation CDC Protoc
Phase
Years
3 Â (Child,200
Adult)
Industry InterventioAllocation MTA76 (SF
64 Years
2 Â (Adult)
Immunologi National CaMale 18 Years toPhase
99 Years
1 Â (Adult,41Older
Number ofSanofi
P Pas All 18 Years and
Phase
older
2 Â (Adult,849
Older
Industry
Adult) InterventioAllocation FUF14|UTN
50 Years
1 Â (Adult)36 NIH InterventioAllocation N01AI0539
Change in Masonic CaAll 18 Years and
Phase
older
1 Â (Adult, 26
Older
Other
Adult) InterventioInterventi 2017LS091
Biological: Hepatitis National TaAll 15 Years toNot
18 Years
Applicable
Â (Child, Adult)
PercentageH. Lee MoffAll 18 Years and
Phase
older
2 Â (Adult, 49
Older
Other|NIH|
Number ofKiromic,
a InAll 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Industry
Severe locaNational InAll 18 Years toPhase
49 Years
1 Â (Adult)92 NIH InterventioAllocation RV 262|10
ImmunogenicNovavax All 60 Years and
Phase
older
2 Â (Adult,
1599
Older
Industry
Adult) InterventioAllocation RSV-E-201
Year 1 RCCUniversity All 18 Years and
Notolder
Applic
Â (Adult,
70549
Older
Adult) CDC-1U01I
SeroconverChangchunAll 1 Year to 7Phase
Years Â4 (Child) 716 Other InterventioAllocation: Non-Rand
Number ofH. Lee MoffAll 18 Years and
Phase
older
2 Â (Adult, 24
Older
Adult) MCC-14744
Occurrence,National C All 18 Years toPhase
55 Years
2 Â (Adult)150 Other InterventioAllocation X11101220
Anti-MeninGlaxoSmithAll 11 Years toPhase
25 Years
3 Â (Child,692
Adult)
61 Years
One monthGlaxoSmith
a All up to 10 Days
PhaseÂ (Child)
Safety, in AIDS MaligFemale 18 Years toPhase
120 Years
Other|NIH|
Adult)
InterventioInterventi AMC-054|
16 Weeks
Immune Res Novartis All 18 Years toPhase
55 Years
3 Â (Adult)138 Industry InterventioAllocation CFTY720D2
EvaluationGlaxoSmithAll 6 Years to 17
Phase
Years
GeometricNational InFemale 9 Years to 17 Years Â (Child)
1321 NIH ObservatioObservatio08-0012
Biological: hepatitis Centers fo All 5 Years to 14 Years Â (Child)400 U.S. Fed|OObservatioTime PerspCDC-NCID-
For safety Medical ReAll up to 3 Days
Phase
Â (Child)
1 48 Other InterventioAllocation PV001
70 Years
Industry
40 Years
The octavaMerck ShaFemale 16 Years toPhase
23 Years
6B AntibodSidney KimAll 18 Years and
Phase
older
2 Â (Adult, 22
Older
Adult) J06102 CD
OccurrenceVaxart|BioAll 18 Years toPhase
49 Years
2 Â (Adult)179 Industry|UInterventioAllocation VXA-CHAL-
Phase
older
3 Â (Adult,
1877
Older
Industry
Solicited a Shantha BiAll 6 Weeks toPhase
8 Weeks
4 Â (Child)
3000 Industry InterventioAllocation SBL/DTPw
to 15 Months
3 Â4021
(Child)
HPV vaccinColumbia UAll Child, AdulNot Applic 956 Other|U.S.InterventioAllocation AAAM3960
Serum Haem GlaxoSmithAll 6 Months toPhase
35 Months
2 Â (Child)
17 Years
3 Â (Child)
OccurrenceGlaxoSmithAll 3 Months toPhase
4 Months
4 Â (Child)
70 Years
Industry
Evaluate thIDRI All 7 Years to 40
Phase
Years
1 Â (Child, Adult)
42 Other InterventioAllocation IDRI-LVPTC
The attitu University All 18 Years to 80 Years Â (Adult,758Older
OtherAdult)ObservatioObservatioOVG2013/
Humoral and Radboud Un All 18 Years toNot
60 Years
ApplicÂ (Adult)72 Other InterventioInterventi UMCNONC
50 Years
SeroconverXiamen UniFemale 18 Years toPhase
25 Years
2 Â (Adult)
1600 Other|InduInterventioAllocation HPV-PRO-0
PercentageNovartis|NAll 18 Years and
Phase
older
2 Â (Adult,126
Older
Industry
Adult) InterventioInterventi V71_40S
SeroprotectShantha BiAll 6 Weeks toPhase
8 Weeks
4 Â (Child)160 Industry InterventioInterventi SBL/DTPwH
Dose of AvGrupo Espan All 18 Years and
Phase
older
1|Ph
Â (Adult, 28
Older
Other
Adult) InterventioInterventi GEMCAD-16
OccurrenceJiangsu ProAll 8 Years to 50
Phase
Years
2 Â (Child,500
Adult)
17 Weeks
3 Â (Child)
Pathologic National CaAll 18 Years and
Phase
older
1|Ph
Â (Adult, 40
Older
Safety and Solvay PhaAll 18 Years toPhase
49 Years
1 Â (Adult)120 Industry InterventioAllocation S203.1.001
proportionInstitut N All 18 Years toPhase
65 Years
2 Â (Adult,45Older
OtherAdult)InterventioAllocation RBM04-34|
Immunogeni Seqirus All 6 Months toPhase
47 Months
3 Â 2502
(Child)
Frequency Radboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)58 Other InterventioAllocation CPS135
Dose-limitiNina BhardAll 18 Years and
Phase
older
1 Â (Adult, 20
Older
Other
The measure UniformedAllS 18 Years toPhase
60 Years
3 Â (Adult)275 U.S. Fed|OInterventioAllocation RV150 Pre
AdolescentUniversity All 11 Years toNot
18 Years
ApplicÂ (Child,
7040 Adult)
Other|U.S.InterventioAllocation IP000312
12 Weeks
Post vaccinNational InAll Child, AdulPhase 4 50 NIH InterventioAllocation 010226|01
99 Years
NIH InterventioAllocation 13-0034|H
Biological: MUC-2-KL Memorial SMale 18 Years and
Phase
older
1 Â (Adult, 15
Older
Adult) 99-056|MS
Number ofImmunomic All 18 Years toPhase
63 Years
1 Â (Adult)22 Industry InterventioAllocation ITI PH IC-
To determiWyeth is nAll 2 Months toPhase
9 Years
To provideSanofi Pas All 42 Days to Phase
365 Days
2 Â (Child)580 Industry InterventioAllocation MET39|UTN
Primary: PrUniversity Female 18 Years toPhase
49 Years
4 Â (Adult)40 Other InterventioAllocation CRC306
Pneumococc University All 6 Years to 17
Phase
Years
4 Â (Child) 50 Other InterventioInterventi OVG 2013/
Number ofRobert Scho All 40 Years toPhase
70 Years
2 Â (Adult,46Older
Adult) PRO07030
Phase
older
2 Â (Adult, Older
6 NIHAdult) InterventioAllocation 980139|98
Safety of aUniversity All 18 Years toPhase
60 Years
1 Â (Adult)20 Other|InduInterventioInterventi PEACHI-02
Phase
older
3 Â (Adult,120
Older
Industry
Measure oTufs UniveFemale 18 Years to 26 Years Â (Adult)48 Other ObservatioObservatio 1603045
65 Years
Safety profSanofi Pas All 16 Years and older Â (Child,614 Adult,
Industry
Older Adult)
ObservatioObservatioHAF85|U11
Anti-HPV GMerck ShaFemale 16 Years toPhase
45 Years
3 Â (Child,
1212Adult)
Industry InterventioAllocation V503-004
to 23 Months
3 Â 793
(Child)
the rate o Walvax BioAll 2 Months toPhase
71 Months
3 Â 2760
(Child)
Industry InterventioAllocation 2.22E+10
Incidence oOlogy BiosAll 16 Years and
Phase
older
3 Â (Child,
1146
Adult,
Industry
Older Adult)
InterventioInterventi 881201
To determin Gradalis, InAll 12 Years and
Phase
older
1 Â (Child,100
Adult,
Industry
Older Adult)
InterventioAllocation CL-PTL-101
Biological: Influenza National InAll 18 Years and
Notolder
Applic
Â (Adult,339
Older
PercentageGlaxoSmithFemale Child, Adult, Older Ad 93 Industry ObservatioObservatio205531|V
Toxin NeutEmergent Bi All 18 Years toPhase
50 Years
2 Â (Adult)168 Industry|NInterventioAllocation EBS.AVA.2
Perceived Christiana All 18 Years and
Phase
older
4 Â (Adult,511
Older
Other
Adult) InterventioAllocation DDD# 6020
48 Years
PercentageSanofi All 42 Days to Phase
89 Days3 Â (Child)
1167 Industry InterventioAllocation M5A07
determinatGamaleya R All 18 Years toPhase
60 Years
4 Â (Adult)
2000 Other InterventioAllocation 01 - GamEv
PercentageNational HeFemale 18 Years toPhase
50 Years
GeometricIntercell U All 18 Years toPhase
64 Years
Humoral anUniversity All 19 Years and
Notolder
Applic
Â (Adult, Older
2 Other|Indu
Number and PATH|MinisAll 9 Months toPhase
9 Months
4 Â (Child)
278 Other InterventioInterventi JEV03
18 Years
4 Â (Child,
1344Adult)
Safety of Sidney KimAll 18 Years and
Phase
older
2 Â (Adult, 60
Older
Adult) J0501|P30
Frequency GlaxoSmithAll 50 Years and
Phase
older
2 Â (Adult,410
Older
Industry
The number Fuda CanceAll 18 Years toPhase
75 Years
OtherAdult)InterventioAllocation CLH-001|2
8 Weeks
Immunogeni Crucell Ho All 60 Days to Phase
120 Days
3 Â (Child)131 Industry InterventioAllocation QVX-V-C00
Number ofCairo UniveAll 18 Years toPhase
65 Years
4 Â (Adult,35Older
OtherAdult)InterventioAllocation CairoU
25 Years
Phase
older
3 Â (Adult,
7542
Older
Industry
1M post-dos GlaxoSmithAll 6 Weeks toPhase
10 Weeks
Measles VaIDinsight| All 9 Months and
Not older
ApplicÂ (Child,
1088Adult,
Adult) 4
ProportionPublic HeaAll 2 Months toPhase
3 Months
4 Â (Child)
300 Other InterventioAllocation RSRSG 12-
safety|immFraunhoferAll 18 Years toPhase
49 Years
1 Â (Adult)100 Industry InterventioAllocation FhCMB HAI
To determin National InAll 18 Years to 76 Years Â (Adult,
2351Older
OtherAdult)ObservatioObservatioH1N1-495-
Change in fNational InAll 18 Years toPhase
50 Years
Change froHelsinki UnAll 18 Years toPhase
80 Years
OtherAdult)InterventioAllocation HUCH
Safety of QButantan I All 3 Years to 59
Phase
Years
3 Â (Child,
6018
Adult)
Other InterventioAllocation FLQ-01-IB
Annual num GlaxoSmithFemale Child, Adult, Older Ad 1 Industry Observational 114420
To evaluat Kaiser Per All 70 Years toPhase
79 Years
1|PhÂ (Older
220Adult)
Other|U.S.InterventioAllocation CDC Protoc
Solicited i Sanofi Pas All 42 Days to Phase
89 Days3 Â (Child)
systemic anLanzhou Ins All 2 Months toPhase
55 Years
Industry|OInterventioAllocation MCV4-001
Adult: Per Merck ShaAll 12 MonthsPhase
to 45 Years
1 Â (Child,
150 Industry
Number ofOhio State All 60 Years and
Notolder
Applic
Â (Adult,
2589
Older
Other
Adult) InterventioAllocation 2010H029
Number ofCraig
a L SlinAll 18 Years and
Phase
older
1|Ph
Â (Adult, 62
Older
Other
Adult) InterventioAllocation 15931|ME
PercentageGlaxoSmithAll 12 MonthsPhase
to 15 Months
3 Â5016
(Child)
serologic rHeinrich-HAll up to 17 Years
PhaseÂ 3(Child) 53 Other|InduInterventioAllocation IKAST-01
80 Years
OtherAdult)InterventioAllocation prostate c
Summary of NovaDigm Female
T 18 Years toPhase
50 Years
1|PhÂ (Adult)
188 Industry InterventioAllocation NDV3A-00
% of serumGlaxoSmithAll 15 Years toPhase
19 Years
2 Â (Child,125
Adult)
Anti-HBs aGlaxoSmithAll 50 Years toPhase
70 Years
Industry
Adult)InterventioAllocation 208129/02
Analysis ofCentre Hosp All 75 Years and older Â (Older200Adult)
Other ObservatioObservatioRNI2016-38
61 Years
1 Â (Adult)57 Industry|OInterventioAllocation PRO-PanFl
local pain Catalan InsAll 18 Years toPhase
95 Years
OtherAdult)InterventioAllocation SINGRIP03
PercentageSeqirus|NoAll 18 Years and
Phase
older
3 Â (Adult,540
Older
Industry
ProportionInternatio All 18 Years toPhase
51 Years
1 Â (Adult)48 Other|InduInterventioAllocation IAVI C101
Incidence oID BiomediAll 18 Years toPhase
49 Years
3 Â (Adult)
7400 Industry InterventioAllocation IDB707-10
GeometricJiangsu ProAll 21 MonthsPhase
to 51 Months
2 Â 773
(Child)
Other|InduInterventioAllocation JSVCT005b
InterventioBoston Med All 9 Years to 26
NotYears
Applic
Â (Child,382
Adult)
Other InterventioInterventi H-34561
Immunogeni Medicago All 65 Years and
Phase
older
2 Â (Older
1001
Adult)
Industry InterventioAllocation CP-Q14VLP
Immunogen University All 18 Years toPhase
65 Years
4 Â (Adult,40Older
OtherAdult)InterventioAllocation DKUA-001
GeometricGlaxoSmithAll 18 Years toPhase
55 Years
59 Years
Safety as National InAll 18 Years toPhase
50 Years
Pneumococc GlaxoSmithAll 28 MonthsPhase
to 32 Months
3 Â 524
(Child)
Industry InterventioAllocation 111345 (Mt
Rate of ToxH. Lee MoffAll 18 Years and
Phase
older
1|Ph
Â (Adult, 56
Older
Other
Number ofEmergent BAll 18 Years toPhase
29 Years
One monthGlaxoSmith
a All 6 Weeks toPhase
10 Weeks
Number and Pfizer All 18 Years toPhase
64 Years
1 Â (Adult)456 Industry InterventioAllocation B3451001|
12 Weeks
Early
older
Phas
Â (Adult, 21
Older
Adult) MC1272|NC
Phase
older
2 Â (Adult,
3124
Older
Industry
Anti-CS antGlaxoSmithAll 18 Years toPhase
45 Years
Number ofU.S. Army All 18 Years to 31 Years Â (Adult)
114 U.S. Fed|OObservatioObservatioA-11048|R
Pain respoWomen's Co All 4 Months toNot6 Months
Applic Â (Child)
Safety: To Sanofi Pas All 2 Months and older Â (Child,
3934Adult,
Industry
Older ObservatioObservatioGPF11|UTN
Adult)
63 Years
1 Â (Adult)17 Industry InterventioAllocation PHIB-2013
Safety andUniversity Male 18 Years toPhase
50 Years
Anti-HBs seHenogen|GAll 15 Years and
Phase
older
3 Â (Child,300
Adult,
Industry
Older Adult)
Phase
older
2 Â (Adult, Older
8 Other
Adult) InterventioInterventi VADOVAR
Antibody TGlaxoSmithAll 11 MonthsPhase
to 21 Months
2 Â 244
(Child)
Overall an Memorial SMale 18 Years and
Phase
older
2 Â (Adult, 30
Older
Other
Incidence oMinsk StateAll 18 Years toPhase
65 Years
4 Â (Adult,40Older
OtherAdult)InterventioAllocation HEM-3_2
Safety of Craig L Sli All 18 Years and
Phase
older
1|Ph
Â (Adult, 30
Older
Other|Indu
Solicited s GlaxoSmithAll 12 MonthsPhase
to 18 Months
4 Â 150
(Child)
50 Years
Immune pers GlaxoSmithAll 12 Years toPhase
15 Years
3 Â (Child)143 Industry InterventioAllocation 100386 (E
45 Years
1|Ph
Â (Adult)17 Other InterventioInterventi VAC079
Immunologic University All 18 Years and
Phase
older
1 Â (Adult, 17
Older
Other
Adult) InterventioAllocation 07-0652 /
Safety of 3Wyeth is nAll 18 Years toPhase
40 Years
1|Ph
Â (Adult)60 Industry InterventioAllocation 6108A1-10
To determiDana-FarbeAll 18 Years and
Phase
older
1 Â (Adult, 70
Older
Other
serum bactPublic HeaAll 18 Years toPhase
40 Years
2 Â (Adult)50 Other InterventioAllocation MNB3
Haemaggluti Seqirus All 18 Years toPhase
64 Years
2 Â (Adult)240 Industry InterventioAllocation CSLCT-CAL-
Immune res The Royal All Child, AdulPhase 2 24 Other InterventioAllocation Eudract n
A change i George Was All 18 Years and older Â (Adult, 25
Older
Other
LaboratoryNational InAll Child, Adult, Older Adult NIH ObservatioObservatioRV 283/WR
TBEV Viral National InAll 18 Years toPhase
100 Years
Change in Chang Gung All 3 Years to 80
Phase
Years
1 Â (Child, Adult,
20 Other
Older Adult)
InterventioInterventi ChangGun
17 Weeks
4 Â (Child)
Lot-to-lot GlaxoSmithAll 6 Weeks toPhase
12 Weeks
3 Â (Child)
CharacterizJonsson CoFemale 18 Years and
Phase
older
1 Â (Adult, Older
Adult) CDR000059
Number ofGlaxoSmith
S All 6 Weeks toPhase
10 Weeks
2 Â (Child)
Safety as Sidney KimAll 18 Years toPhase
120 Years
Adult) J0885|P30
Effects of National InAll 18 Years to 65 Years Â (Adult,58Older
NIH Adult)ObservatioObservatio5P01AI571
49 Years
4 Â (Adult)
300 Industry InterventioAllocation MI-MA205
All safety Kirby Inst All 18 Years toPhase
55 Years
1|PhÂ (Adult) 8 Other InterventioAllocation NCHECR-A
GeometricUniversity
m All 18 Years and
Phase
older
1 Â (Adult,353
Older
Other|Indu
Adult) InterventioAllocation UHL 08162
Immunologi University All 16 Years and
Phase
older
2 Â (Child, Adult,
Older Adult) 10M-03-3|
80 Years
OtherAdult)InterventioAllocation breast can
IndependentFred HutchFemale 18 Years toPhase
60 Years
1 Â (Adult)
126 Other|NIHInterventioAllocation IRB-6003|
Best overalAVAX TechnAll Child, AdulPhase 3 387 Industry InterventioAllocation A/100/040
to 18 Months
3 Â1437
(Child)
40 Years
3 Â (Child,
340 Adult)
ProportionJiangsu Pr All 20 Years toNot
70 Years
ApplicÂ (Adult,
342Older
OtherAdult)InterventioAllocation JSVCT061
Mortality Bandim Hea All up to 1 Month
Not Applicable
Â (Child) Other InterventioAllocation 2008-7041
GenerationRadboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)15 Other InterventioAllocation BMGF1|NL4
Maintenanc VanderbiltAll 50 Years and older Â (Adult,510
Older
Other|U.S.ObservatioObservatioSerum
Adult) 200
23 Years
3 Â (Child,
3055 Adult)
ImmediateResearch InAll 18 Years toPhase
50 Years
1 Â (Adult)36 Other InterventioAllocation VPT-I-01/2
Post-vacci UniformedAll 18 Years toPhase
49 Years
4 Â (Adult)
1077 U.S. Fed InterventioAllocation IDCRP-070
Number and Bavarian NFemale 18 Years and
Phase
older
1 Â (Adult, 15
Older
Industry
Adult) InterventioInterventi BNIT-BR-0
80 Years
OtherAdult)InterventioAllocation liver canc
ProportionLondon SchAll 18 Years toNot
64 Years
ApplicÂ (Adult)
156 Other InterventioAllocation txt4flujab
To assess tOlogy BiosAll 18 Years and
Phase
older
1|Ph
Â (Adult,
1000
Older
Industry
SeroconversGlaxoSmithAll 5 Weeks toPhase
10 Weeks
2 Â (Child)
Safety|Imm Instituto All 18 Years toPhase
60 Years
1|PhÂ (Adult)15 Other InterventioInterventi 6889|CNPq
Incidence CureVac A All 18 Years toPhase
40 Years
1 Â (Adult)
101 Industry InterventioAllocation CV-7201-1
Diagnosis oTelethon KAll 14 Years to 18 Years Â (Child,
508 Adult)
Other ObservatioObservatioCVID/2015
18 Years
1|PhÂ (Adult)20 Other InterventioAllocation pancreatic
Biological: Avian Flu Mahidol UnAll 18 Years toPhase
49 Years
1 Â (Adult) Other Interventional GPO AVIAN
Count of PStanford Un All 6 Months toPhase
49 Years
Other|NIHInterventioAllocation SU-31136-
to 15 Months
2 Â1259
(Child)
Phase A: NGlaxoSmithAll 11 MonthsPhase
to 22 Months
3 Â5803
(Child)
To measureNorwegianAll I 15 Years toPhase
16 Years
4 Â (Child)83 Other InterventioInterventi SM07-01
Number ofHelsinki
c UnAll 18 Years toPhase
64 Years
4 Â (Adult)
100 Other InterventioAllocation Ty21a-ASC
Percent of University All 18 Years toNot
75 Years
ApplicÂ (Adult,
1205Older
OtherAdult)InterventioAllocation 14-0402-1
Humoral resGlaxoSmithAll 18 Years toPhase
60 Years
3 Â (Adult)
Changes inFred HutchAll 18 Years and
Phase
older
2 Â (Adult, 11
Older
Other|Indu
Adult) InterventioInterventi CITN-04|N
Comparison Hospital ClAll 18 Years and
Phase
older
1|Ph
Â (Adult, 60
Older
Other
Adult) InterventioAllocation DCV-02/M
Dalhousie Female Child, Adult, Older Ad 504 Other ObservatioObservatio 114141
OccurrenceH. Lee MoffAll up to 21 Years
PhaseÂ 1(Child, Adult)0 Other InterventioInterventi MCC-1718
21 Years
Number ofPurdue UniMale 18 Years toNot
21 Years
ApplicÂ (Adult)24 Other|InduInterventioAllocation 1.51E+09
ProportionCenters fo All 18 Years and
Phase
older
3 Â (Adult,1600
Older
U.S.Adult)
Fed|OInterventioInterventi CDC-IRB-6
Mean changeRutgers, T All 50 Years and
Notolder
Applic
Â (Adult,316
Older
Other|Indu
Serum will Centers fo All up to 48 Hours
Not Applic
Â (Child) 500 U.S. Fed|OInterventioAllocation CDC-NIP-3
Adverse EvPATH|Micro All 18 Years toPhase
49 Years
Safety|Imm ReiThera SrAll 18 Years toPhase
75 Years
1 Â (Adult,72Older
Industry
Adult)InterventioAllocation RSV001|20
Signs and Medigen BiAll 20 Years toPhase
60 Years
1 Â (Adult)36 Industry InterventioAllocation CT-AI-11
ImmediateInstitute All 18 Years toPhase
30 Years
1 Â (Adult)75 Industry|UInterventioAllocation IVAC A/H5
To assess BiondVax PAll 55 Years toPhase
75 Years
Industry
Adult)InterventioAllocation BVX-003
Meningococ GlaxoSmithAll 12 Years toPhase
18 Years
Summary of Sanofi Pas All 18 Years and
Phase
older
Industry
Adult) InterventioAllocation MEL11
64 Years
2 Â (Adult) 444 Industry InterventioAllocation B7471002
persistenc Novartis|NAll 11 Years toPhase
20 Years
Industry InterventioAllocation M14P2E1|I
18 Years
Comparison National InAll 2 Months toPhase
6 Months
1 Â (Child)
60 NIH|IndustInterventioAllocation ACTG 292|11268
55 Years
The prevalCenters fo All Child, AdulPhase 4 4000 U.S. Fed|OInterventioAllocation CDC-NCID-
Symptom Sc HaukelandAll 18 Years toPhase
80 Years
2 Â (Adult, 3Older
OtherAdult)InterventioAllocation 16816 NSD|
Comparison University All 18 Years toPhase
85 Years
1 Â (Adult, 7Older
Adult) 11-0545|N
12 Weeks
Number ofIDRI|MedicAll 18 Years toPhase
49 Years
1 Â (Adult) 105 Other|InduInterventioAllocation IDRI-FPVPX
Safety: Do University All 18 Years and
Phase
older
1|Ph
Â (Adult, 39
Older
Adult) 10464|UVA
Biological: Vero Cell- Ology BiosAll 16 Years and
Phase
older
2|Phase
Â (Child,
3 Adult,
Industry
Older Adult)
Evaluate noNational CaFemale 12 Years toPhase
20 Years
4 Â (Child,
25000Adult)
NIH|OtherInterventioAllocation 999917108
ProportionUniversity All 18 Years toPhase
65 Years
1 Â (Adult,25Older
Other|Indu
Adult)InterventioAllocation PEACHI-03
To assess aNovavax All 18 Years toPhase
49 Years
1 Â (Adult) 150 Industry InterventioAllocation NVX 757.1
Serum BactGlaxoSmithAll 18 Years toPhase
55 Years
50 Years
1 Â (Adult)65 Other InterventioAllocation IAVI S001
Meningococ London SchFemale 18 Years toPhase
40 Years
3 Â (Adult) 200 Other InterventioAllocation SCC 1585
Vaccine-IndAlexey MukAll 18 Years toPhase
55 Years
2 Â (Adult)52 Other|InduInterventioAllocation Pro000197
The primarImmune Res All 5 Years to 17
Phase
Years
1 Â (Child) 12 Industry|OInterventioAllocation IR902-007
SeroprotectGlaxoSmithAll 5 Weeks toPhase
10 Weeks
2 Â (Child) 450 Industry InterventioAllocation 444563/01
Number ofGruppo ItaAll 18 Years toPhase
120 Years
OtherAdult)InterventioAllocation CML 0206|
Anti-MeninGlaxoSmithFemale 9 Years to 25
Phase
Years
3 Â (Child,1300
Adult)
Collection U.S. Army All 18 Years toPhase
50 Years
1 Â (Adult) 0 U.S. Fed|OInterventioInterventi NMRC.2012
50 Years
14 Years
3 Â (Child)1245 Industry InterventioAllocation 104896 (m
49 Years
OccurrenceIDRI|Bill All 18 Years toPhase
60 Years
1 Â (Adult)45 Other InterventioAllocation IDRI-LCVTC
determine Queen
t SaovAll 1 Year to 15 Years Â (Child) 45 Other ObservatioObservatioRC5704
fever Columbia UAll 24 MonthsNotto 59
Applic
Months Â 656 (Child)
Other|U.S.InterventioAllocation AAAK8100
Number ofJanssen
P VaAll 12 MonthsPhase
to 24 Months
1|Ph Â (Child)48 Industry InterventioAllocation CR108465|
Bacille-Cal University All up to 3 DaysNotÂ Applic
(Child) 49 Other InterventioAllocation NR-0138
GeometricNational
45 Years
Adverse EvInstitut Pa All 18 Years toPhase
45 Years
1 Â (Adult)64 Industry InterventioAllocation 2015-060
Safety andNovaDigm All T 18 Years toPhase
50 Years
1 Â (Adult)160 Industry|UInterventioAllocation NDV3-002
Presence oSanaria In All 18 Years toPhase
35 Years
1 Â (Adult)67 Industry|OInterventioAllocation GA1|NL566
45 Years
Number ofSanofi
p Pas All 2 Years to 55 Years Â (Child,100
Adult)
Industry ObservatioObservatioMTA92|U11
Incidence Merck ShaFemale 16 Years toPhase
23 Years
3 Â (Child,
12167 Adult)
64 Years
49 Years
60 Months
1 Â (Child)
Comparison M.D. AnderAll 18 Years andPhase
older
2 Â (Adult, 71
Older
Other
Patient MaM.D. AnderAll 18 Years andPhase
older
1 Â (Adult, 38
Older
Other|Indu
Measuremen Centre for All 6 Weeks toNot8 Weeks
ApplicÂ (Child)22 Other InterventioInterventi HicVac Rot
60 Years
3 Â (Adult)
2256 Industry InterventioAllocation GID23
Number ofGlaxoSmith
s Female 18 Years toPhase
40 Years
Number/Per PATH All 12 MonthsPhase
to 45 Years
1|Ph Â (Child,
304 Other
Adult) InterventioAllocation VAC-010
The receiptThe UniverAll Child, AdulNot Applic 537 Other InterventioAllocation UW15-383
to 15 Months
3 Â1742
(Child)
to 18 Months
3 Â 756
(Child)
To describeState Univ All 18 Years toPhase
60 Years
4 Â (Adult)60 Other|U.S.InterventioAllocation 568085
Titers for GlaxoSmithAll 3 Years to 9Phase
GeometricTakeda
M All 2 Years to 17
Phase
Years
2 Â (Child)
1800 Industry InterventioAllocation DEN-204|P
To developNational InAll 18 Years to 65 Years Â (Adult,
1000Older
NIH Adult)ObservatioObservatio140194|14
HPV vaccinLe BonheurAll 9 Years to 99
NotYears
Applic
Â (Child, Adult,
70 Other
Older Adult)
InterventioInterventi VAC for HP
40 Years
Number ofDuke UniveAll 18 Years andPhase
older
1 Â (Adult, Older
2 Other
To describePfizer All 6 Years to 17
Phase
Years
4 Â (Child)100 Industry InterventioInterventi B1851190|
OccurrenceIDRI|Bill All 18 Years toPhase
60 Years
1 Â (Adult)48 Other InterventioAllocation IDRI-LMVT
To measureUniversity All 12 MonthsNot to 59
Applic
Months Â (Child)
17 Other InterventioInterventi Pfizer-Pre
Change from University All 7 Years to 70
Phase
Years
4 Â (Child,122
Adult,
Other
Older Adult)
InterventioAllocation OVG 2016/
Evaluate h Intercell U All 18 Years toPhase
49 Years
1|PhÂ (Adult)
276 Industry InterventioAllocation IC82-102
safety endBGI, China All 18 Years toNot
75 Years
OtherAdult)InterventioInterventi BGI-002
50 Years
Occurrence, Marcus AltAll 18 Years toPhase
60 Years
1 Â (Adult)20 Other|InduInterventioAllocation PARC001|G
Behavioral: Vaccine National InAll 18 Years andNotolder
Applic
Â (Adult,
4892Older
NIHAdult) InterventioPrimary PuHIVNET D01
GeometricMerck
m ShaAll up to 10 Days
Phase
Â (Child)
2 566 Industry InterventioAllocation V232-056|
Number ofLudwig InsAll 18 Years andPhase
older
1 Â (Adult, 17
Older
Other
Adult) InterventioAllocation LUD2005-0
the first a University All 18 Years andNotolder
Applic
Â (Adult, 90
Older
Other
45 Years
older
2 Â (Adult,354
Older
Industry
older
3 Â (Child,230
Adult,
Industry
Older Adult)
For women: National InFemale 13 Years toPhase
39 Years
2 Â (Child, Adult)
12 Weeks
PCR-derived University All 18 Years toPhase
45 Years
1|Ph
Â (Adult)30 Other InterventioAllocation VAC054|20
Positive anLEO PharmAll 18 Years toPhase
54 Years
2 Â (Adult)
212 Industry InterventioAllocation LP0162-13
To assess tNovavax All 18 Years toPhase
49 Years
2 Â (Adult)
221 Industry InterventioAllocation NVX 755.2
Analysis o National HeAll 18 Years and older Â (Adult,203Older
NIHAdult) ObservatioObservatio090239|09
16 Weeks
3 Â (Child)
Rates of seCenters forAll
Disease Control
6 Months
andto
Phase
Prevention|FundaciÃ³n
24 Months
1|Ph Â (Child)
450 U.S.Dominicana
Fed|OInterventioAllocation
de InfectologÃa,CDC-ISO-4
Santo Domingo, Dominican Re
QuantificatOswaldo CrAll 9 Months to 23 Months Â (Child)60 Other ObservatioObservatioCPqRR - M
the safety Jiangsu ProAll 12 Years toPhase
60 Years
1 Â (Child, Adult)
OccurrenceH. Lee MoffFemale 18 Years and Phase
older
1|Ph
Â (Adult, Older
5 Other
To assess tCedars-SinAll 18 Years and
Phase
older
1 Â (Adult, 35
Older
Other
to 3 Years
3 Â (Child)
ProgressioDartmouth- All 18 Years and
Phase
older
2 Â (Adult, Older
Adult) D0708|R0
to 18 Months
2 Â 391
(Child)
Change froNematollahAll Child, AdulPhase 4 52 Other InterventioAllocation behdasht-
55 Years
1|Ph
Â (Adult)24 NIH InterventioAllocation N01-AI053
Signs and sHIV VaccineAll 18 Years toPhase
45 Years
1 Â (Adult)
184 Other InterventioAllocation HVTN 086/
19 Years
2 Â (Child,
189Adult)
50 Years
2 Â (Child,
100Adult)
Other InterventioAllocation LEISH2b
40 Years
1 Â (Adult)
PercentageNovartis All 6 Weeks toPhase
59 Months
2 Â (Child)
120 Industry InterventioAllocation H01_05TP
Number ofPATH|Beijin
s All up to 14 Days
PhaseÂ (Child)
3 750 Other InterventioAllocation VAC-015
OccurrenceTampere Un Female 16 Years to 19 Years Â (Child,10000Adult)
Other|InduObservatioObservatio115006 (H
Number and Pfizer All 65 Years toPhase
85 Years
59 Years
2 Â (Adult)
126 NIH InterventioAllocation 06-I-0235
Anti Pertu Sanofi All 15 Months to 59 Months Â (Child)
90 Industry ObservatioObservatioNGB00001|
Biological: pGA2/JS2 National InAll 18 Years toPhase
40 Years
1 Â (Adult)30 NIH InterventioMasking: DHVTN 045|10593
Rate of pa University Female 18 Years and Phase
older
2 Â (Adult, 38
Older
Adult) 9760|NCI-
pain respoThe Hospita All 2 Months toPhase
6 Months
4 Â (Child)
120 Other InterventioAllocation 1E+09
Stage1: Se LG Chem All 6 Weeks toPhase
8 Weeks
2|Ph
Â (Child)
1417 Industry InterventioAllocation LG-VCCL00
Immunogeni Sanofi All 42 Days to Phase
84 Days3 Â (Child)
1941 Industry InterventioAllocation P3T06
Phase
older
2 Â (Adult,
3024
Older
Industry
OccurrenceGlaxoSmithAll 1 Year and older Â (Child, 1012
Adult,Industry|OObservatioObservatio
Older Adult) 109737
60 Years
1 Â (Adult)
Acquisitio National InAll 18 Years toPhase
45 Years
2 Â (Adult) 0 NIH|U.S. FInterventioAllocation PAVE 100|10500
Rates of l National InAll 20 Years toPhase
49 Years
Phase
Years
4 Â (Child,
1200
Adult,
Industry
Older Adult)
InterventioMasking: NB1851140|
49 Years
Number ofPatrick
p Ot All 18 Years and
Phase
older
1 Â (Adult, 15
Older
Other|Indu
Frequency Valneva
o AuAll 18 Years toPhase
45 Years
1 Â (Adult)
120 Industry InterventioAllocation VLA1553-1
Rate of pa University All 18 Years and older Â (Adult,111Older
Other
Adult) ObservatioObservatioRECHMPL1
Biological: Rabies vacMahidol UnAll 12 MonthsPhase
to 18 Months
2 Â 200
(Child)
Other InterventioAllocation M49P2
Incidence rVaccitech LAll 18 Years and
Phase
older
2 Â (Adult,
6000
Older
Industry
To elicit a University All 18 Years toPhase
45 Years
2 Â (Adult)
150 Other|InduInterventioAllocation HP-000596
Titers for GlaxoSmithAll 6 Months toPhase
17 Years
3 Â (Child)
GeometricAssistance All 18 Years toPhase
49 Years
2 Â (Adult)60 Other InterventioAllocation P130903
PercentageChongqingAll 18 Years toPhase
65 Years
2 Â (Adult,
360Older
Adult) 71006.01
50 Years
2 Â (Adult)
Measles - Interactiv All 6 Weeks toNot
12 Weeks
Applic Â (Child)
655 Other InterventioAllocation IRD_IRB_2
EffectiveneNational InAll 18 Years to 75 Years Â (Adult,
3518Older
OtherAdult)ObservatioTime PerspAH1N1-483
Safety (locNational InAll 18 Years toPhase
50 Years
HPV Immun National CaFemale 12 Years to 20 Years Â (Child,
376 Adult)
NIH ObservatioObservatio999912021
50 Years
1 Â (Adult)48 Other InterventioAllocation G001
PSA doubliDavid M LuMale 18 Years toPhase
90 Years
2 Â (Adult,66Older
Adult) 201705744
45 Years
ApplicÂ (Adult)48 Other|InduInterventioAllocation CRC305A
35 Years
1 Â (Adult) 2 Industry InterventioAllocation H-249-004
Phase
older
3 Â (Adult,112
Older
Industry
PercentagePfizer All 3 Months toPhase
6 Months
4 Â (Child)
RecruitmenDesmond Tu All 12 Years to 17 Years Â (Child)
1400 Other|InduObservatioObservatio35384|CT.
ImmunogenicSeqirus All 65 Years and
Phase
older
3 Â (Older
1778
Adult)
influenza vUniversity All 18 Years toPhase
49 Years
4 Â (Adult)20 Other InterventioInterventi IRB-30000
Summary of National CaAll 18 Years toPhase
99 Years
1 Â (Adult,19Older
Assess eff Bristol-My All 18 Years toPhase
65 Years
1 Â (Adult,80Older
Industry
Adult)InterventioAllocation IM101-049
Incidence National I All 18 Years toPhase
65 Years
1 Â (Adult,90Older
NIH|Other|
Adult)InterventioAllocation RV 422
Safety andMemorial SAll 18 Years and
Phase
older
1 Â (Adult, Older
Adult) 07-100|MS
Phase
older
3 Â (Adult,120
Older
Industry
To assess tOlogy BiosAll 6 Months toPhase
17 Years
1|PhÂ (Child)
400 Industry InterventioAllocation 820903|EU
Number ofCraig L Sli All 18 Years and
Phase
older
1|Ph
Â (Adult, 48
Older
Other
Measure plaHIV VaccinAll 18 Years and older Â (Adult,209
Older
Other
Adult) ObservatioObservatioHVTN 802
ProportionMuhimbili A Ull 18 Years toPhase
45 Years
1|PhÂ (Adult)20 Other|U.S.InterventioInterventi HIVIS 06
OccurrenceBavarian NAll 55 Years and
Phase
older
1 Â (Adult, Older
0 Industry
Adult) InterventioAllocation RSV-MVA-0
Developmen Columbia UAll 18 Years and
Phase
older
1|Ph
Â (Adult, 16
Older
Other|Indu
Adult) InterventioInterventi AAAB8413|
Immunogeni Solvay Bio All 18 Years and
Phase
older
3 Â (Adult,120
Older
Industry
Numbers an Novavax All 60 Years and
Phase
older
3 Â (Adult,
11850
Older
Industry
Endpoint: GlaxoSmithAll 6 Weeks toPhase
12 Weeks
2 Â (Child)
60 Years
4 Â (Adult)
The rate o Liquidia TeAll 18 Years and
Phase
older
1|Ph
Â (Adult,152
Older
Adult) LIQC10-00
Dose-limit Jonsson CoAll 18 Years and
Phase
older
1 Â (Adult, Older
Adult) CDR000058
PercentageBiogen All 18 Years toPhase
55 Years
2 Â (Adult)71 Industry InterventioAllocation 109MS307
Immunogeni Seqirus All 12 MonthsPhase
to 7 Years
3 Â (Child)
1601 Industry InterventioAllocation V118_05E3
to 17 Years
3 Â (Child)
toxicity|R Southern CFemale 18 Years toPhase
85 Years
1 Â (Adult,25Older
OtherAdult)InterventioAllocation QI-Breast
immune reMemorial SAll 18 Years and
Phase
older
1 Â (Adult, 45
Older
Adult) 99-023|CD
HIV-specifiNational InAll 18 Years toPhase
50 Years
antibody riTuen Mun A Hll 18 Years and
Phase
older
4 Â (Adult, 90
Older
Other
Adult) InterventioAllocation NTWC/CRE
The proporCorporacion All 18 Years and
Notolder
Applic
Â (Adult,200
Older
Other
Adult) InterventioInterventi HMT2
TabulationNational CaAll 18 Years and
Phase
older
1 Â (Adult, 10
Older
NIHAdult) InterventioInterventi 100138|10
Phase
older
3 Â (Adult,
1707
Older
Industry
Feasibilit VanderbiltAll 5 Years to 11
Phase
Years
4 Â (Child) 40 Other|U.S.InterventioAllocation IIV4/LAIV4
Specific h Institut N All 18 Years toPhase
60 Years
2 Â (Adult)
120 Other|InduInterventioInterventi C09-32|20
OccurrenceGlaxoSmithAll up to 1824 Days Â (Child) 5394 Industry ObservatioObservatio 116929
older
3 Â (Adult,100
Older
Industry
Evaluate s National InAll 18 Years toPhase
70 Years
1 Â (Adult,50Older
7 Months
2 Â (Child)
301 Industry|OInterventioAllocation 112899|20
10 Months
3 Â (Child)
Number ofSanofi
S Pas All 7 Years to 17 Years Â (Child)334 Industry ObservatioObservatioCYD59|U11
older
3 Â (Adult,137
Older
Industry
T Cell ImmThe Univers All 18 Years and older Â (Adult, 15 Older
Other
Adult) ObservatioObservatioKOPA-H1N1
Rate of Su Valneva AuAll 2 Months to Phase
17 Years
3 Â (Child)100 Industry InterventioAllocation IC51-322
Safety of Anne Marga All 18 Years toPhase
70 Years
1 Â (Adult,39Older
OtherAdult)InterventioAllocation 2015/692|
Disease re University Male 18 Years andPhase
older
2 Â (Adult, 13
Older
Adult) 9845|UCCR
DetermineInternatio All 2 Years to 5Not
Years
Applic
Anti-measlGlaxoSmithAll 7 Years andPhase
996 Industry
Older Adult)
HemagglutinJiangsu ProAll 3 Years to 90
Phase
Years
2 Â (Child,
2200Adult,
Other|Indu
Older Adult)
The proportSteven DeekAll 18 Years toPhase
65 Years
1|Ph
Â (Adult,60Older
Other|NIH|
Adult)InterventioAllocation DAIDS-ES
Most effecJonsson CoAll 18 Years toPhase
70 Years
2 Â (Adult,60Older
HI antibodSinovac BioAll 3 Years to 11
Phase
Years
2 Â (Child) Industry|OInterventioAllocation PRO-sPanFlu-2002
SCR (SerocValneva AuAll 18 Years andPhase
older
3 Â (Adult,867
Older
Industry
Adult) InterventioAllocation IC51-301
ProportionFrench NatAll 18 Years andPhase
older
2 Â (Adult,212
Older
Other|Indu
Adult) InterventioAllocation ANRS 114
Kinetics o MedImmune All 18 Years toPhase
65 Years
2 Â (Adult,31Older
Industry
Adult)InterventioAllocation D153 P004
HemagglutinShanghai InAll 18 Years toPhase
60 Years
2 Â (Adult)480 Industry InterventioAllocation SIBP-2009
Number ofBrigham anAll 66 Years andNotolder
Applic
Â (Older
228000 Adult)
Other|U.S.InterventioAllocation 2014-P-00
Safety and National CaAll 18 Years toPhase
100 Years
Efficacy o Genocea BiAll 18 Years toPhase
55 Years
2 Â (Adult)98 Industry InterventioAllocation GEN-004-0
22 Years
GeometricGlaxoSmithAll 6 Months to Phase
35 Months
3 Â 3317
(Child)
50 Years
1 Â (Adult)91 Other|NIHInterventioAllocation EBL01|201
Local and McMaster AUll 18 Years toPhase
55 Years
1 Â (Adult)24 Other InterventioAllocation REB 09-00
ELISA for Centers fo All 50 Years toPhase
64 Years
1 Â (Adult)30 U.S. Fed|OInterventioAllocation CDC-NIP-3
Number ofGlaxoSmithAll 6 Months and older Â (Child,1060 Adult,
Industry
Adult) 207737
Changes FroNational CaMale 18 Years toPhase
100 Years
85 Years
Industry
Adult)InterventioAllocation GID25
safety|Eff University All 18 Years andPhase
older
1 Â (Adult, Older
0 Other
Safety/tol Vaccibody Female 18 Years andPhase
older
1|Ph
Â (Adult, 34
Older
Industry
Adult) InterventioAllocation VB C-01
ProportionPfizer All 50 Years toPhase
85 Years
Industry
Adult)InterventioAllocation B5091002
SeroconversGlaxoSmithAll 11 MonthsPhase
to 22 Months
3 Â 330
(Child)
Time to OcGlaxoSmithAll 6 Weeks toPhase
12 Weeks
2 Â (Child)
ProportionGlaxoSmithAll 12 Months to 27 Months Â2413 (Child)
Number ofMount SinaAll 18 Years toPhase
60 Years
3 Â (Adult)468 Other|InduInterventioAllocation CRT113936
PercentageNovartis All 6 Weeks toPhase
45 Years
Industry InterventioAllocation H01_02TP
35 Months
3 Â12046
(Child)
Serum HemagGlaxoSmithAll 17 MonthsPhase
to 48 Months
3 Â 470
(Child)
SeroconversChina NatioAll 3 Months to Phase
3 Months
4 Â (Child)
702 Industry|OInterventioAllocation sIPV/DTaP-
Evaluate T University All 18 Years andPhase
older
1|Ph
Â (Adult, 23
Older
Adult) 6658|NCI-
Oral rotav London SchFemale 16 Years and older Â (Child,200 Adult,
Other|U.S.ObservatioObservatioQA919
Older Adult)
2-fold ris Region SkaAll 18 Years and
Phase
older
4 Â (Adult,300
Older
Other
Adult) InterventioAllocation IPS-BOOST
Safety (lo VaxInnate All 18 Years toPhase
49 Years
1 Â (Adult)60 Industry|OInterventioAllocation VAX102-01
GeometricMerck ShaFemale 16 Years toPhase
26 Years
35 Years
1 Â (Adult) 0 Industry InterventioAllocation H-249-005
Number ofBeijing MinAll 2 Months toPhase
5 Years
3 Â (Child)
1560 Industry InterventioAllocation 2014L0021
12 Weeks
40 Years
Safety|Im Medicago|H All 18 Years toPhase
60 Years
1 Â (Adult)100 Industry|OInterventioAllocation CP-H7VLP-
Rate of subValneva AuAll 18 Years toPhase
49 Years
1 Â (Adult)67 Industry InterventioAllocation VLA1601-1
Number ofYale UniverAll 18 Years toPhase
90 Years
Other Adult)InterventioAllocation 1.51E+09
Presyncope|Duke UniveAll 11 Years toNot
21 Years
ApplicÂ (Child,
1820Adult)
Grade 3 orIrsiCaixa|FAll 18 Years toPhase
60 Years
1 Â (Adult)48 Other InterventioAllocation ChAd-MVA.
Compare vacThe New YoAll 18 Years and
Notolder
Applic
Â (Adult,
4000
Older
Other
Adult) InterventioAllocation 091603|D
Phase
older
2 Â (Adult,385
Older
Industry
Safety of Henan Canc All 18 Years toPhase
70 Years
1 Â (Adult,30Older
Other Adult)InterventioInterventi HN2019NI
12 Weeks
Phase
older
3 Â (Child,160
Adult,
Other
Older Adult)
InterventioAllocation 12-195C
The NeutraEmergent BAll 28 Years and
Phase
older
2 Â (Adult,357
Older
Industry
Change in Massachuse All 18 Years toPhase
65 Years
Other Adult)InterventioAllocation 18114
Comparison Galena BioFemale 18 Years and
Phase
older
3 Â (Adult,758
Older
Industry
Adult) InterventioAllocation NeuVaxâ„¢
15 Years
to 13 Months
3 Â 521
(Child)
Number ofSanofi|PRAAll 18 Years toPhase
48 Years
63 Years
Industry InterventioAllocation DEN-303
Anti-Prote GlaxoSmithAll 51 Years toPhase
73 Years
1 Â (Adult,81Older
Industry
Number ofDuke UniveAll 18 Years and
Phase
older
1 Â (Adult, 12
Older
Other|Indu
The primarMannkind All 18 Years and
Phase
older
1|Ph
Â (Adult, 19
Older
Industry
Adult) InterventioInterventi CDR000006
1.VariationUniversity All 18 Years and
Phase
older
4 Â (Adult,100
Older
Other
Adult) InterventioAllocation 04 MICV AI
The Number Crucell Ho All 18 Years toPhase
55 Years
1 Â (Adult)25 Industry|OInterventioAllocation CR100965|
Number ofJanssen VacAll 18 Years toPhase
50 Years
1|PhÂ (Adult)
393 Industry|NInterventioAllocation CR106152|
Number ofInstitut N All 20 Years toPhase
45 Years
1 Â (Adult)66 Other InterventioAllocation C12-18 AM
To determiImmunoVacc All 18 Years and
Phase
older
1 Â (Adult, 23
Older
Industry
Adult) InterventioAllocation ONC-DPX-0
Frequency National
55 Years
PSA responNational CaMale 18 Years and
Phase
older
2 Â (Adult, 86
Older
Vaccinatio University All 18 Years toPhase
80 Years
1 Â (Adult,45Older
Other|Indu
Adult and PATH All up to 40 Years
Phase
Â 1|Ph
(Child, Adult)
Number ofGlaxoSmithAll up to 7 Days
Phase
Â (Child)
2 480 Industry|OInterventioAllocation 111315
Inter-houseStanford UAll up to 59 Months
Not Applic
Â (Child)1828 Other InterventioAllocation 31546
PercentageSeqirus|NoAll 18 Years and
Phase
older
3 Â (Adult,539
Older
Industry
45 Years
Immunogen Imperial C All 18 Years toPhase
45 Years
1 Â (Adult)30 Other InterventioAllocation CRO2049|2
49 Years
1|PhÂ (Adult)
140 U.S. Fed|I InterventioAllocation S-14-13|W
to 23 Months
3 Â1000
(Child)
Incidence oNovavax|BiFemale 18 Years toPhase
40 Years
3 Â (Adult)
4636 Industry|OInterventioAllocation RSV-M-301
40 Years
PercentageChongqingAll 18 Years toPhase
65 Years
2 Â (Adult,
378Older
Adult) 71006.04
The occurrGlaxoSmithAll 18 Years toPhase
25 Years
40 Years
SeroprotecThe UniverAll 21 Years and
Phase
older
2|Ph
Â (Adult, 94
Older
Other
Adult) InterventioAllocation UW 11-209
Immunogeni Murdoch Ch Female 12 Years to 26 Years Â (Child,37Adult)
Other ObservatioObservatioHPV girls
12 Weeks
2 Â (Child)
Molecular University All 18 Years and
Phase
older
2 Â (Adult, 23
Older
Other|Indu
Adult) InterventioAllocation RHMCAN070
Integrated Michigan SAll 18 Years and older Â (Adult, 60
Older
Other
Adult) ObservatioObservatio15-1029F
PercentageLG Life Sci All 12 MonthsPhase
to 15 Months
3 Â 122
(Child)
Industry InterventioAllocation LG-VHCL00
Efficacy o University All 18 Years toPhase
45 Years
Safety and NewLink Ge Male 19 Years and
Phase
older
1|Ph
Â (Adult, Older
8 Industry
Adult) InterventioAllocation NLG0103|3
Solicited a GlaxoSmithFemale 18 Years toPhase
30 Years
2 Â (Adult)
12 Weeks
3 Â (Child)
Phase
older
2 Â (Adult,548
Older
Industry
Adult) InterventioAllocation FUF16|UTN
Adverse Eve PowderMeAll 18 Years toPhase
50 Years
1 Â (Adult)48 Industry InterventioAllocation PM HBV-00
Incidence oMerck SharFemale 18 Years to 45 Years Â (Adult)
54516 Industry|OObservatioObservatioV501-033|
PercentageMerck SharAll 18 Years toPhase
65 Years
1 Â (Adult,39Older
Adult) V920-002|N
Immune resp U.S. Army All 18 Years toPhase
65 Years
2 Â (Adult,
1316Older
U.S. Fed
Adult)InterventioAllocation A-13205
Immunogeni Telethon KFemale 18 Years to 45 Years Â (Adult)50 Other ObservatioObservatioIRB 1515
50 Years
1 Â (Adult)33 Other|InduInterventioAllocation PEACHI-04
HospitalizaUniversity All 6 Weeks toPhase
12 Weeks
4 Â (Child)
7204 Other|InduInterventioInterventi RB 06.117
Measuremen GlaxoSmithAll 18 Years and
Phase
older
4 Â (Adult,280
Older
Industry
50 Years
1 Â (Adult)
144 NIH InterventioAllocation HVTN 060|10057
Number ofPauline
a VeMale 18 Years toPhase
49 Years
1 Â (Adult)45 Other InterventioAllocation NVI-256A|
to 24 Months
2 Â 312
(Child)
5 Years
4 Â (Child)32 Industry InterventioAllocation GRC40
Rate of Td Children's All 18 Years and
Early
older
Phas
Â (Adult,149
Older
Other
Cytokine l Bandim Hea All 4 Months toPhase
9 Months
4 Â (Child)
400 Other|InduInterventioAllocation NOVO-262
AssessmentUniversity All 18 Years toPhase
45 Years
1 Â (Adult) 8 Other InterventioInterventi VAC077
ProportionsPfizer All 65 Years toPhase
85 Years
Therapeutic Amvac Kf.Female 18 Years toPhase
55 Years
3 Â (Adult)
240 Industry InterventioAllocation LATVAC 1-
Biological: recombinaNational CaAll 18 Years and
Phase
older
1 Â (Adult, 12
Older
NIHAdult) InterventioInterventi CDR000006
Levels of Sri EdupugAll 18 Years to 24 Years Â (Adult)74 Other|InduObservatioTime PerspIRB000073
PercentageGlaxoSmithAll 6 Months to 64 Years Â (Child,
414Adult)
Industry|OObservatioObservatio 201598
50 Years
1 Â (Adult)75 Other|InduInterventioAllocation IAVI B004
Safety and Hebei YandAll 18 Years toNot
70 Years
OtherAdult)InterventioInterventi IDH1
17 Years
3 Â (Child)
The Immune National UAll 21 Years toPhase
90 Years
4 Â (Adult,
240Older
Other|Indu
40 Years
anti-HBs tiUniversity All 18 Years to 60 Years Â (Adult)
300 Other|InduObservatioObservatioREB16-027
PathologicSidney KimAll 18 Years toPhase
100 Years
Other|Indu
Adult)
Adverse EvPowderMeAll 18 Years toPhase
50 Years
1 Â (Adult)36 Industry InterventioAllocation PJ HSV-001
To determin Tata Memor Female 18 Years and
Notolder
Applic
Â (Adult,
1000
Older
Other
Safety andNovavax All 18 Years toPhase
40 Years
1|PhÂ (Adult)
230 Industry InterventioAllocation H5N1 VLP-
Serum AntiUniversity All 10 Years toPhase
16 Years
4 Â (Child)
359 Other InterventioAllocation H13-00049
50 Years
1 Â (Adult)48 Other InterventioAllocation MERS001
SeroprotecHadassah M All 20 Years toPhase
95 Years
1|Ph
Â (Adult,
200Older
OtherAdult)InterventioAllocation 16-05.08.
1 month afGlaxoSmithAll 8 Weeks toPhase
16 Weeks
Evaluate e University All 19 MonthsNot andApplic
older Â (Child,
31567Adult,
Older Adult) 10-0823|1
43 Years
1|Ph
Â (Adult)82 NIH InterventioAllocation DAIT ADVN
Years3Â (Child) 119 Industry InterventioInterventi JEC22|U11
Safety: evaNational InAll 18 Years toPhase
49 Years
60 Years
WillingnesUniversity Male 18 Years to 59 Years Â (Adult)609 Other|InduObservatioObservatioMerck-558
St. MichaelFemale Child, Adult, Older Ad 150 Other ObservatioObservatio06-190
Frequency National I All 18 Years toPhase
50 Years
1 Â (Adult) 0 NIH|OtherInterventioAllocation HVTN 099|11782
50 Years
1 Â (Adult) 0 U.S. Fed InterventioAllocation S-14-03|F
The nature,University All 18 Years toPhase
55 Years
1 Â (Adult)40 Other InterventioAllocation OXTREC 71
45 Years
1 Â (Adult)150 NIH|OtherInterventioAllocation 999907051
Frequency National
o InAll 18 Years andPhase
older
2 Â (Adult, Older
0 NIHAdult) InterventioAllocation 06-0069
Time to PSKael-GemVax Male 18 Years andPhase
older
2 Â (Adult, 54
Older
Adult) CDR000055
Change in tCenters fo All 6 Weeks toPhase
6 Weeks
4 Â (Child)456 U.S. Fed|OInterventioAllocation PR-14114
Rate of Fi GlaxoSmithAll 6 Weeks toPhase
17 Months
3 Â 15459
(Child)Industry|OInterventioAllocation 110021|20
Number ofMayo ClinicMale 18 Years andPhase
older
2 Â (Adult, Older
Adult) MC0554|0
Microneutra National InAll 18 Years andPhase
older
2 Â (Adult,300
Older
Safety, wit Craig L Sli All 18 Years andPhase
older
1 Â (Adult, 53
Older
Other|NIH|
Safety andDana-FarbeAll 18 Years andPhase
older
1 Â (Adult, 30
Older
Adult) 04-126|R2
17 Years
rate of im University All 18 Years andPhase
older
3 Â (Adult,276
Older
Other|Indu
50 Years
1 Â (Adult)28 Other InterventioAllocation HAV001
ProgressionSouthwestAll 18 Years andPhase
older
2 Â (Adult, 19
Older
Adult) CDR00003
MTD of DCBaylor Col All 18 Years andPhase
older
1 Â (Adult, 43
Older
Other
40 Years
Antibody aUniversity All 19 Years toEarly
65 Years
PhasÂ (Adult,
124Older
Adult) HIV PPV23
Number and Sanofi All 18 Years toPhase
50 Years
SeroconverThe UniverAll 18 Years toPhase
30 Years
3 Â (Adult)160 Other InterventioAllocation UW 14-016
protective Soroka UniAll 18 Years andNotolder
Applic
Â (Adult, 75
Older
Other
Adult) InterventioAllocation sor026511c
51 Years
50 Years
Number ofNational I All 18 Years toPhase
60 Years
2 Â (Adult)400 NIH|IndustInterventioAllocation VRC 704
GeometricPfizer All 2 Years andPhase
251 Industry
Older Adult)
InterventioAllocation 6115A1-30
PercentageMerck ShaAll 12 MonthsPhase
to 23 Months
3 Â1412
(Child)
ProportionInternationAll 18 Years toPhase
45 Years
2 Â (Adult)32 Other|InduInterventioAllocation CH-PR-02
Frequency Institute
a o All 6 Weeks toPhase
8 Weeks
3 Â (Child)360 Other|InduInterventioInterventi VX-2017.0
to 63 Months
2 Â 382
(Child)
Industry InterventioAllocation V59P5E1|2
45 Years
The primarAdimmuneAll 6 Months to Phase
18 Years
Industry InterventioAllocation FLU10T11B
To evaluat PT Bio Far All 6 Weeks toPhase
11 Weeks
3 Â (Child)540 Industry InterventioAllocation Penta BS18
GMTs (Geom Valneva AuAll 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation VLA15-201
vaccine sa University Male 18 Years toPhase
50 Years
1|PhÂ (Adult)40 Other|InduInterventioAllocation HIV-CORE0
Number ofNational I All 18 Years toPhase
50 Years
1 Â (Adult)30 NIH|IndustInterventioAllocation VRC 313
Immunogeni Internatio All 18 Years toPhase
45 Years
2 Â (Adult)
1015 Other InterventioAllocation PR-12030
Non-accideBandim Hea All up to 72 Hours
PhaseÂ 4(Child) 2332 Other InterventioAllocation BCG15050
Afer each GlaxoSmithAll 6 Weeks toPhase
12 Weeks
18 Years
Immunogeni Crucell Ho All 6 Months to Phase
35 Months
3 Â 1356
(Child)
Industry InterventioAllocation TG0826INF
Vaccine effFraser HeaAll 65 Years and older Â (Older 1000
Adult)
Safety of Vaxil TheraAll 18 Years andPhase
older
1|Ph
Â (Adult, 15
Older
Industry
Adult) InterventioAllocation VAXIL-001
older
2 Â (Adult, 45
Older
Industry
4 Years
4 Â (Child)
10000 Industry InterventioAllocation JEC17|U11
Safety: advNational InAll 18 Years toPhase
60 Years
64 Years
2 Â (Adult)140 Industry|OInterventioAllocation BioMed 05
Safety (locInternationAll 18 Years toPhase
50 Years
1 Â (Adult)56 Other InterventioAllocation IAVI B001
Immune res Inge MarieAll 18 Years andPhase
older
1|Ph
Â (Adult, 48
Older
Other
Adult) InterventioInterventi MPN19H2
Assess the Uppsala Uni Male 18 Years andPhase
older
1|Ph
Â (Adult, 15
Older
Other|Indu
Adult) InterventioAllocation pVAX/rhPS
OccurrenceBavarian NAll 18 Years toPhase
65 Years
1 Â (Adult,63Older
Industry
Adult)InterventioAllocation RSV-MVA-0
PercentageFundacionMale 18 Years toPhase
36 Years
4 Â (Adult)158 Other|InduInterventioInterventi GESIDA100
PercentageNational I All up to 14 Weeks
PhaseÂ2 (Child) 202 NIH InterventioAllocation P1072|106
Incidence Roswell ParFemale 18 Years andPhase
older
1|Ph
Â (Adult, 18
Older
Adult) i 60417|N
antibody r Region SkaAll 18 Years andNotolder
Applic
Â (Adult,300
Older
Other
Adult) InterventioAllocation 2011/341|V
Objective Zhejiang P All 18 Years toPhase
70 Years
1 Â (Adult,20Older
Other|Indu
Adult)InterventioInterventi INEO-P-00
Evaluate thMilton S. All 18 Years andNotolder
Applic
Â (Adult, Older
0 Other
Adult) InterventioInterventi PSHCI 08-
To measureBaylor Col All 18 Years andPhase
older
1 Â (Adult, Older
6 Other
Adult) InterventioInterventi 19747-PRI
To determiNational CaAll 18 Years toPhase
120 Years
Number ofJhpiego|JoAll Child, Adult, Older Ad 43 Other|InduObservatioObservatioIRB000075
efficacy of University All 18 Years toPhase
45 Years
Incidence Pfizer All 18 Years andPhase
older
1 Â (Adult, 97
Older
Industry
Adult) InterventioInterventi C3621001|
25 Years
3 Â (Child,
18729Adult)
Number ofMerck ShaAll 12 MonthsPhase
to 15 Months
3 Â1027
(Child)
Cell-mediaAVAX TechnAll Child, AdulPhase 1|Ph 6 Industry InterventioAllocation A/100/060
Solicited a EnimmuneAll 6 Months to Phase
6 Years
2 Â (Child)122 Industry InterventioAllocation EV-RB1401
nasal IgA rLondon SchAll 24 MonthsPhase
to 59 Months
4 Â 365
(Child)
Other InterventioAllocation SCC 1502
DetermineHadassah M All 18 Years andPhase
older
2 Â (Adult, 15
Older
Other|Indu
Adult) InterventioAllocation 191203-HMO-CTIL
Drug: AMA1-C1/Alhydr National InAll 2 Years to 3Phase
Years1|Ph
Â (Child) 900 NIH InterventioPrimary Pu999906081
Anti-diphthGlaxoSmithAll 6 Years to 8Phase
Matched VE McGill UniAll 8 Weeks to 3 Years Â (Child)374 Other|InduObservatioObservatioMCH-ID-11
69 Days3 Â (Child)454 Industry InterventioAllocation 114260|20
Immune resp Centers fo All 6 Weeks toPhase
6 Weeks
4 Â (Child)
Frequency National
40 Years
Anti-hepatGlaxoSmithAll 18 Years toPhase
40 Years
Safety|Imm PaxVax, IncAll 18 Years toPhase
50 Years
1 Â (Adult)66 Industry InterventioAllocation PXVX-VC-0
Optimal doJonsson CoAll 18 Years andPhase
older
1|Ph
Â (Adult, 28
Older
Adult) CDR000006
Percentage,GlaxoSmithAll 65 Years andPhase
older
1 Â (Older Adult)
Safety (in Swiss TropAll 5 Years to 45
Phase
Years
1 Â (Child, Adult)
50 Other|InduInterventioAllocation PMAL03
69 Years
3 Â (Adult,64Older
Other|Indu
Adult)InterventioAllocation 08-0189-A
to 15 Months
2 Â 657
(Child)
12 Weeks
2 Â (Child) 409 Industry InterventioAllocation 792014/00
Safety|antJonsson CoAll 18 Years andPhase
older
1|Ph
Â (Adult, Older
Adult) CDR000006
PrevalenceUniversity Female 16 Years toPhase
39 Years
3 Â (Child, 210
Adult)
Other InterventioAllocation 2-Nov-05
98 Days2 Â (Child) 46 Industry InterventioAllocation 6108K2-20
The primary University All 6 Months to Not
17Applic
Years Â (Child)
50 Years
1 Â (Adult) 164 Industry InterventioAllocation CR106479|
Number ofGlaxoSmithAll 12 Weeks to Phase
16 Weeks
4 Â (Child)
10 Weeks
Highest GrPATH All 1 Year to 40Phase
Years1|Ph
Â (Child, 248
Adult)
Other InterventioAllocation VAC-040
17 Years
ApplicÂ (Child)48 Other|NIHInterventioAllocation 1R01CA20
Measure ofInstitut N All 18 Years andNotolder
Applic
Â (Adult,500
Older
Other|Indu
Adult) InterventioInterventi C12-57|20
45 Years
PercentageWyeth is nAll 2 Months to Phase
6 Months
3 Â (Child)
Safety andWashington Male 18 Years andPhase
older
1 Â (Adult, 20
Older
Other|Indu
To evaluateUniversity All 18 Years andPhase
older
1 Â (Adult, Older
0 Other
Adult) InterventioAllocation 806693|UP
DetermineInternatio
i All 1 Year to 45Phase
Years1|Ph
Â (Child,1016
Adult)
Toxicity of Sidney KimFemale 18 Years andPhase
older
1 Â (Adult, 60
Older
Adult) J0085 CDR
Occurrence, GlaxoSmithAll 40 Years toPhase
80 Years
1 Â (Adult,30Older
Industry
Receipt of Kaiser Per All 19 Years toNot
64 Years
ApplicÂ (Adult)
Summary of Sanofi All 510 Days toPhase
578 Days
3 Â (Child) 458 Industry InterventioAllocation A3L16
Immune res University All 60 Years andNotolder
Applic
Â (Adult, 21
Older
Other
Post-chall U.S. Army All 18 Years toPhase
45 Years
1|PhÂ (Adult)
113 U.S. Fed InterventioAllocation NMRC.2006
older
2 Â (Adult,208
Older
Industry
Immunogeni Sanofi All 18 Years toPhase
40 Years
The primary DynPort VaAll 18 Years toPhase
55 Years
3 Â (Adult) 0 Industry InterventioAllocation rBV A/B-03
55 Years
adverse evLigoCyte P All 18 Years toPhase
50 Years
1 Â (Adult)61 Industry InterventioAllocation LV01-102
10 Weeks
64 Years
2 Â (Adult) 980 NIH InterventioAllocation 13-0033|H
36 Months
4 Â (Child)
to 14 Months
3 Â 468
(Child)
Booster ef Statens SerAll 15 MonthsPhase
to 18 Months
3 Â 666
(Child)
Other|InduInterventioInterventi VIPV-07 E1
Change froUniversity Male 18 Years toNot
55 Years
ApplicÂ (Adult)30 Other InterventioAllocation CRC306B
Response rCIPRA SA|Na All up to 10 Weeks
Not Applic
Â (Child) 579 Other|NIHInterventioAllocation CIPRA-SA P
Improving Carilion C All 18 Years toNot
110Applic
Years Â (Adult,
2509 Older
Other|Indu
Adult)
InterventioInterventi Clark_Mer
Cytotoxic TCraig L Sli Female 18 Years toPhase
120 Years
2 Â (Adult,6 Older
Adult) 10134|UVA
Evaluate c Michael A.All 50 Years and older Â (Adult, 19 Older
Other
Adult) ObservatioObservatioMMvax-pil
ProportionGreen CrosAll up to 4 Weeks
PhaseÂ 3(Child) 750 Industry InterventioAllocation GC3107_P
50 Years
1 Â (Adult)35 Other|NIHInterventioAllocation VAC044
50 Years
local AEs Centers fo All 18 Years toPhase
61 Years
4 Â (Adult)1560 U.S. Fed|OInterventioAllocation CDC-NCID-
SeroprotecBritish Col All 6 Months to Phase
23 Months
3 Â (Child)
262 Other InterventioAllocation PHAC 6273
Local and European M Male 18 Years toPhase
45 Years
1 Â (Adult)56 Other|InduInterventioAllocation AMA-1_1_0
Incidence oNational InAll 18 Years toPhase
35 Years
1 Â (Adult) 477 NIH InterventioAllocation 999918084
Immunogeni GlaxoSmithAll 18 Years toPhase
49 Years
Biological: Group C Pfizer All 2 Months toPhase
6 Months
3 Â (Child)
serotype-spNabi BiophAll 18 Years and
Phase
older
3 Â (Adult, 99
Older
Industry
Adult) InterventioAllocation Nabi-1372
Percentage2A PharmaAll 18 Years toPhase
45 Years
1 Â (Adult)20 Industry InterventioAllocation 2AP01-01|
Safety: In U.S. Army All 12 MonthsPhase
to 50 Years
2 Â (Child,
636 U.S.
Adult)
Fed|I InterventioAllocation A-14040|W
To evaluateLaval Univ All 8 Years to 10
Phase
Years
4 Â (Child)1129 Other InterventioAllocation HBV-257 ex
Features oCraig L Sli All 18 Years toPhase
120 Years
Adult) 13498|R01
AcceptabilMCM VacciAll 46 Days to Phase
89 Days
Adverse EvGreen CrosAll 19 Years toPhase
64 Years
1 Â (Adult)20 Industry InterventioInterventi GC3107_P
PercentagePfizer All 3 Months to 23 Months Â (Child)
100 Industry ObservatioObservatio0887X1-45
55 Years
HemagglutinBanner HeaAll 50 Years toPhase
64 Years
4 Â (Adult) 100 Other|InduInterventioAllocation Flu Vaccine
Safety(pro EuBiologicsMale 20 Years and
Phase
older
1 Â (Adult, 20
Older
Adult) UBC101
Evaluation University All 18 Years and
Phase
older
1|Ph
Â (Adult, 50
Older
Adult) 7425|NCI-
24 Years
1 Â (Adult) 158 Industry InterventioAllocation V502-002|
PercentageBiogen All 18 Years toPhase
60 Years
4 Â (Adult)60 Industry InterventioAllocation 101MS404
Measure ofVaccitech All 18 Years toEarly
50 Years
PhasÂ (Adult) 6 Industry|OInterventioInterventi FLU008
Mean Numbe Indiana UniAll 18 Years and
Notolder
Applic
Â (Adult,
1747
Older
Adult) 0205-04|R
Serum IgG Novavax
a All 60 Years and
Phase
older
2 Â (Adult,1330
Older
Industry
HaemagglutiSinovac BioAll 18 Years toPhase
60 Years
4 Â (Adult) 566 Industry InterventioAllocation PRO-INF-4
Incidence oTD VaccineAll 18 Years toPhase
50 Years
Safety of Queen ElizAll 18 Years toPhase
64 Years
4 Â (Adult)10 Other InterventioAllocation qeii
PercentageMerck ShaAll 6 Weeks toPhase
12 Weeks
2 Â (Child)1152 Industry InterventioAllocation V114-003
PercentageDynavax TeAll 40 Years toPhase
70 Years
Industry
Adult)InterventioAllocation DV2-HBV-1
PercentagePfizer All up to 40 Years
586 Industry InterventioAllocation C1091002
DetermineHawaii BiotAll 18 Years toPhase
45 Years
1 Â (Adult)25 Industry InterventioAllocation HBV-002-C
ProgressionGynecologiFemale 18 Years and
Phase
older
2 Â (Adult,171
Older
Adult) GOG-0255|
Tumor-specSidney KimAll 18 Years toPhase
70 Years
Adult) J0115|P30
Efficacy a University All 18 Years toPhase
45 Years
23 Years
2 Â (Child, 129
Adult)
ReactogeniShanghai I All 12 Years and
Phase
older
1|Ph
Â (Child,360
Adult,
Older Adult) 2016L0990
49 Years
1 Â (Adult) 245 NIH InterventioAllocation 10-0017|N
Number ofSanofi
60 Years
1|PhÂ (Adult)
572 Industry InterventioAllocation VYF01|U11
Adverse evMymetics CFemale 18 Years toPhase
45 Years
1 Â (Adult)24 Industry|OInterventioAllocation MYM-V101-
To evaluateGlaxoSmithAll 18 Years toPhase
45 Years
1|PhÂ (Adult)
Drug: THERATOPEÂ® vOncothyreoFemale 18 Years and
Phase
older
2 Â (Adult, Older
Industry
Adult) InterventioPrimary PuSTn-BR-10
Safety - O U.S. Army All 18 Years toPhase
45 Years
Biological: Cold-adaptNational I All 5 Years to 17
Phase
Years
1|Ph
Â (Child)300 NIH InterventioAllocation P1057|10612|PACTG P1057
The impactUniversity All up to 18 Years Â (Child, Adult)
2260 Other ObservatioObservatio224/T-3
GeometricGlaxoSmithFemale 9 Years to 17
Phase
Years
Safety|Im Memorial SAll 18 Years toPhase
120 Years
Other|NIH|
Adult)
InterventioInterventi 06-085|P3
Serum conceSormland CAll 18 Years and
Phase
older
2|Ph
Â (Adult,200
Older
Other
Adult) InterventioAllocation 2011/4-31
To collect Dana-FarbeAll 18 Years and
Phase
older
1 Â (Adult, 65
Older
Other
The occurreGlaxoSmithAll 5 Months toPhase
17 Months
2 Â 1500
(Child)
28 Years
3 Â (Adult)229 Industry InterventioInterventi MENACWY-T
Biological: Varicella VNational I All 2 Years to 18
Phase
Years
1 Â (Child, Adult)
60 NIH InterventioMasking: NPACTG 391|10614|ACTG 391
Adverse eve National InAll 2 Years to 9Phase
Years1|Ph
Â (Child) 157 NIH InterventioAllocation 04-077
10 Weeks
Safety andSeqirus All 18 Years toPhase
64 Years
2 Â (Adult)400 Industry InterventioAllocation CSLCT-PAN
older
1 Â (Adult, 80
Older
Industry
Adult) InterventioInterventi V212-013|
Participan Virginia C Female 18 Years toPhase
45 Years
2|Ph
Â (Adult)82 Other InterventioAllocation 94-078
59 Years
4 Â (Adult)
1600 Industry InterventioAllocation FST00002|
Anti-CHIKVPaxVax, IncAll 18 Years toPhase
45 Years
2 Â (Adult)415 Industry InterventioAllocation PXVX-CV-3
50 Years
Incidence Istituto Sc All 18 Years andPhase
older
2 Â (Adult, 51
Older
Other
VZV ELISPOT Merck ShaAll 60 Years andPhase
older
2 Â (Adult,180
Older
Industry
Dose limitiVBI VaccineAll 18 Years toPhase
70 Years
1|Ph
Â (Adult,38Older
Industry
Adult)InterventioAllocation VBI-1901-
Change froNational InAll 18 Years toEarly
64 Years
PhasÂ (Adult)40 NIH|OtherInterventioAllocation DAIT ADRN
Significant National InAll 18 Years to 49 Years Â (Adult)10 NIH ObservatioObservatio130020|13
Immunogen Internatio All 6 Weeks toPhase
6 Weeks
4 Â (Child)
To provideSanofi Pas All 12 MonthsPhase
to 15 Years
3 Â (Child)
720 Industry InterventioAllocation HAF78
Evaluation Protein Sc All 65 Years andPhase
older
3 Â (Older870
Adult)
Industry InterventioAllocation PSC03
PercentageAssistance All 75 Years andPhase
older
3 Â (Older140
Adult)
Other InterventioAllocation P050601
Safety as Washington Female 18 Years andPhase
older
1 Â (Adult, 46
Older
Adult) 20140710
Safety(PhasKinki Univ All 20 Years toPhase
80 Years
1 Â (Adult, 9Older
Safety andBaylor ResAll 21 Years toPhase
75 Years
1|Ph
Â (Adult,30Older
OtherAdult)InterventioInterventi 005-065-0
Safety andSeqirus All 18 Years toPhase
45 Years
1 Â (Adult)400 Industry InterventioAllocation CSLCT-PAN
Immuno-viro French NatAll 18 Years toPhase
55 Years
Varicella-z Seoul NatioAll 50 Years andNotolder
Applic
Â (Adult, 60
Older
Other
Adult) InterventioAllocation H1511046
Number ofImperial C All 18 Years toPhase
45 Years
1 Â (Adult)14 Other InterventioAllocation X001
Safety andValneva AuAll 18 Years andPhase
older
3 Â (Adult,
2675
Older
Industry
50 Years
1 Â (Adult)75 Industry InterventioAllocation PM FLP-00
older
3 Â (Adult,
4561
Older
Industry
Safety andNewLink Ge All 21 Years toPhase
65 Years
1|Ph
Â (Adult,54Older
Adult) NLG0101|0
Incidence NantBioSciAll 18 Years andPhase
older
1 Â (Adult, 16
Older
Industry
65 Years
1|Ph
Â (Adult,
115Older
OtherAdult)InterventioAllocation CCER 14-2
Serotype OUniversity All 40 Years andPhase
older
3 Â (Adult,181
Older
Adult) 477|U10H
Reduce burd US Departm All 60 Years andPhase
older
3 Â (Adult,
38456
Older
U.S.Adult)
Fed|I InterventioAllocation 403
The number World HealAll 5 Months to 48 Months Â15800 (Child)
Other ObservatioObservatioRTSS MVIP
303 Industry
Older Adult)
InterventioInterventi 6115A1-30
9 Months
2 Â (Child)
PercentagePfizer All 18 Years andPhase
older
3 Â (Adult,
3921
Older
Industry
Safety andSidney KimFemale 18 Years toPhase
120 Years
1|PhÂ (Adult,
16 Older
Adult) J0323 CDR
AssessmentNovavax All 60 Years andPhase
older
1 Â (Adult,220
Older
Industry
Adult) InterventioAllocation NVX757.10
Memory resp Leiden UniAll 18 Years toPhase
50 Years
2 Â (Adult)30 Other InterventioAllocation R5
Safety|Imm Mark Hathe All up to 96 Hours
PhaseÂ 2(Child) 248 Other InterventioAllocation G1100570/
PercentageUniversity All 20 Years to 23 Years Â (Adult)134 Other ObservatioObservatioOVG 2011/
Influenza St. AntoniuAll 18 Years andNotolder
Applic
Â (Adult, 98
Older
Other
45 Years
3 Â (Adult)
Part A: Nu PATH All 18 Years toPhase
50 Years
1|Ph
Â (Adult)81 Other InterventioAllocation VAC 006
Occurrence,GlaxoSmithMale 18 Years toPhase
40 Years
to 15 Months
3 Â4538
(Child)
Antibody tiJN-InternaAll 18 Years to 55 Years Â (Adult)50 Industry ObservatioObservatioJN-NM-002
Immune res Stanford UnAll 6 Months and older Â (Child, 555Adult,
OtherOlder ObservatioObservatioSU-111420
Adult)
Number ofPHAC/CIHRAll 18 Years and older Â (Adult,
7645Older
Other|Indu
Adult) ObservatioObservatiopcirn-surv
ImmunogenicGlaxoSmithAll Child, AdulPhase 3 996 Industry InterventioAllocation 100478
Percent of U.S. Army All 18 Years and
Phase
older
2 Â (Adult,
2000Older
U.S.Adult)
Fed|I InterventioAllocation WRAIR 749
Safety andVaxGen|Nati All 18 Years toPhase
55 Years
2 Â (Adult)480 Industry|NInterventioAllocation VAX006
Biological: HER-2/ne University Female 18 Years and older Â (Adult, OlderOther
Adult) Expanded Access 25914
Change in National CaMale 18 Years and
Phase
older
2 Â (Adult, 32
Older
OccurrenceGlaxoSmithAll 6 Months toPhase
9 Years
3 Â (Child)
VaccinationUniversity All up to 7 Days Â (Child) 384 Other ObservatioObservatio2019-A003
40 Years
1 Â (Adult)48 Industry InterventioAllocation 6108A1-10
Number ofChristopheAll 16 Years and
Notolder
Applic
Â (Child,
10597Adult,
Other
Older Adult)
InterventioAllocation 001|HP 14
CD8 T cell AssistanceAll 18 Years toPhase
45 Years
1|Ph
Â (Adult)60 Other InterventioAllocation P120201|2
Immunologi University All 18 Years to 65 Years Â (Adult, 0Older
OtherAdult)ObservatioObservatioPCV13HIV-
To assess National CaAll 12 Years toPhase
26 Years
NIH InterventioAllocation 090024|09
HemagglutiGlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,110
Older
Industry
Number ofBiondVax PAll 50 Years toPhase
65 Years
2 Â (Adult,37Older
Industry
Adult)InterventioAllocation BVX-006
cellular TBMedical UnAll 18 Years and
Phase
older
4 Â (Adult, 67
Older
Other
Adult) InterventioAllocation FSME low-r
To assess University All 18 Years and
Phase
older
1 Â (Adult, 72
Older
Other
incidence oZhejiang P All 1 Year to 15 Years Â (Child) 394 Other ObservatioObservatioZJCDC2016
Safety|Imm European MaAll 18 Years toPhase
45 Years
1 Â (Adult)30 Other InterventioAllocation EudraCT:
to 14 Months
2 Â1851
(Child)
Anti-Human GlaxoSmithFemale 20 Years toPhase
60 Years
12 Weeks
3 Â (Child)
Frequency National
50 Years
Levels of Sanofi Pas All 10 Years toPhase
17 Years
2 Â (Child)
Frequency SahlgrenskAll
o 18 Years and older Â (Adult, OlderOther
Adult) ObservatioObservatioALFGBG-14
Incidence Valneva AuAll 17 Years and older Â (Child,
20000Adult,
Industry
Older Adult)
ObservatioObservatioIC51-401
Vaccine preUniversity All 18 Years toPhase
50 Years
1|Ph
Â (Adult)55 Other InterventioAllocation MAL 034
percentageAssistanceAll 18 Years toPhase
55 Years
3 Â (Adult)99 Other|InduInterventioAllocation P050706
Antibody tiCenter for All 6 Weeks toPhase
13 Weeks
3 Â (Child)
10020 Other InterventioAllocation HNCDC-00
25 Years
Overall SurNational CaMale 18 Years and
Phase
older
2 Â (Adult, 10
Older
Serum conceSormland CAll 18 Years and
Phase
older
2|Ph
Â (Adult,250
Older
Other
Adult) InterventioAllocation 2011/4-31/
Safety|Hum Inovio PhaAll 18 Years toPhase
50 Years
1 Â (Adult)22 Industry InterventioInterventi FLU-002
Tetanus antKorea UnivAll 50 Years and
Phase
older
4 Â (Adult,462
Older
Other
Adult) InterventioAllocation 2013GR00
Number ofBiontech
A RAll 18 Years and
Phase
older
1 Â (Adult,115
Older
Industry
Adult) InterventioInterventi RB_0003-0
Cohorts 1, Dana-FarbeAll 18 Years and
Phase
older
1 Â (Adult, 46
Older
Other|Indu
cellular imMedical UnAll 18 Years toPhase
99 Years
4 Â (Adult,60Older
OtherAdult)InterventioAllocation IX-sensesc
HemagglutinRadboud Un All 18 Years and
Notolder
Applic
Â (Adult, 30
Older
Other
Number ofMedigen Va All 2 Months toPhase
6 Years
3 Â (Child)
3200 Industry InterventioAllocation CT-EV-31
safety and Memorial SAll Child, AdulPhase 1 19 Other|NIHInterventioAllocation 03-007|P3
Recurrent InmunotekAll 12 MonthsPhase
to 36 Months
3 Â 120
(Child)
Industry|OInterventioAllocation MV130-SLG
Safety/tol Duke Univ All 18 Years and
Phase
Older
Other|Indu
Adverse eve IDRI|Bill All 18 Years toPhase
40 Years
2 Â (Adult)60 Other InterventioAllocation IDRI-LCVPX
25 Years
Number ofGenocea BiAll 18 Years toPhase
50 Years
1|Ph
Â (Adult)
143 Industry InterventioAllocation GEN-003-0
120 Days
3 Â (Child)807 Industry InterventioAllocation A5I15
Number ofM.D. AnderAll 18 Years and
Phase
3 Other|Indu
Safety: Gr University All 18 Years toPhase
79 Years
1 Â (Adult,22Older
Adult) 6346|NCI-
Safety of t U.S. Army All 18 Years toPhase
35 Years
2 Â (Adult)255 U.S. Fed|I InterventioAllocation A-13399|1
35 Years
Maximum M T .D. AnderAll 18 Years and
Phase
older1|Ph
Â (Adult, Older
2 Other
Adult) InterventioAllocation DM99-412
PercentageGlaxoSmithAll 25 Years and
Phase
Older
Industry
SeropositivPfizer All 3 Years to 18
Phase
Years
4 Â (Child,375
Adult)
12 Weeks
Number and Herlev HosAll 18 Years toPhase
120 Years
OtherAdult)InterventioInterventi AA1833
Drug: MSP1(42)-FVO National InAll 18 Years toPhase
50 Years
1 Â (Adult) 0 NIH InterventioPrimary Pu999904216
Number ofFrank Lieb All 18 Years and
Phase
older1|Ph
Â (Adult, 22
Older
Other|Indu
Adult) InterventioInterventi 05-115|NI
Pre and posNational InAll 65 Years and
Phase
older4 Â (Older100Adult)
NIH InterventioAllocation AG0055
PercentageMitsubishiAll 11 Years toPhase
12 Years
3 Â (Child)446 Industry|OInterventioAllocation BKD1A
Toxicities FukushimaAll 20 Years toPhase
80 Years
1 Â (Adult, 6Older
At M7: AntiGlaxoSmithAll up to 7 Days
Phase
Â (Child)
Short-termThe UniverAll 15 Years toPhase
26 Years
Other InterventioAllocation 19-0058|R
50 Years
1 Â (Adult)50 NIH|OtherInterventioAllocation AGS-v PLU
4 Years2 Â (Child)
1320 Industry|OInterventioAllocation 114174|20
B and T ce University All 18 Years toNot
55 Years
ApplicÂ (Adult)60 Other|NIHInterventioAllocation 13-2405|R
60 Years
Industry|OInterventioAllocation JEC13|U11
Antibody CGlaxoSmithFemale 18 Years toPhase
45 Years
Primary toxUniversity All 18 Years toPhase
80 Years
1 Â (Adult,59Older
OtherAdult)InterventioAllocation UPCC 1340
Demonstrat GlaxoSmithFemale 10 Years toPhase
14 Years
3 Â (Child)
clincal hepCenters fo All 2 Years to 40
NotYears
Applic
Â (Child,
1500
Adult)
U.S. Fed|OInterventioAllocation CDC-NCID-
49 Years
3 Â (Adult)
1739 Industry InterventioAllocation B7471008
GeometricSanofi Pas All 15 MonthsPhase
to 18 Months
3 Â 881
(Child)
Industry InterventioAllocation A3L21
Tolerabili Statens Se All 18 Years toPhase
50 Years
1 Â (Adult)18 Other InterventioAllocation HIV-BIS N
Number ofVaxInnate All 18 Years toPhase
49 Years
1|Ph
Â (Adult)60 Industry InterventioAllocation VAX102-09
Information Sanofi Pas All 40 Years toPhase
75 Years
Industry
Toxicity|I Rockefelle Male 18 Years and
Phase
older1|Ph
Â (Adult, 13
Older
Other
Adult) InterventioInterventi RDA-0537
The Rate ofGenexine, Female 19 Years toPhase
50 Years
2 Â (Adult)72 Industry InterventioAllocation GX-188E_C
OccurrenceGlaxoSmithAll 18 Years and
Phase
Older
Industry
The rate ofUniversity Female 27 Years to 45 Years Â (Adult)
2800 Other|InduObservatioObservatioC2018001F
safety|ImmMemorial SAll 18 Years and
Phase
Older
Other
Phase
Older
Other
PhaseYears
Number ofIndiana
P UniFemale 18 Years and
Phase
older3 Â (Adult,
2031
Older
Adult) 0601-09|R
Immune res Marker TheFemale 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation FRV-002
RecurrenceSanofi Pas All 18 Years toPhase
85 Years
Industry
The incide LongeveronAll 65 Years toPhase
90 Years
1|Ph
Â (Older83 Adult)
Industry InterventioAllocation 00-0000-0
Adverse eve IDRI|Bill All 18 Years toPhase
40 Years
1 Â (Adult)12 Other InterventioAllocation IDRI-LCVPX
SerologicalHelmholtz All 65 Years to 80 Years Â (Older 200Adult)
Safety andMerck ShaAll 18 Years toPhase
50 Years
16 Weeks
Phase
Older
Industry
GeometricNational
70 Years
Number ofCenters fo All 14 Years and
Notolder
Applic
Â (Child,
1962
Adult,
U.S.Older
Adult) 6721
Percent of Merck ShaAll 12 MonthsPhase
to 23 Months
3 Â1200
(Child)
12 Weeks
ProportionThe ClevelaAll Child, AdulNot Applic 800 Other InterventioAllocation IRB 7370
Proliferati Wake Forest All 18 Years and older Â (Adult, 55 Older
Adult)
Phase
older3 Â (Adult,
4048
Older
Industry
Number ofAbramson FCemale 18 Years and
Phase
older1|Ph
Â (Adult, 29
Older
Other
Adult) InterventioAllocation UPCC 2981
Adverse EvBaylor Col All 18 Years toPhase
75 Years
1 Â (Adult, 2Older
OtherAdult)InterventioInterventi H-30087 TA
Phase
Older
Industry
To evaluateWyeth is nAll 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation 6112K2-10
DLT assessNouscom SAll 18 Years toPhase
85 Years
1 Â (Adult,34Older
Industry
Adult)InterventioAllocation NOUS-209-
CHIKV seruNational InAll 18 Years toPhase
45 Years
Immunogeni Medigen Va All 20 Years toPhase
70 Years
2 Â (Adult,54Older
Industry
Adult)InterventioAllocation CT-DV-21
the Response to Pneumo University All 60 Years and older Â (Adult, 45 Older
Other
Adult) ObservatioObservatio 2.01E+08
Incidence oHospices CiAll 18 Years and
Notolder
Applic
Â (Adult,541
Older
Other
Adult) InterventioInterventi 2013.814|
SeroprotecGlaxoSmithAll 6 Weeks toPhase
8 Weeks3 Â (Child)140 Industry InterventioAllocation 217744/06
40 Years
Safety andSeqirus All 6 Months toPhase
8 Years
2 Â (Child)220 Industry InterventioAllocation CSLCT-PAN
OccurrenceLimmaTechAll 18 Years toPhase
50 Years
1 Â (Adult)30 Industry|OInterventioAllocation SF2A-1
Pneumococc Pfizer All 50 Years and
Phase
Older
Industry
Adult) InterventioAllocation 6115A1-30
Type-specifNabi BiophAll 18 Years and
Phase
Older
Industry
1. To dete Prof. Eliza All up to 6 Months Â (Child) 93 Other ObservatioObservatioP13UK
Event RateSanofi Pas All 7 Years to 16 Years Â (Child)3203 Industry ObservatioObservatioCYD57|U11
Safety of i University All Child, AdulPhase 1 12 Other InterventioInterventi Cyntax
Number ofNational InAll 1 Year and Phase
Adult,NIH|OtherInterventioAllocation
Older Adult) C15-33|PR
Local inje Statens Se All 18 Years toPhase
45 Years
1 Â (Adult)66 Other InterventioAllocation CHLM-02
Duration|Sa National InAll 18 Years toPhase
50 Years
The antibod Sanofi All 41 Months to 43 Months Â 455 (Child)
Industry ObservatioObservatioA3L26|UTN
Phase
Older
Industry
Anti-HA anAbbott BiolAll 18 Years and
Phase
older3 Â (Adult,
3138
Older
Industry
Vaccinia viNational InAll 18 Years and older Â (Adult, 69 Older
Clinical Ef BiondVax PAll 50 Years and
Phase
older3 Â (Adult,
12463Older
Industry
Adult) InterventioAllocation BVX-010
Response rGlaxoSmithAll 65 Years and
Phase
Adult)
ProportionEuroVacc FAll 18 Years toPhase
45 Years
1 Â (Adult)72 Other InterventioAllocation EV06
Adverse Eve Research InAll 18 Years toPhase
50 Years
1 Â (Adult)36 Other InterventioAllocation VIT-I-01/2
Cluster of Centre HosAll 18 Years toNot
85 Years
OtherAdult)InterventioInterventi P/2013/17
Anti-HAV tiSinovac BioAll 12 MonthsPhase
to 10 Years
4 Â (Child)
400 Industry InterventioAllocation PRO-HA-400
Other: Observation HIV VaccineAll Child, Adult, Older Ad 54 Other|NIHObservatioObservatioHVTN 403|
Positive f Boston VA A Rll 18 Years and
Phase
older
2 Â (Adult, 38
Older
Other
Adult) InterventioAllocation IRB 1831
Biological: TBC-3B VaNational InAll 18 Years toPhase
60 Years
1 Â (Adult)18 NIH InterventioMasking: DAVEG 014A|10561|AVEG 014A
objective Affiliated All 18 Years and
Phase
older
1|Ph
Â (Adult, 30
Older
Other
Adult) InterventioInterventi 307-CTC-D
Antibody tiLeiden UniAll 18 Years and older Â (Adult,104
Older
Other
Adult) ObservatioObservatioP09.187
52 Years
To determiGradalis, InFemale 18 Years and
Phase
older
2 Â (Adult, 44
Older
Industry
12 Weeks
2 Â (Child)
Frequency ModernaTX,
a All 18 Years toPhase
49 Years
1 Â (Adult)
120 Industry|UInterventioAllocation mRNA-189
N AntibodyU.S. Army All 18 Years toPhase
45 Years
2 Â (Adult)86 U.S. Fed|I InterventioAllocation WRAIR 115
Frequency National
50 Years
55 Years
Safety andSeqirus All 65 Years and
Phase
older
2 Â (Older200
Adult)
Industry InterventioAllocation CSLCT-PAN
SeroconversPan AmericMale 6 Weeks toNot
2 Months
Applic Â (Child)
HD-TIV compVanderbiltAll 18 Years and
Phase
older
2 Â (Adult,138
Older
Other
Adult) InterventioAllocation VICC BMT
PercentageSanofi Pas Female Child, Adult, Older Ad 214 Industry ObservatioObservatioDNG16
Frequency National
40 Years
1|PhÂ (Adult)
Evaluate s PaxVax, In All 18 Years toPhase
35 Years
1 Â (Adult)25 Industry|UInterventioAllocation PXVX-AD-0
ProgressionNational CaAll 18 Years and
Phase
older
2 Â (Adult, 70
Older
ProportionCentre for All 6 Weeks to 15 Weeks Â (Child)
420 Other|NIHObservatioObservatioROVAS 01|
80 Years
2 Â (Adult,
145Older
Industry
45 Years
1|PhÂ (Adult)
HospitalizaInsight Th All 65 Years and older Â (Older1100
Adult)
Other|InduObservatioObservatioINSI-20180
GeometricNational
64 Years
2 Â (Adult)
Frequency National
40 Years
1 Â (Adult)80 NIH InterventioAllocation 04-059|N0
Adverse PrTeva PharmFemale 17 Years to 50 Years Â (Child, Adult)
0 Industry|UObservatioTime PerspDR-501-40
8 Years
2 Â (Child)
Biological: Varicella VNational I All 12 MonthsPhase
to 8 Years
1 Â (Child)
127 NIH InterventioPrimary PuPACTG 265|10613|ACTG 265
Study 1 - PKEMRI-WellAll 24 MonthsPhase
to 36 Months
1 Â 100
(Child)
Other InterventioInterventi KEMRI_CT_
65 Years
1 Â (Adult,36Older
Adult) 201606
Adverse eveNational InAll 18 Years and
Phase
older
1|Ph
Â (Adult, 35
Older
Number ofVirginia C Female 18 Years toPhase
35 Years
1 Â (Adult) 0 Other|InduInterventioInterventi HM200048
Number ofVaxInnate All 65 Years and
Phase
older
2 Â (Older120
Adult)
Industry InterventioInterventi VAX125-02
70 Years
1 Â (Adult,64Older
Industry
Adult)InterventioAllocation V710-002
Herpes ZosThe UniverAll 18 Years toPhase
60 Years
2|PhÂ (Adult)
100 Other InterventioAllocation HKU 11-17
The number Astellas P All 18 Years and
Phase
older
4 Â (Adult, 43
Older
Industry
Adult) InterventioAllocation 0485-CL-0
Number ofGlaxoSmith
s All 6 Weeks toPhase
9 Weeks
3 Â (Child) 0 Industry InterventioInterventi 201124|20
21 days afGlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,660
Older
Industry
Adult) InterventioAllocation IDB-200-0
Incidence GlaxoSmithAll up to 1 Year Â (Child) 390659 Industry ObservatioObservatio 112229
Number ofOlogy BiosAll 18 Years and
Phase
older
3 Â (Adult,550
Older
Industry
Incidence Pevion BioAll 18 Years toPhase
45 Years
1 Â (Adult)30 Industry InterventioAllocation PHEPC001
OccurrenceGlaxoSmithAll 14 Weeks to 5 Years Â (Child)
643 Industry ObservatioObservatio 111426
PrevalenceGlobal All All 12 Years and older Â (Child,460
Adult,
Other|Indu
Older Adult)
ObservatioObservatioHPV Study
Phase
older
2 Â (Adult,692
Older
Industry
*Safety evaAfrican MaAll 18 Years toPhase
55 Years
1 Â (Adult)40 Other InterventioAllocation AMA1_02_
Safety andVaxGen All 18 Years toPhase
34 Years
1|PhÂ (Adult)
150 Industry InterventioAllocation VAX012
Number ofSanofi
P Pas All 56 Years andPhase
older
1|Ph
Â (Adult,216
Older
Industry
Adult) InterventioAllocation MTA29
Number ofSanofi
p Pas All 10 Years andPhase
older
1|Ph
Â (Child,
1365Adult,
Industry
Older Adult)
InterventioAllocation ADC01|U11
Solicited BiomedicalAll 18 Years andPhase
older
2 Â (Adult,305
Older
U.S.Adult)
Fed|I InterventioAllocation BP-C-1700
To determiWyeth is nAll 42 Days to Phase
100 Days
to 12 Months
1 Â 360
(Child)
Industry InterventioAllocation MET32
antibody raHospices CiAll 65 Years andPhase
older
Other InterventioInterventi 2010.621
PercentagePfizer All Child, AdulPhase 3 184 Industry InterventioAllocation MENACWY-T
Number ofLondon SchAll 1 Year and older Â (Child, Adult,
630 Other|Indu
Older Adult)
ObservatioObservatioVAC52150E
Rate of Su Valneva AuAll 2 Months to Phase
18 Years
3 Â (Child,
1869Adult)
Industry InterventioAllocation IC51-323
Is the inf The ClevelaAll 18 Years toPhase
65 Years
4 Â (Adult,36Older
OtherAdult)InterventioAllocation 4675|RPC
Frequency U.S. Army All 18 Years toPhase
65 Years
U.S. Fed
22 Years
Safety and PepTcell Li Male 18 Years toPhase
40 Years
1 Â (Adult)48 Industry InterventioAllocation FLU-v-001
Measure seWilliam PoAll 3 Years to 5Phase
Years2Â (Child) 280 Other InterventioAllocation PCVFU927
Immunogeni PATH|InstiAll 6 Months to Phase
71 Months
2 Â (Child)
296 Other|U.S.InterventioAllocation MF59-TIV-
49 Years
Objective Sir Run Ru All 18 Years toPhase
75 Years
1 Â (Adult,30Older
Other|Indu
Adult)InterventioInterventi INEO-P-00
55 Years
40 Years
Biological: rgp120/H National InAll 18 Years toPhase
60 Years
1 Â (Adult)40 NIH InterventioMasking: DAVEG 011
70 Years
Industry
CMV events City of HopAll 18 Years toPhase
75 Years
Adult) 13494|NCI
To assess U.S. Army All 18 Years toPhase
45 Years
1|Ph
Â (Adult)
104 U.S. Fed|I InterventioAllocation WRAIR 103
EvaluationStatens Se Female 18 Years toPhase
45 Years
1 Â (Adult)35 Other InterventioAllocation CHLM-01
vaccinatio University All 24 Weeks to 28 Weeks Â (Child) 20 Other ObservatioObservatio368/2019
Change in iJohns HopkFemale 13 Years to 45 Years Â (Child,800Adult)
Other|InduObservatioObservatioR01ES0269
Number ofVU UniversAll 18 Years andPhase
older
1 Â (Adult, 15
Older
Other
55 Years
17 Years
3 Â (Child)400 Industry InterventioAllocation DEN-315|U
The HPV-16National CaFemale 9 Years to 25
Phase
Years
3 Â (Child,
1240Adult)
NIH InterventioAllocation 999919009
ProportionOlivera FinMale 18 Years andPhase
older
1 Â (Adult, 14
Older
Other|Indu
Antibody sNational InFemale 11 Years toPhase
12 Years
4 Â (Child) 0 Other InterventioAllocation LIS144|20
Frequency University All 18 Years andPhase
older
3 Â (Adult, Older
4 Other
Adult) InterventioAllocation 2011/04B
To determiUniversity All 18 Years andPhase
older
2 Â (Adult, 24
Older
Other|Indu
Adult) InterventioAllocation 15232B
Frequency Dalhousie
65 Years
1 Â (Adult,40Older
Other|Indu
Adult)InterventioAllocation CI1401
25 Years
1 mth afe GlaxoSmithAll 11 MonthsPhase
to 18 Months
2 Â 689
(Child)
Frequency Seqirus
a All 6 Months to Phase
17 Years
4 Â (Child)
Rectal tempWyeth is nAll 56 Days to Phase
112 Days
ImmediateBaylor Col All 18 Years toPhase
45 Years
Pneumococc Wyeth is nAll 60 Years toPhase
64 Years
DetermineOttawa
t HosAll 18 Years andPhase
older
1 Â (Adult, 24
Older
Other
Adult) InterventioInterventi 20160855-
Solicited Green CrosAll 19 Years toPhase
64 Years
2 Â (Adult)213 Industry InterventioAllocation GC3111_P
Patient indUniversity Female 16 Years toPhase
26 Years
Other|InduInterventioInterventi 518236
To assess tBeth Israe All 18 Years andPhase
older
1|Ph
Â (Adult, 40
Older
Other|Indu
40 Years
Number ofImmunoVacc Female 18 Years andPhase
older
1 Â (Adult, 19
Older
Industry
Adult) InterventioAllocation ONC-DPX-S
Increase inEvidation All 18 Years toNot
65 Years
ApplicÂ (Adult,
77983Older
Adult) EH-002
Number ofOlogy BiosAll 18 Years andPhase
older
3 Â (Adult,110
Older
Industry
Receipt of Columbia UAll 18 Years andNotolder
Applic
Â (Adult,
1000
Older
Other
Induction oCureVac A Male 18 Years andPhase
older
2 Â (Adult, 35
Older
Industry
Adult) InterventioAllocation CV-9104-0
GeometricGreen CrosAll 18 Years toPhase
60 Years
3 Â (Adult)414 Industry InterventioAllocation GC3110B_
Immune reRadboud Un All 18 Years toPhase
75 Years
The number University All 11 Years toNot
18 Years
ApplicÂ (Child,
5663Adult)
Other InterventioAllocation IRB201200
MTD definedNational CaAll 18 Years andPhase
older
1 Â (Adult, 22
Older
Comparison University All 18 Years and older Â (Adult,792Older
Other
Adult) ObservatioObservatioDOPPIO
The primarImmune Res All 3 Months to Phase
16 Years
2 Â (Child) 26 Industry InterventioAllocation IR-HIV-007
Biological: Approved iNational InAll 18 Years toPhase
49 Years
2 Â (Adult)840 NIH InterventioPrimary PuDMID 00-0
serogroup London SchAll 1 Year to 29 Years Â (Child, Adult)
0 Other ObservatioObservatioVES_5840
ContinuousNational I All 18 Years andPhase
older
2 Â (Adult,313
Older
NIH|Indust
Adult) InterventioAllocation Nabi - 45
HPV vaccinUniversity All 11 Years to 21 Years Â (Child,223Adult)
VAS scale oHopital Fo All 18 Years toNot
75 Years
ApplicÂ (Adult,
220Older
OtherAdult)InterventioAllocation 2013/35
response|sMemorial SMale 18 Years andPhase
older
1 Â (Adult, 21
Older
Adult) 98-048|P3
Change in Genocea BiAll 18 Years toPhase
50 Years
Number ofSanofi All 4 Years to 7Phase
Change in The UniverAll 18 Years toPhase
65 Years
1 Â (Adult,20Older
OtherAdult)InterventioAllocation HSC-MS-16
Safety and Biofabri, S All up to 50 Years
Phase
Â 1|Ph
(Child, Adult)
54 Industry|OInterventioAllocation MTBVAC-0
Measuremen Erasmus Me All 18 Years andPhase
older
4 Â (Adult,800
Older
Other
Adult) InterventioAllocation SNO-T-07-
Number ofGlaxoSmithFemale 18 Years to 45 Years Â (Adult)
Biological: HIV-1 C4- National InAll 18 Years toPhase
50 Years
1 Â (Adult)30 NIH|IndustInterventioMasking: DDATRI 101|11741|DATRI 0101
14 Weeks
3 Â (Child)
Influenza Public HeaAll 4 Years to 11
NotYears
Applic
Â (Child)
145142 Other InterventioAllocation 2016_FluIn
seroprotectBoston ChiAll 5 Years and older Â (Child, Adult,
146 Other
Older Adult)
ObservatioObservatio07-09-034
SeroconverEpicentre|All 9 Months to Phase
60 Years
4 Â (Child,
1630Adult)
Other InterventioAllocation YEFE_2017
Efficacy|s Laboratori All 18 Years toPhase
65 Years
2|PhÂ (Adult,
108Older
Adult) CASVAC04
Number ofGlaxoSmithFemale 10 Years to 25 Years Â (Child,
3091Adult)
The primarUniversity All 18 Years toPhase
70 Years
Other|Indu
12 Weeks
2 Â (Child)
Anti-HBs aGlaxoSmithAll 18 Years andPhase
older
3 Â (Adult,116
Older
Industry
Immunogeni GlaxoSmithAll Child, AdulPhase 4 0 Industry InterventioAllocation 116763|20
rate of pCRUniversity Female 18 Years andPhase
older
2 Â (Adult,102
Older
Other
Demonstrat GlaxoSmithFemale 10 Years toPhase
25 Years
SCR (SerocValneva AuAll 18 Years andPhase
older
3 Â (Adult,374
Older
Industry
Biological: HIV-1 Pe United Biom All 18 Years toPhase
50 Years
1 Â (Adult) Industry InterventioMasking: D091|UBI V106
Vaginal an Oslo UniverFemale 18 Years to 20 Years Â (Adult)315 Other ObservatioObservatio2014/2333
Safety of Eurocine VAll 50 Years toPhase
75 Years
1|PhÂ (Adult,
298Older
Industry
Adult)InterventioAllocation EURO 17-0
Adverse eveNational CaAll 19 Years andPhase
older
1|Ph
Â (Adult, 69
Older
Child's behFlorida StaAll 48 MonthsNot to 72
Applic
Months Â 150
(Child)
Other InterventioAllocation 2011.68
Anti-pneum University All 18 Years to 35 Years Â (Adult)50 Other ObservatioObservatioIRB201401
SeroprotecKorea UnivAll 19 Years andPhase
older
4 Â (Adult,174
Older
Other
Adult) InterventioAllocation KUGH1317
Related SeBavarian NAll 56 Years toPhase
80 Years
Industry
Adult)InterventioAllocation POX-MVA-
50 Years
1 Â (Adult) 4 U.S. Fed InterventioInterventi S-12-23|F
Boostrix vaGlaxoSmithAll up to 2 Months Â (Child) 1 Industry ObservatioObservatio 210031
GeometricPfizer All 56 Days to Phase
59 Years
Immunogeni GlaxoSmithAll 18 Years toPhase
64 Years
Demonstrate Centre for All 18 Years andPhase
older
4 Â (Adult,812
Older
Other
Adult) InterventioInterventi 003-01-19
Safety U.S. Army All 18 Years toPhase
45 Years
1|PhÂ (Adult)72 U.S. Fed|I InterventioAllocation WRAIR #84
OccurrenceGlaxoSmithMale 18 Years toPhase
44 Years
PercentagePfizer All 3 Months to Phase
6 Months
3 Â (Child)
65 Years
Industry
Adult)InterventioInterventi 205214|20
The PrimarWashington All 18 Years andNotolder
Applic
Â (Adult, 32
Older
Other
Adult) InterventioAllocation HRPO 07-0
To evaluat University All 18 Years andPhase
older
2 Â (Adult, 70
Older
Other|Indu
Adult) InterventioInterventi 081010|C-
Immune res Jan WalewsAll 18 Years toNot
120Applic
Years Â (Adult,
12 Older
OtherAdult)InterventioInterventi MSCMI-40-
Cell cycle- Jonsson CoAll 18 Years andPhase
older
1 Â (Adult, 40
Older
Other|NIH|
ProportionSeoul NatioAll 18 Years toNot
65 Years
ApplicÂ (Adult,
318Older
OtherAdult)InterventioAllocation SNUH-IMJ-
Number ofNational CaMale 18 Years andPhase
older
2 Â (Adult, 44
Older
OccurrencePatricia L All 65 Years toPhase
80 Years
Other InterventioAllocation 2011 P 00
ProgressionGynecologiFemale 18 Years andPhase
older
3 Â (Adult, Older
Adult) CDR00005
Overall re Lene MeldgAll 18 Years andPhase
older
2 Â (Adult, 20
Older
Other|Indu
Adult) InterventioInterventi MY18H2|20
Participan Sanofi Pas All 1 Year and Phase
Adult,Industry
Older Adult)
InterventioAllocation VRV12|U11
Anti-HBs i Hui ZhuangAll 16 Years toPhase
30 Years
4 Â (Child,
2040Adult)
Other InterventioInterventi PRO-HBV-0
Immunoglob Royal Live All 17 Years andPhase
older
4 Â (Child, Adult,
40 Other
Older Adult)
InterventioAllocation BAL0601|I
to 15 Months
3 Â 750
(Child)
To establi Memorial SAll Child, AdulEarly Phas 20 Other|NIHInterventioInterventi 00-142|NCI
Biological: trivalent Roswell ParAll 1 Year to 20Not
Years
Applicable
Â (Child, Adult)
Other|NIHInterventioPrimary PuRP 99-12|
18 Years
3 Â (Child,
1330Adult)
Clinical be Inge MarieAll 18 Years andPhase
older
2 Â (Adult, 41
Older
Other
Adult) InterventioInterventi MM1120
Biological: Immunothe Cell GenesMale 18 Years andPhase
older
1|Ph
Â (Adult, 36
Older
Industry
Adult) InterventioAllocation G-9705A
To demonstUniversity All 18 Years toPhase
50 Years
1|PhÂ (Adult) 8 Other|NIHInterventioAllocation VAC035
Varicella-z Seoul NatioAll 50 Years andNotolder
Applic
Â (Adult, 86
Older
Other
Adult) InterventioAllocation H1705030
Tolerabili Baylor CollMale 18 Years andPhase
older
1 Â (Adult, 14
Older
Adult) CDR000057
To investi Goethe UnAll 18 Years andPhase
older
4 Â (Adult,500
Older
Other
Adult) InterventioAllocation JWG11.200
SeroprotectLeiden UniAll 18 Years andPhase
older
1|Ph
Â (Adult, 12
Older
Other
Adult) InterventioAllocation MENID-1|2
Number ofSidney
p KimFemale 19 Years andPhase
older
1 Â (Adult, 48
Older
Adult) J1955|IRB
AcceptabiliPierre Van All 18 Years toNot
65 Years
ApplicÂ (Adult,
102Older
OtherAdult)InterventioAllocation cev2012-va
Attack rateHenogen All 16 Years toPhase
25 Years
Industry InterventioAllocation HN/P001-EBV-003
Biological: fowlpox vi Eastern CoMale 18 Years andPhase
older
2 Â (Adult, 60
Older
Adult) CDR000006
Safety of aNational InAll 18 Years toPhase
60 Years
1 Â (Adult)18 NIH InterventioAllocation 5R01AI050
Barriers t Louisiana All 18 Years and older Â (Adult,400Older
Other
Adult) ObservatioObservatioSTUDY000
Is to deter Memorial SAll 18 Years andPhase
older
1 Â (Adult, 18
Older
Adult) 99-122
The Geomet Medigen Va All 20 Years toPhase
50 Years
3 Â (Adult)842 Industry InterventioAllocation CT-QV-31
Safety and Bavarian NAll 18 Years toPhase
50 Years
1 Â (Adult)45 Industry|OInterventioAllocation WEV-MVA-
Incidence Swiss TropiAll 18 Years toPhase
30 Years
1 Â (Adult)46 Other InterventioAllocation PEV001
Number ofGlaxoSmith
S Female 25 Years andPhase
older
3 Â (Adult, 92
Older
Industry
determine AlphaVax, All 18 Years andPhase
older
1|Ph
Â (Adult, 28
Older
Adult) AVX701|P0
Analgesic University Female 18 Years toPhase
65 Years
3 Â (Adult,
3420Older
older
2 Â (Adult, 46
Older
Other
Vaccine re Centers fo All 42 Days to Phase
48 Days4 Â (Child)
1890 U.S. Fed|OInterventioAllocation 19058
To describeNational InAll 18 Years toPhase
50 Years
Infant per Emory UnivAll 18 Years toPhase
40 Years
Endpoints :GlaxoSmithAll 5 Weeks toPhase
7 Weeks
Part A DosU.S. Army All 18 Years toPhase
50 Years
1|Ph
Â (Adult)70 U.S. Fed|OInterventioAllocation NMRC.2006
Phase
Years
3 Â (Child,149
Adult)
ImmediateEuropean M All 18 Years toPhase
50 Years
1 Â (Adult)35 Other InterventioAllocation VAC027.1|E
ProgressionNational CaAll 18 Years andPhase
older
2 Â (Adult, 26
Older
Number ofOswaldo CrMale 18 Years toPhase
49 Years
2 Â (Adult)30 Other InterventioAllocation Sm14-2a-S
Immunogeni Queen SirikAll 9 Months to Phase
14 Months
2|Ph Â (Child)
200 Other InterventioInterventi Trivivac20
Biological: Immunothe Cell GenesMale 18 Years andPhase
older
1|Ph
Â (Adult, 80
Older
Industry
Adult) InterventioAllocation G-0010
50 Years
evidence ofInge MarieAll 18 Years andPhase
older
1 Â (Adult, 14
Older
Other
Adult) InterventioInterventi LU 1006 -
23 Years
2 Â (Child,
2409
Adult)
64 Years
33 Years
1 Â (Adult)12 NIH InterventioAllocation R01AI050467|UCLA MIG-001
proportionThe UniverAll 65 Years andNotolder
Applicable
Â (Older Adult)
Other InterventioPrimary PuHKUCTR-1
To determiMemorial SFemale 19 Years andPhase
older
1 Â (Adult, 26
Older
Other
ProportionUniversita All 2 Years to 85 Years Â (Child,2400
Adult,
Other
Older Adult)
ObservatioObservatioUZVACC
To evaluat National HeAll 18 Years toPhase
85 Years
1 Â (Adult, 9Older
Full vaccin GlaxoSmithAll 12 Weeks to 5 Years Â (Child) 0 Industry ObservatioObservatio 116494
GeometricUniversity All 70 Years andPhase
older
4 Â (Older183
Adult)
Other InterventioAllocation CYTEL-Prot
To evaluat St. Jude ChAll 18 Years toPhase
40 Years
1 Â (Adult) 6 Other|NIHInterventioInterventi EnvDNA|I
Antibody cGlaxoSmithAll 11 MonthsPhase
to 14 Months
3 Â 120
(Child)
Causality Cancer ResAll 18 Years andPhase
older
1 Â (Adult, 45
Older
Other|Indu
Parental MIndiana UniAll 18 Years andNotolder
Applic
Â (Adult,802
Older
Other
GeometricGlaxoSmithAll 4 Years to 6Phase
Years3Â (Child)4209 Industry InterventioAllocation 213503/04
The serocoJiangsu Pr All 60 Days to Phase
45 Years
1|Ph
Â (Child,60
Adult)
Other InterventioAllocation 2017L0093
Evaluation Opexa TherAll 18 Years toPhase
65 Years
1|Ph
Â (Adult,16Older
Industry
Difference The UniverAll 65 Years toPhase
82 Years
4 Â (Older1861
Adult)
Other|U.S.InterventioAllocation YHT005.1
Drug: VRC-HIVDNA00National InAll 18 Years toPhase
40 Years
1 Â (Adult)50 NIH InterventioPrimary Pu030022|03
Time from Telethon
r KAll 6 Months to Phase
12 Months
4 Â 1000
(Child)
Other InterventioAllocation CVID/2015
Immune res University All 18 Years andPhase
older
1 Â (Adult, 12
Older
Other
The measursigma-tau i.All 18 Years toPhase
80 Years
Industry
Adult)InterventioAllocation ST1472-DM
Number ofJanssen
P VaAll 60 Years andPhase
older
1 Â (Adult, 73
Older
Industry
Incidence Emergent BAll 18 Years toPhase
50 Years
1 Â (Adult)105 Industry|NInterventioAllocation EBS.AVA.2
Types 1 anUniversity All 7 Weeks toPhase
9 Weeks
4 Â (Child)570 Other InterventioAllocation IPV002AB
ImmediateAfrican MaAll 1 Year to 2Phase
Years Â1 (Child) 45 Other InterventioAllocation MSP3_BF_
17 Years
4 Â (Child)
1345 Industry InterventioAllocation MTA21
Kaplan-Meie U.S. Army All 18 Years toPhase
30 Years
3 Â (Adult)
16402 U.S. Fed|OInterventioAllocation RV144|HSR
Number and ReiThera SAll 18 Years toPhase
65 Years
1 Â (Adult, 9Older
Adult) HCV004|20
Meningococ GlaxoSmithAll 4 Years to 34
Phase
Years
2 Â (Child,271
Adult)
Number ofPfizer All 6 Weeks and older Â (Child, 3006Adult,
Industry
Older Adult)
ObservatioTime PerspB1851076
To determiNational InAll 18 Years toPhase
50 Years
Biological: The currenUniversity Female 18 Years and older Â (Adult, 37 Older
Other|NIHObservatioObservatio805443|UP
Adult)
SeroconversUniversity Female 9 Years to 18 Phase
37 Other InterventioAllocation CHUBX 201
Safety and Washington All 18 Years andPhase
Older
Other|Indu
immunogeni Zhejiang P All 6 Months to Phase
11 Months
4 Â 1134
(Child)
Other|InduInterventioAllocation ZJCDC2019
SeropositivPfizer All 18 Years andPhase
Older
Industry
Adult) InterventioAllocation 690701|EU
Biological: human papEisenhowerFemale 18 Years to 26 Years Â (Adult) 300 U.S. Fed ObservatioObservatioDDEAMC 0
Safety andVaxGen All 18 Years toPhase
40 Years
1 Â (Adult)100 Industry InterventioAllocation VAX005
To assess tU.S. Army All 12 MonthsPhase
to 47 Months
2 Â 400
(Child)
U.S. Fed|OInterventioAllocation WRAIR 112
Safety andOslo UniverAll 18 Years andPhase
older1|Ph
Â (Adult, 15
Older
Other
Adult) InterventioAllocation DC-004|20
PET-CT scanHackensackAll 21 Years toNot
55 Years
ApplicÂ (Adult)16 Other|NIHInterventioAllocation R21AI0771
Drug: recombinant mo SouthwestAll 18 Years andPhase
0 Other|NIHInterventioMasking:
Adult) NCDR0000441167|S0348|U10C
Evaluation GlaxoSmithAll 18 Years toPhase
19 Years
4 Â (Adult) 0 Industry InterventioInterventi 116762
Number ofSanofi
p Pas All 60 Days to Phase
5007 Industry InterventioInterventi IPV34|UTN
GeometricNovartis V All 23 MonthsPhase
to 27 Months
3 Â 508
(Child)
acute toxi University All 18 Years andPhase
Older
Other
Adult) InterventioInterventi EC 5/6/29
OccurrenceGlaxoSmithAll 6 Weeks to 5 Years Â (Child) 28 Industry ObservatioTime Persp 113381
Biological: Inactivat National InAll 18 Years andPhase
older1|Ph
Â (Adult, 83
Older
NIHAdult) InterventioAllocation 05-0129|In
Rate of po Hillel Yaff All Child, AdulNot Applic 208 Other InterventioAllocation HYMC104-
Pertussis-sCentre Hosp Female 18 Years to 60 Years Â (Adult) 120 Other ObservatioObservatioPertussis
HPV, Cervi University Female 18 Years toNot 26 Years
ApplicÂ (Adult)70 Other InterventioAllocation H11-272
Number ofGlaxoSmith
s All up to 5 DaysPhase
Â (Child)
2 121 Industry InterventioAllocation 210602-00
Anti-RV IgAGlaxoSmithAll 6 Weeks toPhase
10 Weeks
Primary ImSeqirus|BiAll 18 Years andPhase
older3 Â (Adult,
3196Older
Adult) V89_18
Older
NIH|Other|
Adult) InterventioAllocation A5247|105
OccurenceAffiris AG|All 18 Years toPhase
65 Years
1 Â (Adult,72Older
Adult) AFFiRiS 0
GeometricSanofi Pas All 6 Months andPhaseolder
3 Â (Child,
6134 Adult,
Industry
Adult) FSQ02|U11
Evaluate saMemorial Sl All 18 Years andPhase
Older
Adult) 98-098|NI
249 Industry
Older Adult)
Rate of SAEValneva AuAll 18 Years toPhase
39 Years
1 Â (Adult)179 Industry InterventioAllocation VLA15-101
HPV-16 viraNational CaFemale 18 Years toPhase
50 Years
2 Â (Adult)139 NIH InterventioAllocation NCI-2012-
NoninferioSK Chemical All 19 Years andPhase
older3 Â (Adult,
1503Older
Industry
Adult) InterventioAllocation NBP607-QI
Parental A Purnima Ma All 18 Years to 55 Years Â (Adult) 800 Other ObservatioTime PerspIISP38250
Humoral anBarbara Ensoli,
All MD|Istituto
18 YearsSuperiore
toPhase
55 Years
di
2 SanitÃ
Â (Adult)
168 Other InterventioAllocation ISS T-002
Adverse evQuratis IncAll 19 Years toPhase
64 Years
2 Â (Adult)107 Industry|OInterventioAllocation CT-QTP101
Safety andShantha BiAll 6 Weeks toPhase
8 Weeks1|PhÂ (Child)
240 Industry|OInterventioAllocation SBL/BRV-T
Anti-rabie Kamada, LtAll 18 Years toPhase
75 Years
2|PhÂ (Adult,
118Older
Industry
Adult)InterventioAllocation KAMRAB-0
Anti-pneum Assistance All 18 Years and older Â (Adult, 30 Older
Other
Adult) ObservatioTime PerspNI15002
EX VIVO meaCentre Hosp All 18 Years andNotolder
ApplicÂ (Adult, 55
Older
Other|Indu
Adult) InterventioInterventi 1608178|
49 Years
1 Â (Adult)224 Industry InterventioInterventi VAX161-01
safety|ImmOklahoma AMll 50 Years toPhase
80 Years
1 Â (Adult,20Older
OtherAdult)InterventioAllocation OMRF11-5
Number ofDuke UniveAll 10 Years toNot
17 Years
ApplicÂ (Child)30 Other|U.S.InterventioAllocation PRO000940
Toxicities Fred HutchAll Child, AdulPhase 1 22 Other|NIHInterventioInterventi 1104.00|N
12 Weeks
3 Â (Child)
Serum HI anGlaxoSmithAll 61 Years andPhase
0 Industry
duration oGamaleya R All 18 Years to 56 Years Â (Adult)60 Other ObservatioObservatio03 - GamE
2167 Industry InterventioAllocation M5A10
2-fold inc National T All 18 Years andPhase
Older
Other
- Safety|- Society forAll 8 Weeks toPhase
12 Weeks
1 Â (Child) 90 Other|NIH| InterventioAllocation 03-153|U0
older2|Ph
Â (Adult,
8031
Older
Industry
Immunogeni Medicago|All 18 Years toPhase
60 Years
2 Â (Adult)
255 Industry|OInterventioAllocation CP-H5VLP-
Safety ObjeBlueWillowAll 18 Years toPhase
49 Years
1 Â (Adult)84 Industry|OInterventioAllocation BW1010-0
to describ Swedish InAll 14 Years toPhase
15 Years
4 Â (Child)
Comparison PATH|NatioFemale 11 Years toNot
13 Years
ApplicÂ (Child)
903 Other InterventioAllocation HPV01
CorrelationUniversity All 18 Years and older Â (Adult,100 Older
Other
Frequency,National InAll 18 Years toPhase
45 Years
apply bloodShanghai PuAll 18 Years toPhase
60 Years
2 Â (Adult) 7 Other InterventioAllocation NCT-0015
Older
Industry
Toxicity p Roswell ParAll 18 Years andPhase
Older
Other|NIH|
Adult) InterventioAllocation I 247913|
ProportionInstitut N Female 18 Years toPhase
35 Years
1 Â (Adult)68 Other InterventioAllocation C14-60|20
Safety|Imm Memorial SAll 18 Years toNot
120Applic
Years Â (Adult,7 Older
Adult) 06-156|P3
Tumor shriIan F. Poll All 12 MonthsPhase
to 21 Years
2 Â (Child,
Adult) PRO13110
Number ofUniversity
70 Years
2 Â (Adult,26Older
OtherAdult)InterventioAllocation 669-19|NC
50 Years
1 Â (Adult)
NK cell funStanford UnFemale 18 Years to 45 Years Â (Adult)94 Other|NIHObservatioObservatioIRB-25182
Occurrence,GlaxoSmithAll 65 Years andPhase
older2 Â (Older146
Adult)
Answers toUniversity All 16 Years and older Â (Child, 1025
Adult,
Other
Older Adult)
ObservatioObservatioIRAS proje
To determiSt. Jude ChAll 18 Years andPhase
Older
Other
Adult) InterventioInterventi DID955|Po
Biological: autologouUniversity All 1 Year and Phase
older Â2 (Child, Adult,Other
Older Adult)
InterventioPrimary PuCDR000007
Adverse EvNicholas BuAll 18 Years andPhase
Older
Other|Indu
Adult) InterventioAllocation 15108|NCI
proportionPHAC/CIHRAll 10 Years to 64 Years Â (Child,138Adult)
Other ObservatioObservatiopcirn-clin-
Biological: NeoantigeWashington All 18 Years and older Â (Adult, Older Other
Adult) Expanded Access:Tre 19-x005
DescriptionFrench NatAll 18 Years and older Â (Adult,488 Older
Other
50 Years
1 Â (Adult)24 Other InterventioAllocation CHIK001
To analyze Cliniques uAll 18 Years andPhase
older1|Ph
Â (Adult, 23
Older
Other|Indu
Adult) InterventioAllocation LUC 09-00
Comparison National I All 6 Months to Phase
7 Months
2 Â (Child)
270 NIH|IndustInterventioAllocation ACTG 225|11202
Overall Re Memorial SFemale 18 Years andPhase
Older
Other|Indu
Occurrence,GlaxoSmithAll 65 Years toPhase
85 Years
Change in George Was All 18 Years and older Â (Adult, 74 Older
Other
Adult) ObservatioObservatioIRB080911
Biological: HIV p24/ Chiron Corp All 18 Years toPhase
50 Years
1 Â (Adult)40 Industry InterventioInterventi 095|V24P1
GeometricMerck ShaAll 6 Weeks toPhase
12 Weeks
3 Â (Child)
Immunogeni Novartis V All 7 Months andPhaseolder
4 Â (Child,
489Adult,
Industry
Adult) V14P38E1|
Biological: Trivalent National InAll 6 Months to Phase
17 Years
4 Â (Child) 60 NIH InterventioAllocation 04-050
Immunogeni Centers fo All 6 Weeks toPhase
7 Weeks4 Â (Child)
Frequency GlaxoSmithAll 60 Years andPhase
Older
Industry
Biological: Influenza National InAll 18 Years toPhase
64 Years
1|Ph
Â (Adult)
The primary Radboud Un All 18 Years toPhase
70 Years
OtherAdult)InterventioAllocation NL2009-01
PercentageGlaxoSmithFemale 18 Years toPhase
40 Years
Safety: phyNational InAll 18 Years toPhase
45 Years
Adverse evQuratis IncAll 14 Years toPhase
18 Years
Industry InterventioAllocation CT-QTP101
Attitudes| University All 21 Years toNot
99 Years
ApplicÂ (Adult,
2000Older
Infant PainUniversity All 1 Month toPhase
12 Months
3 Â (Child)
Cell-MediaGlaxoSmithAll 60 Years and
Phase
older
2 Â (Adult,129
Older
Industry
Biological: Smallpox vSanofi All 18 Years toPhase
25 Years
2 Â (Adult)230 Industry InterventioAllocation VVL04
SeroconverKorea UnivAll 65 Years and
Phase
older
4 Â (Older224
Adult)
Other|InduInterventioAllocation FLUADPPV
Evaluate thNational InAll 18 Years toPhase
70 Years
1 Â (Adult,70Older
Safety|CelUniversity All 12 Years toPhase
50 Years
49 Years
4 Â (Adult)300 Industry InterventioAllocation MED-VA-FL
Anti-HPV 6University Female 9 Years to 26
NotYears
Applic
Â (Child, Adult)
27 Other|InduInterventioInterventi 15960A|ME
Date of fir Michael MFemale 18 Years and
Phase
older
1 Â (Adult, Older
8 Other|Indu
Number ofMatthew Ga All 18 Years and
Phase
older
1 Â (Adult, 15
Older
Other|Indu
ProportionDynavax TeAll 18 Years toPhase
75 Years
Industry
ProportionTribhuvan All 7 Months toPhase
36 Months
4 Â (Child)
500 Other|U.S.InterventioAllocation 69/2018
15 Years
3 Â (Child)
immunoglob Aghia SophiAll 18 Years and
Phase
older
4 Â (Adult, 40
Older
Other
Adult) InterventioAllocation 51198eAS
To demonstr PepTcell Li Male 18 Years toPhase
50 Years
1 Â (Adult)54 Industry InterventioAllocation HIV-v-001
Safety: To Sanofi Pas All 18 Years toPhase
45 Years
40 Years
1|PhÂ (Adult)
252 NIH|Other| InterventioAllocation HVTN 100
Frequency Inviragen All 21 Years toPhase
45 Years
1 Â (Adult)36 Industry InterventioAllocation INV-EVR-1
Safety of Astellas P All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation CB01-202
Evaluate NNabi BiophAll 18 Years toPhase
65 Years
3 Â (Adult,
1000Older
Industry
Adult)InterventioAllocation Nabi-4515
All seizure GlaxoSmithAll 6 Weeks to 9 Months Â 120794
(Child) Industry|OObservatioObservatio217744/08
Compare thAga Khan UAll 9 Months toPhase
12 Months
4 Â (Child)
840 Other|NIHInterventioAllocation MIPV|ACTR
To evaluateWyeth is nAll 18 Years toPhase
50 Years
1 Â (Adult)91 Industry InterventioAllocation 6120K1-10
Number ofGlaxoSmith
s All 6 Months toPhase
7 Months
1 Â (Child)
GeometricChiltern PeAll 18 Years toPhase
70 Years
Industry
Adult)InterventioAllocation V111_16TP
45 Years
Receipt of Johns HopkAll 28 Years toNot
40 Years
ApplicÂ (Adult)
107 Other InterventioAllocation RC1LM010
Anti-HBs s GlaxoSmithAll 15 Years and
Phase
older
3 Â (Child,165
Adult,
Industry
Older Adult)
Vaccinatio University All 18 Years and
Notolder
Applic
Â (Adult,
7206
Older
Other
Adult) InterventioAllocation HUM00135
Immune res Centers fo All 55 Years toPhase
70 Years
1 Â (Adult,90Older
Adult) CDC-NCID-
Influenza University Female 18 Years to 45 Years Â (Adult)
50 Years
3 Â (Adult)55 Industry InterventioInterventi V72_74|20
50 Years
1 Â (Adult)60 Other InterventioAllocation HV-002
duration oGamaleya R All 18 Years to 56 Years Â (Adult)60 Other ObservatioObservatio02 - GamE
The number Anhui Zhif All 18 Years toPhase
45 Years
1 Â (Adult)25 Industry|OInterventioAllocation LTao-AEC/BCO2-â… -healthy|LT
Biological: Inactivate Ology BiosAll 18 Years toPhase
45 Years
1|PhÂ (Adult)
rate of HIVFrench NatAll 18 Years and
Phase
older
3 Â (Adult,178
Older
Other|Indu
Vaccine resGlaxoSmithAll 7 Years to 10
NotYears
Applic
Â (Child) 0 Industry InterventioAllocation 204476
Antibody leMcMaster AUll 18 Years toPhase
24 Years
4 Â (Adult) Other InterventioAllocation HVT-2016
DeterminatCureVac A Male 18 Years toPhase
75 Years
Industry
Adult)InterventioInterventi CV-9103-0
Biological: dendritic Jonsson CoAll 18 Years andPhase
older
1 Â (Adult, Older
Other|NIHInterventioPrimary
Adult) PuCDR000006
to 76 Months
3 Â 582
(Child)
50 Years
2 Â (Adult)64 Industry|UInterventioAllocation 117014
Overall surUniversity All 20 Years toPhase
80 Years
2 Â (Adult,60Older
HIV-infecteFrench NatAll 18 Years andPhase
older
3 Â (Adult,437
Older
Other|Indu
Number ofUniversity All 19 Years andPhase
older
2 Â (Adult, 19
Older
Adult) 260-00|P3
Comparison CambridgeAll 40 Years andPhase
older
2 Â (Adult,124
Older
Other
Adult) InterventioAllocation CCTU0155
Safety (Fr Craig L SlinAll 18 Years andPhase
older
1 Â (Adult, 11
Older
Other
Biological: recombin Herbert Ir All 18 Years andPhase
older
1 Â (Adult, Older
Adult) PuCDR000006
Number ofPauline
a VeAll 56 Days to Phase
63 Days1|Ph
Â (Child)140 Other InterventioAllocation NVI-256B|
older
1 Â (Adult, Older
5 Other
Adult) InterventioInterventi 04-178|NI
older
3 Â (Child,228
Adult,
Industry
Older Adult)
InterventioInterventi 207347|20
Serious AdBavarian No All 18 Years toPhase
55 Years
2 Â (Adult)581 Industry|NInterventioAllocation POX-MVA-
Changes inNational CaAll 18 Years andNotolder
Applic
Â (Adult, 30
Older
Pain of im MMJ Labs LAll 4 Months to Phase
12 Years
2|PhÂ (Child)
345 Industry|NInterventioAllocation H09501|R
45 Years
Pneumococc University All 18 Years and older Â (Adult, 36 Older
Other
Adult) ObservatioObservatioSPICE
older
4 Â (Adult,203
Older
Industry
To provideSanofi All 18 Years toPhase
40 Years
1 Â (Adult)375 Industry InterventioAllocation FUF04
immunoglob Aghia SophiAll 18 Years toPhase
60 Years
4 Â (Adult)37 Other InterventioInterventi 51657MoH
SeroprotecGlaxoSmithAll up to 4 Months
PhaseÂ3 (Child) 308 Industry InterventioAllocation 104021
PercentageHoffmann-All 18 Years toPhase
55 Years
3 Â (Adult)102 Industry InterventioAllocation BN29739|2
Vaccinatio Bandim Hea All 6 Months to Phase
8 Months
4 Â (Child)
7800 Other InterventioAllocation IC18-CT95-
The safety AGIRx Ltd. All 18 Years toPhase
75 Years
Industry
Adult)InterventioAllocation AGI - 101H
17 Years
35 Years
2 Â (Child,
2100 Adult)
Haemagglut GlaxoSmithAll 1 Year to 10Phase
SeroprotecThe UniverAll 27 Years andPhase
older
2|Ph
Â (Adult,120
Older
Other
Evaluate NNabi BiophAll 18 Years toPhase
65 Years
3 Â (Adult,
1000Older
Adult) Nabi-4514|
Change in John SundyAll 18 Years toEarly
50 Years
PhasÂ (Adult)60 Other InterventioAllocation Pro000242
40 Years
Number ofCentre
H HospAll 18 Years and older Â (Adult,800 Older
Other
Adult) ObservatioObservatioB07620142
Number ofGlaxoSmithAll up to 5 Years Â (Child) 68000 Industry ObservatioObservatio 115056
To determinSt George' Female 18 Years toPhase
45 Years
Antibody tiSanofi Pas All 56 Days to Phase
89 Days3 Â (Child)700 Industry InterventioAllocation MET52|201
Serotype-sPATH All 6 Weeks toPhase
8 Weeks
3 Â (Child)
12 Weeks
3 Â (Child)
Safety - M U.S. Army All 18 Years toPhase
50 Years
1|PhÂ (Adult)18 U.S. Fed|I InterventioAllocation WRAIR 124
Incidence Istituto Sc All 19 Years andPhase
older
2 Â (Adult, 19
Older
Other
12 Weeks
NotYears
Applic
Â (Child) 41 Other|InduInterventioInterventi 13-2769
Base StageMerck ShaFemale 9 Years to 26
Phase
Years
3 Â (Child,766
Adult)
SeroconverFidec CorpAll 5 Weeks toPhase
7 Weeks
3 Â (Child) 0 Other InterventioAllocation IPV-003-A
Time to Tr National CaMale 18 Years toPhase
110 Years
49 Years
4 Â (Adult)300 Industry InterventioAllocation D2560C00
Humoral: Re U.S. Army All 18 Years toPhase
45 Years
49 Years
HPV comple University All 10 Years toNot
21 Years
ApplicÂ (Child,
749Adult)
Other|U.S.InterventioAllocation 5K08HS017
Toxicity a Roswell ParFemale 18 Years andPhase
older
1 Â (Adult, 18
Older
Other|NIH|
Adult) InterventioInterventi I 127008|
Change in Centers fo All 6 Weeks toPhase
7 Weeks
3 Â (Child)738 U.S. Fed|OInterventioAllocation ICDDRB-RR
Evaluate thBeijing ChaAll 18 Years toPhase
55 Years
2 Â (Adult)300 Other InterventioAllocation cycdc2015
49 Years
Safety|TumImmunovati All 18 Years andPhase
older
1|Ph
Â (Adult, Older
0 Industry
Adult) InterventioInterventi ITL-019-H
64 Years
4 Â (Adult)985 Industry InterventioAllocation PJ-501-14
Immunogeni Avant ImmAll 18 Years toPhase
55 Years
2 Â (Adult)180 Industry InterventioAllocation Ty800-07-
OccurrenceGlaxoSmithAll 18 MonthsPhase
to 48 Months
2 Â 180
(Child)
Immunogeni University All 18 Years andPhase
older
1|Ph
Â (Adult, 10
Older
Other
Adult) InterventioInterventi CCRG 11-0
Safety - in University Male 18 Years andPhase
older
1|Ph
Â (Adult, 36
Older
Other|Indu
Adult) InterventioAllocation ADVANCE
Blood and National InFemale 18 Years toPhase
50 Years
1 Â (Adult)48 NIH InterventioAllocation HVTN 054|10121
LaboratoryMcMaster AUll 6 Months to Phase
72 Months
4 Â 2500
(Child)
Other InterventioAllocation AV-IIV
Biological: CancerVa CancerVax All 18 Years toPhase
80 Years
Industry
Adult)InterventioAllocation CV-MMAIT-4-001|JWCI-MC-4-0
Biological: CancerVa CancerVax All 18 Years toPhase
80 Years
3 Â (Adult,
1118Older
Industry
Adult)InterventioAllocation CV-MMAIT-3-001|JWCI-MC-3-0
Frequency Stanford Un All 6 Months to Phase
10 Years
1 Â (Child) 80 Other|NIHInterventioAllocation SU-31256|
ResolutionCangene Co All Child, Adult, Older Ad 100 Industry|UObservatioObservatioVA-005
Detection aUniversity All Child, Adult, Older Ad 6 Other ObservatioObservatioHCVP-1
Biological: Whole vir Ology BiosAll 18 Years toPhase
45 Years
1|PhÂ (Adult)
Number ofMerck SharAll 18 Years toPhase
45 Years
2 Â (Adult)
3000 Industry|OInterventioAllocation V520-023|
Biological: AMA1-C1|National InAll 18 Years toPhase
45 Years
1 Â (Adult)54 NIH InterventioPrimary Pu999904175
Biological: Influenza National InAll 18 MonthsPhase
to 18 Years
3 Â 15000
(Child,NIH|Indust
Adult) InterventioMasking: NDMID 99-021|AV012
overall su SouthwestAll 18 Years andPhase
older
2 Â (Adult, Older
Adult) CDR00002
Safety andUniversity All 18 Years andPhase
older
1|Ph
Â (Adult, 41
Older
Other|NIH|
Adult) InterventioInterventi 05103|P30
Time to RelH. Lee MofAll 16 Years andPhase
older
1 Â (Child, Adult,
73 Other|NIH|
Older Adult)
InterventioAllocation MCC-15651
GMTs for I Valneva AuAll 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation VLA15-202
17 Years
49 Years
Number ofGlaxoSmithAll 6 Weeks to 24 Weeks Â (Child)
SeroconverAga Khan UAll up to 24 Hours
Not Applic
Â (Child) 1000 Other InterventioAllocation 1891-Ped-
Anti-rotav GlaxoSmithAll 6 Weeks toPhase
10 Weeks
Influenza Public HeaAll 2 Years to 3Not
Years
Applic
Â (Child)
21786 Other InterventioAllocation 2016_FluI
Incidence Viscogel A All 22 Years toPhase
50 Years
1|PhÂ (Adult)
130 Industry|OInterventioAllocation VSG-2011-
To assess tVaxInnate All 18 Years toPhase
49 Years
Percent whGlaxoSmithAll 6 Weeks toPhase
12 Weeks
50 Years
45 Years
1 Â (Adult)80 Industry InterventioAllocation 205496|V1
17 Years
ApplicÂ (Child)24 Other|NIHInterventioInterventi 5R01CA20
Immune Ana Gradalis, InAll 18 Years andPhase
older
2 Â (Adult, Older
3 Industry
Adult) InterventioAllocation CL-PTL 107
Pain using University All 6 Years to 16
NotYears
Applic
Â (Child) 64 Other InterventioAllocation H18-01851
Number ofFraunhoferAll 18 Years toPhase
49 Years
1 Â (Adult)30 Industry InterventioAllocation FhCMB rPA
45 Years
Safety|Cli Abramson FCemale 18 Years andEarly
older
Phas
Â (Adult, 67
Older
Other
Adult) InterventioPrimary PuUPCC 1980
Safety as Imperial C All 18 Years toPhase
50 Years
1 Â (Adult)28 Other InterventioAllocation CUTHIVAC
to 23 Months
2 Â (Child)
Number ofIDRI|Aeras| All 18 Years toPhase
50 Years
17 Years
Incidence Wroclaw Me All Child, Adult, Older Ad 250 Other ObservatioObservatio779/2019
PRNT GMT|E Bavarian NAll 18 Years toPhase
40 Years
3 Â (Adult)
4005 Industry InterventioAllocation POX-MVA-
Safety and Swedish InAll 18 Years toPhase
60 Years
1 Â (Adult)12 Other InterventioAllocation DermHIVI
12 Weeks
Incidence National C All 18 Years and
Phase
older
1 Â (Adult, 32
Older
NIH|Indust
Adult) InterventioInterventi NCI-2015-
PercentageMerck ShaAll 42 Days to Phase
Grade 3 orNational InAll 18 Years toPhase
50 Years
1|PhÂ (Adult)21 NIH InterventioAllocation A5187|10010|ACTG A5187
The effec University All 18 Years toPhase
45 Years
Percent of National InAll 18 Years toPhase
55 Years
2 Â (Adult) 3 NIH InterventioInterventi 170017|17
Immune res AVAX TechnAll 18 Years and
Phase
older
1|Ph
Â (Adult, 82
Older
Industry
Adult) InterventioAllocation A/100/040
to 13 Months
3 Â 468
(Child)
ProgressioJulius-MaxiAll 19 Years toPhase
90 Years
OtherAdult)InterventioAllocation SuMo-Sec-
12 Weeks
Immune respInstitut Pa All 18 Years toPhase
50 Years
2 Â (Adult)111 Industry InterventioAllocation RBM 2004.
Biological: Immunothe Cell GenesMale 18 Years and
Phase
older
1|Ph
Â (Adult, 50
Older
Industry
Serum BactNovartis V All 11 Years toPhase
18 Years
To evaluat Dynavax TeAll 18 Years to 75 Years Â (Adult,147Older
Industry
Adult)ObservatioObservatioDV2-HBV-1
PreliminaryUniversity All 18 Years and
Phase
older
1|Ph
Â (Adult, Older
1 Other
Adult) InterventioAllocation 20057158|
AssessmentCenters fo All 6 Weeks toPhase
7 Weeks
4 Â (Child)760 U.S. Fed|OInterventioAllocation ICDDRB-RR
Biological: Immunothe Cell GenesMale 18 Years and
Phase
older
1|Ph
Â (Adult, 20
Older
Industry
Grade 3 orNational I All 18 Years and
Phase
older
1 Â (Adult, 60
Older
NIHAdult) InterventioAllocation HPTN 027|10141
The primaryMedImmunAll 18 Years toPhase
49 Years
2 Â (Adult)300 Industry InterventioAllocation MI-CP154
Objective Roswell ParAll 18 Years and
Phase
older
2 Â (Adult, 24
Older
Adult) I 82419|N
Duration ofHospital NAll 1 Year to 3Not
YearsApplic
Â (Child) 204 Other InterventioAllocation PCV-001
MV Coverag Bandim Hea All up to 3 Months
Not Applic
Â (Child) 1050 Other InterventioAllocation MIMI-01
To demonstrBiovest IntAll 18 Years and
Phase
older
3 Â (Adult,629
Older
Industry
Adult) InterventioAllocation BV 301
Safety andSidney KimFemale 18 Years and
Phase
older
1 Â (Adult, 48
Older
Adult) J0656|NA_
Biological: Smallpox Bristol-My All 18 Years toPhase
60 Years
1 Â (Adult) Industry InterventioPrimary Pu063A|AI452-003001
45 Years
3 Â (Adult)30 Industry InterventioInterventi TD532|U11
Carriage d Arto PalmuAll 3 Years to 9 Years Â (Child)3900 Other|InduObservatioObservatioFinIP-carr
Early
older
Phas
Â (Adult, 26
Older
Adult) MC1641|NC
Safety: So University All 11 Years toPhase
49 Years
1|PhÂ (Child,72
Adult)
Other InterventioAllocation TB042
Number ofUNC LinebeAll 18 Years and
Phase
older
2 Â (Adult, 17
Older
Adult) LCCC 0418
ImmediateNational InAll 2 Years to 21
Phase
Years
1 Â (Child, Adult)
7 NIH|IndustInterventioInterventi DAIT VZV
Subject ReU.S. Army All 18 Years toPhase
65 Years
U.S. Fed
Biological: Combined GlaxoSmith
d All 10 Years toPhase
18 Years
3 Â (Child,
4116 Adult)
to 69 Months
2 Â1737
(Child)
Immunologi National CaAll 18 Years and
Phase
older
1 Â (Adult, 42
Older
65 Years
Industry
Adult)InterventioAllocation VRV11
Residual anAssistance All 18 Years and older Â (Adult, 19 Older
Other
Adult) ObservatioTime PerspNI 15001
Number ofPATH|Bill All 6 Weeks toPhase
8 Weeks
3 Â (Child)
8200 Other|InduInterventioAllocation CVIA 061
Number ofIrsiCaixa| All 18 Years toPhase
99 Years
1 Â (Adult,15Older
Other|Indu
Adult)InterventioInterventi BCN02-Rom
T cell imm University All 12 Years toPhase
17 Years
2 Â (Child)36 Other InterventioAllocation TB036
Biological: MontanideUniversity All 18 Years and
Phase
older
2 Â (Adult, 23
Older
Other
Adult) InterventioAllocation 10M-03-8
12 Weeks
3 Â (Child)
The proporSanofi Pas All 18 Years toPhase
29 Years
SeroconverKorea Unive All 60 Years and
Phase
older
4 Â (Adult,
1195
Older
Other|Indu
Adult) InterventioAllocation FLUPCV13
MBPS|Subst Jordan UniAll 10 MonthsNotto 18
Applic
Months Â 132
(Child)
Memory for University All 18 Years toNot
26 Years
ApplicÂ (Adult)
175 Other InterventioAllocation RIR13914
Mortality|The UniverAll 18 Years and
Phase
older
3 Â (Adult,
4000
Older
Other
Measuremen MedImmune All 6 Months toPhase
36 Months
2 Â (Child)
173 Industry InterventioAllocation D153-P002
EDSS changHadassah M All 18 Years toPhase
60 Years
1|PhÂ (Adult)30 Other InterventioAllocation TCV-HMO-C
Biological: Vero Cell- Ology BiosAll 18 Years and
Phase
older
2|Ph
Â (Adult,
1400
Older
Industry
Adult) InterventioAllocation 231|Eudra
50 Years
OccurrenceCancer ResAll 18 Years and
Phase
older
1 Â (Adult, 16
Older
Other
Adult) InterventioPrimary PuCDR000067
PercentageMedImmunAll 18 Years toPhase
49 Years
Biological: 7.5ug H1NCenters fo All 6 Months toPhase
35 Months
3 Â (Child)
Rate of re-University Female 18 Years toPhase
75 Years
2 Â (Adult,75Older
Adult) 1996-295|
Number ofMerck ShaAll 18 Years and
Phase
older
1 Â (Adult, 37
Older
Industry
PregnancyEmergent BFemale Child, Adult, Older Ad 580 Industry|UObservatioObservatioEBS.AVA.0
Number ofMedImmune All 6 Years to 17
Phase
Years
2 Â (Child)240 Industry InterventioAllocation D153-P526
Number ofPfizer All 42 Days to Phase
55 Years
25 Years
Industry InterventioAllocation 107476 (M
A Phase I, First Affil All 18 Years toPhase
60 Years
1 Â (Adult)61 Other|InduInterventioAllocation GR2015VC
Any seriousPT Bio Far All 2 Months to 11 Months Â 4000
(Child)Industry ObservatioObservatioPMS Penta
Phase
older
2 Â (Adult,
1343
Older
Industry
the rate ofBeijing 302All 18 Years toPhase
50 Years
1|PhÂ (Adult)40 Other InterventioAllocation Beijing302
DiphtheriaSanofi Pas All 40 Years and
Phase
older
3 Â (Adult,342
Older
Industry
Adult) InterventioInterventi RPV04C
40 Years
Number ofTakeda All 18 MonthsPhase
to 45 Years
2 Â (Child,
360 Industry
Adult) InterventioAllocation INV-DEN-2
The seroprBritish Col All 29 Months to 51 Months Â (Child)
30 Other ObservatioObservatioCIHR 2009
HaEmek Med All Child, Adult, Older Ad 40 Other ObservatioObservatio 4180905
Antibody rWyeth is nAll 7 Weeks toPhase
10 Weeks
2 Â (Child)240 Industry InterventioAllocation 6029A1 D1
To determiAbramson FCemale 18 Years and
Phase
older
1 Â (Adult, 36
Older
Other|Indu
The number MedImmune All 6 Years to 17
Phase
Years
Number ofTokyo UnivAll 20 Years toPhase
85 Years
OtherAdult)InterventioAllocation IMSUT-PPK
seroconverThe UniverAll 21 Years and
Notolder
Applic
Â (Adult,240
Older
Other
Ratio of G Emergent BAll 18 Years toPhase
65 Years
Industry
Antibody tiSanofi Pas All 6 Months toPhase
19 Months
3 Â (Child)
Biological: MVA-CSO National InAll 18 Years toPhase
50 Years
1 Â (Adult) 0 NIH InterventioAllocation 04-070|NMIMR: CPN 042/03-0
Measure ofNational InFemale 15 Years to 25 Years Â (Child,
4791 Adult)
to 23 Months
3 Â1236
(Child)
Safety afeGlaxoSmithAll 9 Years to 13
Phase
Years
To evaluateImmunovati All 18 Years and
Phase
older
2 Â (Adult, 15
Older
Industry
Adult) InterventioInterventi ITL-022-H
Safety (locVaxInnate All 18 Years toPhase
49 Years
Incidence Merck ShaAll 18 Years and
Phase
older
3 Â (Adult,
5305
Older
Industry
Out-of-RanOsivax S.A All 18 Years toPhase
49 Years
1 Â (Adult)72 Industry InterventioAllocation OVX836-00
50 Years
1|PhÂ (Adult)
326 NIH|U.S. FInterventioAllocation RV 172|10
PercentageBavarian No All 18 Years toPhase
40 Years
Identificat Institut N Male 18 Years toNot
40 Years
ApplicÂ (Adult)24 Other InterventioInterventi INSERM-C1
Immunogen University All 18 Years and
Phase
older
4 Â (Adult,195
Older
Other
Adult) InterventioAllocation UPenn FLU
The incidenPeter MacCAll 18 Years and
Phase
older
1 Â (Adult, 32
Older
Other
Adult) InterventioInterventi MYPHISM
Incidence Merck ShaAll 18 Years and
Phase
older
3 Â (Adult,
1257
Older
Industry
64 Years
Safety - M U.S. Army All 18 Years toPhase
50 Years
1|PhÂ (Adult)24 U.S. Fed|I InterventioAllocation WRAIR 125
Seroconvers Chiang MaiAll 18 Years toPhase
60 Years
3 Â (Adult)132 Other InterventioAllocation MED-10-10
Estimated G laxoSmithAll 47 Months to 15 Years Â (Child) 1 Industry Observational 201477
15 Months
2 Â (Child)
The PrimarInstitut N All 18 Years toPhase
32 Years
1 Â (Adult)54 Other InterventioAllocation C14-80|20
Influenza vUniversity All 4 Years to 19
NotYears
Applic
Â (Child,
18540
Adult)
Other InterventioAllocation Version 3.
80 Years
1 Â (Adult,17Older
Adult) HP-000413
6 month ovWuerzburgAll 3 Years to 21
Phase
Years
1|Ph
Â (Child, Adult)
25 Other InterventioInterventi HIT-HGG R
Pro and anHealth Sci All 18 Years and
Phase
older
4 Â (Adult,150
Older
Other
Adult) InterventioAllocation AMRIC Dr.A
SeroconverChinese AcAll 2 Months toPhase
3 Months
4 Â (Child)
55 Years
50 Years
to describeJiangsu Pr All 3 Years to 7 Years Â (Child)7901 Other ObservatioObservatioJSEPI001
80 Years
1 Â (Adult,
1055Older
Industry
Change in Boston Med Female 16 Years toPhase
45 Years
Other InterventioAllocation H-39051
Safety University All 18 Years and
Phase
older
1 Â (Adult, Older
0 Other
Adult) InterventioAllocation PERFORMA
55 Years
4 Â (Adult)60 Industry InterventioInterventi EFC14375/
Biological: HIVAC-1e|National InAll 18 Years toPhase
60 Years
1 Â (Adult)35 NIH InterventioAllocation AVEG 002A|10538
Stage I: CoMerck ShaFemale 9 Years to 45
Phase
Years
3 Â (Child,
1990
Adult)
Industry InterventioInterventi V503-024
Incidence oCHU de Que Female 14 Years toPhase
16 Years
3 Â (Child)
3364 Other InterventioAllocation ICI-VPH-1
Impact of aCentre HosAll 65 Years and older Â (Older 1475
Adult)
Other|InduObservatioObservatio12-09|201
Biological: MN rgp120National InAll 18 Years toNot
60 Years
ApplicÂ (Adult)36 NIH InterventioMasking: DAVEG 014C|10562
The effect University All 18 Years toPhase
45 Years
MTD of IFNNational CaAll 18 Years and
Phase
older
1 Â (Adult, 33
Older
Immunogenic British Col All 18 Months to 3 Years Â (Child)50 Other ObservatioObservatioCIHR 2009
Time to relSidney KimAll 18 Years toPhase
70 Years
1 Â (Adult, 1Older
Other|NIHInterventioMasking:
Adult) NJ06118 CD
Biological: dendritic National CaAll 18 Years and
Phase
older
1 Â (Adult, 40
Older
ParasitemiaRadboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)40 Other InterventioAllocation BMGF2b
Clinical re University All 18 Years and
Phase
older
2 Â (Adult, 17
Older
Other
Adult) InterventioAllocation FD-R-0025
60 Years
Biological: dendritic Jonsson CoAll 18 Years and
Phase
older
1 Â (Adult, 14
Older
Adult) PuCDR000006
Number ofSanofi Pas All up to 3 Days
Phase
Â (Child)
3 622 Industry InterventioAllocation A3L15
Tetanus vaHospices CiAll 18 Years and older Â (Adult,261
Older
Other
To screen hNational InAll 18 Years to 50 Years Â (Adult)
1500 NIH ObservatioObservatio160039|16
National InAll 18 Years to 64 Years Â (Adult)30 NIH ObservatioObservatio06-0005
Humoral imNina BhardAll 18 Years and
Phase
older
2 Â (Adult, 43
Older
Other|Indu
Adult) InterventioAllocation GCO 14-07
Biological: HIVAC-1e|National InMale 18 Years toPhase
60 Years
1 Â (Adult)13 NIH InterventioMasking: NAVEG 002B|10539
Incidence rSK Chemical All 20 Years toPhase
59 Years
1 Â (Adult)100 Industry InterventioAllocation NBP607_Fl
Frequency Vaxart All 18 Years toPhase
49 Years
AssessmentGlaxoSmithAll up to 5 Years Â (Child) 1 Industry ObservatioObservatio 203129
Safety of vCentre HosAll 18 Years and
Phase
older
1|Ph
Â (Adult, 16
Older
Other|Indu
Adult) InterventioAllocation P009-2010
Absence / PNantes UniAll up to 16 Years Â (Child) 800 Other ObservatioObservatioRC15_032
25 Years
3 Â (Adult)
How fast doRijnstate HAll 18 Years and older Â (Adult, 60
Older
Other
Adult) ObservatioObservatioHepatitis A
26 Years
Retention|INorthwester Male 18 Years toNot
25 Years
ApplicÂ (Adult)
147 Other|NIHInterventioAllocation 1R21CA208
18 Years
2 Â (Child,
1063Adult)
GMT for AntValneva AuAll 18 Years and
Phase
older
3 Â (Adult,639
Older
Industry
Maximum Roswell
to ParFemale 18 Years and
Phase
older
1|Ph
Â (Adult, Older
Adult) I 243013|
Base Study:Merck ShaFemale 20 Years toPhase
45 Years
3 Â (Adult)
Effectiven University All 19 MonthsNotandApplic
older Â (Child,
78354Adult,
Change in aStatens Se All 18 Years and
Phase
older
4 Â (Adult,151
Older
Other
Adult) InterventioAllocation BJK001
Number ofMcMaster AUll 18 Years toPhase
55 Years
1 Â (Adult)28 Other InterventioAllocation M002
Efficacy agBharat BioAll 6 Weeks toPhase
7 Weeks
3 Â (Child)
6800 Industry|OInterventioAllocation BBIL/ROTA/0
Biological: Transgeni Cosmo BioMale 18 Years and
Phase
older
1 Â (Adult, 18
Older
Industry
Adult) InterventioAllocation TLI-CA-TRT
number ofCentre Hosp All 18 Years and
Phase
older
2 Â (Adult,104
Older
Other|Indu
Frequency Abt
o AssociaAll 18 Years and older Â (Adult,2400
Older
Industry|UObservatioObservatioHHSD2002
Adult)
Safety - SoLimmaTechAll 8 Months toPhase
50 Years
1|PhÂ (Child,
592Adult)
Industry|OInterventioAllocation S4V01
Number ofUniversity All up to 6 Months
PhaseÂ3 (Child) 16 Other InterventioAllocation Impfstudie
o All 18 Years toPhase
49 Years
1 Â (Adult)181 Industry InterventioAllocation mRNA-164
The share NPO PetroAll 18 Years toPhase
60 Years
2|PhÂ (Adult)
609 Industry InterventioAllocation GriQv-III-1
55 Years
1 Â (Adult)123 Industry|NInterventioAllocation 05-0005|A
Disease-fr National CaAll Child, AdulPhase 2 NIH InterventioPrimary PuCDR000006
Safety of University Female 18 Years and
Phase
older
1 Â (Adult, Older
Adult) 11276|UV
IgA AntiboNational C All 20 Years toNot
49 Years
ApplicÂ (Adult) 5 U.S. Fed InterventioInterventi IRB 604-20
90 Days1 Â (Child) 25 Industry InterventioInterventi 112581
ProportionUniversity All 18 Years toPhase
80 Years
3 Â (Adult,36Older
OtherAdult)InterventioAllocation DR190111-
Anti-Polyr GlaxoSmithAll 6 Weeks toPhase
15 Months
3 Â (Child)
HemagglutiNational InAll 18 Years toPhase
49 Years
Safety|HepaVaxine Pty All 18 Years and
Phase
older
1 Â (Adult,240
Older
Adult) HBV002
to 24 Months
3 Â 475
(Child)
38 Years
1|PhÂ (Adult)
Sero-respoUniversity All 12 Years toPhase
24 Years
Other|NIHInterventioAllocation ATN 024
SeroprotecCrucell Ho All 60 Years and
Phase
older
4 Â (Adult, 52
Older
Industry
Adult) InterventioAllocation INF-V-A00
Number ofGlaxoSmith
55 Years
2 Â (Adult)61 Industry|OInterventioAllocation 209003|17
Number ofNovavax
a All 65 Years and
Phase
older
2 Â (Older1375
Adult)
Industry InterventioAllocation qNIV-E-201
Incidence GlaxoSmithAll 42 MonthsPhase
to 9 Years
3 Â (Child)
PercentagePepTcell L All 18 Years toPhase
60 Years
2 Â (Adult)175 Industry|OInterventioAllocation FLU-v 003
63 Years
1 Â (Adult)24 Industry InterventioAllocation PHI-2012
24 Years
PercentageGlaxoSmithAll 18 Years and
Phase
older
4 Â (Adult,206
Older
Industry
AssessmentNational InAll 18 Years toPhase
45 Years
ProportionJoseph BaaFemale 18 Years and Early
older
Phas
Â (Adult, 29
Older
Other
Adult) InterventioInterventi CASE16107
PercentageTakeda All 6 Weeks toPhase
8 Years
2 Â (Child)840 Industry InterventioAllocation NOR-202|2
50 Years
1 Â (Adult)114 NIH InterventioAllocation IAVI V001
VolunteersRadboud Un All 18 Years toPhase
35 Years
1|Ph
Â (Adult) 0 Other InterventioAllocation MMV|NL42
Specific T- University All 18 Years toPhase
70 Years
1 Â (Adult, 9Older
Other
Adult)InterventioAllocation MyelomVa
The serocoJiangsu ProAll 60 Days to Phase
45 Years
1 Â (Child,100
Adult)
Other|InduInterventioAllocation 2017L0093
Drug: autologous tumo Boston Med All 18 Years andPhase
older
1 Â (Adult, Older
9 Other
Infant BehaUniversity All 2 Months to Phase
7 Months
3 Â (Child)
Immune res National CaAll 18 Years andPhase
older
2 Â (Adult, 40
Older
ProportionInstitut P All Child, Adult, Older Ad 3500 Industry|OObservatioObservatio2015-055
Immune T-cNational CaAll 18 Years andPhase
older
2 Â (Adult, 60
Older
NY-ESO-1-sLudwig InsAll 18 Years andPhase
older
1 Â (Adult, Older
9 Other
objective Affiliated All 18 Years toPhase
70 Years
1|Ph
Â (Adult,30Older
Other
Adult)InterventioInterventi 307-CTC-D
To assess tNewLink Ge All 18 Years andPhase
older
1|Ph
Â (Adult, Older
7 Industry
Adult) InterventioAllocation NLG0105
Average ofNational InAll 18 Years toPhase
55 Years
2 Â (Adult)25 NIH|OtherInterventioAllocation AIN504/A5
Immunogeni GlaxoSmithAll 4 Years to 6Phase
Years2Â (Child) 401 Industry InterventioAllocation 213503/04
Adverse evGeneos The All 18 Years andPhase
older
1|Ph
Â (Adult, 12
Older
Industry
Adult) InterventioInterventi GT-30
Number ofOlogy BiosAll 18 Years andPhase
older
1|Ph
Â (Adult,408
Older
Industry
Adult) InterventioAllocation 820902|EU
The primary MedImmunAll 18 Years toPhase
49 Years
40 Years
2 Â (Adult)252 Industry InterventioAllocation mRNA-164
To assess tStanford Un All 18 Years andPhase
older
1 Â (Adult, Older
0 Other
Adult) InterventioAllocation SU-09112008-1298|COR0008
40 Years
B-cell humo National InAll 18 Years toPhase
65 Years
1 Â (Adult,29Older
Adult) A5232|101
PercentageGlaxoSmithFemale 18 Years toPhase 45 Years
Phase
Years
2 Â (Child) 75 Industry InterventioAllocation 6096A1-30
AbstinenceCytos Biot All 18 Years toPhase
70 Years
Industry
Adult)InterventioAllocation CYT002-Ni
Biological: QS21|BioloMemorial SAll 16 Years andPhase
older
2 Â (Child, Adult,
24 Other|NIHInterventioPrimary
Older Adult) Pu99-012|CD
45 Years
Incidence London SchAll 5 Months to Phase
17 Months
3 Â 5920
(Child)
Other InterventioAllocation ITDCZJ29
Subjects rePfizer All 18 Years toPhase
49 Years
Adverse evLG Life Sci All 6 Weeks and older Â (Child, 3000
Adult,
Industry
Older Adult)
ObservatioObservatioLG-VFOS00
CutaneousSeoul Nati All 20 Years toPhase
60 Years
2|Ph
Â (Adult)
123 Other|InduInterventioAllocation CJ_SPX_301
Number ofSanofi
p Pas All 12 MonthsPhase
to 15 Years
4 Â (Child)
355 Industry InterventioInterventi HAF87|U11
Change FroMerck ShaAll 70 Years toPhase
89 Years
4 Â (Older 243
Adult)
PercentageGenentech,All 18 Years toPhase
64 Years
4 Â (Adult)91 Industry InterventioAllocation NA25256
GeometricValneva AuAll 18 Years andPhase
older
3 Â (Adult,192
Older
Industry
OccurrenceKing AbdulAll 18 Years toPhase
50 Years
1 Â (Adult)24 Other InterventioAllocation CT18/004/
Solicited a National InAll 18 Years toPhase
60 Years
Number and Immune Tar All 18 Years toPhase
55 Years
1 Â (Adult)48 Industry|OInterventioAllocation FP-01.1_C
ProgressioNantKwest,All 18 Years andPhase
older
2 Â (Adult, Older
0 Industry
Adult) InterventioAllocation QUILT-3.08
older
4 Â (Adult,667
Older
Industry
Number ofAbramson FCemale 18 Years and Phase
older
1 Â (Adult, Older
0 Other
Safety and Epimmune| All 18 Years toPhase
60 Years
1 Â (Adult)32 Industry|OInterventioAllocation EP-HIV-109
Number ofAffiris AG Male 18 Years toPhase
65 Years
1 Â (Adult,36Older
Industry
Adult)InterventioAllocation AFF007
Drug: Detox-B adjuvanNational Cancer Instit18 Years andPhase
older
1 Â (Adult, Older
NIHAdult) InterventioPrimary PuCDR000006
T Cell ImmNational CaAll 17 Years andPhase
older
2 Â (Child, Adult,
36 NIHOlder Adult)
InterventioAllocation NCI-2013-
Percent of National I All 7 Years to 12
Phase
Years
2 Â (Child)130 NIH InterventioAllocation P1047|101
Pneumococc Wyeth is nAll 70 Years andPhase
older
3 Â (Older938
Adult)
Hemagglutin Novavax All 65 Years andPhase
older
3 Â (Older
2650
Adult)
Industry InterventioAllocation qNIV-E-301
Number ofDalhousie All 50 Years toPhase
64 Years
1 Â (Adult)40 Other|InduInterventioAllocation CI1204
PercentageMCM Vaccin All 46 Days to Phase
Number ofSanofi Pas All Child, Adult, Older Ad 622 Industry ObservatioObservatioSTA10
to 18 Months
3 Â 847
(Child)
Industry InterventioAllocation A5I19
64 Years
3 Â (Adult)
HPV vaccinHospices CiFemale 9 Years to 18 Years Â (Child, Adult)
62 Other ObservatioObservatio69HCL18_0
microbiome Academisch All Child, Adult, Older Ad 76 Other|U.S.ObservatioObservatioAIGHD-CSP
Vaccine sa University Male 18 Years andPhase
older
1 Â (Adult, 40
Older
Other
Adult) InterventioAllocation VANCE01
Change in Andrew SikAll 18 Years andPhase
older
2 Â (Adult, 30
Older
Other|Indu
Maternal HLisa Christ Female 18 Years to 42 Years Â (Adult)287 Other ObservatioObservatio2008H026
45 Years
1|PhÂ (Adult)48 Other InterventioAllocation VAC055|20
Percent of Merck ShaAll 12 Years toPhase
12 Years
Drug relateMemorial SAll 18 Years andPhase
older
1 Â (Adult, 20
Older
Other|Indu
Biological: standard-tJohns HopkAll 2 Months to 15 Months Â (Child)
700 Other|InduObservatioObservatioGR059114
Tolerabili Merck ShaFemale 16 Years toPhase
23 Years
3 Â (Child,
3882 Adult)
Frequency ModernaTX, All 12 MonthsPhase
to 49 Years
1 Â (Child,
114 Industry
Adult) InterventioAllocation mRNA-165
55 Years
4 Â (Child,
3948Adult)
Industry InterventioInterventi 205341|V5
ProportionOhio StateAll 18 Years andNotolder
Applic
Â (Adult,624
Older
Other
undetectabFrench NatAll 18 Years andPhase
older
3 Â (Adult, Older
8 Other|Indu
Overall VacMedImmune All 18 Years and older Â (Adult,4411
Older
Industry|OObservatioTime
Adult) PerspMI-MA-18
Disease CoH. Lee MoffAll 18 Years andPhase
older
2 Â (Adult, 41
Older
Other|Indu
National TaAll 18 Years and older Â (Adult,185Older
Other
Adult) Observational 201002050
Solicited l University All 18 Years toPhase
65 Years
1 Â (Adult,60Older
Adult) HP-000625
The differ Mahidol UnAll 18 Years andNotolder
Applic
Â (Adult, 60
Older
Other
Adult) InterventioAllocation Si178/201
To estimateGlaxoSmithAll up to 5 Years Â (Child) 1270 Industry ObservatioObservatio 110467
InflammatoUniversity Male 30 Years toEarly
60 Years
PhasÂ (Adult)24 Other|NIHInterventioAllocation 14-13204
120 Years
1|PhÂ (Adult,
23 Older
OtherAdult)InterventioInterventi CDR00002
Public HeaAll 42 Months to 6 Years Â (Child)500 Other ObservatioObservatioDIPS
Evaluation Protein Sc All 18 Years toPhase
49 Years
3 Â (Adult)
65 Years
to assess Ludwig InsAll 18 Years andPhase
older
1 Â (Adult, 12
Older
Other
KnowledgeUniversity
a All 16 Years toNot
19 Years
ApplicÂ (Child,
120Adult)
Number ofSanofi All 2 Years to 55
Phase
Years
3 Â (Child,300
Adult)
Industry InterventioAllocation MTA51|UTN
Objective rSidney KimAll 18 Years toPhase
100 Years
Other|Indu
Adult)
InterventioAllocation J1790|IRB
Phase I (SaCureVac A Male 18 Years andPhase
older
1|Ph
Â (Adult,197
Older
Industry
Adult) InterventioAllocation CV-9104-0
The probabi GiveWell|NeAll 12 MonthsNot to 16
Applic
Months Â7500
(Child)
Safety of African MaAll 12 MonthsPhase
to 24 Months
1 Â (Child)
45 Other InterventioAllocation MSP3_TN_
T cell prol University All 18 Years to 65 Years Â (Adult,270Older
Adult)
30 Years
3 Â (Adult)
To determiNational CaAll 18 Years toPhase
99 Years
1 Â (Adult, 0Older
Dose-limitiJonsson CoAll 1 Year to 18Phase
7 Other|NIHInterventioInterventi CDR000042
The primarUniversity All 1 Month toNot 6 Months
Applic Â (Child)
151 Other InterventioAllocation H-04-18-4
older
4 Â (Adult,120
Older
Industry
Objective Huashan Ho All 18 Years toPhase
70 Years
OtherAdult)InterventioAllocation DC810011
Safety on Statens SerMale 18 Years toPhase
40 Years
1 Â (Adult)39 Other InterventioAllocation THYB-03
Vaccinatio Institut Pa All 9 Months andNot older
ApplicÂ (Child,
4000Adult,
Industry
Adult) 2017-048
The occurreNational InAll 18 Years toPhase
45 Years
13 Years
4 Â (Child)306 Industry InterventioInterventi 112682
safety in London SchFemale 18 Years toPhase
40 Years
3 Â (Adult)600 Other InterventioAllocation SCC 1433
Maximum Bellicum
to PMale 18 Years andPhase
older
1 Â (Adult, 18
Older
Adult) BP-PC-001
Anti-HA indSanofi Pas All 18 Years toPhase
60 Years
2 Â (Adult)62 Industry InterventioAllocation GID26
Biological: Fluzone National InAll 10 Weeks to Phase
22 Weeks
1 Â (Child)
Biological: APL 400-0 Wyeth-Leder All 18 Years toPhase
60 Years
1 Â (Adult) Industry InterventioMasking: N004|04/400-003-04
Anti-HBs s GlaxoSmithAll 15 Years andPhase
older
3 Â (Child,141
Adult,
Industry
Older Adult)
Immune res National InAll 18 Years toPhase
50 Years
1|PhÂ (Adult)
The proportDana-FarbeAll 18 Years andPhase
older
1 Â (Adult, 10
Older
Other|Indu
OccurrenceBavarian NAll 18 Years toPhase
32 Years
1 Â (Adult)50 Industry InterventioAllocation POX-ELS-0
Survey/QuesUniversity Female 18 Years and older Â (Adult,679Older
Other
Adult) ObservatioObservatio11-1149a
Biological: Influenz National InAll 18 Years toPhase
65 Years
1 Â (Adult,37Older
40 Years
National InAll 65 Years to 99 Years Â (Older60 Adult)
NIH ObservatioTime Persp05-0028
DetermineUniversity
t All 18 Years andPhase
older
1 Â (Adult, Older
Adult) CDR000006
Response RSidney KimAll 18 Years toPhase
70 Years
2 Â (Adult,36Older
Medically-GlaxoSmithAll Child, Adult, Older Ad 9206 Industry ObservatioObservatio 113585
HPV vaccinBoston Med All 9 Years to 65
NotYears
Applic
Â (Child, Adult,
60 Other
Older Adult)
InterventioInterventi H-36669
Incidence Roswell ParAll 18 Years andPhase
older
1 Â (Adult, Older
Adult) I 171010|
Cohort 1 aJanssen ReAll 18 Years toEarly
55 Years
PhasÂ (Adult)48 Industry InterventioAllocation CR108590
HBV DNA leChang Gung All 31 Years toPhase
76 Years
OtherAdult)InterventioAllocation 104-3167C
safety of KUniversity Female 18 Years toPhase
80 Years
1 Â (Adult,15Older
OtherAdult)InterventioAllocation 01 KV 954
Gene expreUniversity All 8 Weeks toPhase
12 Weeks
4 Â (Child)187 Other|InduInterventioAllocation OVG2012/0
serotype s University All 5 Weeks toPhase
18 Months
3 Â (Child)
600 Other InterventioAllocation PCV1+1
Median IL1Sidney KimAll 18 Years toPhase
100 Years
1|PhÂ (Adult,
62 Older
Other|NIH|
Adult)
InterventioAllocation J1568|IRB
DescriptiveUniversity All 14 MonthsPhase
to 26 Months
2 Â (Child)
90 Other InterventioAllocation OVG 2012/
older
3 Â (Adult,331
Older
Industry
Adult) InterventioInterventi 6115A1-30
Change in IDinsight| All Child, AdulNot Applic 60 Other InterventioAllocation 1
OccurrenceDalhousie All 18 Years toPhase
50 Years
1 Â (Adult)39 Other InterventioAllocation PE1201
Number ofNational CaAll 5 Years to 35
Phase
Years
2 Â (Child, Adult)
42 NIH InterventioInterventi 970052|97
To assess tInstitut Pa All 18 Years toPhase
70 Years
1 Â (Adult,20Older
Industry
Adult)InterventioInterventi 2014.14
Drug: Interleukin-12|National InAll 18 Years andPhase
older
1 Â (Adult, 12
Older
NIHAdult) InterventioPrimary PuA5049|AACTG A5049|10893|A
interferen London SchAll 9 Months to Phase
10 Months
4 Â 1504
(Child)
Other InterventioAllocation SCC 1327
50 Years
T Cell Act University All up to 24 Hours
PhaseÂ 2(Child) 149 Other InterventioAllocation MV-00-9-9
Biological: VRC-HIV National InAll 18 Years toPhase
50 Years
1|PhÂ (Adult)
Anti-Vi serGlaxoSmithAll 18 Years toPhase
65 Years
3 Â (Adult,
1034Older
Industry
immunomedi University All 18 Years toPhase
55 Years
4 Â (Adult)262 Other InterventioInterventi 01/2011 U
immunogenic Queen Saov All 15 Years toPhase
60 Years
4 Â (Child,210
Adult)
Other InterventioAllocation RC5301
Vaccine SaMassachuse All 18 Years toPhase
55 Years
1 Â (Adult) 8 Other InterventioAllocation 2008P-000
ProportionSanofi Pas All 46 Days to Phase
76 Days3 Â (Child)350 Industry InterventioAllocation HXM01C|20
Clinical e National I All 18 Years toPhase
35 Years
1 Â (Adult)12 NIH|OtherInterventioAllocation DAIT ITN0
EvaluationGlaxoSmithAll 8 Weeks toPhase
16 Weeks
older
4 Â (Adult,110
Older
Industry
Adult) InterventioInterventi MTA00093|
To compareUniformedAll S 18 Years to 50 Years Â (Adult)132 U.S. Fed|OObservatioObservatioIDCRP-053
DetermineSouthern
G CMale 18 Years andNotolder
Applic
Â (Adult,150
Older
Other|Indu
Adult) InterventioInterventi #33245
Immune stMackay Mem All 20 Years andPhase
older
2 Â (Adult,150
Older
Other
Adult) InterventioAllocation MMH-I-S-3
To determin University All 18 Years andPhase
older
1 Â (Adult, Older
1 Other
Adult) InterventioInterventi 12175A
Prevent acNovaDigm MaleT 17 Years toPhase
35 Years
2 Â (Child,382
Adult)
Industry|OInterventioAllocation NDV3A-006
Number ofJhpiego|UnAll Child, Adult, Older Ad 36 Other|U.S.ObservatioObservatioIRB000075
Anti-PRP anGlaxoSmithAll 15 MonthsPhase
and older
Industry
Adult) 101477
For safety Medical ReAll up to 3 DaysPhase
Â (Child)
1|Ph 72 Other InterventioAllocation PV002
Number and Emergent BAll 18 Years toPhase
50 Years
2 Â (Adult)187 Industry InterventioAllocation MS01.13
Safety of t University All 18 Years andNotolder
Applic
Â (Adult, 15
Older
Adult) NCDR000038
Biological: FluMist|BiNational InAll 5 Years to 9Phase
Years4Â (Child) 40 NIH InterventioAllocation 04-079
Biological: HER-2/neuUniversity All 18 Years toPhase
120 Years
1 Â (Adult, Older
OtherAdult)InterventioPrimary PuCDR000006
tabulation National CaAll 18 Years toPhase
99 Years
1 Â (Adult,41Older
to 24 Months
3 Â (Child)
85 Years
Industry
Local inje IDRI|Nation All 18 Years toPhase
55 Years
1 Â (Adult)48 Other|NIHInterventioAllocation IDRI-TBVP
50 Years
1 Â (Adult) 0 NIH|OtherInterventioAllocation HVTN 132|
12 Weeks
3 Â (Child)
Difference Evidation All 18 Years andNotolder
Applic
Â (Adult,
94321
Older
Industry
Adult) InterventioAllocation EH-008
older
1 Â (Adult,341
Older
Industry
Anti-hepatGlaxoSmithAll 12 MonthsPhase
to 13 Months
3 Â1474
(Child)
Cervical i GlaxoSmithFemale 15 Years toPhase
25 Years
2 Â (Child,
1113Adult)
ProportionSt. Justine Female 18 Years toPhase
60 Years
4 Â (Adult)
1240 Other InterventioAllocation MSSS-PERT
Number ofHerbert LyAll 18 Years andPhase
older
2 Â (Adult, 39
Older
Other|Indu
24 Months
4 Â (Child)
128 Industry InterventioInterventi 205336|V5
Number ofAlopexx
p VaAll 18 Years andPhase
older
1|Ph
Â (Adult, 16
Older
Industry
Adult) InterventioAllocation AV-101-16
DeterminatThe Hospita All 9 Months to Phase
18 Years
Number ofGlaxoSmithAll 6 Weeks to 24 Weeks Â (Child)
Immunogen Public HeaAll 7 Weeks toPhase
11 Weeks
4 Â (Child)392 Other InterventioAllocation sched1
To determiMemorial SMale 18 Years andPhase
older
1 Â (Adult, 15
Older
Other
Frequency GlaxoSmithAll 18 Years andPhase
older
2 Â (Adult,425
Older
Industry
to 18 Months
3 Â 745
(Child)
anti-PRP a GlaxoSmithAll 6 Weeks toPhase
8 Weeks
Number ofIDRI|Bill All 18 Years toPhase
49 Years
1 Â (Adult)39 Other InterventioAllocation IDRI-LVVPX
Grade 3 orNational I All 6 Years to 23
NotYears
Applic
Â (Child,101
Adult)
NIH InterventioAllocation P1061s|10
knowledge|u University Female 15 Years toPhase
60 Years
3 Â (Child,120
Adult)
Other InterventioAllocation 11-0231-E
Hospitaliz Internatio All 6 Months and older Â (Child,1860Adult,
Other|Indu
Older ObservatioObservatioICID-2012
Adult)
Toxicity|N National CaAll 1 Year to 74Phase
Years1|Ph
Â (Child, Adult,
10 NIHOlder Adult)
Number ofIDRI|AmeriAll 18 Years toPhase
55 Years
1 Â (Adult)24 Other InterventioAllocation IDRI-LEPVP
PathologicNantKwest,All 18 Years and
Phase
older
2 Â (Adult, Older
0 Industry
â€¢SeroproUniversity All 18 Years to 75 Years Â (Adult,61Older
OtherAdult)ObservatioObservatioKUOA-03-I
Safety as University Female 18 Years and
Phase
older
1 Â (Adult, 66
Older
Adult) 6532|NCI-
The percent University All 18 Years toPhase
49 Years
4 Â (Adult)135 Other|NIHInterventioAllocation 59331
Change in aNational InAll 18 Years toPhase
40 Years
1 Â (Adult)25 NIH|OtherInterventioAllocation DAIT ADVN
Solicited i National InAll 18 Years toPhase
40 Years
Biological: APL 400-0 Wyeth-Leder All 18 Years toPhase
60 Years
1 Â (Adult) Industry InterventioMasking: D005|400-003-05
safety of National UAll 21 Years toPhase
99 Years
OtherAdult)InterventioAllocation GA04/26/1
Rate of Su Valneva AuAll 9 Months toPhase
20 Years
Industry InterventioInterventi IC51-324
Immunogeni M.D. AnderAll 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Other
to 14 Months
2 Â 508
(Child)
Industry InterventioAllocation 104703 (Pr
Overall surHeinrich-HAll 18 Years and
Phase
older
2 Â (Adult,136
Older
Other
Adult) InterventioAllocation GlioVax
Phase I, N Nina BhardAll 18 Years and
Phase
older
1|Ph
Â (Adult, 34
Older
Other|Indu
Size of WheAlbert B. SAll 18 Years toNot
45 Years
ApplicÂ (Adult)87 Other InterventioInterventi SVI-06-01
Evaluate saAlphaVax, IAll 18 Years toPhase
40 Years
1|PhÂ (Adult)
216 Industry InterventioAllocation AVX502-00
Biological: Combinat National InAll 18 Years toPhase
60 Years
To provideSanofi All 56 Days to Phase
70 Days
3 Â (Child)442 Industry InterventioAllocation E2I28
Safety ind CanSino BiAll 18 Years toEarly
49 Years
PhasÂ (Adult)
120 Industry|OInterventioAllocation CS-CTP-PBPV-â… a
Memory B Imperial
C C All 18 Years to 55 Years Â (Adult)16 Other ObservatioObservatio16SM3542
Any seriousPT Bio Far Female 18 Years to 39 Years Â (Adult)
200 Industry|OObservatioObservatioTd0417
The appearNational InAll 18 Years toPhase
49 Years
4 Â (Adult)
2349 NIH InterventioAllocation 04-060|IR
Evaluation Protein Sc All 6 Months toPhase
59 Months
1|Ph Â (Child)
Glucose-HyUniversity All up to 7 Days Â (Child) 270 Other ObservatioObservatioPR14083
Safety and National InAll 18 Years and
Phase
older
1 Â (Adult, 18
Older
NIHAdult) InterventioAllocation P01AI0436
Immunologi Heat BiologAll 18 Years and
Phase
older
2 Â (Adult, Older
0 Industry
Adult) InterventioAllocation HS110-10-
Number ofProtein Sc All 50 Years toPhase
64 Years
3 Â (Adult)602 Industry InterventioAllocation PSC06
Plaque RedBavarian NAll 18 Years toPhase
42 Years
3 Â (Adult)440 Industry|UInterventioAllocation POX-MVA-
50 Years
To assess tBeth Israe All 18 Years and
Phase
older
1 Â (Adult, 45
Older
Other
To evaluateGlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,110
Older
Industry
Serious AdNational InAll 18 Years and
Phase
older
2 Â (Adult,
1500
Older
NIHAdult) InterventioAllocation 999915071
ProportionGary ArcheAll 3 Years to 35
Phase
Years
1 Â (Child, Adult)
30 Other InterventioInterventi Pro000798
Change in GlaxoSmithAll Child, Adult, Older Ad 474 Industry ObservatioObservatio 113385
University All 15 Years to 19 Years Â (Child,
255Adult)
Other ObservatioObservatioATN 006
Phase
older
4 Â (Adult,769
Older
Industry
Adult) InterventioAllocation TD526
Biological: gp160 Va National InAll 18 Years and
Phase
older
1 Â (Adult, 52
Older
NIH|Indust
Adult) InterventioPrimary PuACTG 137|11112
Barretos C Female 10 Years to 16 Years Â (Child)
1574 Other|InduObservatioObservatioVaccine HC
50 Years
1|PhÂ (Adult)41 U.S. Fed|OInterventioAllocation WRAIR 128
GeometricMerck ShaFemale 9 Years to 15
Phase
Years
OccurrenceAffiris AG All 40 Years toPhase
68 Years
1 Â (Adult,26Older
Industry
Adult)InterventioAllocation AFFiRiS 0
Number ofRhoVac APSMale 18 Years and
Phase
older
1|Ph
Â (Adult, 22
Older
Adult) RhoVac-00
120 Days
Efficacy anSidney KimAll 18 Years and
Phase
older
2 Â (Adult, Older
Adult) J0579 CDR
ProportionDynavax TeAll 18 Years and
Phase
older
3 Â (Adult,155
Older
Industry
Adult) InterventioAllocation DV2-HBV-1
Immune res Karolinska All 18 Years toPhase
90 Years
Objective Affiliated All 18 Years andPhase
older
1|Ph
Â (Adult, 30
Older
Other
Adult) InterventioInterventi 307-CTC-D
The serocoJiangsu ProAll 60 Days to Phase
90 Days2 Â (Child)600 Other|InduInterventioAllocation JSVCT042
Anti-dipht GlaxoSmithAll 5 Years to 6Phase
10 Weeks
older
2 Â (Adult, Older
2 Other
Adult) InterventioInterventi MCC 1495
Molecular M.D. AnderAll 18 Years andPhase
older
2 Â (Adult, Older
5 Other|Indu
Adverse evVac4All|CeAll 18 Years toPhase
44 Years
1|PhÂ (Adult)36 Industry|OInterventioAllocation Pf PEBS-Ia
GMCs of HP Murdoch Ch Female 15 Years to 17 Years Â (Child)200 Other ObservatioObservatio2014.5.FN
Drug: Anthrax Vaccin Eunice KenAll 18 Years toPhase
45 Years
50 Years
1 Â (Adult)30 NIH InterventioAllocation 11-I-N237|
cholera-re Brigham anAll 12 Months and older Â (Child,2207Adult,
Other|NIHObservatioObservatio2012P0003
Older Adult)
toxicity SouthwestAll 18 Years toPhase
80 Years
1 Â (Adult,14Older
Adult) S0114|U1
the vaccin Centre Hosp All 18 Years toNot
65 Years
ApplicÂ (Adult,
172Older
OtherAdult)InterventioInterventi PI-2019-02
The safety University All 18 Years toPhase
45 Years
Biological: HIV p24/ National InAll 18 Years toPhase
60 Years
1 Â (Adult)40 NIH InterventioMasking: DAVEG 032|10581
Response, Cedars-SinAll 18 Years andNotolder
Applic
Â (Adult, 69
Older
Other
45 Years
ApplicÂ (Adult)49 Other InterventioAllocation CRC305C
Number and Mayo ClinicAll 18 Years andEarly
older
Phas
Â (Adult, 30
Older
Adult) MC0578|P
Change in Imperial C All 2 Years to 18
Phase
Years
4 Â (Child,479
Adult)
Other InterventioInterventi 16SM3348|
ProportionLG Chem All 6 Weeks toPhase
8 Weeks
2 Â (Child)230 Industry InterventioAllocation LG-VECL00
Phase I: T Canadian CAll 18 Years andPhase
older
1|Ph
Â (Adult, 56
Older
Other
Adult) InterventioAllocation I214
Safety Obj Seqirus Female Child, Adult, Older Ad 550 Industry ObservatioObservatioCSLCT-OBS
Local and sNational InAll 18 Years toPhase
50 Years
Vaccine-relGlaxoSmithMale 18 Years toPhase
75 Years
1 Â (Adult,25Older
Industry
patients' c Yonsei UniAll up to 5 Years Â (Child) 200 Other|InduObservatioObservatiorota-001|y
CHMP criteSK Chemical All 6 Months to Phase
18 Years
Industry InterventioAllocation NBP607-QI
Biological: VRC-HIVA National InAll 18 Years toPhase
50 Years
Biological: HER-2/neuUniversity All up to 120 Years
PhaseÂ1 (Child, Adult,
60 Other
Older Adult)
InterventioInterventi 14798|UW-
Number ofU.S.a Army All 18 Years toPhase
45 Years
1 Â (Adult)40 U.S. Fed InterventioAllocation A-16682|N
25 Years
Ability to University All 18 Years andPhase
older
1 Â (Adult, Older
Adult) 7266|NCI-
12 Weeks
2 Â (Child)
1104 Industry InterventioAllocation 102370 (pr
26 Years
Immunogeni GlaxoSmithAll 12 Weeks to Phase
16 Weeks
3 Â (Child)
SeroconverHepNet StuAll 18 Years toPhase
60 Years
Safety ass UMN Pharm All 20 Years andPhase
older
3 Â (Adult, 55
Older
Industry
Hepatitis AUniversity All 12 Years toNot
15 Years
ApplicÂ (Child)60 Other InterventioAllocation HEP-2016
Number ofIDRI All 18 Years toPhase
45 Years
older
3 Â (Older
68000
Adult)
Industry InterventioAllocation QHD00012|
Number and Novavax All 60 Years andPhase
older
1|Ph
Â (Adult,330
Older
Industry
Adult) InterventioAllocation tNIV-E-101
Patient wi Stanford Un All 17 Years toPhase
70 Years
1|PhÂ (Child,30
Adult,
Older Adult) BMT155|7
CHMP criteSK Chemical All 6 Months to Phase
18 Years
Industry InterventioAllocation NBP607_Fl
Immunogen Public HeaAll 50 Years toPhase
79 Years
OtherAdult)InterventioAllocation PNCA
PercentageTongji Hos All 18 Years toPhase
65 Years
4 Â (Adult,94Older
Other|Indu
Adult)InterventioAllocation Endeavor st
70 Days3 Â (Child)600 Industry InterventioAllocation IPV13
Phase
older
1|Ph
Â (Adult,590
Older
Industry
Adult) InterventioAllocation pPCV-001
Safety|Imm DermatologiAll 18 Years and
Phase
older
1|Ph
Â (Adult, 30
Older
Other
Biological: gp160 Va National InFemale 16 Years toPhase
40 Years
NIH InterventioInterventi ACTG 234|VEU 102|11211
Estimate thNational CaFemale 30 Years to 38 Years Â (Adult)
869 NIH ObservatioObservatio999917173
Rabies Vir GlaxoSmithAll 10 Years toPhase
22 Years
Industry InterventioInterventi 205634|V4
To assess National InAll 18 Years toPhase
50 Years
Immune reDana-Farber All Child, AdulPhase 2 40 Other|NIHInterventioAllocation CDR000036
50 Years
1 Â (Adult)32 Other InterventioAllocation IAVI P002
Quantifica University All 18 Years toPhase
50 Years
1 Â (Adult)40 Other InterventioAllocation TB015|COR
11 Weeks
Relapse-fr University All 18 Years and
Phase
older
2 Â (Adult, 38
Older
Adult) 6166 (FH/
Incidence NantKwest,All 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Industry
Safety(PhasKinki Univ All 20 Years toPhase
80 Years
1 Â (Adult, 7Older
Frequency SahlgrenskAll
o 18 Years to 80 Years Â (Adult,
110Older
OtherAdult)ObservatioObservatioMMV-305
Incidence Gritstone All 18 Years and
Phase
older
1|Ph
Â (Adult,214
Older
Industry
Adult) InterventioAllocation GO-004
Immunogeni Themis Bi All 18 Years toPhase
55 Years
1 Â (Adult)48 Industry InterventioAllocation MV-ZIKA-1
To determinNational CaMale 18 Years toPhase
85 Years
1 Â (Adult,30Older
NIH Adult)InterventioPrimary Pu050167|05
38 Years
2 Â (Adult)524 NIH InterventioAllocation 09-0002|P
Safety and Crucell Ho All 19 Years toPhase
65 Years
Industry
Adult)InterventioAllocation RAB-M-A0
to 60 Months
3 Â 270
(Child)
Biological: GVAX leukCell GenesAll 18 Years toPhase
60 Years
2 Â (Adult)55 Industry InterventioAllocation K-0009
Rabies NeutQueen Saov All 15 Years toNot
60 Years
ApplicÂ (Child,
105Adult)
Other InterventioAllocation RC5506
70 Years
OtherAdult)InterventioInterventi 307-DC/CI
To evaluat Maria LiljeAll 18 Years and
Phase
older
1|Ph
Â (Adult, 20
Older
Other|Indu
Adult) InterventioAllocation El-porCEA
GeometricNovartis All 18 Years toPhase
43 Years
1 Â (Adult)315 Industry InterventioAllocation V113_01E1
Solicited BiomedicalAll 18 Years toPhase
49 Years
2 Â (Adult)366 U.S. Fed|I InterventioAllocation BP-I-17-0
The fold-i Dana-FarberAll 18 Years and
Phase
older
1 Â (Adult, 45
Older
Adult) 18-202|1P
56 Days3 Â (Child)226 Industry InterventioAllocation E2I41
ome|HIV Infections National InAll Child, Adult, Older Ad 200 NIH ObservatioObservatio5R01AI047
Describe thCentral HosAll 18 Years and
Phase
older
4 Â (Adult, 40
Older
Other
Percent of University All 18 Years toPhase
65 Years
1 Â (Adult,24Older
Adult) 18-2502|U
SeroprotecLG Life Sci All up to 6 Months
PhaseÂ3 (Child) 289 Industry InterventioAllocation LG-VACL00
60 Years
2 Â (Adult)402 Industry|OInterventioAllocation PRO-PanFl
NP-specificOsivax S.A.All 18 Years toPhase
65 Years
Adult) OVX836-00
ProportionSociety forAll 6 Weeks toNot
7 Weeks
ApplicÂ (Child)
400 Other InterventioAllocation SAS/RCN/2
The primaryUniversity Male 18 Years and
Phase
older
1 Â (Adult, 22
Older
Adult) 2004-036
Evaluation Clinica Un All 18 Years toPhase
70 Years
2 Â (Adult,26Older
OtherAdult)InterventioInterventi DEND/GM|
Immunogeni Novavax|PFemale 18 Years toPhase
35 Years
2 Â (Adult)330 Industry|OInterventioAllocation NVX757.20
PercentageMerck ShaAll 3 Months toPhase
3 Months
1 Â (Child)
45 Years
NeutralizinNovavax All 60 Years toPhase
80 Years
Industry
Adult)InterventioAllocation RSV-E-205
evaluate s AlphaVax, IAll 18 Years toPhase
45 Years
1 Â (Adult)40 Industry InterventioAllocation AVX601-00
Phase
older
3 Â (Adult,606
Older
Industry
Adult) InterventioAllocation VRV13|201
Safety and TechnischeAll 18 Years and
Phase
older
1 Â (Adult, Older
2 Other
Adult) InterventioInterventi ATZ-1068-
Drug: interleukin-2| National Cancer Instit16 Years andPhase
older
1 Â (Child, Adult,
NIHOlder Adult)
Number ofOswaldo CrAll 8 Years to 11
Phase
Years
2 Â (Child) 95 Other InterventioAllocation Sm14 Phase
59 Years
Rate of subValneva AuAll 65 Years andPhase
older
Years3Â (Child)1045 Industry InterventioAllocation TD517
Number ofGlaxoSmithFemale 26 Years and Phase
older
3 Â (Adult,164
Older
Industry
Objective Fuzhou Gen All 18 Years andPhase
older
1|Ph
Â (Adult,100
Older
Other
Adult) InterventioAllocation fuzhough0
Incidence Merck ShaAll 50 Years toPhase
59 Years
3 Â (Adult)
Biological: Diphtheri National I All 2 Years to 18
NotYears
Applic
Â (Child,300
Adult)
NIH InterventioPrimary PuP1024|PACTG 1024|10609|AC
vaccinationMichael A.All Child, Adult, Older Ad 10000 Other ObservatioObservatioHMvax-regi
Hepatitis St. Joseph All 18 Years andPhase
older
4 Â (Adult,200
Older
Other
60 Years
3 Â (Adult)900 Industry InterventioAllocation DEN-305|U
Immunogeni Nabi BiophAll 18 Years toPhase
55 Years
3 Â (Adult)260 Industry InterventioAllocation Nabi-4516
PercentageCentral HosAll 6 Months to 17 Years Â (Child)500 Other ObservatioObservatio2019-A019
Number ofRoss
p UniverAll Child, AdulPhase 4 159 Other|InduInterventioInterventi 18-13-EX
Anti-HBs aGlaxoSmithAll 7 Years to 9Phase
To determiLudwig InsAll 18 Years andPhase
older
1|Ph
Â (Adult, 14
Older
Other
Number ofVical All 18 Years toPhase
50 Years
1|PhÂ (Adult)
165 Industry InterventioAllocation HSV2-101
Number ofBaylor Col All 18 Years andPhase
older
1 Â (Adult, 24
Older
Other
Adult) InterventioInterventi H-42712 M
Anti-HBs aGlaxoSmithAll 4 Years to 6Phase
Adverse evInstituto All 18 Years toPhase
26 Years
1 Â (Adult)25 Other InterventioAllocation TAMOVAC-
Anti-HPV-1GlaxoSmithFemale 9 Years to 14 Phase
Years
To determinDana-FarbeAll Child, AdulPhase 1 12 Other InterventioAllocation 05-115
Toxicity m JosÃ© Mord All 17 Years toPhase
60 Years
Other InterventioInterventi 4484/04
- To comparMedImmune All 6 Weeks toPhase
24 Weeks
safety ass Sheba Medi All 16 Years toPhase
60 Years
1|PhÂ (Child,20
Adult)
Other InterventioAllocation SHEBA-98-
ProportionInstitut Pa All Child, Adult, Older Ad 1150 Industry|OObservatioObservatio2017-056
Immune Res Massachuse Female 18 Years and Phase
older
1 Â (Adult, 20
Older
Other|Indu
InvestigateHadassah M All 55 Years andPhase
older
1|Phase
Â (Adult,
2 Older
Other
The safety MedImmune All 18 Years andPhase
older
3 Â (Adult,120
Older
Industry
Adult) InterventioAllocation D153 P510
Number ofJudit
P Pich MartÃ
All nez|Fundacion
18 Years andPhase
Clinic
older
per
1 Â a(Adult,
la Recerca
36
Older
Other
BiomÃ©dica
Adult) InterventioAllocation DCV3/RisV
Response|C National CaAll 16 Years andPhase
older
2 Â (Child, Adult,
11 NIHOlder Adult)
39 Years
1 Â (Adult)100 U.S. Fed|I InterventioAllocation S-12-12|1
Level of C Ottawa HosAll 18 Years andNotolder
Applic
Â (Adult,300
Older
Other
Adult) InterventioAllocation TPA 90189
Efficacy i National HeAll 18 Years toPhase
85 Years
2 Â (Adult,10Older
Phase
Years
The protectUniversity All 5 Months to Phase
17 Months
1|Ph Â (Child)
To demonstrEastern Vi Female 18 Years toNot 26 Years
ApplicÂ (Adult)
100 Other|InduInterventioInterventi 33249
Number ofCarnegie MAll 18 Years toNot
100Applic
Years Â (Adult,
12531 Older
OtherAdult)InterventioAllocation P30AG034
Antibody RMerck ShaAll 12 MonthsPhase
to 15 Months
4 Â 653
(Child)
THE TITER Laureate InFemale 18 Years toNot 55 Years
ApplicÂ (Adult) 6 Other InterventioAllocation LIBR # 201
older
3 Â (Adult,473
Older
Industry
GeometricUniversity All 18 Years toPhase
65 Years
2 Â (Adult,90Older
OtherAdult)InterventioAllocation 1036320|5
Change in sOttawa HospAll 25 Years toNot
45 Years
ApplicÂ (Adult)40 Other InterventioAllocation 20170081-
Local tolerArchivel FaAll 18 Years toPhase
50 Years
2 Â (Adult)95 Industry InterventioAllocation RUTISAPH
To determin Cytheris S All 18 Years andPhase
older
1|Ph
Â (Adult, 24
Older
Industry
Adult) InterventioAllocation CLI-107-1
Rate of HPUniversity All 11 Years toNot
17 Years
ApplicÂ (Child)10 Other|U.S.InterventioAllocation STUDY000
Incident c GlaxoSmithFemale 20 Years toPhase30 Years
Type of ac Sanofi Pas All Child, Adult, Older Ad 1633 Industry ObservatioObservatioCYD00082|
Change in pThe UniverAll 11 Years toNot
17 Years
ApplicÂ (Child)
1000 Other InterventioAllocation HSC-SPH-1
ProportionLG Life Sci All 49 Days to Phase
84 Days3 Â (Child)217 Industry InterventioAllocation LG-VHCL00
MicroneutrCenters fo All 18 Years toPhase
65 Years
Adult) 7179
GeometricState
M Univ All 18 Years toPhase
60 Years
4 Â (Adult)103 Other|U.S.InterventioAllocation 790117
The primarCosmo BioAll 18 Years andPhase
older
2 Â (Adult, 20
Older
Industry
Adult) InterventioInterventi CB-10-01-
Number ofLG Chem All 19 Years toPhase
55 Years
1 Â (Adult)42 Industry InterventioAllocation LG-VDCL00
Biological: ras pepti Memorial SAll 17 Years andPhase
older
1 Â (Child, Adult,
Older Adult) Pu98-037|MS
Immunogenic Barbara Ensoli,
All MD|Italian
18 Years
Ministry
toPhase
45 Years
of 2Foreign
Â (Adult)
Affairs
200 Other
- General Direction
for Cooperation
ISS T-003
and Development|Istituto
Toxicity o Japanese FAll 20 Years toPhase
75 Years
1 Â (Adult, 6Older
OtherAdult)InterventioInterventi TB-454
Overall surHoag Memor All 16 Years andPhase
older
2 Â (Child,200
Adult,
Other
Older Adult)
Safety of HFred HutchAll 18 Years toPhase
55 Years
1 Â (Adult)10 Other|InduInterventioInterventi 49596-J|8
Antibody rWyeth is nAll 57 Days to Phase
112 Days
Number ofPT Bio Far All up to 1 DayPhase
Â (Child)
4 143 Industry InterventioInterventi bOPV 0416
50 Years
Number ofSanofi
55 Years
1|PhÂ (Adult)
381 Industry InterventioAllocation HSV15|U11
Postdose SAstraZenecAll 12 Years toPhase
21 Years
Industry InterventioAllocation D3250C00
FLACC obser MMJ Labs LAll 4 Years to 6Not
Years
Applic
Â (Child) 60 Industry|NInterventioAllocation 08-028|1R
PercentageBiosearch SAll 65 Years andPhase
older
2 Â (Older Adult)
98 Industry InterventioAllocation P039
Number ofXiangya Hos All 18 Years toPhase
75 Years
1 Â (Adult,30Older
OtherAdult)InterventioInterventi XYM001
65 Years
Industry
Adverse Eve Yonsei UnivAll 19 Years toNot
35 Years
ApplicÂ (Adult)15 Other InterventioAllocation 1-2017-00
Efficacy: T French NatAll 18 Years toPhase
65 Years
OtherAdult)InterventioAllocation EHVA T01/
Post-dose 3GlaxoSmithAll 56 Days to Phase
83 Days3 Â (Child)
Number ofNational I All 2 Months andPhase
older
Adult) 2015-IPOV
PercentageFrench NatAll 21 Years toPhase
55 Years
Immune resp Oryx GmbHAll 18 Years andPhase
older
1 Â (Adult, 11
Older
Industry
Adult) InterventioInterventi VICORYX-2
73 Years
3 Â (Adult,
1954Older
Industry
% of gradeLudwig-Max All 18 Years toPhase
75 Years
50 Years
1 Â (Adult)20 U.S. Fed InterventioAllocation S-10-0003|
University All 12 Months to 16 Months Â (Child)32 Other ObservatioTime PerspDMID 03-1
Neutralizi PaxVax, In All 18 Years toPhase
65 Years
2 Â (Adult,60Older
Adult) EBSI-CV-31
GeometricTakeda
M All 18 Years toPhase
60 Years
3 Â (Adult)924 Industry InterventioAllocation DEN-304
Provision oUniversity Female 18 Years toNot 45 Years
ApplicÂ (Adult)
420 Other InterventioAllocation Pro000073
Mortality|Bandim Hea All up to 30 Days
Phase
Â (Child)
4 3361 Other InterventioAllocation CVK-2013-
Percent of National I All 9 Months to Phase
24 Months
2 Â (Child)
220 Other InterventioAllocation 2017-JECE
65 Years
3 Â (Adult,
1197Older
Industry
Adult)InterventioAllocation V920-012|
SeroprotecCrucell Ho All 18 MonthsPhase
to 47 Months
4 Â 251
(Child)
Industry InterventioAllocation EPA-V-A00
Difference Leiden UniAll 18 Years toNot
45 Years
ApplicÂ (Adult)23 Other InterventioAllocation ITCHHI
Immunoglobu Merck ShaAll 7 Months to Phase
17 Years
Biological: gp160 Va National InAll 18 Years toPhase
60 Years
1 Â (Adult)22 NIH InterventioPrimary PuAVEG 013A|10559
Cellular i National CaFemale 18 Years and Phase
older
1|Phase
Â (Adult,
2 OlderNIHAdult) InterventioAllocation CDR000006
Number ofMerck ShaAll 6 Weeks toPhase
47 Years
ProgressioNational CaAll 18 Years toPhase
100 Years
Incidence oLondon SchAll 18 MonthsPhase
to 24 Months
3 Â1200
(Child)
Other InterventioAllocation ITDCVG31
12 Weeks
12 Weeks
3 Â (Child)0 Industry InterventioAllocation V260-036
Vaccinatio Asan MedicAll 18 Years and older Â (Adult,287Older
Other
49 Years
1 Â (Adult)271 Industry InterventioAllocation ZIK-101|U
Local ReacNational I All 15 Years toPhase
35 Years
2 Â (Child,
2338 Adult)
NIH|IndustInterventioAllocation VRC 705
Area UnderJanssen VaAll 18 Years toPhase
50 Years
50 Years
Incidence Makerere UAll 2 Years to 12
Phase
Years
2|Ph
Â (Child)150 Other InterventioAllocation #REC REF
Dose limitiRoswell ParAll 18 Years andPhase
older
1|Ph
Â (Adult,181
Older
Adult) I 286816|
Safety: Sa Merck ShaAll 18 Years toPhase
35 Years
Biological: GM2-KLH vMemorial SAll 18 Years andPhase
older
1 Â (Adult, Older
Adult) Pu97-123|MS
Biological: TherapeutNational InAll 18 Years and older Â (Adult, 78Older
NIHAdult) ObservatioTime PerspA5172|10184|ACTG A5172
Safety as ImmunoVacc Female 18 Years andPhase
older
1 Â (Adult, 37
Older
Industry
Immunogeni Ottawa HosAll 18 Years toPhase
60 Years
3 Â (Adult)285 Other InterventioAllocation CTN237
Self-ReporUniversity All 65 Years toNot
85 Years
ApplicÂ (Older
650
Adult)
To evaluat GlaxoSmithFemale 10 Years toPhase
14 Years
20 Years
Industry InterventioAllocation 101695 Ex
Rate of DisYale UniverAll 18 Years andPhase
older
1 Â (Adult, 51
Older
Other
Frequency Wayne StatFemale 18 Years toPhase
50 Years
1 Â (Adult)37 Other|InduInterventioInterventi 0412GARDA
Phase
Years
3 Â (Child)
To provideSanofi All 4 Years to 6Phase
Years4Â (Child) 123 Industry InterventioAllocation E2I57|UTN
Event-free National CaAll 18 Years andPhase
older
1|Ph
Â (Adult, 37
Older
The proporThe UniverAll Child, AdulNot Applic 2800 Other InterventioAllocation GML003.4
Cellular imNational InAll 18 Years toPhase
45 Years
OccurrenceSumagen All 18 Years toPhase
50 Years
1 Â (Adult)33 Industry InterventioAllocation SAV-CT01
5 Years
4 Â (Child)
6200 Other InterventioAllocation 91096-2do
Safety of t Karolinska All 18 Years toPhase
74 Years
1 Â (Adult,10Older
OtherAdult)InterventioAllocation MAT-02|20
Participan Sanofi Pas All 18 Years toPhase
55 Years
2 Â (Adult)18 Industry InterventioAllocation MTA16
The percent ProbiomicsAll 18 Years toPhase
49 Years
1|PhÂ (Adult)
300 Industry InterventioAllocation ProFlu200
Overall R UNC LinebeFemale 18 Years toPhase
120 Years
Adult) LCCC 0310
Faces Pain Nantes UniAll 4 Years to 15
NotYears
Applic
Â (Child)220 Other InterventioAllocation RC17_003
Primary CoAduro BiotAll 18 Years andPhase
older
2 Â (Adult,303
Older
Adult) ADU-CL-04
64 Years
12 Weeks
PercentageLeiden UnivAll 18 Years andPhase
older
4 Â (Adult, 51
Older
Other
Adult) InterventioAllocation MICH P10.
Overall surEli Lilly All 18 Years andPhase
older
3 Â (Adult,515
Older
Adult) SILVA EOR
Adverse effNational InAll 65 Years andPhase
older
2 Â (Older180
Adult)
Other: Survey Ann & RoberMale 9 Years to 26 Years Â (Child,800
Adult)
Other ObservatioTime PerspMerck IISP
Level of P Womack Arm All 18 Years andNotolder
Applic
Â (Adult,300
Older
U.S.Adult)
Fed InterventioAllocation 416446
Immunogeni Menzies ScAll up to 38 Days
Phase
Â (Child)
4 425 Other InterventioAllocation 605810|A
18 Years
Biological: APL 400-0 Apollon|NIH All 18 Years andPhase
older
1 Â (Adult, 16
Older
Industry
Adult) InterventioMasking: N089|APL 400-003RX101
Local respoNational CaAll 18 Years and
Phase
older
2 Â (Adult, 28
Older
Incidence oGlaxoSmithAll 18 Years toPhase
64 Years
3 Â (Adult)
Seroconvers Crucell Ho All up to 1 DayPhase
Â (Child)
3 1738 Industry InterventioAllocation HVG-V-A00
To performMedImmune All 18 Years toPhase
60 Years
2 Â (Adult)240 Industry InterventioAllocation D153 P003
Number ofLudwig InsAll 18 Years and
Phase
older
1|Ph
Â (Adult, 56
Older
Other|Indu
Number and PATH|InterAll 5 Years to 39
NotYears
Applic
Â (Child,103
Adult)
Other InterventioAllocation VAC 008|P
To assess VanderbiltAll 8 Years to 18 Years Â (Child, Adult)
17 Other|U.S.ObservatioObservatioCISA 2013
Biological: ras pepti Memorial SAll 17 Years and
Phase
older
1 Â (Child, Adult,
Older Adult) Pu99-028|CD
Anti-HBs I GlaxoSmithAll 12 Years toPhase
13 Years
4 Â (Child)301 Industry InterventioInterventi 106793|20
39 Years
Likelihood Philipps U All 18 Years toNot
69 Years
OtherAdult)InterventioAllocation ROMA_199
All episodeMedImmune All 11 MonthsPhase
to 24 Months
2 Â1200
(Child)
Industry InterventioAllocation D153-P522
65 Years
U.S. Fed
Phase
Years
Frequency Hospices CiFemale 11 Years to 19 Years Â (Child,
150Adult)
Other ObservatioObservatio69HCL19_0
Physical e Statens SerAll 18 Years toPhase
55 Years
1 Â (Adult)20 Other InterventioAllocation THYB-02
safety (loc National InAll 18 Years toPhase
70 Years
1 Â (Adult,51Older
Overall SurLeo W. JenAll 18 Years and
Phase
older
2 Â (Adult, 24
Older
Other
Adult) InterventioAllocation LJCC 09-0
to 24 Months
3 Â 831
(Child)
PneumococFakultas K All Child, AdulPhase 4 56 Other InterventioAllocation 1
Phase
Years
4 Â (Child, Adult)
18 Other|NIHInterventioAllocation SU-24965|
Drug: Id-KLH Vaccin National CaAll 18 Years and
Phase
older
1 Â (Adult, 42
Older
NIHAdult) InterventioPrimary Pu960133|96
14 Weeks
3 Â (Child)
to 23 Months
2 Â 257
(Child)
AUC|Cmax| H. LundbecAll 50 Years toPhase
85 Years
1 Â (Adult, 3Older
Industry
Adult)InterventioAllocation 18086A
Change froUppsala UnAll 17 Years and
Phase
older
2 Â (Child, Adult,
85 Other
Older Adult)
InterventioAllocation EPN 00-25
Biological: BCG vacci Ludwig InstAll 18 Years and
Phase
older
1 Â (Adult, Older
Adult) NCDR00003
Biological: QS21|BiolFox Chase All 18 Years and
Phase
older
1 Â (Adult, Older
Adult) FCCC-9802
Biological: recombinaUConn HeaAll 18 Years toPhase
120 Years
OtherAdult)InterventioInterventi UCHC-0111
To provideSanofi Pas All 18 Years toPhase
57 Years
2 Â (Adult)978 Industry InterventioAllocation GID15
To assess tShanghai W All 18 Years toPhase
45 Years
1 Â (Adult)70 Industry|OInterventioAllocation WanMal00
Safety if l Craig L Sli All 18 Years toPhase
120 Years
1|PhÂ (Adult,
173 Older
Adult) N11491|UVA
Number ofNational CaAll 19 MonthsPhase
to 35 Years
1|Ph Â (Child,
44 NIH
Adverse evKiromic, InAll Child, AdulPhase 1|Ph 3 Industry InterventioInterventi KIROVAX-0
- Changes iCanadian PAll up to 16 Years Â (Child) 2500 Other|InduObservatioObservatioROTA 2010
30 Years
40 Years
1|PhÂ (Adult)
132 NIH|Other| InterventioAllocation HVTN 107
SeropositivBaxter HeaAll 25 Years and
Phase
older
4 Â (Adult,243
Older
Industry
Biological: PSA prost University Male 18 Years toPhase
120 Years
2 Â (Adult, Older
Adult) PuMSGCC-007
Biological: alpha fet Jonsson CoAll 18 Years and
Phase
older
1|Ph
Â (Adult, Older
Adult) PuCDR0000389221|UCLA-030200
Anti-hepatiGlaxoSmithAll 16 Years toPhase
20 Years
to 23 Months
4 Â 283
(Child)
Number ofGlaxoSmithAll 6 Weeks to 167 Days Â (Child)332 Industry ObservatioObservatio 112896
Vaccine indEuroVacc FAll 18 Years toPhase
45 Years
1 Â (Adult)49 Other InterventioInterventi EV07
Safety and Crucell Ho All 5 Years to 17
Phase
Years
2 Â (Child) 48 Industry InterventioAllocation RAB-M-A0
60 Years
1 Â (Adult)20 NIH InterventioPrimary PuAVEG 013B|10560
Biological: NY-ESO-1 National CaAll 16 Years and
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
InterventioMasking: NCDR000006
Use of a FHI 360|MiAll 18 Years and
Notolder
Applic
Â (Adult,800
Older
Other
Anti-hepatCrucell Ho All 12 MonthsPhase
to 15 Months
3 Â 327
(Child)
Industry InterventioAllocation CR106637|
Whether thThe Immuno All 12 MonthsPhase
to 23 Months
4 Â 240
(Child)
Other InterventioAllocation Asclin 003
The effect Green CrosAll 19 Years and
Phase
older
3 Â (Adult,
1630
Older
Industry
Adult) InterventioAllocation GC3106_A
Safety: detNational InAll 18 Years toPhase
40 Years
1 Â (Adult)21 NIH InterventioAllocation 05-0009|T
safety|fea Memorial SAll 18 Years and
Phase
older
1 Â (Adult, 15
Older
Adult) 03-125|MS
Determinati GlaxoSmithAll up to 15 Years Â (Child) 1 Industry ObservatioObservatio 116721
to 64 Months
4 Â 288
(Child)
Safety of Massachuset All 18 Years toPhase
65 Years
1|Ph
Â (Adult,15Older
Adult) 2008p0015
Changes inDag Kvale|All 18 Years toPhase
65 Years
2 Â (Adult,60Older
OtherAdult)InterventioAllocation OUSCOX2
Number ofNational CaAll 18 Years and
Phase
older
2 Â (Adult, Older
4 NIHAdult) InterventioInterventi 080056|08
To confirmUniversity All 12 Years to 25 Years Â (Child,
337Adult)
Other|NIHObservatioObservatioATN 052
GeometricSiegrist
m Cl All 11 Years toPhase
15 Years
2 Â (Child)60 Other InterventioAllocation CER 2016-
Response to Public HeaAll 50 Years toPhase
80 Years
4 Â (Adult,
100Older
OtherAdult)InterventioAllocation CMVfluvac
- To descr Ludwig InsAll 18 Years and
Phase
older
1|Ph
Â (Adult, 28
Older
Other
Number ofIDRI|AerasAll 18 Years toPhase
45 Years
Biological: EnvPro National InAll 18 Years and
Phase
older
1 Â (Adult, 10
Older
NIHAdult) InterventioAllocation P01AI0451
HPV 6 GMTDuke UniveFemale 9 Years to 18 Years Â (Child,331
Adult)
Other|U.S.ObservatioTime PerspPro000143
Anti-PT, anGlaxoSmithAll 6 Weeks toPhase
8 Weeks
3 Â (Child)60 Industry InterventioInterventi 217744/04
To provide Sanofi Pas All 12 MonthsPhase
to 13 Months
4 Â 470
(Child)
Industry InterventioAllocation HAF65
- Rate of Ludwig InsAll 18 Years and
Phase
older
2 Â (Adult,111
Older
Other
71 Days3 Â (Child)
2133 Industry InterventioAllocation A3L04
Biological: aldesleuki National CaAll 16 Years and
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
Change in Mayo CliniAll 19 Years toPhase
64 Years
Biological: NY-ESO-1 Columbia UAll 18 Years and
Phase
older
1 Â (Adult, Older
Adult) PuAAAB2273|
Parent's inUniversity All 18 Years and
Notolder
Applic
Â (Adult, 79
Older
Other
5 Years
2 Â (Child)
378 Industry InterventioAllocation MTA26
Phase
older
3 Â (Adult,120
Older
Industry
Antigen-spUniversity Male 18 Years and
Notolder
Applic
Â (Adult, 10
Older
Other
Incidence Roswell ParAll 18 Years and
Phase
older
1 Â (Adult, 18
Older
Adult) I 191511|
Biological: Wetvax (A National InAll 18 Years toPhase
32 Years
1|Ph
Â (Adult)
Biological: rgp120/HI National InAll 18 Years toPhase
60 Years
1 Â (Adult)56 NIH InterventioPrimary PuAVEG 008|AVEG Protocol 008|
Local and EuBiologicsAll 18 Years toPhase
45 Years
1 Â (Adult)75 Industry InterventioAllocation UTCV_101
Varicella, GlaxoSmithAll 15 MonthsPhase
to 6 Years
2 Â (Child)
Biological: MUC1-KLHMemorial SFemale 18 Years and
Phase
older
1 Â (Adult, Older
Adult) Pu99-121|CD
EvaluationGlaxoSmithFemale 15 Years toPhase
32 Years
3 Â (Child, Adult)
Combined Merck
In ShaFemale 16 Years to 26 Years Â (Child,
4453Adult)
Industry ObservatioObservatioV503-021
EBOV-speciUniversity All 18 Years to 68 Years Â (Adult,
100Older
OtherAdult)ObservatioObservatio2016-0091
Biological: sargramosDana-Farber All 2 Years andPhase
Older Adult) 03-365|P3
Percent of National I All 9 Months toPhase
24 Months
3 Â (Child)
Varicella s GlaxoSmithAll 15 MonthsPhase
to 6 Years
2 Â (Child)
49 Years
1 Â (Adult)80 U.S. Fed InterventioAllocation S-13-10|A
Tumor Resp H. Lee MoffAll 18 Years and
Phase
older
2 Â (Adult, 69
Older
Other
Faces Pain University All 5 Years to 9 Years Â (Child) 57 Other ObservatioObservatioE 23795
Incidence oNational CaFemale 18 Years andPhase
older
1|Ph
Â (Adult, 75
Older
10-year gl National CaFemale 24 Years to 34 Years Â (Adult)
Serum antiGlaxoSmithAll 6 Weeks toPhase
12 Weeks
Serum Neut Merck ShaAll 6 Weeks toPhase
12 Weeks
Biological: Aventis P National InAll 18 Years toPhase
32 Years
GeometricUniversity All 18 Years andPhase
older
1|Ph
Â (Adult,606
Older
Other|Indu
Adult) InterventioAllocation UHL10492
Safety andUltimovacsAll 18 Years andPhase
older
1|Ph
Â (Adult, 12
Older
Adult) UV1/hTERT
Adverse P Johns HopkFemale 15 Years toNot
49 Years
ApplicÂ (Child,
2758Adult)
Number ofStanford Un All 1 Year to 30Phase
8 Other|NIHInterventioAllocation SU-17218-
Number ofMerck
S ShaFemale 16 Years toPhase
23 Years
2 Â (Child,
1158Adult)
Adverse evVaxon BiotAll 18 Years andPhase
older
1 Â (Adult, 23
Older
Industry
Adult) InterventioAllocation Vx-006-10
50 Years
1 Â (Adult)26 Other InterventioAllocation VAC057|20
Overall surUniversity All 16 Years andPhase
older
2 Â (Child, Adult,
Older Adult) 10M-03-1|
Incidence Gritstone All 18 Years andPhase
older
1|Ph
Â (Adult,144
Older
Industry
Adult) InterventioAllocation GO-005
50 Years
1 Â (Adult)16 NIH InterventioInterventi HVTN 121|
Registrati Immunicu All 18 Years andPhase
older
1 Â (Adult, 12
Older
Industry
Adult) InterventioInterventi IM-101|20
Child's MeSeattle Ch All Child, AdulNot Applic 562 Other InterventioAllocation 1R21HD08
Number ofBiontech RAll 18 Years andPhase
older
1 Â (Adult, 29
Older
Industry
Adult) InterventioInterventi RB_0001-0
PercentageJanssen VaAll 12 MonthsPhase
to 50 Years
1|Ph Â (Child,
48 Industry
Adult) InterventioAllocation CR108371|
ELISA sero Bavarian NoAll 18 Years toPhase
30 Years
49 Years
2 Â (Adult)
1002 Industry InterventioAllocation DEN-106|U
to 21 Months
2 Â 163
(Child)
older
3 Â (Adult,133
Older
Industry
Part 1 studBilthoven BAll 42 Days to Phase
83 Months
3 Â (Child)
1120 Industry InterventioAllocation OPV-03/PR
Number ofGlaxoSmithAll 6 Weeks to 19 Weeks Â (Child) 522 Industry Observational 111664
Immunogeni Sanofi Pas All 2 Years andPhase
405 Industry
Older Adult)
InterventioAllocation RAB28
1. OccurrenGlaxoSmithAll 6 Weeks toPhase
13 Weeks
3 Â (Child)
The immuno Radboud Un Male 18 Years andPhase
older
2 Â (Adult, 21
Older
Other
Adult) InterventioAllocation EudraCT 2
The proporNational InAll 18 Years andPhase
older
2 Â (Adult,620
Older
Base StudyMerck ShaFemale 16 Years toPhase
26 Years
3 Â (Child,
14840 Adult)
OccurrenceGlaxoSmithAll 6 Weeks to 5 Years Â (Child) 0 Industry ObservatioObservatio 116290
Biological: BCG vacci Onyvax|Nat All 18 Years andPhase
older
1|Phase
Â (Adult,
2 OlderIndustry
Overall Su Sidney KimAll 18 Years andPhase
older
2 Â (Adult, 93
Older
Other|Indu
Adult) InterventioAllocation J14113|AD
GeometricBavarian NAll 18 Years toPhase
55 Years
2 Â (Adult)651 Industry InterventioAllocation POX-MVA-
To screen sNational InAll 18 Years and older Â (Adult, 2000
Older
MTD of faliNational CaAll 18 Years andPhase
older
1 Â (Adult, 18
Older
PercentageMerck ShaMale 20 Years toPhase
64 Years
EvaluationEmergent PAll 18 Years toPhase
45 Years
2 Â (Adult)210 Industry|UInterventioAllocation EBS.AVA.2
Seropositi Bavarian NAll 18 Years toPhase
65 Years
4 Â (Adult,22Older
Industry
Adult)InterventioInterventi POX-MVA-0
50 Years
Descriptiv Dalhousie All 42 Days to Phase
3 Months
3 Â (Child)253 Other|InduInterventioAllocation SP91
Incidence Minervax Female 18 Years toPhase
40 Years
GeometricPfizer All 4 Years to 5Phase
Years4Â (Child) 335 Industry InterventioAllocation B1841009|
Incidence Roswell ParFemale 18 Years andPhase
older
1 Â (Adult, Older
Adult) I 277115|
OccurrenceGlaxoSmithAll 6 Years to 8Phase
70 Years
3 Â (Adult,
8374Older
Industry
Change in Genocea BiAll 18 Years toPhase
50 Years
PercentageBavarian No All 18 Years toPhase
55 Years
2 Â (Adult)745 Industry|NInterventioAllocation POX-MVA-0
RecruitmenMEE Produc Female Child, AdulNot Applic 240 Other InterventioAllocation Merck-IISP
Time-to-eveVaxon BiotAll 18 Years andPhase
older
2 Â (Adult,221
Older
Industry
Adult) InterventioAllocation Vx-001-20
GMT of theGlaxoSmithAll 18 Years andPhase
older
3 Â (Adult,239
Older
Industry
Clinical r National CaAll 18 Years andPhase
older
2 Â (Adult, 50
Older
Incidence oGlaxoSmithAll up to 5 Years Â (Child) 1 Industry ObservatioObservatio 116830
Biological: incomplet Craig L Sli All 12 Years andPhase
older
2 Â (Child, Adult,
Older Adult) 10524|UVA
Biological: filgrasti Hoag Memor All 18 Years andPhase
older
2 Â (Adult, Older
Other
60 Years
Evaluate t Beijing ChaFemale 20 Years to 45 Years Â (Adult)
1000 Other ObservatioObservatiocycdc2018
Biological: Tick-bornePfizer All 1 Year to 5Phase
Years Â2 (Child) Industry InterventioAllocation 199
Safety andimmatics BAll 18 Years andPhase
older
1 Â (Adult, Older
6 Industry|NInterventioInterventi
Adult) IMA950-10
Adverse evLars MÃ¸ll All 18 Years andPhase
older
1 Â (Adult, 10
Older
Other
Adult) InterventioInterventi FL1701|20
Number ofCureVac A Male 18 Years toPhase
40 Years
1 Â (Adult)72 Industry InterventioAllocation CV-8102-2
older
1 Â (Adult, Older
8 Other
Safety|EffiVaxtrials S All 6 Weeks toPhase
6 Weeks
2 Â (Child)240 Other InterventioAllocation IPV005AB
Biological: Tick-bornePfizer All 6 Years to 15
Phase
Years
2 Â (Child) Industry InterventioAllocation 205
To evaluateDalhousie All 6 Weeks and older Â (Child,10000
Adult,
Other|Indu
Older Adult)
ObservatioObservatioGS1001|RE
Safety (Oc University All 18 Years toPhase
60 Years
1 Â (Adult) 9 Other InterventioInterventi CCRG15-00
Anti-hepatGlaxoSmithAll 18 Years andPhase
older
3 Â (Adult, 51
Older
Industry
Adult) InterventioInterventi 100556 (Y1
50 Years
DeterminePublic HeaAll 18 Years andPhase
older
4 Â (Adult, 30
Older
Other
Adult) InterventioInterventi StaMen
Safety|Im ProvidenceAll 18 Years andPhase
older
1 Â (Adult, 11
Older
Other
Adult) InterventioInterventi PHS 10-14
Number ofBaylor
p Col All Child, AdulPhase 1 26 Other|NIHInterventioInterventi H-32335 V
To assess University Female 18 Years andPhase
older
1 Â (Adult, 14
Older
Other
Adult) InterventioAllocation 707800|UP
50 Years
Evaluation French NatAll Child, Adult, Older Ad 55 Other ObservatioTime PerspANRS HB E
Safety andReiThera SrAll 18 Years toPhase
65 Years
1 Â (Adult,35Older
Adult) HCV002TV|
Improved iAga Khan UAll 1 Month toPhase
5 Years
4 Â (Child)
60000 Other InterventioAllocation 2432-PED-
Serotype 6NICHD Neon All up to 3 Months Â (Child) 368 Other|NIHObservatioObservatioNICHD-NR
Measuremen National InAll 18 Years toPhase
50 Years
Years4Â (Child) 300 Industry InterventioInterventi 112688
To immunizNational InAll 18 Years toPhase
45 Years
Anti-HI An GlaxoSmithAll 18 Years andPhase
older
3 Â (Adult,117
Older
Industry
Incidence Genticel|PFemale 25 Years toPhase
65 Years
1 Â (Adult,13Older
Industry
Adult)InterventioInterventi PC10VAC0
Safety - ( FranÃ§ois SAll 18 Years toEarly
55 Years
PhasÂ (Adult)39 Other InterventioAllocation CHADOX
Incidence oGynecologiFemale 18 Years andPhase
older
2 Â (Adult, 67
Older
Other|Indu
Adult) InterventioInterventi GOG-0265|
Safety: se National InAll 18 Years toPhase
38 Years
Safety dataNational InAll 18 Years toPhase
50 Years
Haemagglut GlaxoSmithAll 18 Years andPhase
older
3 Â (Adult,113
Older
Industry
Safety: Nu ScandinaviAll 18 Years toPhase
65 Years
Adult) OEV 123
70 Years
Industry
ProportionDuke UniveAll 18 Years andPhase
Older
Other
49 Years
Years3Â (Child)4011 Industry InterventioAllocation 115158|20
Number ofSanofi
p Pas All 6 Months to Phase
17 Years
2 Â (Child)664 Industry InterventioAllocation QHD04|U11
Number ofUniversity Female 18 Years andPhase
older1|Ph
Â (Adult, 61
Older
Other
Frequency National
o I All 18 Years toPhase
40 Years
1 Â (Adult)132 NIH|Other| InterventioAllocation HVTN 111
Phase
Years3 Â (Child,
1518
Adult)
Objective M.D. AnderAll 18 Years andPhase
Older
Adult) 2017-0302
The primarUniversity All 18 Years andNotolder
Applic
Â (Adult, 30
Older
Other
Number ofGenexine,
p Female 18 Years toPhase
60 Years
2 Â (Adult)134 Industry InterventioAllocation HPV-EU-00
To determiInge MarieFemale 18 Years andPhase
0 Other
Adult) InterventioAllocation MA 0822
Immunogeni California All 18 Years toPhase
69 Years
2 Â (Adult,32Older
OtherAdult)InterventioInterventi rBV A/B-CL
Presence oGlaxoSmithAll 2 Months to 6 Years Â (Child) 1 Industry ObservatioTime Persp114535|21
Change serLaboratorioAll up to 2 Weeks
Phase
Â 3(Child) 320 Other InterventioAllocation:Birmex-EC
Overall Su EMD SeronAll 18 Years andPhase
older3 Â (Adult,
1513
Older
Industry
Adult) InterventioAllocation EMR 63325
Fever >= 1 Columbia UAll 6 Months to 23 Months Â (Child)
530 Other|U.S.ObservatioTime PerspAAAJ0504
Number and Immune Tar All 65 Years toPhase
74 Years
1 Â (Older 120
Adult)
Industry InterventioAllocation FP-01.1_C
Increase thUniversity All 18 Years toPhase
50 Years
1 Â (Adult)10 Other InterventioInterventi NIH/LAMM
NaÃ¯ve T-cUSDA, West All 12 Months to 24 Months Â 258 (Child)
U.S. Fed|OObservatioObservatioPR-13068
50 Years
1 Â (Adult)32 Other InterventioAllocation HIV-CORE
50 Years
Time to th GlaxoSmithAll 1 Year to 4Phase
Years Â2 (Child) 2022 Industry InterventioAllocation 257049/02
49 Years
HaemagglutiUniversity All 65 Years to 85 Years Â (Older54 Adult)
Other ObservatioObservatioCoSREC192
Frequency GlaxoSmith
45 Years
Vaccine-relGlaxoSmithFemale 18 Years andPhase
3 Industry
Assess the National InAll 18 Years toPhase
45 Years
1|Ph
Â (Adult)47 NIH InterventioAllocation 04-084
70 Years
1 Â (Adult,20Older
Increase inNational CaMale 18 Years andPhase
Older
Biological: autologouRoswell ParAll 18 Years toPhase
75 Years
1 Â (Adult, Older
Safety ass Astellas P All 20 Years andPhase
9 Industry
Adult) InterventioInterventi 0113-CL-1
Adverse EvBiondVax PAll 18 Years toPhase
49 Years
1|Ph
Â (Adult)63 Industry InterventioAllocation BVX002
50 Years
Safety|TranUniversity All 18 Years andPhase
2 Other|Indu
Adult) InterventioInterventi ISRCTN470
GeometricValneva AuAll 18 Years andPhase
Older
Industry
To estimat St. Jude C Female 9 Years to 26 Years Â (Child,587
Adult)
Other ObservatioObservatioHPV1
Safety andLondon SchMale 18 Years toPhase
45 Years
1 Â (Adult)32 Other InterventioAllocation ITDCVG28|
Biological: CG8123| Cell GenesAll 18 Years andPhase
Older
Industry
Adult) InterventioAllocation D-0031
Anti-hepatGlaxoSmithAll 7 Years to 17
Phase
Years3 Â (Child)178 Industry InterventioAllocation 100561 (Y6
SeroprotecCrucell Ho All 18 Years andPhase
Older
Industry
Frequency National
50 Years
Subjects WFraunhoferAll 18 Years toPhase
50 Years
1 Â (Adult)44 Industry InterventioAllocation FhCMB Pfs
30 Years
4 Â (Adult)13 Other|NIHInterventioAllocation SU-25537|
Number ofBiomedicalAll 18 Years toPhase
49 Years
2 Â (Adult)422 U.S. Fed|I InterventioAllocation BARDA CSN
Rate of DLTDana-Farber All 18 Years andPhase
older
1 Â (Adult, 20
Older
Adult) 18-279|1R
Fully Vacci University All 11 Years toNot
18 Years
ApplicÂ (Child,
10599 Adult)
Other|U.S.InterventioAllocation RSRB00026
Vaccinatio Radboud Un All 1 Year and older Â (Child, 1005
Adult,Other
Older Adult)
ObservatioObservatio2017-3339
Biological: P3C541b National InAll 18 Years toPhase
60 Years
45 Years
1|PhÂ (Adult)48 Other InterventioAllocation VAC059|20
pneumococc Centers fo All 18 Years andNotolder
Applic
Â (Adult,
7000
Older
U.S.Adult)
Fed|OInterventioAllocation CDC-NIP-4
Phase
Years
To measureChildren's All 2 Months to 4 Months Â (Child)230 Other ObservatioObservatioEVMS
The primary Imperial C All 18 Years andPhase
older
1 Â (Adult, 12
Older
Other
Adult) InterventioAllocation CRO930|G0
18 Months
4 Â 1394
(Child)
AssessmentNovavax All 18 Years toPhase
50 Years
1 Â (Adult)230 Industry InterventioAllocation EBOV-H-10
Years1Â (Child) 200 Industry InterventioAllocation 257049/03
ProportionGreen CrosAll 12 MonthsPhase
to 12 Years
2|Ph Â (Child)
828 Industry InterventioAllocation MG1111_P
Opsonophag Korea UnivAll 18 Years andPhase
older
4 Â (Adult, 70
Older
Other
Adult) InterventioAllocation 2014GR00
The Geomet Merck ShaAll 50 Years andPhase
older
3 Â (Adult,250
Older
Industry
Immune res Menzies ScAll 9 Months to Phase
3 Years
4 Â (Child)261 Other InterventioAllocation 1046999
Safety asseGenexine, Female 19 Years to 50 Years Â (Adult)67 Industry ObservatioObservatioGX-188E_C
to 60 Months
2 Â 461
(Child)
Number ofGamaleya R All 18 Years toPhase
55 Years
1|PhÂ (Adult)
162 Other InterventioAllocation 01-BVRS-G
Biological: gp160 VacNational InAll 18 Years toPhase
60 Years
Difference Sidney KimAll 18 Years toPhase
100 Years
OtherAdult)InterventioAllocation J13138|NA
Confirm noCanadian IAll 11 Years toPhase
15 Years
4 Â (Child)324 Other InterventioAllocation CT17_CIRN
60 Years
4 Â (Adult)
AssessmentMologen AAll 18 Years andPhase
older
1|Ph
Â (Adult, 19
Older
Industry
Adult) InterventioInterventi MGN1601-C
ProportionGermans Tri All 25 Years toPhase
50 Years
4 Â (Adult)33 Other InterventioAllocation VIHCREC01
Biological: InactivatedSanofi Pas All 60 Years toPhase
85 Years
2 Â (Adult,
1080Older
Industry
Adult)InterventioAllocation GID16
The proport Sheffield All 18 Years andPhase
older
2|Ph
Â (Adult, 30
Older
Other
Adult) InterventioAllocation STH17302
25 Years
Twenty One Sanofi Pas All Child, Adult, Older Ad 327293 Industry ObservatioObservatioTD512
ProgressioJonsson CoAll 18 Years andPhase
older
2 Â (Adult, 18
Older
Other
Biological: Tick-BornePfizer All 16 Years toPhase
65 Years
4 Â (Child, Adult,
Industry
Adult) 225
Number ofSanofi
30 Years
1 Â (Adult)150 Industry InterventioAllocation FBP00001|
Feasibility Dana-FarbeAll 18 Years andPhase
older
1 Â (Adult, 20
Older
Other
Biological: rgp120/HIVGenentech,All 18 Years andPhase
older
1 Â (Adult, Older
Industry
Adult) InterventioPrimary Pu075A|V0200g
Immunologi University All 18 Years andNotolder
Applic
Â (Adult, 56
Older
Adult) 6271|P30
Biological: HIV CTL National InAll 18 Years toPhase
40 Years
OccurrenceGlaxoSmithAll 11 Weeks to Phase
17 Weeks
2 Â (Child)
Safety: ac National InAll 18 Years toPhase
60 Years
Immune Res Janssen VaAll 18 Years toPhase
50 Years
older
3 Â (Adult,143
Older
Industry
ProgressioSidney KimAll 18 Years toPhase
120 Years
Adult) J05121|P3
17 Weeks
3 Â (Child)
KnowledgeSt. MichaelFemale 14 Years to 46 Years Â (Child,100Adult)
Other ObservatioObservatio06-190 par
number ofAssiut UnivAll 20 Years toPhase
60 Years
3 Â (Adult)45 Other InterventioAllocation PPDG
pancreaticThe Affili All 18 Years andNotolder
Applic
Â (Adult, 30
Older
Other
Adult) InterventioInterventi zkx12019
45 Years
4 Â (Adult)240 Other|InduInterventioAllocation:BioVacSafe
Biological: aldesleuk National CaAll 18 Years and
Phase
older
2 Â (Adult, Older
Number ofInnaVirVaxAll 18 Years toPhase
55 Years
1|PhÂ (Adult)33 Industry InterventioAllocation IVVAC-3S/
PercentageSynermoreAll B 18 Years toPhase
50 Years
1|PhÂ (Adult)
164 Industry|OInterventioAllocation SYN023-00
12 Weeks
4 Â (Child) 15 Industry InterventioInterventi 114351
To assess ReiThera SrAll 18 Years toPhase
50 Years
1 Â (Adult)41 Industry|OInterventioAllocation HCV001|20
Overall surUniversity All 18 Years and
Phase
older
1|Ph
Â (Adult, 20
Older
Other
Adult) InterventioInterventi CCRG14-00
Dose-limitiNantCell, I All 21 Years and
Phase
older
1|Ph
Â (Adult, Older
3 Industry
64 Years
Number ofNational CaAll 18 Years and
Phase
older
2 Â (Adult, Older
3 NIHAdult) InterventioInterventi 080055|08
Solicited U.S. Army All 18 Years toPhase
50 Years
Biological: liposomal NYU Langon All 18 Years toPhase
75 Years
2 Â (Adult, Older
Adult) CDR000006
The primary Nina BhardAll 18 Years and
Phase
older
1 Â (Adult, 26
Older
Other
The occuran University All 18 Years toPhase
55 Years
40 Years
Number and University All 18 Years toPhase
45 Years
1 Â (Adult)66 Other InterventioAllocation PAMVAC1_
Evaluation Shiga UnivAll 20 Years toPhase
85 Years
1 Â (Adult, 9Older
OtherAdult)InterventioAllocation SUMS-21-
- The prim MedImmunAll 18 Years toPhase
64 Years
3 Â (Adult)330 Industry InterventioAllocation AV024
Safety, tol Wiseman ResAll 18 Years toPhase
120 Years
1|PhÂ (Adult,
24 Older
Industry
Adult)
Length of Swiss TropiAll 18 Years toPhase
45 Years
1|PhÂ (Adult)16 Other InterventioAllocation 4-Sep
Impact of National InAll 18 Years and
Phase
older
1 Â (Adult, 40
Older
Number ofBiondVax PAll 65 Years and
Phase
older
2 Â (Older120
Adult)
Industry InterventioAllocation BVX-005
All advers OncoPep, IAll 18 Years toPhase
95 Years
1 Â (Adult,22Older
Industry
number ofS. Andrea Hospital|Italian
All 18 Years
Multiple
and
Phase
older
Sclerosis
2|Ph
Â (Adult,
Foundation|Istituto
80
Older
Other
Adult) InterventioAllocation
Superiore di SanitÃ NEU - BCG
Frequency GlaxoSmith
o All 18 Years toNot
50 Years
ApplicÂ (Adult)46 Industry InterventioInterventi 113737
49 Years
4 Â (Adult)300 Industry InterventioAllocation CD-VA-FluM
Nature of sUniversity Female 25 Years to 33 Years Â (Adult)
11700 Other ObservatioObservatioHPVAC (29
For each s University All 6 Weeks toPhase
8 Weeks
2 Â (Child)552 Other|NIHInterventioAllocation 03-042|FN
Number ofAbramson ACll 18 Years and
Early
older
Phas
Â (Adult, 10
Older
Other
50 Years
Safety and Malaria Vaccine
All and Drug
18 Years
Development
toPhase
45 Years
1 Center|Centro
Â (Adult)40 Other|Indu
mÃ©dico InterventioAllocation
Imbanaco|AsoclinicMVDC
InmunologÃ
2003 a Ltda.
45 Years
1 Â (Adult)230 NIH|OtherInterventioAllocation 999913109
DetermineUniversity All 5 Years to 45
Phase
Years
1 Â (Child, Adult)
Change in aVirginia C All 18 Years and
Notolder
Applic
Â (Adult, 60
Older
Other
Adult) InterventioAllocation HM200148
Phase
older
1|Ph
Â (Adult,332
Older
Industry
Increase t NYU LangoAll 8 Years to 17
NotYears
Applic
Â (Child) 51 Other InterventioInterventi 11028
SeroprotectUniversity All 5 Years to 18
Phase
Years
4 Â (Child, Adult)
27 Other InterventioAllocation PPV23JIA-
BehavioralMilton S. All 3 Months toNot11Applic
Months Â (Child)
98 Other InterventioAllocation SeedHatie
Occurrence, Bavarian NoAll 18 Years toPhase
40 Years
Positive a Karolinska All 1 Year and Not
older
Applic
Â (Child, Adult,
250 Other
Older Adult)
InterventioAllocation 2012/251-
Frequencies GlaxoSmithAll 18 Years toPhase
70 Years
2 Â (Adult,34Older
Industry
55 Years
3 Â (Child,
2428Adult)
Industry InterventioAllocation DV2-HBV-1
SeroconverDuke UniveAll 6 Months toNot47Applic
Months Â (Child)
Local & sy Wyeth is nAll 18 Years toPhase
25 Years
Number ofMedImmune All 18 Years toPhase
49 Years
4 Â (Adult)300 Industry|UInterventioAllocation MI-CP215|
Provide a pNational InAll 18 Years toPhase
45 Years
1 Â (Adult)75 NIH InterventioAllocation 01-416|CV
65 Years
NIH Adult)InterventioAllocation P01AI0557
Biological: ALVAC(2 National InAll 18 Years toPhase
60 Years
Behavior cCentre Hosp All 12 Years to 18 Years Â (Child,21Adult)
Other ObservatioObservatio18-DSP-02
AutologousFavrille|NaAll 18 Years and
Phase
older
2 Â (Adult,238
Older
Industry|NInterventioMasking:
Adult) NFAV-ID-09
Procedure: Blood TesNational InAll 18 Years toPhase
50 Years
To describeSanofi Pas All 6 Months toPhase
18 Years
Industry InterventioAllocation GPA04
OccurrenceU.S. Army All 18 Years toPhase
50 Years
1 Â (Adult)52 U.S. Fed|OInterventioAllocation S-14-07|N
Primary OuMedical Uni All 18 Years and
Phase
older
1 Â (Adult, 12
Older
Other
Change in cCenters fo All Child, AdulPhase 4 3200 U.S. Fed|OInterventioAllocation CDC-NCID-
Safety|AntU.S. Army All 18 Years toPhase
50 Years
1 Â (Adult)30 U.S. Fed|OInterventioAllocation A-17085|W
OccurrenceGlaxoSmithAll 10 Years to 18 Years Â (Child,
10000 Adult)
Incidence oJonsson CoAll 16 Years and
Phase
older
1 Â (Child, Adult,
TolerabilityUniversity All 18 Years toPhase
80 Years
OtherAdult)InterventioAllocation RNA-Mel-0
General safInstitut N Male 19 Years toPhase
31 Years
1 Â (Adult)48 Other InterventioAllocation BT06-04|2
Incidence oCity of HopAll 18 Years and
Notolder
Applic
Â (Adult, Older
Adult) 08121|P3
To evaluat ProvidenceMale 18 Years and
Phase
older
1|Ph
Â (Adult, 18
Older
Other|Indu
Adult) InterventioAllocation PPMC-EACR
40 Years
Physical e Statens SerMale 18 Years toPhase
55 Years
1 Â (Adult)36 Other InterventioAllocation THYB-01|E
Normal liv Novartis V Female Child, Adult, Older Ad 4529 Industry ObservatioObservatioV111_12
Incidence oUniversity All 18 Years and
Phase
older
1|Ph
Â (Adult, 31
Older
Adult) 7866|NCI-
Quantitati Ezra Cohen| All 18 Years and
Phase
older
1 Â (Adult, 30
Older
Other
The rate ofSheba Medi All 15 Years toPhase
50 Years
Other InterventioAllocation SHEBA-01-
Numbers ofGlaxoSmithAll 6 Years to 10
Phase
Years
Biological: recombinaNational CaMale 18 Years and
Phase
older
2 Â (Adult, Older
NIHAdult) InterventioAllocation CDR000025
Overall SurAlliance foAll 18 Years and
Phase
older
2 Â (Adult, 90
Older
Other|NIH|
Adult) InterventioAllocation A071101|U
Ten day cho PaxVax, IncAll 18 Years toPhase
45 Years
Cytotoxic Eastern CoAll 18 Years and
Phase
older
2 Â (Adult,175
Older
Adult) CDR00003
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
Number ofUniversity Male 18 Years toPhase
30 Years
1 Â (Adult)24 Other InterventioAllocation CP97/104|
Disease-freEuropean OAll 18 Years toPhase
80 Years
3 Â (Adult, Older
OtherAdult)InterventioAllocation CDR000006
Influenza vTel-Aviv S All 6 Months toNot2 Years
ApplicÂ (Child)
200 Other InterventioAllocation TASMC-13-
Biological: MVA-mBN8 Bavarian NAll 6 Months toPhase
6 Years
2 Â (Child)90 Industry InterventioAllocation MEA-HFN-
Phase
older
2 Â (Adult,600
Older
Industry
Adult) InterventioAllocation GPA02
Time to theGlaxoSmithAll 5 Months to 17 Months Â 1500(Child)
National InAll 18 Years and older Â (Adult,
1000
Older
NIHAdult) Observational 030079|03
Adverse evNantes UniAll 60 Years and
Phase
older
1|Ph
Â (Adult, Older
5 Other
Adult) InterventioAllocation BRD/05/10
To measureNational InAll 18 Years to 100 Years Â (Adult,
205 Older
NIH Adult) ObservatioTime Persp100187|10
Dose LimitAbramson FCemale 18 Years and
Phase
older
1 Â (Adult, 12
Older
Other
Adult) InterventioPrimary PuUPCC 2681
Clinical ob National InAll 18 Years toPhase
40 Years
Drug: Id-KLH Vaccine National CaAll 18 Years and
Phase
older
1 Â (Adult, 21
Older
Percent chMayo ClinicAll 18 Years toPhase
120 Years
Adult) CDR000054
Number ofMedImmune All 2 Years to 17
Phase
Years
4 Â (Child)326 Industry|UInterventioAllocation MI-CP217|
Number ofBoston Med Female 9 Years to 17
NotYears
Applic
Â (Child)100 Other InterventioInterventi H-34457
Number ofJanssen
P VaAll 18 Years toPhase
50 Years
1|PhÂ (Adult)
155 Industry InterventioAllocation CR108207
Biological: Detox-B OncothyreoFemale 18 Years andPhase
older
3 Â (Adult,950
Older
Industry
SeropositivGlaxoSmithAll 12 MonthsPhase
to 18 Months
3 Â 398
(Child)
Biological: FluMist National InAll 21 Years toPhase
49 Years
Percentage,Medicago All 18 Years toPhase
49 Years
1 Â (Adult)100 Industry InterventioAllocation CP-H1VLP-
44 Years
39 Years
1 Â (Adult)100 U.S. Fed|I InterventioAllocation S-11-23|W
Biological: aldesleuki National CaAll 18 Years andPhase
older
1 Â (Adult, Older
To determiInternatio All Child, Adult, Older Ad 97 Other|NIH| ObservatioObservatioIMPAACT P
Suitability London SchMale 15 Years toPhase
45 Years
1|Ph
Â (Child,
120
Adult)
Other InterventioAllocation ITDCVG37|
PercentageTakeda All 6 Weeks toPhase
49 Years
1|Ph
Â (Child,
340
Adult)
Industry InterventioAllocation IPV-102|U
The occuren University All 18 Years toPhase
55 Years
Safety andVical All 18 Years toPhase
45 Years
1 Â (Adult)56 Industry InterventioAllocation IPT1-101
Cell-mediaNational InAll 12 Months to 36 Months Â (Child)
69 NIH ObservatioObservatioDAIT ADVN
older
2 Â (Adult,182
Older
Industry
Response CancerVax All 18 Years toPhase
80 Years
2 Â (Adult, Older
Industry
Adult)InterventioMasking: NCDR000043
85 Years
1 Â (Adult, 9Older
Nasopharyn UMC Utrech All 2 Months to Phase
3 Months
3 Â (Child)
1005 Other InterventioAllocation MINOES 01
Solicited I Sanofi Pas All 18 Years andPhase
older
2 Â (Adult,124
Older
Industry
Clinical r Jonsson CoAll 16 Years andPhase
older
2 Â (Child, Adult,
6 Other
Older Adult)
Response rNational CaAll 18 Years andPhase
older
1|Phase
Â (Adult,
2 Older
Identify geNational InAll 3 Years to 99 Years Â (Child,4830
Adult,
NIHOlder Adult)
ObservatioObservatio999917077
National InAll 18 Years to 60 Years Â (Adult) NIH Observational HVTN 903|
National InAll 18 Years to 60 Years Â (Adult)
1324 NIH Observational 020127|02
45 Years
1|Ph
Skin prick Bandim Hea All 3 Years to 9 Years Â (Child) 487 Other ObservatioObservatio2011-BHP-
older
1 Â (Adult, 13
Older
Adult) MCC-15280
Biological: MAGE-10.AHerbert Ir All 18 Years andPhase
older
1 Â (Adult, Older
Adult) CDR000006
The primary Agenus IncAll 18 Years andPhase
older
2 Â (Adult, 20
Older
Industry
Adult) InterventioAllocation C-100-26
55 Years
Recurrence- Radboud Un All 18 Years andPhase
older
3 Â (Adult,210
Older
Other
Biological: APL 400-0 National InAll Child, AdulPhase 1 41 NIH InterventioPrimary Pu960050|96
15 Years
Biological: recombinaNational CaMale 18 Years andPhase
older
1 Â (Adult, 46
Older
NIHAdult) InterventioInterventi CDR000006
Fold ChangPfizer All 50 Years andPhase
older
2 Â (Adult,112
Older
Industry
Adult) InterventioAllocation A3921237|
to 18 Months
3 Â 339
(Child)
Industry InterventioAllocation PNA19
Years3Â (Child)8687 Industry InterventioAllocation 107070|10
PercentageMayo ClinicAll 18 Years toEarly
120 Years
Phas Â (Adult,
45 Older
Adult) CDR000058
Anti-nicot Nabi BiophAll 18 Years toPhase
65 Years
1|Ph
Â (Adult,74Older
Industry
Number ofHerbert LyAll 18 Years andPhase
older
1 Â (Adult, 18
Older
Other
MagnitudeImperial C All 18 Years toPhase
45 Years
1 Â (Adult)40 Other InterventioAllocation CRO2059|2
older
4 Â (Adult,180
Older
Industry
Adult) InterventioInterventi V211-034
OccurrenceGlaxoSmithAll 6 Weeks to 5 Years Â (Child)622 Industry ObservatioObservatio 114469
GeometricMedical UnAll 18 Years andPhase
older
4 Â (Adult, 67
Older
Other
Adult) InterventioInterventi 311_FU201
TTHGR for SouthwestAll Child, AdulPhase 3 969 Other|NIHInterventioAllocation S1602|NCI
proportionWashington All Child, AdulNot Applic 28143 Other InterventioAllocation 14674-001
50 Years
1 Â (Adult)26 U.S. Fed|I InterventioAllocation A-14620.a
Change in Roswell ParAll 18 Years andNotolder
Applic
Â (Adult, Older
Adult) I 250113|
Solicited r PATH|InterAll 12 MonthsPhase
to 24 Months
1 Â (Child)
Drug: VRC4302 National InAll Child, AdulPhase 1 21 NIH InterventioPrimary Pu010079|01
77 Days3 Â (Child)
Biological: BCG vacci AVAX TechnAll 18 Years toPhase
120 Years
Industry
Adult)
64 Years
1|Ph
Â (Adult)
PercentageUCB PharmAll 18 Years andPhase
older
4 Â (Adult,224
Older
Industry
Adult) InterventioAllocation RA0017
Biological: aldesleuk Milton S. All 1 Year to 30Phase
10 Other InterventioPrimary PuCDR000040
Lesion rec Vical All 18 Years toPhase
50 Years
2 Â (Adult)261 Industry InterventioAllocation HSV2-201
Biological: EP2101 EpimmuneAll 18 Years andPhase
older
1 Â (Adult, 18
Older
Industry
Adult) InterventioAllocation EP2101-10
Drug: BB IND 6989 Eunice KenAll 18 Years toPhase
45 Years
9 Weeks
Antibody rDartmouth- All 18 Years and older Â (Adult, 30Older
Other
Adult) ObservatioObservatioD0748
Biological: incomplet University All 12 Years andPhase
older
2 Â (Child, Adult,
Older Adult) 10049|UVA
PercentageMillenniumAll 18 Years toPhase
39 Years
1 Â (Adult)127 Industry InterventioAllocation C13013|20
Biological: ALVAC-CEAGeorgetown All 18 Years andPhase
older
2 Â (Adult, 24
Older
Adult) CDR000006
Biological: gp160 M Walter Reed All 18 Years toPhase
55 Years
1 Â (Adult) U.S. Fed InterventioMasking: DRV124
event-free Hoag Memor All 16 Years andPhase
older
2 Â (Child, Adult,
56 Other
Older Adult)
InterventioInterventi DC Melan
AutologousNational CaFemale Child, AdulPhase 1 12 NIH InterventioInterventi NCI-2012-
Biological: aldesleuk National CaAll 18 Years andPhase
older
2 Â (Adult, Older
safety (PhaTokyo UnivAll 20 Years toPhase
85 Years
1|Ph
Â (Adult,14Older
OtherAdult)InterventioInterventi Breast-A24-
Number ofAVIR GreenAll 18 Years toPhase
60 Years
1|Ph
Â (Adult)80 Industry InterventioAllocation GHB-CS08
PercentageUniversity All 70 Years andPhase
older
4 Â (Older Adult)
10 Other|InduInterventioInterventi STUDY0000
Biological: EP HIV-10 National InAll 18 Years toPhase
40 Years
Number ofBiondVax
P PAll 18 Years toPhase
49 Years
2 Â (Adult)200 Industry InterventioAllocation BVX-004
older
2 Â (Child, Adult,
NIHOlder Adult)
Primary MUniversity All 18 Years toPhase
80 Years
2 Â (Adult,27Older
OtherAdult)InterventioInterventi UPCC 027
Registrati Immunicum All 18 Years andPhase
older
1 Â (Adult, 18
Older
Adult) IM-102|20
Seroconvers Green CrosAll 6 Months to Phase
35 Months
3 Â (Child)
260 Industry InterventioAllocation GC3110A_I
PercentageLudwig InstFemale 18 Years andPhase
older
2 Â (Adult, 23
Older
Other
Adult) InterventioInterventi LUD 2002-
50 Years
Disease staUniversity Female 18 Years andPhase
older
1|Ph
Â (Adult, Older
0 Other|Indu
Safety andVical All 18 Years toPhase
45 Years
1 Â (Adult)47 Industry InterventioAllocation IPT1-102
Cellular i National CaFemale 18 Years andPhase
older
2 Â (Adult, 21
Older
NIHAdult) InterventioMasking: N990137|99
Patients wiBavarian NAll 18 Years andPhase
older
1 Â (Adult, 18
Older
Industry
Adult) InterventioInterventi MVA-BN-BR
Biological: Tick-BornePfizer All 6 Months to Phase
47 Months
2|PhaseÂ 3(Child)
Industry InterventioAllocation 146A
Results of National HeAll 18 Years and older Â (Adult, 26Older
NIHAdult) ObservatioTime Persp090245|09
Number ofTakeda|Wal All 18 Years toPhase
45 Years
1 Â (Adult)80 Industry|UInterventioAllocation INV-DEN-1
Biological: incomplet Abramson ACll 18 Years toPhase
120 Years
Adult) PuCDR00003
Drug: NP-016 VaccineNational EyAll 1 Year and Phase
400 NIH
Older Adult)
InterventioPrimary Pu040157|04
University All 18 Years to 75 Years Â (Adult,68Older
OtherAdult)ObservatioObservatioUofA - Ad
Number ofLudwig InstFemale 18 Years andPhase
older
1 Â (Adult, 13
Older
Other
Adult) InterventioInterventi LUD2007-0
Unified Pa NYU LangoAll 65 Years andNotolder
Applic
Â (Older164
Adult)
Biological: hepatitis National HeMale 18 Years toPhase
36 Years
3 Â (Adult) NIH InterventioAllocation 303|P01HL
EvaluationUniversity All 13 Years toNot
39 Years
ApplicÂ (Child,
184
Adult)
Other InterventioAllocation CHU-0273|
Achievemen Laboratoir Male 18 Years and
Phase
Older
Adult) MED-GX301
Number ofCureVac A All 18 Years and
Phase
Older
Industry
Adult) InterventioInterventi CV-9202-0
Overall su Kael-GemVax All 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation KG 1/2012
OccurrenceUniversity All 6 Months and older Â (Child, Adult,
1 Other|Indu
Older ObservatioObservatio200405
Adult) (H
Safety and Baylor ReseAll 18 Years and
Phase
older1|Ph
Â (Adult, Older
0 Other
Biological: MVA-MUC1 Jonsson CoAll 18 Years and
Phase
Adult) PuTRANSGENE
Biological: ALVAC(2 National I All up to 3 Days
Phase
Â (Child)
1 48 NIH InterventioMasking: DACTG 326|PACTG 326|10601
Change in Karolinska All 18 Years toPhase
65 Years
2 Â (Adult,20Older
Other|Indu
SeroconverValneva AuAll 18 Years and
Phase
Older
Industry
To compareBavarian No All 18 Years toPhase
50 Years
1|Ph
Â (Adult)30 Industry|NInterventioAllocation HIV-POL-00
85 Years
1 Â (Adult,18Older
Cytotoxic TUniversity All 18 Years toNot
85 Years
HPV immun Public HeaFemale Child, Adult, Older Ad 93 Other ObservatioObservatioHPVfollow
45 Years
1|Ph
Immunogenic French NatAll 18 Years toPhase
55 Years
1|Ph
Â (Adult)
To provideSanofi All 6 Weeks toPhase
19 Months
4 Â (Child)
387 Industry InterventioAllocation E2I29
Maximum VA To Office All 21 Years and
Phase
1 U.S.Adult)
Fed|OInterventioInterventi CLIN-004-
50 Years
New infectDartmouth- All 13 Years toPhase
15 Years
Phase I: prRadboud Un All 18 Years toPhase
45 Years
1|Ph
Â (Adult)36 Other|InduInterventioAllocation LSA3_01_0
Safety (toxAkita Univ All 20 Years toPhase
80 Years
1 Â (Adult, 9Older
OtherAdult)InterventioInterventi AUGIS-001
PercentageMerck ShaAll 6 Years to 17
Phase
Years3 Â (Child)400 Industry InterventioAllocation V114-030|
National InAll Child, Adult, Older Ad 240 NIH Observational 020026|02
Biological: BCG vacci GynecologiFemale 18 Years and
Phase
Adult) PuCDR00000
To establisCelldex Th All 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation CDX1307-0
Biological: recombin National CaAll 18 Years and
Notolder
Applicable
Â (Adult, Older
Drug: VRC-WNVDNA0National InAll 18 Years toPhase
65 Years
1 Â (Adult,30Older
Biological: BCG vacci European OAll 18 Years and
Phase
Older
Other
Adult) InterventioAllocation EORTC-089
50 Years
Antibody rTampere Uni All 45 Years toPhase
90 Years
4 Â (Adult,32Older
OtherAdult)InterventioAllocation R09082M|2
Frequency Kamada, LtAll up to 17 Years
Phase
Â 3(Child) 30 Industry InterventioInterventi KamRAB-0
Survival atRoyal LiverAll 18 Years and
Phase
older3 Â (Adult,
1110
Older
Other
Biological: Heat Shoc UConn HeaFemale 18 Years and
Phase
older1|Ph
Â (Adult, 15
Older
Other
Biological: recombin National I All 18 Years and
Phase
safety and National InAll 18 Years toPhase
50 Years
1|Ph
Â (Adult)
800 NIH InterventioAllocation 999919099
The UniverMilton S. All 6 Weeks toNot
4 Months
Applic Â (Child)
140 Other InterventioAllocation IRB NO. 20
SeropositivGlaxoSmithAll 6 Weeks to 12 Weeks Â (Child)1 Industry ObservatioTime Persp114793|444
Skin infect University All 2 Months toPhase
18 Years
The primary MedImmunAll 6 Months toPhase
59 Months
3 Â 8500
(Child)
Biological: rgp120/H National InFemale 16 Years toPhase
40 Years
NIH InterventioInterventi ACTG 235|AVEG 104|11212
To describ MedImmunAll 1 Year to 9Phase
Years Â1 (Child) 120 Industry InterventioAllocation MI-CP130
49 Years
Phase
older3 Â (Adult,
1726
Older
Industry
Child pain University All 4 Years to 6Not
Years
Applic
Â (Child) 77 Other InterventioAllocation UCaliforni
Number ofMedImmunAll 1 Month toPhase
11 Months
1|Ph Â (Child)
Safety AdvAltimmune,All 18 Years toPhase
65 Years
1 Â (Adult,60Older
Industry
Adult)InterventioAllocation FP02.2_CS
Medical CoAll 18 Years to 45 Years Â (Adult) 545 Other ObservatioObservatioIDF 1047-
number ofUniversity
r All 25 Years toPhase
76 Years
Other|Indu
Adult)InterventioAllocation CHA-UA-20
Phase
Years
Maximum Jonsson
to CoAll 21 Years andPhase
older
1 Â (Adult, 17
Older
Other|NIH|
Adult) InterventioInterventi 03-06-008
Measles anBandim Hea All 6 Years to 10
Phase
Years
4 Â (Child)1960 Other|InduInterventioAllocation LTAB-2288
Biological: PSA RNA-pDuke Univer Male 18 Years andPhase
older
1|Ph
Â (Adult, 17
Older
Adult) Pu0408|DUMC
Serotype-sAgence deAll up to 4 Years
Phase
Â (Child)
4 663 Other InterventioAllocation PCV13-Imm
Biological: EP2101 EpimmuneAll 18 Years andPhase
older
1 Â (Adult, 18
Older
Industry
Adult) InterventioAllocation EP2101-10
older
3 Â (Adult, 50
Older
Industry
Adult) InterventioAllocation 100551 (EX
OccurrenceGlaxoSmithAll up to 364 Days Â (Child) 786 Industry ObservatioTime Persp 104435
compare im MedImmunAll 12 MonthsPhase
to 15 Months
3 Â1200
(Child)
Industry InterventioAllocation AV018
feasibility Columbia UAll 2 Years to 11
NotYears
Applic
Â (Child)266 Other|U.S.InterventioInterventi AAAO5253
Biological: ALVAC(2) National InAll 19 Years andPhase
older
1 Â (Adult, 12
Older
NIHAdult) InterventioMasking: NAI-04-006|GCRC M01-RR00102
The primarMedImmunAll 8 Months to Phase
36 Months
3 Â (Child)
200 Industry InterventioAllocation D153 P500
The primary AdimmuneAll 3 Years to 17
Phase
Years
3 Â (Child)122 Industry InterventioInterventi FLUV12T13
Safety pri Hookipa BiAll 18 Years toPhase
45 Years
1 Â (Adult)54 Industry|OInterventioAllocation H-100-001
Seroconvers Valneva AuAll 50 Years andPhase
older
2 Â (Adult,500
Older
Industry
Adult) InterventioAllocation VLA84-201
Proliferat University All 18 Years toPhase
50 Years
1 Â (Adult)12 Other InterventioAllocation TB018|Eud
Attack rateLimmaTechAll 18 Years toPhase
50 Years
2 Â (Adult)67 Industry|OInterventioAllocation SF2A-2B
60 Years
4 Â (Adult) 135 Industry InterventioInterventi 100571 (M
60 Years
4 Â (Adult)78 Industry InterventioAllocation 100576 (Y1
Change in Bandim Hea All 50 Years andPhase
older
4 Â (Adult, 40
Older
Other
Adult) InterventioAllocation BCGadult
Feasibilit Carolyn BriAll 18 Years andPhase
older
1 Â (Adult, 12
Older
Other|Indu
Number ofThomas JefAll 18 Years andPhase
older
2 Â (Adult, 81
Older
Other
14 Weeks
Mortality Bandim Hea All up to 30 Days
Phase
Â (Child)
4 2320 Other InterventioAllocation ICA4-CT-2
Median over Gary ArcheAll 18 Years andPhase
older
2 Â (Adult, 48
Older
Other
Antibody tiSt. AntoniuAll 18 Years andPhase
older
4 Â (Adult, 60
Older
Other
PercentageGary ArcheAll up to 35 Years
11 Other InterventioInterventi Pro000928
BCG respoThe Univers All 18 Years toEarly
99 Years
Other
Drug: Myeloma Immun National CaAll 18 Years toPhase
60 Years
Biological: MF59|BiolNational InFemale 16 Years toPhase 40 Years
1 Â (Child, Adult)
0 NIH InterventioInterventi ACTG 233|11210
Biological: ALVAC-H National InAll 18 Years toPhase
60 Years
1 Â (Adult)60 NIH InterventioPrimary PuAVEG 038|10586
Safety|MuU.S. Army All 18 Years toPhase
40 Years
1 Â (Adult)32 U.S. Fed InterventioAllocation NMRC 2003
Safety|ReaUniversity All 18 Years toPhase
50 Years
1 Â (Adult)15 Other InterventioInterventi FLU004|20
Grade 3 AdGenetic ImAll 18 Years toPhase
50 Years
1 Â (Adult) 9 Industry InterventioAllocation GIHU004
60 Years
1 Â (Adult)57 NIH|IndustInterventioMasking: DAVEG 009|V0385g
55 Years
1 Â (Adult) 190 Industry InterventioAllocation B4901001|
PercentageAstellas P All 18 Years toPhase
85 Years
1|PhÂ (Adult,
618Older
Adult) 3772-CL-1
AssessmentIstituto Superiore
All di SanitÃ
18 Years toPhase
50 Years
1 Â (Adult)27 Other InterventioAllocation ISST-001
Biological: HER-2/neuCase Compr Female 18 Years and Phase
older
1 Â (Adult, OlderOther|NIHInterventioMasking:
Adult) NPMXA1103
Blood sampAbbott All 20 Years andPhase
older
4 Â (Adult,226
Older
Industry
Adult) InterventioAllocation M03-600
Biological: Hib conjugPublic HeaAll 9 Months toPhase
4 Years
4 Â (Child) Other InterventioAllocation Hibboost
laboratory-McMaster AUll Child, AdulPhase 4 4771 Other InterventioAllocation MCT 8811
20 Years
50 Years
Drug: VCR-HIVDNA00National InAll Child, AdulPhase 1 0 NIH InterventioPrimary Pu020279|02
serotype-sNabi BiophAll 18 Years and
Phase
older
3 Â (Adult,120
Older
Industry
Comparison Epimmune|N All 18 Years and
Phase
older
2 Â (Adult, Older
Industry
Number ofPfizer All 18 Years toPhase
65 Years
2 Â (Adult,13Older
Industry
Adult)InterventioInterventi B1971042
EvaluationUniversity All 18 Years toPhase
79 Years
2 Â (Adult,40Older
Adult) 7621|IRB-
Biological: MN rgp12 VaxGen|NIH All 18 Years toPhase
60 Years
3 Â (Adult)
5000 Industry InterventioMasking: DVAX 004
12 Weeks
3 Â (Child)
Biological: therapeut Abramson ACll 18 Years and
Phase
older
1 Â (Adult, 30
Older
Adult) PuCDR000041
ImmediateBaylor Col All 18 Years toPhase
45 Years
Adverse EveNational InAll 18 Years toPhase
32 Years
1 Â (Adult)91 NIH InterventioAllocation 02-017|PO
RecurrenceModernaTXAll 18 Years and
Phase
older
2 Â (Adult,150
Older
Industry
Biological: Heat Shoc University All 18 Years and
Phase
older
1 Â (Adult, 10
Older
Other
SeroconversFidec CorpAll 5 Weeks toPhase
7 Weeks
3 Â (Child)
773 Other InterventioAllocation IPV004
Inicidence Instituto NFemale 25 Years toPhase
45 Years
4 Â (Adult)
Number ofPepTcell Li All 18 Years toPhase
55 Years
2 Â (Adult)
153 Industry|NInterventioAllocation FLU-v-004
45 Years
1 Â (Adult) 0 NIH InterventioAllocation URMC 15-001
Anti-rotav National I All 6 Weeks toPhase
12 Weeks
2|PhÂ (Child)
799 Other InterventioAllocation Rotavin-M
Adverse evN.N. PetroAll 18 Years and
Phase
older
1|Ph
Â (Adult, 80
Older
Other
Adult) InterventioAllocation 07-Ð“ÐµÐ
40 Years
1 Â (Adult)
251 Industry InterventioAllocation GPF01
Safety DosU.S. Army All 18 Years toPhase
55 Years
60 Years
1 Â (Adult)28 NIH|IndustInterventioMasking: DAVEG 006X|VEU 006|V0199g|
2-year recuCure&SureAll 18 Years toPhase
75 Years
2|Ph
Â (Adult,80Older
Adult) CS-CH-19
DetermineNational I Female 18 Years and
Phase
older
1|Ph
Â (Adult,153
Older
NIHAdult) InterventioAllocation R01DC0059
Number ofMorphogene All 18 Years and
Phase
older
1 Â (Adult, 20
Older
Adult) NMSC 2019
Biological: whole-cellNational InAll 2 Months toPhase
3 Months
3 Â 10000
(Child)NIH|OtherInterventioAllocation 199/11953
Investigat Aeras|StateAll 64 Days to Phase
196 Days
1|Ph
Â (Child)
243 Other|InduInterventioAllocation C-015-404
OccurrenceGlaxoSmithK All 6 Months toNot50Applic
Years Â (Child,
2004Adult)
Industry|OInterventioInterventi 200274
Tumor contJonsson CoAll 18 Years and
Phase
older
2 Â (Adult, 37
Older
Adult) NCDR000042
The primaryMichael HaAll 18 Years and
Phase
older
1|Ph
Â (Adult, Older
Adult) ITL-002-H
Phase
older
4 Â (Adult,506
Older
Industry
Safety|Im Michael Mo All 18 Years and
Phase
older
1 Â (Adult, 14
Older
Adult) 2840|1R2
tetanus se Shiraz UnivAll 20 Years toPhase
80 Years
2 Â (Adult,40Older
OtherAdult)InterventioAllocation 86_3893
50 Years
1 Â (Adult) 0 NIH InterventioAllocation HVTN 125|
Measuremen National InAll 18 Years to 35 Years Â (Adult)87 NIH ObservatioObservatio999914159
OccurrenceMassachuse All 65 Years toPhase
80 Years
Other InterventioAllocation 2010 P 00
Number and Clinica Un All 3 Years to 40
Phase
Years
1|Ph
Â (Child, Adult)
10 Other InterventioInterventi DEND/TIA|
seroconversZhejiang P All 60 Days to Phase
75 Days4 Â (Child)528 Other|InduInterventioAllocation ZJCDC2017
The primaryAdimmuneAll 18 Years and
Phase
older
3 Â (Adult,120
Older
Industry
Adult) InterventioInterventi FLUV12T1
SeroconversPaxVax, IncAll 46 Years toPhase
64 Years
3 Â (Adult)
398 Industry InterventioAllocation PXVX-VC-2
Overall SurNational CaAll 18 Years and
Phase
older
3 Â (Adult,815
Older
120 Years
1 Â (Adult,9 Older
Adult) J0745|NA_
The trial i University All 18 Years toPhase
60 Years
1 Â (Adult)10 Other InterventioAllocation 0509115|N
Incidence oMayo ClinicAll 18 Years toEarly
90 Years
Adult) LS1081|NC
To compareUniversity All 18 Years to 65 Years Â (Adult,110Older
Adverse evUniversity All 18 Years toPhase
55 Years
1 Â (Adult) 2 Other InterventioAllocation TB040
Human Papi Merck ShaFemale 9 Years to 17 Phase
Years2 Â (Child)107 Industry InterventioAllocation V501-028|
Serum antiJohns HopkAll 18 Years toPhase
40 Years
1|PhÂ (Adult)
Biological: rgp120/H National I All 13 Years andPhase
Adult,
NIH|Indust
Older Adult)
InterventioInterventi ACTG 209|11186
safety (PhaTokyo Medic All 20 Years toPhase
85 Years
1 Â (Adult,10Older
OtherAdult)InterventioInterventi MBCCTA-00
Tolerabilit University All 18 Years andPhase
9 Other
Adult) InterventioInterventi DCIC 11 1
50 Years
45 Years
1 Â (Adult)65 Other|InduInterventioAllocation HP-000655
Best OveraH. Lee MofAll 16 Years andPhase
Adult,
Other|NIH|
Older Adult)
InterventioAllocation MCC-15400
45 Years
17 Years
Primary O University Male 18 Years toNot
60 Years
ApplicÂ (Adult)
IPD causedJohns HopkAll 1 Month to 59 Months Â 23350(Child)Other ObservatioObservatio 8547
PercentageTakeda|Nati All 18 Years toPhase
45 Years
1 Â (Adult)67 Industry|NInterventioAllocation 11-0049|U
Incidence oJonsson CoAll 16 Years andPhase
Drug: VRC-WNVDNA0National InAll 18 Years toPhase
50 Years
PercentageCrucell Ho All 18 Years andPhase
Older
Industry
Biological: diphtheriaNational Institute
All of Allergy
6 Weeks and
toPhase
Infectious
12 Weeks
3 Diseases
Â (Child)
13250(NIAID)|Istituto
Superiore di SanitÃ
199/11954
|Office of Rare Diseases (OR
Mean log10 National InAll 18 Years toPhase
65 Years
2 Â (Adult,92Older
NIH Adult)InterventioAllocation 1R01AI051
Drug: VRC-HIVADV01National InAll 20 Years toPhase
37 Years
Number ofGlaxoSmithFemale Child, Adult, Older Ad 1 Industry|OObservatioObservatio 207221
Drug: VRC-EBODNA01National InAll 18 Years toPhase
44 Years
IntraprostaSidney KimMale 21 Years andPhase
older1|Ph
Â (Adult, 29
Older
Other|Indu
Adult) InterventioAllocation J1265|NA_
Biological: MVA-mBNBavarian NAll 18 Years toPhase
55 Years
1 Â (Adult)15 Industry InterventioPrimary PuHIV-MAG-0
Number ofNational CaAll 18 Years toPhase
100 Years
1|PhÂ (Adult,
51 Older
Biological: human papNational CaFemale 18 Years and Phase
Safety(PhasTokyo UnivAll 20 Years toPhase
85 Years
OtherAdult)InterventioInterventi IMS-OKA2
Safety as H. Kim LyerAll 18 Years andPhase
Older
Adult) CDR000043
85 Years
OtherAdult)InterventioInterventi IMS-MKA0
Safety(PhasTokyo UnivAll 20 Years toPhase
85 Years
OtherAdult)InterventioInterventi IMS-OKA0
safety(PhasTokyo UnivAll 20 Years toPhase
85 Years
OtherAdult)InterventioInterventi Breast-A02-
Immunogeni Merck ShaAll 20 Years toPhase
40 Years
Hepatitis Third Affil All 18 Years toPhase
65 Years
1|PhÂ (Adult,
450Older
OtherAdult)InterventioAllocation SunYatSen
Receipt of University All 18 Years andNotolder
Applic
Â (Adult,
50000
Older
Other
Immune res Maria SkloAll 18 Years andPhase
older1|Ph
Â (Adult, 22
Older
Other
Biological: Tumor RNAUS Departm Male 10 Years andPhase
U.S.Older
Fed Adult)
InterventioAllocation CLIN-021-02S
MonitoringUConn HeaFemale 18 Years and Phase
Older
Other
Adult) InterventioInterventi Q16-158-3
OccurrenceTehran UniAll 16 Years toPhase
60 Years
2|PhÂ (Child,
150Adult)
Other InterventioAllocation CT110-138
Anti-HAV i GlaxoSmithAll 41 Years andPhase
Older
Industry
60 Years
1 Â (Adult)37 NIH InterventioMasking: DAVEG 016B|10566
Number ofAeras|StatAll 18 Years toPhase
50 Years
1 Â (Adult)25 Other InterventioAllocation C-032-456
HPV16 andCentre HosFemale 27 Years to 46 Years Â (Adult) 606 Other ObservatioObservatioP/2019/45
C-reactive University Female 18 Years toNot
45 Years
ApplicÂ (Adult)
100 Other InterventioInterventi REB15/141
Biological: ALVAC-HI National InAll 18 Years toPhase
60 Years
Day 22/DayCopenhagen Female Child, AdulNot Applic 296 Other|InduInterventioAllocation H1N1v
Biological: ALVAC(2) National InAll 18 Years toPhase
60 Years
1 Â (Adult)
100 NIH InterventioMasking: DAVEG 034|AVEG 034A|10583
Toxicity at University All 18 Years toPhase
80 Years
Adult) PuCDR00005
SBA-MenCGlaxoSmith
t All 6 Weeks toPhase
12 Weeks
3 Â (Child)
Number ofMatrivax
p RAll 18 Years toPhase
55 Years
1 Â (Adult)45 Industry InterventioAllocation Typhax-10
50 Years
Biological: 9 valent Public HeaAll 7 Weeks toPhase
18 Months
2 Â (Child)Other InterventioAllocation PNC1/2
Comparison Mayo CliniAll 18 Years and
Notolder
Applic
Â (Adult, Older
0 Other
Adult) InterventioAllocation MC1083|NC
Number ofPfizer
s All 8 Weeks toPhase
11 Weeks
3 Â (Child)
The ConfidEmergent PAll 18 Years toPhase
65 Years
3 Â (Adult,
3861Older
Adult) EBS.AVA.2
Pain severiÃ‡ankÄ±rÄ± All 4 Months toNot6 Months
Applic Â (Child)
128 Other InterventioAllocation CANKIRI K
Serologic Johns HopkAll up to 8 Weeks
Not ÂApplic
(Child) 300 Other InterventioAllocation IRB000037
Number ofPrima BioMFemale 18 Years and
Phase
older
2 Â (Adult, Older
9 Industry
Adult) InterventioInterventi CAN-003X
Injection s IDRI|Bill All 18 Years toPhase
54 Years
The purpose AdimmuneFemale Child, Adult, Older Ad 398 Industry ObservatioObservatioFLU10001
ight|Stunting|Intestinal BiomedicalAll 6 Years to 10 Years Â (Child) 99 Other ObservatioObservatioEPLS11-MS
Biological: ALVAC-CEAHerbert Ir All 18 Years and
Phase
older
2 Â (Adult, Older
Adult) CDR000006
Safety|MucU.S. Army All 18 Years toPhase
45 Years
1 Â (Adult) 0 U.S. Fed InterventioAllocation WRAIR 106
Primary - Guy's and All 18 Years toPhase
90 Years
4 Â (Adult,
214Older
OtherAdult)InterventioAllocation 430321|20
To assess tUniversity All 18 Years and
Phase
older
2 Â (Adult, 27
Older
Other
Adult) InterventioAllocation UMCC 9947
Antibody rMerck ShaAll 12 MonthsPhase
to 18 Months
2 Â1100
(Child)
Industry InterventioAllocation V205C-010
Number ofHerlev HosAll 18 Years toPhase
90 Years
18 Years
4 Â (Child,
647 Adult)
Industry InterventioAllocation Td516
ImprovemeMassachuse All 18 Years toPhase
65 Years
2 Â (Adult,
150Older
OtherAdult)InterventioAllocation 2013P0026
Immunogeni Immune Tar All 18 Years toPhase
55 Years
1 Â (Adult)49 Industry|OInterventioAllocation FP-01.1_C
Adverse eve Cytos Biot All 18 Years toPhase
69 Years
2 Â (Adult,83Older
Industry
Adult)InterventioAllocation CYT006-An
Seroconvers GlaxoSmithFemale 18 Years toPhase
35 Years
3 Â (Adult)
hepatitis BChinese UnAll 18 Years and
Phase
older
4 Â (Adult,130
Older
Other
Adult) InterventioAllocation CRE-2005.
Maximum Roswell
fo ParAll 18 Years toNot
65 Years
Adult) I 124207|
Biological: rHAO TrivaNational InAll 65 Years toPhase
80 Years
90 Days
Incidence oNantKwest,All 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Industry
Number ofReiThera SAll 18 Years toPhase
64 Years
1 Â (Adult)55 Industry|OInterventioAllocation HCV003|20
Establishi Swedish InsAll Child, Adult, Older Ad 5400 Other ObservatioObservatio2007/132-
Culture anUniversity All 18 Years toPhase
55 Years
HPV vaccinUniversity Female 13 Years to 17 Years Â (Child)
410 Other ObservatioTime PerspMISP 3670
Immunologi Valneva AuAll 18 Years toPhase
65 Years
2 Â (Adult,66Older
Industry
Adult)InterventioAllocation IC41-201
PercentageSanofi Pas All 9 Years and older Â (Child,
30000
Adult,Industry
Older Adult)
ObservatioObservatioDNG15|U11
Phase
older
1 Â (Adult, 30
Older
Other
Phase I: AsUniversity Male 18 Years toPhase
75 Years
Other|Indu
4-week assCeltic Pha All 18 Years and
Phase
older
2 Â (Adult,522
Older
Industry
Adult) InterventioAllocation TA-NIC/04
Time to AdM.D. AnderAll Child, AdulPhase 1 2 Other|NIHInterventioAllocation 2005-0379
Immunogeni United BioAll 50 Years to 80 Years Â (Adult,14Older
Industry|OObservatioObservatioUBI
Adult) Protoc
Number ofJanssen ScAll 18 Years toPhase
55 Years
1 Â (Adult)32 Industry InterventioAllocation 64300535H
Change in EUniversity All 18 Years toPhase
75 Years
4 Â (Adult,45Older
PrevalenceMenzies ScFemale 17 Years toPhase
39 Years
Other InterventioAllocation NHMRC 49
Receipt of University All 11 Years toNot
15 Years
ApplicÂ (Child)
7546 Other InterventioAllocation PCAIR|OPP
Number ofDana-FarbeAll 18 Years and
Phase
older
2 Â (Adult, 25
Older
Other|Indu
50 Years
Biological: APL 400- National InAll 18 Years toPhase
60 Years
Biological: MN rgp12 VaxGen|NIH All 18 Years and
Phase
older
1 Â (Adult,120
Older
Industry
Adult) InterventioPrimary PuVAX 002
Neutralizi Merck ShaAll 12 MonthsPhase
to 18 Months
3 Â1997
(Child)
Number ofSanofi
p Pas All 12 Months and older Â (Child, 50Adult,
Industry
OlderObservatioObservatioJEC18|U11
Adult)
Change froUniversity Male 45 Years toPhase
80 Years
OtherAdult)InterventioAllocation 167/2003
Serum GMT University Female 9 Years to 26
Phase
Years
4 Â (Child, Adult)
43 Other|InduInterventioAllocation Gardasil in
Safety and Affiris AG All 50 Years toPhase
85 Years
1 Â (Adult,20Older
Industry
Adult)InterventioInterventi AFF004A
Immunogeni GlaxoSmithAll 40 Years and
Phase
older
4 Â (Adult,460
Older
Industry
To identif University All 18 Years to 70 Years Â (Adult,
101Older
OtherAdult)ObservatioObservatio2012/11
Biological: human papSteward St.Female 18 Years and
Phase
older
1 Â (Adult, Older
Adult) PuCDR000006
Overall Su Aduro BiotAll 18 Years and
Phase
older
2 Â (Adult, 93
Older
Adult) ADU-CL-01
Biological: Meningoc Public HeaAll 18 Years toPhase
55 Years
2 Â (Adult)30 Other InterventioAllocation MNB1
ProportionNational CaAll 18 Years toPhase
79 Years
2 Â (Adult,48Older
NIH Adult)InterventioAllocation NCI-2011
Number ofInovio
P PhaFemale 18 Years toPhase
55 Years
2 Â (Adult)167 Industry InterventioAllocation HPV-003
National InAll up to 45 Years Â (Child, Adult)
515 NIH Observational 999902248
74 Days
3 Â (Child)792 Industry InterventioAllocation E2I42
Safety andEnterome|All 18 Years and
Phase
older
1|Ph
Â (Adult, 32
Older
Industry
Adult) InterventioAllocation EOGBM1-1
Impact on Gc enocea BiAll 18 Years toPhase
50 Years
Neural actiUniversity All 30 Years toEarly
60 Years
PhasÂ (Adult)80 Other|NIHInterventioAllocation 15-18367
60 Years
Immunologi Inge MarieMale 18 Years and
Phase
older
2 Â (Adult, 43
Older
Other
Adult) InterventioAllocation UR1121
MeasuringBeatrice OAll 2 Months toNot4 Months
Applic Â (Child)
72 Other InterventioAllocation SormlandC
60 Years
NIH|IndustInterventioMasking: DAVEG 201|10588
To compareMedImmunAll 5 Years to 17
Phase
Years
4 Â (Child)
3022 Industry InterventioAllocation MI-MA004
To evaluat Genocea BiAll 18 Years toPhase
55 Years
Biological: Hepatitis GlaxoSmithAll 18 Years toPhase
50 Years
4 Â (Adult)632 Industry Interventional 106640
55 Years
Antibody rMerck ShaAll 12 MonthsPhase
to 18 Months
2 Â1210
(Child)
Th9 cells Beijing MuAll 3 Years to 60 Years Â (Child, Adult)
94 Other ObservatioObservatioBJCDCWJ2
Change in GlaxoSmithAll up to 15 Years Â (Child) 1 Industry ObservatioObservatio 205369
28 Years
Receipt of National BuAll 18 Years and older Â (Adult,
1801
Older
Other|NIHObservatioObservatio0006|P30
Adult)
Anti-diphthGlaxoSmithAll 18 MonthsPhase
to 20 Months
4 Â 720
(Child)
Immune Res National CaAll 18 Years toPhase
75 Years
2 Â (Adult,20Older
Number ofGlaxoSmithAll 427 Days toPhase
577 Days
3 Â (Child)
National InAll up to 16 Months Â (Child) 32 NIH ObservatioTime Persp03-140
Device: Auto-injectorNational InAll 18 Years toPhase
50 Years
Biological: VRC-HIV National InAll 18 Years toPhase
50 Years
OccurrenceUniversity All 18 Years and
Phase
older
1|Ph
Â (Adult, 64
Older
Other|Indu
Adult) InterventioInterventi UCL/12188
OccurrenceTehran UniAll 16 Years toPhase
60 Years
2|PhÂ (Child,
100Adult)
Other InterventioAllocation J/423/1058
GeometricAdvagene BAll 20 Years toPhase
40 Years
1 Â (Adult)36 Industry|OInterventioAllocation DCB07030-
Numbers ofAbramson FCemale 18 Years and
Notolder
Applic
Â (Adult, 12
Older
Other
Adult) InterventioMasking: NUPCC 4081
LaboratoryNational I All Child, Adult, Older Ad 175 Other|U.S.ObservatioObservatioMatFluVac
Johns HopkAll Child, Adult, Older Ad 1000 Other|U.S.ObservatioObservatioCAIH-LTNP
EstimationGlaxoSmithAll up to 5 Years Â (Child) 1 Industry ObservatioObservatio 116829
MagnitudeNational InAll 18 Years toPhase
50 Years
Plasma conc Karolinska Male 18 Years toPhase
40 Years
1 Â (Adult)36 Other InterventioAllocation DNR-2014/
Local and U.S. Army All 18 Years toPhase
40 Years
1 Â (Adult) 0 U.S. Fed InterventioAllocation NMRC 2002
Biological: PneumocoWyeth is nAll 2 Years to 5 Years Â (Child) 250 Industry ObservatioTime Persp0887X1-44
25 Years
Industry InterventioAllocation 109616 (Y
OccurrenceGlaxoSmithAll up to 1 Year Â (Child) 134 Industry ObservatioTime Persp 106175
Number ofProtein Sc All 50 Years and
Phase
older
3 Â (Adult,
2640
Older
Industry
Growth of M b edical CoAll 18 Years and older Â (Adult, Older
0 Other
Adult) ObservatioObservatioPRO00027
To demostra MedImmune All 6 Years to 17
Phase
Years
3 Â (Child)
Biological: CYT004- Cytos Biot All 18 Years and
Phase
older
1|Phase
Â (Adult,
2 Older
Industry
Adult) InterventioAllocation CYT004-MelQbG10 02
Drug: VRC-HIVADV01National InAll 18 Years toPhase
44 Years
Immunogeni University All 18 Years and
Phase
older
2 Â (Adult, 50
Older
Other
Adult) InterventioPrimary PuCCRG 09-0
The primary MedImmune All 60 Years and
Phase
older
3 Â (Adult,
3000
Older
Industry
Adult) InterventioAllocation D153-P507
Adverse eve Cytos Biot All 18 Years toPhase
69 Years
2 Â (Adult,60Older
Industry
Safety andImevaX All 18 Years toPhase
50 Years
Newly deteUMC Utrech All Child, AdulNot Applic 3269 Other|InduInterventioInterventi 2013-85
PreventionUniversity All up to 24 Hours
PhaseÂ 4(Child) 12000 Other InterventioAllocation UCT REC 2
Biological: Dendritic Oslo UniverMale 45 Years and
Phase
older
1|Phase
Â (Adult,
2 Older
Other
Adult) Interventional DC Prostate
Biological: ALVAC-hB National CaAll 18 Years and
Phase
older
1 Â (Adult, 15
Older
Biological: FluzoneÂ®National InAll 18 Years toNot
40 Years
ApplicÂ (Adult)15 NIH InterventioAllocation 05-0055|In
Number ofCliniques uAll 18 Years and
Phase
older
1|Ph
Â (Adult, Older
6 Other
Biological: CYT004- Cytos Biot All 18 Years and
Phase
older
1|Phase
Â (Adult,
2 Older
Industry
Drug: EBV-LMP-2 National InAll Child, AdulPhase 1 99 NIH InterventioPrimary Pu040118|04
Evaluate thCedars-SinAll Child, AdulPhase 2 50 Other InterventioInterventi 3368
Toxicity Memorial SAll 21 Years and
Notolder
Applic
Â (Adult, 34
Older
Other
National InAll 32 Weeks to 36 Weeks Â (Child)71 NIH ObservatioTime Persp04-046
Dose LimitiCentre HosAll 18 Years toPhase
89 Years
Other|Indu
Adult)InterventioInterventi UCPVax|20
Safety if l Craig L Sli All 12 Years and
Phase
older
1 Â (Child, Adult,
Older Adult) N11490|UVA
Safety ite CanSino BiAll 2 Months toPhase
6 Years
1 Â (Child)400 Industry|OInterventioAllocation CS-CTP-DTcP-â…
Phase
older
3 Â (Adult,302
Older
Industry
Biological: MVA-BN Bavarian NMale 20 Years toPhase
55 Years
1 Â (Adult)90 Industry InterventioAllocation MVA-POX-0
AssessmentUniformedAll 18 Years toPhase
55 Years
1|PhÂ (Adult)
176 U.S. Fed|I InterventioAllocation IDCRP-035
Phase
older
1|Ph
Â (Adult, Older
0 Industry
85 Years
OtherAdult)InterventioInterventi CRC-A02-I,
EvaluationProtein Sc All 18 Years toPhase
49 Years
1|PhÂ (Adult)
392 Industry InterventioAllocation PSC22 GLA
85 Years
OtherAdult)InterventioInterventi IMS-MKA2
Phase
older
1|Ph
Â (Adult,173
Older
Industry
Multiple Cell GenesAll 18 Years toPhase
70 Years
Industry
Adult)InterventioAllocation K-0007
Adverse EvSeoul Nati Male 18 Years toPhase
45 Years
1 Â (Adult)20 Other|InduInterventioAllocation GC1109_P1
To examineArgos TherAll 18 Years and
Phase
older
1|Ph
Â (Adult, 26
Older
Industry
Adult) InterventioAllocation MB-002-00
Primary: 1 Valneva AuAll 18 Years and
Phase
older
3 Â (Adult,304
Older
Industry
Tolerabilit Merck ShaAll 6 Weeks toPhase
8 Weeks
3 Â (Child) 151 Industry InterventioAllocation V441-001|
Tolerabili University All 18 Years and
Phase
older
1|Ph
Â (Adult, 19
Older
Other|Indu
Adult) InterventioInterventi IMA950 Pol
Change in The Univers All 63 Years toPhase
90 Years
1 Â (Adult,50Older
OtherAdult)InterventioAllocation:20180171
45 Years
Participan Sanofi Pas All 15 Years toPhase
23 Years
2 Â (Child, 145
Adult)
The serocon Sinovac BioAll 2 Months toPhase
49 Years
1|PhÂ (Child,
708Adult)
Industry InterventioAllocation PRO-sIPV-
The primary MedImmune All 6 Months toPhase
35 Months
3 Â 1920
(Child)
To demostra MedImmune All 6 Months toPhase
71 Months
3 Â 2200
(Child)
Maximum University
T All 18 Years and
Phase
older
1|Ph
Â (Adult, 23
Older
Other
Pain severiÃ‡ankÄ±rÄ± All Child, AdulNot Applic 70 Other InterventioAllocation 2018/9
Antibody rPublic HeaAll 18 Years and older Â (Adult,120Older
Other|Indu
Adult) ObservatioObservatioMPX Imvan
Number ofMemorial SAll 1 Year to 120
Phase
Years
1 Â (Child, 35
Adult,
Older Adult) 06-113|MS
Number ofGlaxoSmith
s All up to 8 Weeks
PhaseÂ 4(Child) 18 Industry InterventioInterventi 201522
The geometr PaxVax, IncAll 18 Years toPhase
45 Years
Phase
older
1|Ph
Â (Adult, Older
0 Industry
85 Years
OtherAdult)InterventioInterventi IMS-NSCLC
ProportionSanaria In All 18 Years toPhase
45 Years
1 Â (Adult)67 Industry|OInterventioAllocation TUCHMI-00
85 Years
OtherAdult)InterventioInterventi IMS-NSCLC
Response ra European OAll 18 Years and
Phase
older
2 Â (Adult,165
Older
Other
Part I and National InAll 18 Years toPhase
65 Years
1 Â (Adult, 0Older
OccurrenceDynavax TeAll 40 Years and
Phase
older
1 Â (Adult, 42
Older
Industry
Adult) InterventioAllocation DV2-HBV-0
Feasibilit Gary ArcheAll 18 Years and
Phase
older
1 Â (Adult, 42
Older
Adult) Pro000038
ProportionAmgen|Swe All 18 Years toPhase
74 Years
4 Â (Adult, Older
Industry
Safety|Imm Ludwig InsAll 18 Years and
Phase
older
1 Â (Adult, 20
Older
Other
DLT evaluatGenexine, Female 18 Years and
Phase
older
1|Ph
Â (Adult, 46
Older
Industry
Adult) InterventioInterventi GX-188E-0
â€¢ To comInstituto d All 3 Months to 6 Years Â (Child) 387 Other ObservatioObservatioMicrobiolo
Inflammatio Internatio All 9 Months toNot
18Applic
Months Â (Child)
Disease Fr Cancer InsiAll 18 Years toPhase
99 Years
Industry
Adult)InterventioAllocation WIRB Proto
Phase
older
1|Ph
Â (Adult, Older
0 Industry
50 Years
Occurrence, Bavarian NoAll 18 Years toPhase
55 Years
1|PhÂ (Adult)
151 Industry|NInterventioAllocation POX-MVA-
Phase
older
2 Â (Adult,690
Older
Industry
GeometricCSL BehrinAll 18 Years and older Â (Adult,491Older
Adult) PerspZLB 1
DiphtheriaSanofi Pas All 60 Years toPhase
99 Years
Industry
Adult)InterventioAllocation RPV03C
Long term MaastrichtAll 18 Years toPhase
65 Years
Other|Indu
Adult)InterventioAllocation MEC 08-5-
Complete hi National CaFemale 17 Years and
Phase
older
2 Â (Child, Adult,
84 NIHOlder Adult)
InterventioAllocation NCI-2012-
Biological: GBS III-TT National InFemale 18 Years toPhase
45 Years
1 Â (Adult)65 NIH InterventioMasking: DDMID 97-004
Ex Vivo MaDartmouth- All 18 Years and
Phase
older
1 Â (Adult, Older
Adult) PuCDR00003
Biological: MN rgp12 VaxGen|NIH All 20 Years toPhase
60 Years
3 Â (Adult)2500 Industry InterventioMasking: DVAX 003
Pre-vaccin University Female 18 Years to 65 Years Â (Adult,400Older
Other|Indu
Adult)ObservatioObservatioUHID-02
55 Years
1|PhÂ (Adult)
268 Other InterventioAllocation 02-BVRS-G
The quadriChinese AcFemale 13 Years toPhase
15 Years
to 18 Months
3 Â 433
(Child)
SAEs and Se Fidec CorpAll 1 Year to 5Phase
Years Â4 (Child) 100 Other InterventioAllocation M3-ABMG
Biological: Hepatitis GlaxoSmithAll Child, Adult, Older Ad 600 Industry ObservatioTime Persp 104147
AbsenteeisMount SinaAll Child, AdulNot Applic 118 Other InterventioAllocation 09-0133-E
Allergen-spNational InAll 5 Months to 7 Months Â (Child) 77 NIH|OtherObservatioObservatioDAIT CoFA
Number ofCIHR CanadAll 18 Years toPhase
65 Years
1|Ph
Â (Adult,79Older
Other|Indu
Adult)InterventioAllocation CTN 147|Co
Drug: rV-PSA|Drug: r National CaMale 18 Years and
Phase
Older
Number ofSidney KimFemale 18 Years and
Phase
Older
Adult) J0866|P50
Biopsy provNational InAll 18 Years toPhase
99 Years
1 Â (Adult,34Older
Immunoglob Massachuse All 50 Years and
Notolder
Applic
Â (Adult, 40
Older
Adult) 2009P001
Biological: AluminumNational InAll 18 Years toPhase
60 Years
1 Â (Adult)110 NIH InterventioMasking: DAVEG 016A|10565
50 Years
ProportionPfizer All 50 Years and older Â (Adult,782Older
Industry
Adult) ObservatioTime Persp6115A1-40
50 Years
60 Years
disease conBart Neyns| All 18 Years and
Phase
Older
Other
Adult) InterventioAllocation UZB-VUB-1
Measuremen MedImmune All 6 Months toPhase
18 Months
2 Â (Child)
PercentageMCM VacciAll 46 Days to Phase
74 Days3 Â (Child)
ImmediateAfrican MaAll 1 Year to 5Phase
Years Â1 (Child) 30 Other InterventioAllocation GMZ2_3_0
Number ofMerck ShaAll 9 Years to 15
Phase
Years3 Â (Child)
Biological: MDX-CTL University All 18 Years and
Phase
Older
Other
Adult) InterventioAllocation FD-R-1975
Intensity oGlaxoSmithAll 18 Years toPhase
40 Years
1|Ph
Â (Adult)
SeroprotecVBI VaccineAll 20 Years toPhase
40 Years
4 Â (Adult)91 Industry InterventioInterventi SciB018
Biological: PSA prostaJonsson CoMale 18 Years and
Phase
Adult) PuUCLA-9909
BCG-induceUniversity All up to 48 Hours
PhaseÂ 1|Ph
(Child) 180 Other InterventioAllocation N06/04/07
Number ofMedImmunAll 5 Years to 17
Phase
Years1 Â (Child) 20 Industry InterventioAllocation MI-CP114
Mean dailyBiomay AGAll 18 Years toPhase
60 Years
2 Â (Adult)181 Industry InterventioAllocation CS-BM32-0
Incidence oIntercell U All 18 Years toPhase
64 Years
safety and Seoul Nati All 20 Years toPhase
28 Years
1 Â (Adult)24 Other|InduInterventioAllocation CJ_SPX_10
National InAll 18 Years to 60 Years Â (Adult) 0 NIH Observational AVEG 025|11541
ProgressionGenitope CAll 18 Years and
Phase
Industry
Duration oRadboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)20 Other InterventioAllocation ZonMw2
Toxicity as Prof. Dr. S All 18 Years and
Phase
older1|Ph
Â (Adult, Older
2 Other
Adult) InterventioInterventi SG269/06
Safety and University All 18 Years and
Phase
older1|Ph
Â (Adult, 82
Older
Other
Adult) InterventioInterventi ERLANGEN
Objective cNational CaAll 18 Years and
Phase
Older
Phase
older1|Ph
Â (Adult, Older
3 Industry
Flow mediaQueen Mary Male 18 Years toPhase
45 Years
1 Â (Adult)64 Other InterventioAllocation 15/LO/078
to 23 Months
3 Â (Child)
Hospital adBandim Hea All up to 42 Days
Phase
Â (Child)
4 15600 Other InterventioAllocation BCGSTRAIN
Anti-HBs coGlaxoSmithAll 11 Weeks toPhase
17 Weeks
3 Â (Child)
Assays on MedImmune All 18 Years toPhase
64 Years
OccurenceMerck ShaAll 6 Weeks toPhase
12 Weeks
3 Â (Child)
120 Years
1|PhÂ (Adult,
31 Older
Adult) J0528|P50
Phase I: DeCureVac A All 18 Years toPhase
75 Years
1|Ph
Â (Adult,46Older
Industry
Documented Nabi BiophAll 18 Years and
Phase
older3 Â (Adult,
3600
Older
Industry
Safety and Mucosis BVAll 18 Years toPhase
49 Years
1 Â (Adult)48 Industry|OInterventioAllocation MUC-SynGE
Biological: ALVAC(2) National InAll 18 Years and
Phase
Older
NIHAdult) InterventioMasking: DA5058s|10674|ACTG A5058s|
Invasive pnUniversity All up to 59 Months Â (Child)4000 Other ObservatioObservatioCOMRU150
Biological: Prevenar Wyeth is nAll 6 Weeks to 9 Years Â (Child)600 Industry ObservatioObservatio0887X-101
Local and National I All 18 Years toPhase
50 Years
Safety(toxiTeikyo Uni All 20 Years toPhase
80 Years
1 Â (Adult, 9Older
OtherAdult)InterventioInterventi TPR07-079
Antibody prMitsubishiAll 2 Months toPhase
43 Months
3 Â (Child)
33 Industry|OInterventioInterventi BK1310-J0
PT specifi London SchFemale 18 Years toPhase
40 Years
4 Â (Adult)600 Other InterventioAllocation SCC 1600
Relative R Pfizer|Kai All 2 Months to 3 Years Â (Child)
53902 Industry|OObservatioObservatio6096A1-40
Antibody LNabi BiophAll 18 Years to 65 Years Â (Adult,300Older
Industry
Adult)ObservatioObservatioNabi-4522
Antibody CPfizer All 121 Days toPhase
72 Months
4 Â (Child)
505 Industry InterventioAllocation B1841008
Any grade 3GlaxoSmithAll 13 MonthsPhase
to 14 Months
3 Â 297
(Child)
SeroconverUCB BiophaAll 18 Years toPhase
55 Years
1 Â (Adult)56 Industry InterventioAllocation UP0034
SeroprotectCrucell Ho All 42 Days to Phase
64 Days4 Â (Child)400 Industry InterventioAllocation QVX-V-A00
Antibody tChinese AcAll 2 Months toPhase
2 Months
3 Â (Child)
1200 Other InterventioAllocation bOPV-PRO-
number ofMassachuse
p All 18 Years and
Phase
Older
Other
Biological: ALVAC(2 National InAll 13 Years and
Phase
older1|Ph
Â (Child, Adult,
94 NIHOlder Adult)
InterventioAllocation A5068|100
ProportionTakeda All 3 Months toPhase
6 Months
3 Â (Child)
416 Industry InterventioAllocation TAK-816/C
Immune res Mahidol UnAll 18 Years toNot
45 Years
ApplicÂ (Adult)60 Other InterventioAllocation MU-CIRB 2
To Evaluat Aeras|UnivAll 126 Days toPhase
182 Days
2 Â (Child)
2797 Other InterventioAllocation C-020-485
Overall Su Merck KGaAll 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation EMR63325
Solicited l Serum InstiAll 18 Years toPhase
45 Years
1 Â (Adult)60 Industry|OInterventioAllocation Dengusiil-
Biological: BCG vacci ProvidenceFemale 18 Years and
Phase
Other
Biological: sargramosSidney KimAll 18 Years and
Phase
older1|Ph
Â (Adult, 30
Older
Adult) PuCDR000006
HCV-RNA 2Valneva AuAll 18 Years toPhase
55 Years
2 Â (Adult)71 Industry InterventioInterventi IC41-202
Phase
Adult,
NIHOlder Adult)
InterventioMasking: DA5057|10673|A5058s|ACTG A
Immunogenic National InAll 18 Years toPhase
49 Years
The PercenUniversity All 18 Years and
Phase
4 Other
Adult) InterventioInterventi UMCC 2005
36 Months
3 Â 2903
(Child)
Industry InterventioAllocation D153 P502
CumulativeEpicentre|All 1 Year and Phase
500 Other
Older Adult)
InterventioInterventi V920-01
Incidence Jonsson CoAll 18 Years toPhase
75 Years
2 Â (Adult, 0Older
Other|NIH|
To provide Sanofi Pas All 7 Years to 19 Years Â (Child,7156
Adult)
Industry ObservatioTime PerspTD511
39 Years
1 Â (Adult) 0 U.S. Fed|I InterventioAllocation S-14-08|D
Adverse efUniversidaFemale 18 Years toPhase
75 Years
1 Â (Adult, 5Older
OtherAdult)InterventioInterventi TEBICA002
safety|tox Memorial SAll Child, AdulPhase 1 9 Other InterventioInterventi 10-229
ProgressionClinica Un All 18 Years and
Phase
Older
Other
Adult) InterventioAllocation CD-2009-0
Plaque RedBavarian NAll 18 Years toPhase
45 Years
3 Â (Adult)
1129 Industry|UInterventioAllocation POX-MVA-
Phase
older1|Ph
Â (Adult, 80
Older
Industry
Tolerabilit Affiris AG All 41 Years to 66 Years Â (Adult,30Older
Industry
Adult)ObservatioObservatioAFF008E|2
Safety|Imm Folia BioteAll 18 Years toPhase
50 Years
1 Â (Adult)48 Industry InterventioAllocation PE1202
Immune ReUniversity All 9 Years and older Â (Child, Adult,
140 Other
Older Adult)
ObservatioObservatioHPVaxResp
Phase
older1|Ph
Â (Adult, Older
0 Industry
Biological: Recombin National Institute of Child, AdulPhase 1 80 NIH InterventioAllocation 01-003|An
Phase
older1|Ph
Â (Adult, 79
Older
Industry
Changes inSt StephensAll 18 Years and
Phase
Older
Other
Adult) InterventioAllocation SSAT 030|
Receipt of University All 18 Years and
Notolder
Applic
Â (Adult,
3272
Older
Other
Phase
older
3 Â (Adult,498
Older
Industry
50 Years
Toxicity anKing's Col All 18 Years and
Phase
older
1 Â (Adult, 24
Older
Other
Adult) InterventioAllocation O5CC14|Eu
Phase
older
1|Ph
Â (Adult, Older
0 Industry
Changes inMayo CliniAll 4 Months to 7 Years Â (Child)300 Other ObservatioObservatio19-001219
GMC of antGlaxoSmithAll 6 Weeks toPhase
12 Weeks
Immunology University All 18 Years toPhase
70 Years
Safety (toxUniversity All 20 Years toPhase
80 Years
1 Â (Adult,10Older
70 Years
1 Â (Adult,60Older
SeroconverSt. Jude C All 1 Year to 4Phase
Years Â1 (Child) 80 Other InterventioAllocation PCVIT
Immunogeni Mayo CliniAll 65 Years and
Phase
older
2 Â (Older100
Adult)
Numbers an Novavax All 24 MonthsPhase
to 72 Months
1 Â (Child)
32 Industry InterventioAllocation RSV-P-101
Use of AntHospital G All 3 Months toNot
5 Years
ApplicÂ (Child)66 Other InterventioAllocation HGNPE 67-
The primarNYU LangoAll up to 21 Years
Phase
Â 1(Child, Adult)
ELISA immuImaxio All 18 Years to 65 Years Â (Adult,
145Older
Industry
Adult)ObservatioObservatio2017-A017
Change in Vrije UniveAll 18 Years toEarly
65 Years
immunologic Radboud Un All 18 Years toPhase
75 Years
Genetic maThe Immuno All 9 Months to 59 Years Â (Child, 10Adult)
Other ObservatioObservatioASCLIN002
To determiImmunovati Female 18 Years toPhase
70 Years
Industry
Adult)InterventioAllocation ITL-014-T
Safety andVaximm G All 18 Years and
Phase
older
1 Â (Adult, 72
Older
Industry
Adult) InterventioAllocation VXM01-01
Solicited s University All 6 Months toPhase
35 Years
Other InterventioAllocation VAC070
The primary University Male 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Other
Adult) InterventioAllocation LAMP hTER
Safety AndMassachuse All 18 Years and
Phase
older
1 Â (Adult, 20
Older
Other|Indu
Drug: dendritic cell National Cancer Instit16 Years and
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
InterventioPrimary PuCDR0000067277|NCI-99-C-013
Phase
older
1|Ph
Â (Adult, Older
0 Industry
Phase
older
1 Â (Adult, Older
ProgressionRoswell ParAll 18 Years and
Phase
older
2 Â (Adult, 64
Older
Adult) I 259614|
Hemagglutin Solvay PhaAll 18 Years toPhase
49 Years
1 Â (Adult)400 Industry InterventioAllocation S205.1.00
Phase
older
1|Ph
Â (Adult, Older
0 Industry
Percent of Johns HopkAll up to 5 Weeks
Not ÂApplic
(Child) 2018 Other|U.S.InterventioAllocation OPP10539
interventi Radboud Un All 18 Years toPhase
75 Years
1 Â (Adult,30Older
OtherAdult)InterventioInterventi 2004-093|
Measure the University All 18 Years toNot
45 Years
ApplicÂ (Adult)44 Other InterventioAllocation MED1354
Phase
older
1|Ph
Â (Adult, Older
0 Industry
tolerabilit Cantonal HoMale 18 Years and
Phase
older
1|Ph
Â (Adult, 15
Older
Other
Adult) InterventioInterventi SG226_02
Safety|TumImmunovati All 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Industry
Adult) InterventioInterventi ITL-017-HC
Phase
older
1|Ph
Â (Adult, 65
Older
Industry
National InAll 18 Years to 70 Years Â (Adult,
958Older
NIH Adult)Observational 030285|03
Biological: NY-ESO-1 Memorial SFemale 18 Years and Phase
older
1 Â (Adult, Older
Adult) NCDR00003
55 Years
1|PhÂ (Adult)
220 Other InterventioAllocation 01-GamEva
Columbia UFemale 18 Years to 26 Years Â (Adult) 150 Other|InduObservatioObservatioAAAD1877
50 Years
Safety|PD-Istituto Sc All 18 Years and
Phase
older
1 Â (Adult, 18
Older
Other
Phase
older
1 Â (Adult,190
Older
Industry
Dose limitiJonsson CoAll 18 Years and
Phase
older
1|Ph
Â (Adult, 33
Older
Adult) CDR000006
Facial PainBerberich, All 4 Years to 6Not
Years
Applic
Â (Child) 42 Other InterventioAllocation Berberich
OccurrenceU.S. Army All 18 Years toPhase
55 Years
1|Ph
Â (Adult)41 U.S. Fed|OInterventioAllocation WRAIR 169
self-reportThomas Jeff All 18 Years andNotolder
Applic
Â (Adult,232
Older
Adult) HopkinsIR
SeroconverValneva AuAll 18 Years andPhase
older
1 Â (Adult, Older
0 Industry
Safety and Clinica Un All 18 Years toPhase
65 Years
1|Ph
Â (Adult, 5Older
OtherAdult)InterventioInterventi CD-AdNS3
National CaFemale 21 Years to 30 Years Â (Adult)
5444 NIH ObservatioTime Persp999910059
Patients wiBavarian NAll 18 Years andPhase
older
1|Ph
Â (Adult, 45
Older
Industry
Adult) InterventioAllocation TAEK-VAC-H
Sylvia Bec All up to 5 Years Â (Child) 667 Other|InduObservatioObservatio09-0371|K
immunologi Radboud Un All 18 Years toPhase
75 Years
1|Ph
Â (Adult,30Older
85 Years
1|Ph
Â (Adult,14Older
OtherAdult)InterventioInterventi CRC-A24-I,
The rate o Seoul NatioAll 20 Years toPhase
75 Years
OtherAdult)InterventioAllocation E+VIP
ProportionJennifer WAll 18 Years andPhase
older
2 Â (Adult, 42
Older
Other|Indu
Overall Re M.D. AnderAll 18 Years andPhase
older
2 Â (Adult, 34
Older
Other|Indu
90 Years
3 Â (Child,
1720
Adult,
Industry
Older Adult)
InterventioAllocation V114-029|
Primary SaGeorge E. All 18 Years andPhase
older
1 Â (Adult, 24
Older
Industry
Adult) InterventioAllocation PV-CC-01
Number ofSanofi Pas All 4 Years to 6Phase
Years3Â (Child)3372 Industry InterventioAllocation M5I02|U11
ency|Asthma Medical CoAll 1 Year to 18 Years Â (Child, Adult)
98 Other ObservatioObservatioCHW 10/12
Incidence NantKwest,All 18 Years andPhase
older
1|Ph
Â (Adult,173
Older
Industry
Tumor ResImmunovati All 18 Years toPhase
70 Years
2 Â (Adult,12Older
Industry
Adult)InterventioInterventi ITL-010-H
Biological: HIV-1 Im National InAll Child, AdulPhase 2 0 NIH InterventioPrimary PuA5120|10938|ACTG A5120|AA
DetermineUniversity
i All 60 Years andNotolder
Applic
Â (Adult, Older
2 Other|Indu
To evaluateOpexa TherAll 18 Years toPhase
55 Years
Incidence Cascadian A T ll 18 Years toPhase
70 Years
1 Â (Adult,90Older
Industry
Adult)InterventioInterventi ONT-10-00
Years4Â (Child) 989 Industry InterventioAllocation P3T10
The Number University All 18 Years toPhase
70 Years
2|Ph
Â (Adult, 4Older
OtherAdult)InterventioInterventi UARK 2003
Number ofPHAC/CIHRAll 18 Years and older Â (Adult, 6525
Older
Other|Indu
Adult) ObservatioObservatiopcirn-surv
cellular a Radboud Un All 18 Years and older Â (Adult, 75Older
Other
Adult) ObservatioObservatioUMCNONC
Guillain-BaHarvard PiAll 11 Years to 21 Years Â 6000000
(Child, Adult)
Other|InduObservatioObservatioPH000274
Adverse evLipotek PtyAll 18 Years andPhase
older
1 Â (Adult, 12
Older
Adult) Lipovaxin
For this PhScott PruitAll 18 Years andPhase
older
1 Â (Adult, 12
Older
Other
6 Months
4 Â (Child)
50 Years
Pre & 1M po GlaxoSmithAll 10 MonthsPhase
and older
Industry
Adult) 759346/00
Safety of t Osaka UnivAll 40 Years toPhase
85 Years
1 Â (Adult,17Older
Change in Immunomic All 18 Years andPhase
older
2 Â (Adult,120
Older
Adult) IRB201400
Rate of so Themis BioAll 18 Years toPhase
55 Years
1 Â (Adult)60 Industry|OInterventioAllocation MV-LASV-1
Biological: Tetanus T National InAll 18 Years andNotolder
Applic
Â (Adult, 50
Older
NIHAdult) InterventioPrimary PuA5046s|ACTG 328 (Main Study
Number ofMedImmunAll 2 Months to Phase
23 Months
1|Ph Â 1338
(Child)
Incidence Yale UniverFemale 18 Years andPhase
older
2 Â (Adult,138
Older
Other
Time to DeOttawa HosAll 18 Years andPhase
older
1|Ph
Â (Adult, 52
Older
Other
45 Years
1|Ph
ProportionNational InAll 18 Years to 50 Years Â (Adult)49 NIH ObservatioObservatio999915197
40 Years
1 Â (Adult)48 U.S. Fed InterventioAllocation RV 158|A-
50 Years
Incidence Agenus IncAll 18 Years andPhase
older
1 Â (Adult, Older
3 Industry
Adult) InterventioInterventi C-610-01
To determin National CaAll 18 Years and
Phase
older
1|Ph
Â (Adult,113
Older
Stage I: CoMerck ShaFemale 20 Years toPhase
45 Years
3 Â (Adult)
6000 Industry InterventioAllocation V503-023
Median Ove Gary ArcheAll 18 Years and
Phase
older
2 Â (Adult,112
Older
Other|Indu
To assess tUniversity All 60 Years and
Notolder
Applic
Â (Adult,205
Older
Other|Indu
The occuran University All 18 Years toPhase
55 Years
National InAll 5 Years and older Â (Child, Adult,
19 NIHOlder Adult)
ObservatioTime Persp090170|09
50 Years
Anti-Vi EL Novartis All 18 Years toPhase
42 Years
2 Â (Adult)51 Industry InterventioAllocation H01_04E1
50 Years
To determiHawaii BiotAll 18 Years toPhase
45 Years
1 Â (Adult)16 Industry InterventioAllocation HBV-001-C
Overall resUniversity Female 18 Years and
Phase
older
2 Â (Adult, 42
Older
Other|Indu
Adult) InterventioAllocation PESCO
Number ofJanssen
P VaAll 18 Years toPhase
50 Years
Safety Pro Aeras|SanoAll 12 Years toPhase
17 Years
2 Â (Child)989 Other|InduInterventioAllocation C-040-404
Laboratory-GlaxoSmithAll 65 Years and older Â (Older Adult)
Maximum M t emorial SAll 18 Years and
Phase
older
1 Â (Adult, 10
Older
Other
Median over Gary ArcheAll 18 Years toPhase
80 Years
Other
Adult)InterventioAllocation Pro000547
Response Oslo UniveAll 18 Years and
Phase
older
2 Â (Adult, 14
Older
Other
Adult) InterventioInterventi 2.2007.11
55 Years
1 Â (Adult)36 Other InterventioAllocation 03-GamFlu
Clinical R National InAll 18 Years and
Phase
older
2 Â (Adult, Older
3 NIHAdult) InterventioAllocation 080155|NC
35 Years
ApplicÂ (Adult)25 Other InterventioAllocation EHMI9
Mortality|Bandim Hea All up to 1 Year
Phase
Â (Child)
4 4800 Other InterventioAllocation ICA-CT-200
111 Days
3 Â (Child)
evaluation Immunovati All 18 Years and
Phase
older
1|Ph
Â (Adult, 50
Older
Industry
Adult) InterventioInterventi ITL-002-C
Tolerabili Axon Neuro All 50 Years toPhase
85 Years
1 Â (Adult,30Older
Industry
Adult)InterventioAllocation AXON CO 1
Number ofUltimovacsAll
p 18 Years and
Phase
older
1 Â (Adult, 20
Older
Industry
Adult) InterventioInterventi UV1/hTER
Change froUniversity All 3 Months toNot
8 Years
ApplicÂ (Child)
580 Other InterventioAllocation RSRB00058
50 Years
Anti-polyr GlaxoSmithAll 18 MonthsPhase
to 24 Months
3 Â 148
(Child)
Influenza i National InAll 18 Years toPhase
55 Years
ReactogeniImperial C All 18 Years toPhase
50 Years
1 Â (Adult)36 Other InterventioAllocation 14SM2306
ConcentratiSt George' Female 18 Years toNot
35 Years
ApplicÂ (Adult)18 Other InterventioAllocation SG09-EN01
The incide National InAll 1 Year to 3Phase
Years Â1 (Child) 200 NIH InterventioAllocation 999908194
to 23 Months
2 Â1551
(Child)
Mortality, Bandim Hea All 6 Months toPhase
23 Months
4 Â 9500
(Child)
Other InterventioAllocation CVK-2006-
Safety|Imm Cascadian AT ll 18 Years toPhase
70 Years
1 Â (Adult,85Older
Industry
Adult)InterventioInterventi ONT-10-00
Atopic sensMurdoch Ch All up to 10 Days
Phase
Â (Child)
3 1272 Other InterventioAllocation BCG12/01|
Phenotype,Prof. SergeAll 18 Years toPhase
75 Years
1 Â (Adult, 8Older
Other
Adult)InterventioInterventi CDR000046
Biological: PA-1-STK Louisiana SAll Child, AdulPhase 1 Other InterventioPrimary PuCDR000006
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
Antibody CGlaxoSmithAll 41 Years and
Phase
older
4 Â (Adult,596
Older
Industry
Incidence oDBV Techno All 18 Years toPhase
40 Years
1 Â (Adult)60 Industry|OInterventioAllocation VBEST
Drug: AMA1/AlhydrogNational InAll 18 Years toPhase
50 Years
Biological: MMR-II|BiNational InAll 12 MonthsPhase
to 12 Months
1|Ph Â 105 (Child)
Hadassah M All up to 80 Years Â (Child, Adult,
300Older
OtherAdult)ObservatioTime Perspengelhard
Biological: QS21|BiolMemorial SAll 18 Years and
Phase
older
2 Â (Adult, Older
Adult) 98-012|CD
Estimate thDalhousie All 16 Years and older Â (Child,
4197
Adult,
Other|Indu
Older Adult)
ObservatioObservatioSOS-VE01
Objective ImmunoVacc All 18 Years and
Phase
older
2 Â (Adult, 24
Older
Industry
Adult) InterventioInterventi ONC-DPX-S
OccurrenceH. Lee MoffAll 18 Years and
Notolder
Applic
Â (Adult, Older
Adult) NCI 8701|
Immunologic European OFemale 19 Years and
Phase
older
2 Â (Adult, 44
Older
Other
Adult) InterventioPrimary PuEORTC-139
OccurrencePDC*line All 18 Years and
Phase
older
1|Ph
Â (Adult, 66
Older
Industry
Adult) InterventioAllocation PDC-LUNG-
Participan Merck ShaAll 12 MonthsPhase
to 17 Months
4 Â1800
(Child)
SeroconverCrucell Ho All 18 Years and
Phase
older
4 Â (Adult,111
Older
Industry
Phase
older
4 Â (Adult,110
Older
Industry
PreventiveNational InAll 18 Years toPhase
35 Years
2|PhÂ (Adult)
5407 NIH|IndustInterventioAllocation HVTN 702
Phase
older
4 Â (Adult,114
Older
Industry
Clearance Genticel Female 25 Years toPhase
50 Years
2 Â (Adult)239 Industry InterventioAllocation PC10VAC0
Comparison University All 18 Years and
Phase
older
1|Ph
Â (Adult, 62
Older
Other
Biological: Nontypea National I All Child, AdulPhase 1 40 NIH InterventioPrimary Pu970114|97
Toxicity pr Robert FerrAll 18 Years toPhase
120 Years
Adult) PCI-03-15
Incidence Pfizer Male 18 Years and
Phase
older
1 Â (Adult,133
Older
Industry
Adult) InterventioMasking: NB7791001|
Biological: MART-1 anUniversity All 18 Years and
Phase
older
1 Â (Adult, 15
Older
Adult) PuCDR000006
Biological: aldesleuk Genzyme, aAll 18 Years and
Phase
older
1|Ph
Â (Adult, 36
Older
Industry
Number ofNational CaMale 18 Years and
Phase
older
1|Ph
Â (Adult, 32
Older
Phase
older
2 Â (Older253
Adult)
The occurre National InAll 18 Years toPhase
50 Years
Relative toTVAX Biome All 18 Years and
Phase
older
1|Ph
Â (Adult, 14
Older
Industry
Adult) InterventioInterventi TVI-AST-00
Maximum National
to CaAll Child, AdulPhase 1 21 NIH InterventioInterventi NCI-2009-
Drug: PCLUS 3-18 MNNational CaAll Child, AdulPhase 1 31 NIH InterventioPrimary Pu940159|94
Pain from aThe Hospita All 18 Years toPhase
80 Years
OtherAdult)InterventioAllocation 1E+09
SeroconverMerck ShaAll 18 Years toPhase
49 Years
1 Â (Adult)98 Industry InterventioAllocation V180-001
number ofGreenstar Female 15 Years toNot
49 Years
ApplicÂ (Child,
28000 Adult)
Industry|OInterventioAllocation Grant #20
Safety Bavarian NAll 18 Years toPhase
50 Years
1 Â (Adult)36 Industry InterventioAllocation HIV-POL-0
ProgressioMarker TheFemale 18 Years and
Phase
older
2 Â (Adult,120
Older
Industry
Adult) InterventioAllocation FRV-004
Biological: ImmunodoNational CaAll Child, AdulPhase 2 114 NIH InterventioPrimary Pu980023|98
Part 1: Ge Merck ShaAll 50 Years toPhase
59 Years
Difference Radboud Un Male 18 Years toPhase
35 Years
2|PhÂ (Adult)40 Other InterventioAllocation BCG_influe
Comparison Scott Halp Female 18 Years and
Phase
older
2|Ph
Â (Adult,440
Older
Other|Indu
Adult) InterventioAllocation DAL07-01
Cellular i Aeras All 18 Years toPhase
45 Years
Adverse EvNational UAll 21 Years toPhase
99 Years
1 Â (Adult,40Older
Other|Indu
Adult)InterventioAllocation GA01/03/1
CumulativeUniversity Female 23 Years toNot
23 Years
ApplicÂ (Adult)
7000 Other InterventioAllocation 102-2793/
Biological: Influenza National InAll 18 Years and
Notolder
Applic
Â (Adult, Older
0 NIHAdult) InterventioInterventi ACTG 340|11311
Immunogeni Pfizer All 16 Years and
Phase
older
3 Â (Child,330
Adult,
Industry
Older Adult)
Presence oThemis Bi All 18 Years toPhase
55 Years
2 Â (Adult)60 Industry InterventioAllocation MV-CHIK-2
PercentageValneva AuAll 18 Years toPhase
49 Years
2 Â (Adult)34 Industry|OInterventioAllocation VLA1701-2
Phase
older
2 Â (Adult,100
Older
NIHAdult) InterventioMasking: DA5024|10070|ACTG A5024|AA
to 24 Months
3 Â 296
(Child)
Industry InterventioAllocation 105239 (m
Analysis ofNovartis V All 4 Years to 14
Phase
Years
4 Â (Child)126 Industry InterventioAllocation M48P3E1
Distant MeSidney KimAll 18 Years toPhase
100 Years
Other|Indu
Adult)
InterventioInterventi J15237|IR
Biological: recombin National CaFemale 18 Years and
Phase
older
2 Â (Adult, Older
Incidence oNational I All 18 Years toPhase
50 Years
1 Â (Adult)538 NIH|OtherInterventioAllocation 150044|15
20 Years
ConfirmedMayo
r ClinicAll 18 Years and
Phase
older
2 Â (Adult, 15
Older
Adult) CDR000058
Safety|OverPaul Graham All 3 Years to 18
Phase
Years
1 Â (Child, Adult)
3 Other|NIHInterventioAllocation PEDSBRN00
RecurrenceAlliance foAll 18 Years and
Phase
older
2 Â (Adult, 56
Older
Adult) CALGB-89
Incidence oPfizer|Kai All Child, Adult, Older Ad 1 Industry|OObservatioObservatio6096A1-40
to 15 Months
3 Â1913
(Child)
PercentageMalaria VaAll 18 Years toEarly
50 Years
PhasÂ (Adult)18 Other InterventioAllocation MVDC-2003
Biological: gp100 ant University All 18 Years and
Phase
older
2 Â (Adult, 48
Older
Adult) CDR000006
6 Years
4 Â (Child)
600 Industry InterventioInterventi E2I59|U11
The primaryUniversity All 18 Years and older Â (Adult, 48Older
Other
Adult) ObservatioObservatioUCL 12/01
Safety: ph Vakzine Pr All 18 Years toPhase
45 Years
1 Â (Adult)24 Industry|OInterventioAllocation VPM1002-Z
Safety|FeaMedical Uni All 18 Years and
Phase
older
1 Â (Adult, Older
1 Other
Drug: Ritonavir|Biol National I All 13 Years and
Phase
older
1 Â (Child, Adult,
46 NIH|Indust
Older Adult)
InterventioMasking: DACTG 246/946|11223|11499
SeroconversAga Khan UAll up to 14 Days
NotÂApplic
(Child) 320 Other InterventioAllocation 1291-Peds
Phase
older
2 Â (Adult, 25
Older
Adult) PuCDR000006
Incidence oLG Chem All 6 Weeks toPhase
8 Weeks
4 Â (Child)
3000 Industry InterventioInterventi LG-VPCL00
Drug: rV-CEA(6D)/TR National CaAll 18 Years and
Phase
older
1 Â (Adult, 12
Older
Biological: AluminumNational InAll up to 3 Days
Phase
Â (Child)
1 0 NIH InterventioPrimary PuACTG 279|11255
75 Days3 Â (Child)588 Industry InterventioAllocation A5I16
Measurable Prof. Eliza Female 13 Years toPhase
15 Years
4 Â (Child)
400 Other InterventioAllocation HPV CSP01
to 24 Months
3 Â 957
(Child)
Number ofMerck ShaAll 42 Days to Phase
90 Days3 Â (Child)
To assess Selecta BioAll 18 Years toPhase
60 Years
1 Â (Adult)82 Industry InterventioAllocation SEL-068/1
FunctionalJohn SampsAll 18 Years toPhase
120 Years
Adult) Pro000009
complete eTransgene All 18 Years toPhase
70 Years
2 Â (Adult,
140Older
Industry
Adult)InterventioAllocation TG4040.02
Phase
older
2 Â (Adult, 60
Older
Adult) CDR000006
Treatment-rFred HutchAll 18 Years and
Phase
older
1 Â (Adult, 12
Older
Adult) 2481.00|N
Growth inhUniversity All 18 Years toNot
45 Years
ApplicÂ (Adult)36 Other InterventioAllocation TB038
Biological: gp100 ant University All 18 Years and
Phase
older
2 Â (Adult, 48
Older
Adult) CDR000006
ProgressioNational CaAll 18 Years toPhase
85 Years
2 Â (Adult,48Older
50 Years
Safety eva University All 18 Years toPhase
55 Years
1 Â (Adult)30 Other|InduInterventioAllocation TB028
Safety andSelecta BioAll 18 Years toPhase
60 Years
1 Â (Adult)72 Industry InterventioAllocation SELA-070/
Objective cNational InAll 18 Years and
Phase
older
2 Â (Adult, 26
Older
Collection GlaxoSmithAll 18 Years toPhase
50 Years
4 Â (Adult)
Linear mixeFred HutchFemale 18 Years toPhase
60 Years
2 Â (Adult)33 Other InterventioAllocation IRB-6940|
49 Years
1 Â (Adult)
University All 2 Years to 7 Years Â (Child) 236 Other ObservatioTime Persp2007/004/
Biological: MART-1 anEastern CoAll 18 Years and
Phase
older
2 Â (Adult, Older
Adult) CDR000006
50 Years
Biological Leiden UniAll 18 Years and
Phase
older
1 Â (Adult, 24
Older
Other|Indu
Adult) InterventioInterventi HPV16HH0
seroprotectSeqirus All 18 Years and
Phase
older
2 Â (Adult,612
Older
Industry
Adult) InterventioAllocation CSLCT-IIV-
TB case deUniversity All Child, AdulNot Applic 39 Other InterventioAllocation IDRC 1027
Drug: AMA1-C1/AlhydNational InAll 18 Years toPhase
45 Years
1 Â (Adult) 0 NIH InterventioPrimary Pu999905117
Biological: gp100 h National CaAll Child, AdulPhase 1 255 NIH InterventioPrimary Pu950145|95
GeometricMerck ShaMale 20 Years toPhase
80 Years
1 Â (Adult,40Older
Industry
Drug: PpPfs25/ISA51 National InAll 18 Years toPhase
50 Years
1 Â (Adult) 0 NIH InterventioPrimary Pu050118|05
Period to tRadboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)30 Other InterventioAllocation ZonMw1
Time to th Shanghai ZAll 18 Years toEarly
65 Years
PhasÂ (Adult,
144Older
OtherAdult)InterventioAllocation B2017-197
Immunologi National CaAll 7 Years andPhase
104 NIHOlder Adult)
Safety Eve BTG InternaAll 25 Years toPhase
65 Years
1 Â (Adult,50Older
OtherAdult)InterventioInterventi PR002-CLN
Efficacy ( European M All 18 Years toPhase
50 Years
1|PhÂ (Adult)26 Other|U.S.InterventioAllocation VAC027.2|E
Rate of subValneva AuAll 65 Years and
Phase
older
1 Â (Older Adult)
82 Industry InterventioAllocation IC84-101
Phase
older
4 Â (Adult,212
Older
Industry
ProportionNational CaMale 18 Years and
Phase
older
2 Â (Adult, 50
Older
The incide Vaxine Pty All 18 Years and
Phase
older
1 Â (Adult,270
Older
Adult) FLU003
Vitamin A pInternatio All 9 Months toNot18Applic
Months Â (Child)
Mortality tBandim Hea All 9 Months toPhase
4 Years
4 Â (Child)
6534 Other InterventioAllocation CVEK2005-
Mortality tBandim Hea All 19 MonthsPhase
to 24 Months
4 Â2871
(Child)
Other InterventioAllocation ICA4-CT-20
Human Papi University Female 18 Years toNot
26 Years
ApplicÂ (Adult)60 Other InterventioAllocation StepUpToP
Complete RNational CaAll 18 Years and
Phase
older
2 Â (Adult, Older
The standar GlaxoSmithAll 18 Years and older Â (Adult,676Older
Industry
PhenotypicUniversity All 7 Years and older Â (Child, Adult,
36 Other
Older Adult)
ObservatioObservatioMICRO150
CompositeAffiris AG All 50 Years toPhase
85 Years
Industry
Adult)InterventioAllocation AFF006A|2
Biological: aldesleuk National InAll 18 Years and
Phase
older
1 Â (Adult, 61
Older
Biological: CYT004-MCytos Biot All 18 Years and
Phase
older
2 Â (Adult, 21
Older
Industry
Adult) InterventioAllocation CYT004-Me
Smoking sta Novartis All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation CNIC002A2
38 Years
1|PhÂ (Adult)72 NIH InterventioAllocation 05-0010|5
Frequency Mannkind All 18 Years and
Phase
older
1 Â (Adult, 26
Older
Industry
Adult) InterventioInterventi CDR000006
Peripheral Internatio Female 22 Years toNot
35 Years
ApplicÂ (Adult)66 Other InterventioAllocation 2008-069
Investigat Green CrosAll 18 Years toPhase
55 Years
2 Â (Adult)299 Industry|OInterventioAllocation GC1109_P
Flacc pain Maharishi All 10 Weeks toNot14Applic
Weeks Â (Child)
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
Incidence Beijing CenAll Child, AdulPhase 4 1000 Other InterventioInterventi BJCDPC-7
PercentageGenentech,All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation U3374g
PrevalenceThe AlfredMale 17 Years to 19 Years Â (Child,
400Adult)
Other|InduObservatioObservatioIISP50939
Rate sensitHopital Fo Female 18 Years and
Notolder
Applic
Â (Adult,400
Older
Other
Adult) InterventioInterventi 2014/08|2
to 23 Months
3 Â 600
(Child)
Industry InterventioAllocation V210-A03|
PerformancPhilipps U All 18 Years and
Notolder
Applic
Â (Adult,135
Older
Other
Adult) InterventioAllocation 2017-39k
59 Years
Tolerabili Axon Neuro All 50 Years toPhase
86 Years
1 Â (Adult,25Older
Industry
Adult)InterventioInterventi AC-AD-002
Number ofMerck ShaAll 60 Years and
Phase
older
2 Â (Adult,309
Older
Industry
Feasibilit John SampsAll 18 Years and
Phase
older
1 Â (Adult, 50
Older
Adult) Pro000066
The rate o Sanofi Pas All up to 59 Months Â (Child)510000 Industry ObservatioObservatioM5A15
Identificat CentogeneAll 18 Years and older Â (Adult,100Older
Industry
Adult) ObservatioObservatioPICOP-GLO
ProgressioThe First All 18 Years toPhase
80 Years
2 Â (Adult,
1200Older
OtherAdult)InterventioAllocation CIKRC001
safety and Dartmouth- All 18 Years and
Phase
older
2|Ph
Â (Adult,
1975Older
Adult) 1R01AI045
Biological: CombinatiNational InAll Child, AdulPhase 1 50 NIH InterventioPrimary Pu990091|99
geographicMerck Medi All 18 Years toNot
60 Years
ApplicÂ (Adult)
430 Industry|OInterventioAllocation 2011-A002
60 Years
Immune rep Radboud Un All 18 Years toPhase
75 Years
1|Ph
Â (Adult,15Older
Other
A 50% reduUniversity All up to 40 Years
Not ÂApplic
(Child, Adult)
200 Other InterventioAllocation IRB-01081
Anti-tumorNational CaAll 18 Years and
Phase
older
1 Â (Adult, 60
Older
To evaluateNabi BiophAll 18 Years toPhase
65 Years
Industry
Overall Su Darren CarAll 18 Years and
Phase
older
2 Â (Adult, 78
Older
Other|Indu
Adult) InterventioAllocation HCRN GI16
Toxicity- Rockefelle All 18 Years and
Phase
older
1 Â (Adult, 19
Older
Other
Adult) InterventioInterventi RDA-0611
PercentageMCM Vaccin All 46 Days to Phase
76 Days
3 Â (Child)385 Industry InterventioInterventi V419-010|
Adverse EvUniversity All 18 Years and
Phase
older
2 Â (Adult, 43
Older
Other
Median PSA Eastern CoMale 18 Years and
Phase
older
2 Â (Adult, Older
Adult) CDR00006
Biological: ALVAC-HI National I All 18 Years toPhase
40 Years
1 Â (Adult)40 NIH|OtherInterventioMasking: DHIVNET 007|10590
Survival|B Cell GenesMale 18 Years and
Phase
older
3 Â (Adult,626
Older
Industry
Adult) InterventioAllocation G-0029|(VI
SeroprotecNational InAll 18 Years toPhase
70 Years
NIH|Indust
Adult)InterventioAllocation ACTG A537
a new tumo Bart Neyns|All 18 Years and
Phase
older
1 Â (Adult, 18
Older
Other
all-cause mAssistance All 60 Years and
Notolder
Applic
Â (Adult,
4000
Older
Other
Adult) InterventioAllocation AOM 0505
CompletionDuke UniveAll 12 MonthsPhase
to 35 Months
4 Â (Child)
to 18 Months
3 Â 168
(Child)
OccurrenceValneva A All 18 Years toPhase
65 Years
1 Â (Adult,32Older
Adult) IC47-101
prevalenceInstitut f All 65 Years and older Â (Older167Adult)
Other|InduObservatioObservatioFluClinic
Clinical r Lars MÃ¸ll All 18 Years and
Phase
older
2 Â (Adult, 20
Older
Other|Indu
Adult) InterventioInterventi CLL19H1|2
Solicited Crucell HolAll 18 Years toPhase
50 Years
1|Ph
Â (Adult)36 Industry|OInterventioAllocation MAL-V-A00
Step I-the Green CrosAll 10 Years toPhase
17 Years
2|Ph
Â (Child)
311 Industry InterventioAllocation GC1107_P2
Individual Crucell Ho All 12 MonthsPhase
to 16 Years
2 Â (Child)
308 Industry InterventioAllocation EPA 001 F
Safety|Tumo National InAll 18 Years and
Phase
older
1 Â (Adult,136
Older
Rate of advNeon TheraAll 18 Years and
Phase
older
1 Â (Adult, 55
Older
Industry
Adult) InterventioInterventi NT-001
Number ofNanoBio
P CoAll 18 Years toPhase
49 Years
1 Â (Adult)199 Industry InterventioAllocation NB-1008-0
FunctionalGary ArcheAll 18 Years toPhase
120 Years
Adult) Pro000005
Antiviral A Bukwang PAll 18 Years toPhase
60 Years
4 Â (Adult)70 Industry InterventioAllocation L-FMAU-40
Safety andInovio PhaAll 18 Years toPhase
55 Years
1 Â (Adult)116 Industry InterventioAllocation FLU-101
Safety andBavarian NFemale 18 Years and
Phase
older
1 Â (Adult, Older
9 Industry
Adult) InterventioAllocation BNIT-BR-0
Primary aim Herlev HosAll 18 Years and
Phase
older
1|Ph
Â (Adult, 25
Older
Other
Adult) InterventioAllocation MM0413
fecal sheddUniversity All 42 Days to Phase
48 Days
3 Â (Child)810 Other InterventioAllocation 00000447|
Number ofUniversity All Child, AdulPhase 4 200 Other InterventioAllocation 17-2090|I
toxicities FukushimaAll 20 Years toPhase
80 Years
1|Ph
Â (Adult,17Older
Other
Adult)InterventioInterventi FPCR1R2-2
Adverse evStatens SerAll 18 Years toPhase
55 Years
1 Â (Adult)38 Other InterventioAllocation ACAF01-01
1 month afGlaxoSmithAll 2 Years to 30
Phase
Years
4 Â (Child,324
Adult)
ic Kidney Disease The Clevel All 18 Years and older Â (Adult, 82
Older
Other
Adult) ObservatioObservatio ###
To assess Masonic CaAll 18 Years and older Â (Adult,112
Older
Other
Adult) ObservatioObservatio2002LS032
Biological: GV1001 Oslo UniverAll 18 Years toPhase
75 Years
1|Phase
Â (Adult,
2 Older
Other
Adult)Interventional P03700
Seropositi Merck ShaAll 12 MonthsPhase
to 17 Months
4 Â1274
(Child)
EvaluationShiga UnivAll 20 Years toPhase
79 Years
2 Â (Adult,45Older
Other|Indu
Adult)InterventioInterventi S488410L
Risk of sevMcGill UniAll 2 Years to 18 Years Â (Child,170
Adult)
Change froUniversity All 3 Months toPhase
15 Years
4 Â (Child)700 Other InterventioAllocation RSRB00073
Negative r Azidus BraFemale 18 Years and
Phase
older
3 Â (Adult,347
Older
Adult) IMUPAN101
Immune res Radboud Un All 18 Years toPhase
75 Years
1|Ph
Â (Adult,40Older
Other
ProgressionFundacion All 18 Years and
Phase
older
2 Â (Adult, 52
Older
Other
Adult) InterventioAllocation MCBRVP|20
Biological Aeras All 18 Years toEarly
55 Years
PhasÂ (Adult)15 Other InterventioInterventi A-051
Change froUniversity Male 18 Years toNot45 Years
ApplicÂ (Adult)45 Other InterventioAllocation CRC305E
Number ofNational I All 9 Months to Phase
24 Months
2 Â (Child)
PercentageMerck ShaAll 12 Months and older Â (Child, 754Adult,
Industry
OlderObservatioTime
Adult) PerspV210-059|
Biological: monoclonaRadiation All 18 Years and Phase
older
2 Â (Adult, Older
Adult) PuRTOG-990
Grade 3 orDavid Garcia AllCinca|IDIBAPS
18 Years- Institut
toPhase
60 Years
d'Investigacions
1|PhÂ (Adult)56 Other
BiomÃ¨diques
August Pi i Sunyer|Felipe
2017-0005GarcÃa - Investigator C
PercentageMedigene All 18 Years toPhase
75 Years
Industry
Adult)InterventioInterventi CD-FDC-00
PercentageAC ImmuneAll 25 Years toPhase
45 Years
1 Â (Adult)16 Industry|NInterventioAllocation ACI-24-13
High expresHealth Sc All 65 Years and older Â (Older Adult)
50 Other ObservatioObservatioProtection
Adverse eve Pfenex, In All 18 Years toPhase
55 Years
1 Â (Adult)54 Industry|UInterventioAllocation PF563-101
Testostero Pepscan ThMale Child, AdulPhase 1|Ph 12 Industry Interventional PEP223-NL
Seroconvers China NatioAll 3 Months to Phase
3 Months
4 Â (Child)
702 Industry|OInterventioAllocation sIPV/DTaP-
Dose LimitiIcahn SchoAll 18 Years and Phase
older
1|Ph
Â (Adult, 56
Older
Other|Indu
Antibody prMitsubishiAll 2 Months to Phase
43 Months
3 Â (Child)
370 Industry|OInterventioAllocation BK1310-J0
The occurre PaxVax, IncAll 18 Years and older Â (Adult,855 Older
Industry
Adult) ObservatioObservatioVIV-PASS-0
immune res Oryx GmbHAll 18 Years and Phase
older
1|Ph
Â (Adult, 22
Older
Industry
Adult) InterventioInterventi MicOryx
Drug: Recombinant VNational CaMale 18 Years and Phase
older
1 Â (Adult, 21
Older
DetectableBaylor Col All 18 Years toPhase
45 Years
2 Â (Adult)48 Other|NIHInterventioAllocation H-38292|U
Number orUniversity All 18 Years toPhase
45 Years
1 Â (Adult)30 Other|InduInterventioAllocation MALACHIT
Incidence Simon M. CMale 18 Years toPhase
50 Years
1 Â (Adult) 3 Other InterventioInterventi CDVAX
To determin University All 18 Years and Phase
older
2 Â (Adult, 40
Older
Other
Adult) InterventioAllocation UARK 2000
PercentageFondazioneAll 18 Years toPhase
70 Years
1 Â (Adult,26Older
OtherAdult)InterventioInterventi DENDR2
ProgressionDana-FarbeAll 18 Years and Phase
older
2 Â (Adult,152
Older
Other
AnamnesticNovosanis All 18 Years toPhase
35 Years
1 Â (Adult)48 Industry InterventioAllocation CP140465_
Risk of gra Assistance All 18 Years and Notolder
Applic
Â (Adult,100
Older
Other
Adult) InterventioInterventi P140315
Effect of a Institut N All 18 Years toNot80 Years
OtherAdult)InterventioAllocation C07-38|20
Titers for GlaxoSmithAll 6 Years to 13Phase
Years
Adverse evEnterome All 18 Years and Phase
older
1|Ph
Â (Adult, 72
Older
Industry
Adult) InterventioInterventi EOADR1-1
feasibility Iwate MediAll 20 Years toPhase
80 Years
1 Â (Adult,20Older
OtherAdult)InterventioInterventi IMU-H18-5
Overall SurGERCOR - M All 18 Years and Phase
older
2 Â (Adult,156
Older
Other|Indu
Adult) InterventioAllocation TEDOPAM D
50 Years
Drug: Human Papillom Indiana UnFemale 9 Years to 18 Years Â (Child, Adult) 72 Other|InduObservatioObservatio0807-02
Change in U.S. Army All 20 Years toPhase
40 Years
2 Â (Adult)40 U.S. Fed|NInterventioAllocation RV 328|19
Change in Pfizer All 18 Years and older Â (Adult, 1540
Older
Industry
geometric SynermoreAll B 18 Years and Phase
older
2 Â (Adult,448
Older
Industry
Adult) InterventioAllocation SYN023-00
Times vira Hospital ClAll 18 Years and Phase
older
4 Â (Adult, 26
Older
Other
Adult) InterventioAllocation 02-0490;
Safety of University All 18 Years toEarly
50 Years
PhasÂ (Adult)25 Other InterventioAllocation VAC069
GeometricGlaxoSmithAll 6 Months to Phase
17 Years
3 Â (Child)
The primarImmune Res All 18 Years toPhase
50 Years
2|PhÂ (Adult)
200 Industry|OInterventioAllocation IR902-231
Safety: ph Vakzine P Male 18 Years toPhase
55 Years
1 Â (Adult)80 Industry InterventioAllocation VPM1002-G
Number ofU.S. Army Medical ReChild, AdulPhase 1 30 U.S. Fed|I InterventioAllocation A-14620.b
PercentageMerck ShaAll 18 Years toPhase
49 Years
3 Â (Adult)
Safety of University All 6 Months to Phase
11 Years
2 Â (Child)168 Other InterventioAllocation TB014|MCC
Immune res PATH|NavalAll 18 Years toPhase
45 Years
1 Â (Adult)50 Other|U.S.InterventioAllocation VAC-050
Anti PT IgASt George'sFemale 18 Years and older Â (Adult, 50Older
Other
Adult) ObservatioObservatio 18.0068
Immunologi Tel-Aviv SoAll 18 Years toNot
60 Years
ApplicÂ (Adult)87 Other InterventioAllocation 0664-17-T
number ofUMC f Utrech
All 18 MonthsPhase
to 72 Months
4 Â 660
(Child)
Other InterventioAllocation Primakid 1
Adverse evInstitut Pa All 18 Years toPhase
65 Years
1 Â (Adult,10Older
Safety: no Statens Se Male 18 Years toPhase
50 Years
1 Â (Adult)12 Other InterventioInterventi EudraCT20
Immunogeni PATH|Serum All 42 Days to Phase
56 Days
3 Â (Child)660 Other|InduInterventioAllocation CVIA-074
99 Years
Industry
Adult)InterventioAllocation CD-VA-MED
Change FroRobert L. All 18 Years toPhase
70 Years
2 Â (Adult,28Older
Other|NIH|
Adult)InterventioAllocation EraMune0
Drug: EF-1 Peptide|DNational CaAll up to 30 Years
Phase
Â 2(Child, Adult)
30 NIH InterventioPrimary Pu970050|97
90 Days
Phase
Years
Biological: keyhole l University All 18 Years toPhase
120 Years
2 Â (Adult, Older
Other|NIH|
Adult)
InterventioPrimary Pu196-99|P3
ProgressioPrima BioMFemale 18 Years and
Phase
older
2 Â (Adult, 63
Older
Industry
Adult) InterventioAllocation CAN-003
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
PercentageMerck ShaMale 9 Years to 15
Phase
Years
3 Â (Child)101 Industry InterventioInterventi V501-200
Clinical e Charite UniAll 18 Years and
Phase
older
2 Â (Adult, 25
Older
Other
Adult) InterventioAllocation HaemaCB
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
Biological: OVA BiP p Memorial SAll 18 Years and
Phase
older
1 Â (Adult, Older
Adult) Pu99-036|CD
Incidence Bristol-My All 18 Years and older Â (Adult,1200
Older
Industry
Adult) ObservatioObservatioCA209-99J
Response ra City of HopFemale 18 Years and
Phase
older
2 Â (Adult, 28
Older
Adult) 16448|NCI
Biological: Anthrax v National InAll 18 Years toPhase
50 Years
2 Â (Adult) 270 NIH InterventioAllocation 04-026|Anthrax CVD 3000
Rockefelle All 18 Years to 45 Years Â (Adult) 8 Other ObservatioObservatioRUH IRB #
Evaluate thDuke Univer All 18 Years and
Phase
older
1|Ph
Â (Adult, Older
Adult) 2030|IRB
Biological: MART-1 anNational CaAll 16 Years and
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
The primarFuda CanceFemale 30 Years to 75 Years Â (Adult,40Older
OtherAdult)ObservatioObservatioCLB-001|2
Clinical r Bristol-MyeAll 16 Years and
Phase
older
2 Â (Child, Adult,
0 Industry|NInterventioAllocation
Older Adult) CDR000048
Safety|Imm Vakzine Pr All up to 8 Days
Phase
Â (Child)
2 48 Industry|OInterventioAllocation VPM1002-Z
vaccine ty Nagasaki UAll 2 Months toPhase
36 Months
4 Â32400
(Child)
Other InterventioAllocation OPP11398
Biological: MART-1 anNational CaAll 16 Years and
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
Date of bi Hanane ELAll Child, Adult, Older Ad 0 Other ObservatioObservatioCHUB-RET
ProportionAndrew SteAll 18 Years toPhase
40 Years
1 Â (Adult)50 Other InterventioInterventi CHIVAS-M
Feasibility University All 18 Years and
Phase
older
1 Â (Adult, Older
Adult) 6223|NCI-
RecurrencePolynoma All 18 Years toPhase
80 Years
3 Â (Adult,
1224Older
Industry
Adult)InterventioAllocation 103A-301
Antibody se Green CrosAll 19 Years toPhase
75 Years
Industry
Adult)InterventioAllocation HTV_P3
49 Years
1 Â (Adult) 124 Industry InterventioAllocation mRNA-165
Clinical be National C All 18 Years and
Phase
older
2 Â (Adult, 35
Older
Other
PrevalenceThe AlfredMale 16 Years to 20 Years Â (Child,200
Adult)
Other|InduObservatioObservatioMerck-548
CharacterizStemline Th All 18 Years and
Phase
older
1|Ph
Â (Adult, 74
Older
Other
Adult) InterventioInterventi STML-701-
Clinical R University All Child, AdulPhase 1|Ph 20 Other|NIHInterventioInterventi 9018|UCCR
Decrease iInmunotekFemale 18 Years toPhase
75 Years
Industry
Adult)InterventioAllocation MV140-SLG
Anti-HPV seLaval UniveFemale 12 Years toPhase
18 Years
Other|U.S.InterventioInterventi CÃ‰: 2017
Mortality|Bandim Hea All up to 5 Months
PhaseÂ4 (Child) 7600 Other InterventioAllocation 6-FY04-51-
Biological: BCG vacci Intracel|NaAll 21 Years toPhase
85 Years
1|Phase
Â (Adult,
2 Older
Industry
Adult)InterventioPrimary PuINTRACEL-
OccurrenceBoehringerAll 18 Years and
Phase
older
1 Â (Adult, 49
Older
Industry
Adult) InterventioInterventi 1155.2
Chinese AcMale 18 Years and older Â (Adult,3000
Older
Other
Adult) ObservatioObservatioHPV and M
Adverse effFukushimaAll 20 Years andPhase
9 Other
Adult) InterventioInterventi FVT-L0701
Anti-nicot Nabi BiophAll 18 Years andPhase
Older
Adult) NIDA-1789
NIHOlder Adult)
Safety Ass Inovio PhaAll 18 Years toPhase
50 Years
1 Â (Adult)240 Industry|UInterventioAllocation EBOV-001
OccurrenceGlaxoSmithAll up to 5 Years Â (Child) 1 Industry ObservatioObservatio 114910
OccurrenceGlaxoSmithAll 36 Months and older Â (Child, 549Adult,
Industry
OlderObservatioObservatio
Adult) 204687
Assess occInner Mongo All 6 Years to 75
NotYears
Applic
Â (Child,240
Adult,
Industry
Older Adult)
InterventioAllocation YL/CL-002
Biological: ALVAC(2) National InAll 18 Years toPhase
60 Years
2 Â (Adult)330 NIH InterventioMasking: DHVTN 203|AVEG 203|10596
Combined Merck
In ShaFemale 16 Years toPhase
26 Years
4 Â (Child,
1030Adult)
Assess theIntercell All 18 Years toPhase
49 Years
2 Â (Adult)500 Industry|UInterventioAllocation PLA201|H
Clinical ou Universite All 65 Years andPhase
older4 Â (Older737
Adult)
Other|InduInterventioAllocation 2414
vaccine ImUniversity All 7 Years to 12
Phase
Years3 Â (Child)117 Other|InduInterventioInterventi 2011/199/
Biological: gp100 ant University All 18 Years toPhase
120 Years
Adult) PuCO98601|U
Number ofNitto DenkMale 20 Years toPhase
49 Years
1 Â (Adult)90 Industry InterventioAllocation NSV0001-0
Decrease iInmunotekAll 35 Years toPhase
85 Years
2|Ph
Â (Adult,
180Older
Industry
Adult)InterventioAllocation MV130-SLG
Biological: Inactivate Sanofi Pas All 2 Months to Phase
18 Months
3 Â (Child)
40 Industry InterventioAllocation IPV17
Feasibility Leiden UniFemale 18 Years andPhase
older1|Ph
Â (Adult, 15
Older
Other
Adult) InterventioAllocation CHIP trial
Biological: AutologouHadassah M All 18 Years andPhase
older1|Ph
Â (Adult, 50
Older
Other
Adult) InterventioInterventi 0359-08-H
injection s Sanofi Pas All 18 Years toPhase
40 Years
3 Â (Adult)500 Industry InterventioAllocation F06-Td5I-3
Biological: MART-1 anEuropean OAll 18 Years andPhase
Older
Other
Maximum Masonic
To CaAll Child, AdulPhase 1 8 Other InterventioAllocation 2008LS05
Safety|Imm Ludwig InsAll 18 Years andPhase
9 Other
Adult) InterventioAllocation NYU 04-53
GeometricGlaxoSmithAll 18 Years andPhase
Older
Industry
Biological: QS21|BiolMemorial SAll 18 Years andPhase
Adult) Pu98-065|CD
Immunologi National CaAll 7 Years andPhase
138 NIH
Older Adult)
Safety as Astellas P All 12 Years toPhase
17 Years
1 Â (Child)20 Industry InterventioAllocation 0892-CL-1
HBsAg lossQin Ning|TAll 18 Years toPhase
65 Years
4 Â (Adult,15Older
OtherAdult)InterventioInterventi NPGV stud
Mother's I University Female 18 Years andNotolder
Applic
Â (Adult, 70
Older
Adult) 149891|P5
ConcentratUniversite Female 18 Years to 26 Years Â (Adult)57 Other ObservatioObservatioB30020152
Anti-idiot University All 18 Years toPhase
120 Years
2 Â (Adult,0 Older
OtherAdult)InterventioInterventi SCCC-02F0
Biological: MART-1 anNational CaAll 18 Years andPhase
older1|Phase
Â (Adult,
2 Older
ProgressionGustave RoAll 18 Years toPhase
70 Years
2 Â (Adult,41Older
OtherAdult)InterventioInterventi IGR Dex2
17 Years
3 Â (Child)
ProductionThe Univers All 18 Years andPhase
Adult) CDR000006
DeterminatGenexine, Female 20 Years toPhase
50 Years
1 Â (Adult) 9 Industry InterventioAllocation GX-188E-S
Evaluate thNovaRx CorAll 18 Years andPhase
Older
Industry
Adult) InterventioAllocation BB-IND 88
Anti-hepatGlaxoSmithAll 4 Years to 5Phase
OccurrenceDynavax TeAll 40 Years toPhase
70 Years
2 Â (Adult,41Older
Industry
Safety|Imm Dartmouth- All 18 Years toPhase
65 Years
1 Â (Adult,59Older
OtherAdult)InterventioAllocation DAR-901-
Biological: MART-1 anNational CaAll 18 Years andPhase
90 Days3 Â (Child) 50 Industry InterventioAllocation 112065
The presenMuhimbili All 18 Years toPhase
40 Years
2 Â (Adult)198 Other InterventioAllocation TaMoVac II
Immune res Aeras|UnivAll 18 Years toEarly
55 Years
PhasÂ (Adult)10 Other InterventioInterventi A-046
Years3Â (Child) 596 Industry InterventioInterventi JEC05|U11
Adverse evOslo UniverAll 18 Years toPhase
70 Years
1|Ph
Â (Adult,20Older
OtherAdult)InterventioInterventi DC-CAST-
PercentageAstellas P All 18 Years and
Phase
older
3 Â (Adult,514
Older
Industry
Incidence Astellas P All 18 Years and
Phase
older
2 Â (Adult,150
Older
Industry
to evaluateGlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,120
Older
Industry
ExpressionsTurku UnivAll 4 Years to 30
Phase
Years
3 Â (Child,180
Adult)
Other InterventioAllocation Tons2
Change in U.S. Army All 20 Years toPhase
40 Years
2 Â (Adult)360 U.S. Fed|NInterventioAllocation RV 306|WR
Overall SurMerck KGaA All 20 Years and
Phase
older
1|Ph
Â (Adult,178
Older
Industry
Nasal ProvCytos Biot All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation CYT005-Al
Biological: CYT005-A Cytos Biot All 18 Years toPhase
55 Years
1|PhÂ (Adult)21 Industry InterventioInterventi CYT005-Al
Event-free Favrille|NaAll 18 Years and
Phase
older
2 Â (Adult, 56
Older
Industry
Safety of t University Male 18 Years toPhase
45 Years
1 Â (Adult)12 Other InterventioAllocation AFTBVAC
Safety as aAstellas P All 18 Years toPhase
55 Years
Serum bactPublic HeaAll Child, Adult, Older Ad 57 Other ObservatioObservatioPRIMEfoll
Number ofDuramed Re All 17 Years and
Phase
older
3 Â (Child,
4040
Adult,
Industry
Older Adult)
InterventioAllocation DR-ADV-30
Changes inGeorge Was Female 18 Years to 45 Years Â (Adult)150 Other ObservatioObservatioGWMDA20
Invasive d Mayo ClinicFemale 18 Years and Phase
older
2 Â (Adult,480
Older
Adult) MC1835|NC
To identif National Un All 22 Years to 80 Years Â (Adult,10Older
OtherAdult)ObservatioObservatioKK001
GMT rate of Green CrosAll 19 Years and
Phase
older
3 Â (Adult,
1299
Older
Industry
Adult) InterventioAllocation GC3110A_
Drug: autologous tumo Jonsson CoAll 18 Years and
Phase
older
1 Â (Adult, 15
Older
Adult) PuCDR000039
Time to pr Favrille|NaAll 18 Years and
Phase
older
3 Â (Adult, Older
Industry
Adult) InterventioAllocation FAV-ID-06
Safety|Imm CuraVac|Ae All 18 Years toPhase
64 Years
1|PhÂ (Adult)24 Industry|OInterventioAllocation CV-0002|2
PercentageSanofi Pas All 14 Years to 27 Years Â (Child,
763Adult)
Industry ObservatioObservatioMTA64
Tissue coll Dana-FarbeAll 35 Years and older Â (Adult, 40Older
Other
Positive A University Female 30 Years to 50 Years Â (Adult)28 Other|NIHObservatioObservatioRSRB # 19
45 Years
1 Â (Adult)23 Other|U.S.InterventioInterventi 16-3283
Biological: lung tum Roswell ParAll 20 Years toPhase
70 Years
1 Â (Adult,20Older
Frequency Sanaria In All 18 Years toPhase
35 Years
1 Â (Adult)30 Industry|OInterventioAllocation TIP5|2012
OccurenceEuropean OFemale 18 Years and Phase
older
2 Â (Adult, Older
0 Other|Indu
Drug: flt3 ligand|Dr National Cancer InstitChild, AdulPhase 2 NIH InterventioPrimary PuCDR000006
Neonatal pa Federal UniAll up to 72 Hours
PhaseÂ 3(Child) 640 Other InterventioAllocation ID: AGC 11
OccurrenceGlaxoSmithFemale 40 Years toPhase70 Years
1 Â (Adult,61Older
Industry
Drug: autologous tumNational Cancer Instit18 Years andPhase
older
2 Â (Adult, Older
HA antibodAdimmuneAll 6 Months toPhase
1 Year
4 Â (Child) 59 Industry InterventioInterventi FLU10T11C
Evaluate s University All 3 Years to 21
Phase
Years
1 Â (Child, Adult)
All cause NeuroVita All 18 Years toPhase
70 Years
Other|Indu
Adult)InterventioAllocation BrCr/2012
70 Years
Other|Indu
Adult)InterventioAllocation MCL/2012
70 Years
Other|Indu
Adult)InterventioAllocation GBM/2012
Best RespoNational CaAll 18 Years and
Phase
older
3 Â (Adult,185
Older
Melan-A, FlCentre Hosp All 18 Years and
Phase
older
1 Â (Adult, Older
9 Other
Adult) InterventioInterventi LUD 1998-
Number ofCrucell
p Ho All 18 Years toPhase
55 Years
2 Â (Adult)240 Industry InterventioAllocation RAB-M-A00
to 23 Months
3 Â 480
(Child)
Safety and GlobeImmAll 18 Years and
Phase
older
1 Â (Adult, 48
Older
Industry
Adult) InterventioAllocation GI-5005-01
The rate o Neon TheraAll 18 Years and
Phase
older
1 Â (Adult, 40
Older
Industry
Adult) InterventioAllocation NT-003
NotYears
Applic
Â (Child)
Objective Sidney KimAll 18 Years toPhase
100 Years
Other|Indu
Adult)
InterventioInterventi J16154|IR
The percenMerck ShaFemale 16 Years toPhase 26 Years
Industry InterventioAllocation 2008_016|
ELISPOT, I Tulane UniAll 50 Years toPhase
70 Years
4 Â (Adult,28Older
Individual Bavarian No All 18 Years toPhase
55 Years
safety and Nuron BiotAll 12 MonthsPhase
to 15 Months
2 Â 220
(Child)
Industry InterventioAllocation CP-NU300-
Change froObjectif R All 18 Years andPhase
older
2 Â (Adult, 65
Older
Other
Adult) InterventioAllocation ORVACS 00
QuestionnaUniversity All 18 Years to 36 Years Â (Adult)600 Other ObservatioObservatioReq-2019-
Toxicity byProvidenceAll 18 Years andPhase
older
1 Â (Adult, 20
Older
Adult) CDR000038
The followiMedImmunAll 6 Months to Phase
36 Months
2 Â (Child)
Compare thUniversity Male 18 Years toNot
39 Years
ApplicÂ (Adult)
Modified BYork UniverAll 5 Months to Not20Applic
Months Â (Child)
128 Other InterventioAllocation York HPRC
Type-specifNabi BiophAll 18 Years andPhase
older
3 Â (Adult,354
Older
Adult) Nabi-1369
The primary MedImmune All 6 Months to Phase
35 Months
3 Â 3000
(Child)
Change in aStanford Un All 10 Years toNot
20 Years
ApplicÂ (Child,40
Adult)
Immunogeni Sanofi All 2 Months to Phase
2 Months
4 Â (Child)
186 Industry InterventioAllocation E2I34
Biological: Fluarix National InAll 18 Years toPhase
64 Years
3 Â (Adult)
1050 NIH InterventioAllocation 04-098|10
feasibility Iwate MediMale 20 Years toPhase
85 Years
OtherAdult)InterventioInterventi IMU-H21-40-Pâ… /â…¡
PercentageAstellas P All 2 Years to 11
Phase
Years
2 Â (Child)260 Industry InterventioAllocation FG-506-06
The serotyp Pfizer All up to 14 Years Â (Child) 457 Industry ObservatioTime Persp0887X1-44
Eunice KenAll 10 Years to 13 Years Â (Child) 0 NIH ObservatioTime Persp999907004
One-year pr Ever SupreAll 20 Years toPhase
75 Years
2 Â (Adult,24Older
Industry
Adult)InterventioAllocation ES-CDCV01
50 Years
Other InterventioAllocation TB008
CD4+ Lymph Aeras|CrucAll 21 Years toPhase
45 Years
2 Â (Adult)26 Other|InduInterventioAllocation C-017-402
National CaAll Child, Adult, Older Ad 60 NIH Observational 860199|86
Health BelSaglik Bili Female 9 Years andNot older
Applic
Â (Child, Adult,
216 Other
Older Adult)
InterventioAllocation 2018/15-
AssessmentGlaxoSmithAll Child, Adult, Older Ad 587 Industry ObservatioTime Persp 116602
PercentageMedImmune All 24 MonthsPhase
to 47 Months
4 Â 200
(Child)
AntibodiesFederal University
Male of SÃ£o
18 Years
Paulo|FundaÃ§Ã£o
toNot
55 Years
ApplicÂ (Adult)
de 34
Amparo
OtherÃ Pesquisa
do Estado de SÃ£o
CEPE2012F
Paulo
Drug: IL-2|Drug: gp1 National CaAll 7 Years andPhase
58 NIH
Older Adult)
Combined Merck
I ShaFemale 18 Years toPhase
26 Years
2 Â (Adult)
PrevalencePATH All 12 Months to 15 Months Â 297 (Child)
Other ObservatioObservatioVAC-011
c peptide Hadassah M All 20 Years toPhase
50 Years
3 Â (Adult) Other InterventioInterventi 911-DIAPEP277
45 Years
Drug: Modified Vacci National InAll Child, AdulPhase 1 195 NIH InterventioPrimary Pu020316|02
Safety/ToleAffiris AG All 50 Years to 80 Years Â (Adult,16Older
Industry
Adult)ObservatioObservatioAFF005B
Humoral reHelsinki UnAll 12 MonthsPhase
and older
4 Â (Child,5Adult,
OtherOlderInterventioInterventi
Adult) TYH20133
Overall Su Swiss Group All 18 Years andNotolder
Applic
Â (Adult, 41
Older
Other
Adult) InterventioInterventi SAKK 11/1
Pfizer All 5 Months to 22 Months Â (Child)
321 Industry Observational 224
Compare the NovaRx CorAll 18 Years toPhase
75 Years
Industry
Adult)InterventioAllocation NR001-03|
safety of Kyushu UniAll 20 Years toPhase
80 Years
1 Â (Adult,18Older
OtherAdult)InterventioInterventi KU-CY5pep
Adverse reNational InAll 18 Years toPhase
40 Years
Overall resAIDS MaligAll 18 Years andPhase
older
2 Â (Adult, 80
Older
Other|NIH|
Adult) InterventioInterventi AMC-103|N
Time weighKirby Insti All 18 Years andPhase
older
1|Ph
Â (Adult, 35
Older
Other|Indu
Adult) InterventioAllocation VIR-NCHR-
blood count Cure&SureAll 18 Years toPhase
75 Years
Adult) CS-CIH-Li-
Evaluate thAlphaVax, IAll 65 Years andPhase
older
1|Ph
Â (Older Adult)
28 Industry InterventioAllocation AVX502-00
The 4 PostMedImmunAll 18 Years toPhase
49 Years
2|PhÂ (Adult)
The immune University All 18 Years toNot
85 Years
ApplicÂ (Adult,
120Older
OtherAdult)InterventioAllocation BB/H00470
Evolution oMedical UnMale 18 Years toPhase
50 Years
1 Â (Adult)20 Other InterventioAllocation 2411.V2.2
Immunologi ProvidenceAll 18 Years andPhase
older
2 Â (Adult, Older
5 Other
Adult) InterventioAllocation PHS IRB 06
65 Years
3 Â (Child,
3800 Adult,
Industry
Adult) 208
To determiDana-FarbeAll 18 Years andPhase
older
2 Â (Adult, 20
Older
Adult) 08-292|R2
FunctionalNHS GreateMale 18 Years toNot
50 Years
ApplicÂ (Adult)20 Other InterventioAllocation GN14NE49
89 Days2 Â (Child)460 Industry InterventioAllocation PR504
All di SanitÃ
18 Years toPhase
50 Years
1 Â (Adult)20 Other InterventioAllocation ISSP-001
toxicity|i University All 18 Years toPhase
75 Years
OtherAdult)InterventioAllocation RNA-Mel-0
Biological: Tick-BornePfizer All 6 Years to 16
Phase
Years
Immune res Mayo ClinicAll 18 Years andEarly
older
Phas
Â (Adult, 23
Older
Adult) MC1177|NC
PercentageEmergent BAll 18 Years toPhase
65 Years
Adult) EBS.AVA.0
Biological: Tick-BornePfizer All 1 Year to 6Phase
Years Â2 (Child) 615 Industry InterventioAllocation 206
to 22 Months
3 Â3388
(Child)
Biological: gp160 VacNational I All 18 Years toPhase
60 Years
1 Â (Adult)55 NIH|IndustInterventioPrimary PuACTG 205|11182|AVEG 101
Part A (dosCentre LeoAll 18 Years andPhase
older
1 Â (Adult, 66
Older
Other|Indu
Adult) InterventioInterventi ET14-035 (I
Primary objHerlev HosAll 18 Years andPhase
older
2 Â (Adult, 50
Older
Other
Adult) InterventioAllocation Dendric cel
Clinical an French NatAll 18 Years toPhase
55 Years
1 Â (Adult)70 Other InterventioAllocation ANRS VAC1
ll Transplantation National InAll Child, Adult, Older Ad 55 NIH Observational 000144|00
Serotype-SPfizer All 60 Years andPhase
older
3 Â (Adult,962
Older
Industry
Adult) InterventioAllocation 6115A1-30
National InAll up to 30 Years Â (Child, Adult)6 NIH ObservatioTime Persp04-041
Specific B St. Jude ChAll 18 Years and older Â (Adult, Older
8 Other
Adult) ObservatioObservatioXPD09-022
Dose LimitLisa H. ButAll 18 Years toPhase
80 Years
1 Â (Adult, 2Older
Adult) 04-101|R0
Immunogeni Sanofi Pas All 15 MonthsPhase
to 18 Months
2 Â 225
(Child)
Industry InterventioAllocation IPV26
Biological: HIV-1 Pep National InAll 18 Years toPhase
60 Years
1 Â (Adult)32 NIH|IndustInterventioMasking: DAVEG 018
GeometricGlaxoSmith
m All 18 Years toPhase
60 Years
ProgressioTVAX Biome All 18 Years andPhase
older
2 Â (Adult, 86
Older
Industry
Adult) InterventioInterventi TVI-AST-00
Primary: DeCliniques All 18 Years andPhase
older
1|Ph
Â (Adult, 19
Older
Other|Indu
Drug: Modified Vacci National InAll Child, AdulPhase 1 80 NIH InterventioPrimary Pu030087|03
Objective M.D. AnderAll 12 Years andPhase
older
2 Â (Child,189
Adult,
Other|Indu
Older Adult)
InterventioAllocation 2004-0069
The Rate oM.D. AnderAll 18 Years toPhase
70 Years
2 Â (Adult, 2Older
Biological: ALVAC-H Walter Reed All 18 Years toPhase
55 Years
1 Â (Adult)36 U.S. Fed InterventioPrimary PuB011|RV 138
55 Years
Industry InterventioInterventi DV2-HBV-1
PercentageMerck ShaAll 20 Years toPhase
35 Years
Adverse effFukushimaAll 20 Years toPhase
80 Years
1 Â (Adult, 5Older
OtherAdult)InterventioInterventi FPCR1R2-1
ProportionThe HIV NeAll 1 Year to 18Phase
80 Other InterventioAllocation HIV-NAT 1
Cohorts 1, Janssen VaAll 60 Years andPhase
older
1|Ph
Â (Adult,669
Older
Industry
IntussusceMerck ShaAll 6 Weeks toPhase
12 Weeks
3 Â (Child)
Recommende Sidney KimAll 18 Years andPhase
older
2 Â (Adult, 70
Older
Other|Indu
Adult) InterventioAllocation J16173|IR
Adverse eve Astellas P All 20 Years toPhase
64 Years
Incidence SK Chemical All 19 Years toPhase
59 Years
1|PhÂ (Adult)
100 Industry InterventioAllocation NBP607QIV
PercentageUniversity Male 18 Years andPhase
older
2 Â (Adult, 41
Older
Other|Indu
Adult) InterventioInterventi UW18008|
Maximum Istari
To OncoAll 18 Years andPhase
older
1 Â (Adult, 61
Older
Adult) Pro000311
55 Years
4 Â (Adult)170 Industry InterventioAllocation MPT01
60 Years
2 Â (Adult)100 Industry InterventioAllocation GPA11
Tolerabili Affiris AG All 40 Years toPhase
68 Years
1 Â (Adult,28Older
Industry
Adult)InterventioAllocation AFFiRiS 0
Immunogenic UMN Pharm All 20 Years toPhase
49 Years
1|PhÂ (Adult)
165 Industry InterventioAllocation 7374-CL-0
To measureUniversity All 12 Years toPhase
25 Years
Rabies neutQueen Saov All 18 Years toNot
60 Years
ApplicÂ (Adult)20 Other InterventioInterventi Feb-17
Number ofPfizer All 6 Weeks to 17 Years Â (Child)649 Industry ObservatioObservatio6096A1-40
Phaseâ… ; Tokyo
safety UnivAll
(NCI CTCAE v.3)20Phaseâ…¡ï¼›time
Years toPhase
85 Years
1|Ph
toÂprogression
(Adult,14Older
Other
(RECIST)|Immune
Adult)InterventioAllocation
response (ELISPOT,
IMSUT-PPK
Perforin/FoxP3 FACS, in
ImmunologDr. Nina B All 18 Years and
Phase
older
1 Â (Adult, 50
Older
Other
Adult) InterventioAllocation NYU 02-10
Safety(toxiWakayamaAll M 20 Years toPhase
80 Years
1 Â (Adult,21Older
OtherAdult)InterventioInterventi WPR2-071
Biological: MelCance University All 25 Years toPhase
75 Years
2 Â (Adult,40Older
The rate o Neon TheraAll 18 Years and
Phase
older
1 Â (Adult, 15
Older
Industry
Adult) InterventioInterventi NT-002; K
ProportionAelix Ther All 18 Years toPhase
60 Years
1 Â (Adult)45 Industry InterventioAllocation AELIX-002
99 Years
2 Â (Adult,
1900Older
Industry
Adult)InterventioAllocation D4420C00
Biological: Fluarix GlaxoSmithAll 65 Years and older Â (Older 1524
Adult)
Industry ObservatioTime Persp 106622
To assess i Fluart InnoAll 18 Years toPhase
99 Years
Industry
Adult)InterventioInterventi FluvalAB-H
Biological: allogenei St. VincentAll 18 Years and
Phase
older
2 Â (Adult, Older
Other
Adult) InterventioPrimary PuSVMC-ONC-
The level Assaf-HaroAll 9 Months toNot
14Applic
Months Â (Child)
100 Other InterventioAllocation 20070567(
Phase
older
1|Ph
Â (Adult, Older
0 Industry
Drug: autologous immGenitope CAll 18 Years and
Phase
older
2 Â (Adult, Older
Industry
Toxicity p Hassane M.All 18 Years and
Phase
older
1 Â (Adult, 21
Older
Adult) 05-140|1R
DefervesceNational TaAll up to 18 Years
Not ÂApplic
(Child, Adult)
Safety as St. Luke's All 18 Years and
Phase
older
2 Â (Adult, 28
Older
Other
Drug: GP100 peptide|National CaAll Child, AdulPhase 2 141 NIH InterventioPrimary Pu980142|98
Effect of V ImmunitorAll 18 Years and
Phase
older
1|Ph
Â (Adult, 30
Older
Industry
Adult) InterventioInterventi Panc-001
to 23 Months
3 Â 611
(Child)
ProportionSK Chemical All 12 MonthsPhase
to 15 Months
3 Â 534
(Child)
Industry InterventioAllocation NBP606_PC
Total time Medical ReAll 4 Months toNot
59Applic
Months Â 2721
(Child)
Other|U.S.InterventioAllocation SCC1495
Number ofRob GruterAll 18 Years and
Phase
older
2 Â (Adult, 33
Older
Other|Indu
Adult) InterventioAllocation iHIVARNA p
Immunogeni University All 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Other
Adult) InterventioAllocation SHCS 610
Number and Aeras|StatAll 18 Years toPhase
50 Years
1|PhÂ (Adult)98 Other InterventioAllocation C-035-456
50 Years
1 Â (Adult)30 NIH|IndustInterventioMasking: DAVEG 003A|10541
Serum bactSt George' All 18 Years to 47 Years Â (Adult)55 Other ObservatioObservatio 2019.037
50 Years
1 Â (Adult)25 NIH|IndustInterventioMasking: DAVEG 003B|10542
GeometricClinical
m R All 50 Years and
Phase
older
1|Ph
Â (Adult,239
Older
Other|Indu
Adult) InterventioAllocation Fib-P-2012
Biological: FormaldehPfizer All 17 Years toPhase
66 Years
4 Â (Child, Adult,
Industry
Adult) 690501
Change in Janssen PhFemale 25 Years and Early
older
Phas
Â (Adult, 40
Older
Industry
ProportionSK Chemical All 42 Days to Phase
98 Days3 Â (Child)534 Industry InterventioAllocation NBP606_PC
Post-vacci SK BioscienAll 6 Months toPhase
35 Months
3 Â (Child)
675 Industry InterventioAllocation NBP607-QI
Tolerabili Weill MedicFemale 18 Years toPhase 90 Years
Infant hepaInstitut d Female 18 Years and Phase
older
3 Â (Adult,499
Older
Other
Adult) InterventioInterventi iTAP-2
Immune res GlaxoSmithAll 56 Days to Phase
83 Days3 Â (Child)800 Industry InterventioAllocation 104733
All di SanitÃ
18 Years
|Regina
and
Phase
older
Elena
1 Â Cancer
(Adult,Institute|University
10
Older
Other
Adult) InterventioAllocation
of Rome Tor Vergata
ISS-DTIC-
Local TolerEurocine VAll 18 Years toPhase
39 Years
1|PhÂ (Adult)
162 Industry InterventioAllocation EURO 15-1
To determiEmory UnivAll 18 Years to 59 Years Â (Adult)97 Other ObservatioObservatioIRB000247
ProportionRegeneronAll 18 Years toPhase
64 Years
2 Â (Adult)194 Industry InterventioAllocation R668-AD-1
Biological: gp160 Va National I All 18 Years toPhase
60 Years
1 Â (Adult)30 NIH|IndustInterventioMasking: DAVEG 004B|10545
Biological: Salmonel National InAll 18 Years toPhase
50 Years
Effect of t Johns HopkAll 18 Years toPhase
60 Years
2 Â (Adult)25 Other InterventioAllocation AAC01-03-
60 Years
1 Â (Adult)25 NIH|IndustInterventioMasking: DAVEG 004A|10544
The rate ofBarcelona IAll 6 Weeks toPhase
8 Weeks
3 Â (Child)
18916 Other InterventioAllocation ICARIA|OP
Overall surChina MediAll 13 Years toPhase
70 Years
Adult) DMR94-IRB
Immunogenic Novavax Female 18 Years toPhase
35 Years
2 Â (Adult)720 Industry InterventioAllocation NVX757.M
ProportionMakerere UAll up to 1 DayPhase
Â (Child)
3 2200 Other InterventioAllocation 2015-114
Number ofGlaxoSmithFemale Child, Adult, Older Ad 1 Industry ObservatioObservatio201476|EU
DetermineNational CaMale 18 Years toPhase
100 Years
75 Years
1|Ph
Â (Adult,15Older
OtherAdult)InterventioInterventi UKER-BLZ-
Complete Queen's UnFemale 18 Years toPhase
75 Years
2 Â (Adult,80Older
CD8 T cell Sidney KimAll 18 Years toEarly
100 Years
Phas Â (Adult,
12 Older
Other|Indu
Adult)
Immunologic GlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,
1847
Older
Industry
Antibody tGrifols TheAll 18 Years toPhase
90 Years
4 Â (Adult, 6Older
Industry
immunogenic Radboud Un All 18 Years toPhase
75 Years
1|Ph
Â (Adult,30Older
Incidence SK Chemical All 20 Years and
Phase
older
1 Â (Adult,150
Older
Industry
Adult) InterventioAllocation NBP608_VZ
12 Years
35 Months
3 Â 2160
(Child)
Biological: aldesleuk National CaMale 18 Years and
Phase
older
2 Â (Adult, Older
SeroconverAstraZenecAll 10 MonthsPhase
to 8 Years
4 Â (Child)250 Industry InterventioAllocation SD-004-07
to 23 Months
3 Â3927
(Child)
Primary aim Inge MarieAll 18 Years and
Phase
older
1|Ph
Â (Adult, 40
Older
Other
Adult) InterventioInterventi UR0414
Overall SurImmunovati All 18 Years and
Phase
older
2|Ph
Â (Adult, Older
0 Industry
Adult) InterventioAllocation ITL-008-I
Serum willVA Office All Child, AdulPhase 4 114 U.S. Fed InterventioAllocation INDB-013-
The number Curevo IncAll 18 Years toPhase
49 Years
1 Â (Adult)90 Industry|OInterventioAllocation CRV-101-1
Feasibility Asterias BiAll 18 Years and
Phase
older
2 Â (Adult, 21
Older
Industry
Adult) InterventioInterventi GRNVAC1 C
All enroll Rabih SaidAll 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Other|Indu
Adult) InterventioInterventi C-100-41|
change in sUniversity All 19 Years to 65 Years Â (Adult,39Older
OtherAdult)ObservatioObservatioF06021700
to 23 Months
3 Â 955
(Child)
45 Years
60 Years
1 Â (Adult)48 NIH|IndustInterventioMasking: DAVEG 007A/B
Safety OveSanofi Pas All 2 Years to 55
Phase
Years
4 Â (Child,538
Adult)
66 Years
3 Â (Child,
3973Adult,
Industry
Adult) 213
60 Years
1 Â (Adult)60 NIH|IndustInterventioMasking: DAVEG 004|10543
Safety eva University All 18 Years and
Phase
older
1|Ph
Â (Adult, 15
Older
Other
Adult) InterventioAllocation GT1999017
Notolder
Applic
Â (Adult, 90
Older
Adult) 08-159
9 Weeks
Incidence Tysana PteAll 21 Years toPhase
50 Years
1 Â (Adult)37 Industry InterventioAllocation YFT-001|C
assess the University All 18 Years toPhase
31 Years
1 Â (Adult)30 Other InterventioAllocation 3369-01|1
A stimulatiNational I All 2 Years to 24
NotYears
Applic
Â (Child, Adult)
81 NIH InterventioAllocation PACTG P10
55 Years
2 Â (Adult)224 Other InterventioAllocation 03 - GamFl
Toxicity|ClCancer VacAll 18 Years and
Phase
older
1|Ph
Â (Adult, 34
Older
Adult) ACIT-1-10
Overall su immatics BAll 18 Years and
Phase
older
3 Â (Adult,339
Older
Industry
Adult) InterventioAllocation IMA901-30
Overview oLudwig InsFemale 18 Years and
Phase
older
1 Â (Adult, 28
Older
Other
Rates of i VanderbiltFemale 18 Years to 45 Years Â (Adult)
375 Other|U.S.ObservatioObservatioCISA 2014 T
The primary AdimmuneAll 18 Years and
Notolder
Applic
Â (Adult,128
Older
Industry
Adult) InterventioAllocation FLU11T12A
The occurre Sanofi All 60 Days to Phase
89 Days
4 Â (Child)800 Industry InterventioAllocation IPV29|UTN
Number ofBill & Meli All 10 Years toPhase
18 Years
2 Â (Child,
1800 Adult)
Other InterventioAllocation Gates MRI
Comparison Queen Mary All 18 Years toEarly
45 Years
PhasÂ (Adult)56 Other InterventioAllocation 11/LO/203
Frequency Pfizer
60 Years
The Differ Protein Sc All 18 Years toPhase
49 Years
1|PhÂ (Adult)
OccurrenceGlaxoSmithFemale 9 Years to 25 Years Â (Child,
1516
Adult)
89 Days
3 Â (Child)
Clinical re St. VincentAll 18 Years and
Phase
older
2 Â (Adult, 40
Older
Other
Adult) InterventioPrimary PuSVMC-ONC-
virologica University All 9 Years to 14 Years Â (Child)
2996 Other ObservatioObservatioUPM REB 2
safety and RockefellerAll 18 Years toPhase
60 Years
1 Â (Adult)43 Other InterventioAllocation SSC-0710
Biological: HIV-1 Pep National InAll 18 Years toPhase
60 Years
Biological: Hepatitis National InAll 18 Years toPhase
50 Years
1 Â (Adult)72 NIH|IndustInterventioMasking: DAVEG 003|10540
Adverse evInge MarieAll 18 Years and
Phase
older
1 Â (Adult, 10
Older
Other
Adult) InterventioInterventi MPN1801|2
Phase
older
1 Â (Adult, 20
Older
NIH|Indust
Adult) InterventioMasking: NACTG 148|11123
Posterior bHarvard UnMale 18 Years toNot
51 Years
ApplicÂ (Adult)
1000 Other InterventioAllocation IRB19-142
Utilizatio Columbia Un All 14 Years toNot
65 Years
ApplicÂ (Child,
1291 Adult,
Older Adult) AAAD1784
80 Years
Industry
Anti-HepatGlaxoSmithAll 14 Years toPhase
15 Years
The distri Chung-AngAll 40 Years and older Â (Adult,384
Older
Other|Indu
Adult) ObservatioObservatioWI221325
The Number Merck ShaAll up to 5 Years Â (Child) 230 Industry ObservatioObservatioV260-031
PercentageJanssen VaAll 18 Years toPhase
60 Years
1 Â (Adult)26 Industry|OInterventioAllocation CR108372|
pneumococc Public HeaAll Child, Adult, Older Ad 280 Other ObservatioObservatioPIN2
The primarImmune Res All 18 Years toPhase
70 Years
Adult) Immune Re
Presence oGlaxoSmithAll 6 Weeks to 12 Weeks Â (Child)1 Industry ObservatioObservatio114444|44
Invasive DiCancer InsiAll 18 Years and
Phase
older
2 Â (Adult,100
Older
Industry
Safety (toxKazuhiko YAll 20 Years and
Phase
older
1 Â (Adult, 18
Older
Other
Adult) InterventioInterventi TWMU103
Immune reOryx GmbHAll 18 Years and
Phase
older
1|Ph
Â (Adult, 26
Older
Industry
Adult) InterventioInterventi VicOryx
To establisCelldex Th All 18 Years and
Phase
older
1 Â (Adult, 48
Older
Industry
Adult) InterventioAllocation CDX-1307-
Frequency Baylor
o Col All 18 Years toPhase
45 Years
1 Â (Adult)60 Other InterventioAllocation SVI-DBL-01
Minimum eff Biomay AGAll 18 Years toPhase
60 Years
Number ofBiofabri, S All up to 96 Hours
PhaseÂ 2(Child) 99 Industry|OInterventioAllocation MTBVAC-0
The maximu Memorial SFemale 18 Years and
Phase
older
1 Â (Adult, 12
Older
Other
Incidence oNational C All 18 Years and
Phase
older
1|Ph
Â (Adult, 22
Older
Other|Indu
Adult) InterventioInterventi HepaVac-1
Safety|Im Duke Univer All 18 Years and
Phase
older
1 Â (Adult, 24
Older
Adult) CDR00000
Change in IUniversity All 18 Years toNot
35 Years
ApplicÂ (Adult)54 Other|NIH| InterventioAllocation 07-1064|2
To examineOslo UniverAll 18 Years and
Notolder
Applic
Â (Adult, 20
Older
Other
Effect of b Dana-FarbeAll 18 Years and older Â (Adult, 11
Older
Other|Indu
Phase 1 - Turnstone A B ll 18 Years and
Phase
older
1|Ph
Â (Adult, 75
Older
Industry
Adult) InterventioInterventi Ad/MG1-MA
MetastasisUniversity Male 18 Years and
Phase
older
2 Â (Adult, 99
Older
Other
Adult) InterventioAllocation CO08801|2
Number ofMerck KGaAll 18 Years and
Phase
older
2 Â (Adult, 34
Older
Industry
Number ofGlaxoSmithAll 6 Months and
Phase
older
Industry
Adult) 218352/05
Serotype-sNabi BiophAll 18 Years and
Phase
older
3 Â (Adult,120
Older
Industry
Number ofFundaciÃ³nFemale 12 Years to 16 Years Â (Child)
130 Other ObservatioObservatioCEC-ICIC-E
Sero-type Nabi BiophAll 18 Years and
Phase
older
3 Â (Adult, 67
Older
Adult) Nabi-1363
To determiUniversity Female 18 Years to 31 Years Â (Adult)
400 Other ObservatioObservatioCER: 15-25
PercentageGenocea BiAll Child, AdulPhase 2 33 Industry InterventioAllocation GEN-003-0
Survival|TiCell GenesMale 18 Years and
Phase
older
3 Â (Adult,408
Older
Industry
Adult) InterventioAllocation G-0034|VI
RecurrenceMichael Mo All 18 Years and
Phase
older
2 Â (Adult, 74
Older
Adult) Pro000076
Serious AdMerck ShaAll 60 Years and
Phase
older
4 Â (Adult,
11999Older
Industry
number ofCHU de ReFemale 25 Years toPhase
45 Years
4 Â (Adult)63 Other InterventioInterventi PO15019
DetermineUniversity All 18 Years toPhase
40 Years
Feasibilit University All 3 Years to 30
Phase
Years
1 Â (Child, Adult)
Antibody reUniversity All 55 Years and
Notolder
Applic
Â (Adult,240
Older
Adult) STUDY000
PercentageGreen CrosAll 18 Years toPhase
60 Years
3 Â (Adult)420 Industry|OInterventioAllocation MG1109_P
minimal reDCPrime BV All 18 Years and
Phase
older
2 Â (Adult, 20
Older
Adult) DCOne-00
Adverse effFukushimaAll 20 Years and
Phase
older
1 Â (Adult, Older
6 Other
Adult) InterventioInterventi FVT-L0901
SeroconversSanofi Pas All 2 Years andPhase
570 Industry
Older Adult)
InterventioAllocation VAJ00001|
The differ FHI 360|GhFemale Child, AdulNot Applic 14050 Other InterventioAllocation 10083
Phase
older
1 Â (Adult, 50
Older
NIHAdult) InterventioMasking: DACTG 221|11198
safety|toleErasmus Me All 18 Years and
Phase
older
1 Â (Adult, 10
Older
Other
Adult) InterventioAllocation MEC-2005
anti-HBs anCangene Co All 20 Years toPhase
55 Years
4 Â (Adult)
1000 Industry InterventioAllocation HB-012
Pre-patentSocrates HAll 18 Years toPhase
45 Years
1|PhÂ (Adult)16 Other InterventioAllocation CIV - 08 -
Phase
older
3 Â (Adult,119
Older
Industry
Adverse evGenexine, All 18 Years toPhase
60 Years
1 Â (Adult)27 Industry InterventioAllocation HB110_HB_
Seropositi Pfizer All Child, AdulPhase 4 179 Industry InterventioAllocation 700802|B9
Time to Bi Dendreon Male 18 Years toPhase
80 Years
Industry
Adult)InterventioAllocation P-11
OccurrenceVLP TherapAll 18 Years toPhase
49 Years
1 Â (Adult)36 Industry InterventioAllocation VLPM01-01
Frequency Instituto All 18 Years and
Phase
older
1|Ph
Â (Adult, 30
Older
Other
Adult) InterventioInterventi MedOPP137
Part A: NumBionor ImmAll 18 Years and
Phase
older
1|Ph
Â (Adult, 26
Older
Industry
Adult) InterventioAllocation BPC01-001
To determinImmunovati All 18 Years toPhase
80 Years
2 Â (Adult,12Older
Industry
Adult)InterventioAllocation ITL-019-C
The primaryAdvaxis, InFemale 18 Years toPhase
45 Years
2 Â (Adult)81 Industry InterventioAllocation Lm-LLO-E7
Biological: HIV-1 C4- National InAll 18 Years toPhase
60 Years
to 24 Months
3 Â 321
(Child)
Industry InterventioInterventi 115389|20
Disease-fr Favrille|NaAll 18 Years and
Phase
older
3 Â (Adult,480
Older
Industry
Adult) InterventioAllocation CDR0000466677|FAV-ID-11|FA
PrevalenceCHU de Que All up to 5 Years Â (Child) 1420 Other|InduObservatioObservatioGSK11418
Poliomyelitis|Tetanus National InFemale 18 Years and older Â (Adult, 12Older
NIHAdult) ObservatioTime Persp03-236
Evaluate thDynavax TeAll 50 Years toPhase
70 Years
1 Â (Adult,25Older
Adult) DV2-HBV-2
15 Years
3 Â (Child)
Incidence aKing Saud All up to 5 Years
NotÂApplic
(Child) 400 Other InterventioAllocation kingsadu
Changes inImmunitorFemale 18 Years toPhase
65 Years
2 Â (Adult,20Older
Industry
Adult)InterventioInterventi V3-OVA-01
Incidence MedImmunAll 1 Month toPhase
23 Months
1|Ph Â (Child)
MTD (Maxim Yonsei UnivAll 19 Years toPhase
65 Years
1 Â (Adult, 0Older
Biological: FavId (Id Favrille All 18 Years and
Phase
older
2 Â (Adult, 22
Older
Industry
Adult) InterventioAllocation FavId-01
To determiNational CaAll 18 Years and
Phase
older
2 Â (Adult,108
Older
S pneumoniaPfizer All 6 Weeks to 18 Years Â (Child,391Adult)
Industry ObservatioObservatio6096A1-40
Compare AE University All 18 Years and
Phase
older
1|Ph
Â (Adult, 50
Older
Adult) CDR000006
Maximum PTrovidenceAll 18 Years and
Phase
older
1 Â (Adult, 11
Older
Other|Indu
Adult) InterventioAllocation 13-012A
The differ Serum InstAll up to 12 Days
Phase
Â (Child)
2 416 Industry|OInterventioAllocation VPM1002-Z
Difference Aga Khan UAll 6 Months to Not12Applic
Months Â (Child)
Immunogeni Crucell Ho All 6 Months to Phase
35 Months
3 Â (Child)
205 Industry InterventioAllocation INF-V-A00
99 Years
Industry
Adult)InterventioAllocation D4420C00
Biological: HIVAC-1e|National InAll 18 Years toPhase
60 Years
difference Helsinki U All 18 Years toPhase
85 Years
1 Â (Adult,60Older
OtherAdult)InterventioAllocation HelsinkiU
the intrau Southeast FUemale 20 Years toPhase
40 Years
4 Â (Adult)180 Other InterventioAllocation H200804
Older
Industry
assessmentUniversity All 1 Year to 5 Years Â (Child) 218 Other|InduObservatioObservatio2009/042/
Identificat Hospices CiAll 1 Year to 60Not
Years
Applic
Â (Child, Adult)
Immunogeni Merck ShaAll 6 Weeks toPhase
12 Weeks
Biological: autologo Genitope CAll 18 Years andPhase
Industry
Incidence oMerck ShaFemale 16 Years toPhase
23 Years
3 Â (Child,
5759
Adult)
SeroconverSK Chemical All 12 MonthsPhase
to 12 Years
2 Â (Child)
152 Industry InterventioAllocation NBP608_VZ
seroconverSK BioscienAll 12 MonthsPhase
to 12 Years
3 Â (Child)
516 Industry InterventioAllocation NBP608_VZ
Adult PartiMerck ShaAll 3 Years andPhase
300 Industry
Older Adult)
InterventioAllocation V114-022|
60 Years
2 Â (Adult)160 NIH InterventioAllocation HVTN 026/HIVNET 026|10529|
Human Th1UniformedAll S 18 Years to 50 Years Â (Adult)68 U.S. Fed|NObservatioObservatioG183ZU|Y1
PercentageGreen CrosAll 18 Years toPhase
58 Years
1|Ph
Â (Adult)
346 Industry|OInterventioAllocation MG1109_P
Tolerabili University All 18 Years andPhase
older1|Ph
Â (Adult, 40
Older
Other
Maximum Mayoto ClinicAll 18 Years andPhase
older1|Ph
Â (Adult, 44
Older
Adult) MC1685|NC
Measure thNew DiscovFemale 20 Years toPhase
35 Years
4 Â (Adult)200 Industry InterventioAllocation IN-US 174
PercentagePfizer All 6 Months to 30 Months Â (Child)239 Industry ObservatioObservatio6096A1-40
Biological: keyhole University All 18 Years toPhase
120 Years
2 Â (Adult, Older
Adult) Pu197-99|P3
Combined Merck
I ShaMale 16 Years toPhase
26 Years
3 Â (Child,
1124
Adult)
older3 Â (Adult,
2220
Older
Industry
Quantifica Fred HutchMale 18 Years andPhase
Older
Adult) CITN12-03
Anti-dipht GlaxoSmithAll 10 Years toPhase
15 Years
Biological: gp160 MNNational InAll Child, AdulNot Applic 10 NIH InterventioPrimary PuHVTN 803|11636
response rJoshua BroAll 18 Years andPhase
older1|Ph
Â (Adult, 30
Older
Other|Indu
Local adveHospital ClAll 18 Years toPhase
55 Years
1 Â (Adult)24 Other InterventioInterventi RisVac02 b
Number ofBaylor
p Col All 3 Years to 70
NotYears
Applic
Â (Child, Adult,
14 Other
Older Adult)
InterventioInterventi H-21942-T
Demonstrat Protein Sc All 18 Years andPhase
older1|Ph
Â (Adult,407
Older
Industry
Drug: Vaccinia Immu National InAll Child, AdulPhase 1 0 NIH InterventioPrimary PuAVEG 801|11551
HemagglutiGlaxoSmithAll 18 Years andPhase
Older
Industry
Change in The UniverAll 11 Years andNotolder
Applic
Â (Child,
1183
Adult,
Other
Older Adult)
InterventioAllocation HSC-SN-15
85 Years
OtherAdult)InterventioAllocation CHUBX 200
Biological: aldesleuk Barbara AnAll up to 65 Years
PhaseÂ 2(Child, Adult, Older
Adult) CDR000006
Number ofGlaxoSmithAll 12 Weeks to Phase
16 Weeks
2 Â (Child)
Overall Re M.D. AnderAll 18 Years andPhase
Older
Other|Indu
Safety andMacroGeniAll 18 Years toPhase
50 Years
1 Â (Adult)73 Industry InterventioAllocation CP-MGD01
Response tEunice KenAll up to 3 DaysNotÂ Applic
(Child) 220 NIH InterventioAllocation 5R01HD03
Clinical t National CaAll 16 Years andPhase
NIHOlder Adult)
Number ofOhioP StateAll 18 Years andNotolder
Applic
Â (Adult, 30
Older
Other
Adult) InterventioInterventi OSU-0704
Vaccinatio University All 18 Years andNotolder
Applic
Â (Adult,489
Older
Adult) R01DA020
49 Years
1|Ph
Â (Adult)72 Other InterventioAllocation IAVI E001
Investigati GlaxoSmithAll 18 Years andPhase
older
3 Â (Adult,120
Older
Industry
8 Weeks
Evaluate s University All up to 30 Years
Phase
Â 1|Ph
(Child, Adult)
17 Other|U.S.InterventioInterventi IRB20150
Incidence oBeijing Tia All 18 Years toPhase
65 Years
1 Â (Adult,30Older
Other
Adult)InterventioInterventi B0011
Ratios of Emergent BAll 18 Years toPhase
45 Years
2 Â (Adult)154 Industry|UInterventioAllocation EBS.AVA.0
50 Years
1 Â (Adult)24 Other InterventioAllocation SVI-GST-03
Clinical e Charite UniAll 18 Years andPhase
older
2 Â (Adult, 25
Older
Other
Adult) InterventioAllocation HaemaCBF
Changes fro ALK-AbellÃAll 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation SHX0562
Estimate t University All 18 Years andPhase
older
4 Â (Adult,400
Older
Other
Adult) InterventioAllocation SJF0001
Toxicity a University All 18 Years andPhase
older
1 Â (Adult, Older
6 Other
Adult) InterventioAllocation CePO-ITA-
45 Years
50 Years
1|Ph
Â (Adult)
120 Other|InduInterventioAllocation A-050
older
3 Â (Adult,
1200
Older
Industry
Prior to doGlaxoSmithAll 12 MonthsPhase
to 15 Months
2 Â 500
(Child)
The proporUniversity All 18 Years and older Â (Adult,103Older
Other
older
3 Â (Adult, Older
7 Industry
GenerationCharite UniAll 18 Years andPhase
older
2 Â (Adult, 25
Older
Other
Adult) InterventioAllocation HaemaCBFW
immune resp Anhui Zhif All 18 Years toPhase
65 Years
2 Â (Adult,
1044Older
Adult) EC-IIb-heal
Percent of McGill UniMale 18 Years andPhase
older
3 Â (Adult, Older
0 Other|Indu
Adult) InterventioAllocation MK0518-048
Effect of ImmunitorAll 18 Years andPhase
older
2 Â (Adult,120
Older
Industry
Adult) InterventioInterventi IMMV5
Number ofXuzhou Med All 18 Years toPhase
80 Years
1|Ph
Â (Adult,50Older
Other
Adult)InterventioInterventi XYFY2016-
Incidence Hendrik StMale 18 Years to 55 Years Â (Adult)
1000 Other|U.S.ObservatioObservatioBRAHMS St
Biological: pneumocoWyeth is nAll 6 Weeks to 24 Months Â (Child)
1000 Industry ObservatioTime Persp0887X-102
Presence oPublic HeaAll 1 Year and older Â (Child, Adult,
450 Other
Older Adult)
ObservatioObservatioPneuCaSt
Safety andInovio PhaAll 18 Years toPhase
50 Years
Safety and Inovio PhaAll 18 Years toPhase
50 Years
1 Â (Adult)12 Industry InterventioInterventi HIV-001
Side EffectSeigo NishAll 18 Years andPhase
older
1 Â (Adult, 18
Older
Other
Number ofAffiris
p AG|All 40 Years toPhase
80 Years
1 Â (Adult, 0Older
Adult) AFF010|2016-001462-
Children WUniversity All 1 Year and Phase
older Â1|Ph
(Child, Adult,
Older Adult) 1-2005-36
Mucosal anImperial C All 18 Years toPhase
50 Years
1 Â (Adult)68 Other InterventioAllocation Ad4HIV
Vaccine ImUniversity All 4 Years to 8 Years Â (Child) 120 Other|InduObservatioObservatio2011/198/
older
4 Â (Adult,
3054
Older
Industry
Typhim Vi rUniversita All 18 MonthsPhase
to 55 Years
4 Â (Child,
200 Other
Adult) InterventioAllocation S57605
Number ofMerck KGaAll 18 Years andPhase
older
2 Â (Adult, 22
Older
Industry
Adult) InterventioInterventi B25-LG-30
OccurrenceGlaxoSmithAll 14 Weeks to 5 Years Â (Child)72 Industry ObservatioObservatio 112560
immunogeni Valneva AuAll 18 Years toPhase
65 Years
Industry
PercentageAstellas PhAll 20 Years toPhase
85 Years
Adult) 3772-CL-1
Number ofInnaVirVaxAll 18 Years toPhase
60 Years
1|Ph
Â (Adult)15 Industry InterventioInterventi IVVAC-3S/
Time to ra Hamilton HMale 19 Years andPhase
older
1|Ph
Â (Adult, 20
Older
Other
Adult) InterventioInterventi CAN-ONC-
Frequency UniversitÃ All 18 Years toPhase
55 Years
1 Â (Adult)160 Other InterventioAllocation CEPI-MVA-
Best respoMayo ClinicAll 18 Years andPhase
older
1 Â (Adult, 30
Older
Adult) MC1372|NC
older
1 Â (Adult,107
Older
Industry
55 Years
1 Â (Adult)40 Other|InduInterventioAllocation TB032
Drug: gp100 antigen|National Cancer Instit16 Years and Phase
NIHOlder Adult)
90 Days3 Â (Child)
Biological: DC vaccineMackay Mem All 30 Years toNot
80 Years
OtherAdult)InterventioAllocation MMH-I-S-1
Safety of aUniversity All 18 Years toPhase
50 Years
OccurrenceGlaxoSmithAll up to 5 Years Â (Child) Industry|OObservational 115055
Number ofEmory UnivAll 6 Weeks toNot24 Months
Applic Â (Child)
Biological: D1/3-MAGE SouthwestAll Child, AdulPhase 2 Other|NIHInterventioMasking: NCDR00000
Safety ass Sensei Bio Male 21 Years toPhase
70 Years
1 Â (Adult,12Older
Industry
Adult)InterventioInterventi PAN0216
Incidence Neovacs All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation TNF-K-001
Alert Canc NYU LangoAll 3 Years andNot
older
Applic
Â (Child,4000
Adult,
Other
Older Adult)
InterventioAllocation RCT CDS
Visual AnalUniversity All 18 Years andPhase
Older
Other
Adult) InterventioAllocation EA-1
50 Years
The 4 PostMedImmunAll 2 Years to 17
Phase
Years3 Â (Child)
Safety of Centre Hosp All 18 Years andPhase
Older
Other
Adult) InterventioAllocation LUD 2001-
Drug: gp100 antigen|D National Cancer Instit16 Years andPhase
NIHOlder Adult)
Time to ObjDendreon Male 18 Years andPhase
Older
Industry
Adult) InterventioAllocation D9901 CDR
The primaryUniversity All 18 Years andPhase
Older
Other
Adult) InterventioAllocation 11447A
Older
Other
Biological: vitespen Memorial SAll 18 Years andPhase
Older
Other
Adult) InterventioPrimary Pu97-034|CD
Breadth ofUniversity All 18 Years toNot
55 Years
ApplicÂ (Adult)30 Other InterventioAllocation CRC306C
To determiAgenus IncAll 18 Years andPhase
Older
Industry
Adult) InterventioAllocation C-100-12 P
antibody leHadassah M All 18 Years toNot
64 Years
ApplicÂ (Adult)
200 Other InterventioAllocation Vaccine-H
Assays to NYU LangoAll 18 Years andPhase
0 Other
Change froAstellas P All 20 Years toPhase
64 Years
Biological: Hepatitis National I All 2 Years to 21
NotYears
Applic
Â (Child,200
Adult)
NIH InterventioPrimary PuACTG P1008|PACTG P1
Biological: MART-1 anBaylor HeaAll 18 Years toPhase
80 Years
1 Â (Adult, Older
Adult) PuBAYUMC-09
Evaluate C Opexa TherAll Child, AdulPhase 2 116 Industry InterventioInterventi 2007-00
Feasibilit University All up to 24 Years Â (Child, Adult)
2300 Other ObservatioObservatioID 263097
Biological: vitespen Memorial SAll 18 Years andPhase
Adult) Pu99-077|CD
Disease fr Chinese PLAll 18 Years toPhase
75 Years
Other|Indu
Adult)InterventioAllocation PLAG-CS-G
ANC|PNC|Co Internatio Female 18 Years toNot 45 Years
ApplicÂ (Adult)
Dose LimitiJonsson CoAll 18 Years andPhase
Older
Adult) CDR000032
Co-infectioHadassah M All up to 40 Years
Phase
Â 4(Child, Adult)
6343 Other InterventioAllocation 0509-08-
Biological: therapeut Duke Univer All 18 Years andPhase
Older
Adult) Pu1716|DUMC
Biological: filgrastim Baylor HeaAll 21 Years andPhase
Adult) PuCDR000006
Drug: Allogenic Dendri National InAll 18 Years andNotolder
Applicable
Â (Adult, Older
NIHAdult) InterventioPrimary PuSPIRAT 1
Biological: therapeutiDuke Univer Male 18 Years andPhase
Adult) Pu0759|DUMC
The proportUniversity All 18 Years toPhase
60 Years
1 Â (Adult)19 Other InterventioAllocation HIV-CORE
Antigen-spStanford Un All 30 Years toNot
65 Years
OtherAdult)InterventioAllocation SU-101820
To evaluat Memorial SAll 7 Years andPhase
12 Other
Older Adult)
Number ofMayo
P ClinicAll 18 Years andPhase
older1|Ph
Â (Adult, 48
Older
Adult) MC038C|NC
Incidence oNovartis V All up to 90 Days Â (Child) 10 Industry ObservatioObservatioV98_23OB
Antibody RMerck ShaAll 4 Years to 6Phase
Years3Â (Child) 801 Industry InterventioAllocation V221-014|
PercentageDana-FarbeFemale 18 Years and Phase
Older
Adult) 18-318
Safety|Im Duke Univer All 18 Years andPhase
Adult) 4180|5910
Bedside reAmerican SAll 56 Days to Not
60 Days
Applic
Â (Child)191 Other InterventioAllocation PIA-09012
Biological: MART-1 anGenzyme, aAll 18 Years and
Phase
older
1|Phase
Â (Adult,
2 OlderIndustry
Biological: gp100 ant National CaAll 16 Years and
Phase
older
2 Â (Child, Adult,
NIHOlder Adult)
Vaccine spMichael PuAll up to 2 Years
Phase
Â (Child)
2 64 Other InterventioAllocation PBMTC NM
T-reg SuppLoyola UnivAll 18 Years and
Phase
older
2 Â (Adult, Older
7 Other|Indu
PercentageMerck ShaAll 6 Weeks to 32 Weeks Â (Child)
3798 Industry ObservatioObservatioV260-037|
The presenUniversity All 6 Months and older Â (Child,
1200 Adult,
Other|Indu
Older ObservatioObservatioOVG
Adult) 2013/
ConcentratUniversite Female 16 Years to 45 Years Â (Child,64Adult)
Other ObservatioObservatioB30020173
To determiJonsson CoAll 18 Years and
Phase
older
3 Â (Adult, Older
Adult) CDR000006
Biological: FormaldehPfizer All 7 Years to 11 Years Â (Child) Industry Observational 700501
Disease ReUniversity All 18 Years and
Phase
older
1 Â (Adult, 25
Older
Adult) PCI-97-04
Safety andNanoBio CoAll 18 Years toPhase
49 Years
1 Â (Adult)125 Industry InterventioAllocation NB-1008-0
Intention Uppsala UnAll 15 Years toNot
18 Years
ApplicÂ (Child,
832Adult)
Other InterventioAllocation RFR-38756
PercentageMerck ShaAll 9 Years to 26 Years Â (Child,
3605
Adult)
Industry ObservatioObservatioV501-059|
Serotype 1University All 6 Months to 48 Months Â 2400(Child)
Other|InduObservatioObservatioOVG 2017/
Biological: rV-DF3/M Dana-Farber All 18 Years and
Phase
older
1 Â (Adult, 20
Older
Adult) 97-050|U0
Phase
older
2 Â (Adult, Older
Biological: BCG vacci European OAll 18 Years and
Phase
older
3 Â (Adult,453
Older
Other
Biological: aldesleuk University All 16 Years and
Phase
older
2 Â (Child, Adult,
Older Adult) CWG-UIC-T
Is to asse Mannkind All 18 Years and
Phase
older
1 Â (Adult, 19
Older
Industry
Adult) InterventioAllocation MKC1106-
Immune Res Crucell Ho All 18 Years toPhase
50 Years
Toxicity|T University All 2 Years to 120
Phase
Years
Adult) CDR000055
Safety: proJuan A. ArnAll 18 Years toPhase
55 Years
1 Â (Adult)30 Other InterventioAllocation RisVac02|E
Disease coimmatics BAll 18 Years and
Phase
older
1|Ph
Â (Adult, 92
Older
Industry
Adult) InterventioInterventi EudraCT Nr
Mean chang GeneOne LiAll 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation Zika-002
Biological: aldesleuki Duke UniverAll 18 Years toPhase
75 Years
1|Phase
Â (Adult,
2 OlderOther|NIHInterventioAllocation
Adult) CDR000006
Evaluate s Inovio PhaFemale 18 Years and
Phase
older
1|Ph
Â (Adult, 10
Older
Industry
Adult) InterventioInterventi HPV-004
PercentageNovartis V Female Child, Adult, Older Ad 3243 Industry ObservatioObservatioV98_15OB
Number ofAnhui
s Zhif All 18 Years toPhase
65 Years
3 Â (Adult,
1802Older
Adult) EC-III-heal
seroprotecGreen CrosAll 18 Years and
Phase
older
3 Â (Adult,376
Older
Industry
Adult) InterventioAllocation GC1107_A
PreS speci Viravaxx A All 18 Years toPhase
60 Years
1|PhÂ (Adult)84 Industry|OInterventioAllocation VVX001-CS
The changeSeoul Nati All 20 Years to 89 Years Â (Adult,
250Older
OtherAdult)ObservatioObservatioTd-TIG
PercentageJanssen ReAll 18 Years and
Phase
older
2 Â (Adult,100
Older
Industry
Number ofMerck ShaAll 9 Years to 46 Years Â (Child,
1080
Adult)
Industry ObservatioObservatioV501-077
Influenza-sNational I All 6 Years and older Â (Child, Adult,
180 NIH|Indust
Older Adult)
ObservatioObservatioVRC 700|H
To evaluat Agenus IncAll 18 Years toPhase
50 Years
2 Â (Adult)80 Industry InterventioAllocation C-400-02
Maximum H. To Lee MoffAll 18 Years and
Phase
older
1 Â (Adult, 22
Older
Other|NIH|
OccurrenceJohns HopkAll 18 Years toPhase
45 Years
1 Â (Adult)30 Other InterventioAllocation CIR259
Biological: Detox-B a GlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,300
Older
Industry
Types, freqModernaTX, All 18 Years toPhase
49 Years
1 Â (Adult)90 Industry|UInterventioAllocation mRNA-132
The changeGenexine, Female 20 Years to 50 Years Â (Adult) 9 Industry ObservatioObservatioGX-188E-F
Induce andHadassah M All Child, AdulPhase 1|Ph 20 Other InterventioAllocation 280303-HM
Number ofGlaxoSmith
S All 9 Months toPhase
19 Months
4 Â (Child)
Samples colNational InFemale 14 Years to 45 Years Â (Child,
1270 Adult)
NIH ObservatioTime Persp999913074
Antibody reAalborg UniAll 18 Years and
Phase
older
3 Â (Adult, 80
Older
Other
Adult) InterventioAllocation VN2005/3
Biological: abagovomMemorial SFemale 18 Years and Phase
older
1 Â (Adult, Older
Adult) 02-122|CD
First part Bristol-MyeAll 18 Years andPhase
older
2 Â (Adult, 75
Older
Industry|NInterventioMasking:
Adult) NCDR000036
Serum AntiMerck ShaAll 6 Weeks toPhase
12 Weeks
Drug: Allogeneic DCs Genzyme, aAll 18 Years andPhase
older
1|Ph
Â (Adult, 30
Older
Industry
Adult) InterventioAllocation DCREN-005
Safety and Anchiano ThAll 18 Years andPhase
older
1 Â (Adult, 38
Older
Industry
Adult) InterventioAllocation BC-BLAD-0
Biological: PROSTVA Bavarian NMale 18 Years andPhase
older
2 Â (Adult,120
Older
Adult) TBC-PRO-0
The level Universita All 2 Years to 64
Early
Years
Phas
Â (Child, Adult)
20 Other InterventioInterventi Pfizer-Pre
ProgressionActivartis All 3 Years to 70
Phase
Years
2 Â (Child, Adult,
87 Industry
Older Adult)
InterventioAllocation GBM-Vax-T
BreakthrougNational InAll 18 Years toPhase
50 Years
ProportionECOG-ACRIN All 18 Years andPhase
older
2 Â (Adult, 70
Older
Adult) CDR00006
16 Years
presence oUniversity All 18 Years andPhase
older
4 Â (Adult,110
Older
Other
Adult) InterventioAllocation PHRI12-ED
Number ofImmunoFron All 18 Years andPhase
older
1 Â (Adult, 23
Older
Industry
Adult) InterventioInterventi IMF001-PR
safety Oxford BioAll 18 Years andPhase
older
2 Â (Adult, 25
Older
Adult) TV2 Renal
Number ofGlaxoSmithAll Child, Adult, Older Ad 1258 Industry ObservatioObservatio208355/12
ImmunizatiAssistanceAll 2 Years andNot
older
Applic
Â (Child, Adult,
156 Other|Indu
Older Adult)
InterventioInterventi ABI-RA-P0
Carriage r Beaumont All 18 Years and older Â (Adult,150Older
Other
Adult) ObservatioObservatioBeamontH
Number ofBiontech Female 18 Years and Phase
older
1 Â (Adult, 39
Older
Adult) BN_0002-0
Biological: CYT004- Cytos Biot All 18 Years andPhase
older
2 Â (Adult, Older
Industry
AssessmentNew DiscovAll 20 Years to 40 Years Â (Adult)450 Industry ObservatioObservatioCN-P919-2
Incidence oPATH All 18 Years toPhase
50 Years
1 Â (Adult)60 Other InterventioAllocation CVIA 064
Incidence oMerck ShaMale 9 Years to 26 Years Â (Child,
114035
Adult)
Industry ObservatioObservatioV501-070|
Number ofWyeth is nAll 50 Years toPhase
85 Years
1 Â (Adult,80Older
Industry
hospitalizeUniversity All 9 Years to 14 Years Â (Child)380 Other ObservatioObservatioUPM REB 2
Safety and Immunovati All 18 Years andPhase
older
2 Â (Adult, Older
0 Industry
Adult) InterventioAllocation ITL-020-HE
Primary aimHerlev HosAll 18 Years andPhase
older
1|Ph
Â (Adult, 40
Older
Other
Adult) InterventioAllocation MA0415
ASP0113 plAstellas P All 18 Years toPhase
70 Years
1 Â (Adult,48Older
Industry
Adult)InterventioAllocation 0113-CL-0
Biological: TroVaxÂ® Oxford BioAll 18 Years andPhase
older
2 Â (Adult, 25
Older
Adult) TV-B2/001
Years3Â (Child) 410 Industry InterventioAllocation HXV01C
Maximum Jonsson
to CoAll 18 Years andPhase
older
1 Â (Adult, 18
Older
Adult) CDR000038
70 Years
OtherAdult)InterventioInterventi 307-CTC-D
Toxicity|R Quantum Im Female 18 Years toPhase
85 Years
OtherAdult)InterventioIntervention Model:
a) MosquitNational InAll 3 Months to 50 Years Â (Child,816Adult)
Diarrheal University All 18 Years toPhase
45 Years
1 Â (Adult)30 Other InterventioInterventi NRC23436
Ultrasensi Federal University
Male of SÃ£o
18 Years
Paulo|FundaÃ§Ã£o
toNot
60 Years
ApplicÂ (Adult)
de 30
Amparo
Other|Indu
Ã Pesquisa
do Estado de SÃ£o
SPARC-7
Paulo|Conselho Nacional
ProgressionOslo UniverAll 18 Years toPhase
70 Years
OtherAdult)InterventioAllocation DEN-STEM
Biological: MART-1 anUniversity All Child, AdulPhase 1 19 Other|NIHInterventioPrimary PuCDR000006
Drug: Lamivudine/ZidAgouron PhAll 13 Years andPhase
older
3 Â (Child,688
Adult,
Industry
Older Adult)
InterventioMasking: DB009|AG1661-202
Biological: tumor-pulsNational C All 10 Years toPhase
70 Years
3 Â (Child, Adult,
NIH Older InterventioMasking:
Adult) NNCRR-M01RR00042-1694|M01
anti hepatiRambam Hea All 55 Years andNotolder
Applic
Â (Adult,100
Older
Other
Biological: HIV-1 Im Agouron PhAll 13 Years andPhase
older
2 Â (Child, Adult,
40 Industry
Older Adult)
InterventioMasking: DB008|AG1661-201
Efficacy|SaEuBiologicsAll 1 Year to 40Phase
Adult)
Industry|OInterventioAllocation UBC301
Biological: Dryvax National InAll 18 Years toPhase
50 Years
Drug: Vaccine: SIGA- National InAll 18 Years toPhase
50 Years
1 Â (Adult) 0 NIH InterventioPrimary Pu060114|06
Varicella Medical Uni All 6 Months to Early
24 Months
Phas Â (Child) 5 Other InterventioInterventi Pro25854
Immune res Wales CancAll 18 Years and
Phase
older
2 Â (Adult, 26
Older
Other
Adult) InterventioInterventi 2010/VCC/
Infection foMalaria VaAll 18 Years toPhase
45 Years
2 Â (Adult)18 Other InterventioAllocation MVDC-200
The primarUniversity All 45 Years toNot
65 Years
ApplicÂ (Adult,
100Older
OtherAdult)InterventioAllocation F3168407
hemagglutin UMN Pharm All 61 Years and
Phase
older
3 Â (Adult, 55
Older
Industry
Adult) InterventioInterventi 7374-CL-0
InterleukinUniversity All 18 Years toNot
40 Years
ApplicÂ (Adult)51 Other|NIHInterventioAllocation 10-1806|R
Incidence Gary ArcheAll 18 Years and
Phase
older
1 Â (Adult, 70
Older
Adult) Pro000342
Developmen National InAll up to 3 Days
Phase
Â (Child)
1 156 NIH|IndustInterventioAllocation ACTG 230|11207
DATA EXTRCentre Hosp All Child, Adult, Older Ad 500 Other ObservatioObservatioQuantin PHRC IR 2009
Immunogeni National InFemale 12 Years to 17 Years Â (Child)
165 NIH ObservatioObservatio06-0043|N
Biological: ALVAC(2 National InAll 18 Years and
Phase
older
1 Â (Adult, Older
NIHAdult) InterventioMasking: NA5130|AACTG A5130|10080|A
Number ofUniversity All 18 Years to 65 Years Â (Adult,50Older
OtherAdult)ObservatioObservatioRCB 2018-
Primary vaLaboratorioAll 18 Years toPhase
55 Years
2 Â (Adult) 8 Industry InterventioInterventi 101-PG-PS
Clinical or University All 18 Years toNot
60 Years
ApplicÂ (Adult)40 Other InterventioAllocation OVG 2016/
Safety andVaximm G All 18 Years and
Phase
older
1 Â (Adult, 14
Older
Industry
Adult) InterventioInterventi VXM01-02
Evaluation Shiga UniveAll 20 Years toPhase
85 Years
OtherAdult)InterventioInterventi SUMS-23-5
ProprietaryMerck ShaFemale 16 Years toPhase
26 Years
2 Â (Child, Adult)
Anti-HAV AGlaxoSmithAll 12 Years toPhase
15 Years
Phase
older
2 Â (Adult,171
Older
Industry
Adult) InterventioAllocation B25-LG-30
85 Years
OtherAdult)InterventioInterventi SUMS-23-5
Adverse EvGreen CrosAll 19 Years toPhase
64 Years
1 Â (Adult)40 Industry InterventioAllocation GC3114_P
Disease buSociety fo All up to 24 Months Â (Child) 200 Other ObservatioObservatioSAS/BBIL/
Number ofSanofi Pas All 15 Years to 40 Years Â (Child,
2400Adult)
Industry ObservatioObservatioVAG00001
PercentageOncoSec Me All 18 Years and
Phase
older
2 Â (Adult, 15
Older
Adult) OMS-I110|
Bayley ScaIWK HealthAll 2 Months to 20 Months Â (Child)
a) Percent Internatio All 22 Years toPhase
35 Years
2|PhÂ (Adult)
RecurrenceGlobeImmAll 18 Years and
Phase
older
2 Â (Adult,176
Older
Industry
Incidence PapiVax BioFemale 25 Years toPhase
70 Years
Other|Indu
Adult)InterventioAllocation PVX2TACIN
49 Years
1 Â (Adult)21 NIH InterventioInterventi CIR 270
12 Weeks
EVR (Early GlobeImmAll 18 Years and
Phase
older
2 Â (Adult,140
Older
Industry
12 Weeks
3 Â (Child)
Safety andPapiVax Bi Female 19 Years and
Phase
older
1 Â (Adult, 30
Older
Other
Adult) InterventioAllocation BB IND 18
ccal (GAS) Infection National InAll up to 20 Years Â (Child, Adult)
663 NIH Observational 999901190
Biological: autologo Agenus IncAll 18 Years and
Phase
older
2 Â (Adult, 40
Older
Industry
Adult) InterventioAllocation C-100-23
DetermineNational CaMale 18 Years toPhase
100 Years
EPI vaccin University All up to 23 Months
Not Applicable
Â (Child) Other InterventioAllocation Jun-55
Phase
older
3 Â (Adult,652
Older
Industry
ConcentratGlaxoSmithK All 18 Years toPhase
45 Years
2 Â (Adult)81 Industry|OInterventioAllocation 116640|20
Change in IUniversity All Child, AdulNot Applic 823 Other InterventioAllocation 03-1082|R
National InAll Child, Adult, Older Ad 300 NIH ObservatioTime Persp05-0081
64 Years
3 Â (Adult)
1000 Industry InterventioAllocation IDB-707-1
50 Years
Tolerabili SL VAXiGE All 19 Years and
Phase
older
1 Â (Adult, 18
Older
Adult) BD03_KT_
Anal dysplaUniversity Male 18 Years and
Notolder
Applic
Â (Adult,
3000
Older
Other|Indu
Adult) InterventioAllocation HPV-SAVE
Clinical an Bharat SerAll 5 Years to 65
Phase
Years
3 Â (Child,500
Adult,
Older Adult) BSV-AMBE I
All Injecti Sanofi Pas All 4 Years to 6 Years Â (Child) 556 Industry ObservatioObservatioCVX01E
AssessmentGlaxoSmithAll 10 Years to 25 Years Â (Child,
1603
Adult)
Number ofClinical
s R All 18 Years toPhase
60 Years
3 Â (Adult) 160 Other InterventioAllocation NASVAC01
Incidence Cytos Biot All 18 Years toPhase
69 Years
1 Â (Adult,48Older
Industry
Adult)InterventioAllocation CYT013-IL
Percent of Genetic ImAll 18 Years toPhase
50 Years
2 Â (Adult)36 Industry|OInterventioAllocation DermaVir P
Number ofEyeGene InAll 50 Years toPhase
70 Years
1 Â (Adult,40Older
Other|Indu
Adult)InterventioAllocation EG-HZ-101
Number ofIan P F. Poll All 12 MonthsNotto 21
Applic
Years Â (Child,
Adult) PRO12050
Procedure: Autologous National CaAll Child, AdulPhase 1 51 NIH InterventioPrimary Pu950146|95
Impact of PInstituto d All up to 36 Months Â (Child)4000 Other|InduObservatioObservatioIAP-036
Dose equiva European OAll up to 85 Years
1288Older
OtherAdult)InterventioAllocation EORTC-309
Phase
older
2 Â (Adult, 50
Older
Number ofAeras|Sano
u All 18 Years toPhase
50 Years
Safety asseUMN Pharm All 20 Years toPhase
40 Years
2 Â (Adult) 180 Industry InterventioAllocation 7373-CL-0
Tolerabilit United NeuAll 60 Years toPhase
90 Years
2 Â (Adult,43Older
Industry
Adult)InterventioAllocation V203-AD
Safety andImugene LiAll 20 Years and
Phase
older
1|Ph
Â (Adult, 82
Older
Industry
Adult) InterventioAllocation IMU.ACS.0
RecurrenceIwate MediAll 20 Years toPhase
80 Years
OtherAdult)InterventioInterventi IMU-H18-5
Dose LimitMayo ClinicFemale 18 Years toPhase
120 Years
Adult) CDR000051
OccurrenceGlaxoSmithAll 12 Weeks and older Â (Child, 885
Adult,
Industry
Adult) 104676
Change in aCentral Ar All 60 Years toNot
80 Years
Adult) 391351
Biological: CYT006-A Cytos Biot All 18 Years toPhase
65 Years
Industry
Safety of Sidney KimAll 18 Years and
Phase
older
2 Â (Adult, 15
Older
Other|Indu
Adult) InterventioInterventi J18145|IR
Dose limit ProvidenceAll 18 Years and
Phase
older
1 Â (Adult, 30
Older
Other
Adult) InterventioAllocation 03-066A
Drug: autologous hu Agenus IncAll Child, AdulPhase 2 35 Industry InterventioAllocation C-100-09|
Number and Aeras All 18 Years toPhase
45 Years
Patients wiBavarian NAll 18 Years toPhase
85 Years
1 Â (Adult,11Older
Industry
Adult)InterventioInterventi BRACHY-MV
Cases of c Lisen ArnhAll 13 Years to 25 Years Â (Child,
500000Adult)
Other|InduObservatioObservatiocondyloma
Collect andAeras|GlaxAll 18 Years to 50 Years Â (Adult)
3253 Other|InduObservatioObservatioC-041-972
Toxicity af National InAll 18 Years toPhase
120 Years
NIH Adult) InterventioMasking: N020284|02
GMR(Geomet SK ChemicalAll 50 Years and
Phase
older
2|Ph
Â (Adult,675
Older
Industry
Adult) InterventioAllocation NBP608_HZ
Via the hosUniversity All 18 Years toNot
45 Years
ApplicÂ (Adult)35 Other InterventioInterventi Lac5-Nasal
Hypersensit The HospitaAll 2 Months toPhase
15 Months
3 Â (Child)
352 Other InterventioAllocation 1E+09
Biological: Trivalent spNational InAll 21 Years and
Phase
older
4 Â (Adult,150
Older
50 Years
1 Â (Adult)24 Other InterventioAllocation HV-03
80 Years
1 Â (Adult,51Older
Industry
All-cause University All 1 Month toPhase
59 Months
4 Â447780
(Child)Other InterventioAllocation OPP118762
Adverse EvGreen CrosAll 65 Years and
Phase
older
Industry InterventioAllocation GC3114_P
PTSD SympBoston UniAll 18 Years and
Phase
older
1 Â (Adult, 45
Older
Other
Adult) InterventioAllocation R01MH066
Number ofBiogen|AbAll 18 Years toPhase
60 Years
2 Â (Adult) 410 Industry InterventioInterventi 205-MS-20
PercentageNational CaAll 18 Years toPhase
100 Years
Adult) 140036|14
Mean change GeneOne LiAll 18 Years toPhase
65 Years
1 Â (Adult,40Older
Industry
Adult)InterventioAllocation Zika-001
Serum anti-University All 45 Years toPhase
66 Years
OtherAdult)InterventioAllocation RHMNUT00
Time to PSRhoVac APMale 18 Years and
Phase
older
2 Â (Adult,180
Older
Industry
Adult) InterventioAllocation RhoVac-00
100 Mcg/ml Albert B. SAll 18 Years toNot
45 Years
ApplicÂ (Adult)12 Other InterventioInterventi SVI-07-02
Total drus The New YoAll 50 Years and
Phase
older
1 Â (Adult, 15
Older
Other
Adult) InterventioAllocation NYEE1009
Establish t University All 18 Years toEarly
45 Years
PhasÂ (Adult)88 Other InterventioAllocation NadA-Lac4
Number ofSanofi Pas All 12 Months to 24 Months Â3214 (Child)
Industry ObservatioObservatioM5A08
Anti-polyr GlaxoSmithAll 18 MonthsPhase
to 24 Months
3 Â 467
(Child)
Varicella Merck ShaAll 12 MonthsPhase
to 75 Years
3 Â (Child,
150 Industry
Adult, Older
Adult) V210-058|
Evaluate saCedars-SinAll Child, AdulPhase 1 22 Other InterventioInterventi 6657
National InAll 18 Years to 60 Years Â (Adult) NIH Observational HIVNET 01
Safety and H. LundbecAll 60 Years toPhase
85 Years
1 Â (Adult,50Older
Industry
Adult)InterventioAllocation 16026A|20
Maternal SUniversity Female 18 Years and Notolder
Applic
Â (Adult,152
Older
Adult) MOMS Sle
To describeMedImmunAll 5 Years to 49
Phase
Years
4 Â (Child,345
Adult)
Industry InterventioAllocation FM026
Evaluate saOncovir, I All 18 Years and
Phase
older
2 Â (Adult,100
Older
Adult) ONC2014-0
Number ofGlaxoSmithAll up to 5 Days
NotÂ Applic
(Child) 2409 Industry InterventioInterventi 200150
Early onsetNovartis|NFemale 18 Years and older Â (Adult, Older 0 Industry
Adult) ObservatioObservatioV98_28OB
OccurrenceGlaxoSmithAll Child, Adult, Older Ad 1 Industry ObservatioTime Persp 116357
severity ofUniversity All 18 Years toPhase
58 Years
3 Â (Adult)30 Other InterventioAllocation 13166B
Presence oBarbara Ensoli,
All MD, PhD|Italian
18 Years toMinistry
45 YearsofÂ Foreign
(Adult)
179Affairs
Other- General
ObservatioTime
Direction forPerspISS
Cooperation
T-003 and Development|Isti
Overall surImmunicum All 18 Years and
Phase
older
2 Â (Adult, 88
Older
Industry
Adult) InterventioAllocation IM-201|20
GeometricMerck ShaAll 46 Days to Phase
89 Days
3 Â (Child)
ProgressionLudwig InsAll 18 Years and
Phase
older
1|Ph
Â (Adult,102
Older
Other|Indu
Number ofAffiris AG All 45 Years toPhase
70 Years
1 Â (Adult,36Older
Adult) AFFiRiS 0
Primary ImU.S. Army All 18 Years and
Phase
older
2 Â (Adult,162
Older
U.S.Adult)
Fed|NInterventioAllocation RV 305|WR
Number ofAffiris AG All 30 Years toPhase
75 Years
1 Â (Adult,30Older
Adult) AFFiRiS 0
Immune res GlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,120
Older
Industry
The symptom Medical UniAll 60 Years toPhase
75 Years
OtherAdult)InterventioAllocation MC56871/
The pneumo Wyeth is nAll 42 Days to Phase
63 Days
12 Weeks
Change in IDartmouth- All 18 Years toPhase
65 Years
Adult) R01MH072
Calcitonin NantCell, I All 18 Years toPhase
100 Years
Adult) QUILT-3.0
Part I: Nu Merck ShaAll 65 Years toPhase
80 Years
Frequency United NeuAll 40 Years toPhase
85 Years
1 Â (Adult,62Older
Adult) UB-312-10
Early vira ChronTechAll 18 Years toPhase
65 Years
2 Â (Adult,32Older
Industry
Adult)InterventioAllocation CVC-202|2
HCO 1100 C mentre HosAll 18 Years toPhase
70 Years
OtherAdult)InterventioAllocation HighCO He
Safety rep Hospital Italiano
All de Buenos
18 Years
Aires|Instituto
and
Early
older
Phas
Â (Adult,
de OncologÃ
12
Older
Other
aAdult)
Ã ngelInterventioInterventi
H. Roffo|National Agency2082for Scientific and Techno
60 Years
PercentageGlaxoSmithAll 427 Days toPhase
730 Days
3 Â (Child)617 Industry InterventioAllocation 104727 (Bo
65 Years
NIH Adult)InterventioAllocation 11-0024|N
ProgressionSecond MilAll 18 Years toPhase
75 Years
OtherAdult)InterventioAllocation SMMU, Sha
Long-term Affiris
t AG All 50 Years and older Â (Adult, 23
Older
Industry
Adult) ObservatioTime PerspAffiris 00
Evidence ofVanderbiltAll 18 Years toNot
64 Years
ApplicÂ (Adult)
1102 Other|U.S.InterventioAllocation VPES
To collect Beth Israe Female 18 Years and Notolder
Applic
Â (Adult,100
Older
Adult) 07-319
Seroconvers University Female 18 Years to 26 Years Â (Adult) 150 Other|InduObservatioObservatioGINI
To evaluateAVIR GreenMale 18 Years toPhase
50 Years
1 Â (Adult)32 Industry|OInterventioAllocation GHB-CS03|
Total HIV Imperial C All 18 Years toPhase
60 Years
2 Â (Adult)60 Other InterventioAllocation CCT-NAPN-
Molecular D p uke Univer
Female 18 Years to 45 Years Â (Adult)85 Other ObservatioObservatioPro000502
DetermineAgenus IncAll 18 Years toPhase
50 Years
1 Â (Adult)35 Industry InterventioAllocation C-400-01
Change in Roswell ParMale 18 Years and
Phase
older
2 Â (Adult, Older
2 Other|NIH|
Summary of Sanofi Pas All 11 Years toPhase
64 Years
Industry InterventioInterventi Td533|UTN
OccurrenceMerck ShaAll up to 12 Weeks
PhaseÂ3 (Child) 7504 Industry InterventioAllocation V260-015|
Number ofGlaxoSmithAll 50 Years and older Â (Adult,
26181
Older
Industry
Number ofMerck ShaAll 12 Months to 23 Months Â7585 (Child)
Number ofGlaxoSmithFemale Child, Adult, Older Ad 245 Industry ObservatioObservatio 201339
Dose limit Judit Pich MartÃ
All nez|Fundacion
18 Years and
Phase
Clinic
older
per
1 Â a(Adult,
la Recerca
21
Older
Other
BiomÃ©dica
Adult) InterventioAllocation iHIVARNA|
Changes inUniversity All 18 Years toPhase
64 Years
1 Â (Adult)17 Other InterventioAllocation IRB#11-00
Risk of EnzGlaxoSmithAll 12 Weeks and older Â (Child,1944Adult,
Industry
Adult) 111562
GMT, usingGreen CrosAll 18 Years toPhase
60 Years
3 Â (Adult)400 Industry InterventioAllocation GC3102C_
Injury Tim Western Un All 17 Years and
Notolder
Applic
Â (Child, Adult,
35 Other
Older Adult)
Biological: Commercial National InAll 20 Years toNot
99 Years
ApplicÂ (Adult,
850Older
Mortality Swiss TropAll Child, AdulPhase 3 13000 Other InterventioAllocation BMGF2858
Biological: FluMist|BiNational InAll 18 Years toPhase
49 Years
Biological: aldesleuk Memorial SMale 18 Years and
Phase
older
1|Ph
Â (Adult, 25
Older
Other
Adult) InterventioPrimary Pu94-134|CD
PercentageAeras|UnivAll 18 Years toPhase
50 Years
The number MedImmune Male 20 Years toPhase
45 Years
Safety andMichael Mo All 18 Years and
Phase
older
1 Â (Adult, Older
8 Other
Antibody prMitsubishiAll 2 Months toPhase
42 Months
3 Â (Child)
260 Industry|OInterventioAllocation BK1310-J0
Overall su NewLink Ge All 18 Years and
Phase
older
2|Ph
Â (Adult,135
Older
Industry
mother-to-Beijing Dit All up to 7 Months Â (Child) 600 Other ObservatioObservatioD1211000
Hospital a Bandim Hea All Child, AdulPhase 4 12006 Other InterventioAllocation BCGSTRAI
GMT (GeometGreen CrosAll 18 Years and
Phase
older
4 Â (Adult,
1139
Older
Industry
Adult) InterventioAllocation GCFLU_P4
The safety Michael Mo All 18 Years and
Phase
older
1|Ph
Â (Adult, 12
Older
Other|Indu
appropriatBoston ChiAll 18 Years and
Notolder
Applic
Â (Adult,800
Older
Adult) 06-07-034
Overall resSandoz|Nov All 18 Years and
Phase
older
3 Â (Adult,629
Older
Industry
Adult) InterventioAllocation CIGG013A2
Level of AnHopital Fo Female 18 Years andNotolder
Applic
Â (Adult,192
Older
Other
Adult) InterventioInterventi 2011/61|2
To evaluateMannkind All 18 Years and
Phase
older
2 Â (Adult, Older
5 Industry
Adult) InterventioInterventi MKC1106-
Biological: MN rgp12 National InAll 18 Years toPhase
60 Years
2 Â (Adult)420 NIH InterventioMasking: DAVEG 202/HIVNET 014|HIVNET
The time ofMinistry ofAll 18 Years toPhase
60 Years
3 Â (Adult)
1020 Other InterventioAllocation CR-01A/20
Number ofGlaxoSmith
S All 18 Years and
Notolder
Applic
Â (Adult,
2000
Older
Industry
The time ofMinistry ofAll 18 Years toPhase
60 Years
3 Â (Adult)300 Other InterventioAllocation CR-01C-1/
Drug: Pneumococcal 7Pfizer All up to 5 Years Â (Child) 408 Industry ObservatioTime Persp0887-1013
to 33 Months
3 Â 230
(Child)
Phase 1 : BioLeadersFemale 20 Years toPhase
50 Years
1|PhÂ (Adult)19 Industry InterventioAllocation UMT2013-B
Clinical maCenters fo All 5 Weeks toNot
16 Weeks
Applic Â (Child)
1516 U.S. Fed|OInterventioAllocation CDC-NCID-
102 Industry
Older Adult)
InterventioAllocation V110-018
Quality of Boston Med All 18 Years and
Notolder
Applic
Â (Adult,128
Older
Other
Compare twoUniversity All 18 Years toPhase
55 Years
2 Â (Adult)219 Other InterventioAllocation G0510031
wheal size Biomay AG| All 18 Years toPhase
60 Years
1|PhÂ (Adult)60 Industry|OInterventioAllocation CS-BM32-0
epidemiologSoroka UniAll up to 5 Years Â (Child) 30000 Other ObservatioObservatiosor415005c
Systemic aFrench NatFemale 21 Years toPhase
50 Years
1 Â (Adult)36 Other|InduInterventioAllocation ANRS VAC1
Number ofCrucell HolAll 18 Years toPhase
50 Years
1 Â (Adult)50 Industry|NInterventioAllocation CR104488|
EvaluationMedImmune Female 18 Years toPhase
30 Years
1|PhÂ (Adult)60 Industry InterventioAllocation MI-CP058
Pain level University All 18 Years and
Notolder
Applic
Â (Adult, 80
Older
Other
Safety|Im H. Kim Lye All 18 Years and
Phase
older
1 Â (Adult, 22
Older
Other
Tolerabilit Affiris AG All 50 Years and older Â (Adult, 22
Older
Industry
Adult) ObservatioTime PerspAffiris 00
HIV-specif Genetic Imm All 18 Years to 55 Years Â (Adult)16 Industry|OObservatioObservatioPHPC-02|2
Safety Affiris AG All Child, Adult, Older Ad 11 Industry ObservatioObservatioAFF004E
To determiHamilton HFemale 16 Years toPhase
80 Years
1 Â (Child, Adult,
5 OtherOlder InterventioAllocation
Adult) file#9427
PercentageNewLink Ge All 18 Years and
Phase
older
1 Â (Adult, 18
Older
Industry
Adult) InterventioInterventi NLG0106
Biological: Wetvax (A National InAll 18 Years toPhase
50 Years
1|PhÂ (Adult)
PercentageSanofi Pas All up to 50 Years
Phase
Â 3(Child, Adult)
600 Industry InterventioAllocation RAB40|U11
Patient RecNorthwesteAll 21 Years and
Notolder
Applic
Â (Adult,600
Older
Other
Adult) InterventioAllocation STU00211
GeometricGlaxoSmithAll 18 Years and
Phase
older
3 Â (Adult,110
Older
Industry
AssessmentLudwig InsAll 18 Years and
Phase
older
1 Â (Adult, 13
Older
Other|Indu
Adult) InterventioInterventi LGS 2009-
Overall SurH. Lee MoffAll 16 Years and
Phase
older
1 Â (Child, Adult,
Older Adult) MCC-13649
RSV challe Imperial C All 18 Years toNot
75 Years
ApplicÂ (Adult,
108Older
OtherAdult)InterventioAllocation 11/LO/102
Evaluation PDS BiotecFemale 21 Years toPhase
65 Years
1 Â (Adult,12Older
Industry
Adult)InterventioAllocation U10-02-11
OccurrenceGlaxoSmithFemale 10 Years and older Â (Child, Adult,
0 Industry
Older Adult)
ObservatioObservatio 113763
ProportionInstitut P All 18 Years toNot
20 Years
ApplicÂ (Adult)49 Industry|OInterventioInterventi 2011-42|2
Phase
older
3 Â (Adult,354
Older
Industry
ProportionPATH|SID TAll 18 Years toNot
55 Years
ApplicÂ (Adult)30 Other InterventioInterventi HS 720
comparisonHospices CiAll 18 Years and older Â (Adult,137
Older
Other
The proporWyeth is nAll up to 60 Months Â (Child)1000 Industry ObservatioTime Persp0887X-101
DetermineNational CaAll 18 Years toPhase
100 Years
Safety profAeras|StatAll 18 Years toPhase
45 Years
1 Â (Adult)60 Other InterventioAllocation C 006 404
Safety of Intercell All 18 Years toPhase
49 Years
1 Â (Adult)501 Industry|UInterventioAllocation PLA101|H
Biological: rgp120/H National InAll 1 Month toPhase
18 Years
NIH|IndustInterventioMasking: DACTG 218|11195
Change in Pfizer Child, Adult, Older Ad 1 Industry ObservatioObservatio6096A1-40
Disease coimmatics BAll 18 Years and
Phase
older
2 Â (Adult, 68
Older
Industry
Adult) InterventioAllocation EudraCT Nr
60 Years
1 Â (Adult)14 NIH|IndustInterventioInterventi AVEG 007C
Incidence Life Resea Female 18 Years toPhase
75 Years
1 Â (Adult,15Older
OtherAdult)InterventioAllocation LRT-I-L01
Physical A The Univers Female 18 Years toNot
40 Years
ApplicÂ (Adult)48 Other|NIHInterventioAllocation UTGSM-04
ProportionImperial C All up to 17 Years
Not ÂApplic
(Child) 4043 Other InterventioAllocation inh051
MagnitudeUniversity All 55 Years toPhase
89 Years
Adult) 18-0580|1
To provideSanofi All Child, AdulPhase 3 212 Industry InterventioAllocation E2I43
Ð¡ytotoxic Research I Female 28 Years toEarly
65 Years
OtherAdult)InterventioInterventi Breast Can
Disease freAdvantagen Male 18 Years and
Phase
older
3 Â (Adult,711
Older
Industry
Adult) InterventioAllocation PrTK03
Number ofMedImmunAll 6 Months toPhase
23 Months
1 Â (Child)
Anti HLA I Hospices CiAll 18 Years toNot
75 Years
ApplicÂ (Adult,
118Older
The number Emergent BAll 17 Years and older Â (Child, Adult,
24 Industry
Older Adult)
â€¢ Rate ofAeras|StatAll 18 Years toPhase
60 Years
2 Â (Adult)900 Other InterventioAllocation A-055
Number and Roxall MedAll 18 Years toPhase
60 Years
1 Â (Adult)48 Industry InterventioAllocation BIA-DPT-P
Number and Sellas Lif All 18 Years and
Phase
older
1|Ph
Â (Adult, 90
Older
Industry
Adult) InterventioAllocation SLS17-201
To characteCancer ResAll 18 Years and
Phase
older
2 Â (Adult, 20
Older
Other|Indu
Adult) InterventioAllocation PH2/048
100 Years
1|PhÂ (Adult,
30 Older
Other|Indu
Adult)
InterventioAllocation J18163|IR
Biological: BCG vacci Memorial SAll Child, AdulPhase 1 24 Other|NIHInterventioPrimary Pu97-024|P3
Incidence oGeneOne Lif All 19 Years toPhase
70 Years
Adult) MERS-002
The PercenNovartis P All 1 Year to 4Phase
Years Â3 (Child) 17 Industry InterventioAllocation CACZ885D2
Biological: HIV-1 Pe National InAll 18 Years toPhase
60 Years
Incidence oUniversity All 18 Years andPhase
older
1|Ph
Â (Adult, 24
Older
Other
Adult) InterventioAllocation IMA950-10
GMR(Geomet SK ChemicalAll 50 Years andPhase
older
Industry
Adult) InterventioAllocation NBP608_HZ
Number ofMerck ShaFemale 9 Years to 23 Phase
Years
Safety of Johns HopkAll 18 Years toPhase
50 Years
1 Â (Adult)60 Other|U.S.InterventioAllocation CIR 315 BS
Immunoresp The Immuno All 12 Months to 24 Months Â 150 (Child)
Other ObservatioTime PerspASCLIN/00
The percenGreen CrosAll 6 Months to Phase
19 Years
Industry InterventioAllocation GC3110A_
SerologicalNasVax LtdAll 3 Months to 3 Years Â (Child) 100 Industry ObservatioObservatioNX10-07
The composi Juventas ThAll 18 Years andPhase
older
Industry
Adult) InterventioAllocation JTCS-007
T-cell resp Bavarian NoAll 18 Years toPhase
60 Years
2 Â (Adult)77 Industry|NInterventioAllocation HIV-NEF-0
Safety of Turnstone A B ll 18 Years andPhase
older
Industry
Adult) InterventioAllocation Ad-MG1-E6
Evaluate thOslo UniveAll 18 Years toPhase
70 Years
1|Ph Â (Adult,24Older
Other|Indu
Adult)InterventioAllocation CTN-Vacc-
Biological: filgrasti University All 18 Years toPhase
80 Years
1|Phase
Â (Adult,
2 Older
Biological: Id-KLH Favrille All 18 Years andPhase
older
Industry
Adult) InterventioAllocation FavId-04
Number ofIwate MediAll 20 Years toPhase
80 Years
1 Â (Adult, OlderOtherAdult)Interventional IMU-H20-3
PPFP upta Jhpiego|UnFemale Child, AdulNot Applic 776 Other|U.S.InterventioAllocation IRB000071
Memory imm University All 9 Months to 10 Years Â (Child) 203 Other|NIHObservatioObservatioCIDRZ 120
Evaluate s AIM Immun All 19 Years toPhase
49 Years
1|Ph Â (Adult)55 Industry InterventioAllocation AMP-600
Biological: P3C541b United Biom All 18 Years toPhase
60 Years
1 Â (Adult) Industry InterventioPrimary Pu090|V103B
Number ofLaboratorioAll 1 Year to 12Phase
Years2Â (Child) 39 Industry InterventioInterventi AR-RACO-2
PreventionFrench NatFemale 15 Years and Phase
older
Other
Older Adult)
InterventioInterventi ANRS 1238
ProgressioEMD SeronFemale 18 Years and Phase
older
Industry
60 Years
ApplicÂ (Adult)50 Other InterventioAllocation RC5504
Anti-PRP aMitsubishiAll 2 Months to Phase
7 Months
2 Â (Child)
157 Industry InterventioAllocation MT-2301-J
number ofCentre
v Hosp
All up to 5 Years Â (Child) 9000 Other ObservatioObservatioPOTHIER Sa
Number ofTakeda All 2 Months to Phase
6 Months
3 Â (Child)
31 Industry InterventioInterventi TAK-816/O
anti-Tat huBarbara Ensoli,
All MD, PhD|Istituto
18 Years andSuperiore
older Â (Adult,
di SanitÃ
93
Older
Other
Adult) ObservatioObservatioISS T-002
Rate of T aHerbert LyAll 18 Years andPhase
older
Other
immunologi Allergy Th All 18 Years toPhase
50 Years
2 Â (Adult)40 Industry InterventioAllocation TreeMATA
Incidence Araclon BioAll 55 Years toPhase
80 Years
Industry
Adult)InterventioAllocation AB1601
Time to re Odense UniAll 18 Years andPhase
older
1|Ph
Â (Adult, 20
Older
Other
Nasopharng Boston Med All Child, Adult, Older Ad 9000 Other|InduObservatioObservatioH-28757
Specific huBarbara Ensoli,
All MD|Istituto
18 Years
Superiore
and older di ÂSanitÃ
(Adult, 73
Older
Other
Adult) ObservatioObservatioISS OBS T-
Measure the University All 18 Years toNot
60 Years
ApplicÂ (Adult)125 Other InterventioAllocation OVG 2014/
to 23 Months
3 Â 598
(Child)
ConjunctivaCytos Biot All 18 Years toPhase
65 Years
2 Â (Adult,64Older
Industry
Adult)InterventioAllocation CYT003-Qb
CD4+ (ClusRush UniveAll 18 Years toPhase
60 Years
4 Â (Adult)15 Other|InduInterventioAllocation ICE-001
Number ofMedicines
45 Years
1 Â (Adult)24 Other|U.S.InterventioAllocation MMV_DSM2
Mean Chang Abbott|NorAll 18 Years toPhase
65 Years
2 Â (Adult,25Older
Adult) L-BT04-09
quality of Azienda OsAll 18 Years toPhase
85 Years
OtherAdult)InterventioAllocation CE 70/06
S. pneumon Sheba MedicAll up to 5 Years Â (Child) 12800 Other|U.S.ObservatioObservatio8024-10
Difference U.S. Army All 18 Years toNot
45 Years
ApplicÂ (Adult)24 U.S. Fed InterventioAllocation: 19239
PreventionFrench NatFemale 15 Years and Phase
older
3 Â (Child, 2000
Adult,
Other
Older Adult)
InterventioAllocation ANRS 1239
OccurrenceUniversity All up to 65 Years Â (Child, Adult, 937Older
Other|Indu
Adult)ObservatioObservatioRG12-208|
The primary Centre HospAll 18 Years toPhase
50 Years
1 Â (Adult)40 Other InterventioAllocation PHRC 2003
12 Weeks
2 Â (Child)
Changes inImmunicu All 18 Years and
Phase
older
1 Â (Adult, Older
6 Industry
Adult) InterventioInterventi IM-103|20
concentratiMassachuse All 18 Years toPhase
55 Years
1 Â (Adult)25 Other InterventioAllocation 2007p-001
AntibodiesSheba Medi All up to 3 Months Â (Child) 50 Other ObservatioObservatioSHEBA-13-
Overall Su Sotio a.s. Female 18 Years and
Phase
older
3 Â (Adult,678
Older
Adult) SOV09|EN
Phase
older
4 Â (Adult, 96
Older
Industry
12 Years
3 Â (Child)751 Industry InterventioInterventi HXV02C|20
Delayed-typLondon SchAll 12 Years toPhase
25 Years
2 Â (Child, Adult)
Other InterventioAllocation KPS10
Response raJonsson CoAll 18 Years and
Phase
older
2 Â (Adult, 14
Older
Adult) 10-001212
Summary of BrightPathAll 18 Years and
Phase
older
1 Â (Adult, 18
Older
Industry
Adult) InterventioAllocation GRN1201-
ProgressionTransgene All 18 Years and
Phase
older
2|Ph
Â (Adult,148
Older
Industry
Adult) InterventioAllocation TG4010.09
Safety andGeneOne LiMale 20 Years toPhase
39 Years
To evaluateTripep AB|All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation CVC-201|E
PercentageMerck ShaAll 5 Years to 17
Phase
Years
Infant's HeInstitut d Female 18 Years and
Phase
older
3 Â (Adult,328
Older
Other|NIH|
Adult) InterventioAllocation U01HD071
To evaluateGreen CrosAll 20 Years toPhase
55 Years
1 Â (Adult)39 Industry InterventioAllocation MG1111_P
Safety of Turnstone A B ll 18 Years and
Phase
older
1 Â (Adult, 40
Older
Industry
Adult) InterventioAllocation Ad/MG1-M
Safety and InternationAll 18 Years toPhase
65 Years
Adult) IAVI T003
Disease coHerlev andAll 18 Years toPhase
100 Years
OtherAdult)InterventioInterventi BCC1810
90 Days
3 Â (Child)
Number ofNovartis P All 18 Years and
Phase
older
3 Â (Adult,
2010
Older
Industry
Adult) InterventioInterventi COMB157G
major congSeqirus Female 18 Years and older Â (Adult, Older
0 Industry
Number ofRoxall
p MedAll 14 Years and older Â (Child, Adult,
50 Industry
Older Adult)
ObservatioObservatioROX-ALE-2
>12% Fall University Male 19 Years toPhase
92 Years
1 Â (Adult,40Older
Adult) IND# 69,6
Injection SPATH|World All up to 50 Years
Not ÂApplic
(Child, Adult)
96 Other InterventioAllocation HS 645
Notolder
Applic
Â (Adult, 27
Older
Industry
Rate of AdVaccibody All 18 Years and
Phase
older
1|Ph
Â (Adult, 65
Older
Industry
Adult) InterventioAllocation VB N-01
signature oInstitut N All 20 Years to 50 Years Â (Adult)12 Other ObservatioObservatioC15-23|20
Safety andTheravectyAll 18 Years toPhase
55 Years
1|PhÂ (Adult)38 Industry InterventioAllocation THV01-11-
Dose LimitCase Compr All 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Other
Adult) InterventioInterventi CASE2Y16
The inductiUniversity All 18 Years toNot
65 Years
OtherAdult)InterventioInterventi TB003
Change in CNational CaMale Child, AdulPhase 2 154 NIH InterventioAllocation NCI-2014-
Peak LevelRadboud Un Male 18 Years toNot
35 Years
ApplicÂ (Adult)30 Other InterventioAllocation LPS-Fluenz
RecurrenceMenarini Female 18 Years and
Phase
older
2|Ph
Â (Adult,888
Older
Industry
Adult) InterventioAllocation ABA-01|AG
Change FroMerck KGaAll 18 Years and
Phase
older
2 Â (Adult,124
Older
Industry
Human papi University Female 18 Years and older Â (Adult,767
Older
Other
Adult) ObservatioObservatioCIN3+plus
Irregular Hanane ELAll Child, AdulNot Applic 100 Other InterventioAllocation CHUB-PRO
Change in Mayo ClinicAll 18 Years and
Notolder
Applic
Â (Adult, Older
Adult) MC1452|NC
Follow-up Children's All 4 Years to 17
NotYears
Applic
Â (Child)195 Other InterventioAllocation 1409-082
Phase
older
3 Â (Adult,
2022
Older
Industry
Mean changeGeneOne LiAll 18 Years toPhase
50 Years
1 Â (Adult)75 Industry|UInterventioAllocation WRAIR 227
To assess tVisterra, InAll 18 Years toPhase
45 Years
2 Â (Adult)46 Industry InterventioAllocation VIS410-20
Evolution oFrench NatAll 18 Years and
Phase
older
2 Â (Adult, 60
Older
Other|Indu
Number ofAduro Biote All 18 Years and
Phase
older
1 Â (Adult, 60
Older
Industry
Adult) InterventioAllocation ADU-CL-02
ProportionPATH All 18 Years toPhase
55 Years
1 Â (Adult)20 Other InterventioInterventi HS 563
Biological: PROSTVACNational CaAll Child, AdulPhase 1 75 NIH InterventioPrimary Pu940118|94
Number ofHoffmann-All 2 Years to 19
Phase
Years
4 Â (Child, Adult)
11 Industry InterventioAllocation PA16215
time from Medicines Allf 18 Years toPhase
45 Years
1 Â (Adult)22 Other InterventioAllocation MMV_DSM2
Participan Fred HutchAll 18 Years to 50 Years Â (Adult)
3500 Other ObservatioObservatioMC-002
The percent Emergent BAll 17 Years and older Â (Child,5001
Adult,
Industry
Older Adult)
Safety; defMorphogene All 18 Years and
Early
older
Phas
Â (Adult, Older
Adult) CM 2017-0
Number ofAeras|HIV All 12 Years toPhase
17 Years
1 Â (Child)84 Other|InduInterventioAllocation HVTN 602
To documen Sunnybrook All 18 Years and
Phase
older
2 Â (Adult, 25
Older
Other|Indu
Safety and InternationAll 18 Years toPhase
49 Years
1|PhÂ (Adult)72 Other InterventioAllocation IAVI E002
45 Years
4 Â (Adult)240 Other|InduInterventioAllocation BioVacSafe
Collection GlaxoSmithAll 18 Years toPhase
55 Years
Disease freUniversity All 18 Years toPhase
70 Years
OtherAdult)InterventioInterventi 1.140.423
Mortality|H PostgraduaAll 18 Years toPhase
85 Years
OtherAdult)InterventioAllocation IP 39
total commGorm GreisFemale Child, AdulPhase 3 125 Other InterventioAllocation H-4-2013 F
malaria moRadboud Un All 1 Year and Not
older
Applic
Â (Child, 6000
Adult,Other
Older Adult)
InterventioAllocation APRIORI1/
Change froNestlÃ© All 70 Years and
Notolder
Applic
Â (Older150
Adult)
Industry InterventioAllocation 12.22.NRC
Vaccine antUniversity All Child, Adult, Older Ad 265 Other|InduObservatioObservatioEUpert IV
Phase 1: S Heat BiologAll 18 Years and
Phase
older
1|Ph
Â (Adult,104
Older
Industry
Adult) InterventioAllocation HS410-101
Biological: MVA-MUCTransgene|U Male 18 Years and
Phase
older
2 Â (Adult, 50
Older
Adult) TG4010.03
Safety and Vaccine anAll 18 Years toPhase
55 Years
1|PhÂ (Adult) 0 Other InterventioInterventi AUR-001
The primarMedImmune All 6 Months toPhase
36 Months
3 Â 2400
(Child)
To evaluat National InAll 18 Years and older Â (Adult,500
Older
Estimate thUniversity All 17 Years to 25 Years Â (Child,
4096Adult)
Other ObservatioObservatioHREC/16/
The infect Hvivo All 18 Years toPhase
45 Years
1|PhÂ (Adult)24 Industry InterventioAllocation RIS-110 (D
Frequency Heat BiologAll 18 Years and
Phase
older
1 Â (Adult, 30
Older
Industry
Adult) InterventioInterventi HS130-001
PercentageAllertein T All 18 Years toPhase
50 Years
1 Â (Adult)15 Industry|OInterventioAllocation DAIT CoFA
Change in USDA, West All 20 Years toNot
49 Years
ApplicÂ (Adult)23 U.S. Fed InterventioAllocation WHNRC 213
Safety evalDynavax TeAll 18 Years and
Phase
older
1 Â (Adult,100
Older
Industry
Adult) InterventioInterventi DV2-HBV-2
ProgressioAnchiano Th All 18 Years and
Phase
older
2 Â (Adult, 12
Older
Industry
Adult) InterventioAllocation BC-PAN-02
Nasal Swa Wake ForesAll 18 Years toNot
49 Years
ApplicÂ (Adult)58 Other InterventioAllocation IRB000313
Collection National InMale 18 Years to 60 Years Â (Adult)
102 NIH ObservatioObservatio09-I-0226|
HCV testingOrganizati All 18 Years toNot
90 Years
ApplicÂ (Adult,
450Older
Adult) U50/CCU9
PrevalenceUniversity All up to 48 Hours Â (Child) 3000 Other ObservatioObservatioM151161
number ofValneva
d AuAll 18 Years toPhase
80 Years
2|PhÂ (Adult,
803Older
Industry
Needle-free Thai Red CrFemale 18 Years toPhase26 Years
2 Â (Adult)150 Other InterventioAllocation GINI Study
Mortality|Bandim Hea All up to 1 Month
Not Applicable
Â (Child) Other InterventioPrimary Pu2007-7041
Diarrhea|AFoundationAll up to 17 Days Â (Child) 1796 Other|NIHObservatioObservatioMAL-ED-47
Efficacy as Sidney KimAll 18 Years toPhase
80 Years
2 Â (Adult,90Older
blocking raBeijing Dit Female 20 Years to 35 Years Â (Adult) 406 Other ObservatioObservatioZ15112222
To evaluateIstituto Superiore
All di SanitÃ
18 Years to 50 Years Â (Adult) 5 Other ObservatioTime PerspISS OBS P-
Safety andInternatio All 18 Years toPhase
65 Years
1 Â (Adult,66Older
OtherAdult)InterventioAllocation IAVI T002
knowledgeSarah Hoste Female 18 Years to 26 Years Â (Adult)50 Other ObservatioObservatio 27816
Serious advNational InAll 18 Years toPhase
45 Years
Ante NatalOnyango SaFemale 16 Years and Notolder
Applic
Â (Child,
7200
Adult,
Other
Older Adult)
InterventioAllocation AFYA 4136
The geomet Merck ShaAll 50 Years and
Phase
older
3 Â (Adult,150
Older
Industry
Biological: gene-modiSt. Jude ChAll up to 21 Years
Phase
Â 1(Child, Adult)
38 Other|NIHInterventioPrimary PuCDR000006
Incidence BriaCell ThFemale 18 Years and
Phase
older
1|Ph
Â (Adult, 24
Older
Industry
Adult) InterventioInterventi 0001|WRI-
To evaluat ImmunoFron All 20 Years and
Phase
older
1 Â (Adult, 25
Older
Industry
Adult) InterventioInterventi IMF001J
Quantity oUniversity All 18 Years toNot
55 Years
ApplicÂ (Adult)52 Other InterventioAllocation TB031
SCRs (SeroValneva AuAll 9 Months toPhase
18 Years
Seroconvers Internatio All 9 Months toPhase
13 Months
4 Â (Child)
300 Other InterventioAllocation PR- 18016
Clinical or University All 18 Years toNot
60 Years
ApplicÂ (Adult)80 Other InterventioInterventi OVG 2013/
120 Years
Adult) 072-06|P
CD4+ T celUniversity All 18 Years toNot
65 Years
Adult) 160089|1R
Area UnderMerck ShaAll 18 Years toPhase
55 Years
2 Â (Adult)80 Industry InterventioAllocation 1654-005|
a designat Beth Israe All Child, AdulNot Applic 54 Other InterventioAllocation 2009P0001
ProlongatioUniversity All 18 Years toPhase
75 Years
OtherAdult)InterventioAllocation DERMA-ER-
Biological: Biologica University All 18 Years to 65 Years Â (Adult, Older
OtherAdult)Expanded Access ICT-7392-Compassionate Use
Biological: BCG vacci Roswell ParAll 18 Years and
Phase
older
2 Â (Adult, Older
Adult) PuCDR000006
Immunogeni Assistance All 18 Years toPhase
75 Years
2 Â (Adult,56Older
OtherAdult)InterventioAllocation P170934J|
Patient's l National InAll Child, Adult, Older Ad 500 NIH ObservatioObservatio06-0096
Biological: PANVACâ„Therion Bi All 18 Years and
Phase
older
3 Â (Adult,250
Older
Industry
Adult) InterventioAllocation TBC-PAN-0
immune res Centre HospAll 19 Years and
Notolder
Applic
Â (Adult, 30
Older
Other
Adult) InterventioAllocation 17-AOI-04
CompositeUniversity All 18 Years and
Phase
older
3 Â (Adult,
1400
Older
Other
Adult) InterventioAllocation IMPI-TRIAL
OccurrenceGlaxoSmithAll 18 Years and
Phase
older
1 Â (Adult, 60
Older
Industry
To identif Pfizer All 18 Years toNot
70 Years
ApplicÂ (Adult,
152Older
Industry
Adult)InterventioAllocation 6115A1-10
Other: 1-Fermented Da Danone ReAll 65 Years toNot
80 Years
ApplicÂ (Older
550Adult)
Industry InterventioAllocation NU356
â€¢ To deteBaylor Col All up to 75 Years
Phase
Â 1(Child, Adult,
11Older
OtherAdult)InterventioAllocation H6408-Leu
50 Years
2 Â (Adult)40 Industry InterventioAllocation GrassMAT
dynamic chJiangsu Pr All 2 Years to 3 Years Â (Child)1297 Other ObservatioObservatioJSVCT002
Safety(PhasWakayamaAll M 20 Years toPhase
80 Years
OtherAdult)InterventioInterventi WEUTC
Occurrences GlaxoSmithAll Child, Adult, Older Ad 1 Industry ObservatioTime Persp 116730
Dose rangeChildren's All 18 Years toPhase
49 Years
1 Â (Adult)60 Other|InduInterventioAllocation CIN-002
LeptospiroCentre Hosp All 18 Years and older Â (Adult,175
Older
Other|Indu
Adult) ObservatioObservatio2015/CHU/
Genomics pSt George' All 18 Years toNot
45 Years
ApplicÂ (Adult) 7 Other InterventioInterventi UBC-INNAT
Comparison University All 18 Years and
Phase
older
1|Ph
Â (Adult, Older
0 Other
Adult) InterventioAllocation MO15/121
To compareNational InAll 18 Years toPhase
50 Years
1 Â (Adult)84 NIH InterventioAllocation AVEG 027|10577
DetermineNational
t InAll 18 Years toPhase
50 Years
1 Â (Adult)57 NIH InterventioAllocation 99-036|BC
Rate of HBsHopital LarFemale 18 Years to 45 Years Â (Adult)28 Other ObservatioObservatioURT-Liver-
To compareThe WistarAll 18 Years and
Notolder
Applic
Â (Adult, 30
Older
Other
Adult) InterventioAllocation 1R01AI051
The occurre National InAll 18 Years toPhase
50 Years
DetermineJanuario C All 18 Years and
Phase
older
2 Â (Adult, Older
6 Other|U.S.InterventioInterventi
Adult) UCSD-1013
ORR defined Karen KellyAll 18 Years and
Phase
older
2 Â (Adult, 33
Older
Other|NIH|
Adult) InterventioInterventi 885316|UC
Frequency CJ HealthCAll 19 Years toPhase
49 Years
1 Â (Adult)60 Industry InterventioAllocation CJ_HFM_1
Long term Affiris AG All Child, Adult, Older Ad 17 Industry ObservatioTime PerspAFF003E
Detection oUniversity All 40 Years to 85 Years Â (Adult,57Older
Other|Indu
Adult)ObservatioObservatioRMH MED 1
TuberculosiBiomedicalAll 11 Months to 12 Years Â (Child)
500 Other|InduObservatioObservatioRIA2016V-
Implementa Agency forAll 30 Years toNot
65 Years
U.S. Fed
Adult)InterventioAllocation 1R21HS01
Tumor gro National CaMale 18 Years toPhase
100 Years
Incidence oH. LundbecAll 60 Years toPhase
85 Years
1 Â (Adult,18Older
Industry
Adult)InterventioInterventi 16026B|20
Duodenal hPrincess A All 18 Years and
Phase
older
2 Â (Adult, 20
Older
Other
Adult) InterventioAllocation 2007/115|
Biological: MTP-PE/MNational InAll 18 Years toPhase
50 Years
1 Â (Adult)64 NIH|IndustInterventioAllocation AVEG 005A/B|10546|10547
Rates of MMedImmunAll 5 Years to 49 Years Â (Child,
63061
Adult)
Industry ObservatioObservatioFM025
85 Years
OtherAdult)InterventioAllocation SUMS-22-1
Phase
older
1 Â (Adult,223
Older
Industry
Toxicity|H Mayo ClinicAll 18 Years toPhase
120 Years
Adult) CDR000057
Tumor objec The Method All 18 Years and
Phase
older
2 Â (Adult, 28
Older
Other|Indu
Adult) InterventioAllocation HMRI IRB#
Number ofJanssen ReAll 18 Years and
Phase
older
2 Â (Adult,848
Older
Industry
The proport National InAll 5 Years to 16 Years Â (Child)
1757 NIH ObservatioObservatio06-0002|B
Change in InternationAll 18 Years toNot
35 Years
ApplicÂ (Adult)
Arm A: ProH. Lee MofAll 18 Years and
Phase
older
2 Â (Adult, 17
Older
Other|Indu
Self-reportDrexel UnivFemale 14 Years toNot
19 Years
ApplicÂ (Child,
480Adult)
The number Sheffield All 18 Years toNot
60 Years
ApplicÂ (Adult)
300 Other InterventioAllocation STH16097
Number ofGlaxoSmithAll 6 Months toNot9 Years
ApplicÂ (Child)
54600 Industry|OInterventioInterventi 116682
No occurreGuangzhouAll Child, AdulNot Applic 41 Other InterventioInterventi DEL
Immunogeni Radboud Uni Female 18 Years and
Phase
older
2 Â (Adult, Older
8 Other
Total nasa PongsakornAll 12 Years and
Phase
older
4 Â (Child, Adult,
84 Other
Older Adult)
Biological: carcinoe Duke Cancer All 18 Years and
Phase
older
1|Phase
Â (Adult,
2 OlderOther|NIHInterventioPrimary
Adult) PuCDR000006
Effect on ImmunitorFemale 18 Years toPhase
65 Years
2 Â (Adult,20Older
Industry
Adult)InterventioInterventi V3-MOMM
serostatus National T All 20 Years to 30 Years Â (Adult)
6000 Other ObservatioObservatio20101212
Collection National InMale 18 Years to 59 Years Â (Adult)21 NIH ObservatioObservatioIDCRP-046
ProportionInternatio All 18 Years toPhase
65 Years
1 Â (Adult,48Older
OtherAdult)InterventioAllocation IAVI T001
phenotypicNational InAll 50 Years and older Â (Adult, Older
6 NIHAdult) ObservatioObservatio06-0092|N
The AntiboGreen CrosAll 19 Years and
Phase
older
3 Â (Adult,317
Older
Industry
Adult) InterventioInterventi GC3101B_
pneumococca Public HeaAll 1 Year and older Â (Child, Adult,
400 Other
Older Adult)
ObservatioObservatioPIN
Safety of t Aaron Diam All 18 Years toPhase
60 Years
1 Â (Adult)63 Other|InduInterventioAllocation ABA-0101
Mortality|Bandim Hea All 6 Months toPhase
5 Years
4 Â (Child)
Incidence Pfizer|JANAll 50 Years toPhase
85 Years
2 Â (Adult,32Older
Industry
Absolute nu GlaxoSmithAll up to 5 Years Â (Child) 1 Industry ObservatioObservatio 116312
HCV testingOrganizati All 18 Years and
Notolder
Applic
Â (Adult,103
Older
Adult) U50/CCU9
Toxicity a University All 18 Years and
Phase
older
1 Â (Adult, 11
Older
Other
Nasopharyn Johns HopkAll 7 Months and older Â (Child,
6628 Adult,
Other|NIH|
Older O
Adult)
bservatioObservatioR01MD004
HBV makers Third Affil All 18 Years toPhase
65 Years
1|PhÂ (Adult,
450Older
The PrimarNational I All 3 Years to 45
Phase
Years
2 Â (Child,145
Adult)
NIH|OtherInterventioAllocation GAD65 (IN
45 Years
1 Â (Adult)40 U.S. Fed InterventioAllocation S-15-19|A
Safety as ImmunoVacc Female 18 Years and
Phase
older
1|Ph
Â (Adult, 85
Older
Industry
Number ofGlaxoSmithAll Child, AdulPhase 4 50 Industry InterventioInterventi 112266
Number ofArdigen|Ma All 18 Years and older Â (Adult, 30
Older
Industry|OObservatioObservatioA.I.mmune
Adult)
The incide United NeuAll 60 Years toPhase
90 Years
2 Â (Adult,34Older
Industry
Adult)InterventioAllocation V203-AD-E
Change in pNIZO FoodMale 18 Years toNot
55 Years
ApplicÂ (Adult)44 Other InterventioAllocation NL54064.0
Frequency University All 18 Years and older Â (Adult,
1560
Older
Other
Adult) ObservatioObservatioSIIP
To evaluateUniversity All 18 Years and
Phase
older
1|Ph
Â (Adult, 20
Older
Other
Symptoms|Fr Imperial C All 18 Years toNot
55 Years
ApplicÂ (Adult)
120 Other InterventioAllocation 13SM0365|
ProportionMitsubishiAll 6 Weeks toPhase
35 Years
Industry InterventioAllocation MT-5625-0
Phase 1b: Heat BiologAll 18 Years and
Phase
older
1|Ph
Â (Adult,121
Older
Industry
Major congGlaxoSmithAll Child, Adult, Older Ad 1 Industry ObservatioObservatio205533|V7
The co-pri Swiss FederAll 6 Months to Not14Applic
Months Â (Child)
155 Other|InduInterventioAllocation DSM-2-707
Maternal, Aga Khan UAll up to 49 Years
Not ÂApplic
(Child, Adult)
Change in tIstari Onc Female 18 Years andEarly
older
Phas
Â (Adult, Older
Adult) Pro000853
PercentageNovartis P All 1 Month toPhase
60 Months
3 Â (Child)
17 Industry InterventioInterventi CACZ885D2
Degree of Vaccitech All 18 Years toPhase
55 Years
2 Â (Adult)155 Industry InterventioAllocation FLU010
Number ofLaboratorioAll 21 Years andPhase
older
2 Â (Adult, Older
7 Industry
Adult) InterventioAllocation AR-RACO-0
Ratio of suSeoul St. MFemale 19 Years toNot
50 Years
ApplicÂ (Adult)50 Other|InduInterventioAllocation GX-188E_G
Immunologi National InMale 18 Years and older Â (Adult, 48Older
NIHAdult) Observational 999907214|07-C-N214|CDR00
PSA incremSamsung Me Male 18 Years andPhase
older
1|Ph
Â (Adult, 12
Older
Other
Adult) InterventioAllocation 2006-10-0
number ofUniversity All 18 Years andPhase
older
1 Â (Adult, Older
0 Other
Adult) InterventioInterventi EKNZ 2015
Biological: Dryvax National Institute of Child, AdulPhase 2 90 NIH InterventioAllocation 01-651
Patient diaDynavax TeAll 18 Years toPhase
65 Years
1 Â (Adult,14Older
Industry
Adult)InterventioInterventi DV4-HBT-0
prevalenceMariella E All 5 Years to 18
NotYears
Applic
Â (Child, Adult)
36 Other InterventioAllocation 947_OPBG
National TaFemale 18 Years to 80 Years Â (Adult,500Older
OtherAdult)ObservatioObservatio 9.26E+09
Melan-A andCentre HospAll 18 Years andPhase
older
1 Â (Adult, 29
Older
Other
Adult) InterventioAllocation LUD 2000-
evaluate t National InAll 2 Years and older Â (Child, Adult,
200 NIHOlder Adult)
ObservatioObservatio020110|02
antibody r National InAll 62 Years toNot
82 Years
ApplicÂ (Adult,
150Older
NIH Adult)InterventioAllocation AG0088|NI
MicroscopiSeattle ChiAll 18 Years toPhase
50 Years
1 Â (Adult)36 Other InterventioAllocation MC-003
To evaluateSyral All 4 Months to Not5 Months
Applic Â (Child)
60 Industry InterventioAllocation:FOS_FOF0
ConjunctivCytos Biot All 18 Years toPhase
65 Years
2 Â (Adult,40Older
Industry
Adult)InterventioAllocation CYT005-Al
Thymus sizeUSDA, West All up to 48 Hours
Not Applic
Â (Child) 300 U.S. Fed|OInterventioAllocation N3-TSA-00
Overall Su Recombio SAll 18 Years andPhase
older
3 Â (Adult,
1082
Older
Adult) EC-AR-1E1
StreptococDepartment All 3 Months to Not4 Years
ApplicÂ (Child)
500 Other InterventioAllocation 11-APN-01
Receipt of University All 65 Years andNotolder
Applic
Â (Older700
Adult)
the IncidenAstraZenecAll 7 Years to 18
Phase
Years
3 Â (Child,
1369
Adult)
Evaluate t Aeras|StatAll 18 Years toPhase
50 Years
Incidence PCI Biotec All 18 Years toPhase
55 Years
1 Â (Adult)96 Industry InterventioAllocation PCIA102-1
PercentagePfizer|Jan All 50 Years toPhase
85 Years
2 Â (Adult,86Older
Adult) 3134K1-20
Time to treNCIC ClinicAll 18 Years andPhase
older
3 Â (Adult, 41
Older
Other
Adult) InterventioAllocation BL11|CAN-
Change in Oregon Hea All 18 Years toNot
80 Years
Change in University All 18 Years to 45 Years Â (Adult)62 Other|NIH| ObservatioObservatio13-2246|P
Treatment University
f All 12 MonthsNot to 5Applic
Years Â (Child)
Nutritiona Aga Khan UAll up to 10 Years
Not ÂApplic
(Child) 500 Other InterventioAllocation 3836-Ped-
To evaluateImmutep S.All 18 Years toPhase
55 Years
1 Â (Adult)48 Industry|OInterventioAllocation P002|Aste
Evaluate t BriaCell ThFemale 18 Years andPhase
older
1|Ph
Â (Adult, 60
Older
Industry
Adult) InterventioAllocation BRI-ROL-0
Vacc-4x Ef Bionor Im All 18 Years toPhase
63 Years
2 Â (Adult)33 Industry InterventioInterventi CT-BI Vacc
Number ofCraig L Sli All 18 Years andEarly
older
Phas
Â (Adult, 25
Older
Other|Indu
Adult) InterventioAllocation CSlingluff
Biological: BCG vacci Anthra PhaAll 18 Years andPhase
older
2 Â (Adult, Older
Industry
Influenza Dalhousie Female Child, Adult, Older Ad 200 Other ObservatioObservatio 114231
SeroprevaleHasselt UniAll 18 Years and older Â (Adult, 1000
Older
Other
Adult) ObservatioObservatioHBVTR-1.0
Change in tUniversity Female 18 Years toPhase
45 Years
4 Â (Adult)34 Other InterventioInterventi UT-Schisto
Biological: REVAXISÂ®Sanofi Pas All 6 Years to 6Phase
Years3Â (Child) 760 Industry InterventioAllocation F05-TdI-30
Number ofGlaxoSmithAll Child, AdulPhase 4 44 Industry InterventioInterventi 112267
AssessmentNovavax|De All 18 Years toPhase
64 Years
1|PhÂ (Adult)
610 Industry|UInterventioAllocation FLU-MI7A-
National InAll 5 Years to 14 Years Â (Child)
1000 NIH ObservatioTime Persp05-0117
Adverse EvAeras|EuroAll 112 Days toPhase
182 Days
1|PhÂ (Child)
487 Other InterventioAllocation C-029-402
A questionnNational TaAll Child, Adult, Older Ad 40 Other ObservatioObservatio200805057
The primaryNewLink Ge All 18 Years andPhase
older
3 Â (Adult,722
Older
Industry
Adult) InterventioAllocation NLG0405|O
AssessmentNovavax All 18 Years andPhase
older
1 Â (Adult,280
Older
Industry
Adult) InterventioAllocation NVX900.PH
Weight chaVA Office All 18 Years toNot
75 Years
ApplicÂ (Adult,
315Older
U.S. Fed
Adult)InterventioAllocation CDX 15-00
The entire VanderbiltAll 18 Years to 49 Years Â (Adult) 2 Other ObservatioObservatioIRB#17039
RibonucleicUniversity All up to 12 Months Â (Child) 315 Other ObservatioObservatioOVG 2017/
Frequency GynecologiAll 18 Years andNotolder
Applic
Â (Adult, Older
Adult) GOG-0243|
Biological: Dendritic National InAll 18 Years toPhase
60 Years
1 Â (Adult) 5 NIH InterventioAllocation R01AI0446
Treatment-eVaximm Gm All 18 Years andPhase
older
1|Ph
Â (Adult, 30
Older
Industry
Adult) InterventioInterventi VXM01-AVE
Initial Pe Pfizer All 18 Years andPhase
older
3 Â (Adult,
4488
Older
Industry
Evaluate DLCellid Co., Female 20 Years toPhase
70 Years
Industry
Adult)InterventioInterventi BVAC-C-P1
To determiMannkind All 18 Years andPhase
older
1 Â (Adult, 12
Older
Industry
Adult) InterventioAllocation MKC1106-P
older
1 Â (Adult, 86
Older
Industry
Toxicities National CaAll 19 Years andPhase
older
1 Â (Adult, 26
Older
Adults: Pe Merck ShaAll 2 Months to Phase
49 Years
1|PhÂ (Child,
338Adult)
University Female 13 Years and older Â (Child,136Adult,
Other|Indu
Older Adult)
ObservatioObservatioOICB08058
Biological: HIV p17/ National InAll 18 Years toPhase
60 Years
Feasibilit Dana-FarbeAll 18 Years andPhase
older
1 Â (Adult, 23
Older
Other
Evidence ofUniversity All 2 Years to 85
NotYears
Applic
Â (Child,200
Adult,
Other
Older Adult)
InterventioInterventi ACH 03-01
PercentageInstitut d All 18 Years andNotolder
Applic
Â (Adult,
1000
Older
Other|Indu
Adult) InterventioAllocation IMEA 38|2
Atopic senBandim Hea All 8 Years to 12 Years Â (Child)
2000 Other ObservatioObservatio2013-VAS-
Number ofPfizer All 65 Years and older Â (Older696 Adult)
Industry ObservatioObservatioB1851121
The main stRadboud Un All 18 Years toPhase
35 Years
1 Â (Adult)40 Other InterventioAllocation EHRVI
PreventionJohns HopkAll 18 Years toPhase
45 Years
2 Â (Adult)36 Other|U.S.InterventioAllocation CIR 233|W
The primarImmune Res All 16 Years andPhase
older
3 Â (Child,500
Adult,
Industry
Older Adult)
InterventioAllocation IR103-007
Bayley III Women and All 23 Weeks to Not32Applic
Weeks Â (Child)
determine National CaMale 18 Years andPhase
older
2 Â (Adult, 34
Older
Years3Â (Child) 649 Industry InterventioAllocation P3T11
Assess MedMedImmunAll 24 Months to 59 Months 29296
Â (Child)
Industry ObservatioObservatioMI-MA162
feasabilit University All 18 Years andNotolder
Applic
Â (Adult, 10
Older
Other
Adult) InterventioAllocation 38RC.19.1
Biological: ALVAC-HI National I All 18 Years toPhase
60 Years
1 Â (Adult)28 NIH|IndustInterventioMasking: DAVEG 012A|AVEG 012B|10557
Collection National InAll 18 Years toPhase
50 Years
ProportionPfizer All 10 Years toPhase
18 Years
Industry InterventioMasking: NB1971033|
ProgressioNewLink Ge All 18 Years andPhase
older
2 Â (Adult, 10
Older
Industry
Adult) InterventioInterventi NLG0605|1
Change in sNIZO FoodMale 18 Years toNot
55 Years
cognitive( Affiris AG All 50 Years toPhase
80 Years
Industry
Adult)InterventioAllocation AFF006|20
Frequency Radboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)24 Other InterventioAllocation CHMI-tran
Parent int University All Child, AdulNot Applic 100 Other InterventioInterventi HRB_CHErI
Biological: APL 400- National InAll 18 Years andPhase
older
1 Â (Adult, 36
Older
NIHAdult) InterventioMasking: DAVEG 033|10582
45 Years
Annual inciEskisehir All up to 18 Years Â (Child, Adult)
1800 Other ObservatioObservatioVARICOMP
35 Years
1|PhÂ (Adult)29 Other InterventioAllocation CHMI-tran
OccurrenceGlaxoSmithFemale 12 Years to 64 Years Â (Child, Adult)
positive ra YiYang ZhuFemale 16 Years to 45 Years Â (Child,
407Adult)
Other ObservatioObservatiotz2008032
blood transCentre Hosp All 18 Years and older Â (Adult,
12000
Older
Other
Adult) ObservatioObservatioP/2013/16
Biological: MN rgp12 National InAll 18 Years toPhase
50 Years
Number ofPfizer All 2 Months to 6 Months Â (Child)
1087 Industry ObservatioObservatioB1851122
Hematopoie Sidney KimAll 18 Years and
Phase
older
1|Ph
Â (Adult, 26
Older
Adult) J0770|P30
% HIV entryUniversity All 18 Years and
Notolder
Applic
Â (Adult,125
Older
Other
Adult) InterventioAllocation Penile mic
To comparePT Bio Far All up to 1 DayPhase
Â (Child)
2 240 Industry InterventioAllocation OPV 0213
Analysis ofUniversity Male 18 Years and older Â (Adult,150
Older
Other
45 Years
Maximum Pfizer
re All 18 Years and
Phase
older
2 Â (Adult, Older
0 Industry
Adult) InterventioAllocation A3671029
blood count Cure&SureAll 18 Years toPhase
75 Years
1 Â (Adult,20Older
Adult) CS-TT-G-01
Biological: BCG vacci Medical ReAll Child, AdulPhase 3 Other InterventioAllocation CDR000007
Sample ColNational InAll 18 Years to 65 Years Â (Adult,
3000Older
Levels of l CONRAD|Joh All 18 Years to 55 Years Â (Adult)64 Other ObservatioObservatioA07-105
Frequency Institut N Female 18 Years and older Â (Adult,919
Older
Other
Adult) ObservatioObservatioC09-24|20
The Post Do MedImmunAll 18 Years toPhase
49 Years
3 Â (Adult)
number ofSouth
H EastAll 18 Years to 50 Years Â (Adult)
992 Other ObservatioObservatioSEARCH 00
60 Years
Incidence GlaxoSmithAll Child, Adult, Older Ad 1 Industry ObservatioTime Persp 116273
50 Years
1 Â (Adult)105 NIH|Other| InterventioAllocation HVTN 137|
Wyeth is nAll 2 Years to 5 Years Â (Child)5000 Industry ObservatioTime Persp 101850
Safety - l National CaMale 18 Years and
Phase
older
1|Ph
Â (Adult, 29
Older
Safety andInternationMale 18 Years toPhase
45 Years
1 Â (Adult)21 Other|NIHInterventioAllocation IAVI A003
To determin Emory UnivAll 18 Years and older Â (Adult,200
Older
Other
AssessmentNew DiscovFemale 20 Years to 35 Years Â (Adult)
600 Industry ObservatioObservatio2017ZX102
ProportionUniversity Male 18 Years and
Phase
older
2 Â (Adult, 15
Older
Other|Indu
Adult) InterventioAllocation 14559|NCI
Receipt of Stanford UFemale 15 Years and
Notolder
Applic
Â (Child,
3112
Adult,
Other
Older Adult)
InterventioAllocation IRB-39719
Frequency London
o SchAll up to 48 Hours
PhaseÂ 2(Child) 200 Other InterventioAllocation RPC389
Biological: AluminumNational InAll 13 Years and
Phase
older
1 Â (Child,130
Adult,
NIHOlder Adult)
InterventioAllocation ACTG 214|11191
ProgressioImmune DeAll 12 Years and
Phase
older
3 Â (Child, Adult,
1 Industry
Older Adult)
InterventioAllocation IMDZ-04-1
To measureUniversity All 18 Years toEarly
45 Years
PhasÂ (Adult)31 Other InterventioAllocation Lactamica-
To evaluateImmutep S.Male 18 Years toPhase
40 Years
1 Â (Adult)60 Industry|OInterventioAllocation P001|Aste
Rate of regAlbert EinsFemale 18 Years toPhase
120 Years
Adult) 03-10-251
Rates of me MedImmunAll Child, Adult, Older Ad 95000 Industry ObservatioTime PerspMA-VA-MED
Drug: Anthrax ImmunNational InAll Child, Adult, Older Ad 400 NIH Observational 020137|02
Time to UTRegion SkaAll 20 Years toNot
85 Years
Other|Indu
Adult)InterventioAllocation RTP-A2003
The number GlaxoSmithFemale 10 Years and older Â (Child,1230
Adult,
Industry
Older Adult)
ObservatioTime Persp 114332
Minimal ReInvectys|MAll 18 Years and
Phase
older
2 Â (Adult, 90
Older
Adult) INVAC1-CT
ImmunizatiInternatio All 1 Year to 3Not
Years
Applic
CR:disappeHadassah M All 12 Years toPhase
70 Years
Adult) 0457-08-H
Measure mea Children's All up to 30 Years Â (Child, Adult)
60 Other ObservatioObservatioPro000115
Incidence Axon Neuro All 18 Years toPhase
85 Years
1 Â (Adult,33Older
Industry
Adult)InterventioAllocation AC-TP-001
12 Weeks
To screen suNational InAll 18 Years to 70 Years Â (Adult,
4000Older
Solicited Crucell Ho All 18 Years toPhase
50 Years
Assess theAlopexx PhMale 18 Years toPhase
35 Years
2 Â (Adult)10 Industry InterventioAllocation AP-GC-201
PercentageModernaTXAll 18 Years and
Phase
older
1 Â (Adult, 90
Older
Industry
Biological: Tetanus T National InAll 16 Years and
Notolder
Applic
Â (Child,288
Adult,
NIHOlder Adult)
InterventioPrimary PuAIEDRP AI-
Mean log10 National InAll 19 Years and
Phase
older
2 Â (Adult, 92
Older
NIH|OtherInterventioMasking:
Adult) DB012|0900-397
Changes inNational InFemale 18 Years to 45 Years Â (Adult)41 NIH ObservatioObservatio100205|10
Breast mil Internatio Female 18 Years toPhase32 Years
2|PhÂ (Adult)
Phase
older
3 Â (Adult,118
Older
Industry
NegativizatClinica Universidad
All de14Navarra,
Years and
Universidad
Phase
older
2 Â (Child,
de Navarra|Hospital
Adult,
24 Other
Older Adult)
Clinic of Barcelona|Hospital
CUN-OMALUniversitari Joan XXIII
Incidence ImmunoBiol All 18 Years toPhase
40 Years
1 Â (Adult)36 Industry InterventioAllocation SPV-001|2
Number ofUniversity
d All 18 Years toNot
85 Years
Phase
older
3 Â (Adult,120
Older
Industry
60 Years
12 Weeks
3 Â (Child)
The primary National InAll 18 Years toPhase
65 Years
1 Â (Adult,75Older
PrevalenceCHU de ReAll 18 Years to 85 Years Â (Adult,
101Older
OtherAdult)ObservatioObservatio2018Ao00
60 Years
1 Â (Adult)150 NIH InterventioMasking: DAVEG 022A|10573
Biological: HIV-1 Im National I All 16 Years and
Phase
older
1 Â (Child, Adult,
45 NIH|Indust
Older Adult)
InterventioMasking: DAIEDRP AI-05-006|905
Phase
older
1 Â (Adult, Older
5 Other|Indu
serum antib Ohio StateFemale 18 Years to 26 Years Â (Adult) 191 Other|NIH| ObservatioObservatioOSU-1009
Patients' s Targovax AAll 18 Years toPhase
99 Years
Industry
Adult)InterventioInterventi CT TG01-0
Biological: MF59|BiolNational InAll 18 Years toPhase
60 Years
Determinati Activartis All Child, AdulPhase 1 67 Industry InterventioAllocation TUVAC1
Incidence oHospices CiAll 18 Years and
Notolder
Applic
Â (Adult,289
Older
Other
Find HealthNational InAll 18 Years to 65 Years Â (Adult,
5000Older
Change froDynavax TeAll 18 Years toPhase
55 Years
2 Â (Adult)738 Industry InterventioAllocation DV1-SAR-0
Behavior CUniversity All 13 Years toNot
15 Years
ApplicÂ (Child)
600 Other InterventioAllocation BREATHE
Number ofMerck ShaFemale 9 Years to 26 Phase
Years
3 Â (Child,250
Adult)
- Rate of Boston ChiAll 18 Years and
Notolder
Applic
Â (Adult,700
Older
Adult) 1 R01 CDC
Length veloVital Pakis Female 13 Years toNot 49 Years
ApplicÂ (Child,
957Adult)
Other InterventioAllocation 002-VPT-IR
Tumor Immu Gradalis, InAll 18 Years and
Phase
older
1 Â (Adult, Older
2 Industry
Adult) InterventioInterventi CL-PTL-123
efficacy w Hadassah M All 20 Years toPhase
45 Years
1|PhÂ (Adult) 0 Other InterventioInterventi 0224-13-H
Recommende Hookipa BiAll 18 Years and
Phase
older
1|Ph
Â (Adult,100
Older
Industry
The effect The UniverAll 18 Years and older Â (Adult,750
Older
Other
Adult) ObservatioObservatioUW 13-270
Patients' c Johann WolAll 18 Years toPhase
35 Years
1 Â (Adult) 8 Other InterventioInterventi AVH-2004/
Contaminati French NatMale 18 Years and
Phase
older
3 Â (Adult,400
Older
Other
1. ProportiInternationAll 18 Years toPhase
45 Years
1|PhÂ (Adult)
225 Other InterventioAllocation IAVI C100
sources of Hamad Med All 3 Months to 14 Years Â (Child)
3000 Industry ObservatioObservatio14-00045
Local and AVIR GreenMale 18 Years toPhase
50 Years
2 Â (Adult)49 Industry InterventioAllocation GHB-CS07|
DecreasedUniversity
b All up to 2 Days
NotÂ Applic
(Child) 30 Other InterventioAllocation 15480A|5
Developmen Helmholtz All up to 3 Months Â (Child) 782 Other ObservatioObservatioHelmholtzC
Safety ass Pharmacolo All 50 Years toPhase
85 Years
2 Â (Adult, Older
OtherAdult)InterventioAllocation PRI#585
ProportionObjectif R All 18 Years toNot
70 Years
OtherAdult)InterventioInterventi ORVACS 01
Biological: Hep-V VaxUniversity All Child, AdulPhase 4 80000 Other InterventioAllocation Qidong-HB
Alcohol us University All 11 Years toPhase
13 Years
4 Â (Child)472 Other InterventioAllocation UGA04560
The primarAVIR GreenMale 18 Years toPhase
50 Years
1 Â (Adult)48 Industry InterventioAllocation GHB-CS01|
PercentageFrench NatMale 18 Years and
Notolder
Applic
Â (Adult,500
Older
Other
Adult) InterventioInterventi ANRS 1236
49 Years
1|PhÂ (Child,
341Adult)
HBV seroloYi-Hua ZhoFemale 20 Years toPhase
40 Years
DetermineAugusta UnMale 18 Years and
Phase
older
2 Â (Adult, Older
7 Other
Adult) InterventioAllocation 11C0231
CorrelationInstitut Cu All 18 Years and
Notolder
Applic
Â (Adult, 60
Older
Other
Adult) InterventioInterventi IC 2014-06
Plasma area National InAll 18 Years toPhase
65 Years
1 Â (Adult,75Older
AssessmentPrima BioMAll 18 Years and
Phase
older
2 Â (Adult, Older
0 Industry
Adult) InterventioInterventi CAN-301
ProportionSanofi Pas All 11 Years toPhase
13 Years
4 Â (Child)278 Industry InterventioInterventi RVX01C
Drug: Thalidomide RockefellerAll 18 Years and
Notolder
Applic
Â (Adult, 12
Older
Other
Adult) InterventioPrimary Pu279A
Biological: Env 2-3 National InAll 18 Years toPhase
50 Years
1 Â (Adult)14 NIH|IndustInterventioAllocation AVEG 005C|10548
HealthcareFundaciÃ³ A I ll 65 Years and
Notolder
Applic
Â (Older314
Adult)
Other InterventioAllocation IIBSP-INT-
Healing timUniversity All 18 Years and
Notolder
Applic
Â (Adult,112
Older
Other
Adult) InterventioAllocation ADF01
50 Years
1 Â (Adult)32 NIH|OtherInterventioAllocation HVTN 136/
Number ofSQZ BiotecAll 18 Years and
Phase
older
1 Â (Adult,200
Older
Industry
Adult) InterventioAllocation SQZ-PBMC-
Evaluate MCellid Co., All 19 Years and
Phase
older
1 Â (Adult, Older
9 Industry
Adult) InterventioInterventi BVAC-B-P1
Maternal DBoston Med Female 15 Years and
Notolder
Applic
Â (Child, Adult,
50 Other
Older Adult)
InterventioAllocation Hood-R03
Rates of s Massachuse All 65 Years and
Notolder
Applic
Â (Older Adult)
Tumor ass Oncovir, I All 18 Years and
Phase
older
1|Ph
Â (Adult, 60
Older
Adult) ONC2018-
Measure ofUniversity All 18 Years and
Phase
older
1 Â (Adult, 24
Older
Adult) IRB-30000
The feasibiDana-FarbeAll 18 Years and
Phase
older
1 Â (Adult, 28
Older
Other
Change FroEli Lilly a All 55 Years toPhase
90 Years
3 Â (Adult,
2129Older
Industry
Adult)InterventioAllocation 15136|H8A
New cardioSorlandet All 18 Years toNot
79 Years
ApplicÂ (Adult,
1600Older
OtherAdult)InterventioAllocation S-07041a (
The Compar Virginia C All 40 Years toPhase
70 Years
2 Â (Adult,42Older
Other|Indu
Adult)InterventioAllocation MCC-11561
Change froEli Lilly a All 55 Years and
Phase
older
3 Â (Adult,
1040Older
Industry
Adult) InterventioAllocation 11934|H8
Proactive sAdvantagen Male 18 Years and
Phase
older
2 Â (Adult,187
Older
Industry
Adult) InterventioAllocation PrTK04
Anti-HAV se GlaxoSmithAll 1 Year to 70 Years Â (Child,3658
Adult,
Industry
Older Adult)
ObservatioTime Persp 113564
The proporRegion SkaAll 18 Years and older Â (Adult,600Older
Other|Indu
Adult) ObservatioObservatio2016/220
Choice of aHendrik StMale 18 Years to 55 Years Â (Adult)
4500 Other|InduObservatioObservatioSTIPnet St
ProportionUniversity All 18 Years and older Â (Adult,600Older
Other
Adult) ObservatioObservatioCHUBX 201
Infectivity University All 18 Years toPhase
45 Years
1 Â (Adult)200 Other|InduInterventioInterventi OXTREC 2-
The incidenGadjah Mad All up to 1 Year
Not
Â Applic
(Child) 757 Other InterventioAllocation WT099875_M
Dose-LimitAshutosh KMale 18 Years and
Phase
older
1 Â (Adult, 24
Older
Other|Indu
NY-ESO-1 sLudwig InsAll 18 Years and
Phase
older
1 Â (Adult, Older
9 Other
Objective RTransgene|All 18 Years and
Phase
older
2 Â (Adult, 39
Older
Industry
Adult) InterventioInterventi TG4010.24
Types of adModernaTX, All 18 Years toPhase
49 Years
1 Â (Adult)60 Industry|UInterventioAllocation VAL-18138
Number and Pfizer All 3 Months to 4 Months Â (Child)
242 Industry ObservatioObservatio0887X1-44
Healthy paShanghai HAll 18 Years toPhase
45 Years
1 Â (Adult)35 Industry InterventioAllocation L47-Ib-01
Biological: serotypes King Saud All 3 Months to 5 Years Â (Child)300 Other ObservatioObservatioking Saud u
mortality Bandim Hea All Child, Adult, Older Ad 1258 Other ObservatioObservatioBandimHP
ProportionAnaptysBio, All 18 Years toPhase
75 Years
2 Â (Adult,10Older
Industry
Adult)InterventioInterventi ANB019-00
Treatment University All 18 Years toPhase
60 Years
2|PhÂ (Adult)
2927 Other InterventioAllocation CORTIS-01
ProgressionBaptist He All 18 Years and
Phase
older
2 Â (Adult, 39
Older
Other|Indu
Adult) InterventioInterventi ESR 15 11
Healthy paShanghai HAll 18 Years toPhase
45 Years
1 Â (Adult)48 Industry InterventioAllocation L47-Ia-01
Putting E. Baylor Col All 15 Years toNot
64 Years
ApplicÂ (Child,65
Adult)
Other InterventioAllocation 5R01HD043
aHAV antibMaastrichtAll 18 Years toNot
70 Years
OtherAdult)InterventioAllocation MEC 10-3-
Frequency WCCT GlobAll 18 Years toPhase
49 Years
Improvemen University All 18 Years andPhase
0 Other
Adult) InterventioInterventi HP-000705
developmen Kuopio UnivAll up to 2 Months
Not Applic
Â (Child) 168 Other InterventioAllocation KUH50216
blood immu Jian Suo|FiAll 18 Years toPhase
85 Years
4 Â (Adult,
100Older
OtherAdult)InterventioInterventi omega-3 P
Survival atAssistanceAll 3 Years to 5 Years Â (Child)1750 Other ObservatioObservatioNI 12001
Far Easter All 18 Years to 20 Years Â (Adult)
1800 Other ObservatioTime Persp 96035
Safety|Imm Vaxart Male 18 Years toPhase
49 Years
1 Â (Adult)37 Industry InterventioInterventi VXA02-002
Tolerabilit Affiris AG All 40 Years toPhase
65 Years
1 Â (Adult,32Older
Industry
Adult)InterventioAllocation AFF008|20
Safety|Imm Vaxart Male 18 Years toPhase
49 Years
Change in Queen's Uni All 65 Years toPhase
85 Years
Other InterventioAllocation 06/NIR03/
Adverse efFundaciÃ³nFemale
Salud de los
30 Years
Andes|Universidad
toPhase
65 Years
1|PhÂ (Adult,
Nacional
15Older
Other
de Colombia|Instituto
Colombiano
TEBICA-00
para el Desarrollo de la Cie
Parasitic Novartis P All 18 Years toPhase
55 Years
1 Â (Adult) 8 Industry|OInterventioInterventi CKAE609A
Change FroGlaxoSmithAll 18 Years toPhase
40 Years
4 Â (Adult)16 Industry InterventioAllocation HZA10989
Biological: Detox-B a QLT Inc.|NaAll 18 Years andPhase
older1|Phase
Â (Adult,
2 OlderIndustry
Full adher Joshua SwaAll Child, AdulNot Applic 70 Other|InduInterventioAllocation Pro000225
Difference Radboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)15 Other InterventioAllocation:TIP3
50 Years
Safety andInovio PhaFemale 18 Years toPhase 46 Years
1 Â (Adult)14 Industry InterventioInterventi HPV-002
Change in tUniversity All 18 Years toPhase
64 Years
1 Â (Adult) 6 Other|NIHInterventioInterventi 15-1626|U
Difference London SchAll 6 Months to Not
14Applic
Years Â (Child)
3840 Other InterventioAllocation ITDCZC58
Safety and Inovio PhaFemale 18 Years toPhase 45 Years
1 Â (Adult)18 Industry InterventioAllocation HPV001
Clinical o National InAll 18 Years toPhase
49 Years
To determin Biogen All 40 Years andPhase
Older
Industry
ProportionRadboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)24 Other InterventioAllocation:BMGF2a
Parental SeChildren's All Child, AdulNot Applic 300 Other InterventioAllocation IHS-1403-
oyl-Phosphate SynthaseNational HAll 2 Years to 99 Years Â (Child, Adult,
4 NIHOlder Adult)
Relative efAllergoph All 18 Years toPhase
65 Years
2 Â (Adult,37Older
Industry
Adult)InterventioAllocation AL0903rB|
EvaluationUniversity All 18 Years and older Â (Adult,200Older
Other
Adult) ObservatioObservatioRECHMPL1
Days from Sanaria In All 18 Years toPhase
30 Years
1 Â (Adult)25 Industry|OInterventioAllocation LACHMI-00
Wheal sizeLaboratorioAll 18 Years toPhase
50 Years
2 Â (Adult)31 Industry InterventioInterventi 6041-PR-P
clinical pr Kasr El AinFemale 25 Years toPhase40 Years
2|PhÂ (Adult)
To determin Stanford UnAll 18 Years andPhase
Older
Adult) HEP0002|N
PercentageMCM Vaccin All 3 Years to 5Phase
Years3Â (Child) 754 Industry InterventioAllocation V419-012|
DistributioUMC Utrech All 60 Years and older Â (Adult,240Older
Other|Indu
Adult) ObservatioObservatioVAC52416
To evaluateRockefellerAll 18 Years toPhase
60 Years
1 Â (Adult)24 Other InterventioAllocation MAC-0682
Biological: DCVax-L NorthwestAll 18 Years to 70 Years Â (Adult, Older
Industry
Adult)Expanded Access 0202EA
Primary obUniversity All 18 Years to 65 Years Â (Adult,16Older
OtherAdult)ObservatioObservatio2014-A012
Biological: BCG vacc European OAll Child, AdulPhase 2 97 Other InterventioAllocation EORTC-309
Overall Su NewLink Ge All 18 Years andPhase
Older
Industry
Receipt of University Female 15 Years and Notolder
Applic
Â (Child,
27633
Adult,
Other
Older Adult)
InterventioAllocation BMGF#225
Mean conce Genentech,All 18 Years toPhase
65 Years
1 Â (Adult,60Older
Industry
Adult)InterventioAllocation ACD2244g
To determin University All 18 Years andPhase
2 Other|Indu
Identify p Rochester All 18 Years andPhase
older2|Ph
Â (Adult, 20
Older
Other
Adult) InterventioInterventi CIC1850-A
Rates of v Centers fo All Child, AdulNot Applic 2788 U.S. Fed InterventioAllocation CDC-NCEZI
Number ofAeras|CrucAll 18 Years toPhase
45 Years
The concenSt George'sFemale 18 Years to 40 Years Â (Adult)
500 Other ObservatioObservatio 2019.006
Diameter of University All 18 Years toNot
60 Years
ApplicÂ (Adult)20 Other InterventioInterventi CRC332
Number ofEMD Serono Male 18 Years and
Phase
older
2 Â (Adult, 28
Older
Adult) EMR 63325
Change in Massachuse All 18 Years and
Notolder
Applic
Â (Adult, 11
Older
Other
Changes inLata MedicFemale 18 Years toNot
45 Years
ApplicÂ (Adult)
1036 Other InterventioAllocation 01_BFC
Safety andRockefelle All 18 Years toPhase
60 Years
1 Â (Adult)32 Other|InduInterventioAllocation BYI-0736
Overall tol Rutgers, ThAll 18 Years toPhase
75 Years
OtherAdult)InterventioInterventi CDR00005
To investigNational InAll 12 Months to 59 Months Â 200 (Child)
To evaluateRockefellerAll 18 Years toPhase
60 Years
1 Â (Adult) 6 Other InterventioInterventi MAC-0718
Safety of Aeras All 18 Years toPhase
45 Years
percent chNational ReAll 12 Years and
Notolder
Applic
Â (Child,
3575Adult,
Other
Older Adult)
InterventioInterventi 66187
Study prodBaylor Col All 18 Years toPhase
45 Years
1 Â (Adult)30 Other InterventioAllocation SVI-CH-01
Number ofUMC p Utrech All up to 2 Weeks Â (Child) 10000 Other ObservatioObservatio116019-1
Safety andUniversity All 3 Years to 18
Phase
Years
1 Â (Child, Adult)
15 Other InterventioInterventi UAB 18113
Skin reacti University All 18 Years to 60 Years Â (Adult)15 Other ObservatioTime PerspH14-02324
60 Years
Biological: Recombin Corixa Cor All 18 Years and
Phase
older
1 Â (Adult, Older
9 Industry
Adult) InterventioAllocation CCL5001-0
Induction oUniversity All 18 Years toPhase
65 Years
1 Â (Adult,11Older
OtherAdult)InterventioInterventi TB001
65 Years
OtherAdult)InterventioAllocation RE19_030_
TherapeutiAssistance All 18 Years and
Phase
older
4 Â (Adult,
1024Older
Other
Adult) InterventioAllocation P070312|S
T lymphocyVaccine and All 18 Years and older Â (Adult, 40Older
Other
Adult) ObservatioObservatioHBV-001
Immunologi Lytix Biop All 18 Years and
Phase
older
1 Â (Adult, 12
Older
Industry
Adult) InterventioInterventi C09-315-0
Percent ablCity of HopMale 18 Years and
Phase
older
2 Â (Adult, 51
Older
Adult) 12367|NCI
35 Years
ApplicÂ (Adult)21 Other InterventioAllocation TIP4
Long-term Novartis
s P All 2 Years to 20
Phase
Years
3 Â (Child, Adult)
0 Industry|OInterventioAllocation CACZ885G2
Objective National InAll 16 Years and
Phase
older
2 Â (Child,179
Adult,
NIHOlder Adult)
Tolerabilit Affiris AG All 50 Years toPhase
80 Years
1 Â (Adult,24Older
Industry
Adult)InterventioAllocation Affiris 002
Qualitativ Medical ReAll 15 Years and
Notolder
Applic
Â (Child,214
Adult,
Other
Older Adult)
InterventioAllocation IRS SCC965
Correlatio St. Jude ChAll 1 Year and older Â (Child, Adult,
24 Other|NIHObservatioObservatioiSCREEN
Older Adult)
Area underCrucell Ho All 18 Years toPhase
45 Years
Tolerabilit Affiris AG All 50 Years and
Phase
older
1 Â (Adult, 24
Older
Industry
Adult) InterventioAllocation Affiris 0
levels of c University All 65 Years toPhase
85 Years
Other InterventioAllocation CHU-0160|
Define typhUniversity All up to 14 Years Â (Child) 192 Other ObservatioObservatio445-12 EP
Safety meaBionor Im All 18 Years toPhase
55 Years
1|PhÂ (Adult)36 Industry InterventioAllocation CTN-BI-Va
Number ofIDRI|OswalAll 18 Years toPhase
55 Years
1|PhÂ (Adult)54 Other InterventioAllocation IDRI-LEPVP
Number ofNovavax|De All 18 Years toPhase
49 Years
1 Â (Adult)333 Industry|UInterventioAllocation NVX778.P1
Number ofNovavax|De All 18 Years toPhase
49 Years
1 Â (Adult)333 Industry|UInterventioAllocation NVX778.P1
MTCT ratesSoutheast FUemale 20 Years to 35 Years Â (Adult)
330 Other ObservatioObservatioH201908
Provide in National HAll 2 Years and older Â (Child, Adult,
250 NIHOlder Adult)
Safety|Imm Aeras All 18 Years toPhase
45 Years
Safety & T National InAll 18 Years toPhase
55 Years
efficacy o University Female 18 Years toPhase
50 Years
Number ofSidney KimAll 18 Years and
Phase
older
2 Â (Adult, 66
Older
Other|Indu
Adult) InterventioAllocation J1918|IRB
frequency London SchMale 18 Years toNot
35 Years
ApplicÂ (Adult)19 Other|InduInterventioInterventi SCC 1529
Cytokine AThe UniverMale 18 Years andPhase
older
2 Â (Adult, Older
0 Other
Adult) InterventioInterventi GU-15-103
Cellular c Hospices CiAll 18 Years toNot
75 Years
Cytokine aThe UniverMale 18 Years andPhase
older
2 Â (Adult, Older
0 Other
Adult) InterventioInterventi GU-15-104
5 Years
4 Â (Child)
Drug: Abacavir sulfat National InAll 18 Years andPhase
older
2 Â (Adult, 40
Older
NIHAdult) InterventioAllocation ACTG A5138|AACTG A5138|AC
Complete ev Hadassah M All 18 Years toPhase
65 Years
OtherAdult)InterventioAllocation pepDCIL2-
Biological: recombinaFox Chase All 18 Years andPhase
older
1 Â (Adult, Older
Adult) CDR000006
Change in VA Office All 60 Years toNot
80 Years
Adult) E1203-R|R
child inte Children's All up to 3 DaysPhase
Â (Child)
3 300 Other InterventioAllocation 2001-4-23
Broadly HIVMichael HoAll 18 Years and older Â (Adult,500Older
Other
Adult) ObservatioObservatioLMU-IMPH
Measure thMennoniteAll 18 Years to 85 Years Â (Adult,312Older
OtherAdult)ObservatioObservatioD9902
Checklist oBuckingham All 18 Years toPhase
75 Years
2 Â (Adult,48Older
OtherAdult)InterventioAllocation RXQ/648
The maximu Janssen ReAll 18 Years toPhase
75 Years
1 Â (Adult,76Older
Industry
Adult)InterventioAllocation CR100889|
AttendanceNHS GreateFemale 22 Years toNot
29 Years
ApplicÂ (Adult)
50000 Other InterventioAllocation GN201905
PercentageShenzhen G All 1 Year to 80Phase
Years1|Ph
Â (Child, 100
Adult,
Other
Older Adult)
InterventioInterventi GIMI-IRB-
Distress b Children's All 3 Years to 21 Years Â (Child, Adult)
60 Other ObservatioObservatio2017-0758
Safety andInovio PhaAll 18 Years andPhase
older
1|Ph
Â (Adult, 22
Older
Adult) HPV-005
Severity-adUniversity All 50 Years andPhase
older
2|Ph
Â (Adult,154
Older
Adult) 2009-0075
Identifica Circassia L All 18 Years toPhase
65 Years
1 Â (Adult,10Older
Industry
Adult)InterventioInterventi RES-004
PercentageXing Xie, Female 18 Years to 65 Years Â (Adult,
4000Older
OtherAdult)Observational IISP 40192
Safety of ( Baylor Col All 18 Years andPhase
older
1 Â (Adult, Older
0 Other
Adult) InterventioInterventi 17656|CL
Socio-demo Case Compr All 18 Years to 24 Years Â (Adult) 0 Other|NIHObservatioObservatioCASE11806
Safety of Yisheng Bi All 21 Years toPhase
65 Years
1 Â (Adult,41Older
Industry
Adult)InterventioInterventi YS-RVON-0
The number GlaxoSmithAll Child, Adult, Older Ad 3405 Industry ObservatioTime Persp 114128
National InAll 18 Years to 45 Years Â (Adult)125 NIH Observational HIVNET 028
Primary EffAivita BiomAll 18 Years toPhase
70 Years
2 Â (Adult,55Older
Industry
Adult)InterventioInterventi CL-GBM-P0
National I All up to 21 Years Â (Child, Adult)
4150 NIH Observational ACTG 219C|ACTG 219|PACTG 2
Number Par Nina BhardAll 18 Years toPhase
55 Years
1|PhÂ (Adult)15 Other|InduInterventioAllocation GCO 13-04
ProgressionShanghai Ch All 18 Years andPhase
older
2 Â (Adult, 70
Older
Other|Indu
Adult) InterventioAllocation ILU02
Biological: Tetanus National InAll 13 Years andPhase
older
2 Â (Child, Adult,
0 NIHOlder Adult)
InterventioMasking: DA5069|10905|ACTG A5069|AA
Drug: RSV challenge m National InAll 21 Years toNot
40 Years
ApplicÂ (Adult)13 NIH InterventioAllocation 04-035
Adverse eve Inovio PhaAll 18 Years andPhase
older
1 Â (Adult, Older
Adult) HPV-006
PercentagePfizer|JANAll 50 Years toPhase
85 Years
Industry
ExpressionNational InAll 2 Years and older Â (Child, Adult,
286 NIHOlder Adult)
ObservatioObservatioDAIT ADVN
HPV infectThe HIV NeAll 12 Years to 24 Years Â (Child,27 Adult)
Other ObservatioObservatioHIV-NAT 1
Biological: V930 Merck ShaAll 18 Years andPhase
older
1 Â (Adult, 26
Older
Industry
DetermineBenovus
t Bio
All 18 Years andPhase
older
1 Â (Adult, Older
4 Industry
Adult) InterventioInterventi BBMPI03-
â€¢ circulaUniversity All 3 Months to 5 Years Â (Child)
1300 Other ObservatioObservatioPneumo01
Number ofMaxivax S All 18 Years andPhase
older
1 Â (Adult, 35
Older
Industry
Adult) InterventioInterventi MVX-2011-
Response RNYU LangoAll 19 Years toPhase
80 Years
2 Â (Adult,10Older
National TaFemale 18 Years to 80 Years Â (Adult,300Older
AcceptabilFrench NatFemale 18 Years toNot
45 Years
ApplicÂ (Adult)14 Other InterventioAllocation ANRS VEP
OccurrenceGlaxoSmithAll 1 Month to 15 Years Â (Child)42 Industry ObservatioObservatio 112158
toxicity|t Ontario Cl All 18 Years andPhase
older
1 Â (Adult, Older
8 Other
Adult) InterventioAllocation CTA-Contro
Frequency Genexine, All 20 Years toPhase
60 Years
1 Â (Adult) 9 Industry InterventioAllocation HB110_HB_
Safety: - i FondazioneAll 18 Years toPhase
70 Years
1 Â (Adult,20Older
OtherAdult)InterventioInterventi DENDR-ST
Overall SurPrecision LAll 18 Years toPhase
80 Years
Industry
Adult)InterventioAllocation ICT-107-20
The time ( Johns HopkFemale 16 Years toPhase 49 Years
1|Ph
Â (Child,
170
Adult)
Other InterventioInterventi JHSPH-TDF
Variation Roxall MedAll 18 Years toPhase
60 Years
2 Â (Adult)151 Industry InterventioAllocation BIA-PHL-P
This study St. Jude ChAll 2 Years and older Â (Child, Adult,
129 Other
Older Adult)
ObservatioObservatioXPD10-150
Groups 1 aCelldex Th All 18 Years and
Phase
older
2 Â (Adult,127
Older
Industry
Adverse evPatrice Jic All 18 Years and
Phase
older
1 Â (Adult, 25
Older
Other
Adult) InterventioInterventi IvesTy21a
Detection National InAll 18 Years and older Â (Adult, Older
NIHAdult) ObservatioObservatioHIVNET 019
Clinical e AgentschapAll up to 7 Days Â (Child) 450 Other|InduObservatioObservatioNL.37233.
National InAll up to 25 Years Â (Child, Adult)
1719 NIH ObservatioTime Persp999910155
SeroprotectCrucell Ho All 42 Days to Phase
64 Days
3 Â (Child)400 Industry InterventioAllocation QVX-V-D00
Frequency National
50 Years
Recording Patrice Ji All 18 Years and
Phase
older
1 Â (Adult, 23
Older
Other|Indu
Adult) InterventioAllocation URO-68/11
Haemoglobi Ghana HealAll 6 Months toNot30Applic
Months Â (Child)
872 Other InterventioAllocation 2003/GD/2
Positive orGlaxoSmithAll 65 Years and older Â (Older Adult)
50 Industry ObservatioObservatioBACDU-00
Rate of MajDynavax TeFemale 18 Years to 70 Years Â (Adult, 300Older
Industry
Adult)ObservatioObservatioDV2-HBV-2
Stunting|CZambia CenAll 6 Months toNot12Applic
Months Â (Child)
526 Other InterventioAllocation GCC 0349-
Clinical R National CaAll 18 Years toPhase
66 Years
2 Â (Adult,45Older
Change in OncoQuestFemale 18 Years toPhase 90 Years
1 Â (Adult,10Older
Industry
Adult)InterventioInterventi QPT-ORE-0
Number ofUMC p Utrech All 60 Years and older Â (Adult,
1040
Older
Other
toxicity|t Ontario Cl All 18 Years and
Phase
older
1 Â (Adult, Older
5 Other
Adult) InterventioAllocation CTA-Contro
35 Years
1|Ph
Â (Adult)24 Other InterventioAllocation PbVac
Detailed c Imperial C All Child, Adult, Older Ad 131 Other ObservatioObservatioCRO1367|0
To examineWinthrop UFemale 20 Years to 90 Years Â (Adult, 169Older
OtherAdult)ObservatioObservatio 9316
Safety|ToleEndocyte All 18 Years and
Phase
older
1 Â (Adult, 13
Older
Industry
Adult) InterventioAllocation EC-FI-003
HospitalizaUS Departm All 40 Years and
Phase
older
2 Â (Adult,426
Older
U.S.Adult)
Fed InterventioAllocation 560
CumulativeDendreon Male 18 Years and
Phase
older
2 Â (Adult, 47
Older
Industry
Adult) InterventioInterventi P11-1|201
To evaluateIstituto Superiore
All di SanitÃ
18 Years to 50 Years Â (Adult)24 Other ObservatioTime PerspISS OBS T-
prevalencePierre Van All 6 Months toNot30Applic
Months Â 5000
(Child)
Other InterventioAllocation 15/45/471
Number ofDendreon Male 18 Years and
Phase
older
2 Â (Adult, Older
8 Industry
Adult) InterventioInterventi P10-1
Number ofState Univ All 18 Years toPhase
45 Years
1 Â (Adult) 9 Other|InduInterventioInterventi 2018-01-
Overall SurDendreon All 18 Years and
Phase
older
2 Â (Adult,142
Older
Industry
Adult) InterventioAllocation N10-1
National InAll 50 Years and older Â (Adult,350
Older
NIHAdult) ObservatioObservatio06-0051
AnnualizedSanofi|RegAll 6 Years to 11
Phase
Years
3 Â (Child)402 Industry InterventioAllocation EFC14153|
Number ofJanssen Bi All 18 Years toPhase
55 Years
1 Â (Adult)130 Industry InterventioAllocation JNJ-184-1
Establishi National InAll 18 Years to 55 Years Â (Adult)
450 NIH|OtherObservatioObservatio999907141
To provide National CaAll 18 Years and older Â (Adult,750
Older
Increase inSidney KimAll 21 Years toPhase
99 Years
2 Â (Adult,40Older
Adult) J1247|2P5
Pf expressiNational InAll 3 Months to 40 Years Â (Child,
1600Adult)
Number ofDendreon Male 18 Years and
Phase
older
2 Â (Adult,104
Older
Industry
Adult) InterventioInterventi P09-1
Phase
older
2 Â (Adult,122
Older
Industry
Change in Fred HutchAll 18 Years toPhase
65 Years
2 Â (Adult, 5Older
OtherAdult)InterventioInterventi 8589|STUD
Descriptio MedImmunAll up to 12 Months
Phase 2Â (Child) 118 Industry InterventioAllocation MI-CP141
Estimate thNational InAll 18 Years to 65 Years Â (Adult, 3Older
Drug: Aldesleukin National InAll 18 Years and
Phase
older
2 Â (Adult,104
Older
NIHAdult) InterventioInterventi ACTG 248|11225
To evaluateBavarian NMale 18 Years toPhase
75 Years
1 Â (Adult,24Older
Industry
Adult)InterventioAllocation BNIT-PR-0
PrevelanceAssiut UnivAll 1 Year to 18 Years Â (Child, 201
Adult)
Other ObservatioObservatioPrev TM
Recording o Cadila PhaAll 18 Years and
Phase
older
1|Ph
Â (Adult, 20
Older
Industry
Adult) InterventioAllocation CR-60/405
PreventiveOregon Hea All 19 Years to 64 Years Â (Adult)
308283 Other|NIHObservatioObservatioIRB000073
Area UnderHvivo All 18 Years toNot
64 Years
ApplicÂ (Adult)46 Industry InterventioAllocation RVL-vCS-0
To assess University All 2 Months to 6 Years Â (Child)35 Other ObservatioObservatio2013/01
Number ofPATH|UniteAll 18 Years toPhase
49 Years
1 Â (Adult)56 Other|U.S.InterventioAllocation VAC-048
ParticipantMJM Bonten All 60 Years and older Â (Adult,6000
Older
Other|Indu
Adult) ObservatioObservatioVAC52416
National InAll 18 Years and older Â (Adult,111Older
NIHAdult) Observational 999904009
Cohort 1 aJanssen ReAll 60 Years and
Phase
older
1|Ph
Â (Adult,
1004
Older
Industry
Child-HBsANational TaFemale 20 Years toPhase 40 Years
Incidence oCity of Ho All 12 Years toPhase
75 Years
Other|NIH|
Older IAdult)
nterventioAllocation 13384|NCI
The Median All India I All Child, AdulNot Applic 41 Other InterventioAllocation dranuthukr
Primary obWyeth is nAll 18 Years toNot
25 Years
ApplicÂ (Adult)87 Industry InterventioAllocation 6108A1-10
Safety on fIRCCS San All up to 12 Years Â (Child) 50 Other ObservatioObservatioBIOGN1
80 Years
1 Â (Adult,36Older
Adult) 4B-16-3|N
AcceptanceNational DMale 16 Years toNot
29 Years
ApplicÂ (Child,
1166Adult)
Other|NIHInterventioInterventi R01DA033
The rate o Qin Ning|TAll 18 Years to 65 Years Â (Adult,
1600Older
OtherAdult)ObservatioObservatioOCEAN stu
monitor the National TaAll up to 5 Years Â (Child) 5040 Other ObservatioObservatio201310064
Dose limit City of HopAll 18 Years and
Phase
older
1 Â (Adult, 36
Older
Adult) 19309|NCI
Drug: VariZIGâ„¢ Cangene Co All Child, Adult, Older Adult Industry Expanded Access VZ-009
Incidence oJonsson CoAll 18 Years and
Phase
older
1 Â (Adult, 12
Older
Adult) 12-000577
Evaluate t University All 18 Years toPhase
60 Years
Serotype pAmerican UAll Child, Adult, Older Ad 300 Other ObservatioObservatioPNEUMOSu
Response Ra Endocyte All 18 Years and
Phase
older
2 Â (Adult, 12
Older
Industry
Adult) InterventioAllocation EC-FI-004
ProgressionOxford Bi Male 18 Years and
Phase
older
2 Â (Adult, 25
Older
Adult) TV2/001/0
Viral Shed WCCT Globa All 18 Years toPhase
45 Years
1 Â (Adult)35 Industry|OInterventioAllocation WCCTG 14-
Phase 1: DNewLink Ge All 16 Years and
Phase
older
1|Ph
Â (Child,160
Adult,
Industry
Older Adult)
InterventioAllocation NLG2102
Identificat Hillel Yaf All up to 65 Years
Not ÂApplic
(Child, Adult,
330Older
OtherAdult)InterventioAllocation 0105-11-
AssessmentGlaxoSmithAll up to 1 Year Â (Child) 1 Industry|OObservatioObservatio 200158
Clearance oLaboratoir All 18 Years toPhase
60 Years
2 Â (Adult)78 Industry InterventioAllocation ADNC-072
Mean chang University All 18 Years and
Notolder
Applic
Â (Adult,727
Older
Other
PrevalenceHospices CiAll 18 Years to 65 Years Â (Adult,75Older
OtherAdult)ObservatioObservatio69HCL16_0
varicella z National I All 60 Years toPhase
90 Years
NIH Adult)InterventioAllocation AG0029|R
Improvemen NambudripAll 3 Years to 10
NotYears
Applic
Â (Child) 48 Other InterventioAllocation Multiclini
Well-Child Yale Unive Female 25 Years toNot 35 Years
ApplicÂ (Adult)
Gene expreUniversity Allof Sao Paulo|FundaÃ§Ã£o
18 Years and
Notolder
Applic
de ÂAmparo
(Adult,Ã60
Older
Pesquisa
Other
Adult)
doInterventioAllocation
Estado de SÃ£o PauloFAPESP:20
The incide Icahn SchoAll 18 Years toPhase
70 Years
1 Â (Adult,25Older
Safety, fea AGO StudyFemale Child, AdulPhase 1|Ph 36 Other InterventioAllocation AGO-OVAR
Bates-JensAntria All 18 Years and
Phase
older
1 Â (Adult, 40
Older
Industry
Adult) InterventioInterventi CW0001
BiomedicalAll 1 Year to 10 Years Â (Child) 410 Other ObservatioObservatioEPLS08-JBS
Western GaAll 18 Years to 80 Years Â (Adult, 0Older
OtherAdult)ObservatioObservatio0025-12-NHR
Disease-FreVaccinogenAll 18 Years and
Phase
older
3 Â (Adult,550
Older
Industry
Adult) InterventioAllocation ASI-2005-0
Immune res University All 35 Years to 49 Years Â (Adult)97 Other ObservatioObservatio2017-0512
Drug: Lopinavir/Rito National InAll Child, AdulNot Applic 22 NIH InterventioMasking: NA5136|10680|ACTG A5136|AA
DetermineBinex All 19 Years toPhase
80 Years
Industry
Adult)InterventioAllocation BX-TK-002
Symptom sc LaboratorioAll 18 Years toPhase
55 Years
Self adminMadinah SaAll 22 Years and
Notolder
Applic
Â (Adult, 66
Older
Other
Adult) InterventioAllocation SBCMM00
Rate of mem Assistance All 18 Years and
Notolder
Applic
Â (Adult,600
Older
Other
Adult) InterventioAllocation K100104J
Number ofKaitlyn KelAll 18 Years and
Phase
Older
Other|Indu
PercentageHoffmann-All 12 Years toPhase
64 Years
3 Â (Child,
3160Adult)
Industry InterventioAllocation MV40618|2
1. Safety National TaFemale 18 Years toPhase
75 Years
1 Â (Adult,12Older
Percent HIVUniversity Female 18 Years toPhase
49 Years
1 Â (Adult)50 Other InterventioInterventi UTorontoB
ProgressionCelldex Th All 18 Years and
Phase
Older
Industry
Adult) InterventioInterventi CDX110-00
Disease-freGliknik Inc.All 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation GL0817-01
99 Years
Industry
Adult)InterventioInterventi D8860C00
Incidence Agence de All Child, Adult, Older Ad 2000 Other|InduObservatioObservatioPneumoTo
Efficacy of Aimmune Th All 4 Years to 17
Phase
Years3 Â (Child)175 Industry InterventioAllocation ARC010
Infectious National InAll 18 Years toPhase
49 Years
65 Years
1 Â (Adult,24Older
Complete re National CaAll 18 Years and
Phase
Older
Secondary University All 18 Years and older Â (Adult,700 Older
Other
Adult) ObservatioObservatioKEK-ZH-Nr.
Measurement Hospices CiAll 18 Years and older Â (Adult, 34 Older
Other
OccurrenceNantes UniAll 18 Years and
Phase
Older
Other
Adult) InterventioAllocation RC14_005
Safety and Circassia L All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation CP001
adverse evLudwig InsAll 18 Years and
Phase
9 Other
Adult) InterventioAllocation LMT2004-0
Incidence University All 18 Years toNot
50 Years
ApplicÂ (Adult) 2 Other InterventioInterventi VAC068|22
Total Rhin Circassia L All 18 Years toPhase
65 Years
Adult) CP005
65 Years
Adult) TR002
Frequency National
50 Years
Best OveraOncoSec Me All 18 Years and
Phase
4 Industry
Adult) InterventioInterventi OMS-I130
DeterminatBoston BioAll 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation BBI-DSP78
overall surCure&SureAll 18 Years toPhase
75 Years
Adult) CS-TT-G-02
Adverse eve Mayo ClinicAll 18 Years and
Phase
Older
Adult) MC1023|NC
Change froCircassia L All 18 Years toPhase
65 Years
Industry
Best OveraOncoSec Me All 18 Years and
Phase
Older
Industry
Adult) InterventioAllocation OMS-I100|
AssessmentBarbara Ensoli,
All MD|Istituto
18 YearsSuperiore
and older
di ÂSanitÃ
(Adult,142
Older
Other
Adult) ObservatioTime PerspISS OBS T-
Combined Roxall
Sy MedAll 5 Years to 60 Years Â (Child,150Adult)
Industry ObservatioObservatioROX-ALE-2
Area underNational InAll 18 Years toPhase
45 Years
Lower RespPulmotect,All 18 Years toPhase
75 Years
2 Â (Adult,20Older
Adult) PUL-042-4
Number ofThe p First All 18 Years toPhase
80 Years
Other|Indu
Adult)InterventioInterventi Neo-MASC
Overall Su Heat BiologAll 18 Years and
Phase
Older
Industry
To provideSanofi All 2 Years to 14 Years Â (Child)1500 Industry ObservatioObservatioCYD34|U11
Visit by L Aga Khan UAll up to 28 Days
NotÂApplic
(Child) 1200 Other|U.S.InterventioAllocation 770-Ped/E
prevalenceUniversity All 18 Years and older Â (Adult, 22 Older
Other
Adult) ObservatioObservatioIRECT-01
Area UnderJanssen ScAll 18 Years toPhase
45 Years
The occurrNational InAll 18 Years toPhase
45 Years
Serum Drug IWK HealthAll 18 Years toNot
55 Years
ApplicÂ (Adult)20 Other|InduInterventioAllocation RC91
Pain Inten Istanbul SaAll 7 Years to 12
NotYears
Applic
Â (Child)120 Other InterventioAllocation 10840098-
Adverse evTasly Tianj All 18 Years toPhase
65 Years
1 Â (Adult,36Older
Industry
Adult)InterventioAllocation TC-2017-0
Procedure: Historical HaEmek Med All up to 40 Years Â (Child, Adult)
200 Other ObservatioObservatio4140905.
Incidence Rutgers, ThAll 18 Years and
Phase
older
1 Â (Adult, 30
Older
Adult) 091804|NC
Tumor respMayo ClinicAll 18 Years and
Phase
older
1|Ph
Â (Adult, 39
Older
Adult) MC1771|NC
changes inImmunitorAll 18 Years and
Phase
older
3 Â (Adult,120
Older
Industry
Adult) InterventioAllocation Immunitor
Diagnosis MelbourneAll 4 Years to 30
Phase
Years
2 Â (Child,110
Adult)
Other InterventioAllocation INIT II
Maximum-to National CaAll 18 Years and
Phase
older
1 Â (Adult, 30
Older
65 Years
2 Â (Adult,48Older
Industry
Overall resMemorial SAll 18 Years and
Phase
older
1|Ph
Â (Adult, 27
Older
Other|Indu
Biological: rindopepi Celldex Th All 18 Years and older Â (Adult, OlderIndustry
Adult) Expanded Access:InteCDX110-05
Number ofTakeda All 6 Months toPhase
19 Years
1|PhÂ (Child,
99Adult)
Industry InterventioAllocation TAK-850/C
A signific Radboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)15 Other InterventioAllocation EHMI-8B
Changes inImmunitorFemale 18 Years toPhase
65 Years
2 Â (Adult,20Older
Industry
Adult)InterventioInterventi V3-Cervix-
Identifica Circassia L All 18 Years toPhase
65 Years
1 Â (Adult,10Older
Industry
Adult)InterventioAllocation RES-003
Overall SurCelldex Th All 18 Years and
Phase
older
3 Â (Adult,745
Older
Industry
Organ specUniversity All 18 Years toNot
65 Years
OtherAdult)InterventioInterventi ZU-HypoCa
Apparent cNational InAll 18 Years toPhase
70 Years
1 Â (Adult,48Older
45 Years
CD4 cell inSt. MichaelFemale 19 Years and older Â (Adult, 98
Older
Other
Fractional Swiss FederFemale 18 Years to 49 Years Â (Adult)50 Other ObservatioObservatioSMILE Stud
Aluminum Centre
c HospMale 18 Years and older Â (Adult, 80
Older
Other
Adult) ObservatioObservatio1708031|2
Number ofGeorgetowAll 18 Years and
Phase
older
2 Â (Adult, 11
Older
Other|Indu
Dose LimitM.D. AnderFemale 18 Years toPhase
75 Years
1 Â (Adult,18Older
Adult) 2016-0400
Change in GemVax & Male 50 Years and
Phase
older
3 Â (Adult,417
Older
Industry
Adult) InterventioAllocation KG8/2019
Phase
older
4 Â (Adult,
1152
Older
Industry
Cervical in National CaFemale 18 Years to 100 Years Â (Adult,
27084 Older
NIH Adult) ObservatioObservatio999917098
European Qu National UnAll 21 Years and
Notolder
Applic
Â (Adult,140
Older
Other
Incidence Roswell ParAll 18 Years and
Phase
older
1 Â (Adult, 18
Older
Other|NIH|
Adult) InterventioInterventi I 49217|N
evaluationNantes UniFemale 18 Years and
Phase
older
1|Ph
Â (Adult, 23
Older
Other|Indu
Adult) InterventioInterventi BRD/10/04
45 Years
complianc London SchFemale 15 Years toNot
45 Years
ApplicÂ (Child,
11523 Adult)
Other InterventioAllocation PD 010607
Detection GlaxoSmithAll 65 Years and older Â (Older Adult)
GenerationInstitut Pa All 18 Years and older Â (Adult, 70
Older
Industry|OObservatioObservatio2017-036
Adult)
50 Years
Effect on t ImmunitorAll 5 Years to 99
Phase
Years
2 Â (Child, Adult,
20 Industry
Older Adult)
InterventioInterventi Imm008
Developmen PX BiosoluAll 18 Years to 70 Years Â (Adult,15Older
Industry
Adult)ObservatioObservatioPX_DCtagT
Symptom sc LaboratorioAll 12 Years toPhase
50 Years
Industry InterventioAllocation 2006-0014
Total Rhin Circassia L All 18 Years to 65 Years Â (Adult,84Older
Industry
Adult)ObservatioObservatioTG002B
Evaluation University All 18 Years and older Â (Adult,355
Older
Other
Assess theAllergy Th All 18 Years toPhase
50 Years
Total Rhin Circassia L All 18 Years to 65 Years Â (Adult,
163Older
Industry
Adult)ObservatioObservatioTG002a
AdherenceNYU LangoAll 18 Years toNot
85 Years
ApplicÂ (Adult,
1200Older
OtherAdult)InterventioAllocation Calendow
DeterminatNationwideAll 18 Years and
Phase
older
1 Â (Adult, Older
2 Other
Phase
older
1 Â (Adult, Older
Partial Ar University All 18 Years toPhase
45 Years
4 Â (Adult)10 Other|U.S.InterventioAllocation HP-000598
Number and Roxall MedAll 18 Years toPhase
60 Years
1 Â (Adult)52 Industry InterventioAllocation BIA-OLEAP
65 Years
Industry
Adult)InterventioAllocation TG002
Measuremen University All 18 Years toPhase
45 Years
4 Â (Adult)10 Other|U.S.InterventioInterventi HP-000591
Maximum-to Cell GenesAll 18 Years and
Phase
older
1 Â (Adult, 75
Older
Industry
Adult) InterventioAllocation V-0046
AssessmentAllergy Th All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation RagweedM
Safety|Imm IDRI|RockefAll 18 Years toPhase
50 Years
1 Â (Adult)17 Other InterventioAllocation MCA-0784
Change froUniversity Female 18 Years and
Phase
older
1|Ph
Â (Adult, 32
Older
Other
Adult) InterventioAllocation HomeTech h
Safety andCircassia L All 18 Years toPhase
65 Years
2 Â (Adult,50Older
Industry
Adult)InterventioAllocation TR001
Assess dif RockefellerAll 18 Years and older Â (Adult,156
Older
Other
Adult) ObservatioObservatioAHU-0759
National InAll Child, Adult, Older Ad 550 NIH ObservatioTime Persp05-0082
Evaluate s Amal TheraAll 18 Years and
Phase
older
1|Ph
Â (Adult, 32
Older
Industry
Adult) InterventioAllocation KISIMA-01
65 Years
2 Â (Adult,50Older
Industry
Adult)InterventioAllocation TG001
Incidence rEVO BioloAll 18 Years toPhase
70 Years
3 Â (Adult,14Older
Industry
Adult)InterventioInterventi GTC AT III
Objective OncoSec Me All 18 Years and
Phase
older
2 Â (Adult, Older
2 Industry
Adult) InterventioInterventi OMS-I120
50 Years
Host respoImperial C All 18 Years toNot
55 Years
ApplicÂ (Adult)40 Other InterventioAllocation JROSM012
clearance First HospiFemale 18 Years toNot
65 Years
ApplicÂ (Adult,
940Older
OtherAdult)InterventioAllocation HH201706
Incidence PrimeVax IAll 18 Years and
Phase
older
1 Â (Adult, 10
Older
Adult) PV001-001
Number ofHospices
c CiAll up to 4 Days Â (Child) 5000 Other ObservatioObservatioPRSVH_20
Phase
older
3 Â (Adult, 34
Older
Industry
Weekly occu GlaxoSmithAll Child, Adult, Older Ad 1 Industry ObservatioTime Persp 117233
Immunogeni Wyeth is nAll 18 Years toPhase
25 Years
1 Â (Adult)73 Industry InterventioInterventi 6108A1-10
ProportionRevance ThAll 18 Years toPhase
75 Years
Industry
ProportionRevance ThAll 18 Years toPhase
75 Years
Industry
The changeUniversity All 65 Years and
Notolder
Applic
Â (Older Adult)
60 Other InterventioAllocation B2018:029
to assess Allergy Th All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation RagweedM
Adverse EvGradalis, InAll 2 Years andPhase
22 Industry
Older Adult)
InterventioInterventi CL-PTL-121
Feasibility NYU Langon All 18 Years and
Phase
older
4 Â (Adult, 11
Older
Other
Incidence University All 2 Years andNot
older
Applic
Â (Child,
15730
Adult,
Other
Older Adult)
InterventioAllocation 18-01-437
National InAll 6 Weeks to 6 Months Â (Child)600 NIH ObservatioTime Persp999907198
Drug: Bacteriophage National InAll Child, AdulPhase 2 5 NIH InterventioPrimary Pu000006|00
injection NorwegianAll 30 Years toPhase
70 Years
2 Â (Adult,15Older
Other|Indu
Adult)InterventioInterventi GADinLADA
Safety|Imm Advantagen All 18 Years and
Phase
older
1 Â (Adult, 12
Older
Adult) LuTK01
EvaluationMassachuse All 18 Years and
Notolder
Applic
Â (Adult, 20
Older
Other
Adult) InterventioInterventi 2018-P000
Incidence oTychan PteAll 21 Years toPhase
60 Years
1 Â (Adult)28 Industry|OInterventioAllocation ZKT-002|C
Incidence Tychan PteAll 21 Years toPhase
45 Years
1 Â (Adult)24 Industry|OInterventioAllocation ZKT-001
To determiCynthia S Female 18 Years and older Â (Adult,487
Older
Other|Indu
Adult) ObservatioObservatioMerck P08
Changes inUniversity Female 18 Years toNot
45 Years
ApplicÂ (Adult)
300 Other|InduInterventioAllocation HS19749(B
6 months Pr Centre HosAll 18 Years and
Phase
older
2 Â (Adult,108
Older
Other|Indu
Adult) InterventioAllocation P/2019/45
1.proportioUniversite Female 18 Years toNot
65 Years
OtherAdult)InterventioAllocation 2414VV
HPV PrevalThe AlfredMale 16 Years to 20 Years Â (Child,
200Adult)
Other|InduObservatioObservatioMSHC-174
Viral copy University All 10 Years and older Â (Child,178
Adult,
Other|U.S.ObservatioObservatio017086-00
Older Adult)
ProgressionNorthwell All 18 Years and
Phase
older
2 Â (Adult, 37
Older
Other
Adult) InterventioInterventi HS16-0181
Mortality|Jena UniveAll Child, Adult, Older Ad 150 Other ObservatioObservatioZKSJ0065
Hemoglobin William BeAll 18 Years toNot
75 Years
At least 1 Virginia C All 18 Years and
Notolder
Applic
Â (Adult, 22
Older
Adult) MCC-10395
Maximum Roswell
tol ParFemale 18 Years and
Phase
older
1|Ph
Â (Adult, 62
Older
Other|NIH|
National InAll up to 99 Years Â (Child, Adult,
20610Older
NIH Adult)ObservatioTime Persp05-0124
Visual Acu NeurotechAll 21 Years and
Phase
older
1 Â (Adult, Older
Adult) NTMT-01
65 Years
Adult) TH002
Types, fre ModernaTX, All 18 Years toPhase
64 Years
1 Â (Adult)201 Industry InterventioAllocation VAL-50644
95 Years
OtherAdult)InterventioInterventi B2018:029
The Anti-t Icahn SchoAll 18 Years and
Phase
older
2 Â (Adult, 10
Older
Other|Indu
None, we isNational TaFemale 25 Years toNot
45 Years
ApplicÂ (Adult)50 Other InterventioInterventi 200706003
PrevalenceHospices CFemale 18 Years and
Notolder
Applic
Â (Adult, 85
Older
Other
Safety|Prog Advantagen All 18 Years and
Phase
older
1 Â (Adult, 19
Older
Adult) MpeTK01
Serum for Cangene Co All 18 Years toPhase
55 Years
1 Â (Adult)40 Industry|UInterventioAllocation AA24424 B
60 Years
1 Â (Adult) 9 NIH InterventioAllocation 180113|18
improvemen Winthrop UAll 40 Years and
Notolder
Applic
Â (Adult,120
Older
Other
ProportionFrench NatFemale 18 Years toPhase
50 Years
4 Â (Adult)933 Other InterventioInterventi ANRS 1234
To identifySt. Jude ChAll up to 18 Years Â (Child, Adult)
13201 Other|NIHObservatioObservatioSIVFRC|N0
Continued National InAll 18 Years and older Â (Adult,
1000
Older
NIHAdult) ObservatioObservatio999919074
To establisFukushimaAll 20 Years and
Phase
older
1|Ph
Â (Adult, 20
Older
Other
Analysis o National InAll 18 Years toPhase
45 Years
1 Â (Adult)60 NIH InterventioAllocation 07-0053|M
Biological: FSME-IM Pfizer All 18 Years toPhase
67 Years
Industry
Overall surSotio a.s. Male 18 Years and
Phase
older
3 Â (Adult,
1170
Older
Industry
Adult) InterventioAllocation SP005|201
40 Years
1 Â (Adult)37 NIH InterventioAllocation 05-0053|M
Change in sQualiCCareAll Child, Adult, Older Ad 738 Other|InduObservatioObservatioQualiCCare
To compareNational InAll 18 Years toNot
64 Years
ApplicÂ (Adult)95 NIH InterventioAllocation 180139|18
V Seronegativity|SyphiNational InMale 18 Years and older Â (Adult,250
Older
NIHAdult) Observational HPTN 036
HPV type|VUniversity All 18 Years and older Â (Adult,141
Older
Other
Adult) ObservatioObservatio2/084/13
Incidence Kirby Inst All 18 Years and
Phase
older
3 Â (Adult,900
Older
Other
Adult) InterventioInterventi HEPP1701
Incidence, Revance ThAll 18 Years and
Phase
older
3 Â (Adult,
2691
Older
Industry
Changes inCentre for Female 18 Years toNot
40 Years
ApplicÂ (Adult)
267 Other|NIHInterventioInterventi CAPRISA 0
Safety as Xencor, IncAll 18 Years and
Phase
older
1 Â (Adult,145
Older
Industry
Adult) InterventioInterventi XmAb1404
National InAll 2 Years to 60 Years Â (Child,400
Adult)
NIH ObservatioTime Persp06-0045
Case WesterAll 1 Month and older Â (Child,445Adult,
Other|NIHObservatioTime
Older Adult) Persp04-110
CompletionFrench NatFemale 18 Years and
Notolder
Applic
Â (Adult,500
Older
Other
Adult) InterventioInterventi ANRS 1238
To compareNational InAll 18 Years to 99 Years Â (Adult,10Older
Time to fir Papua NewAllG 5 Years to 10
Phase
Years
4 Â (Child)524 Other InterventioAllocation: 7200734
Number ofColumbia
a UFemale 18 Years toPhase
85 Years
Adult) AAAA9722
60 Years
1 Â (Adult)38 NIH|U.S. FInterventioAllocation 160119|16
Military MyNational InAll 18 Years to 90 Years Â (Adult,
300Older
Pre- and p National InMale 21 Years toNot
30 Years
ApplicÂ (Adult)29 NIH InterventioInterventi 11704
Safety andCircassia L All 18 Years toPhase
65 Years
2 Â (Adult,50Older
Industry
Adult)InterventioAllocation TH001
To characteNational InAll 18 Years to 100 Years Â (Adult,
200 Older
NIH Adult) ObservatioObservatio150154|15
Expand theAdvantagen All 18 Years and
Phase
older
2 Â (Adult, 52
Older
Industry
Adult) InterventioInterventi BrTK02
DetermineNational
t InAll 18 Years toPhase
50 Years
National InAll 6 Weeks and older Â (Child,
20000
Adult,
NIHOlder Adult)
ObservatioTime Persp06-0013
National InAll up to 12 Months Â (Child) 550 NIH ObservatioTime Persp06-0081|Fi
National InAll 1 Year to 5 Years Â (Child) 300 NIH ObservatioTime Persp04-027
Selection LaboratorioAll 1 Year to 10Phase
Years1Â (Child) 15 Industry|OInterventioInterventi AR-RACO-1
To determiWesley Med All Child, AdulNot Applic 153 Other|InduInterventioInterventi 09-068
National InAll 5 Years to 15 Years Â (Child)2193 NIH ObservatioTime Persp05-0093
The AntireCentre for Female 18 Years andNotolder
Applic
Â (Adult, 59
Older
Other
Adult) InterventioAllocation CAPRISA 0
A signific Radboud Un All 18 Years toNot
35 Years
ApplicÂ (Adult)15 Other InterventioAllocation:TIP1
Virologic University All 18 Years andPhase
older
4 Â (Adult,152
Older
Other
Adult) InterventioAllocation P03-0051|
ccal Carriage University All Child, Adult, Older Ad 1000 Other ObservatioObservatioSMRU_09-2
Maternal, pNational InAll up to 45 Years Â (Child, Adult)
airborne emWake ForesAll 18 Years and older Â (Adult, 29Older
Other
To determinNational InAll 18 Years toPhase
75 Years
NIH|Indust
Biological: M-M-Râ„ Merck ShaAll 12 MonthsPhase
to 18 Months
3 Â 752
(Child)
50 Years
1|PhÂ (Adult)74 NIH InterventioAllocation 130215|13
Procedure: surgical French NatFemale 18 Years to 65 Years Â (Adult,676Older
OtherAdult)ObservatioObservatio2007-A007
The combineBarnes-JewAll 18 Years toNot
64 Years
ApplicÂ (Adult)
428 Other InterventioAllocation 2.01E+08
Efficacy:|TAlbert Sch All up to 5 Months
PhaseÂ4 (Child) 1189 Other InterventioAllocation 28574
National InAll 18 Years to 60 Years Â (Adult)100 NIH ObservatioObservatio5R01AI047
Number ofNational HeAll 18 Years toPhase
75 Years
2 Â (Adult,10Older
CompositeWright StaAll 18 Years toPhase
65 Years
2 Â (Adult,99Older
Other|Indu
Adult)InterventioAllocation 183-09-FB
Treatment Internatio All 2 Months to Not
5 Years
ApplicÂ (Child)
Primary OuChildren's All 5 Years to 17
Phase
Years
1 Â (Child) 10 Other InterventioAllocation APP-18-00
Rate of pn Liverpool All 18 Years and older Â (Adult, 38Older
Other
Adult) ObservatioObservatio 1E+08
75 Years
4 Â (Adult,63Older
Adult) DAIT ARA0
National CaAll 21 Years and older Â (Adult, Older
0 NIHAdult) Observational 999905237
The rate o Beijing Dit All 1 Year to 3 Years Â (Child) 400 Other ObservatioObservatioZ14110700
Incidence aNational InAll 18 Years toPhase
50 Years
DetermineNational HeAll up to 20 Years
Phase
Â 2(Child, Adult)
48 NIH|OtherInterventioAllocation 551|P50HL
To documentImperial C All 18 Years toNot
60 Years
ApplicÂ (Adult)
112 Other InterventioAllocation 13SM1837
Amount ofCentre for All 18 Years toPhase
45 Years
1|PhÂ (Adult)24 Other InterventioAllocation CHDR1807
Tissue acquNational CaAll up to 75 Years Â (Child, Adult,
214Older
Change in VIRxSYS CoAll 18 Years toPhase
65 Years
2 Â (Adult,60Older
Industry
Adult)InterventioAllocation VRX496-US
1. IncidencLondon SchAll 2 Months to Phase
24 Months
2|Ph Â 2419
(Child)
Other InterventioAllocation ITDCVF01
Obtain histSt. Jude ChAll Child, Adult, Older Ad 100 Other ObservatioObservatioGENEFU
Number ofFred HutchAll 1 Year and Phase
older Â1|Ph
(Child, Adult,
7 Other
Older Adult)
InterventioAllocation 2323.00|6
Number ofDenver HeaAll 17 Years andNotolder
Applic
Â (Child,762
Adult,
Other
Older Adult)
Absorbed dUniversity All 18 Years toEarly
55 Years
PhasÂ (Adult) 6 Other InterventioInterventi 2017-0100
Maternal rUniversity Female Child, Adult, Older Ad 7967 Other ObservatioObservatioB9RUHL0
To assess tUniversity All 18 Years andNotolder
Applic
Â (Adult, Older
0 Other|Indu
Adult) InterventioAllocation IRB#06111
Time to OcGlaxoSmithAll 18 Years andPhase
older
2 Â (Adult,137
Older
Industry
Episodes oNational InAll 6 Months to 99 Years Â (Child,
1650Adult,
NIH OlderObservatioObservatio999911050
Adult)
Number ofUniversity
g All Child, Adult, Older Ad 200 Other ObservatioObservatioGENIGASU
Airway reacRambam He All 4 Years to 7 Years Â (Child) 42 Other ObservatioObservatioEvaluation
49 Years
1|PhÂ (Adult)
110 Industry InterventioAllocation TAK-850/C
Incidence aNational InAll 18 Years toPhase
50 Years
OscillationUniversity All 18 Years toNot
65 Years
OtherAdult)InterventioInterventi I16037 (M
Immune res University All 18 Years to 60 Years Â (Adult)30 Other|InduObservatioObservatio2011/08
Safety and National HeAll 18 Years andPhase
Older
Biological: DC RCC-R National C All 18 Years andPhase
NIH|OtherInterventioPrimary
Adult) PuNCRR-M01RR00030-0153|M01
To establi Sidney KimAll 18 Years andPhase
Older
Other
Adult) InterventioInterventi 11G.532
Change of N f IZO FoodAll 18 Years toNot
55 Years
49 Years
Other InterventioAllocation MAC_001|2
Number ofFundacion All up to 1 Month
Not Applic
Â (Child) 300 Other InterventioAllocation INFANT-001
Developmen University All 18 Years toPhase
50 Years
1 Â (Adult)16 Other|U.S.InterventioAllocation CHRMS 10-
Safety|Inf Immune Tar All 18 Years toPhase
45 Years
1 Â (Adult)29 Industry InterventioAllocation H1N1_CS_
National InAll 18 Years and older Â (Adult, 89Older
Number ofSotio
P a.s. Male 18 Years andPhase
Older
Industry
Area underUniversity Female 16 Years toPhase
49 Years
Other InterventioInterventi VIR19001
Biological: BCG vacci NSABP Foun All up to 79 Years
Phase
Â 3(Child, Adult, Older
Adult) PuCDR000007
ecurrent StaphylococcalNational InAll 2 Years and older Â (Child, Adult,
22 NIHOlder Adult)
Institut N All 18 Years to 60 Years Â (Adult)40 Other ObservatioObservatioC11-33|20
National InAll 13 Years to 18 Years Â (Child,356Adult)
NIH ObservatioTime Persp080032|08
To evaluateUniversity All 18 Years toNot
90 Years
ApplicÂ (Adult,
2017Older
OtherAdult)InterventioAllocation INFZ-ZPHI-
Total daily NIZO FoodMale 20 Years toNot
55 Years
ApplicÂ (Adult)40 Other|InduInterventioAllocation N132716.0
Overall Re National CaAll 18 Years toPhase
99 Years
2 Â (Adult,16Older
National InAll 2 Years and older Â (Child, Adult,
870 NIHOlder Adult)
Observational 000125|00
Success wilAssistance All 6 Months to Phase
15 Years
3 Â (Child) 20 Other InterventioAllocation P110105|2
Safety and Pulmatrix IAll 18 Years toPhase
45 Years
1 Â (Adult)24 Industry InterventioAllocation 601-0001P
One or morUniversity All 18 Years toNot
45 Years
ApplicÂ (Adult) 0 Other|InduInterventioAllocation 8145
Prolonged VA Office All Child, AdulNot Applic 350 U.S. Fed InterventioAllocation IIR 11-300
The number AssistanceAll 18 Years and older Â (Adult,420Older
Other
Change in MetroHealtAll 5 Years to 17
NotYears
Applic
Â (Child)120 Other InterventioAllocation IRB18-007
Fecal ETECNIZO FoodMale 20 Years toNot
55 Years
ProgressionGustave RoAll 18 Years andPhase
Older
Other
Change in ImmunitorFemale 18 Years toPhase
65 Years
2 Â (Adult,30Older
Industry
Adult)InterventioInterventi Myoma01
Number ofCharite UnAll up to 24 Months Â (Child) 900 Other|InduObservatioObservatioNV25182
Myositis A National InAll Child, Adult, Older Ad 719 NIH ObservatioObservatio999905200
Decrease fObjectif R All 18 Years toPhase
70 Years
2 Â (Adult,29Older
Other|Indu
Adult)InterventioAllocation ORVACS 01
QuantificatObjectif R All 18 Years and older Â (Adult, 11Older
Other
Adult) ObservatioObservatioORVACS 00
PrevalenceLondon SchAll 6 Months to Phase
14 Years
4 Â (Child)
22300 Other InterventioAllocation ITDCVP54
Drug: RSV Polyclonal National InAll Child, AdulPhase 4 120 NIH InterventioPrimary Pu990083|99
HIV testingRTI Intern Female 10 Years toNot
24 Years
ApplicÂ (Child,
1125Adult)
Other|NIHInterventioAllocation 1UG3HD09
In adult soNational CeAll 18 Years toPhase
65 Years
2 Â (Adult,76Older
Establish aNational CaAll 18 Years to 100 Years Â (Adult,
876 Older
NIH Adult) ObservatioObservatio999999046
1. MeasureArgos TherAll 18 Years andPhase
older1|Ph
Â (Adult, 22
Older
Industry
Adult) InterventioAllocation AGS-003-0
Changes inNational InAll 18 Years toPhase
70 Years
1 Â (Adult,36Older
tuberculin Taichung VAll Child, AdulPhase 4 300 Other|U.S.InterventioAllocation TCVGH-940
National InFemale 18 Years to 99 Years Â (Adult,120Older
NIH Adult)ObservatioTime Persp999909004
Incidence Merck ShaFemale 9 Years and older Â (Child,
189629
Adult,
Older Adult)
Changes inUniversity All 18 Years andNotolder
Applic
Â (Adult,320
Older
Adult) CDFA93.53
PercentageIndiana UnFemale 18 Years to 60 Years Â (Adult)200 Other|InduObservatioObservatio 1.71E+09
Rate of sti University All Child, AdulPhase 4 99700 Other InterventioAllocation HP-000842
Incidence Bristol-My All 18 Years and
Phase
older
1|Ph
Â (Adult,234
Older
Industry
Adult) InterventioAllocation CA021-002
ProportionAssistance All 7 Years and older Â (Child, 20000
Adult,
Other
Older Adult)
ObservatioObservatioNI16035HL
Generate au Baylor Col All up to 70 Years
12Older
OtherAdult)InterventioInterventi H9454|Euc
Subjects e UCB BiophaAll 18 Years and
Phase
older
2 Â (Adult, 66
Older
Industry
Adult) InterventioAllocation TP0001
number ofAraclon BioAll 50 Years toPhase
85 Years
1 Â (Adult,24Older
Industry
Adult)InterventioAllocation AB1203
Transmissi National I All Child, AdulPhase 4 900 Other InterventioAllocation NL27938.0
Response tNational HeAll 18 Years toPhase
72 Years
2 Â (Adult,40Older
time to re Universita All 18 Years and
Phase
older
2 Â (Adult, 15
Older
Other
Adult) InterventioInterventi S62092|20
The primarPublic HealFemale 18 Years toNot
45 Years
ApplicÂ (Adult)
171 Other InterventioAllocation LN0182
LLANTO PaiClaudia AriAll 1 Year to 6Not
YearsApplic
Â (Child) 200 Other InterventioAllocation VRPedPain
At least 2 Stanford UFemale 15 Years and
Notolder
Applic
Â (Child,
3581
Adult,
Other
Older Adult)
InterventioAllocation TBGI
Number ofMerck HealAll 18 Years toPhase
45 Years
1 Â (Adult)50 Industry InterventioAllocation MS201618_
Determinati GlaxoSmithAll Child, Adult, Older Ad 10982 Industry ObservatioObservatio 115927
National InAll 18 Years and older Â (Adult,157Older
NIHAdult) Observational 060030|06
The primary Kirby Insti All Child, Adult, Older Ad 0 Other ObservatioObservatioPIPET C
Completenes University All 2 Months to 14 Years Â (Child)101 Other ObservatioObservatio11-1362
The primary Kirby Insti All Child, Adult, Older Ad 0 Other ObservatioObservatioPIPET B
incidence London SchAll 2 Months toNot24Applic
Months Â 2485
(Child)
Other InterventioAllocation DFID-R760
PercentagePfizer|JANAll 50 Years toPhase
85 Years
Industry
Change of Jean-Pierr Female 25 Years and
Phase
older
3 Â (Adult,327
Older
Other
Adult) InterventioAllocation UA-IHU- 2
CumulativeVCS Founda Female 25 Years toNot
69 Years
ApplicÂ (Adult,
76181Older
Other
Adult)InterventioAllocation Exec-PP-12
hepatitis BCHU de ReAll 18 Years and older Â (Adult,450Older
Other
Adult) ObservatioObservatio2015Ao00
Incidence aPfizer|JANAll Child, AdulPhase 2 50 Industry InterventioAllocation 3134K1-22
safety ass JANSSEN AlAll 50 Years toPhase
85 Years
Industry
Adult)InterventioAllocation AAB-001-2
Objective Yale UniverAll 18 Years and
Phase
older
2 Â (Adult, Older
0 Other
Create Bio National CaAll 1 Year to 99 Years Â (Child,1000
Adult,
NIH
Older Adult)
Cortisol re University All up to 1 Year Â (Child) 39 Other ObservatioObservatio11685A
The incidenBeijing Shi All 18 Years toPhase
70 Years
Other
Adult)InterventioAllocation BeijingShij
Times seri University Female 18 Years toNot
25 Years
ApplicÂ (Adult)
225 Other InterventioInterventi UF 9554
ProportionNeovacs All 18 Years toPhase
70 Years
2 Â (Adult,40Older
Industry
Adult)InterventioAllocation TNF-K-003
prevalenceCentre HosAll 40 Years to 74 Years Â (Adult,400Older
Other
Adult)ObservatioObservatioP-2011-11
Change in OHSU Knigh All 19 Years to 64 Years Â (Adult)
938132 Other|NIHObservatioObservatio1R01CA20
Toxicity|R University All Child, AdulPhase 1 37 Other|NIHInterventioInterventi 010101|P3
PrevalenceUniversity All 18 Years and
Notolder
Applic
Â (Adult,
1342
Older
Adult) Nompilo
ProportionIndiana UnAll Child, AdulNot Applic 1350 Other InterventioAllocation 0311-04B|2
clinical pe Nanjing PLAll 65 Years and
Phase
older
Other InterventioAllocation 2009NLY03
Number ofNational
i C Female 21 Years toPhase
99 Years
Other
Adult)InterventioInterventi NCC OV-02
Event-free University All up to 18 Years
650 Other InterventioAllocation UKM12_002
Characteri Actelion|CAll 18 Years and older Â (Adult,193Older
Industry|OObservatioObservatioAC-052-43
Adult)
Incidence oM.D. AnderAll 18 Years and
Phase
older
1 Â (Adult, Older
Adult) 2015-0152
Measuremen National InAll 6 Months to 65 Years Â (Child,
4800Adult,
NIH OlderObservatioObservatio999917180
Adult)
Incidence Hospital ClAll up to 3 Months
PhaseÂ1|Ph
(Child) 1498 Other InterventioAllocation TIM
Patient su The 108 MiAll 30 Years toNot
70 Years
ApplicÂ (Adult,
130Older
OtherAdult)InterventioAllocation HCC and H
Detection oU.S. Army All 18 Years toPhase
55 Years
Death rateBritish ThoAll 16 Years andPhase
older
4 Â (Child,400
Adult,
Other
Older Adult)
InterventioAllocation BTS Opport
immune dyUniversity All up to 35 Years Â (Child, Adult)
124 Other ObservatioObservatio2005-12-0
50 Years
Intensity oOslo UniverAll 18 Years toPhase
40 Years
2 Â (Adult) 6 Other InterventioAllocation 2009/1907
enhance ove Weill MedicAll 19 Years toPhase
90 Years
OtherAdult)InterventioInterventi 1.61E+09
Prosthetic Assistance All 18 Years and older Â (Adult,229 Older
Other
Adult) ObservatioObservatioCRC076057
40 Years
1|PhÂ (Adult)
160 NIH|IndustInterventioAllocation HVTN 120|
prevalenceKU Leuven|Female 18 Years toNot 45 Years
ApplicÂ (Adult)
1100 Other InterventioAllocation T005116N
Primary outAga Khan UAll up to 15 Days
NotÂApplic
(Child) 7400 Other|InduInterventioAllocation 586-Ped/E
CD95 LiganCANbridgeAll L Child, Adult, Older Ad 62 Industry ObservatioObservatioCAN-B1-00
RhinoconjuCytos Biot All 18 Years toPhase
65 Years
Industry
Adult)InterventioAllocation CYT003-Qb
Cohort-speMedicines All 18 Years toPhase
45 Years
1 Â (Adult) 0 Other|InduInterventioAllocation MMV_MMV3
ComorbiditAssistanceAll 18 Years andNotolder
Applic
Â (Adult,970
Older
Other|Indu
Adult) InterventioAllocation P100113|P
Change in Tampere Un All 167 Days toPhase
197 Days
3 Â (Child)
1920 Other InterventioAllocation iLiNS-DOSE
PercentageIstari Onc All 12 Years toPhase
21 Years
Industry|OInterventioInterventi Pro000712
Evaluate t Aeras|StatAll 18 Years toPhase
50 Years
AcceptabiliTreatment All 18 Years and older Â (Adult, 79 Older
Other|NIHObservatioObservatio1408|R21
Adult)
Risk of earUniversity Female 18 Years and older Â (Adult, 35274
Older
Other|Indu
Diarrhoea Internatio Male 6 Months to Phase
24 Months
2 Â (Child)
Precise com Ministry o All 18 Years to 65 Years Â (Adult,180Older
OtherAdult)ObservatioTime PerspSKS/LTBI/0
ReactogeniAltimmune,All 18 Years toPhase
49 Years
1 Â (Adult)145 Industry InterventioAllocation ALT201-10
Part A: To Bionor ImmAll 18 Years toPhase
55 Years
1|PhÂ (Adult)36 Industry InterventioAllocation CT-BI Vacc
Disease actTurkish Le All 18 Years and older Â (Adult, 1400
Older
Other
Adult) ObservatioObservatioTRASD
To assess tQingdao Un All 18 Years toPhase
70 Years
OtherAdult)InterventioInterventi DCCIK001
Identify of Seoul St. MAll Child, Adult, Older Ad 50 Other ObservatioObservatioKC15SISI0
Number ofPieris Pha All 18 Years andPhase
older
1|Ph
Â (Adult, 11
Older
Industry
Adult) InterventioAllocation PCS_03_16
PrevalenceUniversity Female 18 Years and older Â (Adult, 65 Older
Other
Adult) ObservatioObservatioNL38266.0
restenosis/Beijing Shi All 18 Years toNot
70 Years
ApplicÂ (Adult,
258Older
OtherAdult)InterventioAllocation liufq_sjt
Drug: sulfadoxine/py National InAll 5 Years to 99
Phase
Years
3 Â (Child, Adult,
0 NIHOlder Adult)
Total LoweImperial C All 18 Years toPhase
55 Years
2 Â (Adult)28 Other|InduInterventioAllocation ORCA2015
â€¢ To deteSt. Jude ChAll up to 21 Years
Phase
Â 1(Child, Adult)
24 Other|NIHInterventioAllocation CYCHAL
Hemoglobin University All 19 Years toNot
75 Years
OtherAdult)InterventioInterventi 146-16-EP
Local and NYU Langon All 20 Years toNot
80 Years
Applicable
Â (Adult, Older
Other|NIHInterventional
Adult) CDR00002
Change in Miami UnivAll 18 Years andNotolder
Applic
Â (Adult, 60
Older
Other
Adult) InterventioAllocation 01368r
CompletionUniversity All 50 Years toNot
75 Years
ApplicÂ (Adult,
7465Older
OtherAdult)InterventioAllocation RSGPB-09-
Change in BUniversity All 2 Years to 7Phase
Years1|Ph
LongitudinHelsinki UnFemale 18 Years and Notolder
Applic
Â (Adult,100
Older
Other
Adult) InterventioAllocation MT-SECFLO
To compareMerck KGaAll 18 Years andPhase
older
1 Â (Adult,104
Older
Industry
The primary Hospital deAll
Clinicas de18Porto
YearsAlegre|FundaÃ§Ã£o
andNotolder
Applic
Â (Adult,252
de
Older
Other
Amparo
Adult)Ã InterventioAllocation
Pesquisa do Estado doUFRGS
Rio Grande
and do Sul, Brazil
KnowledgeHospital deAll Clinicas de18Porto
YearsAlegre|FundaÃ§Ã£o
andNotolder
Applic
Â (Adult,200
de
Older
Other
Amparo
Adult)Ã InterventioAllocation
Pesquisa do Estado doUFRGS
Rio Grande
and do Sul, Brazil
National InAll up to 99 Years Â (Child, Adult,
926Older
NIH Adult)ObservatioTime Persp02-050
Number ofPfizer|JANAll 52 Years toPhase
87 Years
2 Â (Adult,53Older
Industry
To find reaUniversity All 18 Years and older Â (Adult, 70 Older
Other
Adult) ObservatioObservatioWue-Immu
AUC(0-infi National InAll 18 Years toPhase
70 Years
1 Â (Adult,36Older
ObservatioHuman Deve Female 18 Years toNot40 Years
ApplicÂ (Adult)
250 Other InterventioAllocation GCC defini
Anti-Tat AnBarbara Ensoli,
All MD|Italian
18 Years
Ministry
to 45 Years
of Foreign
Â (Adult)
Affairs
531 Other
- Dir. Gen. ObservatioTime
for Cooperation PerspISS
and Development|Istituto
OBS T- Superior
Number ofNational
s InAll 18 Years toPhase
99 Years
to 23 Months
3 Â (Child)
Overall Su Biothera All 18 Years andPhase
older
3 Â (Adult,217
Older
Industry
Adult) InterventioAllocation BT-CL-PGG
Annual agePfizer All up to 36 Months Â (Child)32867 Industry ObservatioTime Persp0887X1-90
s|Neoplasms National CaAll Child, Adult, Older Adult NIH Observational 770066|77
Incidence oInstitut P All up to 2 Days Â (Child) 125 Industry|OObservatioObservatioZIKA_2016
Reduction French NatAll 18 Years andNotolder
Applic
Â (Adult,
3057
Older
Other
Adult) InterventioInterventi ANRS PREV
The proporGenitope CAll 18 Years andPhase
older
1|Ph
Â (Adult, 86
Older
Industry
Adult) Interventional 2005-11
Incidence oHealth Sci All up to 90 Days Â (Child) 150 Other ObservatioObservatioXJTU-CDSP
Biological: VARIVAXÂ Merck ShaAll 12 MonthsPhase
to 15 Months
4 Â 500
(Child)
CompositeUniversity All Child, Adult, Older Ad 1490 Other ObservatioObservatioN14/03/01
Airway SymUniversity All 18 Years toPhase
40 Years
2 Â (Adult)31 Other|NIHInterventioAllocation 14427|U01
HIV-1 provWashington All 18 Years andPhase
older
1 Â (Adult, Older
0 OtherAdult) InterventioInterventi 2.02E+08
PPG excursUniversity All 18 Years toNot
80 Years
Other|Indu
Adult)InterventioAllocation H-1500407
Safety of Baylor Col All 18 Years andPhase
older
1 Â (Adult, Older
9 OtherAdult) InterventioInterventi H11541|Cl
Number ofBenaroya RMale 18 Years andPhase
older
2 Â (Adult, Older
6 Other|Indu
Adult) InterventioInterventi IRB07028|
The primary Genexine, Female 19 Years toPhase
45 Years
1 Â (Adult)32 Industry InterventioAllocation GX-I7M-HP
Number ofKarolinska
p All Child, AdulNot Applicable Other InterventioPrimary PuSwedish Pr
In-hospitalAssistance All 18 Years and older Â (Adult,527 Older
Other
Adult) ObservatioObservatioCRC11040|
Bone MinerUniversity All 20 Years toPhase
70 Years
Other Adult)InterventioAllocation HUM00014
The analysiMemorial SMale Child, Adult, Older Ad 758 Other|InduObservatioObservatio04-062
Malaria in Institut de All 6 Months to Phase
20 Years
3 Â (Child,
18000Adult)
Other InterventioAllocation InstitutRD
Immunologi Rambam He All 18 Years to 45 Years Â (Adult)70 Other ObservatioObservatio0032-13-R
To determin Capital He All 65 Years andPhase
older
Other|InduInterventioAllocation CVT-E002-
Number ofNational InFemale 18 Years toPhase 50 Years
Drug: Actimmune RegInterMuneAll Child, Adult, Older Ad 6 Industry ObservatioTime PerspGIOS-003
OccurrenceGlaxoSmithAll 9 Years to 25 Years Â (Child,1053
Adult)
Time to re Sun Yat-senAll 18 Years toPhase
100 Years
OtherAdult) InterventioAllocation 2007043-H
Change of V vanWorld PAll 18 Years toPhase
80 Years
Industry
Adult)InterventioAllocation 2004L0453
Malaria CaLondon SchAll 6 Months andNot older
ApplicÂ (Child,
1500Adult,
Other Older InterventioAllocation
Adult) NewNetsPr
Biological: FSME-IM Pfizer All 1 Year to 15Phase
Years3Â (Child) Industry InterventioAllocation 209
particle si Wake ForesAll 18 Years and older Â (Adult, 55 Older
Other
75 Years
ApplicÂ (Adult,
1372Older
Adult) 1R18DP001
Disease-FreOHSU Knigh All up to 70 Years
Phase
Â 2(Child, Adult,
37Older
Adult) IRB000002
OccurrenceGlaxoSmithFemale 12 Years to 64 Years Â (Child, Adult)0 Industry ObservatioObservatio 201086
The clinic Alvine PhaAll 18 Years to 75 Years Â (Adult,20Older
Industry
Adult)ObservatioObservatioALV0801
Number ofJohns HopkAll 18 Years toNot
50 Years
ApplicÂ (Adult)47 Other|U.S.InterventioAllocation CIR303 B7
Number ofHaEmek Med All 3 Months to 12 Months Â (Child)
122 Other ObservatioObservatio0138-10-E
Neutralisi Imperial C All 18 Years toPhase
55 Years
1 Â (Adult)50 Other InterventioAllocation 18HH4893
composite Universita All 18 Years and older Â (Adult,400 Older
Other
Adult) ObservatioObservatioS57284
Negative aUniversity All 18 Years andNotolder
Applic
Â (Adult,
1800
Older
Adult) STUDY000
Quality of Saarland UAll 18 Years and older Â (Adult, 58 Older
Other
Adult) ObservatioObservatioPQ-HOM-0
to compareUniversity A Hll 18 Years to 60 Years Â (Adult) 172 Other ObservatioObservatio2016_04|2
PercentageMakerere UAll 18 Years toPhase
90 Years
3 Â (Adult,30Older
OtherAdult)InterventioAllocation HS1258
ProportionSolidarMedAll Child, AdulNot Applic 1800 Other InterventioAllocation DoDoPi-1
number ofAssistanceFemale 18 Years andNotolder
Applic
Â (Adult, 48
Older
Other
AssessmentProf. Dr. All 12 Years and older Â (Child,108 Adult,
Other
Older Adult)
ObservatioTime PerspBC Grass B
Morbidity Nantes UniAll up to 36 Months
Not Applic
Â (Child)7290 Other InterventioAllocation RC18_004
Evaluation PreventiveFemale 30 Years toPhase
45 Years
1 Â (Adult) 642 Other|InduInterventioInterventi PERCAPS I
DevelopmeUniversity All up to 30 Years
PhaseÂ 1(Child, Adult)0 Other InterventioAllocation 13.0176
Receipt of Johns HopkFemale 15 Years toNot
49 Years
ApplicÂ (Child,
415Adult)
Other InterventioAllocation NA_00084
Incidence GeneOne LiAll 19 Years toPhase
65 Years
1 Â (Adult,32Older
Industry
Adult)InterventioAllocation HCV-003
Number and Radboud Un All 18 Years toPhase
35 Years
1 Â (Adult)20 Other InterventioAllocation NL69779.0
The proporHuashan Ho Female 18 Years and older Â (Adult,233 Older
Other
Adult) ObservatioObservatioRWD-0
Incidence rUniversitÃ All up to 10 Years
PhaseÂ 4(Child) 1680 Other|U.S.InterventioAllocation NET-06-08
Campylobac Johns HopkAll 18 Years toPhase
50 Years
2|PhÂ (Adult)30 Other|U.S.InterventioAllocation CIR296
To DetermiXinqiao HoAll 18 Years toPhase
70 Years
1 Â (Adult,20Older
OtherAdult)InterventioAllocation XQDC2018
PercentageClementia All 6 Years andPhase
40 Industry
Older Adult)
InterventioAllocation PVO-1A-20
The modula University All 60 Years toNot
80 Years
OtherAdult)InterventioAllocation UREC14/06
Presence oFundaciÃ³ A I ll 65 Years and older Â (Older149 Adult)
Other ObservatioObservatioIIBSP-NEU
hrHPV DNAUniversite Female 18 Years to 64 Years Â (Adult) 100 Other ObservatioObservatioB30020173
Accrual ratThe Hospita All 4 Years to 9Not
Years
Applic
Â (Child) 40 Other InterventioAllocation 1E+09
Frequency Neovacs
50 Years
1|PhÂ (Adult)28 Industry InterventioAllocation IFN-K-001
PercentageClementia All 6 Years to 65
Phase
Years2 Â (Child, Adult,
17 Industry
Older Adult)
InterventioAllocation PVO-1A-20
PostpartumThird Affil Female 18 Years toPhase
45 Years
4 Â (Adult) 111 Other InterventioAllocation Safety of a
Change froClementia All up to 65 Years Â (Child, Adult,100Older
Industry
Adult)ObservatioObservatioPVO-1A-00
Safety of Clementia All 6 Years to 65
Phase
40 Industry
Older Adult)
InterventioInterventi PVO-1A-20
Facility 4 Moi UniverAll up to 50 Years
Not ÂApplic
(Child, Adult)
15 Other InterventioAllocation UMoi2
40 Years
2 Â (Adult)60 Other|NIHInterventioAllocation 19157|1U0
toxicity|cl University All 18 Years toPhase
75 Years
OtherAdult)InterventioAllocation rM28-001
Number ofColumbia UAll 18 Years andPhase
6 Other|Indu
Adult) InterventioInterventi AAAF2403
ExpressionNational InAll 6 Years to 65 Years Â (Child, Adult,
84 NIH|OtherObservatioObservatioDAIT
Older Adult) ADRN
Number ofAeras|StatAll 18 Years toPhase
60 Years
OccurrenceGlaxoSmithK Female 15 Years to 25 Years Â (Child,1046Adult)
Industry|OObservatioObservatio 114101
Incidence oDiane GeorAll up to 40 Years
EarlyÂPhas
(Child, Adult)
25 Other InterventioInterventi AAAL0156
Adverse Eve Gruppo Onc All 18 Years andPhase
older1|Ph
Â (Adult, 71
Older
Other
Queen Saov All 18 Years to 30 Years Â (Adult) 550 Other ObservatioObservatioTAI5501
Objective Provectus All 18 Years andPhase
Older
Industry
Adult) InterventioInterventi PV-10-MM
Event-free Swiss Group All 18 Years toPhase
75 Years
2 Â (Adult,90Older
OtherAdult)InterventioInterventi SAKK 16/1
LaboratoryUniversity All 18 Years andNotolder
Applic
Â (Adult,
1400
Older
Adult) 1U01CK000
Difference Aga Khan UAll up to 1 DayPhase
Â (Child)
4 900 Other|U.S.InterventioAllocation PEGS
Wechsler Pr Children's All 4 Years to 5Phase
Years3Â (Child) 302 Other InterventioAllocation 2003-10-3
Frequency Baxalta
a noAll 18 Years toPhase
55 Years
1 Â (Adult) 8 Industry InterventioAllocation HuBChE-02
FrequenceBaxalta noAll 18 Years toPhase
55 Years
1 Â (Adult)28 Industry InterventioAllocation HuBChE-01
compare the AssistanceAll 75 Years and
Notolder
Applic
Â (Older Adult)
78 Other InterventioAllocation 2008 -21
85 Years
ApplicÂ (Adult,
775Older
Adult) 12-1338
Event free Pfizer All 18 Years and
Phase
older
3 Â (Adult,999
Older
Industry
Notolder
Applic
Â (Adult,
1420
Older
Adult) HUM00008
Change in Sotio a.s. Male 18 Years and
Phase
older
2 Â (Adult,150
Older
Industry
Adult) InterventioAllocation SP003
Change in McGill UniAll 18 Years and
Notolder
Applic
Â (Adult,689
Older
Other
Adult) InterventioAllocation S065653b
Feasibility Helmholtz All 1 Year to 3 Years Â (Child) 75 Other ObservatioObservatio 6506
Secondary National
a InAll Child, Adult, Older Ad 4500 Other ObservatioObservatioPHIRST-SA
Pain asses Federal UniAll up to 28 Days
Phase
Â (Child)
3 160 Other InterventioAllocation 1386/06
OccurrenceGlaxoSmithAll 6 Months and older Â (Child,
13380 Adult,
Older Adult) Persp 114001
Improved ma Eunice KenAll Child, AdulNot Applic 170 NIH InterventioAllocation R21 HDJ28
Measure thAlbert Sch All 6 Months toPhase
59 Months
4 Â (Child)
139 Other InterventioAllocation IPTi-DRWG
Cmax of exNIZO FoodFemale 65 Years toNot
85 Years
ApplicÂ (Older30Adult)
Other|InduInterventioAllocation NL57345.0
Presence oCentre Hosp All 18 Years and
Notolder
Applic
Â (Adult,915
Older
Other
Developmen Seattle ChiAll 18 Years toPhase
50 Years
1 Â (Adult) 6 Other InterventioMasking: NMC-001
Complete Altor BioS All 18 Years and
Phase
older
2 Â (Adult,160
Older
Industry
Adult) InterventioInterventi CA-ALT-803
Red blood Scanquin ReAll 18 Years and older Â (Adult,
1500
Older
Other
Adult) ObservatioTime PerspPPOC-08-0
50 Years
incidence rUniversity All 6 Months toNot10Applic
Years Â (Child)
262 Other InterventioAllocation A10828
Evaluation University All 6 Weeks toNot
18 Years
ApplicÂ (Child,
2000 Adult)
Other|U.S.InterventioAllocation 8858|AHRQ
University All up to 7 Days Â (Child) 120 Other ObservatioObservatio08-177
Lower limbUniversite All 3 Years to 25 Years Â (Child, Adult)
50 Other ObservatioObservatio34264|T0
Optimal BiM.D. AnderFemale Child, AdulPhase 1|Ph 30 Other|NIHInterventioAllocation ID02-115|
Changes inArchivel FaAll 18 Years toPhase
99 Years
1 Â (Adult,40Older
Industry|OInterventioAllocation:RUTIVAC-1
Adult)
The PrimarUniversity All 18 Years toNot
70 Years
OtherAdult)InterventioInterventi I10 014
Presence oBrigham anMale Child, AdulEarly Phas 1 Other InterventioInterventi 2015P0010
National InAll 2 Years to 25 Years Â (Child,237
Adult)
NIH Observational 999906147
response rMemorial SAll 18 Years and
Phase
older
2 Â (Adult, 80
Older
Other
Identificat Nantes UniAll 7 Years to 70
NotYears
Applic
Â (Child,120
Adult,
Other
Older Adult)
InterventioAllocation BRD07/5-A
Faces Pain Hamilton HAll 2 Years to 18
NotYears
Applic
Â (Child, Adult)
50 Other InterventioAllocation no number
Change in Damascus A Ull 12 MonthsNotto 12
Applic
Months Â (Child)
92 Other InterventioAllocation DM20AM1
BiomarkersEmory UnivAll 6 Weeks toNot
32 Weeks
Applic Â (Child)
Hadassah M All up to 18 Years Â (Child, Adult) Other ObservatioObservatioyael12-HMO-CTIL
PercentageProvidenceAll 18 Years toPhase
67 Years
2 Â (Adult, 2Older
OtherAdult)InterventioInterventi IND110875
Identificat University All 18 Years toPhase
50 Years
Time to di University All 6 Months toNot12Applic
Months Â 1200
(Child)
Other InterventioAllocation STUDY000
Response rClinica Un All 18 Years and
Phase
older
2 Â (Adult, 27
Older
Other
Adult) InterventioAllocation CD-2007-0
Safety andGeneOne LiAll 19 Years toPhase
65 Years
1 Â (Adult,18Older
Industry
Adult)InterventioAllocation VGX-6150-
PostpartumNorthwesteFemale 16 Years toNot
50 Years
ApplicÂ (Child,
400Adult)
Other|NIHInterventioAllocation STU00209
Pain memory Vrije UniveAll 8 Years to 12
NotYears
Applic
Â (Child)104 Other InterventioAllocation ROBOTDIST
Taipei MedAll Child, Adult, Older Ad 1800 Other ObservatioObservatio 99014
Change FroPfizer|JANAll 50 Years toPhase
80 Years
2 Â (Adult,63Older
Industry
Complete RH. Lee MofAll 18 Years and
Phase
older
2 Â (Adult, 34
Older
Other|Indu
OccurenceUniversity
o All 18 Years and
Phase
older
1|Ph
Â (Adult, 33
Older
Other
Adult) InterventioAllocation ONK USZ 0
Maximum Gustave
To RoAll 18 Years and
Phase
older
1 Â (Adult, 19
Older
Other
Adult) InterventioInterventi CSET 2010/
To evaluateASST FatebAll 18 Years toPhase
55 Years
3 Â (Adult)45 Other|InduInterventioAllocation 130/2011/
HospitalizeSimon KrabAll 18 Years and older Â (Adult, 7500
Older
Other
Adult) ObservatioObservatioPredict-00
anti-3S an InnaVirVaxAll 18 Years toPhase
60 Years
2 Â (Adult)90 Industry InterventioAllocation IPROTECT1
PostpartumJunaid-ur- Female 15 Years toNot 44 Years
ApplicÂ (Child,
970Adult)
National I All 18 Years and older Â (Adult,522Older
NIH|OtherObservatioObservatioCHAVI
Adult) 002
Duration ofBioniche LiAll 18 Years andPhase
older
3 Â (Adult, Older
0 Industry
Adult) InterventioAllocation EN3348-30
Identificat SocietÃ Italiana
All Talassemie
Child, Adult,
ed Emoglobinopatie|University
Older Ad 1400 Other of Campania
ObservatioObservatioAsplenia
"Luigi Vanvitelli"
Change froInternatio All 4 Months to Not
6 Months
Applic Â (Child)
Study the iFederico IIAll 3 Months to Phase
5 Years
3 Â (Child)90 Other InterventioAllocation IN001
ProportionGhana HealFemale 15 Years toNot 49 Years
ApplicÂ (Child,
912Adult)
Other InterventioAllocation GHS-ERC:
|Virus Diseases University All 18 Years to 65 Years Â (Adult, 0Older
OtherAdult)ObservatioObservatioTCell
Parasite p London SchAll 5 Years andPhase
older4Â (Child,
10746
Adult,
Other
Older Adult)
InterventioAllocation ITCRAA691
ProportionUniversity Female 18 Years toNot 45 Years
ApplicÂ (Adult)
292 Other InterventioAllocation IRB#15-00
Changes inTabriz UnivFemale 18 Years toPhase 41 Years
2 Â (Adult)50 Other InterventioAllocation TabrizUMS-i
Safety Ass Inovio PhaAll 18 Years toPhase
65 Years
1 Â (Adult,90Older
Industry
Adult)InterventioAllocation HBV-001
Comparison University All 18 Years toPhase
65 Years
2 Â (Adult,97Older
OtherAdult)InterventioAllocation ZU-SkinSIT
First sever Bernhard NAll Child, Adult, Older Ad 2400 Other ObservatioObservatioPV5940
(Clinical) Hospital C All up to 1 WeekNotÂApplic
(Child) 349 Other InterventioAllocation AgeMal
Change in cUniversity All 18 Years andNotolder
Applic
Â (Adult,746
Older
Other
Adult) InterventioAllocation R34DK093
Use of canWashington All 18 Years andNotolder
Applic
Â (Adult,
4762
Older
Other
Recording o Cadila PhaAll 18 Years andPhase
older
2 Â (Adult,122
Older
Industry
Adult) InterventioAllocation CR-60/915
Number ofUniversity
v All 18 Years and older Â (Adult,132Older
Other
Adult) ObservatioObservatioDSO-2011-
Cure rates National InAll 6 Months to 10 Years Â (Child)344 Other ObservatioObservatioNIMRTanza
Airway SymUniversity All 18 Years toNot
40 Years
ApplicÂ (Adult)26 Other|NIHInterventioAllocation 12673|R01
49 Years
1 Â (Adult)156 Industry InterventioAllocation VAL-33985
Intention tSarah Huf|Female 24 Years toNot 64 Years
ApplicÂ (Adult)
14597 Other InterventioAllocation 14IC2120
ProportionNational T All 20 Years and older Â (Adult,275Older
Other
Adult) ObservatioObservatio201710056
Non-urgentBronx-LebaFemale Child, AdulNot Applic 323 Other InterventioAllocation 09 15 11 1
Titer of a Biomay AGAll 18 Years toPhase
60 Years
Duration oMarshfieldAll 1 Year to 79Not
Years
Applic
Â (Child, 194
Adult,
Older Adult) 1U01IP000
Area underUniversity All 18 Years toPhase
50 Years
3 Â (Adult)64 Other InterventioAllocation IKSIT_2011
Platelet a University All 18 Years to 95 Years Â (Adult,500Older
OtherAdult)ObservatioObservatioMACCE and
A change inUniversity All 18 Years toNot
99 Years
OtherAdult)InterventioInterventi F17010500
Efficacy of University All 18 Years toPhase
70 Years
OtherAdult)InterventioAllocation 2016GA03|
Identify et Institut P All Child, Adult, Older Ad 800 Industry|OObservatioObservatio2013-024
Procedure: ScreeningBarts & ThAll Child, Adult, Older Ad 200 Other ObservatioObservatioTB-02-04-
HBsAg posit Wu Jiang|CAll 25 Years and older Â (Adult,
76220
Older
Other
Adult) ObservatioObservatioBJCDCWJ2
Mortality|EInstitut N All 1 Year and Phase
126 Other
Older Adult)
InterventioInterventi C14-63
identify byCentre HosAll 18 Years to 75 Years Â (Adult,600Older
OtherAdult)ObservatioObservatio2016/CHU/
The proport Virginia C All 18 Years toNot
75 Years
ApplicÂ (Adult,
5500Older
Adult) PD300045|
Change in Institute All 5 Years andNot
older
Applic
Â (Child,2900
Adult,
Other
Older Adult)
InterventioAllocation CYSTISTOP
Overall SurThe First All 18 Years toPhase
75 Years
OtherAdult)InterventioAllocation CZ1H-BC-0
Effectiven University All 18 Years toPhase
75 Years
2 Â (Adult, 8Older
Other|Indu
Adult)InterventioInterventi IND 10634
Enhancemen Hadassah M All 18 Years andPhase
older
2 Â (Adult, 24
Older
Other
Smoking StVanderbilt All 18 Years andNotolder
Applic
Â (Adult,199
Older
Other
Compare UT Loyola UnivFemale 18 Years and
Notolder
Applic
Â (Adult,225
Older
Other
MyastheniaAlexion PhAll 18 Years and
Phase
older
3 Â (Adult,125
Older
Industry
Adult) InterventioAllocation ECU-MG-30
Phase Ib: Transgene|All 18 Years and
Phase
older
1|Ph
Â (Adult, 52
Older
Industry
Adult) InterventioInterventi TG4001.12
Change in AbbVie All 18 Years toPhase
100 Years
Industry
Adult)
InterventioInterventi M13-538|2
Infectivity Sanaria IncAll 18 Years toPhase
45 Years
1 Â (Adult)36 Industry|OInterventioAllocation BACHMI-0
Detection oRadboud Un All up to 5 Years Â (Child) 179 Other ObservatioObservatioOMVac clin
Combined VA f Midwest All Child, AdulNot Applic 4000 U.S. Fed InterventioAllocation 4140-B
Number ofUniversity All 1 Month to 17 Years Â (Child)50 Other ObservatioObservatioIGRAManP
sexually t Indiana UnAll 12 Years to 21 Years Â (Child,
2831Adult)
Other|U.S.ObservatioObservatio130803899
response ofSingapore All 12 Years toPhase
80 Years
Adult) CIK#3/200
Number ofYale Unive All 18 Years and
Notolder
Applic
Â (Adult, 60
Older
Other|Indu
The primary National EyAll 18 Years and
Phase
older
1 Â (Adult, Older
ertension|Sickle Cell National HeAll 5 Years and older Â (Child, Adult,
308 NIHOlder Adult)
Observational 999906189
Taipei MedAll 20 Years and older Â (Adult,300
Older
Other
Adult) ObservatioTime Persp 99071
Incidence oJohns HopkAll up to 36 Months
Phase 3Â (Child)4678 Other|NIHInterventioAllocation IRB000003
Host respoImperial C All 18 Years toNot
55 Years
ApplicÂ (Adult)43 Other InterventioAllocation 12/LO/127
Biological: HIV-1 Im The Immune All 18 Years and
Notolder
Applicable
Â (Adult, Older
Industry
Adult) InterventioPrimary Pu094|902
Notolder
Applicable
Â (Adult, Older
Industry
Adult) InterventioMasking: N093|901
Change in AIDS ClinicAll 18 Years and
Phase
older
2 Â (Adult,121
Older
Adult) ACTG A53
Rabin MediAll up to 20 Years Â (Child, Adult)
200 Other ObservatioObservatio0061-07-R
Reduction University All up to 6 Weeks
Not ÂApplic
(Child) 480 Other InterventioAllocation AD/13/479
Characteri Institut Pa All 10 Weeks to 9 Months Â (Child)19 Industry|OObservatioObservatio2016-097|
differentia Imperial C All 18 Years toNot
55 Years
ApplicÂ (Adult)45 Other InterventioAllocation 09/H0712/
change in m JawaharlalAll 6 Months toPhase
59 Months
3 Â (Child)
208 Other InterventioAllocation MDPG05/0
Influenza vUS Departm All 18 Years to 89 Years Â (Adult, 0Older
U.S. Fed
Adult)ObservatioObservatioRRP 10-04
Type 2 DiaHelsinki UnAll 3 Years to 50 Years Â (Child,680
Adult)
Other ObservatioObservatioRadiel 5Y
ProportionHospices CiAll 18 Years and older Â (Adult,500
Older
Other
Level of h The UniverAll 10 Years toNot
20 Years
ApplicÂ (Child,
732Adult)
UndetectedNational T All 18 Years toPhase
60 Years
2|PhÂ (Adult)
120 Other|InduInterventioAllocation 145R3
rculosis|HIV InfectionsCase WesteAll 3 Months to 15 Years Â (Child)
250 Other ObservatioTime PerspRES104272
Time to PSThe Method Male 18 Years and
Phase
older
2 Â (Adult, 11
Older
Other|Indu
Adult) InterventioAllocation HMRI IRB#
Level of k CHU de ReAll 18 Years and older Â (Adult,191
Older
Other
Adult) ObservatioObservatio2016Ao00
Toxicity ( MaastrichtAll 18 Years and
Phase
older
1 Â (Adult, 18
Older
Other
Adult) InterventioInterventi L19-IL2
ProgressioSheng Liu|Female 18 Years to 75 Years Â (Adult,
620Older
OtherAdult)ObservatioObservatioLonghuaH(
All-causes London SchAll 3 Months toPhase
119 Months
4 100000
Â (Child)
Other InterventioAllocation PSP01|400
Drug: Anti-HIV Immu Abbott All 18 Years and
Phase
older
1 Â (Adult, 12
Older
Industry
Adult) InterventioPrimary Pu060A|0001-008
Drug: F105 MonoclonNational InAll 18 Years and
Phase
older
1 Â (Adult, Older
8 NIHAdult) InterventioPrimary PuACTG 232|11209
Institutio Jhpiego|MiAll 15 Years toNot
49 Years
ApplicÂ (Child,
2767Adult)
Other|U.S.InterventioInterventi IRB 8902
PercentageNational CaAll 4 Years to 55
Phase
Years
2 Â (Child, Adult)
76 NIH InterventioAllocation 110136|11
Receipt of NorthwesteFemale 15 Years toNot
45 Years
ApplicÂ (Child,
600Adult)
Other InterventioAllocation SP0052930
PK/PD relaMedicines All 18 Years toPhase
55 Years
1|PhÂ (Adult)13 Other|InduInterventioInterventi QP14C12
incidence/aInternatio All 18 Years toNot
45 Years
ApplicÂ (Adult)
80 Years
2 Â (Adult,24Older
NIH Adult)InterventioAllocation 040287|IN
Reduction EnzymaticaAll 18 Years toNot
65 Years
Industry
Adult)InterventioAllocation ENZY-001
Clinical R National CaAll 7 Years andPhase
170 NIHOlder Adult)
Drug: ADA PBSC|Drug: National HAll Child, Adult, Older Ad 10 NIH Observational 900195|90
PrevalenceAssiut UnivAll up to 5 Years Â (Child) 100 Other ObservatioObservatiolatent tube
Reduction EnzymaticaAll 16 Years toNot
70 Years
ApplicÂ (Child,88
Adult,
Industry
Adult) ENZY-002
Change fromUniversity All 18 Years toNot
80 Years
ApplicÂ (Adult,
120Older
OtherAdult)InterventioAllocation CHU-420|2
Number ofAstraZenecAll 2 Years to 6Phase
Years3Â (Child) 100 Industry InterventioAllocation D2560C00
â€¢ To asseTata Memor Female 18 Years toPhase99 Years
3 Â (Adult,
1600Older
OtherAdult)InterventioAllocation TMH projec
Participan Alexion PhAll 18 Years andPhase
Older
Industry
Adult) InterventioAllocation ECU-NMO-
The infectiSanaria IncAll 18 Years toPhase
45 Years
1 Â (Adult)30 Industry|OInterventioAllocation TUCHMI-0
Incidence National CaAll 18 Years andPhase
Older
Physician National InAll Child, Adult, Older Ad 1550 NIH ObservatioObservatio030099|03
Drug: CD34+ cells tra National HAll 1 Month and Phase
older
1 Â (Child, Adult,
8 NIHOlder Adult)
DifferencesUniversitÃ All 18 Years andNotolder
Applic
Â (Adult, 90
Older
Other|Indu
Adult) InterventioAllocation PNEU-PV33
Safety Ass MEDA PharAll 3 Months to Phase
12 Months
3 Â 2418
(Child)
Industry InterventioAllocation CASM981C
The compet National InMale 18 Years toPhase
36 Years
DeterminatiGlaxoSmithAll up to 5 Years Â (Child) 1 Industry ObservatioObservatio 116311
reduced naMartin-LutAll 60 Years toPhase
75 Years
2 Â (Adult,96Older
Other|Indu
Adult)InterventioAllocation KKSH-38|2
The primarErasmus Me All 18 Years andPhase
9 Other
Estimate t Pfizer All 1 Month to 24 Months Â (Child) 1 Industry ObservatioObservatioB1851193
Maternal aBeijing Dit Female 18 Years to 35 Years Â (Adult) 400 Other ObservatioObservatioKY2018-01
To evaluat JANSSEN AlAll 50 Years toPhase
89 Years
Industry
Adult)InterventioAllocation ACC-001-A
Antibody LCancer AdvAll 18 Years toPhase
90 Years
2 Â (Adult, Older
Industry
Adult)InterventioAllocation CC4
Long term Hospices CiAll Child, Adult, Older Ad 4030 Other ObservatioObservatio69HCL16_0
Number ofPfizer All 18 Years and older Â (Adult,659 Older
Industry
Number ofCelldex Th All 18 Years toPhase
55 Years
1 Â (Adult)30 Industry InterventioAllocation CDX301-02
EffectiveneJordi Gol i Gurina
All Foundation|Instituto
45 Years toNot
75 Years
Applic
deÂSalud
(Adult,
3640
Carlos
Older
Other
III|Department
of Health, Generalitat
4R15/032|
de Catalunya|Parc San
safety of Baylor Col All 18 Years andPhase
9 Other
Adult) InterventioAllocation H11967|CL
EnrollmentBaylor Col All up to 18 Years
Not ÂApplic
(Child, Adult)
430 Other InterventioAllocation H-38428
Number ofAbbott All up to 6 Months Â (Child) 82 Industry ObservatioObservatioPMOS-PERU
Biological: HIV-1 Im National CaAll Child, AdulPhase 1 32 NIH InterventioPrimary Pu950172|95
PreU7-53 isGenethon|IMale 12 Years to 20 Years Â (Child,45 Adult)
Other ObservatioObservatioGHN007.1
mother preAga Khan UAll Child, AdulNot Applic 3000 Other InterventioAllocation 753-Ped/E
Safety knowAssistance All 18 Years toNot
75 Years
ApplicÂ (Adult,
129Older
OtherAdult)InterventioAllocation K151201
Wyeth is nAll up to 14 Years Â (Child) 160 Industry ObservatioTime Persp0887X-101
Drug: Prevenar Wyeth is nAll 6 Months to 24 Months Â 3293 (Child)
Industry ObservatioTime Persp0887X-100
To evaluat Dana-FarbeAll 18 Years andPhase
9 Other|Indu
Adult) InterventioInterventi 07-097|RV
Change in Mehrotra, All 18 Years andNotolder
Applic
Â (Adult,116
Older
Other
Adult) InterventioAllocation Sep-75
Characteri Mexican Em All Child, Adult, Older Ad 5819 Other|NIHObservatioObservatioILI002|HH
Lupus-relaBrigham anAll 18 Years andNotolder
Applic
Â (Adult, 90
Older
Other
Adult) InterventioAllocation IRB 2019P
Change in RUniversity Female 21 Years toEarly 65 Years
PhasÂ (Adult,
224Older
% of COPDSeattle
c In All 18 Years toNot
89 Years
ApplicÂ (Adult,
504Older
Adult) 1U01HL142
FluMist UsMedImmune All Child, Adult, Older Ad 321697 Industry|OObservatioObservatioMI-MA175
PrevalenceFrench NatAll 6 Months and older Â (Child, 3119Adult,
OtherOlder ObservatioObservatioANRS
Adult) 1235
Reasons forUniversitÃ All 18 Years and older Â (Adult, 1022
Older
Other
Adult) ObservatioObservatioKVHH-KVSH
microbioloCervesi Hosp All 20 Years to 35 Years Â (Adult)100 Other ObservatioObservatioNEW MICR
Change in Case Compr All Child, AdulNot Applic 128 Other InterventioInterventi CASE11Z17
Safety|AlleCardiff Un All 18 Years toPhase
40 Years
1|PhÂ (Adult)27 Other InterventioAllocation SPON817-1
Anti-KLH An University All 18 Years toNot
45 Years
ApplicÂ (Adult)18 Other|NIHInterventioInterventi UNMSCOR|
Change FroMerck SharAll 18 Years toPhase
85 Years
1 Â (Adult,14Older
Industry
Adult)InterventioAllocation 0736-006|
Height|WeiMario NegrAll up to 45 Days Â (Child) 5000 Other ObservatioObservatioNASCITA|I
Number ofEmergent Bi All 18 Years toPhase
45 Years
1 Â (Adult) 7 Industry|NInterventioAllocation DMID 15-0
The cure raAssiut UnivAll 15 Years toPhase
40 Years
Other InterventioAllocation Bleomycin
Establish University All 18 Years toPhase
50 Years
1 Â (Adult)50 Other|U.S.InterventioAllocation NMRC.2006
C3 serum m University All 4 Years andPhase
0 Other
Older Adult)
InterventioInterventi UIowa
Objective Tianjin Med All 18 Years toPhase
80 Years
1 Â (Adult,15Older
OtherAdult)InterventioInterventi CIH-RXB-2
Number ofVU UniversMale 18 Years toPhase
80 Years
1 Â (Adult,28Older
Other|Indu
Adult)InterventioInterventi G-0016
Procedure: platelet t National HeAll 15 Years toPhase
75 Years
3 Â (Child, Adult,
NIH Older InterventioAllocation
Adult) 309|U01H
Detection Evidation All 18 Years and older Â (Adult,4900
Older
Industry|OObservatioObservatioSTUDY000
Adult)
Presence oWest VirginAll Child, Adult, Older Ad 400 Other ObservatioObservatioWVU-0001
CompositeVA Office All 18 Years and
Notolder
Applic
Â (Adult,366
Older
U.S.Adult)
Fed InterventioAllocation SDP 12-17
Inspirator Swiss Para All 18 Years and older Â (Adult,500
Older
Other
Frequency Aeras|StatAll
a 12 Years toPhase
17 Years
2 Â (Child) 0 Other InterventioAllocation A-043
PrevalenceGlaxoSmithAll Child, Adult, Older Ad 521 Industry ObservatioObservatio 114989
Child line Boston UniAll Child, AdulNot Applic 12240 Other|U.S.InterventioAllocation H-38950|T
Biological: autologo The ClevelaAll 18 Years and
Phase
older
2 Â (Adult, 40
Older
Adult) PuCDR000006
Number ofMayos CliniAll 18 Years and older Â (Adult,892
Older
Other
Linear gro Sokoine UnAll 6 Months toNot7 Months
Applic Â (Child)
600 Other InterventioAllocation 879/13
incidence Murdoch Ch All up to 18 Years Â (Child, Adult)
120 Other ObservatioObservatio35266C
49 Years
1|PhÂ (Adult)55 Industry InterventioInterventi TAK-850/C
Measuremen Trinidad anMale Child, Adult, Older Ad 25 Other ObservatioObservatioZIKAFERTI
Patient sa Rijnstate HAll 18 Years and
Notolder
Applic
Â (Adult, 55
Older
Other
Toxicity at University All up to 18 Years
PhaseÂ 1|Ph
(Child, Adult)
29 Other InterventioAllocation UCL/09/00
NeurologicIRCCS PolicAll 3 Years to 17
NotYears
Applic
Â (Child) 40 Other InterventioAllocation 2.01E+10
saliva coll NorthwesteAll 18 Years and older Â (Adult, 90
Older
Other
Adult) ObservatioObservatioNICU2Home
All-cause mGeisinger CAll 18 Years and
Notolder
Applic
Â (Adult,600
Older
Other
PCR-confirImperial C All 18 Years toNot
55 Years
ApplicÂ (Adult)20 Other|U.S.InterventioInterventi 19HH5451
ProportionHospices CiFemale 18 Years and older Â (Adult,164
Older
Other
Biological: aldesleuk Barbara AnAll 18 Years and
Phase
older
2 Â (Adult, Older
Adult) PuCDR000006
Safety andUniversity All 3 Years to 18
Phase
Years
1 Â (Child, Adult)
18 Other InterventioInterventi UAB 1472|
Under-5 chStanford UAll 18 Years toNot
65 Years
ApplicÂ (Adult,
9999Older
Viral load Duke UniveAll 18 Years toPhase
55 Years
1 Â (Adult)50 Other|U.S.InterventioInterventi Pro000825
Incidence oInstitut de Female Child, AdulNot Applic 2341 Other InterventioAllocation IRSSOOO1
Number ofGlaxoSmithAll 6 Months toNot6 Years
ApplicÂ (Child)
Mean Chang National InAll 18 Years and
Phase
older
2 Â (Adult, 84
Older
NIHAdult) InterventioAllocation A5343|120
Injection SCancer AdvMale 18 Years and
Phase
older
2 Â (Adult, Older
5 Industry
Adult) InterventioAllocation CC1C
Patients w Emory UnivAll 18 Years to 80 Years Â (Adult,92Older
Other|Indu
Adult)ObservatioObservatioIRB000291
Develop ofJohns HopkAll 18 Years toPhase
45 Years
1 Â (Adult)25 Other|U.S.InterventioInterventi CIR 240|W
Developmen Johns HopkAll 15 Years toPhase
45 Years
Other|U.S.InterventioInterventi CIR 193 (B)
Trigger's f AkusherstvAll 1 Year to 3 Years Â (Child) 300 Other ObservatioObservatioAkusherstv
OseltamiviSt. Louis All up to 6 Months Â (Child) 19 Other|InduObservatioObservatioTAM 027
Clinical ( National UnAll 21 Years and
Phase
older
2|Ph
Â (Adult,150
Older
Other
Adult) InterventioInterventi DSRB Domain E/2011/1772
Part A: Sk GlaxoSmithAll 18 Years toPhase
55 Years
Quality of University All 18 Years and
Notolder
Applic
Â (Adult,442
Older
Adult) SCUSF 050
descriptiv Emory UniveFemale 12 Years to 45 Years Â (Child, 396Adult)
Other|NIHObservatioTime PerspIRB000017
Evaluation UniversidaAll 1 Year and Not
older
Applic
Â (Child, 2000
Adult,Other
Older Adult)
InterventioInterventi IIET-05
Incidence GlaxoSmithAll 5 Years to 13
NotYears
Applic
Â (Child)
Changes inUniversity All 7 Months and
Not older
ApplicÂ (Child,
240000 Adult,
Adult) R01A1050
evaluate t Memorial SAll 18 Years and
Phase
older
1|Ph
Â (Adult, 68
Older
Other
Event FreeBristol-My All 18 Years and
Phase
older
3 Â (Adult,700
Older
Industry
Adult) InterventioAllocation CA209-7G8
Mean (Â± sMcGill UniAll 12 MonthsPhase
to 24 Months
4 Â1760
(Child)
Other InterventioAllocation 10-242-PE
Evaluate r Baylor Col All up to 40 Years
Not ÂApplic
(Child, Adult)8 Other InterventioInterventi H-16447-S
Complete RMerck ShaAll 18 Years and
Phase
older
3 Â (Adult,550
Older
Industry
Adult) InterventioAllocation 3475-676|
T cell pro Nanjing UnFemale 20 Years toPhase40 Years
1|PhÂ (Adult)
292 Other InterventioInterventi BL2015007
Average NuUniversity All 65 Years and
Notolder
Applic
Â (Older280Adult)
Other|NIHInterventioAllocation STUDY000
safety|im Institut Pa All 18 Years toPhase
65 Years
OtherAdult)InterventioInterventi ALLO-WT1/
ComplicatiHarvard Sch Female 18 Years toNot 40 Years
ApplicÂ (Adult)
109 Other InterventioAllocation Saving Live
Collect ad david andrAll 18 Years and
Phase
older
1 Â (Adult, 32
Older
Other
Adult) InterventioInterventi 14G.96
Health car Boston Med All up to 1 Month
Not Applic
Â (Child) 1205 Other|NIHInterventioAllocation H-33061|
to 18 Months
3 Â 405
(Child)
Moderate-ViUniversity All 50 Years and
Notolder
Applic
Â (Adult,182
Older
Adult) 1611S9932
EducationaSt George' Female 18 Years and Notolder
Applic
Â (Adult,
1100
Older
Other
Adult) InterventioAllocation PB-PG-021
CommunityUniversity All 45 Years toNot
64 Years
ApplicÂ (Adult)
Change froFederal University
All of Uberlandia|Conselho
5 Years to 15
NotYears
Applic
Â (Child)
Nacional
122deOther
Desenvolvimento
CientÃfico eF3046|CN
TecnolÃ³gico
Moderate-ViUniversity All 50 Years and
Notolder
Applic
Â (Adult, 30
Older
Adult) 1611S9932
Malaria IncLondon SchAll 6 Months toPhase
10 Years
4 Â (Child)
28000 Other InterventioAllocation WHO_IR_S
Phase
older
2 Â (Adult, 43
Older
Other
Adult) InterventioInterventi Sutent V5
Phase
older
1 Â (Adult, 34
Older
Industry
Phase
older
3 Â (Adult,
3000
Older
Industry
Adult) InterventioMasking: D092|806
Biological: Diphtheri National I All 2 Years to 18
Phase
Years
1 Â (Child, Adult)
92 NIH InterventioPrimary PuACTG 402|10607|PACTG 402
serum DMPS Banner HeaAll 18 Years and
Phase
older
1 Â (Adult, Older
9 Other
Adult) InterventioAllocation DMPS 09-1
Number ofSabine Mue All 2 Years andPhase
19 Other
Older Adult)
InterventioInterventi PNOC 009|
HouseholdUniversity All 18 Years and
Notolder
Applic
Â (Adult,
2400
Older
Other
Rate of cerAugusta UniFemale 21 Years and Notolder
Applic
Â (Adult,100
Older
Other
PerformancUniversity All 18 Years and
Notolder
Applic
Â (Adult,225
Older
Other
Change in Children's Female 15 Years and Notolder
Applic
Â (Child,120
Adult,
Other
Older Adult)
InterventioAllocation IRB 15-01
number ofErasmus
c MeAll Child, AdulPhase 1 10 Other InterventioInterventi NL24050.0
ConcentratiInmunotekAll 12 Years toPhase
65 Years
Industry
Adult) MM09-SIT-
ConcentratiInmunotekAll 14 Years toPhase
65 Years
Industry
Adult) MG56-SIT-
Incidence Pfizer|JANAll 50 Years toPhase
85 Years
2 Â (Adult,40Older
Industry
To determiMerck ShaAll 18 Years and
Phase
older
1 Â (Adult, 41
Older
Industry
Incidence Centers fo All Child, AdulNot Applic 949609 U.S. Fed|OInterventioAllocation U49CE001
Change froJanssen ReAll 18 Years toPhase
65 Years
2 Â (Adult,10Older
Industry
Adult)InterventioInterventi CR108416
Phase I: DeNational CaAll 18 Years toPhase
70 Years
1|PhÂ (Adult,
180Older
Change in Washington All 6 Months toNot12Applic
Months Â 1228
(Child)
Other InterventioAllocation FSM-001-2
Number and University All 65 Years and
Notolder
Applic
Â (Older2332
Adult)
Incidence Colorado SAll Child, AdulPhase 2|Ph 2712 Other InterventioAllocation 5375011|
Number ofCascadian A T ll 18 Years and
Phase
older
1 Â (Adult, 22
Older
Industry
Adult) InterventioInterventi ONT-10-10
ProportionSotio a.s. Male 18 Years and
Phase
older
2 Â (Adult, 63
Older
Industry
Dietary Di FHI 360|IntFemale 15 Years toNot
49 Years
ApplicÂ (Child,
2590Adult)
DistributioEmory Unive All 18 Years and older Â (Adult,1050
Older
Adult)
At risk dr Yale Unive All 21 Years and
Notolder
Applic
Â (Adult,319
Older
Other|NIH|
Objective Fuda CanceAll 18 Years toPhase
75 Years
2 Â (Adult,90Older
Other|Indu
Adult)InterventioAllocation CD3-MUC1 i
75 Years
2 Â (Adult,90Older
Other|Indu
75 Years
2 Â (Adult,90Older
Other|Indu
75 Years
2 Â (Adult,90Older
Other|Indu
75 Years
2 Â (Adult,90Older
Other|Indu
75 Years
2 Â (Adult,90Older
Other|Indu
75 Years
2 Â (Adult,90Older
Other|Indu
Adult)InterventioAllocation CIK and Bis
StructuredMaharishi All 15 Years to 45 Years Â (Child,
318Adult)
Immunologi Great Ormo Male up to 16 Years
Not ÂApplic
(Child) 1 Other InterventioInterventi 06MI10
Neonatal mLondon SchAll up to 12 Months
Phase 3Â (Child)15000 Other InterventioAllocation Newhints|
EHR-docume University All 18 Years and
Notolder
Applic
Â (Adult,431
Older
Other
Adult) InterventioAllocation AD-11-461
2-Item PerPhilipps U All 18 Years and
Notolder
Applic
Â (Adult,171
Older
Other
Striatal D University All 18 Years toEarly
65 Years
To evaluateIntercell U All 18 Years toPhase
40 Years
Phase
older
2 Â (Adult, 24
Older
Industry
Safety|EffiCell GenesAll 18 Years and
Phase
older
2 Â (Adult, 50
Older
Industry
Adult) InterventioAllocation P-0011
Clinical di Johns HopkAll 18 Years toPhase
45 Years
1 Â (Adult)30 Other|U.S.InterventioAllocation CIR 218|H
50 Years
CD3 cell coDavid WilliMale Child, AdulPhase 1|Ph 8 Other InterventioInterventi IND14067
Overall Su OSE ImmunAll 18 Years and
Phase
older
3 Â (Adult,363
Older
Industry
Adult) InterventioAllocation OSE2101C3
Part 1: Inc Janssen ReMale 18 Years and
Phase
older
1 Â (Adult, 26
Older
Industry
Part 1: Inc Janssen ReAll 18 Years and
Phase
older
1 Â (Adult, 18
Older
Industry
Nasal respoUniversity All 18 Years to 35 Years Â (Adult)
138 Other|NIHObservatioObservatio05-PED-10
Safety of t Advantagen All 18 Years and
Phase
older
1 Â (Adult, 15
Older
Industry
Adult) InterventioAllocation BrTK01
Number ofSanaria
v In Male 20 Years toPhase
35 Years
1 Â (Adult)30 Industry|OInterventioAllocation BSPZC1
The primary FluGen IncAll 18 Years toNot
49 Years
ApplicÂ (Adult)12 Industry InterventioAllocation FGN-NSR-2
Phagocytosi Laval Univ All 18 Years toNot
55 Years
ApplicÂ (Adult)58 Other|InduInterventioAllocation INAF-119
Immune Res Dendreon Male 18 Years and
Phase
older
2 Â (Adult, 68
Older
Industry
Death of aMedicines All 18 Years and
Phase
older
2 Â (Adult, 18
Older
Other
Adult) InterventioAllocation MDGH-MOX
Change of RWTH AachAll 18 Years and
Notolder
Applic
Â (Adult, Older
7 Other
Adult) InterventioAllocation CTCA-16-1
PTSD SympVA Office All 18 Years toNot
65 Years
ApplicÂ (Adult,
183Older
U.S. Fed
Adult)InterventioAllocation ZDA1-03-
Self Repor Weill MediAll 19 Years and
Notolder
Applic
Â (Adult,500
Older
Other
Adult) InterventioAllocation PCORI-R-A
Disease-fr Hoffmann-All 18 Years and
Phase
older
2 Â (Adult, 80
Older
Industry
Adult) InterventioAllocation GO41836|2
Referral toBoston Med All Child, AdulNot Applic 250 Other|U.S.InterventioAllocation H-35533|R
Phase
older
2 Â (Adult, 69
Older
Industry
PercentageGenentech,All 18 Years and
Phase
older
1 Â (Adult,770
Older
Industry
Adult) InterventioAllocation GO39733|2
Drug: Anti-HIV Immu National InAll 2 Years to 12
Phase
Years
1 Â (Child) 45 NIH|IndustInterventioPrimary PuACTG 273|11249
Safety/toleNovartis All 40 Years toPhase
85 Years
2 Â (Adult,31Older
Industry
Adult)InterventioAllocation CCAD106A
Caries statFederal UniAll up to 12 Months
Phase 3Â (Child) 500 Other InterventioAllocation UFPEL-PP
Safety and Novartis P All up to 85 Years
177Older
Industry
Adult)InterventioAllocation CCAD106A2
Sexual Ori Fenway Com All 18 Years and
Phase
older
1 Â (Adult, 12
Older
Other
Safety/toleNovartis All Child, AdulPhase 2 24 Industry InterventioAllocation CCAD106A
85 Years
2 Â (Adult,21Older
Industry
Excessive wUniversity All up to 2 Months
Not Applic
Â (Child) 202 Other|NIHInterventioAllocation A4540315
85 Years
2 Â (Adult,27Older
Industry
Maximum M.D.To AnderAll 16 Years and
Phase
older
1|Ph
Â (Child, Adult,
3 Other|Indu
Older Adult)
Halimetry University All 18 Years toPhase
25 Years
2 Â (Adult)45 Other InterventioAllocation HALIURU
Change froUniversity All Child, AdulNot Applic 68 Other InterventioAllocation B70720162
KnowledgeLady HardiFemale 18 Years and older Â (Adult,293Older
Other
Adult) ObservatioTime PerspLadyHardi
Duodenal VThe PrinceAll 18 Years and
Phase
older
1|Ph
Â (Adult, 12
Older
Other
Adult) InterventioInterventi AU/3/BOB
Overall SurDendreon Male 18 Years and
Phase
older
3 Â (Adult,512
Older
Industry
Adult) InterventioAllocation D9902B
Study of p Assistance All 3 Months toNot6 Months
Applic Â (Child)
58 Other InterventioInterventi P071228|2
Halitosis S University All 14 Years toNot
21 Years
ApplicÂ (Child,
130Adult)
Other InterventioAllocation halitose01
55 Years
2 Â (Adult)72 NIH InterventioAllocation Aim 1|385
HbA1c|Blood University All 18 Years and
Notolder
Applic
Â (Adult,
5000
Older
Other|Indu
Adult) InterventioAllocation 16867B (TR
Change in Palo Alto MAll 18 Years and
Notolder
Applic
Â (Adult,191
Older
Adult) 14-10-365
Recovery uWashington All 6 Months toNot59Applic
Months Â 1957
(Child)
Maternal rColumbia UFemale 18 Years and
Notolder
Applic
Â (Adult,258
Older
Adult) AAAO5601
Primary OpAmerican All 6 Months and older Â20000000
(Child, Adult,
OtherOlder ObservatioObservatioIRIS
Adult) Regist
Uptake of Virginia C All 18 Years toNot
75 Years
ApplicÂ (Adult,
1092Older
OtherAdult)InterventioAllocation HM200119
OccurrenceGlaxoSmithAll Child, Adult, Older Ad 1 Industry ObservatioObservatio 205049
49 Years
Other|NIHInterventioAllocation R01MH111
Number ofJiangsu T- All 18 Years toPhase
45 Years
1 Â (Adult)26 Industry InterventioAllocation Tmab-GW0
The proport University Female 18 Years and
Notolder
Applic
Â (Adult,377
Older
Other
Adult) InterventioAllocation UCCAREWP
Change in University All 18 Years and
Notolder
Applic
Â (Adult, 65
Older
Other
Adult) InterventioAllocation ULimerick
Maternal wHenry M. JFemale 18 Years toNot
35 Years
ApplicÂ (Adult)58 Other InterventioAllocation NHCL.2012
PerformancUniversity All 50 Years and
Notolder
Applic
Â (Adult,182
Older
Adult) 1R01NR010
ProportionBionor Im All 18 Years toPhase
55 Years
2 Â (Adult) 137 Industry InterventioAllocation CT-BI Vac
NHLBI recoTotal ChildAll up to 19 Years
Not ÂApplic
(Child, Adult)0 Industry|OInterventioAllocation 1R44HL11
Change in Q Emory UnivAll 18 Years and
Notolder
Applic
Â (Adult,121
Older
Other
Malaria in University All 5 Years to 14
NotYears
Applic
Â (Child)
Mean Asthm University All 18 Years toNot
65 Years
OtherAdult)InterventioAllocation H-2006-01
Changes inLata MedicFemale 18 Years and
Notolder
Applic
Â (Adult,
2728
Older
Other|Indu
Adult) InterventioAllocation 02_MSAKH
Human Papi Ulla BondeFemale 15 Years to 60 Years Â (Child,546Adult)
Other|InduObservatioObservatioHPV AND
PercentageCedars-SinAll 18 Years toPhase
70 Years
2 Â (Adult,60Older
Other|Indu
Adult)InterventioAllocation ATG Pilot
PrevalenceInternationAll up to 17 Months
Phase 4Â (Child)2400 Other InterventioAllocation IFPRI-201
Biological: MTP-PE/MNational InAll 18 Years toPhase
50 Years
1 Â (Adult) 8 NIH|IndustInterventioPrimary PuAVEG 103|11546|AVEG 103A|
CompositeLawson Hea All 18 Years and
Notolder
Applic
Â (Adult,400
Older
Other
Adult) InterventioAllocation LawsonHRI
Presence oEtablissemAll 18 Years to 65 Years Â (Adult,770Older
Other|Indu
Adult)ObservatioObservatio10/B/01
Clinical d University All 1 Month to 18 Years Â (Child,83Adult)
Other ObservatioObservatioRECHMPL1
Overall su Sellas Life All 18 Years and
Phase
older
3 Â (Adult,116
Older
Industry
Adult) InterventioAllocation SLSG18-30
Compare thUniversity All 4 Years to 18
Phase
Years
1 Â (Child,101
Adult)
Other|InduInterventioAllocation GABA-GAD
Eyberg ChiUniversity All Child, AdulNot Applic 124 Other InterventioAllocation UOXSIKF01
Human Leuco Assiut UnivAll 1 Year to 3 Years Â (Child) 100 Other ObservatioObservatioIDM
50 Years
1 Â (Adult)27 NIH InterventioAllocation HVTN 130/
Long actin Jack Steve Female 14 Years toPhase
19 Years
Other InterventioAllocation 90AP2678-
CompositeUniversity
a Female 18 Years to 50 Years Â (Adult)
1670 Other ObservatioObservatioHUM00101
Rates of cuCenters fo Female 15 Years and
Phase
older
3 Â (Child,
8000
Adult,
U.S.Older
Adult) CDC-NCID-
Similar ra Makerere UAll 18 Years toPhase
90 Years
OtherAdult)InterventioAllocation DN2017
Number ofWeill
p MedicAll 18 Years to 65 Years Â (Adult,
200Older
ConfirmedUniversity Male 16 Years and
Notolder
Applic
Â (Child,700
Adult,
Other
Older Adult)
Clinical im National InAll 18 Years toNot
99 Years
ApplicÂ (Adult,
674Older
The PercenMerck ShaAll 18 Years toPhase
55 Years
1 Â (Adult)448 Industry InterventioAllocation P06042|EU
Safety (al Axon Neuro All 50 Years toPhase
85 Years
Industry
Adult)InterventioAllocation AC-AD-003
Primary Ef Cerus CorpAll 10 Years and
Phase
older
3 Â (Child, Adult,
86 Industry
Older Adult)
InterventioAllocation CLI 00076
DetermineEisai
t Inc. All 18 Years and
Phase
older
1 Â (Adult, 22
Older
Industry
Adult) InterventioAllocation ZYC3-002
post-exposAssistance All up to 120 Years Â (Child, Adult,
250 Other
Older Adult)
ObservatioObservatioAPHP19691
Assemble aNational InAll 13 Years and older Â (Child,600
Adult,
NIHOlder Adult)
ContraceptUniversity Female 14 Years and
Notolder
Applic
Â (Child,300
Adult,
Older Adult) K12HD001
Number ofCarman GiaAll 18 Years toPhase
80 Years
RecurrenceUNICANCER All 18 Years and
Phase
older
3 Â (Adult,614
Older
Other|Indu
Adult) InterventioAllocation UC-0160/1
RecurrenceAzienda OsMale 30 Years and
Phase
older
4 Â (Adult,140
Older
Other
Bladder caTurku UnivAll 18 Years and
Phase
older
3 Â (Adult,300
Older
Other
Adult) InterventioAllocation Finnbladde
The effica AstraZenecAll 18 Years toPhase
130 Years
Industry
Adult)
InterventioAllocation D419JC000
complete rMedical Ent All 18 Years and
Phase
older
3 Â (Adult,106
Older
Industry
Adult) InterventioInterventi RITE-1
Phase 1: DNoah Hahn, All 18 Years and
Phase
older
1|Ph
Â (Adult,186
Older
Other|Indu
Adult) InterventioAllocation HCRN GU1
Disease fr University All 18 Years and
Phase
older
3 Â (Adult,500
Older
Other
Adult) InterventioAllocation ANZUP 130
Maximum Northweste
To All 18 Years and
Phase
older
1 Â (Adult, 27
Older
Other|Indu
Adult) InterventioInterventi NU 15U06|
Maximum Tt he Univers All 18 Years and
Phase
older
1 Â (Adult, 18
Older
Other
Adult) InterventioAllocation HSC20120
RFS time|PMedical EnAll 18 Years and
Phase
older
3 Â (Adult, Older
0 Industry
Adult) InterventioAllocation CLN-002-00
To Assess University All 18 Years toNot
89 Years
OtherAdult)InterventioInterventi 14-1359.cc
PercentagePfizer All 2 Months to 5 Years Â (Child)
9707 Industry ObservatioObservatio0887X-101
Up to dateSt. MichaelAll Child, AdulNot Applic 13 Other InterventioAllocation SMH-16-38
Part A: Fr National InAll 18 Years toPhase
50 Years
The number National InAll 15 Years toNot
99 Years
ApplicÂ (Child,
150Adult,
Adult) 16-0098|H
Safety Pro Altor BioS All 18 Years and
Phase
older
1|Ph
Â (Adult, 52
Older
Adult) CA-ALT-801
Reduction A i ga Khan UAll up to 28 Days
Phase
Â (Child)
4 1450 Other InterventioAllocation 3106-Ped-
Disease-freUniversity All 18 Years toPhase
90 Years
OtherAdult)InterventioAllocation UTV-119-1
Assess the Endo Pharm All 18 Years and
Phase
older
2|Ph
Â (Adult, 90
Older
Industry
Adult) InterventioInterventi A9301/A93
Response tMemorial SAll 18 Years and
Phase
older
3 Â (Adult, 50
Older
Other
Efficacy o National InFemale 18 Years toPhase
45 Years
2 Â (Adult)234 NIH InterventioAllocation 09-0070|DM
Hospitaliz University All 6 Months to 8 Years Â (Child)
1517 Other|InduObservatioObservatio16-1785
RecurrenceMedical EnAll 18 Years and
Phase
older
3 Â (Adult,190
Older
Industry
Adult) InterventioAllocation 102.1
local toxic National UAll 18 Years and
Phase
older
2|Ph
Â (Adult,140
Older
Other
Adult) InterventioAllocation NMRC/008
Condomless NorthwesteMale 13 Years toNot
18 Years
ApplicÂ (Child,
1878 Adult)
Other|NIHInterventioAllocation 5U01MD01
Internaliz New York UFemale 18 Years toNot
45 Years
ApplicÂ (Adult)
200 Other InterventioAllocation TW011084
OccurrenceGlaxoSmithFemale 15 Years to 25 Years Â (Child, Adult)
2 Industry|OObservatioObservatio 114176
Etiology ofGÃ¶teborgAll 18 Years and older Â (Adult,310
Older
Other
Adult) ObservatioObservatioFATB Study
o evaluate George AlbAll 18 Years and
Phase
older
1 Â (Adult, Older
2 Other
Adult) InterventioAllocation PANC0003|
Delivery i University Female 16 Years toNot
49 Years
ApplicÂ (Child,
572Adult)
Anti-Tat AnThymon, L All 18 Years toPhase
50 Years
1|PhÂ (Adult)27 Industry InterventioAllocation THYMON-1
Immunoglob Duke Univ All 18 Years and older Â (Adult, 11Older
Other|Indu
Adult) ObservatioObservatioPro000439
Anti-Tat AnThymon, L All 18 Years toPhase
50 Years
ParticipantNational I All 18 Years toEarly
50 Years
PhasÂ (Adult)19 NIH|OtherInterventioAllocation DAIT ITN04
Objective PDS BiotecAll 18 Years and
Phase
older
2 Â (Adult, 96
Older
Industry
Adult) InterventioInterventi PDS0101-H
Number ofVA Office All 18 Years toNot
99 Years
ApplicÂ (Adult,
309Older
U.S. Fed
Adult)InterventioAllocation SDP 10-04
Change in Inner Mongo All 25 Years toNot
45 Years
ApplicÂ (Adult)
240 Industry InterventioAllocation YL/CL-003
Number ofGlaxoSmith
s All 18 Years toNot
40 Years
ApplicÂ (Adult)
Comparison Sotio a.s. All 18 Years and
Phase
older
1|Ph
Â (Adult,105
Older
Industry
Adult) InterventioAllocation SLU01|201
Incidence BCN Checkp Male 18 Years and older Â (Adult,900Older
Industry|OObservatioObservatioBCP-FTD-2
Adult)
Rate of decCrucell HolAll 18 Years and
Phase
older
2 Â (Adult, Older
Adult) CR102576|
Survival r Sotio a.s. Male 18 Years and
Phase
older
2 Â (Adult, 60
Older
Industry
Change in FHI 360|UnFemale 18 Years and
Notolder
Applic
Â (Adult,
6536
Older
Adult) 1236187|1
Number ofBiogen
p All 18 Years toPhase
55 Years
1 Â (Adult)29 Industry InterventioAllocation 234HV101|
Estimating American UAll up to 5 Years Â (Child) 1600 Other ObservatioObservatioPED.GD.06
Score on a Assistance All 18 Years and older Â (Adult,300Older
Other
Adult) ObservatioObservatioAOM02020
seeking in University All 18 Years and
Notolder
Applic
Â (Adult,907
Older
Adult) HHSN2762
Caregiver aBoston Med All up to 9 Months
Not Applic
Â (Child) 0 Other|U.S.InterventioAllocation H-37185|T
Induction Johann WolAll 7 Years to 28 Years Â (Child, Adult)
68 Other ObservatioObservatioFRA-2012-
Incidence UmeÃ¥ Univ All up to 8 Weeks
Not ÂApplic
(Child) 252 Other|InduInterventioAllocation LIME2014
Up to DateJohns HopkAll 18 Years and
Notolder
Applic
Â (Adult,158
Older
Other
HPV prevalChulalongkAll Child, Adult, Older Ad 175 Other ObservatioObservatioIRB NO. 40
changes ofThe First AAll Child, Adult, Older Ad 600 Other ObservatioObservatioStatinsHBV
Identify anUniversity Female 18 Years toNot
39 Years
ApplicÂ (Adult)
2267 Other InterventioAllocation IHS-1306-
Number ofOrchard ThAll up to 65 Years
PhaseÂ 2(Child, Adult,6Older
Adult) OTL-103-4
Biological: aldesleuk Barbara AnAll 18 Years and
Phase
older
2 Â (Adult, 60
Older
Adult) NCDR000006
ComorbiditAssistance All 18 Years toNot
80 Years
ApplicÂ (Adult,
503Older
Incidence Wendy F Ha Female 18 Years toNot
55 Years
ApplicÂ (Adult)
1620 Other InterventioAllocation 44929|MAT
Change in University Female 18 Years and
Notolder
Applic
Â (Adult,200
Older
Other
Adult) InterventioAllocation STUDY001
Change in University Female 15 Years and
Notolder
Applic
Â (Child,
1680
Adult,
Older Adult) HUM00161
DSS Invest Duke UniveAll up to 6 Months
Not Applic
Â (Child) 2329 Other|NIHInterventioAllocation Pro000209
Evaluation GlaxoSmithAll 18 Years and older Â (Adult,757Older
Industry
cost-effectAssistance Female 18 Years and older Â (Adult, 2532
Older
Other
Adult) ObservatioTime PerspP 060410|
Drug: Indinavir sulfa National InAll 18 Years and
Notolder
Applic
Â (Adult, 24
Older
NIHAdult) InterventioMasking: NACTG 387|11346
Diagnostic Karolinska All up to 12 Years Â (Child) 600 Other ObservatioObservatio2018/1676
Safety|ToxMilton S. All 2 Years andPhase
20 Other|NIHInterventioMasking:
Older Adult) NCDR000061
To acceler Sanford HeAll Child, Adult, Older Ad 20000 Other ObservatioObservatio03-10-014|
Difference FHI 360|UnFemale 18 Years and
Notolder
Applic
Â (Adult,
9234
Older
Adult) 1234890-6
Minimum In Novartis P All 20 Years toPhase
60 Years
2 Â (Adult)25 Industry InterventioAllocation CKAE609A
visits by Johns HopkAll Child, AdulNot Applicable Other InterventioAllocation NA_00001
A mindfulnFederal UniAll 18 Years toNot
65 Years
ApplicÂ (Adult,
142Older
OtherAdult)InterventioAllocation CEP639061
Annual clinUniversity All 6 Months and
Not older
ApplicÂ (Child,
122872Adult,
Adult) U19AI1293
Maximum University
co All 18 Years toNot
85 Years
OtherAdult)InterventioAllocation FAT Study
Change froRyerson UnAll 18 Years and older Â (Adult,900
Older
Other
Adult) ObservatioObservatioREB 2010-
72 hours thUniversity All 18 Years and older Â (Adult, 30
Older
Other
Adult) ObservatioObservatio2015-AO19
Phase
older
2 Â (Adult, 27
Older
Industry
Civilizatio University All up to 18 Years Â (Child, Adult)
12000 Other ObservatioObservatioLIFE Child
OccurrenceSunovion|SAll 18 Years and
Phase
older
1 Â (Adult, 64
Older
Industry
Adult) InterventioInterventi D8350004
ProgressioSotio a.s. Female 18 Years and
Phase
older
2 Â (Adult, 30
Older
Industry
Adult) InterventioInterventi SOV06|201
Difference University All 18 Years toNot
29 Years
ApplicÂ (Adult)
522 Other InterventioAllocation SSC2359|1
HIV Viral Thymon, L All 18 Years toPhase
50 Years
Relapse-freNantKwest,All 18 Years and
Phase
older
2 Â (Adult, Older
0 Industry
CD8 T cell Cynthia L GAll 18 Years toPhase
65 Years
1 Â (Adult, 6Older
Other|Indu
Adult)InterventioAllocation 13-3613|D
Reduction Aga Khan UAll 6 Months toNot24Applic
Months Â 4200
(Child)
Other InterventioAllocation Stunting S
ProgressioGradalis, InAll 2 Years andPhase
114 Industry
Older Adult)
InterventioAllocation CL-PTL-130
Conditioni Orchard ThAll Child, AdulPhase 1|Ph 8 Industry|OInterventioInterventi 201228|20
Compare inTotal Chil All 1 Month toNot
2 Years
Applic
Â (Child)
16630 Industry|NInterventioAllocation R44HD089
Regimen LiNewLink Ge All 18 Years and
Phase
older
1 Â (Adult, 16
Older
Industry
Adult) InterventioInterventi NLG0401|1
Overall su Sotio a.s. Female 18 Years and
Phase
older
2 Â (Adult, 22
Older
Industry
Adult) InterventioAllocation SOV03
Overall Su Bavarian NMale 18 Years and
Phase
older
3 Â (Adult,
1297
Older
Industry
Adult) InterventioAllocation BNIT-PRV-
Rate of pa Ajou UniveAll 60 Years toPhase
75 Years
Other|Indu
Adult)InterventioAllocation AJIRB-GEN
Change in Roswell PaAll 18 Years and
Phase
older
1|Ph
Â (Adult, 23
Older
Other|Indu
Number ofMerck ShaAll Child, Adult, Older Ad 682 Industry ObservatioObservatioP05557
DeterminatBoston BioAll 18 Years and
Phase
older
2 Â (Adult,219
Older
Industry
Cohort 1: Medicines All 18 Years toPhase
45 Years
1 Â (Adult)32 Other|InduInterventioAllocation MMV_P218
OccurrenceCelldex Th All 18 Years toPhase
99 Years
Industry
Adult)InterventioInterventi CDX1401-0
Age-appropAga Khan UAll Child, AdulNot Applic 48 Other InterventioAllocation 4676-WCH-
Phase Ib: DBoston BioAll 18 Years and
Phase
older
1|Ph
Â (Adult, 84
Older
Industry
The develoTechnischeAll 4 Months toPhase
7 Months
2 Â (Child)
1040 Other|InduInterventioAllocation GPPAD-03-
Number ofNational
p InMale 18 Years toPhase
50 Years
2 Â (Adult)
2700 NIH InterventioAllocation HVTN 704/
Overall re Oslo UniveAll 18 Years and
Phase
older
2 Â (Adult, 20
Older
Other|Indu
Adult) InterventioInterventi Lymvac-2
Safety baseAdvantagen All 18 Years and
Phase
older
1 Â (Adult, 27
Older
Industry
Adult) InterventioAllocation PaTK01
Safety & TolScancell LtAll 18 Years and
Phase
older
1|Ph
Â (Adult, 35
Older
Industry
Adult) InterventioInterventi SCIB1-001
Overall Re H. Lee MofAll 18 Years and
Phase
older
2 Â (Adult, 17
Older
Other
RecurrenceJanssen ReAll 18 Years and
Phase
older
2 Â (Adult,280
Older
Industry
Box ownersUniversity All up to 2 Months
Not Applic
Â (Child) 30 Other InterventioAllocation H2017:390
Randomized X4 Pharmac All 12 Years and
Phase
older
3 Â (Child, Adult,
28 Industry
Older Adult)
InterventioAllocation X4P-001-1
Change froPfizer All 12 Years toPhase
17 Years
3 Â (Child)225 Industry InterventioAllocation B7451036|
study-specUniversity Female Child, AdulNot Applic 400 Other InterventioAllocation HP-000762
The primary NorthwestAll 18 Years toPhase
70 Years
Industry
Genetic: Allovectin-7 Vical All 18 Years and
Phase
older
3 Â (Adult, Older
Industry
Adult) InterventioAllocation VCL-1005-207
Part A: Ch Biogen All 18 Years toPhase
75 Years
Industry
Adult)InterventioAllocation 230LE201|
Genetic: Allovectin-7 Vical All 18 Years and
Phase
older
2 Â (Adult,133
Older
Industry
Adult) InterventioInterventi VCL-1005-
Comparison Vastra GotAll Child, Adult, Older Ad 80 Other ObservatioObservatiover 1.0|01
Control PreNational TaAll 20 Years and
Notolder
Applic
Â (Adult,128
Older
Other
Adult) InterventioAllocation 1-1-7-05-1
Care coordiUniversity All 3 Years and older Â (Child,2118
Adult,
Other
Older Adult)
ObservatioObservatio14-2045
LongitudinaNational I Male Child, Adult, Older Ad 541 NIH|OtherObservatioObservatioDAIT RDCR
Subjects i Mount SinaMale 18 Years toPhase
70 Years
Adverse evCrucell HolAll 18 Years toPhase
50 Years
1 Â (Adult)64 Industry|NInterventioAllocation FLU-M8-A0
Recall of ABaylor Col All 21 Years and
Phase
Older
Adult) HHSA2901
Adverse evCrucell HolAll 18 Years toPhase
50 Years
1 Â (Adult)64 Industry|NInterventioAllocation FLU-M6-C0
Change in Boston Med All Child, AdulNot Applic 76 Other InterventioAllocation H-35188
Number ofAssistance All 18 Years and older Â (Adult,400Older
Other
Adult) ObservatioObservatioNI-2015
72 Years
Outcomes Foujian ProvAll Child, Adult, Older Ad 95 Other ObservatioObservatioK2018-09-
National I University Female 14 Years toNot
24 Years
ApplicÂ (Child,
312
Adult)
Other|U.S.InterventioAllocation D89MC231
Drug: Syngeneic LympNational HAll Child, AdulPhase 1 48 NIH InterventioPrimary Pu960051|96
Genomic an University All up to 55 Years Â (Child, Adult)
200 Other|NIHObservatioObservatioIRB201500
PreventiveUniversity All 50 Years and
Phase
Older
Other
Adult) InterventioAllocation IU48DP09-
Mortality|World HealAll 2 Months toPhase
23 Months
3 Â 8268
(Child)
Other InterventioAllocation ERC.00027
The incidenNantes UniAll up to 24 Hours
Not Applic
Â (Child) 8698 Other InterventioAllocation BRD/10/06
AntiplateleOutpatientAll 18 Years and older Â (Adult,
600000
Older
Other
Adult) ObservatioObservatio2016-OEIS
Iron statu Cornell UnAll 12 MonthsNotto 18
Applic
Months Â 223
(Child)
Other InterventioAllocation IRB #: 140
Change in VanderbiltAll 21 Years and
Notolder
Applic
Â (Adult,250
Older
Adult) 190825|5K
The differeNational InAll 18 Years toPhase
99 Years
4 Â (Adult,62Older
Early Viro Mashhad Un All 18 Years toPhase
70 Years
2 Â (Adult,40Older
OtherAdult)InterventioAllocation Mashhad
Rate of maAmgen|Orga Female 1 Year to 100 Years Â (Child,375
Adult,
Industry|OObservatioObservatio20150338
Older Adult)
Number ofCentre Hosp All 18 Years toNot
65 Years
ApplicÂ (Adult,
164Older
OtherAdult)InterventioAllocation PI2016_84
Number ofUniversity Female 15 Years and older Â (Child,1200
Adult,
Other
Older Adult)
ObservatioObservatioMRCZ/A/1
Rate of maSanofi|RegFemale Child, Adult, Older Ad 375 Industry|OObservatioObservatioOBS14703|
50 Years
1 Â (Adult)124 NIH InterventioAllocation HVTN 127/
Rabies Vir Grifols TheAll 18 Years toPhase
65 Years
1 Â (Adult,12Older
Industry
Adult)InterventioInterventi GTI1301
Number ofHIV PreventMale 18 Years and
Notolder
Applic
Â (Adult,
1553
Older
Adult) HPTN 061|
Asthma con MaastrichtAll 18 Years toNot
70 Years
ApplicÂ (Adult,
160Older
Other|Indu
Adult)InterventioAllocation METC 18-0
Drug: Cryptosporidi Univax BiolAll 18 Years and
Phase
Older
Industry
Adult) InterventioMasking: D081A|UNX-4101
Incidence X4 Pharmac All Child, Adult, Older Ad 0 Industry ObservatioObservatioX4-WHIM-
Desirabili National InAll 6 Months toPhase
71 Months
4 Â (Child)
o The prevBandim Hea All up to 6 Hours
NotÂApplic
(Child) 788 Other InterventioAllocation 2007HT
ProportionGlaxoSmithAll 3 Months to 5 Years Â (Child)10 Industry ObservatioObservatio 113932
To study thAsociacion Instituto Child, Adult, Older Ad 907 Other ObservatioObservatioHOSPIGRIP
OccurrenceGlaxoSmithAll 3 Months to 5 Years Â (Child)66 Industry ObservatioObservatio 111337
A significa Radboud Un All 18 Years toNot
45 Years
ApplicÂ (Adult)15 Other InterventioAllocation EHMI-8
The primary Vertex PhaAll 18 Years toPhase
45 Years
2 Â (Adult)140 Industry InterventioAllocation VX11-787-
To evaluateTaiMed BioAll 18 Years toPhase
40 Years
1 Â (Adult)25 Industry|OInterventioAllocation TMB-108
To assess Queen Fabio All up to 18 Years Â (Child, Adult)
250 Other ObservatioObservatioP2020/Hem
Incidence Advaxis, InAll 18 Years and
Phase
5 Industry
Adult) InterventioAllocation ADXS-NEO-
Incidence oUniversity All 18 Years toPhase
65 Years
OtherAdult)InterventioAllocation UHLillle|
Toxicity E Augusta UnAll 18 Years and
Phase
2 Other
Adult) InterventioInterventi 11-C-0100
Cost per caPATH|UniteAll 6 Months and
Not older
ApplicÂ (Child,
4636Adult,
Quality of Lille CathoAll 18 Years and
Notolder
Applic
Â (Adult,174
Older
Other
Adult) InterventioAllocation RC-P0071
ProgressionNina BhardAll 14 Years and
Phase
8 Other|Indu
Older Adult)
InterventioInterventi GCO 13-16
PercentageUniversity A Hll 8 Years to 50 Years Â (Child,240
Adult)
Other ObservatioObservatio2011_21|2
weight los University All 18 Years and
Phase
older
2 Â (Adult,194
Older
Adult) P01AT0050
Early BacteNational InAll 18 Years toPhase
65 Years
2 Â (Adult,75Older
50 Years
Vitamin D Bangor UniMale 17 Years toNot
35 Years
ApplicÂ (Child,
260
Adult)
Other InterventioAllocation 692/Gen/1
Participan NorthwesteMale 18 Years toNot
29 Years
ApplicÂ (Adult)
901 Other|NIHInterventioAllocation 1R01DA035
PercentageAstraZenecAll 40 Years and older Â (Adult,976Older
Industry
Adult) ObservatioObservatioRO-2455-4
Safety andNewLink Ge All 18 Years and
Phase
older
2 Â (Adult, 47
Older
Industry
Appearance National I All up to 4 Months Â (Child) 8668 NIH|Other| ObservatioObservatioDK095300;
NeurodevelThe HospitFemale Child, AdulPhase 3 2294 Other InterventioAllocation 1E+09
Number ofAuritec PhaAll 18 Years toEarly
45 Years
PhasÂ (Adult) 8 Industry|NInterventioInterventi RTB-010|U
change in hHospital Mutua
All de Terrassa|Public
6 Months toNot14
Health
Applic
YearsAgency
Â (Child)
492
of Barcelona|Hospital
Other InterventioInterventi
Vall d'Hebron|Hospital
P16/094 Sant Joan de Deu|In
Feasibility Rutgers, ThAll 18 Years toNot
29 Years
ApplicÂ (Adult)65 Other|NIHInterventioAllocation 201500019
Serum Conc Hoffmann-All 10 Years toPhase
18 Years
Industry InterventioAllocation WA39085|2
The primarAssistance All 18 Years and older Â (Adult,400Older
Other
Adult) ObservatioObservatioHAO 1702
DB Period:Teva BrandAll 18 Years toPhase
70 Years
Industry
Adult)InterventioAllocation TV48125-C
Nasal carriPoitiers UnAll 18 Years and
Notolder
Applic
Â (Adult, 70
Older
Other
Adult) InterventioInterventi ONCOVIR
Number ofFrench
c NatAll up to 5 Years Â (Child) 460 Other ObservatioObservatioANRS 1214
Infant len Johns HopkFemale 15 Years toNot 49 Years
ApplicÂ (Child,
5280
Adult)
Other|NIHInterventioAllocation IRB000042
Number ofNational
P InAll up to 24 Months
Phase 2Â (Child) 155 NIH InterventioAllocation 09-0065
Drug: Globulin, ImmuAmerican Na All 18 Years and
Notolder
Applicable
Â (Adult, Older
Other
Adult) InterventioPrimary Pu079A|219-90
Drug: Anti-HIV Immu Eunice KenFemale 13 Years toPhase 60 Years
3 Â (Child,1600
Adult)
NIH InterventioInterventi ACTG 185
Drug: Globulin, ImmuNational InAll 3 Months toPhase
12 Years
3 Â (Child) 250 NIH InterventioMasking: DACTG 051|11025
Drug: Zidovudine|DruNational I All 18 Years and
Phase
older
1 Â (Adult, Older
6 NIH|Indust
Adult) InterventioMasking: NACTG 080|11055
Drug: CD4-IgG National InAll up to 60 Years
30 NIH|IndustInterventioMasking: NACTG 146|D0190g
PercentageNational InAll 6 Months toPhase
85 Years
NIH OlderInterventioAllocation
Adult) 07-0051|U
Compare the Maura Palm All 18 Years to 35 Years Â (Adult)400 Other ObservatioObservatio1382/2019
Adverse EvTaiga BioteAll 1 Month toPhase
4 Years
1 Â (Child) 8 Industry InterventioInterventi TBX-1400-
The mean ra AstraZenecAll Child, Adult, Older Ad 5020 Industry ObservatioObservatioD2287R00
ProportionUNC LinebeMale 18 Years and older Â (Adult,101Older
Other
Adult) ObservatioObservatioLCCC 1218
- To measurSociety fo All 6 Months toNot30Applic
Months Â 2482
(Child)
Other InterventioAllocation ERB3514PL
Number ofNational InAll 4 Years to 10
Phase
Years
2 Â (Child)170 NIH|OtherInterventioAllocation DAIT AAD
Changes inOslo MetroAll 18 Years and
Notolder
Applic
Â (Adult, 96
Older
Other
Adult) InterventioAllocation REK S-0741
The primary University All 18 Years and
Phase
older
2 Â (Adult, 52
Older
Other|NIH|
Adult) InterventioAllocation 1111M0658
Change in sFood for t Female 18 Years and Notolder
Applic
Â (Adult,
1248
Older
Other
Adult) InterventioAllocation FHU-ECF
Average Il Materia MeAll 1 Month toPhase
3 Years
3 Â (Child)142 Industry InterventioAllocation MMH-AD-0
Evaluation Hospices CiAll 18 Years and older Â (Adult, 1493
Older
Other
Phase
older
1 Â (Adult, Older
6 Other|Indu
AdjudicatePfizer All 18 Years toPhase
76 Years
Industry
Adult)InterventioAllocation A3921086|
Evaluate t Nantes UniAll 18 Years and
Phase
older
2 Â (Adult, 11
Older
Other
Adult) InterventioInterventi RC14_042
DetermineMassBiolo
i All 18 Years and
Phase
older
2 Â (Adult,200
Older
Other|Indu
Adult) InterventioAllocation CA-GCDX-0
Phase
older
2 Â (Adult, 48
Older
Industry
Bacteriolo National InAll 18 Years toPhase
60 Years
Duration ofMateria MeAll 1 Month toPhase
6 Years
4 Â (Child)
1036 Industry InterventioAllocation MMH-AD-0
EstimationHIV PreventAll 18 Years and older Â (Adult,2099
Older
Other|NIHObservatioObservatioHPTN
Adult) 064|
The feasibiTata Memor Female 30 Years toNot
55 Years
ApplicÂ (Adult)
227 Other InterventioInterventi TMHPO176
Quantity oUniversity All 70 Years andNotolder
Applic
Â (Older308
Adult)
Other|NIHInterventioAllocation 1607S9092
Percent of National I All Child, AdulPhase 3 5610 NIH|IndustInterventioAllocation A5300B/I2
75 Years
2 Â (Adult,
1200Older
NIH Adult)InterventioAllocation 999916133
ProportionRennes UniFemale 18 Years andNotolder
Applic
Â (Adult,100
Older
Other
Adult) InterventioAllocation Rennes Un
Parental a University All up to 2 Years
NotÂApplic
(Child) 303 Other InterventioAllocation 82296
older2|Ph
Â (Adult,
5000
Older
NIH|Indust
Adult) InterventioAllocation HPTN 083|
Time to theMateria MeAll 6 Months to Phase
6 Years
4 Â (Child)287 Industry InterventioAllocation MMH-ER-0
The number Toronto EaAll 50 Years andNotolder
Applic
Â (Adult,470
Older
Other
Adult) InterventioAllocation TEGH001 P
Birth weig Brigham anFemale Child, AdulPhase 4 5280 Other InterventioAllocation 2018P0024
PercentageMateria MeAll 18 Years toPhase
60 Years
4 Â (Adult)161 Industry InterventioAllocation MMH-ER-0
Hemoglobin University All 18 Years andNotolder
Applic
Â (Adult,300
Older
Other
Malaria in Brian Foy|All Child, AdulPhase 3 4700 Other InterventioAllocation 18-1803H
The time f National InAll 12 Years toPhase
99 Years
Adult) 16-0092|H
Adjusted hCerus CorpAll 18 Years andPhase
Older
Industry
Adult) InterventioAllocation CLI 00126
45 Years
3 Â (Adult)
3200 NIH InterventioAllocation HPTN 084|
Study medicJohnson & All Child, Adult, Older Ad 124 Industry ObservatioObservatioCR004408|
Number ofPfizer All 18 Years andPhase
Older
Industry
Change in Lallemand All 6 Years to 16
Phase
Years3 Â (Child)150 Industry InterventioAllocation LPI-1201
TB diseaseCenters forAll 12 Years andPhase
older3 Â (Child,
2516
Adult,
U.S.Older
Adult) 6655
Average durMateria MeAll 18 Years toPhase
60 Years
3 Â (Adult)282 Industry InterventioAllocation MMH-ER-0
Time to NoNational InAll Child, AdulPhase 2 98 NIH InterventioAllocation 10-I-0043|
Number ofPfizer All Child, Adult, Older Ad 479 Industry ObservatioObservatioA3921336
Immunologi Institut Pa All 18 Years toNot
100Applic
Years Â (Adult,
800 Older
Industry
Adult)
InterventioAllocation 2010-06|1
One-year OGlaxoSmithAll 18 Years andPhase
Older
Industry
HBA1C|Tota Universite All Child, AdulNot Applic 375 Other InterventioInterventi A0456
CumulativePATH|Rwand All 6 Months and older Â (Child,3669 Adult,
OtherOlder ObservatioObservatio1409734-2
Adult)
CumulativePATH|NatioAll 6 Months and older Â (Child,6734 Adult,
OtherOlder ObservatioObservatio1379279-2
Adult)
Incidence Bristol-My All 18 Years andPhase
older1|Ph
Â (Adult,435
Older
Industry
Adult) InterventioAllocation CA012-004
Number ofHvivo|GlaxAll 60 Years toNot
75 Years
Industry
Adult)InterventioInterventi RVL-OCS-0
Disease Fr GlaxoSmithAll 18 Years andPhase
older3 Â (Adult,
1351
Older
Industry
PercentageSanquin ReAll 18 Years andNotolder
Applic
Â (Adult,567
Older
Other|Indu
Adult) InterventioAllocation ABR30643
Change in Vanderbilt Female 18 Years toNot
50 Years
ApplicÂ (Adult)
198 Other InterventioAllocation R01HD447
Compare thNantes UniAll 18 Years andPhase
0 Other
Child MortColumbia UAll 15 Years andNotolder
Applic
Â (Child,
65000
Adult,
Other
Older Adult)
InterventioAllocation AAAA8202
Safety of dUppsala UnAll 18 Years andPhase
older1|Ph
Â (Adult, Older
4 Other|Indu
Adult) InterventioInterventi AS Dnr201
49 Years
DeterminatNantes UniAll 18 Years andPhase
older1|Ph
Â (Adult, Older
0 Other|Indu
Total bodyEthiopian All 3 Years to 5Not
Years
Applic
Â (Child) 138 Other InterventioAllocation EPHI_IAEA
Area UnderBaxalta now All 2 Years to 65
Phase
52 Industry
Older Adult)
Older
Industry
Birth weighTampere Un All 15 Years andPhase
older3 Â (Child,
1391
Adult,
Other
Older Adult)
InterventioAllocation iLiNS-DYA
SCL-20 depUniversity Female 18 Years andNotolder
Applic
Â (Adult,168
Older
Adult) R01MH084
Phase 1: OEMD Serono All up to 18 Years
Phase
Â 1|Ph
(Child, Adult)
148 Industry InterventioAllocation MS100070-
New mental Children's All Child, Adult, Older Ad 396000 Other ObservatioObservatioFP0002461
Number ofViiV Healt All 18 Years andPhase
older
3 Â (Adult,618
Older
Industry
Newborn he Harvard ScFemale 18 Years toNot
45 Years
ApplicÂ (Adult)
4467 Other InterventioAllocation newborn2
The primarTheracloneAll 18 Years toPhase
45 Years
2 Â (Adult)64 Industry InterventioAllocation TCN-032-0
Disease-freCancer ReseAll 18 Years andPhase
older
3 Â (Adult,242
Older
Other
Adult) InterventioAllocation CRC-TU-BL
RSV viral PulmocideAll 18 Years toPhase
55 Years
1|PhÂ (Adult)56 Industry InterventioAllocation PC_RSV_00
PercentageViiV Healt All 18 Years andPhase
older
3 Â (Adult,628
Older
Industry
Time To SpOtsuka PhaAll 18 Years toPhase
69 Years
Industry
Adult)InterventioAllocation 242-09-21
Change in mDuke UniverAll 60 Years and older Â (Adult,250 Older
Other|NIHObservatioObservatioPro001034
Adult)
Success-ratNew York PAll up to 7 Years
NotÂApplic
(Child) 134 Other InterventioAllocation ITI
Hamilton dUniversity Female 18 Years toNot
45 Years
ApplicÂ (Adult)
4205 Other|NIHInterventioAllocation 5U19MH09
Incidence Boston Med All up to 64 Years
Not ÂApplic
(Child, Adult)
325 Other|NIHInterventioAllocation H-31407|
The plateleTerumo BCAll 16 Years andEarly
older
Phas
Â (Child,118
Adult,
Industry
Older Adult)
InterventioAllocation CTS-0028
30% improv Institut N All 2 Years to 20
Phase
Years
2|Ph
Â (Child, Adult)
24 Other InterventioAllocation C05-40
ProportionCerus CorpAll 11 Years andPhase
older
3 Â (Child,600
Adult,
Industry
Older Adult)
InterventioAllocation CLI 00125
Phase A - University All 18 Years toNot
45 Years
ApplicÂ (Adult)80 Other InterventioAllocation RHM MED1
PercentageGenentech,All 50 Years andPhase
older
2 Â (Adult,360
Older
Industry
Adult) InterventioInterventi GN28525|2
Rate of pa Rennes UniAll 18 Years andPhase
older
2 Â (Adult, 17
Older
Other
The compariUniversity All 60 Years andNotolder
Applic
Â (Adult,
7000
Older
Other
Adult) InterventioAllocation RC31/17/0
3- and 5-yeThe First AFemale 18 Years toNot
65 Years
ApplicÂ (Adult,
204Older
OtherAdult)InterventioAllocation ZYZC20160
Rates of p Heart of E All 18 Years andNotolder
Applic
Â (Adult,
1000
Older
Other|Indu
Adult) InterventioAllocation 2017069R
Number ofLVCT HealtAll 15 Years andNotolder
Applic
Â (Child,
2100
Adult,
Other
Older Adult)
InterventioInterventi NON-SSC N
Skilled de University Female 14 Years toNot
45 Years
ApplicÂ (Child,
2550Adult)
Other InterventioAllocation 09-086KU
to evaluateSuez CanalAll Child, AdulNot Applic 39 Other InterventioInterventi Well-child
Assess saf Orchard ThAll 1 Month and Phase
older
1|Ph
Â (Child, Adult,
20 Industry|NInterventioInterventi
Older Adult) IND 15440
Treatment University All 40 Years toPhase
85 Years
OtherAdult)InterventioAllocation RECHMPL19
Change froArray BioPAll 18 Years andPhase
older
3 Â (Adult,160
Older
Industry
Adult) InterventioAllocation ARRAY-797
Adverse EvCelgene CoAll 18 Years toPhase
55 Years
1 Â (Adult)64 Industry InterventioAllocation CC-220-CP
AssessmentEmergent BAll Child, AdulPhase 4 100 Industry|UInterventioInterventi 200137
Viral Load University All 18 Years andPhase
older
3 Â (Adult,224
Older
Other
Adult) InterventioAllocation PHAO13-TP
An index s NestlÃ© All 6 Weeks to 4 Months Â (Child)4000 Industry ObservatioObservatio17.12.INF
occurrenceUniversity All 18 Years toPhase
99 Years
OtherAdult)InterventioAllocation PHRN09 -
Number ofNational I All 16 Years andPhase
older
2 Â (Child,137
Adult,
Older Adult) DAIT ITN03
ProportionMassachuse All 21 Years andNotolder
Applic
Â (Adult,
10000
Older
Other
PercentageViiV Healt All 18 Years andPhase
older
3 Â (Adult,
1049
Older
Adult) 207966|20
Glycemic cBaylor Col All 18 Years andNotolder
Applic
Â (Adult,126
Older
Adult) K23DK1103
Child AbusJohns HopkFemale Child, AdulNot Applic 380 Other InterventioAllocation 99-0155|C
Maximum St.ef Jude ChAll up to 21 Years
Phase
Â 2(Child, Adult)
140 Other InterventioInterventi HAP2HCT
Increase inWestat|Mak All 1 Year to 13Not
Years
Applic
Â (Child) 77 Other InterventioAllocation 170901
24-month ovIstari OncoAll 18 Years andPhase
older
2 Â (Adult,112
Older
Adult) Pro000770
older
1 Â (Adult, 33
Older
Industry
MilwaukeePhilipps U All 18 Years andNotolder
Applic
Â (Adult,120
Older
Other
PercentageWyeth is nAll 12 Months to 18 Months Â3641 (Child)
Industry ObservatioTime Persp0887X1-46
Clinical R Leonard ApAll 18 Years andPhase
older
1|Ph
Â (Adult, 30
Older
Other|Indu
Adult) InterventioInterventi UPCI 11-0
Measuremen University All 18 Years to 99 Years Â (Adult,200Older
Isometric University All 18 Years and
Notolder
Applic
Â (Adult, Older
Adult) IRB201500
Person YeaGlaxoSmithAll 18 Years and
Phase
older3 Â (Adult,
2278
Older
Industry
MaidstoneUnited Ki Sheffield United Kingdom" https://ClinicalTrials.gov/show/NCT00480025
Overall su Orchard ThAll Child, Adult, Older Ad 50 Industry ObservatioObservatioSTRIM-003
Phase
Older
Other
Adult) InterventioAllocation IgG2CT001
Notolder
Applic
Â (Adult,360
Older
Other
Adult) InterventioAllocation AD-1306-0
Survival ofUniversity All 2 Months and
Phaseolder
1|Ph
Â (Child,15
Adult,
Adult) 17-22799|
Success (e Sansum DiaAll 7 Years and older Â (Child,5000
Adult,
Other|Indu
Older Adult)
ObservatioObservatio2017 - 600
preterm biYale Unive Female Child, AdulPhase 4 1000 Other InterventioInterventi 1.3E+09
49 Years
2 Â (Adult) 0 Industry InterventioInterventi TAK-850/C
Measure cyUniversity A Hll 40 Years and
Notolder
Applic
Â (Adult,100
Older
Other
Adult) InterventioAllocation 2013_76|2
Number ofKonkuk UniAll 40 Years and older Â (Adult,2000
Older
Other
Adult) ObservatioObservatioKUH10103
Change in tUniversity All 18 Years and
Notolder
Applic
Â (Adult,500
Older
Adult) UH3DA0448
Change froMcMaster FUemale 16 Years and
Notolder
Applic
Â (Child,492
Adult,
Older Adult) MacMillan
Malaria infLondon SchAll 6 Months toNot14Applic
Years Â (Child)
4200 Other InterventioAllocation ITDCZN11
Number ofOslon UniveAll 18 Years toPhase
65 Years
Peripheral University All 18 Years to 80 Years Â (Adult,40Older
OtherAdult)ObservatioObservatioEMPATHY
Phase
Years3 Â (Child)127 Industry InterventioAllocation 0881A1-33
Total direc Brigham anAll 18 Years and
Notolder
Applic
Â (Adult,500
Older
Other
Total direc Brigham anAll 18 Years and
Notolder
Applic
Â (Adult, 91
Older
Other
New or worBrigham anAll 18 Years and
Notolder
Applic
Â (Adult, 51
Older
Other
Total cost Brigham anAll 18 Years and
Notolder
Applic
Â (Adult, 21
Older
Other|Indu
Adult) InterventioAllocation 2016P0013
Number ofUniversity
50 Years
COPD Asses Lawson Hea All 40 Years and
Notolder
Applic
Â (Adult,182
Older
Other|Indu
Success (e Sansum DiaAll 19 Years and
Notolder
Applic
Â (Adult, 30
Older
Other|Indu
Adult) InterventioInterventi LY2017-60
Number ofSt. Jude ChMale up to 24 Months
Phase 1|Ph
Â (Child) 28 Other|NIHInterventioInterventi LVXSCID-N
Start Date Primary CompletioCompletionFirst Poste Results Fir Last UpdatLocations Study Doc URL
14-Jun-18 4-Apr-19 1-Jun-20 1-Oct-19 1-Oct-19 Imperial C "Study Prohttps://Cl
6-Apr-17 6-Sep-17 6-Dec-17 ### 17-Jan-18 UBS Buritis, Boa Vistahttps://Cl
23-Sep-16 6-Mar-17 6-Mar-17 ### 3-Apr-18 3-Apr-18 Birmingham "Study Prohttps://Cl
15-Apr-18 5-Sep-19 Mar-20 10-Apr-18 ### University Health Nethttps://Cl
24-Jul-17 31-Mar-18 ### 4-Jan-18 7-Mar-19 Vaccine Trial Centre, https://Cl
Mar-11 Mar-13 Mar-13 31-Oct-12 31-Oct-12 National Liver Instit https://Cl
20-Oct-17 30-Dec-19 ### 20-Oct-17 3-Jan-19 University of Pennsyl https://Cl
1-Jun-19 1-Sep-19 1-Dec-19 26-Apr-18 2-Apr-19 Research and Education https://Cl
at The Christ Hospital, Cincin
18-Jun-15 26-Jun-19 27-Jun-19 ### ### ginia, McLean, Virginia,
https://Cl
United States|Sentara Norfol
19-Mar-19 Dec-20 Dec-21 16-Jul-18 18-Apr-19 Wellcome Trust Sangehttps://Cl
1-Mar-20 31-Dec-22 ### 21-Jan-20 21-Jan-20 https://Cl
25-May-18 5-Sep-19 5-Mar-20 ### ### University Health Nethttps://Cl
20-Nov-18 20-Jan-20 20-Jan-20 ### ### Centro de Estudos e Phttps://Cl
May-16 Dec-19 Dec-19 6-May-16 27-Jul-17 Clifford Craig Founda https://Cl
6-Sep-17 20-Dec-20 ### ### 27-Jan-20 Medical Research Couhttps://Cl
May-07 Feb-09 Feb-09 ### 1-Dec-16 Infectious Diseases Uhttps://Cl
Oct-13 Jun-14 Jun-14 7-Apr-14 7-Apr-14 National Cheng Kung https://Cl
U
15-Jul-16 13-Feb-17 ### 25-Jul-16 ### ### Chandler, A"Study Prohttps://Cl
Sep-15 Dec-15 Mar-16 22-Jul-14 22-Jun-16 Unidade de Ensaios ClÃ https://Cl
nicos para ImunobiolÃ³gicos,
Aug-10 Aug-11 Oct-11 1-Nov-12 3-Jan-13 University of Coloradhttps://Cl
Mar-16 Mar-20 Jun-20 ### 7-Jun-19 Guangdong 999 Brainhttps://Cl
1-Mar-19 Dec-20 Mar-21 3-Jun-19 3-Jun-19 Medical University ofhttps://Cl
Jul-10 May-12 Jul-12 ### ### Benchmark Research,https://Cl
S
1-Feb-15 31-Jan-16 31-Jan-16 ### 24-Jun-19 University of Coloradhttps://Cl
May-12 Oct-13 Mar-14 2-Aug-12 26-Apr-19 26-Apr-19 Indian Institute of S https://Cl
27-Aug-18 31-Dec-22 ### 27-Jul-18 ### Mayo Clinic in Rocheshttps://Cl
Jul-16 Jul-18 20-Jun-16 20-Jun-16 https://Cl
1-Mar-12 30-Nov-16 ### 5-Apr-12 ### National Institute of https://Cl
Sep-11 Aug-16 Aug-16 5-Oct-11 ### Dept infectious dise https://Cl
Jun-08 Jul-08 Jul-08 ### 1-Dec-16 Site 1, 2 and 3, Hess https://Cl
Oct-11 Nov-11 Nov-11 29-Oct-12 29-Oct-12 Touro University Califhttps://Cl
Sep-20 Sep-21 Sep-23 1-Nov-17 ### University Health Nethttps://Cl
Oct-13 Jan-21 Jan-22 5-Nov-13 10-Jan-19 Robert H. Lurie Comprhttps://Cl
Sep-10 Jun-11 Jun-11 7-Oct-10 ### ### Masonic Cancer Centehttps://Cl
31-Oct-19 3-Jan-23 23-Jun-23 ### ### University of Alabamahttps://Cl
at Birmingham, Birmingham, A
15-Oct-18 15-Oct-20 ### ### 18-Oct-18 Chinese PLA General Ho https://Cl
9-Jul-18 9-Nov-18 9-Nov-18 10-Jan-18 10-Oct-19 University of Manito https://Cl
Dec-08 Jul-09 Nov-09 ### 1-Dec-16 PestlÅ‘rinc-Pestszen https://Cl
28-May-19 31-Aug-19 ### 4-Jun-19 13-Jan-20 13-Jan-20 Shanghai C"Study Prohttps://Cl
19-Sep-17 12-Oct-18 ### ### ### The Catholic Universihttps://Cl
1-Jul-17 1-Feb-18 1-Jul-18 11-Jul-17 11-Jul-17 Maharaj Nakorn Chianhttps://Cl
Nov-07 Jul-08 Jul-08 ### 18-Apr-13 ### Balve, Germany|Duishttps://Cl
14-Jan-20 Jul-20 Jul-20 13-Jan-20 23-Jan-20 Johnson County Clin-Thttps://Cl
Aug-16 Oct-16 Oct-16 1-Aug-16 ### Emory University Schohttps://Cl
May-11 Jun-11 Jun-11 28-Apr-11 28-Jan-16 28-Jan-16 Dipartimento di Medicina
https://Cl
e Scienze dell'Invecchiame
23-Aug-19 23-Aug-21 ### ### ### Mackay Memorial Hosp https://Cl
10-Apr-17 26-Feb-19 ### 6-Nov-17 9-Dec-19 Chris Hani Baragwanahttps://Cl
May-15 Jul-15 Sep-15 20-Oct-14 14-Oct-15 Guanyun County Cente https://Cl
Jun-10 Jun-10 Jul-10 25-Jun-10 ### Dipartimento di Medicina
https://Cl
29-Oct-18 30-May-20 29-Oct-20 ### 9-Dec-19 Washington University https://Cl
Dec-13 Jul-15 Jul-15 ### 20-Jan-16 https://Cl
Jun-11 Nov-14 Nov-14 14-Jul-11 2-Apr-15 ### Sacre-Coeur Hospitalhttps://Cl
12-Sep-11 Jan-14 Jan-14 8-Sep-11 ### Centre pour le Devel https://Cl
May-14 Sep-14 Sep-14 3-Jun-14 ### ### Research Institute of https://Cl
Feb-15 Jul-15 Jul-15 ### ### https://Cl
Nov-09 Nov-10 Jul-11 2-Dec-09 ### ### Vaccine Research Unihttps://Cl
20-May-17 10-Nov-17 1-Jul-18 28-Apr-17 11-Jan-18 Hubei Provincial Centhttps://Cl
Oct-16 Jun-17 Jun-21 4-May-17 ### University Health Nethttps://Cl
4-Oct-17 30-Apr-19 30-Apr-19 ### 30-Jul-19 American Academy ofhttps://Cl
P
21-Aug-17 19-Mar-18 ### ### ### Mohiul Islam Chowdhhttps://Cl
Jun-14 Sep-14 Sep-14 1-Sep-14 9-Apr-15 Vaccine Trial Centre, https://Cl
1-Apr-19 1-Jul-20 ### 1-May-19 1-May-19 Rocking Horse Communi https://Cl
Mar-14 Jun-16 Dec-16 29-Jul-14 3-Oct-19 18-Oct-19 Peking University, Beihttps://Cl
Jun-09 Jul-09 Jul-09 11-Jun-09 23-Apr-12 Dipartimento di Medicina
https://Cl
Nov-12 Sep-13 Oct-13 30-Oct-12 13-Jan-15 13-Jan-15 Ordinace praktickehohttps://Cl
lekare pro deti a dorost, Jarome
May-13 Oct-13 Jun-14 4-Apr-13 ### ### 82 Children s Inv Res https://Cl
Jul-07 Aug-07 Aug-07 6-Aug-07 17-Jan-13 24-Jan-13 Betriebsaerztlicher https://Cl
Nov-12 Apr-13 May-13 ### ### Henan Center for Dis https://Cl
21-Nov-18 Nov-19 Dec-19 4-Dec-18 4-Dec-18 Bumrungrad Internatio https://Cl
Sep-09 Oct-10 Jan-11 20-Oct-10 4-Apr-12 Monroe County Depart https://Cl
Jul-12 Aug-12 Aug-12 26-Jul-12 27-Jan-14 21-Apr-14 University Hospital G https://Cl
Jul-16 Jun-26 Dec-27 ### 18-Jul-18 Unidade de SaÃºde da https://Cl
FamÃlia Oiteiro I, Alhandra, Pa
Apr-10 May-10 Jun-10 ### 3-Jan-13 Fletcher Allen Healthhttps://Cl
Sep-16 Feb-19 Feb-19 ### 23-Jan-18 Chaoyang of Provincial https://Cl
1-Mar-18 Dec-18 Apr-19 9-May-18 9-May-18 Shandong P"Study Prohttps://Cl
28-Aug-09 Nov-19 Dec-19 ### 5-Mar-19 U.S. Army Medical Reshttps://Cl
Aug-11 Mar-13 Jul-13 24-Jul-13 24-Jul-13 Tuoketuo Centers for https://Cl
31-Aug-17 2-May-18 12-Jun-18 4-Oct-17 ### Site 222, Mobile, Ala https://Cl
Jun-12 Apr-14 May-14 8-May-14 ### Huairou District Centehttps://Cl
23-Sep-18 30-Sep-20 ### 3-Oct-18 ### Louis Stokes Clevelanhttps://Cl
1-Nov-18 28-Feb-19 ### ### ### Kroger Pharmacy, Midl https://Cl
Jan-13 Mar-15 Sep-16 1-Feb-13 14-Jun-17 Center for Immunizatihttps://Cl
12-May-17 14-Jun-17 6-Nov-17 ### ### McGill University Heahttps://Cl
Sep-08 Mar-10 Dec-10 2-Oct-08 2-Dec-11 Miami Research Associ https://Cl
Aug-11 Mar-12 Jun-12 ### 10-Jul-13 Xicheng Centers For Dhttps://Cl
May-14 Jul-14 Dec-14 ### 29-Apr-15 Jatinegara Primary Hehttps://Cl
16-Jul-18 31-Dec-19 30-Jan-20 9-Mar-18 5-Feb-20 Puskesmas Jatinegara,https://Cl
Oct-11 Jul-12 Aug-12 13-Oct-11 ### Jiangsu Provincial Ce https://Cl
20-Jun-17 30-Jun-19 11-Oct-19 ### ### The Catholic Universihttps://Cl
Oct-15 Feb-16 Aug-16 ### 10-Apr-17 https://Cl
Sep-12 Jun-14 Jun-15 ### ### ### University del Valle, https://Cl
Sep-09 Jan-10 Feb-10 ### 13-Oct-10 CIC Vaccinologie Hopithttps://Cl
Jul-12 Aug-12 Aug-12 13-Jul-12 27-Jan-14 ### Bernhard Nocht Insti https://Cl
5-Jan-12 3-Mar-16 1-Sep-16 27-Jan-12 31-Jul-17 29-Jan-18 National In"Study Prohttps://Cl
Oct-08 Dec-11 Sep-12 ### ### Nanchang Center for hDttps://Cl
Jun-16 Jun-20 Sep-20 21-Jun-16 7-Jun-19 Guangdong 999 Brainhttps://Cl
Jan-13 Jun-13 May-14 28-Jan-13 3-Feb-15 3-Feb-15 1 Miami Research Asso https://Cl
Mar-16 Mar-16 Jun-16 ### ### DongBa clinical centerhttps://Cl
Nov-16 Jun-17 Jun-17 ### 10-Oct-17 CHUV, Lausanne, Swithttps://Cl
Jan-13 Sep-13 Sep-13 4-Oct-12 ### ### ICDDR,B, Dhaka, Ban https://Cl
Jan-17 Dec-18 Dec-19 ### 13-Jan-20 School of Medicine athttps://Cl
Sep-04 Dec-04 May-05 27-Jun-07 ### 1-Jan-16 WojewÃ³dzki Szpital Dhttps://Cl
8-Mar-17 31-Jan-20 31-Jan-20 17-Apr-17 19-Apr-18 SingHealth Investigat https://Cl
Sep-16 Dec-17 Dec-17 ### 30-Apr-19 Hubei Province Centehttps://Cl
Oct-06 Nov-09 Nov-09 7-Apr-08 ### 9-Apr-18 Commonwealth Cancer https://Cl
C
Sep-11 Nov-11 Dec-11 ### ### GuangXi Center for Dihttps://Cl
Apr-15 Feb-16 Feb-16 7-May-15 ### National Taiwan Univehttps://Cl
15-Dec-14 30-Jun-18 30-Jun-18 5-Oct-11 5-Jul-19 https://Cl
Jun-07 Jul-07 Jul-07 ### 25-Jan-12 Dipartimento di Medicina
https://Cl
30-Mar-17 28-Feb-18 30-Jun-18 23-Jan-18 23-Jan-18 Faculty of Medicine Shttps://Cl
Apr-13 Jun-13 Apr-18 12-Apr-13 ### Beijing Chaoyang Disthttps://Cl
Feb-07 Dec-07 Jul-08 ### 6-Mar-15 6-Mar-15 Oxford, United King https://Cl
Nov-12 Mar-13 Aug-13 3-Jun-14 3-Jun-14 Incheon St. Mary's Hoshttps://Cl
24-Feb-17 10-Oct-17 10-Oct-17 ### 10-Oct-18 Investigational Site, https://Cl
30-May-18 1-Apr-22 1-Apr-23 ### ### Special Immunizationshttps://Cl
Aug-14 Sep-15 Jul-17 ### ### Malaria Vaccine and Dhttps://Cl
Jul-12 Dec-15 May-16 19-Jul-12 7-Aug-14 Bandim Health Project https://Cl
1-Jul-18 Jun-19 Jul-20 25-Apr-16 29-Oct-18 Steve Biko Academic H https://Cl
6-Jun-17 5-Jun-18 5-Jun-18 ### 6-Sep-19 Columbia University M https://Cl
Nov-13 Apr-14 Apr-14 31-Oct-13 6-Mar-15 30-Oct-15 06 Kosin University https://Cl
Oct-08 Mar-10 Apr-10 ### ### ### Otto von Guericke U https://Cl
May-13 Dec-13 Dec-13 3-Jun-13 1-Oct-14 1-Oct-14 Site 71 - Ordinace vÅ https://Cl
31-Mar-19 31-Jan-21 ### 16-Apr-19 16-Jul-19 Shenzhen Geno-immune https://Cl
28-Aug-17 31-Aug-19 ### ### ### https://Cl
Oct-14 Jan-16 Jan-16 13-Oct-14 14-Jan-16 Mount Sinai Hospital,https://Cl
Jul-11 Sep-12 Sep-12 ### 15-Oct-19 Shin Nippon Biomedica https://Cl
15-Nov-19 Sep-20 Jan-21 1-May-19 ### Nepalgunj medical colhttps://Cl
Oct-04 Apr-08 Apr-08 8-Feb-05 4-Apr-17 4-Apr-17 Markey Cancer Centerhttps://Cl
Jun-14 Oct-14 Aug-15 27-Jun-14 7-Apr-17 7-Apr-17 4, De La Salle Health https://Cl
Oct-13 Dec-14 Jul-15 21-Jan-13 9-Oct-15 Kwong Wah Hospital,https://Cl
Jul-13 Feb-15 Nov-15 29-Jul-13 ### ### The Hope Clinic - Emohttps://Cl
23-Oct-18 1-Apr-19 1-Apr-19 8-Nov-18 8-Jul-19 Imperial College Healhttps://Cl
Aug-13 May-16 May-16 25-Jul-13 ### East Carolina Universihttps://Cl
24-May-18 Nov-19 Jan-20 16-Jul-18 30-Jan-19 Centre Hospitalier Le https://Cl
Jul-13 May-14 Dec-14 12-Jul-13 23-Apr-15 23-Apr-15 Mid Atlantic Urology https://Cl
Jul-09 Oct-12 Nov-13 7-Oct-08 13-Jun-14 13-Jun-14 Children's Hospital B https://Cl
1-Jul-18 25-Jan-20 25-Jan-20 10-Jul-18 ### Hazaribagh Field Clin https://Cl
Jul-07 Aug-07 Aug-07 ### 1-Dec-16 The Health Centre, Suhttps://Cl
Nov-09 Feb-15 Aug-18 30-Oct-12 ### Centro MÃ©dico Cuau https://Cl
20-Oct-15 21-Nov-16 ### ### ### CCST, Christchurch, https://Cl
Nov-15 Jul-16 Nov-16 9-Sep-16 ### ### https://Cl
1-May-19 31-Dec-22 ### 4-Jan-19 7-Jun-19 Mayo Clinic in Floridahttps://Cl
Jan-12 Feb-12 Feb-12 31-Jan-12 ### ### Johns Hopkins Centerhttps://Cl
31-Jan-18 24-Mar-18 ### ### 26-Apr-19 Rheumatology Division https://Cl
of Hospital das ClÃnicas da Fa
1-May-19 May-20 May-20 11-Jul-18 ### Hubei Provincial Centhttps://Cl
Nov-08 Jun-09 Jun-09 ### 1-Dec-16 Vaccination and Travehttps://Cl
Jun-09 Jun-09 Jun-09 24-Jul-09 7-Apr-17 Site 2, Giessen, Ger https://Cl
27-Oct-17 17-Mar-19 31-Jul-19 ### 5-Jun-19 University of Californhttps://Cl
4-Dec-18 26-Jul-19 26-Jul-19 ### 5-Aug-19 Vanderbilt Universityhttps://Cl
10-Jun-19 May-20 May-21 ### 27-Jun-19 Marisa Toups, Austin,https://Cl
Sep-15 Jan-17 Jul-17 3-Aug-15 17-Oct-16 KAVI-ICR, University ohttps://Cl
May-12 Jun-12 Jun-12 4-May-12 ### 27-Jun-18 Study Site, London, https://Cl
Jul-15 Apr-16 Aug-16 ### 1-Sep-16 Jiangsu Provincial Ce https://Cl
Dec-13 May-14 Aug-14 3-Jun-14 3-Jun-14 https://Cl
Feb-12 Mar-12 Mar-12 ### 8-Aug-14 Indiana University Sc https://Cl
Jun-10 Jun-10 Jul-10 29-Jun-10 27-Jan-16 27-Jan-16 Dipartimento di Medicina
https://Cl
Sep-10 Oct-14 Oct-14 6-Sep-10 ### Virginia Commonwealth https://Cl
9-Oct-19 1-Sep-20 1-Dec-20 ### 10-Oct-19 University of North Cahttps://Cl
Jul-10 Nov-11 Nov-11 7-May-10 ### ### https://Cl
2-Oct-17 May-20 Mar-21 3-May-16 ### International Centre https://Cl
Sep-10 Jan-12 Jan-12 5-Oct-10 23-Jan-14 21-Apr-16 Clinical Research Cenhttps://Cl
Feb-06 Feb-19 Dec-19 ### 2-Jan-20 Special Immunizationshttps://Cl
Sep-11 Jun-12 Dec-12 2-Feb-12 ### Monroe Carell Jr. Chilhttps://Cl
13-Sep-18 13-Dec-18 ### 3-Aug-18 ### 18-Jan-20 General Aca "Study Prohttps://Cl
Jan-11 Mar-12 Aug-12 4-Sep-14 4-Sep-14 Institute of Medical https://Cl
20-Nov-14 23-Apr-15 ### 22-Oct-14 28-Jul-17 5-Dec-19 GSK Investigational Sihttps://Cl
Jun-07 10-Jul-07 22-Apr-08 Werksarztzentrum Hehttps://Cl
Oct-14 Jun-17 Dec-17 ### ### Gloucestershire, Glouhttps://Cl
Oct-08 Apr-09 Nov-09 ### 18-Jan-13 24-Jan-13 Tampere Vaccine Resehttps://Cl
May-14 25-Jul-19 30-Jul-19 ### 22-Jul-19 Baylor University Medihttps://Cl
Apr-14 Dec-17 Dec-17 20-Oct-17 20-Oct-17 https://Cl
19-Dec-17 28-Mar-18 ### 5-Jan-18 11-Jan-19 Sanofi Pasteur Invest https://Cl
Oct-15 Oct-21 Nov-22 15-Oct-14 6-Feb-20 University of Arkansashttps://Cl
5-Nov-18 Oct-23 Oct-23 15-Oct-18 16-Oct-19 University of Marylanhttps://Cl
Feb-09 Nov-12 Nov-12 5-Mar-09 22-Jan-14 14-Jun-17 37, 50 Birmingham Ped https://Cl
Oct-11 Jan-12 Jan-12 17-Oct-11 ### 8-Jun-17 03, Novartis Investig https://Cl
Sep-12 Oct-12 Oct-12 10-Apr-14 10-Apr-14 Seoul St. Mary's Hospihttps://Cl
Jun-09 Jul-09 Jul-09 ### ### The Health Centre, Suhttps://Cl
10-Jul-12 2-Jan-13 Jun-13 16-Jul-12 16-Jul-18 National Cheng Kung https://Cl
U
1-Feb-19 28-Aug-19 1-Jan-21 ### ### University of Rochesthttps://Cl
Jul-06 Mar-09 Mar-09 6-May-09 12-Apr-11 16-Jul-12 U.T. M.D. Anderson Cahttps://Cl
Jul-12 Aug-12 Aug-12 13-Jul-12 29-Jan-14 ### University of Rostoc https://Cl
Feb-12 Dec-15 Dec-16 3-Oct-12 24-Oct-19 Centre for the Evaluahttps://Cl
Sep-09 May-11 May-11 ### ### Dept infectious diseahttps://Cl
Nov-11 Jun-14 Jun-14 31-Jul-12 14-Jul-16 2-Jul-17 University of Pittsburhttps://Cl
23-Nov-15 Jun-18 30-Jun-18 ### ### SAMIC Eldorado Hospit https://Cl
Apr-14 Dec-17 Dec-17 ### ### https://Cl
2-Jan-20 Jun-21 Jun-21 ### 18-Jan-20 CCVTM, University ofhttps://Cl
Jul-14 Dec-16 ### 22-Jul-14 1-Jun-18 Primary Care, Flourtohttps://Cl
21-Jun-11 31-Dec-21 ### 20-Jun-11 26-Jul-19 Ohio State Universityhttps://Cl
Oct-06 Oct-09 Oct-09 6-Jan-10 11-Jan-10 Universidade Cidade dhttps://Cl
May-11 May-11 Jun-11 ### 7-Dec-11 Dipartimento di Medicina
https://Cl
Oct-14 Jul-15 May-20 ### 30-Jul-19 ### https://Cl
Feb-16 Oct-16 Oct-16 6-Nov-16 8-Nov-16 SingHealth Investigat https://Cl
Dec-11 Apr-13 Apr-13 ### ### Hope Clinic of the Emhttps://Cl
Apr-11 Aug-13 Apr-22 12-Apr-11 ### Oslo University Hosp https://Cl
3-Jan-19 18-Aug-19 1-Apr-20 23-Jan-19 ### Jiangsu Provincial Ce https://Cl
Aug-12 Jun-15 Dec-15 ### ### 24-Jun-16 Rochester General Hohttps://Cl
12-May-16 11-Sep-17 6-Sep-18 22-Oct-18 22-Oct-18 https://Cl
Jul-12 Jul-12 Jul-12 10-Jul-12 29-Jan-14 ### University Hospital G https://Cl
Sep-15 Nov-16 5-May-15 ### Center for Immunizatihttps://Cl
19-Jul-17 16-Oct-18 31-Oct-18 16-Oct-17 ### Future Colony, Karachhttps://Cl
4-Jun-19 29-May-20 ### 29-Jul-19 31-Jul-19 Infectious Disease Cl https://Cl
Jan-13 Jul-13 Jul-14 11-Jan-13 ### 30-Jan-19 1 Tatum Highlands Med https://Cl
8-Mar-18 30-Aug-20 ### 4-Apr-17 ### Pasteur Institute, Ho https://Cl
Sep-11 Aug-12 Feb-14 4-Oct-11 ### Hospital Regional Mathttps://Cl
10-Jan-19 31-Mar-19 2-Apr-19 3-Jan-19 3-Jan-19 https://Cl
Nov-09 Apr-10 Jul-10 2-Dec-09 ### ### Vaccine Research Unihttps://Cl
1-Dec-19 1-Dec-20 1-Dec-20 7-Jun-18 ### https://Cl
Nov-06 Aug-07 Aug-07 6-Dec-06 1-Dec-16 University of Tamper https://Cl
23-Apr-18 17-Jul-18 ### 5-Jan-18 16-Jan-19 Crie - Unifesp, Sao Pahttps://Cl
Jul-09 Jun-15 Jun-15 10-Jul-09 15-Jul-15 Alberta Health Servichttps://Cl
Oct-16 Oct-17 Dec-17 5-Sep-16 5-Sep-16 https://Cl
1-Apr-18 31-Dec-23 ### 18-Apr-18 23-Apr-19 Mayo Clinic, Rochestehttps://Cl
1-Mar-18 30-Jun-18 30-Jul-18 30-Apr-19 3-May-19 Hung Yen, Kim Dong, https://Cl
10-Oct-18 Jan-20 Jan-20 ### 6-Nov-19 WRAIR Clinical Trials https://Cl
1-Jan-20 30-Mar-22 30-Jun-24 ### 4-Dec-19 Washington University https://Cl
Nov-10 Dec-10 Dec-10 6-Nov-13 6-Nov-13 Hasan Sadikin Hospitahttps://Cl
7-Sep-17 12-Sep-18 ### 6-Oct-17 4-Dec-18 CRS, MÃ¶nchengladbhttps://Cl
11-Oct-18 28-Feb-19 31-Jan-20 9-Oct-18 5-Feb-20 The Hope Cl "Informed https://Cl
May-13 Jun-14 Jun-14 ### 2-Nov-14 5-Dec-14 320, Novartis Investighttps://Cl
2-Apr-18 30-Apr-21 30-Apr-23 15-Jun-18 ### Changhai Hospital, Shhttps://Cl
May-19 Sep-20 Sep-22 9-Apr-19 9-Apr-19 https://Cl
Mar-10 Apr-11 25-Jan-10 ### ### University of Rochesthttps://Cl
Jun-08 Jul-08 Jul-08 9-Sep-08 1-Dec-16 Site 1, Chieti, Italy|Si https://Cl
21-Feb-18 30-Nov-21 ### 16-Jan-18 10-Apr-19 Vanderbilt Universityhttps://Cl
20-Feb-17 20-Feb-20 20-Apr-20 3-Feb-17 ### Immunitor LLC, Ulaanhttps://Cl
Mar-13 Mar-14 Feb-15 ### 7-Apr-15 ### GSK Investigational Sihttps://Cl
Mar-15 Jun-15 Jun-15 1-Dec-11 9-May-17 University of Louisvillhttps://Cl
14-Jun-17 31-Jul-18 31-Jul-18 14-Jun-17 8-Aug-18 DV Pediatrics, Canton,https://Cl
13-Dec-17 8-Apr-19 8-Apr-19 8-Jan-18 ### Accel Research Sites, https://Cl
Sep-05 Dec-05 Apr-06 ### 11-Jan-13 ### WojewÃ³dzki Szpital Dhttps://Cl
Sep-13 Feb-14 Apr-14 ### 12-Jan-15 Nrf/Dst Vpd Rmpru, Shttps://Cl
Dec-07 Apr-08 Apr-10 22-Oct-09 9-Nov-09 Hospital Son Dureta, Phttps://Cl
Nov-18 Sep-19 Sep-20 31-Oct-18 31-Oct-18 https://Cl
31-Mar-14 20-Nov-14 ### ### 5-Sep-18 Respiratory and Menihttps://Cl
Dec-13 Mar-17 Mar-17 30-Jan-14 ### University of Alabamahttps://Cl
Jan-10 Aug-10 Nov-10 6-Jan-10 30-Oct-14 Dr. Firdausi Qadri, M https://Cl
Dec-07 Mar-11 Dec-14 7-Dec-07 26-Jun-15 Mayo Clinic - Scottsd https://Cl
Nov-15 Oct-17 Dec-17 ### ### ### Auburn Uni"Study Prohttps://Cl
21-Feb-20 31-May-21 ### 18-Jun-19 ### Ouelessebougou Healt https://Cl
9-Dec-19 4-Jun-24 4-Jun-25 7-Mar-19 ### Special Immunizationshttps://Cl
Feb-05 Feb-05 Feb-09 30-Apr-13 ### ### Department of Pediathttps://Cl
Aug-09 Oct-09 Nov-09 9-Oct-09 1-Dec-16 01, Chieti, 66100, Ita https://Cl
Sep-11 Feb-12 Feb-12 ### ### Student Health Centerhttps://Cl
26-Mar-19 30-Jun-20 30-Oct-20 4-Apr-19 ### Songzi Center for Dis https://Cl
Dec-13 May-14 Jul-14 23-Jun-15 23-Jun-15 Jiangsu Provincial Ce https://Cl
Jun-16 Jun-20 Sep-20 21-Jun-16 7-Jun-19 Guangdong 999 Brainhttps://Cl
May-06 Mar-07 Mar-07 ### 5-Nov-13 9-Oct-18 FUNCEI, French 3085,https://Cl
May-07 Mar-08 Mar-09 ### 9-Jul-12 Centro de Pesquisas Rhttps://Cl
May-13 Dec-15 Mar-16 ### 7-Aug-14 Centre de Recherche https://Cl
24-Apr-18 1-Mar-20 1-Mar-20 5-Jul-18 5-Jul-18 Bristol Children's Va https://Cl
Mar-10 Apr-10 Aug-10 ### 12-Apr-10 Institute of microbiolhttps://Cl
3-Jul-07 31-Mar-08 ### 21-Jun-07 ### 13-Jan-20 GSK Investigational S https://Cl
Oct-15 Apr-16 Apr-16 ### ### ### Imperial College Lon https://Cl
17-Jun-15 21-Mar-20 ### 28-Jan-15 22-Oct-19 Washington University https://Cl
Jan-11 Sep-11 Jan-12 ### ### Chaoyang District Cenhttps://Cl
Sep-12 May-13 May-16 2-Nov-12 18-Apr-18 ### Brown Univeristy, Prohttps://Cl
Oct-07 Jul-08 Jul-08 7-Mar-08 16-Jan-13 ### Site 14, Denver, Colo https://Cl
Jul-11 Jan-12 Jul-12 6-Jun-11 ### ### CESFAM Gabriela Mistr https://Cl
Jun-09 Jun-09 Jun-09 ### 27-Jan-16 27-Jan-16 Site 2: Ufficio Igiene ehttps://Cl
SanitÃ Pubblica di Lanciano, A
27-Dec-17 1-Dec-20 1-Dec-20 4-Oct-17 22-Jan-20 Mayo Clinic, Rochestehttps://Cl
30-Nov-18 31-Dec-19 30-Jun-20 11-Jan-19 11-Jan-19 University of Califor https://Cl
May-16 Jun-16 21-Jun-16 21-Jun-16 https://Cl
1-Nov-16 1-May-17 1-May-17 5-Oct-16 1-May-17 https://Cl
Sep-11 Oct-12 Dec-12 9-Aug-11 ### ### Limbe Health Center, https://Cl
Sep-11 Jul-12 Aug-12 9-Sep-11 ### 4-Feb-13 Manoj Sharma, Cincinn https://Cl
Mar-13 Mar-14 Oct-14 4-Dec-13 ### Ganyu, Lianyungang, h J ttps://Cl
May-13 Jun-13 Jun-13 ### 15-Jan-14 27-Jun-18 Study Site, London, https://Cl
Dec-08 Feb-09 May-09 26-Jan-09 ### Shahid Modarres Hospi https://Cl
Jan-17 Jan-19 May-19 11-Jan-17 30-Jan-18 Ha'Emek Medical cente https://Cl
6-Mar-17 Dec-20 Dec-20 ### 18-Apr-19 Vaccine Evaluation Cehttps://Cl
17-May-17 31-Jul-20 31-Jul-20 4-May-17 5-Dec-19 MRC - University of https://Cl
27-Feb-18 10-Sep-18 ### ### ### Sanofi Pasteur Invest https://Cl
6-Apr-18 30-Apr-21 30-Apr-21 18-Apr-18 3-Oct-19 Emory University Hosp https://Cl
Aug-09 Mar-10 Mar-10 22-Jul-09 13-Apr-11 31-Oct-12 University of Marylanhttps://Cl
30-Oct-17 25-Jun-18 25-Jun-18 ### ### Hakeem Abdul Hameed https://Cl
C
31-Mar-15 18-Aug-15 ### 2-Jul-17 ### Espoo, Finland|Helsinhttps://Cl
Sep-10 Apr-11 Apr-11 ### 2-Feb-17 Florida Research Netwo https://Cl
Aug-11 Oct-11 Sep-12 7-Jan-11 ### ### Alabama Clinical Therhttps://Cl
30-Nov-15 15-Jan-16 31-Jul-16 3-May-17 4-May-17 https://Cl
Jan-12 Jan-13 Jan-13 ### 31-Jan-13 Walter Reed Army Inst https://Cl
28-Nov-16 8-Jan-17 ### 17-Oct-16 19-Apr-19 19-Apr-19 Clinical Center of Ser https://Cl
Oct-14 Dec-14 Jan-15 4-Nov-15 4-Nov-15 Jiangsu Provincial Ce https://Cl
Oct-05 Dec-05 May-06 ### 28-Jan-13 ### Bardstown, Kentucky,https://Cl
22-Feb-17 26-Oct-17 26-Oct-17 4-Nov-16 26-Oct-18 Investigational Site https://Cl
7-Sep-12 Dec-17 Dec-17 24-Jun-13 ### Virgen del RocÃo Hospital,
https://Cl
Seville, Spain
Jun-08 Jul-08 Jul-08 ### 28-Jan-16 28-Jan-16 Ufficio Igiene e SanitÃhttps://Cl
Pubblica di Lanciano, ASL Lanc
Apr-15 Dec-15 Dec-15 ### 26-Oct-18 Maputo Central Hospihttps://Cl
Jul-16 18-Oct-16 1-Dec-16 ### ### ### The Hope Clinic of th https://Cl
19-Nov-13 8-Apr-19 8-Apr-19 ### ### National Institutes ofhttps://Cl
Jul-08 Aug-08 Aug-08 8-Sep-08 5-Jan-12 The Health Centre, H https://Cl
Jul-16 Dec-16 ### ### https://Cl
Jan-12 Jan-15 Jan-15 6-Jan-12 21-Jul-15 Emory University, Atl https://Cl
Jan-09 Dec-09 Jun-10 27-Jan-09 5-Oct-16 University of Missourhttps://Cl
Jun-13 Jul-13 Jul-13 30-Jun-16 30-Jun-16 Centro de Pesquisas ClÃhttps://Cl
nicas do Instituto da CrianÃ§a
Oct-12 Jun-13 Oct-13 24-Oct-12 ### 7-May-15 Hoover, Alabama, Unit https://Cl
Aug-12 Feb-13 Feb-13 7-Aug-12 ### University Cheikh Anthttps://Cl
Sep-11 Oct-12 Oct-12 28-Apr-11 2-Dec-13 26-Jun-18 Planned Parenthood of https://Cl
Jan-12 Sep-15 Sep-15 16-Jan-12 ### Pingle Center for Dis https://Cl
Jan-17 Apr-21 Oct-21 ### ### Yale New Haven Hospihttps://Cl
Feb-10 Apr-12 Apr-12 19-Oct-09 28-Jan-13 Makerere University https://Cl
Dec-19 Dec-20 Dec-21 1-Feb-17 7-May-19 Flinders University, A https://Cl
Apr-09 Jul-10 Sep-10 26-Oct-09 ### The Center for Vacci https://Cl
Apr-05 Nov-06 Nov-06 6-Dec-05 ### ### Kaiser Permanente Vac https://Cl
11-Sep-18 30-Dec-21 ### ### 4-Nov-19 Capital Medical Univer https://Cl
Apr-15 Jun-15 Jun-15 ### 21-Jul-15 https://Cl
Jun-07 Jul-07 Jul-07 ### 1-Dec-16 Dipartimento di Medicina
https://Cl
Nov-12 Mar-13 Mar-13 ### 3-May-13 MoÃ¯ssala health disthttps://Cl
Oct-14 Nov-14 Dec-14 7-Oct-14 19-Oct-15 19-Oct-15 Santa Rosa, Californiahttps://Cl
May-13 Jul-13 Jul-13 ### ### Nrf/Dst Vpd Rmpru, Shttps://Cl
Apr-11 Jun-13 Dec-18 9-Mar-11 5-May-14 16-Oct-17 National Institute fo https://Cl
Jul-11 Aug-11 Aug-11 27-Jul-11 ### Family Doctor's Offic https://Cl
4-Oct-18 Dec-23 Dec-24 1-Aug-18 7-Nov-19 Special Immunizationhttps://Cl
May-14 Nov-14 Feb-15 ### 26-Jun-18 ### Accelovance, Inc, Hunhttps://Cl
3-Nov-17 Apr-20 Aug-20 ### ### Clinical Research Cenhttps://Cl
Mar-12 May-12 Aug-12 ### 2-Aug-16 Dingxing Center for Dhttps://Cl
Oct-12 Dec-14 Dec-14 ### ### University of Michigahttps://Cl
19-Feb-18 Mar-22 Mar-23 ### 6-Feb-20 H. Lee Moffitt Cancerhttps://Cl
25-Nov-19 Feb-23 Dec-23 ### 5-Dec-19 UMCG, Groningen, Nehttps://Cl
Apr-06 Aug-06 Aug-06 4-Apr-06 ### Oxford Vaccine Group,https://Cl
23-Apr-18 23-Jun-18 ### ### 26-Apr-19 Rheumatology Division https://Cl
Sep-11 Oct-11 Oct-11 ### 12-Oct-11 UniversitÃ¤t Rostock https://Cl
Oct-13 Dec-16 Dec-16 ### ### Inova Fairfax Hospitalhttps://Cl
Sep-09 Dec-16 Dec-16 21-Apr-11 7-Mar-17 International Centre https://Cl
13-Sep-16 31-May-17 1-Jun-17 ### 27-Jul-17 Columbia University M https://Cl
8-Jan-18 8-Jan-20 8-Jan-21 5-Jan-18 5-Feb-19 Service de Maladies Ihttps://Cl
Jan-08 May-10 Dec-14 ### 26-Jun-15 University of Louisvillhttps://Cl
Aug-10 Jan-12 Jan-12 22-Jun-10 ### 15-Jun-18 Centro de Salud Lo Barnechea,
https://Cl Santiago, Chile|Centro
Feb-15 Jun-18 Jun-18 1-Jun-15 18-Jan-18 Inje University Busanhttps://Cl
Jul-10 Sep-12 May-16 15-Apr-10 8-Sep-17 Brigham and Women's https://Cl
Mar-16 Dec-16 Feb-17 ### ### Hebei Provincial Centhttps://Cl
1-Mar-16 7-Jul-17 10-Jul-17 2-Oct-15 ### Fundacion para la Sa https://Cl
Apr-12 Oct-15 Oct-15 ### ### Sidney Kimmel Compre https://Cl
Oct-10 Aug-12 Dec-12 ### ### University of Alberta https://Cl
Sep-12 Dec-12 Feb-13 ### 16-Apr-14 16-Apr-14 Bardstown, Kentucky,https://Cl
Oct-15 Oct-15 Dec-15 6-Apr-16 6-Apr-16 Cho Gao Health Centrhttps://Cl
Sep-16 Oct-17 Dec-28 7-Aug-14 7-Sep-17 University of Pittsbu https://Cl
27-Apr-18 27-Jul-20 27-Jul-22 6-Sep-18 6-Sep-18 HÃ´pital de la Croix https://Cl
16-Oct-19 1-Jan-20 1-Mar-20 10-Jan-20 10-Jan-20 Centre for Clinical V https://Cl
5-Jun-19 Mar-20 Mar-20 24-Jun-19 24-Jun-19 UConn Health, Farminhttps://Cl
May-14 7-Dec-16 31-Jul-19 16-Apr-14 ### Walter Reed Army Instihttps://Cl
Jul-12 Jul-14 Jul-14 4-Dec-12 9-Mar-15 Grady Health System,https://Cl
May-10 Dec-12 Apr-13 ### 15-Oct-19 Shin Nippon Biomedica https://Cl
26-Jul-17 31-Aug-17 ### 27-Jul-17 1-Aug-17 Shanxi Provincial Cenhttps://Cl
Oct-09 Sep-10 Sep-10 ### 6-Aug-12 ### Emory University, Atl https://Cl
17-Apr-17 29-Dec-19 29-Apr-20 7-Apr-17 10-Oct-19 UConn Center On Agin https://Cl
Sep-13 Oct-17 Oct-17 ### ### University of Texas Mhttps://Cl
Aug-11 Mar-14 Mar-14 ### ### Center for Immunizatihttps://Cl
Jan-15 23-Apr-18 23-Apr-18 27-Oct-14 30-Apr-18 City of Hope Medical https://Cl
31-Jul-19 Aug-20 Aug-20 19-Jul-18 23-Jan-20 Boston Medical Center https://Cl
Sep-12 Oct-15 Oct-15 ### 24-Jun-19 University of Coloradhttps://Cl
Apr-11 Jul-11 Jul-11 6-Nov-13 6-Nov-13 Hasan Sadikin Hospitahttps://Cl
Oct-10 Oct-12 Oct-12 16-Jul-10 29-Apr-13 Emory Children's Cente https://Cl
Apr-12 Aug-13 ### 9-Nov-15 Oxford Vaccine Grouphttps://Cl
Aug-10 Sep-10 Sep-10 9-Jun-10 15-Apr-15 ACHIEVE Research, Alhttps://Cl
Apr-20 Apr-24 Apr-24 5-Feb-20 5-Feb-20 University of SÃ£o Pahttps://Cl
Nov-08 Mar-10 Oct-10 2-Jun-14 2-Jun-14 Jiangsu Provincial Ce https://Cl
Nov-07 Jan-08 Jun-08 ### 1-Dec-16 University of Tamper https://Cl
Jul-14 Jun-15 Jan-17 4-Sep-14 30-Jan-17 NewYork-Presbyterianhttps://Cl
Nov-09 Nov-11 Nov-11 23-Oct-09 ### 21-Apr-14 37 Alabama Clinical Thttps://Cl
Nov-16 Jul-19 Nov-19 9-Mar-18 ### Bandim Health Project https://Cl
Feb-10 Jun-10 Jun-10 ### 3-Jan-13 Johns Hopkins Projecthttps://Cl
Jun-16 Dec-19 Dec-20 5-May-16 26-Oct-18 Douala General Hospit https://Cl
Oct-12 Nov-13 Jun-14 19-Jun-12 ### VA Palo Alto Health Chttps://Cl
Dec-09 Nov-10 Nov-10 3-Mar-10 1-Jun-12 Azienda Ospedaliera U https://Cl
Sep-14 Dec-14 Dec-14 8-Aug-14 16-Oct-15 16-Oct-15 Site 286, Los Angeles https://Cl
Mar-07 Aug-07 Jan-08 ### ### 28-Jan-15 Birmingham, Alabama, https://Cl
10-May-13 28-Aug-19 ### ### 9-Apr-18 ### National In"Study Prohttps://Cl
1-Jul-17 1-Jul-18 1-Oct-18 17-Jul-17 17-Jul-17 Maharaj Nakorn Chianhttps://Cl
20-Apr-18 30-Sep-20 ### 26-Jun-17 28-Jan-20 Washington University https://Cl
1-Apr-15 1-Apr-21 1-Apr-22 ### 7-Feb-20 Emory University Hosp https://Cl
Jun-13 Jan-15 ### ### https://Cl
Jul-15 Apr-18 Apr-18 10-Oct-13 24-Apr-18 Central Pharmacy, Duhttps://Cl
15-Jul-16 28-Feb-17 ### 25-Jul-16 ### Birmingham, Alabama, https://Cl
Nov-07 Mar-10 May-11 ### 28-Jan-19 28-Jan-19 https://Cl
15-Sep-16 9-Dec-16 9-Dec-16 ### 8-Jan-18 5-Feb-18 Bardstown, Kentucky,https://Cl
Sep-12 Dec-12 Dec-12 ### 1-Oct-13 19-Apr-17 Center for Vaccinologhttps://Cl
16-Jul-17 15-Sep-17 ### ### 2-Jan-19 Shangyu District Centhttps://Cl
Dec-11 Sep-13 Sep-13 10-Jan-12 ### Center for Immunizatihttps://Cl
12-Mar-19 Oct-20 Oct-21 5-Nov-18 ### University of Pennsyl https://Cl
25-Aug-17 15-Jan-18 15-Jan-18 ### 8-Feb-19 8-Feb-19 Kaiser Perm "Study Prohttps://Cl
Feb-14 Jul-16 Jul-16 10-Jul-14 1-Feb-17 Center for Immunizatihttps://Cl
Oct-13 Jan-14 Mar-14 ### 6-Feb-19 ### Research Institute of https://Cl
Jul-12 Sep-12 Feb-13 10-Jul-12 ### Jurong, ZhenJiang, Ji https://Cl
Aug-08 Jul-10 Jul-10 24-Jul-08 ### ### Novartis Investigatio https://Cl
Dec-10 Feb-18 Feb-18 ### ### Memorial Sloan Kettehttps://Cl
Apr-07 Jul-07 Dec-07 24-Apr-07 5-May-10 1-Oct-15 Site 2: C1425AWK, Buhttps://Cl
1-Aug-14 31-Jul-15 31-Jul-15 ### 1-May-17 University of Rochesthttps://Cl
Oct-06 Apr-08 Sep-08 19-Oct-06 ### 14-Apr-16 Norfolk, Virginia, Uni https://Cl
18-Oct-17 14-Oct-27 14-Oct-27 26-Oct-17 26-Oct-17 The Hospital District https://Cl
Sep-15 Dec-15 Jul-16 ### ### ### Santa Rosa, Californiahttps://Cl
Feb-08 May-09 Jul-09 ### 8-Dec-11 Institute for Pharmaco https://Cl
29-Jul-18 27-May-19 3-Jun-19 ### 4-Jun-19 Mirpur Field Office, https://Cl
May-06 May-06 Aug-06 9-Aug-12 9-Aug-12 https://Cl
16-Jan-19 31-Jan-20 31-Jan-23 16-Jan-19 16-Jan-19 Hunan Provincal Tumo https://Cl
May-13 Dec-13 Dec-14 3-Nov-13 ### ### Sparrow Dialysis at S https://Cl
6-Nov-18 31-May-20 ### 7-Nov-18 ### Naval Medical Centerhttps://Cl
Oct-20 Dec-20 Dec-20 1-Jan-14 18-Jan-20 Children's Hospital C https://Cl
Sep-15 4-Apr-16 4-Apr-16 ### 9-Feb-18 Milford, Connecticut,https://Cl
Jan-11 Oct-11 Dec-11 11-Jan-11 ### Cetero, Fargo, North https://Cl
Nov-15 Feb-16 Feb-16 5-Nov-15 28-Jan-19 ### Hung Ha District Healhttps://Cl
Apr-15 Aug-15 Aug-15 ### ### https://Cl
5-Jan-14 28-Jul-17 28-Jul-17 ### 2-Aug-17 City of Hope Medical https://Cl
28-Nov-17 15-Apr-19 ### 6-Aug-18 2-Oct-19 CTC North GmbH & Co https://Cl
Oct-14 May-15 May-15 2-Oct-14 3-Feb-16 27-Jan-17 03, Centro MÃ©dico hUttps://Cl
Jun-08 Aug-08 Aug-08 ### 24-Jan-14 I.P.A.S., Ligornetto, S https://Cl
3-Dec-18 31-Dec-19 ### 3-Aug-18 11-Oct-19 Groupe de Recherchehttps://Cl
May-07 Feb-16 Dec-16 13-Oct-14 4-May-17 School of Public Hea https://Cl
3-Dec-18 3-Jun-19 3-Jul-19 ### ### https://Cl
Aug-12 Jul-15 Jul-15 30-Jul-12 12-Oct-16 University of Arkansashttps://Cl
Aug-11 Dec-11 Dec-11 ### ### ### Royal Children's Hosphttps://Cl
Jun-08 Apr-10 Dec-10 18-Apr-08 4-Nov-15 ### Site 13: Liceo Diego Aracena
https://Cl
de Lo Barnechea, Monse
Sep-12 Sep-13 Dec-13 7-Aug-12 6-Mar-15 Miami Research Associ https://Cl
Nov-15 Dec-16 Dec-16 9-Sep-15 17-Jun-16 https://Cl
29-Mar-00 20-May-03 ### ### ### University of Marylanhttps://Cl
Jun-09 Aug-10 Aug-10 23-Jul-09 ### https://Cl
May-13 Dec-13 Dec-13 ### 3-Jun-15 3-Jun-15 Institut de Recherchehttps://Cl
Jul-07 Feb-08 Dec-10 13-Jul-07 10-Apr-15 Vaccine Evaluation Cehttps://Cl
Dec-02 May-12 Mar-13 3-Mar-09 3-Jun-14 Walter Reed Army Med https://Cl
Aug-16 Jun-17 Sep-17 5-Dec-16 26-Oct-17 Xiangcheng County Cehttps://Cl
Jul-09 May-10 May-10 12-Jun-09 3-Jan-13 Center for Immunizatihttps://Cl
May-11 Jul-15 Jul-15 6-May-11 5-Jan-16 Memorial Sloan Kettehttps://Cl
1-May-18 31-Dec-19 ### ### ### Changhai Hospital, Shhttps://Cl
Oct-08 Nov-13 Jun-14 5-Dec-13 14-Jul-16 Tianjin center for dis https://Cl
Sep-13 Sep-14 Sep-15 ### ### Aava Medical Centre,https://Cl
15-Oct-18 30-Apr-20 30-Jun-23 21-Oct-19 23-Oct-19 National Taiwan Univehttps://Cl
May-06 May-06 Jun-06 9-Aug-12 9-Aug-12 https://Cl
Jun-12 Oct-12 Oct-12 20-Jul-12 ### ### Seishinkai Inoue Hosphttps://Cl
Nov-06 Dec-10 Mar-11 ### 23-Apr-12 27-Apr-12 https://Cl
17-Jul-15 30-Oct-19 ### 24-Jun-15 ### University Hospitals https://Cl
Sep-09 Apr-10 May-10 8-Apr-10 ### "Csolnoky Ferenc" V https://Cl
15-Apr-16 20-Dec-16 ### 27-Apr-16 ### Birmingham, Alabama, https://Cl
14-Dec-17 1-Oct-19 1-Oct-19 24-Jan-18 ### Accel Research Sites, https://Cl
21-Dec-18 30-Sep-22 ### ### ### M D Anderson Cancerhttps://Cl
26-Jul-19 Nov-19 Mar-20 1-Oct-19 1-Oct-19 Hanbin District Centehttps://Cl
1-Apr-19 30-Jun-20 ### ### ### Shenzhen People's Hohttps://Cl
Oct-13 Jul-14 Jul-14 ### 21-Apr-17 21-Apr-17 Novartis Investigationhttps://Cl
Oct-07 Dec-07 Jun-08 ### 1-Dec-16 Dipartimento di Medicinahttps://Cl
Sep-11 Apr-13 Oct-13 5-Oct-11 8-Sep-14 8-Sep-14 UZ Leuven, Herestraathttps://Cl
Dec-12 Feb-14 Aug-15 7-Jan-13 2-Nov-15 Athens OBGYN, Athens https://Cl
4-Dec-19 30-Jun-20 30-Jun-20 ### 6-Dec-19 USDA, ARS, Western Hu https://Cl
25-Mar-17 31-Jul-19 30-Jun-21 6-Dec-16 16-Apr-19 Surrey Memorial Hospi https://Cl
Dec-04 Sep-06 Sep-08 ### ### Jiangsu Provincial Ce https://Cl
1-Sep-14 31-Aug-17 ### ### 17-Oct-19 Department of Clinicahttps://Cl
18-Sep-18 17-May-19 14-Jun-19 ### 1-Nov-19 (Site 225) Coastal Cl https://Cl
Aug-03 May-04 May-04 6-Oct-06 ### ### Department of Pediathttps://Cl
Jan-12 Mar-13 Mar-13 11-Jan-12 ### Ganyu, Lianyungang, h J ttps://Cl
Aug-09 Apr-10 Apr-10 22-Jul-09 13-Apr-11 ### University of Marylanhttps://Cl
Jul-11 Jan-12 Jan-12 ### ### Garuda Primary Healthttps://Cl
Dec-09 May-12 Jul-13 15-Oct-09 ### Seattle Children's Hoshttps://Cl
31-Jan-20 31-Jul-22 30-Jun-23 ### 13-Jan-20 Johns Hopkins Schoolhttps://Cl
Mar-10 Mar-12 Apr-12 1-Jul-10 18-Jul-18 Instituto de Pesquisa https://Cl
Sep-11 Sep-13 Sep-13 ### ### Washington University https://Cl
3-Jun-11 1-Aug-14 ### 14-Jun-11 ### ### Denpasar, Bali, Indo https://Cl
Jan-13 Jun-13 Jun-14 28-Jan-13 20-Apr-15 16-Jan-19 3 Meridian Clinical R https://Cl
Nov-06 Dec-06 May-07 ### 1-Dec-16 Azienda ULSS 13 di Mihttps://Cl
Sep-13 Dec-13 Jul-14 ### ### ### Santa Rosa, Californiahttps://Cl
Aug-09 Sep-09 Feb-10 ### ### District Doctor's Off https://Cl
Nov-13 May-14 May-14 ### ### Ghent University Hoshttps://Cl
Jan-10 Feb-10 Feb-10 ### 21-Oct-19 University of Marylanhttps://Cl
9-Aug-17 2-Apr-19 2-Apr-19 4-Apr-17 30-Jul-19 University of Puerto https://Cl
Sep-12 Feb-13 Feb-13 11-Apr-12 1-Jun-15 1-Jun-15 Navrongo Health Resehttps://Cl
Nov-06 Jan-08 Jan-08 ### 1-Dec-16 Presidio Distrettuale Nhttps://Cl
1-Sep-15 7-Mar-18 30-Apr-20 10-Jan-20 10-Jan-20 Disease prevention a https://Cl
Jan-08 Sep-08 Sep-08 5-Feb-08 22-Jan-09 Shaheed Modarres Medi https://Cl
22-Apr-19 15-Jan-20 ### ### 12-Jul-19 Unidade de Pesquisa https://Cl
ClÃnica do Hospital das ClÃnica
20-Mar-17 5-Oct-17 5-Oct-17 ### 22-Jul-19 22-Jul-19 Pasteur Ins"Study Prohttps://Cl
5-Dec-18 Dec-23 Dec-24 ### 7-Feb-20 H. Lee Moffitt Cancerhttps://Cl
Dec-09 Feb-10 Jun-10 11-Jan-10 11-Jan-10 National Taiwan Univehttps://Cl
22-Jun-17 Oct-20 Oct-20 7-Aug-17 6-Sep-17 Hubei Province Centehttps://Cl
Apr-10 May-10 May-10 ### 8-Jun-11 Christian Medical Colhttps://Cl
Sep-11 Dec-12 Dec-12 ### ### ### Birmingham Pediatrics, https://Cl
806 Saint Vincent's Drive, Suit
18-Dec-19 18-Jul-22 ### 4-Dec-19 18-Jan-20 HÃ´pital GÃ©nÃ©ral https://Cl
Oct-14 Jun-16 Jun-16 ### 1-Sep-16 Pizhou Center for Dishttps://Cl
Jan-14 Jul-15 Sep-15 ### ### HÃ´pitaux Universitaihttps://Cl
Nov-14 Apr-15 Mar-16 ### 17-Apr-15 Q-Pharm Pty Limited,https://Cl
Apr-10 Nov-10 Nov-10 4-Dec-09 8-Feb-12 8-Feb-12 Pfizer Investigational https://Cl
30-Jul-15 15-Dec-16 12-Jan-17 4-Aug-15 ### https://Cl
Jun-19 Dec-23 Dec-24 2-Apr-19 2-Apr-19 https://Cl
May-10 May-12 Jun-12 7-May-10 19-Apr-13 Centre de Support enhttps://Cl
Oct-07 Feb-08 Jul-08 ### 16-Jan-13 ### Site 09, Fayetteville, Arkansas,
https://ClUnited States|Site 10,
30-Nov-17 30-Nov-18 ### ### ### Fuda cancer institut https://Cl
30-Nov-17 30-Nov-18 ### ### ### Cancer institute of https://Cl
Oct-11 Jul-13 Jul-13 19-Jan-12 19-Jan-12 Luigi Sacco Hospital , https://Cl
Aug-16 Jul-17 Jul-17 2-Nov-16 ### Center for Immunizatihttps://Cl
Jan-20 Jan-22 Jan-23 18-Jul-14 9-Jan-19 Southeastern Regionahttps://Cl
Sep-14 Dec-16 Mar-17 ### ### https://Cl
30-Nov-17 30-Nov-18 ### ### ### Fuda cancer institut https://Cl
Oct-14 Mar-15 Mar-15 ### 7-Dec-18 2-Jan-19 CVD-Mali, Bamako, Mhttps://Cl
Oct-13 Apr-16 Dec-20 1-Oct-12 16-Jan-19 Instituto da CrianÃ§a https://Cl
do Hospital das ClÃnicas da Fac
Jan-15 May-17 May-17 7-Oct-15 ### UCSF Benioff Childrenhttps://Cl
14-Nov-19 Nov-20 Nov-21 5-Nov-19 2-Dec-19 L'Institut National https://Cl
Jul-07 May-09 Jun-09 20-Jun-07 ### 1-Oct-14 Oxford Vaccine Group,https://Cl
23-Jun-17 1-Nov-20 1-Nov-20 31-Jan-17 ### University of Alabamahttps://Cl
28-Jul-14 22-Jun-15 22-Jun-15 8-Sep-14 ### Broward Research Grou https://Cl
Sep-05 Sep-06 Sep-07 20-Oct-05 28-Jan-09 Seattle Children's Ho https://Cl
Jul-11 Dec-11 May-12 8-Jun-11 15-Apr-15 University of British https://Cl
Oct-14 Oct-14 Apr-15 ### ### Center for Disease Prehttps://Cl
May-11 Nov-11 ### ### Drug Reseach Center,https://Cl
Feb-06 Apr-07 Apr-07 1-Mar-06 1-Dec-16 Encinitas, California https://Cl
Sep-09 5-Oct-18 5-Oct-19 2-Sep-09 ### University of Pittsburhttps://Cl
Nov-07 Dec-07 Jun-08 ### 24-Jun-10 8-May-12 Centro de Salud Galv https://Cl
Dec-13 Jun-14 Dec-14 14-Jan-14 27-Jun-17 10-Jul-18 Site 116, Phoenix, Ar https://Cl
Jun-13 Dec-14 May-15 ### ### John Hopkins Bloomber https://Cl
22-Aug-16 29-Jul-19 29-Jul-19 3-Feb-16 ### Biomat Bellflower, Belhttps://Cl
Oct-16 Jun-18 Jul-18 3-Jun-15 ### 2-Oct-19 University "Study Prohttps://Cl
Jan-04 Jun-07 Dec-09 ### 11-Jan-17 University of Texas-H https://Cl
Sep-07 Apr-09 Aug-09 ### ### ### University of Pittsburhttps://Cl
Oct-11 Sep-12 Mar-13 ### 9-Feb-16 Centers for Immunizathttps://Cl
28-Mar-07 20-Feb-11 ### 6-Jun-14 29-Jan-18 ### Osaka, Japan https://Cl
8-Jun-11 Nov-14 5-Mar-18 16-Jun-11 ### 17-Apr-19 Fortaleza, CE, Brazil|VitÃ³ria,
https://Cl
ES, Brazil|Goiania, GO, B
Feb-06 Apr-09 Apr-09 ### 31-Jan-17 31-Jan-17 https://Cl
1-Nov-19 31-Jul-23 31-Jul-23 7-Jun-19 ### https://Cl
Nov-13 Oct-14 Sep-15 8-Nov-13 2-Jul-18 The Center for Pharma https://Cl
Dec-11 May-13 May-13 8-Dec-11 ### ### Seoul National Univers https://Cl
28-Dec-18 15-Apr-20 15-Apr-20 ### ### Optimal Research, Peo https://Cl
Jan-10 Sep-10 May-12 7-Dec-09 6-May-14 9-Oct-18 Oxford Vaccine Group,https://Cl
Jun-12 Mar-13 Jun-13 27-Jun-12 21-Oct-13 2-Mar-16 Sacramento, Californihttps://Cl
8-Dec-17 9-Mar-18 ### ### 10-Jul-19 Baylor College of Medhttps://Cl
Aug-12 Apr-14 Apr-14 ### 21-Jul-14 Stanford University Schttps://Cl
Oct-14 May-16 24-Oct-14 19-Apr-17 University of Rochesthttps://Cl
Sep-14 Mar-17 Jun-17 ### 14-Oct-16 National Cancer Centrhttps://Cl
Apr-11 Jul-12 Jul-12 3-May-11 6-May-14 ### 401 Paideia Jeronimohttps://Cl
13-May-19 13-Dec-19 13-Apr-20 2-May-19 ### Jiangsu Provincial Ce https://Cl
Aug-12 Jan-13 Jan-13 ### ### Garuda Primary Health https://Cl
Nov-07 Apr-10 Aug-10 ### 15-Oct-14 ### East Vantaa Clinic, https://Cl
Nov-09 Apr-11 Apr-11 ### 27-Oct-11 Site Reference ID/Invhttps://Cl
16-Sep-19 Apr-20 Jun-20 ### ### https://Cl
Jun-13 Sep-20 Sep-20 21-Jun-13 ### N. N. Petrov Researchhttps://Cl
Feb-04 Jun-09 Jun-09 4-May-06 19-Jul-17 19-Jan-18 USAMC-AFRIMS/Departm https://Cl
Apr-11 Oct-12 Oct-12 ### 9-Oct-15 Holdsworth House, Byr https://Cl
Apr-15 Nov-15 30-Apr-19 ### 18-Oct-18 Centre for Clinical V https://Cl
31-Mar-17 5-May-17 3-Apr-18 20-Apr-17 ### Scintipharma, Inc., L https://Cl
Sep-09 Oct-09 Nov-09 30-Oct-09 ### Beijing Centers for Dihttps://Cl
16-May-14 11-Jul-18 31-Jul-19 12-Jun-13 6-Aug-19 ### Hillman Can "Study Prohttps://Cl
Aug-10 Aug-11 Nov-11 14-Jul-10 12-Jun-14 26-Jun-14 301, Tatum Highlandshttps://Cl
Aug-16 Mar-17 May-17 ### ### Gaozhou Center for Dhttps://Cl
Oct-09 Nov-10 Nov-10 8-Oct-09 ### ### Usc La Nichd Crs, Alh https://Cl
Sep-15 Sep-16 Nov-17 5-Oct-15 18-Jan-19 Ã‰quipe de recherchhttps://Cl
Nov-15 Mar-16 Mar-16 23-Oct-15 15-Jan-19 15-Jan-19 Clinical Center of Ser https://Cl
Oct-13 Dec-15 Feb-16 ### ### Cantonal Hospital Aarhttps://Cl
Oct-13 Jan-14 Jun-14 13-Oct-14 6-Apr-15 ### https://Cl
25-May-19 Feb-20 Dec-23 ### ### The Central Hospital ohttps://Cl
Jan-06 4-Apr-06 ### Nanning, Guangxi, Chhttps://Cl
16-Nov-17 16-Aug-18 1-Dec-18 ### ### Center for Infectious https://Cl
Nov-11 Dec-12 Mar-13 4-Jan-13 ### Beijing Huaxin Hospithttps://Cl
Jun-08 Apr-11 Jul-12 25-Jul-08 8-Jul-13 Baylor University Medi
https://Cl
Apr-10 Dec-10 Mar-11 ### ### Bristol Children's Va https://Cl
8-Oct-13 30-Jun-14 30-Jun-14 ### ### Miami Research Associ https://Cl
20-Dec-17 11-Oct-22 ### 1-Nov-17 5-Feb-20 University of Rochesthttps://Cl
25-Sep-18 May-19 Apr-20 8-Aug-16 10-Oct-18 â€¢ Unidade de Ensaioshttps://Cl
ClÃnicos para ImunobiolÃ³gi
27-Oct-16 27-Jun-18 ### ### 14-Oct-19 14-Oct-19 GSK Investi"Study Prohttps://Cl
Dec-10 Feb-11 Feb-11 10-Jan-11 ### GuangXi Center for Dihttps://Cl
1-Feb-18 1-Apr-19 1-Jul-20 18-Jan-18 18-Jan-18 CIC Cochin Pasteur, P https://Cl
1-Mar-20 30-Nov-20 28-Jan-21 9-Aug-19 5-Feb-20 https://Cl
Jan-12 Mar-13 Mar-13 11-Jan-12 ### Donghai County Center https://Cl
Oct-10 May-13 May-13 7-Oct-10 3-May-19 3-May-19 Monroe Carell Jr. Chilhttps://Cl
Jan-16 Jun-16 Aug-16 ### 1-Sep-16 Guanyun County Cente https://Cl
18-Jun-13 2-Feb-15 2-Feb-15 9-Apr-14 21-Jun-19 Emavundleni Desmond https://Cl
Jun-07 Jul-07 Jul-07 ### 1-Dec-16 Azienda Sanitaria USLhttps://Cl
Apr-11 Jan-14 Dec-14 21-Apr-11 20-Jan-16 9-May-16 Site 55 - Instituto d https://Cl
Nov-08 Mar-09 Aug-10 7-May-10 7-May-10 National Health Cent https://Cl
1-Jun-19 1-May-20 1-May-20 ### ### BC Centre for Diseasehttps://Cl
21-Feb-19 Jun-20 Mar-21 ### 10-Apr-19 St Georges Universit https://Cl
10-Oct-12 21-Aug-15 ### 31-Jul-12 23-Jan-17 ### Emory Vaccine Centerhttps://Cl
Oct-04 Oct-09 Oct-13 2-Jan-08 2-Jul-17 2-Jan-20 U.S. Army Medical Reshttps://Cl
Jun-13 May-14 Sep-14 13-Jun-13 3-Dec-14 Pembroke Pines, Florihttps://Cl
9-May-08 2-Sep-08 8-Jan-09 8-May-08 19-Oct-17 ### GSK Investigational S https://Cl
Jan-10 Mar-10 Apr-10 ### ### Department of examina https://Cl
Nov-15 May-17 May-17 7-Sep-15 12-Jul-18 12-Jul-18 Cincinnati "Study Prohttps://Cl
Jun-15 19-Sep-17 ### ### 7-Nov-18 CharitÃ© Berlin, Neuhttps://Cl
6-Oct-17 30-Oct-19 ### 19-Oct-17 19-Oct-17 Hunan Provincial Centhttps://Cl
Mar-05 May-06 May-06 5-Apr-06 6-Nov-15 6-Nov-15 University of Tamperehttps://Cl
Jan-08 Apr-11 Apr-11 1-Jul-11 28-Oct-11 https://Cl
Jun-16 Dec-17 Jun-18 4-Jul-16 2-Aug-17 JCCT, Lenexa, Kansas,https://Cl
Jul-08 Jun-10 Apr-11 4-Aug-08 ### ### Children's Hospital B https://Cl
Apr-11 Feb-13 Mar-13 26-Apr-11 ### Asan Medical Center, https://Cl
Mar-14 Nov-15 Nov-15 10-Apr-14 ### ### Respiratory and Menihttps://Cl
Oct-09 14-Nov-14 Oct-16 ### 21-Apr-17 Cedars Sinai Medical hCttps://Cl
1-Jun-18 31-Mar-19 ### 4-May-18 7-Aug-19 Kaiser Permanente Col https://Cl
Dec-11 Dec-14 Dec-14 20-Apr-12 8-May-15 University of Californhttps://Cl
Feb-07 Nov-09 Nov-09 ### 8-Jul-14 8-Jul-14 National Cancer Insti https://Cl
Jul-11 Jan-12 Dec-12 27-Jan-11 5-Dec-12 St George's - Univers https://Cl
Mar-12 Mar-13 Mar-13 3-Apr-12 ### Guangxi Provincial Cehttps://Cl
Oct-06 Nov-08 Nov-08 ### ### ### Albi, France|Amiens, https://Cl
Nov-10 Dec-10 Dec-10 ### 8-Dec-17 Bristol Children's Va https://Cl
Oct-05 Mar-06 Aug-07 ### ### 14-Apr-16 Norfolk, Virginia, Uni https://Cl
1-Sep-16 31-Dec-16 1-Apr-18 ### ### https://Cl
Sep-05 Oct-05 Apr-06 5-Apr-06 18-Jan-13 ### 2nd Department of Int https://Cl
3-Jun-15 18-Sep-17 ### 23-Apr-15 ### ### Singapore "Statistic https://Cl
12-Dec-13 1-May-15 8-Sep-16 ### ### University of Marylanhttps://Cl
Sep-16 30-Apr-17 30-Apr-18 28-Oct-16 ### Center for Immunizathttps://Cl
Oct-07 Apr-08 Apr-08 ### 1-Feb-11 24-Jun-13 Durham Regional Hospi https://Cl
20-Sep-17 29-Dec-17 ### ### ### The catholic universithttps://Cl
Dec-13 Apr-14 Jun-14 21-Oct-14 ### Guzhen Center for Di https://Cl
Dec-12 Jun-15 Jun-15 ### ### https://Cl
Sep-10 May-11 Oct-12 6-Aug-10 26-Jul-16 Walter Reed Army Inst https://Cl
Oct-10 Apr-12 Sep-12 6-Oct-10 8-Mar-13 8-Mar-13 Vanderbilt-Ingram Can https://Cl
Aug-04 Dec-04 Dec-04 ### 13-Oct-17 Group Health Research https://Cl
Apr-06 Apr-06 May-06 9-Aug-12 9-Aug-12 https://Cl
Feb-12 Oct-13 Apr-14 ### 13-Oct-17 Group Health Research https://Cl
12-Sep-19 15-Sep-20 ### ### ### Aarhus University Hohttps://Cl
Jan-10 Jan-10 Jan-10 ### ### Jizhou County, Hebei,https://Cl
3-Sep-19 11-Nov-19 ### 3-Dec-19 4-Dec-19 Child Health Dept. Drhttps://Cl
22-Feb-18 22-Feb-21 ### ### ### First Affiliated Hos https://Cl
Jun-10 Jul-10 Jul-10 22-Jun-10 5-Jan-12 UniversitÃ¤t Rostock https://Cl
9-Apr-18 14-Jan-19 14-Jan-19 ### 5-Feb-20 5-Feb-20 University "Statistic https://Cl
Oct-13 Jul-15 ### ### Johns Hopkins Univershttps://Cl
8-May-15 Nov-18 Nov-18 29-Apr-15 ### Rockefeller Universit https://Cl
Sep-15 Apr-18 Apr-18 16-Jul-12 6-Apr-18 Queen Saovabha Memor https://Cl
Oct-12 Apr-13 Apr-13 24-Oct-12 30-Apr-13 Hebei Provincial Centhttps://Cl
May-14 Dec-14 Dec-14 1-Jul-13 ### Unidade de Ensaios ClÃhttps://Cl
nicos para ImunobiolÃ³gicos,
Jun-12 Jul-13 Jul-13 1-Jun-12 6-Dec-18 Emory Children's Centhttps://Cl
Feb-15 Jul-15 Jul-15 15-Jan-16 15-Jan-16 SingHealth Investigat https://Cl
29-Sep-15 31-Aug-20 ### 28-Apr-15 3-Jun-19 Washington University https://Cl
Oct-04 Mar-06 Mar-06 6-Dec-05 ### 28-Jun-18 Rochester, Minnesota,https://Cl
11-Apr-17 Sep-19 Dec-20 1-Feb-18 9-May-18 Univeristy Hospitals https://Cl
5-Jun-19 Aug-20 Aug-20 ### ### Laishui Center for Di https://Cl
3-Sep-19 24-Jan-22 24-Jan-22 15-Jul-19 ### Emory Vaccine Centerhttps://Cl
Sep-11 Feb-12 Feb-12 8-Sep-11 ### ### Colorado Springs, Colhttps://Cl
Sep-10 Mar-11 Sep-11 ### ### ### Centro de AtenciÃ³n ehttps://Cl
1-Apr-19 1-Apr-22 1-Aug-22 ### ### Center for Experimenthttps://Cl
5-Jan-18 31-Mar-21 ### 20-Apr-17 ### Johns Hopkins Schoolhttps://Cl
Jul-09 Dec-18 Dec-18 ### 3-Oct-17 Hospital of the Univerhttps://Cl
Jun-10 May-14 May-14 22-Jun-11 ### The University of Ala https://Cl
12-Apr-19 Aug-20 Feb-21 9-Apr-19 9-Apr-19 St Georges Universit https://Cl
31-May-17 31-Dec-18 ### 16-Jan-18 16-Jan-18 Tan Tock Seng Hospitahttps://Cl
Sep-15 Feb-19 Aug-19 ### ### Bio Products Laborat https://Cl
Jul-12 Jul-13 Jul-13 12-Jun-12 ### ### Christian Medical Centhttps://Cl
May-13 Mar-14 Nov-14 ### 6-Mar-15 ### UOC Medicina Internahttps://Cl
Jul-08 Oct-08 Oct-08 ### 8-Feb-12 Vaccination site, Shij https://Cl
Mar-12 Jul-12 Jul-13 9-Feb-12 ### 4-Apr-16 Center for Vaccinologhttps://Cl
25-May-17 15-Jul-18 ### ### ### Changshan Center forhttps://Cl
Oct-14 Dec-19 Dec-19 ### 1-Aug-18 Center on Aging, UCon https://Cl
Nov-09 Jan-11 Dec-12 ### ### Necker Hospital, Parishttps://Cl
11-Mar-08 20-Jun-08 18-Jun-09 ### ### 3-Jan-20 GSK Investigational S https://Cl
17-Dec-18 Jun-19 Feb-23 ### ### Ministry of Public He https://Cl
4-Feb-15 3-May-16 1-Nov-17 ### 1-May-18 Cochin Port Royal Hosp https://Cl
Aug-12 Dec-12 Oct-13 ### 8-Dec-14 8-Dec-14 Institute of Specific https://Cl
Feb-14 Feb-17 Feb-17 ### ### National Institute of https://Cl
Jun-06 Nov-08 Nov-08 ### 4-Dec-13 Emory Vaccine Center- https://Cl
Oct-13 Aug-17 Aug-17 7-Nov-13 11-Oct-18 ### Center for "Statistic https://Cl
22-Apr-17 1-Nov-17 1-Nov-17 6-Sep-17 2-Jan-19 Dongguan Municipal hCttps://Cl
Nov-10 Mar-11 Apr-11 ### 27-Oct-11 ### Idaho Falls, Idaho, U https://Cl
Aug-09 Oct-09 Mar-11 2-Sep-09 1-Dec-16 Gent, Antwerpen, Belhttps://Cl
18-Apr-18 28-Jul-18 Aug-20 ### ### Research Institute fo https://Cl
Jul-11 Mar-13 Jun-13 18-Jul-11 25-Apr-14 25-Apr-14 Goyang, Korea, Repubhttps://Cl
Oct-09 Apr-10 Apr-10 3-Nov-09 20-Jan-12 National Taiwan Univhttps://Cl
22-Dec-15 15-Sep-16 ### ### 4-Apr-17 Optimal Research, Mel https://Cl
24-May-17 23-Jul-19 23-Jul-19 ### 1-Aug-19 302 AusTrials Pty Ltd https://Cl
3-Dec-19 Feb-22 Feb-22 ### ### Baylor Scott & White hRttps://Cl
Oct-09 Aug-11 Aug-11 22-Jun-09 11-Oct-12 11-Oct-12 NGO Via Libre, Lima, https://Cl
Aug-11 Nov-11 Dec-12 1-Jan-13 ### Xinglong County Cente https://Cl
May-15 Jun-18 Dec-18 6-Dec-13 31-Jan-19 Hospital Gustavo Fricke,
https://Cl
ViÃ±a del Mar, ValparaÃso, C
Sep-10 Aug-13 Aug-13 ### ### ### St. Jude Children's R https://Cl
Jun-12 Oct-19 Oct-19 ### 25-Oct-19 Los Angeles County De https://Cl
4-Feb-19 28-Feb-21 ### 9-May-18 18-Jan-20 National Institutes ofhttps://Cl
Sep-09 Jan-12 ### ### Faculty of Tropical M https://Cl
20-Nov-18 Oct-20 Oct-21 19-Jul-18 ### University of Pennsyl https://Cl
Jun-16 Nov-16 Nov-16 27-Jun-16 7-Nov-16 Incheon St. Mary's Hohttps://Cl
23-Oct-18 31-Mar-20 30-Jun-20 25-Oct-18 7-Dec-18 M.A. Sante, Douala, https://Cl
Oct-14 May-15 May-15 7-Nov-14 4-Oct-16 27-Oct-17 Coastal Clinical Rese https://Cl
Aug-13 Nov-16 Nov-16 7-Jun-13 18-Oct-17 Kaiser Permanente Col https://Cl
Sep-14 Apr-15 Apr-15 20-Jan-14 ### Center for Immunizatihttps://Cl
Sep-13 Dec-15 Jun-16 ### 1-Aug-16 Institute of Medical https://Cl
Sep-09 Dec-09 Dec-09 5-Jun-09 12-Oct-15 NZOZ Centrum Zdrowia https://Cl
3-Dec-19 Jun-20 Jul-20 5-Dec-19 5-Dec-19 https://Cl
Nov-13 May-15 Jul-15 6-Dec-13 ### Chaoyang District Cenhttps://Cl
Dec-12 Jul-13 Jul-13 18-Apr-12 ### National Institute of https://Cl
Nov-15 Oct-16 Jan-17 ### 9-Feb-18 St Istvan St laszlo Ho https://Cl
Nov-09 Feb-11 Feb-11 9-Oct-09 5-Mar-12 7-Aug-13 University of Marylanhttps://Cl
Jul-15 Sep-15 Oct-15 ### 14-Oct-15 Phase 1 vaccine clinichttps://Cl
Nov-13 Jul-14 Jul-14 ### ### ### Huntsville, Alabama, https://Cl
Dec-11 Apr-12 Apr-12 ### ### Rajarajeshwari Medica https://Cl
Sep-08 Oct-13 Oct-13 ### 6-Oct-14 6-Oct-14 Pfizer Investigational https://Cl
Sep-15 Dec-15 Dec-15 ### ### ### https://Cl
Nov-14 Dec-14 Jan-15 ### 9-Nov-15 9-Nov-15 DingXing Center for Dhttps://Cl
Mar-05 6-Apr-06 ### Weilheim, Germany https://Cl
26-Mar-13 11-Jun-18 30-Jun-20 6-Dec-12 18-Jan-20 Roswell Park Cancer Ihttps://Cl
Sep-09 Apr-10 Apr-10 28-Oct-09 20-Jan-12 National Taiwan Univehttps://Cl
22-Oct-18 Jul-21 Jul-22 ### 8-Aug-19 The Hope Clinic of th https://Cl
Jul-14 Jul-21 Jan-22 7-Sep-15 31-Jan-19 CharitÃ© - Universit https://Cl
Aug-14 Dec-17 Dec-17 9-Nov-16 9-Nov-16 https://Cl
Jan-14 Mar-14 Apr-14 8-May-14 8-May-14 https://Cl
Aug-15 Aug-19 Aug-19 ### 9-Nov-18 UO Oncologia Medica,https://Cl
Jul-16 31-Jul-17 30-Jun-18 30-Jun-16 18-Jul-18 Mother and Child Hoshttps://Cl
15-Oct-18 30-May-19 30-Jun-19 ### 10-Jan-20 Atlanta VA "Statistic https://Cl
Oct-09 Jan-10 Dec-14 28-Oct-09 ### ### Haukeland Universityhttps://Cl
11-Apr-18 9-Jul-19 ### 4-Oct-17 ### ### National In"Study Prohttps://Cl
Oct-08 May-09 May-09 ### 24-Jan-14 UCL St. Luc - Pharmachttps://Cl
Dec-14 Feb-15 Jul-15 ### ### Phase 1 vaccine clinichttps://Cl
Sep-09 May-10 May-10 ### ### 3-Dec-12 Saint Louis Universit https://Cl
Aug-15 24-Apr-17 24-Apr-17 ### 29-Jan-19 Charles A. Sammons Ca https://Cl
Oct-13 Jan-16 ### 27-Jul-16 University of Rochesthttps://Cl
12-May-15 31-Dec-21 1-Mar-22 ### 13-Jan-20 National Institutes ofhttps://Cl
Apr-08 Aug-09 Aug-09 ### ### ### Clinical Trials Center https://Cl
1-Mar-16 30-Dec-19 1-Oct-20 19-Jul-18 ### International Agency https://Cl
Oct-12 Dec-12 Jan-13 21-Oct-15 21-Oct-15 Korea University Ansahttps://Cl
Aug-12 Aug-13 Aug-13 6-Feb-12 6-Mar-15 6-Mar-15 Monticello High Schoo https://Cl
Mar-10 Sep-11 Oct-11 ### 2-Dec-13 ### Bangkok, Thailand|Bahttps://Cl
Sep-09 Dec-09 Dec-09 ### 9-May-13 Bristol Children's V https://Cl
25-Jun-13 12-Apr-16 12-Apr-16 2-Jul-13 ### ### Vadodara, Gujarat, Inhttps://Cl
Jan-11 Jun-11 Jul-11 10-Jan-11 25-Jul-11 GuangXi Center for Dihttps://Cl
Dec-16 8-Oct-19 8-Oct-19 ### 6-Feb-20 UF Health Family Medic https://Cl
Nov-08 Jun-09 Jun-09 ### ### Arya vysya maternity https://Cl
Oct-99 Nov-16 Nov-16 ### ### https://Cl
19-May-16 9-Feb-17 9-Feb-17 1-Jan-16 ### https://Cl
Mar-07 Mar-12 Mar-13 ### ### Fukushima Medical Un https://Cl
Apr-06 May-07 Dec-07 ### 18-Jun-14 18-Jun-14 Andria, Italy|Catania,https://Cl
18-Oct-19 1-Apr-20 1-Apr-20 1-Oct-19 ### University of Californhttps://Cl
May-10 Nov-12 Nov-12 ### 4-May-15 Parkland Health & Hos https://Cl
31-May-12 1-Sep-15 ### ### 25-Jul-16 ### GSK Investigational S https://Cl
10-May-17 14-Mar-18 ### 4-Mar-16 ### ### GSK Invest"Study Prohttps://Cl
Jul-13 Aug-13 Aug-13 18-Jun-13 ### ### Antwerp University Cehttps://Cl
Oct-15 Mar-16 May-16 ### 8-May-17 9-Jun-17 https://Cl
Oct-05 Apr-08 Apr-08 6-Apr-06 8-Feb-12 Mainz, Kehl, NeumÃ¼n https://Cl
Oct-15 Jul-16 ### ### 12-Jul-17 https://Cl
May-09 Dec-12 Apr-13 6-May-09 ### Niakhar Demographichttps://Cl
S
1-Feb-20 1-Feb-21 1-Aug-21 ### ### Department of Medicihttps://Cl
13-Jun-17 19-Dec-17 ### 3-May-17 ### Infectious Disease Cl https://Cl
Oct-12 Jun-15 Jun-15 30-Jul-15 ### ### https://Cl
Jul-10 Jan-12 Jan-12 17-Jun-09 ### University of Rochesthttps://Cl
Oct-10 May-12 May-12 ### ### ### University of Pittsburhttps://Cl
1-Jul-16 18-Mar-17 18-Jan-19 6-Jul-16 14-Jun-19 ### Singapore,"Study Prohttps://Cl
Jul-10 Mar-11 Mar-12 ### ### Manchester Medical M https://Cl
May-13 Aug-13 Aug-13 1-Jan-15 1-Jan-15 https://Cl
Mar-08 Jan-10 Jan-10 14-Apr-08 10-Apr-15 10-Oct-17 GrÃ¤ssl, Hall in Tirol, Austria|HÃ¤ckel,
https://Cl Kirchdorf, Aust
Feb-09 Aug-10 Aug-10 ### 3-Mar-15 3-Mar-15 Altenburger, Eisenstadt, https://Cl
Austria|GrÃ¤ssl, Hall in Tirol,
Nov-10 Dec-25 Dec-25 ### 18-Oct-19 The Hope clinic of Emhttps://Cl
Mar-12 Aug-12 Aug-12 ### ### KEMRI/Wellcome Trust https://Cl
Aug-13 Nov-13 Apr-14 30-Jul-13 9-Oct-15 Minami Clinic, Kagos https://Cl
13-Oct-17 31-Oct-18 31-Oct-18 3-Oct-17 ### The Boathouse Surgerhttps://Cl
Apr-08 Sep-09 Sep-09 ### 15-Oct-10 8-Aug-11 Curitiba, Brazil|Flori https://Cl
20-Aug-19 Dec-20 Dec-20 1-Apr-19 ### Binza and Kingasani Mhttps://Cl
Oct-06 Jun-07 Sep-08 23-Oct-06 ### 14-Apr-16 Layton, Utah, United https://Cl
Aug-12 Aug-12 Sep-12 ### ### National Cheng Kung https://Cl
U
Oct-09 Aug-10 Aug-10 9-Oct-09 9-Feb-12 ### UAB Pediatric Infecti https://Cl
23-Feb-17 Nov-20 Mar-21 15-Jul-16 ### Mwanza Interventionhttps://Cl
1-Aug-17 2-Sep-19 2-Jan-20 24-Apr-17 30-Jan-19 St Georges Universit https://Cl
31-May-18 4-Dec-20 4-Dec-20 ### ### GSK Investigational Sihttps://Cl
Aug-09 Oct-09 Apr-11 4-Sep-09 ### Gent, Antwerpen, Anthttps://Cl
Sep-09 Jul-12 Jul-12 8-Jul-09 ### Comprehensive Ruralhttps://Cl
H
Oct-11 Nov-12 Nov-12 4-Nov-11 ### Centre for Clinical V https://Cl
16-Jan-04 30-Jun-24 30-Jun-24 3-Jun-19 ### University of Marylanhttps://Cl
12-Feb-20 30-Jul-22 ### ### ### Hospital Universitariohttps://Cl
Virgen de Las Nieves, Granada,
Aug-09 Mar-10 Aug-11 3-Sep-09 1-Dec-16 Gent, Antwerpen, Belhttps://Cl
Aug-07 Mar-11 Jun-11 ### ### ### Ark-La-Tex Pediatric https://Cl
Sep-09 Feb-10 Jul-11 3-Sep-09 12-Oct-11 Gent, Antwerpen, Belhttps://Cl
Apr-05 May-05 Jun-05 ### ### Ewha Womans Universi https://Cl
Jul-11 Dec-11 Dec-11 ### 8-Jan-13 25-Jan-13 Instituto Mexicano dehttps://Cl
InvestigaciÃ³n ClÃnica, S.A. de
27-Mar-17 4-Sep-17 4-Sep-17 9-Nov-17 9-Nov-17 Bio-Manguinhos/Fiocru https://Cl
Mar-15 5-Jun-19 ### 1-Apr-15 ### https://Cl
Sep-07 Oct-07 May-08 1-Oct-07 ### University of Tamper https://Cl
Jan-12 Jan-13 Jan-14 ### ### Institute of Tropical https://Cl
Sep-06 Sep-10 Sep-10 9-Dec-10 ### Department of Clinicahttps://Cl
Apr-12 Nov-12 Dec-12 11-Jan-12 ### ### Ben Luc Health Centehttps://Cl
Feb-09 Sep-13 Feb-14 ### 26-Jul-19 26-Jul-19 Sanofi Pasteur Investihttps://Cl
15-Dec-15 Jun-20 Jun-21 9-Jun-15 ### Special Immunizationhttps://Cl
Apr-13 Nov-13 Feb-14 9-Apr-13 ### Royal Free Hospital; https://Cl
23-Apr-19 14-Aug-20 25-Jun-21 ### 18-Jan-20 GSK Investigational Sihttps://Cl
Oct-09 Mar-10 Mar-10 ### ### Hospital Erasme, Brushttps://Cl
Sep-04 Jul-05 Oct-06 6-Dec-05 18-Jun-14 18-Jun-14 Vaccine Evaluation Cehttps://Cl
27-May-08 May-09 ### 4-Apr-18 Mary Crowley Cancerhttps://Cl
R
Oct-07 Aug-08 Nov-08 ### ### ### Hoover, Alabama, Unit https://Cl
Dec-10 Feb-12 Feb-12 6-Dec-10 3-Dec-14 Miller Children's Hos https://Cl
Jun-04 May-11 May-11 9-May-06 2-May-12 5-Dec-12 UT MD Anderson Cance https://Cl
Jun-14 Jul-14 Jul-14 ### 7-Dec-16 7-Dec-16 https://Cl
Nov-09 Jan-10 Jul-10 2-Dec-09 2-Jan-12 CHU de BesanÃ§on-HÃ´ https://Cl
May-08 Dec-25 Dec-25 10-Jun-08 18-Oct-19 The Hope Clinic of th https://Cl
Sep-08 28-Jul-08 ### Johns Hopkins Bayview https://Cl
Jan-09 Feb-09 Dec-11 3-Jul-08 ### Ministry of Health andhttps://Cl
Mar-15 Mar-15 Mar-15 6-Mar-15 ### ### Research Facility ID https://Cl
Sep-06 Jun-07 Sep-08 17-Oct-06 ### 18-Apr-12 Alabaster, Alabama, Uhttps://Cl
Feb-10 Jun-11 Jun-11 ### 23-Oct-12 23-Oct-12 Mayo Clinic, Rochestehttps://Cl
19-Nov-18 30-Dec-19 ### ### ### Henan Prov"Study Prohttps://Cl
1-Sep-19 31-Aug-22 31-Jul-23 ### 4-Oct-19 University of Coloradhttps://Cl
Oct-11 Jun-12 Feb-13 11-Apr-13 11-Apr-13 University of Kentuckhttps://Cl
Apr-11 Mar-12 Sep-12 20-Apr-11 ### Nanning, Guangxi, Chhttps://Cl
30-Jul-09 5-Oct-09 5-Oct-09 13-Jul-09 ### ### GSK Investigational Sihttps://Cl
May-15 Sep-20 Sep-20 6-May-16 6-May-16 Gaozhou District Centhttps://Cl
2-Dec-13 30-Mar-20 ### ### 10-Jan-20 Research Site, Gaineshttps://Cl
Nov-08 May-11 Dec-26 ### 27-Jan-20 Dana-Farber Cancer In https://Cl
May-09 Apr-14 Jul-15 ### ### Clinical Trials Center https://Cl
30-Jul-18 Apr-20 Sep-20 26-Jul-18 ### Marshfield Clinic - M https://Cl
Sep-14 Feb-16 Feb-16 1-Oct-14 ### Department of Paediat https://Cl
Jun-12 Feb-13 Feb-13 21-Jun-12 1-Jun-15 1-Jun-15 ICDDR,B Kamalapur, https://Cl
Jun-16 Aug-16 Aug-16 1-Jul-16 ### Taixing county diseasehttps://Cl
Aug-12 Sep-13 Sep-13 19-Jun-12 ### Pediatrics 5280, Centhttps://Cl
Jul-01 Sep-12 Mar-13 ### 3-Jun-14 Walter Reed Nationalhttps://Cl
Nov-13 Aug-14 Aug-14 ### 8-Dec-15 8-Dec-15 Huntsville, Alabama, https://Cl
1-Jan-16 31-Oct-19 31-Oct-19 5-Apr-16 ### International Centre https://Cl
Aug-16 Aug-20 Feb-21 1-Jun-16 9-Oct-19 Birmingham VAMC, Birm https://Cl
3-May-07 4-Feb-08 4-Feb-08 ### 14-Apr-09 21-Apr-17 https://Cl
Dec-09 Mar-10 May-10 12-Jan-10 ### GuangXi Center for Dihttps://Cl
22-Feb-18 1-Apr-19 1-Apr-20 9-Feb-17 31-Oct-18 Center for Cancer Im https://Cl
7-May-19 Feb-20 Feb-20 31-Oct-19 4-Nov-19 Q-Pharm Pty Limited,https://Cl
Nov-07 Jun-08 ### ### Thi Son commune heahttps://Cl
Mar-13 Jun-13 Oct-13 23-Jan-13 9-Oct-15 PS Clinic, Fukuoka Ci https://Cl
Mar-14 Oct-14 Dec-14 ### 3-Jun-15 Biological treatment https://Cl
24-Oct-13 30-Jun-24 30-Jun-24 ### ### Universtiy of Marylanhttps://Cl
May-12 Dec-12 Dec-12 10-Jul-12 ### Matlab, Chandpur, B https://Cl
16-Sep-18 15-May-21 ### 3-Oct-18 ### Kaiser Permanente Nor https://Cl
1-Aug-17 30-Apr-19 30-Jun-19 ### 9-Jan-19 Rehri goth, Ibrahim Hhttps://Cl
Aug-11 Dec-14 Dec-14 ### ### 7-May-18 Stanford LPCH Vaccinehttps://Cl
23-Oct-18 9-Oct-19 9-Oct-19 10-Oct-18 5-Nov-19 Fakultni nemocnice Krhttps://Cl
Mar-20 Mar-21 Oct-21 26-Jun-19 14-Jan-20 https://Cl
Jan-08 Apr-08 Oct-08 1-Apr-08 7-Apr-17 Centro ClÃnico La Quinta,
https://Cl
Guatemala City, Guatemala
Mar-12 May-12 Aug-12 ### 2-Aug-16 Dingxing Center for Dhttps://Cl
Oct-06 Jul-08 Jul-08 ### ### ### Napoli, Campania, Italhttps://Cl
Jan-11 May-11 Jun-11 ### 10-Jun-11 https://Cl
19-Dec-18 15-Nov-22 ### ### ### Kargeno Research andhttps://Cl
3-Jun-08 16-Feb-16 ### 13-Jan-16 2-Jan-20 Special Immunizationshttps://Cl
Jun-06 Oct-07 Jun-08 6-Jul-06 22-Oct-13 22-Oct-13 Alabang, Muntinlupa https://Cl
Ci
1-Oct-14 Sep-17 Dec-20 ### ### ### H. Lee Moff"Study Prohttps://Cl
Apr-16 Apr-18 Apr-18 2-May-16 ### https://Cl
Aug-12 Sep-12 Sep-12 25-Jul-12 12-Oct-12 District Doctor's Offi https://Cl
Dec-16 Dec-20 May-23 ### 25-Oct-19 Dana-Farber Cancer In https://Cl
18-May-15 17-Aug-18 ### ### 27-Jan-20 University of Rochesthttps://Cl
Mar-09 Sep-12 Sep-12 ### ### ### Chapel Hill Pediatric https://Cl
1-Apr-19 Feb-20 Mar-20 ### ### Sarah E Williams, Nashttps://Cl
Jun-03 Jul-04 Jul-05 24-Apr-06 2-Oct-17 2-Oct-17 Walter Reed Project https://Cl
3-Oct-19 Mar-22 Mar-22 18-Apr-16 ### Investigational Site https://Cl
Feb-11 Dec-15 Dec-16 1-Mar-11 7-Aug-14 Bandim Health Project https://Cl
Mar-08 Apr-09 Oct-09 ### 9-Jun-11 ### Children's Investigat https://Cl
Oct-13 Aug-14 Oct-14 6-Dec-13 ### Henan Provincial Cenhttps://Cl
5-Nov-13 25-Nov-15 ### ### 5-Feb-20 5-Feb-20 Syracuse, New York, Uhttps://Cl
Oct-06 Aug-08 Aug-08 ### 8-Aug-12 8-Aug-12 Bad Kreuznach, Germhttps://Cl
May-14 Mar-16 Mar-17 8-May-14 ### Center for Health Re https://Cl
5-Jun-19 Feb-20 Dec-23 ### ### Shanxi Center for Dis https://Cl
Apr-15 Sep-16 Sep-16 7-Jul-15 7-Jul-15 Division of Allergic https://Cl
May-18 Jun-19 Dec-19 18-Jan-18 18-Jan-18 https://Cl
12-Sep-19 Apr-20 Apr-20 ### 28-Jan-20 Investigational Site https://Cl
6-Oct-06 22-Oct-07 24-Oct-07 ### 14-Apr-09 ### https://Cl
7-Apr-09 Oct-14 14-Oct-14 14-Apr-09 29-Jul-19 29-Jul-19 Singapore, Singaporehttps://Cl
1-Apr-19 1-May-20 1-May-20 ### ### Adelante Healthcare https://Cl
24-Oct-14 15-Aug-18 ### 9-Sep-14 11-Oct-18 Providence Health & Shttps://Cl
Oct-09 Mar-14 Dec-14 ### 5-Jan-15 Washington University https://Cl
Oct-16 Jan-17 May-18 ### 9-Aug-18 Albion Street Group https://Cl
Oct-08 Feb-09 Dec-10 9-Sep-11 9-Sep-11 University of Michigahttps://Cl
May-11 Jul-12 Nov-12 ### ### ### Pierrefonds, Quebec,https://Cl
30-Aug-16 Nov-19 Dec-20 ### 6-Dec-18 WRAIR Clinical Trials https://Cl
7-Apr-17 1-Jul-17 6-May-18 24-Apr-17 ### Celerion, Inc., Lincol https://Cl
Oct-10 Jul-11 Dec-11 ### ### Seoul National Univers https://Cl
Mar-14 May-15 May-15 16-Apr-14 ### Biological treatment https://Cl
Jul-15 Dec-20 Dec-20 16-Jul-15 6-Sep-19 Saint Louis Universityhttps://Cl
22-Feb-17 31-Jul-17 ### 9-Dec-16 6-Mar-18 Medical University Viehttps://Cl
2-Jul-19 31-Aug-20 ### 1-Aug-19 6-Nov-19 Makerere University- https://Cl
Sep-11 Nov-12 Nov-12 ### ### 25-Apr-17 NZOZ Bioscience Sp zohttps://Cl
25-Jan-19 25-Oct-19 ### 15-Jan-19 15-Jan-19 Sheng-Chieh Lin, Newhttps://Cl
9-Apr-18 30-Mar-21 ### 5-Jan-18 ### Mayo Clinic"Informed https://Cl
18-Sep-17 21-May-18 ### 28-Jun-18 28-Jun-18 Research Institute fo https://Cl
Dec-09 Mar-10 Dec-10 27-Apr-10 12-Jul-16 12-Jul-16 University of Pennsylvhttps://Cl
Oct-08 Jul-20 Jul-20 23-Jun-08 ### Loyola Univeristy Medhttps://Cl
Jan-16 Mar-16 15-Jul-16 ### 26-Oct-17 Dingxing County Cente https://Cl
3-Mar-16 Feb-20 Jan-21 ### 29-Jan-20 CHRU de Montpellier,https://Cl
Oct-10 May-12 Aug-12 ### 26-Oct-17 26-Oct-17 Scripps Clinic, San D https://Cl
20-Aug-18 18-Mar-20 ### 18-Jun-18 1-Aug-19 City of Hope Medical https://Cl
Feb-14 Mar-15 Mar-15 ### 3-Jun-15 Biological treatment https://Cl
21-Feb-18 Jan-21 Jan-21 3-Oct-17 11-Oct-19 Malawi Liverpool Wellhttps://Cl
Jun-12 Aug-14 Mar-15 27-Apr-12 17-Apr-15 MS Building Health S https://Cl
Sep-12 Jan-13 Jan-13 6-Sep-12 ### ### Mengshan Center forhttps://Cl
Feb-08 Jul-10 Oct-10 ### ### 19-Apr-13 Site 85 - Birmingham https://Cl
3-Mar-08 11-Apr-08 11-Apr-08 ### ### 8-Jun-18 GSK Investigational Sihttps://Cl
11-Feb-19 12-Oct-20 12-Oct-20 ### ### Cincinnati "Informed https://Cl
21-Feb-17 26-Oct-21 26-Oct-21 1-Feb-17 8-Nov-19 Simon-Williamson Clin https://Cl
Aug-13 Nov-13 Jan-14 2-Sep-13 21-Apr-14 7-Mar-16 Jiangsu, Jiangsu, Chinhttps://Cl
Feb-11 Nov-12 Nov-12 ### ### Kenya AIDS Vaccine I https://Cl
Nov-12 Mar-13 Mar-13 ### ### 16-Apr-14 Federal State Budgetahttps://Cl
Sep-08 Dec-08 ### 7-Aug-09 Johns Hopkins Bayview https://Cl
Mar-12 Dec-15 Jan-16 27-Oct-11 7-Feb-17 ### UCLA CARE Center CRS, https://Cl
7-Nov-16 19-Jul-18 19-Jul-18 2-Jul-17 18-Jul-19 Ansan, Korea, Republihttps://Cl
18-Feb-14 6-Jan-15 6-Jan-15 5-Feb-14 5-Apr-18 7-May-18 The Rockefeller Univehttps://Cl
Sep-11 Jul-12 Jul-12 ### 3-Jul-18 Wake Forest Universithttps://Cl
Jan-16 Mar-17 Mar-17 12-Jan-16 ### ### Rockefeller"Study Prohttps://Cl
Oct-08 Jun-09 Dec-09 4-Sep-08 2-Nov-11 3-Apr-15 Advanced Clinical Reshttps://Cl
Oct-10 Apr-12 May-12 5-Oct-10 2-Oct-14 9-Oct-18 Birmingham, Alabama, https://Cl
Oct-12 Jun-13 Oct-14 ### 21-Apr-15 Hotel-Dieu Hospital, Phttps://Cl
Mar-15 Sep-15 Feb-16 17-Apr-15 2-Mar-16 La Paz Medical Centerhttps://Cl
1-Mar-18 28-Dec-18 Jan-20 9-Aug-19 5-Nov-19 Beijing Center for Dishttps://Cl
Jan-10 Sep-12 Nov-12 8-Feb-10 6-Feb-13 San Pablo City, Philip https://Cl
Mar-14 Oct-15 Mar-16 17-Jan-14 1-Jun-16 Service d'Immunologie https://Cl
Jul-10 Apr-13 Apr-13 22-Jun-10 ### ### Alabama Clinical Therhttps://Cl
31-Mar-20 31-Oct-22 31-Oct-22 17-Jun-19 5-Dec-19 Washington University https://Cl
Feb-09 Jan-15 Jan-15 ### ### University Medical c https://Cl
22-May-17 15-May-18 30-Jul-18 ### 9-May-18 university of Antwerphttps://Cl
3-Feb-20 3-Sep-21 ### 29-Oct-19 28-Jan-20 GCAM Eagle Pass Cente https://Cl
1-May-10 31-Jul-11 31-Jul-11 11-Jul-11 13-Apr-17 Children's Hospital B https://Cl
14-Apr-14 18-Aug-17 ### 11-Apr-14 30-Jan-20 Mayo Clinic, Rochestehttps://Cl
Aug-08 Mar-09 Mar-09 13-Jan-10 14-Jan-10 Hezhou Center for Di https://Cl
20-Oct-17 1-Jul-20 1-Jul-20 ### 3-Jan-19 University of Pennsyl https://Cl
14-Apr-16 23-Nov-16 28-Oct-18 8-Dec-15 14-Jun-19 4-Nov-19 Investigational Site https://Cl
Sep-13 May-15 May-15 23-Oct-13 31-Jan-17 University of Califor https://Cl
Sep-15 Sep-16 30-Jun-17 22-Oct-15 31-Jan-19 IWK Health Centre, Ha https://Cl
Aug-06 Nov-07 Apr-08 23-Jun-06 ### ### Manila, Philippines|Qhttps://Cl
8-Dec-16 4-Jun-18 4-Jun-18 18-Oct-16 ### Center for Virology a https://Cl
16-Aug-13 15-Sep-19 ### ### ### San Diego, California https://Cl
23-Apr-17 30-Apr-20 30-Apr-20 18-Jan-17 5-Jun-19 M D Anderson Cancerhttps://Cl
Jan-14 Jun-15 Sep-15 2-Jul-14 28-Jul-15 Centre Hospitalier Reghttps://Cl
12-Dec-17 20-Nov-19 ### ### ### Walmart Pharmacy, Athttps://Cl
Feb-06 Jul-09 Jun-14 2-Jan-08 9-Mar-17 3-Jan-20 U.S. Army Medical Reshttps://Cl
Sep-10 Apr-11 Apr-11 4-Aug-10 ### University of Rochesthttps://Cl
Oct-10 Jan-13 Jun-13 ### 19-Oct-16 ### Dartmouth-Hitchcockhttps://Cl
1-Nov-17 31-Jul-18 31-Jul-18 ### 5-Jul-19 Frontier Healthcare https://Cl
Oct-09 Nov-09 Feb-10 11-Jan-11 11-Jan-11 Shiraz University Of Mhttps://Cl
Feb-07 Oct-07 Dec-07 ### ### 13-Jun-11 UCLA Center For Vaccihttps://Cl
1-Apr-17 30-Apr-18 30-Apr-18 4-Apr-17 ### Center for Immunizathttps://Cl
Feb-11 Jan-20 Jan-20 4-Feb-11 ### The Hope clinic of Emhttps://Cl
Sep-10 Dec-11 Dec-11 30-Jul-13 3-Mar-17 21-Apr-17 Stanford University Schttps://Cl
25-Aug-16 20-Jul-18 20-Jul-18 10-Oct-19 10-Oct-19 https://Cl
27-Jul-15 28-Jan-17 28-Jan-17 ### 1-Mar-18 1-Mar-18 Vadodara, "Study Prohttps://Cl
Sep-13 Apr-16 Dec-17 15-Apr-16 8-Mar-17 GuangXi Center for Dihttps://Cl
12-Sep-06 30-Jan-07 30-Jan-07 2-Aug-06 ### 2-Jan-20 GSK Investigational Sihttps://Cl
Oct-11 Jan-16 Jan-16 7-Jul-11 6-Mar-19 ### Military Hospital, Bruhttps://Cl
Aug-08 Jan-18 Jan-18 26-Jan-09 ### Lund, Sweden https://Cl
Nov-11 Jun-14 Oct-15 ### ### Jiangsu Provincial Ce https://Cl
30-Sep-15 28-Jun-19 3-Jul-19 28-Jul-15 4-Nov-19 Freetown, Sierra Leo https://Cl
11-Sep-17 Dec-20 Dec-20 ### 18-Apr-19 Vaccine Evaluation Cehttps://Cl
09-0060|N01AI80007C Nov-10 Nov-10 ### 16-Oct-18 https://Cl
Mar-10 Apr-10 Apr-10 ### 1-Dec-16 CPC Clinic, Medipolis https://Cl
Nov-09 Nov-09 Apr-10 ### ### https://Cl
Nov-05 Jan-06 Nov-07 14-Oct-09 16-Oct-09 Butajira Hospital, Buthttps://Cl
19-Jul-18 Dec-20 ### 7-Mar-18 20-Jul-18 Women's and Children' https://Cl
Nov-15 Apr-16 Apr-16 ### 25-Apr-17 https://Cl
Jan-13 Apr-14 Apr-14 ### ### UPMC Hillman Cancerhttps://Cl
C
Jun-05 21-Apr-06 ### G. D'Annunzio Universihttps://Cl
23-Jun-09 5-Oct-09 5-Oct-09 ### 6-Jan-17 3-Jan-20 GSK Investigational S https://Cl
Jul-12 Jul-12 Jul-12 4-Jul-12 6-Aug-12 Site Reference ID/In https://Cl
28-Mar-19 19-Oct-19 ### ### ### Anaheim Clinical Tria https://Cl
Jun-13 Sep-15 Nov-15 10-Jul-13 7-Dec-18 7-Dec-18 Site 34, General Pedi https://Cl
Aug-07 Jun-17 Jun-17 ### 5-Jan-16 Dongtai Center for Dihttps://Cl
Oct-12 Jul-13 Jul-13 16-Oct-12 29-Oct-13 Mount Sinai Hospital,https://Cl
18-Apr-17 28-Sep-17 ### 12-Apr-17 6-Mar-18 Puskesmas Jatinegara,https://Cl
Nov-08 Dec-08 Jan-09 21-Jan-09 ### ### Jizhou City, Hebei, Chhttps://Cl
Nov-09 Feb-10 Feb-10 23-Oct-09 15-Apr-15 Alberta Children's Hohttps://Cl
Nov-04 Jul-06 Sep-06 ### 30-Jun-11 University of Kentuckhttps://Cl
Dec-13 May-15 Jul-15 ### ### University of Rochesthttps://Cl
Oct-11 Aug-14 Aug-14 2-Apr-12 4-Nov-14 https://Cl
May-04 Jul-05 Jul-05 28-Jan-08 ### 14-Apr-16 Oakland, California, https://Cl
Oct-09 Dec-09 Dec-09 22-Oct-09 1-Dec-16 Sites 1,2,3,4,5, Kago https://Cl
Jun-12 May-16 Aug-17 19-Jun-12 ### University of Pittsburhttps://Cl
May-09 May-09 May-09 27-Apr-09 18-Jul-12 28-Jun-18 Chiltern (Early Phase https://Cl
Jun-05 21-Apr-06 ### G. D'Annunzio Universihttps://Cl
26-May-19 Feb-20 Dec-23 ### ### Xinghualing Methadon https://Cl
Aug-15 Dec-15 Jul-16 2-Sep-15 20-Oct-16 ### Bardstown, Kentucky,https://Cl
Nov-15 Apr-17 Jun-17 23-Oct-15 ### Gandhi Medical Colleg https://Cl
28-Feb-20 31-Aug-21 31-Jul-24 3-Mar-17 1-Nov-19 Washington University https://Cl
Oct-12 Mar-13 Mar-13 ### 22-Oct-14 1-Nov-17 Poudre Valley Hospitahttps://Cl
Apr-11 Jul-12 May-15 ### ### 12-Apr-17 https://Cl
Jul-04 Jul-10 Dec-16 ### ### https://Cl
Jan-11 Oct-13 Mar-14 6-Dec-10 24-Oct-14 ### Boston Medical Center https://Cl
Jun-10 Mar-13 Mar-13 22-Jun-10 ### Duke Cancer Researchhttps://Cl
Mar-10 Sep-10 Sep-10 2-Apr-10 ### University of Rochesthttps://Cl
Oct-12 May-13 May-13 ### 6-Jan-17 ### National Jewish Healthttps://Cl
9-Mar-17 27-Oct-17 27-Oct-17 7-Mar-17 7-Mar-17 https://Cl
Jul-13 Mar-16 Dec-16 18-Jun-15 16-Oct-17 ### University of Coloradhttps://Cl
Oct-07 Jun-08 Jun-08 ### 10-Oct-11 27-Jan-17 5, Krakow, Poland|1, https://Cl
Jun-12 May-15 Sep-17 8-Mar-10 ### Malaria Vaccine of Dehttps://Cl
Mar-06 Jun-11 Jun-12 12-Apr-06 13-Jun-13 Baylor University Medi https://Cl
7-Sep-19 12-Mar-21 ### ### ### Liuzhou Center for Dihttps://Cl
21-Feb-17 15-Mar-19 Jan-20 ### 21-Jun-19 University of Coloradhttps://Cl
May-09 Jun-09 Jul-09 24-Jul-09 17-Jan-14 Allschwil, Switzerlan https://Cl
Aug-04 Jun-08 Jun-08 26-Oct-05 19-Jul-13 ### University of Californhttps://Cl
May-16 Jun-16 Jul-16 23-Jan-17 23-Jan-17 Kazakh National Medic https://Cl
Jul-06 19-Jul-06 ### Werksarztzentrum Her https://Cl
Mar-07 Apr-07 Oct-07 ### ### 13-Jun-11 Baylor College of Medhttps://Cl
May-04 Jan-06 May-10 6-Mar-09 7-Jul-11 ### https://Cl
Sep-09 Dec-09 Jul-10 ### 4-Nov-10 MUHC Vaccine Study https://Cl
C
Sep-14 Dec-14 Dec-14 3-Oct-14 7-Aug-15 11-Jun-19 Anaheim Clincial Tria https://Cl
Aug-00 Nov-03 13-Jul-09 2-May-18 University of Virginia,https://Cl
6-Jun-16 5-Dec-16 5-Dec-16 ### 8-Jan-18 8-Jan-18 Vinh Long, Vinh Longhttps://Cl
2-Oct-17 13-Mar-18 ### 7-Apr-17 ### Gloucestershire primahttps://Cl
6-Nov-18 21-Jan-19 23-Jan-19 ### ### Rushan City Center f https://Cl
Jan-14 6-May-15 6-May-15 8-Oct-12 4-Apr-18 https://Cl
May-07 Aug-07 Feb-08 ### 4-Aug-10 21-Apr-14 Buenos Aires, Argentihttps://Cl
12-Sep-09 23-Sep-10 ### ### ### ### GSK Investigational S https://Cl
Jul-10 Aug-11 Dec-11 2-Mar-09 3-Jan-13 University of Rochestehttps://Cl
1-Sep-16 30-Apr-19 30-Apr-19 4-May-16 24-Jun-19 https://Cl
5-Jul-18 Dec-22 Dec-22 14-Jun-18 23-Jul-19 Winship Cancer Instithttps://Cl
Feb-10 Mar-11 Apr-12 1-Apr-16 5-Jun-17 ### https://Cl
14-Nov-19 31-Dec-21 30-Jun-22 7-Aug-19 ### The Hope Clinic, Decahttps://Cl
21-Feb-20 31-Aug-20 ### 17-Apr-19 ### Mrtc/Usttb, Bamako, https://Cl
Aug-13 Jun-17 Dec-17 ### ### Academic Medical Cen https://Cl
Jul-07 Mar-09 Mar-09 ### 5-Mar-13 5-Mar-13 Almeria, Spain|Almerhttps://Cl
Dec-07 Apr-09 May-09 14-Apr-08 8-Dec-11 Institute for Pharmaco https://Cl
7-Apr-14 20-May-17 ### 13-Jun-18 13-Jun-18 https://Cl
Oct-06 Feb-07 Jul-07 ### 16-Apr-08 Multi-Organ Transplanhttps://Cl
Oct-05 Jan-06 Sep-07 21-Apr-09 1-Jan-10 14-Apr-16 Little Rock, Arkansas https://Cl
Dec-12 Jun-13 Sep-13 9-Jan-13 ### ### Center for Immunizatihttps://Cl
Nov-09 Mar-10 Mar-10 27-Oct-09 27-Oct-09 Tel Aviv Medical Cente https://Cl
18-Jul-11 4-Feb-14 Apr-14 8-Aug-11 29-Jul-19 29-Jul-19 Acapulco, Guerrero, https://Cl
Feb-13 Apr-14 Dec-15 6-Feb-13 9-Feb-18 Redding, California, https://Cl
May-14 Mar-16 Mar-20 15-Apr-14 18-Jan-20 Pediatric Infectious Dhttps://Cl
Feb-14 Dec-14 Jun-15 ### ### 20-Oct-15 Ludhiana, Punjab, Indhttps://Cl
Mar-10 Oct-10 Oct-10 2-Feb-10 7-Mar-11 Center for Immunizatihttps://Cl
Oct-05 Jun-10 Jun-10 9-Aug-11 9-Aug-11 Lady Hardinge Medical https://Cl
Sep-07 Dec-07 Dec-07 ### ### Center for Immunizatihttps://Cl
Nov-13 Jan-14 Jan-14 ### 2-Jun-14 Cleveland Clinic, Clevhttps://Cl
Oct-98 Mar-01 Apr-02 ### 12-Oct-15 https://Cl
May-16 Aug-18 Aug-18 13-Jul-15 17-Oct-17 Huaiyin District Cent https://Cl
17-Jul-18 Jun-20 Jan-21 ### ### SRI Biosciences Clinichttps://Cl
Aug-11 Jan-12 Jan-12 5-Aug-11 ### ### Mackay Memorial Hospi https://Cl
7-Sep-16 11-Jul-18 ### 22-Apr-16 2-Aug-19 Associacao Obras Socihttps://Cl
Dec-11 Oct-13 Oct-13 25-Apr-14 25-Apr-14 Istituto di Clinica del https://Cl
1-Jan-16 1-Jan-21 1-Jan-21 8-Jun-17 26-Jul-18 Hospices Civils de Ly https://Cl
May-20 Jul-23 Jul-24 ### ### Instituto de Pesquisa https://Cl
Oct-09 Dec-09 Jan-10 5-Nov-09 ### Beijing Centers for Dihttps://Cl
Aug-09 Mar-10 Mar-10 22-Jul-09 11-Apr-11 31-Oct-12 University of Iowa, I https://Cl
Sep-14 Feb-15 Aug-15 ### ### Seoul National Univers https://Cl
Jan-08 Sep-08 Sep-08 5-Feb-08 22-Jan-09 Shaheed Modarres Medi https://Cl
Feb-09 Feb-16 Aug-16 1-Apr-09 7-Dec-15 Kemri Wellcome Trusthttps://Cl
3-Mar-11 May-13 May-13 2-Mar-11 6-Aug-18 RMPRU, Chris Hani Bahttps://Cl
Jul-13 Aug-13 Aug-13 18-Jun-13 ### ### Ghent University & Hohttps://Cl
Sep-03 Aug-04 ### ### https://Cl
Jan-10 Aug-10 Aug-10 ### 21-Jan-13 H:S Rigshospitalet, https://Cl
4-Nov-19 4-Nov-19 Dec-20 ### ### Hospital Clinico San https://Cl
14-Sep-19 Aug-22 Dec-22 6-Feb-19 27-Jan-20 Ed Clarke, Banjul, Ou https://Cl
Oct-08 Jul-11 Jul-11 ### 13-Oct-11 St. Jude Children's R https://Cl
7-Sep-17 31-Jan-18 1-Apr-18 ### 11-Jan-18 St George's, Univers https://Cl
Aug-15 Apr-16 Dec-18 ### ### Oxford Vaccine Group,https://Cl
Nov-07 Jan-08 May-08 23-Oct-08 ### PilisvÃ¶rÃ¶svÃ¡r Distrhttps://Cl
Jan-09 Nov-10 Dec-10 ### ### Department of Infectio https://Cl
Oct-09 Dec-09 Feb-10 5-Jun-09 19-Oct-11 Clinical Pharmacologyhttps://Cl
Sep-11 Jul-15 Jul-15 14-Oct-11 6-Aug-15 Kaiser Permanente Sou https://Cl
Aug-13 Sep-13 Sep-13 19-Jun-13 3-Feb-14 ### Rostock University, D https://Cl
Oct-08 Oct-08 Oct-08 9-Nov-11 9-Nov-11 https://Cl
May-03 Jan-08 Jan-08 29-Jul-05 ### National Institute of https://Cl
Feb-01 Nov-03 Oct-04 2-Oct-09 5-Oct-09 Service d'Hepatologiehttps://Cl
13-Oct-16 19-May-17 11-Jul-17 ### ### Research Institute forhttps://Cl
Apr-13 Apr-17 Oct-17 17-Jan-13 ### Children's Hospital o https://Cl
Mar-12 Apr-13 Aug-13 ### 17-Jun-14 Christian Medical Collhttps://Cl
21-Dec-10 25-Jul-17 25-Jul-17 ### 5-Nov-18 Memorial Sloan Kettehttps://Cl
1-Jan-19 Jan-20 Jul-20 ### 3-Jul-18 https://Cl
13-Apr-18 31-Oct-19 31-Oct-19 25-Jan-18 ### Hospital Universitariohttps://Cl
Puerta de Hierro, Majadahonda
Oct-07 May-08 ### 5-Nov-09 Institute for Pharmacohttps://Cl
Aug-09 Mar-10 Mar-10 2-Aug-11 ### "Csolnoky Ferenc" V https://Cl
Jun-05 4-Apr-06 26-Oct-06 Mainz, Kehl, Traunre https://Cl
3-Sep-10 1-Jan-13 9-Jan-13 23-Jul-10 ### ### Navy Medical Research https://Cl
Dec-03 Dec-06 Jan-07 4-Jun-07 16-Jan-13 SGS Biopharma, Antwe https://Cl
Jun-11 Apr-13 Dec-14 30-Jun-11 3-Apr-15 Franklin Pediatric Asshttps://Cl
Sep-13 Dec-13 Jul-14 ### ### ### Bardstown, Kentucky,https://Cl
May-09 May-20 May-20 2-Jun-09 ### Memorial Sloan Kettehttps://Cl
Jan-16 15-Sep-17 Dec-19 ### 28-Oct-19 Duke University Medic https://Cl
May-07 Jul-09 Jul-09 16-Apr-07 ### 9-Nov-18 University of Bamako,https://Cl
Jul-11 Dec-14 Dec-14 20-Jun-11 ### Alabama CRS, Birmingh https://Cl
31-Mar-20 30-Jun-23 ### 11-Jul-19 ### Washington University https://Cl
Sep-11 Feb-14 Feb-14 9-Jan-13 10-Jul-14 ICDDR,B, Dhaka, Ban https://Cl
Sep-15 2-Dec-17 Dec-18 ### 18-Oct-18 Centre for Clinical V https://Cl
Oct-13 Dec-13 May-14 7-Oct-13 8-Oct-13 Department of Pediatrhttps://Cl
Aug-05 Apr-07 Apr-07 ### 2-Nov-10 Vancouver General Hohttps://Cl
Sep-10 Jan-12 Jan-12 25-Jun-10 13-Jan-16 Emory Vaccine Centerhttps://Cl
May-07 Jun-09 Jun-09 7-Mar-07 14-Jul-10 15-Oct-12 Benton, Arkansas, Unihttps://Cl
Nov-10 Dec-17 Dec-18 ### 7-Mar-16 Institute of Medicine https://Cl
Sep-07 Jan-08 Jan-08 19-Jul-07 13-Jul-12 13-Jul-12 https://Cl
Jul-07 Apr-08 Oct-08 ### 4-Oct-10 ### San Jose, Costa Rica, https://Cl
7-Dec-17 23-Jul-18 23-Jul-18 ### 29-Jul-19 Coastal Carolina Resehttps://Cl
Sep-09 Dec-10 Dec-10 ### ### ### Stanford University - https://Cl
5-Jan-09 2-Nov-09 2-Nov-09 ### ### ### GSK Investigational S https://Cl
Nov-12 Jun-13 Sep-13 ### 9-Feb-18 Chandler, Arizona, Unhttps://Cl
1-Dec-14 30-Apr-17 1-May-17 ### ### https://Cl
Oct-05 Jan-07 Jan-07 3-Oct-05 ### UCLA Center For Vaccihttps://Cl
Sep-09 Jul-19 Jul-21 18-Jun-09 1-Sep-16 MNJ Institute of Oncohttps://Cl
Jun-10 Mar-13 ### ### KEMRI/CDC- IEIP survhttps://Cl
May-06 Feb-08 Oct-08 2-Jun-06 2-Dec-11 Alta Clinical Researc https://Cl
Dec-17 Jul-18 Jul-18 7-Dec-17 11-Jan-18 https://Cl
31-Jul-19 31-Mar-21 ### ### ### People's hospital of https://Cl
Nov-11 Jan-13 Jan-13 ### 14-Jan-13 Kings Cardiology Grouhttps://Cl
5-Oct-10 Nov-12 Feb-13 ### 24-Jul-19 24-Jul-19 Adelaide, Australia|Chttps://Cl
1-Mar-17 15-Aug-17 ### 8-Nov-17 11-Apr-18 University of Pennsyl https://Cl
Nov-14 Jan-15 May-15 2-Nov-14 20-Jan-16 https://Cl
Oct-13 Nov-13 Nov-13 14-Oct-13 ### Kanto, Japan|Kyushu,https://Cl
Oct-14 Dec-14 Apr-15 24-Jun-15 24-Jun-15 https://Cl
Dec-15 Feb-17 Mar-17 ### 15-Oct-18 Bagamoyo Research and https://Cl
Jul-09 Sep-09 Dec-09 22-Jul-09 8-Aug-12 University Hospitals Lhttps://Cl
Jul-03 Sep-04 Jul-05 ### 31-Jul-17 31-Jul-17 Bandiagara Malaria Prhttps://Cl
10-Jun-13 10-Feb-14 ### 10-Apr-13 7-Mar-17 18-Oct-18 GSK Investigational S https://Cl
28-Mar-16 5-Jan-18 3-Jan-19 ### 23-Jan-19 Boston, Massachusetthttps://Cl
Oct-07 May-08 Jun-08 ### ### 14-Apr-16 Norfolk, Virginia, Uni https://Cl
Nov-15 Jul-16 ### 20-Oct-15 12-Jul-17 https://Cl
Aug-15 1-Nov-17 Jan-19 26-Jun-15 4-Apr-18 Centre for Clinical V https://Cl
10-Jan-19 15-Sep-19 ### 8-Jan-19 30-Oct-19 Auburn University, A https://Cl
9-Apr-18 18-Feb-19 ### ### 3-Apr-19 Gantiwarno Primary He https://Cl
Oct-10 Dec-11 Dec-12 2-Sep-10 5-May-14 ### Chris Hani Baragwanat https://Cl
Jul-11 Jul-13 Jul-13 3-Jun-11 29-Jul-13 Centre for Clinical V https://Cl
Aug-10 Oct-12 Dec-12 ### ### ### VitÃ³ria, Brazil https://Cl
Aug-03 Aug-05 Aug-05 13-Jul-07 10-Jun-11 Saint Louis Universityhttps://Cl
Mar-15 Nov-15 Feb-19 ### 5-Jul-18 Paxvax, Redwood City,https://Cl
Mar-12 Apr-14 Apr-14 8-Mar-12 ### 9-Oct-18 Osmania Medical Colle https://Cl
2-Apr-10 19-Aug-11 ### ### ### ### GSK Investigational Sihttps://Cl
22-Mar-18 22-Oct-19 22-Oct-19 9-Mar-18 ### Clinical Research Institute
https://Cl
Saltillo, Saltillo, Coahuila, M
Nov-01 Dec-09 Dec-09 27-Jan-03 24-Jul-19 Hoag Cancer Center at https://Cl
Jun-08 Jul-13 Feb-15 23-Apr-08 24-Jul-14 ### H. Lee Moffitt Cancerhttps://Cl
Sep-12 Apr-14 Dec-14 9-Dec-11 12-Jan-15 6-Feb-15 H. Lee Moffitt Cancerhttps://Cl
7-Dec-18 15-May-20 ### 11-Oct-18 9-Jan-20 National Institutes ofhttps://Cl
Nov-14 Jun-16 Dec-16 17-Oct-14 ### ### Reliant Medical Grouphttps://Cl
Dec-11 Jun-13 Jun-13 9-Jan-12 16-Oct-14 Yonsei University: Wohttps://Cl
29-Sep-19 31-Dec-21 ### 23-Jul-19 23-Jul-19 District sanitaire de https://Cl
Nov-12 Sep-14 Sep-14 ### ### ### Accelovance,Inc., Hunhttps://Cl
Nov-14 Feb-16 Jun-16 30-Apr-14 ### Centre de Recherche https://Cl
1-Jul-18 Dec-19 May-20 31-Jan-19 31-Jan-19 Children's Mercy Hospi https://Cl
13-Aug-14 29-Apr-15 25-Apr-16 3-Mar-14 ### 12-Jul-18 GSK Investigational S https://Cl
30-Sep-16 23-Jul-18 23-Jul-18 27-Oct-15 2-Jan-19 MHAT St. Ekaterina, Dimitrovgrad,
https://Cl Bulgaria|MHAT Sv
20-Jun-11 ### University of Iowa - I https://Cl
11-Sep-14 25-Dec-15 17-Jun-16 25-Jun-14 15-Jun-18 15-Jun-18 GSK Investigational Sihttps://Cl
May-13 Jun-13 Jun-13 ### 15-Jan-14 28-Jun-18 Study Site, London, https://Cl
Sep-06 Jun-08 Jun-08 8-Sep-06 ### ### Fayetteville, Arkansa https://Cl
Aug-12 Jul-13 Dec-18 16-Jul-12 9-Apr-18 Centre for Clinical V https://Cl
Jan-05 Apr-06 Apr-06 22-Oct-04 21-Jan-08 Johns Hopkins Schoolhttps://Cl
Aug-05 Jun-06 Jul-06 13-Jul-05 4-Jul-08 National Institute of https://Cl
Dec-13 May-14 Apr-15 ### 25-Oct-16 25-Oct-16 Site 23, Alabama Clinhttps://Cl
Jan-00 May-02 16-Jun-08 9-Sep-16 https://Cl
5-May-05 Jan-23 Jan-24 ### 5-Feb-20 St. Jude Children's R https://Cl
Jun-13 Apr-16 8-Apr-16 3-Jun-13 1-May-18 19-Jun-18 Mary Crowley Cancerhttps://ClR
Nov-13 Oct-15 Aug-16 17-Oct-13 26-Oct-17 222, Novartis Investighttps://Cl
29-Oct-12 4-Aug-14 4-Aug-14 27-Jul-12 9-Mar-15 ### https://Cl
Aug-13 Sep-14 Sep-14 ### ### 11-Jun-19 Site 04: Accelovance, https://Cl
Feb-20 Feb-21 Dec-21 ### ### https://Cl
Nov-08 Jan-09 Jan-09 13-Jan-17 3-Mar-17 17-Apr-17 https://Cl
Dec-10 Mar-12 Sep-12 ### 16-Apr-15 Taipei Veterans Genera https://Cl
21-Jan-16 29-Jun-18 29-Jun-18 7-Jan-16 ### 29-Oct-19 St. Jude C "Study Prohttps://Cl
27-Mar-06 28-Oct-06 28-Oct-06 3-Apr-06 ### GSK Investigational S https://Cl
Oct-09 May-10 Jan-11 14-Jul-11 1-Aug-11 Fondazione IRCCS Istihttps://Cl
May-06 Jul-06 Oct-06 ### 6-Sep-12 Jiangsu Provincial Ce https://Cl
May-15 Aug-15 Jun-16 5-May-15 26-Jun-15 Optimal Research, Hun https://Cl
Jun-09 Jun-11 Dec-11 29-Apr-09 29-Apr-09 https://Cl
Apr-15 Nov-16 Nov-16 ### ### Illinois Department ohttps://Cl
Sep-05 Feb-07 Feb-07 ### 5-Aug-10 https://Cl
Apr-20 Oct-21 Oct-21 ### ### IHI Clinical Trial Faci https://Cl
May-13 Apr-19 Apr-19 12-Jul-13 ### Sharett Institute of https://Cl
Oct-16 Nov-16 Dec-16 10-Jan-17 7-Jun-18 Kazakh National Medic https://Cl
29-Jul-16 5-Oct-16 1-Oct-17 ### ### Celerion, Inc., Lincol https://Cl
Mar-06 May-06 May-06 28-Jun-06 ### Danyang CDC, Danyang https://Cl
21-Feb-20 19-May-24 ### ### ### National Institutes ofhttps://Cl
Nov-10 May-12 May-12 3-Nov-10 12-Jun-12 Columbia University M https://Cl
Aug-08 Dec-20 Jan-21 ### 10-Apr-19 Massachusetts Genera https://Cl
Nov-13 Dec-13 Jan-14 ### ### Yangzhong Center forhttps://Cl
24-Sep-18 4-Jan-19 4-Jan-19 ### 23-Jan-19 University "Study Prohttps://Cl
14-Jul-08 28-Jan-09 28-Jan-09 14-Jul-08 ### 8-Jun-18 GSK Investigational Sihttps://Cl
26-Feb-15 7-Apr-15 9-Sep-15 18-Jun-15 28-Oct-16 ### Benchmark Research https://Cl
Au
28-Aug-17 14-Feb-19 ### 12-Jun-17 9-Sep-19 Centers for Disease Chttps://Cl
29-Sep-17 1-Dec-17 1-Dec-17 26-Oct-17 24-Oct-19 Site 205, Halifax,
Research Center ofNoNevada
https://Cl
1012 East Sahara Avenue
Dec-08 Mar-11 Nov-11 ### 9-Jul-13 9-Jul-13 Vancouver, Washington, https://Cl
United States|167 The Vanco
Jul-10 Apr-11 Dec-11 5-Apr-13 5-Apr-13 Mirpur, Dhaka, Bangl https://Cl
Sep-13 Sep-19 Sep-20 4-Apr-13 4-May-18 McGill University - D https://Cl
Aug-11 Aug-12 Nov-12 8-Sep-11 8-May-14 8-May-14 Chuzhou, China|Nanjihttps://Cl
Jul-15 Jul-16 Jul-16 ### ### Imperial College Lon https://Cl
1-Aug-17 Jan-19 Dec-19 26-Jan-17 ### CHUM, MontrÃ©al, Qhttps://Cl
Feb-11 Jun-12 Jun-12 ### 4-Mar-13 Maastricht Universityhttps://Cl
Oct-11 Jul-13 Jun-15 ### 6-Feb-17 Roswell Park Cancer Ihttps://Cl
Aug-15 Nov-16 Nov-16 ### 1-Feb-17 Center for Immunizatihttps://Cl
4-Sep-15 31-Dec-19 Dec-20 4-May-15 29-Jan-20 UPMC CancerCenter at https://Cl
1-Dec-17 1-Dec-18 ### ### 3-Jan-19 Obispo Rafael Torija, https://Cl
Sep-10 Nov-11 Dec-11 5-Oct-10 17-Apr-12 Daejeon, Korea, Repub https://Cl
25-Apr-18 25-Sep-19 ### ### ### BUDS, Haryana, Indiahttps://Cl
Oct-09 Jul-11 Feb-12 9-Feb-10 6-Jan-16 Hopital Cochin, Paris,https://Cl
Feb-15 Sep-15 ### 27-Jan-15 ### Hospital Maternidad https://Cl
Nov-13 Nov-14 Nov-14 ### 5-Jul-18 Sidney Kimmel Compre https://Cl
26-Sep-08 16-Feb-10 ### ### 29-Jul-19 ### Chulucanas Morropon, https://Cl
Mar-08 Jun-09 Jun-09 ### 3-Jan-13 Center for Immunizatihttps://Cl
Mar-96 Oct-99 Oct-99 18-Jun-08 7-Sep-16 https://Cl
Sep-11 May-13 Nov-13 1-Sep-11 6-Aug-14 20-Apr-15 Mobile, Alabama, Unit https://Cl
1-Nov-18 31-May-19 ### 9-Jan-19 ### Innovations for Poverhttps://Cl
Oct-14 Jun-15 Jun-15 ### 28-Jan-16 Clinical Trial Unit La https://Cl
Nov-13 Feb-14 Apr-15 ### ### Yandu, China https://Cl
Sep-19 Oct-19 Apr-20 26-Jun-19 4-Sep-19 RCA, Hollywood, Florihttps://Cl
Oct-12 Jan-14 Jan-14 4-Jan-13 1-May-15 Hospital Universitariohttps://Cl
MasquÃ©s de Valdecilla, Santa
Oct-08 Mar-09 May-09 ### ### Centers for Disease Cohttps://Cl
Nov-07 Jan-10 Jan-10 12-Jul-07 ### 19-Apr-11 Amanzimtoti, South Af https://Cl
Mar-11 Apr-14 Apr-14 30-Jun-10 ### Instituto de Pesquisa https://Cl
ClÃnica Evandro Chagas (IPEC) -
Nov-08 Jul-12 Jul-12 ### 1-Aug-12 International Centre https://Cl
Oct-06 Jul-07 Feb-08 23-Oct-06 30-Apr-10 14-Apr-16 Mesa, Arizona, Unitedhttps://Cl
Jan-14 Nov-14 Nov-14 ### 3-Jan-18 3-Jan-18 Center in the Park, Phhttps://Cl
1-Dec-14 29-Nov-17 ### ### 21-Oct-19 21-Oct-19 GSK Investi"Study Prohttps://Cl
1-Aug-16 14-Aug-17 ### 22-Jun-16 ### Center for Vaccine D https://Cl
Aug-14 Dec-14 Jun-15 ### 19-Oct-15 19-Oct-15 Bardstown, Kentucky,https://Cl
1-Apr-18 30-Nov-18 ### 22-Jan-20 22-Jan-20 University Hospital Bahttps://Cl
Oct-01 Nov-06 Nov-06 ### ### Hechi City Center for https://Cl
Sep-05 Feb-06 Mar-07 ### 3-Jun-09 14-Apr-16 Norfolk, Virginia, Uni https://Cl
Mar-13 10-Mar-17 ### ### 17-Jul-18 University of Birmin https://Cl
13-Jun-18 4-Mar-19 4-Mar-19 ### 26-Jul-19 Baylor College of Medhttps://Cl
Mar-12 Dec-13 Feb-14 9-Mar-12 3-Nov-16 ### Bangalore, Karnataka,https://Cl
5-Oct-16 24-Apr-17 24-Apr-17 7-Sep-16 2-Jul-18 ### David Geff"Statistic https://Cl
May-10 Apr-12 Dec-12 26-Apr-10 4-Feb-13 Saint Louis Universityhttps://Cl
30-Sep-19 Dec-22 Dec-22 ### ### Stanford University Schttps://Cl
Jul-16 Jul-16 ### ### Center for Immunizatihttps://Cl
May-14 Jun-14 Jun-14 24-Apr-14 ### Korea University Gurohttps://Cl
Apr-16 Dec-16 Dec-17 4-May-16 4-May-16 Beijing Ditan Hospitalhttps://Cl
15-Apr-15 7-Feb-20 ### 12-Jul-19 ### Medical University Viehttps://Cl
Aug-12 Aug-14 Sep-14 16-Apr-12 ### University of Coloradhttps://Cl
15-Jul-16 7-Jul-17 7-Jul-17 9-Jun-16 ### ### University "Statistic https://Cl
14-Oct-16 31-Dec-23 ### 2-Jun-16 ### Hope Clinic - Emory Vhttps://Cl
Mar-20 Sep-22 Sep-22 ### ### Johns Hopkins Univershttps://Cl
28-Dec-09 1-Dec-14 ### 5-Jan-10 5-Mar-15 11-Apr-18 H. Lee Moffitt Cancerhttps://Cl
16-Jul-14 17-Jun-15 17-Jun-15 ### 1-Nov-19 MUHC-Vaccine Studyhttps://Cl
Sep-14 31-Mar-17 ### ### 16-Jan-18 Gloucestershire, Glouhttps://Cl
Jun-13 Jan-18 Dec-18 ### ### Maoming Center for Dhttps://Cl
Feb-14 Apr-15 Jun-15 ### 4-Feb-16 ### https://Cl
3-May-13 3-Jul-14 20-Apr-16 28-Jan-13 25-Jan-19 25-Jan-19 GSK Investigational Sihttps://Cl
Nov-13 Apr-14 Oct-14 ### 4-Nov-15 4-Nov-15 Dipartimento di Prevehttps://Cl
Mar-07 Nov-09 Jul-10 29-Apr-09 29-Apr-09 Elisabethinen Hospitahttps://Cl
Sep-96 Jun-01 Jun-01 ### ### Anchorage Neighborho https://Cl
Oct-04 Mar-10 Mar-10 10-Jan-05 ### ### H. Lee Moffitt Cancerhttps://Cl
16-Nov-17 26-Feb-18 1-Aug-18 ### ### Child Health Dept. Drhttps://Cl
Oct-11 Mar-12 Mar-12 19-Jan-12 19-Jan-12 National Cheng Kung https://Cl
U
Nov-16 Aug-17 ### ### Guangdong Provincialhttps://Cl
Mar-09 Dec-09 Dec-09 23-Apr-09 13-Apr-11 6-Oct-15 https://Cl
2-Oct-06 1-Nov-06 ### ### 7-May-13 8-Jun-18 GSK Investigational S https://Cl
Feb-09 Sep-09 Aug-13 7-Jan-10 29-Jan-14 CDC Occupational Clinhttps://Cl
Jun-10 Jul-13 ### 9-Nov-15 Oxford Vaccine Grouphttps://Cl
Mar-13 Feb-14 Mar-14 12-Jan-12 5-Jun-13 Regional Medical Reshttps://Cl
Oct-06 21-Jun-06 20-Apr-17 Chiltern Internationa https://Cl
Mar-06 6-Apr-06 ### G. D'Annunzio Universihttps://Cl
11-May-18 11-May-21 ### ### 3-Jan-20 City of Hope Medical https://Cl
Sep-19 Sep-20 Apr-21 8-Mar-19 24-Jun-19 Children's Hospital o https://Cl
Oct-10 Sep-17 Sep-17 18-Oct-10 ### 12-Jun-18 Memorial S"Study Prohttps://Cl
Jun-13 Jul-13 Jul-13 24-Jul-13 24-Jul-13 https://Cl
Mar-09 Mar-10 Jun-10 ### 25-Apr-13 25-Apr-13 Instituto da CrianÃ§ahttps://Cl
11-Jun-15 23-Jan-16 ### ### ### 2-Aug-18 GSK Investigational S https://Cl
Apr-10 Jul-10 Dec-10 7-Jan-10 ### Hebei Province, Chin https://Cl
10-Sep-12 10-Oct-14 3-Mar-15 16-Jul-12 18-Oct-17 18-Oct-17 GSK Investigational Sihttps://Cl
Sep-07 Dec-08 Apr-09 ### ### 2-Aug-16 Muntinlupa City, Alabhttps://Cl
11-Jul-16 8-Sep-16 16-Apr-17 18-Jul-16 3-Aug-17 Ohio State Universit https://Cl
1-Nov-18 31-Dec-19 ### 15-Oct-18 15-Oct-18 Nkanu East Health cen https://Cl
23-Dec-15 31-Dec-20 ### 30-Jun-15 7-Feb-20 Emory Clinic - Winshiphttps://Cl
Mar-13 Apr-14 May-16 1-Apr-13 24-Jun-16 Centre for Clinical V https://Cl
Sep-19 Mar-20 Sep-20 1-Aug-19 1-Aug-19 https://Cl
Aug-11 Jul-16 6-Dec-11 ### Bandim Health Project https://Cl
Apr-12 May-13 May-13 2-Oct-12 16-Jan-14 Thatta, Hyderabad, Thhttps://Cl
Apr-15 Aug-18 Aug-18 6-Apr-15 24-Oct-19 Chulalongkorn Univers https://Cl
9-May-18 13-Apr-19 13-Apr-19 13-Apr-18 2-Aug-19 Nalat Sompagdee, Ban https://Cl
Nov-11 Feb-13 Feb-13 16-Jul-10 31-Jan-14 University of Marylanhttps://Cl
Apr-16 Jun-17 Jun-17 19-Apr-16 16-Jun-17 International Centre https://Cl
Dec-18 Dec-21 Dec-21 ### ### City of Hope Medical https://Cl
Jan-09 Jan-10 Jan-10 15-Jun-09 3-Jan-13 Center for Immunizatihttps://Cl
Sep-16 Apr-18 Sep-18 ### ### ### Marshfield"Study Prohttps://Cl
Apr-15 8-Nov-16 5-Dec-16 4-Mar-15 5-Apr-18 5-Apr-18 College of Medicine ahttps://Cl
Jun-15 Feb-22 Feb-22 5-Jun-14 26-Jun-19 Fred Hutch/Universit https://Cl
Mar-09 Jul-10 Nov-13 ### ### ### Haukeland Univeristyhttps://Cl
Feb-07 Feb-14 Jul-21 1-Mar-07 27-Jun-19 Dana-Farber Cancer In https://Cl
8-Oct-18 1-May-20 1-Dec-20 9-Nov-18 9-Oct-19 University of Houstonhttps://Cl
May-13 Sep-14 Sep-14 ### ### ### 51, Northern Californhttps://Cl
Nov-06 Jun-08 Jun-08 ### ### ### Bydgoszcz, Poland|Dehttps://Cl
1-Oct-19 30-Sep-22 ### 6-Sep-19 6-Sep-19 Malawi-Liverpool-Well https://Cl
7-Oct-11 Dec-15 ### 29-Jul-11 18-Oct-18 Oxford Vaccine Group,https://Cl
Nov-12 Jun-15 Dec-15 30-Jul-12 26-Oct-18 McMaster University,https://Cl
Sep-10 Nov-11 Nov-11 30-Jul-10 31-Jan-13 ### Saint Louis Universit https://Cl
Jul-05 Oct-06 Oct-06 3-Apr-06 3-Jun-13 Baylor College of Medhttps://Cl
Aug-15 Jun-16 Jun-16 ### 1-Aug-16 Hebei Provincial Centhttps://Cl
26-Jun-17 7-Jul-17 7-Jul-17 19-Jun-17 13-Apr-18 HÃ´pital Neurologiquehttps://Cl
Oct-15 Apr-16 Jul-16 22-Oct-15 12-Jul-16 Quality Food Centers https://Cl
Jun-06 ### ### Dipartimento di Medicina
https://Cl
e Scienze dellâ€™Invecchia
10-Sep-17 29-Sep-18 ### 3-Jun-19 3-Jun-19 Jiangsu Provincial Ce https://Cl
Jan-03 Aug-12 Aug-12 18-Jan-06 ### ### Sidney Kimmel Compre https://Cl
18-Sep-07 3-Sep-08 6-Jan-09 ### 6-Oct-17 6-Jun-18 GSK Investigational Sihttps://Cl
3-Sep-13 24-Oct-16 26-Jan-17 18-Jul-13 ### University of Miami, https://Cl
Sep-09 Dec-09 May-10 ### 29-Jul-11 ### Chandler, Arizona, Unhttps://Cl
May-14 Jul-15 Jul-15 9-Oct-15 12-Oct-15 Institute of Technolo https://Cl
May-10 Jun-20 Jun-24 ### 10-Apr-19 Beth Israel Deaconesshttps://Cl
19-Oct-18 Aug-21 Aug-22 ### ### CharitÃ© Berlin, Neuhttps://Cl
31-May-16 1-May-22 10-Jan-23 22-Jan-16 12-Jun-19 Rockville, Maryland, https://Cl
Sep-10 Sep-20 Sep-25 9-Sep-10 ### The Norwegian Radium https://Cl
Oct-09 Sep-15 Nov-16 27-Oct-14 ### University of Rostockhttps://Cl
Jul-00 Apr-11 Apr-11 27-Jan-03 29-Jan-14 Hoag Cancer Center at https://Cl
17-Jul-18 16-Sep-19 ### 22-Jan-20 22-Jan-20 Guangdong Provincialhttps://Cl
20-Mar-19 Oct-19 Jun-20 1-Apr-19 3-Apr-19 Rapid Medical Researc https://Cl
Jun-16 Mar-17 Apr-17 5-Apr-16 ### Icddr,B, Dhaka, Bang https://Cl
16-Oct-08 4-Dec-09 4-Dec-09 2-Oct-08 5-Apr-12 31-Jul-18 GSK Investigational Sihttps://Cl
23-Jun-18 16-Aug-19 ### 2-Jul-18 12-Jul-18 Huaiyin District Cent https://Cl
1-Oct-19 18-Dec-19 ### ### ### Clinical Research Atl https://Cl
13-Sep-10 14-Feb-12 ### 8-Jul-10 ### ### Cangene Plasma Resour https://Cl
Feb-09 Dec-09 Jun-10 17-Apr-09 3-Apr-12 Chris Hani Baragwanahttps://Cl
Sep-06 Nov-07 Mar-08 ### 15-Apr-08 St George's Vaccine I https://Cl
Aug-10 Apr-17 Apr-17 ### ### ICDDR,B, Dhaka, Ban https://Cl
Dec-04 Jul-09 Jul-09 ### 19-Jun-13 University of Wisconshttps://Cl
30-Jan-20 Jun-23 Dec-23 21-Jun-19 5-Feb-20 Hope Clinic, Atlanta, https://Cl
Aug-11 Nov-11 Dec-11 1-Aug-11 19-Apr-12 Jiangsu Provincial Ce https://Cl
Jun-12 Jun-13 Dec-13 12-Jun-12 ### Center for the Evaluahttps://Cl
5-Apr-06 1-Jun-07 19-Jun-07 ### ### ### GSK Investigational Sihttps://Cl
26-Aug-16 Dec-20 Dec-21 1-Aug-16 2-Jan-20 H. Lee Moffitt Cancerhttps://Cl
Aug-09 Dec-10 Mar-11 7-Aug-09 14-Jan-14 Angers, France|Chatehttps://Cl
Sep-06 Oct-11 Oct-11 13-Oct-06 2-Nov-12 Hradec Kralove, Czec https://Cl
Mar-08 Jul-09 Oct-10 28-Apr-08 7-Nov-13 7-Nov-13 Site 22, Bad Kreuzna https://Cl
30-Aug-17 31-Dec-19 1-Mar-20 26-Jun-19 26-Jun-19 Medical University o https://Cl
12-Jun-17 Dec-19 Dec-19 ### 18-Jun-19 CU Center for Midwifhttps://Cl
Nov-13 Jun-14 Oct-14 10-Oct-13 2-Aug-16 ### Maine Research Assochttps://Cl
Dec-09 Jan-10 Jan-10 ### ### Hunan Provincial Cenhttps://Cl
15-Jan-20 15-Jan-21 15-Jan-21 13-Jan-20 13-Jan-20 https://Cl
Sep-04 4-Apr-06 ### Istituto di Pediatria, UniversitÃ
https://Cl degli Studi di Milano,
May-15 Feb-18 Apr-18 18-Apr-17 ### ### Institute "Study Prohttps://Cl
Dec-19 Dec-23 Dec-24 ### ### Special Immunizationhttps://Cl
Mar-09 Aug-14 Dec-14 3-Apr-09 24-Jul-19 24-Jul-19 Sanofi Pasteur Invest https://Cl
Oct-08 Sep-09 Dec-11 ### 1-Jan-16 Alabama Vaccine Resehttps://Cl
Jan-13 Aug-13 Aug-13 ### ### Emory Vaccine Centerhttps://Cl
May-08 Apr-11 Dec-12 ### 1-Jan-15 University of Alberta https://Cl
Jan-10 Oct-13 Oct-13 1-Dec-09 30-Jan-14 Burbank, California, Uhttps://Cl
Jan-10 Jul-10 Jul-10 ### ### 15-Jul-15 Rochester, Minnesota,https://Cl
Oct-14 Apr-15 Jul-16 4-Oct-18 5-Oct-18 Integrated Health Posthttps://Cl
Jul-12 Aug-12 Sep-12 20-Apr-12 21-Jun-12 Hosp das Clinicas da https://Cl
Oct-08 May-09 Jul-09 15-Oct-08 ### 14-Apr-16 Hoover, Alabama, Unit https://Cl
14-Sep-18 24-Jun-19 24-Jun-19 3-Aug-18 16-Jul-19 Achieve Clinical Rese https://Cl
16-May-18 28-Dec-18 9-Jul-19 ### 15-Jul-19 Synexus - Midlands, https://Cl
Jan-99 May-00 May-00 20-Jan-14 ### Winnipeg, Manitoba,https://Cl
Feb-10 Aug-11 Mar-12 9-Jul-10 29-Apr-19 Clinical Research Uni https://Cl
18-Nov-16 1-Jan-22 1-Jan-23 9-Nov-16 5-Nov-19 Rady Children's Hospihttps://Cl
12-Jun-16 3-Oct-17 3-Oct-17 22-Jan-16 ### University of Chicago,https://Cl
Jan-06 Dec-06 Apr-09 ### 14-Apr-17 20-Jun-17 Walter Reed Army Inst https://Cl
14-Sep-17 9-Oct-18 1-Mar-19 5-Jul-17 31-Oct-19 31-Oct-19 GSK Investi"Study Prohttps://Cl
Nov-13 Jan-14 Mar-14 29-Apr-15 ### St. Michael's Hospita https://Cl
Aug-05 Nov-05 Nov-05 ### 3-Jul-09 26-Jan-15 https://Cl
18-Jul-17 28-Jan-18 8-Feb-18 19-Jun-18 17-Oct-18 Yizhou Center for Dis https://Cl
Jul-16 Aug-17 Dec-17 ### ### Sherry Chen, Taipei, https://Cl
Nov-08 Oct-10 Jan-13 ### 2-Jun-16 Brigham and Women's https://Cl
Jul-04 Jun-08 Nov-09 11-Apr-07 12-Jan-10 Beth Israel Deaconesshttps://Cl
Jul-09 Jun-12 Jun-12 6-Jun-13 6-Jun-13 Medical University ofhttps://Cl
Jan-11 Jan-13 Jan-13 ### 21-Jul-14 21-Jul-14 Emory University, Dephttps://Cl
May-05 Nov-05 Nov-05 4-Apr-06 ### Centre for Clinical V https://Cl
Oct-10 Oct-14 Oct-14 18-Oct-10 12-Oct-15 12-Jun-19 KeeTaek Kim internal https://Cl
12-Sep-17 30-Sep-19 ### ### ### National Taiwan Univehttps://Cl
Sep-14 Dec-14 Apr-15 ### ### 26-Apr-18 Marshfield Clinic - M https://Cl
May-14 Jan-15 ### ### Hunan Provincial Cenhttps://Cl
Mar-14 Jun-16 Dec-16 25-Jul-13 ### University Hospitals https://Cl
29-Aug-18 8-May-19 ### ### 18-Jan-20 GSK Investigational Sihttps://Cl
Dec-16 Jan-20 Jan-25 15-Apr-14 1-Nov-16 Duke University Medic https://Cl
10-Oct-17 24-Apr-18 5-Sep-19 3-Oct-17 ### Duke University, Durhhttps://Cl
Feb-08 Feb-11 Feb-11 4-Jul-08 ### 2-Jul-17 Childrens Hospital of https://Cl
Feb-09 Jan-11 Jan-11 1-Apr-09 8-Dec-17 Oxford Vaccine Group,https://Cl
Dec-09 Oct-14 Oct-14 ### ### ### Beth Israel Deaconesshttps://Cl
Aug-04 Feb-06 Feb-06 29-Jan-09 ### 14-Apr-16 Norfolk, Virginia, Uni https://Cl
Mar-07 Sep-08 Nov-09 ### ### ### Growing Up Pediatricshttps://Cl
30-Sep-13 27-Jan-16 Dec-19 1-Oct-13 7-Jun-19 Pasteur Institute of https://Cl
May-11 Mar-15 Mar-15 4-Apr-11 14-Apr-17 29-Oct-18 Macassa Lodge, Hamilhttps://Cl
16-Oct-12 Aug-20 Aug-20 ### 6-Sep-19 The Sidney Kimmel Cohttps://Cl
6-Apr-18 14-Jun-20 ### ### 18-Jul-19 EVMS Otolaryngology,https://Cl
8-Dec-09 13-Aug-10 ### 9-Dec-09 ### ### GSK Investigational S https://Cl
20-May-13 12-Jun-17 12-Jun-21 15-Oct-12 17-Jul-18 ### University "Study Prohttps://Cl
10-Jun-08 8-May-09 8-May-09 ### 14-Jun-10 8-Jun-18 GSK Investigational Sihttps://Cl
12-Jul-18 16-Nov-18 ### 27-Jun-18 ### ### Daido Clin "Study Prohttps://Cl
Oct-09 Sep-11 Sep-11 3-Nov-09 1-Jul-13 University of Kentuckhttps://Cl
Oct-19 May-20 May-21 24-Oct-18 ### https://Cl
Nov-11 Jul-13 ### ### Silom Community Clinhttps://Cl
13-Nov-14 Mar-15 5-Mar-15 31-Oct-14 ### CCBR, Aalborg, Denmhttps://Cl
Nov-08 Feb-09 Feb-09 ### ### the CDC of Dingxing chttps://Cl
27-Feb-17 15-Dec-18 ### ### 1-Mar-17 https://Cl
Nov-15 Mar-16 Aug-16 30-Oct-15 31-Jan-19 31-Jan-19 Department of Pulmohttps://Cl
Nov-11 Jun-12 Nov-12 4-Nov-11 4-Nov-11 Rheumatology Institute https://Cl
1-Nov-17 31-Aug-20 ### ### ### University Hospital Bahttps://Cl
1-Feb-08 18-Aug-08 ### 3-Mar-08 26-Jun-17 6-Jun-18 GSK Investigational Sihttps://Cl
May-15 12-Apr-17 21-Apr-17 2-Jun-15 6-Nov-17 Biokinetic Europ Ltd, https://Cl
20-Jul-19 Jun-21 Dec-22 ### 25-Jul-19 Insight Therapeutics, https://Cl
29-Apr-15 3-Jun-15 3-Jun-15 ### ### 9-Oct-17 GSK Investigational Sihttps://Cl
Jul-07 Sep-12 Sep-12 2-Aug-07 4-Apr-16 16-Jun-16 University of Pittsburhttps://Cl
Aug-12 May-13 May-13 6-Sep-12 8-May-13 Jiangsu Provincial Ce https://Cl
7-Sep-18 17-Jan-19 11-Jun-19 ### 22-Oct-19 GSK Investigational S https://Cl
Sep-13 Jun-16 Dec-16 17-Jun-14 30-Jul-18 ### University of Pittsbu https://Cl
Nov-12 Jul-21 Sep-21 2-Nov-12 4-Jun-19 UPMC Hillman Cancerhttps://Cl
C
12-Jun-17 7-Jun-18 7-Jun-18 ### 16-Oct-18 International Center https://Cl
25-Aug-10 29-Oct-10 12-Oct-15 ### 8-Nov-17 8-Nov-17 Muntinlupa City, Phil https://Cl
10-Jul-17 20-Dec-17 ### 6-Oct-17 26-Jan-18 Queen Elizabeth Hospi https://Cl
17-Jun-15 17-Jul-15 17-Jul-15 6-Jun-18 1-Aug-18 1-Aug-18 Sanofi Pasteur Investihttps://Cl
2-Dec-07 12-Jul-08 12-Jul-08 26-Oct-07 ### 20-Jul-18 GSK Investigational Sithttps://Cl
Mar-16 Feb-20 Feb-20 9-Feb-16 18-Jul-19 International Centre https://Cl
Jun-10 Dec-11 Dec-11 15-Jun-11 ### Dr Kalifa Bojang, Ban https://Cl
Apr-16 May-16 Aug-16 ### 26-Oct-17 Xiangcheng County Cehttps://Cl
Aug-10 Aug-11 Aug-11 2-Aug-10 8-Nov-11 National Institute fo https://Cl
Apr-14 Feb-16 Feb-16 7-Feb-14 21-Oct-16 Massachusetts Genera https://Cl
13-Oct-15 30-Apr-19 30-Apr-19 ### ### San Diego, California https://Cl
5-Feb-07 20-Oct-08 20-Oct-08 2-Feb-07 28-Oct-19 28-Oct-19 GSK Investigational https://Cl
Sep-06 Aug-08 Feb-09 6-Oct-06 2-Jun-11 14-Apr-16 Montgomery, Alabama, https://Cl
Feb-13 Feb-14 Mar-14 8-Jul-15 8-Jul-15 Dienst Nefrologie, OLhttps://Cl
Sep-05 Mar-07 Mar-07 4-Oct-05 ### Saint Louis Universityhttps://Cl
Sep-14 Apr-15 Apr-15 ### 8-Oct-15 Usc La Nichd Crs, Alh https://Cl
Jan-12 Oct-16 Oct-16 6-May-11 15-Jan-19 15-Jan-19 Sidney Kimmel Compre https://Cl
Mar-12 Apr-16 Apr-16 ### 1-May-18 7-Aug-19 Mary Crowley Cancerhttps://Cl
R
Sep-09 Mar-12 Mar-12 9-Nov-09 ### ### Department Infectiouhttps://Cl
Feb-16 Dec-19 Dec-19 ### ### Queen Saovabha Memor https://Cl
Mar-14 Sep-14 Mar-15 ### 8-Oct-15 ### Aichi, Japan|Chiba, https://Cl
Oct-11 Dec-11 Dec-11 9-Aug-11 ### 9-Sep-13 Covance Clinical Resehttps://Cl
Oct-20 Dec-20 Aug-21 19-Jul-18 ### University Hospitals https://Cl
8-Feb-09 11-Dec-12 14-Oct-16 12-Jun-08 9-May-18 Brigham and Women's https://Cl
23-Sep-13 11-Jan-16 11-Jan-16 ### ### ### GSK Investigational Sihttps://Cl
May-09 Oct-10 Jun-11 8-May-09 9-Oct-15 General Hospital of Vhttps://Cl
Nov-15 Sep-16 Sep-16 9-Nov-15 12-Oct-17 Kaiser Permanente Vac https://Cl
Mar-03 Aug-03 May-04 15-Oct-08 ### ### Jonesboro, Arkansas, https://Cl
17-Feb-09 13-Jun-11 27-Jun-12 26-Jan-09 6-Jul-12 ### GSK Investigational S https://Cl
31-Jul-18 6-Aug-19 6-Aug-19 6-Jul-18 ### Coastal Clinical Rese https://Cl
15-Aug-17 31-Dec-18 ### ### ### National Institute fo https://Cl
May-13 Jun-15 Nov-15 3-May-13 ### University of Virginia,https://Cl
Dec-06 Jun-08 Dec-09 ### 7-Jun-10 HIV-NAT Thai Red Crohttps://Cl
1-Sep-15 30-Mar-20 ### 1-Feb-17 17-Apr-19 Medical University ofhttps://Cl
May-11 Mar-12 Sep-12 3-Jun-11 ### Regional Medical Reshttps://Cl
Nov-15 Feb-20 Feb-20 4-May-15 30-Apr-19 City of Hope Medical https://Cl
Feb-08 Jul-11 Oct-15 ### 2-Nov-16 Brigham and Women's https://Cl
Jun-04 May-10 May-10 2-Jan-08 14-Jul-17 3-Jan-20 U.S. Army Medical Reshttps://Cl
Aug-15 Dec-16 5-Feb-16 13-Jan-17 Tulane Clinical Transl https://Cl
Aug-12 Aug-13 Oct-13 ### 15-Oct-15 Institute of Medicin https://Cl
Jun-08 Oct-08 Dec-09 21-Apr-08 ### Miami Research Associ https://Cl
3-Oct-19 31-Mar-22 ### 25-Jul-19 14-Oct-19 University of Minnes https://Cl
Mar-05 Apr-05 Apr-05 ### ### GSK Investigational S https://Cl
May-09 Dec-11 Feb-12 4-May-09 ### University of Virginia https://Cl
Dec-05 Aug-06 Aug-06 ### 7-Nov-11 UCLA Center For Vaccihttps://Cl
Apr-16 Apr-20 Sep-20 26-Apr-16 1-Sep-17 Dept of Hematology, https://Cl
Apr-15 Sep-15 Jul-16 5-May-15 ### Santo Domingo, Domihttps://Cl
28-Jul-17 31-Oct-20 31-Oct-20 ### 14-Oct-19 MD Anderson Cancerhttps://Cl
C
Feb-11 Oct-15 Apr-16 7-Nov-14 4-May-16 Radboud University Nhttps://Cl
26-Oct-12 28-Aug-15 ### 22-Oct-12 5-May-17 5-May-17 Vanderbilt University https://Cl
Jul-13 Oct-16 8-Apr-17 ### 5-Jul-19 Service d'Immunologie https://Cl
Jun-07 May-09 May-09 ### 4-Jun-10 21-Apr-11 Calgary, Alberta, Ca https://Cl
9-Mar-19 30-Apr-20 30-Apr-20 3-Apr-19 3-Apr-19 Sichuan Provincial Cehttps://Cl
Jan-12 Feb-12 Feb-12 1-Dec-11 9-Aug-13 9-Aug-13 Bellevue Hospital, N https://Cl
12-Apr-18 6-May-19 3-Apr-20 ### ### GSK Investigational S https://Cl
Aug-09 Sep-10 Nov-10 ### 14-Jan-14 Espoo, Finland|Helsinhttps://Cl
Apr-04 Oct-06 Oct-06 ### 13-Jan-14 PRA International, Lehttps://Cl
1-Mar-13 7-Jan-16 6-Jan-17 14-Jan-13 ### 6-Jun-18 GSK Investigational S https://Cl
29-Sep-09 22-Nov-10 ### 7-Sep-09 ### 26-Jun-19 GSK Investigational S https://Cl
Oct-13 Apr-14 Jul-14 23-Oct-13 20-Jan-16 20-Jan-16 Taipei, Taiwan|Taoyuhttps://Cl
8-Oct-09 21-May-10 ### ### ### ### GSK Investigational S https://Cl
Oct-06 Jul-08 Jul-08 ### ### ### Ferrol, A Coruna, Spahttps://Cl
30-Sep-10 6-Jul-12 ### 19-Jul-10 7-Jun-17 30-Apr-18 GSK Investigational S https://Cl
7-Nov-18 20-Dec-18 ### 7-Dec-18 10-Jan-19 UNSA, Nice, France https://Cl
19-Aug-10 25-Feb-11 29-Jul-11 19-Jul-10 8-Jun-17 26-Jun-18 GSK Investigational Sihttps://Cl
Apr-13 Apr-20 Apr-21 2-Jul-13 ### Memorial Sloan Ketter https://Cl
Mar-08 Dec-10 Apr-11 ### 15-Apr-11 Royal Childrens Hospithttps://Cl
Jan-15 Feb-15 Feb-15 ### 3-Apr-15 Broward Research Grou https://Cl
1-Sep-17 1-Nov-17 ### 8-May-17 15-Jul-19 15-Jul-19 University "Study Prohttps://Cl
Aug-02 Aug-04 Sep-04 10-Jun-08 10-Jun-08 Tropical Medicine, Mahttps://Cl
Jun-15 23-Mar-16 ### 8-May-15 5-Jul-19 5-Jul-19 The Hope Clinic, Decahttps://Cl
Oct-09 Nov-12 Mar-14 ### ### ### Fulton County Departhttps://Cl
7-Sep-11 Sep-13 2-Sep-13 ### 29-Jul-19 29-Jul-19 Cali, Colombia|Lima, https://Cl
Sep-07 Sep-08 Mar-09 ### ### ### Manila, Philippines|Qhttps://Cl
13-Feb-07 17-Mar-08 25-Jul-08 24-Jan-07 ### 20-Jul-18 GSK Investigational S https://Cl
1-Apr-19 9-Jun-20 ### 17-Apr-19 23-Jul-19 North Alabama Researc https://Cl
Apr-09 Mar-10 Jun-10 20-Apr-09 14-Jan-14 Espoo, Finland|Helsinhttps://Cl
May-14 Feb-15 Feb-15 ### ### Johns Hopkins Bayviehttps://Cl
21-Aug-13 2-Nov-18 Nov-23 ### ### University of Miami, https://Cl
Mar-16 Jun-18 Dec-18 ### ### Hillman Cancer Center https://Cl
6-Apr-18 Mar-21 Mar-22 2-Jan-18 ### H. Lee Moffitt Cancerhttps://Cl
30-Sep-19 10-Dec-19 ### ### 7-Feb-20 Investigational Site https://Cl
Nov-09 Jul-10 Jun-12 7-Jan-10 23-Jul-13 United States Embasshttps://Cl
Nov-09 Mar-10 Jun-10 ### 4-Jun-10 Princess Margaret Hoshttps://Cl
24-Feb-10 10-Jun-11 ### 12-Jan-10 ### ### https://Cl
May-10 Nov-11 Oct-12 24-Jun-10 ### ### Gent, Belgium https://Cl
Jan-13 Jun-14 Nov-14 ### ### ### Centre Hospitalier Unhttps://Cl
Dec-12 Feb-14 Feb-14 2-Jan-17 2-Jan-17 https://Cl
Oct-08 Dec-09 Feb-10 ### ### University of Alberta https://Cl
1-Nov-03 10-Mar-04 ### ### 4-Jun-09 ### GSK Investigational Sihttps://Cl
Mar-14 Feb-15 Aug-15 ### ### Manila, Philippines|Mhttps://Cl
Oct-07 Dec-15 Mar-17 9-Apr-13 12-Jun-17 11-Jul-17 Stanford University Schttps://Cl
Jan-11 Dec-16 Dec-16 ### ### Baylor University Medihttps://Cl
30-Apr-19 Dec-20 Jun-22 9-Jul-18 ### KEMRI/Wellcome Trust https://Cl
Sep-08 Mar-11 Mar-11 ### 28-Jun-11 ICDDR,B, Dhaka, Ban https://Cl
Jul-12 Aug-12 Aug-12 28-Jun-12 ### ### CROSS-Research SA, Ahttps://Cl
Feb-13 Sep-14 Sep-14 ### ### 11-Jun-15 icddr, b Kamalapur, https://Cl
Jun-10 Mar-11 Mar-11 11-Jun-10 ### Hospital for Tropical https://Cl
May-10 May-11 May-11 ### ### Dept infectious diseahttps://Cl
Oct-09 Dec-10 Dec-10 30-Apr-13 30-Apr-13 Xiangshui Center for https://Cl
18-Jul-17 21-Dec-21 ### ### 10-Jul-19 Fred Hutch/Universit https://Cl
Dec-01 Jan-07 Jan-07 ### ### National Institute of https://Cl
Oct-06 Sep-07 Jul-08 19-Oct-06 ### 14-Apr-16 Norfolk, Virginia, Uni https://Cl
21-Jul-16 1-Dec-20 1-Dec-20 ### 7-Nov-19 Flipse Building, Coral https://Cl
18-Jun-08 9-Nov-09 ### ### 27-Oct-17 ### GSK Investigational Sihttps://Cl
Sep-09 Nov-09 Oct-10 9-Sep-09 27-Jan-11 14-Apr-16 Premier Health Resear https://Cl
5-Nov-15 Oct-18 Mar-20 23-Jul-15 13-Jan-20 City of Hope Medical https://Cl
15-Jun-19 28-Feb-20 30-Oct-20 8-May-19 ### Rapid medical Researchttps://Cl
Dec-08 Sep-09 Sep-09 ### 23-Jan-13 23-Jan-13 Akron Children's Hosphttps://Cl
3-Dec-18 20-May-20 ### 9-Oct-18 26-Jul-19 MGH, Boston, Massachu https://Cl
Jun-10 Jun-10 Jul-10 5-Oct-09 2-Apr-12 Instituto Nacional de https://Cl
Oct-00 Jun-04 Jun-04 14-Jul-05 ### GSK Investigational S https://Cl
Jun-14 Sep-15 Sep-16 25-Jun-14 ### Kindercare, Toronto, https://Cl
8-Apr-14 Feb-19 Dec-20 ### 6-Feb-20 H. Lee Moffitt Cancerhttps://Cl
31-Jul-19 Jan-22 Jan-23 ### 5-Feb-20 Moi University Schoohttps://Cl
Oct-15 25-Aug-16 ### 22-Oct-15 4-Dec-17 Beijing Chaoyang Distrhttps://Cl
Oct-15 Oct-19 Apr-20 7-Dec-15 12-Apr-19 Northwestern Universi https://Cl
Dec-12 Aug-13 Aug-13 2-Feb-12 4-May-15 Armauer Hansen Resea https://Cl
20-Jun-17 4-Jul-17 31-Jul-17 3-Oct-19 3-Oct-19 Vaccine Trial Centre, https://Cl
Sep-12 Dec-15 Dec-15 ### ### University of Coloradhttps://Cl
Jan-14 Sep-14 Sep-14 17-Oct-13 ### ### Medical Research Couhttps://Cl
Oct-10 Feb-12 Feb-12 ### 1-Jan-16 University of Rochesthttps://Cl
14-Jun-18 Apr-20 Apr-20 ### 7-Jan-20 Centre de Recherch https://Cl
Apr-16 Jul-16 Nov-16 19-Oct-18 19-Oct-18 https://Cl
Feb-10 Apr-11 Apr-12 ### 16-Apr-12 Hannover Medical Schttps://Cl
Sep-11 Apr-13 Oct-13 3-Oct-11 16-Jul-14 16-Jul-14 Cali, Colombia|San Johttps://Cl
Oct-04 Mar-06 25-Oct-12 25-Oct-12 University of Califor https://Cl
Jan-07 ### 24-Apr-08 Centrum BadaÅ„ Farma https://Cl
17-Feb-11 26-Jul-11 26-Jul-11 30-Jun-10 ### 2-Jan-20 GSK Investigational S https://Cl
May-07 Jan-10 ### 13-Jan-10 Center for Immunizatihttps://Cl
15-Nov-16 13-Feb-18 ### 27-Oct-16 ### ### GSK Investi"Study Prohttps://Cl
17-Jul-18 31-Oct-20 ### ### 9-Sep-19 Centers for Disease Chttps://Cl
Oct-10 Jan-14 Jan-14 1-Sep-10 4-Feb-15 ### NZOZ "HIPOKRATES-II" https://Cl
16-May-19 16-Dec-19 ### ### ### Suining County Centerhttps://Cl
Feb-16 Jun-16 Jan-17 3-Mar-16 26-Apr-17 Bangkok, Thailand|Khhttps://Cl
Jun-10 Sep-13 ### 10-Jun-10 7-Dec-16 12-Apr-17 UCLA Medical Center,https://Cl
Aug-03 Mar-04 May-04 15-Oct-08 24-Apr-09 14-Apr-16 London, United King https://Cl
Dec-09 Jun-10 Dec-10 ### ### Belinger Centrum Reishttps://Cl
Aug-06 Feb-08 Oct-08 4-Jul-06 22-Jul-10 4-Dec-13 Jonesboro, Arkansas, https://Cl
Jan-10 Sep-11 Dec-11 4-Feb-10 ### LingChuan County, Gui https://Cl
Apr-08 Sep-08 Sep-08 ### 9-Oct-08 Helen Joseph Hospitahttps://Cl
Mar-16 Nov-18 May-19 ### 18-Jan-20 18-Jan-20 FUNDEP (Bel "Statistic https://Cl
12-Dec-16 Dec-18 Dec-19 23-Jan-18 23-Jan-18 'Aghia Sophia' Childrehttps://Cl
7-Jan-19 28-Jul-19 28-Jul-19 7-Jan-19 ### Clinical Pharmacolog https://Cl
1-Apr-19 31-Mar-22 ### ### ### Shenzhen People's Hohttps://Cl
17-Feb-16 16-Jun-18 16-Jun-18 29-Jan-16 5-Jun-19 Great Lakes Naval Stathttps://Cl
Jun-13 Dec-15 Mar-19 28-Jan-16 ### McGill University He https://Cl
Mar-09 May-09 Feb-10 ### 6-Sep-12 Jiangsu Provincial Ce https://Cl
1-Sep-17 7-Jan-18 30-Oct-18 ### ### Advagene Biopharma,https://Cl
Apr-15 May-16 May-16 15-Apr-15 ### Kaihua Center for Dishttps://Cl
4-Mar-13 3-Dec-19 3-Dec-19 ### 5-Dec-19 National Institutes ofhttps://Cl
Sep-12 Jan-17 Dec-19 1-Jun-16 5-May-17 Samara State Medicalhttps://Cl
May-10 Jan-13 Jan-14 12-Apr-10 ### Georgetown University https://Cl
1-Dec-18 31-Dec-19 ### ### 4-Sep-19 "City polyclinic â„ https://Cl
15-Sep-08 18-Jun-10 5-Jan-11 ### 19-Jun-12 8-Jun-18 GSK Investigational S https://Cl
5-Jul-17 15-Jan-19 15-Jan-19 ### ### Boston Medical Center https://Cl
15-Jan-19 17-Mar-19 ### 5-Dec-18 10-Apr-19 Investigational Site https://Cl
Jul-05 Jul-07 Jul-07 12-Jul-05 21-Jan-08 Vanderbilt Universityhttps://Cl
30-Mar-15 5-Nov-16 23-Jun-17 2-Aug-17 2-Aug-17 https://Cl
26-Aug-19 24-Sep-20 ### 9-Sep-19 15-Oct-19 Ghent University Hosp https://Cl
Nov-06 Nov-07 Nov-07 ### ### 13-Apr-17 https://Cl
Sep-12 May-14 Apr-15 ### ### WCCT, Cypress, Califohttps://Cl
9-Jul-12 24-Mar-14 9-Jul-18 2-Jul-12 9-Oct-18 Mayo Clinic, Rochestehttps://Cl
18-Mar-14 30-Dec-15 ### 27-Jan-14 ### 18-Oct-19 GSK Investigational Sihttps://Cl
Feb-15 Apr-15 Apr-15 25-Jun-15 ### ### https://Cl
6-Feb-18 17-Apr-18 2-Nov-18 1-Mar-19 1-Mar-19 Guanyun Center for Dihttps://Cl
May-15 1-May-19 6-Sep-19 11-Jul-14 ### "Multiprofile Hospitalhttps://Cl
for Active Treatment (MHAT)-D
21-Feb-20 1-Jun-25 1-Feb-30 30-Apr-18 ### National Heart, Lung https://Cl
Oct-13 Jun-15 Dec-15 ### 5-Jan-16 Cali, Colombia|San Johttps://Cl
Nov-14 Jun-15 Jun-15 4-Dec-14 ### Anaheim Clinical Tria https://Cl
Aug-10 Aug-10 Mar-11 ### 16-Jul-18 https://Cl
Feb-09 Jun-12 Dec-12 ### 8-Nov-16 ESPOIR Pour La SantÃ© https://Cl
Aug-00 Feb-01 16-Jun-08 ### https://Cl
Dec-10 Feb-13 Feb-13 3-Nov-10 ### National Institute of https://Cl
11-Apr-16 28-Aug-17 8-Oct-18 13-Apr-16 1-Nov-19 5-Feb-20 GSK Invest"Study Prohttps://Cl
28-Mar-14 19-Jun-15 19-Jun-15 17-Jan-14 1-Aug-16 8-Aug-17 Universiteit Antwerp https://Cl
Apr-14 Aug-14 Mar-15 4-Apr-14 21-Jul-15 Instituto Central do Hospital
https://Cl
das ClÃnicas da Faculdad
Jul-07 Nov-09 Nov-09 ### 8-Jul-11 1-Apr-16 Azienda USL 7 of Siena https://Cl
Oct-01 Aug-07 Aug-07 29-Jul-05 ### Aga Khan University, https://Cl
Mar-11 May-12 Sep-12 ### 4-Jun-15 4-Jun-15 Ordinace praktickehohttps://Cl
Apr-16 Jun-19 Jun-20 6-Mar-15 ### Cancer Center at the U https://Cl
14-Oct-16 5-Dec-18 5-Dec-18 2-Nov-16 7-Dec-18 Saint Louis Universityhttps://Cl
Oct-12 Dec-12 Dec-12 9-May-14 ### ### Stanford University Schttps://Cl
18-Feb-20 8-Sep-20 2-Feb-21 14-Jan-20 14-Jan-20 Coastal Clinical Rese https://Cl
6-Mar-12 9-Jan-15 30-Jun-20 ### 21-Oct-19 Fred Hutchinson Canchttps://Cl
Jan-09 Jun-10 Jun-11 2-May-11 2-May-11 1st Department of Ped https://Cl
15-Oct-19 31-Dec-19 1-Feb-20 6-Dec-19 ### Tongji Hospital of To https://Cl
Feb-09 Jul-12 Jul-12 4-Feb-09 ### ### Sidney Kimmel Compre https://Cl
Feb-16 Dec-19 May-20 ### ### University of Alabamahttps://Cl
Jun-09 Nov-09 May-10 23-Jun-09 23-Jun-09 Disciplina de Immunologia
https://Cl
ClÃnica e Alergia do HC- F
Mar-13 Apr-16 Apr-16 12-Oct-12 1-Dec-16 https://Cl
Nov-11 Nov-11 Mar-12 19-Jan-12 ### Henan Province Centehttps://Cl
Jan-15 Jan-19 Jan-19 30-Jul-15 23-Oct-19 University of Antwer https://Cl
7-Aug-19 24-Aug-21 ### 25-Jul-19 5-Feb-20 Children's of Alabamahttps://Cl
Dec-12 Apr-13 8-May-12 ### Oxford Vaccine Grouphttps://Cl
Nov-14 Nov-15 Nov-15 5-Nov-14 ### CTC North GmbH & Chttps://Cl
Sep-04 Nov-05 Nov-05 ### 18-Jan-08 Center for Immunizatihttps://Cl
Sep-14 Jan-16 May-16 20-Oct-14 5-Sep-18 University of Wisconshttps://Cl
Jun-07 Aug-07 Aug-07 8-Jan-07 7-Dec-09 National Institute of https://Cl
Sep-12 Nov-12 Feb-13 ### 4-Nov-13 4-Nov-13 Boca Raton, Florida, https://Cl
Feb-12 Oct-12 Dec-12 8-Mar-12 8-Mar-12 GuangXi Center for Dihttps://Cl
20-Sep-07 1-Nov-07 2-Nov-07 ### ### 8-Jun-18 GSK Investigational S https://Cl
Oct-11 Aug-13 Aug-13 ### 1-Aug-17 City of Hope Medical https://Cl
Apr-14 Apr-14 Apr-14 ### 10-Apr-14 Siaya District Hospitahttps://Cl
1-Apr-17 13-Jul-18 ### ### 2-Jul-19 Vaccinology & Immunol https://Cl
1-Apr-19 1-Jun-23 1-Jun-23 30-Oct-19 ### Mayo Clinic in Floridahttps://Cl
28-Oct-18 30-Sep-19 1-Nov-19 6-Feb-19 3-Sep-19 University of PÃ©cs, https://Cl
Apr-12 31-Jul-16 31-Jul-16 19-Apr-12 7-May-18 Mid-Atlantic Gynecolohttps://Cl
28-Sep-11 8-May-14 8-May-14 28-Oct-11 ### ### Radiant Research, Inchttps://Cl
Jan-20 Jul-23 Dec-23 ### ### https://Cl
Dec-14 Apr-18 ### ### https://Cl
Jun-08 Dec-09 Dec-09 3-Jun-08 11-Jan-11 28-Jun-11 Pfizer Investigational https://Cl
6-Oct-16 31-May-17 1-Jun-17 ### 27-Jul-17 Columbia University M https://Cl
12-Dec-18 31-Oct-21 31-Oct-21 ### 7-Feb-20 The 1917 Clinic at UAhttps://Cl
24-Apr-17 18-Jan-23 18-Jan-23 1-May-17 22-Jan-20 Alabama Clinical Therhttps://Cl
18-Aug-14 18-Apr-15 18-Apr-15 4-Aug-14 20-Jun-16 6-Jun-18 GSK Investigational S https://Cl
1-Mar-18 25-Jan-19 12-Jun-19 ### ### Inner Mongolia Autonhttps://Cl
Nov-08 Apr-09 Jul-09 ### ### ### Taipei, Taiwan https://Cl
Jan-05 Jun-10 Jun-10 26-Jul-11 26-Jul-11 University of Helsinkihttps://Cl
20-Mar-18 31-Dec-19 2-Jun-20 ### 18-Jan-20 GSK Investigational S https://Cl
Apr-16 Jun-17 Jun-17 ### 11-Oct-17 Mayo Clinic, Rochestehttps://Cl
Jan-20 Nov-20 May-21 ### ### Cincinnati Children's https://Cl
Oct-13 3-Jun-14 13-Jan-16 30-Oct-13 5-Apr-17 Thomas Jefferson Univ https://Cl
Mar-14 Jun-14 Dec-14 ### ### Garuda Primary Health https://Cl
7-Oct-19 22-Jul-22 22-Jul-22 ### 7-Feb-20 City of Hope Medical https://Cl
7-Jul-16 13-Feb-18 ### ### 3-Jun-19 27-Jun-19 GSK Investi"Study Prohttps://Cl
Mar-05 Jun-06 18-Jun-08 19-Jul-16 Murdoch Childrens Res https://Cl
Jun-14 Nov-15 Nov-15 30-Apr-14 29-Jul-16 PAREXEL Early Phase C https://Cl
Nov-18 May-19 Jan-20 ### ### Suiping Ce"Study Prohttps://Cl
Apr-10 Jul-11 Jul-11 ### ### BCG Oncology, PC, Pho https://Cl
Jun-19 Dec-24 Dec-25 2-Apr-19 2-Apr-19 https://Cl
Jan-07 Nov-12 Dec-14 11-Jan-07 26-Jun-15 Northwestern Universit https://Cl
Jul-14 Jun-15 Jul-15 16-Jan-15 31-Jan-17 31-Jan-17 Medical University ofhttps://Cl
Mar-10 Feb-11 Feb-11 ### ### Chaim Sheba Medicalhttps://Cl
9-Jan-19 31-Dec-21 ### 8-Aug-19 8-Aug-19 Belarussian Researchhttps://Cl
28-Jan-16 Feb-20 Feb-20 17-Jul-14 ### Duke University Medic https://Cl
Oct-14 Jun-18 Jun-18 ### 7-Aug-18 Rigshospitalet, The https://Cl
Feb-15 May-16 May-16 ### ### Eskenazi Health Outpa https://Cl
Nov-11 Dec-15 Feb-17 ### 9-Oct-17 24-Jul-18 Huntsville, Alabama, https://Cl
Oct-10 Dec-10 Dec-10 27-Oct-10 ### 9-Sep-13 Covance Clinical Resehttps://Cl
Jul-15 May-16 Oct-16 22-Jun-15 19-Oct-16 Department of Medicihttps://Cl
Sep-09 Jun-11 28-Jan-09 ### Center for Immunizatihttps://Cl
Dec-16 Oct-17 Aug-18 ### ### Liu Zhou Centre for Dhttps://Cl
Oct-13 Jul-15 Jul-15 21-Apr-16 17-Jan-18 Vaccine and Immunothe https://Cl
Jul-13 Jun-15 Jun-15 ### ### The University of Tol https://Cl
Mar-02 Nov-02 Nov-02 ### ### Docnor House, Durban https://Cl
Mar-05 Dec-05 Dec-05 ### ### Baylor College of Medhttps://Cl
16-Sep-16 19-Dec-16 24-Jun-17 ### ### Ha Nam Health Center, https://Cl
HÃ Nam, Vietnam
Feb-13 Dec-13 Dec-14 10-Apr-13 20-Jan-16 Hunan Centers for Di https://Cl
Jun-16 Jan-17 Mar-17 3-Apr-15 2-Jul-17 Inno-6041 study site https://Cl
May-16 Jan-19 Dec-19 2-Sep-15 3-Apr-19 Rheumatology Associat https://Cl
May-08 Nov-10 Dec-10 3-Apr-08 7-May-08 Malaria Research Traihttps://Cl
Nov-10 Jan-11 Feb-11 20-Oct-10 15-Jun-11 Canadian Center for Vhttps://Cl
Jun-13 Dec-13 Mar-14 6-Aug-13 23-Apr-14 Makere University- Johttps://Cl
4-Apr-18 Sep-19 Dec-19 ### 30-Apr-19 UZ Leuven, Leuven, Bhttps://Cl
Mar-16 Jul-16 ### ### https://Cl
Mar-08 Jul-12 Jul-12 ### ### Center for Immunizatihttps://Cl
Dec-10 Mar-11 Mar-11 12-Jan-11 16-Oct-12 16-Oct-12 Department of Pediatr https://Cl
17-Jun-13 10-Oct-13 ### 28-Jan-13 6-Jan-17 25-Oct-18 GSK Investigational S https://Cl
23-Sep-19 16-Oct-21 16-Oct-23 ### 3-Dec-19 Sidney Kimmel Compre https://Cl
Apr-15 26-May-17 ### 3-Jun-14 27-Jun-18 ### Emory Vacci "Study Prohttps://Cl
Dec-08 31-Dec-17 ### 25-Jun-09 31-Jan-19 Twentynine Palms, Calhttps://Cl
12-Sep-19 Sep-22 Sep-22 9-Sep-19 6-Nov-19 Hillel Yaffe medical cehttps://Cl
Oct-09 Feb-10 Dec-10 6-Nov-09 ### HÃ´pital Henri Mondor https://Cl
Dec-09 Nov-11 Nov-12 20-Jan-10 9-Oct-15 Princess Margaret Hospital
https://Cl
for Children, Subiaco, Aus
18-May-18 25-Jun-19 5-Nov-19 ### ### National Institutes ofhttps://Cl
Sep-13 31-Mar-17 ### ### ### Gloucestershire primahttps://Cl
28-Jul-06 1-Dec-07 4-Dec-07 26-Jun-06 ### 20-Jul-18 GSK Investigational Sihttps://Cl
Jul-11 Apr-12 Oct-12 7-Apr-11 ### ### University of Coloradhttps://Cl
Aug-10 Sep-12 Feb-13 25-Jun-10 30-Jan-14 Seoul National Univers https://Cl
17-Apr-08 Dec-09 Feb-10 ### 11-Jun-19 11-Jun-19 Investigational Site 0 https://Cl
20-Sep-19 18-Dec-19 ### 11-Jun-19 ### General Academic Pedi https://Cl
Jul-07 Jul-20 Jul-20 20-Jul-07 7-Aug-19 Memorial Sloan-Kettehttps://Cl
9-Dec-19 8-Apr-24 8-Apr-24 ### 5-Feb-20 GSK Investigational Sihttps://Cl
Sep-16 1-Jun-20 1-Dec-20 ### 5-Dec-18 University of Californhttps://Cl
Jun-14 May-15 May-15 27-Jun-14 ### Biological treatment https://Cl
Jul-07 Dec-08 Jan-10 9-Jan-08 11-Jan-16 Mayo Clinic, Rochestehttps://Cl
17-Nov-11 9-Jan-13 9-Feb-17 2-May-11 ### 18-Jul-19 GSK Invest"Study Prohttps://Cl
10-Aug-09 16-Sep-10 27-Oct-10 3-Aug-09 7-Aug-17 ### GSK Investigational Sihttps://Cl
Jul-09 Aug-11 Jan-12 22-Jul-09 ### ### Avenue Albert 1er 185,https://Cl
5000 Namur, Belgium|Avenue
Oct-10 Jan-11 Jan-11 3-Sep-10 8-Feb-11 UMN Investigational Shttps://Cl
Nov-10 Nov-14 Dec-20 ### 17-Apr-19 University of Coloradhttps://Cl
19-Sep-18 Dec-22 Jun-23 27-Jul-18 ### ORPRN, Por"Study Prohttps://Cl
9-Dec-12 1-Dec-17 ### 6-Jan-14 ### International Centre https://Cl
Jun-09 Jun-10 Dec-10 ### 3-Mar-11 Public Health Research https://Cl
Nov-18 Apr-19 Oct-19 ### ### British Columbia Centhttps://Cl
Nov-14 Feb-15 Apr-15 ### 20-Jan-16 https://Cl
1-Oct-19 30-Apr-20 30-Jul-20 19-Jul-19 19-Jul-19 https://Cl
Feb-10 Oct-10 Oct-10 ### 13-Oct-10 Institute of Social an https://Cl
Sep-09 Dec-09 Apr-10 3-Dec-09 8-Dec-11 Hebei Province, Chin https://Cl
Aug-04 Feb-07 Feb-07 ### 31-Jul-12 U.T.M.D. Anderson Can https://Cl
Oct-13 Jan-14 Apr-14 ### ### Public Health Ontariohttps://Cl
Mar-08 Nov-09 Jan-10 ### ### ### The Clinical Trials U https://Cl
Mar-12 Aug-13 2-Sep-13 2-Sep-13 Tel Aviv Sourasky Medi https://Cl
23-Jan-18 17-Aug-18 8-Oct-18 ### ### Guanyun Center for Dihttps://Cl
22-Jun-16 16-Sep-16 ### 13-Jul-16 ### Optimal Research, Mel https://Cl
6-Dec-11 27-Sep-13 ### 8-Dec-11 14-Jun-19 14-Jun-19 Alabaster, Alabama, Uhttps://Cl
Jan-16 Jun-20 Dec-35 26-Jun-15 ### KU Cancer Center, Faihttps://Cl
Oct-09 Sep-11 Mar-12 12-Oct-09 ### ### Bucaramanga, Colomb https://Cl
Dec-09 Mar-13 Jun-13 22-Jun-10 24-Jun-14 Columbia University https://Cl
Sep-12 Jun-14 Jun-14 7-Feb-12 12-Jan-15 Respiratory and Menihttps://Cl
Jun-10 Nov-10 Nov-10 ### 9-May-13 Oxford Vaccine Group,https://Cl
Jul-10 Jul-10 Jul-10 13-Jul-10 1-Dec-16 Cambridge, Massachus https://Cl
Jul-09 Feb-11 Aug-11 29-Jul-09 ### GiÃ¨res, France|Monthttps://Cl
Oct-06 Dec-09 Dec-09 ### 9-Feb-10 MRC, Banjul, Gambiahttps://Cl
Sep-11 May-13 May-13 5-Apr-12 1-Apr-15 Hospital Universitari https://Cl
Mar-14 Aug-15 Aug-15 ### ### KAVI-Kangemi clinic, https://Cl
4-Nov-18 Oct-26 Oct-38 30-Oct-18 15-Oct-19 University of Marylanhttps://Cl
Jun-09 Aug-09 Aug-09 7-Jun-10 7-Jun-10 Department of Pediatr https://Cl
1-Jan-17 ### ### Hertordshire primar https://Cl
15-Feb-17 30-Nov-19 May-20 ### 29-Jan-20 IWK Health Centre, Ha https://Cl
1-Aug-11 1-Oct-15 1-Oct-15 21-Jun-17 21-Jun-17 https://Cl
Oct-09 Mar-11 Jun-11 2-Jun-09 12-Oct-11 Department of Medicihttps://Cl
Mar-13 Aug-13 Aug-13 ### 16-Oct-13 Xinxing Center for Di https://Cl
Feb-06 6-Apr-06 ### Regensburg, Germanhttps://Cl
Apr-10 Dec-10 Jun-11 2-Jun-10 4-Sep-14 HIV-NAT, The Thai Redhttps://Cl
1-Oct-18 1-Jun-19 ### ### ### National Institute for https://Cl
Jun-14 Apr-15 Apr-15 1-Jul-14 ### Biological treatment https://Cl
24-Mar-16 27-Apr-20 30-Jul-20 ### ### https://Cl
May-12 Dec-12 Dec-12 ### ### 5-Dec-18 ICDDR,B, Dhaka, Ban https://Cl
Sep-09 Jan-11 Jun-11 ### 14-Jan-14 Espoo, Finland|Helsinhttps://Cl
Nov-13 3-May-19 3-May-19 11-Jul-13 ### UCSF Helen Diller Famhttps://Cl
Feb-09 Mar-11 Mar-11 ### 15-Apr-11 SZMC, Jerusalem, Israhttps://Cl
Oct-11 Dec-11 Mar-12 25-Oct-11 ### PÃ©ter Vajer, Biatorbhttps://Cl
12-Jul-10 17-Feb-11 ### 7-May-10 ### ### GSK Investigational S https://Cl
Nov-11 Dec-14 Dec-14 ### 22-Jul-15 Aberdeen Royal Infir https://Cl
Nov-19 Apr-20 Aug-20 ### 6-Sep-19 https://Cl
Aug-20 May-22 May-23 ### ### University of Alabam https://Cl
Mar-12 Mar-14 Mar-14 ### ### University of Rochesthttps://Cl
19-Dec-16 28-Nov-19 Dec-19 ### ### Muntinlupa, Alabang,https://Cl
12-Oct-18 Dec-19 Jan-21 19-Oct-18 31-Oct-19 University Hospital G https://Cl
6-Sep-17 30-Apr-19 30-Apr-19 ### 24-Jun-19 University of Coloradhttps://Cl
Jun-13 Apr-15 Apr-15 9-Apr-13 ### 7-Sep-16 Emory Vaccine Centerhttps://Cl
Sep-07 Dec-13 Dec-13 ### 9-Apr-15 9-Apr-15 Clinical Research Advhttps://Cl
Nov-07 Jan-08 Dec-08 ### ### ### ATRIUM Gesundheitsze https://Cl
Oct-16 Sep-18 Sep-18 ### ### Bangkok, Thailand https://Cl
22-Nov-12 1-Aug-19 ### ### ### Cancer Institute ï¼† https://Cl
24-Sep-18 1-Mar-21 1-Mar-21 ### 9-Sep-19 University of Rochesthttps://Cl
Mar-06 Oct-06 Oct-07 ### 7-Apr-11 14-Apr-16 Munich, Lindwurmstrhttps://Cl
21-Nov-17 14-Mar-18 ### 8-Nov-17 2-Apr-19 Garuda Primary Healthttps://Cl
8-Nov-17 Jan-20 Jun-20 4-May-17 ### WRAIR, Clinical Trials https://Cl
29-Aug-16 19-Oct-18 Dec-18 ### 1-Feb-19 Institute of Tropical https://Cl
Sep-11 Feb-15 Feb-15 14-Oct-11 ### Riverside Medical Cenhttps://Cl
Sep-10 Jun-12 Jun-12 22-Jun-10 ### University of Marylanhttps://Cl
Mar-11 Jun-12 Jul-12 2-Mar-11 7-Feb-13 RMPRU, Chris Hani Bahttps://Cl
25-Sep-17 15-Dec-17 ### ### ### Nouvel HÃ´pital d'Esthttps://Cl
24-May-12 2-Jan-14 2-Jan-14 9-Apr-12 21-Oct-19 Vanderbilt University https://Cl
15-Oct-09 27-May-10 ### 9-Oct-09 5-Apr-12 ### GSK Investigational S https://Cl
20-Feb-01 1-Apr-03 1-Jul-03 27-Jan-03 20-Jun-17 Massachusetts General https://Cl
Oct-09 May-11 Dec-11 ### ### ### Instituto de Medicin https://Cl
2-Dec-10 28-Sep-12 Jan-13 6-Dec-10 29-Jul-19 29-Jul-19 Ipoh, Perak, Malaysi https://Cl
3-Jan-07 15-Aug-08 ### ### 3-Jul-18 3-Jul-18 GSK Investigational Sihttps://Cl
15-Jun-19 Mar-20 Mar-20 28-Jun-19 2-Jul-19 State Primary Health https://Cl
Aug-10 Aug-12 Jul-14 1-Sep-09 ### ### Johns Hopkins Univershttps://Cl
Jul-06 Apr-08 Jan-11 21-Jun-06 27-Jun-12 27-Jun-12 Thanh Thuy District Hhttps://Cl
May-03 Jun-09 Jun-09 6-May-09 ### https://Cl
Apr-10 Oct-10 Oct-10 5-Apr-10 27-Jun-11 Children's Mercy Hospi https://Cl
Apr-14 Jun-14 Jun-14 30-Jun-16 30-Jun-16 Centro de ReferÃªnciahttps://Cl
de ImunobiolÃ³gicos Especiais
6-Nov-17 Nov-20 Nov-20 ### ### BHU 51-B, Karachi, Sihttps://Cl
16-Oct-06 14-Nov-06 ### 11-Oct-06 ### GSK Investigational S https://Cl
Jun-13 31-Dec-20 30-Apr-21 9-Jul-13 ### Center for Immunizatihttps://Cl
Apr-12 Dec-12 Dec-13 13-Apr-12 13-Apr-12 National Institute of https://Cl
29-Jun-18 29-Jan-19 29-Jan-19 6-Jun-18 5-Feb-20 5-Feb-20 National In"Study Prohttps://Cl
8-Apr-19 Dec-20 Dec-20 ### ### Investigational Site https://Cl
29-Jun-11 28-Jun-12 ### 27-Jun-11 5-Dec-13 13-Jan-20 GSK Investigational S https://Cl
Jul-06 Dec-11 May-13 9-Feb-06 31-Jul-14 National Institute of https://Cl
1-Aug-17 Oct-20 Nov-21 8-Jan-16 ### Antwerp University Hhttps://Cl
Sep-07 Jan-12 Nov-16 ### ### 1-Feb-17 Duke University Medic https://Cl
25-Apr-18 Dec-22 Dec-22 ### 10-Jan-20 Investigational Site https://Cl
Mar-06 Mar-07 Mar-07 ### 3-Jun-13 University of Iowa, I https://Cl
10-Mar-19 17-Jun-19 ### 9-Apr-19 21-Jan-20 Yun County Center forhttps://Cl
8-May-17 21-Nov-17 15-Jun-18 ### 26-Apr-19 26-Apr-19 Optimal He"Study Prohttps://Cl
Dec-12 Jun-14 Dec-14 ### ### Shanghai municipal cehttps://Cl
Mar-07 Aug-08 Aug-08 9-Apr-07 ### Center for Immunizatihttps://Cl
Oct-10 Oct-11 Oct-11 2-Nov-10 ### ### Hope Clinic of the Emhttps://Cl
May-11 Oct-14 Nov-14 17-Jun-11 14-Apr-15 International Centre https://Cl
Sep-09 Jul-11 Jul-13 1-Dec-09 5-Aug-13 CIC Vaccinologie Hopithttps://Cl
9-Oct-17 18-May-18 ### 26-Jan-17 8-Jul-19 Center for Vaccinologhttps://Cl
Jan-12 Jun-13 Oct-13 12-Jan-12 ### Surrey Clinical Resea https://Cl
Oct-12 Mar-13 Mar-13 15-Jan-13 ### Kansai, Japan|Kantouhttps://Cl
Jan-03 Jan-08 Feb-09 ### 19-Jun-12 22-Jun-12 Schneider Childrens Ho https://Cl
Aug-09 Oct-09 Apr-10 ### 1-Dec-16 Hebei Province, Chin https://Cl
Mar-09 23-Jan-09 23-Jan-09 Department of Oncolog https://Cl
Sep-16 Mar-19 Sep-19 5-Sep-16 7-Sep-16 https://Cl
Sep-15 Jul-16 Jul-16 4-Sep-15 ### ### Maastricht UMC, Maas https://Cl
Mar-14 Dec-14 Dec-15 ### 6-Mar-15 Johnson County Clin-Thttps://Cl
Feb-14 Nov-15 Nov-15 ### 3-Dec-15 Medical Research Coun https://Cl
Jul-13 Oct-13 Jun-14 11-Jul-13 18-Jul-18 Osaka, Japan https://Cl
12-Mar-13 22-May-14 8-Apr-15 ### ### 18-Oct-18 GSK Investigational Sihttps://Cl
Oct-09 Dec-09 Mar-10 2-Oct-09 ### ### Durham, North Carolin https://Cl
Aug-12 Aug-15 Aug-15 ### 14-Oct-15 International Centre https://Cl
5-Sep-19 14-Sep-21 ### ### ### Boston Medical Center https://Cl
Jul-11 Nov-11 Nov-11 3-Jun-11 5-May-14 5-May-14 Kempegowda Institute https://Cl
12-Jan-16 29-Dec-16 ### 26-Oct-15 ### Baylor College of Medhttps://Cl
Mar-07 Feb-08 Feb-08 ### 8-May-09 9-Apr-13 Baylor College of Medhttps://Cl
Oct-08 Jan-09 Jun-09 ### 1-Sep-11 ### North Central Arkansahttps://Cl
Oct-97 Dec-98 Dec-98 ### ### https://Cl
Feb-08 Jan-12 Nov-12 30-Jan-08 17-Oct-13 7-Sep-15 Alabama Therapeuticshttps://Cl
Jan-08 Nov-10 Nov-10 ### ### FONTAINE HÃ©lÃ¨ne,https://Cl
May-12 Dec-12 Dec-12 8-Dec-16 ### 21-Apr-17 https://Cl
28-Feb-20 31-Dec-20 ### 27-Jan-20 27-Jan-20 https://Cl
1-Apr-20 1-Apr-21 30-Jun-21 ### ### Universidad CEU-Carde https://Cl
Sep-14 May-17 Aug-17 25-Jul-14 ### Chang-Guang Memorial https://Cl
May-08 May-09 Nov-09 29-Jan-09 2-Apr-14 ### Lima, Peru https://Cl
Apr-13 Jun-18 Aug-20 9-Apr-13 10-Jan-20 Memorial S"Study Prohttps://Cl
Sep-12 Mar-13 Aug-13 ### 9-May-16 University of Calgary,https://Cl
27-Sep-16 9-Mar-17 ### ### 23-Jan-19 23-Jan-19 Site 434, B"Study Prohttps://Cl
Oct-07 Jun-08 Nov-08 30-Oct-07 ### ### Alabaster, Alabama, Uhttps://Cl
Sep-12 Nov-12 May-13 ### ### ### Aichi, Japan|Ibaraki, https://Cl
Oct-05 Jun-08 Jun-08 19-Oct-05 4-Aug-09 9-Dec-16 GSK Investigational S https://Cl
Aug-10 May-12 May-12 2-Sep-10 ### ### https://Cl
24-Jul-12 25-Sep-14 3-Mar-18 ### ### Mayo Clinic, Rochestehttps://Cl
31-Aug-15 21-Aug-17 ### ### 17-Apr-18 3-Oct-19 The Canberr "Study Prohttps://Cl
27-Jan-20 27-Jun-20 ### ### ### Tropical Disease Founhttps://Cl
Sep-13 Feb-14 Feb-14 ### 27-Jun-19 Sandwell General Hoshttps://Cl
Oct-05 Sep-07 Apr-09 16-Jan-08 7-Mar-14 7-Mar-14 https://Cl
Feb-14 Sep-16 Sep-16 ### ### https://Cl
15-Dec-07 1-Dec-08 28-Apr-09 ### 6-Jan-10 ### GSK Investigational S https://Cl
13-Jan-17 28-Nov-17 ### 5-May-17 3-May-18 University Medical C https://Cl
19-Sep-17 Dec-22 Dec-22 18-Oct-17 5-Apr-19 Stanford LPCH Vaccinehttps://Cl
Jan-11 Nov-12 Nov-12 ### 12-Oct-15 Minglanilla, Cebu, P https://Cl
Oct-13 Apr-16 May-17 8-Dec-15 7-Dec-16 The Hospital for Sick https://Cl
Feb-13 Aug-14 Aug-14 18-Jan-13 ### University of Surrey, https://Cl
1-May-06 1-Jul-06 1-Dec-06 26-Jun-06 1-Nov-10 24-Jul-17 Little Rock Allergy & https://Cl
1-Dec-16 Jul-19 Jul-19 ### 25-Jun-19 Sanofi Pasteur Investihttps://Cl
Aug-16 Feb-21 Feb-22 11-Jul-16 ### Lee Moffitt Cancer Cehttps://Cl
Oct-13 Jun-15 Dec-15 ### 20-Apr-16 Singhealth Investigat https://Cl
Apr-07 Jun-08 Jun-08 18-Oct-07 ### ### Experimental Tuberculhttps://Cl
1-Oct-09 28-Dec-09 ### ### 30-Jan-12 1-Aug-18 GSK Investigational S https://Cl
Mar-12 Oct-12 Dec-12 ### ### Melbourne, Australia|https://Cl
Mar-10 Sep-10 Dec-10 ### 14-Jan-14 Rennes, France|Rueilhttps://Cl
21-Oct-19 1-Feb-20 1-Feb-20 4-Sep-19 24-Oct-19 Vanderbilt Universityhttps://Cl
Jun-06 ### ### Dipartimento di Medicina
https://Cl
e Scienze dellâ€™Invecchia
Sep-15 Jan-17 Feb-17 2-Sep-15 25-Jul-17 Academic Medical Cen https://Cl
Aug-14 Aug-14 Aug-14 6-Feb-15 6-Feb-15 https://Cl
29-Aug-10 12-May-12 ### 29-Jul-10 24-Jun-13 6-Aug-18 GSK Investigational S https://Cl
Apr-07 Jan-08 Jan-08 5-Apr-07 ### ### GSK Investigational S https://Cl
Jan-15 Aug-15 Aug-15 7-Jan-15 ### Biological treatment https://Cl
21-Oct-19 1-Jul-21 1-Jul-21 11-Jul-19 9-Jan-20 CCVTM, University ofhttps://Cl
25-Sep-06 4-Jun-07 6-Nov-07 ### ### 10-Jun-19 GSK Investigational Sihttps://Cl
Apr-15 Oct-19 Oct-19 ### 26-Jun-19 10-Jul-19 Cancer Cent "Study Prohttps://Cl
19-Mar-19 4-Jun-19 4-Jun-20 19-Apr-19 23-Apr-19 University of Vermonthttps://Cl
Sep-13 Feb-16 Sep-16 30-Jul-15 25-Oct-19 25-Oct-19 Medical University Viehttps://Cl
16-Apr-18 1-Feb-20 1-Feb-20 30-Apr-18 25-Apr-19 Northwest Arkansas Pe https://Cl
Jul-12 8-Feb-19 Aug-20 ### 18-Jul-19 University of Alabamahttps://Cl
Jan-10 May-10 Oct-10 15-Oct-09 5-May-16 5-May-16 Johnson County Clin-Thttps://Cl
Jan-10 Aug-10 Dec-10 21-Jan-10 ### Institute for Pharmaco https://Cl
Sep-13 Aug-14 Aug-14 ### ### ### https://Cl
Sep-13 Aug-14 Jun-15 ### 25-Apr-17 Manila, Philippines|Mhttps://Cl
Apr-12 Sep-12 Nov-12 18-Apr-12 8-May-13 Funing county Centerhttps://Cl
Apr-05 Jun-06 Dec-06 9-Mar-09 31-Jul-09 14-Apr-16 Little Rock, Arkansas https://Cl
3-Oct-13 2-Jun-14 ### 1-Oct-13 ### 2-May-18 GSK Investigational S https://Cl
Jun-06 Feb-07 Jun-07 8-Jun-06 4-Nov-16 GSK Investigational Sihttps://Cl
28-Feb-19 28-Feb-21 30-Jun-22 6-Jul-18 6-Mar-19 Beth Israel Deaconesshttps://Cl
26-Mar-12 31-Jan-16 1-Feb-19 ### 5-Apr-17 6-Aug-19 H. Lee Moffitt Cancerhttps://Cl
Aug-10 Feb-11 Jun-11 1-Aug-12 2-Oct-12 Sanhe Centre for Disehttps://Cl
Sep-16 Jul-17 Sep-17 17-Jun-16 17-Oct-17 Xiaokui Hu, Taixing, J https://Cl
May-07 Jan-09 Apr-09 7-Jun-07 6-Jul-11 ### Birmingham, Alabama, https://Cl
13-Jun-19 17-Mar-20 ### ### 10-Jan-20 Roswell Park Cancer Ihttps://Cl
1-May-18 1-Feb-20 1-Feb-21 26-Jan-18 ### Herlev Hospital, Herl https://Cl
Dec-06 May-08 May-08 ### 8-Jul-09 13-Apr-17 https://Cl
23-Oct-18 4-Feb-20 ### 11-Jul-18 18-Jan-20 Cincinnati Children's https://Cl
7-May-18 Mar-20 Mar-20 ### 3-Dec-19 Arizona Department of https://Cl
12-Aug-11 29-Nov-11 ### ### 16-Apr-14 ### GSK Investigational Sihttps://Cl
May-16 Jun-17 Oct-17 14-Jan-16 ### Institute of Infectio https://Cl
12-Aug-19 31-Dec-21 30-Apr-22 ### ### KEMRI-Wellcome Trust https://Cl
1-Sep-06 12-Apr-07 12-Apr-07 ### ### 8-Jun-18 GSK Investigational S https://Cl
Nov-09 Sep-10 Sep-10 28-Oct-09 ### Centre for Clinical V https://Cl
Oct-10 Mar-11 Apr-11 11-Oct-10 ### 23-Oct-13 Hoover, Alabama, Unit https://Cl
Oct-15 Jan-16 Jun-16 9-Feb-16 6-Feb-17 ### https://Cl
Dec-08 Sep-10 Nov-15 ### 12-Apr-19 University of Pittsburhttps://Cl
2-Aug-18 31-Oct-20 31-Oct-20 12-Jun-18 ### Saint Louis Universityhttps://Cl
12-Sep-16 24-Nov-16 ### 9-Sep-16 ### ### GSK Investigational S https://Cl
31-Jan-17 31-Jul-20 31-Jul-20 ### ### Klein Buendel, Inc., https://Cl
15-Jun-12 10-Aug-16 ### 6-Nov-19 6-Nov-19 https://Cl
Aug-11 Dec-11 Mar-12 ### ### Cincinnati Children's https://Cl
Apr-15 Jul-16 Jul-16 7-Jan-15 30-Apr-18 4-May-18 Pediatric Hematology/O https://Cl
Mar-11 Jun-11 May-12 ### 6-Oct-15 Accelovance, Huntsvilhttps://Cl
Nov-06 Apr-07 Aug-07 2-Oct-06 4-Nov-16 GSK Investigational Sihttps://Cl
May-10 Oct-12 Dec-12 3-Aug-11 ### ### Department Tropical Phttps://Cl
Jan-10 Aug-10 Sep-10 21-Jan-10 14-Jan-14 Chandigarh, India|New https://Cl
1-Feb-14 5-Nov-23 5-Nov-23 4-Feb-14 13-Jan-20 National Institutes ofhttps://Cl
Feb-14 Mar-15 Mar-15 ### 23-Jan-19 23-Jan-19 Centre d'Investigatio https://Cl
Mar-95 Mar-99 ### ### Kangasala Study Clinihttps://Cl
Oct-05 6-Apr-06 ### University of Tamper https://Cl
Jun-10 Sep-15 Sep-15 8-Jun-10 4-Apr-17 Johns Hopkins Univershttps://Cl
Jul-13 Dec-14 Dec-14 7-Mar-13 26-Jun-17 26-Jun-17 University of Rochesthttps://Cl
30-Mar-16 May-21 May-25 ### 18-Apr-19 WCMC Department ofhttps://Cl
G
Aug-09 Oct-09 Nov-09 ### 23-Oct-09 KFLA Public Health D https://Cl
Apr-13 Apr-15 Apr-15 12-Apr-13 14-Jun-16 14-Jun-16 Birmingham Pediatrichttps://Cl
Jan-11 Oct-14 Jan-15 7-Dec-10 ### Center for Immunizatihttps://Cl
Jan-20 31-Jul-20 31-Jul-20 ### ### New York State Deparhttps://Cl
Jan-07 Nov-07 Feb-08 ### 3-Nov-08 St George's Vaccine I https://Cl
Apr-11 Feb-12 Feb-12 27-Apr-11 ### Site 21: GZA campus Shttps://Cl
May-07 Dec-07 Feb-08 18-Apr-07 2-Feb-10 2-Feb-10 Harvey Pediatrics, Jo https://Cl
Jul-11 Jan-12 Feb-12 19-Jan-12 27-Apr-12 Guangxi Provincial Cehttps://Cl
Oct-11 Jun-13 Jul-13 2-Oct-12 19-Apr-13 Stony Brook Hospital,https://Cl
Apr-16 Apr-21 Apr-21 14-Apr-16 31-Jan-20 Memoral Sloan Ketterhttps://Cl
Nov-09 Mar-13 Mar-13 11-Jun-09 21-Apr-14 21-Apr-14 Pfizer Investigational https://Cl
31-Jul-18 7-Aug-19 17-Oct-19 25-Jun-18 1-Nov-19 De La Salle Health Sc https://Cl
Oct-05 Nov-06 Nov-06 13-Apr-06 5-Dec-12 6-Dec-12 Burbank, California, https://Cl
Feb-10 Nov-10 Nov-10 5-Apr-10 ### National Hospital Or https://Cl
Feb-07 Aug-07 Aug-07 ### ### Allschwil, Switzerlandhttps://Cl
21-Jul-16 Aug-18 ### ### 19-Apr-19 Center for Global Heahttps://Cl
Apr-08 Aug-08 Aug-08 14-Apr-08 ### ### GSK Investigational S https://Cl
Sep-11 May-13 May-13 ### ### 28-Jan-15 Washington Hospital hCttps://Cl
Aug-08 May-09 Aug-09 ### ### 21-Apr-15 Alabang, Philippines|https://Cl
Feb-13 Mar-16 Mar-16 ### ### Centre d'Investigationhttps://Cl
Feb-12 Oct-12 Apr-13 ### 5-Jun-14 5-Jun-14 Comprehensive Clinichttps://Cl
6-Nov-15 5-Jul-16 ### 23-Jun-17 23-Jun-17 https://Cl
Sep-11 Aug-12 Dec-12 8-Dec-11 8-Dec-11 Guiqiang Wang, Beijinhttps://Cl
Apr-20 Apr-21 Jun-21 19-Apr-18 7-Jan-20 Department of Interna https://Cl
Feb-10 Sep-10 May-12 7-Dec-09 ### 1-Oct-14 Oxford Vaccine Group,https://Cl
Feb-08 Aug-08 Jan-09 ### 22-Jul-11 Baylor College of Medhttps://Cl
Jul-08 Feb-12 Feb-12 ### ### Center for Health andhttps://Cl
23-Jun-16 15-Sep-16 ### 11-Jul-16 ### Vaccine Evaluation Cehttps://Cl
Mar-08 Dec-09 May-13 ### ### 2-Oct-14 Bangkok, Thailand|Bahttps://Cl
Oct-13 Oct-14 Oct-16 9-May-17 9-May-17 Centre for Clinical V https://Cl
Mar-15 Jun-16 Jun-16 ### ### Mercy Hospital for Wo https://Cl
Aug-06 Sep-09 Sep-11 6-Mar-06 19-Apr-10 University College M https://Cl
Jun-10 Dec-10 Jun-11 3-Nov-10 28-Jul-11 Hospital of St. Rapha https://Cl
1-Nov-18 Jul-21 Jul-21 ### ### Vaccine Evaluation C https://Cl
7-Oct-12 2-Jul-13 ### ### 6-Oct-14 14-Jun-19 GSK Investigational Sihttps://Cl
Oct-02 Nov-14 Nov-14 5-Jan-10 ### ### Upmc Upci Hcc, Pittsbhttps://Cl
1-May-18 31-May-20 1-May-21 18-Jan-18 6-Jun-18 University Hospital, https://Cl
12-Jan-11 10-Aug-13 ### 6-Dec-10 ### ### https://Cl
Aug-14 Dec-15 Feb-16 9-Dec-14 6-Jan-17 Bassett Healthcare N https://Cl
Aug-14 Nov-14 Apr-15 ### ### ### Site 296, Huntsville, https://Cl
Jan-09 May-12 May-12 30-Jun-08 25-Jul-14 Duke University Medic https://Cl
Nov-05 Jun-06 5-Aug-05 ### GSK Investigational https://Cl
1-Jun-17 30-Sep-21 ### ### 27-Jan-20 Emory Winship Cancer https://Cl
May-02 Jul-06 Jul-06 2-Sep-05 16-Apr-08 University Health Nethttps://Cl
Sep-15 Apr-16 Jul-16 ### 4-Nov-16 4-Nov-16 Ansan-si, Korea, Repuhttps://Cl
Jan-07 Dec-16 Dec-17 3-Sep-07 ### Sibley Memorial Hospi https://Cl
Apr-10 Sep-10 Apr-11 11-Oct-10 6-Feb-13 Avenida Vital Brasil 1 https://Cl
Feb-08 Dec-10 Nov-11 3-Apr-07 4-Jun-12 Hematology-Oncologyhttps://Cl
&
Nov-09 Oct-12 ### ### University of Virginia,https://Cl
Oct-06 Sep-08 Sep-08 ### ### Center for Immunizatihttps://Cl
Mar-15 Mar-16 Mar-16 4-Mar-15 ### University of North Cahttps://Cl
Dec-03 Sep-05 Jan-06 ### ### GSK Investigational Sihttps://Cl
5-Mar-18 Oct-20 Dec-20 ### 18-Jan-20 Center for "Informed https://Cl
1-Dec-15 1-Aug-16 ### 17-Jun-19 6-Feb-20 UF Health Pediatrics -https://Cl
Nov-09 Feb-10 Feb-10 23-Oct-09 10-Apr-15 Calgary Health Servichttps://Cl
Dec-09 Sep-10 Dec-12 9-Jan-14 24-Apr-14 University of Miami, https://Cl
Mar-11 Nov-11 Jan-12 9-Mar-11 8-Apr-16 8-Apr-16 Chandler, Arizona, Unhttps://Cl
Jun-06 Jul-07 Jul-07 4-Jul-06 21-Jan-08 Center of Immunizatiohttps://Cl
Apr-03 Jun-04 Feb-08 ### 29-Apr-11 16-Jul-12 Enoggera, Queensland https://Cl
Feb-11 Jun-11 Jun-11 12-Jul-11 27-Apr-12 Guangxi Provincial Cehttps://Cl
21-Mar-19 Sep-20 May-21 ### ### KEMRI Well"Study Prohttps://Cl
Oct-13 May-14 Jun-15 22-Oct-13 22-Oct-13 Queen Mary Hospitalhttps://Cl
a
Jul-08 May-10 May-10 2-Jul-08 ### 25-Oct-11 Guadalajara, Jalisco https://Cl
Jun-07 Jul-08 Aug-08 22-Jan-07 3-Apr-08 Medical Research
Williamsburg, Unihttps://Cl
Virginia, United States|Investigational S
30-Jul-13 12-Jun-18 12-Jun-18 27-Jun-13 5-Jul-19 5-Jul-19 Taiwan|Investigational
"Study Prohttps://Cl
Site 426, New Taipei City, Taiw
Jun-08 Mar-09 Nov-09 3-Jun-08 ### 2-Nov-11 Pfizer Investigational https://Cl
Oct-10 Feb-11 Apr-11 6-Oct-10 ### Seoul, Korea, Republihttps://Cl
29-Aug-17 30-Nov-20 ### ### 7-Aug-19 The Hope Cl "Study Prohttps://Cl
Oct-08 Apr-09 Apr-09 ### 9-May-16 Center For Vaccinologhttps://Cl
May-05 Nov-05 5-Aug-05 ### GSK Investigational S https://Cl
Sep-09 May-10 Oct-10 ### ### 14-Apr-16 Hoover, Alabama, Unit https://Cl
9-Oct-18 20-Mar-19 Dec-19 15-Jan-19 1-Feb-19 CHI CrÃ©teil, CrÃ©tehttps://Cl
2-Dec-08 28-Feb-13 6-Dec-18 10-Jun-08 ### 4-Oct-19 H. Lee Moffitt Cancerhttps://Cl
12-Sep-17 30-Nov-17 ### ### 13-Jan-20 13-Jan-20 GSK Investi"Study Prohttps://Cl
1-Oct-09 17-May-10 ### 23-Oct-09 2-May-17 ### GSK Investigational Sihttps://Cl
30-Nov-18 May-21 May-22 ### 27-Jan-20 AIDS Clinical Trials U https://Cl
3-Feb-09 18-Aug-10 ### ### 18-Jun-18 GSK Investigational S https://Cl
15-Nov-19 1-Jun-20 1-Jan-21 6-Sep-19 ### University of Alabam https://Cl
Aug-04 Sep-07 Sep-07 ### 2-Jul-09 Medical Oncology Hem https://Cl
Oct-11 Feb-13 Jun-13 ### ### ### University of Iowa - https://Cl
8-Aug-17 18-Oct-17 18-Apr-18 ### 25-Jan-19 Pizhou County Centerhttps://Cl
Dec-05 Apr-06 26-Jul-06 9-Nov-07 China-Japan Friendship https://Cl
Dec-05 Jul-08 Jul-08 ### ### 7-Aug-12 UT MD Anderson Cance https://Cl
May-04 Mar-08 Mar-08 19-Jul-06 8-Jul-14 8-Jul-14 National Institutes ofhttps://Cl
Mar-02 Nov-08 Nov-08 9-Feb-06 8-Jan-13 18-Jan-13 Rockefeller Universit https://Cl
27-Aug-14 5-Apr-17 5-Apr-17 4-Sep-14 5-Jul-18 Hope Clinic - Emory Vhttps://Cl
5-Dec-12 17-Dec-13 ### ### ### 7-Sep-18 GSK Investigational Sihttps://Cl
8-Sep-09 23-Sep-10 ### ### ### 25-Jun-19 GSK Investigational Sihttps://Cl
18-Apr-11 22-Jun-12 2-Nov-12 ### 4-Feb-19 7-May-19 GSK Investigational Sihttps://Cl
Apr-14 Jul-15 Aug-15 7-May-14 27-Apr-16 Bagamoyo Research and https://Cl
28-Apr-14 10-May-17 ### 17-Jan-14 21-Jul-17 University of Alabamahttps://Cl
Jan-10 Nov-12 Jun-16 22-Jan-10 21-Jun-16 Brigham and Women's https://Cl
Dec-03 Oct-05 Oct-05 7-Nov-05 ### Rockefeller Universit https://Cl
Mar-20 Feb-22 Aug-27 ### 18-Jan-20 https://Cl
6-Nov-15 12-Feb-19 ### ### ### BoboDioulasso, Burkihttps://Cl
Jul-05 Jan-06 Mar-06 9-Aug-05 ### ### https://Cl
2-Dec-08 2-Jul-09 2-Jul-09 ### ### ### GSK Investigational S https://Cl
Sep-03 Oct-06 Oct-06 9-Apr-08 21-Jan-13 Centre Bydgoszcz, By https://Cl
Sep-12 Jan-15 Jan-15 ### 8-Jan-16 ### Rigshospitalet, Cop https://Cl
Jun-06 Mar-08 11-Apr-08 11-Apr-08 Great Ormond Street https://Cl
Nov-08 May-09 Nov-09 ### ### Stanford University - https://Cl
Nov-06 Jul-10 Jul-10 3-Nov-06 ### Centre for Clinical V https://Cl
23-Jun-14 27-Jan-17 9-May-14 ### ### Massachuset"Study Prohttps://Cl
Apr-07 Aug-08 30-Jan-07 4-Mar-15 San Francisco Vaccinehttps://Cl
Jan-15 Feb-16 Mar-16 6-Apr-15 ### Department of Pediatr https://Cl
Apr-10 Aug-12 Aug-12 23-Apr-10 ### https://Cl
Oct-03 Aug-04 Aug-04 ### ### GSK Investigational S https://Cl
Jun-07 Sep-08 Sep-08 24-Apr-07 ### ### Torun, Bydgoszcz, Po https://Cl
7-Mar-17 29-Aug-17 ### ### 16-Apr-19 ### Phase 3: H"Statistic https://Cl
16-Jul-15 7-Mar-17 ### ### ### 30-Apr-19 Avail Clini "Statistic https://Cl
13-May-19 8-Feb-21 17-Jul-21 1-May-19 ### 0003-UMHAT Dr. Georgi https://Cl
Stranski EAD, Pleven, Bulgari
21-Feb-17 29-May-18 ### 24-Apr-19 29-Oct-19 Q-Pharm, Herston, Quhttps://Cl
Mar-16 Jun-16 Aug-16 20-Jul-15 ### https://Cl
19-Jul-19 16-Dec-20 ### ### ### GSK Investigational Sihttps://Cl
8-Sep-09 28-Sep-10 ### ### ### ### GSK Investigational S https://Cl
Dec-09 Mar-11 Mar-11 ### 5-Oct-11 Hospital Garrahan, Combate
https://Cl
de Los Pozos 1881, Ciud
Mar-14 Apr-15 Apr-15 13-Jan-14 21-Jun-16 Surrey Clinical Resea https://Cl
Mar-20 Dec-24 Dec-24 7-Oct-19 5-Feb-20 Sidney Kimmel Compre https://Cl
Nov-05 Feb-06 Feb-06 ### 9-Apr-12 11-Apr-12 Orlando Clinical Resehttps://Cl
Mar-11 May-11 Dec-12 8-Mar-11 10-Jul-13 https://Cl
30-Mar-16 29-Feb-20 6-Oct-15 9-Jan-20 Banner University Med https://Cl
Jan-07 Jan-09 8-Aug-07 6-Jan-14 M. D. Anderson Cancer https://Cl
Oct-14 Jan-16 Jan-16 2-Oct-14 27-Oct-16 San Diego, California https://Cl
Jun-14 Apr-15 Jun-15 ### 29-Jun-18 Walter Reed Army Inst https://Cl
Apr-11 Sep-12 Jun-13 ### ### Aga Khan University, https://Cl
1-Dec-09 14-Jan-11 14-Jan-11 ### 4-May-17 ### GSK Investigational Sihttps://Cl
Sep-16 3-Apr-18 ### ### ### 11-Jun-19 Centers for"Study Prohttps://Cl
Sep-03 May-04 May-04 21-Oct-08 21-Oct-08 University Hospital L https://Cl
Apr-10 Jul-10 Dec-10 28-Jun-10 28-Jun-10 Rheumatology Division https://Cl
14-Sep-09 30-Apr-10 30-Apr-10 ### 28-Jan-19 ### GSK Investigational Sihttps://Cl
Sep-03 6-Dec-05 6-Dec-05 University of Oxford https://Cl
Aug-10 Aug-11 Aug-13 ### 3-Mar-14 24-Apr-14 Vanderbilt Universityhttps://Cl
Aug-10 Oct-16 Oct-16 ### 9-May-17 University of Louisvillhttps://Cl
Jan-13 Dec-13 Dec-13 ### ### https://Cl
25-Feb-20 15-Jul-24 15-Jul-24 ### 22-Jan-20 https://Cl
19-Aug-14 16-Nov-18 ### ### 3-Dec-19 3-Dec-19 GSK Investi"Study Prohttps://Cl
Nov-13 Feb-14 Feb-14 ### ### Tel Aviv Medical Centerhttps://Cl
Jun-13 Jan-14 Jun-14 19-Jun-13 19-Jun-13 https://Cl
Jul-09 Sep-09 Oct-09 ### 30-Oct-09 Beijing Centers for Dihttps://Cl
Nov-10 Mar-11 Aug-11 3-Nov-10 ### University of Texas Mhttps://Cl
May-09 Dec-11 Dec-11 ### ### Women's and Children' https://Cl
25-May-07 30-Jun-08 13-Oct-08 ### ### GSK Investigational Sihttps://Cl
Jan-10 May-10 May-10 ### 15-Oct-19 University of Marylanhttps://Cl
1-Jun-18 9-Jun-20 9-Jun-20 8-Jun-18 28-Oct-19 Mobile Pediatric Clin https://Cl
Sep-04 Feb-06 ### ### IDEWE, Leuven, Belg https://Cl
Apr-10 Feb-11 May-11 3-Dec-10 ### Tianjin Centers for Di https://Cl
1-Apr-17 31-Mar-18 ### 11-Apr-17 ### Center for Infectious https://Cl
Oct-06 Mar-07 Oct-07 24-Oct-06 ### 1-Dec-11 Harrisburg, Arkansas,https://Cl
16-May-18 14-Feb-19 ### ### 1-Mar-19 Cincinnati Children's https://Cl
May-10 Jun-10 Nov-10 ### 13-Jun-12 17-Jan-14 Center for the Evaluahttps://Cl
Apr-11 Apr-16 Apr-16 20-Apr-11 22-Jun-16 22-Jun-16 National Institutes o https://Cl
6-Apr-17 25-May-18 ### 5-Apr-17 14-Jun-19 ### Usc La Nic "Statistic https://Cl
Oct-16 Jul-21 Jul-21 25-Oct-16 28-Oct-16 Bandim Health Projechttps://Cl
23-Mar-08 8-Jun-11 8-Jun-11 4-Apr-08 2-Aug-18 2-Aug-18 GSK Investigational S https://Cl
Jun-10 Apr-12 Apr-12 22-Jun-10 ### 7-Oct-15 Columbia University M https://Cl
Feb-13 15-May-17 Sep-18 ### 16-Jul-18 Case Western Reservehttps://Cl
Sep-14 Dec-14 Oct-15 ### 29-Jan-16 29-Jan-16 Nanning, Guangxi, Chhttps://Cl
Sep-10 Jan-13 Apr-15 31-Jan-12 20-Jan-16 20-Jan-16 Yokoyama Children's Chttps://Cl
Nov-09 Nov-10 Nov-10 9-Oct-09 ### ### University of Iowa, I https://Cl
11-Aug-09 30-Aug-10 ### 4-Aug-09 ### ### GSK Investigational S https://Cl
Jul-08 Feb-09 Jul-09 2-Nov-08 9-Oct-15 Heartland Research As https://Cl
Feb-09 Apr-11 Apr-11 ### ### National Taiwan Univehttps://Cl
Feb-09 May-09 Aug-10 ### ### Unterer Graben 2, Efehttps://Cl
3-Nov-17 2-Nov-20 ### ### ### UNC Lilongwe Project,https://Cl
Aug-04 Apr-05 Apr-05 ### 5-Dec-14 University of Texas Mhttps://Cl
Nov-07 Jul-08 Aug-08 ### 21-Apr-14 21-Apr-14 Arkansas Medical Rese https://Cl
Oct-09 Dec-10 Jan-11 26-Jan-10 6-Dec-13 Seoul National Univers https://Cl
Dec-11 Dec-13 Dec-13 ### 4-Nov-16 Walter Reed Army Inst https://Cl
Sep-16 Nov-16 Nov-16 8-Sep-16 26-Jun-17 Seoul National Univers https://Cl
Jan-09 Feb-13 Jul-15 ### ### Comprehensive Cancer https://Cl
Apr-09 Dec-11 Mar-12 ### ### University Medical C https://Cl
Mar-07 Feb-11 Jun-11 ### 1-Mar-12 Center for Immunizati
, Kozloduy, https://Cl
Bulgaria|MHAT "Sv. Nikolay Chudotvorets"
29-Mar-17 28-Sep-20 ### ### ### Medical Care Corporation
https://Cl
Hose-kai Marunouchi Hosp
Jun-07 Aug-20 Oct-24 18-Jun-07 ### Dana-Farber Cancer In https://Cl
Jul-09 Nov-10 Feb-12 13-Jul-09 4-Mar-15 7-Apr-15 Hospital Privado de CÃ³rdobahttps://ClCMC SA, Naciones Unid
Jun-09 Mar-10 Mar-10 9-Oct-09 ### Wellcome Trust Clinichttps://Cl
Feb-16 Feb-20 Feb-20 3-Mar-16 3-May-19 Consulate General of https://Cl
17-Sep-19 15-Jun-23 15-Jun-23 ### 5-Feb-20 GSK Investigational S https://Cl
Jul-14 28-Oct-18 28-Oct-18 ### ### Medical University ofhttps://Cl
Apr-13 May-16 Sep-17 4-Apr-13 8-Oct-19 UAB Comprehensive Ca https://Cl
Jan-09 Aug-12 Sep-14 12-Jan-09 ### Alabama CRS, Birmingh https://Cl
Nov-08 Sep-11 Sep-11 ### 12-Jun-17 Baylor University Medi https://Cl
Sep-11 Mar-13 Jun-13 5-Oct-11 10-Jan-18 Dhaka, Bangladesh https://Cl
Jul-18 Jul-19 Jul-20 9-Jun-15 9-Sep-19 https://Cl
10-Sep-09 24-Nov-10 ### 3-Sep-09 ### ### GSK Investigational Sihttps://Cl
Apr-15 Oct-15 Oct-15 ### 4-Apr-16 Center for Immunizatihttps://Cl
IAVI V002|10419 ### ### https://Cl
14-Sep-18 3-Jun-20 3-Jun-20 ### ### Vanderbilt University https://Cl
22-Mar-10 17-Mar-14 ### ### 2-Mar-18 GSK Investigational S https://Cl
15-Sep-17 31-Jan-18 ### 24-Jul-18 ### Groupe Hospitalier Parhttps://Cl
Mar-03 Jun-09 Jun-10 ### ### ENT Department, Lund https://Cl
Feb-11 Dec-13 Dec-13 31-Jan-11 4-Jun-14 ### Queen Saovabha Memor https://Cl
7-Dec-12 23-May-14 ### ### 1-Jun-15 ### H. Lee Moffitt Cancerhttps://Cl
Nov-13 Jun-17 Nov-17 17-Jul-14 8-Aug-18 National Instiute of Phttps://Cl
Jul-07 Sep-07 Feb-08 ### 9-Oct-15 University of Hong Kohttps://Cl
Aug-07 Jul-08 Jan-13 ### 16-Oct-14 Alabama Vaccine CRS,https://Cl
May-09 Jan-12 Oct-13 ### 9-Aug-16 GSK Investigational Sihttps://Cl
8-Jan-19 Aug-20 Aug-20 25-Jan-19 ### Center for "Informed https://Cl
8-Jan-20 Feb-23 Jul-23 7-Jan-20 13-Jan-20 Bandim Health Project https://Cl
20-Aug-19 Jan-20 Jun-20 ### ### Medical Research Couhttps://Cl
Oct-07 Dec-09 Sep-10 15-Jul-08 25-Jun-13 https://Cl
Jan-07 Aug-09 8-May-06 7-Aug-09 Vanderbilt Universityhttps://Cl
Feb-10 Jul-10 Aug-10 27-Oct-09 15-Apr-15 Dalhousie University,https://Cl
1-Jun-19 31-Dec-21 ### ### ### SkÃ¥ne University hohttps://Cl
Dec-07 Jul-08 Jul-08 ### 3-Apr-14 ### Ankara, Turkey https://Cl
Nov-13 Dec-14 Dec-15 1-Nov-13 9-Feb-18 ### Columbia University, https://Cl
Jul-10 Aug-10 Aug-10 7-Jul-10 ### University Clinic for https://Cl
Nov-08 Dec-08 Jul-09 31-Oct-08 29-Oct-15 Coastal Clinical Rese https://Cl
1-Feb-12 1-Jan-14 10-Jan-14 2-Mar-12 9-Jan-15 18-Jul-19 Heart Center of the Rhttps://Cl
Dec-13 Jun-14 May-15 ### ### Accelovance, San Dieghttps://Cl
Jan-18 Jul-18 Sep-18 ### ### https://Cl
3-Jan-08 10-Nov-08 ### 7-Feb-08 12-Apr-17 3-Jan-20 GSK Investigational S https://Cl
May-09 Aug-10 Aug-10 2-Mar-09 5-Jan-11 5-Jan-11 Pfizer Investigational https://Cl
Feb-09 Jan-12 Jan-12 9-Feb-09 10-Jan-17 GSK Investigational Sihttps://Cl
15-Apr-13 Apr-23 Apr-23 6-Feb-13 7-May-19 Oslo University Hospihttps://Cl
13-Oct-09 2-Mar-10 17-Jun-10 ### ### ### GSK Investigational Sihttps://Cl
Oct-06 Oct-08 Oct-08 4-Oct-06 ### 24-Jan-13 Atherstone, United https://Cl
Jul-07 Sep-08 Nov-12 14-Jun-07 4-Jun-15 Alabama Vaccine CRS,https://Cl
Dec-11 Jul-12 Dec-12 ### ### Guangzhou, Guangdong https://Cl
Feb-11 Mar-15 Mar-15 ### 19-Jun-15 University of Marylanhttps://Cl
25-Jul-18 17-Jan-20 Mar-20 4-Jan-19 5-Feb-20 University of Chicagohttps://Cl
Apr-09 May-12 Nov-13 3-Apr-09 8-Dec-15 UPMC Hillman Cancerhttps://Cl
C
Nov-06 Dec-07 Dec-07 31-Jul-06 4-Mar-09 24-Oct-11 University of Bamako,https://Cl
30-Jun-08 15-Jan-09 15-Jan-09 1-Jul-08 ### GSK Investigational S https://Cl
Aug-09 Oct-09 Oct-09 17-Jun-11 4-Jul-16 Preventive Medicine https://Cl
Sep-08 May-18 Dec-18 21-Oct-11 2-Oct-15 Laval University Rese https://Cl
Oct-14 Nov-14 Nov-14 ### 5-Dec-14 Korea University Gurohttps://Cl
30-Nov-10 29-Jul-11 3-Aug-11 7-Nov-10 28-Apr-17 ### GSK Investigational Sihttps://Cl
10-Jul-15 1-Sep-22 1-Sep-23 ### 13-Jan-20 National Institutes ofhttps://Cl
26-Aug-19 24-Sep-20 ### 6-Sep-19 15-Oct-19 Ghent University Hosp https://Cl
Dec-10 Jul-11 Jul-11 ### ### Jiangsu Provincial Ce https://Cl
May-03 Aug-06 Aug-06 ### ### Hispanic Health Counc https://Cl
Jun-13 Jul-14 Nov-14 ### ### INC Research, Toront https://Cl
Nov-14 Dec-18 Nov-20 11-Apr-16 11-Apr-16 https://Cl
Sep-09 Apr-20 Jun-20 ### ### U.S. Army Medical Reshttps://Cl
Mar-16 24-Aug-17 1-Jul-19 13-Jan-16 ### Case Clinical Researc https://Cl
Sep-09 Nov-11 Nov-11 17-Oct-08 ### UBHT, Bristol, Avon, https://Cl
Jan-10 Jan-11 Jul-11 ### 24-Apr-14 Pfizer Investigational https://Cl
29-May-17 Dec-18 Dec-28 27-Apr-17 30-Jul-18 Instituto Nacional de https://Cl
Sep-06 Jan-07 ### 29-Jan-07 Quintiles Lenexa (QLX) https://Cl
Sep-18 Aug-20 Aug-20 ### 23-Jul-19 https://Cl
28-Nov-19 13-Sep-20 ### 6-Dec-19 6-Dec-19 qixian Center for Dis https://Cl
Jul-09 Jul-12 Jul-12 ### ### Alabama Vaccine CRS,https://Cl
Jul-04 Oct-12 Dec-20 10-Jan-05 4-Sep-13 7-Feb-20 H. Lee Moffitt Cancerhttps://Cl
6-Oct-18 31-Mar-19 ### 9-Oct-18 23-Apr-19 The University of Tex https://Cl
Oct-03 Jun-04 Jun-04 ### 10-Jun-10 7-Oct-15 https://Cl
29-Aug-18 Dec-22 Dec-22 ### ### Scottsdale Healthcarehttps://Cl
15-Nov-17 31-Aug-18 ### ### 6-Sep-18 Centre pour le DÃ©vehttps://Cl
Jan-14 May-15 May-15 28-Jun-13 ### The Rockefeller Univehttps://Cl
Nov-02 Nov-04 Nov-08 20-Apr-10 20-Apr-10 Phetchabun Provincehttps://Cl
May-05 Apr-09 ### 6-Jan-14 Mayo Clinic Scottsdalhttps://Cl
11-May-16 31-May-21 ### 9-Nov-15 6-Sep-19 M D Anderson Cancerhttps://Cl
Apr-13 Jun-13 Jun-13 ### ### University of British https://Cl
Oct-10 Nov-11 Nov-11 ### ### Gent University & Hoshttps://Cl
Jul-15 Jan-16 Jan-16 30-Jun-15 6-Feb-19 6-Feb-19 Centre Hospitalier Unihttps://Cl
Oct-08 Jul-09 Jul-09 ### ### University Medical C https://Cl
Aug-10 Oct-11 Dec-11 9-Aug-10 5-May-14 5-May-14 Cali, Colombia|San Johttps://Cl
Feb-05 Apr-05 Apr-05 22-Oct-04 3-Jan-13 Johns Hopkins Schoolhttps://Cl
Mar-13 Nov-13 Dec-13 ### ### Aga Khan University, https://Cl
11-Jun-09 11-Jan-10 11-Jan-10 1-Jun-09 19-Jan-11 ### GSK Investigational Sihttps://Cl
Aug-16 Nov-17 Nov-17 ### 8-Mar-18 Center for Immunizatihttps://Cl
Mar-14 Oct-14 Nov-14 ### ### Radboud University Mhttps://Cl
26-Jan-18 31-Aug-18 ### 17-Oct-17 23-Oct-19 23-Oct-19 GSK Investi"Study Prohttps://Cl
Oct-10 Apr-18 Apr-18 ### 6-Apr-18 Queen Saovabha Memor https://Cl
1-Jul-19 31-Dec-19 ### 18-Apr-19 18-Apr-19 https://Cl
May-06 Jul-07 Jul-07 5-May-06 ### 26-Jan-15 https://Cl
25-Apr-18 Apr-19 Jun-19 ### ### University of Californhttps://Cl
10-Oct-16 2-Dec-16 8-May-17 ### ### The Catholic Univ. of https://Cl
Mar-05 Jan-07 Feb-07 ### ### GDRU, Quintiles Ltd, https://Cl
25-Nov-13 1-Feb-14 19-Jan-15 3-Dec-13 ### GSK Investigational Sihttps://Cl
Jan-09 May-12 May-12 ### ### Providence Portland M https://Cl
2-Jul-18 Dec-20 Dec-20 13-Jun-18 3-Oct-19 D. Y. Patil Medical C https://Cl
3-Jun-09 17-Sep-10 ### 5-May-09 9-Oct-17 ### GSK Investigational Sihttps://Cl
Jun-08 Jul-08 Dec-08 ### ### 22-Oct-10 Covance, Daytona Beac https://Cl
1-Jun-19 Jun-20 Aug-20 ### ### Wellington Dufferin Ghttps://Cl
Sep-12 Aug-13 Aug-13 ### 5-Feb-15 5-Feb-15 C3ID Clinic, Eastern Vhttps://Cl
Oct-02 Sep-13 Sep-13 ### 26-Jan-15 Providence Portland M https://Cl
Jun-06 Apr-10 Apr-10 ### 16-Jul-10 Center for Immunizatihttps://Cl
Jan-02 Dec-05 Jul-06 11-Jun-04 15-Jul-13 22-Jul-13 Sidney Kimmel Compre https://Cl
Jul-07 Mar-08 Mar-08 ### ### ### Bydgoszcz, Poland|Byhttps://Cl
Sep-09 May-13 May-13 ### 12-Apr-17 12-Apr-17 GSK Investigational Sihttps://Cl
Mar-12 Jan-13 Jan-13 ### 18-Jul-13 CMAX, Adelaide, Austr https://Cl
May-11 Dec-11 Mar-13 26-Apr-11 ### Malaria Research andhttps://Cl
Jul-16 Nov-17 Nov-17 6-Jul-16 2-Nov-18 International Centre https://Cl
7-Feb-18 25-Aug-18 ### 5-Feb-18 5-Apr-19 Bagamoyo Research and https://Cl
3-May-19 30-Jun-23 30-Jun-24 18-Jul-19 18-Jul-19 Cancer Care Specialisthttps://Cl
Jul-12 Apr-15 Nov-15 26-Jun-14 ### Radboudumc, Nijmege https://Cl
29-Aug-18 Jul-20 Jul-20 4-Sep-18 5-Sep-18 Ross University Schoohttps://Cl
28-Jun-17 Jun-21 Jun-21 6-Jul-17 ### Alivio Medical Centerhttps://Cl
Oct-09 Jan-10 Sep-10 9-Apr-10 12-Oct-11 Emilia Romagna, Italyhttps://Cl
1-Aug-19 Jul-20 Dec-21 22-Jul-19 ### MRC/UVRI & LSHTM Ug https://Cl
19-Aug-19 22-Dec-20 ### 29-Apr-19 22-Jan-20 Centre National de Fohttps://Cl
Nov-11 Jun-12 Aug-12 23-Jan-12 16-Jul-18 National Taiwan Univehttps://Cl
Sep-11 Oct-12 Apr-13 ### 2-Jul-13 Centre of Clinical Va https://Cl
Nov-15 Dec-15 Mar-16 ### ### Bangkok, Thailand|Khhttps://Cl
Oct-07 Dec-07 Dec-07 6-Nov-07 ### Antwerpen, Belgium|M https://Cl
7-Jul-19 30-May-21 30-Jul-21 ### ### Biyang County Centerhttps://Cl
Jan-05 Jan-09 9-Sep-05 ### University Health Nethttps://Cl
Oct-96 Apr-99 Apr-99 17-Jun-08 17-Jun-08 GSK Clinical Trials Ca https://Cl
30-Apr-20 31-Aug-22 31-Jan-24 26-Jul-18 5-Dec-19 Washington University https://Cl
Nov-19 Feb-21 Feb-21 4-Sep-19 14-Oct-19 https://Cl
Oct-06 Jan-07 Jan-07 ### 21-Jan-08 Center for Immunizatihttps://Cl
Jan-07 Dec-07 Jan-13 1-Jan-07 7-Sep-12 Centers for Disease Chttps://Cl
16-Nov-16 25-Mar-19 ### 1-Dec-16 28-Jun-19 Mexico City, Mexico https://Cl
15-Oct-07 12-Dec-07 ### 16-Oct-07 7-May-13 26-Jun-19 GSK Investigational Sihttps://Cl
Mar-13 Jan-15 Jan-15 ### 2-Jan-17 University of Iowa - https://Cl
Jun-14 Dec-15 Dec-19 ### ### Madarounfa Health Dihttps://Cl
May-10 May-11 May-11 9-Jul-10 ### Children's Hospital ofhttps://Cl
Nov-15 Dec-15 Dec-15 ### ### Ben Luc Health centr https://Cl
Sep-10 Dec-11 Mar-12 15-Apr-13 21-Apr-17 ### Stanford University Schttps://Cl
2-Aug-16 14-Mar-19 ### 21-Jul-16 ### Hope Clinic - Emory Vhttps://Cl
16-May-11 22-Nov-11 4-May-12 ### 7-Aug-17 ### GSK Investigational Sihttps://Cl
Sep-06 Jan-07 6-Jul-06 29-Jan-07 GDRU Quintiles Ltd, https://Cl
24-Jan-11 10-Jan-17 10-Jan-17 ### 16-Jul-18 ### GSK Investigational Sihttps://Cl
Aug-09 Oct-09 Oct-10 9-Sep-09 ### 2-Dec-15 Instituto de Atencion https://Cl
26-Aug-19 30-Nov-20 30-Jun-21 2-May-19 30-Oct-19 Alabama CR "Informed https://Cl
Mar-05 Feb-07 Feb-07 ### ### Greater Huntsville Fa https://Cl
Jun-16 Nov-16 Dec-16 ### ### Sanjiang Center for Dhttps://Cl
Jan-07 Jun-14 Jun-14 1-Sep-06 ### Stanford University Schttps://Cl
Feb-16 Aug-21 Aug-24 2-Apr-15 31-Jan-20 FundaÃ§Ã£o de Medicina https://Cl
Tropical Doutor Heitor Viei
9-Dec-10 5-Jan-12 5-Jan-12 ### 6-Jun-14 ### GSK Investigational Sihttps://Cl
1-Sep-19 1-Feb-30 1-Feb-30 ### 6-Aug-19 https://Cl
2-Mar-16 17-May-16 ### ### 1-Nov-19 Broward Research Grohttps://Cl
Jun-13 Mar-14 Aug-14 19-Jun-13 20-Jun-13 Beijing Ditan Hospitalhttps://Cl
Sep-09 Nov-09 Nov-09 16-Oct-09 1-Dec-16 Osaka pref., Kagoshimhttps://Cl
5-Dec-15 12-Aug-16 ### ### ### Jiangsu Provincial Ce https://Cl
11-Jun-07 30-Mar-08 ### 13-Jun-07 ### 20-Jul-18 GSK Investigational Sihttps://Cl
20-Apr-15 11-Jan-17 11-Jan-17 28-Apr-15 1-Jun-18 Preventive Medicine Chttps://Cl
17-Jul-12 7-Mar-16 ### 22-Jul-11 ### Masonic Cancer Centehttps://Cl
11-Oct-17 9-Jan-19 9-Jan-19 30-Jan-18 31-Jan-19 Vaxinfectio - Antwer https://Cl
Nov-11 Jul-16 Jul-16 ### 9-Nov-16 8-Feb-17 Beth Israel Deaconesshttps://Cl
Oct-09 Jun-11 Jun-11 23-Oct-09 7-Oct-11 St.Jude Children's Re https://Cl
12-Oct-09 9-Nov-09 4-Nov-10 ### 6-Aug-18 6-Aug-18 GSK Investigational S https://Cl
Oct-06 Sep-11 Mar-12 20-Oct-09 6-Aug-12 GiÃ¨res, France|Lagorhttps://Cl
Aug-08 Aug-12 Aug-12 ### ### ### Memorial Sloan-Kettehttps://Cl
31-Mar-16 31-Mar-17 ### ### 27-Apr-17 https://Cl
Jan-13 Apr-13 Apr-13 23-Jan-13 1-Jul-14 East Valley Family Ph https://Cl
Jun-07 Oct-09 Feb-10 ### ### ### Sector-12, Chandigarhhttps://Cl
28-Jan-20 18-Sep-20 ### 18-Jan-20 18-Jan-20 University of Antwerphttps://Cl
Aug-15 May-17 May-17 18-Apr-18 18-Apr-18 Royal Liverpool Hospihttps://Cl
Feb-07 Feb-08 Feb-09 8-Mar-07 4-Mar-11 14-Jul-15 Helal Ahmar, Mecca, https://Cl
Jan-09 Jun-11 Jun-11 ### 1-Aug-16 ### Los Angeles County De https://Cl
Nov-11 Jul-12 Oct-12 ### ### Oklahoma Medical Res https://Cl
Jan-12 Dec-12 Dec-12 12-Jan-12 ### The University of Ho https://Cl
Aug-09 Jul-11 Jul-11 ### 2-Nov-11 Saint Louis Universit https://Cl
11-Sep-18 27-Sep-18 ### ### 2-Apr-19 2-Apr-19 Indiana Uni"Study Prohttps://Cl
Sep-06 Jun-08 Jun-08 27-Oct-06 12-Oct-09 12-Apr-17 https://Cl
Jan-10 Jan-10 Oct-10 21-Jan-10 14-Jun-17 Institute for Pharmaco https://Cl
2-May-16 Jun-20 Jun-20 ### ### Investigational Site 1 https://Cl
Sep-10 1-Sep-11 Oct-12 ### 3-Oct-18 Walter Reed Army Medi https://Cl
Dec-06 Mar-10 Mar-10 ### 6-Oct-14 13-Oct-14 Research Institute fo https://Cl
Jan-04 Dec-04 8-Aug-08 8-Aug-08 GSK Clinical Trials Ca https://Cl
Jun-05 Nov-06 Nov-06 5-Apr-06 1-Nov-13 9-Oct-18 Children's Hospital o https://Cl
15-Apr-19 31-Dec-23 ### ### ### Rigshospitalet, Cope https://Cl
Oct-15 8-May-17 Dec-17 ### ### Beijing Friendship Hoshttps://Cl
1-Oct-09 19-Apr-10 19-Apr-10 5-Oct-09 16-Jan-19 16-Jan-19 GSK Investigational Sihttps://Cl
27-Mar-17 15-May-17 1-Mar-18 ### ### University Hospital - https://Cl
9-Oct-08 15-Dec-09 ### 15-Oct-08 24-Apr-12 31-Jul-18 GSK Investigational S https://Cl
Mar-11 Jun-11 Jun-11 ### 2-Jan-12 Donghai Center for Dihttps://Cl
Oct-12 Dec-22 Dec-22 ### 5-Nov-19 Haukeland Universityhttps://Cl
4-Oct-19 Feb-22 Feb-22 29-Oct-19 6-Feb-20 Investigational Site https://Cl
Oct-08 Apr-16 Apr-16 ### ### ### University of Massachhttps://Cl
1-Mar-14 2-Jul-15 17-Jun-16 27-Jan-14 5-Jul-17 1-Mar-18 GSK Investigational Sihttps://Cl
Apr-07 Jun-08 Jun-08 ### ### ### Sidney Kimmel Compre https://Cl
21-Oct-19 31-Dec-21 ### ### 3-Dec-19 Washington University https://Cl
Feb-11 Nov-12 Nov-12 27-Jan-11 ### IU Medical Group Prim https://Cl
Feb-11 Aug-14 Dec-14 ### 29-Jan-14 Chulalongkorn Memori https://Cl
Oct-10 Dec-10 Mar-11 22-Oct-10 ### Hebei Province, Chin https://Cl
Nov-18 Mar-19 Jun-19 ### ### Suining Co"Study Prohttps://Cl
30-Jul-18 12-Mar-19 ### 18-Jul-18 7-Jan-20 Baney Clinical Researhttps://Cl
Nov-13 Mar-15 Dec-15 ### ### Center for Immunizatihttps://Cl
Oct-05 Feb-06 5-Oct-05 22-Jan-07 University Clinical R https://Cl
16-Oct-18 31-Jul-22 31-Jan-28 20-Apr-17 ### Washington University https://Cl
3-Sep-19 Oct-20 Oct-20 ### 5-Feb-20 Investigational Site https://Cl
4-Dec-18 26-Feb-20 ### 13-Jun-18 ### Cevaxin Vaccination Center,
https://Cl
David, ChiriquÃ, Panama|
28-Dec-16 12-Jul-17 ### ### ### https://Cl
Apr-11 Feb-13 May-13 15-Jun-11 7-Feb-19 VU University Medicahttps://Cl
4-Oct-17 20-Dec-19 30-Apr-20 5-Feb-18 ### Center for Immunizathttps://Cl
Apr-07 Apr-08 Oct-09 9-Mar-12 17-Oct-14 Makerere University https://Cl
2-Oct-18 2-Apr-19 2-Apr-19 ### 5-Jun-19 University of Californhttps://Cl
7-May-09 6-Jan-15 6-Jan-15 8-Apr-09 27-Apr-11 18-Jan-20 GSK Investigational S https://Cl
Nov-05 Aug-06 Aug-06 28-Jan-08 28-Jan-08 EPI immunization centhttps://Cl
23-Jan-07 23-Jan-08 ### 7-Nov-06 ### 6-Feb-18 GSK Investigational S https://Cl
28-Jun-11 12-Dec-17 ### ### 8-May-18 Moores UCS "Study Prohttps://Cl
15-Jun-18 Jan-20 Mar-20 ### 3-Oct-19 Malawi-Liverpool-Welhttps://Cl
Dec-08 Sep-09 Sep-09 10-Jul-08 3-Jan-13 Center for Immunizatihttps://Cl
Nov-04 Aug-05 Aug-05 ### 12-Jan-10 Rochester Medical Centhttps://Cl
Feb-11 Jun-12 Dec-13 9-Sep-11 ### ClÃnica Universidad dehttps://Cl
Navarra, Pamplona, Navarra,
Oct-15 Sep-19 ### 1-Feb-19 Johns Hopkins Bloombe https://Cl
Jan-11 Jul-12 Jan-13 13-Jan-11 13-Jan-11 Redwood Clinic, Balt https://Cl
Jan-07 May-08 May-09 26-Oct-06 11-Oct-13 11-Oct-13 Universidad Rey Juanhttps://Cl
16-Jul-11 25-Apr-12 25-Apr-12 21-Jul-11 2-Jul-17 https://Cl
Oct-06 Dec-06 11-Oct-06 7-Oct-16 GSK Investigational S https://Cl
5-Mar-20 26-Mar-22 ### 27-Jan-20 ### Cincinnati Children's https://Cl
Apr-07 Jun-10 Sep-10 ### ### Jiangsu Provincial Ce https://Cl
Nov-04 Dec-05 Dec-06 10-Jul-06 24-Jul-17 24-Jul-17 University of Bamako,https://Cl
17-Apr-15 31-Mar-20 ### 9-Mar-15 23-Oct-19 NIH Clinical Center, https://Cl
Jul-03 Sep-03 Sep-03 4-Feb-09 26-Oct-09 14-Apr-16 Norfolk, Virginia, Uni https://Cl
25-Apr-19 30-Jun-19 ### ### ### Alberta Health Servichttps://Cl
Oct-09 Nov-10 Apr-11 12-Oct-09 ### Berliner Centrum Rei https://Cl
Jun-08 Jun-11 Jun-11 1-Aug-08 ### ### Masonic Cancer Centehttps://Cl
1-Apr-20 1-Oct-20 20-Jun-22 ### ### Henan Province Centehttps://Cl
Oct-05 Jul-06 Jul-06 18-Oct-05 ### UCLA Center For Vaccihttps://Cl
2-Jun-18 2-Dec-18 ### ### ### Research Institute of https://Cl
29-Mar-16 2-Nov-16 2-Nov-16 ### 16-Jul-18 20-Jun-19 GSK Investi"Study Prohttps://Cl
Apr-13 Jan-16 Jan-16 23-Apr-13 7-May-19 University of Kentuckhttps://Cl
Apr-10 Jun-11 Jul-11 ### ### Mount Sinai Hospital,https://Cl
Oct-11 Dec-18 Dec-18 17-Jun-11 9-Jan-19 Institute of Hematolohttps://Cl
10-Mar-14 19-Jul-16 Apr-19 31-Jan-14 1-May-18 Service des Maladies https://Cl
I
18-Dec-18 Oct-19 Oct-19 26-Oct-18 11-Jan-19 icddr,b study clinics https://Cl
4-Oct-10 6-Jun-11 6-Jun-11 ### 17-Jun-13 ### GSK Investigational Site,
https://Cl
Chandler, Arizona, United Sta
Sep-92 Dec-97 Dec-97 16-Jun-08 16-Jun-08 GSK Clinical Trials Ca https://Cl
15-Nov-17 Mar-20 Apr-20 ### ### HÃ´pital St Louis, Par https://Cl
Jun-08 Dec-15 Jan-16 17-Apr-08 3-Dec-15 Cancer Treatment Cent https://Cl
Sep-10 Jun-14 Jun-14 ### ### Teen Health Centers, https://Cl
4-Jun-17 20-Feb-18 ### ### 29-Jul-19 29-Jul-19 Hospital of"Study Prohttps://Cl
Jan-08 May-08 Jun-08 ### ### 14-Apr-16 Grove City, Pennsylvahttps://Cl
Sep-09 Nov-09 Dec-10 9-Sep-09 ### 7-Dec-15 Miami Research Associ https://Cl
18-Apr-14 20-Apr-15 20-Apr-15 ### ### Saint Petersburg Stat https://Cl
Jul-10 Jun-12 Jun-12 ### 3-Jan-13 Center for Immunizatihttps://Cl
Jun-07 Mar-13 Mar-13 11-Apr-07 ### 14-Jan-16 Usc La Nichd Crs, Alh https://Cl
Dec-14 Jul-16 Sep-16 ### 9-May-17 Department of Paediat https://Cl
Oct-07 Sep-09 Sep-10 17-Jan-13 17-Jan-13 University of Michigahttps://Cl
5-Feb-18 Nov-20 Nov-21 3-Mar-17 ### PÃ´le de MÃ©decine https://Cl
I
Jun-10 Jul-10 Jul-10 17-Jun-10 ### Site Reference ID/In https://Cl
5-Apr-10 13-Dec-10 ### ### ### ### GSK Investigational Sithttps://Cl
8-Oct-07 10-Jun-08 10-Jun-08 8-Oct-07 ### 8-Jun-18 GSK Investigational S https://Cl
May-08 Apr-09 May-09 11-Jul-07 ### ### Chandler, Arizona, Unhttps://Cl
Feb-10 Mar-10 Jul-10 5-Feb-10 9-Oct-15 Sanatorium Leech, Grhttps://Cl
Oct-09 Dec-09 Dec-10 16-Oct-09 ### ### Bentonville, Arkansashttps://Cl
Jan-11 Mar-12 Mar-12 2-Feb-11 19-Jul-17 Vanderbilt Clinic, Co https://Cl
15-Oct-18 20-Mar-20 ### 26-Jul-18 5-Apr-19 Duke University Medic https://Cl
Sep-11 Oct-11 Oct-11 3-Aug-11 ### Family Doctor's Offic https://Cl
Sep-15 Jan-16 Jun-16 ### 18-Apr-17 ### Site 296, Huntsville, https://Cl
1-Nov-12 21-Feb-13 19-Jun-13 22-Oct-12 3-Apr-14 7-Sep-18 GSK Investigational S https://Cl
15-May-12 30-Oct-23 30-Oct-23 ### 20-Oct-17 https://Cl
14-Oct-19 Mar-20 Apr-20 ### 13-Jan-20 DÃ£o LafÃµes Groupin https://Cl
28-Jun-07 31-Aug-10 28-Jul-11 27-Apr-07 4-Sep-13 16-Jul-19 GSK Investigational Site, https://Cl
Godoy Cruz, Mendoza, Argen
Jul-14 Dec-15 Dec-15 21-Apr-14 30-Jan-17 30-Jan-17 Avail Clinical Resear https://Cl
20-Mar-12 31-Jan-16 31-Jan-16 16-Apr-12 ### ### National Institutes ofhttps://Cl
Jan-20 Jan-21 Jan-21 4-Dec-19 4-Dec-19 Dr. Moewardi Districthttps://Cl
Mar-11 Aug-11 Feb-14 5-Jan-12 23-Oct-17 Medical University V https://Cl
24-Jan-07 7-Mar-08 ### 17-Jan-07 ### 2-Jan-20 GSK Investigational Sihttps://Cl
6-Jan-14 Mar-20 Mar-25 4-Mar-13 6-Sep-19 University of Miami, https://Cl
Mar-02 Sep-04 Sep-04 1-May-02 9-Apr-10 ImClone Investigationhttps://Cl
3-Apr-17 16-Oct-17 ### 28-Oct-16 ### CEVAXIN, Panama, Pan https://Cl
Sep-10 Oct-10 Apr-11 ### 22-Jun-11 ACHIEVE Research, Alb https://Cl
May-12 Sep-12 Dec-12 ### ### ### Nagoya City, Aichi, J https://Cl
Feb-09 Jun-20 Jun-20 ### ### Children's Hospital o https://Cl
31-Jan-18 22-May-18 1-Sep-20 ### ### ### National In"Informed https://Cl
7-Nov-05 Aug-08 Jun-23 25-Apr-06 6-Aug-19 Brigham and Women's https://Cl
RV 156|10468 Mar-06 9-Mar-12 ### Makerere University https://Cl
Sep-11 Jan-13 Mar-16 ### ### The Sidney Kimmel Cohttps://Cl
Aug-09 Feb-15 Mar-15 27-Jul-11 2-Jun-15 Tri County Health dephttps://Cl
9-Apr-08 28-Aug-09 8-Jan-10 4-Apr-08 ### ### GSK Investigational S https://Cl
Feb-13 Feb-15 Oct-16 ### 4-Apr-16 2-Feb-17 H.Lee Moffitt Cancer https://Cl
Jan-10 Jun-10 Jun-10 14-Jan-10 ### The University of Ho https://Cl
2-Oct-19 31-Oct-21 31-Oct-21 6-Sep-19 15-Oct-19 Emory University Hosp https://Cl
12-Nov-09 26-Jun-10 26-Jul-10 ### ### ### GSK Investigational S https://Cl
8-Apr-13 Apr-23 Apr-23 ### 7-May-19 Oslo University Hospihttps://Cl
Jun-14 7-Dec-15 7-Dec-15 14-Jul-14 ### Center for disease cohttps://Cl
Jan-15 Jun-16 Jun-16 ### ### University of Rochesthttps://Cl
2-May-07 16-Apr-08 ### 24-Apr-07 2-Apr-18 8-Jun-18 GSK Investigational Sihttps://Cl
Aug-11 Jul-13 Jul-13 ### 2-Jun-16 Brigham and Women's https://Cl
1-Aug-17 1-Dec-18 1-Apr-19 12-Jun-17 ### Assiut university hosphttps://Cl
May-07 Sep-07 Dec-07 ### ### https://Cl
Sep-05 Jan-06 Feb-06 ### 5-Dec-14 Stanford University S https://Cl
25-Apr-14 31-Dec-15 ### 18-Jun-14 ### Seoul National Univershttps://Cl
26-Mar-15 6-Apr-17 6-Apr-17 6-Apr-15 11-Apr-19 Hope Clinic - Emory Vhttps://Cl
Jun-05 Sep-05 Sep-05 6-May-05 21-Jan-08 Johns Hopkins Schoolhttps://Cl
May-08 Oct-08 Oct-08 4-Jul-07 ### 13-Apr-17 https://Cl
Jul-09 Dec-09 Dec-09 26-Jun-09 ### HÃ´pital Gabriel Monhttps://Cl
Nov-08 Jan-09 Apr-09 ### 9-Oct-08 Hadassah U. hospital,https://Cl
22-Aug-16 5-Sep-18 5-Sep-18 8-Mar-18 8-Nov-19 The Rockefeller Univehttps://Cl
Feb-09 Jun-11 Jun-11 27-Jun-11 27-Jun-11 Far Eastern Memorialhttps://Cl
Dec-09 Jun-10 Jan-11 ### ### Clinica Indisa, Av. S https://Cl
Aug-12 Dec-14 Dec-14 ### 7-Jan-15 Centre for Clinical V https://Cl
1-Jul-17 15-Aug-18 ### 2-Jul-17 4-Jan-19 Jiangsu Provincial Ce https://Cl
Jul-09 Mar-16 Mar-16 4-Sep-09 ### 24-Apr-19 Sidney Kimmel Compre https://Cl
Oct-15 Nov-15 Nov-15 5-Oct-15 ### GSK Investigational S https://Cl
12-Feb-19 22-Feb-20 ### ### ### Coastal Clinical Rese https://Cl
Feb-07 ### 23-Apr-08 Center 7, Aschaffenb https://Cl
22-May-19 Jun-20 Aug-20 ### ### Alberta Health Servichttps://Cl
Nov-11 Apr-12 Apr-12 8-Nov-11 ### ### Centrum ockovani a chttps://Cl
28-Dec-01 8-Jun-04 11-Jun-04 ### ### https://Cl
21-May-13 28-Sep-18 ### 4-Apr-12 ### Samuel Oschin Compreh https://Cl
19-Sep-08 28-May-09 ### ### ### GSK Investigational S https://Cl
22-Sep-06 30-Jan-07 ### 24-Apr-17 GSK Investigational S https://Cl
2-Oct-18 1-Feb-21 1-Feb-21 ### ### GSK Investigational S https://Cl
Jan-14 Dec-14 Dec-14 ### 5-Oct-16 Quintiles Drug Researhttps://Cl
16-Sep-13 10-May-17 May-19 24-Oct-14 19-Oct-17 Henri Mondor Hospital https://Cl
6-Feb-12 17-Feb-14 ### 9-Jan-12 9-Jan-17 ### GSK Investigational Sihttps://Cl
Jul-11 Nov-11 May-12 22-Jul-11 ### Jiangsu Provincial Ce https://Cl
Nov-09 Feb-10 Feb-10 23-Oct-09 10-Apr-15 McMaster University,https://Cl
21-Apr-14 24-Sep-14 22-Jan-16 ### 25-Jan-18 ### Walter Reed Army Inst https://Cl
6-Sep-17 1-Jun-23 ### ### ### National Taiwan Univehttps://Cl
Mar-06 Oct-07 Oct-07 ### ### O.L.Vrouwziekenhuis A https://Cl
May-05 Jun-05 9-Aug-05 ### National Institute of https://Cl
3-Jun-19 1-Dec-22 1-Dec-22 4-Dec-17 5-Jun-19 Mayo Clinic, Rochestehttps://Cl
May-07 Mar-08 Mar-08 22-Apr-08 22-Apr-08 https://Cl
Aug-04 Aug-05 6-Dec-04 ### University of Kentuckhttps://Cl
Mar-13 Jul-13 Jul-13 ### ### Guangzhou Haizhu Dishttps://Cl
Sep-12 Mar-13 Jun-13 ### 4-Jun-15 7-Aug-15 Columbia University, https://Cl
20-Oct-06 1-Feb-07 5-Feb-07 11-Oct-06 29-Apr-13 8-Jun-18 GSK Investigational S https://Cl
Oct-06 Mar-07 ### 28-Oct-16 GSK Investigational Sihttps://Cl
21-Sep-17 31-Aug-19 ### ### ### 4th Department of Inthttps://Cl
Dec-03 Oct-09 Oct-09 11-Jun-04 10-Jun-13 26-Jun-18 Norris Cotton Cancer https://Cl
Feb-15 Dec-15 Jul-16 ### 11-Jul-16 Instituto Evandro Chahttps://Cl
8-Sep-17 2-Nov-17 19-Apr-18 ### ### ### Sanofi Past"Study Prohttps://Cl
Aug-10 Jul-12 Dec-12 ### ### ### Taichung, Taiwan|Tai https://Cl
Jan-12 Feb-12 Feb-12 18-Jul-12 20-Jun-19 20-Jun-19 Bel-Rea Institute, De https://Cl
22-Oct-08 6-Sep-11 ### 24-Oct-08 ### 10-Jun-19 GSK Investigational Sihttps://Cl
Nov-11 Dec-11 Apr-12 ### ### https://Cl
Jun-09 Nov-09 Nov-09 ### 29-Jan-10 Center for Immunizatihttps://Cl
Oct-97 Jul-06 Jun-09 22-Jan-03 8-Jun-11 St. Jude Children's R https://Cl
Jan-16 Sep-17 Nov-17 ### 16-Oct-18 University of Marylanhttps://Cl
30-Jun-08 27-May-09 ### 1-Jul-08 6-Jan-17 ### GSK Investigational S https://Cl
10-Nov-08 19-Aug-09 ### 24-Oct-08 9-Jul-13 ### GSK Investigational S https://Cl
28-Jul-11 2-Aug-12 5-Oct-12 23-Jun-11 ### 7-Sep-18 GSK Investigational Sihttps://Cl
Mar-02 Feb-06 Dec-15 19-Jan-11 ### https://Cl
Jun-09 Jul-09 Jul-09 15-Apr-09 ### Site Reference ID/In https://Cl
Feb-08 Mar-10 Mar-10 ### ### Health Protection Ag https://Cl
Oct-06 Mar-08 Mar-08 13-Oct-06 8-May-08 Perth, Western Austral https://Cl
Apr-06 Jan-07 3-May-06 12-Oct-16 GSK Investigational S https://Cl
7-Dec-18 13-May-25 ### ### ### National Institutes ofhttps://Cl
12-Aug-19 Dec-20 Dec-20 ### ### Queen Mary Hospital,https://Cl
Jan-11 Jun-12 Jun-12 ### ### University of Virginia,https://Cl
Jun-13 Dec-14 ### ### https://Cl
Mar-08 Mar-09 May-09 8-May-08 25-Jun-09 Smt NHL Municipal Me https://Cl
Jan-04 May-09 Jan-18 ### ### 5-Feb-19 UNMC Eppley Cancerhttps://Cl
C
14-Jun-16 22-Jul-19 ### 5-Feb-20 Dana-Farber Cancer In https://Cl
Feb-15 Oct-15 Dec-15 9-Mar-15 9-Mar-15 Malaquias Lopez Cervhttps://Cl
Jun-16 Dec-18 Mar-19 13-Jun-16 20-Jun-17 Sherief Abd-Elsalam, https://Cl
28-Oct-19 20-Dec-19 May-20 18-Jul-19 ### Investigational Site https://Cl
Aug-09 May-10 May-10 22-Jul-09 ### 22-Apr-13 Emory Children's Cente https://Cl
27-Oct-05 7-Apr-06 7-Apr-06 ### 2-Jan-20 GSK Investigational S https://Cl
Sep-07 Oct-09 Apr-11 18-Oct-07 5-May-11 The Rockefeller Univehttps://Cl
Sep-13 Mar-14 May-14 ### 24-Jun-14 Columbia University, https://Cl
Jun-08 May-11 May-24 23-Jun-08 5-Mar-19 Texas Children's Hospihttps://Cl
8-Dec-17 2-Mar-18 13-Jul-18 ### ### ### Prism Rese"Study Prohttps://Cl
23-Dec-06 7-Sep-07 ### 26-Jul-06 4-Jun-18 3-Jul-18 GSK Investigational Sihttps://Cl
Jun-06 Dec-09 Dec-09 ### 3-Jan-13 Center for Immunizatihttps://Cl
Apr-11 Jun-12 Jan-13 9-Jul-10 15-Apr-11 SZMC, Jerusalem, Israhttps://Cl
28-May-19 27-May-20 30-Jun-20 ### ### https://Cl
11-Jun-14 20-Mar-15 ### 1-Apr-14 6-Jul-17 Emory Children's Centhttps://Cl
18-Jun-13 29-Jun-15 29-Jun-15 ### 9-Jan-17 9-Jul-19 GSK Investigational S https://Cl
Nov-11 May-13 Nov-13 ### 12-Jan-15 Nanning, Guangxi, Chhttps://Cl
15-Sep-17 28-Nov-17 ### 28-Jul-17 ### ### Sanofi Past"Study Prohttps://Cl
Oct-04 Sep-09 Sep-09 1-Dec-04 2-Jul-12 Johns Hopkins Univershttps://Cl
Jan-08 Dec-11 Apr-14 ### 1-Apr-16 University of Cancer Ihttps://Cl
Nov-14 Dec-16 Dec-16 ### ### Bundang CHA Generalhttps://Cl
Feb-10 Sep-10 Mar-12 ### ### ### Advanced Clinical Reshttps://Cl
Sep-14 Jun-15 Jun-15 17-Oct-14 ### Sheffield Teaching Hohttps://Cl
Jul-16 Oct-19 Oct-23 17-Apr-15 18-Jul-16 https://Cl
Jun-11 Sep-11 Dec-11 ### ### GuangXi Center for Dihttps://Cl
30-Nov-10 12-Apr-11 12-Apr-11 1-Dec-10 ### 5-Mar-19 https://Cl
Dec-08 May-09 Jun-09 2-Dec-08 29-Oct-15 Quality of Life Medic https://Cl
26-Oct-18 Jan-20 Jun-20 9-Oct-18 ### University Hospital B https://Cl
8-Oct-13 Jul-19 Jul-19 31-Oct-13 9-Nov-18 UO Immunoterapia e https://Cl
la
Mar-14 Apr-16 Nov-16 ### 26-Apr-17 Daejeon, Korea, Repub https://Cl
16-Feb-06 29-Jan-14 29-Jan-14 ### ### 2-Jan-20 GSK Investigational S https://Cl
20-Jun-14 Aug-16 27-Jun-18 5-Dec-13 18-Oct-18 University of Oxford, https://Cl
20-Aug-12 21-Apr-15 1-Mar-20 ### 9-Dec-19 Roswell Park Cancer Ihttps://Cl
28-Feb-20 28-Apr-21 28-Apr-31 ### ### Lineberger Comprehens https://Cl
Aug-16 Aug-17 Dec-17 ### 25-Jul-19 25-Jul-19 Rushan Cen"Study Prohttps://Cl
15-Oct-07 1-Nov-07 ### 2-Oct-07 5-Sep-12 8-Jun-18 GSK Investigational S https://Cl
Mar-20 Mar-24 Mar-24 30-Jan-20 ### Sidney Kimmel Compre https://Cl
Jan-09 Mar-10 Sep-13 ### 3-Jun-14 University Hospitals Lhttps://Cl
1-Dec-12 1-Jan-15 1-Jan-15 26-Jun-19 26-Jun-19 https://Cl
Dec-13 Oct-14 Mar-15 5-Mar-14 27-Jan-16 https://Cl
Nov-07 Apr-08 Apr-08 14-Jan-09 14-Jan-09 University of Arizona,https://Cl
Sep-06 Jun-09 Sep-09 3-Oct-06 14-Jan-14 Antwerpen, Belgium|A https://Cl
Jul-10 Nov-10 Dec-10 3-Feb-10 4-Oct-10 Christian Medical Collhttps://Cl
Mar-15 Feb-16 Feb-16 8-Apr-16 19-Apr-17 Maharaj Nakorn Chianhttps://Cl
Sep-07 Jun-08 Dec-09 ### 19-Jan-11 https://Cl
Nov-97 Apr-09 Apr-09 10-Jul-08 ### City of Hope Comprehe https://Cl
4-Jun-19 Jun-20 Dec-20 2-Nov-18 ### Queen Saovabha Memor https://Cl
Jan-07 Feb-11 Dec-11 ### ### ### Dr Atul's Child Hospi https://Cl
31-Jan-18 11-Apr-18 11-Apr-18 ### ### Drug Research Cente https://Cl
Oct-00 Jun-03 Jun-07 6-Mar-14 6-Mar-14 Marine Recruit Traininhttps://Cl
Dec-15 Jul-16 ### ### https://Cl
Jun-09 Nov-14 Nov-14 15-Jul-09 17-Apr-17 Radboud University Nhttps://Cl
Jun-10 Jul-10 Jul-10 7-Jun-10 6-Oct-15 Antwerpen, Belgium|https://Cl
Sep-08 Aug-14 Jan-15 8-Dec-08 ### Oakland, California, Uhttps://Cl
Apr-07 May-10 May-10 9-May-07 7-Jun-11 Memorial Sloan Kettehttps://Cl
Jul-16 May-19 May-20 ### 5-Feb-19 Ann & Robert H. Luriehttps://Cl
Sep-15 Aug-16 Aug-16 22-Apr-16 4-Oct-18 4-Oct-18 Seoul National Univers https://Cl
Sep-09 Nov-10 Nov-10 ### ### The University of Ho https://Cl
Oct-14 20-Apr-16 20-Apr-16 17-Oct-14 ### Center for Vaccine D https://Cl
8-Feb-18 8-Aug-19 14-Oct-19 7-Jan-20 13-Jan-20 Disease prevention anhttps://Cl
Jul-09 1-Nov-19 1-Nov-19 4-Dec-09 ### Hasbro Children's Hoshttps://Cl
Nov-14 Mar-15 Mar-15 6-Nov-14 ### Columbia University https://Cl
Mar-13 Mar-21 Mar-22 22-Oct-13 ### The Rockefeller Univehttps://Cl
Oct-09 Dec-09 Jul-10 ### ### https://Cl
Mar-14 Mar-21 Jun-22 25-Jul-14 ### Johns Hopk"Informed https://Cl
31-Aug-07 31-Dec-07 ### ### ### ### GSK Investigational S https://Cl
May-10 Jun-10 Jun-10 ### 6-Oct-15 Gieres, France|MONTP https://Cl
Mar-07 Aug-11 Aug-11 29-Jan-07 5-Sep-12 5-Sep-12 Pfizer Investigational https://Cl
Oct-10 Nov-10 Nov-10 2-Sep-10 3-Apr-12 17-Jan-14 Center for the Evaluahttps://Cl
Jan-20 Mar-23 Mar-23 ### ### MRC/UVRI and LSHTM https://Cl
30-Aug-06 25-Aug-07 ### 4-Aug-06 ### ### GSK Investigational S https://Cl
Dec-16 Apr-20 May-20 28-Apr-17 ### University of Rochesthttps://Cl
28-Sep-11 6-Jul-13 6-Jul-13 28-Oct-11 ### ### Coastal Clinical Rese https://Cl
28-Oct-19 Sep-20 Sep-21 11-Jun-19 ### University of Marylanhttps://Cl
1-Jan-09 2-Aug-12 2-Aug-12 1-Dec-08 ### 12-Jul-18 GSK Investigational S https://Cl
1-Aug-17 Jun-20 Dec-20 24-Jul-17 ### Queen Saovabha Memor https://Cl
Nov-16 Oct-19 18-Oct-16 10-Apr-19 Sunnybrook Health Schttps://Cl
Nov-01 Nov-05 27-Jan-03 25-Jan-13 Fox Chase Cancer Cent https://Cl
Dec-12 Jun-13 ### 11-Apr-17 Fred Hutchinson Canchttps://Cl
Apr-19 May-20 May-20 ### ### https://Cl
Jun-06 Jul-07 Aug-07 7-Jun-06 4-Nov-16 GSK Investigational S https://Cl
Sep-11 Aug-14 Aug-14 23-Jan-13 13-Apr-17 University of Utah, Sahttps://Cl
5-Dec-14 23-Jun-16 23-Jun-16 ### 2-Jan-20 5-Feb-20 https://Cl
Mar-06 Jun-06 Jun-06 15-Oct-08 ### ### https://Cl
Jun-11 Aug-11 May-12 27-Jun-11 9-Oct-15 Medical Co. LTA PS Clhttps://Cl
May-09 Jun-09 Jul-09 24-Jul-09 14-Jan-14 Angers, France|Tiercehttps://Cl
Nov-15 Aug-20 Aug-21 4-Aug-15 28-Jun-19 University of Virginia https://Cl
18-Nov-16 Sep-21 Sep-22 8-Nov-16 3-Aug-17 The University of Ho https://Cl
Nov-09 Feb-11 Mar-11 8-Oct-09 27-Jul-16 Univ. of Rochester HVhttps://Cl
2-Sep-16 30-Dec-20 ### ### ### Fred Hutch/Universityhttps://Cl
Nov-07 Jun-08 Dec-08 3-Dec-07 ### Radiant Research Tucshttps://Cl
May-09 6-Oct-17 6-Oct-17 ### ### ### Alabama CR "Study Prohttps://Cl
Nov-99 Sep-00 May-01 16-Jun-08 ### https://Cl
4-Aug-09 7-Apr-10 ### 9-Sep-09 8-Aug-17 SNBL, Baltimore, Mary https://Cl
May-10 Sep-10 Dec-11 4-Mar-10 ### ### Vaccine Trial Centre, https://Cl
9-Mar-07 4-Sep-07 4-Sep-07 7-Feb-07 ### 2-Jan-20 GSK Investigational Sihttps://Cl
Sep-06 Feb-10 Feb-10 ### ### The Sidney Kimmel Cohttps://Cl
12-Nov-07 26-Feb-09 20-Jul-09 1-Nov-07 5-Mar-10 25-Jun-18 GSK Investigational Sihttps://Cl
May-09 Aug-10 Oct-10 ### ### German Jordanian Unihttps://Cl
14-Jul-09 26-Apr-11 ### 15-Jun-09 ### ### GSK Investigational Sihttps://Cl
Mar-16 Jun-16 Sep-16 28-Jan-16 ### https://Cl
Feb-20 Oct-20 Nov-20 ### ### University of Florida, https://Cl
17-Feb-09 23-Jul-09 15-Oct-09 3-Feb-09 5-Aug-10 3-Jan-20 GSK Investigational Sihttps://Cl
Apr-16 4-Oct-18 1-May-20 ### ### Insight Therapeutics, https://Cl
16-Jan-17 12-Apr-17 ### 1-Dec-16 16-Oct-18 8-Oct-19 GSK Investi"Statistic https://Cl
7-Feb-14 16-Jun-15 21-Apr-16 3-Feb-14 24-Apr-18 24-Apr-18 GSK Investigational Sihttps://Cl
Oct-10 Feb-13 Nov-13 ### ### ### University of Pittsbu https://Cl
Nov-09 May-10 May-10 ### 18-Jul-13 Universtity Clinical https://Cl
Apr-03 Apr-04 Aug-04 7-Apr-03 30-Jun-11 Walter Reed Army Inst https://Cl
1-Oct-14 16-Mar-15 23-Jun-15 ### 12-Apr-16 7-Sep-18 GSK Investigational Sihttps://Cl
Jul-07 ### ### Local Institution, Kubhttps://Cl
Jun-10 Mar-12 Mar-12 4-Dec-09 ### Noguchi Memorial Inshttps://Cl
Mar-06 Dec-06 Dec-06 ### ### University of Marylanhttps://Cl
Jun-06 Jun-09 Jun-10 ### 6-Nov-17 University of Michigahttps://Cl
Oct-08 Sep-11 Sep-12 27-Jun-08 ### 24-Apr-14 Michael E DeBakey VAhttps://Cl
Aug-05 Oct-05 5-Aug-05 ### GSK Investigational S https://Cl
Feb-12 Aug-14 Aug-14 27-Jun-11 29-Jan-16 Saint Louis Universityhttps://Cl
16-Jul-19 4-Mar-21 4-Mar-21 17-Jan-19 26-Jul-19 San Juan Hospital, Rehttps://Cl
27-Aug-10 30-Dec-10 ### 30-Jun-10 ### ### GSK Investigational S https://Cl
Aug-15 Mar-17 Mar-17 ### ### ### Espoo Vacc"Study Prohttps://Cl
19-Sep-17 14-Sep-18 6-Feb-19 10-Jul-18 ### University of Rochesthttps://Cl
1-May-17 Sep-19 Sep-20 ### 7-Feb-19 Shanghai Children's Mhttps://Cl
12-Dec-11 15-Mar-12 ### 5-Dec-11 ### GSK Investigational S https://Cl
Jun-07 Apr-17 Dec-17 27-Jun-07 ### Children's Hospital o https://Cl
Oct-07 Sep-13 Sep-22 ### 6-Oct-11 University of Navarrahttps://Cl
Oct-09 Dec-09 Dec-09 ### 8-Feb-10 National Hospital Or https://Cl
16-Jul-12 1-Mar-14 ### ### ### 9-Jan-19 Emory University, Atl https://Cl
Jul-13 Nov-16 Apr-17 26-Jul-13 6-Jul-17 LSU Stanley S. Scott https://Cl
May-11 Sep-11 Sep-11 2-May-11 18-Oct-13 18-Jun-18 Dr. Johannes Kandzorhttps://Cl
1-Oct-07 25-Feb-10 26-Jul-10 4-Jun-07 ### 20-Jul-18 GSK Investigational S https://Cl
1-Sep-08 7-Mar-09 7-Mar-09 ### ### ### GSK Investigational Sihttps://Cl
Sep-08 Jul-14 Jul-14 4-Nov-08 6-Jun-19 6-Jun-19 Masonic Cancer Centehttps://Cl
Oct-07 May-08 May-08 3-Apr-07 ### University of Miami, https://Cl
Jun-08 Jun-09 Sep-10 20-Jun-08 29-Jul-16 29-Jul-16 Fowey River Practice https://Cl
Jul-02 ### ### The Hospital for Sick https://Cl
Feb-13 Jun-15 Oct-15 5-Oct-12 9-Feb-17 ### California Departmenthttps://Cl
Sep-11 Jun-12 Dec-12 ### ### ### Little Rock, Arkansas https://Cl
Jan-15 Jul-16 Apr-17 ### 13-Oct-16 Radbdoudumc, Nijmeg https://Cl
Oct-14 28-May-16 ### 24-Oct-14 29-Jun-17 Aichi, Japan|Chiba, https://Cl
Sep-16 Jan-21 Jan-22 9-Aug-16 ### UCSF Children's Hospihttps://Cl
Jan-02 Apr-02 Apr-02 17-Jan-11 7-Sep-16 https://Cl
Oct-09 Mar-10 Apr-10 21-Jun-11 4-Jul-16 Preventive Medicine https://Cl
Oct-98 Jun-10 Jun-10 ### ### ### Scott & White Hospitahttps://Cl
Jul-09 May-10 Aug-10 26-Jan-10 2-Aug-16 Pingle Center for Dis https://Cl
Nov-10 Dec-11 Feb-12 ### 14-Jan-14 14-Jul-15 Dothan, Alabama, Unit https://Cl
Dec-15 Aug-16 Dec-16 23-Oct-07 4-May-15 National Institute of https://Cl
Feb-09 Feb-11 Apr-15 3-Dec-08 21-Jun-16 Alabama CRS, Birmingh https://Cl
May-05 May-09 May-10 ### 12-Jul-11 Papua New Guinea Ins https://Cl
30-Nov-16 31-Dec-19 1-Jun-20 6-Nov-16 ### China West Hospital, https://Cl
Oct-09 Feb-11 Feb-11 5-Feb-10 ### Hopital Pitie Salpetri https://Cl
Apr-08 Feb-09 Mar-09 5-May-08 4-Jun-14 4-Jun-14 Cancer Center of Carol https://Cl
5-Jul-16 30-Mar-18 ### 19-Apr-16 1-Jun-18 University of Iowa - https://Cl
1-Jun-17 1-Dec-19 1-Dec-20 ### ### https://Cl
Jan-17 1-May-17 1-May-17 ### ### Emory University, Atl https://Cl
2-Jul-08 May-15 Mar-20 4-Aug-08 5-Jun-19 ### Sidney Kimmel Compre https://Cl
Jan-16 Feb-20 Feb-20 ### ### Trialoffice Haematol https://Cl
1-Apr-09 25-Jun-09 25-Jun-09 ### 4-Apr-17 6-Jun-18 GSK Investigational Sihttps://Cl
15-Jul-18 30-Sep-20 ### 26-Jul-18 9-Jan-20 International Centre https://Cl
Mar-09 Jun-10 Jun-10 19-Jan-09 18-Jul-11 ### Pfizer Investigationa https://Cl
Nov-13 Mar-14 Mar-14 2-Apr-14 ### Vaccine Trial Centre, https://Cl
May-12 Nov-12 Nov-12 18-Apr-12 3-Feb-14 3-Feb-14 Research Site, Miami,https://Cl
Jun-04 Sep-07 Sep-09 24-Jan-07 4-Mar-14 Dana-Farber Cancer In https://Cl
23-Oct-13 27-Feb-14 3-Jul-14 3-Nov-13 13-Apr-15 7-Sep-18 GSK Investigational Sihttps://Cl
26-Oct-07 3-Jun-09 3-Jun-09 ### ### 11-Jan-19 https://Cl
Feb-08 Dec-08 Dec-08 25-Jan-08 4-Sep-09 GSK Investigational S https://Cl
Sep-11 Feb-14 Feb-14 ### 4-Mar-16 Policlinico di Modena,https://Cl
Jun-06 Aug-06 Aug-06 5-Jun-06 ### Stanford University, https://Cl
1-Jan-08 30-Apr-08 30-Apr-08 7-Feb-08 ### 6-Jun-18 GSK Investigational Sihttps://Cl
24-Aug-15 Nov-20 Nov-20 8-Apr-15 ### Cancer Institute of N https://Cl
Dec-13 14-Feb-17 Oct-19 14-Jan-14 18-Jan-20 Medizinische Univershttps://Cl
8-Sep-09 16-Nov-09 8-Oct-10 3-Sep-09 4-Mar-11 ### GSK Investigational S https://Cl
17-Oct-18 Apr-22 Apr-22 ### ### Investigational Site https://Cl
1-Feb-17 1-Feb-19 1-Feb-19 3-Feb-17 ### Department of Hemato https://Cl
Apr-05 Sep-06 Sep-06 15-Jul-05 ### George Washington Uni https://Cl
1-Aug-19 10-Jun-21 26-Oct-21 11-Jun-19 22-Jan-20 Optimal Research, Hun https://Cl
Jul-14 18-Feb-19 ### ### 28-Jan-20 ### UPMC Hillm "Study Prohttps://Cl
Jun-09 Mar-12 Apr-12 13-Apr-10 ### National Taiwan Univehttps://Cl
8-Jan-14 Apr-20 Apr-21 ### 8-Nov-19 Cedars-Sinai Medical hCttps://Cl
Aug-15 Oct-16 Oct-16 ### 6-Feb-17 Wonju Sevrance Christ https://Cl
Jul-00 Jan-02 ### ### ### BIDMC, Boston, Massa https://Cl
Aug-11 Jun-15 Aug-15 25-Oct-11 ### John Hopkins Center https://Cl
9-Dec-10 9-Jan-12 9-Jan-12 11-Oct-10 2-Apr-13 1-Aug-18 GSK Investigational S https://Cl
Oct-02 Dec-03 ### 5-Dec-14 Kaiser Permanente Vac https://Cl
Aug-09 Mar-10 Jun-10 6-Aug-09 11-Jul-11 14-Apr-16 Miami Beach, Florida,https://Cl
19-Jul-19 Dec-21 Dec-21 28-Jun-19 ### Instituto de Cardiologia
https://Cl
do Distrito Federal, Brasilia, D
5-Apr-16 26-Jul-18 26-Oct-19 2-Sep-15 18-Oct-19 UT Southwestern Medic https://Cl
1-Nov-18 30-Sep-21 ### 14-Jan-19 21-Jan-20 Ralph H. Johnson VA M https://Cl
19-Jan-17 14-Nov-17 ### 19-Jan-17 ### Cevaxin, Panama Cityhttps://Cl
GSK Investigational Site, Mesa, Arizona, United States
1-Aug-10 9-May-14 27-Jul-15 19-Jul-10 1-May-17 11-Jul-18 Floersheim, Hessen, Germany|GSK
https://Cl Investigational Sit
12-Jun-18 20-Sep-18 ### 30-Jan-19 31-Jan-19 Pizhou Center for Dishttps://Cl
Oct-04 Dec-14 Dec-20 11-Apr-07 ### 28-Jan-20 Beth Israel Deaconesshttps://Cl
4-Oct-10 15-Jun-11 15-Jun-11 9-Sep-10 ### ### GSK Investigational S https://Cl
Mar-06 Sep-07 Sep-07 9-Mar-06 1-Jun-15 H. Lee Moffitt Cancerhttps://Cl
18-Sep-06 15-Nov-07 ### 28-Jun-06 15-Jan-19 15-Jan-19 GSK Investigational Sihttps://Cl
May-13 Apr-14 Dec-14 15-Apr-13 6-Aug-15 Centro de Estudios e https://Cl
21-Dec-17 31-May-19 ### ### ### UT Southwestern Medic https://Cl
Jun-04 Nov-06 2-Jan-06 ### Norwegian Institute https://Cl
Feb-01 Dec-01 Apr-02 ### 11-Jun-13 Universitaetskliniku https://Cl
19-Jan-17 31-Dec-20 ### 27-Oct-16 ### Center For Human Rep https://Cl
20-Apr-10 Apr-23 Apr-23 ### 22-Apr-19 Sidney Kimmel Compre https://Cl
Mar-14 Jul-18 Feb-19 ### ### DC Klinieken Oud Zui https://Cl
6-Jun-18 26-Sep-18 ### 30-Jan-19 30-Jan-19 Guanyun Center for Dihttps://Cl
Oct-05 Jul-06 Mar-08 31-Oct-08 3-Nov-08 Department of Infectihttps://Cl
15-Jun-15 19-Jan-18 19-Jan-18 15-Apr-15 7-Nov-19 Creteil, France|Mars https://Cl
14-Sep-17 2-Sep-19 2-Sep-19 ### ### Guangdong Province hCttps://Cl
Nov-09 Dec-10 Feb-11 31-Jul-09 9-Oct-15 General Practice, Blu https://Cl
Feb-20 Feb-26 Mar-26 ### ### I-REIVAC/CIC1417 Coch https://Cl
Feb-14 Dec-15 May-16 11-Oct-13 21-Apr-17 21-Apr-17 Duke University Healthttps://Cl
1-May-15 1-May-18 1-May-18 ### 6-Apr-18 6-Apr-18 "Statistic https://Cl
Jan-15 Jan-16 Jan-16 ### 19-Apr-17 Maharaj Nakorn Chianhttps://Cl
Jun-08 Aug-09 Aug-09 10-Jun-08 22-Jun-17 Massachusetts General https://Cl
Sep-10 Jan-11 Dec-11 ### 1-Dec-16 University of Tamperehttps://Cl
7-Oct-04 15-Dec-05 ### ### 6-Aug-10 ### GSK Investigational S https://Cl
Jun-16 Dec-19 Jun-20 18-Jun-18 18-Jun-18 University Medical C https://Cl
Jun-12 Oct-13 Mar-14 1-Sep-10 ### Multiple General Prachttps://Cl
4-Apr-19 Nov-20 Nov-22 1-Apr-15 8-May-19 Women & Infants Cent https://Cl
13-Nov-16 25-Mar-17 ### 18-Jan-20 18-Jan-20 SB Istanbul Training ahttps://Cl
Aug-09 Nov-09 Apr-10 ### 9-Aug-11 ### Chandler, Arizona, Unhttps://Cl
Dec-06 Jun-08 Jun-08 ### 10-Jul-09 ### https://Cl
Nov-06 Apr-08 Jul-08 ### 9-May-14 9-May-14 Estado de Mexico, Mehttps://Cl
Nov-07 Jul-11 Feb-13 ### ### University of Pennsyl https://Cl
Sep-97 Feb-98 Feb-98 ### ### https://Cl
Jan-05 Aug-07 Aug-07 ### ### Rockefeller Universit https://Cl
19-Jan-17 31-Dec-20 ### 27-Oct-16 ### Center For Human Rep https://Cl
8-Aug-16 10-Mar-17 ### 8-Feb-16 ### ### GSK Investig
Sep-14 Feb-15 Mar-15 11-Apr-14 27-Jun-19 Ulster Hospital, Bel https://Cl
29-Jan-20 1-Jan-27 1-Jan-27 23-Jan-20 7-Feb-20 Boston Children's Hoshttps://Cl
Apr-16 Apr-18 Apr-18 1-Apr-16 ### National Jewish Healthttps://Cl
1-Aug-17 31-Dec-18 ### 31-Jan-17 ### Center for Vaccine Dehttps://Cl
Nov-99 Dec-04 Oct-09 1-Nov-02 27-Jul-12 Texas Children's Hospihttps://Cl
Sep-13 Nov-13 Nov-13 18-Jan-17 9-Mar-17 21-Apr-17 https://Cl
Sep-13 Aug-18 Aug-18 1-May-14 6-Mar-19 UZA, Antwerp, Belgiuhttps://Cl
Dec-08 Dec-14 Dec-15 26-Jun-09 30-Jan-18 Twentynine Palms, Calhttps://Cl
Mar-12 Feb-13 Sep-13 ### 1-Dec-14 ### Department of Pediatr https://Cl
Jan-11 Feb-13 Feb-13 11-Jan-10 ### GSK Investigational Sihttps://Cl
20-Aug-09 5-Mar-13 5-Mar-13 ### 5-Jul-18 https://Cl
17-Sep-08 16-Jan-12 16-Jan-12 8-Aug-08 ### 5-Nov-19 GSK Investigational Sihttps://Cl
14-Dec-18 Mar-22 Mar-22 6-Jun-18 10-Jan-20 Investigational Site https://Cl
1-Sep-18 21-Dec-18 ### 18-Jul-18 ### Seoul National Univers
GSK Investigational https://Cl
Site, Mesa, Arizona, United States
16-Mar-16 15-Mar-19 ### ### ### Investigational Site, Koethen,
https://ClSachsen-Anhalt, Germa
30-Jun-04 31-Dec-10 ### ### 2-May-12 8-Mar-19 Proyecto Epidemiologihttps://Cl
Nov-06 Nov-08 Nov-08 5-Dec-06 2-Dec-09 Soroka Medical Center https://Cl
Aug-05 Feb-06 7-Dec-06 7-Dec-06 Centre for Clinical V https://Cl
5-Jun-18 5-Apr-21 5-Apr-21 28-Jun-18 2-Oct-19 Qps Mra, Llc, South Mhttps://Cl
11-Jun-15 28-Apr-17 21-Jul-17 5-Dec-14 9-Oct-19 Mayo Clinic in Arizonahttps://Cl
Dec-11 Oct-12 Oct-12 12-Oct-11 ### Clinical Research Cenhttps://Cl
Aug-09 14-Dec-17 ### 22-Jun-07 13-Jan-20 13-Jan-20 Stanford Un "Study Prohttps://Cl
Jun-08 Aug-08 Sep-08 18-Jul-08 17-Jan-14 Edinburgh, United K https://Cl
May-14 Oct-14 Oct-14 ### 24-Oct-14 Aalst, Belgium|Gent, https://Cl
10-Sep-18 12-Nov-18 ### 6-Aug-18 ### ### Investigat "Study Prohttps://Cl
Mar-11 Oct-13 Mar-14 ### 28-Oct-14 28-Oct-14 Kaiser Permanente Vac https://Cl
Sep-11 Jan-12 Jan-12 27-Jul-11 ### ### Investigational Site https://Cl
Mar-14 Jul-15 Jul-15 ### 18-Jul-18 CHUV CRC, Lausanne,https://Cl
28-Oct-05 1-Mar-07 1-Mar-07 8-Nov-05 ### 2-Jan-20 GSK Investigational Sihttps://Cl
31-Mar-17 31-Jul-21 31-Jul-24 6-Jan-17 ### Mayo Clinic in Arizon https://Cl
1-Aug-19 31-Aug-21 ### ### ### University of Coloradhttps://Cl
1-Aug-17 Mar-20 Mar-20 ### ### Augusto Leopoldo Ayrhttps://Cl
Jan-13 Apr-14 Apr-14 16-Jan-13 22-Jul-15 Univeristy of Michigahttps://Cl
27-Nov-17 9-Mar-20 10-Apr-20 ### 18-Jan-20 GSK Investigational S https://Cl
1-Dec-10 13-Jun-16 13-Jun-16 ### 3-Dec-19 National Institutes ofhttps://Cl
Sep-12 Jan-14 Jan-14 15-Oct-12 6-Mar-14 Pfizer Investigational https://Cl
Nov-14 26-Oct-18 26-Oct-18 7-Jan-15 5-Dec-18 Phramongkutklao Hosp https://Cl
Apr-03 Mar-05 Feb-10 ### 7-Jul-11 2-Feb-15 https://Cl
Aug-11 Dec-12 Aug-13 30-Jun-11 ### Department of Infectihttps://Cl
Nov-08 Apr-09 Feb-12 26-Jan-09 16-Oct-12 Westside OBGYN, Burl
GSK Investigational https://Cl
2-Aug-10 24-Jul-15 24-Jul-15 19-Jul-10 ### 12-Jul-18 Potsdam, Brandenburg, https://Cl
Germany|GSK Investigationa
1-Mar-18 22-May-20 ### 19-Jul-17 ### Icahn School of Medichttps://Cl
17-Jan-11 17-Jul-12 4-Jun-15 ### ### ### GSK Investigational S https://Cl
5-Jun-14 14-Oct-16 14-Oct-16 8-Apr-14 ### ### GSK Investigational S https://Cl
25-Sep-13 4-Dec-13 23-Oct-14 ### ### ### GSK Investigational Sihttps://Cl
Jul-08 Apr-13 Oct-13 15-Jul-08 ### ### GSK Investigational Sihttps://Cl
1-Feb-16 28-Oct-16 ### 22-Jan-16 6-Feb-18 Simon Williamson Clinhttps://Cl
1-Feb-17 18-Dec-19 ### 3-Feb-17 16-Apr-19 Immunitor LLC, Ulaanhttps://Cl
17-Nov-06 14-Sep-09 ### 8-Nov-06 ### 10-Jun-19 GSK Investigational Sihttps://Cl
Oct-14 May-15 May-15 ### ### 27-Oct-16 Benchmark Research https://Cl
-
24-Mar-17 21-Mar-19 ### 8-Sep-16 19-Apr-19 Emory Children's Cente https://Cl
27-Sep-18 9-Aug-20 ### 1-Aug-18 ### Doral Medical Researchttps://Cl
Sep-07 May-08 Oct-08 ### 9-Oct-15 University Hospital, https://Cl
Oct-04 Nov-05 Mar-07 28-Jan-09 ### ### CÃ³rdoba, Argentina https://Cl
Sep-11 Feb-12 Feb-12 ### ### ### Pfizer Investigational https://Cl
Sep-11 Dec-11 Dec-11 16-Jan-17 ### ### https://Cl
Oct-09 Dec-09 Dec-09 23-Oct-09 ### Maxima Medisch Centr https://Cl
Sep-13 Nov-15 Dec-15 2-Aug-13 3-Jun-15 Ghent University Hoshttps://Cl
Jun-07 Sep-07 19-Jun-07 ### Center for Immunizatihttps://Cl
5-Dec-05 30-Nov-06 Dec-07 4-Nov-05 29-Oct-18 29-Oct-18 Walter Reed Army Insti https://Cl
4-Jan-18 May-20 Aug-20 29-Jan-19 29-Jan-19 Guangxi Provincial Cehttps://Cl
Jan-14 Sep-22 Sep-22 14-Apr-15 ### Arthur G. James Cance https://Cl
Sep-09 Jan-10 Jan-10 ### ### ### Stanford University Schttps://Cl
Sep-10 Jul-12 Sep-26 1-Sep-10 ### Texas Children's Hospihttps://Cl
Jul-98 Jul-05 8-Sep-05 8-Apr-11 The International Cenhttps://Cl
Aug-09 Nov-09 Apr-10 ### 3-Oct-12 ### Study Site, Huntsvillehttps://Cl
13-Apr-10 28-Jun-10 28-Jun-10 21-Apr-10 ### GSK Investigational S https://Cl
Oct-05 Mar-11 16-Jan-08 30-Jul-14 30-Jul-14 https://Cl
Sep-15 May-16 May-16 ### ### Eskenazi Health Outpa https://Cl
28-May-19 1-Apr-20 1-Jan-21 10-Jan-19 ### University of Wisconshttps://Cl
Mar-08 Aug-09 Dec-09 ### ### Werderstrasse 3, Badhttps://Cl
Sep-10 May-12 Apr-14 ### ### Magee-Womens Hospita https://Cl
Jul-03 Mar-08 Mar-08 ### 6-Mar-12 Bandim Health Projechttps://Cl
1-Oct-16 31-Mar-17 26-Apr-19 ### 10-Jul-19 https://Cl
Jun-03 Oct-06 Feb-11 ### ### https://Cl
May-16 21-Mar-20 ### ### ### Fred Hutch/Universit https://Cl
Sep-16 5-Jan-17 ### 3-May-18 University of Rochesthttps://Cl
Aug-12 Dec-12 Dec-13 8-Jul-15 9-Jul-15 Xinyi Center for Dise https://Cl
10-Oct-18 20-Aug-19 10-Jan-20 ### 22-Jan-20 Zhejiang Provincial C https://Cl
Aug-09 Apr-10 Apr-10 22-Jul-09 ### 1-Aug-12 Emory Vaccine Centerhttps://Cl
Sep-11 Dec-11 Jan-12 5-Sep-11 19-Apr-12 Funing county Centerhttps://Cl
Dec-08 Jan-09 Mar-09 2-Apr-12 20-Jun-12 Yanting County, Mianhttps://Cl
10-Jun-18 May-21 May-24 ### ### Beijing Youan Hospitahttps://Cl
1-Jul-18 1-Apr-19 25-Jul-19 7-Jun-18 13-Jun-18 https://Cl
Jul-11 Sep-13 Mar-14 ### 1-Apr-16 Maharaj Nakorn Chianhttps://Cl
Jun-14 Dec-15 Jun-16 ### ### 26-Jun-17 University of Coloradhttps://Cl
Mar-01 Feb-09 Feb-09 27-Jan-03 ### ### Memorial Sloan-Kettehttps://Cl
3-Oct-06 1-Nov-06 ### ### 22-Apr-13 8-Jun-18 GSK Investigational Sihttps://Cl
8-May-14 Dec-22 Jun-23 27-Jul-18 ### Rheumatology Associat https://Cl
Sep-07 Aug-08 Feb-09 3-Oct-07 24-Jan-11 14-Apr-16 AlKhaleej, Qassim, Sahttps://Cl
14-Feb-20 Jan-22 Sep-22 ### 5-Feb-20 CHU de BesanÃ§on, Bes https://Cl
Mar-03 Jul-09 Aug-09 ### ### ### New York-Presbyterian https://Cl
May-06 Apr-08 Jul-13 9-May-06 ### 10-Oct-18 Dartmouth-Hitchcockhttps://Cl
Sep-12 Sep-15 Sep-17 ### ### 23-Jan-18 Children's Hospital C https://Cl
Dec-05 Mar-06 ### ### Baton Rouge General https://Cl
M
2-Oct-13 12-Feb-20 ### ### ### Canberra Hospital, Gahttps://Cl
1-Jun-19 31-Dec-22 1-Jun-23 31-Oct-19 31-Oct-19 Qiu Li, Chengdu, Sich https://Cl
29-Oct-13 20-Aug-15 ### ### 3-Dec-19 University of Bamakohttps://Cl
Apr-10 Oct-10 Oct-10 6-Nov-09 ### https://Cl
Aug-05 Jan-06 5-Sep-05 ### CDC Arctic Investigat https://Cl
30-Aug-18 26-Jul-19 ### ### 18-Jan-20 GSK Investigational Site,
https://Cl
Salvador, BahÃa, Brazil|GSK
18-May-09 5-Aug-09 5-Aug-09 ### 19-Jul-17 ### GSK Investigational S https://Cl
Nov-00 Sep-02 Sep-02 6-Aug-08 ### https://Cl
Jun-07 Jul-07 Jul-07 26-Jun-07 17-Jan-14 Edinburgh, United K https://Cl
7-Oct-19 Oct-22 Oct-23 10-Apr-19 27-Jan-20 Makerere University https://Cl
26-Jun-18 31-Jul-18 ### ### 1-Oct-19 Vaccine Trial Centre, https://Cl
Aug-11 Jul-12 Jul-12 28-Jul-11 1-Dec-16 Moon's Pediatrics Clinhttps://Cl
Sep-09 Jun-10 Sep-10 10-Jul-09 ### https://Cl
Dec-01 Apr-10 27-Jan-03 24-Jan-13 Mount Sinai Medical https://Cl
Dec-14 Jan-16 Jun-16 9-Mar-15 9-Mar-15 Kantonsspital Aarau, https://Cl
Apr-16 May-19 May-19 27-Jan-16 13-Jun-19 Kaiser Per "Study Prohttps://Cl
1-Oct-14 14-Jan-15 4-May-15 ### 9-Mar-17 3-Apr-18 GSK Investigational Sihttps://Cl
Aug-06 Oct-08 Oct-08 ### ### University of Marylanhttps://Cl
Oct-00 Jan-05 Jan-05 9-Jun-08 ### https://Cl
Jul-05 May-13 May-13 5-Aug-08 ### ### Oakland, California, Uhttps://Cl
22-Aug-18 9-Mar-20 9-Mar-20 ### ### GSK Investigational Sihttps://Cl
Jun-06 Jun-13 Jun-13 ### 6-Jul-17 Cincinnati Children's https://Cl
Dec-14 Dec-16 Dec-16 ### 24-Jan-17 Royal Prince Alfred Hhttps://Cl
Oct-12 Jul-24 ### 4-Nov-19 ZNA Stuivenberg, Antw https://Cl
Sep-05 Dec-06 Dec-12 7-Sep-05 6-Dec-12 National Taiwan Univehttps://Cl
Sep-08 May-11 May-11 ### 16-Jun-11 The Kirby Institute, https://Cl
Aug-10 Sep-11 Jul-12 ### ### BIOCANCER Clinical Rhttps://Cl
Mar-19 Jan-20 Jun-20 11-Oct-18 25-Jan-19 https://Cl
Sep-06 Dec-06 ### 12-Oct-16 GSK Investigational S https://Cl
Nov-08 Mar-09 Nov-10 ### 27-Oct-17 Baylor College of Me https://Cl
May-07 Jan-08 Jan-08 ### 26-Apr-17 St. Jude Children's R https://Cl
1-Jul-15 1-Jul-20 1-Jul-21 16-Jul-15 ### University of Wisconshttps://Cl
Jul-06 Aug-07 Aug-07 23-Jun-06 17-Jan-14 Allschwil, Switzerla https://Cl
18-Apr-18 20-Nov-19 ### ### ### Coastal Clinical Rese https://Cl
Jun-09 Mar-10 Mar-10 ### 6-Apr-11 13-Jun-12 Emory University Schohttps://Cl
Aug-13 Apr-14 Apr-14 30-Jul-13 31-Oct-14 8-Jun-17 Novartis site, Marbu https://Cl
Jun-10 Jan-11 Jan-11 ### ### Allschwil, Switzerlandhttps://Cl
Mar-06 Oct-07 Oct-07 ### ### O.L.Vrouwziekenhuis A https://Cl
Feb-14 Sep-14 4-Mar-14 ### Department of Oncolo https://Cl
Sep-12 Dec-12 May-13 6-Nov-14 6-Nov-14 Guangxi Provincial Cehttps://Cl
Mar-16 Mar-19 Mar-19 21-Jul-17 ### UO Immunoterapia e https://Cl
La
Nov-09 Apr-10 Apr-10 3-Nov-09 3-Nov-09 https://Cl
16-Mar-09 17-Feb-14 ### ### ### ### University of Wiscon https://Cl
Nov-13 Mar-14 Apr-14 8-Oct-14 29-Jun-16 29-Jun-16 https://Cl
Nov-09 Dec-11 Dec-11 ### 3-Jan-13 Center for Immunizatihttps://Cl
Jan-10 Feb-10 Feb-10 ### 21-Oct-19 Shin Nippon Biomedica https://Cl
Jan-02 Jan-04 Jan-04 ### ### https://Cl
Oct-16 Oct-18 Oct-18 13-Apr-17 18-Oct-18 CHU Brugmann, Brusse https://Cl
Mar-11 Dec-11 Feb-12 ### ### Department of Rheumat https://Cl
26-Apr-06 10-Feb-09 ### 21-Apr-06 ### 4-Sep-18 GSK Investigational Sihttps://Cl
Mar-11 Dec-12 Dec-12 13-Jan-12 5-Feb-13 Center for Immunizatihttps://Cl
May-04 May-07 ### ### New York Presbyteriahttps://Cl
Aug-10 Mar-12 Aug-12 ### 28-Jul-11 Ottawa Hospital Resea https://Cl
Feb-05 Nov-09 Oct-10 8-Sep-05 8-Apr-14 New York Blood Center https://Cl
8-Dec-16 17-Jul-17 7-Dec-17 8-Dec-16 3-Aug-18 ### GSK Investi"Study Prohttps://Cl
Oct-06 Oct-08 Dec-08 4-Feb-09 2-Sep-13 2-Sep-13 https://Cl
25-Apr-16 2-Jun-19 Jun-20 9-Sep-15 4-Sep-19 University of Miami, https://Cl
Oct-06 May-12 Jan-15 19-Oct-06 ### UPMC Cancer Center https://Cl
a
May-05 Nov-05 Nov-05 5-Aug-05 ### GSK Investigational S https://Cl
Oct-09 Jan-10 Sep-10 2-Dec-11 2-Dec-11 Univ. of Alabama Birmhttps://Cl
Feb-16 Nov-16 May-19 15-Apr-16 8-Mar-17 Hezhou Center for Di https://Cl
Sep-10 Dec-19 Dec-19 5-Sep-11 ### University of Miami Shttps://Cl
Nov-05 Oct-12 Oct-12 ### 16-Oct-19 16-Oct-19 UT MD Anderson Cance https://Cl
1-Feb-18 1-Mar-19 1-Apr-19 21-Apr-17 7-Mar-18 St. Mary's Health Centhttps://Cl
Sep-09 Apr-10 Apr-10 9-Nov-09 ### ### Northwestern Medical https://Cl
Sep-07 May-08 May-08 2-Oct-07 ### 6-Dec-17 University of Michigahttps://Cl
Jan-10 Sep-10 Dec-18 9-Dec-09 ### Malindi District Hospihttps://Cl
19-Nov-14 18-Nov-15 ### 23-Jan-17 ### ### Stanford University Schttps://Cl
28-Jul-17 31-Oct-18 31-Jan-19 ### ### https://Cl
Sep-15 Nov-15 Dec-15 7-Sep-15 6-Jan-17 6-Jan-17 Covance, Daytona Beac https://Cl
12-Dec-18 Dec-19 Dec-19 ### ### Dartmouth-Hitchcockhttps://Cl
21-Jul-17 15-Oct-19 Mar-20 18-Jul-17 6-Sep-19 Emory University, Atl https://Cl
Sep-06 Jun-07 Jun-07 ### ### GSK Investigational Sihttps://Cl
Jun-13 Jun-14 Jun-14 4-May-15 4-May-15 https://Cl
19-Jul-10 23-Aug-12 ### 12-Jul-10 ### GSK Investigational Sihttps://Cl
Aug-15 16-May-17 ### 28-Oct-15 6-Nov-17 Zambia Emory HIV Res https://Cl
Jun-15 Jul-19 Jul-20 ### 1-Jul-19 Thunder Bay Regionalhttps://Cl
Aug-15 Apr-16 Apr-16 7-Aug-15 7-Aug-15 https://Cl
16-May-19 10-Dec-20 30-Apr-21 16-Apr-19 ### University of Califor https://Cl
23-Jul-15 8-Apr-16 26-Jan-17 8-Jul-15 ### ### GSK Investigational S https://Cl
30-Jul-10 24-May-13 ### 22-Jun-10 16-Jan-19 16-Jan-19 GSK Investigational Sihttps://Cl
Jul-14 Nov-14 Dec-16 ### ### NIZO food research, https://Cl
30-Dec-19 Apr-21 Apr-21 29-Oct-19 6-Feb-20 Investigational Site https://Cl
Jan-13 May-13 Jun-13 29-Apr-13 31-Jan-18 Faculty of Tropical M https://Cl
14-Jul-16 22-Feb-19 ### 29-Jun-16 7-Jan-20 Soweto, South Africa https://Cl
Apr-10 Sep-11 Jul-12 ### 5-Jun-13 Centro MÃ©dico SÃ£o https://Cl
F
Oct-14 Dec-14 Dec-14 ### ### https://Cl
Apr-11 Dec-12 Dec-12 6-Mar-12 ### Cervical Cancer-Free https://Cl
25-Aug-09 16-Dec-09 ### ### 6-Aug-19 6-Aug-19 GSK Investigational Sihttps://Cl
Nov-15 May-18 Sep-18 15-Oct-15 25-Oct-17 Visions Clinical Rese https://Cl
Nov-13 Feb-14 May-14 ### ### CHU Sainte-Justine, https://Cl
Oct-16 Mar-17 Jun-17 13-Jan-17 1-Nov-17 Korea University ANSA https://Cl
Apr-99 Feb-00 13-Jun-08 13-Jun-08 GSK Clinical Trials Ca https://Cl
Nov-12 Aug-14 Sep-14 9-Jul-12 ### Centre for Clinical V https://Cl
7-Jan-19 17-Dec-19 ### 17-Oct-18 ### Duke University Primahttps://Cl
Aug-08 Nov-08 Nov-08 ### ### ### Norfolk, Virginia, Uni https://Cl
Oct-09 Mar-12 Mar-12 ### 25-Apr-12 Specialities Hospital, https://Cl
Jul-11 Jan-12 Jan-12 8-Jul-11 ### Fukui City, Fukui Pre https://Cl
8-Jun-04 16-Jan-05 16-Jan-05 24-Apr-06 ### GSK Investigational S https://Cl
11-Dec-03 23-Oct-04 23-Oct-04 24-Apr-06 ### GSK Investigational Sihttps://Cl
Oct-09 Apr-12 Jun-12 24-Jan-11 19-Jan-17 https://Cl
Mar-08 Apr-08 Apr-08 ### ### 9-Oct-15 https://Cl
Oct-12 Jan-13 Jan-13 16-Jan-17 9-Mar-17 ### https://Cl
Nov-07 May-10 Oct-11 8-Aug-07 26-Jul-11 ### UCLA Clinical AIDS Rehttps://Cl
1-May-92 1-Jul-92 1-Jul-92 17-Jun-08 2-Jun-17 https://Cl
Sep-16 Dec-18 Dec-18 ### 23-Jan-19 Paradigm Research, Re https://Cl
Feb-07 May-09 May-09 19-Oct-06 25-Oct-16 GSK Investigational S https://Cl
26-Aug-13 1-Nov-13 20-Oct-14 4-Sep-13 8-May-17 GSK Investigational Sihttps://Cl
25-Sep-19 10-Jan-20 8-Jan-21 ### 22-Jan-20 GSK Investigational S https://Cl
May-10 Aug-10 Sep-10 2-Aug-10 2-Aug-10 Peking University Peop https://Cl
Sep-09 Feb-11 Feb-11 16-Oct-09 ### ### Veterans Association https://Cl
31-May-18 1-Dec-19 1-Dec-19 7-Jun-18 24-Apr-19 B. J. Medical College https://Cl
Jul-05 May-13 May-13 ### ### 19-Apr-16 Oakland, California, Uhttps://Cl
Dec-06 Jan-09 Apr-09 15-Jan-07 2-Jun-11 14-Apr-16 Tuscaloosa, Alabama,https://Cl
1-Sep-17 31-Aug-20 ### ### 21-Jan-20 Syneos Health, Wilmin https://Cl
1-Aug-19 30-Sep-19 31-Oct-19 30-Jul-19 ### Peking University Heahttps://Cl
Jan-06 Sep-10 Sep-10 ### 13-Oct-11 10-Jan-18 Univ. of California D https://Cl
Sep-06 Jul-21 Jul-21 19-Oct-06 ### Sidney Kimmel Compre https://Cl
Aug-09 Jan-13 ### 6-Sep-13 BH10/513, Lausanne,https://Cl
Nov-05 May-06 7-Nov-05 7-May-08 Research Institute forhttps://Cl
Jul-12 Jan-13 Jun-13 17-Jul-12 3-Dec-13 3-Dec-13 Incheon, Chung gu, Khttps://Cl
Oct-16 Mar-17 Mar-17 18-Oct-16 25-Oct-16 Anna Taddio, Torontohttps://Cl
14-Mar-17 May-18 May-18 ### ### Postgraduate Institut https://Cl
Sep-09 May-11 Apr-12 ### 25-Jul-12 1-Aug-12 Birmingham, Alabama, https://Cl
16-Mar-17 31-Aug-17 ### ### 7-Mar-19 28-Jun-19 GSK Investi"Study Prohttps://Cl
26-Feb-15 20-Feb-20 ### ### ### M D Anderson Cancerhttps://Cl
Oct-06 Feb-08 8-Sep-06 8-May-08 UCSF Positive Health h Pttps://Cl
May-09 Jan-11 Jan-11 29-Apr-09 25-Oct-13 Site Reference ID/Invhttps://Cl
30-Oct-18 16-Apr-19 2-Sep-19 ### 4-Oct-19 GSK Investigational S https://Cl
3-Jan-11 31-Mar-14 ### ### 31-Jan-19 31-Jan-19 GSK Investigational S https://Cl
11-Oct-10 9-Jun-11 9-Nov-11 20-Oct-10 ### 19-Jun-18 Program For The Study https://Cl
2-Feb-09 17-Feb-14 Dec-19 ### ### H. Lee Moffitt Cancerhttps://Cl
15-May-11 24-Apr-13 24-Apr-13 9-Jun-11 ### Schneider Children's H https://Cl
Oct-05 Apr-09 Apr-09 29-Jan-07 ### 2-Sep-11 OHSU Knight Cancer In https://Cl
Nov-99 Apr-01 Mar-05 26-Jun-09 21-Oct-10 https://Cl
8-Aug-19 1-Jul-20 3-Sep-20 25-Jul-19 ### Institute of Specific https://Cl
4-Aug-17 19-Dec-19 30-Apr-20 24-Jul-17 13-Jan-20 University "Informed https://Cl
5-Jun-17 25-Jun-18 25-Jun-18 ### 2-Jul-19 2-Jul-19 Clinical Re "Study Prohttps://Cl
Nov-19 Jun-21 Dec-21 9-Oct-19 11-Oct-19 https://Cl
Oct-09 Mar-10 Apr-10 27-Oct-09 27-Oct-09 Tel Aviv Medical Centerhttps://Cl
Mar-08 Oct-08 Oct-08 3-Feb-09 11-Jan-10 13-Apr-17 https://Cl
Jun-99 Mar-09 Mar-09 19-Jul-04 31-Jan-13 Memorial Sloan-Kettehttps://Cl
14-Oct-09 9-Nov-10 9-Nov-10 9-Oct-09 31-Jan-19 31-Jan-19 GSK Investigational S https://Cl
21-Aug-12 6-Dec-12 ### ### ### ### GSK Investigational S https://Cl
11-May-06 1-Jul-06 18-Jul-06 3-May-06 1-May-13 8-Jun-18 GSK Investigational Sihttps://Cl
20-Jul-08 28-Feb-09 ### 4-Jul-07 9-Jul-10 17-Apr-17 https://Cl
27-Jun-17 20-May-18 ### 11-Jul-17 11-Jul-17 Pontificia Universidadhttps://Cl
Jul-10 Dec-10 Nov-11 29-Jul-10 31-Jul-12 Miami Research Associ https://Cl
5-Jun-08 13-Aug-08 8-Jan-09 12-Jun-08 7-Feb-14 31-Jul-18 GSK Investigational S https://Cl
Dec-07 31-Jul-20 31-Jul-21 ### 25-Oct-19 Holden Comprehensive https://Cl
Jul-15 Aug-17 ### ### University Hospitals https://Cl
Apr-16 Apr-16 Apr-16 ### 9-May-18 https://Cl
Sep-06 Aug-07 ### 11-Jan-07 https://Cl
5-Oct-16 30-Apr-20 ### 16-Jun-16 ### Diakonie-Klinikum St https://Cl
May-09 Jun-09 Nov-09 ### ### Butantan Institute, Sahttps://Cl
15-Jan-17 13-Dec-17 ### ### ### Sechenov First Moscohttps://Cl
31-Mar-15 16-Dec-16 ### 14-Jan-15 28-Jan-19 Duke Human Vaccinehttps://Cl
In
Aug-08 Aug-10 Apr-19 ### 7-Aug-19 https://Cl
May-08 May-12 May-12 ### 30-Jul-14 Academic hospital Mahttps://Cl
Mar-11 Nov-12 Dec-14 ### ### 3-Jan-20 Department of Clinicahttps://Cl
Sep-13 Nov-13 May-14 22-Jan-15 22-Jan-15 https://Cl
Aug-07 Jan-09 Feb-09 ### ### 6-Oct-09 National Taiwan Univehttps://Cl
Nov-15 28-Apr-17 28-Apr-17 ### 25-Jan-19 Mulago National referhttps://Cl
Nov-11 Apr-14 Nov-16 14-Jun-12 ### Papua New Guinea Ins https://Cl
Apr-10 Dec-11 Dec-11 ### 6-Jun-14 Centre National de Rehttps://Cl
18-Oct-16 31-Aug-17 ### 9-Nov-16 ### Ohio State Universit https://Cl
Feb-05 Jul-06 Jul-06 ### ### GSK Investigational S https://Cl
Mar-07 Sep-08 Nov-08 6-Apr-07 19-Oct-12 19-Oct-12 Chandler, Arizona, Unhttps://Cl
Jul-03 Dec-08 Dec-08 9-Aug-05 5-Jul-10 27-Jan-15 Medical College of Gehttps://Cl
Oct-13 Dec-17 Jun-18 14-Oct-13 7-Jun-19 7-Jun-19 Espoo Vacci"Study Prohttps://Cl
Jan-09 Sep-10 Sep-10 ### ### ### Pfizer Investigational https://Cl
Sep-10 Mar-16 Aug-16 22-Jun-16 ### Meharry Medical Colle https://Cl
11-Sep-19 30-Jan-20 ### 18-Apr-19 4-Dec-19 RSND, Semarang, Cent https://Cl
Jan-14 Feb-15 Jul-15 26-Jan-17 26-Jan-17 Aga Khan University, https://Cl
Jul-12 Dec-13 Dec-14 1-Apr-13 20-Jan-16 Guangdong Centers for https://Cl
Jun-11 Jun-15 Apr-16 ### ### ### Oakland, California, Uhttps://Cl
14-Feb-19 30-Apr-20 30-Apr-20 ### 6-Nov-19 Penn State College ofhttps://Cl
1-Oct-15 14-Apr-18 14-Apr-18 7-Oct-15 8-May-18 GSK Investigational S https://Cl
Apr-03 May-05 10-Jun-11 10-Jun-11 KAVI (Kenya AIDS Vacchttps://Cl
Aug-12 Mar-20 Mar-20 30-Apr-12 ### City of Hope Medical https://Cl
Mar-10 Dec-12 Dec-12 ### ### Covance Clinical Resehttps://Cl
27-Aug-09 30-Apr-11 3-Dec-20 22-Jul-09 13-Jan-15 16-Oct-17 https://Cl
1-Apr-16 28-Jun-16 28-Jun-16 27-Apr-16 11-Jul-17 26-Jun-18 GSK Investigational Sihttps://Cl
Sep-15 Dec-15 Dec-15 18-Jan-17 ### ### https://Cl
25-Jun-18 30-Apr-20 30-Apr-21 24-Jul-18 18-Jul-19 Johns Hopkins Univershttps://Cl
Jan-08 Sep-08 Dec-08 29-Jan-08 22-Jan-14 Quezon city, Manila, https://Cl
Oct-16 24-May-17 Mar-20 14-Oct-16 ### Case Western Reservehttps://Cl
Jun-08 Oct-08 Oct-09 18-Jul-08 9-Oct-15 Privatklinik Leech, https://Cl
7-Aug-18 Feb-21 Feb-21 1-Aug-18 ### American Academy ofhttps://Cl
Pe
Apr-09 Dec-12 Dec-12 ### ### ### GSK Investigational Sihttps://Cl
1-May-18 31-May-20 ### 13-Apr-18 30-Apr-19 University of Califor https://Cl
Mar-06 ### 1-Nov-06 Site 1, Nanjing, Chinahttps://Cl
Feb-16 Jan-18 Jan-18 6-Jan-16 ### Respiratory and Menihttps://Cl
29-Jan-19 15-Sep-20 ### 18-Jun-18 ### Alabama CRS "Informed https://Cl
Apr-16 Oct-16 Feb-17 ### 20-Apr-17 Radboud university mhttps://Cl
3-Nov-16 1-Aug-17 1-Aug-17 4-Nov-16 ### New Haven Clinical Rhttps://Cl
15-Oct-07 21-Dec-07 4-Jun-08 ### ### 8-Jun-18 GSK Investigational S https://Cl
30-Oct-08 2-Jun-09 2-Nov-09 ### 9-May-18 9-May-18 GSK Investigational Sihttps://Cl
Mar-08 Feb-09 Feb-09 19-Oct-07 ### Baylor College of Medhttps://Cl
Jun-04 Sep-07 May-11 ### 9-Jul-13 UCLA CARE Center CRS,https://Cl
Aug-08 Nov-12 Nov-12 20-Jul-09 ### Centre for Clinical V https://Cl
Aug-15 Mar-17 Jul-17 ### 1-Aug-17 Guangdong Center forhttps://Cl
Oct-16 Jul-18 Dec-18 18-Oct-16 ### McGill University He https://Cl
Sep-02 Jul-03 18-Jan-07 18-Jan-07 University of Oxford, https://Cl
Dec-15 8-Sep-17 8-Sep-17 28-Oct-15 ### ### Rockefeller"Study Prohttps://Cl
2-Jul-07 28-Mar-08 ### 27-Jun-07 ### 4-Sep-18 GSK Investigational Sihttps://Cl
18-Jun-19 May-21 May-21 ### ### Investigational Site https://Cl
Dec-06 Apr-12 Apr-12 28-Jul-08 25-Jun-12 City of Hope Comprehe https://Cl
Jun-11 Dec-12 Dec-12 ### ### International Centre https://Cl
Apr-12 Jun-12 Jul-12 18-Jan-12 22-Apr-19 22-Apr-19 Research Institute of https://Cl
3-Sep-04 31-Jul-09 3-Apr-17 ### ### ### https://Cl
1-May-18 31-Oct-22 31-Oct-22 31-Oct-18 31-Oct-18 Northeast Valley Healhttps://Cl
15-May-14 6-Jan-16 6-Jan-16 ### ### ### California Research F https://Cl
Nov-06 Nov-08 Dec-12 6-Oct-06 ### Alabama Vaccine CRS,https://Cl
May-17 May-20 May-20 10-Jul-15 13-Apr-17 https://Cl
19-Jun-07 31-Mar-09 ### ### ### 2-Jan-20 GSK Investigational S https://Cl
Dec-11 Apr-13 Apr-13 9-Dec-11 12-Apr-16 25-Jul-16 National Institutes ofhttps://Cl
Oct-05 May-07 20-Jun-07 ### 20-Jan-10 https://Cl
1-May-17 28-Aug-17 ### 1-Feb-17 ### St. Mary's Health Centhttps://Cl
20-Feb-18 19-Jul-19 19-Jul-19 23-Oct-17 2-Aug-19 University of Alabamahttps://Cl
Sep-04 May-07 ### ### ### New York, New York, https://Cl
15-Mar-18 19-Nov-18 ### 13-Apr-18 ### Optimal Research, San https://Cl
Apr-07 Dec-08 Dec-08 1-Jun-07 ### 3-Feb-14 BogotÃ , Colombia https://Cl
8-Jan-09 Oct-11 Jul-19 13-Apr-09 5-Nov-18 Brigham and Women's https://Cl
Oct-12 14-Dec-14 ### ### 9-Oct-18 Mayo Clinic, Rochestehttps://Cl
Apr-07 Feb-08 Feb-08 1-Sep-06 ### ### Phramongkutklao Hosp https://Cl
10-Nov-16 30-Aug-17 5-Feb-18 6-Nov-16 ### 2-Jul-19 GSK Investi"Study Prohttps://Cl
Apr-14 Jul-17 Jul-17 3-Mar-11 2-Oct-18 2-Oct-18 Hope Clinic"Study Prohttps://Cl
Mar-07 Jul-09 Nov-09 8-Mar-07 ### O.L.Vrouwziekenhuis A https://Cl
11-Jul-16 20-Jul-17 20-Jul-17 8-Jun-17 25-Jun-18 25-Jun-18 "Study Prohttps://Cl
20-Mar-14 11-May-16 13-Apr-17 ### 1-Aug-18 1-Aug-18 GSK Investigational Sihttps://Cl
Aug-11 Dec-11Dec-11 ### ### https://Cl
Mar-02 Jan-04 3-Oct-06 ### GSK Investigational S https://Cl
Nov-09 Oct-10 Oct-10 27-Jul-11 1-May-12 1-May-12 Yubari Kibounomori, https://Cl
Oct-15 29-Jul-17 29-Jul-17 ### ### ### Internation"Study Prohttps://Cl
DMID 01-632 Dec-01 Dec-01 ### ### University of Marylanhttps://Cl
Oct-12 8-Nov-17 Dec-19 5-Sep-12 ### University of Pittsbu https://Cl
Nov-06 Sep-07 Jan-08 6-Nov-06 ### Eastern Virginia Medichttps://Cl
Jan-14 Jul-20 Dec-20 28-Oct-13 3-Jan-20 Brigham and Women's https://Cl
16-Oct-08 26-May-09 4-Dec-09 13-Oct-08 4-Sep-14 ### GSK Investigational S https://Cl
Jan-08 Apr-08 Apr-08 ### ### Vaccination and Travehttps://Cl
Oct-16 Sep-20 Sep-21 13-Jul-16 ### Blacktown Hospital, https://Cl
Sep-08 Mar-09 Mar-09 ### 18-Jul-13 University Clinical R https://Cl
Jun-08 Jun-10 Jun-11 4-Sep-08 13-Jan-11 Ochsner Health Systehttps://Cl
14-Feb-18 26-Sep-19 ### 17-Oct-17 11-Oct-19 Emory Vaccine Centerhttps://Cl
11-Sep-17 22-Nov-17 ### 13-Oct-17 ### ### Sanofi Past"Statistic https://Cl
Jun-08 Sep-08 Dec-08 2-Jul-08 30-Jul-12 Worldwise Travellers https://Cl
10-Sep-09 27-Nov-10 ### ### ### ### GSK Investigational Sihttps://Cl
24-May-17 9-Jul-18 ### ### 24-Jul-19 ### GSK Investi"Study Prohttps://Cl
P1082|10776 Nov-14 26-Jul-13 ### https://Cl
Aug-16 May-17 Jan-18 9-Aug-16 5-Feb-18 Rockville, Maryland, https://Cl
1-May-19 1-May-19 1-May-19 ### 30-Oct-19 https://Cl
Jun-11 Jul-13 Jul-13 ### 25-Jul-14 Columbia University M https://Cl
May-14 Mar-15 Mar-15 ### ### ### 12, Novartis Investigahttps://Cl
Oct-05 Feb-06 Sep-09 2-Dec-05 ### Hospital of the Joha https://Cl
Sep-07 Feb-08 Feb-08 27-Jun-07 ### ### https://Cl
Jul-03 Jul-05 Jul-05 8-Jul-03 2-Jul-12 Johns Hopkins Univershttps://Cl
27-Sep-10 3-Nov-11 1-Oct-12 ### ### ### GSK Investigational S https://Cl
Nov-09 Feb-10 Feb-10 1-Dec-09 1-Mar-10 University Hospitals https://Cl
24-May-18 5-Jun-19 Dec-19 6-Jun-18 ### Shandong Center for h Dttps://Cl
12-Oct-17 24-May-19 ### 18-Oct-17 2-Oct-19 Achieve Clinical Rese https://Cl
Nov-15 Mar-19 Mar-19 ### 6-Nov-18 IWK Health Centre, Ha https://Cl
23-Oct-07 1-Dec-07 ### 2-Oct-07 27-Jul-12 8-Jun-18 GSK Investigational S https://Cl
May-12 May-14 May-14 7-Sep-12 ### Comprehensive Ruralhttps://Cl
H
P1059|10051|PACTG P1059 Feb-09 6-Apr-05 ### Children's Hospital L https://Cl
Nov-16 Dec-17 Feb-18 9-Aug-16 15-Oct-18 La Paz Medical Centerhttps://Cl
Feb-09 Dec-10 Dec-10 20-Jan-14 20-Jan-14 Queen Mary Hospital,https://Cl
17-Oct-07 18-Mar-13 ### 10-Oct-07 17-Apr-14 ### GSK Investigational S https://Cl
Jul-09 Dec-09 Dec-09 8-May-14 ### 6-Jun-18 Stanford LPCH Vaccinehttps://Cl
15-Dec-15 30-Aug-16 1-Aug-17 21-Oct-15 ### ### GSK Investigational Sihttps://Cl
28-Mar-17 Dec-19 Dec-19 ### ### Centre for Clinical V https://Cl
Oct-11 22-Mar-16 ### 17-Oct-11 ### ### Mary Crowley Cancerhttps://Cl
R
30-Apr-19 30-Jun-22 ### ### 12-Apr-19 https://Cl
Jan-10 Dec-10 Mar-11 28-Apr-10 6-Feb-13 Centro de Pesquisa Clinica
https://Cl
do Instituto da CrianÃ§a d
20-Mar-15 2-Jul-15 21-Jun-16 ### ### 3-Jul-18 GSK Investigational S https://Cl
17-Dec-18 Dec-20 Jun-21 ### ### Center for Cancer Im https://Cl
10-Aug-11 27-Feb-12 3-Jul-12 6-Jun-11 9-Jun-17 18-Jun-19 GSK Investigational Sihttps://Cl
Sep-12 Jun-13 Jun-13 ### ### University of Rochestehttps://Cl
4-Oct-10 16-Feb-11 ### 30-Jun-10 ### ### GSK Investigational Sithttps://Cl
Apr-06 Dec-06 3-Apr-06 ### CPC Phase I Unit, Lenhttps://Cl
22-Jan-19 5-Nov-19 ### 26-Jul-18 ### George Research Centhttps://Cl
Jul-16 Jun-20 Aug-22 5-Apr-16 18-Jan-20 University of Califor https://Cl
Sep-14 Jul-16 Jul-16 ### 6-Jun-17 Advanced Specialty Re https://Cl
Jul-05 Dec-06 27-Apr-05 ### Northwest Kinetics, I https://Cl
Dec-06 Nov-08 ### ### Society for Applied Sthttps://Cl
Aug-12 Dec-14 Dec-14 ### ### HVTN Clinical Researchttps://Cl
Apr-12 Aug-14 Jan-16 5-Apr-12 24-Jan-17 Alabama CRS, Birmingh https://Cl
Aug-99 Jun-07 Jan-10 1-Aug-05 ### University of Alabam https://Cl
1-Apr-08 12-May-09 1-Dec-10 4-Apr-08 ### 26-Jun-19 GSK Investigational S https://Cl
Mar-02 Mar-09 Mar-09 27-Jan-03 ### Memorial Sloan-Kettehttps://Cl
Aug-08 Jul-09 Oct-10 8-Jul-08 9-Oct-15 Allgemeines Krankenha https://Cl
Apr-07 Oct-09 Oct-09 ### ### ### Muntinlupa City, Phil https://Cl
8-Jul-16 27-Aug-18 30-Jun-21 2-Jun-16 2-Dec-19 Birmingham, Alabama, https://Cl
9-Jul-18 19-Dec-18 ### 16-Jul-18 2-Jan-20 ### GSK Investi"Study Prohttps://Cl
Apr-10 May-11 May-12 ### ### University of Yamanashttps://Cl
24-Jan-19 1-Jul-20 1-Jul-20 18-Jul-18 ### Center for "Informed https://Cl
Jun-19 Dec-24 Dec-24 ### ### https://Cl
18-Jan-17 1-Jan-21 1-Jun-22 5-Nov-18 ### Rocky Mountain Regiohttps://Cl
Sep-05 Mar-06 Mar-06 4-Oct-05 ### ### https://Cl
Jan-08 Jan-09 Jan-09 ### 21-Jan-09 Department of Infectihttps://Cl
Feb-15 Jun-15 Dec-15 ### ### https://Cl
Nov-12 Nov-13 Nov-13 ### 9-Jan-14 Mirpur Health Clinic, https://Cl
18-Oct-17 Sep-20 Sep-20 ### ### Center of Infectious https://Cl
1-Aug-17 31-Aug-18 ### ### 20-Oct-17 Centre for Health Be https://Cl
Dec-14 Jun-17 Jun-17 13-Jan-17 17-Oct-17 https://Cl
Jan-03 Jan-08 Jan-08 26-Jun-08 9-Jan-12 Memorial Sloan-Kettehttps://Cl
Jun-09 Jul-09 Sep-09 17-Jun-09 ### Johnson County Clin Tr https://Cl
3-Oct-14 12-Dec-18 ### ### ### Stanford University, Shttps://Cl
Jan-14 Apr-14 Apr-14 ### 30-Apr-14 Centre for Clinical V https://Cl
May-07 Aug-12 Aug-12 19-Jul-07 ### University of Miami Shttps://Cl
1-Jan-97 31-Dec-14 ### 5-May-17 9-May-17 https://Cl
Feb-06 Nov-06 Nov-06 20-Jan-06 ### Stanford University, Shttps://Cl
15-Dec-17 20-Aug-19 ### ### 10-Jun-19 Mahavir Hospital & Rehttps://Cl
6-Oct-08 15-May-09 ### ### 23-Apr-12 ### GSK Investigational S https://Cl
Dec-05 Jun-07 Apr-08 ### 9-Apr-13 9-Apr-13 University of Virginia https://Cl
13-Sep-16 24-Oct-17 ### 8-Aug-16 19-Jul-19 ### GSK Investi"Study Prohttps://Cl
Nov-10 Apr-11 Feb-12 ### 19-Jun-12 25-Jun-12 Scottsdale, Arizona, https://Cl
Aug-14 Jun-15 Oct-15 26-Jun-14 13-Oct-17 Clinical Trials Center https://Cl
Mar-02 Mar-03 26-Jul-02 30-Jun-11 University of Kentuckhttps://Cl
Jan-09 Oct-09 Dec-09 28-Jan-09 10-Jun-13 Buenos Aires, Argent https://Cl
Jul-05 Jun-06 Jun-06 27-Apr-07 22-Jan-14 https://Cl
Nov-05 Aug-06 Aug-06 ### 8-Jun-09 14-Apr-16 Taipei, Taiwan https://Cl
Sep-10 Mar-13 Mar-13 ### 18-Jan-17 ### Renmin Hosptial of Wu https://Cl
6-Feb-17 21-Sep-17 ### 26-Jan-17 ### 5 sites in Philippines, https://Cl
4-Mar-10 25-Jun-10 ### ### 9-Mar-18 GSK Investigational S https://Cl
20-Oct-08 13-Nov-13 ### 21-Jul-08 ### 26-Jun-19 GSK Investigational Sihttps://Cl
11-Sep-15 26-Jan-16 26-Jan-16 ### ### 30-Oct-18 https://Cl
1-Feb-16 7-Sep-17 ### 2-Apr-18 Center for Immunizatihttps://Cl
Feb-00 Apr-01 Apr-01 24-Oct-11 5-Aug-16 https://Cl
17-Nov-09 25-Nov-10 ### 28-Oct-09 ### ### GSK Investigational S https://Cl
Jan-14 Apr-16 May-16 6-Jan-14 ### Institut National de https://Cl
Feb-04 Jul-08 Jul-08 5-Apr-05 4-Dec-12 ### Children's Hospital o https://Cl
20-May-17 21-May-17 ### ### ### Sheyang Center for Dihttps://Cl
Dec-10 Apr-11 Apr-11 ### 20-Jun-12 Mayo Clinic, Rochestehttps://Cl
18-Oct-17 27-Nov-19 ### 9-Jun-17 ### Bridge HIV CRS, San Fhttps://Cl
Jul-11 Jul-18 Jul-19 8-Jul-11 3-Jun-19 ### University "Study Prohttps://Cl
Apr-10 May-11 Jul-13 ### ### Cancer Prevention and https://Cl
8-Dec-09 30-Sep-10 ### 3-Aug-09 9-Jan-17 ### GSK Investigational S https://Cl
21-Aug-15 20-Jan-17 ### ### 11-Jan-18 Centre for Clinical V https://Cl
Oct-05 Dec-07 Dec-07 27-Apr-09 ### Desmond Tutu HIV Cen https://Cl
Apr-05 Nov-05 23-Jun-05 ### University of Iowa - https://Cl
Mar-10 Dec-19 Dec-22 ### 18-Jan-20 Beth Israel Deaconesshttps://Cl
28-May-18 23-Jul-19 Dec-19 24-Jul-18 ### Shandong Center for h Dttps://Cl
1-May-06 1-Jan-07 31-Jul-07 27-Apr-06 3-Aug-17 23-Jul-18 GSK Investigational S https://Cl
12-Jan-18 28-Feb-18 ### ### 29-Jul-19 29-Jul-19 Sekino Rins"Study Prohttps://Cl
Oct-08 Dec-11 Dec-11 ### 22-Jun-17 UPMC Cancer Centers, https://Cl
11-Apr-07 28-Apr-08 28-Apr-08 25-Apr-07 ### 8-Jun-18 GSK Investigational S https://Cl
Sep-11 Jun-12 2-Sep-11 2-Sep-11 Liuzhou CDC, Liuzhouhttps://Cl
Dec-16 Jul-20 Dec-20 26-Apr-16 ### Chan Soon-Shiong Inst https://Cl
Jul-00 Mar-09 Mar-09 27-Jan-03 ### Memorial Sloan-Kettehttps://Cl
Feb-11 Jan-15 Feb-15 3-Mar-11 24-Oct-16 24-Oct-16 University of Chicagohttps://Cl
9-Nov-15 15-May-17 ### ### 3-May-18 3-May-18 GSK Investi"Study Prohttps://Cl
Apr-14 Feb-18 Aug-18 4-Sep-13 ### ### Research In"Study Prohttps://Cl
13-Oct-14 25-Aug-15 ### 21-Oct-14 23-Oct-19 23-Oct-19 https://Cl
Oct-03 May-05 May-05 24-Oct-11 5-Aug-16 GSK Investigational Sihttps://Cl
Jul-07 Jul-11 Jul-11 9-Aug-07 ### GSK Investigational Sihttps://Cl
Aug-16 Dec-16 Dec-17 5-Oct-16 5-Sep-18 NIZO food research, https://Cl
24-Feb-11 13-May-11 9-Nov-11 5-Apr-17 6-Mar-19 6-Mar-19 https://Cl
8-Feb-10 30-Dec-14 ### ### 25-Jun-19 Madison, Wisconsin, https://Cl
Dec-07 Aug-11 Aug-11 30-Jul-07 13-Jul-12 ### Pfizer Investigational https://Cl
Aug-10 Aug-12 1-Aug-12 ### ### Cliniques Universitairhttps://Cl
1-Nov-19 Nov-21 Nov-21 ### ### Amsterdam Universityhttps://Cl
Oct-03 Nov-04 Nov-04 14-Jan-13 14-Jan-13 GSK Investigational Sihttps://Cl
Jan-07 May-13 May-13 ### 7-Nov-17 City of Hope Comprehe https://Cl
Oct-14 Aug-15 Aug-15 ### ### Clinical and Translati https://Cl
Jun-13 Jan-14 Jan-16 ### 26-Jun-13 Shanxi Centers for Di https://Cl
1-May-20 30-Jun-25 30-Jun-25 ### ### University of Minnesohttps://Cl
Apr-10 Nov-11 Nov-11 25-Apr-11 25-Apr-11 Texas Children's Hospihttps://Cl
17-Aug-16 1-Sep-17 16-Apr-18 ### 21-Jun-18 Hansa Sanatorium GmbH https://Cl
May-13 Oct-13 Oct-13 26-Jul-13 26-Jul-13 Aga Khan University, https://Cl
1-Jun-11 17-Jan-13 ### 4-Aug-10 6-Jun-19 6-Jun-19 GSK Investigational S https://Cl
Mar-11 Oct-12 Apr-13 ### ### UCLA CARE Center CRS, https://Cl
Sep-04 Aug-09 Oct-09 22-Oct-04 23-Jun-11 11-Jul-11 Arizona Cancer Centerhttps://Cl
Apr-12 Dec-18 Dec-18 ### ### VA San Diego Healthca https://Cl
PRO-sPanFlu-2001 ### ### Beijing Centers for Dihttps://Cl
Jan-08 Jan-16 Jan-17 9-Jan-17 9-Jan-17 https://Cl
Sep-05 Feb-06 27-Apr-07 27-Apr-07 https://Cl
Mar-10 Jun-11 Jun-11 3-Dec-09 28-Oct-19 28-Oct-19 Walter Reed Army Inst https://Cl
1-Mar-03 1-Dec-03 ### ### 23-Jul-12 ### GSK Investigational S https://Cl
Apr-15 Jun-15 Feb-17 ### 3-May-17 Kaifeng County Centerhttps://Cl
Jan-07 Aug-12 Aug-12 ### 24-Jul-15 Soweto HVTN CRS, Joh https://Cl
Apr-11 Jan-16 Jan-16 24-Jan-11 ### ### Sidney Kimmel Compre https://Cl
Jul-07 Oct-08 Apr-09 20-Apr-07 6-May-09 Homagama MOH Divisio https://Cl
Aug-06 May-08 May-09 ### 1-Feb-17 3-Jan-20 US Army Medical Resea https://Cl
21-Jul-17 11-Nov-19 ### ### ### Albert Einstein Colle https://Cl
Aug-13 Sep-14 Sep-14 2-Sep-15 2-Sep-15 https://Cl
Oct-11 Mar-13 Mar-13 12-Oct-11 ### Medical Research Couhttps://Cl
Apr-06 Dec-08 ### ### Alabama Vaccine CRS,https://Cl
Sep-05 Feb-08 Jan-10 2-Aug-05 ### Alabama Vaccine CRS,https://Cl
Dec-13 Sep-14 Oct-14 9-Dec-13 ### ### Fukuoka, Japan|Hokka https://Cl
Feb-13 Jul-13 Jul-13 ### ### The Catholic Universithttps://Cl
10-Dec-15 12-Dec-18 ### 5-Nov-15 ### Silver Spring, Maryl https://Cl
Sep-09 Aug-13 May-14 ### ### Department of Oncolo https://Cl
Jun-10 Dec-10 Dec-10 22-Oct-10 2-Nov-12 Retroscreen Virology https://Cl
31-Mar-10 31-Dec-21 ### ### ### Department of Clinicahttps://Cl
24-Jun-11 13-Sep-12 ### ### 6-Oct-17 13-Jan-20 GSK Investigational Sihttps://Cl
P1049|10165|IMPAACT Nov-13 ### 5-Sep-13 https://Cl
1-Jun-18 16-Oct-22 16-Oct-22 ### 1-Oct-19 Birmingham Universithttps://Cl
Oct-10 Apr-16 Jun-20 25-Jun-13 ### Radboud University Nhttps://Cl
4-Oct-07 17-Dec-14 ### ### 26-Jan-16 ### GSK Investigational Sihttps://Cl
Oct-10 Dec-12 Dec-12 6-Oct-10 ### Brigham and Women's https://Cl
24-Jul-18 1-May-21 1-Jun-21 ### 29-Jan-20 National Institutes ofhttps://Cl
Mar-06 Jul-07 Jul-07 3-May-06 21-Jan-08 Center for Immunizatihttps://Cl
6-Dec-16 4-Apr-17 4-Apr-17 ### 1-Mar-18 https://Cl
25-Sep-06 21-Dec-07 ### 29-Jun-06 ### 20-Jul-18 GSK Investigational S https://Cl
Oct-08 Jun-09 Jul-09 20-Oct-08 ### ### Hoover, Alabama, Unit https://Cl
Sep-04 Apr-06 Apr-06 29-Jan-09 ### 14-Apr-16 Norfolk, Virginia, Uni https://Cl
Mar-16 Jun-16 May-17 30-Jun-14 20-Jun-16 https://Cl
Oct-04 Dec-05 1-Sep-06 23-Oct-07 1st Dept. of Coronaryhttps://Cl
22-Feb-19 7-Jun-19 7-Jun-19 ### 8-Aug-19 Investigational Site https://Cl
Aug-09 Oct-09 Apr-10 15-Jul-09 ### 28-Jun-18 Study Site, Westmead, https://Cl
Sep-06 Jul-07 Aug-08 ### 9-Oct-15 9-Oct-15 Gloucester, United https://Cl
Sep-14 May-15 May-15 28-Apr-14 1-Jul-16 1-Jul-16 Achieve Clinical Rese https://Cl
Jun-06 28-Jun-06 8-Feb-10 Site 1, Berlin, Germa https://Cl
3-Dec-15 14-Feb-17 ### 29-Jul-15 ### Washington University https://Cl
24-Feb-17 2-Aug-21 2-Aug-21 2-Jan-17 ### Ponce School of Medihttps://Cl
14-Sep-11 5-Jun-13 5-Jun-13 ### 5-Jul-18 National Institutes ofhttps://Cl
Oct-06 May-07 May-07 ### 4-Nov-16 GSK Investigational Sihttps://Cl
Jan-17 Nov-17 May-19 1-Feb-17 7-May-19 Flinders University, A https://Cl
Oct-17 Dec-17 Dec-18 ### 2-Jan-20 Department of Clinicahttps://Cl
Sep-03 May-06 Jul-06 23-Jun-08 13-Jan-14 Gribomont, Belgium|K https://Cl
Nov-11 Mar-13 Nov-13 ### 6-Oct-11 Dan Turner, Tel Aviv, Ihttps://Cl
Jun-15 Jan-17 Jan-17 8-Jun-15 9-Nov-18 ### TASK Applied Scienceshttps://Cl
Dec-08 Aug-15 Aug-15 ### 24-Jul-17 24-Jul-17 Emory Healthcare & Ch https://Cl
A5220|10148|ACTG A5 Nov-07 Sep-08 6-Jan-06 ### Northwestern Universi https://Cl
Sep-07 Oct-09 Jan-10 8-Aug-06 ### ### Sidney Kimmel Compre https://Cl
6-Mar-13 18-Jun-15 ### ### ### ### GSK Investigational S https://Cl
23-Aug-18 Dec-21 Dec-21 ### 7-Feb-20 Vaccine Evaluation Cehttps://Cl
May-06 Sep-09 Sep-09 ### 7-Apr-14 13-Oct-17 Group Health Research https://Cl
Jan-12 Sep-12 Dec-12 27-Jan-12 ### ### Nagoya City, Aichi, J https://Cl
5-Oct-07 8-May-08 8-May-08 5-Oct-07 30-Apr-13 14-Jun-19 GSK Investigational S https://Cl
25-May-09 4-Feb-15 4-Feb-15 4-Sep-09 6-Feb-20 National Institutes ofhttps://Cl
Aug-09 Mar-10 Dec-10 6-Aug-09 11-Jul-11 ### Hoover, Alabama, Unit https://Cl
Apr-04 Apr-05 Apr-10 ### ### University of Massachhttps://Cl
16-Nov-18 12-Jul-19 ### ### 2-Jan-20 Masonic Cancer Centehttps://Cl
### ### National Taiwan Univehttps://Cl
May-00 Jun-05 Jun-12 27-Jan-03 ### H. Lee Moffitt Cancerhttps://Cl
28-Jul-17 31-Oct-18 31-Jan-19 ### ### https://Cl
Feb-10 Dec-13 Jun-15 ### ### Rockville Vaccine Ass https://Cl
Oct-14 Mar-16 Mar-16 17-Oct-14 6-Jun-17 Nothern California Cl https://Cl
Apr-13 May-15 Dec-15 4-Jun-13 2-Oct-17 ### University of Pittsbu https://Cl
Jun-14 Aug-14 Aug-14 25-Jun-14 1-Sep-14 Shenzhen Luohu Distrhttps://Cl
Oct-06 Jun-12 Jun-12 28-Jan-08 ### ### H. Lee Moffitt Cancerhttps://Cl
Aug-12 Oct-14 Jan-15 12-Oct-12 6-May-15 Beijing Youan Hospitalhttps://Cl
10-Jan-13 16-Jan-14 16-Jan-14 14-Jan-13 6-Sep-17 6-Sep-17 GSK Investigational S https://Cl
1-Aug-07 12-Oct-09 12-Oct-09 25-Jul-07 4-Oct-17 4-Oct-17 GSK Investigational S https://Cl
Oct-04 Jul-05 Jul-05 24-Apr-06 ### GSK Investigational Sihttps://Cl
Aug-09 Nov-12 Nov-12 28-Apr-08 11-Apr-14 ### YRG Care, Chennai, Inhttps://Cl
1-Jan-06 1-Jan-07 25-Jan-07 ### 4-Apr-17 8-Jun-18 GSK Investigational S https://Cl
Aug-10 May-11 May-11 ### 19-Jun-12 19-Jun-12 Novartis Investigativehttps://Cl
15-Feb-18 12-May-19 ### 20-Jun-17 ### https://Cl
2-Jun-10 5-Mar-14 5-Mar-14 ### 29-Oct-18 Kaiser Permanente Cre https://Cl
May-01 Mar-05 Mar-08 2-Sep-05 ### Alaska Native Medicalhttps://Cl
Nov-09 Jun-11 Sep-11 ### 3-Feb-12 Medical Research Coun https://Cl
31-Aug-15 31-Mar-17 ### ### 23-Jul-18 ### GSK Investi"Study Prohttps://Cl
13-Aug-19 29-Apr-20 ### ### 4-Oct-19 GSK Investigational S https://Cl
Dec-05 Aug-07 Aug-07 1-Dec-05 8-Jun-15 https://Cl
Jan-07 Apr-09 Sep-10 9-Mar-07 24-Jul-15 ### Sidney Kimmel Compre https://Cl
31-Aug-16 19-May-17 19-Jan-18 ### 26-Jul-18 WCCT Global, Costa Me https://Cl
13-Jul-12 4-Nov-16 1-Feb-17 4-Jun-12 23-Jan-18 23-Jan-18 GSK Investigational S https://Cl
Jan-09 Dec-12 Feb-13 7-Apr-09 6-May-09 School of Public Healhttps://Cl
Jul-07 Sep-08 Nov-08 28-Jun-06 20-Jul-12 ### GSK Investigational Sihttps://Cl
Dec-14 Dec-17 Dec-17 ### 25-Jan-18 Columbia University M https://Cl
30-Sep-10 22-Mar-11 ### 6-Sep-10 24-Apr-12 27-Jul-18 GSK Investigational Sihttps://Cl
7-Apr-04 24-Jul-07 24-Jul-07 ### 10-Apr-17 7-Jan-19 GSK Investigational S https://Cl
Jan-05 Jul-05 Jul-05 ### ### GSK Investigational S https://Cl
5-Aug-19 15-Jun-21 15-Jun-21 19-Jul-19 5-Feb-20 GSK Investigational S https://Cl
Apr-09 Apr-11 Apr-11 ### 27-Jun-11 IEND, Khartoum, Sud https://Cl
Jan-14 Mar-14 ### ### 5-Apr-18 Edinburgh Royal Infi https://Cl
Sep-10 Aug-11 Jun-12 27-Jul-12 27-Jul-12 University Medical C https://Cl
19-Sep-13 6-Feb-16 14-Jul-16 ### 6-Jul-17 Johns Hopkins Centerhttps://Cl
Mar-11 Dec-11 Oct-13 ### 5-Jan-16 Jiangsu Provincial Ce https://Cl
Apr-15 May-15 May-15 28-Apr-15 19-Oct-15 19-Oct-15 100, Salvador, Bahia, https://Cl
Mar-08 Apr-09 May-09 ### 25-Jun-09 Deccan College of Med https://Cl
12-Mar-18 May-20 May-20 ### 6-Feb-20 Hospital ClÃnic Barcelona,
https://Cl
Barcelona, Spain|Hospital
Oct-15 Jun-16 Jul-16 14-Oct-15 1-Sep-16 Dr. Alie H Wurie, Fre https://Cl
1-Dec-03 1-Feb-07 1-Feb-07 ### 7-Feb-17 6-Jun-18 GSK Investigational S https://Cl
21-Feb-20 31-Dec-21 ### 30-Jan-20 ### National Institutes ofhttps://Cl
Oct-07 May-08 May-08 23-Jan-08 30-Jun-08 https://Cl
Jun-09 Mar-13 Mar-13 9-Dec-11 ### Service d'Immunologie https://Cl
6-Sep-19 15-May-20 ### ### 18-Jan-20 4035 CCR Research, Mo https://Cl
1-Apr-19 2-Dec-20 2-Dec-20 23-Jan-19 4-Apr-19 Radboud university mhttps://Cl
Apr-16 Jul-20 Jul-20 ### 11-Jul-19 Icahn School of Medichttps://Cl
Dec-02 Jul-13 Jul-13 ### 9-Oct-14 Naval Medical Centerhttps://Cl
Apr-11 Jan-13 Dec-13 ### 2-May-17 University of Arkansahttps://Cl
24-Jun-09 31-Mar-10 9-Dec-10 ### 28-Jul-14 6-Jun-18 GSK Investigational S https://Cl
28-Aug-08 19-Sep-26 ### ### ### National Institutes ofhttps://Cl
Oct-14 Jul-16 Jul-16 ### 6-Jul-17 Emory Vaccine Centerhttps://Cl
Oct-06 Nov-07 Aug-08 ### 1-Apr-14 1-Apr-14 Bangkok, Thailand|Khhttps://Cl
Sep-99 Jun-08 Jun-08 18-Jun-04 31-Jan-13 Memorial Sloan-Kettehttps://Cl
Jun-14 Mar-15 Mar-15 ### ### East West Medical Reshttps://Cl
Nov-02 Sep-07 ### ### https://Cl
Dec-09 May-12 Sep-12 14-Jan-10 25-Apr-17 Birmingham, Alabama, https://Cl
Oct-12 Oct-14 Oct-14 19-Oct-12 3-Aug-18 Surrey CRC, Egerton Rhttps://Cl
Aug-13 Apr-16 Jan-17 ### 9-May-17 Oxford University Hoshttps://Cl
Oct-08 Oct-11 Oct-12 16-Oct-08 3-Feb-14 7-Jan-19 Digestive Disorders Clhttps://Cl
Aug-98 Nov-08 Nov-08 4-Nov-99 14-Jun-12 25-Jul-14 National Cancer Insti https://Cl
21-Jul-15 26-Jan-17 31-Oct-17 5-Oct-15 11-Oct-18 St James's Hospital, Dhttps://Cl
Jul-06 30-Jun-06 30-Jan-09 Site 1, Tessenderlo, https://Cl
1-Jun-16 10-Jun-18 10-Jun-18 18-Jul-19 4-Sep-19 https://Cl
May-08 Dec-14 Apr-16 ### 6-Jul-16 CIC Vaccinologie - Hophttps://Cl
Apr-13 Nov-15 May-16 23-Apr-13 26-Jul-16 Seoul, Korea, Republihttps://Cl
20-Sep-17 19-Nov-18 ### ### ### ### Universitat"Study Prohttps://Cl
1-Aug-07 26-May-08 27-Oct-08 27-Jul-07 24-Jan-19 24-Jan-19 GSK Investigational S https://Cl
Apr-16 Jun-17 13-Apr-16 13-Apr-16 https://Cl
Jul-12 Apr-13 Apr-13 ### 9-Oct-15 Holdsworth House Medi https://Cl
Dec-09 6-Dec-18 Jan-19 3-Feb-10 ### Florida Cancer Speci https://Cl
Oct-05 Mar-06 Mar-06 6-Apr-06 ### University of Marylanhttps://Cl
30-Sep-14 8-Dec-17 8-Dec-17 ### 21-Jun-19 21-Jun-19 GSK Investi"Study Prohttps://Cl
Jan-13 Feb-14 Dec-14 18-Jan-13 ### ### Miami Research Associ https://Cl
Oct-12 Jul-14 Jul-14 4-Nov-12 16-Jul-14 Christiana Care Healthttps://Cl
Nov-04 Feb-06 Nov-07 ### 5-Dec-12 5-Dec-12 Herston, Queensland,https://Cl
Oct-03 May-06 Nov-06 15-Oct-08 ### 1-Feb-12 Montgomery, Alabama, https://Cl
3-Aug-17 31-Dec-19 31-Jan-20 7-Mar-17 ### Centre de recherche en https://Cl
Ã©pidÃ©miologie, microbio
2-Jun-10 19-Jul-16 19-Jul-16 ### 1-Jul-19 6-Aug-19 National Institutes ofhttps://Cl
Sep-08 Nov-09 Nov-09 ### 21-Apr-14 29-Jan-20 Solano Clinical Researhttps://Cl
Jul-00 Mar-02 Apr-08 ### 17-Jan-18 https://Cl
7-Jul-07 7-Nov-07 6-Oct-08 20-Apr-07 8-Feb-19 8-Feb-19 Homagama MOH Divisio https://Cl
25-Jan-06 8-Aug-06 8-Aug-06 26-Jan-06 ### ### GSK Investigational Sihttps://Cl
Dec-05 Feb-09 ### 15-Jul-15 15-Jul-15 Sidney Kimmel Compre https://Cl
12-Jan-09 2-Jul-10 2-Jul-10 5-Dec-08 ### 26-Jun-19 GSK Investigational Sihttps://Cl
Feb-14 Feb-15 Feb-15 ### 3-Jun-15 Biological treatment https://Cl
18-Sep-07 1-Jun-08 6-Jun-08 ### 24-Jul-09 8-Jun-18 GSK Investigational Sihttps://Cl
Apr-10 Jul-10 Apr-11 ### 24-Jun-13 9-Sep-13 Pasteur Institute, Ho https://Cl
Jan-10 May-10 Nov-10 ### ### Cairo, Egypt https://Cl
14-Jan-08 22-Dec-08 1-Dec-09 18-Oct-07 ### 26-Jun-18 GSK
GSK Investigational
Investigational Sihttps://Cl
16-Apr-16 28-Jul-23 28-Jul-23 ### 4-Oct-19 Korea, Republic of|GSK https://Cl
Investigational Site, Incheon,
Dec-05 Aug-06 20-Apr-06 ### GSK Investigational Sihttps://Cl
12-May-17 11-Sep-17 ### 9-Jul-19 9-Jul-19 All Babies are Equal I https://Cl
Jul-13 Apr-17 Apr-17 11-Jul-13 5-Apr-17 GP surgeries in Glouchttps://Cl
Nov-10 Jul-11 Jul-11 1-Dec-10 ### Heartland Research As https://Cl
Sep-10 Apr-11 Sep-14 ### ### National Institute fo https://Cl
Oct-11 Jan-13 ### 14-Jun-16 Bridge HIV CRS, San Fhttps://Cl
Jan-13 4-Oct-17 4-Oct-17 1-Feb-13 5-Oct-17 Helsinki University C https://Cl
15-Apr-20 31-Dec-20 ### 25-Apr-19 16-Oct-19 https://Cl
Feb-10 Feb-10 Feb-10 8-Oct-12 8-Oct-12 https://Cl
May-03 Feb-05 Feb-05 ### 13-Oct-17 Group Health Research https://Cl
17-Sep-18 Aug-22 Aug-22 ### ### Investigational Site https://Cl
Jun-15 Apr-16 Jun-16 25-Jun-15 25-Jun-15 Hubei CDC, Wuhan, Hhttps://Cl
25-Sep-09 16-Apr-10 5-Jan-11 6-Oct-10 ### ### https://Cl
Mar-11 Dec-11 Dec-11 27-Jan-12 1-Feb-19 1-Feb-19 The Ohio State Univerhttps://Cl
1-May-14 May-21 May-21 30-Apr-14 4-Oct-19 MDAnderson Cancer https://Cl
Cen
9-Nov-12 25-Nov-14 16-Apr-15 8-Oct-12 28-Jun-18 ### GSK Investigational Sihttps://Cl
Sep-03 Jun-06 Oct-06 ### 7-Jun-12 University Childrens https://Cl
Jul-13 May-15 May-16 ### 20-Jun-18 18-Jul-18 Precision Trials LLC, https://Cl
Mar-05 Jul-05 Jul-05 ### ### GSK Investigational Sihttps://Cl
Jun-97 May-99 13-Jun-08 13-Jun-08 GSK Clinical Trials Ca https://Cl
17-May-17 10-Mar-18 ### 28-Apr-17 5-Oct-18 CHU Amiens Picardie,https://Cl
Jan-07 Mar-07 Mar-08 17-Apr-08 17-Apr-08 China-Japan Friendship https://Cl
Sep-03 May-04 ### ### Raval Nord, Barcelonahttps://Cl
Apr-14 Apr-15 Apr-15 ### 4-Nov-16 001, Novartis Investi https://Cl
Jan-20 May-21 Jul-22 13-Jan-20 13-Jan-20 George Washington Un https://Cl
Sep-05 May-07 ### ### Benchmark Research,https://Cl
S
Nov-12 Jan-13 Feb-13 ### 23-Oct-13 Jiangsu Provincial Ce https://Cl
Apr-16 15-May-18 ### 24-Jun-16 2-Jan-20 https://Cl
Apr-16 Jul-16 Jan-17 13-Jul-16 25-Oct-19 Paradigm Research - https://Cl
Oct-09 Jun-16 Dec-16 17-Jul-09 ### University of Alberta https://Cl
8-Nov-10 5-Nov-12 5-Nov-12 11-Oct-10 ### ### GSK Investigational S https://Cl
14-Nov-11 1-Apr-14 10-Apr-14 ### 24-Jan-17 ### GSK Investigational Sihttps://Cl
Jan-06 Dec-07 Dec-07 1-Sep-05 29-Jun-16 San Francisco Vaccinehttps://Cl
Mar-08 Nov-11 Nov-11 ### 19-Oct-16 GSK Investigational S https://Cl
Apr-03 Jun-07 May-14 27-Jan-03 9-May-14 H. Lee Moffitt Cancerhttps://Cl
Jan-03 Jun-03 Nov-03 31-Jan-03 ### ### Orlando Clinical Resehttps://Cl
Nov-02 ### 8-Dec-06 Manila, Philippines https://Cl
Aug-11 Jan-13 Jan-13 2-Jun-11 4-Mar-19 Broward Research Grou https://Cl
Mar-05 Dec-05 Dec-05 ### 16-Jan-17 GSK Investigational S https://Cl
11-Nov-13 16-Nov-16 ### 8-Oct-13 ### Mayo Clinic, Rochestehttps://Cl
27-Apr-06 1-Jul-06 7-Jul-06 4-May-06 24-Jun-13 8-Jun-18 GSK Investigational S https://Cl
26-Mar-07 1-Jul-07 13-Jul-07 5-Mar-07 25-Apr-17 GSK Investigational S https://Cl
May-06 1-Mar-11 Jun-11 15-Jun-06 ### ### Chon Buri Regional Hohttps://Cl
Jul-09 Nov-10 Nov-10 7-Aug-09 1-Mar-11 Women's College Hospi https://Cl
Dec-09 Jan-11 Jul-11 ### ### Bordeaux, France|Lillhttps://Cl
Sep-13 Dec-13 Dec-13 21-Oct-13 30-Apr-14 East West Medical Reshttps://Cl
Jun-10 May-11 May-11 23-Jun-11 3-Oct-12 KEMRI/Wellcome Trust https://Cl
Feb-06 Mar-07 Mar-07 ### ### O.L.Vrouwziekenhuis A https://Cl
Apr-12 3-May-18 3-May-18 6-Apr-12 ### Westmead Hospital, Shttps://Cl
1-Nov-07 18-Mar-08 29-Apr-08 6-Dec-07 28-Jun-17 8-Jun-18 GSK Investigational S https://Cl
Nov-00 May-03 Mar-09 ### ### Memorial Sloan-Kettehttps://Cl
1-Jul-18 31-Dec-19 ### 7-Aug-18 22-Oct-19 Minsk Scientific Prac https://Cl
13-Nov-18 8-Jan-21 8-Mar-21 6-Aug-18 4-Oct-19 University of Virginia,https://Cl
Nov-00 Apr-01 Apr-01 16-Oct-06 ### https://Cl
12-Dec-16 3-Sep-19 3-Sep-19 ### ### National Institutes ofhttps://Cl
Sep-03 Dec-03 Dec-03 ### 7-Sep-16 GSK Investigational S https://Cl
24-Jan-20 Nov-21 Nov-21 ### ### CCVTM, University ofhttps://Cl
Aug-08 Jun-16 Jun-16 ### ### Washington University https://Cl
Oct-08 May-10 May-10 28-Oct-08 ### Pfizer Investigational https://Cl
16-Oct-03 Sep-16 Jun-20 ### 6-Nov-19 Massachusetts General https://Cl
Feb-06 Mar-07 5-Mar-07 ### University of Sheffie https://Cl
Jul-09 Sep-09 Mar-10 14-Jul-09 ### 28-Jun-18 Study Site, Adelaide, https://Cl
Oct-07 Dec-11 ### 17-Jan-08 12-Apr-17 Royal Bournemouth hhttps://Cl
Jun-09 Jul-10 Jul-10 ### 30-Jul-10 George Washington Uni https://Cl
Jul-10 Jun-12 Jun-12 23-Apr-10 ### Makerere University https://Cl
25-Sep-09 23-Dec-16 ### ### 5-Jul-18 5-Jul-18 National Institutes o https://Cl
Mar-13 Feb-16 Feb-16 ### 2-May-17 2-May-17 Chang Gung Memorial https://Cl
2-Nov-04 23-Aug-07 ### ### 7-Feb-17 2-Jan-20 GSK Investigational S https://Cl
Nov-05 Jun-06 ### ### GSK Investigational Sihttps://Cl
Jul-08 Apr-09 27-Jun-08 30-Oct-15 Jonsson Comprehensive https://Cl
30-Apr-07 15-Sep-08 7-Oct-09 ### ### ### GSK Investigational S https://Cl
Dec-08 Jun-13 Jun-13 ### ### ### Sidney Kimmel Compre https://Cl
Jul-05 Mar-11 Oct-13 13-Oct-05 ### New York University Shttps://Cl
May-09 May-09 Dec-09 2-Apr-09 13-Jul-11 14-Jul-11 Covance CRU, Inc., Dahttps://Cl
Aug-07 Jul-08 Feb-09 5-Jun-06 13-Jun-12 HIV-NAT (The HIV Neth https://Cl
Aug-07 Jan-08 Sep-08 ### 21-Jul-09 University Hospitals Lhttps://Cl
May-04 Sep-07 Sep-07 11-Jun-04 ### University of Southern https://Cl
Sep-05 Jun-10 Jul-10 21-Jul-05 ### Fred Hutchinson Cance https://Cl
Jul-16 Jan-19 Jan-21 ### 3-Dec-15 https://Cl
25-Apr-07 21-Jan-08 14-Jun-08 20-Apr-07 3-Aug-09 2-Jan-20 GSK Investigational S https://Cl
Mar-97 Mar-99 13-Jun-08 13-Jun-08 GSK Clinical Trials Ca https://Cl
1-Aug-18 19-Feb-19 ### ### ### Lianshui Xinyi Center https://Cl
Jul-08 Jun-14 Jan-15 8-Jul-08 ### Bandim Health Project https://Cl
Jun-14 Jul-15 Jul-15 6-Mar-14 ### Radboud university mhttps://Cl
Sep-09 Jul-10 Jan-14 ### ### https://Cl
Dec-02 Sep-04 Feb-09 ### 8-Mar-10 13-Jan-15 https://Cl
Oct-13 Apr-14 Feb-15 17-Jul-15 20-Jul-15 https://Cl
Sep-12 Oct-13 Oct-13 ### ### ### Naval Medical Centerhttps://Cl
Jun-10 Sep-12 Sep-12 29-Jun-10 ### Alta Bates Comprehens https://Cl
Sep-13 Dec-15 Dec-15 4-Jul-13 24-Oct-16 London School of Hyghttps://Cl
Jan-07 Sep-07 18-Jan-07 9-Oct-15 Kinemed, Graz, Austrihttps://Cl
Sep-03 Sep-04 Sep-04 4-Oct-06 ### GSK Investigational Sihttps://Cl
Jul-12 Jul-13 Jul-13 24-Apr-12 25-Apr-12 Hospital das Clinicas https://Cl
Oct-13 8-Feb-18 8-Feb-18 ### 29-Oct-18 Abteilung fÃ¼r Infek https://Cl
Oct-15 Mar-18 Dec-18 3-Jul-15 10-Apr-19 Princess Ma "Study Prohttps://Cl
May-12 Aug-12 3-Aug-12 8-Aug-12 Faculty of Tropical M https://Cl
17-Sep-14 20-Nov-17 ### 23-Jan-17 ### ### Stanford Un "Study Prohttps://Cl
3-Jun-09 21-Jul-10 18-Jun-12 ### 4-Nov-11 3-Jan-20 GSK Investigational Sihttps://Cl
1-Sep-05 12-Oct-06 12-Oct-06 ### ### ### GSK Investigational S https://Cl
Apr-07 Jun-07 9-Aug-07 9-Aug-07 Norwegian Institute ohttps://Cl
Oct-13 Dec-19 Dec-19 23-Apr-14 23-Apr-14 University of Helsinkihttps://Cl
Jun-14 Dec-15 Jun-16 13-Jun-16 ### ### University of Coloradhttps://Cl
Mar-07 Jul-07 Jun-08 ### 27-Oct-16 GSK Investigational S https://Cl
13-Sep-13 31-Oct-16 ### 11-Oct-13 7-Feb-18 8-Jun-18 Emory Unive "Study Prohttps://Cl
Nov-06 Dec-11 Dec-11 ### ### Hospital ClÃnic, Barcelona,
https://Cl
Spain
Apr-10 Jul-10 Dec-12 15-Jun-11 19-Jan-17 Children's and Women' https://Cl
14-Apr-16 21-Aug-17 ### 20-Apr-16 ### https://Cl
Feb-04 Apr-04 Apr-05 22-Oct-08 ### ### Atlanta, Georgia, Uni https://Cl
Aug-15 May-16 May-16 27-Jul-15 ### ### https://Cl
23-Feb-17 Aug-22 Aug-22 ### 7-Nov-19 Tshuapa site, Boendehttps://Cl
10-Oct-17 28-Sep-18 ### 4-Aug-17 ### Rutgers University, P https://Cl
Sep-02 Mar-05 ### ### Ponce School of Medihttps://Cl
Sep-12 Jan-13 Jan-13 1-Nov-12 ### ### Research Institute of https://Cl
May-13 Aug-15 Aug-15 6-Mar-13 26-Apr-16 Centre for Clinical V https://Cl
Aug-12 Mar-13 May-13 ### 25-Oct-13 National Taiwan Univehttps://Cl
Jun-14 Aug-14 Aug-14 24-Jun-14 ### ### Ben Luc Health Centehttps://Cl
Sep-09 Mar-10 Mar-10 ### 31-Jul-12 Tasmc Crc, Tel Aviv, Ishttps://Cl
Jul-02 Jun-03 Jun-03 ### ### https://Cl
Jun-08 Apr-10 Jun-10 ### ### 14-Apr-16 Tucson, Arizona, Unithttps://Cl
10-Oct-17 10-Dec-18 ### 18-Oct-17 ### ### Anaheim Cli"Study Prohttps://Cl
Oct-04 Dec-05 Dec-05 4-Apr-06 ### Centre for Clinical V https://Cl
Feb-09 Mar-14 Mar-14 ### 14-Apr-15 14-Apr-15 Queensland Paediatric https://Cl
ACTG 292|11268 Oct-99 ### ### Usc La Nichd Crs, Los https://Cl
Jul-13 Apr-16 Apr-16 11-Apr-13 ### Centre for Clinical V https://Cl
Aug-06 May-07 13-Jul-05 ### https://Cl
Oct-08 Oct-09 Jun-10 ### 28-Apr-15 28-Apr-15 Department of Medicihttps://Cl
5-Dec-11 2-Feb-15 Mar-18 29-Apr-13 9-Mar-18 University of Chicago,https://Cl
10-Feb-06 8-Sep-06 9-Feb-06 ### GSK Investigational Sihttps://Cl
Sep-12 Jan-14 Jan-14 6-Aug-12 ### Covance, Inc., Daytonhttps://Cl
Jul-03 May-06 5-Aug-04 ### University of Virginia https://Cl
Dec-03 Jul-04 ### 9-Oct-15 PANTAMED Sp.z o.o., https://Cl
29-Nov-17 31-Dec-22 ### 8-Jun-17 ### Agencia Costarricensehttps://Cl
4-Dec-17 4-Aug-19 4-Aug-22 ### ### Centre for Cinical Va https://Cl
Dec-10 Dec-11 Dec-11 7-Feb-11 8-Mar-12 Healthcare Discoveriehttps://Cl
9-Apr-07 30-Nov-07 ### ### ### ### GSK Investigational Sihttps://Cl
Mar-13 Mar-15 15-Oct-12 ### Kenya AIDS Vaccine Inhttps://Cl
19-Dec-18 Jun-20 Dec-20 ### ### Medical Research Couhttps://Cl
Dec-10 Sep-12 Apr-13 21-Jan-11 ### 5-Mar-14 Duke Center for Nicothttps://Cl
Nov-17 Nov-19 Nov-19 25-Jul-14 ### Multiple Sclerosis Ce https://Cl
Nov-01 Mar-03 30-Jun-06 9-Sep-16 Pretoria, South Africahttps://Cl
Mar-07 Jul-14 Jul-14 27-Apr-07 ### ### Universita Degli Studihttps://Cl
di Bari, Bari, Italy|Ospedali Riun
11-Jan-13 29-Apr-14 29-Apr-14 ### 3-Jul-18 3-Jul-18 GSK Investigational S https://Cl
Jun-13 Jun-14 Jun-14 30-Apr-13 30-Apr-15 Naval Medical Researc https://Cl
Nov-98 Jul-99 16-Jun-08 16-Jun-08 GSK Clinical Trial Cal https://Cl
Oct-05 Jan-09 Jan-09 21-Apr-06 1-Mar-10 ### GSK Investigational S https://Cl
1-Nov-16 28-Mar-17 ### 3-Oct-16 5-Nov-19 Vanderbilt University https://Cl
Oct-04 Aug-06 ### ### Universidade Federal https://Cl
Feb-14 Mar-15 Jan-16 16-Jan-15 16-Jan-15 https://Cl
Jan-13 Apr-14 May-14 9-Jan-13 24-Jun-14 Centers for Disease Chttps://Cl
21-Jan-19 2-Nov-20 31-Oct-21 31-Jul-18 ### Barwon Health, Geelong, https://Cl
Australia|Telethon Kids Insti
Feb-11 Jul-12 Jul-12 3-Feb-11 ### Tijuana General Hospithttps://Cl
10-Jun-19 29-Aug-20 ### ### ### Emory Child "Informed https://Cl
Sep-16 Jun-17 Dec-17 13-Jun-16 11-Apr-18 Tel Aviv Souraski Medic
https://Cl
Sep-11 Mar-12 Dec-12 6-Oct-11 ### Cetero Research Clinichttps://Cl
12-May-17 25-Oct-18 25-Oct-18 ### 5-Mar-19 Leiden University Med https://Cl
5-Apr-06 19-Jun-07 19-Jun-07 17-Oct-05 ### ### GSK Investigational Sihttps://Cl
Feb-16 25-Jul-16 25-Jul-16 4-Mar-16 ### Moscow, Russian Fede https://Cl
14-Jun-02 31-Jul-07 ### ### ### 2-Dec-19 https://Cl
Sep-13 Nov-14 Nov-14 ### ### Emory Vaccine Centerhttps://Cl
-
2-Jun-08 1-Mar-09 ### 9-Jun-08 ### 8-Jun-18 GSK Investigational Sihttps://Cl
13-Oct-17 26-Dec-19 30-Apr-21 ### 10-Apr-19 Center for Immunizatihttps://Cl
May-10 May-20 May-20 ### 15-Jul-19 University of Texas Mhttps://Cl
10-Mar-09 24-Feb-17 ### ### 3-Mar-17 University of Texas Mhttps://Cl
22-Jan-19 10-May-19 ### 10-Oct-19 14-Oct-19 George Clinical Reseahttps://Cl
Sep-06 Jul-07 Dec-07 3-Oct-06 14-Jan-14 Angers, France|Vilni https://Cl
11-Jul-17 14-Jul-17 14-Jul-17 19-Jun-17 15-Oct-18 GSK Investigational Sihttps://Cl
7-Feb-07 3-Dec-07 3-Dec-07 29-Jan-07 4-Jun-18 4-Jun-18 GSK Investigational Sihttps://Cl
Apr-14 Dec-15 Dec-15 ### 12-Jun-18 10-Oct-19 Kenya Medical Researhttps://Cl
Nov-15 Aug-16 Aug-16 28-Oct-15 28-Jul-16 United Christian Hosphttps://Cl
25-Aug-14 14-Aug-15 ### 9-Jul-14 3-Jul-18 3-Jul-18 GSK Investigational Sihttps://Cl
22-Oct-07 10-May-08 7-Oct-08 22-Oct-07 14-Jan-19 14-Jan-19 GSK Investigational S https://Cl
24-Mar-15 22-Sep-16 ### 2-Mar-15 27-Jan-20 State University of N https://Cl
23-Jul-07 4-Dec-09 4-Dec-09 17-Jul-07 3-Jun-14 25-Oct-18 GSK Investigational Sihttps://Cl
1-Dec-14 18-Feb-19 ### ### ### Hospital Maternidad N https://Cl
16-Sep-14 30-Sep-24 ### ### 13-Jun-19 National Institutes ofhttps://Cl
30-Aug-18 30-Nov-18 30-Jun-19 27-Apr-18 ### LeBonheur Children'shttps://Cl
7-Apr-16 17-Dec-18 ### 26-Jan-16 29-Jul-19 Centre National de R https://Cl
Jan-10 Oct-13 Oct-13 7-Oct-10 ### Duke University Medic https://Cl
14-Dec-18 17-Apr-19 17-Apr-19 ### 13-Jun-19 Manipal Hospital / Dehttps://Cl
Jul-04 May-06 ### ### ClÃnica de Leishmaniasis,
https://Cl
Hospital Nacional Sur Este E
1-Feb-12 30-Jun-20 ### 7-Feb-12 1-Nov-19 UCLA, Los Angeles, Cahttps://Cl
18-Apr-18 14-Feb-19 ### 5-Oct-18 ### University of Turku, https://Cl
May-11 Dec-11 Oct-12 ### 18-Oct-12 Privatklinik Leech, G https://Cl
Dec-17 Dec-18 Jun-19 14-Jun-17 ### https://Cl
Dec-14 Nov-16 ### 1-Feb-17 Center for Immunizatihttps://Cl
Jun-05 Sep-07 Jan-10 7-Jul-05 ### Massacusetts Generalhttps://Cl
HIVNET D01 ### 24-Jun-05 Los Angeles County / https://Cl
May-06 Jul-07 Jul-07 5-May-06 ### https://Cl
May-07 May-12 May-13 ### 9-Jan-17 9-Jan-17 Krankenhaus Nordweshttps://Cl
Jul-10 Dec-11 Dec-11 19-Jul-11 ### Kansas University Schhttps://Cl
3-Apr-08 3-Apr-09 3-Apr-09 ### 3-Feb-17 ### GSK Investigational Sihttps://Cl
21-Feb-12 26-Feb-13 ### 7-Feb-12 14-Jan-19 14-Jan-19 https://Cl
Apr-99 Jan-00 Jan-00 16-Jun-08 ### https://Cl
P1091|11687 Aug-14 ### 7-May-14 https://Cl
27-Jan-12 4-Aug-14 19-Oct-15 25-Apr-11 6-Aug-19 6-Aug-19 GSK Investigational S https://Cl
Mar-14 Dec-14 Dec-14 23-Jan-14 9-Jan-15 NIHR Wellcome Trusthttps://Cl
C
13-Jul-18 17-Sep-19 ### 19-Jun-18 ### Leo Pharma Investigathttps://Cl
May-09 Oct-09 Oct-09 ### 18-Jul-13 University Clinical R https://Cl
18-Sep-09 ### 6-Feb-20 National Institutes ofhttps://Cl
1-Oct-06 2-Jul-07 2-May-08 23-Oct-06 ### ### GSK Investigational S https://Cl
Oct-06 Nov-09 May-10 11-Oct-06 9-Jun-10 Hospital InfantÃl Dr. Robert
https://Cl
Reid Cabral, Santo Domin
Apr-15 Apr-17 Dec-17 ### 13-Jul-17 Centro de Pesquisas https://Cl
Aug-12 Jan-13 Mar-13 ### ### Jiangsu Provincial Ce https://Cl
Jun-14 Dec-20 Dec-20 13-Jan-15 3-Jan-20 H. Lee Moffitt Cancerhttps://Cl
Apr-07 May-12 May-12 ### ### Cedars Sinai Medical h c ttps://Cl
12-Feb-07 8-Aug-07 8-Aug-07 11-Jan-07 ### ### GSK Investigational Sihttps://Cl
Feb-09 Jan-13 Jan-13 4-Jun-09 1-Dec-15 1-Dec-15 Dartmouth-Hitchcockhttps://Cl
18-Aug-10 3-Dec-10 3-Dec-10 29-Jul-10 11-Apr-17 21-Jan-20 GSK Investigational S https://Cl
Sep-11 Jul-12 Jul-12 8-Mar-12 8-Mar-12 Baqiyatallah Universithttps://Cl
Mar-03 Feb-05 13-Jan-03 ### National Centre in HI https://Cl
19-Dec-11 7-Oct-13 9-Dec-15 ### 21-Jun-19 Perinatal HIV Resear https://Cl
1-Dec-14 26-Mar-15 11-Jun-15 7-Nov-14 6-Dec-17 ### GSK Investigational Sihttps://Cl
1-Mar-20 Sep-21 Dec-21 ### 28-Jan-20 https://Cl
9-Feb-10 14-Jan-11 21-Oct-11 1-Feb-10 7-Jun-12 ### GSK Investigational Sihttps://Cl
Oct-11 Aug-12 Aug-12 ### 10-Apr-14 10-Apr-14 Research Institute fo https://Cl
Aug-15 Jun-16 Jun-16 5-May-15 1-Sep-16 Kenya Medical Researhttps://Cl
May-11 Dec-24 Dec-24 13-Jul-11 ### VÃ¤estÃ¶liitto Seksu https://Cl
Aug-12 May-13 Mar-14 18-Jul-12 4-Mar-19 Broward Research Grou https://Cl
Aug-06 Mar-10 Dec-14 2-Oct-06 ### 31-Jul-18 National Institutes ofhttps://Cl
12-Apr-17 9-Jul-18 9-Jul-18 ### 18-Oct-18 Investigational Site, https://Cl
HVTN 045|10593 Apr-03 ### 4-May-12 Alabama Vaccine CRS,https://Cl
3-Apr-17 31-Dec-20 ### 24-Jan-17 9-Aug-19 Fred Hutch/Universit https://Cl
Jul-06 Jun-07 Jul-08 19-Oct-06 ### The Hospital for Sick https://Cl
31-May-17 18-Jan-19 14-Jun-19 ### ### Research Institute fo https://Cl
May-01 Jan-04 Jan-04 21-Apr-08 31-Jan-12 Fayetteville, AR 7270 https://Cl
15-Jul-15 23-Dec-16 ### 30-Jun-15 4-Jan-18 4-Jan-18 GSK Investigational S https://Cl
Feb-08 Oct-10 Oct-10 ### 29-Oct-12 GSK Investigational https://Cl
29-Mar-06 1-Nov-06 ### 3-Apr-06 8-May-17 GSK Investigational S https://Cl
PAVE 100|10500 9-Jul-07 ### https://Cl
Dec-16 Jun-18 8-Nov-16 2-Oct-18 University of Rochesthttps://Cl
Aug-14 Jul-15 Jul-15 14-Jan-14 1-Jul-16 1-Jul-16 King George Hospital,https://Cl
6-Mar-13 9-Jan-18 22-Apr-19 7-Mar-13 7-Oct-19 National Institutes ofhttps://Cl
3-Mar-19 Dec-19 Sep-22 1-Nov-16 12-Apr-19 Dana Farber Cancer Inhttps://Cl
5-Mar-18 13-Jul-18 28-Jul-19 ### ### Optimal Research, LLChttps://Cl
1-Jan-16 1-Nov-17 ### 13-Jan-20 13-Jan-20 Uhmontpellier, Montpe https://Cl
Aug-02 Oct-02 Sep-05 23-Jun-08 24-Oct-08 https://Cl
18-Mar-19 15-Oct-19 1-Oct-21 ### 27-Jan-20 Paratus Clinical Pty https://Cl
Jul-14 Mar-15 Mar-15 ### ### Centre pour le DÃ©vehttps://Cl
1-Oct-10 1-Jul-11 1-Jul-11 ### ### ### GSK Investigational S https://Cl
Dec-14 Jun-16 May-18 31-Oct-14 ### https://Cl
Apr-09 Nov-11 May-13 ### 18-Jan-17 1-Oct-19 The PLA Beijing Milit https://Cl
21-Aug-18 21-Aug-20 ### 18-Jul-18 ### Emory Children's Centhttps://Cl
23-May-11 8-Mar-14 8-Mar-14 ### ### https://Cl
Nov-09 Apr-10 Sep-14 3-Dec-09 ### National Institute fo https://Cl
Feb-06 Aug-07 ### 4-Mar-15 Alabama Vaccine CRS,https://Cl
2-Jan-12 28-Jun-17 27-Jan-12 5-Apr-18 District of Nakasang https://Cl
15-Jun-18 17-Jan-20 ### 6-Jun-18 5-Feb-20 George Washington Uni https://Cl
Dec-07 31-Jul-20 31-Jul-21 ### 25-Oct-19 Holden Comprehensive https://Cl
Sep-13 Jan-14 Jan-14 10-Jan-13 ### University of Surrey, https://Cl
Oct-06 Jul-07 Jul-07 27-Jan-06 22-Jan-14 University of Alabamahttps://Cl
30-Sep-11 22-Oct-11 22-Oct-11 ### ### 7-Sep-18 GSK Investigational S https://Cl
Nov-10 Mar-12 Mar-12 1-Dec-10 ### ### Sotobo Children's Cli https://Cl
Aug-09 Feb-11 Feb-11 23-Jul-09 ### Desmond Tutu HIV Cen https://Cl
17-Oct-17 11-Dec-17 ### 19-Oct-17 ### Coastal Clinical Rese https://Cl
Sep-20 Dec-20 Dec-20 ### ### https://Cl
10-Mar-11 20-Jun-14 20-Jun-14 ### 6-Feb-20 National Institutes ofhttps://Cl
Aug-04 Jan-05 Jan-05 20-Jan-06 13-Apr-11 Qutintiles Phase I Se https://Cl
27-Jan-15 19-Apr-17 19-Apr-17 3-Feb-15 5-Dec-17 Makerere University https://Cl
Oct-07 Nov-15 Nov-15 ### ### Memorial Sloan-Kettehttps://Cl
Jun-07 ### 30-Jan-09 Site 1, Tessenderlo, https://Cl
Sep-09 Apr-10 Mar-11 ### 9-Oct-15 General Practice, Ef https://Cl
12-May-15 18-Aug-17 8-Jan-18 23-Apr-15 2-Jul-18 Cancer Center at the U
https://Cl
11-Jul-08 11-Jul-15 1-Jul-16 9-Nov-17 9-Nov-17 Alabama Vaccine CRS,https://Cl
Mar-12 May-12 May-12 28-Oct-11 ### Muhimbili University https://Cl
Sep-16 27-Oct-17 27-Oct-17 ### ### https://Cl
Mar-06 Sep-11 Sep-12 22-Jun-10 ### ### Center for Liver Dise https://Cl
Jun-08 Jul-08 Jul-08 24-Apr-08 ### Site 1, Tessenderlo, https://Cl
Nov-15 Dec-16 Dec-16 ### ### Research Site US062, https://Cl
Aug-05 Nov-05 ### ### GSK Investigational Sihttps://Cl
11-Oct-16 1-May-17 1-May-17 ### 3-Aug-18 2-Jan-20 GSK Investi"Study Prohttps://Cl
Sep-10 Dec-11 Dec-11 20-Oct-10 1-Mar-13 Accelovance - Melbouhttps://Cl
May-06 Jan-11 Oct-12 ### 5-Oct-15 Jonsson Comprehensive https://Cl
28-Feb-15 2-May-16 2-May-16 ### 2-Jun-17 2-Jun-17 Research Site, Gilber https://Cl
29-Jan-16 15-Nov-16 9-May-17 22-Oct-15 24-Apr-19 24-Apr-19 Investigational Site- https://Cl
Dec-08 Jul-10 Jul-10 ### ### 31-Jul-13 Pfizer Investigational https://Cl
May-08 Feb-10 Feb-15 15-Jul-08 ### Quantum Immunologic https://Cl
May-99 Jun-08 ### 30-Oct-13 Memorial Sloan-Kettehttps://Cl
May-11 Sep-13 ### 7-Aug-09 7-Mar-18 Seattle Vaccine and Phttps://Cl
Nov-15 Nov-18 Jan-19 22-Jun-15 4-Sep-19 Department of Medicihttps://Cl
1-Apr-18 1-Apr-19 1-Apr-20 9-Mar-18 8-Feb-19 Hospital Universitari https://Cl
31-May-10 9-Feb-15 ### 14-Jun-10 13-Jan-20 National Institutes ofhttps://Cl
1-Oct-10 25-Jan-11 24-Jun-11 9-Sep-10 ### ### GSK Investigational S https://Cl
10-Oct-16 1-Feb-17 1-Feb-17 ### 23-Apr-18 23-Apr-18 Centers for"Study Prohttps://Cl
Nov-09 Jan-10 May-10 ### 2-Jan-12 Centre hospitalier Ly https://Cl
27-Nov-12 8-Feb-17 8-Feb-17 ### ### GSK Investigational Sihttps://Cl
Apr-07 Jan-08 Jan-08 5-Apr-07 30-Jul-10 ### GSK Investigational S https://Cl
25-Oct-17 3-Sep-19 2-Jan-20 14-Jun-17 6-Jan-20 National Institutes ofhttps://Cl
7-Jul-10 30-Apr-11 ### 2-Apr-10 ### 27-Jun-19 GSK Investigational S https://Cl
9-Nov-09 21-Feb-11 ### 1-Sep-09 ### 8-Jun-18 GSK Investigational Sihttps://Cl
29-Mar-16 27-Apr-16 27-Apr-16 11-Jul-16 23-Jan-19 Investigational Site, https://Cl
1-Apr-11 23-Nov-17 ### ### ### 19-Jun-19 GSK Investi"Study Prohttps://Cl
Nov-09 ### ### University Clinic of R https://Cl
Jan-10 Aug-13 Aug-13 13-Jan-10 ### ### Tampa Clinical Resea https://Cl
Nov-15 Sep-19 Sep-19 21-Jul-15 ### Haukeland Universityhttps://Cl
Nov-01 Mar-03 Jan-05 27-Jan-03 7-Mar-14 University of Chicago https://Cl
Jan-06 Jan-06 Dec-08 24-Apr-07 12-Jun-12 ICDDR,B, Dhaka, Ban https://Cl
1-Jul-14 24-May-15 ### ### 10-Apr-17 6-Jun-18 GSK Investigational Sihttps://Cl
Jul-09 Sep-09 Feb-10 ### ### Taizhou Municipal Cen https://Cl
1-Aug-18 1-Dec-20 1-Dec-20 30-Jul-18 ### University of Californhttps://Cl
8-Oct-10 31-Jan-20 31-Jan-21 ### ### University of Los Angehttps://Cl
PRO-sPanFlu-2002 ### ### Beijing Centers for Dihttps://Cl
Jul-06 Jul-07 Feb-08 17-Apr-06 4-Feb-14 ### Ankara, Turkey https://Cl
Sep-05 Sep-06 Sep-06 30-Jan-08 ### 2-Jun-16 https://Cl
Feb-03 Jan-06 8-Sep-05 ### https://Cl
Sep-01 Dec-01 Dec-01 ### ### David M. Radin, MD, https://Cl
Jul-09 Jul-11 Jul-11 15-Apr-11 ### Hunan Provincial Cenhttps://Cl
Sep-14 Jan-15 Sep-15 ### 12-Jul-17 Centers for Medicare https://Cl
28-Jun-14 6-Apr-17 ### 2-Jul-14 ### National Institutes ofhttps://Cl
Sep-14 Apr-16 Apr-16 17-Apr-14 6-Apr-18 Royal Liverpool Univehttps://Cl
28-Nov-07 14-May-08 ### 3-Sep-07 8-Jul-09 7-Sep-18 GSK Investigational S https://Cl
1-Oct-08 5-Mar-09 1-Jun-09 2-Oct-08 27-Jul-10 31-Jul-18 GSK Investigational Sihttps://Cl
17-Sep-14 22-Aug-17 ### ### 6-Jul-18 Centre for Clinical V https://Cl
Jun-09 Dec-12 Jul-13 2-Dec-08 8-Sep-17 McMaster University https://Cl
Jan-04 Mar-05 ### ### Emory University Schohttps://Cl
5-Oct-18 4-Jan-19 4-Jan-19 ### 4-Jun-19 GSK Investigational S https://Cl
31-May-14 28-Jul-17 16-Jan-18 3-Jun-14 12-Oct-18 12-Oct-18 National In"Study Prohttps://Cl
Sep-07 Feb-09 Apr-09 21-Oct-08 17-Jun-15 Lyon Sud, France https://Cl
Jun-07 Jun-10 Jun-12 27-Jun-07 11-Jan-13 University of Marylanhttps://Cl
Aug-15 31-Jan-19 31-Jan-19 ### 4-Mar-19 UniversitÃ¤tskliniku https://Cl
22-Jan-14 2-May-15 5-May-15 3-Feb-14 4-Dec-18 Vince & Associates Clhttps://Cl
Mar-06 Dec-06 13-Jul-06 13-Oct-08 GSK Investigational https://Cl
21-May-12 26-Jul-16 26-Jul-16 6-Mar-12 ### ### GSK Investigational Sihttps://Cl
May-09 Jun-12 Jun-12 4-Feb-13 4-Feb-13 https://Cl
Oct-09 Mar-10 Jul-10 26-Oct-09 15-Jun-11 20-Apr-12 North York General Ho https://Cl
Mar-11 Jun-12 Jun-12 27-Oct-10 10-Apr-14 1-May-14 K.E.M. Hospital Reseahttps://Cl
1-Oct-11 31-Oct-14 ### ### 8-Mar-17 ### GSK Investigational S https://Cl
6-Oct-12 6-May-13 5-Jun-13 8-Oct-12 14-Jul-14 7-Sep-18 GSK Investigational S https://Cl
10-Aug-19 31-Dec-19 ### ### ### Shaanxi Provincial Cehttps://Cl
Oct-08 Jul-13 Dec-14 ### ### ### Fred Hutchinson Canchttps://Cl
1-Oct-17 1-Jun-20 1-Jun-20 18-Oct-17 31-Jan-19 Centro de Investiga https://Cl
14-Jun-16 3-Sep-18 1-Oct-21 4-Dec-18 9-Jan-20 https://Cl
Sep-07 Oct-08 Oct-08 29-Jan-08 ### Johnson County Clinichttps://Cl
Oct-07 May-09 May-09 30-Oct-07 8-Jun-15 https://Cl
Oct-06 Jan-07 Jan-07 18-Oct-06 22-Jan-14 Academic Dermatology https://Cl
Sep-14 Dec-15 Jun-16 ### ### Henan Provincial Cenhttps://Cl
25-Aug-09 23-Jul-10 23-Jul-10 1-Sep-09 ### 18-Jan-20 GSK Investigational Sihttps://Cl
Jun-97 Feb-98 17-Jun-08 17-Jun-08 GSK Clinical Trials Calhttps://Cl
Dec-13 Sep-14 Dec-14 ### ### Canadian Science Cenhttps://Cl
24-Feb-18 26-Jun-18 ### 7-Feb-18 5-Jul-19 New Orleans Center fo https://Cl
Sep-15 Oct-17 Jun-18 2-Oct-15 30-Jan-19 30-Jan-19 Yale Unive "Study Prohttps://Cl
Mar-15 Jun-16 Jun-16 2-Feb-15 7-Jul-16 Boston Medical Center https://Cl
Oct-12 Oct-15 Oct-15 23-Oct-12 29-Apr-16 Germans Trias i Pujol https://Cl
Feb-04 Oct-05 ### ### Center for Urban Epi https://Cl
11-May-05 4-Jul-06 4-Jul-06 ### ### ### GSK Investigational S https://Cl
2-Sep-19 30-Oct-21 ### ### ### Henan Cancer Hospitahttps://Cl
7-Aug-06 27-Apr-07 17-Oct-07 26-Jun-06 7-Dec-18 7-Dec-18 GSK Investigational S https://Cl
Nov-12 Sep-13 24-Oct-12 ### St. Michael's Health Chttps://Cl
Jan-03 Apr-03 Oct-03 31-Jan-03 ### ### PRA International, Lehttps://Cl
1-Jan-19 1-Jan-22 1-Jan-22 10-Jul-18 17-Jul-18 https://Cl
Nov-11 21-Sep-16 ### ### ### Alabama Oncology, Bes https://Cl
Mar-98 May-99 16-Jun-08 16-Jun-08 GSK Clinical Trials Ca https://Cl
11-Sep-03 16-Jan-06 16-Jan-06 ### ### 6-Aug-18 GSK Investigational Sihttps://Cl
May-05 Sep-06 Sep-06 27-Apr-06 ### ### Clinical Pharamacologhttps://Cl
12-Nov-19 30-Mar-23 7-Dec-23 27-Jun-19 6-Dec-19 Synexus - Optimal Reshttps://Cl
22-Jun-17 25-Mar-20 ### 28-Jun-17 ### GSK Investigational Sihttps://Cl
Nov-13 Jun-17 Jul-19 1-Jul-13 18-Jul-19 Duke University Medic https://Cl
Jan-02 Mar-03 Apr-03 27-Jan-03 ### Arizona Cancer Centerhttps://Cl
Oct-04 May-05 ### ### University of Perugia,https://Cl
23-Sep-14 30-Nov-15 ### ### ### Boston, Massachusetthttps://Cl
22-Dec-14 29-Aug-17 18-Jul-22 ### 17-Jun-19 Aurora, Colorado, Unhttps://Cl
Jan-14 Mar-15 Jul-15 ### 2-Feb-16 CNRFP, Ouagadougou,https://Cl
B
Mar-10 Apr-11 Nov-11 ### ### Rush University Medichttps://Cl
Jan-17 29-Aug-18 29-Oct-19 2-Aug-16 27-Jan-20 Alabama CRS, Birmingh https://Cl
Jan-00 Mar-07 27-Jan-03 24-Jan-13 Dana-Farber Cancer In https://Cl
1-Jul-19 30-Jun-21 ### ### ### University of Virginia https://Cl
12-Jan-15 Apr-16 3-Nov-16 4-Dec-14 2-Aug-19 2-Aug-19 Medical Research Couhttps://Cl
13-Jan-11 30-Apr-14 ### 1-Nov-10 ### ### GSK Investigational S https://Cl
Feb-15 28-Feb-17 ### 3-Mar-15 ### "Study Prohttps://Cl
Apr-14 May-15 May-15 8-Apr-14 9-May-16 102, Novartis Investighttps://Cl
2-Jun-16 4-May-20 5-May-20 ### ### Cincinnati Children's https://Cl
Jun-13 Jun-15 Dec-15 3-Mar-14 3-Mar-14 Imperial College Lon https://Cl
Aug-15 Dec-16 Mar-18 20-Apr-15 ### University of Marylanhttps://Cl
5-Jun-07 26-Feb-08 ### ### ### ### GSK Investigational Sihttps://Cl
Dec-15 Mar-19 Jul-19 9-Dec-15 ### Research Site US115, https://Cl
20-Feb-07 13-Jun-08 13-Jun-08 ### 1-Oct-19 1-Oct-19 GSK Investi"Study Prohttps://Cl
Jun-10 Jan-14 Jan-14 ### 26-Jun-19 26-Jun-19 The First Affiliated https://Cl
Sep-03 Oct-03 Oct-03 ### 7-Sep-16 GSK Investigational Sihttps://Cl
Jun-06 ### 13-Oct-08 GSK Investigational S https://Cl
Jan-16 Dec-18 Mar-19 3-Dec-15 22-Oct-19 University of Hong K https://Cl
Mar-12 Mar-12 Mar-12 11-Jul-13 15-Jun-17 15-Jun-17 Royal Childrens Hospithttps://Cl
11-Jul-12 25-Apr-13 22-Jan-14 11-Jun-12 16-Jun-14 16-Jul-19 GSK Investigational Site, https://Cl
Benesov, Czechia|GSK Investi
1-Feb-11 Feb-13 ### 12-Apr-11 7-Sep-18 Royal Devon and Exethttps://Cl
Nov-15 Sep-21 Sep-21 13-Jan-16 7-Oct-19 Clinical and Translati https://Cl
Jul-08 Mar-09 Mar-09 1-Dec-10 1-Dec-10 Korea University Ansahttps://Cl
18-Jul-19 Nov-20 Nov-20 5-Jul-19 ### Centre for Clinical V https://Cl
Mar-05 Sep-07 Sep-07 4-Mar-05 2-Jul-09 University of Nebras https://Cl
Oct-99 Sep-04 Sep-04 9-Jun-08 ### https://Cl
Dec-03 Mar-07 Mar-07 ### 28-Oct-16 GSK Investigational Site,
https://Cl
Colonia Caroya, CÃ³rdova, Ar
Oct-09 Dec-10 Mar-11 6-Aug-09 3-Oct-11 3-Oct-11 Anaheim, California, https://Cl
Jan-06 Dec-07 16-Jan-06 ### Queen Mary Hospital,https://Cl
29-May-07 2-Dec-14 2-Dec-14 1-Mar-10 ### 11-Jul-17 https://Cl
7-Oct-14 10-Dec-15 ### 31-Oct-14 12-Jul-19 12-Jul-19 https://Cl
Nov-04 Nov-04 May-06 27-Jan-06 9-Jun-15 Pentagon, Washington, https://Cl
10-May-16 14-Sep-16 10-Apr-18 3-Dec-19 ### Papua New Guinea Ins https://Cl
Oct-14 Aug-16 31-Oct-17 ### 11-Oct-18 Centre for Clinical V https://Cl
May-07 Dec-10 Jun-11 ### 22-Oct-13 Clinical Investigation https://Cl
Mar-05 Dec-05 Dec-05 ### ### GSK Investigational Sihttps://Cl
HVTN 060|10057 May-08 ### ### Alabama Vaccine CRS,https://Cl
Aug-11 Sep-11 Feb-12 17-Oct-12 ### Szpital Internistyczn https://Cl
13-May-10 2-Sep-10 2-Sep-10 19-Apr-10 12-Apr-17 1-Oct-19 GSK Investigational Sihttps://Cl
Sep-08 Jan-09 Jan-09 ### 1-Apr-10 14-Apr-16 Norfolk, Virginia, Uni https://Cl
Jul-13 Mar-14 Mar-15 ### 3-Apr-15 Karabots Primary Carehttps://Cl
Jan-06 Jan-07 ### ### Bandim Health Projechttps://Cl
27-Sep-19 27-Sep-20 ### 17-Oct-19 17-Oct-19 CCVTM, University ofhttps://Cl
Feb-16 Feb-17 Feb-17 1-Apr-16 13-Jul-18 SOUSEIKAI Sumida Hosp https://Cl
Jun-14 Apr-15 Jul-15 24-Jun-14 29-Oct-14 Kaali Institute, Buda https://Cl
Oct-99 Apr-06 ### ### Albert Einstein Comprhttps://Cl
Mar-10 Dec-12 Dec-12 ### 5-Mar-14 The Hope Clinic of th https://Cl
26-Oct-15 16-Feb-18 ### 14-Apr-15 28-Jun-19 23-Jul-19 GSK Investi"Study Prohttps://Cl
Dec-11 Mar-13 ### 2-Sep-13 Kenya AIDS Vaccine Inhttps://Cl
Feb-16 Jan-19 Jan-19 ### ### Beijing Tiantan Hospihttps://Cl
7-Mar-11 21-Jul-11 26-Jan-14 8-Mar-11 ### 22-Oct-18 GSK Investigational S https://Cl
Dec-13 May-16 May-16 ### ### Moral Neighbourhoodhttps://Cl
L
Aug-10 Jul-12 Jul-12 23-Jul-10 ### Emory Children's Cente https://Cl
Aug-16 Dec-19 Dec-20 7-Dec-16 17-Apr-19 University of Calgary,https://Cl
13-Dec-17 Jan-23 Jan-23 ### ### Sidney Kimmel Compre https://Cl
Aug-04 Jul-05 10-Jan-06 29-Jan-07 Westover Heights Clinhttps://Cl
Nov-09 Dec-10 Dec-10 ### ### Tata Memorial Hospithttps://Cl
Jul-07 Nov-08 Nov-08 ### 21-Jun-13 Healthcare Discoveries https://Cl
Sep-14 Aug-15 May-16 23-Jun-14 ### ### Vaccine Evaluation Cehttps://Cl
14-Mar-18 Jul-21 Jul-21 16-Jan-18 21-Oct-19 Centre for Clinical V https://Cl
Oct-05 Apr-06 ### 7-Nov-06 Hadassah Medical Orga https://Cl
Oct-04 May-05 May-05 ### 10-Jan-17 GSK Investigational S https://Cl
May-10 Dec-10 Sep-12 ### 21-Jun-13 Denver, Colorado, Unihttps://Cl
Aug-08 Apr-11 Apr-11 28-Jul-08 ### 13-Jan-14 University of Califor https://Cl
11-Jul-13 11-Mar-14 ### 16-Jul-13 ### ### Investigational Site 0 https://Cl
14-Sep-11 24-Apr-18 24-Apr-19 ### ### National Institutes ofhttps://Cl
7-Oct-09 9-Oct-09 26-Oct-10 5-Oct-09 5-Mar-18 26-Jun-19 GSK Investigational S https://Cl
Dec-08 Jan-09 Jan-09 ### 15-Jan-10 ### https://Cl
Oct-06 Jan-08 Jul-09 ### ### St. Michael's Hospita https://Cl
HVTN 099|11782 Aug-18 28-Oct-13 5-Nov-14 https://Cl
Apr-16 Jun-17 Dec-17 ### 2-Jan-20 Department of Clinicahttps://Cl
Dec-14 Feb-16 Sep-16 ### 14-Apr-16 KEMRI Wellcome Trust https://Cl
15-Dec-06 15-Dec-06 ### ### 2-Jul-17 Doneguebougou Malar https://Cl
Sep-10 Sep-10 3-Oct-08 3-Aug-15 The University of Tex https://Cl
Mar-07 Sep-12 9-Aug-07 9-Aug-12 Warren Grant Magnuson https://Cl
Apr-15 Dec-15 Dec-15 9-Apr-15 20-Jul-16 Mirpur Clinic (Intern https://Cl
27-Mar-09 1-Mar-11 31-Jan-14 ### 9-Oct-19 9-Oct-19 GSK Investigational S https://Cl
Jan-09 Dec-09 Mar-10 ### ### 5-Nov-13 Mayo Clinic Cancer Cehttps://Cl
2-Oct-19 31-Dec-25 ### 19-Jul-19 23-Oct-19 National Institutes ofhttps://Cl
25-Oct-19 25-Mar-24 ### 5-Jul-19 ### GSK Investigational Sihttps://Cl
Oct-12 Jul-14 Oct-14 25-Apr-12 ### University of Virginia,https://Cl
Sep-05 May-07 1-Jan-20 ### 8-Feb-19 Dana Farber Cancer Inhttps://Cl
1-Feb-10 27-Sep-10 ### ### 25-Jan-17 ### GSK Investigational Sihttps://Cl
27-Sep-13 Aug-18 Sep-19 ### 4-Feb-19 CHU Nord, Amiens, Frhttps://Cl
15-Mar-17 Jan-20 Jan-20 23-Jan-17 6-Nov-19 Centre for Clinical V https://Cl
Mar-04 Aug-07 Aug-07 ### 24-Jul-12 https://Cl
Jan-20 Jan-24 Nov-25 8-Nov-19 8-Nov-19 Baylor College of Medhttps://Cl
Mar-97 May-98 17-Jun-08 17-Jun-08 GSK Clinical Trials Ca https://Cl
Jul-10 Jun-14 Mar-15 4-Aug-15 7-Aug-15 The University of Tol https://Cl
Feb-10 Sep-10 Sep-10 ### ### Allschwil, Switzerlandhttps://Cl
Mar-14 Nov-14 Nov-14 3-Apr-14 5-Dec-14 The University of Ho https://Cl
May-12 Dec-12 Mar-13 ### 7-Jun-12 Soroka UMC, Beer- She https://Cl
11-Feb-20 11-Nov-20 ### 6-Feb-20 6-Feb-20 Clinical Research Atlahttps://Cl
Dec-11 May-13 ### ### ### Bridge HIV CRS, San Fhttps://Cl
18-Nov-15 6-Mar-18 6-Mar-18 ### ### ### Instituto DermatolÃ³gico
y CirugÃa de Piel, Santo Dom
18-Jan-10 16-May-13 ### ### 21-Apr-14 ### University of Kentuckhttps://Cl
5-Jun-12 2-Jul-13 27-Jan-14 ### 2-Jul-14 31-Oct-18 https://Cl
Jul-10 Apr-11 Jun-11 ### ### Department of Prevent https://Cl
8-Feb-18 May-19 May-19 8-Dec-17 ### Thai Binh Health Cen https://Cl
Feb-08 Jul-10 Sep-10 28-Jan-08 ### 24-Oct-14 Clinical Trials Resea https://Cl
21-Dec-18 1-May-20 1-Jan-21 18-Jul-18 ### University of Marylanhttps://Cl
Jul-10 Apr-11 May-11 ### ### https://Cl
20-Dec-19 15-Mar-20 ### ### ### Garuda Primary Healthttps://Cl
17-Dec-18 Jan-20 Oct-20 7-Dec-18 1-Oct-19 Clinical Research Conhttps://Cl
Oct-13 Oct-15 Dec-15 23-Apr-15 23-Apr-15 National Amyloidosishttps://Cl
29-Mar-19 Feb-20 Feb-21 ### 19-Jun-19 The Hope Clinic of th https://Cl
Jun-12 Dec-15 Dec-15 8-Jan-13 ### International Centre https://Cl
Nov-15 Dec-19 Apr-20 21-Jul-15 ### Bandim Health Project https://Cl
Apr-06 Oct-06 20-Jun-06 ### GSK Investigational S https://Cl
4-Oct-10 7-Jul-11 7-Jul-11 ### 13-Jul-12 7-Sep-18 GSK Investigational S https://Cl
Oct-09 Jan-10 Jan-10 8-Mar-11 ### 6-Feb-14 Guangxi Zhuang Autohttps://Cl
Nov-11 Apr-13 Jun-13 ### 1-Oct-12 Fraser Health Authorihttps://Cl
Sep-10 May-13 May-13 2-Nov-10 9-Aug-13 Hadassah Medical Cent https://Cl
8-Sep-03 10-Sep-07 ### ### 6-Jul-17 8-Nov-18 GSK Investigational Sihttps://Cl
Nov-13 Apr-15 Oct-15 ### 4-May-16 4-May-16 Bangkok, Thailand|Bahttps://Cl
25-Feb-10 12-Dec-11 ### ### 2-Jul-17 National Institutes ofhttps://Cl
May-16 Mar-20 Sep-20 28-Jun-16 5-Feb-20 Medical University ofhttps://Cl
Mar-09 Aug-11 Aug-11 ### 25-Apr-12 University of Rochesthttps://Cl
10-Jul-19 10-Jul-22 10-Jul-22 9-Aug-19 9-Aug-19 Herlev Hospital, Her https://Cl
Dec-08 Nov-11 Nov-11 ### ### Department of Oncolo https://Cl
Aug-15 Dec-15 May-16 17-Apr-15 ### Johnson County Clin-Thttps://Cl
15-Oct-18 15-Dec-20 ### ### 5-Feb-20 Hospital RamÃ³n y Cajal,
https://Cl
Madrid, Spain|Hospital Fun
Dec-09 Jan-14 Jan-14 14-Apr-09 22-Jul-15 22-Jul-15 Gaborone CRS, Gaboro https://Cl
15-Mar-20 3-May-21 3-May-22 8-Nov-18 5-Feb-20 Roswell Park Cancer Ihttps://Cl
Oct-11 31-Dec-17 ### ### 3-Oct-18 SkÃ¥ne University hohttps://Cl
24-Oct-17 1-Nov-20 1-Nov-20 ### ### Zhejiang Provincial P https://Cl
Dec-12 Dec-14 Dec-15 20-Jul-11 ### https://Cl
Dec-06 Oct-08 Aug-13 11-Apr-07 3-Feb-14 The Methodist Hospita https://Cl
13-Mar-09 2-Aug-12 18-Jun-09 ### National Institutes ofhttps://Cl
Jun-16 Sep-17 Sep-17 19-Jan-18 19-Jan-18 https://Cl
17-Oct-16 27-Jun-19 27-Jun-19 6-Oct-16 ### Guys and St Thomas' https://Cl
27-Nov-18 25-Dec-23 ### ### 29-Jan-20 UCSD Medical Centerhttps://Cl
-
6-May-04 3-Nov-06 ### 22-Jul-05 20-Jan-10 ### GSK Investigational S https://Cl
Mar-06 Sep-07 Sep-07 27-Apr-05 ### 12-Apr-17 https://Cl
Jan-06 Jan-14 Jan-14 2-Mar-06 3-Dec-15 Highlands Oncology Gr https://Cl
Dec-14 Jan-16 Jan-16 ### ### China Medical Univershttps://Cl
30-Jan-17 19-Dec-18 Dec-19 ### ### Medical Research Couhttps://Cl
191203-HMO-CTIL ### ### Hadassah Medical Orga https://Cl
19-Jan-06 8-Dec-06 21-Jun-06 2-Jul-17 Bancoumana Clinical https://Cl
Mar-07 May-07 ### 28-Oct-16 GSK Investigational Sihttps://Cl
Feb-12 Dec-14 Dec-14 8-Nov-11 29-Jan-16 19-Apr-16 The Montreal Childrehttps://Cl
4-Mar-11 24-Feb-12 ### 7-Mar-11 2-Apr-13 ### GSK Investigational S https://Cl
Sep-16 May-17 May-17 27-Jul-16 18-Jul-18 International Center https://Cl
Jan-12 Jan-12 ### 3-Dec-12 Baylor College of Medhttps://Cl
Sep-92 May-96 Dec-98 13-Jun-08 13-Jun-08 GSK Clinical Trials Calhttps://Cl
Apr-12 Aug-12 Jan-13 25-Apr-12 ### University of Kentuckhttps://Cl
Mar-02 Sep-05 Jun-09 27-Jan-03 2-Oct-15 Jonsson Comprehensive https://Cl
3-Oct-05 1-Nov-05 4-Nov-05 26-Apr-06 8-May-17 GSK Investigational S https://Cl
Jan-08 Mar-09 Mar-09 9-Aug-07 ### Bagamoyo Research an https://Cl
Nov-08 May-09 Jun-09 4-Nov-08 2-Sep-11 ### Mount Sinai Hospital,https://Cl
14-Oct-11 12-Nov-12 ### 18-Oct-11 28-Jul-14 ### GSK Investigational Sihttps://Cl
1-Mar-03 1-Feb-04 ### 9-Aug-05 23-Jul-12 ### GSK Investigational Sihttps://Cl
Jul-99 May-02 Jun-02 1-Oct-03 2-Oct-15 Jonsson Comprehensive https://Cl
Mar-06 Jan-09 3-Apr-06 ### Menzies School of Hea https://Cl
Jan-09 Jun-09 Sep-09 ### ### ### Hospital Clinico Universitario
https://Cl
de Santiago, Santiado d
18-Oct-17 19-Apr-18 4-May-18 ### 5-Jun-19 University of Californhttps://Cl
8-Jan-15 2-Jul-15 8-May-17 ### 14-Jun-17 Rockville, Maryland, https://Cl
12-Nov-10 28-Mar-12 8-Dec-12 7-Nov-10 31-Jan-19 ### GSK Investigational S https://Cl
16-Apr-12 25-Feb-13 ### ### 25-Jan-19 2-Jan-20 GSK Investigational Sihttps://Cl
10-Aug-16 4-Jan-18 4-Jan-18 7-Sep-15 ### ### KEMRI-Well"Study Prohttps://Cl
7-Aug-18 30-Jul-19 21-Oct-19 26-Jul-18 ### American Academy ofhttps://Cl
Pe
Dec-12 Apr-13 May-13 9-Jan-13 9-Jan-13 Institut National de https://Cl
16-Jun-04 21-May-09 ### ### 1-Feb-10 21-Apr-17 https://Cl
Sep-07 Aug-08 Aug-08 ### 8-Aug-12 8-Aug-12 Nagoya-shi, Aichi, J https://Cl
14-Sep-18 14-Oct-21 ### ### 3-Sep-19 National Cancer Insti https://Cl
Jan-08 Oct-09 Oct-09 5-Feb-09 ### https://Cl
Feb-08 Dec-10 Dec-10 ### 12-Jul-11 Firdausi Qadri, Dhakahttps://Cl
Jan-04 Aug-08 8-Oct-04 20-Jul-11 Sidney Kimmel Compre https://Cl
12-Mar-09 7-Apr-09 7-Apr-09 ### 31-Oct-17 GSK Investigational Sihttps://Cl
Sep-12 Apr-13 Apr-13 ### ### Kaiser Permanente Cohttps://Cl
Feb-06 Apr-07 Sep-07 ### ### ### Cordoba, Provincia d https://Cl
1-Aug-16 1-Aug-17 ### 15-Jun-18 15-Jun-18 https://Cl
May-07 Jul-09 Sep-10 12-Jun-07 ### ### Center for Immunizatihttps://Cl
Dec-05 Jun-08 Apr-09 1-Mar-07 ### 14-Apr-16 HOPE Research Instituhttps://Cl
Aug-06 Aug-07 Jan-08 8-Aug-08 ### Adelaide, Australia https://Cl
Oct-17 Mar-19 Sep-19 ### 4-Dec-18 https://Cl
P01AI047490 12-Jun-03 ### Institute of Human Vihttps://Cl
Nov-08 Oct-09 Oct-09 ### 6-May-15 University of Marylanhttps://Cl
7-Mar-09 13-Nov-09 ### ### 29-Oct-10 3-Jan-20 GSK Investigational Sihttps://Cl
Sep-13 Jan-15 Jan-15 ### 6-Jul-17 University of Marylanhttps://Cl
Sep-03 Jan-04 Jul-04 4-Feb-09 ### 14-Apr-16 Norfolk, Virginia, Uni https://Cl
Nov-04 Mar-05 Mar-05 9-May-06 ### GSK Investigational Sihttps://Cl
15-May-18 3-Oct-18 3-Oct-18 ### ### Cevaxin, Panama Cityhttps://Cl
May-14 Feb-16 Feb-16 9-Jan-14 8-Feb-16 Surrey Clinical Resea https://Cl
Apr-05 Dec-13 Jun-14 ### ### https://Cl
Jan-13 Jan-14 Jan-14 ### ### 19-Jul-17 Carilion Clinic, Roanohttps://Cl
Feb-08 Feb-08 Feb-08 7-Sep-06 ### University of Virginia https://Cl
30-Dec-14 28-Jan-16 ### ### ### Aurora Health Care, https://Cl
1-Jun-19 30-Jun-20 30-Jun-20 ### ### https://Cl
Jun-11 Mar-13 Mar-13 ### ### Centre for Clinical V https://Cl
28-Nov-17 17-Jan-19 4-Jun-19 30-Jan-18 18-Jan-20 Center for "Informed https://Cl
May-02 Feb-10 Feb-10 13-Jul-05 ### Dr Scott Parker, Birm https://Cl
Aug-08 Mar-09 Mar-09 8-Jul-08 4-Aug-11 4-Aug-11 Coquitlam, British C https://Cl
Nov-05 Sep-07 Aug-08 8-Aug-08 8-Aug-08 Radboud University Nhttps://Cl
3-Apr-18 30-Jun-19 30-Jun-20 27-Apr-18 ### Malaria Research andhttps://Cl
29-Nov-10 6-Sep-11 ### 7-Nov-10 ### GSK Investigational Sihttps://Cl
Apr-02 Jan-03 ### ### FreistÃ¤dter Strasse https://Cl
Aug-05 Dec-05 Apr-06 ### 4-Jan-08 multiple sites: conta https://Cl
28-Feb-19 Apr-20 Apr-20 26-Apr-19 6-Sep-19 Celerion Inc., Belfas https://Cl
Jul-07 Apr-10 Apr-10 3-May-07 6-Jun-17 2-Jul-17 San Juan Batista Medihttps://Cl
Sep-95 Oct-11 May-12 ### ### Vladimir Gilca, Queb https://Cl
May-08 Jun-09 26-Jun-08 ### University of Virginia https://Cl
23-Nov-11 9-Oct-13 9-Oct-13 ### 2-Apr-19 2-Apr-19 https://Cl
14-Dec-17 31-Mar-18 ### 6-Dec-17 ### Korea University Gurohttps://Cl
Dec-09 Aug-11 Aug-11 ### ### ### Russian State Medicalhttps://Cl
Aug-15 8-Jun-17 ### 1-May-15 ### The Hope Clinic of th https://Cl
Sep-15 Dec-15 Feb-16 ### ### Pulmonary Associates, https://Cl
Sep-12 Feb-13 Feb-13 16-Oct-12 ### Chungnam National Un https://Cl
Jul-11 Nov-13 ### ### Fred Hutchinson Canchttps://Cl
Apr-06 Dec-07 Nov-09 ### 21-Jun-11 3-Feb-16 https://Cl
Jan-08 Nov-09 Dec-09 ### 29-Jul-11 ### Research Site 1, Full https://Cl
18-Sep-17 2-Nov-17 2-Nov-17 ### ### Centre for Clinical V https://Cl
Jun-03 Jun-07 Oct-07 ### 16-Oct-17 9-Nov-18 Chicago Department of https://Cl
Oct-15 Nov-16 Nov-16 30-Oct-15 6-Jun-17 Nothern California Cl https://Cl
Sep-07 Nov-07 9-Nov-07 9-Nov-07 https://Cl
Oct-08 Mar-09 Jul-09 ### ### Shin Nippon Biomedica https://Cl
Jul-06 May-08 12-Jun-06 23-Oct-07 https://Cl
14-Oct-10 31-Jul-12 31-Jul-12 6-Oct-10 30-Apr-19 30-Apr-19 https://Cl
Feb-10 Jan-11 May-11 1-Nov-09 11-Jan-18 ### Huntsville, Alabama, https://Cl
14-Jan-19 31-May-22 ### 5-Dec-18 ### Wits Reproductive Hehttps://Cl
May-08 Jun-09 Jun-09 1-Jul-08 16-Jun-09 Covance Clinical Resehttps://Cl
Jul-10 Sep-15 6-Mar-09 6-Sep-17 ### University of South Ahttps://Cl
Apr-01 Dec-04 Apr-09 27-Jan-03 ### Sidney Kimmel Compre https://Cl
30-Oct-18 10-Jun-19 10-Jun-19 16-Oct-18 ### NIHR Clinical Resear https://Cl
Jun-15 Nov-15 Dec-15 ### 18-Jan-17 GSK Investigational S https://Cl
29-Dec-17 29-Aug-18 ### ### ### Suiping Ce"Study Prohttps://Cl
May-11 Sep-12 Sep-12 ### 18-Jan-13 University of Marylanhttps://Cl
15-Jan-20 Jan-21 Jan-21 29-Oct-19 21-Jan-20 Investigational Site https://Cl
Nov-09 Sep-10 Sep-10 ### 13-Jul-12 CEVAC, Ghent, Belgi https://Cl
Aug-95 Jan-97 Jan-97 17-Jun-08 17-Jun-08 GSK Clinical Trials Ca https://Cl
Aug-02 Aug-05 10-Oct-02 23-Jan-08 Berkeley, California, https://Cl
Aug-12 Jun-14 Jun-15 19-Jul-12 8-Jul-19 8-Jul-19 Walter Reed Army Insti https://Cl
P1057|10612|PACTG P1057 Jan-06 ### ### UAB, Dept. of Ped., Dhttps://Cl
Feb-15 Aug-18 Aug-20 25-Jan-16 ### Department of Microbi https://Cl
24-Oct-09 8-Dec-10 8-Dec-10 16-Oct-09 27-Jun-12 ### GSK Investigational Sihttps://Cl
Oct-06 Jun-09 Jun-09 ### 2-Mar-16 2-Mar-16 Memorial Sloan Kettehttps://Cl
Sep-11 Dec-13 Jun-14 ### ### Dept infectious diseahttps://Cl
Nov-06 Jun-14 Jun-14 29-Jan-07 27-Jun-19 Dana-Farber Cancer In https://Cl
28-Sep-17 16-Jul-20 ### 8-Sep-17 ### GSK Investigational S https://Cl
1-Aug-17 11-Apr-18 11-Apr-18 16-Jun-17 ### Research Institute fo https://Cl
PACTG 391|10614|ACTG 391 Mar-04 ### 29-Oct-14 Long Beach Memorialhttps://Cl
M
Jan-06 Apr-07 Apr-07 ### ### UCLA Center For Vaccihttps://Cl
16-Mar-05 7-Feb-08 ### 9-Dec-05 ### ### GSK Investigational Sihttps://Cl
Jul-06 Sep-06 3-May-06 19-Jul-16 CMAX, a division of I https://Cl
24-Jan-12 25-Sep-12 ### 27-Oct-11 ### ### https://Cl
Jun-07 Oct-09 Oct-09 ### ### ### Virginia Commonwealth https://Cl
3-Nov-17 22-May-18 ### ### 25-Jun-19 Sanofi Pasteur Investihttps://Cl
18-Apr-18 Apr-20 Dec-20 ### 6-Sep-19 Johnson County Clin-Thttps://Cl
16-Mar-18 11-May-20 9-Nov-20 24-Jan-18 ### Alabama CRS, Birmingh https://Cl
Dec-19 Jun-22 Dec-26 ### ### Istituto Scientifico R https://Cl
Nov-01 Feb-03 Jul-06 25-Apr-05 ### https://Cl
6-Dec-17 Oct-20 Nov-20 ### 3-Dec-19 Massachusetts General https://Cl
Nov-11 Feb-12 Mar-12 26-Jan-12 1-Mar-17 National Jewish Healthttps://Cl
17-Nov-12 17-Apr-13 12-Jul-19 ### 18-Oct-19 National Institutes ofhttps://Cl
May-12 Dec-12 Dec-12 4-Jul-12 8-Jan-13 Matlab, Matlab, Chanhttps://Cl
Jun-07 May-08 Aug-08 7-Jun-07 22-Jan-14 Guilin City, Guangxi, https://Cl
Oct-06 May-07 May-07 2-Nov-06 ### Center of Vaccine Devhttps://Cl
Oct-05 May-06 Mar-08 ### ### Assistance Publique-Hhttps://Cl
7-Jan-15 30-Jun-22 31-Jan-27 30-Jul-14 ### Washington University https://Cl
Sep-08 Sep-10 Sep-10 ### 6-Apr-12 department of surgery https://Cl
Jul-05 Jun-07 Jun-07 2-Aug-05 12-Jun-17 Mary Crowley Medical https://Cl
Oct-05 Nov-06 ### 19-Jul-16 CMAX, a division of I https://Cl
Jul-11 Feb-17 Dec-17 ### 18-Jan-19 Voir Liste Des Centreshttps://Cl
Mar-16 Aug-17 Aug-17 ### 13-Oct-17 Seoul National Univers https://Cl
Oct-13 Nov-15 Nov-15 22-Oct-13 7-Nov-19 7-Nov-19 NIHR/Wellcome Trusthttps://Cl
I
Oct-05 Nov-06 30-Jan-08 ### ### https://Cl
Aug-06 Jan-07 4-Jul-06 29-Jan-07 Guys Research Drug Un https://Cl
23-Jan-08 15-Oct-08 ### ### 7-Feb-14 8-Jun-18 GSK Investigational Sihttps://Cl
Nov-03 Nov-12 Mar-13 ### ### National Institutes ofhttps://Cl
10-Aug-18 30-Dec-19 ### 12-Jun-18 11-Apr-19 Chan Soon-Shiong Inst https://Cl
Nov-14 Apr-15 Jan-16 ### 8-Mar-16 University Hospitals https://Cl
Mar-07 May-11 May-11 9-Apr-07 ### ### University of Alabamahttps://Cl
Nov-98 Apr-04 Feb-11 1-Jan-01 4-Jul-13 VA Medical Center, Bihttps://Cl
25-Feb-19 Dec-22 Dec-22 16-Jan-19 21-Jan-20 Kintampo Health Resehttps://Cl
Mar-10 Apr-13 Apr-13 ### ### ### Pfizer Investigational https://Cl
5-Jul-07 23-Oct-08 ### 9-May-07 ### 25-Jun-19 GSK Investigational Sihttps://Cl
12-Dec-18 9-Dec-19 9-Dec-19 ### ### Accel Research Sites, https://Cl
Nov-03 Jan-10 Jan-10 21-Jul-05 20-Jul-18 20-Jul-18 Sidney Kimmel Compre https://Cl
Oct-12 Jul-13 Mar-14 17-Oct-12 5-Mar-14 Genova Clinical Reseahttps://Cl
Oct-14 Feb-16 Feb-16 28-Oct-14 28-Oct-14 Leiden University Med https://Cl
Oct-12 May-15 May-15 26-Jul-12 ### Desmond Tutu TB Centr https://Cl
Nov-11 Apr-12 25-Oct-11 9-Nov-15 Oxford Vaccine Grouphttps://Cl
Oct-12 Jun-13 Jun-13 16-Oct-12 31-Jan-14 Medisch Centrum Leeu https://Cl
17-Feb-11 26-Sep-11 ### 14-Jan-11 3-Dec-13 ### GSK Investigational Sihttps://Cl
Sep-12 Oct-13 Jan-14 3-Dec-12 ### ### Center for Immunizatihttps://Cl
22-Feb-07 27-Aug-08 ### ### ### GSK Investigational Sihttps://Cl
10-Oct-12 3-Feb-15 ### ### ### ### GSK Investigational Sihttps://Cl
Jun-15 Aug-15 Sep-15 16-Jul-15 12-Apr-16 IRC Clinics, Towson, https://Cl
Jul-93 Jul-10 Jul-10 18-Oct-05 9-Nov-09 Palo Alto Medical Fouhttps://Cl
Oct-10 Feb-11 Feb-11 ### ### ### BC Children's and Wom https://Cl
May-04 Mar-05 Mar-05 ### ### GSK Investigational Sihttps://Cl
9-Jul-01 19-Jan-04 Jan-05 6-Feb-06 ### ### Shree Birendra Hospihttps://Cl
Apr-04 Jul-05 6-Jan-05 12-Jan-06 UCLA Ctr for Vaccine https://Cl
16-Jun-15 ### Hospital of the Univerhttps://Cl
Mar-05 Sep-07 4-May-05 23-Jan-13 University of Maryla https://Cl
Feb-10 Aug-11 Sep-11 18-Jan-10 18-Jan-17 GSK Investigational Sihttps://Cl
12-Apr-19 12-Oct-20 12-Apr-21 17-Apr-19 22-Apr-19 CHU Angers, Angers, https://Cl
Apr-09 Jul-12 Jul-12 13-Apr-09 ### 6-Aug-15 Miami Research Associ https://Cl
15-Oct-14 28-Feb-15 ### 4-Aug-17 4-Aug-17 https://Cl
Oct-12 Dec-12 Apr-13 16-Oct-12 5-Aug-13 GH Cochin - Broca - Hhttps://Cl
Jan-15 Jan-17 Jan-17 6-Feb-15 10-Jan-17 Istituto di Clinica de https://Cl
6-Nov-08 22-Sep-12 4-Feb-13 ### 30-Jan-20 National Institutes ofhttps://Cl
18-Jul-08 9-Aug-08 9-Aug-08 18-Jul-08 ### 26-Jun-19 GSK Investigational S https://Cl
Nov-14 Mar-15 Jun-15 ### ### Clinical Research Centhttps://Cl
Dec-08 Nov-10 Nov-10 8-Dec-08 22-Jul-11 Institute of Specific https://Cl
Apr-13 Nov-15 Nov-15 ### ### Centre for Clinical V https://Cl
Nov-16 31-Aug-17 ### 6-Dec-16 11-Jan-18 https://Cl
Oct-06 Dec-07 9-Nov-06 ### Institut for Tropical https://Cl
20-Nov-07 24-Feb-09 ### ### ### 9-Oct-18 GSK Investigational Sihttps://Cl
Sep-09 Feb-15 Feb-15 27-Jul-09 2-May-11 ### GSK Investigational S https://Cl
13-Feb-08 31-Jul-09 ### ### 20-Jul-12 ### GSK Investigational Sihttps://Cl
May-12 Sep-14 Oct-16 17-Apr-12 ### Columbia P&S CRS, New https://Cl
Jul-14 Oct-15 Jun-16 24-Jul-14 9-Feb-18 Birmingham, Alabama, https://Cl
Oct-09 Jan-11 Aug-11 7-Dec-10 16-Jan-12 Transplant Institute, https://Cl
Mar-11 Jun-13 Jun-13 14-Apr-11 ### Military Vaccine Agenc https://Cl
Mar-09 Feb-10 Feb-11 30-Apr-09 ### Centre for Clinical V https://Cl
Jun-03 Oct-06 Oct-09 ### ### CIC de vaccinologie Chttps://Cl
Aug-12 Jun-14 Dec-14 ### ### https://Cl
26-Oct-10 13-Jan-16 19-Apr-17 ### 24-Jul-19 24-Jul-19 GSK Investigational Sihttps://Cl
Aug-10 Oct-12 Oct-15 16-Jun-10 23-Jul-14 ### Mayo Clinic in Florid https://Cl
Jan-15 Feb-16 Jun-17 ### 27-Apr-17 Dept infectious diseahttps://Cl
May-11 Aug-12 Aug-12 27-Jul-11 ### Vince and Associates https://Cl
1-Nov-13 30-Apr-16 ### 11-Jun-18 11-Jun-18 https://Cl
Mar-15 Dec-21 May-22 8-Apr-15 18-Jan-20 Johann Wolfgang Goet https://Cl
Nov-14 Aug-20 Aug-21 ### ### Massachusetts General https://Cl
Nov-10 Oct-12 Nov-13 20-Jul-11 ### https://Cl
Oct-18 Jan-19 Jan-19 ### ### https://Cl
1-Apr-19 Mar-22 Mar-22 6-Mar-19 ### Mackay Memorial Hosp https://Cl
Sep-04 Sep-11 Sep-11 4-Mar-05 ### Memorial Sloan-Kettehttps://Cl
Oct-12 May-16 Feb-17 ### ### Hospital de Manises, https://Cl
Jun-07 Jan-10 Jan-10 8-May-08 19-Jun-13 Duke Comprehensivehttps://Cl
C
Aug-05 Mar-06 21-Jul-05 5-May-06 Programa de Estudio https://Cl
Jun-09 Feb-11 Feb-11 29-Jun-09 15-Oct-12 20-Oct-16 GSK Investigational S https://Cl
Jul-12 9-May-14 9-May-14 ### 1-Jun-18 University of Alabamahttps://Cl
Feb-06 May-07 Sep-08 6-Feb-06 7-Jan-15 Espoo, Finland|Helsinhttps://Cl
24-Nov-14 21-Feb-17 ### ### ### ### University "Study Prohttps://Cl
Feb-96 Aug-00 ### ### ### Cancer Center, Univershttps://Cl
Jul-05 Sep-06 Sep-06 ### 4-Feb-13 U.S. Army Research Uhttps://Cl
Jun-05 May-06 May-06 21-Jun-07 ### https://Cl
Dec-01 Jul-04 Jan-05 ### 31-Oct-18 MD Anderson Cancerhttps://Cl
C
5-Oct-17 14-Jul-22 14-Jul-22 ### 4-Oct-19 GSK Investigational Sihttps://Cl
May-05 Jul-08 Nov-08 ### ### Grieskirchner Strassehttps://Cl
16-Sep-16 29-May-17 ### ### 23-Jan-19 ### GSK Investi"Study Prohttps://Cl
28-Jan-19 1-Jan-21 1-Jan-22 23-Oct-18 ### Herlev Hospital, Cen https://Cl
9-Jun-04 6-Feb-08 21-Jun-06 2-Jul-17 Quintiles Phase 1 Serhttps://Cl
Dec-06 Sep-09 Jun-16 6-Oct-08 ### 7-Feb-18 Hillman Cancer Center https://Cl
Apr-01 Aug-12 Aug-12 17-Oct-05 4-Aug-15 National Institute on https://Cl
Apr-14 Aug-14 Aug-14 21-Apr-14 ### 13-Jan-17 Investigational site, https://Cl
Apr-08 Mar-10 Mar-12 ### ### Fukushima Medical Un https://Cl
30-Sep-03 16-Jul-04 17-Jul-06 6-Jan-20 GSK Investigational Sihttps://Cl
17-Jun-19 28-Feb-22 ### 9-May-19 19-Jun-19 University of Texas Mhttps://Cl
8-Jul-19 Jan-20 Aug-20 5-Jul-19 ### University of Marylanhttps://Cl
9-Feb-11 18-Mar-13 ### ### 21-Apr-14 19-Jun-19 GSK Investigational S https://Cl
Aug-14 Jun-21 Jun-21 ### 4-Oct-19 University of Coloradhttps://Cl
Jun-15 Mar-16 Jun-16 8-Jul-15 ### ### Preventive Medicine https://Cl
14-Oct-15 14-Aug-17 24-Oct-17 3-Mar-15 28-Jan-19 28-Jan-20 GSK Investi"Study Prohttps://Cl
Dec-06 Dec-17 Dec-17 3-Feb-09 23-Oct-19 Greenbaum Cancer Cent https://Cl
Jun-04 Mar-06 Mar-06 ### ### GSK Investigational Site,
https://Cl
North Adelaide, South Austra
Sep-03 May-05 ### ### Sanitary Epidemiologhttps://Cl
14-Feb-19 9-Oct-19 9-Oct-19 4-Feb-19 5-Feb-20 Anaheim Clinical Tria https://Cl
Mar-08 May-09 Jul-09 9-Apr-08 26-Jun-13 ### Estado de Mexico, Mehttps://Cl
Aug-09 Jun-12 Jun-12 10-Jun-10 15-Oct-12 8-Aug-13 Hospital Nacional Si https://Cl
Jun-09 Jul-09 Aug-09 17-Jun-09 ### ### Jean Brown Research,https://Cl
Oct-10 Nov-12 Mar-13 29-Oct-10 18-Jul-18 Redding, California, https://Cl
Jun-06 Dec-13 Mar-15 28-Jun-06 18-Apr-16 18-Apr-16 Rockefeller Universit https://Cl
Jul-14 Mar-16 Mar-16 ### 12-Jul-17 Keimyung University D https://Cl
Feb-92 Dec-92 Dec-92 17-Jun-08 17-Jun-08 GSK Clinical Trials Ca https://Cl
1-Aug-19 31-Dec-20 ### 16-Jul-19 19-Jul-19 https://Cl
31-Jan-14 Nov-20 Nov-20 ### 9-Dec-19 Memorial Sloan Kettehttps://Cl
Dec-20 Dec-22 Dec-24 ### 13-Jan-20 https://Cl
Sep-10 Jan-11 Jan-11 16-Jan-17 ### ### https://Cl
Nov-06 Jan-11 Jan-11 13-Oct-08 9-Jul-13 9-Jul-13 Indiana University Med https://Cl
Apr-16 Dec-21 Dec-21 1-Nov-15 28-Jan-19 Moffitt Cancer Centerhttps://Cl
Feb-09 Jul-11 Jun-12 15-Oct-08 ### Tampa, Florida, Unit https://Cl
Nov-16 Jan-21 Mar-21 6-Dec-16 ### Clinical Research of https://Cl
Aug-05 Feb-06 21-Jul-05 5-May-06 Programa de Estudio https://Cl
y Control de Enfermedades Trop
Feb-15 May-16 May-16 ### ### https://Cl
Apr-05 Aug-06 Mar-11 ### 2-Nov-15 https://Cl
Sep-06 Apr-07 ### ### GSK Investigational S https://Cl
Aug-13 Sep-13 Sep-13 24-Jun-13 ### ### University Medical https://Cl
12-Dec-18 20-Apr-20 20-Apr-20 ### ### Emory Children's Centhttps://Cl
1-Feb-16 4-Dec-17 4-Dec-17 ### ### https://Cl
26-Sep-02 9-Jun-03 9-Jun-03 ### ### https://Cl
4-Sep-12 15-Jul-13 7-May-14 16-Jul-12 ### ### GSK Investigational S https://Cl
Sep-04 Apr-05 ### ### Cleveland Clinic, Clevhttps://Cl
May-16 17-Apr-19 Apr-20 21-Apr-16 27-Jan-20 Comprehensive Cancer https://Cl
9-Nov-09 10-Jan-11 1-Feb-11 ### ### ### GSK Investigational S https://Cl
Mar-11 Mar-19 ### ### Abramson Cancer Cente https://Cl
Feb-13 Apr-15 Apr-15 ### 8-Feb-16 Houston Methodist Hos https://Cl
11-Jul-08 22-Apr-10 ### 21-Jul-08 7-Feb-14 9-Jul-18 GSK Investigational Sihttps://Cl
Dec-04 Feb-07 ### 5-Dec-07 Sacramento, Californihttps://Cl
21-Oct-19 Apr-21 Sep-22 1-Aug-19 10-Jan-20 City of Hope Comprehhttps://Cl
30-May-17 17-Jan-19 17-Jan-19 23-Jan-17 1-Feb-19 Emory Children's Centhttps://Cl
12-Dec-17 10-May-19 ### 2-Apr-18 ### National Taiwan Univehttps://Cl
Dec-07 Jun-08 Jun-08 22-Jun-12 21-Jun-17 https://Cl
Dec-13 Apr-15 Apr-15 23-Jul-14 ### Hospices Civils de Lyohttps://Cl
Jan-01 Nov-02 Nov-02 13-Apr-09 7-Sep-16 https://Cl
8-Aug-12 25-Nov-13 ### 6-Aug-12 ### GSK Investigational Sihttps://Cl
Sep-06 Jul-07 1-Sep-06 19-Jul-16 Murdoch Childrens Res https://Cl
Feb-15 May-15 Sep-15 ### ### WRAIR Clinical Trial Chttps://Cl
Oct-07 Dec-07 Dec-07 ### ### ### Fukuoka-shi, Fukuokahttps://Cl
Mar-05 Aug-05 Nov-05 ### 4-Jan-08 Trialogic Research, Mhttps://Cl
Nov-10 May-12 Jun-13 ### ### Multiple GP surgerieshttps://Cl
10-Sep-13 15-Jun-16 Aug-16 ### 29-Jul-19 ### Ratchaburi, Muang Dis https://Cl
Aug-12 Dec-17 Dec-17 25-Jul-16 ### Westmead Hospital Dhttps://Cl
31-Mar-17 Jan-20 Jun-24 ### ### Centre nat"Informed https://Cl
1-Nov-19 Dec-20 Mar-21 24-Apr-19 4-Oct-19 https://Cl
9-Dec-15 31-Mar-18 3-Jul-18 ### ### University of Bamakohttps://Cl
Apr-10 Nov-11 Dec-11 16-Apr-10 ### Bertsham, South Afri https://Cl
Nov-05 Jun-06 Nov-06 13-Apr-06 5-Dec-12 6-Dec-12 Chicago, Illinois, Un https://Cl
Jan-10 Aug-10 Aug-10 21-Oct-09 ### Site Reference ID/Invhttps://Cl
4-Feb-03 ### ### ### National Institutes ofhttps://Cl
1-Aug-18 May-20 Dec-20 1-Mar-18 ### JagielloÅ„skie Centruhttps://Cl
Oct-03 Feb-05 Feb-05 ### 15-Apr-13 GSK Investigational S https://Cl
Sep-14 Jan-16 Jan-16 3-Mar-15 22-Jan-16 Uganda Virus Research https://Cl
Oct-13 Apr-14 Feb-15 11-Jan-17 11-Jan-17 National Center for T https://Cl
Mar-14 Sep-16 Sep-17 3-Mar-15 5-Apr-18 Service de nÃ©phrol https://Cl
Mar-06 Oct-17 Oct-17 ### 4-Sep-19 Changzhou City Center https://Cl
Apr-02 Jul-09 Jul-09 25-Jan-02 2-Sep-10 Univ of Alabama at Bihttps://Cl
Apr-05 Jan-11 Apr-14 22-Jan-14 ### ### VA Boston Healthcarehttps://Cl
AVEG 014A|10561|AVEG 014A/B Jul-96 ### ### St. Louis Univ. Schoo https://Cl
Jul-13 Dec-16 Dec-16 ### ### Department of Hematop https://Cl
Nov-09 Feb-10 Feb-10 ### 30-Jan-12 Leiden University Med https://Cl
1-Dec-09 4-Oct-10 4-Oct-10 7-Sep-09 13-Apr-17 ### GSK Investigational S https://Cl
Feb-11 Dec-20 Dec-20 7-Mar-11 ### Florida Cancer Speciahttps://Cl
13-Aug-09 27-Jan-10 27-Jan-10 2-Sep-09 14-Apr-17 3-Jan-20 GSK Investigational S https://Cl
30-Jul-19 Feb-21 Jul-21 ### ### Meridan Clinical Res https://Cl
Jan-06 Jun-07 Mar-08 10-Jul-06 26-Oct-18 26-Oct-18 Walter Reed Army Inst https://Cl
6-Jul-18 8-Feb-19 1-Sep-19 2-Aug-18 18-Jan-20 Johns Hopk"Informed https://Cl
Oct-13 Jan-16 Jan-16 1-Oct-13 28-Jan-16 Centre for Clinical V https://Cl
Oct-06 Jun-07 ### 19-Jul-16 CMAX, a division of IDhttps://Cl
Aug-01 Jan-03 1-Dec-05 1-Dec-05 https://Cl
9-Oct-17 1-Jan-21 1-Jan-22 7-Jun-17 ### University of Alabamahttps://Cl
23-Mar-20 Mar-21 Mar-21 17-Jul-19 ### https://Cl
7-Dec-16 7-Aug-19 ### ### 6-Sep-19 Alabama CRS, Birminghttps://Cl
1-May-17 27-Nov-17 ### ### 18-Jun-18 Cincinnati Children's https://Cl
15-Dec-18 31-Jul-19 31-Jul-19 31-Jul-18 16-Oct-18 https://Cl
1-Apr-12 30-Apr-15 30-Apr-16 26-Jun-13 ### ### Centre for Infectious https://Cl
8-Jul-14 19-Apr-17 19-Apr-17 3-Mar-14 1-Aug-18 1-Aug-18 GSK Investi"Study Prohttps://Cl
6-Mar-12 25-May-18 ### ### 22-Jul-19 ### University "Study Prohttps://Cl
13-Jul-18 15-Feb-19 Mar-20 26-Jul-18 ### Insight Therapeutics, https://Cl
2-Nov-18 22-Apr-20 22-Apr-20 ### ### University of Alabamahttps://Cl
May-06 Apr-08 Apr-08 4-Jul-06 12-Apr-13 Baylor College of Medhttps://Cl
Dec-11 Apr-14 Apr-14 24-Apr-12 21-Apr-14 INC Research, LLC (Rehttps://Cl
20-Oct-09 21-Mar-11 ### ### ### ### GSK Investigational S https://Cl
PACTG 265|10613|ACTG 265 Nov-05 ### ### Long Beach Memorialhttps://Cl
M
4-Nov-04 3-Jul-06 3-Jul-06 9-Mar-18 ### Kilifi District Hospital https://Cl
14-Dec-17 30-Jan-18 30-Jan-18 ### ### ### GSK Investi"Study Prohttps://Cl
Apr-06 Dec-06 Dec-06 6-Apr-06 ### St. Jude Children's R https://Cl
Nov-15 Aug-16 Feb-17 3-Nov-15 1-Mar-18 https://Cl
Sep-09 Apr-10 Mar-11 ### 14-Jul-11 2-Oct-14 JCCT, Lanexa, Kansas,https://Cl
Sep-06 Oct-07 Oct-07 ### 17-Oct-11 10-Apr-15 https://Cl
Dec-14 Sep-19 Oct-19 ### 24-Oct-19 Ivan Hung, Hong Konhttps://Cl
Jul-07 Jul-08 Jul-08 28-Jun-07 2-Feb-12 Birmingham, Alabama, https://Cl
1-Dec-17 1-Aug-18 1-Aug-18 25-Apr-17 ### https://Cl
Sep-06 Nov-06 ### 7-Oct-16 GSK Investigational Sihttps://Cl
20-Apr-09 4-Nov-16 4-Nov-16 3-Apr-09 25-Jan-19 25-Jan-19 GSK Investigational S https://Cl
Apr-07 Jun-07 Feb-10 18-Apr-07 9-Oct-15 University Hospital, https://Cl
Dec-06 Jun-08 9-Mar-07 8-Feb-10 Vaccine and Immunoth https://Cl
23-Feb-08 11-Jun-10 11-Jun-10 9-Aug-10 3-Jan-20 GSK Investigational S https://Cl
Mar-11 Mar-12 Sep-12 ### 18-Jul-11 Community of Sikoro,https://Cl
13-Mar-12 15-Feb-13 ### 20-Jan-12 ### ### https://Cl
May-07 Jun-08 Jun-08 6-Feb-07 3-Apr-08 Malaria Research andhttps://Cl
Oct-04 Jul-06 ### 15-Jan-07 Stanford University, Ghttps://Cl
Oct-07 Jan-08 Oct-08 2-Apr-09 ### ### Scottsdale, Arizona, https://Cl
22-Apr-16 22-Feb-17 ### 27-Oct-15 ### Birmingham, Alabama, https://Cl
9-May-18 14-Jan-19 ### 8-May-18 18-Jan-20 Johnson County Clin-Thttps://Cl
Dec-04 Dec-05 12-Jan-06 29-Jul-09 https://Cl
Apr-08 Feb-09 Apr-09 ### 6-Feb-18 Herston, Australia|Mehttps://Cl
Nov-10 Apr-12 Apr-12 3-Feb-11 ### UnitÃ© de Recherchehttps://Cl
C
Jul-13 Nov-17 Nov-17 17-Jul-13 17-Jun-19 17-Jun-19 Espoo Vacci"Study Prohttps://Cl
22-Jul-19 Sep-22 Apr-23 29-Jan-19 ### EBOVAC Rokupr clinichttps://Cl
Mar-10 Feb-11 Jul-11 ### ### 6-May-16 Research Institute fo https://Cl
Oct-02 Apr-03 8-Jan-07 11-Jan-07 Cleveland Clinic Founhttps://Cl
Mar-08 Apr-20 Jun-20 ### ### U.S. Army Medical Reshttps://Cl
Nov-08 Jun-10 Jun-10 17-Oct-08 27-Jun-11 2-Nov-16 GSK Investigational S https://Cl
Apr-10 Jul-10 Jul-10 ### 15-Oct-10 Quintiles Drug Researhttps://Cl
Dec-09 Sep-11 Sep-12 ### ### PNG Institute of Medhttps://Cl
Apr-13 Sep-13 Sep-13 ### 22-Oct-13 Institut de Recherch https://Cl
May-11 Sep-12 Sep-12 ### 25-Jan-13 Emory Children's Cente https://Cl
7-Feb-18 Mar-21 Mar-21 7-Sep-18 4-Sep-19 Sir Run Run Shaw Hoshttps://Cl
Jul-04 Apr-05 Mar-07 ### ### ### Herston, Queensland,https://Cl
Jun-93 Jul-94 Jul-94 13-Jun-08 13-Jun-08 GSK Clinical Trials Ca https://Cl
### 24-Jun-05 St Louis Univ School https://Cl
31-Aug-12 30-Jan-14 30-Jan-14 5-Sep-12 ### GSK Investigational S https://Cl
21-May-15 May-20 May-20 ### 16-Jul-19 City of Hope Medical https://Cl
Dec-03 Jan-06 Jan-06 1-Jan-04 ### Walter Reed Army Inst https://Cl
Jul-16 31-Jul-17 31-Jul-17 1-Jun-16 ### NIHR/Wellcome Trusthttps://Cl
27-Sep-19 Oct-21 Oct-21 ### ### University Hospital https://Cl
14-Oct-18 28-Feb-20 ### 29-Apr-19 6-May-19 JiVitA Maternal and https://Cl
Apr-14 Dec-17 Dec-17 ### ### VU University Medicahttps://Cl
Jan-10 Jan-11 Jan-11 ### ### Centre of Clinical Va https://Cl
14-Dec-17 26-Jan-19 26-Jan-19 ### ### ### Biodextra, "Study Prohttps://Cl
1-Mar-19 30-Sep-22 ### 2-Nov-18 ### Agencia Costarricensehttps://Cl
Jun-06 Jan-08 Dec-15 8-Sep-06 12-Jul-16 Hillman Cancer Center https://Cl
Sep-10 Apr-11 Apr-11 9-Mar-10 ### https://Cl
Jan-12 Aug-12 ### 9-Nov-15 Oxford Vaccine Grouphttps://Cl
23-Apr-07 Jun-18 Jun-18 ### ### University of Chicago,https://Cl
Nov-14 Mar-15 Jun-15 ### 9-Feb-16 https://Cl
23-Apr-07 31-Oct-07 11-Apr-08 2-Apr-07 12-Apr-17 8-Jun-18 GSK Investigational Sihttps://Cl
Nov-05 Mar-06 ### ### GSK Investigational S https://Cl
Mar-09 Feb-10 Feb-10 19-Jan-09 29-Jul-11 ### The Canberra Hospitalhttps://Cl
May-05 Dec-06 Dec-06 ### ### https://Cl
Nov-11 Aug-14 Dec-14 ### ### Americaninhas Vaccinhttps://Cl
Nov-07 Feb-10 Feb-10 ### 9-May-11 22-Jul-11 Pfizer Investigational https://Cl
21-Nov-17 Jan-20 Jan-20 ### ### The Ottawa Hospital, https://Cl
14-Oct-19 Feb-21 May-21 23-Jan-20 23-Jan-20 The Catholic Univ. of https://Cl
29-Apr-19 1-Dec-19 30-Jun-20 1-Mar-18 8-Jul-19 University of Alabam https://Cl
Dec-02 Jun-05 Feb-08 ### ### BIDMC, Boston, Massa https://Cl
Jan-95 Feb-96 Feb-96 16-Jun-08 16-Jun-08 GSK Clinical Trials Calhttps://Cl
Dec-11 May-13 May-13 ### 21-Apr-17 Roswell Park Cancer Ihttps://Cl
Sep-16 Dec-16 Jun-17 ### 21-Oct-16 Evidation Health, Santhttps://Cl
Jun-09 Jul-09 Jul-09 22-Jul-09 9-Oct-15 Medical University ofhttps://Cl
Jan-13 Mar-13 May-13 7-Jan-13 24-Jun-14 Columbia University, https://Cl
Jun-14 Apr-16 Apr-16 ### 13-Jun-16 Nationales Zentrum fhttps://Cl
Oct-16 Dec-16 May-17 ### ### https://Cl
Apr-04 Feb-09 24-Oct-05 ### Radboud University Nhttps://Cl
1-Aug-13 1-Apr-14 ### ### ### University of Florida, https://Cl
Oct-03 Nov-07 6-Nov-03 ### Dana-Farber Cancer In https://Cl
21-Dec-17 1-Dec-21 1-Dec-21 ### 6-Aug-19 Hospital of the Ludw https://Cl
Nov-17 Nov-19 Nov-19 ### ### Clinical Site TBA, San https://Cl
Aug-00 Sep-00 ### ### UCLA Center for Vaccihttps://Cl
Feb-12 May-13 Nov-13 ### ### Center for Vaccine D https://Cl
May-06 Sep-07 Dec-07 26-Apr-06 12-Jan-17 David Geffen School ohttps://Cl
May-12 9-Nov-15 5-Jul-16 ### 18-Apr-17 UNC Pediatric Clinic, https://Cl
Dec-13 Dec-14 Dec-14 4-Mar-14 19-Jan-15 Centre Hospitalo-Univhttps://Cl
Jun-98 Mar-09 Mar-09 27-Apr-04 ### Memorial Sloan-Kettehttps://Cl
Jul-14 Feb-16 Feb-16 15-Apr-14 16-Oct-17 University of Alabamahttps://Cl
Oct-06 Jun-09 Jul-09 21-Jul-06 ### ### Little Rock, Arkansas https://Cl
7-Feb-18 Feb-20 Feb-20 ### 8-Jul-19 Sudhakar Selvaraj, Hohttps://Cl
Sep-15 Sep-16 Mar-18 6-Apr-16 1-May-18 South African Tubercuhttps://Cl
Apr-04 May-08 Feb-10 ### 2-Jun-10 Erasmus Medical Centhttps://Cl
14-Jul-16 31-May-17 ### 2-May-16 1-Oct-19 1-Oct-19 GSK Investi"Study Prohttps://Cl
DATRI 101|11741|DATRI 0101 Jun-02 ### 6-May-13 Duke Univ Med Ctr, Dhttps://Cl
Sep-04 Aug-06 Aug-06 1-Sep-05 ### GSK Investigational Site,
https://Cl
Brno, Czech Republic|GSK In
Sep-16 Mar-17 Apr-17 ### 9-Apr-19 https://Cl
Oct-07 Feb-08 Feb-08 11-Oct-07 1-May-08 Children's Hospital B https://Cl
6-Nov-17 21-Feb-18 ### ### ### KEMRI, Kilifi, Kenya| https://Cl
Apr-09 Dec-18 ### 2-Sep-15 Instituto MÃ©dico Ale https://Cl
1-Jul-10 20-Feb-14 ### 12-Apr-10 ### 23-Jul-18 GSK Investigational Sihttps://Cl
Jun-09 Oct-10 Oct-10 ### 5-Dec-14 University of Oxford, https://Cl
31-May-01 30-Apr-03 30-Apr-03 9-Oct-06 ### https://Cl
May-97 Jun-98 Jun-98 16-Jun-08 16-Jun-08 GSK Clinical Trials Ca https://Cl
May-15 Jul-19 Jul-19 28-Apr-14 ### GSK Investigational Sihttps://Cl
24-Jan-19 Nov-21 Nov-21 19-Oct-16 6-Feb-20 Highlands Oncology Gr https://Cl
Sep-04 Jul-05 Jul-05 ### ### GSK Investigational S https://Cl
Sep-05 Feb-06 Nov-07 16-Jan-08 ### 29-Apr-14 https://Cl
091|UBI V106 ### 24-Jun-05 Univ of California at https://Cl
Nov-16 Feb-17 Feb-17 17-Oct-16 ### Oslo University Hospihttps://Cl
9-Feb-18 30-Jun-18 ### ### ### Site 5, BorÃ¥s, Swed https://Cl
Dec-99 Dec-07 27-Jan-03 7-Jan-13 M D Anderson Cancerhttps://Cl
Oct-11 Aug-12 Aug-12 1-Nov-11 ### Tallahassee Primary Chttps://Cl
Dec-16 Mar-19 ### 12-Jun-15 ### Uf Ctsi Crc, Gainesvillhttps://Cl
Jun-09 Aug-10 Aug-10 6-Mar-09 10-Jan-19 10-Jan-19 Orlando Clinical Resehttps://Cl
30-Apr-13 30-Jun-13 30-Jun-13 3-May-13 ### ### Department of Clinicahttps://Cl
15-Feb-19 15-May-19 ### 4-Jun-19 4-Jun-19 GSK Investigational S https://Cl
Aug-11 Jan-13 Jan-13 12-Jul-11 ### ### Gabinet Lekarski, Debhttps://Cl
Oct-02 27-Jan-03 23-Oct-07 University of Coloradhttps://Cl
May-15 Oct-19 Oct-19 ### ### GSK Investigational S https://Cl
25-Nov-19 Jun-20 Dec-20 ### ### Kalulushi district all https://Cl
Apr-01 Feb-02 ### 2-May-14 WRAIR Clinical Trials https://Cl
22-Jul-13 9-Apr-14 ### 23-Jul-13 ### GSK Investigational S https://Cl
24-Sep-10 30-Nov-11 ### ### 12-Oct-12 ### Sunrise Children's Cl https://Cl
5-Oct-15 5-Dec-22 5-Dec-22 ### ### GSK Investigational S https://Cl
Jul-07 Jul-11 Jul-11 20-Jul-09 25-Jul-16 25-Jul-16 Washington University https://Cl
17-Jun-09 Apr-14 Apr-14 ### ### UCSF Department of Ne https://Cl
Sep-03 Jun-17 Dec-17 10-Jul-09 ### Maria Sklodowska-Curhttps://Cl
8-Jan-20 1-Aug-24 1-Aug-25 ### ### UCLA / Jonsson Compre https://Cl
Sep-16 Aug-17 Aug-17 ### 27-Oct-16 Seoul National Univ. https://Cl
Feb-07 Nov-12 Nov-12 ### 1-Jul-13 4-Jan-17 University of Chicago,https://Cl
Feb-12 May-13 May-13 6-Mar-12 11-Jan-17 Massachusetts Genera https://Cl
Aug-08 Jan-12 9-Jun-08 9-Apr-13 https://Cl
18-Feb-19 Feb-21 Aug-21 ### ### Department of Hemato https://Cl
21-Oct-19 Sep-20 Aug-21 16-Oct-19 13-Jan-20 Investigational Site https://Cl
Sep-09 Nov-11 ### ### Guangxi Centers for Dhttps://Cl
Feb-03 Oct-03 4-Sep-06 8-Aug-08 Wellcome Trust Labora https://Cl
2-Jul-07 25-Mar-08 ### 4-Jul-07 18-Jan-19 18-Jan-19 GSK Investigational Sihttps://Cl
Dec-03 Jun-11 Jun-11 ### 10-Jun-11 Memorial Sloan-Kettehttps://Cl
Aug-00 Nov-02 27-Jan-03 31-Jan-13 Hackensack Universityhttps://Cl
26-Sep-06 22-Nov-07 ### ### 8-Oct-09 20-Jul-18 GSK Investigational Sihttps://Cl
May-12 Sep-16 Sep-16 5-Mar-12 ### Trine Zeeberg Iverse https://Cl
Dec-98 Feb-01 1-Sep-05 1-Sep-05 https://Cl
Jan-10 Sep-10 Sep-10 ### ### Centre for Clinical V https://Cl
1-Jul-17 23-Aug-18 ### 20-Jun-17 4-Apr-19 Seoul National Univers https://Cl
Apr-06 Jul-11 Jul-11 ### 6-Nov-12 Dan L. Duncan Cancerhttps://Cl
Nov-09 Mar-10 Mar-10 ### ### Hivcenter, Frankfurt https://Cl
Jan-13 Feb-14 Feb-14 1-Feb-13 29-Oct-14 Leiden University Med https://Cl
Mar-20 Dec-21 Dec-21 18-Oct-19 22-Jan-20 Johns Hopkins Univershttps://Cl
Apr-12 May-12 May-12 16-Oct-13 ### University of Antwerphttps://Cl
HN/P001-EBV-003 2-Feb-07 2-Feb-07 GSK Clinical Trials Ca https://Cl
Aug-99 Jun-02 16-Jun-04 27-Jan-10 Indiana University Cahttps://Cl
Jun-06 Sep-07 Sep-08 6-Feb-04 29-Oct-12 UCLA Center for HIV ahttps://Cl
Jul-16 Mar-17 Jun-20 ### ### Louisiana State Univehttps://Cl
Jun-02 Sep-11 Sep-11 16-Jun-08 ### Memorial Sloan Kettehttps://Cl
30-Oct-18 3-Jul-19 3-Jul-19 24-Oct-18 ### National Taiwan Univehttps://Cl
7-Oct-19 30-Jun-20 30-Jun-20 18-Oct-19 ### Johnson County Clin-Thttps://Cl
Nov-03 Oct-05 ### ### https://Cl
May-09 Sep-10 Sep-10 ### 13-Oct-11 20-Oct-16 GSK Investigational S https://Cl
Sep-07 May-10 May-10 ### 12-Jul-12 Duke University Medic https://Cl
Oct-13 Aug-17 Sep-18 9-Sep-13 ### Mount Sinai Hospital,https://Cl
28-Nov-03 22-Jan-10 22-Jan-10 ### 23-Jun-17 ### Peter MacCallum Cance https://Cl
6-Oct-19 Jan-21 Feb-21 ### 27-Jan-20 icddr,b study clinics https://Cl
17-Jun-11 9-Mar-14 ### 1-Jul-11 ### National Institutes ofhttps://Cl
Jul-16 13-Aug-19 ### ### 16-Oct-19 Universidad del Vall https://Cl
Jun-05 Jan-06 ### ### GSK Investigational S https://Cl
12-Oct-06 Feb-16 Dec-19 25-Oct-06 ### Naval Medical Researc https://Cl
15-Oct-12 23-Apr-14 6-Oct-16 26-Jun-12 8-May-15 ### GSK Investigational S https://Cl
Apr-06 Jan-07 ### 1-Mar-07 Centre for Clinical V https://Cl
1-Jun-00 31-Aug-05 1-Jun-20 5-Jun-00 14-Jan-20 National Institutes ofhttps://Cl
6-Dec-16 6-Apr-17 2-Jun-17 3-Feb-17 ### Biomedical Research h Cttps://Cl
Sep-12 Jan-15 Aug-15 8-Jan-13 8-Jan-13 Queen Sirikit Nationalhttps://Cl
Dec-01 Apr-05 1-Sep-05 ### South Orange Countyhttps://Cl
M
12-Oct-15 25-May-17 ### ### 17-Jul-17 CCVTM, University ofhttps://Cl
Jun-10 Aug-12 Aug-12 13-Oct-10 ### Center for Cancer I https://Cl
Sep-99 Mar-04 Jul-09 ### 9-Apr-10 23-Oct-15 https://Cl
22-Aug-12 26-Oct-12 ### 7-Aug-12 18-Jun-18 GSK Investigational Sihttps://Cl
R01AI050467|UCLA MIG-001 ### ### University of Californhttps://Cl
Oct-15 Nov-15 18-Apr-16 6-May-16 https://Cl
Nov-10 Mar-17 Mar-17 ### ### Memorial Sloan Kettehttps://Cl
Oct-14 Jun-17 Oct-20 29-Jan-19 30-Jan-19 UZ Leuven, Leuven, Bhttps://Cl
22-Dec-05 26-Oct-07 26-Oct-07 ### 2-Jul-17 National Institutes ofhttps://Cl
Dec-14 Dec-15 Dec-15 7-Nov-13 9-Mar-15 https://Cl
May-07 Aug-08 Dec-10 18-Apr-07 ### University Hospital Z https://Cl
Feb-05 Nov-09 Nov-09 ### 26-Apr-17 St. Jude Children's R https://Cl
Aug-06 Dec-06 5-Jun-06 7-Oct-16 GSK Investigational S https://Cl
Jul-10 Feb-15 Feb-15 18-Oct-10 14-Oct-15 Addenbrooke's Hospithttps://Cl
May-12 May-12 May-12 ### ### https://Cl
6-Jan-05 1-Nov-06 4-Dec-06 8-Sep-05 5-Feb-20 5-Feb-20 GSK Investigational Sihttps://Cl
24-Nov-17 9-Mar-18 ### ### ### Jiangsu Provincial Ce https://Cl
Jul-02 Jun-07 Dec-08 7-Jan-08 11-Jan-17 Bellaire Neurology, Behttps://Cl
7-Oct-17 Sep-21 Sep-22 6-Nov-17 2-Nov-18 The University of Ho https://Cl
17-Oct-02 5-May-09 23-Oct-02 2-Jul-17 National Institutes ofhttps://Cl
27-Mar-18 Dec-20 Dec-20 21-Oct-16 ### Menzies School of Hea https://Cl
1-May-17 Dec-20 Dec-20 ### ### University of Pennsyl https://Cl
Nov-09 May-10 Jul-10 ### ### Second Division of Nehttps://Cl
8-Nov-16 14-Mar-18 29-Jan-19 6-Oct-16 ### Miami, Florida, Unitehttps://Cl
Dec-10 May-12 Jun-12 ### ### ### Miami Research Associ https://Cl
Apr-13 May-14 Jun-14 26-Apr-13 ### Facultad de Medicinahttps://Cl
Apr-07 May-08 May-08 ### 7-May-08 Projet de DÃ©veloppe https://Cl
Apr-05 Mar-07 Sep-07 22-Oct-08 ### ### Jonesboro, Arkansas, https://Cl
Oct-03 Jul-06 Jun-09 ### 19-Oct-18 24-Apr-19 Ban Lamung District Ho https://Cl
Mar-12 Oct-12 Feb-13 5-Oct-12 ### Azienda Ospedaliera Un https://Cl
19-May-08 19-Dec-08 ### 18-Apr-08 ### ### GSK Investigational Sihttps://Cl
Dec-11 May-14 May-14 18-Jul-11 30-Jan-17 30-Jan-17 Private Clinic, Lipa C https://Cl
15-Feb-17 28-Dec-18 ### ### 7-Feb-19 National Institutes ofhttps://Cl
Oct-06 Jun-11 Jun-11 ### 5-Oct-16 Department of Obstetr https://Cl
Oct-12 May-15 Nov-16 ### 31-Jul-15 CHU de Bordeaux, HÃ´p https://Cl
31-Oct-18 31-Jul-21 ### 5-Feb-18 27-Jan-20 Washington University https://Cl
16-Sep-19 30-Apr-20 30-Apr-20 21-Oct-19 21-Oct-19 Liandu Center for Dis https://Cl
Jul-07 Jul-10 Sep-10 18-Jul-07 ### Hospital in Debica - https://Cl
Aug-07 Jul-09 16-Jul-07 4-Aug-08 Eisenhower Army Medi https://Cl
Jun-03 9-Feb-05 24-Jun-05 Emory University Schohttps://Cl
Mar-05 Apr-06 ### 4-Feb-13 Walter Reed Project, https://Cl
Aug-09 Jun-12 Jun-12 ### ### The Norwegian Radium https://Cl
Sep-08 Aug-11 Aug-11 8-Oct-08 ### Hackensack Univarsityhttps://Cl
CDR0000441167|S0348|U10CA032102 ### 24-Jan-13 https://Cl
7-May-18 28-Jan-19 28-Jan-19 12-Jun-17 2-Mar-18 https://Cl
Dec-10 Dec-11 Jun-12 17-Jan-11 ### Beijing, Beijing, Ch https://Cl
Jun-10 Nov-10 Sep-11 8-Jun-10 10-Apr-15 10-Apr-15 amostatnÃ¡ ordinace https://Cl
praktickÃ©ho lÃ©kaÅ™e pro d
Mar-05 Nov-07 Dec-08 2-Feb-09 9-Feb-10 Antwerp University Hhttps://Cl
May-10 Jul-13 Jul-13 11-Jan-10 ### GSK Investigational Sihttps://Cl
Nov-05 Sep-06 Sep-06 6-Apr-06 ### Sanofi Pasteur, Swif https://Cl
20-Feb-17 1-Apr-17 1-Jul-17 ### ### Hillel Yaffe Medical C https://Cl
1-Mar-17 1-Jun-19 1-Sep-19 9-May-18 ### CHU Saint-Pierre, Brushttps://Cl
Dec-11 Oct-12 Dec-13 8-Jun-15 8-Jun-15 https://Cl
17-May-10 5-Nov-10 9-Dec-10 3-May-10 ### 5-Nov-19 GSK Investigational S https://Cl
Jul-04 Apr-06 Dec-06 ### 8-Feb-17 GSK Investigational S https://Cl
Sep-06 Mar-07 29-Jun-06 28-Oct-16 GSK Investigational S https://Cl
11-Jul-16 4-Oct-17 4-Oct-17 20-Jul-16 4-Apr-19 4-Apr-19 Optimal Res "Study Prohttps://Cl
29-Apr-09 22-Sep-11 3-Jan-12 ### 10-Oct-12 1-Feb-18 Alabama Therapeuticshttps://Cl
Jul-15 May-16 ### 27-Jul-15 20-Oct-17 Medical University ofhttps://Cl
9-Jan-20 Sep-20 Sep-20 ### 28-Jan-20 Investigational Site https://Cl
Sep-01 Apr-11 Apr-11 18-Jun-08 20-Apr-11 Memorial Sloan Kettehttps://Cl
14-Jan-06 1-Oct-06 17-Oct-06 ### ### 8-Jun-18 GSK Investigational Sihttps://Cl
Jan-17 28-Sep-17 16-Jan-19 4-Jan-17 18-Oct-19 eStudy Site, La Mesa,https://Cl
Sep-04 Jun-07 8-Sep-04 3-Jun-13 University of Califor https://Cl
Sep-14 Dec-14 May-15 10-Jun-15 10-Jun-15 https://Cl
Jun-14 Jun-15 Dec-15 3-Mar-11 29-Oct-14 Public Health Research https://Cl
Sep-08 Jun-12 Dec-12 ### 4-Mar-16 San Gerardo Hospital,https://Cl
31-May-18 Mar-20 Jun-20 16-Jan-19 ### Ajou University Hospihttps://Cl
Sep-09 Aug-10 Sep-10 ### 3-Feb-10 Christian Medical Collhttps://Cl
Apr-13 Aug-14 Aug-14 20-Jan-14 31-Jul-14 Prism Research Inc, Shttps://Cl
Jun-15 May-18 Nov-18 4-Jun-15 ### AP-HP ; Cochin Hospita https://Cl
14-Dec-17 Nov-20 Nov-21 ### 13-Jun-19 CHU de Saint-Etienne,https://Cl
Jun-12 Jun-13 Nov-13 ### ### Miami Research Associ https://Cl
Jan-12 Dec-17 Oct-18 10-Jan-12 ### Oklahoma Medical Res https://Cl
4-Jun-18 19-Jul-18 19-Jul-18 ### ### ### Centers for"Study Prohttps://Cl
Mar-96 Dec-02 ### 6-May-19 Fred Hutchinson Canchttps://Cl
18-Jun-10 18-Nov-11 17-Jul-13 23-Oct-09 ### 12-Jul-18 GSK Investigational Sihttps://Cl
May-10 Jul-11 Jul-11 ### ### GSK Investigational Sihttps://Cl
Oct-16 25-Dec-17 ### ### ### Federal state budget https://Cl
Nov-05 Jul-08 Feb-09 ### ### ### Tuscaloosa, Alabama,https://Cl
Mar-09 Apr-10 Apr-10 22-Apr-09 15-Jul-10 National Taiwan Univehttps://Cl
Jan-05 May-05 May-05 20-Jan-06 2-Jul-08 Society for Applied Sthttps://Cl
Dec-07 Aug-11 Aug-11 ### 4-Nov-12 2-Oct-15 https://Cl
Nov-10 Jul-11 Sep-11 ### 31-Jul-12 Kendle Early Stage, T https://Cl
8-Jan-20 May-20 Mar-21 1-Nov-19 18-Jan-20 Johnson County Clin-Thttps://Cl
Apr-09 Oct-09 Jun-10 ### 7-Jun-10 Swedish Institute for https://Cl
Oct-07 Jan-10 Jan-10 5-Sep-07 8-Sep-11 14-Apr-17 National Institute of https://Cl
Nov-07 Jan-10 Jun-10 ### ### University of Alberta https://Cl
7-Jan-13 12-May-15 ### 18-Apr-11 28-Jan-19 Cincinnati Children's https://Cl
Oct-09 Apr-10 May-10 26-Jan-10 26-Jan-10 Shanghai Public Healthttps://Cl
18-Jul-13 9-Aug-13 9-Aug-13 17-Jun-13 16-Jan-15 7-Sep-18 GSK Investigational S https://Cl
9-Mar-16 9-Nov-22 9-Nov-23 8-Jan-15 26-Apr-19 Roswell Park Cancer Ihttps://Cl
Jan-16 19-Sep-18 ### 18-Jan-16 ### CNRFP, Ouagadougou,https://Cl
20-Mar-07 24-Jan-20 24-Jan-20 7-May-07 29-Jan-20 Memorial Sloan Kettehttps://Cl
Jan-15 Aug-22 Aug-22 6-Feb-15 ### Children's Hospital o https://Cl
May-16 1-Jun-21 1-Jun-21 7-Mar-16 ### University of Nebras https://Cl
Apr-13 Sep-14 24-Oct-18 5-Feb-13 ### Alabama CRS, Birmingh https://Cl
14-Aug-12 1-Aug-20 ### 22-Jun-17 11-Apr-19 Stanford University, Shttps://Cl
20-Jan-04 30-Mar-05 ### ### 30-Oct-19 GSK Investigational S https://Cl
1-Jun-17 Nov-19 Nov-19 ### ### Bristol University H https://Cl
Oct-97 Oct-09 Oct-09 ### ### St. Jude Children's R https://Cl
Dec-71 ### 26-Jul-11 New Jersey Medical Shttps://Cl
13-Apr-17 30-Jun-21 30-Jun-21 5-Oct-16 31-Jan-20 University of Californhttps://Cl
Jan-11 Mar-11 Nov-12 ### 4-Jul-12 Centre Hospitalier C https://Cl
16-Apr-19 16-Apr-19 Washington University https://Cl
Dec-08 Sep-16 ### ### 1-Jun-17 CIC Cochin Pasteur, hÃhttps://Cl
1-Jul-10 23-Aug-10 31-Jan-11 13-Jul-10 4-Aug-17 6-Sep-18 GSK Investigational S https://Cl
31-Jul-18 30-Sep-19 ### 18-Jul-18 18-Oct-19 Centre for Clinical V https://Cl
Sep-10 Oct-13 8-Apr-11 10-Oct-12 Cliniques universitair https://Cl
ACTG 225|11202 Aug-01 ### ### UAB, Dept. of Ped., Dhttps://Cl
6-May-16 May-20 May-20 6-May-16 1-Mar-19 Memorial Sloan Kettehttps://Cl
28-Nov-09 5-Jul-10 5-Jul-10 ### 25-Apr-17 21-Jan-20 GSK Investigational S https://Cl
1-May-06 1-Jan-07 8-Jan-07 ### 8-May-17 GSK Investigational Sihttps://Cl
Sep-09 Aug-14 Aug-14 27-Jun-11 ### Medical Faculty Assochttps://Cl
095|V24P1 ### 24-Jun-05 Creighton Univ Med Ct https://Cl
Oct-05 Jul-06 Jul-06 ### 9-Sep-10 1-Apr-15 https://Cl
Feb-05 Oct-05 Oct-05 21-Apr-06 25-Jul-17 Olsztyn, LubartÃ³w, Khttps://Cl
Nov-04 Sep-06 ### ### Mount Sinai Hospital,https://Cl
5-Nov-17 30-Jun-19 30-Jun-19 29-Jun-17 23-Apr-19 International Center https://Cl
14-Feb-07 4-Oct-07 14-Jul-10 ### 8-Jan-19 ### GSK Investigational S https://Cl
Mar-05 Feb-06 27-Jun-05 ### UCLA Center For Vaccihttps://Cl
Apr-10 Nov-14 Nov-14 ### 17-Apr-17 Radboud University Nhttps://Cl
5-Nov-19 7-Jul-20 6-Jun-21 15-Oct-19 5-Feb-20 GSK Investigational S https://Cl
Jun-08 May-10 Dec-10 7-Apr-08 7-Feb-11 Cincinnati Children's https://Cl
2-Apr-19 Sep-20 Dec-20 16-Jan-19 23-Jul-19 HALLYM UNIV. Chunche https://Cl
May-12 Dec-12 May-13 ### 24-Oct-12 Dr. Tommy Ho Pediatrihttps://Cl
28-Feb-11 20-Jun-13 20-Jun-13 ### 5-Oct-17 ### GSK Investigational S https://Cl
Sep-05 Dec-06 Jan-07 ### 1-Feb-12 Gieres, France|Lagordhttps://Cl
Oct-13 Dec-13 Jan-14 ### ### https://Cl
1-Apr-19 30-Jun-21 ### 24-Jan-19 ### National Institutes ofhttps://Cl
Nov-16 30-Sep-19 ### 9-Sep-16 28-Jan-20 Centre for Tropical Mhttps://Cl
May-13 Dec-13 Dec-13 ### ### ### Research Site, Miami,https://Cl
Nov-08 Aug-10 Dec-11 6-Nov-08 ### ### University of Chicago,https://Cl
Mar-07 Jan-10 Jan-10 ### ### Duke Comprehensivehttps://Cl
C
8-May-19 Apr-20 Apr-20 2-Dec-17 18-Jun-19 Icahn School of Medichttps://Cl
Sep-09 Jan-12 Jan-12 ### ### Clinical Research Assohttps://Cl
15-Nov-18 15-Jul-19 ### 30-Oct-18 2-Nov-18 Kanti Children's Hos https://Cl
22-Apr-10 16-Jun-11 16-Jun-11 ### ### ### https://Cl
Dec-15 1-Mar-17 Mar-17 2-Feb-17 2-Feb-17 https://Cl
Nov-09 Apr-11 Apr-11 ### ### Elton John Centre, S https://Cl
Aug-08 Oct-09 Jan-10 ### 3-Mar-15 Tlalpan, Mexico|Vallehttps://Cl
2-Feb-15 7-Aug-18 7-Aug-18 ### 22-Apr-19 CAPRISA eThekwini CR https://Cl
Aug-11 Nov-11 Apr-12 20-Jun-11 6-May-15 Investigational Medichttps://Cl
Jan-06 Nov-09 Nov-10 1-Feb-06 7-Aug-13 Arizona Cancer Centerhttps://Cl
Mar-10 Nov-11 Nov-11 12-Apr-10 9-May-12 NicVAX Investigator, https://Cl
Apr-03 Jun-06 Jun-06 7-Sep-05 13-Jan-14 https://Cl
Oct-12 Sep-13 Oct-13 ### 16-Jan-14 Aga Khan University, https://Cl
Aug-05 Aug-07 ### 5-Dec-07 Birmingham, Alabama, https://Cl
8-Apr-19 16-Jan-20 ### ### 5-Feb-20 GSK Investigational Site,
https://Cl
Atlanta, Georgia, United Stat
Mar-10 Oct-11 Aug-12 ### 14-Jun-13 Centro de Estudos dehttps://Cl
10-Mar-14 2-Nov-16 2-Nov-16 3-Feb-14 28-Jan-19 Cincinnati Children's https://Cl
Jan-10 Sep-11 Sep-11 ### ### Harriet Lane Clinic, https://Cl
Dec-99 Nov-00 Nov-00 3-Oct-06 ### https://Cl
11-Nov-17 30-Apr-18 30-Apr-18 6-Nov-17 ### Emmi Soluti"Study Prohttps://Cl
May-02 Jun-03 ### ### Alaska Native Medicalhttps://Cl
Dec-11 Dec-15 Dec-15 ### 14-Apr-17 University of Utah Hea https://Cl
Dec-14 Apr-15 Apr-15 2-Dec-14 1-Nov-15 5-Jan-16 01, Novartis Investigahttps://Cl
Jan-17 13-Dec-18 ### 20-Jul-16 4-Apr-19 Centre de Recherch https://Cl
Oct-16 25-Dec-17 ### ### ### Federal state budget https://Cl
16-Apr-18 4-Sep-18 30-Oct-19 20-Jan-17 2-Jan-20 Shanghai Public Healthttps://Cl
Jan-06 ### 9-Oct-15 Allgemeines Krankenha https://Cl
May-08 Dec-11 Feb-13 2-May-08 ### Centre de Soins de l'Ihttps://Cl
1-Jun-16 1-Oct-17 1-Oct-17 ### ### https://Cl
Sep-16 Aug-17 7-Jul-16 4-Aug-17 McMaster University,https://Cl
Jan-09 Dec-09 Sep-13 29-Jan-09 ### UniversitÃ¤tsklinikumhttps://Cl
Jul-97 Jun-02 27-Jan-03 30-Oct-15 Jonsson Comprehensive https://Cl
14-May-09 21-Nov-12 ### 1-May-09 ### ### GSK Investigational S https://Cl
20-May-13 24-Mar-14 ### ### ### 26-Jun-19 GSK Investigational Sihttps://Cl
Nov-08 Oct-10 Oct-11 15-Oct-09 15-Oct-09 First Department of Shttps://Cl
Jun-07 Dec-08 Sep-12 ### 23-Jul-13 Hopital Cochin CIC dehttps://Cl
Sep-00 Mar-08 Apr-08 27-Jan-03 ### 4-Sep-18 UNMC Eppley Cancerhttps://Cl
C
Jun-18 Jul-20 Jan-21 3-May-18 3-May-18 https://Cl
Jul-12 Sep-15 Sep-15 ### ### University of Virginia https://Cl
Aug-01 27-Jan-03 ### Herbert Irving Comprhttps://Cl
Feb-12 Nov-12 May-13 17-Oct-12 ### NZOZ Centrum Zdrowia https://Cl
Apr-09 Apr-09 Apr-09 ### 11-Jul-16 University of Pittsburhttps://Cl
28-Feb-18 29-Jun-18 29-Jun-18 ### 10-Jun-19 10-Jun-19 GSK Investi"Study Prohttps://Cl
Jun-06 Mar-09 Oct-09 21-Apr-06 3-Jan-19 3-Jan-19 Alabama Vaccine Resea https://Cl
Oct-00 May-06 ### 25-Jan-13 Mayo Clinic, Rochestehttps://Cl
Apr-10 Apr-11 Apr-11 29-Jun-10 22-Jun-11 https://Cl
11-Apr-19 30-Apr-20 30-Apr-20 1-Feb-19 ### Emory Children's Cente https://Cl
Jan-20 Aug-20 Dec-20 18-Jun-19 ### University Hospital https://Cl
5-Nov-07 30-Apr-08 30-Apr-08 23-Oct-07 15-Jan-19 13-Jan-20 GSK Investigational S https://Cl
Apr-08 Sep-09 Aug-10 23-Apr-08 17-Apr-12 San Diego, California https://Cl
Oct-10 Feb-12 6-May-13 6-May-13 'Aghia Sophia' Childrehttps://Cl
12-Sep-05 1-Nov-06 ### ### 12-Jul-17 6-Jun-18 GSK Investigational S https://Cl
27-Oct-15 14-Feb-17 ### ### 6-Jun-18 6-Feb-20 North Centr "Statistic https://Cl
Mar-95 Jan-06 Jan-06 ### ### Bandim Health Projechttps://Cl
Jun-08 Dec-09 Dec-09 16-Jul-08 22-Apr-16 WCO (Great Poland Ca https://Cl
7-Aug-18 Dec-20 Dec-20 26-Jul-18 ### American Academy ofhttps://Cl
Pe
30-Apr-18 14-May-21 ### 3-Apr-18 ### Alabama Clinical Therhttps://Cl
15-Sep-10 26-May-11 ### 8-Sep-10 28-Jun-12 ### GSK Investigational S https://Cl
1-Oct-16 31-Mar-19 31-Jul-19 12-Oct-17 22-Oct-19 University of Hong K https://Cl
Oct-09 Jul-11 Jul-11 4-Feb-09 9-May-12 NicVAX Investigator, https://Cl
Apr-11 Jun-11 Jun-11 30-Jun-11 6-Dec-12 Duke University Medic https://Cl
8-Jan-09 4-May-09 10-Jun-10 ### 25-Jan-13 8-Aug-18 GSK Investigational S https://Cl
Jun-15 Jun-20 Jun-20 18-Jul-18 18-Jul-18 Instituut voor Tropis https://Cl
11-Jan-19 12-Dec-24 ### ### ### GSK Investigational S https://Cl
Sep-07 Oct-08 Jan-09 ### ### St George's Vaccine I https://Cl
10-Oct-18 Mar-22 Mar-22 ### ### Investigational Site https://Cl
21-Jun-17 6-Jun-18 Dec-19 23-Jun-17 ### ### Medical Re"Study Prohttps://Cl
Sep-06 Oct-07 Mar-08 28-Jun-06 20-Jul-12 ### GSK Investigational Sihttps://Cl
Apr-06 Oct-06 Apr-07 10-Apr-06 ### ### Walter Reed Army Inst https://Cl
Apr-16 Apr-19 Apr-23 ### 9-Nov-18 UO Immunoterapia e https://Cl
Lab
1-Jan-06 1-Jan-07 23-Jan-07 ### 29-Oct-18 29-Oct-18 GSK Investigational Sihttps://Cl
Sep-14 Apr-15 Sep-15 ### ### ### University of North Cahttps://Cl
31-Aug-18 1-May-19 19-Oct-23 10-Apr-18 ### Yangchun Center For https://Cl
Jul-17 Oct-18 Nov-18 11-Jan-17 27-Jun-17 https://Cl
23-Feb-07 27-Apr-17 8-Jun-17 ### ### ### National In"Study Prohttps://Cl
30-May-17 14-Dec-17 ### ### 4-Jan-19 4-Jan-19 Research Si"Study Prohttps://Cl
20-Aug-04 13-Mar-06 1-Nov-06 ### 10-Oct-18 Vaccine Clinical Rese https://Cl
Jun-15 Jan-16 Jan-16 16-Jun-15 ### ### Research Site, South https://Cl
Apr-12 May-14 Oct-14 ### 6-Feb-15 Culver Medical Group,https://Cl
Apr-09 Oct-11 Jun-13 ### 13-Jan-14 Roswell Park Cancer Ihttps://Cl
Oct-14 Jul-15 Aug-15 ### ### Mirpur clinic (Intern https://Cl
Dec-14 Aug-15 Dec-15 ### 20-Jan-16 https://Cl
1-Nov-16 30-Oct-18 30-Oct-18 ### 9-Nov-18 Walter Reed Army Insti https://Cl
Dec-13 Feb-18 Jul-18 ### 22-Jan-20 Hebrew University-Had https://Cl
Nov-14 Jan-15 Jan-15 ### ### ### Optimal Research LLC,https://Cl
Jul-07 Oct-07 Jun-08 10-Jul-07 2-Jul-08 Accelovance LLC, Sanhttps://Cl
7-Apr-06 15-Sep-06 ### ### 25-Apr-17 GSK Investigational https://Cl
Feb-11 Feb-14 8-Feb-11 12-Jul-13 Antwerp University Hhttps://Cl
10-Dec-18 10-Dec-20 ### 24-Jan-19 ### Department of Oncolo https://Cl
HVTN 054|10121 Oct-06 14-Jul-05 4-Mar-15 San Francisco Vaccinehttps://Cl
Nov-16 Dec-19 ### 10-Jan-17 McMaster University,https://Cl
CV-MMAIT-4-001|JWCI-MC-4-001 24-Jan-03 24-Jun-05 Arizona Cancer Centerhttps://Cl
CV-MMAIT-3-001|JWCI-MC-3-001A 24-Jan-03 24-Jun-05 Arizona Cancer Centerhttps://Cl
30-Sep-14 14-Jan-19 14-Jan-19 5-Mar-18 ### Stanford University, Shttps://Cl
Aug-07 Aug-18 Feb-19 17-Jun-11 ### https://Cl
Apr-09 Aug-10 Aug-10 ### ### San Francisco Generalhttps://Cl
Jun-06 6-Jul-06 9-Oct-15 University Hospital, https://Cl
Nov-04 Sep-07 Sep-09 8-Nov-04 ### 6-Oct-15 https://Cl
23-Apr-04 22-Jan-08 21-Jun-06 2-Jul-17 Malaria Research andhttps://Cl
DMID 99-021|AV012 Nov-05 ### ### Pedro A. Piedra, M.D.https://Cl
Jan-03 May-03 May-03 27-Jan-03 13-Jun-12 MBCCOP - Gulf Coast,https://Cl
Oct-05 Aug-13 Aug-13 ### ### UCSF Department of Ne https://Cl
28-Jul-10 Apr-20 Apr-21 6-Aug-10 3-Oct-19 H. Lee Moffitt Cancerhttps://Cl
26-Jun-19 Apr-20 Mar-21 ### 3-Oct-19 Clinical Research Conhttps://Cl
7-Aug-18 Jul-20 Jul-20 1-Aug-18 ### American Academy ofhttps://Cl
Pe
2-May-16 30-Nov-16 ### 19-Apr-16 4-Oct-17 4-Oct-17 Research Site, South https://Cl
16-Nov-06 31-Mar-10 17-Jul-10 18-Jul-06 3-Aug-11 8-Jun-18 GSK Investigational Sihttps://Cl
Apr-12 May-13 May-13 27-Apr-12 29-Jun-15 Aga Khan University, Khttps://Cl
20-Feb-19 11-Oct-19 ### ### 29-Jan-20 GSK Investigational Sihttps://Cl
Oct-16 Mar-17 Mar-17 3-Oct-16 ### https://Cl
Mar-12 Dec-12 Dec-12 16-Apr-12 ### Karolinska Trial Alli https://Cl
Jun-09 Oct-09 Dec-09 16-Jun-09 ### Universite of Coloradhttps://Cl
Jul-05 May-06 ### ### GSK Investigational Sihttps://Cl
15-Nov-06 1-Dec-09 1-Dec-09 ### ### 19-Jun-19 GSK Investigational S https://Cl
1-Mar-16 31-Aug-17 ### ### 7-Jun-19 28-Jun-19 GSK Investi"Study Prohttps://Cl
7-Aug-18 Feb-21 Feb-21 1-Aug-18 ### American Academy ofhttps://Cl
Pe
Mar-12 Aug-16 Aug-16 6-Jan-12 1-May-18 ### Mary Crowley Cancerhttps://Cl
R
1-Oct-18 1-Oct-19 1-Oct-19 3-Oct-18 18-Jan-19 BC Children's Hospitahttps://Cl
Aug-14 May-15 May-15 ### ### Walter Reed Army Instihttps://Cl
Apr-12 Apr-13 Apr-13 7-Mar-12 ### University of Marylanhttps://Cl
May-10 30-May-18 ### ### 11-Jun-18 Ovarian Cancer Resear https://Cl
11-Aug-16 22-Dec-17 ### 28-Oct-15 8-Jan-18 NIHR/Wellcome Trusthttps://Cl
I
11-Jan-17 19-Feb-19 ### 7-Oct-16 6-Feb-20 GSK Investigational Site,
https://Cl
Anaheim, California, United S
Sep-13 Jul-15 Jul-15 ### 1-Feb-18 SATVI, Wor"Study Prohttps://Cl
7-Aug-18 Jul-20 Jul-20 26-Jul-18 ### American Academy ofhttps://Cl
Pe
13-Jan-20 3-Apr-20 3-Apr-20 10-Jan-20 10-Jan-20 Family Medicine Depahttps://Cl
Feb-13 Nov-13 Jun-14 15-Jun-10 3-Jan-19 3-Jan-19 Alabama Vaccine Resea https://Cl
Sep-06 Oct-09 Dec-09 9-Jun-10 9-Jun-10 South Hospital, Stoc https://Cl
17-May-10 11-Oct-11 11-Oct-11 ### ### ### GSK Investigational S https://Cl
6-Jun-16 14-Feb-20 ### ### 5-Feb-20 Mayo Clinic in Florid https://Cl
13-Feb-07 4-Sep-07 23-Oct-07 6-Mar-07 20-Jun-18 20-Jun-18 https://Cl
A5187|10010|ACTG A5187 Sep-07 29-Jul-05 ### Ucsd, Avrc Crs, San https://Cl
Jan-13 Oct-13 Oct-13 ### ### Wellcome Trust CRF, https://Cl
17-Nov-16 22-Jul-18 9-Oct-18 ### 16-Oct-18 National Institutes ofhttps://Cl
Jun-05 Jun-08 Jun-08 ### 3-Dec-15 University of Arizona https://Cl
11-Nov-03 3-Dec-07 3-Dec-07 ### 24-Jul-09 ### GSK Investigational Sihttps://Cl
Apr-03 20-Apr-05 28-Jul-06 Julius-Maximilians-U https://Cl
1-Feb-14 18-Mar-16 ### 7-Nov-13 26-Jun-18 ### GSK Investigational Sihttps://Cl
May-05 Sep-06 Apr-07 ### 8-Aug-18 CIC de Vaccinologie Chttps://Cl
May-99 Jan-01 1-Sep-05 1-Sep-05 https://Cl
Dec-10 Jul-11 Jul-11 ### 24-Oct-11 CESFAM Gabriela Mistr https://Cl
Dec-10 Aug-13 Aug-13 25-Jan-11 ### Clinical Research Assohttps://Cl
Jan-09 Apr-10 Apr-10 ### ### 16-Oct-17 Memorial Regional Hos https://Cl
Dec-15 Feb-16 Feb-16 ### 25-Jan-18 International Center https://Cl
May-99 Mar-01 1-Sep-05 1-Sep-05 https://Cl
HPTN 027|10141 May-09 6-Dec-04 4-May-12 Makerere University- https://Cl
May-07 Dec-07 Dec-07 ### ### Covance Daytona Beach https://Cl
28-Feb-20 2-May-22 2-May-23 ### 5-Feb-20 Roswell Park Cancer Ihttps://Cl
21-May-18 30-Oct-18 30-Oct-18 ### ### Hospital Moinhos de h Vttps://Cl
Mar-16 Jan-18 Jan-18 25-Jan-16 25-Jan-16 Varela Health Center, https://Cl
Varela, Cacheu, Guinea-Bissau|
Jan-00 Dec-12 Dec-12 ### 3-Feb-12 https://Cl
Nov-08 Jun-20 Jun-20 ### ### Sidney Kimmel Compre https://Cl
063A|AI452-003001 ### ### Bristol - Myers Squib https://Cl
Dec-09 Feb-10 Apr-10 ### ### ### Viet Tri, Phu Tho Pro https://Cl
Aug-13 Dec-16 Dec-16 ### ### National Institute fo https://Cl
17-May-19 1-May-22 1-May-22 8-May-19 14-Jun-19 Mayo Clinic, Rochestehttps://Cl
1-Jul-19 31-Jan-22 31-Jan-22 ### 10-Oct-19 MRC/UVRI"Study
a Prohttps://Cl
Dec-05 Feb-13 27-Oct-17 ### 9-May-17 ### Lineberger Comprehens https://Cl
Feb-98 16-Jun-01 16-Jun-01 ### ### University of Alabamahttps://Cl
3-Jun-08 27-Jun-16 Jun-17 2-Jan-08 ### ### U.S. Army Medical Reshttps://Cl
Nov-02 Apr-04 Apr-04 27-Apr-05 9-Sep-16 GSK Investigational Sihttps://Cl
Apr-05 May-07 May-07 9-May-06 ### 9-Dec-16 GSK Investigational https://Cl
Nov-00 Apr-10 3-Feb-04 ### Lombardi Comprehensi https://Cl
18-Apr-17 5-Jan-18 5-Jan-18 9-May-17 28-Jan-19 Investigational Site, https://Cl
Sep-15 Dec-15 Aug-16 4-Jun-15 ### AP-HP ; Cochin Hospitahttps://Cl
10-Oct-19 15-Aug-24 ### 8-Jul-19 28-Oct-19 Centre for Infectious https://Cl
Feb-16 Sep-16 30-Oct-17 ### 17-Jan-18 Germans Trias i Pujol https://Cl
Jun-14 Jan-15 Jan-15 1-Jul-14 30-Jan-15 MRC/UVRI Uganda Res https://Cl
May-04 Apr-07 Sep-09 ### ### USC/Norris Comprehens https://Cl
1-Jul-10 22-Jun-12 ### 15-Jun-10 1-Feb-19 1-Feb-19 GSK Investigational Site, https://Cl
Haabneeme, Estonia|GSK Inv
Sep-02 Mar-03 Sep-03 31-Jan-03 22-Jan-14 Orlando Clinical Resehttps://Cl
Sep-14 Mar-15 Mar-15 ### 1-Apr-15 Korea University Ansahttps://Cl
14-Jul-17 20-Dec-17 3-Apr-18 ### ### Maternal and child hehttps://Cl
Mar-05 Jun-05 ### ### University of Michigahttps://Cl
23-Oct-19 30-Sep-22 ### 29-Oct-19 7-Nov-19 University of Hong K https://Cl
Sep-01 Dec-01 Dec-01 ### ### Suncoast Clinical Res https://Cl
May-02 Sep-08 Mar-09 7-Oct-11 7-Oct-11 Dept of Neurology,Hahttps://Cl
Nov-04 Jul-05 ### 9-Oct-15 Vienna General Hospihttps://Cl
24-May-07 5-May-14 5-May-14 ### ### National Institutes ofhttps://Cl
Mar-05 Apr-11 Apr-11 22-Jun-10 ### University of Birmin https://Cl
6-Jun-18 27-Dec-18 ### 20-Jun-18 ### ### Research Si"Study Prohttps://Cl
Dec-09 Feb-10 Jun-10 ### ### Lingchuan County CDC, https://Cl
Nov-96 Dec-03 2-Dec-05 5-Oct-15 University of Wisconshttps://Cl
Aug-08 Apr-11 Apr-11 ### 3-Jun-14 ### https://Cl
Jul-12 Feb-20 Feb-20 31-Jul-12 5-Apr-19 Naval Health Researchhttps://Cl
Jun-03 Jul-03 Jul-03 ### 2-Mar-12 Catholic University https://Cl
Oct-11 Jan-12 Jan-12 ### 7-Sep-18 Pfizer Investigational https://Cl
Jun-06 Jun-06 Jan-09 16-Jun-06 2-Mar-10 ### GSK Investigational Sithttps://Cl
Mar-15 Jul-15 Jul-15 ### 16-Jul-15 First affiliated hospi https://Cl
May-14 Aug-14 Dec-14 ### 6-Nov-17 West Java Provincial https://Cl
11-Oct-09 9-Nov-09 ### ### ### ### GSK Investigational Sihttps://Cl
Jun-13 Dec-14 Jul-15 17-Jun-13 24-Jul-13 Beijing 302 Hospital, https://Cl
Jan-11 May-12 May-12 2-Feb-11 ### Sanofi Pasteur MSD inhttps://Cl
Jul-07 Jan-09 Feb-09 8-Jan-09 16-Jan-12 19-Jan-12 Miami Research Associ https://Cl
16-Nov-11 1-Apr-16 15-Apr-16 18-Jan-12 ### 18-Jul-19 Program For The Study https://Cl
Oct-10 5-Nov-10 5-Nov-10 BC Centre for Diseas https://Cl
Dec-05 Mar-07 ### 1-Jun-07 Pediatric Dpt A', HaE https://Cl
Jun-97 Apr-98 Apr-98 12-Apr-06 ### https://Cl
Nov-07 Dec-09 Dec-09 ### ### University of Pennsyl https://Cl
Oct-00 Jan-01 Jan-01 ### 6-Mar-12 University of Antwer https://Cl
May-08 May-09 May-09 ### ### 22-Jul-11 Research Hospital, Thhttps://Cl
Nov-10 Feb-11 Feb-11 ### ### The University of Ho https://Cl
24-Feb-15 3-Jan-17 6-Jun-17 15-Jan-15 9-Jan-18 8-Feb-19 GSK Investi"Study Prohttps://Cl
4-Oct-18 Aug-22 Aug-22 2-Oct-18 ### Investigational Site https://Cl
04-070|NMIMR: CPN 042/03-04 Jul-08 ### 23-Jan-19 Naval Medical Researc https://Cl
26-Jul-15 30-Jun-21 30-Jun-21 15-Jun-15 10-Apr-19 Malaria Research andhttps://Cl
13-Nov-15 25-Oct-16 25-Oct-16 7-Oct-15 11-Oct-17 ### GSK Investigational S https://Cl
Nov-03 May-04 Oct-04 9-Dec-05 ### GSK Investigational S https://Cl
Jul-16 Jun-17 Mar-19 7-Apr-15 22-Jan-20 National Cancer Insti https://Cl
Jul-08 Mar-09 Jun-09 8-Aug-08 ### University of Rochesthttps://Cl
24-Jun-11 11-Apr-17 11-Apr-17 6-Dec-10 13-Apr-18 ### "Study Prohttps://Cl
12-Jun-18 7-Aug-19 7-Aug-19 20-Jul-18 ### Centre for the Evaluahttps://Cl
May-06 Jun-12 Jun-12 26-Jul-05 24-Jul-14 Kenya Med. Researchhttps://Cl
Jul-06 Nov-09 Apr-10 21-Apr-06 9-Jan-19 9-Jan-19 Alta Clinical Researchhttps://Cl
LLC, Tucson, Arizona, United Sta
May-14 Nov-15 May-16 30-Apr-14 30-Apr-14 Centre d'Investigationhttps://Cl
Nov-10 Apr-11 Apr-11 ### 13-Apr-17 13-Apr-17 Clinical Trials Unit. https://Cl
30-May-18 30-Dec-19 ### ### ### Peter MacCallum Cance https://Cl
30-Nov-10 23-Dec-15 ### 27-Oct-10 2-Jul-18 ### https://Cl
28-Jul-07 17-Jun-08 24-Oct-08 2-Aug-07 7-Feb-14 ### GSK Investigational S https://Cl
Apr-06 Oct-06 Apr-07 10-Apr-06 ### ### Walter Reed Army Inst https://Cl
Jan-11 Oct-11 Apr-12 3-Feb-11 3-Feb-11 Maharaj Nakorn Chianhttps://Cl
Feb-15 Jun-15 Jun-15 ### 2-Nov-15 https://Cl
1-Aug-04 15-Sep-05 ### ### ### ### GSK Investigational Sihttps://Cl
Sep-15 Mar-17 Dec-17 ### 2-Jan-20 2-Jan-20 Karolinska "Study Prohttps://Cl
4-Dec-17 22-Dec-17 ### 12-Oct-17 ### University of Rochesthttps://Cl
Nov-05 Oct-12 Oct-12 ### 17-Oct-19 University of Marylanhttps://Cl
7-Feb-18 31-Jan-22 31-Jan-22 ### ### University Children's https://Cl
Sep-15 25-Sep-18 Jan-19 1-Oct-15 6-Aug-18 Health Sciences Northhttps://Cl
15-Apr-18 25-Feb-19 12-Oct-19 13-Jan-20 13-Jan-20 Disease prevention a https://Cl
Nov-05 Jul-06 Jul-06 ### 20-Oct-10 22-Jul-15 https://Cl
HVTN 049|10054 Sep-07 ### 4-May-12 Saint Louis Univ. Sch https://Cl
1-Oct-15 2-Feb-17 2-Feb-17 ### 6-Jun-17 wujin district CDC, C https://Cl
21-Jan-19 12-Dec-19 6-Nov-20 24-Jan-19 18-Jan-20 GSK Investigational Sihttps://Cl
Feb-20 Sep-21 Mar-22 ### ### https://Cl
Jan-14 Jan-14 Jan-14 ### 14-Jan-14 https://Cl
20-Oct-15 16-Mar-16 ### 29-Oct-15 6-Nov-17 6-Nov-17 Osaka, Japan https://Cl
AVEG 002A|10538 Dec-92 ### ### Vanderbilt Univ. Hosphttps://Cl
27-Apr-19 29-Mar-20 ### 4-Apr-19 25-Oct-19 Kaihua country Centerhttps://Cl
Nov-13 Dec-21 Dec-21 ### 5-Feb-20 Centre Hospitalier U https://Cl
Nov-15 Oct-16 Oct-17 15-Jul-13 23-Jan-20 Centre Hospitalier Unhttps://Cl
AVEG 014C|10562 Jul-99 ### ### JHU AVEG, Baltimore,https://Cl
Apr-12 Nov-12 Nov-12 20-Jun-12 ### Centre for Clinical https://Cl
Jun-05 Jan-13 Mar-15 ### 20-Apr-15 Ohio State Universit https://Cl
Feb-10 ### ### BC Centre for Diseas https://Cl
Apr-07 Mar-10 Mar-10 7-May-07 ### Sidney Kimmel Compre https://Cl
Apr-99 Oct-02 Nov-02 9-Feb-04 ### University of Pennsyl https://Cl
Oct-14 Nov-15 Nov-15 ### ### Radboud university mhttps://Cl
Sep-04 Sep-07 ### ### University of Pittsbu https://Cl
16-Oct-08 14-Jan-11 14-Jan-11 21-Oct-08 2-Jul-17 National Institutes ofhttps://Cl
Jun-97 Apr-01 ### 2-Oct-15 Jonsson Comprehensive https://Cl
Aug-06 May-08 Aug-09 ### 2-May-14 2-May-14 Soweto, Johannesburg https://Cl
9-Nov-17 23-Dec-17 ### ### 12-Jun-18 Service Urgence et R https://Cl
8-Dec-16 30-Sep-25 ### ### ### National Institutes ofhttps://Cl
Mar-06 May-06 May-06 20-Jun-06 ### Stanford University, Shttps://Cl
Jul-15 Dec-19 Dec-19 8-Jan-15 11-Jul-19 New York University https://Cl
AVEG 002B|10539 Dec-92 ### ### Children's Hospital & https://Cl
Sep-12 Oct-12 Nov-12 ### ### Korea University Gurohttps://Cl
Apr-11 Aug-12 Sep-12 14-Apr-11 3-Jan-13 San Diego, California,https://Cl
16-Jun-16 18-May-17 ### 19-Apr-16 10-Jun-19 GSK Investigational S https://Cl
Jun-10 Apr-14 Apr-14 4-Mar-11 15-Oct-14 Oncology Department, https://Cl
Oct-16 Mar-18 Dec-18 ### ### https://Cl
May-13 Feb-15 Feb-15 ### ### ### Coastal Clinical Rese https://Cl
Jul-10 Jul-15 Jul-15 ### 28-Jun-16 Rijnstate Hospital, A https://Cl
Oct-07 May-11 May-11 ### ### https://Cl
3-Jan-18 30-Jun-19 30-Jun-19 ### 29-Jul-19 Northwester"Informed https://Cl
21-Aug-14 22-May-15 3-Mar-16 8-Aug-14 21-Jul-17 27-Jun-19 GSK Investigational Sihttps://Cl
Sep-06 Apr-07 Sep-07 16-Jan-08 23-Jan-14 4-May-16 https://Cl
Dec-13 Sep-17 ### ### https://Cl
31-Dec-08 11-May-12 ### 3-Feb-09 12-Oct-17 4-Feb-19 https://Cl
18-Feb-15 14-Jul-17 14-Jul-17 8-May-14 ### Children's Outcomes https://Cl
Jul-13 Aug-14 Aug-14 ### ### Statens Serum Instit https://Cl
5-Sep-17 31-Dec-20 30-Apr-21 13-Jan-15 6-Jun-19 McMaster University https://Cl
Mar-11 Dec-13 Apr-14 ### 12-Jun-12 Shirdi Sai Baba Rural https://Cl
Apr-03 ### ### University of Californhttps://Cl
13-Apr-15 Dec-21 Dec-21 2-Oct-14 27-Jan-20 CHU Amiens-Picardie,https://Cl
28-Sep-16 Jul-19 Jul-19 6-Nov-17 6-Nov-17 Soroka Medical Center https://Cl
2-Sep-19 Sep-21 Jan-22 ### 9-Sep-19 KEMRI-Centre Geograp https://Cl
Mar-15 Dec-16 May-17 ### 25-Oct-17 University Childrens https://Cl
13-Nov-17 Jul-20 Jul-20 ### ### Research Centers of Ahttps://Cl
Nov-16 Jun-17 Aug-17 ### ### Smorodintsev Research https://Cl
Oct-05 Apr-07 Apr-07 30-Oct-05 ### Accelovance, Huntsvilhttps://Cl
Aug-00 Dec-05 27-Jan-03 20-Jun-13 Warren Grant Magnuson https://Cl
Jun-04 Feb-06 Jun-07 9-Sep-04 20-Jun-14 20-Jun-14 University of Virginia https://Cl
Sep-12 Dec-12 Dec-12 ### 4-Sep-14 ### Malcom Randall VA Med https://Cl
4-Aug-09 13-Nov-09 ### 13-Jul-09 ### ### GSK Investigational S https://Cl
22-Feb-06 27-Aug-07 ### ### 6-Aug-12 ### GSK Investigational Sihttps://Cl
Sep-08 Jul-09 Nov-09 23-Jun-08 16-Jul-10 ### The Hope Clinic of th https://Cl
Jul-13 Oct-17 May-19 ### 7-May-19 Flinders Medical Centr https://Cl
1-Oct-08 27-May-10 ### ### 24-Apr-17 8-Jun-18 GSK Investigational S https://Cl
Apr-07 Apr-09 Apr-09 ### ### University of Iowa, I https://Cl
Jan-04 Jan-08 Jun-09 4-Apr-05 28-Jun-13 ### Childrens Hosp of Loshttps://Cl
Oct-11 Aug-12 Aug-12 21-Oct-11 ### Dept. of Health Scienhttps://Cl
5-Feb-19 30-Apr-19 ### 31-Jan-19 4-Oct-19 GSK Investigational Sihttps://Cl
24-Sep-18 27-Nov-18 26-Apr-19 5-Sep-18 ### US135, Hollywood, Flo https://Cl
18-Sep-14 31-Jan-17 31-Jan-17 4-Aug-14 ### ### GSK Investi"Study Prohttps://Cl
Aug-16 18-Jul-17 18-Jul-17 ### 8-Apr-19 8-Apr-19 Isala, Zwol"Informed https://Cl
Oct-12 May-13 Jun-13 15-Oct-12 ### East West Medical Reshttps://Cl
17-Nov-15 23-Sep-16 ### ### ### 8-Nov-18 GSK Investigational Sihttps://Cl
8-Mar-12 30-Sep-16 ### ### ### ### GSK Investigational Sihttps://Cl
13-Jun-07 5-Feb-09 5-Feb-09 19-Jun-07 2-Jul-17 QIMR - CLive Berghofehttps://Cl
19-Aug-09 29-Aug-13 21-Jan-16 ### 23-Jul-18 Case Medical Center, https://Cl
23-Jun-15 20-Jun-18 20-Jun-18 2-Jun-14 1-Apr-19 1-Apr-19 Centro de "Study Prohttps://Cl
Nov-05 Apr-07 26-Jul-05 8-Jul-14 KEMRI, Ctr. for Geogrhttps://Cl
Apr-13 Dec-13 Apr-14 4-Feb-13 ### Leiden University Med https://Cl
Mar-02 Feb-04 Mar-04 2-Oct-09 2-Oct-09 University Hospital https://Cl
21-Aug-17 19-Dec-17 ### ### ### Jiangsu Provincial Ce https://Cl
Apr-04 Mar-07 Mar-07 10-Jan-05 4-Jan-13 Cancer Research Cente https://Cl
Jul-15 Aug-16 Aug-16 21-Jul-15 23-Jul-15 Pediatric Consultantshttps://Cl
Jun-04 Jun-07 Jun-07 5-Aug-04 15-Apr-15 University of Southern https://Cl
22-Jan-17 Nov-19 Nov-19 6-Dec-16 15-Jul-19 Institut Pasteur of https://Cl
9-Apr-14 28-Mar-16 2-May-14 ### University of Chicagohttps://Cl
Jun-04 Dec-06 ### 5-Nov-10 Dept. of Immunology,https://Cl
Aug-14 Aug-16 Nov-16 ### ### Affiliated Hospital to https://Cl
Nov-05 Sep-07 ### 1-Jun-15 Northwestern Universit https://Cl
Mar-06 Aug-07 Oct-10 ### 11-Jun-13 Ucsd Aiedrp, San Dieghttps://Cl
Nov-02 Sep-04 Sep-04 9-Dec-05 ### GSK Investigational Sihttps://Cl
Mar-20 May-21 Jul-21 31-Jan-20 31-Jan-20 Johns Hopkins Hospita https://Cl
Aug-09 Nov-09 Apr-10 ### 9-Oct-15 Sanatorium Leech, Gra https://Cl
Aug-04 Feb-05 ### ### SFBC International, Inhttps://Cl
23-Dec-19 Aug-21 Aug-21 18-Jan-20 18-Jan-20 Benchmark Research,https://Cl
S
SU-09112008-1298|COR0008 28-Oct-08 24-Jan-12 Stanford University Schttps://Cl
Jun-95 Jan-96 Jan-96 16-Jun-08 16-Jun-08 GSK Clinical Trials Calhttps://Cl
Aug-07 Jul-09 Jul-09 27-Oct-06 9-Dec-14 UCSD Antiviral Researhttps://Cl
5-Nov-19 30-Jul-20 ### 24-Oct-19 31-Jan-20 GSK Investigational S https://Cl
Jan-10 Sep-10 Sep-10 19-Jan-09 ### ### Pfizer Investigational https://Cl
Dec-03 Mar-05 Oct-05 ### ### University Hospital L https://Cl
Mar-99 Aug-05 Aug-05 8-May-03 25-Jun-13 Memorial Sloan-Ketter https://Cl
15-Dec-08 29-Sep-10 14-Jul-11 9-Dec-08 25-Jan-13 ### GSK Investigational S https://Cl
17-Apr-17 15-Jan-20 30-Jun-20 8-May-17 ### Institut de Recherch https://Cl
29-Aug-18 29-Mar-19 ### ### 12-Jun-19 Collaborative Neuroschttps://Cl
Mar-15 May-16 Sep-16 6-Oct-14 7-Oct-14 https://Cl
Jan-08 Jun-08 Dec-08 5-Feb-08 9-Jul-13 9-Jul-13 Seoul National Univers https://Cl
Dec-13 Sep-14 Aug-15 ### 1-Oct-15 Beijing, China https://Cl
31-Oct-14 9-Apr-15 9-Apr-15 9-Oct-14 ### 30-Oct-18 https://Cl
Sep-10 Dec-11 Jun-12 16-Jul-10 7-Dec-12 7-Dec-12 Anniston, Alabama, Un https://Cl
Sep-05 Jul-06 Aug-08 16-Jan-08 ### ### https://Cl
1-Jan-20 1-Sep-20 1-Jan-21 ### ### King Abdulaziz Medicahttps://Cl
29-Jul-14 7-Jan-16 7-Jan-16 1-Aug-14 ### National Institutes ofhttps://Cl
Jan-12 May-12 Sep-12 3-Sep-12 29-Jul-13 Q-Pharm Pty Ltd, Brishttps://Cl
Aug-18 30-Dec-19 ### 20-Jun-18 ### Chan Soon-Shiong Inst https://Cl
24-Jul-12 18-Dec-13 ### 25-Jun-12 9-Jan-15 31-Jul-18 GSK Investigational S https://Cl
Sep-14 Jun-15 29-Oct-14 ### Abramson Cancer Cente https://Cl
Oct-06 Apr-08 ### ### AIDS Research Allianchttps://Cl
May-11 Jul-12 Jul-12 27-Jan-11 5-Oct-12 Department for Clinichttps://Cl
Mar-95 2-Mar-07 28-Apr-15 Medicine Branch, Bethttps://Cl
Apr-99 Sep-13 Sep-13 18-Jul-03 ### ### Providence Portland M https://Cl
Oct-06 Aug-09 Aug-09 20-Jun-06 16-Jan-12 ### Usc La Nichd Crs, Alh https://Cl
Nov-07 Jul-10 Jul-10 19-Oct-07 ### 14-Jul-11 Pfizer Investigational https://Cl
14-Oct-19 Mar-20 Nov-20 9-Oct-19 ### US135, Hollywood, Flhttps://Cl
May-15 14-Mar-17 ### 16-Jun-15 5-Feb-20 IWK Health Centre, Ha https://Cl
30-Mar-12 27-Sep-13 ### ### ### ### https://Cl
11-Apr-18 30-May-18 ### ### ### Sanofi Pasteur Investihttps://Cl
Sep-06 Sep-07 Jul-08 24-Jul-06 7-Jan-15 Aalen, Germany|Ais https://Cl
13-Jul-06 1-Mar-07 7-Mar-07 29-Jun-06 7-Aug-18 7-Aug-18 GSK Investigational Sihttps://Cl
Nov-18 May-19 Oct-19 ### ### Service Mucoviscidoshttps://Cl
Sep-13 Nov-13 Nov-13 ### ### https://Cl
Jun-15 15-May-18 ### ### ### University of Oxford, https://Cl
Dec-13 Aug-22 Aug-23 5-Dec-13 ### Icahn School of Medichttps://Cl
Oct-13 May-17 Aug-19 ### ### ### The Ohio S"Study Prohttps://Cl
Sep-13 Aug-14 Aug-14 21-Jun-13 1-Oct-14 Wellcome Trust CRF, https://Cl
22-Jun-05 6-Oct-05 6-Oct-05 4-Jul-07 18-Jan-19 https://Cl
11-Nov-19 11-Nov-20 ### ### ### Memorial Sloan Kettehttps://Cl
May-00 Sep-04 1-Nov-05 1-Nov-05 Chawama Clinic, Lusahttps://Cl
28-Jun-02 30-Jun-04 ### ### ### https://Cl
4-Nov-19 Jan-22 Jan-22 30-Oct-19 ### Central Research Assohttps://Cl
15-Mar-13 22-Jan-18 22-Jan-18 11-Jan-13 ### ### GSK Investi"Study Prohttps://Cl
Jan-12 31-Oct-19 ### 17-Jul-13 ### Arthur G. James Cance https://Cl
Aug-05 Jul-08 Jul-08 19-Jul-05 21-Jul-16 Hopital Principal, Dakhttps://Cl
Sep-08 Nov-08 Dec-08 ### ### ### Chatsworth, Californihttps://Cl
29-Mar-18 Apr-20 Apr-21 23-Jan-18 ### H. Lee Moffitt Cancerhttps://Cl
Mar-10 ### 13-Apr-10 https://Cl
Mar-15 27-Sep-16 ### ### ### Centre pour le Devel https://Cl
Mar-15 Oct-16 Nov-16 ### 4-Apr-17 Faculty of Medicine, Shttps://Cl
Apr-08 Jul-10 Jul-10 9-Apr-08 ### GSK Investigational S https://Cl
1-Jan-18 30-Dec-18 ### ### 25-Jun-19 San Francisco Veterans https://Cl
Oct-02 Oct-11 May-12 7-Mar-03 ### Dermatologische Klinihttps://Cl
Dec-07 ### ### Health Protection Ag https://Cl
Sep-07 May-08 May-08 5-Oct-07 ### Impact Clinical Trial https://Cl
17-Apr-19 15-Apr-24 15-Apr-24 ### 18-Jan-20 National Institutes ofhttps://Cl
Dec-04 Jan-06 ### 22-Jun-09 Krankenhaus Nordwest https://Cl
Jan-10 Sep-10 Sep-10 14-Jan-10 3-Mar-17 University of Califor https://Cl
Jun-10 Feb-11 Jun-11 ### 3-Feb-12 6-Feb-12 Bangalore, India|Mum https://Cl
5-Dec-17 Oct-23 Oct-23 16-Jun-17 ### Johns Hopkins SKCCC,https://Cl
Aug-12 Aug-16 Jan-17 ### ### KrajskÃ¡ zdravotnÃ, a.s.
https://Cl
- Nemocnice Chomutov, o.z.O
1-Jul-18 20-Feb-20 ### ### ### Primary Hea "Study Prohttps://Cl
Oct-07 Aug-08 4-May-07 ### Kwashemshi village, https://Cl
May-15 May-23 May-24 ### 23-Jan-20 University of Florida, https://Cl
14-Jan-03 22-Aug-09 ### 1-Apr-03 3-Nov-11 ### GSK Investigational Sihttps://Cl
15-Jun-11 31-Oct-11 1-Jul-11 2-Jul-17 National Institutes ofhttps://Cl
Jan-05 Oct-09 Mar-10 6-Apr-05 6-Aug-12 Jonsson Comprehensive https://Cl
1-Aug-18 30-Dec-18 1-May-19 ### ### University of Ottawa,https://Cl
May-10 May-10 May-10 30-Apr-10 18-Jul-12 ### Chiltern (Early Phas https://Cl
Mar-12 1-Dec-19 1-Feb-20 ### 1-Feb-19 Huashan hospital, Fudhttps://Cl
Dec-08 Apr-10 Apr-10 14-Jan-10 17-Apr-15 https://Cl
1-Sep-19 30-Mar-20 ### 4-Feb-19 13-Jun-19 https://Cl
11-Jan-19 23-May-21 ### 6-Jun-18 ### International Center https://Cl
12-Oct-09 7-Apr-10 7-Apr-10 ### 1-Mar-11 ### GSK Investigational S https://Cl
11-Mar-16 19-Feb-19 Dec-19 ### ### Sukuta Health Centrehttps://Cl
Apr-09 Jul-11 Mar-12 ### 8-Oct-19 University of Texas H https://Cl
Nov-07 Feb-08 Jun-08 1-Feb-08 14-Jan-14 Lyon, Cedex, France| https://Cl
Oct-04 Aug-06 Oct-06 4-Oct-05 ### Cincinnati Children's https://Cl
004|04/400-003-04 ### 24-Jun-05 Univ of Pennsylvania https://Cl
Dec-99 3-Oct-06 3-Oct-06 GSK Clinical Trials Ca https://Cl
Mar-04 Mar-07 14-Jan-04 ### Alabama Vaccine CRS,https://Cl
1-May-20 30-Sep-21 ### 17-Jul-17 5-Feb-20 Dana Farber Cancer Inhttps://Cl
Sep-03 Feb-06 ### 21-Apr-06 Focus Clinical Drug https://Cl
Aug-16 Nov-16 Nov-16 6-Nov-16 19-Jan-17 University of Coloradhttps://Cl
Oct-05 Mar-06 Mar-06 18-Oct-05 ### University of Rochesthttps://Cl
2-Dec-08 23-Jul-12 23-Jul-12 6-Nov-06 ### Saint Louis Universityhttps://Cl
25-Apr-05 30-May-05 ### ### 28-Jan-19 University of Marylanhttps://Cl
Mar-00 Mar-05 Mar-05 8-Jan-04 5-Aug-13 https://Cl
15-Jan-10 Dec-14 Dec-20 11-Jan-10 8-Oct-19 5-Feb-20 Sidney Kim"Study Prohttps://Cl
31-Oct-09 20-Oct-10 6-Apr-11 16-Oct-09 16-Jan-18 GSK Investigational S https://Cl
14-Aug-18 19-Apr-19 19-Apr-19 ### 9-Oct-19 Boston Medical Center https://Cl
5-Sep-12 29-May-14 ### ### ### Roswell Park Cancer Ihttps://Cl
8-Apr-19 26-Dec-19 ### ### 29-Jan-20 Clinical Pharmacolog https://Cl
1-May-15 21-Dec-18 ### 22-Jul-15 30-Jul-19 Chang Gung Memorial https://Cl
Mar-02 Jul-08 Jan-10 ### ### Univ. of Tuebingen, https://Cl
21-Jul-14 Jun-16 27-Apr-18 6-Mar-14 19-Oct-18 Oxford Vaccine Group,https://Cl
9-Jan-17 26-Feb-19 ### 25-Oct-16 9-Dec-19 Chris Hani Baragwanahttps://Cl
Feb-16 Jun-22 Feb-23 ### 6-Nov-19 Sidney Kimmel Compre https://Cl
Sep-12 Feb-13 Jan-15 ### 2-Oct-17 Centre for Clinical V https://Cl
Nov-09 May-12 May-12 ### 10-Jun-13 10-Jun-13 Pfizer Investigational https://Cl
Oct-13 Mar-14 May-14 24-Jun-15 1-Jul-15 https://Cl
Jun-08 Feb-09 Mar-09 19-Jun-08 ### ### Marietta, Georgia, Unhttps://Cl
Aug-15 Mar-17 Dec-17 ### 19-Jan-17 IWK Health Centre, Ha https://Cl
Dec-96 Sep-08 Sep-08 4-Nov-99 12-Jun-12 15-Jun-12 National Institutes ofhttps://Cl
Feb-15 Oct-19 Dec-21 ### 9-Jan-20 Centre LÃ©on BÃ©rard, https://Cl
A5049|AACTG A5049|10893|ACTG A504 May-04 ### ### Rush Presbyterian - Shttps://Cl
Jul-13 Apr-15 Jul-15 7-May-13 ### Medical Research Coun https://Cl
23-Jan-07 5-Nov-08 5-Nov-08 26-Jan-07 2-Jul-17 Johns Hopkins Univershttps://Cl
Jun-10 Apr-12 ### ### ### https://Cl
Dec-03 Oct-05 5-Nov-03 10-Apr-15 Alabama Vaccine CRS,https://Cl
May-02 Jun-03 Nov-05 ### 9-Sep-16 https://Cl
Sep-12 Dec-14 Sep-15 8-Mar-13 5-May-17 University of Roma Lahttps://Cl
Jun-10 Apr-18 Apr-18 4-Jun-10 6-Apr-18 Suda Sibunruang, Banhttps://Cl
Jan-11 Jul-12 Jul-12 ### 2-Oct-15 Massachusetts Genera https://Cl
Apr-13 Jul-14 Feb-15 24-Apr-13 ### Sanofi Pasteur MSD Inhttps://Cl
Mar-03 Mar-07 Mar-07 4-Apr-03 8-Feb-17 Children's Hospital, https://Cl
Mar-02 Jan-03 Jan-03 ### ### https://Cl
Dec-15 Feb-16 Mar-16 ### 7-Nov-16 7-Nov-16 Bardstown, Kentucky,https://Cl
Oct-09 Dec-09 Dec-18 16-Oct-09 11-Oct-18 Naval Medical Centerhttps://Cl
Jun-08 Jun-12 Jun-12 24-Apr-08 ### VA Long Beach Healthc https://Cl
Oct-06 Sep-07 Dec-09 ### 3-Mar-08 Mackay Memorial Hosp https://Cl
May-03 Sep-11 Jan-12 22-Jul-09 ### The Uniiversity of Chihttps://Cl
30-Jan-18 19-Jul-19 15-Oct-19 6-Mar-18 29-Jan-20 Fort Benning, Fort Behttps://Cl
Nov-16 Jul-17 Jul-17 28-Jun-18 28-Jun-18 https://Cl
Jan-05 Apr-05 Apr-05 ### ### GSK Investigational Sihttps://Cl
Nov-09 Jul-11 Oct-11 ### 16-Jun-11 Kenyatta National Hoshttps://Cl
May-08 Dec-08 Dec-08 ### 7-Jun-17 7-Jun-17 Miami Research Associ https://Cl
Mar-03 Apr-11 9-Sep-04 ### University of Virginia https://Cl
Aug-05 Jun-07 ### ### Stanford University, Shttps://Cl
Mar-99 Jan-01 Jan-01 23-Apr-04 ### University of Washinghttps://Cl
18-Apr-11 12-May-16 21-Jul-16 25-Apr-11 5-Jul-18 National Institutes ofhttps://Cl
1-Jun-09 3-Aug-09 3-Aug-09 15-Jun-09 19-Oct-17 19-Jan-18 GSK Investigational S https://Cl
Aug-13 Mar-16 Mar-16 ### 22-Jul-13 https://Cl
Jun-15 Sep-16 Sep-16 9-Jul-15 30-Jul-18 30-Jul-18 SOUSEIKAI Sumida Hosp https://Cl
2-Oct-18 Mar-20 Mar-20 29-Oct-18 3-Sep-19 Saint Louis Universityhttps://Cl
Sep-20 30-Sep-22 ### 1-Aug-19 28-Oct-19 https://Cl
27-Jul-18 29-May-23 ### 8-Aug-18 ### GSK Investigational Sihttps://Cl
13-Mar-19 8-Apr-19 8-Apr-19 ### 24-Oct-19 Evidation Health, Sanhttps://Cl
2-Nov-07 25-Jan-10 26-Jan-10 ### 16-Apr-19 ### https://Cl
6-Oct-03 9-Jun-09 9-Jun-09 ### 1-Apr-10 31-Jul-18 GSK Investigational Sihttps://Cl
Jan-01 Apr-03 Apr-03 4-Jun-08 ### https://Cl
1-Jun-19 Mar-20 Dec-21 9-Apr-19 ### CLSC MontÃ©rÃ©gie,https://Cl
1-Mar-19 Oct-20 Oct-21 ### 8-Apr-19 Duke University, Durhhttps://Cl
13-Jul-15 28-Dec-17 ### ### 1-Apr-19 27-Jun-19 GSK Investi"Study Prohttps://Cl
22-Mar-17 23-Apr-18 23-Apr-18 3-Aug-16 ### Inflamax Research, Inhttps://Cl
Jun-99 ### ### The Hospital for Sick https://Cl
2-Sep-08 15-Jun-13 15-Jun-13 ### ### ### GSK Investigational Sihttps://Cl
Apr-05 Jan-10 Jan-10 ### ### Hertordshire Primaryhttps://Cl
Nov-97 Mar-09 Mar-09 17-Jun-08 31-Jan-12 Memorial Sloan-Kettehttps://Cl
10-Oct-05 14-May-06 ### 26-Apr-06 8-Aug-18 8-Aug-18 GSK Investigational S https://Cl
10-Feb-05 1-Mar-06 ### ### ### 6-Jun-18 GSK Investigational Sihttps://Cl
Aug-03 Jan-04 Aug-04 3-Feb-10 9-Sep-16 GSK Investigational Sihttps://Cl
Apr-14 Dec-15 Dec-15 ### ### Covance, Inc., Daytonhttps://Cl
Feb-06 Aug-06 Aug-06 ### ### UAB, Dept. of Ped., Dhttps://Cl
Jul-12 Feb-13 Feb-13 11-Jul-12 29-Oct-13 Mount Sinai Hospital,https://Cl
Jun-12 Dec-12 Dec-13 19-Jun-12 19-Jun-12 International Centre https://Cl
22-Feb-08 18-Oct-13 ### 18-Jun-09 8-May-14 12-Apr-17 National Institutes ofhttps://Cl
2-Oct-17 5-Mar-19 5-Mar-19 5-Oct-17 11-Apr-19 Covance Clinical Resehttps://Cl
Sep-18 Jun-20 Dec-21 12-Jun-18 ### Chan Soon-Shiong Inst https://Cl
Aug-10 Aug-11 Dec-11 23-Jun-10 ### University of Alberta https://Cl
Oct-01 Mar-10 1-Dec-23 ### 4-Nov-19 Fred Hutchinson Canchttps://Cl
28-Oct-15 30-Jun-20 30-Jun-21 3-Mar-17 16-Apr-19 University of Rochesthttps://Cl
Dec-07 Dec-08 Dec-08 ### 11-Jan-17 National Jewish Healthttps://Cl
26-Sep-13 6-Mar-17 6-Mar-17 2-Aug-13 6-Feb-20 National Institutes ofhttps://Cl
005|400-003-05 ### 24-Jun-05 Walter Reed Army Inst https://Cl
Nov-10 Nov-16 Jun-17 25-Oct-10 22-Jun-16 Wakayama Medical Univ https://Cl
Oct-10 Oct-12 Sep-14 ### 29-Apr-15 29-Apr-15 Tampa, Florida, Unit https://Cl
Apr-11 ### 3-Aug-12 https://Cl
Jul-05 Feb-08 Feb-08 5-Aug-05 7-Oct-16 GSK Investigational S https://Cl
6-Mar-18 6-Sep-22 6-Jun-23 10-Jan-18 ### Klinik fÃ¼r Neurolog https://Cl
Sep-10 11-Mar-13 ### 3-Mar-10 ### ### New York University https://Cl
Aug-09 Jan-12 Dec-12 14-Jul-09 1-Aug-18 1-Aug-18 Centro de Pesquisas Rhttps://Cl
Apr-07 Sep-07 Sep-07 ### ### Johnson County Clin-Thttps://Cl
HVTN 041|10196 Jun-03 5-Dec-01 4-May-12 Alabama Vaccine CRS,https://Cl
Apr-06 Apr-08 Jul-08 27-Apr-06 16-Apr-12 Seoul, Korea, Republihttps://Cl
15-Feb-20 30-Sep-20 30-Apr-22 ### 27-Jan-20 Henan Province Centehttps://Cl
6-Mar-17 15-Jun-17 ### ### 20-Jun-18 Dr Lucy Garvey, Paddhttps://Cl
29-Aug-17 15-Jan-18 31-Jan-18 ### 6-Mar-18 Jakarta Provincial Minhttps://Cl
Oct-04 Jul-07 Jul-07 ### 5-Dec-14 Ann Arbor West, Annhttps://Cl
A
Oct-06 Jul-07 Jul-07 13-Jun-06 ### Kentucky pediatric /Ahttps://Cl
Nov-14 Dec-18 Dec-18 20-Apr-16 ### The International Cenhttps://Cl
Feb-03 ### ### University of Pittsburhttps://Cl
Dec-11 Dec-13 Dec-13 5-Jan-12 ### Mary Crowley Cancerhttps://Cl
R
Sep-07 Apr-08 Apr-08 5-Oct-07 27-Jul-11 27-Jul-11 Kaiser Permanente Ped https://Cl
Mar-15 Mar-17 Aug-17 1-Aug-13 5-Dec-19 5-Dec-19 Brian Allg "Statistic https://Cl
Sep-13 Jun-15 Sep-15 31-Oct-12 31-Jul-19 George Washington Uni https://Cl
Apr-05 Apr-12 Jan-20 11-Apr-07 1-Nov-19 Beth Israel Deacones https://Cl
Jul-07 Aug-07 23-Jul-07 4-Nov-16 GSK Investigational S https://Cl
20-Jan-15 1-Jun-16 1-Jun-20 26-Jan-15 1-Aug-17 ### Liberian Ministry of https://Cl
29-Jun-18 Jan-20 Jan-23 3-Oct-17 ### Duke University Medic https://Cl
Nov-09 Apr-12 Apr-12 28-Jan-13 4-Feb-13 GSK Investigational Sihttps://Cl
Dec-03 Feb-04 Feb-04 ### 1-Mar-17 Children's Hospital o https://Cl
Jun-08 Sep-09 Dec-09 10-Jul-08 30-Apr-14 30-Apr-14 Coquitlam, British C https://Cl
ACTG 137|11112 May-93 ### ### Stanford CRS, Palo Al https://Cl
Sep-10 Dec-11 Dec-11 12-Jul-10 25-Jan-12 https://Cl
Sep-06 Apr-07 Sep-07 6-Oct-06 8-Jun-15 Clinical Trials Center https://Cl
23-Feb-11 20-Dec-11 ### ### ### ### https://Cl
2-Feb-16 28-Feb-17 ### 2-Dec-15 5-Jun-17 Studienzentrum der Phttps://Cl
30-Mar-17 1-Aug-18 ### 27-Jun-17 3-Sep-19 Rigshospitalet, Cop https://Cl
3-Jan-07 1-Jun-07 25-Jun-07 ### ### 6-Jun-18 GSK Investigational S https://Cl
Aug-06 May-07 May-07 23-Jun-06 3-May-12 Sidney Kimmel Compre https://Cl
Dec-10 Feb-12 Aug-12 6-Sep-10 ### Aschaffenburg, Germhttps://Cl
Aug-13 Dec-15 Dec-15 4-Jul-13 15-Jan-16 Karolinska University https://Cl
Jun-13 Dec-16 Dec-16 12-Jul-13 ### Department of Hematop https://Cl
28-Dec-17 26-May-18 ### 3-Apr-19 3-Apr-19 Jiangsu Provincial Ce https://Cl
1-Apr-09 18-Nov-09 ### ### 18-Apr-17 6-Jun-18 GSK Investigational Sithttps://Cl
27-Sep-06 11-Feb-08 15-Jan-09 9-Feb-06 8-Jul-13 ### GSK Investigational S https://Cl
May-07 Jun-10 Aug-10 21-Oct-08 21-Jun-12 24-Jan-13 HLeeMoffitt, Tampa, Fhttps://Cl
Dec-06 Sep-13 Sep-13 ### 30-Apr-14 ### UT MD . Anderson Can https://Cl
May-12 May-13 Aug-13 ### ### Centre Hospitalier Unhttps://Cl
Feb-15 Mar-15 Mar-15 28-Oct-14 ### Colonial War Memorial https://Cl
8-Sep-04 ### 16-Jun-05 2-Jul-17 Georgetown Universityhttps://Cl
Aug-11 Aug-13 Aug-13 ### ### Johns Hopkins Univershttps://Cl
Oct-12 Mar-14 Mar-17 ### 10-Jul-19 Hopital St Nicholas, Shttps://Cl
Jun-01 Nov-08 Nov-08 27-Jan-03 6-Mar-15 Bay Regional Medicalhttps://Cl
11-Mar-19 11-Sep-19 ### ### ### Centre Hospitalier dehttps://Cl
17-Jun-19 Jun-21 Jun-21 3-Jun-19 30-Jan-20 Guy's and St Thomas'https://Cl
AVEG 032|10581 Mar-01 ### ### UAB AVEG, Birmingham, https://Cl
May-05 Dec-07 Dec-07 27-Jan-09 27-Jan-09 Cedars-Sinai Medical hCttps://Cl
Jan-13 Jun-13 Nov-13 18-Jan-13 ### University of Surrey, https://Cl
Apr-06 Oct-11 Oct-11 7-May-07 31-Oct-14 Mayo Clinic, Rochestehttps://Cl
Oct-16 Mar-17 Mar-17 ### 26-Apr-19 ### "Study Prohttps://Cl
25-May-18 5-Oct-18 ### ### ### LG chem, Seoul, Ganghttps://Cl
31-Oct-14 Jun-20 Dec-20 7-Nov-14 ### BCCA - Vancouver Canc https://Cl
31-Aug-17 31-Aug-20 ### ### 1-Apr-19 Syneos Health, Wilmin https://Cl
HVTN 063|10058 Jul-08 27-Jun-05 ### Brigham and Women's https://Cl
1-Mar-05 7-Nov-06 7-Nov-06 8-Sep-05 2-Jun-17 GSK Investigational S https://Cl
May-08 Jun-09 Jun-09 1-May-08 ### Wonju Christian Hospihttps://Cl
Sep-14 Feb-15 Jun-15 3-Dec-15 3-Dec-15 https://Cl
HVTN 057|10123 May-06 9-Sep-04 4-May-12 Johns Hopkins Bloombe https://Cl
Apr-96 Jan-04 Jan-04 30-Jul-04 ### University of Washinghttps://Cl
Jul-11 Aug-12 Apr-13 27-Jun-11 27-Apr-15 Walter Reed Army Insti https://Cl
17-Jan-08 18-Jul-11 18-Jul-11 4-Jan-08 ### 3-Jan-20 GSK Investigational Sihttps://Cl
Jun-12 Jun-14 13-Oct-10 ### Fred Hutchinson Canchttps://Cl
11-Apr-05 24-Jul-06 ### ### 20-Jul-12 19-Jul-18 GSK Investigational Sihttps://Cl
24-Mar-14 22-Apr-15 22-Apr-15 15-Apr-14 1-Nov-18 1-Nov-18 Sanofi Pasteur MSD Inhttps://Cl
Jan-99 Mar-00 Mar-00 24-Oct-11 16-Jun-17 https://Cl
Nov-10 Feb-12 Apr-12 ### 16-Apr-12 Medical School Hannhttps://Cl
Feb-15 Apr-15 Apr-15 ### ### Fukuoka, Japan https://Cl
Sep-16 Dec-20 Dec-20 ### 8-Nov-19 Alberta Children's Hoshttps://Cl
Jan-12 Aug-12 May-13 2-Dec-11 ### Comprehensive Clinichttps://Cl
4-Nov-19 Sep-21 Sep-21 24-Oct-19 5-Feb-20 Investigational Site https://Cl
18-Sep-17 14-Mar-18 29-Oct-18 ### 17-Oct-19 Research Site US108, https://Cl
Apr-03 Apr-06 Dec-08 ### ### Stanford University Schttps://Cl
Nov-13 Mar-14 Jul-14 3-Dec-15 3-Dec-15 https://Cl
Jun-13 Dec-16 Apr-17 ### 9-May-18 Anhui Provincial Hosphttps://Cl
Jun-06 Sep-08 Dec-08 4-Jul-06 22-Jan-14 Guilin City,, China|Pi https://Cl
6-Dec-19 9-Jun-21 9-Jun-21 ### 14-Jan-20 Research Centers of Ahttps://Cl
Apr-05 4-Aug-05 ### Dermatologische Klinihttps://Cl
ACTG 234|VEU 102|11211 Jul-98 ### ### Yale Univ Med School,https://Cl
18-Jul-18 31-Dec-22 ### 13-Oct-17 25-Oct-19 Agencia Costarricen shttps://Cl
16-Dec-16 12-Mar-17 ### ### 12-Apr-17 GSK Investigational S https://Cl
23-Apr-09 18-Jul-12 29-Apr-09 ### Johns Hopkins Univershttps://Cl
Mar-04 11-Jun-04 9-Feb-09 Massachusetts General https://Cl
Nov-08 Apr-10 Apr-10 ### ### St Stephen's Centre https://Cl
Aug-07 Apr-10 Apr-10 7-Apr-08 1-Jul-10 CCVTM, University ofhttps://Cl
19-Sep-13 6-Jun-14 6-Jun-14 ### 9-Apr-15 ### https://Cl
Mar-04 Jun-15 22-Jun-06 ### Fred Hutchinson Canchttps://Cl
31-Aug-18 31-Aug-20 ### ### ### Chan Soon-Shiong Inst https://Cl
Nov-06 Jun-09 Jul-09 ### 6-Apr-12 department of surgery https://Cl
Dec-10 9-Dec-10 9-Dec-10 Transplant Institute, https://Cl
13-Feb-19 Jul-22 Mar-23 ### ### Mayo Clinic Arizona, https://Cl
4-Apr-17 4-Jan-18 17-Apr-18 ### 26-Apr-18 Medical University ofhttps://Cl
8-Jun-05 1-Feb-08 1-Dec-11 13-Jun-05 ### National Institutes ofhttps://Cl
Feb-10 Apr-11 Apr-11 5-Jun-09 ### Emory Vaccine Centerhttps://Cl
Mar-08 Jul-08 Jul-08 10-Apr-08 ### MDS Pharma Serviceshttps://Cl
,
Sep-06 Nov-07 May-11 3-Aug-06 20-Jul-12 ### GSK Investigational Sihttps://Cl
Mar-01 Jan-06 30-Jun-05 ### University of Californhttps://Cl
Jul-12 Jul-13 Oct-13 ### ### ### Queen Saovabha Memor https://Cl
Aug-14 Aug-16 Nov-16 ### ### https://Cl
Dec-09 Feb-17 Oct-17 8-Feb-10 6-May-15 Department of Oncolo https://Cl
Apr-15 Jun-15 Jun-15 9-Mar-15 ### ### Site 02, Center for V https://Cl
20-Sep-17 15-Dec-17 9-Nov-18 ### ### 5-Dec-19 Johnson Cou "Study Prohttps://Cl
11-Oct-18 31-Aug-21 ### ### 1-Nov-19 Beth Israel Deaconesshttps://Cl
Feb-06 Apr-08 Dec-08 ### 16-Apr-12 New Delhi, India https://Cl
Apr-03 ### ### Core Immunology Labor https://Cl
Jul-12 Jul-17 Feb-18 3-Oct-12 16-Jun-16 PÃ´le HÃ©matologie h Cttps://Cl
22-Apr-19 Aug-20 Aug-20 ### ### University of North Cahttps://Cl
Aug-09 Nov-11 Nov-11 11-Jul-13 11-Jul-13 The Catholic Universihttps://Cl
Sep-07 Nov-07 ### 9-Nov-07 https://Cl
11-Dec-19 Sep-20 Jan-21 ### ### Centre for Vaccinolo https://Cl
Oct-12 May-13 May-13 4-Oct-12 26-Jun-13 Centre for Health Reshttps://Cl
Mar-05 Aug-08 Aug-08 ### ### University of Wisconshttps://Cl
Oct-09 Aug-14 Aug-14 1-Nov-09 3-Sep-14 ClÃnica Universidad de https://Cl
Navarra, Pamplona, Spain
Oct-12 Apr-13 May-13 11-Oct-12 7-Mar-14 Anaheim Clinical Tria https://Cl
2-Apr-19 16-Aug-20 ### ### 12-Jul-19 Meitetsu Hospital ( Sihttps://Cl
Jul-04 May-05 May-05 ### ### GSK Investigational S https://Cl
Jan-17 Apr-17 ### 20-Jan-17 ### Research Site AU004,https://Cl
Apr-07 Jul-08 Jul-08 ### ### Cincinnati Center for https://Cl
1-Jul-19 Aug-20 Dec-20 ### 6-Feb-20 Investigational Site https://Cl
Dec-14 18-Jul-17 13-Jul-18 28-Oct-14 ### III.Medizinische Klin https://Cl
Jul-00 6-Mar-07 28-Apr-15 Surgery Branch, Bethhttps://Cl
13-Dec-18 1-Jul-19 7-Aug-19 10-Jan-19 9-Dec-19 Biomedical Research h Cttps://Cl
15-Nov-08 7-Jun-09 7-Jun-09 ### 16-Jun-17 ### GSK Investigational Sihttps://Cl
Jun-10 Jun-11 Oct-11 8-Jul-10 ### Institut fÃ¼r Spezif https://Cl
Apr-07 Nov-09 Dec-09 30-Apr-07 3-Dec-10 7-Feb-14 Birmingham, Alabama, https://Cl
29-May-12 9-Jan-15 9-Jan-15 ### ### 12-Jul-18 GSK Investigational Sihttps://Cl
Mar-09 Jun-15 Dec-15 ### 8-Mar-11 Fuzhou General Hospit https://Cl
Oct-07 Jan-10 Jan-10 ### 2-May-11 12-Apr-17 https://Cl
P1024|PACTG 1024|10609|ACTG P1024 Nov-04 ### ### UAB, Dept. of Ped., Dhttps://Cl
Aug-14 Dec-24 Dec-25 ### 15-Jan-19 Aurora Health Care, https://Cl
Nov-04 Nov-06 ### 20-Apr-07 St. Joseph's Healthcahttps://Cl
28-Feb-18 29-May-18 ### ### 20-Jun-19 Coastal Clinical Rese https://Cl
May-11 Oct-11 Oct-11 20-Jun-11 ### NicVAX Investigator, Hhttps://Cl
4-Nov-19 Apr-20 Apr-20 ### ### CHRU Nancy, Vandoeuv https://Cl
24-Oct-18 28-Mar-19 ### ### ### Ross University Schoohttps://Cl
Jul-06 Dec-06 26-Jul-06 12-Oct-16 GSK Investigational S https://Cl
Jan-05 Apr-07 5-Sep-05 ### Cliniques Universitai https://Cl
Dec-13 Jun-15 Feb-16 8-Jan-14 ### Alabama Vaccine Resea https://Cl
1-Jun-20 1-Jan-22 1-Nov-26 3-Dec-18 9-Dec-19 https://Cl
Jun-06 Nov-06 12-Jun-06 7-Oct-16 GSK Investigational S https://Cl
Aug-11 Mar-13 Aug-13 2-Aug-11 4-Dec-13 Centro de Investiga https://Cl
Feb-15 Aug-15 Nov-15 ### 20-Jul-15 https://Cl
Jan-05 Jul-06 Jun-20 ### 6-Nov-19 Children's Hospital B https://Cl
Oct-04 Dec-05 ### ### Instituto MÃ©dico Ale https://Cl
May-02 Dec-02 ### 3-Oct-06 University of Tamperehttps://Cl
Jul-98 Dec-07 ### 24-Jan-07 Multiple Sclerosis Cenhttps://Cl
11-Apr-19 Dec-20 Dec-20 2-Jan-18 6-Feb-20 Centre de SantÃ© Urbainhttps://Cl
Ã base Communautaire (C
12-Dec-17 31-Dec-21 ### 5-Dec-17 ### Massachusetts General https://Cl
Dec-06 ### 28-Apr-11 Hadassah Medical Orga https://Cl
Apr-01 Jun-01 ### 25-Oct-06 Austin & Repatriationhttps://Cl
May-16 22-May-19 ### ### 26-Jul-19 Hospital ClÃnic, Barcelona,
https://Cl
EspaÃ±a, Spain
10-Sep-04 5-Aug-08 5-Aug-08 ### 11-Oct-12 1-Aug-17 National Cancer Insti https://Cl
Nov-12 20-Jan-17 ### 10-Oct-12 ### Clinical Research Centhttps://Cl
Aug-09 Mar-10 Dec-10 ### 26-Oct-11 Ottawa Hospital Resea https://Cl
Jun-07 Apr-10 Apr-10 20-Jun-07 9-Jul-14 9-Jul-14 National Institutes ofhttps://Cl
1-Feb-08 8-Jul-08 8-Jul-08 ### 5-Jul-17 6-Jun-18 GSK Investigational S https://Cl
7-May-19 Aug-21 Aug-21 1-Apr-19 ### Institut de Recherchehttps://Cl
Sep-09 Sep-12 Oct-12 ### ### Sentara Norfolk Genera https://Cl
20-Sep-17 20-Jan-18 20-Jan-18 25-Apr-18 25-Apr-18 Rutgers University, N https://Cl
Apr-06 Mar-08 Mar-08 11-Apr-06 3-Aug-09 13-Apr-17 https://Cl
Jul-15 Mar-16 Mar-16 14-Apr-15 ### 23-Jan-18 Laureate Institute fo https://Cl
Jun-07 Feb-08 Feb-08 ### ### 12-Apr-17 https://Cl
Dec-14 1-Sep-21 2-Sep-21 5-Sep-14 18-Oct-19 University of Californhttps://Cl
15-Sep-17 30-Aug-18 30-Jun-19 31-Jul-17 ### University of Ottawa https://Cl
Jun-10 May-11 May-11 3-Jun-10 24-Jan-13 Parexel Int. Bloemfonthttps://Cl
Dec-09 Nov-12 Mar-13 7-Dec-09 18-Oct-12 Hopital Henri Mendor- https://Cl
30-Sep-16 30-Sep-19 ### 12-Jul-19 6-Nov-19 University of Minnesohttps://Cl
Nov-03 Jul-07 Jul-07 19-Jul-05 4-Nov-16 GSK Investigational Sihttps://Cl
Jan-20 Jan-28 Jan-28 2-Oct-19 13-Jan-20 https://Cl
1-Mar-15 31-Aug-18 ### 12-Apr-17 3-May-18 The University of Tex https://Cl
Jul-07 Aug-08 ### ### Seoul National Univerhttps://Cl
12-Sep-18 31-Jul-20 31-Jul-20 29-Oct-18 ### Kaiser Permanente Nor https://Cl
Apr-16 Aug-18 Feb-19 ### 27-Jan-20 State University of N https://Cl
Jun-07 Jul-11 Jul-14 22-Jun-09 ### City of Hope, Duarte, https://Cl
3-Jul-17 6-Sep-17 ### 5-Jul-17 ### Korea University Gurohttps://Cl
Jun-99 Dec-01 ### 16-Jan-13 Memorial Sloan-Kettehttps://Cl
Mar-12 May-14 Jul-14 20-Jan-12 4-Mar-16 Medunsa Clinical Reshttps://Cl
Oct-07 May-08 Jun-08 ### 15-Jul-08 Takuya Takayama M.D. https://Cl
Dec-06 Oct-12 Oct-12 ### 10-Jan-14 Hoag Cancer Institutehttps://Cl
Nov-15 1-Dec-18 1-Dec-18 8-Oct-15 14-Jan-19 University of Washinghttps://Cl
May-01 Nov-02 ### ### Paris, France https://Cl
Jul-16 Mar-17 Mar-17 16-Oct-17 8-Nov-17 Hasan Sadikin Hospitahttps://Cl
Sep-04 Aug-07 ### ### Alabama Vaccine CRS,https://Cl
30-Jan-20 Feb-23 Feb-23 10-Jan-20 10-Jan-20 Investigational Site https://Cl
1-Jul-16 24-Jan-17 24-Jan-17 28-Jun-16 1-Mar-18 24-Oct-18 Research Si"Study Prohttps://Cl
Jan-09 Jun-09 Jul-10 1-Jun-09 25-Jun-10 Sandy Springs Pediatrhttps://Cl
1-Oct-15 7-Jan-16 30-Apr-16 ### ### https://Cl
1-Sep-19 1-Sep-21 1-Sep-22 ### ### Xiangya Hospital, Cenhttps://Cl
28-Mar-19 8-Sep-23 8-Sep-23 7-Mar-19 ### GSK Investigational S https://Cl
1-Dec-17 11-Sep-19 ### ### 5-Dec-19 Department of Interna https://Cl
20-Feb-19 11-Jul-19 11-Jul-19 ### ### CHUV, Lausanne, Swithttps://Cl
Aug-04 Apr-05 Apr-05 24-Apr-06 ### GSK Investigational S https://Cl
Nov-15 25-Jul-16 31-Oct-16 ### 29-Jun-17 Preventive Medicine https://Cl
Sep-04 Nov-07 Dec-07 21-Jul-05 6-Jun-08 CIC de Vaccinologie Chttps://Cl
Jun-15 May-17 May-17 ### 2-Jul-17 Krankenhaus Nordweshttps://Cl
1-Jun-07 1-Sep-11 1-Mar-16 22-Jun-07 ### ### GSK Investigational Sihttps://Cl
5-Nov-13 31-Mar-18 ### ### 12-Oct-18 Hospital of the Univ https://Cl
Dec-11 Sep-13 Sep-13 2-Jan-12 22-Apr-15 WRAIR, Clinical Trials https://Cl
Jan-04 May-05 ### ### University of Rochesthttps://Cl
15-Oct-19 15-Sep-20 ### 20-Jun-19 21-Jun-19 https://Cl
12-Feb-18 20-Jul-18 14-Jan-19 6-Feb-18 17-Jul-19 Optimal Research, Hun https://Cl
Sep-10 Aug-11 Mar-13 29-Jul-11 19-Apr-19 Mexican National Insthttps://Cl
Oct-13 1-Oct-17 1-Oct-17 ### 19-Jun-18 Maternity Ward, Natihttps://Cl
2-Jun-17 12-Aug-17 ### 29-Jun-17 ### Hoa Binh Provincial https://Cl
17-Aug-15 2-May-16 ### 20-Jul-15 12-Oct-18 12-Oct-18 https://Cl
Mar-10 Apr-11 Apr-11 9-May-11 ### ### Medical College and Chttps://Cl
17-Dec-18 2-Sep-19 2-Sep-19 11-Oct-18 4-Sep-19 Leiden University Med https://Cl
25-Jun-19 30-Mar-20 8-Mar-21 ### 5-Feb-20 Tampereen yliopisto Ehttps://Cl
AVEG 013A|10559 May-95 ### ### St. Louis Univ. Schoo https://Cl
Jun-00 Jul-06 27-Jan-03 20-Jun-13 NCI - Center for Canc https://Cl
Sep-09 Mar-10 Mar-10 6-Aug-09 15-Apr-11 2-Nov-15 https://Cl
5-Apr-17 1-Aug-20 1-Aug-21 ### 5-Feb-20 Lombardi Comprehensiv https://Cl
Jan-03 Dec-03 ### 2-Sep-16 Bandim Health Project https://Cl
Aug-00 Jul-01 Jul-01 23-Jan-07 ### https://Cl
Dec-09 Aug-10 Sep-10 28-Oct-09 9-Oct-15 https://Cl
Nov-13 Dec-15 Mar-16 ### 12-Jul-16 Asan Medical Center, https://Cl
13-Nov-17 28-Dec-18 ### ### ### Clinical Research of https://Cl
29-Mar-17 4-Oct-19 4-Oct-19 12-Apr-17 ### QPS-Miami Research https://Cl
Associates, Miami, Florida, Unit
16-Oct-17 10-Jul-18 ### 7-Nov-17 10-Jul-19 hVIVO Services Limit https://Cl
Sep-07 Jan-10 Jan-10 7-Apr-08 9-Feb-10 CCVTM, University ofhttps://Cl
22-Aug-18 Sep-19 Dec-19 ### ### Department of paediahttps://Cl
22-Dec-16 9-Jun-20 9-Jun-21 4-Nov-16 ### Roswell Park Cancer Ihttps://Cl
Oct-06 Aug-07 Jan-09 ### ### https://Cl
Jan-98 Nov-01 Nov-01 ### ### Memorial Sloan-Kettehttps://Cl
A5172|10184|ACTG A5172 May-04 ### ### Harbor-UCLA Med. Ctr. https://Cl
23-Aug-13 8-Sep-16 ### 6-Nov-17 6-Nov-17 Winthrop University Hhttps://Cl
Oct-08 Apr-09 Aug-09 2-Oct-08 28-Apr-17 Southern Alberta Clinhttps://Cl
1-Sep-19 1-Dec-19 ### ### ### University of Nottin https://Cl
Nov-05 Aug-06 ### ### GSK Investigational Sihttps://Cl
21-Apr-04 10-Jan-08 10-Jan-08 23-Jun-06 ### 10-Jun-19 GSK Investigational Sihttps://Cl
Oct-14 Dec-15 Dec-15 17-Oct-14 ### Yale University, New https://Cl
Jan-13 Jan-15 Nov-15 4-Dec-12 5-Nov-18 5-Nov-18 DCaTS-Clinical Researhttps://Cl
21-Nov-11 27-Oct-15 27-Oct-15 31-Oct-11 ### ### GSK Investigational S https://Cl
Dec-09 Sep-10 Jan-11 ### 5-Oct-11 Bangkok, Thailand|Bahttps://Cl
Nov-02 Jun-11 Jun-11 ### 13-Apr-12 13-Apr-12 National Institutes o https://Cl
Sep-08 Dec-10 Dec-10 ### ### The University of Ho https://Cl
May-05 Jan-07 Jan-07 26-Jun-06 3-Jun-13 University of Rochesthttps://Cl
Mar-12 Mar-13 Sep-13 7-Mar-12 9-Sep-13 Anthony Mills, MD Inthttps://Cl
Nov-03 Dec-14 ### ### Bandim Health Projechttps://Cl
Oct-13 Jun-18 Dec-18 ### ### Karolinska University https://Cl
Jan-04 Apr-04 Apr-04 15-Oct-08 27-Apr-09 ### Bristol, United King https://Cl
Mar-06 Jan-07 ### 9-Jan-07 Good Health Solutionhttps://Cl
Jan-04 Oct-09 Oct-09 5-Aug-04 9-May-17 20-Jun-17 Lineberger Comprehens https://Cl
4-Oct-17 Apr-19 Oct-19 18-Jul-17 8-Jan-18 La Roche sur Yon Univhttps://Cl
5-Feb-14 Jan-16 ### 9-Dec-13 3-May-18 4-Jun-18 Scottsdale Healthcarehttps://Cl
16-Aug-16 30-Jan-18 30-Jan-18 8-Dec-15 23-Oct-19 University of Iowa - https://Cl
23-Aug-05 27-Dec-07 ### ### 18-Jan-13 ### GSK Investigational https://Cl
Apr-10 Mar-15 Mar-15 23-Apr-10 ### Leiden Univeristy Med https://Cl
Sep-98 Oct-02 Oct-02 ### 8-Apr-10 https://Cl
Nov-00 Dec-02 Dec-02 ### 17-Oct-14 University of Rochesthttps://Cl
Aug-10 Aug-11 Aug-11 9-Sep-10 15-Jul-11 Pediatric Private prachttps://Cl
Sep-16 Dec-18 Dec-18 21-Jun-16 ### Walter Reed Nationalhttps://Cl
Aug-11 21-Sep-17 ### 4-Aug-10 18-Oct-18 Menzies School of Hea https://Cl
Mar-11 Oct-12 Feb-13 ### ### ### Espoo Vaccine Researc https://Cl
089|APL 400-003RX101 ### 24-Jun-05 Univ of Pennsylvania https://Cl
Jun-04 Feb-06 12-Jul-04 9-Jun-14 University of Chicago,https://Cl
Sep-05 Oct-05 May-06 ### ### GSK Investigational S https://Cl
May-11 Nov-12 Nov-13 6-May-11 4-Mar-14 Center for Disease Cohttps://Cl
Jul-01 Oct-01 ### 25-Oct-06 West Coast Medical Ass https://Cl
20-Dec-17 Mar-21 Dec-24 ### 25-Jul-19 Research Facility, Hu https://Cl
Aug-13 Apr-16 Apr-16 ### 8-Feb-19 8-Feb-19 Icddr,B, Dhaka, Bang https://Cl
Sep-13 Apr-14 Apr-17 ### 3-May-17 Baylor Institute for https://Cl
Jul-99 May-02 May-02 1-Oct-03 19-Jun-13 Memorial Sloan-Kettehttps://Cl
18-Feb-14 23-Sep-14 ### 3-Feb-14 ### 6-Jun-18 GSK Investigational S https://Cl
8-Sep-17 7-May-20 7-May-20 7-Sep-17 ### GSK Investigational Sihttps://Cl
23-Oct-19 31-Dec-20 30-Apr-21 5-Aug-19 31-Oct-19 University of Koblen https://Cl
Oct-02 Mar-03 May-03 ### 8-Dec-08 Respiratory Medicinehttps://Cl
Sep-07 Dec-19 Jun-20 ### 9-Dec-19 U.S. Army Medical Reshttps://Cl
Sep-10 Dec-11 Dec-11 13-Jan-17 9-Mar-17 6-Jun-18 https://Cl
Dec-19 Apr-20 Apr-20 ### 2-Dec-19 HÃ´pital Femme MÃ¨re https://Cl
Sep-07 Jun-09 Jun-09 29-Jun-09 21-Jan-13 Leiden University Med https://Cl
3-Mar-09 21-Jun-10 21-Jun-10 ### 2-Jul-17 National Institutes ofhttps://Cl
Jul-06 Jul-13 Dec-15 ### 17-Oct-18 East Carolina Universihttps://Cl
1-Oct-11 16-Jan-12 16-Jan-12 10-Oct-11 13-Apr-17 6-Jun-18 GSK Investigational S https://Cl
1-Sep-13 1-Feb-14 1-Feb-14 ### ### Fakultas Kedokteran Uhttps://Cl
Oct-12 Nov-12 Nov-12 18-Jan-17 9-Mar-17 9-Mar-17 https://Cl
9-Sep-96 5-Mar-10 5-Mar-10 4-Nov-99 2-Jul-17 National Institutes ofhttps://Cl
25-Jan-07 1-Mar-08 ### 11-Jan-07 4-May-09 8-Jun-18 GSK Investigational Site,https://Cl
Bondy, France|GSK Investiga
24-Nov-09 12-Oct-10 2-Mar-11 ### 6-Oct-17 6-Oct-17 GSK Investigational Sihttps://Cl
12-Dec-18 11-Mar-19 27-Jun-19 28-Jan-19 17-Jul-19 University of Eastern https://Cl
Jan-01 Jan-08 Jan-10 20-Jun-16 21-Jun-16 https://Cl
May-03 Apr-06 7-Oct-03 22-Jul-13 Memorial Sloan-Kettehttps://Cl
Oct-00 Jan-02 Jan-02 9-Jun-04 11-Jul-13 https://Cl
Jan-01 Jan-04 Jan-04 27-Jan-03 28-Apr-17 University of Connecthttps://Cl
Sep-05 Jun-08 Sep-08 ### 14-Jan-14 Antwerpen, Belgium|https://Cl
Jan-06 1-Feb-06 14-Apr-15 Shanghai Changhai Hohttps://Cl
Mar-05 Feb-10 Feb-10 11-Jul-05 1-Sep-17 Fox Chase Cancer Cent https://Cl
2-Jun-07 30-Aug-12 ### 18-Jun-09 ### 15-Jun-18 National In"Study Prohttps://Cl
28-Jul-17 30-Aug-18 ### ### 14-Oct-19 San Antonio, Texas, Uhttps://Cl
Mar-12 Dec-19 Dec-19 4-Jul-12 10-Jan-19 Alberta Children`s Hohttps://Cl
31-Jan-13 2-Apr-14 2-Apr-14 ### ### 6-Jun-18 GSK Investigational Sihttps://Cl
19-Jun-17 12-Dec-19 ### ### ### Polana Canico Healthhttps://Cl
Apr-12 Jun-15 Jun-15 23-Apr-12 24-Jun-15 Prywatny Gabinet Leka https://Cl
Jan-00 Dec-01 Dec-01 ### 5-Nov-19 https://Cl
CDR0000389221|UCLA-0302008-02 8-Oct-04 4-Oct-12 https://Cl
Oct-03 Nov-07 Nov-07 18-Oct-05 1-May-09 ### GSK Investigational S https://Cl
14-Feb-08 25-Jun-08 25-Jun-08 ### ### 6-Jun-18 GSK Investigational S https://Cl
3-Aug-09 20-Feb-10 23-Apr-10 13-Jul-09 ### 2-Jan-18 GSK Investigational Sihttps://Cl
15-Mar-17 1-Jan-18 31-Jul-18 5-Jan-18 7-Feb-19 Uganda Virus Research https://Cl
May-08 Oct-08 Oct-08 2-Jul-08 ### Research Institute fo https://Cl
AVEG 013B|10560 May-97 ### ### St. Louis Univ. Schoo https://Cl
Nov-00 Jul-05 27-Jan-03 19-Jun-13 Warren Grant Magnuson https://Cl
Feb-10 Oct-11 Dec-11 4-May-10 ### Rwanda health care fac https://Cl
14-Mar-07 8-Jul-13 8-Jul-13 3-Mar-11 8-Apr-19 Beer-Sheva, Israel|Pethttps://Cl
Oct-12 Jan-13 Dec-13 29-Jan-13 11-Jul-16 CMS Heitor BeltrÃ£o,https://Cl
Nov-15 Nov-15 18-Jan-16 ### Korea University Gurohttps://Cl
Feb-06 Sep-07 Aug-08 ### 9-May-14 University of Marylanhttps://Cl
Nov-03 Apr-18 Apr-18 ### 25-Apr-18 Memorial Sloan Kettehttps://Cl
Dec-13 Sep-14 Oct-14 7-May-12 1-Apr-15 https://Cl
May-07 May-10 May-10 2-Apr-07 ### ### GSK Investigational S https://Cl
Aug-09 Dec-13 Dec-13 2-Feb-09 8-Mar-16 8-Mar-16 Infectious Disease Unhttps://Cl
Oct-10 Nov-14 Nov-14 4-Jan-11 ### Department of Infectihttps://Cl
Jan-08 Mar-11 Mar-11 ### 19-Apr-12 28-Oct-15 National Institutes ofhttps://Cl
Oct-05 Jun-08 Jun-08 2-Sep-05 ### Children's Hospital ofhttps://Cl
27-Oct-16 9-Mar-17 9-Mar-17 27-Oct-16 8-May-17 Pediatric clinical tri https://Cl
Mar-07 Sep-07 5-Mar-07 ### Hertordshire Primar https://Cl
Jan-05 Mar-09 Dec-09 5-Sep-05 22-Jun-09 Clinique Universitair https://Cl
Aug-12 May-14 May-14 ### ### Johnson County Clin-Thttps://Cl
Aug-03 9-Feb-04 ### St. Jude Children's R https://Cl
Mar-09 Sep-12 Sep-12 31-Oct-14 31-Oct-14 Chapel Hill Pediatric https://Cl
Sep-00 May-01 May-01 13-Apr-09 7-Sep-16 https://Cl
Sep-06 Dec-09 Apr-10 12-Apr-06 22-Jan-14 Izmir, Turkey https://Cl
Sep-05 Dec-08 Dec-11 ### ### Sydney Melanoma Unit https://Cl
Jul-06 Jan-08 Feb-08 12-Apr-06 ### 21-Apr-14 Mexico DF, Mexico|Lihttps://Cl
Jul-99 May-03 ### 20-Jun-13 Surgery Branch, Bethhttps://Cl
1-Oct-17 Dec-20 Dec-20 ### 7-Jan-20 Mayo Clinic in Rocheshttps://Cl
Apr-01 Jun-05 Jun-05 27-Jan-03 ### Herbert Irving Comprhttps://Cl
Jun-11 Jun-12 Jul-12 8-Jun-11 ### UMHS Outpatient Pedi https://Cl
Dec-04 Mar-06 Oct-07 ### 8-Jan-10 ### Little Rock, Arkansas https://Cl
1-Jul-13 2-Aug-13 2-Aug-13 24-Jun-13 1-Dec-14 7-Sep-18 GSK Investigational S https://Cl
Aug-15 Dec-18 Dec-18 30-Jun-15 9-Jan-19 University of Arkansashttps://Cl
Mar-12 Jul-16 Jul-16 1-Feb-12 4-Oct-16 Roswell Park Cancer Ihttps://Cl
May-02 Aug-02 10-Jun-02 ### Kaiser Permanente Vac https://Cl
AVEG 008|AVEG Protocol 008|10553 Jul-94 ### ### JHU AVEG, Pittsburgh,https://Cl
16-Mar-19 31-Aug-19 ### ### 9-Dec-19 De La Salle Health Scihttps://Cl
Apr-06 Nov-06 17-Jul-06 7-Oct-16 GSK Investigational Sihttps://Cl
Feb-00 Feb-02 Feb-02 28-Jun-04 19-Jun-13 Memorial Sloan-Kettehttps://Cl
Jan-15 Apr-15 Apr-15 1-Apr-14 20-Jul-15 https://Cl
Nov-16 Jan-20 Apr-20 14-Oct-16 ### https://Cl
Dec-00 Aug-06 Aug-08 7-Oct-03 ### Dana-Farber/Harvardhttps://Cl
C
30-Sep-17 6-Feb-18 8-Apr-18 ### ### Hoa Binh Provincial https://Cl
Mar-06 Nov-06 Nov-06 18-Jul-06 7-Oct-16 GSK Investigational S https://Cl
Dec-14 17-Feb-16 ### ### ### Clinical Trials Center https://Cl
2-Oct-07 21-Sep-15 31-Jan-19 ### 1-Nov-16 8-Nov-19 H. Lee Moffitt Cancerhttps://Cl
Oct-11 Nov-11 Nov-11 8-Feb-12 8-Feb-12 Alberta Children's Hoshttps://Cl
22-Sep-17 31-Mar-20 ### 2-Jul-17 ### Banner University Med https://Cl
19-Mar-09 ### 23-Jan-20 Proyecto Epidemiologihttps://Cl
Aug-03 Jan-04 Jan-04 ### 7-Sep-16 GSK Investigational Sihttps://Cl
May-03 Aug-04 Aug-04 ### 12-Apr-11 5-Oct-15 https://Cl
Feb-03 Feb-03 ### ### University of Iowa - I https://Cl
Nov-08 Sep-13 Dec-13 ### 3-Jun-14 University Hospitals Lhttps://Cl
2-Feb-15 Feb-20 Feb-25 27-Oct-14 7-May-19 Oslo University Hospihttps://Cl
Jun-15 30-Oct-16 30-Oct-16 16-Jul-15 16-Apr-19 30-Apr-19 Johns Hopkins Bloombe https://Cl
Oct-13 Dec-13 Dec-13 13-Jan-17 9-Mar-17 6-Jun-18 https://Cl
May-00 May-04 Sep-09 ### 3-Aug-10 7-Oct-15 https://Cl
Mar-14 Oct-14 May-17 ### 19-Jun-19 251 General Airforce https://Cl
Aug-14 Oct-15 Oct-15 3-Jul-14 3-Dec-15 Centre for Clinical https://Cl
Oct-03 Jun-05 Jun-05 8-Jun-06 ### USC/Norris Comprehens https://Cl
18-Jul-19 Dec-22 Dec-23 ### ### Mayo Clinic Arizona, https://Cl
19-Dec-18 15-Sep-20 ### 7-Aug-18 23-Oct-19 Alabama CR "Informed https://Cl
Feb-12 Dec-13 Dec-13 2-Feb-12 12-Oct-15 Dept of Oncology, Unihttps://Cl
Mar-16 11-Jun-18 11-Jun-18 ### 1-Oct-19 1-Oct-19 "Study Prohttps://Cl
Jun-12 May-15 Jul-15 ### 18-Jan-20 Medizinische Univershttps://Cl
29-Nov-17 17-Apr-20 17-Apr-20 6-Oct-17 5-Feb-20 Heartland Research Ahttps://Cl
Apr-03 Nov-03 Dec-05 ### 10-Jan-19 Swiss Pharma Contract https://Cl
6-Aug-14 19-May-15 ### 17-Jul-14 29-Jun-16 18-Jul-19 Hope Research Instituhttps://Cl
22-Aug-07 20-Feb-08 ### 8-Aug-07 ### ### GSK Investigational S https://Cl
Oct-05 Jan-06 Jan-06 4-Jul-07 ### https://Cl
8-Jun-16 14-Feb-18 ### ### 29-Jul-19 Matlab Hospital Reseahttps://Cl
22-Nov-08 25-May-09 ### 24-Oct-08 30-Jul-10 ### GSK Investigational S https://Cl
Dec-04 Aug-08 Oct-08 1-Dec-05 14-Jan-14 Calcutta, India|Hyderhttps://Cl
5-Aug-03 20-Oct-05 1-Sep-05 ### GSK Investigational Site,
https://Cl
Villanueva, Mendoza, Argenti
Sep-15 Sep-17 6-Mar-19 ### ### Radboud University Nhttps://Cl
May-01 Apr-06 Apr-06 ### ### National Institutes https://Cl
24-Sep-07 10-Apr-13 7-Jul-16 15-Oct-07 ### ### https://Cl
Apr-13 Apr-14 Apr-14 4-Mar-13 9-Sep-13 https://Cl
Apr-00 27-Jan-03 ### St. George's Hospital https://Cl
16-Dec-14 21-Jul-17 21-Jul-17 ### 8-Oct-19 6-Feb-20 University "Study Prohttps://Cl
Mar-13 Jan-14 Jun-14 ### ### Miami Research Associ https://Cl
27-Nov-12 8-May-12 ### National Institutes ofhttps://Cl
1-Feb-10 1-Apr-20 30-Apr-08 5-Feb-20 Rutgers Cancer Instit https://Cl
8-Mar-19 7-Nov-19 7-Nov-19 ### ### Souseikai PS Clinic ( https://Cl
12-Aug-19 Jan-20 Feb-21 ### ### Avail Clinical Resear https://Cl
22-Apr-10 14-Nov-14 ### ### ### Palo Alto Medical Foun https://Cl
5-Sep-06 5-May-09 ### 2-Jul-17 National Institutes ofhttps://Cl
May-10 Jul-10 Jan-11 6-Oct-09 15-Jun-11 Canadian Center for https://Cl
9-Jan-19 14-Oct-19 ### 16-Jan-19 7-Jan-20 Simbec Research Limihttps://Cl
Nov-10 Mar-11 Mar-11 ### ### ### Chengxiang Town Hosp https://Cl
8-Dec-17 15-Aug-18 ### 14-Jul-16 1-May-18 Roswell Park Cancer Ihttps://Cl
Jan-07 Feb-07 4-Dec-06 27-Oct-16 GSK Investigational Sihttps://Cl
Apr-14 Oct-15 Oct-15 21-Apr-14 10-Jan-18 ### Clinical Research Advhttps://Cl
Nov-15 Jul-16 ### 4-Aug-15 ### University of Alabamahttps://Cl
Apr-06 Feb-07 Aug-07 21-Apr-06 9-Jan-19 6-Mar-19 Harrison Clinical Re https://Cl
May-13 Jul-13 Jul-13 28-Oct-11 10-Oct-13 Pre-selected beauty shttps://Cl
Aug-12 Jan-17 Jan-17 4-Sep-13 19-Jun-19 Fakultni nemocnice Plhttps://Cl
Sep-02 Apr-03 8-Aug-08 8-Aug-08 GSK Clinical Trials C https://Cl
Mar-01 Mar-06 27-Jan-03 16-Jan-13 Cancer and Leukemiahttps://Cl
G
Aug-13 Feb-14 Feb-14 5-Aug-13 ### https://Cl
Sep-03 Feb-07 5-Aug-04 ### Washington Cancer Ins https://Cl
Aug-92 Aug-02 May-06 28-Jun-04 ### Hoag Memorial Hospita https://Cl
25-Jan-08 21-Jun-10 21-Jun-10 31-Jan-08 2-Jul-17 National Institutes ofhttps://Cl
1-Oct-18 30-Jul-21 ### 6-Sep-18 ### https://Cl
Mar-02 Aug-02 ### ### Grieskirchner Strass https://Cl
Aug-11 Apr-14 Apr-14 27-Jul-11 ### Neuro-Oncology Branch https://Cl
12-Dec-17 Dec-20 Dec-20 ### ### Herlev Hospital, Her https://Cl
Sep-14 Sep-15 Nov-16 ### 6-Jun-18 CRS Clinical Resear https://Cl
24-Jan-14 17-May-16 ### ### ### ### Mount Sinai Medical h Cttps://Cl
Apr-14 Sep-14 Mar-15 10-Apr-14 20-Jul-15 Hospital del NiÃ±o, https://Cl
Sep-01 Mar-02 ### ### Neuschwansteinstrasshttps://Cl
Dec-10 Jan-13 Mar-13 10-Jan-11 10-Jan-11 Canadian Center for Vhttps://Cl
30-May-17 Jun-20 Dec-20 2-Dec-15 ### Antwerp University Hhttps://Cl
1-Nov-04 2-Mar-05 2-Mar-05 ### ### ### GSK Investigational S https://Cl
Aug-08 Jan-11 Jan-11 ### ### Centre Hospitalier Le https://Cl
Jul-07 Aug-07 18-Jul-07 ### Health Protection Ag https://Cl
Jan-11 Jun-12 Apr-18 27-Apr-11 12-Apr-18 Providence Health & Shttps://Cl
Apr-14 Apr-21 Apr-36 1-Oct-13 31-Jan-20 Houston Methodist Hos https://Cl
Aug-05 Aug-08 Aug-08 ### 23-Oct-19 University of Pennsyl https://Cl
21-Oct-16 31-Jan-21 31-Jan-21 24-Oct-16 ### Bancoumana Malariahttps://Cl
Dec-10 Jun-14 Jun-14 ### ### Chu Dijon, Dijon, Fra https://Cl
Nov-09 Apr-13 Apr-13 ### 23-Apr-15 Wellcome Clinical Reshttps://Cl
Jul-13 Jul-17 Apr-19 25-Jul-13 10-Jan-19 Aga Khan University, https://Cl
Jul-04 Jul-07 Mar-09 9-Jan-06 ### University of Alabamahttps://Cl
Mar-15 Jul-16 Feb-17 ### 8-Feb-18 Center for Immunizatihttps://Cl
26-Apr-11 28-Sep-11 ### 12-Apr-11 ### 6-Jun-18 GSK Investigational S https://Cl
Jun-07 Aug-08 Aug-08 ### ### University of Iowa, Iohttps://Cl
11-Jul-13 5-Aug-13 5-Aug-13 17-Jun-13 12-Jan-15 7-Sep-18 GSK Investigational S https://Cl
Aug-15 Aug-16 Aug-16 ### 2-Dec-16 University of Louisvi https://Cl
22-Jan-19 30-Jun-20 ### 10-Oct-19 10-Oct-19 Centre hospitalier unhttps://Cl
23-May-11 2-Oct-18 ### ### University of Alabamahttps://Cl
May-09 Mar-11 Mar-11 10-Apr-09 ### University of Iowa - I https://Cl
Oct-07 Jan-10 Jan-10 ### 9-Aug-13 Alabama Vaccine CRS,https://Cl
19-Jul-12 10-Aug-12 ### 25-Jun-12 14-Oct-13 7-Sep-18 GSK Investigational S https://Cl
12-Jun-17 15-Apr-19 15-Apr-19 2-Nov-18 8-Nov-19 LÃ¤Ã¤kÃ¤rikeskus Aava https://Cl
Jan-94 Nov-95 Nov-95 13-Jun-08 13-Jun-08 GSK Clinical Trials Ca https://Cl
Nov-05 May-08 May-08 10-Jun-14 16-Jul-14 25-Jul-14 https://Cl
Jul-05 Jan-06 2-Aug-05 9-May-07 Radiant Research, Sanhttps://Cl
21-Jun-12 6-Jul-15 9-Nov-15 18-Jun-12 ### ### GSK Investigational Sihttps://Cl
9-Oct-18 16-Oct-19 16-Oct-19 5-Oct-18 ### Investigational Site https://Cl
Jan-15 Feb-20 Feb-21 ### 8-Mar-19 Highlands Oncology Gr https://Cl
21-Jun-16 11-Jul-18 11-Jul-18 ### 21-Jun-19 Aurum Tembisa CRS, Jhttps://Cl
12-Dec-13 19-Jun-15 24-Jul-17 ### 26-Apr-16 8-Aug-18 https://Cl
14-Nov-18 31-Jan-20 31-Jan-20 ### ### M D Anderson Cancerhttps://Cl
Oct-04 Jun-06 Jun-06 ### 5-Oct-15 University of Wisconshttps://Cl
1-Oct-15 1-Feb-18 ### 5-Oct-15 10-Jun-19 GSK Investigational S https://Cl
Aug-15 Mar-18 Aug-18 4-Nov-15 12-Jul-17 East Tallinn Central https://Cl
Jul-09 May-12 9-Jul-09 ### Department of Oncolo https://Cl
7-Mar-19 Apr-20 May-20 ### 27-Jan-20 California Departmenthttps://Cl
May-10 May-10 May-10 27-Jul-12 27-Jul-12 https://Cl
Jun-13 Dec-13 Jan-14 5-Jun-13 ### Hospital General de Chttps://Cl
British Columbia Cancer Agency, Vancouver, British Co
Jan-07 Apr-12 Apr-15 8-Dec-06 ### ### Spain|Research Site, Barcelona,
https://Cl Spain|Research Site,
Nov-11 Apr-12 Jun-12 9-Nov-11 21-Jul-14 21-Jul-14 Centers for Disease Chttps://Cl
Sep-12 Apr-13 Apr-13 5-Oct-12 29-Jul-13 https://Cl
Jun-15 Mar-20 Mar-20 ### 10-Apr-18 Beckman Laser Instituhttps://Cl
Oct-14 Sep-15 Sep-15 6-Jan-14 ### University of Califor https://Cl
Oct-10 Apr-14 Apr-14 28-Jun-10 30-Apr-14 Centre for Clinical V https://Cl
HVTN 101|11933 Jan-17 ### ### https://Cl
Jul-03 Apr-05 Apr-05 ### ### GSK Investigational https://Cl
Jun-06 Dec-06 ### 18-Jul-07 Radiant Research, Dayhttps://Cl
Oct-16 Sep-17 Sep-17 ### 26-Oct-17 Lincolnshire West CC https://Cl
5-Sep-05 28-Oct-05 28-Oct-05 3-Jun-14 ### GSK Investigational Sihttps://Cl
10-Mar-05 29-Sep-08 ### 1-Sep-05 ### GSK Investigational Sihttps://Cl
Feb-06 Jan-07 Jan-07 ### 10-Jun-11 Cincinnati Children's https://Cl
6-Aug-09 3-Sep-10 3-Sep-10 9-Sep-09 2-Jul-17 National Institutes ofhttps://Cl
12-Aug-13 1-Jan-21 1-Jan-21 4-Jun-13 ### National Institutes ofhttps://Cl
Jan-01 Jul-03 Aug-03 27-Jan-03 7-Mar-11 Roswell Park Cancer Ihttps://Cl
20-Jun-13 19-Jan-15 19-Jan-15 19-Jul-13 23-Jan-19 Kantou, Japan|Kyushuhttps://Cl
Jun-09 Oct-09 Nov-09 7-Apr-09 ### ### Tasmc Crc, Tel Aviv, Ishttps://Cl
Jul-05 May-06 May-06 7-Sep-05 ### GSK Investigational S https://Cl
Feb-12 Nov-14 Nov-14 ### ### Velindre NHS Trust, https://Cl
Dec-07 Feb-08 Jun-08 16-Jan-08 ### ### Medizinische Universihttps://Cl
May-10 Nov-12 Nov-12 5-May-10 ### St . Jude Children's https://Cl
Jan-04 Jul-04 21-Jul-05 12-Jan-17 Medical Research Couhttps://Cl
Mar-03 Jan-06 ### ### https://Cl
16-Feb-04 15-Apr-09 15-Apr-09 ### ### ### GSK Investigational Sihttps://Cl
Jul-12 Aug-12 Aug-12 28-Jun-12 ### ### Covance Clinical Resehttps://Cl
Sep-10 Oct-12 Feb-16 ### ### Alabama CRS, Birmingh https://Cl
Oct-13 Aug-14 Jan-15 ### 18-Jan-17 8-Mar-17 Accelovance, Rockvillhttps://Cl
Dec-12 Feb-13 Feb-13 18-Jan-17 9-Mar-17 21-Apr-17 https://Cl
Mar-16 13-May-16 ### ### ### Radiant Research, Inchttps://Cl
1-Nov-19 31-Mar-21 ### 26-Apr-19 17-Jul-19 Dana Farber Cancer Inhttps://Cl
Dec-09 Dec-10 Dec-10 27-Jan-10 ### 20-Jan-16 https://Cl
17-Jun-17 31-Oct-17 ### 5-Jun-17 4-Sep-18 Clinical Research Un https://Cl
### 24-Jun-05 Johns Hopkins Univ / https://Cl
Jan-15 Oct-15 Oct-15 ### 3-Dec-15 NIHR WTCRF, Universihttps://Cl
Mar-04 Jun-05 ### ### Kaiser Permanente, Athttps://Cl
Nov-06 Jan-08 Feb-08 13-Oct-06 ### ### Sydney Children's Hoshttps://Cl
Jun-10 Sep-10 Mar-12 8-Jun-11 29-Jul-15 Children's Hospital ofhttps://Cl
Sep-09 Oct-11 Oct-11 ### 4-Sep-13 St. Stephen's AIDS T https://Cl
Jul-12 Nov-14 Sep-15 8-Aug-12 ### ### Birmingham, Alabama, https://Cl
Feb-15 Apr-16 Apr-16 ### ### Q-Pharm Pty Ltd., Brihttps://Cl
15-Mar-04 26-Apr-05 26-Apr-05 ### ### GSK Investigational https://Cl
Nov-16 Apr-18 Oct-18 ### ### The catholic universithttps://Cl
2-Apr-15 31-Jan-17 ### ### ### https://Cl
31-Oct-12 9-Apr-13 9-Apr-13 7-Feb-12 ### ### https://Cl
12-Mar-13 Mar-20 Jun-20 ### 18-Oct-18 Menzies School of Hea https://Cl
Mar-15 Nov-18 Nov-18 8-Apr-15 12-Jul-17 Korea University Gurohttps://Cl
24-Mar-05 1-Mar-06 3-Mar-06 ### 1-Mar-17 8-Jun-18 GSK Investigational Sihttps://Cl
7-Nov-19 1-Dec-20 ### 17-Oct-19 8-Nov-19 Research Institute of https://Cl
AVEG 010|10555 Dec-94 ### ### Univ. of Rochester AVhttps://Cl
Dec-13 Dec-20 Dec-20 21-Oct-13 6-Jan-20 Sidney Kimmel Compre https://Cl
20-Sep-18 Dec-20 Mar-21 3-Oct-18 22-Jul-19 Children's Hospital R https://Cl
14-Dec-07 14-Jan-08 14-Jan-08 4-Jan-08 ### 27-Jun-19 GSK Investigational S https://Cl
Nov-10 Aug-13 Sep-18 ### ### CharitÃ© - Universti https://Cl
Jan-06 Jul-09 Jul-09 7-Feb-06 4-Nov-09 Germans Trias i Pujol https://Cl
Jan-06 Feb-07 Feb-07 ### 14-Jan-14 Adelaide, Australia|Chttps://Cl
Aug-15 Mar-20 Mar-20 5-May-15 ### Royal Hallamshire Hoshttps://Cl
4-Mar-05 27-Mar-06 ### 4-Oct-05 ### ### GSK Investigational Sihttps://Cl
Jan-06 Jul-11 Dec-12 ### 13-Apr-16 17-Jul-18 Oakland, California, https://Cl
Jan-12 Aug-19 Dec-19 9-Jul-12 1-Feb-16 Jonsson Comprehensive https://Cl
Mar-04 May-04 ### ### SGS Biopharma Resear https://Cl
6-Nov-19 Feb-20 Feb-20 30-Oct-19 5-Feb-20 Investigational Site https://Cl
1-Sep-19 31-Dec-21 ### 5-Dec-17 24-Jun-19 Dana Farber Cancer Inhttps://Cl
075A|V0200g ### 24-Jun-05 Walter Reed Army Inst https://Cl
Apr-06 Mar-10 Mar-10 ### 5-Apr-17 Fred Hutchinson Canchttps://Cl
Apr-04 Jun-06 14-Jan-04 5-Mar-15 Alabama Vaccine CRS,https://Cl
Jan-01 Apr-03 Apr-03 31-Jan-07 ### https://Cl
Sep-08 May-12 May-12 ### 2-Aug-13 Brigham and Women's https://Cl
H
21-Sep-15 7-Jun-16 ### 7-Sep-15 12-Jun-17 Huntsville, Alabama, https://Cl
Jul-07 May-08 May-08 ### ### 11-Apr-17 https://Cl
Sep-06 Sep-17 Sep-17 ### ### ### Sidney Kim"Study Prohttps://Cl
Dec-03 Jul-07 Jul-07 ### 4-Nov-16 GSK Investigational S https://Cl
Nov-07 Oct-13 Oct-13 15-Jan-08 ### St. Michael's Hospita https://Cl
1-Jun-17 Jun-18 Dec-18 ### ### https://Cl
Dec-13 Dec-16 Mar-17 12-Jul-13 12-Jul-13 Nanjing Drum-Tower https://Cl
Ho
Oct-14 Dec-17 Dec-17 ### 7-Jun-17 Center for Vaccinologhttps://Cl
Oct-97 May-07 27-Jan-03 20-Jun-13 Warren Grant Magnuson https://Cl
Feb-12 Feb-13 Dec-14 8-Mar-12 2-Feb-15 Hopital Pitie Salpetri https://Cl
Aug-16 Dec-17 Jan-18 6-Nov-16 ### ### inVentiv Cl"Statistic https://Cl
11-Nov-10 18-Apr-11 18-Apr-11 ### 17-Apr-12 ### GSK Investigational Sihttps://Cl
Jul-07 Aug-10 Feb-11 ### 23-Apr-15 Centre for Clinical V https://Cl
Dec-15 Dec-20 Dec-22 7-Jan-16 ### Antwerp University Hhttps://Cl
26-Jun-17 7-Dec-17 7-Dec-17 25-Apr-17 ### Medical Oncology Asshttps://Cl
9-Jan-17 19-Dec-18 ### 9-Jan-17 8-Nov-19 Emory Children's Centhttps://Cl
Jan-08 Feb-11 Feb-11 7-Feb-08 10-Apr-12 28-Oct-15 National Institutes ofhttps://Cl
24-Jan-14 20-Dec-16 Feb-17 ### ### Naval Medical Researc https://Cl
Jun-98 Jul-00 19-Jul-04 ### Kaplan Cancer Centerhttps://Cl
Feb-09 Jan-10 Dec-14 13-Jan-09 8-Jan-15 Icahn School of Medichttps://Cl
Jun-03 Mar-05 29-Jan-07 29-Jan-07 Centre for Clinical V https://Cl
Oct-06 Sep-07 Sep-07 2-Oct-06 ### Stanford University, https://Cl
May-16 10-Nov-17 ### 6-Jan-16 26-Jun-18 Institut de Recherchehttps://Cl
Feb-10 Mar-19 Mar-19 ### ### Shiga University of Mhttps://Cl
Aug-02 Aug-03 Apr-04 18-Oct-05 ### SFBC International Inchttps://Cl
Nov-04 9-Nov-04 5-Feb-18 Glendale Memorial Hos https://Cl
Mar-04 Jul-04 Nov-04 ### ### Department of Ambula https://Cl
Jul-06 Feb-11 Feb-11 ### 2-May-12 Warren Grant Magnuson https://Cl
Aug-11 Jan-12 Jan-12 ### ### Hadassah medical cent https://Cl
Nov-12 Jun-16 Sep-16 31-Oct-12 ### Winship Cancer Instithttps://Cl
Nov-01 Sep-07 Apr-08 ### ### Department of Neurolhttps://Cl
1-Apr-10 7-Dec-10 7-Dec-10 7-Apr-10 27-Jun-17 GSK Investigational S https://Cl
May-10 Jun-10 Dec-10 15-Apr-10 14-Jul-11 18-Jul-11 Miami Research Associ https://Cl
4-Dec-17 4-Dec-27 4-Dec-27 1-Nov-17 ### CHU de Brest, Brest, https://Cl
Nov-05 Jan-08 Aug-08 ### 21-Oct-08 Colonial War Memorial https://Cl
Jun-12 20-Nov-15 ### 8-Aug-12 25-Jun-19 Abramson Cancer Cente https://Cl
Jul-07 Jan-11 Jan-11 ### ### University Cape Townhttps://Cl
Jul-05 Mar-06 Apr-06 5-Mar-10 8-Mar-10 Malaria Vaccine and Dhttps://Cl
27-Mar-13 22-Dec-15 ### 4-Jun-13 5-Jul-18 Malaria Research andhttps://Cl
Apr-20 Apr-22 Apr-22 ### ### Ifakara Health Instituthttps://Cl
Mar-20 May-20 May-20 ### ### Virginia Commonwealth https://Cl
25-May-18 30-Dec-19 ### 20-Jun-18 ### Chan Soon-Shiong Inst https://Cl
Jan-13 May-14 May-14 ### 6-Feb-19 Winthrop University Hhttps://Cl
Jan-08 Jun-11 Jun-12 22-Jul-14 22-Jul-14 Centro de DispensaÃ§https://Cl
Jan-07 19-May-08 ### ### ### University Pediatric Ahttps://Cl
Apr-04 Dec-05 ### 10-Jan-19 Department of Infecthttps://Cl
1-Sep-15 Dec-19 ### ### ### Stockholm CF Center,https://Cl
25-Jun-07 23-Jun-08 23-Jun-08 27-Jun-07 ### 26-Jun-19 GSK Investigational S https://Cl
Dec-06 Feb-08 Mar-08 ### ### ### Edmonton, Alberta, https://Cl
Sep-14 Mar-16 Mar-16 ### 7-Feb-18 Duke University Healthttps://Cl
Mar-06 Mar-07 ### 5-Dec-07 Herson, Queensland, https://Cl
A
Aug-09 Sep-09 Mar-10 24-Jul-09 5-Sep-11 ### Covance Daytona Beach https://Cl
Jul-02 Jul-05 Jul-05 7-Jan-08 12-Apr-13 University of Marylanhttps://Cl
Dec-04 Feb-07 Oct-07 5-Jan-05 1-Oct-08 University Hospitals ohttps://Cl
HVTN 039|10200 Dec-05 ### ### Alabama Vaccine CRS,https://Cl
1-Mar-13 31-May-13 5-Dec-13 ### ### https://Cl
Sep-04 Jun-11 4-Mar-05 2-Aug-13 UAB Comprehensive Can https://Cl
9-Dec-04 ### ### 2-Jul-17 National Institutes ofhttps://Cl
Jun-07 Dec-09 Jun-10 27-Jun-07 14-Jan-14 Bangkok, Thailand https://Cl
15-Sep-18 30-Dec-19 Oct-20 ### 26-Oct-18 NMRC Clinical Trials https://Cl
Aug-12 Sep-14 May-16 3-Sep-12 ### Medical University ofhttps://Cl
Sep-01 Nov-03 ### ### CDC Arctic Investigat https://Cl
Feb-12 Oct-12 Dec-12 ### 15-Jan-13 Clinical Trials Center https://Cl
Mar-06 Dec-06 Dec-06 1-Mar-06 13-Jan-14 GSK Investigational Sihttps://Cl
3-Jan-17 8-Apr-19 8-Apr-19 ### ### UCLA / Jonsson Compre https://Cl
Apr-07 Aug-11 Dec-12 ### 16-Jan-13 Department of Dermat https://Cl
Aug-10 Jun-11 Jan-12 ### 31-Jan-12 Karolinska University https://Cl
Nov-08 Jun-10 Jun-10 6-Aug-09 8-Jun-15 City of Hope Comprehe https://Cl
Jul-05 Jul-05 21-Jul-05 ### Providence Portland M https://Cl
Nov-93 Apr-95 Apr-95 16-Jun-08 16-Jun-08 GSK Clinical Trials Calhttps://Cl
Nov-05 Mar-08 Jun-08 28-Oct-09 21-Jan-13 Leiden University Med https://Cl
Jan-10 Nov-10 Nov-10 ### ### Buenos Aires, Argentihttps://Cl
5-Feb-14 31-Mar-18 ### 2-Oct-17 Fred Hutch/Universit https://Cl
26-Jul-18 Aug-22 Aug-23 26-Jun-18 7-Jan-20 UCSD Medical Center,https://Cl
May-02 Dec-06 ### ### Sheba Medical Centerhttps://Cl
22-Feb-14 10-May-14 ### ### ### 2-Aug-18 GSK Investigational S https://Cl
Aug-02 Oct-07 27-Jan-03 19-Jun-13 Warren Grant Magnuson https://Cl
May-13 3-Apr-17 ### 12-Jun-19 12-Jun-19 Anchorage"Study Prohttps://Cl
Sep-13 Nov-14 Nov-14 11-Jul-13 2-Jul-18 University of Marylanhttps://Cl
Mar-05 Aug-11 Jan-14 6-Nov-03 3-Jan-13 28-Oct-15 Veterans Affairs Medihttps://Cl
Oct-99 Oct-07 27-Jan-03 20-Jun-13 Warren Grant Magnuson https://Cl
Sep-98 Mar-99 Sep-99 19-Jan-12 ### Centre d'Investigationhttps://Cl
Dec-99 27-Jan-03 9-Feb-09 Royal Perth Hospital, https://Cl
Nov-13 Apr-15 ### 26-Jun-14 Sourasky Medical Cente https://Cl
Jun-09 Jul-10 Aug-10 30-Apr-09 27-Jul-12 Chris Hani Baragwanahttps://Cl
Jun-06 Dec-08 Mar-09 ### 14-Jan-14 Ghent, Belgium|Leuve https://Cl
28-Sep-17 21-Jun-21 21-Jun-21 ### 3-Jun-19 GSK Investigational S https://Cl
9-Jan-03 1-Dec-07 1-Dec-07 13-Jan-03 2-Jul-17 National Institutes ofhttps://Cl
Nov-09 Apr-17 Apr-17 17-Jun-10 26-Jul-16 Cellule de Promotion https://Cl
10-Aug-10 ### 5-Feb-20 National Institutes ofhttps://Cl
Mar-11 Oct-15 ### 19-Jul-16 Abramson Cancer Cente https://Cl
Dec-03 Dec-06 ### 8-Nov-12 Project Brave HIV Va https://Cl
30-Jan-97 31-Jul-99 2-Nov-10 4-Nov-99 2-Jul-17 National Institutes ofhttps://Cl
Mar-07 Apr-09 2-Jan-13 7-May-07 ### Mayo Clinic, Rochestehttps://Cl
Aug-09 Sep-09 Mar-10 24-Jul-09 ### ### Coastal Clinic Resear https://Cl
8-May-17 21-May-18 8-Jun-18 27-Jan-17 9-Jul-18 Boston Medical Center https://Cl
31-Mar-17 3-Jan-22 3-Jan-22 17-Oct-16 ### Alabama Vaccine Resea https://Cl
Jan-99 Jan-07 Dec-08 3-May-04 ### Biomira Inc., Edmont https://Cl
Jul-04 Dec-04 Dec-04 4-Dec-06 ### GSK Investigational S https://Cl
Oct-06 Apr-07 Apr-07 9-Oct-06 ### Eastern Virginia Medichttps://Cl
Feb-11 Jul-11 Nov-11 ### ### Accelovance, Rockvillhttps://Cl
2-Aug-04 15-Jan-08 6-Aug-04 2-Jul-17 National Institutes ofhttps://Cl
Sep-12 Sep-15 Nov-17 ### 25-Jan-19 25-Jan-19 WRAIR, Clinical Trials https://Cl
Aug-96 ### 29-Apr-15 Surgery Branch, Bethhttps://Cl
May-10 Dec-12 Aug-13 ### 1-Apr-15 Miller Children's Hos https://Cl
Jun-04 Dec-04 21-Jul-05 12-Jan-17 Medical Research Couhttps://Cl
7-Jun-17 3-Apr-18 18-Oct-18 ### 31-Jan-20 31-Jan-20 CEVAXIN - "Statistic https://Cl
Feb-04 Nov-05 Nov-05 7-Apr-08 7-Apr-08 Centre for Clinical V https://Cl
Aug-07 Sep-08 3-Jul-08 ### Accelovance, San Dieghttps://Cl
Dec-05 Sep-09 Sep-09 4-Dec-06 11-Jan-17 National Jewish Healthttps://Cl
28-May-02 19-Jul-11 19-Jul-11 ### ### 2-Jan-20 GSK Investigational S https://Cl
Jul-05 ### ### Comprehensive Cancer https://Cl
Jun-05 Feb-08 ### ### https://Cl
Aug-07 Sep-07 Dec-07 5-Sep-07 ### 14-Apr-16 Norfolk, Virginia, Uni https://Cl
2-Nov-12 2-Nov-20 2-Nov-21 2-Oct-12 28-Jun-19 University of Californhttps://Cl
Mar-99 Nov-05 27-Jan-03 20-Jun-13 Warren Grant Magnuson https://Cl
4-Sep-17 2-May-19 2-May-19 4-Apr-17 ### PREVAIL C. H. Rennie https://Cl
Apr-03 May-07 22-Jan-02 31-Oct-12 Haiti-GHESKIO, Port-au https://Cl
27-Feb-02 8-Apr-13 1-Mar-02 5-Dec-19 National Institutes ofhttps://Cl
Aug-16 21-Dec-17 ### ### 13-Jun-18 NIHR Wellcome Trusthttps://Cl
Oct-11 Dec-11 Dec-11 ### ### Bandim Health Projechttps://Cl
Nov-08 Apr-12 Apr-12 ### ### H. Lee Moffitt Cancerhttps://Cl
1-Apr-11 27-Mar-12 2-Apr-12 ### 5-Jul-17 ### GSK Investigational S https://Cl
Oct-01 27-Jan-03 ### Herbert Irving Comprhttps://Cl
Sep-03 Nov-07 6-Dec-04 9-Mar-09 London, United King https://Cl
21-Jul-16 Jun-19 Jun-19 ### ### Seoul, Korea, Republihttps://Cl
Oct-16 Jan-21 Dec-23 ### 23-Jan-20 NKI-AvL, Amsterdam,https://Cl
Mar-96 Apr-01 ### 4-Mar-08 National Institute of https://Cl
May-04 Jun-04 Jun-04 ### ### 20-Apr-17 GSK Investigational Sihttps://Cl
Dec-96 May-06 ### ### Massachusetts Genera https://Cl
Jun-14 Jun-15 Jul-15 ### 11-Apr-18 11-Apr-18 NEA Baptist Clinic, J https://Cl
Nov-07 Mar-08 Apr-09 15-Jan-08 18-Jun-15 Bangkok, Thailand|K https://Cl
Jan-07 Jul-08 Jul-08 ### 14-Oct-09 9-Dec-16 GSK Investigational S https://Cl
28-Aug-08 21-Apr-15 21-Apr-15 ### 31-Oct-18 Mayo Clinic in Arizonahttps://Cl
Jan-08 Oct-10 Oct-10 21-Jan-08 9-May-12 Accelovance, Inc., Rohttps://Cl
1-May-20 1-May-22 1-May-24 ### ### https://Cl
Jun-13 Jan-14 Dec-15 ### ### Surrey Clinical Resea https://Cl
Apr-12 Oct-12 Oct-12 ### ### 12-Apr-17 https://Cl
Dec-10 Sep-15 Sep-15 ### 13-Jan-17 GSK Investigational S https://Cl
Feb-14 Jun-14 Jun-14 17-Jan-14 ### Institute for Specific https://Cl
7-Feb-17 15-Feb-22 Feb-25 ### 8-Aug-19 Mayo Clinic Hospital, https://Cl
1-Feb-16 30-Oct-16 ### ### ### Washington State Unihttps://Cl
Apr-08 Dec-08 Jun-09 24-Apr-08 ### Department of Clinic https://Cl
14-Oct-14 17-Mar-17 ### 23-Jun-14 6-Jan-20 6-Jan-20 Roswell Par"Study Prohttps://Cl
Nov-16 10-Jan-18 10-Jan-18 14-Oct-16 10-Apr-18 Mirpur Field Office, https://Cl
Jan-01 Mar-05 5-Feb-01 4-Mar-08 National Institute of https://Cl
Aug-12 Apr-14 Apr-14 ### 16-Jul-14 Jiangsu Province Guanhttps://Cl
Dec-98 23-Apr-04 3-Dec-15 Cancer and Blood Insthttps://Cl
Oct-14 Jul-16 ### 13-Oct-14 28-Jan-19 28-Jan-19 Mount Sinai Hospital,https://Cl
Sep-09 Jun-10 Feb-11 12-Oct-09 20-Jun-11 1-Aug-18 Birmingham, Alabama, https://Cl
Nov-04 Nov-07 10-Jan-05 ### Penn State Cancer Inshttps://Cl
Sep-16 Apr-18 Dec-18 19-Jul-16 ### Alabama Vaccine Resea https://Cl
Jan-03 ### ### University of Califor https://Cl
9-Jan-06 ### 13-Jan-06 2-Jul-17 National Institutes ofhttps://Cl
May-01 Mar-03 Mar-03 31-Oct-07 30-Oct-15 https://Cl
Feb-08 1-Mar-12 5-Jan-16 28-Apr-09 ### Dartmouth-Hitchcockhttps://Cl
Aug-02 Nov-05 5-Aug-04 ### Cancer Center at the U https://Cl
Sep-11 May-12 Jul-12 ### 21-Jul-14 21-Jul-14 ICON Development Sohttps://Cl
Jan-98 Nov-04 Nov-04 14-Apr-04 ### Lombardi Cancer Cente https://Cl
Apr-98 ### 24-Jun-05 Walter Reed Army Inst https://Cl
Oct-00 Sep-07 Sep-07 29-Jul-09 15-Jul-16 Hoag Memorial Hospita https://Cl
Oct-97 Apr-04 ### 23-Jan-13 M D Anderson Cancerhttps://Cl
Feb-96 May-03 ### 20-Jun-13 Medicine Branch, Bethttps://Cl
May-08 Mar-09 Mar-09 ### ### The Institute of Medihttps://Cl
Jan-11 Aug-11 Aug-11 9-Jun-11 10-Jan-14 Medical University Vihttps://Cl
Feb-16 Nov-19 Nov-19 8-Dec-15 5-Dec-19 5-Dec-19 University "Study Prohttps://Cl
HVTN 048|10197 Sep-05 ### 14-Apr-15 Brigham and Women's https://Cl
Jul-10 May-11 Jun-11 17-Jun-10 31-Jul-12 Clinical Research Centhttps://Cl
May-01 May-04 27-Jan-03 19-Jun-13 Warren Grant Magnuson https://Cl
Apr-11 Dec-15 Dec-18 ### 29-Jul-19 University of Marylanhttps://Cl
Oct-13 28-Jun-17 28-Jun-17 1-Nov-13 ### Dept. of Transplantathttps://Cl
30-Sep-17 31-May-18 ### ### ### The Catholic Univ.of https://Cl
Dec-04 May-09 May-09 3-Jun-05 ### ### Roswell Park Cancer Ihttps://Cl
27-Dec-17 25-Sep-19 ### ### 31-Oct-19 Columbia P"Informed https://Cl
Jan-12 Jan-13 Mar-13 29-Jan-08 2-May-17 University of Pennsyl https://Cl
Aug-07 Sep-08 Feb-11 10-Jun-08 ### Accelovance, San Dieghttps://Cl
26-Jul-99 17-Dec-07 25-Jan-13 4-Nov-99 6-Oct-17 National Institutes ofhttps://Cl
8-Jan-20 Dec-20 Mar-21 22-Oct-19 18-Jan-20 National Cancer Insti https://Cl
Apr-98 Jun-99 ### ### Wiener Strasse 50/2, https://Cl
30-Sep-09 25-Jun-14 15-Oct-09 6-Oct-17 National Institutes ofhttps://Cl
22-Jan-13 1-Nov-13 ### ### 4-Jan-17 18-Jul-19 SUNY Upstate Medicalhttps://Cl
Feb-04 Dec-07 Dec-07 ### 5-Feb-20 Abramson Cancer Cente https://Cl
19-Apr-04 ### 22-Apr-04 2-Jul-17 National Institutes ofhttps://Cl
Aug-12 Apr-14 Nov-14 25-Apr-12 1-Jan-15 University of Alberta https://Cl
14-Nov-08 24-Jan-11 24-Jan-11 5-Dec-08 ### ### Roswell Park Cancer Ihttps://Cl
Sep-16 12-Apr-18 12-Apr-18 ### 10-Jan-20 New York University Shttps://Cl
Nov-78 Jun-80 28-Oct-99 ### https://Cl
Mar-16 30-Nov-16 ### 26-Jul-16 2-May-18 CHU Clermont-Ferrand https://Cl
Nov-14 Aug-18 Dec-19 ### 5-Sep-18 S.C. di Oncologia, A.S.O.https://Cl
"Santi Antonio e Biagio e Ces
Apr-13 Jul-16 Jul-16 5-Aug-13 5-Aug-16 Innsbruck Medical Unhttps://Cl
May-12 May-16 May-16 17-Apr-12 19-Apr-12 https://Cl
Aug-14 Aug-15 Dec-15 ### ### https://Cl
Jul-08 Mar-10 Mar-10 ### 12-Jun-17 https://Cl
Apr-00 May-04 ### 26-Jun-13 Jonsson Comprehensive https://Cl
ACTG 326|PACTG 326|10601 Apr-05 ### ### Long Beach Memorialhttps://Cl
M
May-13 Nov-13 Dec-13 7-May-13 16-Jun-14 Immunedeficiency Uni https://Cl
Dec-07 Oct-09 Oct-09 16-Jan-08 27-Jun-12 ### Medizinische Universihttps://Cl
Jan-07 Dec-07 Jan-09 19-Oct-06 10-Jul-09 CharitÃ©, Campus Virhttps://Cl
Jan-00 3-Jun-09 19-Jun-13 University of Virginia,https://Cl
Dec-16 Aug-17 Dec-17 23-Jun-16 ### Gloucestershire primahttps://Cl
26-Aug-16 15-Feb-17 ### 5-Oct-16 6-Nov-19 6-Nov-19 Centre Nat"Study Prohttps://Cl
Jul-07 Dec-08 Oct-09 22-Jun-07 ### HÃ´pital Henri Mondor https://Cl
Oct-03 Feb-06 Feb-06 ### 16-Apr-12 Manila, Philippines https://Cl
1-Oct-11 1-Mar-17 1-Mar-17 10-Apr-12 18-Jan-18 VA Greater Los Angelehttps://Cl
8-Dec-15 19-Jan-17 19-Jan-17 9-Nov-15 20-Jun-17 CCVTM, University ofhttps://Cl
Mar-16 Feb-20 Feb-20 ### 3-Dec-19 Muhimbili University https://Cl
Oct-07 Oct-08 Oct-08 31-Jul-07 ### Radboud University Nhttps://Cl
Feb-08 Apr-16 Dec-16 ### 23-Jun-15 Akita University Hosiphttps://Cl
5-Nov-19 5-Jun-21 5-Jun-21 19-Apr-19 ### Perinatal HIV Researchttps://Cl
Oct-01 Oct-03 1-Nov-01 4-Mar-08 National Institute of https://Cl
Jul-99 Apr-01 23-Apr-04 11-Apr-13 University of Alabamahttps://Cl
Jan-06 May-09 Dec-09 1-Apr-08 26-Jul-10 Henry Ford Health Syshttps://Cl
Aug-04 Feb-06 8-Sep-04 20-Jun-13 Warren Grant Magnuson https://Cl
3-Mar-06 ### 8-Mar-06 2-Jul-17 National Institutes ofhttps://Cl
Mar-98 Jan-00 ### 6-Mar-12 University of Alabamahttps://Cl
15-Oct-15 29-Aug-17 ### 8-Oct-15 ### ### Centre for "Study Prohttps://Cl
Jun-09 Dec-13 Dec-13 12-Jun-09 ### Tampere University Ho https://Cl
31-Mar-17 Dec-19 Jun-20 ### ### ACH, Little Rock, Arkahttps://Cl
Sep-06 Mar-13 23-Jan-07 ### North Devon District https://Cl
Dec-00 Oct-02 ### 8-Oct-08 University of Connecthttps://Cl
Jun-01 27-Jan-03 30-Apr-15 Warren Grant Magnuso https://Cl
21-Feb-20 30-Apr-20 30-Apr-21 ### ### Malaria Vaccine Centhttps://Cl
1-Nov-03 11-Oct-06 11-Oct-06 8-Sep-05 ### General Ambulatory Pe https://Cl
Feb-14 Dec-14 Dec-14 3-Jun-14 6-Apr-15 https://Cl
1-May-17 Dec-18 Dec-18 27-Apr-17 2-May-17 Pediatrician Clinic,Consultants,
Clinical Research N https://ClInc, Hoover, Alabama, U
Oct-04 Dec-05 9-Aug-05 7-Jul-06 States|Alpine Pediatrics,
https://Cl
Pleasant Grove, Utah, Unite
ACTG 235|AVEG 104|11212 Jul-98 ### ### San Francisco Gen. Hohttps://Cl
Jun-06 May-07 28-Jun-06 3-Sep-08 Edinger Medical Group https://Cl
22-Oct-15 31-Aug-17 ### 24-Jul-15 ### University of Iowa - https://Cl
23-Oct-06 28-Feb-07 ### 9-Oct-06 ### 10-Jun-19 GSK Investigational Sihttps://Cl
Jun-11 Jan-13 Jan-13 23-Jun-11 1-Feb-13 Pediatric Medical Grou https://Cl
Oct-07 Apr-09 Apr-09 30-Jul-07 ### ### Children's Investigat https://Cl
Jul-15 13-Oct-17 5-Jun-18 14-Jul-15 9-Jan-19 Pusan National Univerhttps://Cl
Dec-11 Jan-13 Apr-13 2-May-12 2-May-12 Israeli Defense Forces,https://Cl
Jul-02 Jun-04 ### ### https://Cl
Jan-06 Mar-07 Nov-07 ### ### ### Jonesboro, Arkansas, https://Cl
26-Feb-09 23-May-17 ### 25-Jan-08 30-Apr-18 VA Greater Los Angelehttps://Cl
Mar-02 Jan-07 ### ### Bandim Health Projechttps://Cl
Jul-99 Jan-02 ### ### Duke Comprehensivehttps://Cl
C
Feb-13 May-14 May-14 16-Apr-12 6-Mar-17 CSPS Accart-Ville, Bo https://Cl
Feb-03 ### 9-Apr-08 University of Southerhttps://Cl
1-Nov-04 20-Dec-04 ### ### ### ### GSK Investigational Sihttps://Cl
Jan-08 Oct-10 Oct-10 16-Jan-08 ### GSK Investigational S https://Cl
Dec-00 Sep-03 Dec-03 ### 8-Feb-08 https://Cl
Dec-14 Apr-16 May-16 ### ### Centers for Disease Chttps://Cl
AI-04-006|GCRC M01-RR00102|U01AI04 Jun-07 ### 9-Mar-15 Aaron Diamond AIDS https://Cl
R
Nov-99 ### 25-Oct-06 Kauppakatu Clinic, Tahttps://Cl
1-Nov-12 28-Jan-13 Mar-13 ### 16-Jul-18 Chang Gung Memorial https://Cl
Jun-16 May-17 Mar-18 14-Jun-16 3-Apr-18 Center for Vaccinologhttps://Cl
Dec-14 May-15 Oct-15 ### 8-Jun-17 8-Jun-17 Optimal Research LLC,https://Cl
Oct-07 Jan-10 Jan-10 24-Oct-07 18-Jan-10 University of Oxford, https://Cl
Dec-15 Sep-16 Jul-17 5-Jan-16 ### Johns Hopkins Bloombe https://Cl
1-Jan-04 1-Mar-13 1-Mar-13 ### 8-Mar-10 ### GSK Investigational Sihttps://Cl
1-Jan-04 1-Mar-13 1-Mar-13 ### 4-Mar-10 23-Jul-18 GSK Investigational Sihttps://Cl
Jan-17 Jun-17 Dec-17 2-Nov-16 1-Feb-17 Bandim Health Project https://Cl
Aug-11 Nov-13 May-15 5-Aug-11 9-Dec-16 Medical University ofhttps://Cl
Apr-20 Dec-22 Dec-24 1-Oct-19 18-Jan-20 Sidney Kimmel Cancerhttps://Cl
22-Jan-16 7-Mar-18 7-Mar-18 21-Apr-15 10-Jun-19 9-Jul-19 GSK Investi"Study Prohttps://Cl
Nov-02 Mar-08 Mar-08 7-Sep-05 ### Bandim Health Projechttps://Cl
30-Sep-19 Dec-23 Dec-23 25-Apr-19 ### Duke University Medic https://Cl
Apr-14 Dec-14 Dec-14 ### ### St. Antonius Hospita https://Cl
5-Oct-18 Apr-20 Aug-20 3-Aug-18 12-Jul-19 Duke University Medic https://Cl
Oct-13 Oct-15 Oct-15 ### 25-Jan-17 The University of Tex https://Cl
Nov-96 Sep-05 4-Nov-99 ### National Cancer Insti https://Cl
ACTG 233|11210 ### ### https://Cl
AVEG 038|10586 May-01 ### ### UAB AVEG, Birmingham, https://Cl
Apr-04 Nov-06 Nov-06 30-Apr-04 30-Apr-15 Walter Reed Army Inst https://Cl
Jun-12 Mar-13 Mar-13 20-Jun-12 2-Dec-14 Centre for Clinical V https://Cl
Jan-05 Jun-06 Jun-06 10-Jul-08 ### ### Saint Laszlo Hospital https://Cl
AVEG 009|V0385g ### 24-Jun-05 St Louis Univ School https://Cl
Dec-12 Jun-15 Jun-15 7-Nov-12 11-Jul-16 11-Jul-16 Ottawa Allergy Reseahttps://Cl
24-Jan-19 Apr-20 Apr-20 14-Jan-19 ### Advanced Clinical Reshttps://Cl
Dec-03 Nov-07 23-Jul-07 1-Mar-11 San Raffaele Hospitalhttps://Cl
Jul-03 Oct-05 ### 5-Feb-14 Ireland Cancer Centerhttps://Cl
Oct-03 Dec-04 Feb-05 1-Apr-08 1-Apr-08 https://Cl
Apr-03 Dec-05 Dec-05 ### ### https://Cl
Sep-08 May-11 Jul-11 7-Apr-09 ### https://Cl
Oct-03 Mar-10Mar-10 18-Oct-05 15-Jul-10 7-Dec-16 GSK Investigational S https://Cl
Mar-10 Oct-10 Oct-10 ### ### Hospital for Tropical https://Cl
Aug-02 Apr-03 Apr-03 ### 2-Oct-15 National Institute of https://Cl
Dec-04 Jun-06 Oct-06 ### 4-Jan-08 Cllinical Research Asohttps://Cl
Dec-04 4-Mar-05 6-Nov-13 Cancer Centers of Flohttps://Cl
Feb-13 Feb-14 Feb-14 15-Jan-13 9-Mar-15 ### Frontage Clinical Ser https://Cl
Apr-98 Sep-03 9-Feb-04 ### ### Cancer Center at the U https://Cl
### 24-Jun-05 Univ of Alabama at Bihttps://Cl
1-Dec-07 30-Dec-08 ### 4-Jan-08 22-Jan-10 ### GSK Investigational Sihttps://Cl
Jan-05 Jul-08 Jul-08 6-Apr-05 ### Abramson Cancer Cente https://Cl
May-12 Jan-15 Jun-15 30-Jun-11 20-Apr-17 22-Jun-17 Children's National Mhttps://Cl
May-04 Aug-07 Aug-07 ### ### Saint Louis Universityhttps://Cl
18-Jul-19 Dec-21 Dec-23 1-Apr-19 6-Feb-20 California Pacific Me https://Cl
Dec-00 Oct-02 ### 24-Jun-05 University of Connecthttps://Cl
23-Oct-17 13-Nov-18 ### 4-Aug-17 ### Hospital Universitari https://Cl
3-Jan-17 1-Sep-17 ### 10-Apr-17 10-Apr-17 Jorge Salmeron, Mexic https://Cl
18-Aug-16 31-Mar-17 ### 8-Jun-17 1-May-19 6-Nov-19 hVIVO Serv"Study Prohttps://Cl
URMC 15-001 Dec-20 1-Nov-16 ### University of Rochesthttps://Cl
May-10 Sep-11 Oct-11 2-Jan-12 2-Jan-12 Preventive Medicine https://Cl
31-Jan-01 31-Dec-18 ### ### 6-Dec-19 N.N. Petrov Researchhttps://Cl
Jan-07 Nov-09 Sep-10 6-Apr-07 14-Jan-14 Brussels, Belgium|Gehttps://Cl
Apr-20 Jun-21 Sep-21 ### ### WRAIR, Clinical Trials https://Cl
AVEG 006X|VEU 006|V0199g|11537 Feb-95 ### ### St Louis Univ School https://Cl
19-Dec-19 5-Aug-22 5-Aug-23 ### ### https://Cl
Oct-00 Dec-04 Dec-04 ### ### HealthPartners Reseahttps://Cl
Nov-19 May-21 Nov-21 ### ### H. Lee Moffitt Cancerhttps://Cl
Apr-91 ### 24-Jun-05 https://Cl
1-Jul-13 22-Dec-17 ### ### 9-Apr-18 PHRU, Chris Hani Barahttps://Cl
1-Jun-16 28-Jun-19 28-Jun-19 7-Oct-15 ### GSK Investigational S https://Cl
Jan-05 Sep-10 6-Apr-05 6-Nov-13 Jonsson Comprehensive https://Cl
Dec-10 Dec-12 Jul-13 9-Feb-10 22-Jan-20 Hadassah-Hebrew Univ https://Cl
26-May-08 3-Nov-08 3-Nov-08 ### 3-Dec-09 ### GSK Investigational Sihttps://Cl
Jan-02 Oct-07 Oct-07 27-Jan-03 8-Sep-14 Duke Comprehensivehttps://Cl
C
Mar-08 Oct-08 Nov-08 26-Jun-08 26-Jul-13 Faghihi Hospital Hemod https://Cl
1-Jan-19 May-19 ### 23-Apr-18 ### Bridge HIV CRS, San Frhttps://Cl
16-Jul-14 16-Jul-14 16-Jul-14 1-Aug-14 ### Malaria Research andhttps://Cl
Sep-11 May-12 May-12 7-Jun-11 11-Jan-17 Massachusetts Genera https://Cl
Sep-14 Sep-18 Sep-21 14-Jul-15 24-Oct-17 University Clinic of https://Cl
2-May-17 30-Dec-17 ### ### ### Chunan Center for Dihttps://Cl
24-Oct-12 25-Dec-12 Mar-13 3-Jan-13 16-Jul-18 National Taiwan Univehttps://Cl
May-14 Feb-15 Jun-15 1-Apr-14 16-Jul-15 Coastal Clinical Rese https://Cl
23-Feb-00 8-Oct-12 31-Jan-13 ### ### 11-Jun-19 University of Alabamahttps://Cl
Mar-08 Aug-11 Jan-13 10-Apr-08 ### Sidney Kimmel Compre https://Cl
Mar-07 Jan-12 Feb-16 9-Mar-07 ### University of Pittsbu https://Cl
Nov-10 24-Nov-15 17-Jul-19 ### 14-Jan-20 Mayo Clinic, Rochestehttps://Cl
Apr-15 Apr-16 Dec-17 5-May-15 ### University of Wisconshttps://Cl
Sep-15 4-Oct-18 4-Oct-18 ### 8-Nov-18 Centre for Clinical V https://Cl
11-Dec-06 18-Sep-09 ### ### ### 21-Apr-17 https://Cl
Aug-04 Dec-06 2-Sep-05 23-Jun-11 ICDDRB, Dhaka, Banghttps://Cl
ACTG 209|11186 Mar-93 ### ### UCLA CARE Center CRS, https://Cl
Dec-09 Jun-12 Nov-14 ### ### Tokyo Medical Univershttps://Cl
Jun-13 23-Mar-17 ### ### ### Grenoble University Hhttps://Cl
7-Mar-19 29-Feb-20 ### ### 23-Jan-20 National Institutes ofhttps://Cl
Nov-15 Jul-18 Jul-18 29-Apr-16 6-Sep-18 University of Marylanhttps://Cl
4-Aug-10 12-Dec-16 Dec-20 6-Aug-10 22-Jan-20 H. Lee Moffitt Cancerhttps://Cl
19-Dec-14 27-Mar-17 ### ### ### ### GSK Investi"Study Prohttps://Cl
May-06 May-07 May-07 16-Jun-06 ### ### https://Cl
Feb-10 Jan-14 May-15 1-May-13 ### Amistad de Los Angele https://Cl
28-Nov-18 31-Dec-21 1-Jul-22 3-Apr-19 8-Apr-19 INCLEN Trust, New Del https://Cl
15-Feb-13 26-Jun-14 26-Jun-14 10-Jan-13 5-Jan-17 18-Jul-19 University of Texas Mhttps://Cl
17-Jul-14 18-Dec-18 ### ### ### Jonsson Comprehensive https://Cl
22-Mar-05 15-Jan-08 ### 2-Jul-17 National Institutes ofhttps://Cl
Jul-13 Aug-13 Aug-13 8-Jul-13 ### CROSS Research S.A. -https://Cl
Sep-92 ### 24-Jun-05 https://Cl
Mar-02 Mar-06 Mar-06 ### ### NY Presbyterian Weillhttps://Cl
13-Apr-05 15-Jan-08 18-Apr-05 2-Jul-17 National Institutes ofhttps://Cl
13-Apr-18 30-Aug-20 ### ### ### GSK Investigational Sihttps://Cl
30-Oct-03 ### 5-Nov-03 ### National Institutes ofhttps://Cl
18-Jan-13 Aug-17 ### 1-Oct-12 1-Nov-18 ### The Sidney"Study Prohttps://Cl
May-08 Feb-09 Apr-09 ### ### Washington University, https://Cl
21-Jul-04 1-Apr-18 ### 26-Jul-04 16-Apr-19 16-Apr-19 National In"Study Prohttps://Cl
Nov-95 27-Jan-03 29-Apr-15 Warren Grant Magnuson https://Cl
May-08 Apr-09 Apr-09 ### ### The Institutute of Mehttps://Cl
Sep-05 Mar-07 May-09 ### ### Lombardi Comprehensi https://Cl
May-08 Apr-09 May-09 ### ### The Institute of Medihttps://Cl
Mar-05 May-05 May-05 5-Aug-05 29-Jan-15 https://Cl
Nov-15 Nov-18 Nov-18 ### ### https://Cl
Sep-09 Jul-12 Jul-12 ### ### University of Pennsyl https://Cl
Oct-02 Apr-10 8-Mar-10 ### Maria Sklodowska-Curhttps://Cl
CLIN-021-02S Sep-05 15-Apr-05 21-Jan-09 Durham VA Medical Ce https://Cl
Nov-16 Oct-26 Oct-26 14-Oct-16 5-Dec-19 UConn Health, Farminhttps://Cl
Jan-07 May-07 Dec-07 1-Feb-07 ### Center for Research &https://Cl
Jan-08 Jun-08 Jun-08 29-Jan-08 ### GSK Investigational S https://Cl
AVEG 016B|10566 Jan-99 ### ### UAB AVEG, Birmingham https://Cl
Nov-11 Dec-12 Jun-13 22-Oct-13 ### ### SATVI Project Office, https://Cl
Feb-20 Aug-20 Dec-20 ### ### CHU BesanÃ§on, Besahttps://Cl
Oct-15 Aug-19 Aug-19 ### 16-Oct-18 South Calgary Primaryhttps://Cl
AVEG 029|10579 Dec-97 ### ### UAB AVEG, Birmingham, https://Cl
Nov-09 Sep-10 Dec-11 ### 5-Feb-15 COPSAC, Gentofe/Cohttps://Cl
AVEG 034|AVEG 034A|10583 Aug-99 ### ### UAB AVEG, Birmingham, https://Cl
Dec-06 Feb-09 11-Jul-07 10-Jan-14 Greenebaum Cancer Cen https://Cl
Apr-06 Nov-06 Nov-06 ### 7-Oct-16 GSK Investigational Sihttps://Cl
28-Mar-16 15-Feb-17 ### 24-Apr-19 24-Apr-19 https://Cl
22-Feb-17 3-Oct-19 14-Jan-20 ### 18-Jan-20 National Institutes ofhttps://Cl
Sep-00 Jan-04 ### ### https://Cl
Nov-10 May-11 20-Jul-10 6-Jun-16 Mayo Clinic, Rochestehttps://Cl
Sep-10 Jan-12 Jun-12 11-Oct-10 ### NZOZ Vitamed, Bydgoszcz,
https://Cl
Poland|WojewÃ³dzki Spec
11-Mar-19 Nov-20 Nov-20 ### 10-Jul-19 Achieve Clinical Rese https://Cl
Apr-15 Aug-15 Jan-16 22-Jun-16 22-Jun-16 https://Cl
Apr-12 Dec-12 Dec-12 18-Apr-12 25-Apr-13 Sylhet, Bangladesh https://Cl
Dec-11 Apr-14 Apr-14 12-Jun-12 8-Dec-17 8-Dec-17 Marin Cancer Care, Inhttps://Cl
Apr-07 Nov-08 Nov-08 14-Jun-07 3-Apr-15 Banaras Hindu Univers https://Cl
Jun-10 Apr-11 May-11 ### ### https://Cl
Oct-11 Oct-11 Oct-11 ### ### Biomedical Research h Cttps://Cl
Dec-01 27-Jan-03 6-Jan-14 University of Alabamahttps://Cl
Aug-04 3-Sep-04 ### Walter Reed Army Inst https://Cl
2-Aug-18 31-Jan-21 1-Feb-22 21-Jun-18 9-Jan-20 Belfast Health and S https://Cl
Mar-00 May-06 ### ### University of Michigahttps://Cl
Oct-04 May-05 May-05 26-Apr-05 ### https://Cl
Feb-10 Feb-12 1-Jan-15 7-Jan-11 ### Department of Haemat https://Cl
May-06 Oct-08 Dec-08 27-Apr-06 21-Oct-10 5-Oct-12 Annapolis, Maryland,https://Cl
Jun-15 Jul-20 Jul-23 7-Mar-14 ### Immunobiology Labs hCttps://Cl
Aug-10 Mar-11 Aug-11 ### ### Hammersmith Medicin https://Cl
Jun-08 Jul-09 Nov-10 4-Jul-08 ### Cytos Biotechnology (https://Cl
Mar-06 Jun-07 Jun-07 ### 4-Nov-16 GSK Investigational S https://Cl
May-05 Dec-09 Dec-09 2-Aug-05 7-Jan-10 Prince of Wales Hospihttps://Cl
Feb-13 Dec-13 9-Feb-11 30-Jan-13 https://Cl
Jun-04 ### ### University of Rochesthttps://Cl
1-Mar-10 19-Nov-10 ### ### 10-Apr-17 6-Jun-18 GSK Investigational S https://Cl
Aug-18 Jan-19 Mar-19 ### ### https://Cl
Dec-10 Jan-16 Jan-16 ### 26-Apr-16 Centre for Clinical https://Cl
Mar-07 May-08 Sep-11 3-Jul-09 3-Jul-09 Swedish Institute for https://Cl
May-10 Jan-12 Jan-12 2-Sep-10 ### Centre for Clinical V https://Cl
Jul-09 Apr-11 Jul-12 10-Jul-09 ### The Center for Familyhttps://Cl
Nov-02 May-04 Sep-04 28-Jan-08 19-Oct-12 https://Cl
14-Dec-16 18-Oct-24 18-Oct-24 31-Oct-16 13-Jan-20 Alta, Brazil|Brasilia https://Cl
Jan-00 Mar-06 Mar-06 ### ### Dana-Farber Cancer In https://Cl
May-09 Dec-10 Dec-10 ### ### 4-Apr-12 University of Florida, https://Cl
May-07 Dec-08 Feb-09 ### 8-Jun-11 Benchmark Research,https://Cl
S
Jul-07 Dec-09 Dec-09 9-Aug-07 30-Jul-12 UT MD Anderson Cance https://Cl
Apr-10 Jul-11 ### 13-Jul-11 National Taiwan Univehttps://Cl
18-Apr-18 1-Mar-21 1-Mar-21 ### ### ZiekenhuisNetwerk An https://Cl
25-Mar-19 Sep-20 Sep-20 ### ### Integrative Physiologyhttps://Cl
Jun-06 Feb-11 Jul-11 14-Jul-08 10-Jul-14 Menzies School of Hea https://Cl
Oct-07 Dec-08 Dec-08 ### 1-Oct-10 ### University of Rochesthttps://Cl
22-Feb-19 31-Jan-24 31-Jan-26 ### 3-Jun-19 Beth Israel Deaconesshttps://Cl
Dec-14 Nov-16 8-Sep-20 ### 4-Dec-19 Alabama CRS, Birminghttps://Cl
Jul-97 Feb-01 Feb-01 ### ### Univ of Alabama at Bihttps://Cl
### 24-Jun-05 Dr Frank Judson / Dirhttps://Cl
Feb-99 Jul-01 Jul-01 ### 23-Oct-15 https://Cl
21-Jul-16 18-Oct-18 18-Oct-18 14-Oct-16 ### 001, Seoul, Korea, Rehttps://Cl
Apr-04 Oct-17 Oct-17 ### ### https://Cl
Nov-07 30-Jun-18 ### ### 7-Jun-18 University of Chicagohttps://Cl
Oct-09 Jul-10 Jul-10 ### 19-Oct-10 Ordination Schmitz, Vhttps://Cl
Apr-03 Sep-04 Sep-04 ### ### GSK Investigational Sihttps://Cl
Oct-13 31-Oct-19 31-Oct-20 ### 9-Jul-19 Centre for Clinical V https://Cl
Nov-99 27-Jan-03 9-Feb-09 St. Elizabeth's Medic https://Cl
21-Sep-11 Oct-16 ### ### 8-May-18 8-May-18 H. Lee Moffitt Cancerhttps://Cl
8-Sep-11 31-Jul-20 ### 5-Feb-20 Ohio State Universit https://Cl
Apr-11 May-14 Apr-15 ### 7-Sep-18 Phoenix, Arizona, Unihttps://Cl
Jul-02 Jul-05 21-Jun-06 7-Jan-09 National Institute of https://Cl
Mar-07 Dec-08 Jan-09 ### 17-Apr-12 Nanning, Guangxi, Chhttps://Cl
Mar-20 Apr-23 Apr-23 4-Oct-19 30-Jan-20 Dana Farber Cancer I https://Cl
Jan-15 Jun-16 Jun-16 ### 16-Oct-17 University of Alabamahttps://Cl
1-Apr-19 Apr-20 Apr-20 9-Feb-17 ### San Francisco Veterans https://Cl
4-Dec-06 ### 6-Dec-06 2-Jul-17 National Institutes ofhttps://Cl
Oct-11 Aug-15 Aug-15 5-Oct-11 ### Center for Cancer Im https://Cl
May-13 Oct-19 Dec-19 1-Mar-13 17-Apr-19 Healthcare center Mahttps://Cl
AVEG 201|10588 Dec-97 ### ### UAB AVEG, Birmingham, https://Cl
Oct-04 Apr-05 Apr-05 ### ### Division of General P https://Cl
Nov-13 Feb-15 Feb-15 ### ### Prism Research, Sainthttps://Cl
May-06 Aug-06 ### ### GSK Investigational S https://Cl
25-Jun-08 20-May-14 ### 3-Jul-08 ### National Institutes ofhttps://Cl
Dec-01 Jun-05 Jun-05 ### ### https://Cl
Aug-11 Apr-12 May-12 ### ### Chifeng, Inner Mongolhttps://Cl
2-Nov-15 23-Sep-16 ### 5-Sep-17 ### https://Cl
15-Jun-10 8-May-12 8-May-12 22-Jun-10 8-Oct-13 ### GSK Investigational Sihttps://Cl
Oct-11 May-12 May-12 20-Oct-11 ### Express Scripts, Saint https://Cl
May-03 Jan-04 16-Oct-07 7-Sep-16 GSK Investigational Sithttps://Cl
8-Feb-01 12-Jan-08 12-Jan-08 ### 24-Jan-13 20-Oct-17 National Institutes ofhttps://Cl
1-Jun-05 1-Jan-06 20-Jan-06 ### ### 9-Jun-17 GSK Investigational S https://Cl
Jun-04 Jun-05 ### ### University of Rochesthttps://Cl
Oct-06 12-Jun-06 23-Jan-19 Virginia Commonwealth https://Cl
18-Jan-05 10-Oct-07 21-Jan-05 2-Jul-17 National Institutes ofhttps://Cl
Mar-20 May-23 May-27 ### ### https://Cl
Jan-07 Sep-07 Dec-07 1-Feb-07 ### Center for Research &https://Cl
28-Nov-12 30-Mar-13 ### ### 7-Jan-20 National Taiwan Univshttps://Cl
May-15 30-May-18 ### ### 1-Jun-18 Ovarian Cancer Resear https://Cl
Jun-15 Sep-17 Dec-17 8-Jun-15 8-Jun-15 Chris Hani Baragwanahttps://Cl
Mar-06 Apr-08 ### ### Johns Hopkins Centerhttps://Cl
Aug-12 Aug-13 Aug-13 ### 1-Sep-14 https://Cl
Jan-11 Aug-12 6-Apr-17 12-Jul-10 ### Brigham and Women's https://Cl
Oct-14 Dec-15 Dec-15 ### ### LinkÃ¶ping Universit https://Cl
Jul-05 Nov-06 Nov-06 28-Jul-05 ### Walter Reed Army Inst https://Cl
Nov-06 Apr-07 20-Jun-07 ### https://Cl
Nov-07 Jul-08 Sep-10 ### 25-Oct-11 9-Dec-16 GSK Investigational Sihttps://Cl
Apr-07 Jan-08 Jan-08 ### 31-Jan-11 GSK Investigational S https://Cl
Mar-13 May-13 May-13 5-Apr-13 ### ### Genova Clinical Reseahttps://Cl
22-Aug-16 19-Aug-18 ### ### ### https://Cl
Oct-02 May-03 ### 3-Oct-06 Berchem, Belgium|Bru https://Cl
CYT004-MelQbG10 02 ### ### Centre Pluridisciplin https://Cl
18-May-04 1-Oct-09 1-Oct-09 ### 2-Jul-17 National Institutes ofhttps://Cl
Jan-10 Dec-14 ### 12-Jul-13 University Hospital https://Cl
Apr-01 Nov-01 ### 3-Oct-06 Department of Familyhttps://Cl
Mar-08 Mar-09 Nov-09 19-Jun-08 2-Dec-09 CRS Mannheim, Mannhe https://Cl
30-Jan-17 23-Dec-18 ### 1-Sep-17 ### ClinicalTrial Site, H https://Cl
Oct-13 Dec-14 Dec-14 ### ### General Practices, Gr https://Cl
Mar-01 Aug-06 19-Oct-05 19-Oct-05 South African Tubercuhttps://Cl
DC Prostate 19-Jan-11 22-Jul-11 Oslo university Hospihttps://Cl
Jan-99 May-01 ### 8-Feb-13 University of Alabam https://Cl
Jun-05 Aug-05 Aug-05 ### ### University of Marylanhttps://Cl
Apr-12 1-Apr-15 1-Apr-15 8-Nov-12 ### Cliniques Universitairhttps://Cl
CYT004-MelQbG10 01 ### ### Dept. of Dermatology,https://Cl
Feb-04 May-06 1-Mar-04 4-Mar-08 National Institutes ofhttps://Cl
Mar-01 Oct-11 Oct-11 ### 3-May-19 Cedars Sinai Medical h c ttps://Cl
Dec-07 Nov-12 Nov-12 18-Jan-08 ### ### Memorial Sloan Kettehttps://Cl
Dec-05 Nov-06 ### ### Hospital de Ninos, "Rhttps://Cl
20-Apr-16 Jan-21 Oct-21 29-Jun-16 ### Centre Hospitalier RÃhttps://Cl
Nov-04 Nov-07 11-Jul-05 ### University of Virginia https://Cl
20-Mar-20 20-Dec-20 20-Jun-21 ### 27-Jan-20 Henan Province Centehttps://Cl
6-Jul-18 17-Jan-20 17-Jan-20 ### 23-Jan-20 Bliss Healthcare Serv https://Cl
Apr-01 Jul-03 ### ### PharmPlanNet Contr https://Cl
Nov-09 Mar-11 Mar-11 ### ### ### Brooke Army Medicalhttps://Cl
C
Feb-18 Jan-19 Mar-19 ### ### https://Cl
Jun-10 Oct-11 Oct-11 22-Jun-10 ### ### Vince and Associates https://Cl
May-08 Oct-09 Oct-09 ### ### The Institutute of Mehttps://Cl
2-Jan-18 Dec-19 Dec-19 ### 16-Jul-19 Chan Soon-Shiong Inst https://Cl
Oct-00 Oct-04 30-Jun-05 ### Johns Hopkins Univershttps://Cl
Feb-09 Dec-09 Dec-09 4-Jun-13 5-Jun-13 Seoul National Univers https://Cl
Jan-04 Sep-08 Sep-08 20-Jul-04 ### University of Califor https://Cl
Sep-08 Jun-10 Jun-10 21-Oct-08 23-Jan-14 4-May-16 Zentrum fÃ¼r Reiseme https://Cl
Mar-02 Aug-03 Aug-03 ### 7-Oct-15 https://Cl
Aug-13 Mar-16 Mar-16 9-Aug-13 20-Apr-16 Geneva University Hos https://Cl
14-Jan-19 31-Dec-20 ### 22-Oct-18 23-Jan-20 UT Health San Antonio https://Cl
Dec-05 Feb-07 Dec-07 ### ### 14-Apr-16 Atlanta, Georgia, Uni https://Cl
Oct-16 Jun-17 Jun-17 7-Dec-16 26-Jul-17 Pizhou City Center fo https://Cl
Feb-02 Nov-02 ### 3-Oct-06 Department of Microbi https://Cl
Oct-02 Jun-03 ### 3-Oct-06 Schneider Children's M https://Cl
Apr-03 Jun-09 May-12 ### ### 16-Apr-14 The University of Chichttps://Cl
28-Mar-18 30-May-18 ### 29-Oct-18 29-Oct-18 Ã‡ankÄ±rÄ± Karatekinhttps://Cl
30-Oct-18 30-May-19 ### ### ### Blackpool Teaching Hhttps://Cl
Oct-06 Mar-11 Mar-11 ### ### ### Memorial Sloan-Kettehttps://Cl
29-May-18 22-Oct-18 22-Oct-18 15-Jun-17 ### GSK Investigational S https://Cl
May-14 Feb-15 Jun-15 ### 2-Jul-18 Coastal Clinical Rese https://Cl
Dec-17 Jan-19 Mar-19 ### ### https://Cl
May-08 Apr-09 Apr-09 7-May-08 ### The Institute of Medihttps://Cl
Apr-14 Dec-15 Apr-16 16-Apr-14 ### Institute of Tropical https://Cl
May-08 Apr-09 Apr-09 7-May-08 ### The Institute of Medihttps://Cl
May-04 Jan-07 12-Jul-04 ### Institut Jules Bordet https://Cl
Sep-07 Sep-07 ### 23-Jan-19 Saint Louis Universityhttps://Cl
Jan-06 Mar-08 Mar-08 25-Jan-07 ### West Coast Clinical Trhttps://Cl
Jan-06 15-Apr-17 Jan-20 ### ### Duke University Medic https://Cl
Nov-03 ### ### https://Cl
Mar-06 Dec-06 Dec-06 7-Mar-06 29-Jan-09 NYU Clinical Cancer Chttps://Cl
23-May-18 30-Jun-20 30-Jun-23 ### ### The Catholic Universihttps://Cl
May-12 Mar-14 Mar-14 ### 2-Sep-16 Instituto de Atencionhttps://Cl
1-Jun-18 31-Mar-19 30-Jun-19 11-Jan-19 ### Clinical Trail Unit ( https://Cl
Jan-15 Jul-22 Jul-22 ### ### University of Alabamahttps://Cl
Dec-17 Feb-19 Apr-19 23-Jun-17 ### https://Cl
Oct-06 May-08 May-08 11-Jul-06 4-Nov-10 ### https://Cl
Jul-05 ### ### Indiana University Sc https://Cl
8-Oct-15 20-Jan-16 20-Jan-16 ### 2-Apr-19 16-Apr-19 https://Cl
Jan-09 May-10 May-10 5-Feb-10 7-Sep-15 CSL Donor Plasma Cent https://Cl
Oct-10 Sep-11 Sep-11 ### ### Sanofi Pasteur MSD Inhttps://Cl
Oct-09 Sep-12 Sep-12 14-Oct-09 ### Maastricht Universityhttps://Cl
Jun-04 Jan-07 6-Feb-03 24-Jan-13 Gynecologic Oncologyhttps://Cl
DMID 97-004 Nov-05 ### ### AIDS Ctr, New York, Nhttps://Cl
Feb-04 Feb-06 Feb-06 11-Jun-04 2-Feb-15 Norris Cotton Cancer https://Cl
Mar-99 Aug-00 ### 24-Jun-05 Kachit Choopanya, Kl https://Cl
May-10 Dec-12 Dec-13 30-Jun-11 30-Jun-11 University Hospital fohttps://Cl
6-Nov-19 1-Dec-20 ### 16-Oct-19 8-Nov-19 ECO-Safety, Sankt-Pethttps://Cl
Jun-10 Jun-14 Dec-14 ### ### https://Cl
1-Jun-06 1-Nov-07 6-Nov-07 ### 23-Oct-09 ### GSK Investigational Sihttps://Cl
Nov-15 Jul-16 ### 21-Oct-15 ### 14-Jan-20 https://Cl
Jun-05 13-Oct-05 16-Oct-08 https://Cl
Oct-09 Jul-10 Jul-10 ### ### Mount Sinai Hospital,https://Cl
Jan-15 14-Jun-16 14-Jun-16 ### 23-Jul-19 Icahn School of Medichttps://Cl
Sep-04 Oct-07 ### ### Medical Arts Health https://Cl
13-Jun-00 ### 19-Jun-00 2-Jul-17 National Cancer Insti https://Cl
Sep-09 Jul-16 Jul-16 2-Oct-09 9-Jul-18 9-Jul-18 University of Alabam https://Cl
Sep-10 Feb-15 Feb-15 4-Jun-10 9-Jan-17 University of Iowa - https://Cl
Nov-09 Sep-11 Jun-12 8-Dec-10 ### Benson-Henry Instituthttps://Cl
AVEG 016A|10565 Sep-97 ### ### St. Louis Univ. Schoo https://Cl
25-Apr-06 2-Dec-09 2-Dec-09 3-May-06 2-Jul-17 National Institutes ofhttps://Cl
Feb-10 Sep-11 Oct-11 ### ### University of South Ahttps://Cl
26-Apr-05 22-Jan-08 2-May-05 2-Jul-17 National Institutes ofhttps://Cl
AVEG 016|10564 May-95 ### ### St. Louis Univ. Schoo https://Cl
Feb-11 Oct-13 Jan-17 ### ### UZ Brussel, Jette, Br https://Cl
Sep-01 Dec-01 ### ### Monroe Clinic, Monrohttps://Cl
26-May-11 13-Mar-13 ### 26-Apr-11 10-Apr-19 30-Apr-19 https://Cl
Jun-08 Jul-09 Aug-09 23-Jun-08 ### Medical Research Unihttps://Cl
8-Oct-03 3-Nov-05 1-Jun-15 ### 4-May-10 ### https://Cl
Aug-01 Jan-03 Jun-05 9-Jan-02 ### Universtiy of Southerhttps://Cl
Mar-00 30-Jul-07 30-Jul-07 GSK Clinical Trials Ca https://Cl
1-Nov-15 7-Feb-17 25-Apr-17 ### ### https://Cl
Dec-00 ### 7-Aug-13 Jonsson Comprehensive https://Cl
May-06 Dec-08 Aug-09 ### ### Desmond Tutu TB Cent https://Cl
1-Aug-05 1-Mar-08 1-May-08 ### 3-Sep-12 ### University of Rochesthttps://Cl
Mar-12 Dec-14 Mar-15 ### ### UniversitÃ¤tsklinik f https://Cl
May-06 Jan-07 Dec-07 ### ### West Coast Clinical T https://Cl
Jun-06 Feb-07 14-Jun-06 19-Apr-07 Seoul National Univers https://Cl
AVEG 025|11541 ### ### https://Cl
Mar-03 Jan-09 6-Nov-03 ### Stanford Cancer Centehttps://Cl
Jan-12 Dec-12 Apr-13 ### 29-Apr-13 Leiden University Med https://Cl
Aug-06 Dec-07 Dec-10 ### ### Cantonal Hospital St.Ghttps://Cl
Jul-03 Mar-14 Mar-14 ### ### Dermatologische Klinihttps://Cl
Nov-05 Jan-07 ### 6-Jun-13 National Cancer Insti https://Cl
14-Aug-17 Oct-18 Dec-18 2-May-17 ### Chan Soon-Shiong Inst https://Cl
Apr-16 Jun-19 Dec-19 ### ### William Harvey Reseahttps://Cl
Feb-08 May-08 May-08 ### 10-Oct-12 12-Apr-17 https://Cl
14-Oct-17 Jan-20 Jul-20 17-Jan-18 5-Nov-19 Bandim Health Projechttps://Cl
Sep-01 Sep-02 Sep-02 ### ### https://Cl
Nov-00 Dec-00 ### 25-Oct-06 Stamford Hospital, Sthttps://Cl
Sep-02 Jun-04 Jun-04 ### 10-Jul-09 ### https://Cl
Nov-05 Jan-13 Jan-13 ### ### ### Sidney Kimmel Compre https://Cl
May-09 Feb-12 May-14 18-Jun-09 ### RWTH Aachen, Aachen, https://Cl
Sep-03 Sep-05 17-Oct-03 11-Jul-06 https://Cl
Oct-16 Jul-17 Dec-17 8-Nov-16 8-Sep-17 Imperial Centre for https://Cl
A5058s|10674|ACTG A5058s|AACTG A50 Sep-04 ### 22-Jul-13 UCLA CARE Center CRS, https://Cl
3-Aug-15 31-Aug-18 30-Jun-19 6-Nov-17 11-Jan-19 Angkor Hospital for https://Cl
Jul-04 Jul-08 ### ### Seoul, Korea, Republihttps://Cl
HVTN 102|11937 Apr-14 Apr-14 17-Oct-13 ### https://Cl
Feb-08 Dec-11 Mar-12 ### 21-Jul-11 Teikyo University, 2-1https://Cl
23-Jun-17 2-Nov-17 9-Aug-18 15-Jun-17 6-Feb-19 Investigational site 1 https://Cl
23-Jan-19 Oct-21 Dec-22 30-Jul-18 ### Sukuta Health Centre,https://Cl
Jun-10 Jun-13 Jun-13 ### 14-Jul-14 14-Jul-14 Northern California Khttps://Cl
Jan-11 Aug-11 Aug-11 ### ### NicVAX Investigator, https://Cl
Sep-10 Sep-12 Sep-12 2-Sep-10 ### ### Baolixiang Clinic, Ba https://Cl
Mar-05 Mar-05 Sep-05 9-Dec-05 ### GSK Investigational Site,
https://Cl
AlmerÃa, Spain|GSK Investig
2-Apr-19 4-Oct-19 4-Oct-19 ### 1-Nov-19 Up0034 001, San Anton https://Cl
May-11 Sep-11 Sep-11 ### ### 9-Sep-13 Research Institute forhttps://Cl
15-Sep-15 Aug-16 Aug-16 3-Aug-18 ### Guangxi Provincial Cehttps://Cl
Jul-13 Jul-18 Jul-30 ### 8-Jan-18 Massachusetts Genera https://Cl
Feb-01 Oct-06 ### 31-Jul-13 Alabama Therapeuticshttps://Cl
Jun-11 Feb-13 Feb-13 23-Jun-11 5-Mar-13 Isumi-shi, Chiba, Ja https://Cl
1-Jan-16 1-Sep-16 1-Aug-17 ### ### https://Cl
Jul-09 Oct-12 6-Aug-09 ### ### South African Tuberculhttps://Cl
Dec-09 Jun-15 Jun-15 ### 2-Aug-16 26-Oct-16 307 Hospital of Chinehttps://Cl
17-Dec-19 30-Dec-20 ### 29-Jul-19 ### CMAX Clinical Researchhttps://Cl
Aug-96 Jul-03 11-Jul-03 4-Apr-13 Earle A. Chiles Resea https://Cl
Apr-96 22-Jan-04 10-Jan-14 Kimmel Cancer Centerhttps://Cl
May-12 Dec-15 Dec-15 2-Apr-12 25-Apr-16 GSK Investigational Sihttps://Cl
Feb-06 Jul-08 Jul-08 28-Jan-08 ### Prof. Dr. Ulrich Spen https://Cl
A5057|10673|A5058s|ACTG A5057|AAC Sep-05 ### ### USC CRS, Los Angeles,https://Cl
Nov-05 Oct-06 Nov-06 ### 3-Jun-13 Saint Louis Universityhttps://Cl
Oct-06 Dec-08 Apr-10 ### 5-Nov-14 8-Dec-15 Universtiy of Michig https://Cl
Sep-00 Apr-02 May-02 ### 10-Apr-09 Tampere University Mhttps://Cl
28-May-18 14-Jul-18 ### ### ### MÃ©decins Sans Front https://Cl
1-Dec-19 1-Dec-20 1-Dec-22 9-Jan-17 9-Aug-19 UCLA / Jonsson Compre https://Cl
Sep-04 Dec-04 Sep-05 5-Sep-07 14-Jan-14 Halifax, Nova Scotia https://Cl
Jan-16 Apr-17 Apr-18 12-Apr-17 12-Apr-17 Upstate Medical Unive https://Cl
1-Aug-19 1-Aug-20 1-Dec-20 ### ### Universidad Nacionalhttps://Cl
17-Oct-11 Oct-20 Oct-20 20-Oct-11 17-Jul-19 Memorial Sloan Kettehttps://Cl
Nov-10 Dec-18 Dec-18 5-May-11 24-Oct-17 Clinica Universidad d https://Cl
19-Jun-19 6-Jan-20 31-Jul-20 9-Oct-18 22-Jan-20 University of Alabamahttps://Cl
6-Nov-17 Nov-18 Dec-19 1-Nov-17 ### Chan Soon-Shiong Inst https://Cl
Jun-13 Feb-15 25-Jun-13 ### Studienzentrum der Phttps://Cl
Apr-14 Dec-17 Dec-17 14-Jul-14 ### Canadian Center for Vhttps://Cl
18-Mar-17 Mar-22 Dec-22 4-Apr-17 15-Oct-18 University Children's https://Cl
Dec-17 Jan-19 Mar-19 23-Jun-17 ### https://Cl
Jul-03 Aug-05 8-Jul-03 ### University of Marylanhttps://Cl
16-Mar-18 Dec-19 Jan-20 ### ### Chan Soon-Shiong Inst https://Cl
Jul-09 Jun-11 Jun-11 14-Jan-10 1-Nov-11 St Stephen's Centre, https://Cl
Oct-09 Nov-09 Apr-10 ### ### University of Pennsyl https://Cl
Apr-12 Jul-12 Nov-12 6-Jan-12 3-Jul-13 12-Apr-17 https://Cl
Oct-05 Sep-07 Sep-07 25-Apr-07 4-Apr-08 University of Oxford, https://Cl
May-08 May-11 Feb-12 18-Jul-08 18-Jul-08 King's College Hospi https://Cl
16-Aug-19 31-Dec-21 ### 2-Oct-19 2-Oct-19 Mayo Clinic, Rochestehttps://Cl
Mar-06 Nov-06 21-Apr-06 7-Oct-16 GSK Investigational S https://Cl
Feb-20 Jul-23 Jul-23 16-Oct-19 16-Oct-19 https://Cl
Aug-06 Dec-08 Dec-09 ### ### University of Yamanashttps://Cl
8-Oct-09 3-Sep-10 3-Sep-10 16-Oct-09 2-Jul-17 National Institutes ofhttps://Cl
9-Aug-19 Feb-21 ### 1-Mar-19 6-Sep-19 St. Jude Children's R https://Cl
30-Oct-19 31-Jan-21 30-Apr-21 ### ### Mayo Clinic in Rocheshttps://Cl
Nov-14 Sep-15 Apr-16 ### 28-Apr-16 University of Calgary https://Cl
Jul-13 May-14 Jul-14 12-Jun-13 4-May-15 3-Mar-17 Hospital General de Nhttps://Cl
Jul-09 Jan-14 Jan-14 9-Jul-09 26-Jan-16 NYU Langone Medicalhttps://Cl
25-Aug-17 12-Apr-18 12-Apr-18 13-Apr-18 8-May-18 SIAAP, Maisons-Laffitthttps://Cl
Feb-12 Sep-15 5-Mar-12 3-Jun-15 Artesis College Antw https://Cl
Jun-09 Apr-16 Apr-16 26-Jun-09 7-Dec-18 Radboud University Nhttps://Cl
30-Jan-17 30-Jan-22 30-Jan-22 6-May-19 ### Assessoria Clinica / B https://Cl
Mar-14 Mar-14 Mar-14 ### 22-Jan-20 Medical Oncology Asso https://Cl
Dec-11 Oct-14 Dec-14 6-Dec-11 8-Jun-15 Clinic of General Sur https://Cl
12-Apr-18 11-Jul-19 11-Jul-19 ### 4-Sep-19 Ifakara Health Instituthttps://Cl
Jan-08 Dec-09 Dec-10 29-Jun-10 2-Dec-11 https://Cl
Nov-16 May-21 May-21 1-Sep-16 ### Massachusetts general https://Cl
CDR0000067277|NCI-99-C-0132 Mar-07 5-Mar-07 20-Jun-13 https://Cl
25-May-18 23-Aug-19 ### 20-Jun-18 ### Chan Soon-Shiong Inst https://Cl
Feb-01 7-Aug-03 30-Apr-15 Medicine Branch, Bethttps://Cl
4-May-15 23-Oct-19 ### ### ### Massachusetts General https://Cl
Jul-07 Nov-07 Sep-08 ### 27-Oct-08 Site 21, Helsinki, Fi https://Cl
Oct-13 Feb-16 Feb-16 17-Jun-13 ### Gem and Asembo Area https://Cl
Feb-08 Nov-14 Nov-14 ### 8-Dec-16 Radboud University Nhttps://Cl
15-Feb-17 Feb-20 Feb-20 8-Jun-18 9-Aug-19 Southampton NIHR Clihttps://Cl
Nov-02 Aug-09 Oct-11 11-Jul-13 ### https://Cl
Nov-14 Jun-15 Jun-15 ### 22-Jan-20 Hadassah-Hebrew Univ https://Cl
13-Jan-18 Dec-19 Dec-19 ### 16-Jul-19 Chan Soon-Shiong Inst https://Cl
3-Sep-03 29-Jun-11 ### 2-Jul-17 National Institutes ofhttps://Cl
May-03 Jul-06 7-Aug-03 26-Apr-11 Memorial Sloan-Kettehttps://Cl
3-Nov-17 30-Nov-18 ### 7-Nov-17 ### Research Institute of https://Cl
May-09 Oct-12 Oct-12 8-Aug-08 5-Nov-12 Columbia University M https://Cl
Jul-14 Dec-15 Dec-15 4-Aug-14 13-Apr-16 Bridge HIV CRS, San Fhttps://Cl
Apr-19 Jan-21 Jan-24 6-Jun-18 ### Istituto Scientifico R https://Cl
25-Nov-13 19-Apr-16 ### ### 25-Jan-19 https://Cl
Jan-01 Dec-04 Oct-08 27-Jan-03 30-Oct-15 Jonsson Comprehensive https://Cl
Jun-07 Aug-07 Aug-07 23-Jul-08 23-Jul-08 Pediatric Medical Grou https://Cl
Jul-10 Jan-12 Jan-12 7-Jul-10 ### ### Clinical Trials Center https://Cl
Apr-13 Oct-14 Oct-14 3-May-16 4-May-16 https://Cl
Jun-12 Dec-12 Mar-13 ### 8-Mar-13 UCLH Foundation Trushttps://Cl
May-11 May-13 May-14 5-Dec-14 24-Oct-17 https://Cl
27-Jan-10 ### ### 5-Apr-18 Proyecto Epidemiologihttps://Cl
30-Jun-20 Dec-22 Dec-24 29-Jan-20 29-Jan-20 https://Cl
Jan-10 Jan-11 Jan-11 ### 9-Sep-11 https://Cl
Dec-03 Nov-10 Nov-10 ### ### Radboud University Nhttps://Cl
Apr-14 Jan-18 ### ### 9-May-18 Seoul National Univers https://Cl
10-Dec-15 Nov-19 Nov-19 ### ### Ohio State Universit https://Cl
23-Dec-15 31-Dec-20 ### 27-Apr-15 ### University of Texas Mhttps://Cl
19-Jun-19 22-Dec-20 ### ### 14-Jan-20 Alabama Clinical Therhttps://Cl
20-Jul-19 20-Oct-20 ### 4-Feb-19 ### Clinical Associates o https://Cl
Apr-11 May-13 Sep-13 2-May-11 ### 3-Jun-15 Birmingham, Alabama, https://Cl
Nov-10 Nov-12 Mar-13 4-Nov-10 1-Jun-15 Children's Hospital o https://Cl
28-Jul-18 Dec-19 Dec-19 16-Jul-18 16-Jul-19 Chan Soon-Shiong Inst https://Cl
Jan-16 1-Jun-17 Nov-17 ### 23-Jan-20 National Cancer Insti https://Cl
A5120|10938|ACTG A5120|AACTG A5120 ### ### https://Cl
Dec-15 Dec-17 Dec-17 9-Nov-16 ### University of South Flhttps://Cl
May-06 Sep-08 Sep-08 28-Oct-05 ### North Central Neurolohttps://Cl
Nov-12 Mar-16 Mar-16 8-Nov-13 ### Mary Crowley Cancerhttps://Cl
R
Feb-04 Jun-05 Sep-05 5-Dec-08 12-Jan-10 14-Apr-16 Jonesboro, Arkansas, https://Cl
Jun-04 Jul-07 May-12 ### 24-Jun-13 24-Jun-13 University of Arkansahttps://Cl
Oct-09 May-10 May-10 3-Feb-11 ### ### https://Cl
Oct-08 Nov-08 Nov-09 ### ### University Medical C https://Cl
Mar-05 31-Dec-09 ### ### ### HealthCore, Inc., Wil https://Cl
Sep-09 Mar-12 Mar-12 20-Jan-10 11-Apr-12 Pain & Anaesthesia Res https://Cl
Jan-08 Mar-13 Jul-13 6-May-08 23-Jan-14 Duke University Medic https://Cl
3-Dec-10 27-Oct-12 27-Oct-12 ### ### ### GSK Investigational S https://Cl
21-Dec-05 25-Jun-09 25-Jun-09 ### 2-Jul-17 National Institutes ofhttps://Cl
Jul-03 Apr-04 24-Apr-06 9-Sep-16 GSK Investigational Sihttps://Cl
Oct-08 Apr-12 Apr-12 ### 16-Oct-12 Ophthalmology, Osaka https://Cl
Aug-16 Jun-23 Jun-24 8-Jun-15 6-Dec-19 University of Florida https://Cl
23-Sep-19 Apr-20 Dec-20 ### 1-Nov-19 University of Antwerphttps://Cl
A5046s|ACTG 328 (Main Study)|AACTG Nov-05 ### ### Univ. of Iowa Healthchttps://Cl
Jun-08 Aug-12 Aug-12 ### ### ### Research Site, Mobile,https://Cl
Alabama, United States|Resea
Jul-16 Apr-21 Oct-21 ### 19-Jun-19 Smilow Cancer Hospithttps://Cl
Apr-04 Jul-10 Nov-10 ### 17-Jun-19 17-Jun-19 The Ottawa Hospital, https://Cl
3-Jul-17 20-Dec-17 ### 29-Jun-17 13-Jun-18 CCVTM, University ofhttps://Cl
4-Sep-15 4-Sep-15 ### 9-Sep-15 ### Malaria Research andhttps://Cl
Jul-05 Dec-08 Dec-08 ### 16-Oct-17 US Military HIV Reseahttps://Cl
17-Dec-14 17-Apr-15 ### 9-Dec-14 14-Apr-17 Oxford, United King https://Cl
16-May-19 Aug-20 Dec-20 ### 31-Jul-19 School of Medicine athttps://Cl
1-May-18 31-Dec-21 ### 11-Apr-18 13-Jan-20 National Institutes ofhttps://Cl
26-Jun-19 1-Feb-27 1-Feb-27 26-Jun-19 22-Jan-20 Lingchuan Center for https://Cl
22-Jul-19 1-Mar-25 1-Mar-25 ### ### Duke University Medic https://Cl
Feb-08 Mar-08 Mar-08 3-Jun-08 23-Apr-09 Wilson Pharmacy, Johhttps://Cl
May-03 Jan-05 29-Jan-07 29-Jan-07 Centre for Clinical V https://Cl
15-Jun-09 8-Jan-15 17-Jun-09 ### National Institutes ofhttps://Cl
Apr-15 Dec-15 Sep-16 3-Mar-15 8-Dec-16 Mwanza, Tanzania|Enhttps://Cl
Oct-11 Dec-11 Dec-11 ### ### ### Centre for the Evaluahttps://Cl
Mar-15 Sep-15 Jun-16 3-Mar-15 8-Dec-16 Nairobi, Kenya https://Cl
Jul-09 Jul-10 Jan-11 10-Jul-09 7-Feb-11 Saint Louis Universityhttps://Cl
12-Feb-18 12-Feb-23 ### 24-Jan-17 ### Princess Margaret Canhttps://Cl
26-Nov-17 23-Sep-19 ### ### 15-Oct-19 Johnson County Clinichttps://Cl
Feb-14 28-Aug-17 6-Oct-17 3-Mar-14 29-Jul-19 4-Sep-19 South Afri "Study Prohttps://Cl
26-May-09 1-Jun-09 29-Jun-09 28-Jul-10 1-Jun-18 GSK Investigational Sihttps://Cl
24-Jul-19 Jul-20 Jul-20 31-Jul-19 ### Memoral Sloan Ketterhttps://Cl
12-Oct-15 Aug-20 Aug-20 ### 7-Nov-19 Duke University Medic https://Cl
Oct-09 Oct-14 Oct-14 ### 23-Oct-14 Oslo University Hospihttps://Cl
15-Oct-18 24-Dec-18 ### ### ### Federal state budgetahttps://Cl
Jun-08 Aug-09 Aug-09 25-Jun-08 ### 28-Oct-15 Warren Grant Magnuson https://Cl
Apr-11 Jun-12 Jun-12 7-Nov-10 22-Jan-14 Radboud University Nhttps://Cl
Aug-02 Nov-13 ### ### Bandim Health Projechttps://Cl
28-Aug-19 16-Nov-21 ### 11-Jul-19 ### Aalborg Universitetshhttps://Cl
Aug-09 Mar-11 May-11 ### 8-Jun-11 Immunovative Clinicalhttps://Cl
May-13 Mar-15 Mar-15 9-May-13 12-Oct-15 Medizinische Universihttps://Cl
9-Jul-18 May-20 May-21 ### 7-May-19 John Wayne Cancer Cen https://Cl
Oct-15 31-Dec-20 ### ### 22-Jan-20 University of Rochesthttps://Cl
Sep-08 Jun-10 Jun-10 20-Oct-08 ### University of Pennsylvhttps://Cl
Jun-06 Oct-06 Oct-06 1-Jun-06 ### GSK Investigational Sihttps://Cl
29-Apr-19 19-Mar-20 ### ### ### National Institutes ofhttps://Cl
15-Aug-15 10-May-17 10-Apr-18 ### ### https://Cl
Sep-09 Jun-10 Jan-11 30-Jul-09 27-Jan-11 St George's Vaccine I https://Cl
11-Aug-08 9-Jun-09 ### 2-Jul-17 Malaria Research andhttps://Cl
Apr-99 Apr-00 Sep-00 ### ### 10-Apr-15 https://Cl
Aug-07 Jun-12 Dec-12 ### 1-Mar-11 Bandim Health Projechttps://Cl
Mar-13 May-15 Sep-15 ### ### University of Coloradhttps://Cl
Jul-13 Dec-21 Jul-22 24-Jul-13 6-Sep-19 Mercy Hospital for Wo https://Cl
Sep-05 Nov-11 ### ### Centre Hospitalier Unhttps://Cl
Aug-97 26-Apr-04 ### Louisiana State Univehttps://Cl
Jan-03 Sep-04 6-Feb-03 19-Jun-13 Warren Grant Magnuson https://Cl
24-Nov-03 21-Dec-04 ### ### 3-Oct-18 ### GSK Investigational S https://Cl
Sep-16 Jan-18 Jan-18 30-Jan-17 28-Jul-17 Center for Vaccinologhttps://Cl
1-Apr-05 22-Dec-06 ### 13-Jun-05 2-Jul-17 National Institutes ofhttps://Cl
Oct-05 Jul-07 Jul-07 ### ### Stanford University, Shttps://Cl
Nov-09 Apr-10 Jul-10 6-Nov-09 6-Nov-09 Hadassah Medical Orga https://Cl
May-98 Feb-01 Feb-01 ### 25-Jun-13 Memorial Sloan-Kettehttps://Cl
Nov-11 Dec-16 Dec-16 25-Jan-12 ### Vancouver General, Vhttps://Cl
Jan-15 Jun-17 Feb-18 ### 18-Jul-17 Ottawa Hospital Resea https://Cl
Nov-96 27-Jan-03 2-Jul-12 Innsbruck Universita https://Cl
10-Sep-19 Nov-20 Aug-22 ### 7-Oct-19 Grand HÃ´pital de Chhttps://Cl
26-Mar-07 15-Jan-08 15-Jan-08 ### ### 4-Feb-19 https://Cl
Jul-08 Jul-08 Jul-08 ### ### 9-Sep-13 Covance Clinical Resehttps://Cl
Jun-10 Jul-10 Jul-10 1-Mar-11 ### 9-Sep-13 Covance Clinical Resehttps://Cl
26-Oct-16 Jul-22 Jul-22 ### ### Walter Sisulu Univer https://Cl
Jun-09 Jun-09 Jun-09 1-Mar-11 20-Jan-12 9-Sep-13 Covance Clinical Resehttps://Cl
Dec-13 Oct-16 Oct-16 8-Oct-13 2-Dec-16 Regionaal Ziekenhuis https://Cl
Heilig Hart Tienen Hospital, Tien
Oct-02 Jun-05 Jun-07 28-Jan-03 ### Dermatologische Klinihttps://Cl
May-97 Apr-01 ### 4-Mar-08 National Institute o https://Cl
Sep-05 Mar-11 Mar-14 ### 18-Apr-16 UPMC Cancer Centers, https://Cl
30-Dec-15 11-Feb-23 ### ### 18-Jan-20 Banner-University Med https://Cl
Jun-00 Dec-00 Oct-02 ### ### USC/Norris Comprehens https://Cl
Mar-99 29-Oct-03 6-Jan-14 Dana-Farber Cancer In https://Cl
22-May-03 7-Mar-06 8-Jun-09 7-May-03 ### 26-Oct-17 National Institutes ofhttps://Cl
30-Oct-15 28-Jan-16 28-Jan-16 9-Oct-15 ### ### https://Cl
20-May-18 14-Nov-19 ### 12-Apr-17 ### Americaninhas Vaccine https://Cl
Apr-10 Mar-11 Mar-11 5-Mar-10 6-Jun-13 Saint Luke's Hospital,https://Cl
Oct-03 Dec-09 Nov-10 6-Nov-03 ### Rutgers Cancer Instit https://Cl
Jun-94 Jan-02 4-Nov-99 4-Mar-08 National Cancer Insti https://Cl
Oct-09 Nov-09 Nov-09 1-Nov-09 19-Jul-11 The Hospital for Sick https://Cl
23-Jul-12 23-Jan-14 ### ### 15-Jan-19 https://Cl
Sep-11 May-15 Jul-15 ### ### Faisalabad, Punjab, Phttps://Cl
Oct-06 Nov-07 11-Oct-06 27-Jan-15 LMU-Munich, Departme https://Cl
26-Jan-17 Dec-20 Dec-20 ### 28-Jan-19 UAB Gynecology Oncolo https://Cl
Nov-97 Sep-00 ### 4-Mar-08 National Cancer Insti https://Cl
12-Dec-08 16-Nov-09 ### 13-Jun-08 8-Nov-19 8-Nov-19 https://Cl
May-14 Sep-14 Sep-14 15-Apr-14 ### Radboud University Nhttps://Cl
Nov-07 Dec-16 Dec-16 4-Nov-07 23-Jun-16 Clinical Trial Researc https://Cl
Oct-09 Dec-10 Dec-13 2-Mar-15 3-Mar-15 https://Cl
21-Feb-19 1-Mar-23 1-Mar-24 ### 8-Apr-19 National University Hhttps://Cl
1-Feb-17 Dec-26 Dec-26 ### 5-May-17 University of Copen https://Cl
ACTG 340|11311 ### 2-May-12 https://Cl
Sep-06 Nov-07 16-Apr-07 ### Centrum Badan Farmako https://Cl
17-Sep-18 10-Oct-19 10-Oct-19 ### 10-Jul-19 Celerion Belfast, Bel https://Cl
4-Jun-18 26-Jun-18 ### 3-Jul-18 7-Dec-18 Department of Interna https://Cl
A5024|10070|ACTG A5024|AACTG A502 Oct-05 ### ### Alabama Therapeuticshttps://Cl
1-Feb-06 15-Mar-07 ### ### 3-Aug-17 6-Jun-18 GSK Investigational Sihttps://Cl
May-09 May-11 May-11 20-Apr-10 8-Dec-11 Winkelhoferstr. 3, E https://Cl
12-Jul-16 Jul-20 Jul-20 7-Jan-16 6-Feb-20 The Sidney Kimmel Cohttps://Cl
Sep-02 Oct-07 27-Jan-03 19-Jun-13 Warren Grant Magnuson https://Cl
7-Jan-15 31-Mar-16 22-Oct-18 8-Jan-15 11-Apr-19 National Institutes o https://Cl
Oct-03 Jul-08 Jul-08 18-Oct-05 ### 8-Dec-16 GSK Investigational S https://Cl
Aug-01 Nov-07 Nov-07 ### ### https://Cl
Jun-11 Sep-13 Sep-13 29-Jan-10 24-Oct-13 Stanford University Schttps://Cl
Dec-01 Mar-07 Jun-10 27-Jan-03 19-Jul-16 Northeast Alabama Reg https://Cl
Jul-10 Apr-15 Apr-15 ### 4-Dec-18 Kaiser Permanente Vac https://Cl
Jun-00 Oct-01 Dec-01 ### ### 7-Aug-15 https://Cl
Jan-05 Mar-05 Dec-06 9-Mar-10 9-Mar-10 Malaria Vaccine and Dhttps://Cl
Mar-98 Sep-01 Nov-02 ### ### USC/Norris Comprehens https://Cl
Jun-11 Nov-15 Nov-15 ### 4-Jan-17 4-Jan-17 Seoul, Korea, Republihttps://Cl
Sep-13 Feb-16 Feb-16 21-Jun-13 27-Oct-17 Royal Free Hospital, https://Cl
Apr-10 Dec-10 Mar-11 29-Apr-10 ### Farmovs-Parexel, Bloehttps://Cl
Oct-12 Jul-13 Nov-13 4-Feb-13 2-Oct-15 Medical University ofhttps://Cl
ACTG 246/946|11223|11499 May-99 ### ### Stanford CRS, Stanford https://Cl
May-10 Jan-11 Jan-11 28-Oct-10 1-Apr-11 Project Office, Aga Khhttps://Cl
Jun-99 May-03 Apr-06 27-Jan-03 ### USC/Norris Comprehens https://Cl
23-Sep-19 12-Oct-20 ### ### ### https://Cl
20-Apr-04 23-Aug-07 ### 22-Apr-04 2-Jul-17 National Institutes ofhttps://Cl
ACTG 279|11255 ### ### https://Cl
Jul-06 Jun-08 Jun-09 23-Jun-06 3-Jun-16 Paris, France|Poznanhttps://Cl
Sep-09 Sep-12 Sep-13 ### ### Public Health Englandhttps://Cl
25-Apr-11 19-Sep-11 ### ### 7-Dec-16 ### GSK Investigational S https://Cl
17-Jun-20 1-Jun-22 1-Jun-22 ### ### https://Cl
Nov-11 Jan-13 Mar-13 ### 7-Jan-16 SGS LSS Clinical Pha https://Cl
Mar-07 Feb-13 Feb-13 ### 21-Jan-16 Duke University Medic https://Cl
May-10 Oct-12 Aug-13 26-Jan-10 ### Hospital, Hannover, https://Cl
Feb-02 Dec-04 Nov-07 27-Jan-03 ### USC/Norris Comprehens https://Cl
Mar-12 Dec-12 21-Apr-11 21-Apr-14 Fred Hutchinson Canchttps://Cl
Feb-15 Nov-16 Nov-16 5-Mar-15 ### Centre for Clinical V https://Cl
Nov-98 Nov-99 Sep-04 ### ### Beckman Research Inst https://Cl
Sep-05 Feb-13 Oct-13 ### 27-Jun-13 15-Jul-14 National Institutes o https://Cl
Apr-13 Jul-14 Jul-14 ### 8-May-17 Centre for Clinical V https://Cl
Jul-13 Dec-14 Dec-14 17-Jun-13 ### Centre for Clinical V https://Cl
11-May-17 18-Oct-18 18-Oct-18 ### ### SGS LSS Clinical Pha https://Cl
Dec-05 Jun-06 Jul-08 ### 14-Jun-12 Warren Grant Magnuson https://Cl
8-Mar-18 22-Sep-23 ### 11-Apr-18 4-Oct-19 GSK Investigational S https://Cl
Jul-09 Feb-12 Feb-12 13-Jan-10 ### Fred Hutchinson Cance https://Cl
Jun-10 Dec-11 Dec-11 3-Jun-09 ### Emory Children's Centhttps://Cl
Feb-07 May-08 May-08 ### ### UH-rouen, Rouen, Seihttps://Cl
Sep-00 Oct-06 27-Jan-03 8-Nov-11 CCOP - Scottsdale Onchttps://Cl
Jul-07 Aug-11 Sep-11 29-Apr-09 ### Lister Ward, Departme https://Cl
Mar-15 Dec-17 Dec-17 1-Jul-16 ### Leiden University Med https://Cl
May-07 Aug-07 Aug-07 ### 19-Jul-16 Chiltern Internationa https://Cl
May-03 Dec-06 ### 24-Oct-07 University of Cape Tohttps://Cl
8-Mar-05 2-Jul-08 21-Jun-06 2-Jul-17 National Institute of https://Cl
Jun-95 Apr-00 ### 4-Mar-08 National Cancer Insti https://Cl
Mar-08 Jun-08 Jun-08 ### 26-Jun-12 ### https://Cl
7-Mar-05 17-Jun-08 ### 2-Jul-17 Johns Hopkins Schoolhttps://Cl
Apr-11 Jan-12 Mar-12 11-Oct-10 2-Apr-12 Leiden University Med https://Cl
Dec-18 Dec-20 Dec-20 ### ### The First Affiliated https://Cl
Jan-06 May-10 May-10 9-Jan-06 ### 19-Oct-12 National Cancer Insti https://Cl
Nov-09 Jun-10 Jun-10 ### ### ### Quintiles Drug Resea https://Cl
Sep-06 Apr-07 ### 19-Oct-07 Imperial College, Uni https://Cl
Dec-10 Apr-13 Apr-13 ### ### Privatklinik Leech, G https://Cl
1-Apr-11 1-Mar-12 1-Mar-12 ### 3-Aug-17 6-Jun-18 GSK Investigational S https://Cl
Feb-06 Oct-10 Oct-10 19-Apr-05 4-Apr-13 30-Jun-15 Baptist Cancer Instit https://Cl
Jul-15 1-Dec-17 1-May-19 9-Jan-15 7-May-19 Flinders University, A https://Cl
1-Nov-16 30-Jun-19 30-Jun-19 ### ### Clinical Trail Unit https://Cl
Oct-05 Dec-11 Dec-11 27-Oct-05 ### Bandim Health Projechttps://Cl
Jul-02 May-06 Sep-06 3-Aug-05 21-Oct-08 Bandim Health Projechttps://Cl
Jun-14 Mar-16 Apr-17 27-Jan-14 ### 3-Aug-17 Hospital of the Univehttps://Cl
Dec-08 Aug-11 Aug-11 18-Jun-09 4-Nov-12 28-Oct-15 National Institutes ofhttps://Cl
Jan-15 Feb-16 Feb-16 1-Jul-13 18-Jan-17 GSK Investigational Sihttps://Cl
30-Jun-17 Dec-19 Dec-19 ### ### Chiangrai Prachanukro https://Cl
Jun-13 Sep-14 Sep-14 ### 24-Jun-15 Landeskrankenhaus Hal https://Cl
May-04 May-07 Sep-08 11-Jun-04 22-Jun-12 Warren Grant Magnuson https://Cl
Apr-08 Dec-09 Jul-10 3-Apr-08 ### Ludwig Institute for https://Cl
Aug-08 Oct-09 Oct-09 ### ### Novartis Investigativ https://Cl
Oct-05 Apr-08 Apr-08 ### 8-Jul-09 5-Jan-15 Brigham and Women's https://Cl
H
Jul-00 Apr-02 Nov-02 ### 10-Jul-12 USC/Norris Comprehens https://Cl
Feb-09 Jul-10 Jul-10 6-Jan-09 3-Jan-13 Shaikh M Ahmad, Dhahttps://Cl
Nov-11 Oct-12 Nov-16 20-Jun-12 ### Seoul National Univerhttps://Cl
Nov-15 Jan-17 Jan-17 19-Jul-17 19-Jul-17 https://Cl
Sep-03 Jul-06 6-Nov-03 19-Jun-13 Warren Grant Magnuson https://Cl
Apr-13 Dec-13 Jun-14 12-Apr-13 12-Apr-13 https://Cl
23-Jan-06 31-Jan-08 ### 26-Jan-06 21-Oct-13 ### Univ of Alabama at Bihttps://Cl
Jan-14 Dec-17 Jul-18 6-Dec-13 ### Melbourne Sexual Heal https://Cl
30-Mar-15 Sep-21 Sep-21 ### ### Hopital Foch, Suresnehttps://Cl
17-Oct-17 14-Aug-18 2-Apr-19 4-Aug-17 ### ### Alabama Cli "Study Prohttps://Cl
14-Oct-17 30-Apr-18 ### 9-Mar-18 ### Schoen Klinik Bad Ar https://Cl
Jul-14 Mar-15 Mar-15 2-Jul-14 ### https://Cl
Jan-14 Aug-16 Dec-16 9-Jan-14 ### Medizinische Universihttps://Cl
Oct-07 Aug-10 Aug-10 19-Oct-07 ### 12-Apr-17 https://Cl
Sep-09 Oct-14 Feb-16 29-Apr-09 17-Oct-16 Duke University Medic https://Cl
Feb-09 Jan-20 Jan-20 4-Mar-09 17-Apr-19 Albany, California, U https://Cl
1-Apr-19 1-Apr-21 1-Nov-21 ### ### Centogene AG, Rostochttps://Cl
Aug-15 Jul-28 Jul-30 1-Jul-15 1-Jul-15 https://Cl
Sep-01 Dec-08 May-09 27-Jan-03 ### Muhimbili University https://Cl
Apr-99 May-01 ### 4-Mar-08 National Institute of https://Cl
May-11 Jul-11 Dec-11 27-Jul-12 27-Jul-12 Biofortis, Nantes, Fra https://Cl
18-Jun-07 15-Apr-09 21-Jun-07 2-Jul-17 National Institutes ofhttps://Cl
Mar-04 Oct-05 Oct-05 ### ### https://Cl
1-Jan-20 1-Dec-22 1-Dec-23 ### ### University of Sao Paulhttps://Cl
Jun-04 Nov-07 5-Aug-04 ### Lombardi Comprehensi https://Cl
Jul-10 Nov-11 Nov-11 ### 9-May-12 NicVAX Investigator, https://Cl
26-Jun-18 Dec-20 Jun-23 6-Jun-18 31-Jan-20 City of Hope, Duarte,https://Cl
Jun-07 Dec-13 Dec-13 6-May-09 ### Rockefeller Universit https://Cl
1-May-13 19-Mar-14 ### 24-Apr-13 ### ### https://Cl
Aug-11 Jun-16 Dec-17 1-Sep-11 ### Abramson Cancer Cente https://Cl
Jul-08 Apr-10 10-Oct-08 ### https://Cl
HIVNET 007|10590 Sep-01 ### ### UVRI - IAVI HIV Vacc https://Cl
Jul-04 Oct-08 Oct-08 ### 5-Nov-08 Central Alabama Oncol https://Cl
18-May-20 5-Dec-21 18-Oct-22 ### 7-Feb-20 https://Cl
Dec-09 Nov-13 May-14 ### 6-May-14 UZ Brussel, Laken, Br https://Cl
Sep-06 Oct-07 2-Aug-06 7-Feb-07 Hopital Saint Antoinehttps://Cl
Oct-13 Mar-14 Mar-14 ### 20-Jan-16 Duke University Healthttps://Cl
19-Apr-06 1-May-07 ### 24-Apr-06 1-Mar-17 6-Jun-18 GSK Investigational Sihttps://Cl
Mar-09 Feb-10 Feb-10 1-Apr-09 19-Oct-12 Parexel International https://Cl
11-Sep-17 30-Nov-17 ### ### ### Whaddon Medical Cen https://Cl
26-Apr-19 1-Oct-20 1-Oct-20 6-May-19 ### Herlev Hospital, Herl https://Cl
Jun-11 May-12 May-12 19-Jul-11 7-Sep-12 Malaria Clinical Trial https://Cl
Aug-11 Nov-13 Nov-13 26-Jul-11 26-Jan-15 The catholic universithttps://Cl
Jun-04 Apr-12 Apr-12 29-Jul-11 29-Jul-14 Sint-Vincentiusziekenhttps://Cl
Jul-04 Aug-10 Oct-10 8-Sep-04 ### Warren Grant Magnuson https://Cl
Oct-16 Dec-20 Dec-20 ### ### City of Hope, Duarte,https://Cl
Mar-09 Aug-09 Sep-10 12-Apr-11 12-Apr-11 Johnson County Clin-Thttps://Cl
24-Apr-07 6-Jul-16 6-Jul-16 ### ### Duke University Medic https://Cl
May-07 Jul-10 13-Jul-07 ### Chungbuk National Un https://Cl
May-11 Aug-13 Aug-13 29-Jul-11 3-Mar-14 Miami Research Associ https://Cl
Jun-07 Sep-10 Sep-10 12-Jun-07 ### Alta Bates Herrick Hohttps://Cl
Sep-04 Apr-10 Apr-10 ### 26-Apr-10 Department of Oncolo https://Cl
Apr-15 Jul-16 Jun-17 22-Jun-15 26-Oct-16 International Centre https://Cl
24-Sep-18 May-20 May-20 25-Jun-18 ### Kinshasa School of Puhttps://Cl
Sep-07 Mar-13 Mar-13 10-Apr-08 ### Fukushima Medical Un https://Cl
Oct-09 Oct-11 Oct-11 17-Jun-09 21-Jan-13 Department of infectihttps://Cl
Jun-05 Nov-05 ### ### GSK Investigational Sihttps://Cl
Nov-06 Apr-08 May-08 31-Oct-07 24-Oct-17 https://Cl
Jul-02 Mar-12 Mar-12 4-Nov-99 ### Division of Hematologhttps://Cl
Jan-05 Sep-11 Sep-12 ### 5-Nov-14 Oslo University Hospihttps://Cl
Apr-06 Jun-10 Jun-10 ### 7-Jul-11 13-Apr-17 https://Cl
May-12 Aug-15 Sep-15 7-May-12 ### Department of Medical https://Cl
Aug-13 Apr-14 Dec-15 24-Jun-13 ### Vaccine Evaluation C https://Cl
25-Sep-18 31-Dec-21 ### ### ### University of Rochesthttps://Cl
Apr-14 Nov-14 Dec-20 ### ### Centro de Pesquisa dahttps://Cl
MEAC - Maternidade Escola As
Sep-99 Jan-09 24-Oct-05 ### Radboud University Nhttps://Cl
Aug-11 Sep-14 Sep-14 ### 4-Nov-14 Hospital ClÃnic Barcelona,
https://Cl
Barcelona, Spain
8-Aug-17 10-Jan-19 10-Jan-19 5-Jun-17 4-Sep-19 Saint Louis Universityhttps://Cl
Feb-15 Jul-15 Jul-15 ### ### Surrey Clinical Resea https://Cl
Apr-15 Sep-15 Nov-15 28-Jun-16 28-Jun-16 District Health Cente https://Cl
Jun-07 May-12 May-12 4-Feb-10 3-Jul-13 4-Sep-15 https://Cl
Mar-01 Dec-04 27-Jan-03 ### University of Alabamahttps://Cl
1-Nov-19 15-Jul-20 15-Jul-20 7-Aug-18 ### https://Cl
Mar-15 Dec-19 Dec-20 1-Apr-15 8-Jul-19 Oslo University Hospihttps://Cl
Mar-16 May-20 May-20 14-Apr-16 28-Jan-20 St. Joseph's Hospital https://Cl
Dec-16 Jan-19 Jan-19 ### ### Health Sciences Northhttps://Cl
Dec-15 Jun-17 Jun-17 14-Jan-16 11-Jul-17 Quintiles Phase One Shttps://Cl
Oct-08 Dec-09 8-May-09 8-May-09 UMC Groningen, Gronhttps://Cl
Aug-19 Oct-19 Feb-20 ### ### Jiangsu Provincial Ce https://Cl
5-Apr-19 Jun-23 Jun-23 ### 12-Apr-19 Icahn School of Medichttps://Cl
Sep-03 Sep-05 3-Oct-03 4-Mar-08 National Institute of https://Cl
Nov-16 Dec-17 Nov-18 ### 6-Feb-19 Fukuoka-shi, Fukuoka,https://Cl
26-Aug-15 6-Oct-16 ### ### 9-Mar-17 Passport Health, Balt https://Cl
Aug-11 Mar-15 May-15 27-Oct-11 23-Jun-15 Krankenhaus Nordweshttps://Cl
1-Nov-04 11-Dec-09 25-Jul-11 ### 2-Jul-17 National Institutes ofhttps://Cl
1-Mar-18 15-Apr-20 ### 1-Jun-17 27-Jan-20 George Washington Uni https://Cl
28-Nov-16 16-Nov-17 ### 8-Aug-16 15-Jul-19 https://Cl
Jan-17 14-Mar-17 8-Jun-17 ### 25-Jul-17 https://Cl
Feb-01 Dec-07 Dec-07 ### 7-Jul-10 University of Arkansahttps://Cl
Apr-10 Oct-11 13-Jun-17 1-Jul-19 1-Jul-19 https://Cl
8-Jan-13 Jun-21 Jan-33 23-Jan-13 27-Jan-20 Massachusetts Genera https://Cl
Mar-16 Dec-16 Dec-16 10-Jul-14 ### Centre for the Evaluathttps://Cl
9-Mar-16 Dec-21 Dec-21 ### 2-Oct-19 UnitÃ© MÃ©dicale de https://Cl
9-Jan-09 26-Mar-12 ### 12-Jan-09 ### UnitÃ© de Recherchehttps://Cl
17-Nov-05 28-Mar-06 ### 6-Sep-06 6-May-19 6-May-19 GSK Investigational S https://Cl
Apr-20 30-Dec-22 30-Oct-23 5-Dec-19 30-Jan-20 MD Anderson Cancerhttps://Cl
C
Feb-07 Feb-07 Feb-10 ### 21-Oct-10 Iwate Medical Univershttps://Cl
7-Feb-19 30-Dec-22 ### 16-Jan-19 ### Clinique de l'Europe, https://Cl
Apr-15 Aug-17 Aug-17 ### ### Centre for Clinical V https://Cl
Nov-11 Dec-18 Dec-18 7-Oct-08 9-Aug-18 Indiana University/Rilhttps://Cl
3-Jul-14 24-May-16 May-20 2-Sep-13 ### Thai Red Cross AIDS https://Cl
30-Nov-17 30-Dec-22 ### 8-Sep-17 6-Feb-20 Hospital Universitari https://Cl
3-Sep-19 Nov-21 Nov-21 ### ### De La Salle Health Sc https://Cl
Apr-03 Mar-06 ### ### Department of Infectious
https://Cl
Diseases, Hospital ClÃnic, C
10-Jan-19 Mar-21 Mar-21 9-Jan-19 ### Centre for Clinical V https://Cl
2-Nov-06 1-Oct-07 19-Oct-07 2-Oct-06 4-Dec-08 8-Jun-18 GSK Investigational Sihttps://Cl
Feb-17 Feb-19 Feb-19 6-Feb-14 ### Multiple Sclerosis Ce https://Cl
Sep-08 Dec-09 Dec-09 9-Sep-08 ### Focus Clinical Drug https://Cl
Apr-08 Dec-08 Jun-09 ### ### https://Cl
16-Jul-18 20-Jan-20 20-Jan-20 6-Jun-18 27-Jan-20 Chinle Comprehensivehttps://Cl
Feb-08 Dec-09 Dec-09 ### 9-Feb-10 University Cape Townhttps://Cl
16-Jan-18 28-Feb-20 ### 19-Jan-18 6-Mar-19 Walter Reed Army Insti https://Cl
7-Aug-18 31-Aug-19 31-Oct-19 11-Jun-19 11-Jun-19 St Georges Universit https://Cl
20-Jan-19 31-Dec-21 ### ### 7-Feb-20 Functional Brain Cente https://Cl
Sep-03 Jun-06 ### ### Julius Center for Hea https://Cl
Jun-08 May-11 ### ### Marseille Institute of https://Cl
Jan-07 Apr-08 Oct-08 5-Mar-09 8-Apr-09 Rigshospitalet, Cop https://Cl
18-Jul-19 Sep-20 Sep-20 1-Apr-19 6-Jan-20 MRCG at LSHTM, Banju https://Cl
Apr-14 Jun-15 Jun-15 16-Apr-14 21-Oct-16 21-Oct-16 Miami Research Associ https://Cl
Nov-09 Jul-13 Jun-14 ### ### ### University of Californhttps://Cl
23-Dec-96 25-Oct-07 25-Oct-07 4-Nov-99 ### National Institutes ofhttps://Cl
18-Oct-18 11-Dec-20 ### 8-Aug-18 ### Alabama Clinical Therhttps://Cl
Jun-08 May-09 Oct-09 19-Jun-08 ### 14-Apr-16 Jonesboro, Arkansas, https://Cl
Jun-99 Jan-02 Nov-03 ### 17-Jan-18 University of Nebras https://Cl
Jul-10 Aug-13 Apr-15 ### 4-Aug-16 ### Marin Cancer Care, Inhttps://Cl
Sep-00 Oct-07 27-Jan-03 19-Jun-13 Warren Grant Magnuson https://Cl
20-Nov-15 8-Aug-18 8-Aug-18 15-Oct-15 6-Sep-19 ### MSD K.K., "Study Prohttps://Cl
Mar-03 Sep-05 ### ### Hem&Onc CharitÃ© CB https://Cl
Jan-98 Jun-03 7-Aug-03 20-Jun-13 Surgery Branch, Bethhttps://Cl
Jun-99 Jun-02 Jun-02 26-Jul-04 19-Jun-13 Memorial Sloan-Kettehttps://Cl
2-May-18 28-Dec-18 1-Apr-19 ### ### Local Institution, Pri https://Cl
1-Feb-18 1-Feb-20 1-Feb-20 13-Apr-17 17-Jul-19 City of Hope Medical https://Cl
04-026|Anthrax CVD 3000 May-07 ### ### University of Marylanhttps://Cl
Dec-07 Jun-08 Jun-08 ### 8-Nov-11 Rockefeller Universit https://Cl
Jun-98 Nov-02 Nov-02 25-Apr-03 6-Nov-13 Duke Comprehensivehttps://Cl
C
Apr-99 Jun-03 7-Aug-03 20-Jun-13 Surgery Branch, Bethhttps://Cl
Jan-14 Jan-15 Feb-15 ### 3-Jun-15 Biological treatment https://Cl
May-06 27-Jul-06 ### https://Cl
Nov-11 Nov-12 Nov-12 ### 29-Oct-13 Children's Infectious https://Cl
Nov-16 Jul-20 Dec-20 ### ### Commune Health Cent https://Cl
Oct-99 Oct-07 27-Jan-03 19-Jun-13 Warren Grant Magnuson https://Cl
1-Feb-18 1-Jul-18 1-Jul-18 17-Jan-18 26-Jul-18 CHU Brugmann, Brusse https://Cl
10-Jul-18 28-Sep-19 30-Apr-20 4-Dec-17 ### Centre for Clinical S https://Cl
Jun-03 May-11 ### ### Fred Hutchinson Canchttps://Cl
Apr-12 1-Jan-25 ### 7-Mar-12 ### Ironwood Cancer andhttps://Cl
R
Dec-07 Oct-12 Oct-12 ### ### https://Cl
4-Dec-17 29-Jul-19 29-Jul-19 8-Jan-18 6-Feb-20 Meridian Clinical Res https://Cl
Nov-07 Dec-09 9-Jan-08 ### National Cancer Centrhttps://Cl
16-Jan-17 31-Dec-19 ### ### 5-Jul-19 Melbourne Sexual Heal https://Cl
May-14 1-Sep-17 22-Jan-18 5-Mar-14 26-Jan-18 University of Alabamahttps://Cl
Jan-97 Aug-02 Nov-02 22-Apr-04 5-Sep-13 University of Chicago https://Cl
Nov-15 Jul-19 Dec-19 7-Sep-15 ### Centro de Salud Univhttps://Cl
1-Oct-16 5-Nov-16 5-Dec-16 ### ### Laval University Rese https://Cl
Nov-04 ### ### Bandim Health Projechttps://Cl
Mar-01 Aug-04 27-Jan-03 ### John and Dorothy Morg https://Cl
Aug-98 Feb-01 30-Jul-14 31-Jul-14 https://Cl
Jul-11 ### ### Institute of Pathogen https://Cl
May-07 Jun-12 Jun-12 ### ### Fukushima Medical Un https://Cl
Oct-04 Aug-06 Aug-06 ### 12-Jan-17 University of Maastri https://Cl
Jun-01 Aug-04 27-Jan-03 19-Jun-13 Warren Grant Magnuson https://Cl
May-15 24-May-18 ### 8-Jun-15 28-Jun-19 QPS MRA, Miami, Flori https://Cl
Oct-10 Dec-10 Dec-10 7-Nov-10 7-Jun-17 https://Cl
21-Oct-16 1-Dec-21 1-Dec-21 26-Jan-16 ### GSK Investigational Sihttps://Cl
Mar-11 Jul-11 Oct-11 3-Sep-12 25-Oct-12 NanMoFang Community https://Cl
HVTN 203|AVEG 203|10596 Apr-03 ### ### Alabama Vaccine CRS,https://Cl
25-Nov-11 27-Aug-16 ### 6-Mar-12 7-Jul-17 ### https://Cl
May-09 Jan-10 Jul-11 ### ### ### Advanced Clinical Reshttps://Cl
Oct-06 Apr-08 Apr-08 ### ### University of Antwer https://Cl
Apr-12 Jun-12 Sep-12 ### 8-Sep-14 UH-rouen, Rouen,, Sehttps://Cl
May-99 Mar-01 Dec-06 ### ### University of Wiscon https://Cl
Oct-16 Mar-17 Sep-17 4-Nov-16 ### OPHAC Hospital, Osakhttps://Cl
Apr-13 Nov-19 Dec-19 29-Apr-13 ### Hospital Universitariohttps://Cl
de Vic, Vic, Barcelona, Spain|H
Nov-05 Feb-06 Apr-06 ### 22-Jan-14 Pingle, China https://Cl
Aug-11 Jan-14 13-Jul-12 7-Jan-14 Leiden University Med https://Cl
Jul-08 Jan-21 Jan-22 25-Jul-08 ### Hadassah Medical Orga https://Cl
Jun-06 Feb-07 Feb-07 ### ### Clermont-Ferrand, Fr https://Cl
Feb-02 Feb-03 27-Jan-03 ### Cliniques Universita https://Cl
Sep-10 May-12 Jun-12 28-Jul-10 2-Dec-17 Masonic Cancer Centehttps://Cl
Aug-05 Jun-07 2-Sep-05 ### NYU Cancer Institute,https://Cl
9-Jul-10 31-Jul-10 31-Jul-10 30-Jun-10 ### 8-Jun-18 GSK Investigational S https://Cl
Aug-98 Nov-01 Nov-01 28-Apr-04 19-Jun-13 Memorial Sloan-Kettehttps://Cl
Apr-03 May-10 May-10 28-Apr-03 ### 23-Oct-12 National Cancer Insti https://Cl
21-Feb-19 Oct-20 Oct-20 ### 7-Oct-19 Arkansas Children's Hhttps://Cl
1-Dec-15 31-Dec-18 ### 6-Nov-17 6-Nov-17 https://Cl
Jun-10 Oct-11 Oct-11 14-Jun-10 ### ### UMHS Outpatient Pedi https://Cl
Sep-15 Dec-15 Dec-15 ### 15-Jun-17 Pierre Van Damme, Wi https://Cl
19-Oct-07 8-Dec-08 8-Dec-08 ### ### Simmons Comprehensive https://Cl
Apr-97 Jul-06 27-Jan-03 20-Jun-13 Warren Grant Magnuson https://Cl
19-May-10 19-Dec-15 ### 9-Jul-10 ### Institut Gustave Roussy
https://Cl
Apr-06 Apr-07 Apr-07 ### 13-Jul-09 ### https://Cl
Jul-02 Jul-06 Jul-06 27-Jan-03 ### University of Texas Mhttps://Cl
Nov-12 Feb-14 Feb-14 6-Jul-12 ### Cheil General Hospitahttps://Cl
Mar-03 Dec-05 Dec-05 29-Jan-10 29-Jul-10 Hoag Cancer Center, N https://Cl
Dec-06 May-07 May-07 ### 28-Oct-16 GSK Investigational S https://Cl
Jul-07 Aug-08 Oct-08 9-Jul-07 ### White Hills Medical Chttps://Cl
Feb-14 Mar-16 Jun-16 ### 2-Aug-16 Dartmouth-Hitchcockhttps://Cl
Aug-04 9-Sep-04 30-Apr-15 Warren Grant Magnuson https://Cl
1-Dec-09 12-Apr-10 12-Apr-10 ### 10-Apr-17 6-Jun-18 GSK Investigational S https://Cl
Nov-12 Dec-14 Jun-15 2-Oct-12 29-Jun-15 Instituto Nacional d https://Cl
May-15 Sep-15 Oct-15 10-Apr-15 9-Oct-15 https://Cl
7-Aug-09 16-Oct-13 16-Oct-13 27-Oct-09 ### ### Muntinlupa, Philippi https://Cl
Jan-09 Feb-13 Feb-13 ### 20-Oct-15 https://Cl
11-Sep-13 28-Sep-17 Mar-22 14-Jun-13 ### ### Site US100"Study Prohttps://Cl
20-Nov-13 13-May-16 Nov-20 1-Nov-13 7-Nov-19 Site US10026, Phoenix https://Cl
Jul-06 Aug-06 29-Jun-06 ### GSK Investigational S https://Cl
Oct-13 Sep-16 Sep-16 ### 21-Apr-16 Department of Otorhin https://Cl
24-Sep-13 Dec-19 May-20 ### ### Royal Thai Army Clini https://Cl
Dec-08 May-14 Jun-15 ### 21-Oct-15 21-Oct-15 Please contact the https://Cl
Feb-06 Feb-07 ### ### University Hospital o https://Cl
Mar-05 Nov-05 3-Apr-08 9-Apr-08 University Hospital Z https://Cl
Aug-04 Nov-09 ### 10-Jan-14 Sarah Cannon Cancerhttps://Cl
C
Mar-03 Jul-05 18-Jan-07 18-Jan-07 MRC Labs, Fajara, Ga https://Cl
13-Dec-16 6-Dec-18 6-Dec-18 1-Aug-16 5-Dec-19 Site US10014, Little https://Cl
Dec-16 Dec-17 Dec-17 23-Jun-16 ### Gloucestershire primahttps://Cl
Sep-06 Dec-07 Dec-07 ### ### 10-Apr-17 Duramed Investigationa https://Cl
16-Jun-17 1-Sep-19 30-Jun-22 ### ### Clinical Municipal Hohttps://Cl
28-Feb-20 15-Jan-25 15-Jan-25 ### 5-Feb-20 Mayo Clinic in Floridahttps://Cl
Jan-12 Dec-14 4-Apr-12 ### Nationa University Hohttps://Cl
Oct-14 Dec-14 Jul-15 2-Feb-15 20-Oct-15 Korea University Gurohttps://Cl
Feb-05 9-Dec-04 28-Jan-08 Jonsson Comprehensive https://Cl
Jul-04 5-Aug-04 2-Aug-13 Comprehensive Cancer https://Cl
Mar-16 30-Sep-18 ### ### 28-Jan-19 University Hospital, https://Cl
Dec-08 Mar-09 Dec-09 ### 13-Jan-11 14-Apr-16 Little Rock, Arkansas https://Cl
Jun-07 Jan-17 Jan-17 18-Jun-07 9-Mar-17 Dana-Farber Cancer In https://Cl
Mar-08 Jul-10 Jul-10 ### 17-Oct-12 17-Oct-12 University of Rochesthttps://Cl
Mar-20 Jun-22 Jun-22 25-Apr-18 25-Jun-19 UNC Center for Envirohttps://Cl
Aug-97 Jun-98 Nov-00 ### 7-Mar-11 Roswell Park Cancer Ihttps://Cl
Sep-12 Dec-13 Feb-14 ### ### Radboud University Nhttps://Cl
May-16 May-19 May-21 17-Jul-15 ### Centre Hospitalier Unhttps://Cl
Feb-98 Mar-07 5-Mar-07 20-Jun-13 Surgery Branch, Bethhttps://Cl
Mar-06 Oct-07 Jul-08 14-Jul-08 14-Jul-08 https://Cl
20-Mar-03 6-Sep-06 6-Sep-06 9-Apr-03 ### GSK Investigational Sihttps://Cl
Jul-95 Mar-07 5-Mar-07 20-Jun-13 Arkansas Cancer Resea https://Cl
Nov-10 Sep-11 ### 16-Jul-12 China Medicine Univer https://Cl
16-May-18 May-22 May-26 7-Nov-17 ### Children's National Hohttps://Cl
Dec-12 Dec-18 Dec-20 1-Feb-13 12-Oct-17 ZAO "NeuroVita Clinichttps://Cl
Dec-12 Dec-18 Dec-20 1-Feb-13 12-Oct-17 ZAO "NeuroVita Clinichttps://Cl
Dec-12 Dec-18 Dec-20 3-Jan-13 12-Oct-17 ZAO "NeuroVita Clinichttps://Cl
Dec-99 May-11 May-11 27-Jan-03 ### ### University of Alabamahttps://Cl
May-99 Jun-07 Jun-07 1-Jun-05 24-Apr-13 Ludwig Institute for https://Cl
Dec-11 Oct-12 Dec-12 26-Oct-10 10-Apr-13 Lotus House, Vasanthhttps://Cl
Mar-98 Jan-99 Jun-99 ### ### 6-Oct-15 https://Cl
Jun-05 Jun-07 Feb-10 27-Jul-05 5-May-10 Huntington Medical Re https://Cl
8-Oct-18 Sep-20 Sep-20 24-Jul-18 9-Dec-19 HonorHealth Research https://Cl
1-Jun-16 22-Aug-18 ### ### ### ### GSK Investigational
"Statistic Site,
https://Cl
ChiriquÃ, Panama|GSK Inves
26-May-17 20-Mar-18 ### 5-Dec-16 8-Oct-19 6-Feb-20 Sidney Kim"Study Prohttps://Cl
Oct-09 Oct-13 Oct-13 ### 14-Jan-11 https://Cl
Jun-13 Jul-15 Jul-15 8-Nov-16 19-Jul-17 19-Jul-17 https://Cl
Aug-08 Dec-08 Jun-09 ### ### ### Harrison Clinical R https://Cl
Mar-13 Jan-14 Apr-14 ### ### Oakland, California, https://Cl
Apr-04 Nov-05 Sep-06 ### ### Northwestern Universi https://Cl
1-Apr-19 1-Jun-19 1-Aug-19 ### ### Jeannot, Geneva, Swihttps://Cl
Jul-04 Mar-10 Mar-10 8-Sep-04 4-Apr-13 Providence Cancer Cen https://Cl
May-05 Jan-06 Jan-06 ### 24-Jul-08 Wee Care Pediatrics, https://Cl
Jul-09 Jan-14 Feb-15 23-Jun-09 30-Jan-17 Friends Community Cen https://Cl
Apr-13 Jan-14 Jan-14 8-Apr-13 14-Apr-15 Dr. Saul Greenberg's Phttps://Cl
Apr-05 Jul-05 Jul-05 ### ### Vanderbuilt Universithttps://Cl
Sep-00 Oct-02 ### 3-Oct-06 The Prince of Wales Hhttps://Cl
Jan-17 16-Apr-18 16-Apr-18 31-Oct-16 ### Stanford University / https://Cl
Dec-05 Sep-07 Jan-09 ### 16-Apr-12 Bangkok, Thailand https://Cl
Dec-04 Dec-04 ### ### University of Marylanhttps://Cl
Jun-09 May-11 May-12 21-Oct-10 23-Jun-11 Iwate Medical Univershttps://Cl
Mar-03 Nov-04 Nov-04 4-Dec-08 ### Kogarah, New South W https://Cl
Nov-11 Nov-12 Nov-12 27-Apr-10 10-Jan-13 Agia Sophia Children'https://Cl
5-Oct-06 17-Jun-08 12-Oct-06 2-Jul-17 National Institute of https://Cl
6-Jun-19 31-Dec-21 30-Jun-22 4-Oct-19 4-Oct-19 China Medical Univershttps://Cl
Oct-05 Jun-08 Jun-08 16-Apr-07 7-Aug-08 University Cape Townhttps://Cl
Dec-09 Mar-12 May-12 ### 13-Oct-14 9-Sep-16 Aurum Institute, Kler https://Cl
Nov-86 Sep-00 ### 4-Mar-08 National Cancer Insti https://Cl
18-Dec-18 15-Apr-19 ### 3-Oct-19 3-Oct-19 Serpil Ã–zdemir, Ankahttps://Cl
Oct-12 Aug-13 Aug-13 29-Oct-12 ### GSK Investigational S https://Cl
8-May-17 29-Sep-17 ### 8-May-17 ### ### Research Si"Study Prohttps://Cl
Jan-13 Sep-14 Dec-16 8-Feb-12 11-Jan-18 Centro de Estudos emhttps://Cl
P
Mar-04 Dec-07 Dec-08 ### 14-Jun-12 National Cancer Insti https://Cl
12-Jun-06 16-Sep-09 ### ### 29-Jun-10 17-Apr-17 https://Cl
25-Sep-14 18-Feb-16 ### ### ### ### Kenya Medical Researhttps://Cl
911-DIAPEP277 21-Jan-11 21-Jan-11 https://Cl
12-Sep-16 22-Jan-18 22-Jan-18 ### ### Kaiser Permanente Was https://Cl
Sep-02 Aug-05 ### 4-Mar-08 National Institute of https://Cl
Dec-11 Jun-13 Oct-13 2-Apr-12 6-Nov-13 Studienzentrum der Phttps://Cl
Feb-15 Oct-19 Feb-20 9-Mar-15 22-Oct-19 https://Cl
27-Jun-17 Jun-20 Dec-24 ### 31-Oct-19 Inselspital Bern, Ber https://Cl
Jun-03 Dec-03 ### ### Grieskirchner Strass https://Cl
Jul-08 Jan-13 Jan-13 ### 8-May-15 Southern Cancer Center, https://Cl
Mobile, Alabama, United Sta
Nov-07 Mar-10 Mar-10 ### 23-Jun-11 Kyushu University Hoshttps://Cl
Oct-10 Jul-13 Jul-13 7-May-10 9-Jan-17 University of Cape Tohttps://Cl
21-Sep-18 21-Jan-21 ### 27-Jul-18 ### University of Californhttps://Cl
Sep-02 Sep-03 2-Jun-06 ### 407 Doctors, Sydney, https://Cl
Mar-12 Nov-16 Nov-19 7-May-14 ### Cancer Insititute and https://Cl
31-Mar-09 15-Jan-10 15-Jun-10 ### ### ### GSK Investigational Sihttps://Cl
Jun-08 Sep-08 Mar-09 30-Jun-08 12-Jul-12 Johnson County Clin-Thttps://Cl
Mar-09 May-09 Oct-09 ### ### 5-Dec-11 Benchmark Research,https://Cl
S
Apr-10 Jul-11 Jan-13 ### 13-Jul-11 University of Readin https://Cl
Aug-11 Aug-12 Dec-13 ### ### Medical University ofhttps://Cl
Jul-09 Jan-15 ### ### ### Providence Portland Mhttps://Cl
Oct-01 Jan-02 ### ### Zespol Opieki Zdrowohttps://Cl
23-Jan-09 Dec-20 Dec-21 3-Feb-09 25-Oct-19 Massachusetts General https://Cl
Jan-16 Sep-16 Jan-17 12-Jan-16 12-Jan-16 https://Cl
Aug-06 Feb-09 Mar-09 ### 14-Jan-14 Coquitlam, British C https://Cl
Jan-04 Nov-07 ### 1-Mar-11 San Raffaele Hospitalhttps://Cl
Jul-04 Jan-07 ### 19-Apr-07 Department of Dermat https://Cl
Feb-02 Aug-02 ### ### Neuschwanstein Strashttps://Cl
27-Jan-15 7-Dec-15 11-Apr-19 ### 14-Jan-20 Mayo Clinic, Rochestehttps://Cl
Nov-11 May-12 May-12 ### ### ### Miami Research Associhttps://Cl
Feb-02 Aug-02 ### ### Grieskirchner Strass https://Cl
24-Oct-07 24-Nov-08 ### ### 17-Oct-17 17-Oct-17 https://Cl
ACTG 205|11182|AVEG 101 Oct-98 ### ### Johns Hopkins Adult Ahttps://Cl
3-Jan-17 Dec-21 Mar-22 ### 5-Feb-20 Institut Bergonie, Bo https://Cl
Dec-06 Nov-09 Nov-09 2-Mar-07 ### Herlev University Ho https://Cl
Jul-04 Dec-05 21-Jul-05 ### Hopital Cochin Centrehttps://Cl
Jun-00 May-02 12-Jun-00 4-Mar-08 National Institute of https://Cl
Dec-09 Oct-10 Oct-10 3-Dec-09 20-Jun-12 20-Jun-12 Pfizer Investigational https://Cl
Aug-05 May-07 May-07 ### ### University of Maryland
https://Cl
Mar-10 Nov-15 Nov-15 29-Apr-11 5-Nov-15 St. Jude Children's R https://Cl
Jun-09 Mar-13 Mar-13 29-Apr-08 3-Dec-15 University of Californhttps://Cl
Apr-09 Oct-09 Dec-09 21-Apr-09 22-Jan-14 Quezon city, Manila, https://Cl
### 24-Jun-05 Johns Hopkins Univ / https://Cl
5-Aug-08 29-Aug-08 ### 4-Aug-08 8-May-17 GSK Investigational S https://Cl
Jun-11 Dec-13 Feb-14 7-Feb-11 24-Oct-16 Saint Luke's Hospital https://Cl
Aug-06 13-Dec-13 ### ### 6-Mar-19 Cliniques Universitairhttps://Cl
Feb-03 Mar-06 5-Feb-03 4-Mar-08 National Institute of https://Cl
Feb-06 Feb-30 Feb-30 20-Jun-06 19-Jun-19 The University of Tex https://Cl
20-Jul-10 23-Feb-17 ### 3-Aug-10 1-Jun-18 1-Jun-18 University "Study Prohttps://Cl
B011|RV 138 ### 24-Jun-05 Walter Reed Army Inst https://Cl
Jun-07 Oct-07 Mar-08 3-Aug-07 12-Apr-17 30-Apr-19 Beeghley Medical Park https://Cl
29-Nov-11 6-Nov-12 6-Nov-12 2-Nov-11 ### 18-Jul-18 https://Cl
Mar-07 Mar-13 Mar-13 ### ### Fukushima Medical Un https://Cl
Apr-09 May-10 May-10 23-Apr-09 7-Jun-10 HIV-NAT, Bangkok, Thahttps://Cl
6-Jul-18 30-Apr-21 5-May-21 19-Apr-18 9-Aug-19 Optimal Research, Hun https://Cl
Jan-01 Oct-04 Oct-04 ### 5-May-11 5-Oct-15 https://Cl
23-Jan-18 Feb-21 Jun-23 ### ### The Sidney Kimmel Cohttps://Cl
18-Jun-15 27-Nov-15 26-Jul-16 11-Jun-15 13-Jan-20 Kanto, Japan https://Cl
17-Feb-14 28-Mar-14 ### 1-Feb-19 1-Feb-19 https://Cl
10-Sep-18 31-Oct-20 31-Oct-22 26-Jul-18 23-Jan-20 University of Wisconshttps://Cl
Sep-08 Nov-10 Nov-10 16-Apr-10 ### https://Cl
25-Apr-12 27-Jun-17 Jun-21 ### ### 28-Oct-19 Duke Unive"Study Prohttps://Cl
Oct-02 May-03 Nov-04 ### 30-Apr-09 14-Apr-16 East Stroudsburg, Penhttps://Cl
Oct-07 Jun-08 Sep-08 17-Oct-07 14-Jan-14 Adelaide, Australia|Qhttps://Cl
Aug-14 Aug-15 ### ### Studienzentrum der Phttps://Cl
May-11 Dec-11 Dec-11 14-Jul-11 ### Kyushu, Japan https://Cl
Aug-05 Nov-07 Nov-07 2-Sep-05 ### Childrens Hosp of Loshttps://Cl
30-Apr-18 30-Dec-19 ### ### ### Queen Saovabha Memor https://Cl
Sep-11 Jan-16 Jan-16 12-Jan-12 ### ### Choi's Pediatric Clin https://Cl
May-08 Apr-09 Apr-09 ### 7-May-09 Research Hospital, Thhttps://Cl
Jul-05 Jul-08 Apr-09 27-Jul-05 ### NYU Clinical Cancer Chttps://Cl
Nov-06 Dec-06 Feb-09 ### ### Wakayama Medical Uni https://Cl
Nov-04 Sep-07 5-Apr-06 ### Surgical Department,https://Cl
4-May-18 Feb-20 Feb-21 ### ### University of Califor https://Cl
7-Jul-17 31-Jan-20 ### 2-Jul-17 6-Jun-19 IrsiCaixa AIDS Researchttps://Cl
29-Sep-15 9-Sep-16 7-Nov-16 24-Jul-15 ### ### Research Site, Sacramhttps://Cl
Mar-06 Dec-06 Dec-06 ### 12-Oct-16 GSK Investigational Sihttps://Cl
Aug-13 Sep-13 Sep-13 ### 20-Oct-15 https://Cl
May-96 Apr-04 29-Apr-04 10-Jul-13 St. Vincent Medical Cehttps://Cl
Mar-08 Jul-09 Oct-09 ### ### Assaf Harofeh Medical https://Cl
Dec-17 Jan-19 Mar-19 5-Jun-17 ### https://Cl
May-07 2-Aug-07 ### Keck School of Medicihttps://Cl
Jan-09 May-12 Jan-15 9-Jan-09 31-Jul-17 Hillman Cancer Center https://Cl
10-Nov-18 31-Dec-22 ### 11-Apr-19 11-Apr-19 National Taiwan Univehttps://Cl
Aug-04 8-Oct-04 ### Midwest Heart Surgery https://Cl
Jul-98 Jun-01 ### 4-Mar-08 National Cancer Insti https://Cl
1-May-17 28-Feb-20 ### ### ### Immunitor LLC, Ulaanhttps://Cl
7-Mar-14 24-Feb-15 13-Oct-15 ### 1-Mar-16 30-Oct-18 https://Cl
Oct-15 Oct-17 Feb-18 7-Oct-16 7-Oct-16 Clinical Research Centhttps://Cl
7-Feb-17 10-Jul-17 ### ### 3-Jan-19 MRC Unit The Gambiahttps://Cl
4-Apr-17 12-Feb-18 ### 5-Sep-16 9-Dec-19 ### Institute f "Study Prohttps://Cl
Dec-10 Dec-11 Jun-12 4-Oct-10 1-Mar-13 https://Cl
Aug-13 Aug-15 Nov-15 ### ### ### eKhayavac "Study
T Prohttps://Cl
AVEG 003A|10541 Oct-92 ### ### St. Louis Univ. Schoolhttps://Cl
Mar-20 Apr-22 Apr-22 27-Jan-20 ### https://Cl
AVEG 003B|10542 Mar-93 ### ### St. Louis Univ. Schoo https://Cl
Aug-12 Aug-13 Jun-14 11-Jul-13 ### https://Cl
May-05 Jun-05 ### ### SGS Biopharma Resear https://Cl
May-12 Nov-13 Nov-13 ### ### Duffel, Belgium|Leuvhttps://Cl
Sep-14 Jun-16 Dec-16 25-Jul-14 23-Jun-16 Confidential, Seoul, Khttps://Cl
Oct-18 Nov-19 Nov-19 15-Oct-18 29-Oct-18 https://Cl
30-Dec-19 30-Dec-21 ### 15-Jan-19 ### Cedars-Sinai Medical https://Cl
2-Aug-18 1-May-22 1-May-23 ### ### Bolikhamxa"Study Prohttps://Cl
Feb-06 Nov-06 ### 7-Oct-16 GSK Investigational S https://Cl
Sep-04 Sep-06 ### ### University Hospital Tohttps://Cl
Sep-16 1-Jun-17 1-Jun-17 ### ### ### Site 2, Li "Study Prohttps://Cl
Nov-06 Feb-10 Oct-11 2-Feb-09 ### Emory University, Atl https://Cl
Aug-14 Aug-15 Sep-15 7-Aug-14 8-Feb-17 Birmingham, Alabama, https://Cl
AVEG 004B|10545 Aug-93 ### 30-Apr-12 St. Louis Univ. Schoo https://Cl
AVEG 028|10578 May-00 ### ### JHU AVEG, Baltimore,https://Cl
18-May-01 21-Aug-01 ### 29-Jun-06 ### Johns Hopkins Univershttps://Cl
AVEG 004A|10544 Oct-94 ### 30-Apr-12 St. Louis Univ. Schoo https://Cl
1-May-20 1-Aug-24 ### 22-Jan-20 27-Jan-20 https://Cl
May-05 Dec-14 Dec-16 ### ### China Medical Univershttps://Cl
Oct-13 Apr-14 Apr-14 11-Oct-13 ### Diablo Clinical Resea https://Cl
Jul-16 Jun-20 Dec-20 ### ### Health Centers in Muhttps://Cl
1-Jun-14 31-May-19 ### ### ### GSK Investigational S https://Cl
22-Dec-15 1-Jan-21 1-Oct-21 7-Jan-16 23-Jan-20 Dana Farber Cancer Inhttps://Cl
Nov-13 Dec-15 Dec-15 ### ### Medical Department h5ttps://Cl
6-Sep-19 1-Sep-20 1-Sep-21 ### ### Centre for "Study Prohttps://Cl
7-Sep-18 Sep-20 Sep-20 ### ### Sidney Kimmel Compre https://Cl
Oct-05 May-06 Jun-06 ### 18-Jan-17 GSK Investigational Sihttps://Cl
Mar-07 Sep-07 Sep-07 ### 20-Jan-16 Long Island Jewish Mehttps://Cl
Sep-15 May-19 Dec-19 12-Oct-15 12-Oct-17 Radboud University Nhttps://Cl
Nov-12 Feb-13 Mar-13 20-Apr-17 20-Apr-17 Korea University Gurohttps://Cl
7-Jun-10 26-Nov-10 ### 7-Jun-10 ### ### GSK Investigational Sihttps://Cl
Mar-02 Nov-02 ### 3-Oct-06 https://Cl
Jun-00 Oct-04 27-Jan-03 29-Apr-15 Warren Grant Magnuson https://Cl
Oct-01 Oct-03 Oct-03 ### ### https://Cl
Mar-00 May-01 May-01 ### 9-Feb-10 ### https://Cl
Sep-04 Dec-09 Oct-10 ### ### Department of Oncolo https://Cl
Dec-17 Dec-19 Oct-20 4-Dec-12 22-Jan-20 National Cancer Insti https://Cl
1-Jan-03 1-Sep-06 1-Jun-12 ### 5-Sep-17 Michael E. DeBakey VA https://Cl
3-Jan-19 4-May-20 1-Sep-20 29-Jan-19 ### The Center for Pharma https://Cl
Jul-07 Dec-11 Aug-14 1-Aug-07 9-Jul-19 Emory University Schohttps://Cl
Dec-15 Dec-18 Dec-18 ### 25-Jan-16 UTHealth Memorial He https://Cl
Oct-07 Apr-09 Apr-09 ### 28-Apr-11 University of Alabam https://Cl
12-Jan-07 27-Mar-08 ### 6-Feb-07 ### ### Alsfeld, Germany|Ba https://Cl
25-Aug-16 15-Dec-16 ### ### 28-Jan-19 University of Marylanhttps://Cl
AVEG 007A/B ### 30-Oct-12 St Louis Univ School https://Cl
Dec-10 Dec-13 Jul-14 5-Jan-11 ### ### General Santos City, https://Cl
May-02 Aug-02 ### ### Zespol Opieki Zdrowothttps://Cl
AVEG 004|10543 Aug-93 ### 30-Apr-12 St. Louis Univ. Schoolhttps://Cl
Jun-80 Jun-00 ### 4-Mar-08 National Institute of https://Cl
Nov-02 Jul-07 Dec-08 30-Jun-05 2-Dec-09 University Hospital Bahttps://Cl
Oct-08 May-11 May-11 ### 7-Feb-13 Dana-Farber Cancer In https://Cl
May-01 Jan-03 Jan-03 31-Oct-07 30-Oct-15 https://Cl
6-Dec-18 1-Jul-19 10-Oct-19 ### 25-Oct-19 SingHealth Investigat https://Cl
Mar-08 Jan-12 May-12 ### ### Hampton Roads Center https://Cl
Feb-00 Sep-06 ### 7-Oct-13 UAB, Dept. of Ped., Dhttps://Cl
18-Oct-19 30-Jun-20 31-Jul-20 26-Jul-19 ### Federal state budgetahttps://Cl
25-Apr-17 Oct-20 Aug-21 ### 9-May-19 Royal Liverpool Univehttps://Cl
Dec-10 Jul-15 Jul-15 ### 12-Oct-17 University of Arkansahttps://Cl
Mar-08 Jun-11 Jun-11 ### 27-Jul-18 27-Jul-18 Memorial Sloan-Kettehttps://Cl
May-14 May-16 ### 6-Aug-14 ### Duke University Dept https://Cl
Aug-11 Mar-12 Mar-12 8-Aug-11 12-Jul-12 National Cheng Kung https://Cl
U
Nov-10 Jun-11 Dec-11 ### 3-Aug-12 Shanghai, China https://Cl
16-Oct-19 Apr-23 Jun-25 5-Nov-19 10-Jan-20 Investigational Site, https://Cl
Mar-12 Dec-16 Jan-17 20-Apr-12 14-Jun-17 William Harvey Hearthttps://Cl
Jun-12 Dec-15 Dec-15 ### 26-Jan-16 INC Research Torontohttps://Cl
May-12 Aug-13 Dec-13 5-Jun-12 ### ### Meridian Clinical Res https://Cl
Oct-10 Sep-13 Sep-13 30-Jun-10 2-Dec-14 GSK Investigational S https://Cl
19-Apr-11 9-May-13 9-May-13 18-Apr-11 ### ### https://Cl
Apr-91 Dec-07 Jun-09 27-Jan-03 10-Jul-13 St. Vincent Medical Cehttps://Cl
Nov-16 Oct-22 Oct-22 ### 23-Apr-18 https://Cl
May-10 Nov-12 Nov-12 ### 8-May-14 Rockefeller Universit https://Cl
### 24-Jun-05 Univ of Alabama at Bihttps://Cl
AVEG 003|10540 May-91 ### ### JHU AVEG, Pittsburgh,https://Cl
20-Jun-18 20-Feb-20 30-Apr-21 25-Jun-18 ### Herlev Hospital, Herl https://Cl
ACTG 148|11123 Jul-93 ### ### NY Univ. HIV/AIDS CRShttps://Cl
31-Oct-19 29-Feb-20 15-Jun-20 ### ### Harvard University, C https://Cl
Jun-08 May-10 May-10 ### ### ### Maternity Hospitals, https://Cl
Aug-08 Jan-10 Jan-10 ### ### 3-Apr-15 https://Cl
23-Aug-16 5-Jul-17 5-Jul-17 14-Jun-16 1-Feb-19 18-Jan-20 GSK Invest"Statistic https://Cl
3-Mar-17 Feb-18 Feb-19 8-Feb-17 25-Jul-17 Seoul National Univerhttps://Cl
Aug-10 Nov-11 Nov-11 6-Sep-10 5-Dec-12 ### https://Cl
5-Mar-18 19-Feb-20 ### 12-Oct-17 ### Beth Israel Deaconesshttps://Cl
14-Feb-18 31-Jul-18 31-Jul-18 23-Jan-18 ### Gloucestershire Primahttps://Cl
Mar-17 Mar-19 Mar-19 ### ### OHSU MS Center, Porthttps://Cl
Apr-10 Jun-10 Jun-10 18-Jan-12 ### https://Cl
Oct-14 Mar-21 Mar-21 ### ### Sarcoma Oncology Rese https://Cl
May-07 Jul-11 Jul-11 ### ### Tokyo Women's Medica https://Cl
Aug-11 Jan-15 May-15 31-Oct-11 23-Jun-15 Krankenhaus Nordweshttps://Cl
Mar-04 May-10 Jun-10 3-Jul-08 26-Jul-10 Henry Ford Health Syshttps://Cl
Jan-16 Jun-17 Dec-17 19-Jun-15 3-Dec-19 Americanin"Study Prohttps://Cl
Oct-11 Mar-12 Oct-12 3-Oct-11 14-Jan-13 Allergy Center Viennahttps://Cl
11-Feb-19 Feb-20 Dec-20 ### ### SATVI: Worcester, Worhttps://Cl
May-06 May-20 May-20 29-Oct-06 4-Jun-19 Memorial Sloan Kettehttps://Cl
18-Sep-17 20-Dec-19 ### 29-Jun-17 5-Feb-20 Universitair Ziekenhuhttps://Cl
Feb-97 Jun-01 Jul-02 28-Apr-04 ### Duke Comprehensivehttps://Cl
C
Jan-08 Mar-14 Apr-14 ### 3-Jun-15 US EPA Human Studies https://Cl
Nov-06 Aug-09 31-Jul-07 1-Jul-11 Rikshospitalet - Radi https://Cl
Oct-10 Jan-18 Jan-18 ### 11-Jan-18 Beth Israel Deaconesshttps://Cl
8-Mar-17 Jan-20 Aug-21 ### 11-Apr-19 Tom Baker Cancer Cenhttps://Cl
23-May-11 Apr-20 Apr-20 26-Apr-11 ### UCSF Helen Diller Famhttps://Cl
Jan-08 Feb-11 Mar-12 ### ### ### Please Contact the https://Cl
3-Oct-03 1-Dec-07 ### ### 2-Jun-09 6-Nov-18 https://Cl
Jun-04 Oct-05 Jan-06 ### 4-Jan-08 Clinical Research Assohttps://Cl
May-16 Mar-17 Apr-17 15-Jun-16 15-Jun-16 https://Cl
Apr-05 May-06 Aug-06 ### 4-Jan-08 National Royal Ortho https://Cl
Sep-16 Jan-17 Sep-17 ### ### "Study Prohttps://Cl
24-May-17 22-Dec-17 11-Jun-18 9-May-17 ### ### University "Study Prohttps://Cl
Jul-05 Aug-08 Jun-09 ### ### Alaska Clinical Resea https://Cl
Feb-05 Jun-09 Mar-13 8-Feb-05 7-Apr-14 14-Oct-15 Lombardi Comprehensiv https://Cl
Sep-07 Jan-09 Jan-09 30-Oct-07 2-Feb-10 12-Apr-17 https://Cl
May-16 Dec-17 Jun-18 20-Jul-16 10-Apr-19 Chu Reims, Reims, Fr https://Cl
Jun-14 Sep-14 Sep-14 ### ### University of Florida https://Cl
17-May-18 Dec-20 Jun-22 11-Jan-18 ### UF Health Shands Childhttps://Cl
18-Jul-16 Apr-21 Apr-21 ### ### University of Rochesthttps://Cl
Aug-13 Oct-13 Mar-14 ### 3-Jul-15 Korea University Ansahttps://Cl
15-Oct-18 Dec-20 Dec-21 5-Oct-18 ### Universitats Kliniku https://Cl
Mar-09 Jun-12 Jun-12 2-Apr-09 ### Fukushima Medical Un https://Cl
26-Sep-18 19-Jan-19 Mar-20 9-Oct-18 14-Oct-19 Investigational Site https://Cl
Feb-09 Aug-09 Aug-09 30-Jul-09 ### Central Region, GHANhttps://Cl
ACTG 221|11198 Oct-96 ### ### Stanford CRS, Palo Al https://Cl
Jan-06 Sep-09 Sep-09 24-Jan-06 ### Department of Pulmon https://Cl
Sep-09 Jun-11 Dec-11 9-Mar-11 9-Mar-11 Cangene Plasma Resour https://Cl
Oct-12 Jun-13 Nov-13 25-Apr-12 15-Jan-14 Malaria Vaccine and https://Cl
10-Jul-12 31-Jul-12 31-Jul-12 ### 6-Dec-13 7-Sep-18 GSK Investigational S https://Cl
Jul-07 Apr-10 Dec-10 9-Aug-07 6-Aug-12 Kangnam St. Mary's Ho https://Cl
26-Apr-09 10-May-17 ### 7-May-09 ### ### Grieskirch "Study Prohttps://Cl
Oct-01 Aug-06 May-15 24-Oct-08 29-Jan-18 29-Jan-18 Alta Bates Comprehens https://Cl
13-Mar-19 Dec-20 Dec-21 8-Mar-19 24-Apr-19 Walter Reed Army Inst https://Cl
6-Jul-18 Jun-20 Jun-20 9-Aug-18 9-Aug-18 Hospital Universitariohttps://Cl
Insular de Gran Canaria, Palma
Mar-14 Aug-15 Dec-15 ### 1-Mar-17 1-Mar-17 Aarhus University Hohttps://Cl
Sep-16 Mar-18 Sep-18 5-Mar-15 22-Jan-20 Banner MD Andersonhttps://Cl
M
Apr-10 Dec-13 Apr-16 4-May-10 27-Jul-16 New Horizons Women's https://Cl
AVEG 020|10570 Apr-99 ### ### Univ. of Rochester AVhttps://Cl
8-Dec-12 9-Apr-13 9-Apr-13 16-Apr-12 5-May-14 21-Jan-20 GSK Investigational S https://Cl
CDR0000466677|FAV-ID-11|FAV-WIRB-20051774 ### ### Tower Cancer Research https://Cl
Sep-12 31-Dec-17 ### ### 3-Mar-17 Centre de recherche https://Cl
Feb-05 ### ### UCLA Center For Vaccihttps://Cl
Nov-13 Feb-15 Mar-15 3-Dec-13 ### Johnson County Clinicahttps://Cl
21-Oct-09 22-Feb-11 ### 2-Oct-09 13-Jan-15 ### https://Cl
Mar-09 Aug-09 Dec-09 ### ### https://Cl
1-Jul-18 30-Nov-19 ### 14-Jun-18 ### Immunitor LLC, Ulaanhttps://Cl
Oct-08 Dec-11 Dec-11 7-Oct-08 20-Jul-16 Research Site, Greenvhttps://Cl
Mar-18 Aug-18 Aug-18 ### 11-Jan-19 https://Cl
Mar-01 ### 24-Jun-05 Scripps Stevens Cancehttps://Cl
21-Sep-17 9-Jan-21 9-Jan-24 12-Jan-17 29-Jan-20 Barrow Neurological Ihttps://Cl
Dec-10 Dec-13 Dec-13 10-Jan-11 ### Arkansas Children's Hhttps://Cl
Aug-98 Jun-01 Jun-01 ### 12-Apr-13 https://Cl
8-Jan-14 18-Jun-18 ### 23-Oct-13 ### Providence Cancer Cen https://Cl
Jun-15 Nov-17 Nov-17 ### 18-Apr-18 Children's Infectious https://Cl
Sep-15 Jun-16 Nov-16 ### ### https://Cl
Oct-10 Nov-10 Nov-10 27-Oct-10 ### 6-Feb-14 Institute of Paediatrics, https://Cl
University of Milan, Fondazio
5-Jan-15 24-Feb-16 ### ### ### ### Research Site, Orlandhttps://Cl
AVEG 002|10537 Jun-93 ### ### Univ. of Rochester AVhttps://Cl
Mar-16 Jun-16 Jul-17 ### ### Helsinki University, L https://Cl
Feb-08 Jul-10 Nov-10 14-Jul-09 14-Oct-09 https://Cl
28-Aug-14 6-Jul-15 6-Jul-15 ### 5-Feb-20 5-Feb-20 https://Cl
Apr-09 Oct-10 Jan-11 22-Jan-10 ### Maison Du DÃ©partem https://Cl
Jan-17 Jul-22 Jul-22 17-Jun-16 ### Hospices Civils de Lyohttps://Cl
Feb-06 Nov-06 Nov-06 ### ### 6-Oct-15 https://Cl
Nov-00 27-Jan-03 4-Dec-13 SuperGen, Incorporate https://Cl
Dec-01 Jul-07 Jan-09 ### ### ### https://Cl
May-16 Jul-16 Nov-16 14-Apr-17 14-Apr-17 Research Insitute for https://Cl
14-Jul-16 28-Jun-17 28-Jun-17 14-Apr-17 8-May-19 De La Salle Health Scihttps://Cl
12-Sep-18 10-Nov-21 ### 21-Jun-18 ### Stanford Health Care https://Cl
HVTN 026/HIVNET 026|10529|HIVNET 0 Jul-04 ### ### Projeto PraÃ§a Onze/H https://Cl
Oct-10 Apr-16 15-Apr-16 4-Feb-11 ### Walter Reed Nationalhttps://Cl
Feb-10 Nov-11 Dec-11 8-Jul-11 ### Korea University Ansahttps://Cl
May-05 Oct-17 Jun-18 29-Apr-15 ### https://Cl
27-Mar-17 15-Feb-21 ### 30-Jan-17 ### Mayo Clinic, Rochestehttps://Cl
1-Mar-12 28-Apr-14 28-Jun-18 8-Dec-11 9-Dec-19 Southwest Hospital, Chttps://Cl
Sep-10 Jan-16 Jan-16 ### 1-Mar-17 1-Mar-17 Penfield Pediatrics, https://Cl
Jun-99 Jan-02 Nov-03 25-Jun-04 17-Jan-18 Stanford University Mhttps://Cl
27-Jun-13 30-Aug-17 ### ### ### 2-Apr-19 "Study Prohttps://Cl
12-Jun-19 3-Apr-20 3-Apr-20 ### 11-Oct-19 Synexus Clinical Rese https://Cl
10-Sep-13 15-May-17 2-Jan-18 20-Jun-13 ### 9-Jul-19 UC San Die"Study Prohttps://Cl
1-Jul-11 3-Sep-12 3-Sep-12 ### ### ### GSK Investigational S https://Cl
HVTN 803|11636 May-05 ### 4-May-12 https://Cl
Dec-13 Nov-20 Nov-20 6-Nov-13 5-Feb-20 Icahn School of Medichttps://Cl
Sep-13 Sep-14 Sep-14 ### ### Hospital ClÃnic i Provincial
https://Cl
de Barcelona, Barcelona, C
Mar-08 Nov-12 Jul-13 4-Jun-12 3-Apr-14 Texas Childen's Hospihttps://Cl
Jul-15 Aug-16 Aug-16 8-Jun-15 26-Oct-17 26-Oct-17 Coastal Clinical Rese https://Cl
AVEG 801|11551 ### ### https://Cl
17-Jun-10 10-Jul-10 10-Jul-10 15-Jun-10 27-Oct-10 ### GSK Investigational S https://Cl
Sep-15 Nov-18 Apr-19 9-Nov-15 12-Jul-19 The University of Tex https://Cl
Apr-10 Jan-15 Jan-15 ### 25-Jun-15 CH Annonay, Annonay, https://Cl
Aug-98 Oct-04 Oct-04 5-Apr-04 8-Apr-13 Barbara Ann Karmanos https://Cl
Sep-98 Sep-99 Sep-99 24-Oct-11 16-Jun-17 https://Cl
4-Apr-18 Jun-20 Jun-20 ### 2-Jan-20 University of Texas Mhttps://Cl
Feb-15 Feb-17 Feb-17 3-Mar-15 ### PAREXEL Baltimore Ear https://Cl
Jan-00 May-04 2-Jul-03 24-Jun-05 Women's and Children' https://Cl
Jan-04 Aug-05 ### 19-Jun-13 Warren Grant Magnuson https://Cl
12-Dec-07 29-Jul-11 29-Jul-11 7-Dec-07 ### ### Arthur G. James Cance https://Cl
Jan-08 Jun-11 Jun-11 6-Feb-08 16-Jan-13 San Francisco Generahttps://Cl
Oct-09 Jun-10 Jul-10 3-Sep-09 9-Aug-10 Kenya Medical Researc https://Cl
Jul-05 Aug-05 Aug-05 ### ### GSK Investigational S https://Cl
1-Jun-07 30-Jan-08 30-Jan-08 ### ### ### GSK Investigational Sihttps://Cl
Apr-10 Sep-20 Sep-20 ### 10-Jan-20 Children's Hospital Lohttps://Cl
1-Apr-18 1-Apr-20 1-Jun-20 8-Jan-18 11-Jul-19 Beijing Tiantan Hospithttps://Cl
Dec-12 Aug-13 Aug-13 ### ### ### The Center for Pharma https://Cl
Oct-14 Jun-16 Oct-16 ### ### George Washington Uni https://Cl
Apr-04 ### ### Hem&Onc CharitÃ© CB https://Cl
Apr-08 Oct-08 Jan-09 ### ### Center for Rhinology https://Cl
Oct-11 Jul-13 Jul-13 14-Oct-11 26-Oct-12 Department of Infectihttps://Cl
Jul-04 Aug-05 ### ### Multidisciplinary Onchttps://Cl
1-Mar-10 31-Mar-10 ### 14-Jul-10 ### GSK Investigational S https://Cl
24-Jan-19 15-Feb-21 ### 14-Oct-16 ### SATVI: Worcester, Worhttps://Cl
13-Mar-10 16-Apr-10 16-Apr-10 ### ### GSK Investigational S https://Cl
13-Jun-19 13-Mar-20 9-Apr-20 ### 11-Oct-19 Synexus ( Site 1001), https://Cl
Jan-03 Jul-03 Jul-03 ### ### https://Cl
Feb-16 Apr-17 Apr-17 9-Dec-15 19-Jan-18 Travel Health Networkhttps://Cl
Aug-10 Feb-11 Feb-11 12-Jul-10 ### 20-Oct-16 GSK Investigational S https://Cl
Apr-02 ### ### Hematology&Oncology https://Cl
Mar-15 Jul-15 Sep-15 ### ### Jurong Province Centehttps://Cl
Jan-09 Aug-11 Aug-11 5-Nov-08 14-Apr-15 Immune Deficiency Trhttps://Cl
Sep-14 Sep-19 Dec-19 3-Oct-14 ### Immunitor LLC, Ulaanhttps://Cl
Sep-16 Aug-19 Aug-19 1-Jun-16 2-Jun-16 https://Cl
1-Jun-18 1-Dec-20 1-Dec-23 ### ### Praxis Dr. Cordes, B https://Cl
Jul-06 Jan-07 Jan-07 20-Jun-07 ### https://Cl
Jan-08 Mar-10 Mar-10 ### ### Health Protection Ag https://Cl
Jun-10 Nov-11 Nov-11 11-Jun-10 ### Vince & Associates, Ohttps://Cl
Jan-11 Aug-12 Aug-12 8-Mar-10 9-Nov-12 University of Pennsyl https://Cl
Jun-10 Dec-14 Dec-14 22-Jun-10 ### ### University of Miami, https://Cl
AFF010|2016-001462- Oct-17 2-May-16 5-Aug-16 University Hospital https://Cl
Apr-05 May-11 May-11 ### 10-Jul-12 10-Jul-12 University of Florida, https://Cl
6-Oct-17 10-Feb-20 ### 23-Jan-18 ### NIHR Imperial Clinicahttps://Cl
Apr-12 Apr-13 Sep-13 18-Jun-12 8-Sep-14 Maison Du DÃ©partem https://Cl
5-Oct-06 20-Jun-07 20-Jun-07 ### 9-Oct-18 9-Oct-18 GSK Investigational S https://Cl
Oct-15 Sep-16 Oct-16 29-Apr-15 7-Oct-15 UZ Leuven, Leuven, Bhttps://Cl
Apr-05 Sep-07 Apr-12 ### ### ### https://Cl
Mar-11 Jun-12 Jun-12 20-Apr-11 18-Jan-17 GSK Investigational Sihttps://Cl
Sep-08 Sep-09 Sep-09 23-Oct-08 19-Oct-12 Univ.-Prof. Dr. Bernd https://Cl
Feb-20 Jul-20 Jul-20 ### ### https://Cl
Apr-15 Apr-17 Apr-17 ### 17-Jun-16 HÃ´pital PitiÃ© SalpÃª https://Cl
Feb-09 Feb-14 Feb-16 ### ### Hamilton Health Sciehttps://Cl
May-20 Dec-21 Dec-21 8-Oct-19 8-Oct-19 CTC North, Hamburg,https://Cl
8-Dec-17 15-Jun-21 15-Jun-21 7-Mar-16 8-Apr-19 Mayo Clinic, Rochestehttps://Cl
1-Jul-10 11-Feb-14 ### 23-Jun-10 ### ### GSK Investigational S https://Cl
Sep-12 Aug-14 Aug-14 ### ### Centre for Clinical V https://Cl
Feb-01 Mar-07 6-Mar-07 ### Surgery Branch, Bethhttps://Cl
14-Dec-18 21-May-21 ### 2-Oct-18 ### Premier Health Resear https://Cl
Jun-05 Jun-06 ### ### https://Cl
Aug-05 Apr-07 4-Apr-07 ### Centre for Clinical V https://Cl
5-Oct-15 20-Jul-22 20-Jul-22 ### ### GSK Investigational S https://Cl
11-Jul-17 15-May-19 ### 5-Jul-17 18-Jun-19 Emory Children's Centhttps://Cl
Sep-02 Mar-06 27-Jan-03 24-Jun-13 Arizona Cancer Centerhttps://Cl
Dec-16 Dec-18 Dec-18 19-Apr-17 7-Jan-19 Urology Centers of Alhttps://Cl
Oct-08 Dec-10 Dec-10 ### 8-Jun-11 Durbanville Medi-Clinhttps://Cl
16-Jan-18 31-Dec-19 ### 30-Jan-18 3-Oct-19 New York University Shttps://Cl
Sep-11 Aug-12 Aug-12 4-Aug-14 ### ### https://Cl
21-Sep-15 22-Aug-17 ### 13-Jul-15 11-Apr-18 Centre for Clinical V https://Cl
Mar-10 Jul-10 Dec-10 ### ### ### Research Site, Birminhttps://Cl
Feb-04 Mar-13 Mar-13 1-Jun-05 22-Apr-13 Oncology Department, https://Cl
Sep-98 Mar-07 5-Mar-07 20-Jun-13 Surgery Branch, Bethhttps://Cl
Nov-99 Sep-04 Sep-04 5-Mar-04 1-Nov-10 1-Nov-10 Cancer Center and Bec https://Cl
Feb-02 May-06 May-07 ### 5-Sep-13 The University of Chichttps://Cl
Oct-03 Mar-07 Mar-07 ### 5-Sep-13 The University of Chichttps://Cl
Mar-97 Jul-02 Jul-02 ### 3-Jul-13 Memorial Sloan-Kettehttps://Cl
Oct-15 Jan-16 Jan-16 ### 26-Jan-16 Surrey Clinical Resea https://Cl
May-05 Mar-06 Mar-06 3-Aug-05 7-Sep-12 San Francisco, Califo https://Cl
Jan-10 Dec-11 Apr-12 ### ### Hadassah Medical Orga https://Cl
Nov-16 Jun-19 Jun-19 28-Apr-16 13-Jan-20 NYU Perlmutter Cancehttps://Cl
13-Apr-17 26-Jan-18 27-Oct-18 5-Apr-17 ### Site JP00001, Shinjukhttps://Cl
ACTG P1008|PACTG P1 May-05 ### 2-Mar-11 Univ of Alabama at Bihttps://Cl
Apr-99 Oct-06 16-Jul-04 26-Jun-13 Baylor University Medi https://Cl
Nov-07 Dec-08 Dec-08 16-Jan-08 ### ### North Central Neurolohttps://Cl
30-Aug-19 30-Apr-20 ### ### ### https://Cl
Nov-99 Aug-01 Aug-01 2-Apr-04 19-Jun-13 Memorial Sloan-Kettehttps://Cl
Nov-14 Dec-17 Dec-17 ### 6-Jun-16 Chinese PLA General Hohttps://Cl
Apr-16 Sep-20 Sep-20 16-Jun-17 23-Jan-20 Icddr,B, Dhaka, Bang https://Cl
Jun-03 Sep-12 Sep-12 ### 2-Oct-15 Jonsson Comprehensive https://Cl
Sep-10 Mar-11 Sep-13 ### 17-Jun-10 Hadassah Medical Cent https://Cl
Feb-00 Aug-02 ### ### Duke Comprehensivehttps://Cl
C
Apr-01 27-Jan-03 ### Baylor University Medihttps://Cl
Jun-05 Jun-05 ### ### Stanford Univ School https://Cl
Nov-00 Mar-03 30-Jul-03 ### Duke Comprehensivehttps://Cl
C
Dec-09 Nov-13 Nov-13 3-Dec-09 8-Jun-16 Weatherall Institute https://Cl
Apr-07 Mar-08 Mar-08 6-Dec-07 ### ### Stanford University Schttps://Cl
Jul-06 Mar-11 Mar-11 ### ### Memorial Sloan-Kettehttps://Cl
30-Nov-06 10-Jul-18 ### ### ### ### Mayo Clini"Study Prohttps://Cl
Sep-13 Sep-14 Sep-14 2-Sep-13 7-Jan-15 Site 12, Changsha, C https://Cl
Aug-00 May-02 May-03 ### 29-Jan-10 28-Jul-15 https://Cl
1-Sep-19 31-Jan-21 31-Jan-26 18-Jul-19 18-Jul-19 Dana Farber Cancer Inhttps://Cl
Sep-03 Aug-06 Sep-06 9-Apr-03 8-Sep-14 Duke Comprehensivehttps://Cl
C
Sep-00 Sep-04 5-Jun-07 5-Jun-07 Wellstar Cobb Hospitahttps://Cl
Nov-00 ### 6-Jan-14 Dana-Farber Cancer Ihttps://Cl
Jan-02 Aug-06 27-Jan-03 20-Jun-13 Warren Grant Magnuson https://Cl
22-Oct-18 1-Aug-26 1-Aug-26 8-Aug-18 ### Mayo Clinic Arizona ahttps://Cl
Oct-08 Jan-12 Jan-12 31-Jul-08 ### ### Loyola Univeristy Medhttps://Cl
Sep-07 Jun-13 Jun-13 ### ### 13-Apr-17 https://Cl
Mar-14 Aug-15 Aug-15 ### 8-Jul-19 Oxford Vaccine Grouphttps://Cl
11-Dec-17 15-Dec-18 ### ### ### university of Antwerphttps://Cl
Jul-01 Jan-02 Dec-02 8-Jan-04 2-Oct-15 Jonsson Comprehensive https://Cl
Jun-05 Jul-06 ### ### BahnhofstraÃŸe 9, Herhttps://Cl
May-98 Mar-01 Feb-04 4-May-04 20-Jan-16 University of Pittsburhttps://Cl
May-11 Jun-12 Jul-12 ### ### Johnson County Clin-Thttps://Cl
Jan-14 Aug-17 1-Aug-17 2-Nov-14 5-Sep-17 Uppsala University, P https://Cl
28-Sep-07 7-May-13 7-May-13 4-Feb-10 ### 17-Apr-17 https://Cl
26-Jun-17 30-Apr-20 31-Oct-20 6-Apr-17 ### Centre for Clinical V https://Cl
3-Mar-99 20-Apr-01 19-Oct-01 ### ### Massachusetts Genera https://Cl
Nov-98 May-03 27-Jan-03 20-Jun-13 Warren Grant Magnuson https://Cl
Sep-99 Oct-02 28-Jul-03 18-Jul-12 Vrije Universiteit M https://Cl
Nov-98 Dec-05 27-Jan-03 26-Jun-13 City of Hope Comprehe https://Cl
Jun-08 Dec-09 May-10 2-Jun-08 3-Aug-10 UCLA Medical Center,https://Cl
Sep-15 Jan-16 Jul-16 7-Sep-15 ### Huntsville, Alabama, https://Cl
Jun-07 Dec-11 Dec-11 31-Jul-07 9-May-17 Penn State Hershey Ca https://Cl
Jun-08 Mar-10 Dec-10 ### ### Hospital ClÃnic de Barcelona,
https://ClBarcelona, Spain|Hosp
Jun-08 Jan-11 May-13 5-Nov-08 ### Medische Oncologie, https://Cl
I
Aug-16 Oct-17 Jun-18 2-Sep-16 5-Dec-18 Clinical Research of https://Cl
Jul-97 Apr-00 Feb-05 ### ### Duke Comprehensivehttps://Cl
Ca
May-14 7-Sep-17 7-Sep-17 24-Jun-14 20-Jul-18 University of Chicagohttps://Cl
Nov-12 Jan-15 Jan-15 ### ### ### Centro Sanitario de Santo
https://Cl
Domingo, Santo Domingo,
May-16 Oct-16 Oct-16 10-Jun-16 6-Jan-17 https://Cl
May-14 Sep-14 Oct-14 ### ### Incheon St. Mary's Hohttps://Cl
6-Aug-18 31-Aug-20 ### ### ### Medical University ofhttps://Cl
Oct-08 Apr-10 Oct-10 19-Apr-11 19-Apr-11 https://Cl
9-May-18 5-Nov-18 11-Jun-19 18-Apr-18 ### ### Heartland C"Study Prohttps://Cl
Feb-08 Jun-10 Jun-10 ### ### https://Cl
Dec-10 Jul-11 Aug-11 ### ### Hope Clinic of the Emo https://Cl
Oct-12 Sep-13 Jan-15 ### 26-Jan-15 Westover Heights Clinhttps://Cl
Oct-09 Sep-13 Sep-15 5-Nov-09 ### H. Lee Moffitt Cancerhttps://Cl
Feb-09 Feb-12 Jun-13 ### ### Center for Immunizatihttps://Cl
Jan-96 2-Sep-04 6-Jan-14 University of Alabamahttps://Cl
21-Dec-16 Jul-19 Jul-19 9-Jan-17 9-Dec-19 San Diego, California,https://Cl
Feb-14 Jan-18 Jan-18 ### 12-Jul-17 Cheil General Hospitahttps://Cl
Feb-04 ### 8-Apr-11 Hadassah Medical Orga https://Cl
19-Sep-16 19-Mar-19 ### 3-Aug-16 14-Jan-20 14-Jan-20 GSK Investi"Study Prohttps://Cl
10-Feb-13 19-Oct-15 ### ### ### Kalisizo Hospital, Rak https://Cl
Mar-07 ### 1-Nov-07 Department of Infectihttps://Cl
Dec-02 Mar-04 Mar-04 9-Apr-03 5-Jun-13 Memorial Sloan-Kettehttps://Cl
May-04 Oct-09 11-Jun-04 26-Apr-10 H. Lee Moffitt Cancerhttps://Cl
Aug-05 Jul-06 Jul-06 ### ### 1-Apr-15 https://Cl
Nov-02 Mar-04 5-Dec-02 5-Mar-15 UCLA Medical Center,https://Cl
Feb-13 Oct-15 Oct-17 14-Jun-13 ### Bnai Zion MC, Haifa, https://Cl
Nov-03 4-Jan-06 Jan-09 3-Mar-04 ### Urology Centers of Alhttps://Cl
Jun-16 Feb-17 Feb-17 ### ### UZ Leuven, Leuven, Vhttps://Cl
Apr-10 Jun-15 Nov-15 4-Oct-10 ### Landesnervenklinik Wa https://Cl
26-Jul-17 16-Aug-19 ### ### ### Kaiser Permanente Was https://Cl
22-Dec-10 20-Aug-18 ### 23-Jan-09 ### ### Veterans Af"Study Prohttps://Cl
19-Jul-13 21-Feb-14 ### 6-May-13 2-Mar-16 ### GSK Investigational S https://Cl
Mar-13 Apr-15 Apr-15 10-Jul-13 ### Rhumatologie, CH de https://Cl
May-11 Nov-13 Mar-14 4-Nov-10 ### Roswell Park Cancer Ihttps://Cl
Aug-04 Jul-08 Jul-08 7-Jun-04 29-Jun-11 Columbia Presbyteriahttps://Cl
1-Aug-03 23-Jun-08 23-Jun-08 ### 17-Jul-09 2-Jan-20 GSK Investigational Sihttps://Cl
Apr-14 Apr-16 Nov-17 17-Apr-14 ### CHU BicÃªtre, Le Krem https://Cl
Jul-14 Jan-16 Jan-16 ### 1-Feb-17 RCSI Education and Rehttps://Cl
Oct-16 Jun-20 Nov-20 ### 18-Jan-20 Johannes Gutenberg U https://Cl
CYT004-MelQbG10 03 ### ### Dept. of Dermatology,https://Cl
1-Jan-20 30-Sep-21 ### ### ### Beijing Youan Hospitahttps://Cl
23-Apr-19 26-Jun-20 26-Jun-20 ### 30-Jan-20 Walter Reed Army Inst https://Cl
23-Jun-11 1-Jun-19 1-Jun-19 ### 21-Jun-19 https://Cl
Oct-06 Feb-10 Feb-10 ### 4-Sep-14 4-Sep-14 Pfizer Investigational https://Cl
1-Sep-17 Nov-22 Nov-22 14-Jan-19 23-Jan-19 Cebu Provincial Hospihttps://Cl
Dec-16 Dec-16 May-17 9-Dec-15 22-Jan-20 National Cancer Insti https://Cl
Sep-04 ### 3-Jan-08 Department of Oncolo https://Cl
30-Dec-13 10-May-16 ### 3-Apr-14 ### Site US10009, Los Anghttps://Cl
Nov-05 Jul-08 Jul-08 ### 1-Aug-08 The Methodist Hospita https://Cl
Oct-08 Dec-09 Mar-10 6-Jun-08 ### UnitÃ Operativa Semplice
https://Cl
di Epidemiologia (UOSE), Q
Apr-04 Jul-08 Oct-09 8-Sep-04 30-Oct-15 Jonsson Comprehensive https://Cl
Feb-16 Feb-18 ### ### Affiliated Hospital to https://Cl
May-08 Mar-11 Sep-11 10-Apr-09 ### Quantum Immunologics https://Cl
20-May-11 ### ### 7-Nov-19 University of Bamakohttps://Cl
May-16 Dec-18 Sep-19 ### ### Haukeland Universityhttps://Cl
Jul-15 Mar-19 Mar-20 ### 2-Aug-18 CCDI, Sao Paulo, SP, Bhttps://Cl
26-Apr-18 1-May-21 1-May-23 7-Jun-18 22-Oct-19 Oslo University Hospihttps://Cl
Oct-01 Jan-03 Jun-05 27-Jan-03 ### USC/Norris Comprehens https://Cl
B009|AG1661-202 ### 24-Jun-05 Agouron Pharmaceutica https://Cl
NCRR-M01RR00042-1694|M01RR000042 6-Nov-00 24-Jun-05 University of Michigahttps://Cl
Feb-09 Feb-10 ### ### https://Cl
B008|AG1661-201 ### 24-Jun-05 Agouron Pharmaceutica https://Cl
May-14 Sep-14 Oct-14 16-Jun-14 8-Dec-14 Antonio D. Ligsay, MDhttps://Cl
Nov-04 ### ### University of Rochesthttps://Cl
13-Mar-06 4-Aug-06 ### 2-Jul-17 National Institute of https://Cl
Dec-15 3-Nov-16 3-Nov-16 ### ### Medical University ofhttps://Cl
Dec-12 Jun-14 Dec-14 3-Apr-12 ### Velindre Cancer Centrhttps://Cl
Dec-06 Dec-06 Mar-07 ### 3-Jun-14 3-Jun-14 Malaria Vaccine and Dhttps://Cl
May-10 Jan-11 Jun-11 ### ### University of Readinghttps://Cl
Oct-13 Nov-13 Nov-13 14-Oct-13 ### Kanto, Japan https://Cl
Dec-10 Mar-13 Mar-13 4-Jan-11 29-Jan-14 UNC Center for Envirohttps://Cl
7-Dec-16 Mar-20 Oct-20 ### ### The Preston Robert Tihttps://Cl
ACTG 230|11207 Jan-99 ### ### Long Beach Memorialhttps://Cl
M
Quantin PHRC IR 2009 Sep-12 ### ### CHU Dijon, Dijon, Frahttps://Cl
Jun-06 Aug-11 Aug-11 ### 9-Sep-13 Cincinnati Children's https://Cl
A5130|AACTG A5130|10080|ACTG A513 Oct-06 ### ### Massachusetts General https://Cl
1-Sep-18 1-Sep-21 1-Sep-21 26-Oct-18 4-Dec-18 Centre Hospitalier Unhttps://Cl
Jun-12 Jul-12 Jul-12 4-May-12 ### Complejo Hospitalariohttps://Cl
TorrecÃ¡rdenas, AlmerÃa, And
27-Feb-17 15-Aug-18 ### 1-Mar-17 10-Jul-19 Oxford Vaccine Group,https://Cl
May-16 Aug-17 Jul-18 ### 19-Oct-18 Neurology Clinic and https://Cl
Aug-11 Mar-19 Mar-19 ### ### Shiga University of Mhttps://Cl
Oct-06 ### 19-Jun-15 https://Cl
1-May-09 1-Jul-14 1-Jul-14 3-Apr-09 5-Jul-10 ### GSK Investigational Sihttps://Cl
Aug-00 Mar-06 Jul-12 ### ### ### Please Contact the https://Cl
Sep-11 Mar-19 Mar-19 ### ### Shiga University of Mhttps://Cl
Sep-06 Sep-12 Sep-12 ### ### St. Michael's Hospita https://Cl
20-Nov-17 22-Dec-17 ### ### ### Korea University Gurohttps://Cl
Jul-09 Sep-09 Sep-10 12-Jan-12 12-Jan-12 Society for Applied Sthttps://Cl
29-Apr-17 19-Dec-18 ### ### ### Investigational Site, https://Cl
3-Jan-12 10-Apr-15 10-Apr-15 ### ### 18-Jan-18 Fred Hutchinson Canchttps://Cl
Jan-15 Oct-17 Oct-17 ### 8-Mar-17 IWK Health Centre, Ha https://Cl
Feb-10 Jun-12 Dec-13 ### 3-Apr-14 Maternal and Child He https://Cl
Jan-06 Feb-15 Feb-15 ### 6-Apr-15 University of Alabamahttps://Cl
22-May-19 30-Aug-21 ### 10-Apr-19 ### Miami Research Associahttps://Cl
Jun-10 Dec-10 Dec-10 23-Apr-10 3-Jan-13 Johns Hopkins Bloombe https://Cl
23-Sep-08 12-Mar-13 ### ### ### ### GSK Investigational S https://Cl
Dec-07 Nov-12 Nov-12 1-Feb-08 3-Jun-14 27-Jun-14 University of Alabamahttps://Cl
30-May-14 11-Jun-15 11-Jun-15 ### 4-Apr-16 ### https://Cl
18-Jul-19 30-Jun-21 ### 12-Apr-19 10-Jan-20 UAB The University https://Cl
3-Jul-01 ### 21-Jun-06 ### Post Graduate Instituhttps://Cl
Jul-02 Dec-05 Dec-05 ### 7-Sep-12 Houston, Texas, Unitehttps://Cl
19-Jan-16 1-Jan-21 1-Jan-21 8-Jan-16 23-Jan-20 National Institutes ofhttps://Cl
Oct-06 Dec-07 Dec-07 6-Oct-08 6-Oct-08 Malaria Research & Trhttps://Cl
22-Jun-18 23-Dec-19 ### ### 14-Jan-20 East Valley Family Ph https://Cl
25-Feb-13 17-May-16 ### 28-Jan-13 4-Jan-19 4-Jan-19 GSK Investigational S https://Cl
Feb-04 Apr-10 Apr-10 ### 17-Apr-19 Denver Health Medical https://Cl
Dec-05 May-06 ### ### Colonial War Memorial https://Cl
Jan-05 May-05 May-05 8-Jul-11 8-Jun-17 https://Cl
Sep-15 Sep-16 Sep-16 ### 1-Nov-16 Miami, Florida, Unitehttps://Cl
27-Apr-18 30-Jan-19 24-Jul-19 3-Jul-18 3-Jul-18 Samsung Medical centehttps://Cl
Nov-15 Nov-20 Dec-20 20-Jul-15 ### BC Centre for Diseasehttps://Cl
Jul-09 Jan-11 Jan-11 7-Apr-09 2-Jun-11 Muzaffarpur, Bihar, Inhttps://Cl
Mar-12 Aug-12 Aug-12 23-Apr-12 ### Centre 11, Almeria, Shttps://Cl
10-Dec-14 2-May-16 2-May-16 14-Apr-14 27-Jun-19 GSK Investigational S https://Cl
Jun-11 Jun-13 Dec-13 15-Jun-11 ### Farabi General Hospithttps://Cl
Jun-09 Nov-11 Nov-11 18-Jun-09 ### Cytos Investigator sit https://Cl
Apr-08 Dec-11 1-Jan-15 8-Jul-08 28-Jan-20 ifi-Medizin GmbH at https://Cl
1-Feb-20 30-Jun-20 ### ### ### Q-Pharm Pty Ltd (Nuchttps://Cl
Aug-12 Feb-21 Feb-21 ### ### Children's Hospital o https://Cl
Jul-95 Jan-02 4-Nov-99 4-Mar-08 National Cancer Insti https://Cl
Mar-11 Mar-14 Mar-14 4-Mar-11 ### Clinica Santa Catalin https://Cl
Mar-97 Apr-05 27-Jan-03 12-Jun-13 Kaiser Franz Josef Hohttps://Cl
Jun-08 Nov-12 Nov-12 30-Jun-08 ### 28-Oct-15 National Cancer Insti https://Cl
Jan-11 May-12 Nov-13 17-Apr-15 24-Jan-17 Centre Hosptialier Unhttps://Cl
Jul-11 Dec-11 Dec-11 12-Oct-11 ### Kyushu, Japan https://Cl
Oct-15 Aug-18 Aug-18 ### 13-Jan-20 27-Jan-20 Kaohsiung "Study Prohttps://Cl
30-Aug-17 Dec-20 Apr-21 10-Jun-16 ### ARENSIA Exploratory hMttps://Cl
Feb-08 Nov-11 Nov-11 ### 23-Jun-11 Iwate Medical Univershttps://Cl
19-Apr-04 Aug-12 7-Nov-17 7-Dec-06 2-Oct-17 1-Mar-19 Mayo Clinic, Rochestehttps://Cl
19-Mar-08 18-Mar-11 ### 4-Apr-08 5-Sep-17 GSK Investigational https://Cl
Jan-13 Aug-13 Aug-13 5-Sep-13 ### Central Arkansas Vetehttps://Cl
Nov-04 Sep-06 Apr-07 13-Jul-07 ### https://Cl
15-Mar-20 Mar-23 Mar-28 2-Aug-19 ### Johns Hopkins Bayviehttps://Cl
Nov-03 May-09 Apr-17 19-Jul-12 15-Jun-17 Providence Cancer Cen https://Cl
Mar-00 Jun-05 Jun-05 23-Apr-04 7-Sep-12 M.D. Anderson Cancer https://Cl
Feb-11 Oct-11 Mar-12 22-Jun-11 ### Lotus Labs, Bangalorehttps://Cl
8-Jan-18 Jun-20 Jun-20 ### 30-Oct-19 Genitourinary Maligna https://Cl
Jun-06 Dec-10 Dec-10 ### ### Department of Medical https://Cl
Aug-14 30-Nov-16 ### ### 1-Feb-17 https://Cl
Sep-02 Sep-10 Nov-10 27-Jan-03 ### Warren Grant Magnuson https://Cl
3-Jan-14 8-Apr-14 7-Mar-15 17-Apr-17 17-Apr-17 Korea University Gurohttps://Cl
1-Feb-19 1-Feb-20 ### 22-Oct-19 22-Oct-19 NIHR Southampton Clihttps://Cl
Dec-11 Apr-16 2-Jan-12 ### Outpatient Clinic, To https://Cl
Nov-06 Jan-07 ### ### Eastern Virginia Medichttps://Cl
1-Feb-18 28-Feb-19 ### ### 5-Feb-20 Centre de RÃ©cherc https://Cl
Aug-07 Oct-07 Dec-07 14-Jan-09 ### 2-Oct-15 https://Cl
1-Aug-19 1-Feb-23 Jan-24 ### ### Centre de Recherche https://Cl
1-Oct-18 13-Dec-18 ### 5-Sep-18 4-Jan-19 Korea University Gurohttps://Cl
Mar-02 Aug-05 2-Jul-07 2-Jul-07 Walter Reed Army Medi https://Cl
31-Mar-10 25-Aug-16 ### 18-Jan-10 9-Nov-18 9-Nov-18 Research Site, Brno, https://Cl
18-Dec-13 18-Sep-18 2-May-19 ### 22-Jan-20 22-Jan-20 National In"Study Prohttps://Cl
Jul-16 Nov-17 Dec-17 22-Jun-16 1-Aug-18 Miami Research Associ https://Cl
Apr-09 Oct-09 Jul-10 ### 2-Dec-14 University of South https://Cl
19-Nov-19 Sep-21 Sep-22 3-Oct-19 9-Dec-19 Aalborg University, https://Cl
Mar-08 May-08 May-08 29-Jan-08 ### ### GWUMC Clinical Trialshttps://Cl
Dec-07 Dec-12 10-Oct-07 3-May-13 New York Eye and Earhttps://Cl
18-Oct-18 1-Sep-19 1-Sep-20 ### 7-Nov-18 NIHR Southampton Clihttps://Cl
Sep-03 Apr-04 Apr-05 15-Oct-08 2-Apr-10 ### Vancouver, British C https://Cl
7-Jun-08 26-Jul-08 26-Jul-08 12-Jun-08 ### 6-Jun-18 GSK Investigational S https://Cl
1-Mar-19 19-Aug-20 ### ### ### Republican Clinical I https://Cl
May-07 Jan-10 Apr-12 ### 30-Oct-14 Cedars Sinai Medical h Cttps://Cl
Aug-99 ### ### San Francisco Dept ofhttps://Cl
Mar-15 4-Jul-19 4-Jul-19 ### ### AT001, Wien, Austri https://Cl
Dec-04 May-08 May-08 ### ### ### University of Californhttps://Cl
Jun-04 Oct-04 Jan-05 ### ### SFBC International, I https://Cl
Mar-15 Jun-21 Dec-21 22-Apr-15 ### Chevy Chase RCCA, Chhttps://Cl
12-Dec-13 3-Oct-17 22-Oct-21 ### ### 3-Dec-19 GSK Investi"Study Prohttps://Cl
May-14 Aug-15 Aug-15 ### 24-Jul-14 Respiratory and Menihttps://Cl
Oct-12 Nov-12 Nov-12 15-Oct-12 29-Apr-13 https://Cl
Jun-04 Jun-06 Jun-06 ### 5-Sep-13 The University of Chichttps://Cl
Jan-15 Apr-16 Oct-16 ### ### Matsontso Mathebulahttps://Cl
Apr-15 9-Aug-19 9-Aug-19 4-May-15 4-Sep-19 University of Illinoi https://Cl
10-May-11 18-Dec-12 26-Jul-13 25-Apr-11 2-May-16 ### https://Cl
28-Dec-16 Aug-22 Aug-22 ### ### Research Facility, Atl https://Cl
Dec-14 Aug-16 Aug-16 17-Oct-14 31-Oct-16 Medical University I https://Cl
Apr-12 Jul-20 Dec-20 ### ### Bang Lamung Districthttps://Cl
11-Dec-14 18-Apr-17 18-Apr-17 21-Oct-14 5-Jun-17 University Hospital B https://Cl
Jun-07 Jul-07 ### 4-Nov-16 GSK Investigational S https://Cl
Jan-11 Sep-14 Dec-14 ### ### https://Cl
Jan-06 May-07 ### ### https://Cl
16-Apr-14 6-Feb-15 ### ### 1-Aug-18 ### GSK Investigational Sihttps://Cl
Feb-06 Apr-09 Aug-12 20-Apr-06 ### ### University of Marylanhttps://Cl
7-Mar-13 31-Dec-19 1-Mar-20 ### 23-Oct-19 NIH Clinical Center, https://Cl
Jan-09 Jan-10 Jan-10 4-Feb-09 4-Feb-11 1-May-15 https://Cl
29-Aug-19 30-Jun-21 30-Jun-21 ### 4-Sep-19 Centre for Human Druhttps://Cl
Apr-11 Jun-12 Jun-12 14-Apr-11 12-Oct-11 I73 Department of Infhttps://Cl
Apr-11 Dec-11 Feb-12 14-Apr-10 7-Jul-11 HÃ´pital de Sion CHCVshttps://Cl
13-Mar-17 13-Mar-19 ### 9-Nov-17 9-Nov-17 Hospital Italiano, Ci https://Cl
16-May-18 20-Mar-19 ### ### 11-Oct-18 15-Jul-19 National In"Study Prohttps://Cl
22-Jan-06 1-Apr-06 23-Apr-06 ### ### ### GSK Investigational S https://Cl
Jul-12 Mar-13 Jun-13 17-Jul-12 ### ### Emory Children's Centhttps://Cl
Jul-15 Dec-19 Dec-20 20-Jul-15 30-Jul-15 https://Cl
Nov-08 Apr-10 Apr-10 8-Jul-08 ### Ordination Schmitz, Vhttps://Cl
May-07 Dec-09 Dec-09 4-May-07 29-Jan-13 29-Jan-13 Monroe Carell Jr. Chilhttps://Cl
Sep-08 Aug-20 Dec-20 3-Dec-08 10-Apr-19 Massachusetts Genera https://Cl
Jan-14 May-16 May-16 ### 9-Jan-19 University of Califor https://Cl
Aug-08 Dec-09 Mar-10 ### 2-Mar-10 Dept of Clinical Phar https://Cl
27-Nov-15 Nov-17 Nov-22 12-Jan-15 ### ### Brighton a "Study Prohttps://Cl
Jan-15 Nov-17 Dec-17 6-Oct-15 29-Jan-18 Children's Hospital L https://Cl
Mar-06 4-Oct-05 27-Oct-08 Indianapolis, Indiana https://Cl
Jan-15 Jul-15 10-Jun-14 ### 24-Jun-16 Roswell Park Cancer Ihttps://Cl
Jun-10 Mar-16 Sep-16 4-Jun-10 4-Jan-17 4-Jan-17 Jung-gu, Incheon, Korhttps://Cl
Mar-07 Mar-09 Mar-09 ### ### 13-Apr-17 GSK Investigational Site,
https://Cl
Mesa, Arizona, United States
3-Jan-10 30-Apr-19 30-Apr-19 20-Jun-18 ### Lazio, Italy|GSK Investigational
https://Cl Site, Genova, Liguria, I
1-Jun-95 1-Sep-10 1-Nov-10 1-Mar-10 3-Nov-11 ### https://Cl
18-May-01 15-Sep-17 ### 8-Aug-18 4-Feb-19 4-Feb-19 "Study Prohttps://Cl
Jun-15 Jun-16 Oct-16 10-Apr-15 1-Nov-17 Hospital ClÃnic de Bacelona,
https://Cl
Barcelona, Spain
Feb-11 Apr-14 Apr-14 5-Nov-15 6-Jul-16 UCLA, Los Angeles, Cahttps://Cl
May-08 May-11 May-11 9-Aug-10 ### GSK Investigational Sihttps://Cl
Jun-13 Jul-13 Jul-13 ### 15-Jan-16 https://Cl
Aug-19 Nov-19 Dec-19 ### 7-Mar-19 https://Cl
25-Oct-05 ### ### University of Connecthttps://Cl
Mar-05 Dec-07 Dec-08 9-Sep-05 ### Ifakara Health Resea https://Cl
Nov-05 Jan-06 ### ### Stanford University, Shttps://Cl
Jan-95 Feb-01 Feb-01 10-Jun-04 25-Jun-13 Memorial Sloan-Kettehttps://Cl
Jul-11 May-14 Sep-14 28-Jun-10 ### ### Hopital Aristide Le D https://Cl
Aug-02 Sep-02 ### 26-Jan-12 https://Cl
Jun-07 Apr-13 Oct-13 6-May-08 ### Duke Comprehensivehttps://Cl
C
1-Apr-19 18-Sep-19 Sep-20 ### 1-Nov-19 Investigational Site, https://Cl
Feb-13 18-May-16 18-Jun-16 24-Jan-13 ### St. Joseph Heritage Hhttps://Cl
Aug-12 Dec-15 Dec-15 1-Oct-14 1-Oct-14 https://Cl
8-Dec-14 24-Nov-17 1-May-18 ### 19-Jun-18 Bandim Health Projechttps://Cl
Jul-09 Jul-11 Apr-12 6-Aug-09 ### Duke University Medic https://Cl
Oct-07 Jul-08 Jan-09 ### 1-May-09 Children's Hospital B https://Cl
1-Dec-11 10-Jul-15 22-Jan-18 ### 16-Oct-18 Investigative site, La https://Cl
Feb-12 May-14 Oct-14 14-Oct-16 1-Feb-17 HÃ´pital Antoine-BÃ©c https://Cl
Oct-10 Sep-11 Jul-12 4-Dec-09 ### The Angeles Clinic anhttps://Cl
AVEG 202/HIVNET 014|HIVNET 014|1058 Jan-00 ### ### UAB AVEG, Birmingham, https://Cl
Sep-11 Sep-14 Sep-14 ### 9-Mar-15 GSK Investigational S https://Cl
Mar-05 Dec-10 Mar-11 ### 6-Jan-14 Mahavir Hospital, Hydhttps://Cl
24-Apr-14 22-Apr-15 24-Apr-15 ### ### ### GSK Investigational S https://Cl
Mar-07 Oct-11 Mar-12 21-Jun-06 26-Apr-13 All India Institute o https://Cl
May-03 Dec-05 Dec-05 ### ### Pfizer Investigational https://Cl
May-06 Jul-06 Sep-10 5-May-06 14-Jan-11 20-Oct-16 GSK Investigational Site,
https://Cl
AlmerÃa, Spain|GSK Investig
Mar-14 Mar-16 Apr-16 21-Jul-14 19-Apr-16 The Dongsan Medicalhttps://Cl
C
Mar-04 Mar-06 Mar-08 ### ### Lwak, Abidha, Ongielohttps://Cl
3-Jun-13 22-Oct-13 22-Oct-13 ### 5-Sep-14 30-Oct-18 https://Cl
15-Nov-17 20-Jan-19 20-Jan-19 8-Aug-17 28-Jan-19 Boston Medical Center https://Cl
Mar-06 Dec-08 Dec-08 ### ### Matrix Institute, Los https://Cl
May-11 Jul-11 Sep-11 ### ### Medical University, Vhttps://Cl
Oct-05 1-Jun-11 1-Jun-11 Pediatric infectious d https://Cl
Jun-03 Apr-05 22-Jul-05 ### Hopital Tenon, Paris, https://Cl
Dec-14 Apr-16 Apr-16 1-Dec-14 6-Jun-16 Miami, Florida, Unitehttps://Cl
Nov-99 Apr-01 Jun-01 9-Dec-05 8-Jan-09 https://Cl
Oct-05 Dec-06 Jan-07 ### 5-Oct-15 https://Cl
Feb-12 Mar-16 Dec-17 6-Feb-12 ### Duke University Medic https://Cl
Jun-08 Nov-09 Nov-09 8-Jul-08 ### Department of Clinicahttps://Cl
Apr-09 Jun-11 Jun-11 11-Jun-09 8-Feb-13 IRCCS Policlinico S. Mahttps://Cl
Jul-11 Apr-13 Nov-13 ### ### Studienzentrum der Phttps://Cl
Oct-04 May-12 May-12 ### 1-Nov-12 Hamilton Health Sciehttps://Cl
May-15 3-Jan-17 1-Feb-32 14-Jan-14 19-Apr-19 University of Iowa Hoshttps://Cl
Jul-03 Jun-04 8-Jul-03 ### Vanderbilt University,https://Cl
29-Jun-12 14-Nov-18 ### 18-Jun-12 ### Muntinlupa, Philippinhttps://Cl
Sep-20 Mar-24 Mar-25 21-Jan-20 7-Feb-20 https://Cl
11-Jul-09 1-Aug-09 1-Aug-09 29-Jun-09 ### ### GSK Investigational S https://Cl
Sep-11 Jul-14 Nov-14 27-Jun-11 ### ### New York University Shttps://Cl
Feb-06 Mar-12 Mar-12 12-Apr-06 ### H. Lee Moffitt Cancerhttps://Cl
5-Mar-19 28-Sep-23 ### 2-Nov-18 ### Imperial College Lon https://Cl
Feb-14 30-Dec-15 ### ### ### Montefiore Medical Ce https://Cl
Apr-13 Apr-14 Apr-14 ### 9-Sep-13 https://Cl
Oct-13 Jun-16 Jun-16 ### ### Service Universitair https://Cl
20-Jun-11 15-Oct-12 15-Oct-12 12-Jul-11 ### 9-Jan-19 https://Cl
Jul-13 Jul-13 Jul-13 ### 19-Jun-15 2-Mar-16 Rainier Clinical Rese https://Cl
10-Apr-19 4-Sep-19 4-Sep-19 25-Jan-19 ### HÃ´pital de la Croix- https://Cl
Feb-07 Feb-08 Feb-08 ### ### Tianjin, China https://Cl
16-Jun-17 22-Nov-19 ### 7-Mar-17 5-Feb-20 National Institutes ofhttps://Cl
May-08 Oct-09 Oct-09 ### ### University of Tamperehttps://Cl
Aug-07 Jun-08 Jun-08 ### ### Solano Clinical Resea https://Cl
ACTG 218|11195 Feb-96 ### ### Long Beach Memorialhttps://Cl
M
9-Jun-10 30-Jun-17 30-Jun-17 20-Apr-11 ### https://Cl
May-07 Aug-09 Aug-09 ### 10-Jul-12 Medizinische Universihttps://Cl
AVEG 007C ### 30-Oct-12 Vanderbilt Univ Hosp,https://Cl
Sep-10 Apr-13 Apr-13 20-Oct-11 1-Mar-13 Hospital Landeskrankhttps://Cl
13-Dec-19 1-Apr-21 1-Apr-21 ### ### The University of Tenhttps://Cl
Aug-09 Feb-11 Feb-11 ### 22-Jul-19 2-Aug-19 Biomedical Research h attps://Cl
Feb-20 Mar-22 Mar-22 ### 18-Jan-20 https://Cl
Oct-05 May-08 Jan-10 ### 17-Apr-12 Soweto, South Africa https://Cl
11-Feb-14 11-Feb-17 ### 13-Apr-17 13-Apr-17 https://Cl
Sep-11 Dec-22 ### 5-Feb-20 Arizona Oncology Serv https://Cl
Jul-07 Nov-09 Apr-10 28-Jun-07 9-Apr-12 19-Jul-12 Arkansas Pediatric Rehttps://Cl
Mar-13 Nov-21 Nov-21 ### 22-Jan-20 Service de NÃ©phrolo https://Cl
Apr-11 4-Feb-19 4-Feb-19 15-Jul-11 ### San Diego, California,https://Cl
31-Jan-19 6-Apr-22 ### 30-Apr-18 4-Sep-19 Task Clinical Researc https://Cl
Jan-11 Jul-11 Aug-11 9-Dec-11 6-May-19 6-May-19 Hospital de Basurto, Bhttps://Cl
28-Jun-19 31-Dec-20 30-Jul-21 3-Dec-18 ### St. Joseph Heritage Hhttps://Cl
Jun-04 Dec-06 1-Dec-05 18-Jul-06 https://Cl
5-Dec-19 Mar-22 Mar-22 6-Dec-18 3-Jan-20 Sidney Kimmel Compre https://Cl
Mar-97 Jan-05 27-Jan-03 18-Jan-13 Memorial Sloan-Kettehttps://Cl
28-Aug-18 Sep-20 Nov-20 26-Oct-18 ### Seoul National Univerhttps://Cl
16-Jan-12 13-Oct-15 13-Oct-15 12-Apr-12 3-Aug-16 ### Novartis Investigativ https://Cl
### 9-Sep-08 Johns Hopkins Univ / https://Cl
25-Oct-18 30-Oct-21 ### ### 7-Jan-20 University Hospitals https://Cl
9-Sep-15 16-Dec-15 28-Apr-16 19-Apr-17 19-Apr-17 Korea University Gurohttps://Cl
Oct-05 Jun-06 Jun-06 ### ### 4-Feb-16 https://Cl
Jan-17 Apr-17 Aug-17 2-Feb-17 14-Jun-19 14-Jun-19 Johns Hopk"Study Prohttps://Cl
May-08 Mar-09 Aug-09 11-Jun-13 17-Jun-13 Bio-Manguinhos/Fiocru https://Cl
Sep-15 Jun-16 Jun-16 4-Sep-15 7-Nov-16 Changwon Fatima Hospi https://Cl
Oct-10 Mar-14 Jul-14 5-Oct-10 ### Ben-Gurion Universityhttps://Cl
Nov-15 Sep-17 Nov-17 9-Sep-15 2-Nov-16 Cardiovascular Associhttps://Cl
Apr-05 Dec-06 ### 1-Oct-12 University of Erlange https://Cl
21-Jun-18 Jun-20 Jun-22 7-Aug-18 11-Apr-19 University of Miami, https://Cl
Nov-11 Mar-12 Mar-12 ### 20-Jun-12 Department of Infectihttps://Cl
Dec-01 Nov-04 Feb-08 27-Jan-03 4-Nov-19 Marlene and Stewart https://Cl
G
Jul-02 17-Jul-02 ### University of Califor https://Cl
Nov-08 Dec-10 Dec-10 7-Dec-10 7-Dec-10 https://Cl
20-Feb-17 30-May-18 ### 13-Jul-18 18-Jul-18 Boru PHCU,"Statistic https://Cl
May-11 Feb-12 Feb-12 ### ### Centre for Infectious https://Cl
Apr-12 Sep-14 Aug-15 4-May-12 26-Jul-18 The University of Al https://Cl
090|V103B ### 24-Jun-05 Beth Israel Hosp, Boshttps://Cl
Nov-16 Nov-19 Jun-20 ### ### Hospital Universitariohttps://Cl
4-Dec-19 Mar-21 Mar-21 ### ### Paulin Fao, Bobo-Diouhttps://Cl
Sep-09 Aug-10 Aug-10 22-Jun-09 24-Jul-14 24-Jul-14 Research Site, Hickor https://Cl
Jun-12 Apr-18 Apr-18 4-Jun-12 9-Apr-18 Queen Saovabha Memor https://Cl
Apr-14 Jan-15 Sep-15 ### 19-Oct-15 Investigational site, https://Cl
Feb-07 Feb-17 ### ### CHU Dijon Bourgogne,https://Cl
Mar-14 Mar-15 Mar-15 ### 26-Apr-16 26-Apr-16 Kumagaya-shi, Saitamhttps://Cl
Sep-13 Jul-16 Dec-16 21-Apr-14 ### Divisione di Malattie Infettive
https://ClAzienda Ospedaliera S.
15-Jan-20 1-Sep-21 1-Sep-22 6-Feb-19 4-Nov-19 https://Cl
Jul-05 Sep-05 12-Jul-05 17-Jun-10 Allied Research Inter https://Cl
8-Feb-18 Feb-22 Feb-22 ### 5-Jul-19 CHU de Montpellier, Montpellier,
https://Cl France|Centre de R
Jun-03 Oct-06 8-Sep-05 6-Oct-06 Department of Endocrhttps://Cl
Apr-10 Mar-15 Mar-15 22-Apr-10 ### ### Pediatric Primary Carhttps://Cl
Apr-08 May-12 ### 4-Mar-16 S.M. Goretti Hospital,https://Cl
Dec-14 22-Sep-18 ### 16-Jul-14 18-Oct-18 Oxford Vaccine Grouphttps://Cl
Jan-09 Oct-09 Dec-09 14-Jan-09 21-Apr-11 12-Apr-17 https://Cl
Dec-07 Mar-09 Mar-09 ### 27-Apr-09 Tartu University Clin https://Cl
Oct-08 Dec-10 Jan-11 20-Oct-08 ### 9-Jun-14 Rush University Medica https://Cl
Mar-16 May-17 May-17 ### 13-Jul-17 Fred Hutchinson Cance https://Cl
Feb-06 Feb-09 11-Jan-06 6-May-10 6-May-10 Saint Louis, Missouri https://Cl
Sep-06 Mar-11 May-12 2-Oct-12 2-Oct-12 A.O.U. San Giovanni Bahttps://Cl
Apr-14 Aug-20 Jan-22 ### ### Sheba Medical Centerhttps://Cl
Mar-20 Jun-21 Sep-21 ### ### https://Cl
14-Dec-19 Dec-20 Jun-21 ### ### Centre Muraz, Bobo-Di https://Cl
Mar-13 28-Sep-15 ### 6-Apr-11 ### University Hospitals https://Cl
Apr-06 Apr-06 Feb-07 12-Jan-09 12-Jan-09 Laboratoire d'anatomo https://Cl
21-Mar-17 4-Oct-18 4-Oct-18 9-Dec-16 23-Oct-19 23-Oct-19 Birmingham "Study Prohttps://Cl
1-Jun-16 10-May-19 ### ### 5-Jul-19 Department of Breasthttps://Cl
Nov-07 Dec-10 Feb-11 5-Feb-08 5-Nov-13 Diabetes Research Cen https://Cl
Mar-14 Feb-17 5-Mar-14 5-Mar-14 https://Cl
May-20 Mar-27 Mar-27 8-Apr-19 4-Nov-19 https://Cl
31-May-08 30-Jun-08 31-Oct-08 ### ### ### https://Cl
Jan-14 Feb-15 Feb-15 ### ### Sanofi Pasteur MSD Invhttps://Cl
19-Oct-05 ### Karonga Prevention Sthttps://Cl
13-Oct-09 31-Jan-22 31-Jan-23 1-Jun-09 ### University of Californhttps://Cl
Apr-16 Mar-18 Mar-18 2-Mar-16 14-Jun-18 The Christ Hospital C https://Cl
Dec-05 Mar-10 Mar-10 ### 16-Jul-14 Centre Hospitalier B https://Cl
Aug-10 Apr-12 Apr-12 ### ### Yonsei University Sevhttps://Cl
Oct-07 Apr-10 Apr-10 ### ### I73 Department of Infhttps://Cl
23-Jan-19 29-Jun-20 29-Jun-20 6-Nov-18 30-Jan-20 Nemours/Alfred I. duPhttps://Cl
Jan-13 Dec-16 Oct-18 ### 14-Jun-19 Prapokklao Hospital, https://Cl
Mar-15 Jul-15 ### 27-Apr-17 https://Cl
15-Jan-20 30-Oct-20 ### ### 10-Apr-19 https://Cl
3-Dec-18 Nov-20 Nov-20 26-Oct-18 ### Center for Virology a https://Cl
1-Nov-18 15-Jan-19 15-Jul-19 22-Oct-18 ### Herlev and Gentofe https://Cl
4-Sep-19 30-Jul-21 30-Jul-21 24-Jul-19 5-Feb-20 Queensland Children https://Cl
s
28-Dec-18 4-Jun-25 4-Jun-25 ### 1-Oct-19 Novartis Investigativehttps://Cl
Sep-14 Jun-20 Jun-20 7-Oct-14 5-Oct-17 PPD, Wilmington, Nort https://Cl
23-May-19 Nov-20 Dec-20 2-Oct-19 2-Oct-19 Hospital Vega Baja Orhttps://Cl
Sep-04 Sep-07 Sep-07 18-Jun-12 18-Jun-12 College of Public Healhttps://Cl
Dec-12 Dec-13 Dec-13 5-Dec-12 8-Feb-17 8-Feb-17 SATVI, University of https://Cl
Jan-12 Jul-15 Aug-15 ### 6-Oct-16 6-Oct-16 Merck KGaA Communic https://Cl
4-Apr-18 Jan-23 Mar-23 7-Jun-18 5-Feb-20 CharitÃ© Research Orhttps://Cl
Sep-15 Sep-16 Sep-16 ### ### https://Cl
Dec-12 Aug-14 ### 4-Feb-14 11-Apr-19 CHU Saint-Pierre, Bruhttps://Cl
Jan-17 Jul-18 Jul-18 22-Jan-16 7-Dec-16 https://Cl
Mar-03 Sep-03 ### ### University of Oxford, https://Cl
3-Jun-15 30-Nov-18 ### ### USC / Norr"Study Prohttps://Cl
Dec-15 Jan-17 Feb-18 ### 19-Apr-19 ### Cedars-Sinai Medical https://Cl
Center, Los Angeles, California, U
Dec-06 Dec-10 Jun-11 5-Jan-07 ### ### Dipartimento di Oncologia, Campobasso, Italy|DH On
https://Cl
Feb-12 Jun-14 Jun-14 10-Jan-12 2-Jun-16 13-Jan-17 NKI (Nederlands Kankhttps://Cl
Jan-15 Dec-15 May-16 ### 16-Jul-19 Viollier AG, Allschwi https://Cl
13-Feb-18 Jan-20 Jan-20 23-Jan-18 13-Jul-18 CHU Brugmann, Brusse https://Cl
Nov-16 5-Sep-17 5-Sep-17 25-Oct-16 ### Mayo Clinic, Rochestehttps://Cl
Oct-14 Dec-18 Dec-18 6-May-15 ### Children's Hospitals https://Cl
5-Aug-09 20-Jan-14 20-Jan-14 13-Jul-09 15-Jan-15 29-Oct-19 GSK Investigational S https://Cl
Feb-16 May-17 Sep-17 1-Feb-16 9-Jan-19 Walter Reed Institutehttps://Cl
May-15 Feb-16 Feb-16 10-Jun-15 5-Apr-16 SGS Life Sciences, An https://Cl
Aug-00 Feb-04 ### ### https://Cl
3-Sep-14 5-Sep-18 ### ### 9-Jan-20 University of Califor https://Cl
May-11 May-11 May-11 ### ### ### Rainier Clinical Rese https://Cl
Mar-94 Mar-00 ### 4-Mar-08 National Cancer Insti https://Cl
Apr-03 Jan-06 Jan-06 15-Oct-15 13-Jan-16 13-Jan-16 Los Angeles, Californ https://Cl
Oct-15 Apr-16 Apr-16 ### 13-Jul-17 UniversitÃ¤tskliniku https://Cl
Jun-10 Dec-25 Dec-25 21-Apr-14 15-Oct-19 Fred Hutchinson Cance https://Cl
Sep-09 Sep-12 Sep-12 ### 30-Jan-18 Alexandria, Virginia, https://Cl
5-Nov-18 Feb-20 Aug-20 ### 6-Nov-19 H. Lee Moffitt Cancerhttps://Cl
May-15 31-Oct-16 9-Dec-16 4-Mar-15 ### ### Desmond Tutu HIV Fou https://Cl
13-Mar-18 May-20 May-21 ### 24-Jul-19 Tom Baker Cancer Cent https://Cl
Oct-09 Oct-10 Oct-10 2-Jul-09 ### MRC-Entebbe, Entebbhttps://Cl
Aug-15 Dec-17 Dec-17 ### 7-Jun-17 Center for Vaccinologhttps://Cl
1-Apr-14 2-Jun-15 2-Jun-15 ### ### GSK Investigational S https://Cl
Aug-16 Jul-20 Jul-20 ### 15-Oct-19 Hematology and Transhttps://Cl
Aug-13 Feb-14 Mar-14 1-Jan-14 ### PIMER, Chandigarh, I https://Cl
Jul-13 Nov-13 Feb-14 7-Oct-15 7-Oct-15 https://Cl
Feb-08 Aug-08 Aug-08 31-Jul-07 ### Kilimanjaro Christian https://Cl
Aug-14 Dec-14 Dec-14 10-Oct-14 10-Apr-15 Leiter des Geriatris https://Cl
12-Oct-15 31-Dec-16 ### 23-Jun-17 23-Jun-17 University of Turku, Thttps://Cl
Dec-13 Dec-17 Apr-18 ### ### ### University "Study Prohttps://Cl
May-02 25-Jun-02 2-Nov-06 Arizona Cancer Centerhttps://Cl
Jan-16 Jan-17 26-Jun-14 ### University of Miami - https://Cl
Sep-01 Dec-01 ### 3-Oct-06 https://Cl
18-May-10 ### 14-Jan-20 National Institutes ofhttps://Cl
1-Feb-18 1-Jul-20 1-Jul-20 5-Feb-18 ### Women's and Children' https://Cl
Jan-08 Dec-08 Dec-08 21-Apr-16 21-Apr-16 hVIVO Services Ltd, https://Cl
18-Oct-19 Nov-20 May-21 7-Oct-19 22-Oct-19 Providence Portland M https://Cl
Oct-09 Oct-10 Oct-10 ### ### Johns Hopkins Univershttps://Cl
Jan-11 Dec-13 Apr-14 21-Jul-11 22-Apr-14 Western Human Nutritio https://Cl
29-Apr-19 Dec-19 Apr-21 2-May-19 9-May-19 DaVita Clinical Researhttps://Cl
Sep-11 Jan-13 May-14 ### 1-Nov-19 1-Nov-19 Winthrop University Hhttps://Cl
14-Nov-16 12-Dec-16 ### 1-Jul-15 2-Oct-18 Wake Forest School Ohttps://Cl
Sep-09 Dec-18 Dec-18 ### ### UCLA Care Center, Loshttps://Cl
Nov-05 May-07 May-07 19-Oct-05 9-Dec-08 BAART/Antioch Methad https://Cl
6-May-16 1-Apr-19 1-Apr-19 29-Oct-18 6-Aug-19 Respirator "Study Prohttps://Cl
Mar-12 Aug-15 Dec-15 ### ### LKH - University Clinichttps://Cl
Graz, Graz, Austria|LKH Salzbur
Jan-14 Dec-19 Dec-23 ### 8-Jul-19 The Thai Red Cross A https://Cl
Feb-08 ### 23-Oct-13 Bandim Health Project https://Cl
Nov-08 Feb-17 Apr-17 ### ### International Centre https://Cl
Sep-13 19-Jun-19 19-Jun-19 ### ### Sidney Kimmel Compre https://Cl
Jul-15 Jun-18 Jun-18 ### ### Beijing Ditan hospitalhttps://Cl
Nov-07 Dec-10 3-Dec-09 1-Mar-11 San Raffaele Hospital,https://Cl
23-Oct-17 31-Dec-19 Dec-20 2-Jul-17 10-Jan-20 Beth Israel Deaconesshttps://Cl
1-Feb-17 1-May-18 1-Jun-18 ### 6-Jun-18 St. Mary's Health Centhttps://Cl
28-May-14 18-Dec-17 ### 4-Jun-13 27-Jan-20 Emory Vaccine Centerhttps://Cl
Jan-17 Oct-19 Dec-19 13-Jan-17 13-Jan-17 Stockholm Environment https://Cl
Mar-07 May-07 May-07 8-Mar-07 4-Jun-15 https://Cl
Dec-91 Aug-07 Aug-07 22-Jan-04 4-Oct-11 St. Jude Children's R https://Cl
5-May-17 22-Nov-18 ### 1-Mar-17 ### St. Joseph Heritage Hhttps://Cl
Nov-09 Mar-12 Dec-12 29-Oct-09 17-Apr-13 Aichi Cancer Center Hhttps://Cl
Mar-14 Jan-15 Jan-15 ### 22-Jan-15 Centre for Clinical V https://Cl
Dec-10 Nov-11 Oct-13 ### ### ### Research Institute forhttps://Cl
27-Sep-18 Sep-19 Sep-20 ### ### Matlab Health Researhttps://Cl
Mar-14 Jan-16 ### ### 19-Oct-18 Centre for Clinical V https://Cl
May-06 Jul-09 Jan-10 11-Jul-07 2-Jul-18 2-Jul-18 H. Lee Moffitt Cancerhttps://Cl
Aug-16 Jan-21 Jan-21 ### 5-Jul-19 UCSD Antiviral Researhttps://Cl
28-Oct-19 31-Aug-20 ### ### 31-Jan-20 HVIVO Services Ltd ( https://Cl
May-09 May-10 May-10 ### ### Beth Israel Deaconesshttps://Cl
Jun-14 Jun-23 Dec-23 ### 6-Jan-20 Dept. of Dermatologyhttps://Cl
ICT-7392-Compassionate Use 31-Jan-14 ### Northwestern Memorial https://Cl
Jul-99 Apr-01 ### 1-Feb-13 Roswell Park Cancer Ihttps://Cl
Aug-19 Sep-22 Aug-23 ### ### CIC 1417 Cochin-Pastehttps://Cl
Feb-07 Sep-08 Sep-08 30-Jan-07 ### Children's Hospital B https://Cl
Jun-04 2-Aug-04 8-Feb-06 University of South Ahttps://Cl
10-Nov-17 10-Nov-17 ### 6-Oct-17 24-Jul-18 Nice Hospital, Nice, https://Cl
Dec-08 Feb-14 Aug-14 ### 3-Sep-14 Groote Schuur Hospithttps://Cl
20-Jul-10 19-Oct-11 ### 12-Jul-10 18-Jun-18 GSK Investigational S https://Cl
Aug-07 Jun-16 Jun-16 30-Jul-07 ### Frontage Clinical Servhttps://Cl
Sep-11 Jun-12 Jun-12 30-Jan-12 ### Faculty of Medicine, Chttps://Cl
Jun-99 Jun-10 Jun-10 15-Apr-03 21-Jan-20 Texas Children's Hosphttps://Cl
Sep-05 ### 17-Jun-10 Allied Research Inter https://Cl
Oct-10 Sep-11 Sep-11 7-Dec-10 ### Jiangsu Provincial Ce https://Cl
Nov-06 Nov-09 30-Apr-08 9-Sep-10 Wakayama Medical Uni https://Cl
Jul-12 Feb-13 Feb-13 ### ### https://Cl
Aug-11 Apr-12 Nov-12 ### 7-May-14 Cincinnati Children's https://Cl
Oct-16 Dec-17 Sep-18 ### ### https://Cl
Sep-06 Sep-07 Sep-07 ### ### St George's Vaccine I https://Cl
Oct-17 Jul-18 Jul-18 ### 4-May-18 https://Cl
AVEG 027|10577 Oct-00 ### ### UAB AVEG, Birmingham, https://Cl
Aug-04 Apr-12 Sep-12 ### 9-May-14 Baylor College of Medhttps://Cl
Nov-11 Nov-13 Nov-13 ### 6-Dec-13 Hopital Lariboisiere, https://Cl
Mar-07 Mar-10 Mar-10 5-Jan-05 ### University of the Wit https://Cl
4-Feb-15 27-Jan-17 27-Jan-17 14-Jan-15 26-Jun-17 Baylor College of Medhttps://Cl
Jan-09 Jul-09 Jul-14 ### ### ### University of Californhttps://Cl
Dec-16 Dec-19 Oct-20 6-Jul-16 28-Oct-19 City of Hope Comprehe https://Cl
2-Dec-19 Nov-21 Dec-21 2-Dec-19 3-Dec-19 Seoul National Univers https://Cl
Sep-10 Dec-10 Jan-11 21-Oct-10 26-Jan-11 Univ. Klinik fÃ¼r Neurhttps://Cl
Sep-12 Dec-15 Dec-15 5-Oct-12 14-Apr-16 Southampton Universihttps://Cl
24-Sep-18 20-Dec-19 ### 7-Dec-18 7-Dec-18 Biomedical Research h Cttps://Cl
Oct-04 May-06 Jul-06 24-Jun-05 ### OKPRN, Oklahoma City https://Cl
22-Jul-13 1-Sep-19 30-Jun-20 11-Jun-13 13-Jan-20 National Institutes ofhttps://Cl
26-Jun-18 27-May-19 ### ### ### FI001, Turku, Finla https://Cl
Oct-07 Dec-08 Sep-09 5-May-08 2-Feb-16 Queensland Institute https://Cl
AVEG 005A/B|10546|10547 Apr-92 ### 30-Apr-12 Univ. of Rochester AVhttps://Cl
Oct-03 Sep-08 Jun-10 13-Jun-05 8-Jan-13 8-Jan-13 Kaiser Permanente Ped https://Cl
Jun-10 Mar-19 Mar-19 ### ### Shiga University of Mhttps://Cl
Sep-11 May-13 May-13 30-Jun-11 ### 23-Jun-16 https://Cl
25-Nov-05 10-May-10 ### 6-Dec-07 31-Oct-18 Mayo Clinic Cancer Cehttps://Cl
May-06 Jan-08 Feb-08 9-Mar-07 ### Baylor College of Medhttps://Cl
12-Nov-15 12-Sep-16 21-Jun-19 ### ### Mesa, Arizona, Unitedhttps://Cl
Apr-06 Sep-09 Sep-09 ### ### Center for Vaccine D https://Cl
1-Sep-17 31-Dec-19 ### ### ### Maternal and Child He https://Cl
30-Nov-11 9-Jan-15 ### 14-Jun-11 ### 6-Aug-19 H. Lee Moffitt Cancerhttps://Cl
26-Jun-17 30-Sep-18 ### ### ### Philasende Clinic, Umlhttps://Cl
Jul-13 Nov-13 ### ### Sheffield Teaching Hohttps://Cl
22-Oct-14 15-Jun-24 15-Jun-24 ### 27-Jan-20 GSK Investigational S https://Cl
1-Oct-16 9-Oct-19 9-Oct-19 1-Nov-18 11-Oct-19 Guangzhou Blood Cenhttps://Cl
8-Apr-19 28-Feb-22 ### ### ### Radboud University Mhttps://Cl
Mar-10 Oct-13 Oct-14 4-May-10 ### Division of Allergy anhttps://Cl
Jun-98 Aug-03 ### 21-Jun-13 Duke Comprehensivehttps://Cl
C
Jul-11 Jul-14 Dec-14 31-Oct-13 31-Oct-13 National Taiwan Univehttps://Cl
Apr-10 4-Jan-19 4-Jan-19 3-Jun-10 ### Naval Medical Centerhttps://Cl
Nov-16 8-Jul-19 8-Jul-19 9-Nov-16 ### Beth Israel Deaconesshttps://Cl
May-07 Dec-08 Dec-08 12-Jan-07 ### Vanderbilt University https://Cl
Nov-15 Aug-17 Jul-22 ### 2-Feb-16 https://Cl
Jul-15 Dec-16 Dec-16 ### ### Gloucestershire primahttps://Cl
5-Apr-19 30-Oct-20 30-Apr-21 ### 9-Apr-19 Orlando Immunologyhttps://Cl
C
Nov-04 Nov-13 ### ### Bandim Health Projechttps://Cl
Aug-09 Jan-13 Jan-13 ### 1-Jan-16 1-Jan-16 Meitetsu Hospital, Ai https://Cl
31-Mar-15 31-Dec-17 ### ### ### https://Cl
Nov-05 Aug-07 Aug-07 19-Oct-05 9-Dec-08 HEPPAC, Oakland, Calihttps://Cl
Mar-06 Mar-09 ### 6-May-15 Oklahoma University hCttps://Cl
Jan-10 Apr-12 Apr-12 9-Mar-10 19-Jan-15 White Mountain Apache https://Cl
Jan-15 Jun-18 Jun-18 5-Sep-13 28-Apr-17 The Third Affiliated https://Cl
Feb-09 May-12 May-12 ### 7-Dec-16 7-Dec-16 Childrens Hospital of https://Cl
1-Oct-15 13-May-16 Dec-19 ### ### Walter Reed Army Instihttps://Cl
Apr-16 Feb-20 Dec-20 ### 9-Jan-20 Stanford University, https://Cl
27-Jan-10 28-Feb-14 ### ### 27-Apr-11 1-Feb-19 GSK Investigational S https://Cl
13-Jun-19 30-Jun-20 ### 30-Oct-19 31-Oct-19 University Clinical C https://Cl
10-Aug-18 31-Oct-19 31-Oct-19 ### ### Kaohsiung Chang Gung https://Cl
Sep-15 Mar-16 Jan-17 4-Sep-15 13-Jan-17 NIZO food research, Ehttps://Cl
Apr-14 Apr-20 Apr-20 12-Jun-19 12-Jun-19 Service de Virologie, https://Cl
13-Nov-19 Sep-21 Dec-21 29-Jan-19 ### University of Arkansashttps://Cl
Apr-12 Sep-20 Mar-21 29-Apr-16 18-Oct-19 National Heart and Luhttps://Cl
3-Jul-18 28-Jun-19 28-Jun-19 25-Apr-18 6-Aug-19 Investigational centerhttps://Cl
15-Apr-15 Dec-19 Dec-21 8-May-15 8-Aug-19 University of Arizona https://Cl
31-Jan-16 30-Nov-19 ### ### 18-Jan-20 GSK Investigational S https://Cl
Jul-14 Dec-15 Dec-15 21-Apr-14 5-Feb-20 Kikoneni Health Centehttps://Cl
Jan-13 Jun-16 Aug-16 13-Jun-16 3-Feb-17 https://Cl
30-Jun-19 Jul-21 Dec-21 21-Jun-18 28-Oct-19 Duke University Medic https://Cl
Nov-10 Nov-14 Nov-14 ### ### ### Novartis Investigativ https://Cl
3-Jun-19 16-Dec-19 ### ### 27-Jan-20 SGS Life Sciences, Cl https://Cl
Sep-09 Aug-12 Jun-14 ### 10-Jul-14 Instituto de OncologÃhttps://Cl
a "Angel H. Roffo", Buenos Aire
30-May-17 Oct-18 Oct-18 2-Jul-17 2-Jul-17 Seoul St. Mary's hospihttps://Cl
999907214|07-C-N214|CDR0000565972 Mar-11 ### ### https://Cl
Jul-06 May-10 May-10 28-Jul-10 ### National Cancer Centehttps://Cl
Mar-20 Sep-21 Sep-21 12-Apr-17 7-Feb-20 https://Cl
Apr-04 Nov-04 ### ### Saint Louis Universityhttps://Cl
Sep-09 May-11 May-11 2-Dec-09 16-Apr-19 Collegium Medicum Un https://Cl
May-15 Dec-16 May-17 ### ### Operating unit of Allehttps://Cl
Jan-03 Dec-08 ### ### National Taiwan Univehttps://Cl
Apr-03 Aug-11 Jun-12 1-Jun-05 22-Apr-13 Ludwig Institute for https://Cl
7-Nov-02 4-Dec-02 ### National Institutes ofhttps://Cl
Aug-02 Jul-06 Jul-06 25-Oct-07 27-Jan-09 University of Illinois https://Cl
Dec-11 Jul-12 Nov-12 ### ### Seattle Biomedical Res https://Cl
Mar-09 Dec-10 Dec-10 29-Jul-09 13-Apr-11 Dr Tormo, Barcelona,https://Cl
Sep-06 Mar-08 Mar-08 ### 11-Jul-13 11-Jul-13 https://Cl
Jan-12 Jul-13 Aug-14 24-Apr-12 ### International Centre https://Cl
Sep-10 Sep-16 Sep-16 26-Oct-11 29-Jul-16 Instituto MÃ©dico CER,https://Cl
Quilmes, Buenos Aires, Argen
Jan-12 Apr-12 Jan-13 5-Dec-11 ### HÃ´pital Archet 1, Nichttps://Cl
Feb-03 Aug-05 ### ### University of Roches https://Cl
Oct-14 Apr-15 Apr-15 21-Oct-14 3-Dec-15 4-Apr-17 Research Site, Akashihttps://Cl
Dec-08 Dec-10 Sep-12 10-Apr-14 27-Apr-16 South African Tubercuhttps://Cl
Sep-16 26-Mar-18 ### 28-Oct-16 ### Covance Clinical Resehttps://Cl
May-07 Jan-13 Jan-13 ### 1-Jan-16 1-Jan-16 Groupe Hospitalier Pihttps://Cl
Apr-06 Jan-12 14-Jul-06 ### Clinical Research Un https://Cl
Feb-12 Dec-13 Dec-14 ### 25-Apr-19 Oregon Health and Scihttps://Cl
Jun-14 Jun-16 Jun-16 ### 4-Apr-18 Center for Environmen https://Cl
26-Sep-19 31-Dec-20 ### 9-May-19 ### Center for Vaccine D https://Cl
1-Mar-16 31-Jul-19 31-Jul-19 17-Jul-18 24-Jul-18 Aga Khan University, https://Cl
May-05 Nov-05 Feb-06 20-Jul-06 25-Apr-08 SGS Aster-Cephac, Parhttps://Cl
16-Mar-18 31-Dec-20 ### 1-Nov-17 ### St. Joseph Heritage Hhttps://Cl
Dec-12 Jan-14 Jan-14 23-Oct-12 6-Mar-17 6-Mar-17 UCLA CARE Center, Los https://Cl
Jun-11 Jul-13 Oct-15 ### 4-Apr-16 4-Apr-16 University of Virginia,https://Cl
Nov-98 Nov-02 18-Jul-03 31-Jan-13 University of Texas - https://Cl
Sep-09 Sep-12 ### 15-Jun-11 University of Calgary https://Cl
1-Sep-17 31-Aug-20 ### 11-Jan-18 27-Jan-20 Ziekenhuis Oost-Limbhttps://Cl
Mar-16 Oct-16 Oct-16 ### 27-Oct-16 UVRI-IAVI HIV Vaccin https://Cl
Feb-07 Jan-08 Jan-08 ### ### Albertville, France| https://Cl
6-Nov-09 25-Jul-14 25-Jul-14 23-Oct-09 13-Jan-11 4-Sep-18 GSK Investigational Sihttps://Cl
Mar-14 Jul-15 Jul-15 5-Mar-14 ### Diablo Clinical Resea https://Cl
Jan-06 Nov-06 1-Feb-06 25-Jan-08 Colonial War Memorial https://Cl
Sep-10 Jan-14 Apr-14 ### 4-Aug-15 8-May-17 Boro Heath Center, B https://Cl
Jan-06 Oct-08 Dec-12 23-Oct-08 23-Oct-08 National Taiwan Univehttps://Cl
Apr-10 May-16 May-16 ### ### University of Alabamahttps://Cl
Jul-13 Aug-14 Aug-14 12-Jul-13 13-Oct-14 Q-Pharm Pty Limited,https://Cl
2-Dec-15 1-Dec-18 ### 21-Apr-16 24-Jul-19 VA Ann Arbor Healthchttps://Cl
1-Jul-17 28-Feb-28 30-Apr-28 18-Apr-17 9-Jan-20 Vanderbilt Universityhttps://Cl
19-Dec-17 Dec-21 Dec-21 ### ### Oxford University Hoshttps://Cl
Oct-07 Jan-09 30-Oct-07 14-Jul-17 Gynecologic Oncologyhttps://Cl
Nov-00 14-Apr-03 ### Massachusetts Genera https://Cl
21-Nov-18 31-Dec-20 ### ### 19-Jul-19 CHU La Timone, Marse https://Cl
5-Feb-07 30-Nov-16 26-Oct-17 ### ### 30-Oct-18 University of Alabamahttps://Cl
Oct-16 Apr-20 Aug-20 ### 18-Jul-18 Samsung Medical Cente https://Cl
Feb-07 Sep-09 Nov-09 18-Jan-07 3-Aug-10 Arizona Cancer Centerhttps://Cl
Mar-07 Jan-12 Jan-12 23-Apr-07 ### ### https://Cl
Mar-02 Nov-07 ### 27-Jan-03 5-Sep-18 Dana-Farber Cancer In https://Cl
15-Sep-15 14-Apr-17 14-Apr-17 ### 17-Apr-18 2-Apr-19 "Study Prohttps://Cl
Jan-09 Dec-10 Jan-11 ### 5-May-17 University of Louisvil https://Cl
AVEG 019|10569 Mar-96 ### 9-May-12 Univ. of Rochester AVhttps://Cl
Jun-13 Jun-20 Jun-20 ### ### Brigham and Women's https://Cl
Oct-95 Dec-15 Dec-15 12-Jun-12 17-Jul-12 University of South Flhttps://Cl
Feb-12 Jul-12 Jan-13 14-Jan-13 ### ### Centre de SantÃ© auhttps://Cl
M
Jan-13 Nov-13 Feb-14 30-Jan-13 ### Bandim Health Project https://Cl
Jun-15 Jan-17 Jan-17 9-Jan-17 ### ### Tokyo, Jap "Statistic https://Cl
Mar-13 Jun-13 Jun-14 4-Apr-13 15-Oct-14 Radboud University Nhttps://Cl
30-Jan-07 26-Oct-07 26-Oct-07 3-Sep-07 5-Apr-17 Center for Immunizatihttps://Cl
Jun-17 Jun-19 Jun-19 ### ### Clinical Site TBA, San https://Cl
Jan-13 Dec-18 Dec-18 ### 4-May-18 Women and Infants' Ho https://Cl
20-Mar-18 1-Dec-23 1-Dec-23 20-Oct-17 18-Jan-20 National Institutes ofhttps://Cl
Mar-05 Dec-06 Apr-07 ### ### 14-Apr-16 Fayetteville, Arkansa https://Cl
Oct-07 Jun-11 Jun-11 ### 8-Mar-12 Research Site, Oakland https://Cl
21-Oct-19 31-Mar-20 30-Apr-20 ### ### Clinical research cen https://Cl
AVEG 012A|AVEG 012B|10557 Jun-95 ### ### JHU AVEG, Baltimore,https://Cl
12-Jun-15 9-Sep-16 9-Sep-16 29-Jun-15 1-May-19 National Institutes ofhttps://Cl
Sep-12 Jan-18 Jan-18 2-Mar-12 3-Aug-18 Clinical Research Advhttps://Cl
Apr-15 30-Jun-16 30-Jul-16 1-Apr-15 ### University of Louisvi https://Cl
26-Sep-18 13-Nov-18 ### 24-Jul-18 ### NIZO Food Research, https://Cl
Sep-10 Dec-13 Dec-13 6-May-10 ### Landeskrankenhaus Hal https://Cl
7-May-18 1-Nov-18 ### 5-Mar-18 17-Jan-19 Radboud university mhttps://Cl
11-Apr-19 Aug-20 Aug-20 ### 15-Oct-19 Mallow Primary Health https://Cl
AVEG 033|10582 Oct-99 ### ### UAB AVEG, Birmingham https://Cl
6-Apr-17 22-Jun-18 22-Jun-18 ### 2-Dec-19 University of Bamakohttps://Cl
Sep-10 Oct-12 Oct-12 27-Jun-13 28-Jul-17 https://Cl
Jun-16 29-Jun-17 29-Jun-17 18-Jul-16 ### Radboud university mhttps://Cl
31-Mar-14 2-Aug-19 2-Aug-19 ### ### GSK Investigational Sihttps://Cl
Jan-08 Dec-10 Dec-11 10-Apr-12 10-Apr-12 Taizhou Hospital of Zhhttps://Cl
Jan-02 Dec-08 Dec-08 22-Jul-16 22-Jul-16 https://Cl
AVEG 036|10585 Mar-00 ### ### JHU AVEG, Baltimore,https://Cl
Mar-14 May-16 May-16 21-Apr-14 19-Jun-17 19-Jun-17 https://Cl
Nov-07 Jun-14 Oct-18 3-Dec-07 ### ### Sidney Kimmel Compre https://Cl
7-Dec-17 7-Dec-19 7-Dec-19 26-Jan-18 26-Jan-18 UVRI-IAVI HIV Vaccin https://Cl
May-13 Jan-14 Feb-14 ### ### Garuda Primary Healthttps://Cl
4-Jun-19 4-Jun-19 Jun-21 5-Jun-19 ### Les HÃ´pitaux Univershttps://Cl
Oct-15 28-Jun-19 28-Jun-19 ### 15-Jul-19 State University of N https://Cl
Jul-07 20-Jun-07 ### https://Cl
Jul-13 Jul-15 May-17 25-Apr-14 ### Beijing Tiantan Hospithttps://Cl
Sep-91 27-Jan-03 ### Middlesex Hospital- https://Cl
10-Sep-03 ### 14-Jan-20 National Institutes ofhttps://Cl
Dec-08 Dec-09 Jul-10 ### 22-Jul-10 Johns Hopkins Bayview https://Cl
Oct-09 Sep-10 Nov-10 1-Sep-10 17-Apr-12 MaternitÃ© Necker-Bru https://Cl
Aug-09 Jan-10 Mar-10 6-Aug-09 13-Jan-12 3-May-18 Coastal Clinical Rese https://Cl
Jul-08 Dec-09 Jun-10 11-Jul-08 ### The Thai Red Cross A https://Cl
AVEG 015|10563 Mar-96 ### ### St. Louis Univ. Schoo https://Cl
Sep-11 May-12 May-12 30-Jan-12 ### https://Cl
13-Jan-20 18-Mar-22 ### ### ### The Hope Clinic of th https://Cl
Oct-05 Apr-07 6-Oct-05 ### Frankfurt, Germany https://Cl
18-Apr-17 1-Aug-21 1-Aug-22 14-Oct-16 7-Feb-20 National Institutes ofhttps://Cl
Sep-14 Feb-18 Feb-18 9-Sep-13 11-Jan-18 Surrey Clinical Rese https://Cl
13-Sep-18 Jan-28 Jan-28 ### 31-Jan-19 Emory Clinic, Atlanta https://Cl
9-Apr-19 30-Sep-20 ### 23-Jan-20 23-Jan-20 Beijing You'an Hospithttps://Cl
6-Oct-16 4-Apr-20 4-Apr-20 22-Jul-15 6-Feb-20 University of Californhttps://Cl
1-Jan-12 31-Aug-14 ### 23-Jan-18 23-Jan-18 https://Cl
Nov-11 Jun-13 ### ### Medical Research Couhttps://Cl
ACTG 214|11191 Sep-96 ### ### UCLA CARE Center CRS, https://Cl
18-Sep-18 19-Nov-18 ### ### 7-Mar-19 Mayo Clinic- Scottsdahttps://Cl
1-Sep-18 1-Sep-19 1-Sep-19 ### 22-Oct-19 NIHR Southampton Clihttps://Cl
Apr-05 Sep-05 Feb-06 20-Jul-06 24-Apr-08 SGS Aster-Cephac, Parhttps://Cl
Mar-04 Aug-05 Aug-05 12-Jan-04 ### Albert Einstein Cancehttps://Cl
Jan-14 Jul-14 Jul-14 ### 7-Sep-16 Research Site, Oakland https://Cl
Feb-02 Mar-04 1-Mar-02 4-Mar-08 Warren G. Magnusonhttps://Cl
C
Mar-03 Dec-06 Dec-06 24-Jun-09 ### Department of Urologhttps://Cl
Sep-10 Jan-14 Jan-14 ### 26-Jan-15 https://Cl
25-Jul-18 Dec-20 Mar-22 ### 16-Jul-19 MD Anderson Cancerhttps://Cl
C
1-Jul-93 30-Nov-95 ### 8-Sep-06 ### Dhaka Hospital, ICDDhttps://Cl
Jan-09 May-14 May-14 4-Mar-09 11-Jun-15 Hadassah University Hhttps://Cl
11-Apr-19 11-Apr-21 11-Apr-22 ### ### Children's National Mhttps://Cl
31-Jul-17 Nov-20 Nov-20 5-Jun-17 ### UniversitÃ¤tsmedizinhttps://Cl
Aug-08 Aug-09 Aug-09 18-Jul-08 23-Jul-10 13-Apr-17 https://Cl
17-Aug-11 17-Jun-11 ### National Institutes ofhttps://Cl
21-Apr-15 9-Jun-16 9-Jun-16 ### ### Miami, Florida, Unitehttps://Cl
29-Nov-17 2-Mar-18 2-Mar-18 19-Jul-17 8-Feb-19 University of North Cahttps://Cl
14-Aug-17 Sep-19 Jun-21 18-Oct-17 ### Florida Cancer Speciahttps://Cl
Oct-99 Jun-04 ### 2-Mar-11 San Francisco Dept ofhttps://Cl
B012|0900-397 Jun-06 ### 2-Nov-12 New York Hosp - Corne https://Cl
30-Sep-11 11-Oct-19 ### 18-Oct-19 National Institutes ofhttps://Cl
Oct-13 Jul-16 23-Jan-14 ### International Centre https://Cl
16-Jun-09 8-Jul-09 8-Jul-09 15-Jun-09 27-Jul-10 ### GSK Investigational S https://Cl
Jan-14 Sep-16 Jun-17 ### ### Departamento de AlergologÃ
https://Cl
a. ClÃnica Universidad d
Oct-97 Sep-00 ### 4-Mar-08 National Cancer Insti https://Cl
Oct-15 Sep-16 Sep-16 9-Oct-15 5-Oct-16 Simbec Research Ltd,https://Cl
Jun-04 Jul-08 3-Jun-09 3-Jun-09 University of Virginia,https://Cl
7-Jul-08 30-Jul-08 30-Jul-08 27-Jun-08 ### ### GSK Investigational S https://Cl
AVEG 022|10572 Nov-97 ### ### UAB AVEG, Birmingham, https://Cl
29-Apr-13 25-Mar-14 ### ### ### ### https://Cl
12-Jun-18 30-Aug-20 ### 27-Apr-18 10-Apr-19 National Institutes ofhttps://Cl
1-Apr-15 1-Sep-16 1-Sep-16 ### ### Damien JOLLY, Reims,https://Cl
AVEG 022A|10573 May-99 ### ### UAB AVEG, Birmingham, https://Cl
AIEDRP AI-05-006|905 ### 30-Jul-08 Joanne Santangelo, Sahttps://Cl
Mar-14 17-Aug-15 ### 23-Apr-13 ### ### Austin Health, LICR Mhttps://Cl
Feb-11 Nov-14 Apr-15 ### 25-Apr-18 Athens, Ohio, United https://Cl
Dec-12 May-19 May-19 10-Oct-14 ### Oslo University Hospihttps://Cl
AVEG 024|10575 Jan-98 ### ### UAB AVEG, Birmingham, https://Cl
Feb-00 Aug-15 Oct-15 ### ### Department of Orthopa https://Cl
4-Oct-16 21-Mar-17 ### ### ### Edouard Herriot Hospihttps://Cl
20-Jul-11 1-Jul-11 ### National Institutes ofhttps://Cl
Apr-06 May-07 Mar-08 13-Oct-06 16-Apr-19 Center Of Research Exhttps://Cl
Feb-15 Dec-20 Dec-20 15-Jun-15 ### University of Californhttps://Cl
21-Mar-11 15-Apr-13 15-Apr-13 ### 3-Jun-14 ### https://Cl
Oct-05 May-06 2-Sep-05 5-Apr-07 Children's Hospital B https://Cl
1-Aug-18 30-Oct-20 ### 21-Jun-18 3-Jan-20 Peri-urban slums of Khttps://Cl
Oct-15 Sep-17 Sep-17 14-Oct-15 ### Texas Oncology P.A., https://Cl
Jan-15 Jan-16 Jan-17 20-Jun-13 6-Mar-18 https://Cl
11-Dec-19 Jan-22 Jun-22 ### 13-Jan-20 Banner MD Andersonhttps://Cl
Ca
Jan-14 Dec-16 Dec-16 ### 12-Jun-17 Department of Obstethttps://Cl
Jul-06 Aug-08 Dec-10 ### ### Goethe University, D https://Cl
Jan-12 30-Jun-16 ### ### ### CHUM - HÃ´pital HÃ´te https://Cl
25-Jan-19 1-Dec-21 1-Dec-21 ### 30-Jan-20 Brigham and Women's https://Cl
H
10-Mar-15 10-Mar-20 ### 8-Feb-17 ### Hamad medical corpor https://Cl
Dec-09 May-10 May-10 2-Mar-10 5-Jan-11 Medical University Vihttps://Cl
Jul-08 Jul-13 Jul-14 ### 9-Oct-13 The University of Chichttps://Cl
Mar-15 Feb-24 Feb-24 13-Jan-16 ### Helmholtz Centre for https://Cl
Apr-05 Apr-08 ### 9-May-12 Pharmacology Research https://Cl
Sep-13 Dec-14 Jul-15 13-Jun-13 ### University Hospital ofhttps://Cl
Sep-83 Dec-04 ### ### Qidong Liver Cancer Ihttps://Cl
10-Dec-12 30-Nov-18 ### 18-Jul-18 19-Jun-19 https://Cl
Mar-07 Jul-08 Aug-08 30-Jul-08 8-Dec-09 Medical University Vihttps://Cl
20-Nov-17 Nov-20 Nov-20 8-Mar-18 ### Centre Oasis, Associahttps://Cl
28-Jan-14 1-Jul-16 1-Jul-1616-Jan-14 30-Apr-19 24-Jun-19 https://Cl
Apr-12 Oct-14 Oct-14 11-Jul-12 2-Dec-14 Nanjing Drum Tower Ho https://Cl
Sep-12 Dec-16 Dec-16 ### 10-Jul-19 10-Jul-19 Georgia Regents Unive https://Cl
Sep-14 Oct-19 Oct-21 29-Jul-16 19-Apr-18 Institut Curie, Paris, https://Cl
4-Jun-19 30-Aug-21 ### 6-Mar-19 ### National Institutes ofhttps://Cl
Feb-15 Mar-15 Mar-15 8-Dec-14 3-Apr-15 https://Cl
Feb-12 Dec-12 Dec-12 7-Mar-12 ### SPMSD Investigationalhttps://Cl
### 24-Jun-05 Aaron Diamond AIDS https://Cl
Rs
AVEG 005C|10548 May-92 ### 30-Apr-12 Univ. of Rochester AVhttps://Cl
Nov-10 Jun-18 Dec-18 28-Jan-11 ### Hospital de la Santa Chttps://Cl
Apr-15 Mar-18 Mar-18 8-Sep-17 8-Jun-18 University of Modenahttps://Cl
Mar-20 10-Feb-22 ### ### ### George Washington Uni https://Cl
28-Jan-20 Nov-22 Nov-22 ### ### HonorHealth, Scottsda https://Cl
26-Feb-18 17-May-19 14-Jun-19 8-Feb-18 ### Severance Hospital, https://Cl
Oct-08 Jun-10 Jun-10 5-Oct-10 10-Oct-16 Boston Medical Center https://Cl
Jan-17 Sep-20 Sep-21 ### ### Massachusetts general https://Cl
25-Sep-18 31-Aug-21 ### 26-Oct-18 1-Nov-19 Chevy Chase RCCA, Chhttps://Cl
23-Sep-19 Sep-22 Sep-24 5-Sep-18 3-Oct-19 University of Alabam https://Cl
Feb-07 30-Jun-15 26-Jan-16 5-Feb-07 18-Apr-17 Brigham and Women's https://Cl
Jul-13 Oct-16 Feb-17 16-Jul-13 ### 9-Oct-19 Xenoscience, Phoenix,https://Cl
Sep-07 Dec-24 Dec-24 ### ### Sorlandet Hospital, https://Cl
21-Jul-08 15-Feb-14 28-Jun-17 3-Jul-08 ### 9-Nov-18 Virginia Commonwealt https://Cl
May-09 Jun-12 Jun-12 ### ### For additional informhttps://Cl
May-16 Sep-20 ### 11-Oct-19 Foothills Urology, Go https://Cl
Mar-10 Sep-10 Sep-10 12-Jul-10 25-Jan-11 GSK Investigational S https://Cl
17-Sep-16 31-Dec-18 ### 30-Jul-18 30-Jul-18 SkÃ¥ne University H https://Cl
24-Apr-19 Mar-21 Mar-24 7-Mar-19 ### Centre Hospitalier Unhttps://Cl
28-Nov-18 Nov-19 Nov-19 ### ### CHU de Bordeaux - sehttps://Cl
May-16 Jan-20 Nov-20 15-Apr-16 ### KEMRI Wellcome Trust https://Cl
21-Jul-14 31-Mar-16 ### 4-Dec-13 2-Aug-18 Timika Research Facilhttps://Cl
1-May-17 1-May-20 1-May-20 ### 2-Nov-18 Icahn School of Medichttps://Cl
Sep-03 Dec-05 ### ### Krankenhaus Nordweshttps://Cl
16-Jan-18 20-Nov-19 Nov-20 ### ### Charlotte, Charlotte https://Cl
15-Aug-17 1-Nov-19 1-Nov-19 30-Oct-17 21-Jan-20 Optimal Research, Roc https://Cl
Oct-08 Aug-14 Aug-14 8-Oct-08 ### Pfizer Investigationa https://Cl
Aug-16 Dec-16 Dec-16 18-Jan-17 23-Jan-17 302 Military Hospital,https://Cl
Feb-09 Oct-09 Dec-09 ### ### https://Cl
Feb-17 Aug-17 13-Jan-17 13-Jan-17 Bandim Health Project https://Cl
4-Mar-19 Sep-19 Dec-19 8-Aug-18 2-Jul-19 Encino Research Group https://Cl
20-Sep-16 31-Dec-19 ### 12-Apr-16 ### Centre for the Aids P https://Cl
17-Aug-18 Jul-20 Jul-20 6-Apr-18 ### Miami Cancer Institute https://Cl
Oct-15 Aug-16 Aug-16 ### ### 302 Military Hospital,https://Cl
Feb-04 Nov-09 Nov-09 ### ### Shepherd Center, Atlahttps://Cl
Oct-10 May-12 Jan-14 29-Oct-12 10-Jan-14 Maastricht Universityhttps://Cl
3-Oct-18 28-Nov-18 ### 26-Oct-18 22-Jan-20 22-Jan-20 WCCT Globa "Study Prohttps://Cl
Jul-17 Dec-20 Dec-22 ### ### https://Cl
Oct-07 Aug-14 Dec-14 ### ### Kuopio University Hoshttps://Cl
Jun-13 Dec-13 Mar-14 30-Jul-13 30-Jul-13 https://Cl
Mar-14 Dec-15 Mar-16 19-Apr-17 19-Apr-17 https://Cl
Oct-07 Oct-08 20-Jun-08 20-Jun-08 Yuan Ze University, Tahttps://Cl
Jan-13 Oct-14 Oct-14 4-Jan-13 ### Scintipharma, Lexingthttps://Cl
Feb-12 May-14 May-14 2-Apr-12 ### Studienzentrum der Phttps://Cl
Sep-12 Nov-13 Nov-13 2-Oct-12 ### Scintipharma, Lexingthttps://Cl
Oct-06 Dec-08 Sep-09 ### 26-Jul-10 Queen's University Behttps://Cl
Jan-14 Jul-18 Aug-18 1-Mar-18 5-Feb-20 FundaciÃ³n Salud de https://Cl
Jul-15 Sep-15 Sep-15 7-Sep-15 23-Jul-19 Novartis Investigativehttps://Cl
Apr-96 Mar-00 ### 4-Mar-08 National Institute of https://Cl
Oct-07 Jul-08 Jul-08 18-Jul-07 ### ### GSK Investigational Sithttps://Cl
Oct-00 ### 6-Nov-13 University of Coloradhttps://Cl
29-Dec-19 31-Dec-20 1-Mar-21 ### 6-Jan-20 Houston Methodist Em https://Cl
Aug-12 Oct-12 Nov-12 26-Jun-12 ### UMC St Radboud, Nijhttps://Cl
21-Feb-20 31-Mar-21 ### ### ### National Institutes ofhttps://Cl
Jul-10 Oct-11 20-Oct-11 ### ### Lyndhurst Gynecologic https://Cl
Mar-16 11-Jul-18 11-Jul-18 ### 7-Oct-19 University of North Cahttps://Cl
Sep-14 Dec-17 Apr-18 ### 27-Apr-18 District Muleba, Mulehttps://Cl
May-08 Jan-11 Mar-11 ### ### Lyndhurst Gynecologic https://Cl
7-Oct-19 8-May-20 8-May-20 5-Aug-19 13-Jan-20 University of Marylanhttps://Cl
Oct-03 Jun-07 Nov-07 ### 20-Oct-09 USC KECK School of Me https://Cl
Aug-14 Oct-14 Nov-14 ### ### UMC St Radboud, Nijhttps://Cl
Jan-16 Feb-17 Mar-18 ### 5-Aug-19 5-Aug-19 Children's "Study Prohttps://Cl
8-Aug-11 17-Apr-13 ### 9-Dec-19 National Institutes ofhttps://Cl
Oct-10 Apr-11 Sep-11 ### 24-Jan-14 Allergopharma GmbHhttps://Cl
20-Dec-19 1-May-20 ### ### ### Uhmontpellier, Montpe https://Cl
Jul-14 Sep-14 Feb-15 ### 23-Apr-15 Centre de Recherch https://Cl
Sep-11 Nov-11 Nov-11 14-Jul-11 ### Hospital Universitariohttps://Cl
de Salamanca, Salamanca, Spa
1-Apr-18 Dec-19 Dec-19 ### 2-Dec-19 Kasr El Ainiy Hospital https://Cl
Jan-04 Oct-07 Oct-07 ### 13-Jan-10 Stanford University Schttps://Cl
26-Apr-16 29-Jul-16 1-Aug-16 3-May-16 27-Jun-19 17-Jul-19 https://Cl
22-Oct-19 Feb-21 Feb-21 7-Oct-19 2-Jan-20 Duke Clinical Researchttps://Cl
Nov-09 Apr-10 Apr-10 ### ### The Rockefeller Univehttps://Cl
### ### University of Arkansahttps://Cl
Jan-15 Jul-17 Dec-19 5-Sep-16 ### Caen University Hospihttps://Cl
Jun-01 Feb-05 27-Jan-03 ### Onze Lieve Vrouw Ziek https://Cl
May-13 29-Jul-16 ### 19-Apr-13 ### Arizona Cancer Centerhttps://Cl
Jan-12 Apr-14 Apr-14 1-Apr-16 1-Apr-16 https://Cl
May-03 ### ### https://Cl
Nov-09 Jan-14 Jan-14 7-Oct-09 10-Oct-19 University of Pennsyl https://Cl
5-Nov-18 Nov-20 Nov-20 5-Nov-18 7-Nov-18 Allergy, Immunology, https://Cl
Nov-06 Jun-08 Jun-08 ### 2-Oct-12 Columbia University Shttps://Cl
Oct-08 Jul-10 Nov-10 13-Apr-15 4-May-16 4-May-16 University of Cape Tohttps://Cl
4-Nov-19 Nov-20 Nov-20 ### ### St George's, Univers https://Cl
Sep-15 Oct-15 Oct-15 ### 14-Oct-15 Surrey Clinical Resea https://Cl
24-Oct-11 25-Nov-16 ### ### 9-Mar-18 9-Mar-18 Please Contact US Med https://Cl
May-15 Feb-19 Feb-19 1-May-15 5-Mar-19 Dana Farber Cancer Inhttps://Cl
Apr-10 Sep-12 Nov-12 28-Jun-11 28-Jun-11 Lata Medical Researchttps://Cl
Jul-11 Mar-13 Mar-13 19-Jul-11 ### The Rockefeller Univehttps://Cl
Oct-07 Feb-14 Jul-14 4-Nov-07 14-Jan-14 Rutgrers University Hhttps://Cl
21-Jul-15 31-Dec-16 12-Jun-18 22-Jul-15 14-Jun-18 Ouelessebougou Clinhttps://Cl
Jun-11 Sep-11 Sep-11 ### ### The Rockefeller Univehttps://Cl
Sep-08 Jun-09 Jul-10 30-Apr-15 27-Apr-16 Kenya Medical Researhttps://Cl
21-May-15 13-May-17 21-Oct-17 30-Jan-18 30-Jan-18 https://Cl
Jan-15 Dec-20 Jun-21 ### 5-Feb-20 George Was "Informed https://Cl
21-Jul-17 31-Dec-20 ### ### ### Varsinais-Suomen sairhttps://Cl
12-Sep-19 1-Sep-22 1-Sep-23 11-Apr-19 ### Children's of Alabam https://Cl
Aug-15 Dec-15 Dec-15 ### ### University of British https://Cl
AVEG 026|10576 Jan-99 ### ### UAB AVEG, Birmingham, https://Cl
May-03 19-Jun-03 6-Dec-06 Cancer Centers of Flohttps://Cl
Nov-01 May-02 ### ### University of Oxford, https://Cl
3-Oct-19 23-Dec-19 1-Jan-20 27-Jun-19 28-Jan-20 Translational Researchttps://Cl
Nov-08 Oct-10 Nov-10 ### 10-Jan-12 CHU Bichat Claude Ber https://Cl
Dec-13 Dec-15 Dec-15 ### ### Virginia Commonwealt https://Cl
Aug-10 Dec-11 Jan-12 18-Oct-10 11-Jan-12 University Hospital https://Cl
7-Jun-13 31-Dec-18 ### 8-Mar-13 3-Jan-20 City of Hope Medical https://Cl
Jul-12 Jan-13 Jan-13 9-Aug-12 ### Leiden University Med https://Cl
Jan-13 Jan-15 Jan-15 ### 15-Oct-15 https://Cl
Mar-04 Jan-07 Feb-08 ### 22-Jun-12 Warren Grant Magnuson https://Cl
Feb-08 Sep-09 Sep-09 ### 19-Oct-10 Ordination Univ. Doz.https://Cl
Oct-04 Oct-08 Jun-09 ### 13-Jan-10 MRC Laboratories, Bahttps://Cl
Oct-14 Mar-16 Aug-16 10-Oct-14 ### St. Jude Children's R https://Cl
2-Oct-13 22-Jan-14 22-Jan-14 ### 12-Apr-19 London, United King https://Cl
Jul-07 Aug-09 Aug-09 3-Jul-07 19-Oct-10 Department of Clinicahttps://Cl
Jun-13 Nov-14 Nov-14 9-Jul-13 ### CHU Clermont-Ferrand https://Cl
Sep-12 Sep-18 Sep-18 27-Oct-16 ### National Hospital of Nhttps://Cl
Sep-12 Nov-13 Nov-13 26-Jun-12 14-Jan-14 Oslo University Hospihttps://Cl
Oct-19 Jun-21 Jun-21 ### ### Oswaldo Cruz Institute https://Cl
May-12 Aug-12 Aug-13 ### 6-Feb-14 Anaheim Clinical Tria https://Cl
Apr-12 Jul-12 Aug-13 9-May-12 6-Feb-14 Anaheim Clinical Tria https://Cl
Aug-19 Aug-21 Aug-21 ### ### The Affiliated Nanjin https://Cl
31-Dec-12 31-Dec-22 ### 30-Jan-13 ### National Institutes ofhttps://Cl
Dec-10 Feb-12 May-12 25-Apr-11 ### St. Louis University Hhttps://Cl
25-Jun-09 27-May-10 ### ### 2-Jul-17 National Institute of https://Cl
Oct-15 Aug-20 Aug-20 25-Jun-15 ### University of Arkansashttps://Cl
17-Sep-19 Sep-24 Sep-27 28-Jun-19 3-Dec-19 Johns Hopkins Univershttps://Cl
29-Mar-18 3-May-18 5-Dec-18 12-Apr-18 16-Jan-19 MRC Unit, Fajara, Ga https://Cl
Dec-16 Jul-18 Jul-21 8-Jun-16 30-Oct-17 UTHealth Memorial He https://Cl
Nov-08 Sep-09 Sep-09 16-Jul-08 ### Centre Hospitalier Ly https://Cl
Dec-16 Jul-18 Jul-21 8-Jun-16 30-Oct-17 UTHealth Memorial He https://Cl
Nov-02 Aug-03 ### ### Bandim Health Projechttps://Cl
ACTG A5138|AACTG A5138|ACTG A5139s Dec-06 ### 9-Mar-15 University of Califor https://Cl
Dec-05 Dec-08 Dec-08 19-Jan-06 21-Apr-15 Hadassah Medical Orga https://Cl
Aug-96 Dec-99 Nov-00 ### 17-Apr-13 Office of S. Terry Kr https://Cl
23-Jul-14 31-Dec-18 ### 10-Oct-14 3-Oct-19 Central Arkansas Vetehttps://Cl
Jul-01 Nov-04 3-Oct-05 3-Oct-05 Children's Hospital ofhttps://Cl
15-Oct-17 31-Oct-19 ### 7-Nov-17 6-Jun-19 NIMR-Mbeya Medicalhttps://Cl
May-10 Dec-10 Dec-10 15-Jul-10 16-Jul-10 https://Cl
Jan-16 Sep-17 Sep-17 30-Oct-15 30-Oct-15 https://Cl
Oct-12 Nov-14 Nov-14 11-Oct-12 ### Antwerp, Belgium|Cahttps://Cl
1-Dec-19 1-Dec-20 1-Mar-21 5-Jun-19 5-Jun-19 https://Cl
1-Sep-19 31-Jan-21 ### ### ### Shenzhen Geno-immune https://Cl
15-Aug-17 28-Feb-18 ### ### ### Cincinnati Children's https://Cl
Jun-14 23-Jan-17 Nov-17 13-Jun-14 20-Jul-18 University of Pennsyl https://Cl
Jun-09 Jun-10 Jun-10 27-Jan-10 12-Oct-15 University of Wisconshttps://Cl
Oct-11 May-14 May-14 28-Jun-11 11-Jun-14 St. Joseph's Healthcahttps://Cl
Nov-11 Oct-12 Oct-13 7-Dec-11 7-Dec-11 Women's hospital, Sch https://Cl
Sep-05 Dec-09 Dec-09 ### ### https://Cl
Jul-08 Jul-09 ### ### Geauga Regional Hospi https://Cl
Apr-17 Dec-19 Dec-19 27-Apr-17 27-Apr-17 National University C https://Cl
Feb-10 Jul-10 Oct-10 ### ### https://Cl
HIVNET 028 ### ### Missie Allen, Researchhttps://Cl
20-Jun-18 Jun-21 Feb-23 17-Jan-18 27-Jan-20 Scripps Health, La Jo https://Cl
ACTG 219C|ACTG 219|PACTG 219C|1119 May-02 ### 7-Oct-13 Univ of Alabama at Bihttps://Cl
Apr-14 26-Jul-16 26-Jul-16 ### ### ### The Rockefeller Univehttps://Cl
Jan-16 Jan-17 Jan-19 1-Feb-16 1-Feb-16 Shanghai Chest Hospithttps://Cl
A5069|10905|ACTG A5069|AACTG A5069|Substudy ### ### https://Cl
Sep-04 May-05 ### ### Rochester General Hos https://Cl
May-14 Sep-18 Sep-18 ### ### University of Pennsyl https://Cl
Jul-09 Dec-13 Dec-13 ### 1-Apr-16 1-Apr-16 Banner Alzheimer's Inhttps://Cl
Jun-05 Feb-10 Feb-10 4-Dec-06 18-Oct-16 National Jewish Healthttps://Cl
Dec-10 Dec-12 Dec-12 ### 1-Apr-15 Department of Pediatr https://Cl
Sep-05 Sep-08 Sep-08 8-Nov-05 ### https://Cl
Jan-15 Dec-16 Jun-17 ### 19-Apr-16 University of Chicago,https://Cl
Sep-11 ### 4-Oct-11 AO L.Sacco, Milano, Ithttps://Cl
Mar-14 Dec-19 Dec-19 17-Jul-14 ### Hopitaux Universitai https://Cl
Jan-13 Mar-15 Mar-15 ### ### ### NYU Clinical Cancer Chttps://Cl
Jan-02 Dec-06 ### ### National Taiwan Univehttps://Cl
Jul-13 Nov-14 Jan-15 26-Oct-12 1-Jul-15 Centre d'investigationhttps://Cl
Jul-09 Dec-11 Dec-11 12-Jul-10 ### GSK Investigational S https://Cl
Mar-06 Jul-09 May-12 ### 4-Jun-12 Sir Mortimer B. Davishttps://Cl
Nov-11 Dec-12 Apr-13 16-Jul-12 20-Jun-13 Seoul St. Mary's Hospihttps://Cl
Sep-16 Jun-17 Jun-17 1-Jul-16 ### https://Cl
Jan-11 Dec-13 Dec-15 20-Jan-11 7-Oct-14 ### University of Alabamahttps://Cl
24-May-18 31-Jul-19 ### ### ### Shoklo Malaria Reseahttps://Cl
Oct-11 Apr-13 Apr-13 ### 29-Apr-19 29-Apr-19 Hospital da Universidhttps://Cl
Oct-11 Jun-13 Jun-13 ### ### American University ohttps://Cl
Dec-11 Apr-15 ### ### ### University of Alabamahttps://Cl
18-Feb-18 1-Mar-21 1-Mar-21 5-Feb-18 ### Dpt Urology- CHUV, Lhttps://Cl
HIVNET 019 May-08 May-08 ### 7-Nov-16 Los Angeles County / https://Cl
Jan-12 Apr-16 Oct-16 1-Sep-15 1-Sep-15 Gelre Hospitals, Ape https://Cl
23-Jun-10 23-Jan-13 12-Jul-10 ### Malaria Research andhttps://Cl
Sep-13 Apr-14 Apr-14 6-Aug-13 15-Jul-14 Research Institute forhttps://Cl
1-Mar-17 5-Jun-19 5-Jun-19 13-Jun-16 27-Jun-19 Case Clinical Researc https://Cl
Jan-12 Feb-15 ### 4-Feb-15 Centre Hospitalier Unhttps://Cl
Jun-05 Apr-06 ### ### District Health Direc https://Cl
Sep-07 Sep-07 ### ### https://Cl
Dec-19 Aug-23 Dec-23 ### 18-Jul-19 PPD Registry Office, https://Cl
Aug-14 Dec-16 Mar-17 9-Sep-14 20-Jun-17 Choma District Medichttps://Cl
29-May-08 29-Jun-16 29-Jun-16 2-May-08 27-Jun-16 ### National In"Study Prohttps://Cl
30-May-17 Sep-21 Sep-21 ### ### Florida Hospital Canchttps://Cl
1-Aug-17 1-Dec-19 1-Dec-19 9-Aug-18 5-Aug-19 University of Antwer https://Cl
Jan-05 Jul-09 May-12 ### 4-Jun-12 https://Cl
29-May-17 28-Mar-18 3-Oct-18 3-May-17 ### Havenziekenhuis, Rothttps://Cl
Dec-09 Feb-11 Feb-11 ### 8-Jul-19 Alder Hey Children's https://Cl
Jan-10 Feb-15 Feb-15 6-Jan-10 2-Jan-17 Winthrop-University H https://Cl
Sep-05 Dec-07 Jun-08 ### 9-Mar-12 Southern Illinois Univhttps://Cl
Jul-06 Sep-10 Sep-10 2-Nov-06 ### ### Carl T. Hayden VA Med https://Cl
Jun-12 Jun-14 Jun-14 ### 9-Dec-15 9-Dec-15 Ludwig Boltzmann-Inshttps://Cl
Sep-07 Dec-10 3-Dec-09 1-Mar-11 San Raffaele Hospital,https://Cl
Oct-15 Dec-18 Dec-18 5-Sep-16 5-Sep-16 University of Antwerphttps://Cl
Dec-11 Apr-15 Apr-15 19-Apr-11 5-Jun-17 5-Jun-17 Orange County Urology https://Cl
4-Feb-19 20-Sep-19 ### ### 6-Jan-20 State University of N https://Cl
Jun-11 Jul-15 Jul-15 ### ### ### Mayo Clinic Hospital, https://Cl
Nov-06 Apr-07 Apr-07 9-Jan-07 ### Vanderbilt University,https://Cl
21-Apr-17 Aug-20 Nov-20 31-Oct-16 ### Investigational Site https://Cl
9-May-18 24-Nov-19 ### 18-Jan-18 29-Jan-20 hVIVO Services Limi https://Cl
1-Aug-07 9-May-07 21-Oct-19 U Mali Faculty Med Phttps://Cl
13-Sep-04 ### 18-Jan-20 National Institutes ofhttps://Cl
Sep-12 Dec-19 Dec-19 2-Oct-12 14-Jan-19 Johns Hopkins Hospita https://Cl
1-May-11 ### ### University of Bamakohttps://Cl
Oct-09 Dec-14 Jun-15 ### 12-Apr-17 ### Georgetown University https://Cl
Oct-08 Apr-12 May-15 15-Jul-08 ### ### UCSD Moores Cancerhttps://Cl
Ce
1-Jan-18 31-Aug-19 ### ### 9-Sep-19 2 West Clinic at Harb https://Cl
Jan-07 Jan-10 Jan-11 11-Jan-07 2-Jul-12 Research Site, Tucsonhttps://Cl
15-May-14 15-Mar-16 ### 3-Jun-14 ### National Institutes ofhttps://Cl
ACTG 248|11225 Mar-02 ### 26-Apr-12 Alabama Therapeuticshttps://Cl
Mar-08 Dec-10 Sep-11 5-Mar-08 ### Urology Centers of Alhttps://Cl
1-Aug-20 1-Oct-20 1-Dec-20 ### 18-Jan-20 https://Cl
Dec-06 Dec-10 ### 11-Jun-09 Lehigh Valley Hospitahttps://Cl
Aug-11 Mar-16 Mar-16 4-Feb-15 ### https://Cl
Jan-14 11-Aug-14 ### ### 27-Jan-20 27-Jan-20 https://Cl
Jun-13 Apr-15 ### ### Oxford University Hophttps://Cl
12-Sep-16 31-Dec-17 ### 28-Jun-16 3-Jun-19 3-Jun-19 Cincinnati "Study Prohttps://Cl
30-Sep-19 Feb-21 Feb-21 ### ### Duke Clinical Researchttps://Cl
6-Oct-03 ### 21-Jun-06 5-Dec-19 University of Mali, B https://Cl
6-Jun-19 13-May-20 1-Dec-22 28-Jan-19 ### Optimal Research, Mel https://Cl
Jan-11 Dec-18 Dec-18 ### ### National Taiwan Univehttps://Cl
18-May-15 May-20 May-20 5-Aug-14 13-Jan-20 City of Hope Medical https://Cl
Aug-08 Jun-09 Jun-09 21-Oct-08 ### ### AIIMS, New Delhi, Delhttps://Cl
Mar-07 Aug-08 Aug-08 12-Jul-07 ### Herson, Queensland, https://Cl
A
31-Aug-18 31-Aug-18 ### ### ### IRCCS ospedale san rahttps://Cl
9-Dec-19 9-Dec-21 9-Dec-22 12-Jun-18 23-Oct-19 USC / Norris Comprehe https://Cl
May-13 Sep-16 Sep-16 24-Apr-14 ### Hanoi Medical Univerhttps://Cl
27-Feb-18 1-Dec-20 1-Dec-22 ### 19-Oct-18 BeiJing YouAn Hospitahttps://Cl
11-Dec-13 6-Feb-18 6-Feb-18 8-Jun-18 18-Jun-18 Chang Bing Show Chwa https://Cl
1-Mar-20 6-Feb-23 6-Feb-23 2-Jan-20 29-Jan-20 City of Hope Medical https://Cl
Feb-06 Dec-09 Dec-09 20-Jun-06 4-Apr-13 https://Cl
10-Dec-12 31-Dec-19 Jan-20 9-Apr-13 7-May-19 Jonsson Comprehensive https://Cl
7-Feb-19 Feb-21 Feb-21 5-Feb-19 3-Oct-19 University of Pennsyl https://Cl
Oct-04 Oct-13 Oct-14 ### 1-Feb-13 American University ohttps://Cl
Jun-07 Aug-08 Mar-09 13-Jun-07 8-Mar-12 University of Nebraskhttps://Cl
Aug-10 Mar-13 Mar-13 3-Sep-10 ### San Bernardino Urolog https://Cl
19-Jan-15 10-Aug-15 ### ### ### 14-Jan-20 https://Cl
Mar-14 18-Apr-18 20-Jun-19 3-Feb-14 ### Eden Medical Center,https://Cl
Jul-12 Jul-16 Jul-16 11-Jul-12 11-Jul-12 Leumit Health Care Syhttps://Cl
Jul-13 Nov-13 Nov-13 2-Jul-13 22-Jul-15 https://Cl
Aug-09 Jul-11 Jul-11 6-Aug-09 ### Parexel Early Phase Clhttps://Cl
Dec-06 Jun-10 Jun-10 27-Jul-07 14-Oct-13 Westside Health Servihttps://Cl
Sep-11 Dec-15 Dec-16 2-Aug-16 2-Aug-16 HÃ´pital Louis Pradel https://Cl
Jul-01 Dec-04 Dec-04 12-Jul-05 ### Cousins Center for Pshttps://Cl
Jun-06 May-07 16-Jan-06 7-May-07 NAET Pain Clinic, Buen https://Cl
1-Apr-19 May-20 May-20 6-Apr-18 3-Apr-19 Center for Wellbeing https://Cl
Feb-11 Dec-11 Aug-13 ### ### Departament of Clinica https://Cl
Aug-09 Jul-13 9-Jul-09 29-Oct-10 Mount Sinai Medical https://Cl
Jul-03 Aug-04 ### 2-Oct-06 Clinic for Gynecologyhttps://Cl
1-Sep-17 Dec-22 Dec-22 ### ### Indiana Regional Medihttps://Cl
Oct-08 Feb-10 Feb-10 6-Mar-12 ### Biomedical Research h Cttps://Cl
0025-12-NHR 19-Jul-12 18-Jun-14 https://Cl
May-15 Jul-20 Jul-22 ### 27-Jul-15 Halifax Health Medicahttps://Cl
1-Jan-18 31-May-19 ### 12-Jun-18 19-Jun-19 University of Wisconshttps://Cl
A5136|10680|ACTG A5136|AACTG A5136| Jun-06 23-Apr-02 ### University of Coloradhttps://Cl
Jan-09 Jan-10 Jan-10 3-Mar-09 ### The Catholic Universihttps://Cl
Oct-07 Sep-09 Dec-09 1-Oct-07 ### Hospital Universitat https://Cl
Jun-16 Dec-16 Dec-16 5-Aug-16 5-Aug-16 https://Cl
25-Sep-17 1-Jan-19 1-Aug-19 6-Sep-17 ### Service des Maladies https://Cl
Mar-16 Mar-19 Mar-21 ### 27-Jun-17 UC San Diego
Central Moores
Alabama https://Cl
C
Research; Pediatrics, Birmingham, A
10-Oct-19 24-May-20 6-Jun-20 ### 5-Feb-20 Rehabilitation Clinic, Akashi,
https://Cl
Japan|Medical Corporati
Jan-03 Mar-06 ### ### National Taiwan Univehttps://Cl
Aug-15 Nov-15 Nov-15 ### ### Kenya AIDS Vaccine Ini https://Cl
Aug-07 Nov-10 May-16 11-Apr-07 16-Jan-18 Celldex Investigationahttps://Cl
30-Mar-17 30-Jun-21 30-Jun-21 ### ### University of Marylanhttps://Cl
26-Jun-17 10-Aug-20 ### ### ### Research Site, San Fr https://Cl
Apr-10 Jun-17 Jun-17 ### 6-Mar-17 Centre mÃ©dico-socia https://Cl
12-Jun-17 15-Feb-19 ### 28-Jun-17 ### UnitÃ© de dermatologi https://Cl
28-Oct-15 27-Nov-18 ### 16-Jun-15 7-Dec-18 Emory Vaccine Centerhttps://Cl
10-Nov-15 1-Apr-17 1-Dec-17 ### ### Emory Vaccine Centerhttps://Cl
6-Jan-20 31-Mar-23 ### ### ### Fairbanks Memorial Ho https://Cl
Jan-16 Jun-17 Jun-17 23-Jun-15 31-Oct-17 University Hospital Zuhttps://Cl
Jul-16 Sep-16 Nov-16 ### ### HÃ´pital de la Croix Rhttps://Cl
Jun-14 Feb-17 Feb-17 6-Feb-14 ### Universitary hospital https://Cl
Jan-08 Jul-08 Jul-08 ### 6-Aug-08 Allergy-Centre-Chari https://Cl
Jul-05 Aug-08 Aug-08 ### 3-Mar-09 Mie University Hospithttps://Cl
3-Mar-18 13-Apr-23 13-Apr-23 ### ### Centre for Clinical V https://Cl
Jan-10 Sep-10 Sep-10 ### 1-Oct-10 Cetero Research, Mishttps://Cl
Sep-10 Aug-11 Aug-11 ### 7-Oct-11 KGK Synergize Inc., L https://Cl
18-Jan-19 22-May-20 ### 8-Nov-18 4-Oct-19 Brigham an"Informed https://Cl
21-May-15 14-Nov-16 ### 26-Jan-15 3-Jan-18 3-Jan-18 UCSF Helen Diller Famhttps://Cl
Nov-15 Aug-18 Sep-18 15-Jul-15 1-Aug-19 USOR - Rocky Mountain https://Cl
20-Aug-18 20-Aug-21 ### ### ### Beijing Tiantan Hospithttps://Cl
Nov-11 Dec-20 Dec-20 2-Jan-12 3-Jan-20 Mayo Clinic, Rochestehttps://Cl
Aug-08 Apr-09 May-09 7-Aug-08 8-Jul-09 Cetero Research, Tor https://Cl
14-Feb-12 21-Mar-16 ### ### ### 9-Oct-19 UCSF Helen Diller Com https://Cl
Mar-08 Feb-12 2-Dec-09 4-Mar-16 S.M. Goretti Hospital,https://Cl
30-Aug-18 30-May-20 ### 29-Jan-19 29-Jan-19 Centre Assistencial Baixhttps://Cl
Llobregat, CornellÃ De Llobre
11-Jun-19 30-Mar-20 ### 10-Apr-19 22-Jan-20 Duke Human Vaccinehttps://Cl
In
21-Jan-19 Nov-19 Dec-19 7-Jan-19 ### Imperial College Healhttps://Cl
Aug-17 Oct-19 Nov-19 2-Jul-17 5-Jul-17 Xiaodong Jiang, Jianghttps://Cl
Jul-14 Dec-17 Apr-18 17-Apr-14 5-Feb-20 5-Feb-20 Highlands O "Study Prohttps://Cl
Aug-10 Nov-11 Mar-12 11-Oct-10 16-Jan-18 Bali, Indonesia|Banduhttps://Cl
Oct-07 Sep-10 Sep-10 8-Jul-11 8-Jul-11 Sukkur, Sindh, Pakist https://Cl
Aug-13 Aug-20 Aug-20 ### 11-Oct-18 https://Cl
7-May-15 21-Sep-15 2-Oct-15 ### 2-Jan-19 London, United King https://Cl
1-Aug-16 31-May-17 ### ### 29-Oct-18 Duke Human Vaccinehttps://Cl
In
Nov-09 Dec-09 Dec-09 27-Oct-09 3-Aug-11 Human Vaccine Challen https://Cl
18-Sep-17 2-Apr-18 ### ### ### Saglik Bilimleri Univerhttps://Cl
8-Jan-18 14-Oct-19 14-Oct-19 ### 4-Dec-19 The First Hospital of https://Cl
Jan-06 Jun-06 5-Apr-07 5-Apr-07 Pediatric Hematologyhttps://Cl
31-Jan-20 30-Sep-24 ### ### 5-Feb-20 Rutgers Cancer Instit https://Cl
15-Nov-17 31-Oct-22 31-Oct-22 30-Oct-17 3-May-19 Mayo Clinic, Rochestehttps://Cl
Jan-15 Nov-19 Dec-19 5-Sep-14 ### Immunitor LLC, Ulaanhttps://Cl
Dec-06 Dec-19 Dec-19 14-Jun-06 ### The Children's Hospithttps://Cl
Apr-04 Jul-04 8-Apr-04 24-Jan-13 University of Chicagohttps://Cl
Mar-09 Apr-10 Apr-10 ### 6-May-10 Alpha Medical Researc https://Cl
20-Dec-17 Dec-20 Dec-20 16-Jan-18 8-Apr-19 Memorial Sloan Kettehttps://Cl
CDX110-05 3-Mar-17 18-Oct-17 https://Cl
Feb-15 May-15 May-15 ### 7-Apr-16 7-Apr-16 Chuou-ku, Tokyo, Japhttps://Cl
Oct-09 Aug-10 Aug-10 ### 9-Nov-10 UMC St. Radboud, Nihttps://Cl
Oct-11 Dec-13 Dec-13 28-Jun-11 22-Jan-14 Kingston GeneralAllen
States|Fletcher HosphHealth
ttps://Cl
Care, Burlington, Vermo
Nov-11 Nov-16 Nov-16 ### 16-Jan-18 Center, Tel Hashomer,https://Cl
Israel|Tel-Aviv Sourasky Medic
30-Mar-17 13-Feb-18 ### ### ### University Hospital Zuhttps://Cl
1-Aug-19 1-Oct-20 1-Oct-20 1-Apr-19 ### Saint Louis Universityhttps://Cl
12-May-17 23-Apr-18 23-Apr-19 30-Jan-17 ### ### University "Study Prohttps://Cl
15-Sep-17 29-Mar-18 30-Jun-18 7-Aug-18 ### Ibn Tofail Universit https://Cl
13-Jun-18 Nov-19 Nov-19 8-Jun-18 ### CHU de Saint Etiennehttps://Cl
Oct-10 Sep-14 Dec-15 ### ### ### Georgetown University https://Cl
16-Jul-18 31-Jul-20 31-Jul-20 24-Oct-17 ### M D Anderson Cancerhttps://Cl
28-Aug-19 31-Aug-20 ### 25-Jul-19 25-Jul-19 Hospital, Parnu, Estonia|East-Tallinn
https://Cl Central Hospital
Aug-14 Dec-16 Dec-16 10-Jul-14 27-Jun-18 27-Jun-18 South Africa|WCR: Wits https://Cl
Clinical Research, Johannesb
15-May-17 2-Mar-22 2-Mar-22 7-Jun-17 18-Apr-19 National Cancer Insti https://Cl
17-Nov-16 24-May-18 ### 4-Apr-17 8-May-18 Rheumatology outpatie https://Cl
27-Mar-18 13-Feb-20 ### 2-Dec-17 ### Roswell Park Cancer Ihttps://Cl
Dec-12 May-17 May-17 ### 27-Jul-18 Hospital, Nantes, Fra https://Cl
17-Nov-14 24-Nov-15 ### 9-Sep-14 ### ### University "Study Prohttps://Cl
Jun-07 Nov-09 Nov-09 29-Jun-07 26-Jan-17 Pissy Health District https://Cl
Mar-08 Feb-09 Feb-09 ### 13-Jan-14 GSK Investigational Sihttps://Cl
25-Jun-18 Aug-21 Aug-21 11-Jun-18 ### Centre Hospitalier https://Cl
Jul-13 Nov-16 Dec-17 16-Jan-13 3-Jun-19 3-Jun-19 University of Wisconshttps://Cl
16-Apr-19 15-Apr-20 15-Jun-20 16-Apr-19 17-Apr-19 Immunitor LLC, Ulaanhttps://Cl
Oct-13 Jun-14 Dec-14 ### 30-Apr-15 Peter MacCallum Cance https://Cl
Sep-07 Oct-09 Oct-09 16-Jul-07 ### Hospital ClÃnico de Salamanca,
https://Cl Salamanca, Spain
Apr-14 Sep-14 Sep-14 ### ### Kanata, Ontario, Can https://Cl
20-Dec-18 28-Feb-19 ### 4-Apr-19 4-Apr-19 Department of Dermato https://Cl
Oct-06 Mar-09 Jun-09 13-Oct-06 17-Jun-10 Allied Research Inter https://Cl
May-13 Aug-13 Sep-13 ### ### https://Cl
Nov-04 Oct-06 ### 7-Jul-15 https://Cl
Mar-16 Jul-19 Jul-19 ### 27-Jan-20 Nationwide Children'shttps://Cl
Jun-98 22-Apr-04 29-Apr-15 Medicine Branch, Bethttps://Cl
Jun-15 8-Aug-17 ### 30-Jun-15 ### ### University "Study Prohttps://Cl
Sep-15 Jun-16 Jun-16 29-Jul-16 1-May-17 Hospital de Zafra, Zafra,https://Cl
Badajoz, Spain|Hospital de H
Aug-11 Jul-13 Aug-13 30-Jun-11 ### Kingston General Hosp https://Cl
Oct-14 Apr-15 Jun-15 ### ### 15-Oct-19 University of Marylanhttps://Cl
Apr-05 Oct-08 Sep-10 3-May-05 3-Oct-08 BCG Oncology, Phoenix https://Cl
May-05 Dec-05 ### 17-Jun-10 Allied Research Inter https://Cl
Sep-12 Dec-13 Dec-13 ### ### Rockefeller Universit https://Cl
Jan-14 1-Jun-16 1-Jun-16 ### ### University of Californhttps://Cl
Apr-09 Nov-09 Nov-09 9-Apr-09 ### Centre de Recherche https://Cl
Dec-12 Jun-13 Jun-13 ### 6-May-14 The Rockefeller Univehttps://Cl
Dec-05 Dec-07 ### 2-May-08 Lautoka Hospital, Lauthttps://Cl
22-Jul-19 15-Jan-21 15-Oct-21 6-Aug-19 7-Jan-20 Honor Health Instituthttps://Cl
Jul-10 Apr-11 Apr-11 20-Jul-10 ### Centre de Recherche https://Cl
Dec-02 Feb-04 Feb-04 ### 16-Oct-12 16-Oct-12 Marietta, Georgia, U https://Cl
8-Jun-12 3-Jun-14 3-Jun-14 17-Apr-12 3-Jan-18 3-Jan-18 UCSF Helen Diller Com https://Cl
7-Jun-17 1-Nov-20 1-Nov-20 9-Jan-17 ### University of Marylanhttps://Cl
May-11 Oct-13 Sep-14 6-May-11 4-Jun-15 St. Mary's Hospital, https://Cl
28-Jan-18 1-Aug-19 1-Jan-20 ### 8-Jul-19 Yang Yang, Shenyang,https://Cl
Feb-20 Jan-22 Sep-22 18-Jun-19 ### https://Cl
Oct-19 Mar-20 Oct-20 30-Oct-19 30-Oct-19 https://Cl
12-Sep-11 20-Sep-17 ### ### 17-Oct-18 30-Oct-19 GSK Investi"Study Prohttps://Cl
Jan-13 Jun-13 Jun-13 ### 10-Jan-17 GSK Investigational S https://Cl
Aug-07 Apr-08 Apr-08 ### ### Herson, Queensland, https://Cl
A
5-Dec-16 3-Nov-17 3-Nov-17 9-Jan-17 4-Oct-19 Encinitas, California https://Cl
8-Dec-16 14-Nov-17 ### 9-Jan-17 4-Oct-19 Birmingham, Alabama, https://Cl
20-Jun-18 Dec-19 Dec-20 26-Jul-18 6-Feb-19 Riverview Health Cenhttps://Cl
May-06 Jul-06 ### 17-Jun-10 Allied Research Inter https://Cl
25-May-17 31-Dec-18 ### 29-Jul-15 5-Feb-20 Arkansas Children's Hhttps://Cl
Jun-15 Apr-16 Apr-16 ### 6-Apr-16 Gouverneur TDC, Newhttps://Cl
Jun-15 Jan-19 Jan-19 12-Jun-18 ### University of Californihttps://Cl
24-Jul-07 ### 30-Jul-07 2-Jul-17 National Institute of https://Cl
Oct-99 Oct-03 4-Nov-99 4-Mar-08 National Institute of https://Cl
Feb-20 Aug-21 Aug-21 ### ### Department of Endocrhttps://Cl
4-May-17 Dec-20 May-22 27-Apr-17 14-Jan-20 University of Pennsyl https://Cl
5-Sep-18 30-Sep-21 ### 25-Jun-18 6-Nov-19 Massachusetts Genera https://Cl
9-Oct-18 31-Dec-20 ### ### ### SingHealth Investigat https://Cl
8-Feb-18 12-Sep-18 4-Dec-18 ### 10-Apr-19 SingHealth Investigat https://Cl
Feb-09 Mar-10 Dec-10 ### 7-Nov-12 Shahin Lockman, Haba https://Cl
1-Jan-20 31-Dec-22 ### ### ### Kenyan Aids Control Phttps://Cl
1-Apr-20 1-Apr-25 1-Apr-25 ### ### CHU of BesanÃ§on, Bhttps://Cl
Apr-10 Dec-10 Dec-10 1-Apr-10 23-Apr-10 Veronique Verhoeven,https://Cl
Sep-10 Sep-13 Sep-13 ### ### ### Alfred Health (Melbouhttps://Cl
Dec-12 Mar-13 Mar-13 16-Jan-13 2-Apr-18 University of Marylanhttps://Cl
May-16 May-21 May-22 15-Jun-16 ### Lenox Hill Brain Tumohttps://Cl
Apr-16 Dec-19 Mar-20 ### 10-Apr-19 University Hospital https://Cl
19-Feb-18 31-May-20 ### ### 18-Jan-20 Beaumont "Informed
G https://Cl
Sep-06 Apr-12 Oct-15 ### 8-Feb-16 https://Cl
1-Aug-14 12-Feb-22 ### 18-Jun-14 15-Oct-19 Roswell Park Cancer Ihttps://Cl
Oct-06 31-Jan-11 31-Jan-11 29-Oct-06 1-Feb-19 Kenya Medical Researhttps://Cl
May-11 Sep-16 Sep-16 4-Apr-11 ### Jules Stein Eye Instit https://Cl
Sep-11 May-13 May-13 6-Oct-11 17-Jul-13 Cetero Research, Mishttps://Cl
Dec-15 Oct-18 Oct-18 ### ### Berlin, Germany https://Cl
20-Jun-18 Dec-19 Dec-20 16-Jul-18 6-Feb-19 Riverview Health Cenhttps://Cl
Oct-12 Dec-13 Dec-14 4-Dec-12 26-Apr-17 6-Dec-17 New York University Lhttps://Cl
Jan-07 Feb-07 Dec-10 ### ### National Taiwan Univehttps://Cl
8-Mar-17 18-Sep-19 ### ### ### Service de GynÃ©colo https://Cl
Oct-13 Dec-15 Oct-20 ### 4-Feb-19 University of Pennsyl https://Cl
Jul-06 Dec-06 Apr-10 7-Aug-06 9-Jun-11 MDS Pharma Services, https://Cl
10-Jul-18 4-Mar-19 15-Jan-20 21-Jun-18 13-Jan-20 National Institutes ofhttps://Cl
Aug-12 Aug-13 Aug-13 6-Dec-12 6-Dec-12 Winthrop University Hhttps://Cl
4-Oct-17 31-Mar-20 ### 19-Oct-16 16-Oct-19 Kampong Cham Provin https://Cl
Jan-04 Mar-14 Mar-14 ### ### First Affiliated Hosp https://Cl
21-Feb-20 31-Dec-29 ### ### ### National Institute of https://Cl
Nov-03 Nov-11 Nov-12 ### 8-Sep-11 Fukushima Medical Un https://Cl
Jul-09 Sep-10 Jan-11 30-Jan-09 ### University of Marylanhttps://Cl
Jun-04 Jul-05 ### ### Hospital
University inof
Debica
South- Alabama
https://Cl
Mitchell Cancer Institute
Apr-14 16-Dec-19 Jun-20 11-Apr-14 4-Feb-19 Carl Gustav Carus, Dresden,
https://Cl
Germany|Waldkrankenh
Mar-09 Dec-10 Nov-11 ### 8-Aug-14 University of Marylanhttps://Cl
1-Jan-18 1-Jun-19 ### 3-Jan-20 7-Jan-20 Hausarztme "Study Prohttps://Cl
5-Sep-18 13-Aug-19 ### ### ### National Institutes ofhttps://Cl
### 8-Aug-08 Rachael McClennen, Shttps://Cl
Nov-13 Apr-14 Apr-14 30-Jan-14 8-Sep-16 Royal Blackburn Hosphttps://Cl
16-Nov-17 30-Apr-19 Dec-19 31-Oct-17 ### South Terrace Sexual https://Cl
9-Dec-16 17-Oct-18 17-Oct-18 ### 4-Oct-19 Birmingham, Alabama, https://Cl
15-May-16 1-Feb-17 1-Feb-17 23-Jan-18 26-Jan-18 CAPRISA, Durban, Kwahttps://Cl
Aug-16 Aug-20 Feb-21 6-Apr-16 2-Dec-19 Mayo Clinic Jacksonvihttps://Cl
11-Dec-06 4-Jan-12 ### ### 31-Jan-19 International Centre https://Cl
### 2-Oct-08 Kenya Medical Researhttps://Cl
26-Nov-19 Sep-21 Sep-21 13-Jun-19 2-Dec-19 Aprosam, San Pedro, hCttps://Cl
28-Mar-17 16-Feb-18 8-Nov-19 ### ### National Institutes ofhttps://Cl
Aug-09 May-10 May-14 ### ### PNG Institute of Medhttps://Cl
Jan-04 Aug-06 Aug-10 6-Mar-08 1-Mar-11 Columbia University, https://Cl
28-May-16 10-Apr-18 30-Apr-18 2-Jun-16 12-Jun-18 12-Jun-18 National In"Study Prohttps://Cl
13-Mar-14 1-Mar-21 1-Mar-21 ### ### Walter Reed Nationalhttps://Cl
Apr-11 Mar-13 Mar-13 ### ### https://Cl
Nov-09 Aug-10 Aug-10 5-Nov-09 ### Centre de Recherche https://Cl
17-Jul-15 12-May-27 ### 29-Jul-15 ### National Institutes ofhttps://Cl
Mar-07 Dec-15 Aug-16 10-Jan-08 11-Apr-17 City of Hope Medical https://Cl
31-Oct-15 1-Nov-17 1-Nov-17 3-Nov-15 3-Dec-19 National Institutes ofhttps://Cl
Sep-06 Sep-10 ### ### Research Institute forhttps://Cl
Feb-07 Apr-07 ### 2-May-08 Colonial War Memorial https://Cl
Mar-06 ### ### Noguchi Memorial Inshttps://Cl
Feb-11 Mar-14 Jun-15 ### 29-Jul-15 Prof. Dr. J. P. Garrah https://Cl
Feb-10 Apr-10 May-11 9-Feb-10 ### Wesley Medical Center https://Cl
13-Jul-06 28-Nov-08 ### ### 4-Feb-19 Hospital Escuela Oscahttps://Cl
Jun-11 Nov-14 Nov-14 1-Jul-11 ### 20-Apr-17 CAPRISA, Durban, Kwahttps://Cl
Apr-10 Nov-10 Nov-10 27-Oct-09 9-Nov-10 Leiden University Med https://Cl
Jan-04 May-10 May-10 2-Sep-05 ### Downtown IDC, Vancou https://Cl
Sep-07 Apr-12 Apr-12 7-May-09 7-May-12 Shoklo Malaria Reseahttps://Cl
30-Aug-10 23-Jul-10 ### Gabriel Toure Pediat https://Cl
17-Sep-19 Apr-20 Jun-20 10-Apr-19 7-Oct-19 Wake Forest School ohttps://Cl
19-May-14 31-Dec-22 ### 6-May-14 18-Jan-20 National Institutes ofhttps://Cl
Jan-05 Jul-06 Jul-16 8-Feb-07 ### France, France|Germhttps://Cl
Sep-13 Sep-15 Sep-15 29-Oct-13 24-Apr-17 24-Apr-17 National Institutes ofhttps://Cl
Nov-07 Nov-12 Dec-12 9-Mar-11 ### https://Cl
Jul-12 Oct-15 Dec-15 2-Mar-12 7-Oct-16 Barnes-Jewish Hospital https://Cl
Dec-02 Mar-07 ### 24-Jan-13 Medical Research Unhttps://Cl
Dec-95 ### ### Fred Hutchinson Cance https://Cl
21-Nov-14 8-Aug-17 8-Aug-17 ### 3-Jan-19 3-Jan-19 National In"Study Prohttps://Cl
Mar-10 Jul-14 Jul-14 ### 7-Dec-15 7-Dec-15 University of Arizona https://Cl
1-Jan-18 31-Aug-20 ### ### ### Dhaka Hospital, icddrhttps://Cl
15-Aug-19 Mar-22 Jun-22 8-Feb-18 27-Jan-20 Children's Hospital Lohttps://Cl
Jan-13 Jan-14 Nov-14 ### ### Royal Liverpool Univehttps://Cl
Mar-09 Nov-13 Jan-14 5-Feb-09 14-Apr-15 ### University of Alabamahttps://Cl
Sep-05 Sep-07 21-Jun-06 ### University of Californhttps://Cl
Oct-14 Oct-17 Dec-17 ### ### https://Cl
5-Jun-17 26-Jun-19 26-Jun-19 ### ### National Institutes ofhttps://Cl
Apr-04 Oct-07 Oct-07 8-Sep-05 12-Jul-16 Children's Hospital ofhttps://Cl
Mar-14 Mar-17 Mar-17 ### 2-Jul-17 Imperial Clinical Res https://Cl
11-Jul-18 23-Oct-18 1-Jan-19 31-Jul-18 22-Oct-18 Centre for Human Druhttps://Cl
24-Feb-04 18-Jun-09 ### National Institutes ofhttps://Cl
Jul-05 Nov-08 Jun-23 ### 8-Jun-11 Stanford AIDS Clinica https://Cl
Jan-05 Apr-08 Jun-08 ### 12-Jan-17 Ministry of Health, K https://Cl
4-Jan-07 Dec-36 Dec-36 11-Jun-08 ### St. Jude Children's R https://Cl
Mar-09 Aug-09 Jan-10 ### 4-Jun-13 ### Seattle Children's, S https://Cl
Sep-05 May-07 Jun-08 3-Aug-09 3-Aug-09 28-Apr-15 Denver Health, Westsihttps://Cl
8-Feb-18 28-Jan-20 28-Jan-20 ### 29-Jan-20 Centre Hospitalier Unhttps://Cl
Sep-11 Oct-13 Oct-13 ### ### Bamba sub-District Hohttps://Cl
Jan-07 19-Jan-07 ### University of Pittsbu https://Cl
12-Jun-13 24-Aug-16 ### ### ### ### GSK Investigational S https://Cl
22-Dec-10 ### ### Rakai Health Science https://Cl
Dec-13 Dec-17 Dec-19 30-Jul-13 ### University of Oxford https://Cl
Aug-13 Aug-15 Aug-15 4-Jan-11 ### Rambam Medical Cente https://Cl
Dec-14 Jan-15 Jan-15 9-Dec-14 ### ### https://Cl
21-Jul-15 21-Oct-16 1-Jun-17 29-Jul-15 2-Jul-17 National Institutes ofhttps://Cl
20-Oct-19 20-Apr-21 ### ### ### https://Cl
Mar-12 Aug-12 ### ### Centre for Clinical V https://Cl
9-Dec-15 4-Feb-21 1-Jul-21 3-Aug-15 1-Nov-19 National Institutes ofhttps://Cl
NCRR-M01RR00030-0153|M01RR000030 6-Nov-00 24-Jun-05 Duke University Medic https://Cl
9-Feb-12 25-Jun-13 25-Jun-13 ### 20-Jun-18 Thomas Jefferson Univ https://Cl
Feb-13 May-13 May-13 ### ### NIZO food research, https://Cl
May-11 Oct-12 Nov-12 19-Jan-11 10-Oct-12 University of Oxford, https://Cl
Apr-12 Dec-16 Dec-16 11-Jul-11 ### Fundacion INFANT, Buhttps://Cl
Jan-10 Dec-10 Sep-11 13-Jan-10 13-Jan-10 Navy Medical Research https://Cl
Jun-13 Oct-13 Oct-13 ### ### SGS Life Sciences, A https://Cl
24-Sep-00 ### ### 3-Dec-19 Washington Hospital hCttps://Cl
Mar-12 Sep-13 Oct-18 8-Apr-14 ### Nemocnice Jihlava,UrologickÃ©
https://Cl oddÄ›lenÃ,, Jihlava,
Oct-19 Oct-21 Oct-21 3-Oct-19 3-Oct-19 https://Cl
Sep-77 May-06 29-Jan-07 24-Jun-13 https://Cl
28-May-09 ### 2-Jun-09 ### National Institutes ofhttps://Cl
Feb-12 Mar-14 Mar-14 ### 13-Jan-15 Cochin Hospital, Parishttps://Cl
10-Dec-07 ### ### 9-Oct-19 National Institutes ofhttps://Cl
Jan-02 Jan-25 Jan-25 2-Oct-07 8-Nov-17 University of Zurich, https://Cl
Oct-10 Dec-10 Apr-11 20-Oct-10 ### NIZO food research, https://Cl
23-Apr-09 13-May-15 8-Nov-17 18-Jun-09 16-Jun-17 24-Jul-18 National In"Study Prohttps://Cl
4-May-00 19-Apr-11 8-May-00 2-Jul-17 National Institutes ofhttps://Cl
Jan-14 Oct-14 Oct-14 7-Jan-14 4-Dec-14 Vincent Gajdos, Clama https://Cl
Jul-09 Sep-09 Oct-09 28-Jul-09 ### Guys Drug Research Uhttps://Cl
Mar-09 Apr-10 Jun-10 24-Jun-10 ### Retroscreen Virology https://Cl
31-May-16 19-Apr-19 19-Apr-19 16-Jul-15 23-Apr-19 Durham VA Medical Ce https://Cl
Sep-13 Sep-19 Mar-20 ### ### Assistance Publique Hhttps://Cl
1-Dec-19 1-Jan-21 1-Jan-22 16-Apr-19 ### MetroHealth medicalhttps://Cl
C
May-11 Jul-11 Jul-11 ### ### ### GSK Investigational S https://Cl
Aug-12 Nov-12 Nov-12 18-Oct-12 ### NIZO Food Research, https://Cl
Nov-16 Nov-18 Nov-20 ### ### Gustave Roussy, Villejhttps://Cl
1-Jun-18 1-Dec-19 ### 8-Jun-18 6-Jul-18 Immunitor LLC, Ulaanhttps://Cl
Dec-09 Jul-10 Sep-11 31-Jan-11 17-Oct-11 Charite University Behttps://Cl
13-Jul-05 21-Jun-06 ### National Institute of https://Cl
Sep-10 Jul-12 Feb-13 ### 13-Jun-13 Groupe Hospitalier Pihttps://Cl
May-09 Oct-09 Nov-09 ### ### Groupe Hospitalier Pihttps://Cl
Jan-11 Nov-12 Dec-12 2-Oct-12 3-Oct-12 PAMVERC office, Mulehttps://Cl
Apr-99 May-01 ### 4-Mar-08 National Institute of https://Cl
Oct-20 Sep-21 Sep-22 24-Jun-19 25-Jun-19 Population Council, L https://Cl
26-Oct-05 31-Jul-07 ### 30-Oct-05 2-Jul-17 National Institutes ofhttps://Cl
1-Nov-99 21-Jun-06 ### NCI Frederick Cancer https://Cl
Jan-06 Feb-12 Feb-12 9-Jan-06 ### UCLA Kidney Cancer Pr https://Cl
28-Apr-09 6-Apr-11 6-Apr-11 1-May-09 6-Oct-17 National Institutes ofhttps://Cl
Jan-04 Nov-06 5-Apr-06 5-Apr-06 Division of Chest Medhttps://Cl
8-Oct-08 ### 15-Oct-08 2-Jul-17 Malaria Research andhttps://Cl
6-Feb-07 13-Dec-10 ### 2-Mar-10 9-Jan-12 11-Jul-17 https://Cl
May-14 Dec-15 Sep-16 25-Apr-14 30-Jan-19 ### Kaiser Permanente Haw https://Cl
1-Sep-19 31-May-21 ### 8-May-19 10-Jul-19 Moi University, Eldor https://Cl
15-Feb-20 15-Feb-23 ### 10-Apr-19 ### Centre pour le Devel https://Cl
Jul-99 May-06 4-Nov-99 4-Mar-08 National Cancer Insti https://Cl
1-Sep-17 4-Oct-22 ### ### 8-Aug-19 Local Institution, Wa https://Cl
May-19 May-19 May-25 5-Mar-19 29-Apr-19 https://Cl
Jan-01 Dec-08 Dec-08 9-Apr-03 18-Jan-20 Texas Children's Hosphttps://Cl
Mar-16 Feb-19 Feb-19 ### ### Tp0001 1101, Adelaidhttps://Cl
1-Jan-14 30-Jul-15 30-Jul-15 14-Apr-17 14-Apr-17 https://Cl
Dec-09 Dec-13 Dec-13 21-Jan-10 21-Jan-10 Institute of Public H https://Cl
21-Jul-05 6-Feb-17 6-Feb-17 ### ### 30-Oct-18 National In"Study Prohttps://Cl
1-Apr-19 1-Apr-20 1-Apr-21 ### 16-Apr-19 UZLeuven, Leuven, Vlhttps://Cl
12-Jun-18 30-Jun-19 ### ### 18-Jan-20 Sri rampura Referral https://Cl
1-Nov-19 1-Nov-20 1-Dec-21 14-Jun-19 31-Oct-19 FundaciÃ³n Universitahttps://Cl
1-Jan-12 30-Nov-14 ### 19-Jun-18 19-Jun-18 https://Cl
10-Feb-20 8-Jul-20 8-Jul-20 31-Jan-20 31-Jan-20 Leiden University Med https://Cl
Jul-12 Aug-15 Aug-15 10-Jul-12 2-Nov-15 https://Cl
18-Nov-05 ### ### 5-Apr-18 National Institutes o https://Cl
### 24-Apr-12 St Vincent's Hospital https://Cl
Dec-11 Sep-12 Sep-12 ### 7-Mar-13 Children's Hospital C https://Cl
### 24-Apr-12 St Vincent's Hospital https://Cl
Nov-11 Nov-11 Nov-11 ### 22-Oct-12 https://Cl
Sep-00 Jun-04 6-Mar-09 26-Jan-17 Navrongo Health Resehttps://Cl
Nov-07 Feb-13 Feb-13 10-Jul-07 1-Jan-16 1-Jan-16 Banner Alzheimer's Inhttps://Cl
Jan-15 Aug-18 Aug-18 26-Jan-15 12-Oct-18 Centre de SantÃ© Lishttps://Cl
Jan-15 Dec-22 Dec-23 ### 5-Feb-20 VCS Foundation, Carlto https://Cl
May-12 Jul-13 Apr-14 ### ### Chu de Reims, Reims,https://Cl
Nov-09 Dec-13 Dec-13 ### 31-Jan-14 Pfizer Investigational https://Cl
Apr-05 Nov-08 Dec-08 ### ### Cleo Roberts Center fhttps://Cl
Jul-15 Jul-17 Jul-17 13-Jul-15 22-Jun-17 Yale University, New https://Cl
7-Jun-97 4-Nov-99 ### National Institutes ofhttps://Cl
Jul-02 Jan-09 Jan-09 ### 9-Oct-13 The University of Chichttps://Cl
Aug-15 Dec-16 Dec-17 4-Sep-15 4-Sep-15 https://Cl
11-Nov-16 Sep-21 Sep-21 27-Oct-16 9-May-19 Pr Reynes, Montpelliehttps://Cl
Dec-09 Oct-12 Sep-13 ### ### Centro especializado https://Cl
en Investigaciones Medicas (CEI
Dec-08 Jun-12 Jun-12 4-Aug-10 ### GSK Investigational Sihttps://Cl
Nov-11 Nov-15 Nov-15 4-Sep-15 8-Feb-16 CHU Jean Minjoz, Be https://Cl
Apr-16 Mar-20 Mar-21 18-Oct-16 21-Jan-20 https://Cl
May-01 Oct-10 Oct-11 ### 6-Nov-15 Cancer Institute of https://Cl
Apr-12 Apr-14 Apr-14 23-Jan-13 17-Apr-19 20000+ Partnership, https://Cl
Jan-05 Jun-10 Jun-10 1-Mar-06 5-Oct-16 Wishard Memorial Hosp https://Cl
May-09 Oct-10 Oct-10 22-Jul-11 22-Jul-11 https://Cl
22-Feb-17 31-Aug-19 ### 4-Apr-17 ### National Cancer Centrhttps://Cl
3-Aug-17 Aug-24 Aug-24 2-Jul-17 ### Univ.Klinik fÃ¼r Kin https://Cl
1-Jul-12 17-Apr-18 17-Apr-18 20-Jun-12 23-Jan-19 The University of Ark https://Cl
9-Aug-19 1-Aug-24 1-Aug-25 2-May-16 7-Nov-19 M D Anderson Cancerhttps://Cl
27-Jan-18 31-Dec-20 ### 9-Oct-17 ### Bancoumana Malariahttps://Cl
Sep-02 Dec-05 ### ### Centro de Investiga https://Cl
Jun-06 Jul-08 Nov-09 ### ### The 108 Military Centhttps://Cl
21-Apr-09 Jun-11 Sep-11 9-Jul-09 ### WRAIR Clinical Trials https://Cl
Jan-09 Sep-11 Sep-11 28-Jul-10 7-Jun-17 GSK Investigational https://Cl
Mar-95 Sep-04 ### ### Llandough Hospital, https://Cl
Mar-06 Mar-10 Mar-10 7-Dec-05 ### UCLA Adult Congenital https://Cl
23-May-19 30-Sep-20 ### ### 5-Feb-20 The Hope Clinic of th https://Cl
Jan-11 Jan-13 Jan-13 ### ### Endokrinologisk polikhttps://Cl
9-Oct-17 30-Dec-21 ### ### 6-Sep-19 Columbia University M https://Cl
Oct-08 Dec-11 Jun-12 2-Sep-10 2-Jun-14 HÃ´pital LARIBOISIEREhttps://Cl
16-Jan-18 15-Oct-19 15-Oct-19 20-Apr-17 6-Nov-19 Bridge HIV"Informed https://Cl
1-Apr-17 Mar-20 Sep-20 ### 12-Jun-17 UZA, Antwerpen, Belghttps://Cl
Jan-07 Oct-10 Oct-10 7-May-08 ### Project Office, Sukkurhttps://Cl
1-Nov-17 1-Dec-17 ### ### ### https://Cl
Nov-08 Apr-10 Nov-10 2-Dec-08 ### Cytos Investigator Sit https://Cl
Jan-18 Sep-18 Dec-18 22-Jun-17 5-Feb-18 Institute of Tropical https://Cl
Mar-11 Oct-15 Jan-16 ### 6-Jul-16 HÃ´pital Cochin, Parishttps://Cl
Nov-09 Aug-12 Aug-14 24-Jul-09 ### University of Malawi https://Cl
5-Dec-17 1-Jul-20 1-Jul-21 6-Feb-17 25-Oct-19 Duke University Medic https://Cl
Nov-07 May-09 May-09 ### ### Karolinska Institutet https://Cl
May-15 4-Apr-17 4-Apr-17 ### 16-Oct-17 Treatment Research In https://Cl
Jul-14 9-Dec-16 ### ### ### Respiratory and Menihttps://Cl
Jan-06 Sep-08 Nov-09 ### 9-Aug-11 Dhaka Hospital, Dhakhttps://Cl
Jul-08 Mar-10 Mar-10 6-Jun-08 ### All India Institute of https://Cl
3-Feb-18 31-Aug-18 Aug-19 ### ### Optimal Research, LLChttps://Cl
Sep-12 Aug-14 Aug-14 11-Oct-12 8-Mar-17 8-Mar-17 EIPMED - Gesellschafhttps://Cl
1-Feb-19 1-Mar-20 1-Mar-24 25-Oct-19 29-Oct-19 Ankara Numune Trainin https://Cl
Jan-11 Dec-12 Sep-13 7-Nov-10 3-Dec-10 Stem cell cencter of https://Cl
Feb-16 Dec-17 Dec-17 8-Feb-16 9-Feb-16 https://Cl
30-Sep-17 30-Mar-19 30-Jun-19 30-Oct-17 21-Oct-19 University Hospital B https://Cl
Feb-12 Oct-15 Jan-16 30-Oct-12 25-Oct-16 Radboud University Nhttps://Cl
Jan-06 Dec-14 Dec-14 3-Sep-15 3-Sep-15 Beijing Shijitan Hospithttps://Cl
Dec-06 Dec-06 6-Mar-06 30-Jan-19 Malaria Vaccine and https://Cl
Oct-15 Feb-18 Feb-18 21-Jan-16 ### St Mary's Hospital, https://Cl
Aug-98 Apr-00 Oct-07 ### 3-Jun-08 St. Jude Children's R https://Cl
May-16 30-Jun-17 30-Jun-17 18-Jul-16 27-Oct-17 Midtown Clinic, Omahhttps://Cl
Jun-00 Dec-04 ### 9-Nov-12 https://Cl
18-Sep-17 Jan-19 Jan-19 ### ### Anxiety Cognition andhttps://Cl
Oct-09 Dec-11 Apr-12 ### 6-Mar-15 Kaiser Permanente Nor https://Cl
Sep-07 Jun-13 Jan-14 3-Dec-15 20-Apr-17 Barbara Davis Center https://Cl
10-Nov-19 30-Nov-22 ### ### ### Children's Hospital, Hhttps://Cl
Apr-08 Oct-09 Sep-11 ### ### https://Cl
Aug-09 Dec-13 Dec-13 4-Oct-10 3-Jan-14 Universidade Federal https://Cl
Aug-09 Jan-13 Jan-13 4-Oct-10 3-Jan-14 https://Cl
17-Sep-01 8-Dec-08 8-Dec-08 ### 4-Feb-19 Cedars Sinai Medical https://Cl
Dec-10 Dec-13 Dec-13 ### ### ### Meitetsu Hospital, Nahttps://Cl
Sep-05 Dec-11 Dec-18 6-Apr-07 ### Dept. of Medicine I, https://Cl
11-Dec-17 11-Jun-20 11-Jul-20 21-Apr-15 ### Saint Louis Universit https://Cl
7-Feb-20 28-Feb-21 ### 5-Feb-20 ### Human Developmenthttps://Cl
R
Oct-10 Feb-13 Jul-13 ### 4-Mar-16 Walter Sisulu Univershttps://Cl
6-Sep-18 6-Sep-21 6-Sep-22 6-Jun-18 ### Emory Vaccine Centerhttps://Cl
Jul-14 Oct-15 Oct-15 25-Jun-12 27-Jan-15 https://Cl
Apr-11 Feb-17 Feb-17 4-Mar-11 13-Jul-17 Northwest Alabama Can https://Cl
Sep-06 Feb-11 Oct-11 29-Jan-07 27-Oct-11 Pfizer Investigational https://Cl
Apr-77 Mar-00 ### 5-Mar-08 National Cancer Insti https://Cl
20-May-19 Jun-21 Jun-21 22-Apr-19 25-Jun-19 Central Hospital Mat https://Cl
3-May-17 3-Apr-20 Oct-20 13-Apr-17 5-Jul-19 HÃ´pital Avicenne, Bohttps://Cl
Mar-06 ### ### https://Cl
May-16 Dec-17 Dec-17 24-Jun-16 24-Jun-16 Health Science Centerhttps://Cl
Dec-04 Sep-05 Sep-05 8-Feb-07 ### Amboise, France|Ance https://Cl
11-Aug-14 1-Jun-18 1-Jun-18 8-May-18 11-Oct-18 Zithulele Hospital, M https://Cl
1-Feb-13 4-May-17 4-May-17 ### 9-Jul-18 9-Jul-18 University "Study Prohttps://Cl
19-Mar-18 30-Sep-25 ### 18-Apr-17 7-Nov-18 https://Cl
Aug-15 Jul-16 Jul-16 ### 21-Jun-19 https://Cl
Dec-02 Mar-10 Mar-10 15-Apr-03 ### The Methodist Hospita https://Cl
Feb-08 Sep-08 Sep-08 ### 20-Jan-11 20-Jan-11 Virginia Mason Medica https://Cl
16-Feb-17 22-Mar-18 ### 9-May-17 23-Oct-18 Chungnam National Uni https://Cl
Apr-02 Dec-13 9-Sep-14 9-Sep-14 SHP, Stockholm, Swe https://Cl
Mar-13 Jun-17 Jun-17 ### 5-Jul-17 Assistance Publique dhttps://Cl
Mar-10 Jul-13 Jul-13 ### ### ### Michigan Center for Ohttps://Cl
May-04 Apr-10 Apr-10 ### ### Memorial Sloan-Kettehttps://Cl
Apr-16 Oct-17 Apr-19 8-Mar-17 ### https://Cl
Aug-13 Jul-14 Jul-16 1-Aug-13 ### Immunology Clinic Rahttps://Cl
Sep-05 May-08 Dec-08 18-Oct-05 7-Jul-11 Alberta Health Servi https://Cl
14-Apr-16 11-Dec-17 ### ### ### ### University "Study Prohttps://Cl
Jan-02 Sep-05 ### 1-Nov-07 InterMune, Inc., Brisbhttps://Cl
Oct-13 Aug-14 Aug-14 1-Oct-13 ### https://Cl
Oct-08 Sep-14 Dec-14 ### 14-Apr-16 Immunotherapy, Guan https://Cl
Aug-05 Dec-05 Dec-05 ### ### https://Cl
Jan-20 Jan-22 Jul-22 30-Apr-19 30-Apr-19 https://Cl
Sep-02 Jan-03 ### ### Grieskirchner Strassehttps://Cl
Jul-20 May-22 Jun-22 6-Apr-18 ### Wake Forest Baptist M https://Cl
Oct-09 Apr-10 Aug-10 ### 18-Oct-10 San Francisco Departm https://Cl
Mar-05 Aug-15 Dec-16 13-Oct-05 ### ### Knight Cancer Institu https://Cl
Nov-13 May-18 May-18 4-Dec-13 27-Oct-14 https://Cl
May-08 Jun-08 Jun-08 ### 11-Jun-09 Nucleus Networks Limi https://Cl
Apr-16 Dec-16 Dec-16 ### 6-Jul-18 6-Jul-18 Johns Hopkins Centerhttps://Cl
Jun-11 Mar-15 Mar-15 ### 1-Sep-15 Pediatric Dpt B - Ha'Ehttps://Cl
19-Mar-19 15-Aug-20 ### 25-Jan-19 ### NIHR Imperial Clinicahttps://Cl
Nov-14 Nov-16 Nov-16 9-Dec-14 30-Jun-16 https://Cl
Feb-20 30-Jun-20 1-Sep-20 30-Jan-20 30-Jan-20 https://Cl
Jun-15 Dec-15 Dec-15 9-Jan-17 9-Jan-17 Saarland University https://Cl
Feb-19 Oct-21 Oct-21 8-Jan-19 8-Jan-19 https://Cl
Jan-13 Feb-14 Mar-14 11-Jan-13 ### ### https://Cl
Oct-11 Feb-12 Feb-12 25-Oct-11 9-Feb-12 Seboche Hospital, Se https://Cl
Jul-13 Jul-16 Jul-17 ### ### Assistance Publique Hhttps://Cl
Mar-15 Oct-15 Oct-15 20-Oct-15 25-Oct-16 https://Cl
1-Nov-18 15-Nov-20 ### 31-Jul-18 21-Oct-19 University Hospital, https://Cl
May-11 Apr-12 Apr-12 19-Apr-11 21-Apr-14 Centro de Salud Portahttps://Cl
Apr-13 Oct-16 Oct-16 25-Oct-13 9-May-17 Pediatric Hematology/O https://Cl
Oct-13 Mar-15 Apr-17 30-Jan-14 ### Johns Hopkins Harriethttps://Cl
4-Sep-18 Dec-19 Mar-20 ### ### Pusan National Univerhttps://Cl
14-Feb-20 6-Aug-20 6-Aug-20 23-Jan-20 23-Jan-20 Radboud University Mhttps://Cl
1-Jan-11 30-Dec-18 ### 6-Jun-19 12-Jun-19 The First People's Hoshttps://Cl
2-Oct-17 Sep-18 Sep-19 ### 11-Apr-18 HÃ´pital GÃ©nÃ©ral https://Cl
d
Oct-14 9-Aug-16 9-Aug-16 31-Oct-14 ### ### Center for Immunizatihttps://Cl
1-Sep-18 30-Aug-20 ### 6-Jul-18 1-May-19 Qingzhu Jia, Chongqi https://Cl
Jul-14 23-May-16 ### 15-Jul-14 23-Oct-17 University of Califor https://Cl
Dec-13 Oct-14 Jan-15 ### ### Department of Food ahttps://Cl
9-May-19 Jun-20 Jun-22 ### ### Hospital de la Santa Chttps://Cl
30-Oct-17 1-Jun-21 1-Jun-21 ### ### university of Antwerphttps://Cl
Jan-16 Sep-16 Dec-16 ### 3-Jan-18 Hospital for Sick Chil https://Cl
Mar-10 Apr-11 Jun-16 28-Jan-10 ### Cliniques Universitai https://Cl
Nov-16 Mar-21 Mar-21 2-Dec-16 30-Jan-19 HÃ´pital Necker-Enfanhttps://Cl
1-Jun-15 31-Dec-17 ### ### ### https://Cl
Dec-14 Feb-20 Feb-20 ### ### University of Califor https://Cl
Jan-16 Jun-19 Dec-19 ### 22-Oct-19 University of Califor https://Cl
Jan-12 Oct-14 Oct-14 15-Jun-17 15-Jun-17 Teso North Ministry ohttps://Cl
Sep-16 Sep-21 Sep-21 ### ### University of Virginia https://Cl
Oct-05 Dec-07 Dec-07 ### 16-Jan-13 University of Tuebin https://Cl
Jul-10 Oct-11 Oct-11 14-Oct-10 ### ### Columbia University M https://Cl
Apr-11 Jan-16 Jan-16 7-Sep-11 28-Apr-17 National Jewish Healthttps://Cl
21-Nov-14 24-Jun-16 24-Oct-16 3-Mar-15 ### ### Task Clinical Researc https://Cl
Nov-12 Aug-13 Aug-13 23-Jul-13 ### GSK Investigational S https://Cl
Mar-13 Dec-19 Dec-19 21-Oct-13 ### Morgan Stanley Childrhttps://Cl
7-Jan-19 30-Jun-24 30-Jun-24 ### ### AO Santa Cr"Study Prohttps://Cl
Jul-12 Jan-13 Mar-13 ### ### Queen Saovabha Memor https://Cl
Sep-07 May-10 Jun-12 ### ### ### California Pacific Me https://Cl
Mar-20 Oct-23 Mar-25 29-Jan-20 29-Jan-20 Kantonsspital Aarau, https://Cl
Nov-11 Aug-13 Aug-13 ### 26-Jan-16 University of Michigahttps://Cl
Sep-14 Apr-16 May-16 15-Jul-14 3-May-16 Rehri goth, Ibrahim Hhttps://Cl
Feb-04 Feb-07 Feb-07 4-Oct-05 2-Jul-10 ### The Children's Hospitahttps://Cl
1-Dec-07 1-Apr-08 1-Aug-08 5-Jun-06 18-Jan-18 Quintiles Phase 1 Serhttps://Cl
1-Jan-07 1-Apr-08 1-Aug-08 5-Jun-06 8-Jan-18 Quintiles Phase 1 Serhttps://Cl
Jan-09 Feb-12 Feb-12 15-Jan-09 ### HOPITAL DE SAINTE MA https://Cl
Sep-12 Jun-14 Jun-14 ### 19-Apr-16 Duke Primary Care Rehttps://Cl
30-Dec-19 10-Jun-24 9-Dec-26 ### 18-Jan-20 Urology San Antonio Phttps://Cl
Oct-06 Apr-08 Apr-08 25-Jun-07 ### University of Michigahttps://Cl
Apr-12 Jun-15 ### 8-Apr-14 ### Brno, Czechia|Hradechttps://Cl
1-Apr-17 28-Feb-18 ### 15-Jun-16 ### World Vision, Toront https://Cl
Nov-13 Jun-14 Jun-14 7-Mar-14 12-Jan-16 Helmholtz Centre for https://Cl
Jan-06 Jul-08 Jul-08 11-Jul-08 11-Jul-08 Albert Sabin Hospital,https://Cl
Mar-11 Dec-13 Dec-13 ### ### GSK Investigational S https://Cl
Oct-08 May-10 May-10 29-Oct-08 29-Oct-08 https://Cl
Mar-07 ### ### Medical Research Unhttps://Cl
Nov-16 Oct-17 Oct-17 20-Jan-17 5-Sep-18 NIZO food research, https://Cl
12-Jul-12 22-Feb-16 ### ### ### HÃ´pital Jean VERDIEhttps://Cl
Feb-10 May-10 Sep-10 28-Jan-10 ### Seattle Biomedical Reshttps://Cl
2-Jun-17 Dec-19 Sep-20 18-Jan-17 7-Aug-19 Alaska Clinical Resea https://Cl
Jan-09 Aug-17 Aug-17 11-Jun-12 12-Apr-16 Leiden University Med https://Cl
20-Feb-18 15-Nov-19 6-Dec-19 3-Jan-18 ### National Institutes ofhttps://Cl
Jul-02 Jul-03 Jan-04 ### ### Malaria Research andhttps://Cl
Dec-00 Dec-07 Dec-07 7-Oct-05 22-Oct-15 University of Rochesthttps://Cl
Nov-08 23-Jun-09 23-Jun-09 Neonatologische Intehttps://Cl
1-Jan-17 31-Dec-19 ### ### 21-Jan-20 University "Informed https://Cl
Jul-02 Nov-05 Apr-07 11-Jun-04 2-Aug-12 M D Anderson Cancerhttps://Cl
16-Jun-17 8-Dec-20 Mar-23 19-Jun-17 1-Nov-19 Germans Trias i Pujol https://Cl
Feb-13 Feb-14 Jun-16 25-Jan-13 ### University Hospital, https://Cl
12-Apr-16 12-Jun-19 12-Jun-19 27-Jul-15 18-Jan-20 Brigham and Women's https://Cl
17-Apr-06 23-Jan-13 29-Jun-06 5-Dec-19 Malaria Research andhttps://Cl
Oct-14 Oct-20 Oct-20 2-Nov-14 9-Sep-19 Memoral Sloan Ketterhttps://Cl
Sep-07 Oct-14 Oct-14 5-Jan-10 9-Sep-15 CHU de Nantes, Nantehttps://Cl
Dec-14 Aug-16 Aug-16 23-Oct-14 ### McMaster Children's https://Cl
Mar-13 May-13 May-13 25-Jul-14 ### ### Faculty of Dentistry, https://Cl
Mar-12 Dec-14 Dec-14 2-Mar-12 6-Mar-15 Emory Children's Centhttps://Cl
yael12-HMO-CTIL 30-Jun-09 30-Jun-09 https://Cl
Jul-12 May-16 May-16 ### 15-Jun-18 15-Jun-18 Providence Sacred Hehttps://Cl
19-Apr-19 Dec-20 Dec-20 11-Apr-19 5-Feb-20 Centre for Clinical V https://Cl
2-Aug-19 2-Aug-21 3-Feb-22 ### 13-Jan-20 Homa Bay County Refe https://Cl
Feb-08 Apr-10 Dec-10 8-Feb-08 ### Oncology Department. https://Cl
Jan-14 Jul-15 Jul-17 3-Jan-14 7-Aug-17 Pusan National Univerhttps://Cl
16-Jan-20 Jan-24 Dec-24 19-Apr-19 18-Jan-20 Northwestern Memorial https://Cl
12-Sep-19 Dec-20 Dec-20 1-Jul-19 16-Oct-19 University Hospital Brhttps://Cl
Mar-10 Apr-10 May-10 ### ### Taipei Medical Univerhttps://Cl
Feb-11 Feb-14 Feb-14 25-Oct-10 ### ### Banner Alzheimer's Inhttps://Cl
16-Feb-17 31-Dec-20 ### ### ### Mount Sinai Medical h Cttps://Cl
Aug-08 Aug-15 Aug-15 ### ### Zurich, Switzerland https://Cl
Mar-11 Nov-15 Mar-16 ### 9-Jun-16 Gustave Roussy Cancer https://Cl
Jun-11 Sep-11 Sep-11 ### 5-Jan-12 Luigi Sacco Hospital, https://Cl
1-Jan-06 31-Dec-17 ### 12-Apr-18 17-Apr-18 "Study Prohttps://Cl
Jan-14 Sep-15 Nov-16 22-Jan-14 17-Jun-16 HÃ´pital Sud Francili https://Cl
15-Sep-18 1-Aug-19 1-Aug-19 2-Aug-18 2-Aug-18 Suraj Social Franchisehttps://Cl
Feb-07 Sep-10 Sep-10 12-Jul-06 9-Apr-14 Uganda Virus Research https://Cl
Jan-10 Feb-14 Feb-17 26-Jan-11 ### Laguna Hills, Califor https://Cl
1-Mar-16 1-Mar-16 ### 27-Jun-18 28-Jun-18 https://Cl
Sep-19 Aug-20 Aug-20 ### ### https://Cl
Jan-14 Oct-14 Jun-15 ### ### University of Naples "https://Cl
1-Apr-19 31-Mar-20 30-Jun-20 8-Apr-19 9-Apr-19 Ellembelle District H https://Cl
Feb-10 Dec-12 Mar-13 4-Feb-10 1-Apr-14 University Hospital https://Cl
Feb-14 Apr-15 Apr-15 ### ### Infectious Diseases https://Cl
Sep-15 1-Jun-16 1-Jun-16 ### 10-Apr-17 University of Californhttps://Cl
20-Sep-16 10-Mar-17 20-Jun-17 5-Jun-17 ### Alzahra hospital, Tabrihttps://Cl
12-Jan-15 22-May-18 ### 1-May-15 15-Oct-19 Research and Educatio https://Cl
Oct-08 Nov-10 Nov-10 22-Oct-08 1-Feb-11 Zurich, Switzerland https://Cl
8-Apr-19 Apr-21 Jun-21 8-Aug-19 8-Aug-19 Bernhard Nocht Insti https://Cl
Sep-05 Mar-09 Mar-09 4-Oct-05 28-Oct-11 Centro de Investiga https://Cl
Jun-13 Mar-15 Mar-15 ### ### https://Cl
Dec-09 Dec-11 Dec-11 9-Dec-09 ### Washington University https://Cl
Aug-08 Feb-14 Feb-14 11-Jun-08 4-May-12 Urocare Hospital, Rajhttps://Cl
Dec-11 May-12 Nov-12 6-Dec-11 ### Nursing home Tezno, https://Cl
Apr-16 Sep-16 Sep-16 2-Jan-18 2-Jan-18 https://Cl
1-Sep-13 20-Apr-17 27-Apr-17 11-Apr-14 ### 9-Jul-18 University "Study Prohttps://Cl
25-May-16 Feb-20 Feb-20 ### 21-Jan-20 Miami Research Associ https://Cl
Feb-15 Feb-16 Feb-16 ### 25-Oct-18 Department of Surgerhttps://Cl
6-Feb-18 22-Feb-19 11-Oct-19 8-Feb-18 ### National Taiwan Univehttps://Cl
Dec-11 Apr-12 Apr-12 ### ### Bronx Lebanon Hospita https://Cl
Jan-16 Oct-16 Jan-17 ### 19-Jan-17 Vienna Challenge Chahttps://Cl
Jan-08 Feb-11 Feb-11 9-Nov-07 14-Jan-15 16-Oct-18 Marshfield Clinic Res https://Cl
Dec-13 Jul-14 Sep-14 8-Apr-11 5-Nov-15 University of Zurich, https://Cl
Oct-11 Apr-20 Oct-20 23-Jan-13 ### Internal and Medical https://Cl
1-Jul-17 18-Jun-18 18-Jun-18 ### 20-Jun-18 UAB Lung Health Centhttps://Cl
19-Jan-18 Feb-20 Mar-20 2-Aug-17 5-Apr-19 University of Dundeehttps://Cl
15-Jul-14 30-Sep-19 ### ### ### Institut Pasteur of https://Cl
Jan-02 Sep-04 ### ### City and Hackney, Lo https://Cl
28-Jul-17 28-Sep-19 10-Jan-20 ### ### Xicheng District Centehttps://Cl
Dec-14 May-15 Sep-15 ### ### The caregivers treat https://Cl
1-Aug-18 31-Jul-19 ### 1-Oct-18 1-Oct-18 CHU de La RÃ©union,https://Cl
Sep-07 Jun-11 Jun-11 9-Jan-08 24-Jul-12 Fairfax Family Practic https://Cl
Mar-16 Sep-20 Nov-20 ### 14-Jan-20 Nyembe and Mtandaza https://Cl
Feb-16 Aug-30 Aug-33 8-Jul-15 ### https://Cl
Feb-10 Oct-11 Nov-11 3-Dec-09 ### 12-Jun-17 University of Pennsyvhttps://Cl
Apr-03 8-Sep-05 28-Apr-11 Hadassah Medical Orga https://Cl
Jul-10 Oct-10 Jan-11 2-Aug-10 ### ### Vanderbilt Universityhttps://Cl
15-Jun-17 30-Dec-19 ### 16-Jun-17 ### Loyola University
University Medhttps://Cl
of Alabama, Birmingham, Alabama, United
Dec-13 Feb-16 Jun-16 ### 7-Feb-18 16-Jul-19 Academisch Medisch https://Cl
Centrum, Amsterdam, Netherla
11-Sep-17 Dec-20 Dec-21 ### 16-Oct-19 Angers, Angers,
Rheum Assoc ofFranchttps://Cl
North Alabama /ID# 135926, Huntsv
24-Jan-14 24-Jul-21 24-Jul-21 30-Jan-14 13-Jan-20 Poland|Gabinet Internistyczno
https://Cl Reum. /ID# 135876, B
Dec-12 May-13 Jul-13 18-Jan-13 4-Apr-16 Centre d'InvestigaciÃ³https://Cl
del Medicament Institut de Rec
Apr-08 Sep-09 Jul-11 ### 20-Jul-11 Canisius Wilhelmina https://Cl
Jul-09 Jun-10 Jul-11 3-Jul-09 3-Jul-09 Minneapolis VA Medichttps://Cl
Apr-15 Apr-19 Dec-20 12-Jan-16 5-May-17 UOC Pediatria, USL9, hGttps://Cl
1-Sep-14 30-Sep-17 ### ### 9-Aug-18 Eskenazi Medical Grou https://Cl
Dec-08 Nov-11 Nov-11 ### ### Dept of Haematology,https://Cl
May-09 May-13 Nov-13 ### 4-Feb-16 4-Feb-16 Yale University Scho https://Cl
22-Jan-10 8-Jul-14 ### 5-Jul-18 National Institutes ofhttps://Cl
15-Jun-06 ### ### ### Ahmadu Bello Universi https://Cl
Aug-10 Aug-13 20-Jan-11 20-Jan-11 Taipei Medical Univers https://Cl
Aug-09 May-14 May-14 6-Nov-08 16-Jan-15 Nepal Nutrition Inter https://Cl
Feb-13 Aug-15 Jan-16 23-Jan-13 ### National Heart and L https://Cl
### 24-Jun-05 Immune Response Corp, https://Cl
### 24-Jun-05 Immune Response Corp, https://Cl
Aug-14 Jun-15 Jul-15 4-Jun-14 7-Jul-16 12-Jun-17 601 University of Cal https://Cl
Jan-08 8-Jul-09 16-Jul-09 https://Cl
Nov-14 Aug-16 Aug-16 3-Mar-16 6-Feb-19 https://Cl
5-Sep-17 31-Dec-18 ### ### 16-Jul-19 CrÃ¨che du Parc, Orsahttps://Cl
Oct-09 Apr-12 Apr-12 9-Jul-10 23-Jul-10 National Heart and L https://Cl
Apr-06 May-08 Jul-08 ### 6-Aug-09 Jawaharlal Nehru Medi https://Cl
Jul-10 Apr-11 Aug-11 5-Jan-11 26-Jun-15 Edward Hines, Jr. VA Hhttps://Cl
Jan-14 Aug-17 Aug-17 29-Jan-14 16-Apr-19 Helsinki University, Hhttps://Cl
Feb-18 Jun-18 Jun-22 29-Jan-18 30-Jan-18 Infection Control unithttps://Cl
Jan-06 Jun-10 Jun-10 ### 13-Jan-17 Queensland Centre for https://Cl
Oct-98 Jun-01 12-Jan-06 12-Jan-06 https://Cl
Oct-07 Sep-10 10-Oct-07 3-Aug-10 Despond TuTu TB Centr https://Cl
Aug-07 Jul-08 Aug-08 ### ### Baylor College of Medhttps://Cl
1-Jan-16 1-May-16 1-Jun-16 ### ### Damien JOLLY, Reims,https://Cl
Dec-15 May-17 May-17 ### ### MAASTRO clinic, Maas https://Cl
1-Jan-17 1-Jan-19 1-Jan-19 6-Nov-17 7-Nov-17 Fudan University Canchttps://Cl
Sep-08 Dec-11 Jul-12 10-Jul-08 ### https://Cl
060A|0001-008 ### ### Univ of Minnesota, Mhttps://Cl
ACTG 232|11209 Mar-96 ### 9-May-12 Beth Israel Deaconesshttps://Cl
22-Nov-18 22-Dec-18 ### ### ### Angoche District, Co https://Cl
19-Apr-11 1-Dec-17 ### 20-Apr-11 23-Apr-19 23-Apr-19 Childrens N"Study Prohttps://Cl
1-Feb-20 31-Aug-23 ### ### ### https://Cl
Feb-15 Jun-15 Jun-15 ### 7-Oct-15 Q-Pharm Clinics, Hershttps://Cl
Dec-05 Dec-06 Dec-06 ### ### Mirpur, Dhaka, Bangl https://Cl
Sep-04 Jul-07 May-09 ### ### National Institutes ofhttps://Cl
Mar-13 Jun-13 Jun-13 ### 7-Feb-19 https://Cl
Mar-01 Jan-02 ### 4-Mar-08 National Cancer Insti https://Cl
Aug-99 May-10 May-10 4-Nov-99 ### ### National Cancer Insti https://Cl
Sep-90 Jul-02 4-Nov-99 4-Mar-08 National Human Genom https://Cl
Feb-20 Feb-21 Feb-21 10-Apr-19 13-Jan-20 https://Cl
23-Mar-16 25-Jul-16 25-Jul-16 24-Jun-15 7-Feb-19 National Heart and Luhttps://Cl
28-Feb-19 31-Jan-21 30-Jun-22 ### ### Chu Clermont-Ferrandhttps://Cl
Nov-14 Feb-15 Feb-15 21-Oct-14 ### ### Research Site, Kameyahttps://Cl
12-Dec-11 Dec-23 Dec-23 5-Aug-13 ### Dr. B Barooha Cancerhttps://Cl
11-Apr-14 17-Jul-18 17-Jul-18 4-Jul-13 26-Jun-19 26-Jun-19 Mayo Clinic"Study Prohttps://Cl
Jun-12 Oct-12 Feb-13 21-Jun-12 4-Apr-16 Eberhard Karls Unive https://Cl
Oct-10 Dec-12 Apr-13 23-Jun-10 ### Moffitt Cancer Centerhttps://Cl
21-Apr-03 ### 27-Jan-20 National Institutes o https://Cl
20-Jun-01 ### 28-Jun-01 ### National Institutes ofhttps://Cl
Jul-10 Dec-15 Jul-16 ### 27-Jan-16 Department of Respirhttps://Cl
Apr-04 Oct-10 Oct-10 18-Jul-05 16-Jan-13 ### Phoenix Children's Hohttps://Cl
23-Apr-17 1-Apr-20 1-Apr-20 ### ### University of North Cahttps://Cl
1-Feb-16 31-Dec-17 ### ### ### https://Cl
Oct-09 Sep-14 Sep-14 11-Jan-10 28-Jan-15 Martin-Luther-Univershttps://Cl
Jan-15 Dec-15 Dec-16 ### ### Erasmus MC, Dept. ofhttps://Cl
1-Aug-18 30-Sep-20 ### 4-Sep-18 13-Jun-19 School of Public Healhttps://Cl
1-Aug-18 1-May-19 1-May-19 1-May-19 1-May-19 Pregnant women, Beiji https://Cl
Jan-11 Jan-14 Feb-14 27-Jan-11 5-Jan-15 Janssen AI Investigatihttps://Cl
Jul-00 Aug-01 Nov-01 ### 20-Jun-17 University Hospital A https://Cl
Jan-88 Dec-16 Dec-25 18-Oct-16 18-Oct-16 Croix Rousse Hospitalhttps://Cl
Dec-13 Mar-16 Mar-16 17-Apr-13 18-Apr-17 18-Apr-17 Chungnam National Uni https://Cl
Oct-11 Nov-12 Jan-13 4-Nov-11 27-Jun-17 Rockefeller Universit https://Cl
15-Feb-17 30-Sep-18 ### 2-May-17 5-May-17 IDIAP Jordi Gol, Barc https://Cl
Jan-03 Mar-10 Mar-10 2-Mar-04 21-Jan-20 The Methodist Hospita https://Cl
13-Jun-16 1-Oct-18 1-Oct-18 31-Jan-18 5-Mar-19 Texas Children's Hospihttps://Cl
Sep-07 Feb-11 Feb-11 21-Apr-10 23-Apr-12 31-Oct-12 Site Reference ID/Invhttps://Cl
Aug-95 Jul-01 ### 4-Mar-08 National Cancer Insti https://Cl
Oct-11 Dec-18 Dec-18 30-Jun-11 12-Apr-16 Myology Institute, Pahttps://Cl
Jul-08 Feb-09 Feb-09 5-Jan-09 9-Jan-18 AKU-Peds Naushero Fer https://Cl
27-Jan-17 26-Nov-18 ### 4-Aug-16 28-Jan-19 Service de Rhumatolog https://Cl
Jan-04 Dec-06 Dec-06 ### 28-Jun-10 AlcalÃ¡ de Henares, Spain|AlcorcÃ³n,
https://Cl Spain|Badalona
Sep-05 Jun-06 Jun-06 ### 29-Jun-10 Auch, France|Brest, https://Cl
Oct-07 Jun-09 Dec-12 12-Oct-07 ### Massachusetts General https://Cl
Aug-10 Aug-13 Aug-13 5-Aug-10 ### ### Mount Sinai School ohttps://Cl
Apr-10 May-14 May-14 ### ### Instituto Nacional de https://Cl
PediatrÃa (INP), MÃ©xico City,
21-Jun-19 May-20 May-22 16-Apr-19 14-Jan-20 Brigham and Women's https://Cl
Jul-20 Jun-22 Jun-22 ### 3-Jun-19 https://Cl
21-May-19 31-Dec-22 ### ### ### VA Greater Los Angelehttps://Cl
Oct-07 Mar-10 Mar-10 ### ### ### Research Site, Researhttps://Cl
19-Oct-17 31-Jul-19 31-Jul-19 12-Jul-17 9-Sep-19 At home, Niakhar, RÃhttps://Cl
May-15 May-17 Jul-17 ### 3-Aug-17 Department of Primarhttps://Cl
Sep-15 Dec-18 Jan-19 3-Feb-16 8-Feb-18 Cervesi Hospital IVF Unhttps://Cl
8-Dec-17 Feb-20 Feb-20 ### 25-Jun-19 Case Western Reservehttps://Cl
Jan-12 Feb-15 Feb-15 ### 28-Jul-15 Countess of Chester, https://Cl
Sep-05 Jun-08 Jun-08 ### ### ### UNM HSC, Albuquerqu https://Cl
31-Mar-07 26-Aug-08 ### ### ### ### https://Cl
1-Apr-19 Apr-26 Apr-26 ### 4-Jun-19 Istituto di Ricerche https://Cl
27-May-16 2-Mar-17 2-Mar-17 2-Mar-16 ### 18-Apr-18 Clinical Re "Statistic https://Cl
1-Apr-18 1-Apr-19 1-Apr-20 ### ### https://Cl
Feb-07 Oct-08 Oct-08 ### 5-Jun-08 University of Vermonthttps://Cl
Nov-14 Oct-16 Oct-16 ### 27-Oct-16 University of Iowa Hea https://Cl
Jul-12 Nov-16 Dec-16 ### ### Tianjin Medical Univerhttps://Cl
Nov-04 Dec-07 Nov-11 16-Jan-12 16-Jan-12 VU university medicahttps://Cl
Aug-89 Jul-97 28-Oct-99 7-Nov-16 https://Cl
13-Dec-19 Mar-20 Jul-20 29-Jan-20 6-Feb-20 Evidation Health, Sanhttps://Cl
Aug-12 Jun-13 Jun-13 ### 2-Jun-15 West Virginia Univershttps://Cl
1-Sep-15 6-Feb-19 6-Feb-19 ### 5-Jun-19 VA San Diego Healthca https://Cl
Oct-16 Jun-20 Jun-20 7-Sep-16 11-Jul-19 Swiss Paraplegic Centhttps://Cl
Jun-18 30-Apr-21 30-Jun-21 ### 10-Apr-18 Aurum Institute - Kle https://Cl
Jan-13 Aug-13 Aug-13 ### ### GSK Investigational Sihttps://Cl
20-Sep-19 Sep-21 Sep-21 19-Jun-19 8-Oct-19 Nyimba District Medihttps://Cl
Aug-97 Jul-98 9-Feb-04 4-Dec-13 Cleveland Clinic Taus https://Cl
Nov-10 Dec-22 Dec-22 ### 4-Feb-19 Mayo Clinic, Rochestehttps://Cl
Sep-14 Aug-15 Aug-15 ### ### Mpwapwa District, Mhttps://Cl
31-Jan-17 31-Jan-20 31-Jan-20 24-Jan-19 24-Jan-19 Royal Hospital for Wohttps://Cl
Mar-14 Apr-14 Apr-14 11-Apr-14 27-Jul-15 27-Jul-15 Sumida-ku, Tokyo, Ja https://Cl
Jul-16 May-17 Aug-17 2-Dec-16 7-May-18 Trinidad and Tobago Ihttps://Cl
Feb-20 Oct-20 Feb-21 5-Feb-20 5-Feb-20 https://Cl
May-12 Nov-15 Nov-15 6-Sep-10 ### Klinik und Poliklinik https://Cl
Sep-13 Apr-14 Sep-14 5-Nov-14 6-Nov-14 https://Cl
Jan-13 Feb-14 Jun-15 ### 6-Oct-15 Prentice Women's Hospi https://Cl
28-Feb-19 Jun-20 Jun-20 15-Jan-19 9-Apr-19 Geisinger Health Systhttps://Cl
11-Feb-20 28-Jun-20 28-Jun-20 ### ### Imperial Clinical Res https://Cl
Jun-97 Jan-04 Jan-04 ### 5-Apr-13 Barbara Ann Karmanos https://Cl
May-16 Apr-20 Oct-20 ### ### Children's of Alabam https://Cl
4-Aug-16 31-Jul-18 31-Jul-18 ### 18-Oct-19 https://Cl
11-Sep-17 8-May-18 ### 2-Jul-17 6-Jul-18 Imperial College Lon https://Cl
Feb-09 Mar-12 Mar-12 6-Nov-13 6-Nov-13 Institut de Recherch https://Cl
23-Sep-13 23-Sep-15 ### 20-Jul-16 4-Oct-19 4-Oct-19 GSK Investi"Study Prohttps://Cl
15-Aug-16 7-Jan-19 15-Jan-21 21-Oct-15 29-Jan-20 29-Jan-20 Barranco C"Statistic https://Cl
May-94 Oct-94 ### ### https://Cl
Nov-09 Dec-13 Dec-13 23-Oct-09 9-Jul-14 Grady North DeKalb Clhttps://Cl
Sep-07 May-08 4-Sep-08 ### 5-Apr-17 Center for Immunizatihttps://Cl
Sep-06 13-Jun-07 13-Jun-07 ### 11-Apr-17 Center for Immunizatihttps://Cl
10-Feb-20 10-Apr-20 ### 6-Jan-20 5-Feb-20 https://Cl
Jan-11 Jan-11 Jan-11 6-Jul-11 6-Jul-11 St. Louis Children's H https://Cl
DSRB Domain E/2011/1772 13-Jan-12 15-Apr-15 National University Hhttps://Cl
22-Feb-13 26-Nov-13 ### 29-Jul-13 ### GSK Investigational S https://Cl
Dec-06 May-10 May-10 ### 31-Jan-14 Contra Costa Regionalhttps://Cl
May-08 Jan-09 Jan-09 ### 2-Feb-16 Emory University, Atl https://Cl
Dec-10 Apr-12 Apr-12 4-Mar-11 4-Mar-11 Instituto de Investig https://Cl
6-Sep-11 30-Jan-15 30-Jan-15 12-Jul-11 26-Apr-17 25-Jun-19 GSK Investigational Sihttps://Cl
Apr-15 Sep-18 Sep-19 ### 3-Mar-17 Kenya Medical Researhttps://Cl
22-Nov-19 Nov-22 Nov-22 ### 5-Feb-20 Memorial Sloan Ketter https://Cl
9-Dec-19 16-Oct-22 ### 4-Nov-19 ### Local Institution, Newhttps://Cl
Sep-11 Jul-13 Jul-13 ### ### Asociacion Civil Selvahttps://Cl
Jul-05 Jul-12 Jul-12 ### 23-Apr-14 Methodist Hospital, Hhttps://Cl
24-Dec-18 19-May-22 ### 18-Oct-18 5-Feb-20 Alaska Urological Ins https://Cl
Mar-15 Jun-17 20-Jul-17 ### 11-Apr-18 Reproductive Medicine https://Cl
1-Oct-19 31-Jan-24 30-Apr-24 ### 1-Oct-19 https://Cl
Mar-13 Mar-15 Mar-15 ### ### Institut Paoli-Calmetthttps://Cl
Apr-14 Oct-14 Oct-14 4-Apr-14 2-Dec-14 Jacaranda Health, Naihttps://Cl
Aug-15 1-Mar-18 Dec-19 24-Jul-15 7-Jan-19 Thomas Jefferson Univ https://Cl
Sep-15 Mar-20 Mar-20 ### 30-Jul-19 South End Community https://Cl
6-Oct-06 11-May-07 ### ### ### ### https://Cl
17-Jul-19 13-Mar-21 ### 26-Apr-19 1-Nov-19 YMCA Burnsville, Burhttps://Cl
17-Jan-17 Jul-20 Sep-20 27-Apr-18 ### St George's, Univers https://Cl
31-Jan-19 31-Jan-22 ### ### ### University of Washinghttps://Cl
Oct-08 Oct-10 Apr-11 10-Jan-12 10-Jan-12 Asthma and Rhinitis Chttps://Cl
27-Mar-18 31-Aug-18 ### 14-Apr-17 1-Nov-19 YMCA Southdale, Edinhttps://Cl
Apr-11 Oct-14 Oct-14 24-Oct-12 26-Oct-12 Malaria Control Prog https://Cl
Jan-09 22-Aug-16 ### ### ### ### Mark P. Sc "Study Prohttps://Cl
1-Oct-08 22-Jun-16 22-Jun-16 30-Jul-08 7-Aug-18 7-Aug-18 GSK Investigational S https://Cl
### 24-Jun-05 Phoenix Body Positivehttps://Cl
ACTG 402|10607|PACTG 402 Jun-06 ### ### Long Beach Memorialhttps://Cl
M
Apr-10 Dec-10 Dec-10 1-Feb-10 22-Jun-11 Department of Medical https://Cl
23-May-17 Sep-20 Sep-21 ### 9-Aug-19 UCSF Helen Diller Famhttps://Cl
15-Feb-19 1-Mar-20 1-Mar-20 ### ### Communities in Rwand https://Cl
1-Jan-20 30-Jun-20 ### 6-Nov-19 6-Nov-19 https://Cl
1-Nov-19 1-Nov-20 1-Jul-21 23-Jan-20 23-Jan-20 UCLA Health Departmen https://Cl
Mar-16 Dec-18 Dec-18 ### 9-Sep-19 9-Sep-19 Children's "Study Prohttps://Cl
Oct-09 Oct-11 Oct-12 ### ### Erasmus Medical Centhttps://Cl
21-Jun-16 Dec-18 Dec-18 25-Jan-16 ### Hospital General Univhttps://Cl
30-Dec-15 Dec-18 Dec-18 13-Jan-16 ### Hospital Universitariohttps://Cl
PrÃncipe de Asturias, AlcalÃ¡ d
Dec-08 Jul-12 Jul-12 ### 1-Jan-16 1-Jan-16 Suwa Red Cross Hospit https://Cl
Aug-07 Sep-08 Apr-09 ### ### https://Cl
Jan-08 Sep-12 Sep-12 1-Aug-08 9-Feb-15 https://Cl
26-Sep-18 25-Mar-21 ### ### ### Instituto Lauro de So https://Cl
27-Jan-17 31-Dec-20 1-Jan-26 8-Aug-16 6-Feb-20 National Institutes ofhttps://Cl
Jun-11 Oct-13 Oct-13 ### 6-Aug-18 Hopital Fort San Miche https://Cl
May-11 Jan-13 ### ### ### University of Wisconshttps://Cl
Jun-15 Nov-15 Dec-15 28-Jul-15 4-Jan-19 4-Jan-19 Colorado St"Study Prohttps://Cl
Nov-14 Jun-16 Jun-16 21-Oct-14 ### UAB Comprehensive Ca https://Cl
Mar-12 Dec-15 Jun-16 8-Apr-14 ### Jablonec nad Nisou, Chttps://Cl
1-Dec-17 24-Dec-18 ### ### 1-May-19 FHI Solutions LLC, Ali https://Cl
Aug-12 Aug-24 Aug-24 21-Apr-15 ### Emory University Hosp https://Cl
Jan-13 31-Jul-18 ### 4-Aug-11 4-Dec-19 Washington DC VAMC, https://Cl
5-Apr-18 5-Apr-20 5-Apr-21 13-Jun-18 ### Institutional Review https://Cl
10-Apr-18 10-Apr-20 10-Apr-21 ### ### Institutional Review https://Cl
12-Apr-18 12-Apr-20 12-Apr-21 26-Apr-18 ### Institutional Review https://Cl
27-Mar-18 27-Mar-20 ### 18-Apr-18 ### Institutional Review https://Cl
25-Mar-18 25-Mar-20 ### 2-Apr-18 ### Biological treatment https://Cl
Nov-15 Jan-17 Jun-17 2-Aug-17 2-Aug-17 https://Cl
Apr-11 Dec-18 Dec-18 4-Aug-10 1-Aug-17 Great Ormond Street https://Cl
Jan-09 Mar-10 Apr-10 ### ### Kintampo Health Resehttps://Cl
2-Jan-14 28-May-17 30-Jul-17 ### 26-Oct-17 San Francisco Generalhttps://Cl
11-Nov-18 30-Mar-19 ### ### ### Schoen Klinik Bad Ar https://Cl
15-Mar-19 30-Apr-23 30-Apr-23 17-Oct-18 ### University of Californhttps://Cl
Oct-06 Dec-06 Jul-08 6-May-08 ### Solano Clinical Resea https://Cl
19-May-09 3-Nov-14 3-Nov-14 ### ### ### GSK Investigational Sihttps://Cl
Jun-02 Jun-04 28-Oct-05 28-Oct-05 Johns Hopkins Univershttps://Cl
Mar-06 Oct-06 ### ### Johns Hopkins Bayview https://Cl
Jul-05 12-Jul-05 17-Jun-10 Allied Research Inter https://Cl
Apr-10 Mar-22 Mar-23 ### ### Mattel
GenesisChildren's Hoshttps://Cl
Cancer Center, Hot Springs, Arkansas, United
Feb-16 Dec-21 Dec-21 13-Jan-16 ### Leczenia chorÃ³b PÅ‚uchttps://Cl
i GruÅºlicy, Otwock, Poland|S
10-Dec-15 3-Jul-18 3-Jul-18 9-Dec-15 9-Aug-19 San Francisco, Califo https://Cl
2-Dec-15 14-Aug-18 22-Oct-18 30-Oct-15 ### Duarte, California, U https://Cl
Jul-99 Aug-03 4-Nov-99 4-Mar-08 National Institute of https://Cl
Jul-06 Sep-11 Sep-11 ### ### UNC Center for Envirohttps://Cl
Nov-05 Jan-10 Jan-11 ### 4-Mar-16 The Ohio State Univerhttps://Cl
Feb-12 Sep-12 Aug-13 ### ### Bagamoyo Research and https://Cl
Dec-12 Dec-12 Dec-12 14-Jan-13 2-Aug-17 Accelovance Inc, Melbhttps://Cl
Aug-08 Dec-08 May-09 8-Aug-08 22-Jun-09 Institute of Nutraceu https://Cl
Sep-11 Dec-14 Dec-14 9-Sep-11 ### ### Urology Center of Alahttps://Cl
13-Jan-20 Jun-20 Sep-20 5-Apr-19 14-Jan-20 Royal Darwin Hospitalhttps://Cl
1-Jun-17 30-Nov-17 ### 17-Apr-17 9-Jan-18 RWTH Aachen Univers https://Cl
Feb-11 Mar-16 Jul-16 ### 9-Mar-17 9-Mar-17 VA Medical Center, Mihttps://Cl
Apr-16 31-Jan-19 31-Jan-19 24-Oct-14 4-Mar-19 Univeristy of Alabam https://Cl
17-Aug-20 30-Sep-25 ### ### ### https://Cl
8-Feb-16 Jul-20 Aug-20 5-Aug-16 7-Feb-20 Boston Medical Center https://Cl
Dec-11 May-16 Jun-16 8-Dec-11 12-Jun-17 ### UCSD Medical Centerhttps://Cl
-
21-Dec-17 11-Sep-20 29-Oct-20 ### ### HonorHealth Research https://Cl
Institute - Bisgrove, Scottsdale
ACTG 273|11249 Apr-98 ### ### UAB, Dept. of Ped., Dhttps://Cl
Oct-08 Nov-10 ### 4-May-12 ATP Clinical Researchhttps://Cl
Jun-10 Jul-11 Dec-12 ### 22-Jul-13 Federal University of P
https://Cl
Mar-10 Dec-12 Dec-12 1-Apr-10 ### Novartis Investigativehttps://Cl
Site, Costa Mesa, California, Un
1-Mar-18 30-Nov-20 ### 13-Jun-18 ### Fenway Community Hea https://Cl
Dec-09 Feb-12 Feb-12 2-Dec-09 26-Jun-13 ATP Clinical Researchhttps://Cl
Sep-09 Jun-11 Jun-11 ### ### Novartis Investigativ https://Cl
Jan-16 31-Aug-16 ### ### ### University of Hawaii https://Cl
Jul-08 Feb-10 ### ### Centre Hospitalier U https://Cl
8-Aug-12 7-Aug-19 7-Aug-19 27-Oct-11 ### University of Texas Mhttps://Cl
5-Mar-18 5-Dec-18 5-Dec-18 ### 4-May-18 UNINOVE, SÃ£o Paulo, https://Cl
31-Oct-16 30-Apr-17 30-Apr-17 ### 25-Oct-17 https://Cl
Jun-15 Jun-16 Jun-16 30-Jun-16 30-Jun-16 https://Cl
Aug-12 Mar-14 Mar-14 ### 13-Oct-14 20-Oct-14 Prince Charles Hospithttps://Cl
Jul-03 Jan-09 Jan-09 24-Jul-03 6-Sep-10 6-Sep-10 South Orange Countyhttps://Cl
U
12-Aug-10 22-Dec-14 7-Nov-17 ### 21-Oct-19 Necker Hospital, Parishttps://Cl
Nov-13 Sep-14 Oct-14 ### 4-Aug-14 Universidade Nove dehttps://Cl
1-Mar-20 15-Jun-20 28-Jun-20 ### 29-Jan-20 Emory University DAIhttps://Cl
Jan-09 Dec-15 Dec-17 ### ### ACCESS Grand Boulevardhttps://Cl
Sep-14 Aug-19 Aug-19 2-Jun-15 4-Dec-18 Palo Alto Medical Foun https://Cl
Jan-13 Nov-13 Nov-13 7-Feb-13 2-Aug-18 Project Peanut Butterhttps://Cl
Feb-15 31-Oct-16 31-Oct-16 16-Apr-15 ### Gugulethu Community https://Cl
Mar-14 Jan-00 Jan-00 30-Jun-15 12-Jul-16 American Academy ofhttps://Cl
O
15-Apr-18 30-Mar-19 ### ### 28-Jan-20 Virginia Commonwealth https://Cl
11-Sep-17 17-Sep-18 ### ### ### GSK Investigational https://Cl
1-Jun-17 Oct-23 Oct-23 8-Nov-16 ### Stellenbosch Universithttps://Cl
Sep-15 10-Oct-16 10-Oct-16 ### ### Tianjin Hematonosis Hohttps://Cl
Mar-15 May-16 May-16 ### 3-May-16 21 General practices https://Cl
Sep-14 Feb-16 Feb-16 ### ### Department of Clinicalhttps://Cl
Nov-14 Sep-17 Sep-17 ### ### Naval Hospital Camp https://Cl
Jan-12 Apr-15 Apr-15 21-Jan-11 31-Jan-18 31-Jan-18 University of Pittsburhttps://Cl
Aug-08 Jun-10 Jun-11 16-Apr-08 5-Jan-17 ### UCLA CARE Center, Los https://Cl
Jul-15 Jun-16 Jul-16 6-May-15 21-Apr-16 Total Child Health, B https://Cl
Jun-14 Jun-17 Jun-17 7-May-13 ### ### Emory Univ"Study Prohttps://Cl
1-May-21 31-Dec-22 30-Jun-23 4-Nov-19 4-Nov-19 https://Cl
Oct-06 Jan-09 Jan-09 1-Aug-06 ### ### University of Wisconshttps://Cl
1-Feb-17 31-Dec-19 ### ### ### Public Health system,https://Cl
Nov-11 Nov-14 Nov-15 11-Jul-13 11-Jul-13 Department of Gyneco https://Cl
13-Sep-18 1-Oct-20 30-Jun-21 ### 1-Oct-19 Cedars-Sinai Medical hCttps://Cl
6-Oct-14 Mar-17 1-May-17 ### 9-Mar-18 Gourcy Health Distri https://Cl
AVEG 103|11546|AVEG 103A|AVEG 103B Sep-95 ### ### Univ. of Rochester AVhttps://Cl
1-Oct-19 30-Jul-21 ### ### ### https://Cl
Jun-10 Jun-10 Jun-10 15-Apr-10 15-Apr-10 French Blood Establishment
https://Cl
of Guadeloupe, Pointe-Ã
Jan-15 Dec-17 Dec-18 ### 18-Apr-19 Uhmontpellier, Montpe https://Cl
Feb-20 Dec-21 Apr-22 18-Jan-20 ### HonorHealth Virginia https://Cl
Jan-15 1-Jul-19 Jul-20 5-Dec-13 19-Jul-19 Children's of Alabam https://Cl
Mar-12 Mar-13 Apr-13 8-Jan-14 8-Jan-14 Department of Socialhttps://Cl
Jan-18 Jan-20 Aug-20 ### ### https://Cl
17-Jul-19 19-Jan-21 19-Jan-21 26-Apr-19 6-Jan-20 Fenway Health (FH) Chttps://Cl
14-Aug-17 Nov-20 Sep-21 21-Jun-17 17-Oct-19 OhioHealth Innovation https://Cl
May-15 Sep-15 Nov-15 7-Jul-15 ### University of Michigahttps://Cl
Apr-04 Nov-07 ### ### Chris Hani Baragwanahttps://Cl
1-Jun-17 30-Jun-22 ### 31-Jan-17 31-Jan-17 https://Cl
Sep-14 28-Mar-18 ### ### ### New York Presbyterian https://Cl
9-May-18 15-May-18 9-Jun-18 ### 20-Jun-18 UNC Project-China, Ghttps://Cl
8-Dec-17 30-Nov-20 ### ### ### Emory Vaccine Centerhttps://Cl
6-Sep-09 13-Apr-10 13-Apr-10 1-Oct-09 11-Jul-11 30-Jan-19 https://Cl
Mar-16 Jun-19 Jun-19 19-Oct-15 ### Ordination Dr. Banchehttps://Cl
Dec-12 21-Dec-17 ### 4-Dec-12 18-Jul-18 Ospedale Regionale per https://Cl
Nov-06 Oct-08 Oct-08 ### ### Dana-Farber Cancer In https://Cl
Oct-19 Jan-22 Jan-22 6-Sep-19 6-Sep-19 https://Cl
2-Jul-96 4-Nov-99 18-Jan-20 National Institutes ofhttps://Cl
Jul-13 Jul-15 9-Jul-13 9-Nov-16 Mathare North Healthhttps://Cl
1-Jan-20 1-Jan-25 1-Jan-30 26-Apr-19 26-Apr-19 https://Cl
17-Jan-19 1-Apr-22 1-Feb-28 10-Jan-19 2-Apr-19 HÃ´pital G. Montpied,https://Cl
15-Jan-19 15-Sep-19 15-Jan-21 ### ### https://Cl
26-Oct-18 1-Nov-23 1-Nov-25 ### 24-Apr-19 HYKS Peijas Hospital, https://Cl
14-May-18 24-Nov-21 ### ### 28-Jan-20 Research Site, Auchenhttps://Cl
4-Apr-19 Jul-22 Mar-25 7-Nov-17 6-Jun-19 BCG Oncology, Phoenix https://Cl
21-Nov-17 1-Sep-22 1-Mar-23 23-Oct-17 ### BCG Oncology, Phoenix https://Cl
Jul-13 Dec-20 Dec-20 28-Oct-16 9-May-18 Concord Repatriationhttps://Cl
10-Feb-17 Jan-20 Feb-20 21-Jun-16 ### Northwestern Universit https://Cl
Mar-12 Apr-15 Apr-15 8-Dec-14 3-Dec-15 The University of Tex https://Cl
CLN-002-00 Jan-20 2-Oct-14 1-Apr-15 https://Cl
24-Feb-15 11-May-16 ### 28-Jul-14 14-Jun-19 14-Jun-19 Donald Lam, MD, Phoen https://Cl
Jul-05 Dec-10 Dec-10 ### ### ### Pfizer Investigational https://Cl
3-Apr-17 Dec-20 Dec-20 ### ### St. Michael's Hospita https://Cl
22-Aug-17 30-Jul-21 31-Jan-22 18-Jul-17 ### Alabama CRS, Birminghttps://Cl
3-May-19 30-Dec-24 1-Apr-25 10-Apr-19 8-Nov-19 University of Minnesohttps://Cl
Apr-12 Apr-15 Mar-18 21-Jun-12 24-Jan-17 University of Alabamahttps://Cl
Nov-14 Nov-15 Nov-15 31-Oct-14 9-Jun-16 Taluka Hospital KN Shhttps://Cl
Jan-94 Jun-02 Jun-02 ### ### Dept. of Surgery/Urolhttps://Cl
Nov-93 Apr-97 Apr-97 ### 12-Jun-15 Stacy Childs, MD, Ala https://Cl
Sep-09 Mar-12 Mar-12 ### ### ### Weill Medical Collegehttps://Cl
Apr-11 Aug-13 Aug-13 29-Oct-10 ### 6-Oct-14 University of Alabamahttps://Cl
4-Feb-17 4-May-18 4-May-18 1-Dec-16 2-Jul-18 Children's Hospital C https://Cl
Feb-02 Dec-13 Dec-13 6-Oct-06 7-Oct-14 University Hospital - https://Cl
Oct-95 Jun-05 ### 4-Mar-11 National University Hhttps://Cl
18-Apr-18 Apr-20 Feb-21 27-Apr-18 ### Northwester "Informed https://Cl
15-Mar-19 Oct-20 Oct-21 9-Oct-18 5-Feb-20 Princess Marina Hosphttps://Cl
26-Sep-11 20-Dec-12 ### 7-Feb-11 26-Jul-18 GSK Investigational Sihttps://Cl
15-May-19 20-Dec-22 1-Feb-23 30-Apr-19 ### Dept. of Infectious https://Cl
Oct-05 Apr-08 Apr-08 22-Oct-07 8-Nov-12 Stanford University Schttps://Cl
23-Jul-13 25-Jun-14 25-Jun-14 ### ### https://Cl
Jun-11 Jun-12 Jun-12 14-Apr-11 ### ### Clinilabs, New York, https://Cl
Jul-13 Oct-14 Oct-14 ### 16-Jul-15 UNC Chapel Hill, Chaphttps://Cl
Sep-10 Apr-11 Apr-11 15-Jun-10 15-Jan-13 18-Jan-13 Clinilabs, New York, https://Cl
Dec-11 Apr-13 Apr-13 ### 12-Apr-16 12-Apr-16 Mount Sinai Medical https://Cl
Jun-20 Jan-23 Mar-24 7-Feb-20 7-Feb-20 https://Cl
Feb-12 Sep-14 Nov-15 14-Jun-10 11-Apr-16 ### Central Arkansas VHShttps://Cl
Aug-11 Nov-11 Mar-12 3-Sep-12 15-Oct-12 NanMoFang Community https://Cl
30-May-19 1-Sep-20 16-Jul-21 3-Aug-18 5-Feb-20 GSK Investigational S https://Cl
Dec-14 Jan-18 Nov-21 12-Jun-15 5-Feb-19 Brno, Czechia|Hradechttps://Cl
5-Jul-19 1-Sep-24 1-Sep-24 25-Jun-19 9-Jul-19 BCN Checkpoint, Barchttps://Cl
Dec-13 Oct-14 Feb-15 ### 4-Mar-14 Fresno, California, U https://Cl
Feb-12 Mar-14 ### 7-Apr-14 ### Brno, Czechia|Hradechttps://Cl
7-Sep-18 Jun-21 Jun-21 ### ### FHI 360, Dhaka, Banghttps://Cl
30-Sep-15 1-Jun-16 1-Jun-16 ### 18-Apr-17 Research Site, Leeds, https://Cl
Jan-11 Jan-13 Jun-13 ### 1-Feb-13 American University ohttps://Cl
Mar-05 Dec-11 Dec-11 ### 15-Oct-12 hopital ambroise Par https://Cl
May-09 Oct-10 Dec-10 15-Jan-10 ### https://Cl
14-Mar-18 Jan-19 Jan-19 8-Feb-18 12-Apr-18 Boston Medical Center https://Cl
Oct-11 Jul-12 Oct-12 12-Apr-13 25-Jul-14 Johann Wolfgang Goet https://Cl
Jun-14 May-19 May-24 3-Apr-14 1-Oct-19 UmeÃ¥ University, Dehttps://Cl
Feb-16 Feb-18 Feb-18 6-Jan-16 ### Johns Hopkins Bayviehttps://Cl
1-Nov-19 31-Mar-20 ### 7-Oct-19 16-Oct-19 Faculty of medicine, https://Cl
Dec-16 Dec-20 21-Jun-16 21-Jun-16 First Affiliated Hospi https://Cl
30-Mar-15 15-Dec-16 ### 5-Jun-14 29-Jan-18 5-Apr-19 University "Study Prohttps://Cl
21-Jan-19 Feb-22 Dec-22 ### ### Ospedale San Raffaelehttps://Cl
Jun-97 Jan-04 Jan-04 27-Jan-03 5-Apr-13 Barbara Ann Karmanos https://Cl
23-Mar-15 16-Oct-17 16-Oct-17 2-Mar-15 ### HÃ´pital Cochin, Parishttps://Cl
13-Mar-19 Jan-23 Jan-23 31-Oct-18 ### Ashland Center for Whttps://Cl
1-Apr-20 1-Jan-23 ### 13-Jun-19 14-Jun-19 https://Cl
29-Jul-19 5-Dec-22 1-Aug-23 25-Jul-19 ### Adawso Health Centerhttps://Cl
Jul-09 Dec-22 Dec-22 1-Aug-11 ### Center for Child and https://Cl
Nov-12 May-13 May-13 15-Oct-12 13-Jan-14 GSK Investigational S https://Cl
Jan-09 Oct-13 Oct-13 30-Jan-09 ### Hopital Saint Antoine,https://Cl
ACTG 387|11346 Oct-00 ### ### Ucsd, Avrc Crs, San Dihttps://Cl
1-Apr-19 Apr-20 Dec-20 2-Apr-19 7-Jan-20 Holy Innocents Child https://Cl
Aug-08 Aug-14 9-Oct-08 ### Penn State Cancer Inshttps://Cl
Jul-10 Dec-00 Dec-00 ### 6-Mar-19 Sanford Health, Siouxhttps://Cl
7-Sep-18 Jun-21 Jun-21 4-Dec-19 4-Dec-19 FHI 360, Dhaka, Banghttps://Cl
Jan-14 Mar-15 Mar-15 19-Apr-13 31-Oct-16 31-Oct-16 Novartis Investigativ https://Cl
Apr-04 Oct-05 11-Jan-07 11-Jan-07 No facility, this is a https://Cl
Sep-14 Sep-14 9-Oct-18 ### ### Marcelo Marcos Piva hDttps://Cl
1-Dec-19 31-Mar-24 ### 2-Dec-19 2-Dec-19 Program in Public Heahttps://Cl
24-Jan-19 24-Sep-19 ### 11-Jan-19 11-Jan-19 Institute of Microbio https://Cl
1-Mar-12 12-Mar-14 12-Apr-17 ### 18-Apr-17 https://Cl
Nov-12 Feb-14 Feb-14 ### 13-Apr-15 GSK Investigational Sihttps://Cl
Jun-16 Jul-17 Jul-17 ### ### University Hospital, https://Cl
Mar-08 Oct-10 Oct-10 23-Apr-08 ### ### Research Site, Nice, https://Cl
Oct-10 Dec-20 Dec-20 ### 12-Jul-18 LIFE Leipzig Research https://Cl
31-Jul-12 17-May-17 ### 18-Jun-12 5-Apr-19 17-Jul-19 The Univers "Study Prohttps://Cl
23-Nov-17 Dec-20 Dec-23 5-Sep-18 7-Nov-18 University Hospital Brno,
https://Cl
Brno, Czechia|Masaryk Mem
Feb-13 Jul-13 Jul-13 12-Jun-13 4-Aug-14 KEMRI Mtwapa, Kilifi https://Cl
Feb-09 May-10 May-10 ### ### ### Conant Medical Clinica https://Cl
Sep-18 30-Dec-19 ### 2-Jul-18 ### Chan Soon-Shiong Inst https://Cl
Mar-14 May-16 May-16 22-Jan-14 4-May-17 University of North Cahttps://Cl
15-Aug-18 Dec-21 Mar-22 ### 5-Apr-19 District Pishin & Quethttps://Cl
21-Aug-18 31-Dec-21 1-Jul-22 12-Apr-18 18-Jan-20 Arkansas Children's Hhttps://Cl
20-Apr-10 3-Oct-18 ### 24-Jan-12 7-Jan-20 Ospedale San Raffaelehttps://Cl
9-Jul-18 31-Aug-21 ### 9-Oct-18 9-Oct-18 Total Child Health, B https://Cl
Jan-16 17-Jul-17 1-Aug-32 2-Jun-15 ### Washington University https://Cl
Jan-14 Aug-16 Aug-16 8-Apr-14 ### Brno, Czech Republic|NovÃ½
- AZ Middelheim, https://Cl
Antwerp, JiÄÃn, Czech Republic
Belgium|Cliniques Univer
28-Nov-11 25-Sep-17 ### ### 8-Aug-19 4-Sep-19 Bristol Haematology
"Statistic &
https://Cl
Oncology Centre, Bristol, UK, U
Jul-10 Sep-12 Sep-12 22-Jun-10 ### Ajou University Medichttps://Cl
Oct-12 8-Apr-16 8-Apr-17 6-Mar-12 26-Jan-18 UPMC Hillman Cancerhttps://Cl
C
Mar-08 Sep-11 Sep-11 29-Jul-08 8-Jan-13 30-Jan-15 https://Cl
8-Dec-17 Apr-20 Oct-20 ### 22-Jan-20 University of Alabamahttps://Cl
11-Dec-18 27-May-19 ### 16-Oct-18 5-Jun-19 SGS Belgium NV Clini https://Cl
Sep-09 Jun-12 Feb-14 30-Jul-09 27-Jun-16 Yale Comprehensive Ca https://Cl
1-Jul-17 31-Jul-20 30-Oct-20 20-Jul-18 26-Jul-18 Aga Khan University, https://Cl
14-Dec-17 Nov-21 May-22 17-Oct-17 22-Jan-20 Decatur Memorial Hosp https://Cl
7-Feb-18 Jan-25 Jan-25 7-Dec-17 5-Jul-19 University Hospitals https://Cl
Mar-16 5-Oct-20 5-Oct-20 ### 24-Oct-19 Alabama CR "Informed https://Cl
Jan-16 Jan-20 Jan-24 9-Feb-16 19-Oct-17 Oslo University Hospihttps://Cl
Aug-08 May-13 Jun-15 ### 29-Oct-15 City of Hope Medical https://Cl
May-10 7-Jul-17 7-Jul-17 7-Jun-10 ### Department of Medica https://Cl
May-06 Jun-12 Jun-12 ### 6-Jan-14 ### H. Lee Moffitt Cancerhttps://Cl
24-Feb-20 26-Oct-22 ### ### 5-Feb-20 Urological Associateshttps://Cl
22-Jan-18 30-Sep-18 ### 8-Jan-18 ### University of Manito https://Cl
17-Oct-19 Sep-21 Oct-22 21-Jun-19 22-Oct-19 California Dermatolog
Clinical Research https://Cl
Center of Alabama, LLC, Birmingham
18-Feb-19 15-Apr-20 15-Apr-20 8-Jan-19 29-Jan-20 Wittenberg, Halle/Saale,https://Cl
Germany|Universitaetsklinik
18-Jul-19 Jan-21 Jan-26 15-Jul-19 ### UMaryland, Baltimore, https://Cl
Dec-06 Nov-16 ### 14-Oct-16 University of Alabamahttps://Cl
VCL-1005-207 Jun-02 9-Dec-02 24-Jun-08 University of Alabama
Pinnacle Research https://Cl
Group LLC, Anniston, Alabama, Un
20-Oct-16 28-Aug-19 ### 28-Jul-16 5-Feb-20 Research Site, Niska Banja,
https://Cl
Serbia|Research Site, Sab
Feb-01 Aug-04 Sep-04 ### 7-Jul-11 Arizona Cancer Centerhttps://Cl
1-Mar-16 31-Dec-23 1-Jan-25 ### 15-Oct-19 Transplantation Centehttps://Cl
29-Nov-18 31-Dec-19 ### 19-Apr-19 6-May-19 Tri-Service General H https://Cl
Mar-15 Jun-17 Jun-17 1-Dec-14 ### https://Cl
Jun-14 Aug-19 Aug-19 ### ### University of Alabamahttps://Cl
Dec-03 Dec-06 ### 3-Oct-07 Mount Sinai Hospital,https://Cl
Jan-13 Nov-13 Nov-13 ### ### Quintiles Early Clini https://Cl
Dec-10 Jan-12 Jun-12 ### ### https://Cl
Feb-13 Nov-13 Nov-13 1-Aug-11 ### Quintiles Early Clini https://Cl
Oct-16 Jan-21 Jan-21 28-Jun-16 6-Nov-19 Boston Medical Center https://Cl
29-Mar-16 3-Jul-23 3-Jul-23 ### ### Cochin hospital, Parishttps://Cl
Aug-13 Dec-19 Dec-19 9-Aug-13 17-Apr-19 University of Coloradhttps://Cl
1-Jul-18 30-Sep-19 31-Oct-19 ### ### Fujian Provincial Hosphttps://Cl
Nov-11 Sep-19 Sep-19 ### 19-Jun-19 https://Cl
Mar-96 Mar-02 4-Nov-99 8-Feb-08 National Human Genom https://Cl
Feb-16 Oct-20 Jan-21 ### 17-Oct-19 UF Health, Gainesvillehttps://Cl
Mar-12 Oct-14 Oct-14 11-Jun-12 ### Community sites, Allehttps://Cl
13-May-17 15-Jan-20 15-Jan-20 26-Apr-17 27-Jan-20 Icddr,B, Dhaka, Banglhttps://Cl
Mar-11 Mar-12 Mar-12 ### 8-Aug-16 Dr SAVAGNER Christop https://Cl
1-Feb-17 Dec-25 Dec-25 ### 4-Apr-18 Outpatient Endovascula https://Cl
8-May-17 16-Jul-18 16-Jul-18 8-Sep-14 30-Jan-19 Centre for the Study https://Cl
Feb-20 Nov-20 Nov-20 ### ### https://Cl
7-Nov-18 24-Oct-19 24-Oct-19 5-Oct-18 ### University of Califor https://Cl
Jun-14 Feb-15 Feb-15 ### 29-Jul-16 Faculty of Traditiona https://Cl
22-Dec-16 28-Apr-32 28-Apr-32 8-Nov-16 17-Oct-19 Research Site, La Jollahttps://Cl
Dec-16 Jan-19 Jan-19 ### 6-Dec-18 CHU Amiens Picardie,https://Cl
26-Jan-16 30-Jun-19 30-Jun-21 ### ### "Informed https://Cl
19-Dec-17 Sep-28 Sep-28 ### 27-Jun-19 New York, New York, https://Cl
2-Feb-18 9-Feb-21 9-Feb-21 ### 25-Oct-19 Alabama CRS, Birminghttps://Cl
Mar-14 May-14 May-14 ### 24-Jul-14 Tempe, Arizona, Unitehttps://Cl
Jul-09 Dec-11 Dec-11 4-Aug-09 ### UCLA Vine Street CRS,https://Cl
29-Apr-19 Sep-21 Sep-21 12-Jun-19 12-Jun-19 Maastricht Universityhttps://Cl
081A|UNX-4101 ### 24-Jun-05 Gabin Med Group, Loshttps://Cl
Jun-18 Mar-22 Mar-22 ### 7-Dec-18 https://Cl
4-Oct-16 16-Dec-19 ### 8-Sep-16 ### University of Alabamahttps://Cl
Jan-07 Oct-07 30-Jan-07 30-Jan-07 Bandim Health Project https://Cl
Jul-10 Apr-11 Apr-11 ### ### GSK Investigational Sihttps://Cl
Oct-12 Jun-13 Jun-13 12-Jul-10 13-Apr-15 https://Cl
5-Oct-17 2-Nov-17 ### 5-Jul-19 5-Jul-19 Iis Biodonostia, San https://Cl
Jun-09 May-11 May-11 ### 13-Jan-14 GSK Investigational Sihttps://Cl
Jan-07 Jul-07 1-Mar-07 ### Radboud University Nhttps://Cl
Mar-12 Oct-12 ### 2-Sep-16 London, United King https://Cl
Feb-11 Sep-12 Sep-12 9-Feb-11 ### Alabama Vaccine Resea https://Cl
1-Jan-20 31-May-20 30-Jun-20 ### ### HÃ´pital Universitairehttps://Cl
7-Jun-18 31-May-20 ### ### 13-Jan-20 Honor Health, Scottsdhttps://Cl
May-01 Nov-06 Nov-06 ### ### University Hospital ofhttps://Cl
Sep-12 Jan-17 Jan-17 ### 10-Jul-19 10-Jul-19 Georgia Regents Unive https://Cl
10-Jan-17 31-Dec-19 ### ### 9-Oct-19 Molly Robertson, Washttps://Cl
Oct-19 Apr-22 Dec-23 ### 24-Oct-19 https://Cl
Nov-13 Aug-14 Aug-14 ### 23-Jan-18 23-Jan-18 Icahn School of Medichttps://Cl
3-Oct-13 3-Apr-19 3-Apr-19 11-Jul-16 11-Oct-19 Amiens University & https://Cl
Aug-09 Aug-13 Aug-13 ### 6-May-14 Osher Center for Integhttps://Cl
5-Dec-12 12-Dec-13 ### 24-Jan-12 15-Oct-18 Task Clinical Researc https://Cl
Aug-14 Feb-16 Feb-16 17-Jun-14 26-Oct-16 Brigham and Women's https://Cl
6-Jan-16 28-Apr-17 ### 27-Apr-17 27-Apr-17 Infantry Training Cen https://Cl
May-13 Mar-17 Mar-17 19-Apr-13 11-Jul-18 11-Jul-18 Emory Unive "Informed https://Cl
Oct-10 Apr-11 Apr-11 1-May-14 2-Nov-16 https://Cl
Jun-14 5-Apr-18 1-May-33 4-Feb-14 ### Oncology Specialists, https://Cl
Sep-04 Sep-25 Sep-25 19-Jan-06 ### University of Coloradhttps://Cl
Nov-14 Apr-16 Apr-16 5-Aug-14 14-Jul-16 Aga Khan University, https://Cl
16-Oct-18 5-Jan-19 5-Jan-19 ### 11-Jun-19 ### Worldwide"Study
C Prohttps://Cl
1-Jan-18 31-Jul-20 31-Jul-20 22-Jan-20 22-Jan-20 Hospital Universitari https://Cl
1-Sep-19 30-Jun-20 ### 3-Sep-19 17-Oct-19 Rutgers Cancer Instit https://Cl
9-Jan-20 26-May-21 ### ### 18-Jan-20 Loma Linda Universityhttps://Cl
23-Mar-18 31-Jul-19 31-Jul-19 9-Mar-18 24-Jul-19 Service de rÃ©animati https://Cl
13-Oct-17 2-Oct-18 ### 13-Oct-17 9-Oct-19 27-Jan-20 Teva Invest"Study Prohttps://Cl
8-Feb-18 9-Jan-20 9-Apr-20 4-Jan-18 5-Jul-19 University Hospital ofhttps://Cl
Nov-07 Feb-18 Mar-18 23-Jan-14 12-Jul-16 HÃ´pital Laquintinie https://Cl
Nov-12 Jul-17 31-Jul-17 5-Apr-13 26-Jul-18 Zvitambo, Harare, Z https://Cl
30-Apr-14 7-Jun-16 21-Jun-16 9-Apr-13 7-Jul-17 7-Jul-17 Emory University Hosp https://Cl
079A|219-90 ### 24-Jun-05 Georgetown Univ Med https://Cl
Aug-07 ### ### UCSD Med Ctr / Pediat https://Cl
ACTG 051|11025 Apr-93 ### ### Kaiser Permanente / U https://Cl
ACTG 080|11055 Apr-93 ### ### Univ of Pittsburgh Mehttps://Cl
ACTG 146|D0190g ### 24-Jun-05 SUNY - Brooklyn, Broohttps://Cl
Apr-09 Feb-15 Feb-15 8-Aug-08 ### ### San Francisco Generalhttps://Cl
17-Jul-19 31-Jul-20 31-Jul-22 ### 1-Oct-19 Research Centre for Fhttps://Cl
Sep-19 Feb-23 Mar-23 9-Aug-16 11-Apr-19 Hadassah Medical Cent https://Cl
30-Jun-17 31-Jan-20 31-Jan-20 27-Apr-17 ### Research Site, Beijin https://Cl
Jun-12 Jul-16 4-May-18 6-Dec-13 ### Medstar Georgetownhttps://Cl
Un
Feb-98 Feb-00 Sep-00 4-Jan-06 3-Apr-12 All India Institute of https://Cl
May-09 May-10 May-10 ### ### GSK Investigational S https://Cl
Aug-08 Nov-14 Nov-14 23-Oct-08 ### ### Mount Sinai School ohttps://Cl
Mar-11 Jul-11 Jul-11 ### 3-Dec-14 Oslo University Colle https://Cl
Sep-14 16-Jul-19 16-Jul-19 ### 27-Jan-20 University of Minnesohttps://Cl
11-Sep-17 15-Apr-19 15-Apr-19 29-Jun-18 7-Feb-20 FH Uganda - Kitgum, https://Cl
Sep-10 Feb-11 Feb-11 ### 7-Jun-17 https://Cl
22-Jan-15 29-Apr-15 29-Apr-15 ### 3-Aug-18 ### LLC Center for Vaccin https://Cl
13-Mar-18 19-May-18 ### 7-Feb-18 ### CHU Clermont-Ferrand https://Cl
13-Dec-16 16-Feb-18 ### ### ### ### Research Fa "Study Prohttps://Cl
Apr-12 Jul-16 Jul-16 ### 16-Oct-17 16-Oct-17 Alliance Clinical Res https://Cl
Mar-16 Jan-17 Jan-17 27-Oct-15 19-Jan-17 CHU, Nantes, France|Ihttps://Cl
Jul-06 Jul-08 Oct-08 10-Jul-06 ### LAC/USC Medical Cente https://Cl
26-May-09 17-Nov-14 ### ### ### 12-Jul-17 GSK Investigational Sihttps://Cl
8-Apr-02 2-Sep-08 ### ### 27-Jan-10 8-Nov-18 Universidade Federal https://Cl
do Espirito Santo - Duke Hubert
3-Oct-17 20-May-19 ### 4-Oct-17 6-Aug-19 Municipal Autonomous https://Cl
Apr-09 Mar-11 Mar-11 15-Oct-09 21-Jan-16 George Washington Uni https://Cl
Apr-18 Apr-18 May-18 25-Jul-17 ### Tata Memorial Hospithttps://Cl
17-Nov-17 1-May-21 1-May-22 31-Oct-17 11-Jul-19 University of Minnesohttps://Cl
3-Jun-19 18-Jun-25 18-Jun-25 26-Jun-18 ### Gaborone CRS, Gaboron https://Cl
21-Jun-17 31-Dec-21 ### 4-Jul-16 5-Feb-20 Kaifeng City Institut https://Cl
10-Jul-19 10-Jul-21 10-Jan-22 ### 6-Nov-19 Rennes University Hoshttps://Cl
1-Jan-18 24-Apr-19 ### ### ### Packard El "Study Prohttps://Cl
Dec-16 30-Mar-22 ### ### 18-Jan-20 Alabama CRS, Birmingham,https://Cl
Alabama, United States|U
7-Oct-16 9-Jan-19 9-Jan-19 1-Feb-17 ### Kazakh Medical Contin https://Cl
Aug-12 Dec-15 Dec-15 24-Jul-12 ### Southlake Regional Hhttps://Cl
1-Mar-20 28-May-21 ### ### 14-Jan-20 https://Cl
Feb-11 Apr-14 Oct-14 5-Mar-13 23-Jun-15 23-Jun-15 Federal State Budgetahttps://Cl
18-Oct-18 1-Dec-21 ### 4-Apr-18 8-Feb-19 University of Chicago,https://Cl
13-Jul-19 Dec-20 Jul-23 ### ### Institut de Recherchehttps://Cl
15-Oct-18 22-May-21 ### 10-Jan-18 ### University of Alabamahttps://Cl
11-May-17 30-Jun-20 ### 31-Jan-17 12-Jul-19 Mayo Clinic Jacksonvihttps://Cl
7-Nov-17 31-May-22 ### ### ### Gaborone CRS, Gaboro https://Cl
Mar-04 Mar-06 ### 30-Apr-13 Sao Paulo, Brazil|So https://Cl
4-Jun-14 13-Sep-16 ### 17-Jan-14 3-Aug-18 3-Aug-18 VA San Diego Healthca https://Cl
Jul-14 Jun-15 Jun-15 4-Sep-15 7-Sep-15 LASERMED Diagnosis https://Cl
a
25-Jan-16 Apr-20 Dec-20 8-Apr-15 28-Jan-19 TBTC Site 82/ ACTG Site https://Cl
801 USCF AIDS CRS, San Fran
Dec-12 Dec-14 Apr-15 10-Jan-13 11-Jan-19 Non-governmental Heal https://Cl
Dec-10 Mar-15 Nov-15 20-Jan-10 ### 5-Sep-17 David Geffen School ohttps://Cl
29-May-18 2-Oct-18 2-Oct-18 5-Jun-19 22-Oct-19 22-Oct-19 Pfizer, New"Study Prohttps://Cl
2-Feb-11 2-Dec-23 2-Dec-23 24-Apr-19 7-Jun-19 Centre mÃ©dical de l'I https://Cl
14-Aug-09 27-Jun-12 1-Apr-15 20-Jul-09 7-Sep-18 ### GSK Investigational S https://Cl
Feb-04 Dec-07 Jun-09 16-Jan-09 16-Jan-09 https://Cl
13-Jan-20 1-Sep-22 ### 18-Jan-20 18-Jan-20 Rwanda Biomedical Ce https://Cl
7-Jul-19 1-Sep-22 ### 8-Nov-19 8-Nov-19 Centre National de R https://Cl
16-Jun-16 12-May-21 15-Oct-21 14-Apr-16 ### University Of Coloradhttps://Cl
12-Mar-19 11-Jul-19 11-Jul-19 18-Apr-19 14-Oct-19 hVIVO Services LimitNew
Site, Camperdown, https://Cl
South Wales, Australia|GSK
1-Dec-08 27-Jan-16 27-Jan-16 ### ### ### Investigational Site, Bari, Puglia, Italy|GSK Investigatio
https://Cl
17-Nov-10 30-Apr-16 30-Jun-16 ### ### McMaster University,https://Cl
Apr-05 Jun-09 Jul-10 30-Jul-14 14-Apr-17 University of Californhttps://Cl
RC15_0088 Jan-17 Jan-17 26-Jul-16 19-Jan-17 CHU de Clermont-Ferrhttps://Cl
Jan-05 25-Jun-16 25-Jun-16 ### 21-Apr-17 Koraro, Koraro, Ethi https://Cl
Feb-14 May-19 May-19 ### 8-May-18 Uppsala University H https://Cl
27-May-14 9-May-16 9-May-16 ### ### ### Research Site, Leeds https://Cl
RC14_0429 Jan-17 Jan-17 16-Oct-15 19-Jan-17 https://Cl
1-Mar-17 30-Jun-17 30-Jun-17 ### ### Ethiopian Public Healhttps://Cl
Sep-08 Oct-09 Dec-09 6-Aug-09 21-Jul-11 ### Washington, D.C., Dishttps://Cl
9-Dec-09 26-Apr-16 26-Apr-16 18-Jan-10 ### ### GSK Investigational S https://Cl
Feb-11 Apr-15 Dec-15 ### ### University of Malawi https://Cl
Jan-10 Apr-14 Aug-14 11-Jan-10 15-Jan-16 University of Washinghttps://Cl
7-Mar-18 1-Jun-22 9-Jun-22 2-Mar-18 ### Children's Hospital C https://Cl
30-Jan-20 Jul-20 Jul-20 3-Jun-19 5-Feb-20 Children's Hospital ofhttps://Cl
28-Oct-16 29-May-18 8-Feb-22 1-Nov-16 13-Jun-19 ### GSK Investi"Study Prohttps://Cl
Sep-13 Oct-15 Mar-16 15-Jan-14 7-Apr-16 Xi'an Jiaotong Univershttps://Cl
Aug-12 Dec-12 Mar-13 1-Nov-12 1-Nov-12 London, United King https://Cl
Oct-09 Oct-13 ### ### Basingstoke and Northttps://Cl
14-Nov-17 9-May-18 9-May-18 ### ### hVIVO Services Ltd, https://Cl
27-Oct-16 30-Aug-18 7-Jul-22 19-Oct-16 29-Oct-19 29-Oct-19 GSK Investi"Study Prohttps://Cl
2-Sep-11 4-Jul-16 4-Jul-16 ### ### ### Tartu, Estonia|Riga, https://Cl
15-Feb-20 15-Feb-23 ### 21-Jan-20 21-Jan-20 Duke University Hospihttps://Cl
Jul-02 Dec-10 Dec-12 ### 7-Dec-09 University of Alabamahttps://Cl
Oct-13 Jun-16 Jun-16 6-Nov-13 28-Oct-16 Michael Mapongwanahttps://Cl
C
Jun-13 25-May-18 31-Jul-18 8-Jul-13 ### Tufs Medical Center https://Cl
Dec-05 Oct-07 Oct-07 9-Dec-05 7-Oct-09 Centre Hospitalier Unhttps://Cl
Jun-06 Jul-08 20-Jun-06 20-Jul-10 Bordeaux CHU, Bordeau https://Cl
5-Dec-18 31-Jan-21 30-Jun-21 8-Mar-18 22-Jan-20 Stanford, Stanford, C https://Cl
22-May-17 2-Feb-21 2-Feb-21 ### ### NIHR Wellcome Trusthttps://Cl
7-Dec-12 8-Feb-17 8-Feb-17 8-Nov-12 ### ### Banner Alz"Study Prohttps://Cl
4-Feb-15 4-Sep-18 4-Sep-18 13-Oct-14 ### CHRU de Lille, Lille, https://Cl
Jan-20 Jan-22 Jan-24 9-Oct-19 9-Jan-20 University Hospital T https://Cl
Jun-17 Jun-22 20-Jan-17 20-Jan-17 Zeng Jie Ye, Guangzh https://Cl
6-Dec-17 3-Jun-19 1-Mar-20 ### 28-Oct-19 Dr. Sarah Pountain, https://Cl
Aug-15 Nov-16 Apr-17 28-Apr-16 28-Apr-16 LVCT Health, Nairobi,https://Cl
Feb-09 Apr-10 Apr-10 ### ### 24 Primary Healthcarehttps://Cl
1-Dec-14 31-Mar-16 ### 6-Jun-19 7-Jun-19 Faculty of Medicine, Shttps://Cl
2-Aug-13 27-Aug-18 ### ### 7-Feb-20 Mattel Children's Hoshttps://Cl
15-Sep-20 15-Dec-22 ### 21-Jan-20 22-Jan-20 CHU Brest - HÃ´pital https://Cl
12-Mar-18 Apr-20 Jul-20 ### 2-Jan-20 Array BioPharma Inves https://Cl
May-13 Dec-13 Dec-13 13-Jan-14 13-Jan-14 Covance Clinical Resehttps://Cl
Sep-19 Jul-25 Jul-25 30-Jun-14 1-Oct-18 https://Cl
Dec-14 23-Aug-17 ### ### 4-Dec-18 UnitÃ© des Maladieshttps://Cl
9-Oct-18 30-Dec-19 ### 12-Oct-18 11-Oct-19 Alexandria Universityhttps://Cl
Nov-11 21-Jan-17 21-Jan-17 ### 1-Nov-17 Service de chirurgie https://Cl
Nov-08 Dec-12 Jun-14 17-Oct-08 9-Oct-14 8-Feb-16 University of Alabamahttps://Cl
31-Aug-18 Dec-19 Dec-20 23-Oct-18 23-Oct-18 Massachusetts Instituhttps://Cl
27-Oct-17 6-Jun-19 ### 2-Oct-17 20-Jun-19 GSK Investigational S https://Cl
13-Jan-18 30-Sep-20 ### 9-Jan-18 6-Nov-19 Baylor College of Medhttps://Cl
Jul-99 21-Feb-04 21-Jan-05 ### ### Johns Hopkins Univershttps://Cl
31-Jan-19 1-Jul-24 1-Jul-25 ### 22-Jan-20 St. Jude Children's R https://Cl
7-Dec-17 30-Jun-19 1-Oct-19 13-Apr-18 21-Oct-19 Makerere University, https://Cl
1-Jun-17 May-21 May-23 8-Dec-16 ### UCSF Neurological Surhttps://Cl
31-Jan-11 17-Apr-18 17-Apr-18 4-Oct-10 9-Oct-19 9-Oct-19 GSK Investi"Study Prohttps://Cl
Nov-18 Jan-19 Jan-19 20-Jul-18 8-Nov-18 https://Cl
Apr-09 Mar-10 Mar-10 6-Aug-09 23-Apr-12 23-Apr-12 Pfizer Investigational https://Cl
Mar-12 6-Feb-18 Feb-19 ### ### 2-Jan-20 Loyola Uni"Study Prohttps://Cl
May-20 Jan-24 Jan-26 16-Oct-18 18-Jan-20 UColorado, Denver, Co https://Cl
Sep-15 7-Jul-16 15-Jul-16 9-Jun-15 19-Jan-18 UF
Site,Health
Kazan,Shands Hospi
Russian https://Cl
Federation|GSK Investigational Si
4-Oct-07 6-Dec-13 ### ### 30-Jan-19 25-Jun-19 SK Investigational Site
31-Mar-17 31-May-37 ### ### ### Orchard Investigationahttps://Cl

5-Dec-19 1-May-21 1-Dec-21 9-Nov-18 30-Apr-19 Royal Infirmary of E https://Cl
20-Aug-14 30-Nov-16 ### 17-Jun-14 9-Oct-18 ### Clinical Directors Ne https://Cl
31-May-18 Jun-38 Jun-38 ### 19-Jun-19 University of Californhttps://Cl
1-Feb-19 Nov-21 Dec-21 5-Feb-19 7-Feb-19 Sansum Diabetes Resea https://Cl
Feb-14 May-17 May-18 20-Jun-14 19-Jan-17 Wayne State Universithttps://Cl
Mar-16 Apr-16 Apr-16 ### ### Toshima-ku, Tokyo, J https://Cl
4-Jul-18 Jul-25 Jul-25 14-Jan-16 ### University hospital ofhttps://Cl
Jan-12 Nov-20 Jan-22 15-Jun-16 7-Mar-18 Konkuk University Hoshttps://Cl
Mar-20 Aug-22 Jul-25 ### ### Vivent Health, Applethttps://Cl
May-11 May-15 May-15 13-Jun-11 9-Jun-15 600 S. Commonwealth https://Cl
A
1-Feb-19 31-Jul-21 31-Oct-21 13-Jun-18 1-Mar-19 District Misungwi, M https://Cl
Oct-19 Jul-23 Dec-23 9-Oct-19 15-Oct-19 Department of Neurolhttps://Cl
13-May-19 Sep-19 Sep-19 ### ### Department of Experihttps://Cl
Sep-09 Jun-11 Jan-13 ### 19-Jul-12 10-Jun-14 Pfizer Investigational https://Cl
18-Jan-18 Sep-21 Sep-21 ### 6-Aug-19 Brigham and Women's https://Cl
6-Jun-17 17-Feb-18 ### 29-Jun-17 ### Brigham and Women's https://Cl
6-Jun-17 20-Jan-18 20-Jan-18 7-Jun-17 ### Brigham and Women's https://Cl
Sep-16 Dec-16 Dec-16 ### 11-Jul-17 Brigham and Women's https://Cl
Feb-07 Jan-10 Jan-10 7-Dec-07 25-Jan-11 25-Jan-11 University of Arkansashttps://Cl
Oct-11 Jan-15 Jan-15 21-Jan-15 30-Jul-18 Amherstburg FHT, Amh https://Cl
10-May-19 31-Dec-19 ### 11-Jul-19 15-Jul-19 Sansum Diabetes Resea https://Cl
17-Aug-16 Aug-25 Aug-34 19-Jan-12 ### University of Califor https://Cl
Year start
2018 d
2017
2016
2018
2017
2011
2017
2019
2015
2019
2020
2018
2018
2016
2017
2007
2013
2016
2015
2010
2016
2019
2010
2015
2012
2018
2016
2012
2011
2008
2011
2020
2013
2010
2019
2018
2018
2008
2019
2017
2017
2007
2020
2016
2011
2019
2017
2015
2010
2018
2013
2011
2011
2014
2015
2009
2017
2016
2017
2017
2014
2019
2014
2009
2012
2013
2007
2012
2018
2009
2012
2016
2010
2016
2018
2009
2011
2017
2012
2018
2018
2013
2017
2008
2011
2014
2018
2011
2017
2015
2012
2009
2012
2012
2008
2016
2013
2016
2016
2013
2017
2004
2017
2016
2006
2011
2015
2014
2007
2017
2013
2007
2012
2017
2018
2014
2012
2018
2017
2013
2008
2013
2019
2017
2014
2011
2019
2004
2014
2013
2013
2018
2013
2018
2013
2009
2018
2007
2009
2015
2015
2019
2012
2018
2019
2008
2009
2017
2018
2019
2015
2012
2015
2013
2012
2010
2010
2019
2010
2017
2010
2006
2011
2018
2011
2014
2007
2014
2008
2014
2014
2017
2015
2018
2009
2011
2012
2009
2012
2019
2006
2012
2012
2009
2011
2015
2014
2020
2014
2011
2006
2011
2014
2016
2011
2011
2019
2012
2016
2012
2015
2017
2019
2013
2018
2011
2019
2009
2019
2006
2018
2009
2016
2018
2018
2018
2020
2010
2017
2018
2013
2018
2019
2010
2008
2018
2017
2013
2015
2017
2017
2005
2013
2007
2018
2014
2013
2010
2007
2015
2020
2019
2005
2009
2011
2019
2013
2016
2006
2007
2013
2018
2010
2007
2015
2015
2011
2012
2007
2011
2009
2017
2018
2016
2016
2011
2011
2013
2013
2008
2017
2017
2017
2018
2018
2009
2017
2015
2010
2011
2015
2012
2016
2014
2005
2017
2012
2008
2015
2016
2013
2008
2016
2012
2009
2013
2012
2012
2011
2012
2017
2010
2019
2009
2005
2018
2015
2007
2012
2014
2013
2011
2011
2018
2014
2017
2012
2012
2018
2019
2006
2018
2011
2013
2009
2016
2018
2008
2010
2015
2010
2016
2016
2012
2010
2012
2015
2016
2018
2019
2019
2014
2012
2010
2017
2009
2017
2013
2011
2015
2019
2012
2011
2010
2012
2010
2020
2008
2007
2014
2009
2016
2010
2016
2012
2009
2014
2007
2013
2017
2018
2015
2013
2015
2016
2007
2016
2012
2017
2011
2019
2017
2014
2013
2012
2008
2010
2007
2014
2006
2017
2015
2008
2018
2006
2019
2013
2018
2020
2015
2011
2015
2015
2014
2017
2014
2008
2018
2007
2018
2012
2011
2008
2012
2015
2000
2009
2013
2007
2002
2016
2009
2011
2018
2008
2013
2018
2006
2012
2006
2015
2009
2016
2017
2018
2019
2019
2013
2007
2011
2012
2019
2017
2004
2014
2018
2003
2012
2009
2011
2009
2020
2010
2011
2011
2013
2006
2013
2009
2013
2010
2017
2012
2006
2015
2008
2019
2017
2018
2009
2017
2010
2011
2019
2014
2014
2014
2010
2015
2019
2010
2007
2017
2017
2011
2016
2020
2014
2017
2014
2013
2015
2019
2007
2017
2014
2005
2011
2014
2011
2006
2009
2007
2013
2013
2016
2016
2004
2007
2011
2007
2011
2006
2019
2013
2011
2018
2010
2012
2017
2012
2014
2014
2011
2019
2012
2007
2009
2019
2013
2004
2011
2015
2017
2009
2014
2010
2016
2009
2015
2015
2013
2013
2019
2006
2017
2011
2008
2010
2013
2017
2018
2016
2010
2018
2020
2012
2010
2016
2013
2007
2011
2008
2019
2019
2012
2004
2013
2008
2010
2015
2015
2017
2005
2008
2016
2008
2011
2014
2009
2018
2011
2007
2011
2012
2006
2010
2005
2016
2005
2015
2013
2016
2007
2017
2013
2012
2010
2010
2004
2006
2012
2019
2010
2019
2018
2010
2018
2013
2015
2015
2012
2014
2012
2015
2015
2004
2017
2019
2019
2011
2010
2019
2018
2009
2010
2019
2017
2015
2012
2013
2008
2012
2017
2014
2009
2008
2018
2015
2012
2014
2006
2013
2017
2010
2009
2018
2011
2009
2015
2017
2019
2009
2011
2015
2010
2012
2019
2009
2018
2016
2018
2014
2013
2014
2013
2009
2019
2013
2012
2015
2009
2015
2013
2011
2008
2015
2014
2005
2013
2009
2018
2014
2014
2014
2015
2016
2018
2009
2018
2008
2014
2009
2015
2013
2015
2008
2016
2012
2012
2010
2009
2013
2011
2016
2008
1999
2016
2007
2006
2019
2010
2012
2017
2013
2015
2005
2015
2009
2020
2017
2012
2010
2010
2016
2010
2013
2008
2009
2010
2012
2013
2017
2008
2019
2006
2012
2009
2017
2017
2018
2009
2009
2011
2004
2020
2009
2007
2009
2005
2011
2017
2015
2007
2012
2006
2012
2009
2015
2013
2019
2009
2004
2008
2007
2010
2004
2014
2009
2008
1900
2009
2015
2006
2010
2018
2019
2011
2011
2009
2015
2013
2008
2009
2018
2014
2012
2016
2012
2001
2013
2016
2016
2007
2009
2018
2019
2007
2013
2014
2013
2012
2018
2017
2011
2018
2020
2008
2012
2006
2011
2018
2008
2006
2014
2016
2012
2016
2015
2009
2019
2003
2019
2011
2008
2013
2013
2006
2014
2019
2015
2018
2019
2006
2009
2019
2014
2009
2016
2008
2011
2016
2017
2010
2014
2015
2017
2019
2011
2019
2018
2017
2009
2008
2016
2016
2010
2018
2014
2018
2012
2012
2008
2008
2019
2017
2013
2011
2012
2008
2012
2016
2014
2011
2016
2008
2010
2012
2015
2018
2010
2014
2010
2020
2009
2017
2020
2010
2014
2008
2017
2016
2013
2015
2006
2016
2013
2017
2014
2017
2006
2010
2010
2017
2009
2007
2017
2011
2010
2016
2015
2013
2006
2011
2008
2011
2015
2017
1900
2010
2009
2005
2018
2015
2013
2005
2009
2012
2019
2013
2007
2012
2017
2008
2009
2004
2013
2011
2004
2009
2012
2009
2005
2019
2015
2015
2020
2012
2011
2004
2011
2010
2010
2012
2017
2013
2007
2012
2006
2019
2017
2009
2004
2016
2006
2007
2004
2009
2014
2000
2016
2017
2018
2014
2007
2009
2010
2016
2018
2010
2019
2020
2013
2007
2007
2014
2006
2005
2012
2009
2011
2013
2014
2014
2010
2005
2007
2013
1998
2016
2018
2011
2016
2011
2016
2020
2009
2009
2014
2008
2009
2011
2013
2003
2010
2019
2019
2008
2017
2015
2007
2009
2009
2011
2013
2008
2003
2001
2016
2013
2012
2010
2019
2018
2007
2009
2005
2010
2003
2011
2013
2009
2016
2007
2011
2020
2011
2015
2013
2005
2010
2007
2010
2007
2007
2017
2009
2009
2012
2014
2005
2009
2010
2006
2017
2019
2011
2010
2017
2014
2013
2014
2015
2009
2003
2013
2016
2007
2015
2015
2019
2018
2010
2011
2010
2003
2015
2012
2010
2018
2001
2008
2012
2018
2014
2011
2019
2012
2014
2018
2014
2016
1900
2014
2013
2006
2012
2005
2005
2013
2000
2005
2013
2013
2012
2013
2020
2008
2010
2016
2006
2009
2006
2015
2009
2015
2005
2020
2013
2016
2016
2006
2020
2010
2008
2013
2018
2008
2015
2017
2017
2008
2010
2013
2011
2015
2017
2011
2011
2015
2015
2017
2010
2018
2009
2015
2013
2008
2008
1996
2011
2018
2014
2013
2019
2012
2008
2007
2011
2008
2006
2014
2014
2016
2014
2018
2001
2005
2013
2018
2012
2016
2010
2019
1900
2014
2016
2015
2012
2016
2016
2020
2009
2014
2014
2013
2014
2013
2013
2007
1996
2004
2017
2011
2016
2009
2006
2009
2010
2013
2006
2006
2018
2019
2010
2013
2009
2015
2010
2012
2007
2016
2018
2015
2013
2019
2011
2012
2015
2018
2011
2016
2018
2009
2016
2015
2015
2009
2007
2018
2013
2006
2019
2011
2012
2010
2005
2015
2017
2015
2006
2017
2003
2007
2013
2009
2014
2010
2018
2016
2010
2009
2000
2018
2019
2016
2008
2018
2019
2010
2009
2006
2010
2004
2020
2011
2012
2006
2016
2009
2006
2008
2017
2017
2013
2009
2020
2004
2015
2019
2009
2008
2013
2008
2010
2010
2014
2012
2008
2018
2018
1999
2010
2016
2016
2006
2017
2013
2005
2017
2016
2008
2004
2009
2011
2005
2010
2017
2014
2014
2014
2018
2016
2017
2008
2009
2009
2004
2007
2013
2011
2012
2018
2009
2013
2008
2018
2009
2019
2011
2014
2008
2017
2015
2011
2017
2008
2015
2019
2015
2007
2012
2018
2013
2012
2017
2010
2017
2015
2007
2016
2010
2016
2010
2014
2015
2007
2006
2013
2005
2014
2012
2012
2009
2016
2014
2011
2020
2009
2013
2009
2015
2003
2009
2018
2017
2013
2006
2015
2011
2015
2008
2004
2015
2012
2008
2019
2005
2009
2005
2016
2015
2017
2011
2012
2013
2007
2019
2012
2018
2009
2004
2013
2009
2013
2009
2006
2010
2018
2010
2013
2008
2015
2017
2002
2015
2009
2011
2007
2007
2019
2009
2014
2013
2016
2018
2019
2009
2009
2010
2010
2013
2012
2008
2003
2014
2007
2011
2019
2008
2012
2013
2010
2010
2009
2017
2001
2006
2016
2008
2009
2015
2019
2008
2018
2010
2000
2014
2014
2019
2015
2015
2012
2017
2012
2014
2010
2018
2016
2010
2011
2004
2007
2011
2007
2016
2018
2010
2019
2016
2010
2003
2009
2006
2010
2008
2016
2016
2019
2019
2016
2013
2009
2017
2015
2013
2012
2010
2018
2008
2017
2019
2005
2015
2019
2006
2012
2012
2014
2015
2018
2015
2020
2013
2014
2010
2009
2000
2010
2016
2014
2014
2007
2001
2011
2016
2016
2012
2020
2012
2009
2019
2009
2016
2009
2013
2011
2015
2019
2012
2014
2004
2014
2007
2012
2012
2007
2011
2014
2017
2019
2018
2012
2011
2020
2014
2008
2016
2018
2017
2014
2018
2008
2005
2018
2016
2020
2013
2014
2019
2016
2005
2014
2018
2010
2019
2007
2014
2010
2019
2016
2014
2015
2011
2010
2015
2009
2016
2013
2013
2002
2005
2016
2013
2016
2016
2008
2010
2013
2018
2016
2008
2010
2013
2019
2015
2008
2019
2009
2009
2018
2013
2006
2011
2010
2008
2019
2007
2019
2016
2014
2007
2011
2009
2009
2010
2010
2018
2012
2009
2018
2014
2019
2010
2009
2004
2013
2008
2012
2018
2016
2011
2016
2009
2009
2012
2010
2010
2009
2006
2011
2014
2018
2009
1900
2017
2011
2009
2013
2006
2010
2018
2014
2016
2012
2009
2013
2009
2011
2010
2011
2019
2020
2012
2016
2018
2017
2013
2007
2007
2016
2012
2018
2006
2017
2017
2016
2011
2010
2011
2017
2012
2009
2001
2009
2010
2007
2019
2010
2006
2003
2010
2014
2017
2006
2013
2012
2018
2019
2011
2006
2017
2007
2018
2006
2019
2017
2012
2007
2010
2011
2009
2017
2012
2012
2003
2009
2009
2016
2015
2014
2014
2013
2013
2009
2012
2019
2011
2016
2007
2008
1997
2008
2008
2012
2020
2020
2014
2008
2013
2012
2016
2007
2012
2005
2010
2012
2015
2020
2013
2005
2014
2007
2017
2017
2011
2013
2013
2006
2016
2016
2013
2007
2009
2012
2010
2019
2006
2015
2014
2010
2007
2015
2019
2006
2015
2019
2013
2018
2012
2010
2010
2013
2013
2012
2005
2013
2006
2019
2012
2010
2016
2007
2019
2018
2006
2018
2018
2011
2016
2019
2006
2009
2010
2015
2008
2018
2016
2017
2012
2011
2015
2011
2006
2010
2010
2014
2014
1995
2005
2010
2013
2016
2009
2013
2011
2020
2007
2011
2007
2011
2011
2016
2009
2018
2005
2010
2007
2016
2008
2011
2008
2013
2012
2015
2011
2020
2010
2008
2008
2016
2008
2013
2015
2006
2010
2018
2012
2002
2018
2011
2014
2014
2009
2005
2017
2002
2015
2007
2010
2008
2009
2006
2015
2003
2018
2015
2009
2009
2011
2006
2003
2011
2019
2013
2008
2007
2013
2008
2010
2017
2008
2005
2009
2018
2008
2017
2009
2018
2009
2019
2004
2011
2017
2005
2005
2004
2002
2014
2012
2009
2011
2014
2014
2010
2003
2020
2015
2005
2008
2003
2012
2006
2008
2006
2014
2007
2015
2010
2003
2007
2017
2015
2019
2017
2016
2019
2009
2009
2014
2020
2005
2011
2016
2007
2014
2014
2011
2009
2016
2003
2010
2009
2003
2010
2010
2013
2020
2014
2013
2013
2009
2010
2009
2007
2010
2018
2004
2010
2017
2006
2018
2010
2011
2017
2016
2008
2010
2013
2014
2010
2009
2009
2008
2009
2009
2017
2004
2007
2009
2011
2016
2009
2009
2007
2017
2007
2009
2009
2016
2019
2014
2013
2009
2008
2011
2018
2009
2015
1900
2018
2010
2017
2003
2011
2012
2013
2007
2007
2009
2019
2020
2019
2007
2007
2010
2019
2007
2013
2010
2008
2012
2013
2018
2008
2009
2009
2013
2009
2006
2007
2011
2011
2018
2009
2006
2008
2009
2008
2014
2010
2015
2019
2010
2003
2013
2014
2009
2016
2009
2010
2017
2006
2018
2019
2009
2004
2018
2003
2018
2017
2014
2002
2005
2016
2013
2010
2015
2008
2010
2005
2013
2009
2016
2014
2018
2010
2019
2006
2018
2016
2005
2013
2009
2018
2009
2008
2019
2012
2002
2006
2002
2007
2009
2012
2011
2016
2018
2019
2012
2018
2017
2009
2019
2019
2011
2011
2015
2007
2019
2005
1996
2020
2019
2006
2007
2016
2007
2013
2014
2010
2015
2010
2016
2011
2006
2011
2009
2019
2005
2016
2007
2016
2010
2019
2016
2013
2009
2015
2007
2015
2012
2017
2011
2009
2009
2006
2008
2016
2013
2007
2020
2015
2007
2009
2011
2012
2009
2018
2006
2010
2016
2010
2006
2004
2005
2019
2015
2009
2017
2008
2011
2012
2019
2008
2014
2007
2019
2011
2011
2010
2018
2018
2013
2005
2018
2019
2018
2016
2011
2017
2007
2018
2009
2005
2007
2011
2018
2008
2004
2011
2015
2011
2007
2011
2006
2020
2007
2004
2015
2003
2019
2009
2008
2020
2005
2018
2016
2013
2010
2011
2014
2018
2010
1992
2017
2008
2010
2017
2008
2009
2014
2010
2007
2014
2007
2018
2010
2010
2007
2008
2010
2009
2011
2018
2011
2015
2012
2012
2019
2007
2014
2012
2020
2011
2007
2014
2002
2017
2010
2012
2009
2018
2005
1900
2011
2009
2008
2013
2010
2019
2009
2013
2014
2015
2007
2011
2017
2007
2005
2014
2015
2005
2008
2009
2008
2016
2009
2009
2012
2017
2009
2015
2019
2007
2019
2011
2001
2013
2008
2006
2018
2014
2013
2012
2011
2009
2014
2017
2006
2005
2019
2007
2004
2013
2012
2006
2006
2017
2003
2015
2017
2010
2012
2008
2011
2009
1997
2016
2008
2008
2011
2002
2009
2008
2006
2006
2018
2019
2011
2013
2008
2004
2016
2015
2016
2019
2009
2005
2007
2013
2008
2017
2006
2006
2011
2019
2014
2013
2011
2017
2004
2008
2014
2010
2014
2016
2011
2010
2008
2018
2013
2014
2006
2014
2012
2020
2016
2007
2020
2009
2012
2013
2007
2006
2010
2015
2007
1997
2019
2007
2018
2000
2015
2009
2010
2008
2007
2016
2015
2009
2014
2018
2009
2014
2013
2009
2014
2007
2010
2007
2010
2020
2006
2016
2011
2019
2009
2017
2016
2001
2012
2019
2006
2011
2014
2006
2011
2009
2015
2016
2009
2016
2007
2009
1999
2009
2010
2007
2006
2007
2009
2009
2016
2020
2009
2016
2017
2014
2010
2009
2003
2014
2007
2010
2006
2006
2008
2005
2012
2019
2010
2015
2017
2017
2011
2007
2007
2009
2012
2013
2011
2007
2008
2008
2007
2008
2002
2013
2011
2015
2014
2016
2002
2009
1998
2009
2010
2015
2009
2005
2016
2009
2008
2016
2017
2017
2008
2016
2009
2018
2009
2013
2012
2004
2013
2007
2008
2011
2006
2008
2015
2013
2009
2018
2017
2005
2019
2014
2009
2014
2015
2000
2011
2010
2002
2009
2019
2016
2018
2017
2010
2018
2004
2010
2006
2006
2013
2017
2004
2001
2017
2010
2014
2018
2005
2015
2017
2009
2020
2014
2015
2015
2008
2010
2004
2016
2012
2019
2016
2009
2006
2006
2007
1997
2005
2017
2016
2014
2020
2016
2017
1999
2013
2013
2008
2012
2011
2009
2008
2018
2018
2016
2004
2006
2005
2018
2015
2011
2009
2008
2014
2018
2011
2011
2014
2005
2017
2019
2017
2013
2017
2010
2012
2014
2003
2011
2008
2010
2018
2011
2014
2013
2008
2016
2017
2006
2014
2017
2018
2007
2004
2011
2011
2009
2013
2007
2005
2018
2014
2009
2010
1998
2009
2010
2005
2015
2019
2008
2010
2003
2016
2003
2016
2016
2012
2018
2009
2011
2008
2018
2018
2011
2014
2001
2006
2014
2007
2020
2003
2006
2012
2005
2013
2019
2013
2010
2005
2018
2009
2000
2007
2019
2018
2011
2009
2001
2014
2016
2014
2006
2000
2005
2018
2006
2014
2012
2005
2008
2010
2019
2006
2008
2007
2015
2006
2018
2009
2013
2010
2006
2014
2012
2016
2009
2009
2013
2009
2010
2002
2016
2011
2006
2011
2004
2010
2005
2016
2006
2016
2006
2005
2009
2016
2010
2005
2018
2009
2007
2010
2014
2017
2015
2018
2017
2006
2013
2010
2015
2015
2015
2019
2015
2010
2014
2019
2013
2016
2010
2014
2011
2009
2015
2013
2016
1999
2012
2019
2008
2009
2011
2004
2003
2009
2008
2012
2007
1992
2016
2007
2013
2019
2010
2009
2018
2005
2006
2017
2019
2006
2006
2009
2005
2012
2016
2017
2009
2017
2015
2006
2009
2018
2011
2010
2009
2011
2005
1999
2019
2017
2017
2019
2009
2008
1999
2009
2012
2006
2008
2017
2010
2008
2007
2015
2016
2006
2016
2009
2017
2015
2008
2008
2011
2013
2007
2015
2011
2010
2016
2005
2007
2003
2013
2009
2010
2019
2014
2012
2011
2019
2015
2003
2012
2010
2009
2016
2015
2018
2008
2016
2008
2018
2009
2018
2006
2016
2019
2016
2016
2007
2008
2008
2004
2008
2015
2016
2002
2015
2007
2019
2006
2011
2012
2004
2018
2014
2006
2017
2007
2011
2005
2017
2018
2004
2018
2007
2009
2012
2007
2016
2014
2007
2016
2014
2011
2002
2009
2015
1900
2012
2006
2014
2008
2008
2016
2008
2008
2018
2017
2008
2009
2017
1900
2016
2019
2011
2014
2005
2007
2003
2010
2009
2018
2017
2015
2007
2012
1900
2016
2009
2007
2009
2015
2017
2011
2019
2010
2015
2018
2011
2012
2010
2006
2019
2016
2014
2005
2006
2012
2012
1999
2008
2002
2008
2007
2016
2018
2010
2019
2019
2017
2005
2008
2015
2012
2017
2017
2014
2003
2009
2014
2014
2007
1997
2006
2017
2008
2005
2016
2010
2014
2002
2009
2005
2005
2010
2017
2010
2008
2015
2016
2000
2009
2014
2004
2017
2010
2017
2011
2010
2009
2015
2005
2005
2010
2018
2006
2018
2008
2007
2011
2016
2000
2011
2015
2014
2014
2003
2007
2016
2011
2010
2007
2010
2019
2003
2007
2014
2013
2020
2010
2016
2013
2011
2011
2004
2012
1900
2008
2005
2010
2003
2015
2007
2011
2007
2006
2017
2013
2011
2006
2005
2013
2013
2015
2009
2010
2010
2011
1900
2018
2010
2007
2010
2018
2006
2016
2006
2008
2004
2016
2004
2019
2009
2006
2014
2006
2015
2017
2011
2006
2017
2017
2003
2011
2015
2008
1900
2007
2013
2018
2006
2012
2007
2009
2009
2004
2018
1900
2000
2017
2010
2014
2013
2014
2006
2012
2013
2007
2004
2009
2006
2010
2018
2010
2001
2009
2015
2019
2005
2007
2016
2012
2009
2007
2014
2010
2004
2005
2019
2009
2014
2010
2013
2011
2015
2008
2018
2015
2003
2020
2007
2009
2019
2019
2016
2002
2011
2009
2008
2014
2006
1999
2014
2002
2009
2012
2013
2008
1998
2015
2006
2016
2008
2013
2017
2007
2016
2012
2009
2005
2014
2013
2012
2004
2003
2017
2010
2008
2000
2007
2006
2005
2009
2014
2007
2010
2010
2008
2016
2005
2017
2013
2010
2010
2011
2013
2020
2010
2003
2018
2015
2009
2011
2014
2012
2003
2015
2013
2005
1997
2017
2007
2003
2014
2020
2005
2012
2016
2016
2009
2010
2011
2006
2008
2003
2003
2002
2011
2005
2013
2006
2007
2006
2009
2009
2013
2010
2006
2012
2007
2000
2018
2018
2000
2016
2003
2020
2008
2008
2003
2006
2009
2007
2009
2010
2009
2013
2004
2005
2008
2007
2008
2005
2009
2007
2007
2004
2015
2005
2016
2007
1997
2018
2008
2014
2009
2002
2013
2012
2010
2015
2013
2007
2003
2012
2013
2015
2015
2012
2014
2009
2005
2007
2013
2014
2007
2013
2006
2010
2016
2004
2015
2017
2017
2002
2012
2013
2012
2014
2009
2002
2008
2017
2004
2009
1900
2013
2006
2008
2011
2006
2012
2003
2003
2017
2017
2010
2007
2013
2018
2010
2017
2001
2007
2013
2013
1998
2005
2016
2004
2014
2013
2019
2011
2019
2016
2011
2017
2006
2016
2002
2013
2008
2017
2010
2009
2019
2006
2017
2007
2014
2015
2014
2007
2015
2007
2014
2014
2018
2016
2010
2018
2004
2012
2018
2011
2017
2014
2005
1900
2006
2007
2010
2008
2012
1999
1900
2012
2014
2018
2009
2009
2006
2006
2015
2012
2014
2007
2007
2009
2010
2011
2003
2011
2014
2020
2010
2011
2015
2011
2012
2006
2017
1900
2017
2006
2017
2001
2015
2008
2006
1900
2016
2014
2013
2019
2018
2016
2002
2019
2014
2010
2014
2009
2018
2011
2009
2006
2012
2018
2007
2013
2006
2011
2010
2009
2017
2020
2011
2004
2015
2007
2007
2009
2015
2008
2012
2016
2006
2008
2015
2005
2016
2010
2006
2015
2016
2008
2008
1999
2011
2015
2018
2010
2010
2016
2009
2012
2007
2017
2010
2009
2016
2011
2009
2010
2015
2001
2006
2014
2009
2018
2010
1900
2006
2005
2003
2001
2009
2014
2014
2014
2007
2008
2014
2009
2004
2018
2014
2007
2007
2015
2014
2006
2012
2009
2009
2011
2011
2012
2019
2008
2017
2016
2007
2007
2006
2014
2009
1997
2013
2018
2015
2015
2012
2004
2005
2019
2006
2012
2003
2019
2011
1998
2003
2005
2019
2017
2013
2002
2004
2014
2014
2014
2010
2017
2000
2019
2015
2011
2015
2014
2016
2013
2015
2007
2015
2007
2010
2003
2006
2016
2012
2012
2011
2015
2008
2019
2005
1999
2003
2009
2006
2007
2014
2004
2016
2014
2007
2005
1900
2011
2010
2008
2013
2006
2019
2016
2014
1999
2010
2015
2011
2016
2011
2013
2010
2016
2017
2004
2009
2007
2014
2018
2005
2004
2010
2008
2013
2011
2009
2008
2006
1900
2016
2014
2006
1900
2007
2015
2009
2009
2019
2019
2012
2005
2010
2013
2017
2004
2020
1997
2010
2010
2014
2012
2020
2011
2015
2010
2012
2010
2018
2008
2018
2010
2019
2018
2013
2019
2012
2015
2006
2010
2009
2011
2010
2003
2013
2010
2016
2009
2019
2008
2015
2018
2009
2020
2011
2017
2012
2006
2009
2016
2016
2018
2004
2006
2006
2014
2017
1900
2006
2007
2012
2011
2016
1900
1992
2012
2002
2005
2008
2008
2011
2003
1999
2006
2009
2017
2015
2010
2012
2016
2018
2012
2004
2007
2018
2008
2008
2004
2009
2012
2006
2016
2007
2005
2006
2017
1900
2008
2009
2013
2003
2004
2018
2014
2005
2013
2008
2014
2019
2011
2017
2002
2008
2005
2018
2010
2002
2005
2019
2007
1995
2008
2011
2017
2009
2015
2015
2012
2011
2006
2008
2017
2003
2015
2007
2008
2006
2010
2010
2019
2008
2010
2001
2018
2015
2017
2011
2020
2009
1995
2002
2012
1900
2015
2009
2006
2011
2006
2017
2017
1900
2006
2005
2006
2012
2007
2017
2018
2018
2019
2001
2017
2011
2012
2012
2007
2006
2005
2015
2008
2005
2005
2011
2016
2013
2005
2006
2008
2003
2018
2014
2007
1998
2019
2010
2007
2018
2003
2012
2014
2012
2011
2012
2011
2012
2007
2012
2015
1993
2010
2004
2001
2004
1900
2005
2010
2019
2009
2014
2012
2015
2008
2008
2014
2008
2013
2016
2006
2007
2009
2008
2012
2014
2009
2011
2009
2003
2012
2010
2010
2015
2011
2013
2015
2014
2010
2018
2019
2004
2012
2007
2005
2009
2012
2006
2014
1996
2005
2005
2001
2017
2005
2016
2019
2004
2006
2001
2014
2008
2003
2019
2019
2011
2014
2015
2015
2006
2004
2003
2019
2008
2009
2009
2010
2006
2014
1992
2019
2014
2020
2010
2006
2016
2009
2016
2005
2015
2005
2006
2013
2018
2016
2002
2012
2004
2016
2009
2011
2013
2008
2004
2019
2017
2017
2007
2013
2001
2012
2006
2015
2007
2005
2010
2013
2012
2017
2019
2015
2010
2005
2010
2003
2018
2003
2014
2013
2014
2006
2002
2005
1900
2013
2009
2009
2011
2009
2019
2006
2018
2013
2006
2001
2017
2020
2016
2017
2018
2012
2014
2012
2018
2018
2006
2011
2009
1900
2004
2017
2006
2015
2009
2006
2014
2007
2017
2006
2009
2007
2006
2008
2011
2012
2007
2004
2007
2016
2018
2004
2008
2010
2013
2019
2010
2002
2008
2008
2010
2009
2013
2011
2018
2004
1993
1900
2012
2015
2003
2016
2019
2018
2014
2010
2017
2019
2006
2010
2012
2007
2014
2007
2005
2009
2005
2011
2007
2017
2019
2019
2002
1995
2011
2016
2009
2013
2014
2016
2004
2013
2003
2017
2017
2000
2012
2006
2012
2013
1998
2014
2006
2018
2015
2004
2016
1900
2004
2016
2007
2017
2009
2010
2009
2001
1997
2015
2019
2004
2005
1900
2016
2018
1999
2011
2016
2013
2009
2013
2019
2011
2002
2015
2019
2001
2013
2010
2015
2007
2009
2003
2020
2016
2007
2012
2008
2019
2019
2009
2003
2007
2003
2000
2006
2012
1998
2010
2017
2006
2009
2013
2020
2012
1900
1999
2006
2016
2002
2018
2019
2003
2009
2007
2013
2003
2019
2011
2016
2005
2006
2012
2006
2000
2016
2012
2001
2015
2010
1999
2012
1900
2015
2010
2014
2005
2014
2007
2005
2006
2010
2012
2005
2017
2002
2017
2002
2018
2017
2009
2016
2010
2013
2007
2005
2003
2012
2008
2011
2017
2006
2012
2018
2019
2007
2007
2003
2005
2009
2008
1900
2018
2010
2010
2005
2010
2005
2017
2017
2011
2010
2004
2006
2016
2009
2015
2020
2001
2006
2017
2004
2014
2014
2008
2018
2009
2013
2015
2017
2012
2012
2018
1996
2010
2010
2016
2005
2009
2005
2007
2010
2020
2009
2007
2007
2013
2009
2013
2016
2016
2007
2015
2016
2013
2012
2004
2017
1997
1971
2017
2011
1900
2008
2010
2018
2010
1900
2016
2009
2006
2009
1900
2005
2005
2004
2017
2007
2005
2010
2019
2008
2019
2020
2012
2011
2005
2013
2019
2016
2013
2008
2007
2019
2009
2018
2010
2015
2009
2008
2015
2011
2006
2010
2003
2012
2005
2019
2010
2014
2010
1999
2017
2002
2011
2014
2017
2016
2018
2006
2008
2016
2016
2009
1997
2009
2013
2008
2007
2000
2018
2012
2001
2012
2009
2018
2006
2000
2010
2019
2020
2007
2008
2010
2005
2015
1995
2008
2018
2018
2010
2016
2009
2011
2009
2015
2019
2007
2018
2017
2006
2006
2016
2006
2014
2018
2017
2007
2017
2004
2015
2012
2009
2014
2014
2016
2013
2014
2007
2006
2011
2018
1900
2016
1900
1900
2014
2007
2009
2006
2004
2004
1900
2003
2005
2010
2019
2018
2016
2006
2012
2019
2016
2012
2009
2005
2006
2016
2018
2012
2018
2014
2012
2010
2016
2017
2013
2018
2020
2013
2006
2010
2016
2007
1900
2013
2016
2005
2003
2003
2014
2005
1999
2010
2010
2009
2015
1999
1900
2007
2020
2018
2016
2000
2008
1900
2009
2013
2019
2019
2005
1998
2008
2002
2005
2000
2017
2015
2019
2016
2014
2004
2010
2002
2014
2017
2005
2019
2001
2002
2004
2007
2005
2018
2009
1996
2008
2012
2003
2011
2006
2015
2014
2009
2013
2011
2007
2011
2010
2005
1997
2007
2000
2008
2010
2015
2018
1900
2015
2015
2003
2016
2008
2011
2018
2006
2006
2014
2010
2018
2010
2007
2006
2011
2015
2004
2015
2017
2005
2018
2015
2018
2005
1900
2015
2019
2020
2014
2015
1900
2019
2013
2015
1900
2012
2005
2010
2007
1999
2014
2004
2008
1997
2006
2017
2016
2006
2015
1900
2012
2011
2016
2010
2016
2013
2010
2007
2018
2014
2006
2013
2008
2015
2013
2017
2011
2003
2015
2016
2019
2015
2017
2016
2005
2000
2004
2012
2009
2020
2006
2008
2013
2008
2007
2004
2011
2019
2018
2014
2016
2012
2015
2012
2007
2009
2015
2005
2013
2002
2017
2004
2015
2004
2017
2014
2004
2014
2005
2006
2002
2020
2009
2004
2019
1900
1995
2007
2019
2010
2003
1999
2008
2017
2018
2015
2008
2013
2014
2010
2005
2020
2014
2012
2018
2012
2014
2006
2011
1995
1999
2006
2007
2019
2015
2012
2018
2006
2006
2018
2013
2015
2013
2013
2013
2005
2019
2000
2002
2019
2013
2012
2005
2008
2018
2010
2015
2015
2008
2018
2002
2007
2007
2019
2004
2010
2010
2017
2012
2018
2007
2015
2003
2011
2005
2018
2010
2012
2008
2019
2019
2009
2016
2009
2007
2004
1900
1999
2004
2020
2003
2016
2005
2008
2005
2000
2010
2009
2018
2012
2019
2015
2002
2014
2017
2016
2012
2009
2013
2008
2015
1996
2015
1900
2013
2007
2010
2003
2002
2012
2010
2011
2013
2003
2002
2015
2009
2008
2006
2003
2018
2016
2005
2009
2008
2003
2005
1999
2011
2009
2013
2015
2018
2020
2018
2019
2007
2003
2001
2019
2019
2015
2017
1999
2008
2005
1997
2005
2005
2003
2014
2006
2012
2012
2008
2017
2018
2010
2001
2015
2007
2013
1900
2010
2010
2011
2005
2018
2010
2009
2007
1900
2006
2020
2017
2017
2004
2006
2014
2003
2011
2007
2015
2013
2005
2007
2015
2018
2009
2003
2008
1900
2010
2006
2011
2016
2017
2007
2006
2010
2013
2013
2017
2009
2006
2007
2006
2012
2015
2004
2011
2012
2001
2019
2019
1900
2005
2013
2006
2016
2018
2014
2017
1900
2005
2008
2014
1900
1996
2011
2008
2012
2005
2014
1999
2010
2015
2016
2012
2019
2017
2003
2013
2004
2013
2006
2019
2005
1900
2018
2016
2009
2004
2008
2007
2013
2004
2018
2006
2010
2019
2017
2005
2010
2008
2006
2001
2012
2014
2009
2015
2017
2018
2006
2003
2012
2019
2009
2007
2019
2012
2005
2009
2012
2019
2004
2017
2007
2019
2014
2000
2018
2008
2010
2007
2012
2009
2007
1900
2014
2004
2018
2011
2019
2018
2006
2005
2013
2020
2006
2011
2015
2005
2004
2002
1998
2019
2017
2006
2001
2016
2004
2012
2009
2007
2008
2019
2009
2017
2006
2015
2007
2014
2017
2010
2009
2016
2003
2020
2015
2007
2018
2016
2007
2017
1999
2012
2007
2006
2015
2001
2016
2004
2020
2016
2009
2015
2019
2019
2017
2019
2004
2015
2004
2015
2007
2013
2011
2004
2019
2018
2010
2013
2017
2015
2010
2018
2019
1900
2000
2009
2017
2003
2000
2009
2013
2017
2017
2017
2007
2018
2016
2006
1998
1900
2013
2008
2019
2005
2004
2014
2013
2011
2009
2002
2008
2005
2012
2003
2013
2004
2006
2004
2017
2014
2016
2005
2010
1998
2000
2010
2016
2011
2011
1900
2004
2005
2011
2001
2017
2013
2013
1999
2014
2017
2019
2002
2007
2010
2019
2007
2009
2006
2011
2013
2012
1996
2007
2009
2018
2001
2003
2000
2001
2005
2006
2005
2007
2017
2012
2013
2017
2012
2000
1900
2003
2008
2009
2017
2008
1900
2000
2010
2007
2012
2015
2006
2003
2013
2007
2009
2010
2008
2005
2016
2007
2005
2012
2003
2009
2000
2006
2005
2006
1999
2017
2001
2011
2004
2013
2015
2012
2002
1900
2019
2006
2000
2015
2016
2016
2000
2017
2006
2014
2007
2011
2017
2009
2003
2003
1900
2008
2015
2015
2013
2000
2014
2014
2003
2019
2018
2012
2016
2012
2017
2003
2014
2007
2005
2016
2008
2004
2003
2015
2001
2007
2013
2000
2014
2013
2012
2010
2019
2019
2010
2006
2010
2019
2010
2017
2007
2014
2015
2006
2013
2012
2002
2001
2013
2003
1992
2008
2018
2002
2011
2017
2014
2014
2014
2001
2010
2017
2004
2008
2007
2011
2014
2005
2016
2010
2009
2013
2004
2015
2011
2007
2013
2015
2019
2011
2009
2007
2012
2017
1994
2005
2005
2012
2018
2015
2016
2013
2018
2004
2015
2015
2009
2019
2010
2013
2007
2011
2012
2015
2014
2010
1900
2003
2006
2016
2005
2005
2006
2009
2013
2001
2013
2009
2005
2012
2007
2010
2004
2003
2004
2012
2010
2013
2012
2016
2019
2009
2017
1900
2015
2004
2006
2010
2009
2012
2015
2004
2016
2015
2012
2013
2015
2005
2019
1900
2013
2018
2007
2010
2006
2006
2015
2005
2006
2012
2004
2019
2019
1900
2006
2004
2001
2008
2015
2007
2006
2003
2007
2017
2013
2014
1997
2012
2016
2010
2007
2015
2017
2017
2008
2014
1998
2009
2003
2006
2016
2010
2002
2004
2004
2006
2011
2012
2001
2010
2010
2017
2005
2012
2007
2005
2013
2020
2020
2018
2013
2008
2007
2004
2015
2007
2006
2014
2006
2009
2002
2004
1900
2013
2004
2004
2007
2018
2012
2001
2012
2006
2017
2007
2010
2008
2005
1993
2005
2010
2014
2018
2002
2014
2002
2013
2013
2005
1999
1998
1999
2013
2009
2006
2017
2003
2009
2010
2011
2003
1997
2007
2009
2017
2017
1999
2004
2006
2011
2004
2012
1996
2010
2004
2017
2004
2007
2005
2002
2005
2010
2005
2007
2012
1999
2017
2003
2002
2016
2011
2008
2011
2001
2003
2016
2016
1996
2004
1996
2014
2007
2007
2008
2008
2020
2013
2012
2010
2014
2017
2016
2008
2014
2016
2001
2012
1998
2014
2009
2004
2016
2003
2006
2001
2008
2002
2011
1998
1998
2000
1997
1996
2008
2011
2016
1900
2010
2001
2011
2013
2017
2004
2017
2012
2007
1999
2020
1998
2009
2013
2004
2004
2012
2008
2016
1978
2016
2014
2013
2012
2014
2008
2000
1900
2013
2007
2007
2010
2000
2016
2016
2007
2003
2011
2015
2016
2007
2008
2019
2001
1999
2006
2004
2006
1998
2015
2009
2017
2006
2000
2001
2020
2003
2014
2017
2004
1900
2006
2015
2006
2011
2007
2015
2011
2002
2006
2009
2002
1999
2013
2003
2004
2008
2000
2014
1900
1999
2012
2016
2014
2007
2015
2004
2004
2017
2011
2020
2016
2002
2019
2014
2018
2013
1996
1900
1900
2004
2012
2005
1900
2012
2019
2003
2003
2003
2003
2008
2003
2010
2002
2004
2004
2013
1998
1900
2007
2005
2012
2004
2019
2000
2017
2017
2016
1900
2010
2001
2007
2020
1900
2019
2000
2019
1991
2013
2016
2005
2010
2008
2002
2008
2019
2014
2011
2014
2017
2012
2014
2000
2008
2007
2010
2015
2015
2006
2004
1900
2009
2013
2019
2015
2010
2014
2006
2010
2018
2013
2014
2005
2013
1992
2002
2005
2018
2003
2013
2008
2004
1995
2008
2005
2008
2008
2008
2005
2015
2009
2002
1900
2016
2007
2008
1900
2011
2020
2015
1900
2009
1900
2006
2006
2016
2017
2000
2010
2010
2019
2015
2012
2011
2007
2010
2011
2001
2004
2018
2000
2004
2010
2006
2015
2010
2008
2006
2005
2013
1900
2010
2018
2010
2007
2010
2009
2002
2016
2000
2009
2007
2007
2010
2018
2019
2006
2007
2019
2014
1997
1900
1999
2016
2004
2007
2009
2003
2013
1999
2011
2005
2011
2011
2002
2007
2020
2015
2019
2006
2011
2013
1900
2004
2013
2006
2008
2001
2011
2015
2010
2011
2003
2001
2005
2004
1900
2005
2020
2007
2012
2015
2015
2006
2012
2011
2014
2005
2006
2007
2007
2013
2016
2002
1900
2004
2010
2001
2008
2017
2013
2001
1900
1999
2005
2012
1900
2004
2001
2007
2005
2016
2004
2020
2018
2001
2009
2018
2008
2010
2008
2018
2000
2009
2004
2008
2002
2013
2019
2020
2005
2016
2002
2002
2003
2018
2018
2006
2018
2014
2017
2008
2014
2008
2004
1900
2006
2006
1900
2006
2018
2012
2018
2015
2017
2006
2005
2015
2009
2010
2009
2004
1900
2004
1999
2010
2019
2010
2006
2015
2005
2009
2015
2004
2000
2009
2010
2009
1900
2006
2010
2005
1900
2011
2001
2011
2008
2003
2001
2000
2015
2000
2006
2005
2012
2006
2006
1900
2003
2012
2006
2003
2005
2017
2016
2008
2017
2001
2000
2002
2005
2009
2003
2016
1900
2015
2004
1900
2008
2017
2019
2010
2011
2010
2005
2019
2011
2015
2013
2001
2011
2016
2009
2009
2019
1996
1996
2012
2006
1900
2005
2006
2000
2018
2019
2004
2016
2019
2011
2010
2019
2017
2013
2014
2017
2017
2003
2018
2009
2009
2012
2005
2008
2017
2019
2006
2020
2006
2009
2019
2019
2014
2013
2009
2017
2012
2009
2017
2014
2011
2018
2008
2016
1900
2018
2001
2015
2007
2017
2013
2008
2017
2017
2002
2014
2018
2003
2003
2017
2009
2014
2019
2013
2001
2007
2010
2013
2012
2011
2010
2020
2010
2003
2008
2014
2015
2015
2019
2019
2011
2010
2018
2016
1900
2015
2006
2012
2004
2004
2009
2008
2005
2009
2008
2010
2005
2003
2008
2016
2019
1900
2008
2016
2004
2017
2015
2005
2014
2019
2018
2019
2019
2008
2003
2009
2015
2011
2015
2009
2018
2017
2014
2009
2019
2015
2009
2018
2008
2011
2002
2019
2009
2013
2018
2015
2008
2006
2019
2015
2009
2008
1999
2007
2013
2013
2005
1997
2003
2003
2016
2005
2005
2009
1998
2011
2015
2013
1996
2019
2007
2008
2010
2016
2009
2013
2002
1997
2005
2015
2000
1999
2003
2015
2018
2010
2003
1994
2009
2012
2011
2006
2017
1997
2008
2014
2007
2009
2019
2017
1900
2006
2018
2018
1900
2006
2009
2016
2002
2015
2003
2001
2011
2001
2010
2000
2005
1998
2011
2013
2010
2012
1900
2010
1999
2019
2004
1900
2006
2009
2011
2020
2011
2007
2010
2002
2012
2015
1998
2005
2013
2013
2017
2005
2018
2009
2010
2007
2000
2007
2015
2007
2003
2005
1995
2008
2005
2011
2018
2006
2009
2006
2010
2011
2006
2015
2016
2005
2002
2014
2008
2015
2017
2013
2004
2008
2008
2005
2000
2009
2011
2015
2003
2013
2006
2014
2015
2017
2017
2014
2014
2007
2009
2009
2019
2015
2001
1999
2011
2007
2004
2020
2004
2010
2018
2007
2013
2011
2008
1900
2004
2020
2009
2006
2013
2006
2009
2017
2019
2011
2011
2004
2004
2016
2009
2007
2007
2011
2007
2004
2015
2018
2007
2009
2005
2006
2002
2005
2006
2012
2013
2018
2014
1999
2011
2017
2015
2015
2007
2001
2019
2015
2016
2016
2015
2008
2019
2019
2003
2016
2015
2011
2004
2018
2016
2017
2001
2010
2013
2016
2016
2009
2005
2020
2007
2019
2015
2011
2014
2017
2019
2003
2019
2006
2017
2008
2008
2018
2008
2018
2018
2019
2003
2008
2007
2019
2014
2009
1996
2018
2008
1999
2010
2000
2015
2003
1998
1999
2018
2018
1900
2007
1998
1999
2014
2006
2011
2016
1999
2018
2018
2003
2012
2007
2017
2007
2017
2014
1997
2015
2016
2004
2001
1998
2011
2007
2004
2001
2015
2010
2016
2011
1900
2011
2009
2006
2012
1999
2016
2013
2005
2011
2008
2006
2002
2010
2005
2010
1998
2003
2019
2015
2010
2015
2007
1997
2010
2006
2002
2012
2003
2006
2007
2014
2004
2009
2012
2015
2009
2009
2013
2013
2006
2013
2013
2008
2006
2005
2004
2003
2016
2016
2006
2017
2020
2012
2014
2005
2004
2016
2008
2007
2008
2020
1997
2012
2016
1998
2006
2003
1995
2010
2018
2012
2012
2012
1999
1999
2011
1998
2005
2018
2016
2017
2009
2013
2008
2013
2004
2019
2004
2005
2009
2013
2005
2000
2017
2005
2004
2009
2003
2011
2006
2019
2005
2009
1986
2018
2012
2017
2013
2004
2006
2014
1900
2016
2002
2011
2015
2017
2003
2008
2007
2010
2018
2002
2012
2009
2008
2009
2010
2011
2009
2001
2009
2016
2006
2004
2004
2002
2015
2011
2002
2007
1900
2017
2006
2004
2000
2009
2005
2010
2009
2009
1900
2008
2011
2006
2003
2006
2010
1900
2007
2011
2007
2009
2018
2001
2018
2015
2014
2018
2008
2012
2002
2007
2014
2011
2005
2018
2011
2008
2005
2006
2004
2018
2017
2015
2006
2013
1996
2008
2017
2007
2009
2018
2004
1998
2017
2014
2015
2017
2017
2010
2013
1900
2020
1900
2012
2005
2012
2014
2018
2019
2018
2006
2004
2016
2006
2014
1900
1900
2001
1900
2020
2005
2013
2016
2014
2015
2013
2019
2018
2005
2007
2015
2012
2010
2002
2000
2001
2000
2004
2017
2003
2019
2007
2015
2007
2007
2016
1900
2010
2002
1900
1980
2002
2008
2001
2018
2008
2000
2019
2017
2010
2008
2014
2011
2010
2019
2012
2012
2012
2010
2011
1991
2016
2010
1900
1900
2018
1900
2019
2008
2008
2016
2017
2010
2018
2018
2017
2010
2014
2007
2011
2004
2016
2011
2019
2006
2017
1997
2008
2006
2010
2017
2011
2008
2003
2004
2016
2005
2016
2017
2005
2005
2007
2016
2014
2018
2016
2013
2018
2009
2018
2009
1900
2006
2009
2012
2012
2007
2009
2001
2019
2018
2014
2016
2010
1900
2012
1900
2012
1900
2013
2009
2009
2018
2008
2018
2001
2017
2010
1998
2014
2015
2015
2010
2015
1900
2016
2008
2014
2009
2017
2006
2000
2001
2016
2016
2018
1900
2010
2010
2005
2017
2012
2010
1999
2013
2019
2013
2011
1900
2013
2013
2008
2015
1900
2010
2015
2010
1998
1998
2018
2015
2000
2004
2007
2008
2009
2005
2007
2010
2018
2012
2014
2004
2008
2011
2004
2010
2019
2010
2019
2003
2016
2010
2002
2015
2009
2014
2016
2018
2006
2008
2010
2011
2010
1900
2005
2017
2012
2006
2015
2005
2011
2008
2020
2015
2009
2020
2017
2010
2012
2001
2018
2005
2005
2015
2017
2002
2016
2008
2018
2011
2015
2010
2004
1998
1999
2002
2003
1997
2015
2005
2010
2016
2017
1900
1999
2007
2019
1999
2014
2016
2003
2010
2000
2001
1900
2000
2009
2007
2006
2006
2013
2000
2019
2003
2000
2000
2002
2018
2008
2007
2014
2017
2001
2005
1998
2011
2014
2007
2017
1999
1998
1999
1998
2008
2015
2007
2008
2008
2016
1997
2014
2012
2016
2014
2018
2008
2018
2008
2010
2012
2009
2009
1996
2016
2014
2004
2016
2013
2007
2002
2004
2005
2002
2013
2003
2016
2010
2017
2010
2013
2013
2011
2004
2003
2014
2014
2016
1900
2020
2019
2011
2006
2017
2016
2004
2013
2005
2008
2004
2016
2008
2011
2016
2015
2018
2001
1900
1900
2009
1900
2014
1900
2006
2015
2012
2006
2010
2013
2010
2016
1900
1900
2006
1900
2018
2012
2017
2016
2011
2006
2009
2000
2011
2006
2017
2009
2017
2012
2015
2010
2006
2019
2010
2008
2007
2014
2019
2001
2002
2016
2006
2018
2013
2004
2005
2005
2015
2018
2015
2009
2012
2014
2011
2009
2008
2020
2012
1995
2011
1997
2008
2011
2011
2015
2017
2008
2004
2008
2013
2004
2020
2003
2000
2011
2018
2006
2014
2002
2014
2019
2011
2006
2018
2007
2019
2018
2002
2010
2013
2016
2009
2019
2008
2007
2018
2003
2008
2019
2007
1999
2015
2004
2004
2015
2013
2014
2012
2004
2015
2015
2011
2016
2014
2012
2014
2007
2011
2006
2014
2006
2013
2009
2019
2011
2011
2017
2018
2006
2012
2015
2008
2007
2008
2014
2008
2015
2015
2006
2015
2010
2007
2010
1995
2001
2015
2011
2008
2013
2019
2005
2005
1900
1995
2011
2002
2007
2019
2013
2012
2014
2010
2009
2007
2011
2012
2010
1900
2011
2005
2014
2007
2003
2006
2014
2004
2013
2017
2006
2011
2005
2003
2014
1999
2005
2012
2008
2009
2011
2004
2015
2003
2012
2020
2009
2011
2006
2019
2014
2013
2013
2011
2013
2019
2007
2017
2008
2007
1900
2010
2007
1900
2010
2019
2009
2020
2005
2014
2011
2007
2013
2011
2019
2011
2019
2004
2019
1997
2018
2012
1900
2018
2015
2005
2017
2008
2015
2010
2015
2005
2018
2011
2001
2002
2008
2017
2011
2012
1900
2016
2019
2009
2012
2014
2007
2014
2013
2020
2005
2018
2003
2010
2008
2014
2009
2007
2008
2016
2006
2006
2014
2020
2019
2013
2006
2017
2016
2007
2014
2020
2008
2014
1900
2009
2016
2005
2010
2007
2019
2013
2015
2020
2018
2018
2019
2018
2014
2019
2004
2012
2012
2018
2015
2012
2017
2003
2015
2015
2006
2012
2015
2018
2016
2014
2009
2016
2015
2000
2014
2011
1994
2003
2015
2010
2009
2018
2015
2018
2009
2015
2014
2016
2013
2013
2008
2014
2015
2013
2002
1900
2001
2010
2018
2008
2019
2009
2011
2019
2011
2016
2009
2005
2016
2012
2014
2008
2008
2013
2015
2007
2017
2017
2014
2017
2007
1991
2017
2009
2014
2010
2018
2014
2006
2016
2019
2009
2014
1900
1999
2019
2007
2004
2017
2008
2010
2007
2011
1999
2005
2010
2006
2012
2011
2016
2006
2017
1900
2004
2011
2007
2015
2009
2016
2019
2010
2012
2018
2004
2013
2018
2007
1900
2003
2010
2011
2005
2006
2015
2006
2017
2011
2017
2013
2014
2016
2019
2010
1998
2018
2011
2010
2016
2007
2015
2015
2019
2004
2009
2015
2005
2006
2010
2015
2009
2015
2016
2010
2019
2018
2015
2014
2019
2012
2018
2015
2016
2014
2013
2019
2010
2019
2009
2017
1900
2006
2020
2004
2009
2015
2003
2003
2002
2002
2011
2009
2006
2012
2010
2012
2003
2014
2008
2016
2007
2006
2012
2014
2019
2016
2005
2018
2012
2011
1998
2009
2017
2016
2007
2009
2014
2006
2010
2006
2010
2013
2015
2017
2017
2007
2000
2018
2007
2016
2007
2007
2002
2015
2009
1900
2013
1995
2012
2013
2015
2013
2007
2017
2013
2018
2005
2007
2019
1900
2015
2012
2015
2018
2010
2018
2019
1900
2017
2010
2016
2014
2008
2002
1900
2014
2007
2017
2013
2019
2015
2007
2013
1991
2003
2008
2009
2009
2008
1900
2011
2020
2005
2017
2014
2018
2019
2016
2012
2011
1900
2018
2018
2005
2004
2014
2002
2003
2010
2018
1993
2009
2019
2017
2008
2011
2015
2017
2017
1999
1900
2011
2013
2009
2014
1997
2015
2004
2008
1900
2013
2018
2015
1900
1900
2014
2011
2012
1900
2000
2016
2011
2006
2015
2011
2005
2018
2015
2015
2019
2014
2006
2012
2019
2015
2009
2008
2015
2005
2013
1983
2012
2007
2017
2014
2012
2012
2014
2019
2015
2012
1900
1900
2010
2015
2020
2020
2018
2008
2017
2018
2019
2007
2013
2007
2008
2009
2016
2010
2016
2019
2018
2016
2014
2017
2003
2018
2017
2008
2016
2009
2017
2019
2016
2018
2015
2004
2010
2018
2017
2007
2013
2014
2007
2013
2012
2012
2006
2014
2015
1996
2007
2000
2019
2012
2020
2010
2016
2014
2008
2019
2003
2014
2016
2011
2010
2019
2014
2011
2018
2004
2016
2019
2009
1900
2015
2001
2013
2012
2003
2009
2018
2006
2008
2019
2015
2011
2015
2010
2011
2007
2015
2011
2008
2015
2015
2017
2019
2015
1900
2003
2001
2019
2008
2013
2010
2013
2012
2013
2004
2008
2004
2014
2013
2007
2013
2012
2012
2019
2012
2012
2019
2012
2010
2009
2015
2019
2018
2016
2008
2016
2002
1900
2005
1996
2014
2001
2017
2010
2016
2012
2019
2019
2017
2014
2009
2011
2011
2005
2008
2017
2010
1900
2018
1900
2014
2016
1900
2004
2014
2009
2005
2010
2005
2015
2011
2014
2013
2002
2013
2009
2006
2011
2016
2011
2018
2011
2011
2011
2018
1900
2012
2010
2013
2017
2012
2005
2007
2019
2014
2008
2017
2017
2005
2017
2009
2010
2005
2006
2012
2007
2015
2011
2019
2011
2006
2017
2018
2007
2004
2012
2011
2009
2008
2018
2007
2014
1900
2008
2020
2006
2011
2014
2013
2016
2019
2003
2019
2011
2015
2008
2007
2018
2019
2013
2018
2013
2020
2006
2012
2019
2004
2007
2010
2015
2014
2012
2013
2009
2006
2011
2001
2006
2019
2011
2009
2003
2017
2008
1900
2015
2018
1900
2009
2007
2016
2017
2016
2019
2003
2015
2007
2017
2017
2010
2017
2015
2015
2020
2016
2016
2014
2008
2005
2018
2010
2010
2019
2015
2015
2018
2011
2008
2012
2008
2018
2019
2019
2017
2014
2010
2007
2013
2015
2016
2009
2017
2018
2006
2020
2017
2015
2006
2004
2009
2017
1900
2015
2009
2018
2011
2011
2017
2019
2017
2015
2017
2018
2010
2018
2019
2014
2017
2016
2018
2012
2014
2007
2008
2018
2013
2019
2013
2007
2014
2018
2006
2013
2004
2016
1998
2015
2015
2011
2014
2005
2005
2012
2014
2009
2012
2005
2019
2010
2002
2012
2017
2011
2018
2020
2019
2011
2013
2007
2016
2016
2018
2006
2017
2015
2015
2007
1999
2020
2017
2018
2018
2018
2009
2020
2020
2010
2010
2012
2016
2016
2018
2006
2014
2006
2011
2011
2015
2018
2012
2007
2017
2013
2006
2018
2012
2017
2004
2020
2003
2009
2004
2014
2009
2018
2018
1900
2013
2017
2016
2016
2016
2006
1900
2019
2017
2009
2004
2016
2014
2011
2009
2015
2007
2015
2006
2007
1900
2011
2010
2006
2011
2010
2004
2007
2010
2019
2014
2005
2013
2007
2012
2002
1995
2014
2010
2018
2019
2013
2009
2005
2014
2017
2004
2014
2018
2004
2005
2005
2007
2009
2005
2018
2011
2007
2013
2010
2013
2013
2014
2015
2019
2012
2015
1900
2012
2013
2011
2012
2010
2013
2000
2012
2019
1977
2009
2012
2007
2002
2010
2009
2000
2014
2009
2009
2016
2013
2019
2011
2012
2016
2018
2009
2005
2010
2009
2011
1999
2020
2005
1999
2006
2009
2004
2008
2007
2014
2019
2020
1999
2017
2019
2001
2016
2014
2009
2005
2019
2018
2019
2012
2020
2012
2005
1900
2011
1900
2011
2000
2007
2015
2015
2012
2009
2005
2015
1997
2002
2015
2016
2009
2008
2011
2016
2001
2012
2005
2009
2017
2017
2012
2019
2018
2002
2006
2009
2009
1995
2006
2019
2011
2017
2008
2018
2017
2007
2017
2008
2018
2011
2009
2017
2007
2015
2014
2006
2008
2018
2012
2019
2011
2016
2017
2012
2006
1900
2015
1998
2016
2000
2017
2009
2007
2019
2008
2009
2009
2001
2010
2005
2017
2020
2010
2018
2014
2011
2006
1977
2019
2017
2006
2016
2004
2014
2013
2018
2015
2002
2008
2017
2002
2013
2010
2004
2016
2013
2005
2016
2002
2013
2008
2005
2020
2002
2020
2009
2005
2013
2008
2016
2011
2019
2014
2020
2015
2019
2013
2011
2013
2015
2018
2011
2013
2013
2018
2020
2011
2017
2014
2018
2014
2013
2019
2017
2016
2010
2016
2015
2014
2016
2012
2016
2005
2010
2011
2014
2012
2013
2019
2012
2007
2020
2011
2014
2004
2007
2007
2009
2012
2019
2006
2012
2017
2013
2016
2006
2011
2008
2007
2016
2012
2010
2017
2009
2018
2002
2000
2008
2017
2002
2017
2013
2016
2006
2014
2007
2014
2013
2012
1900
2012
2019
2019
2008
2014
2020
2019
2010
2011
2017
2008
2011
2011
2006
2014
2018
2007
2010
2016
2019
2014
2019
2010
2014
2015
2016
2015
2008
2019
2005
2013
2009
2008
2011
2016
2013
2016
2015
2018
2011
2016
2008
2013
2011
2017
2018
2014
2002
2017
2014
2018
2007
2016
2016
2010
2003
2010
2017
2013
2017
2014
2012
2008
2009
2015
2014
2008
2009
2010
2006
2010
2009
2013
1900
1900
2014
2008
2014
2017
2009
2006
2010
2014
2018
2006
1998
2007
2007
2016
2015
2017
2008
1900
1900
2018
2011
2020
2015
2005
2004
2013
2001
1999
1990
2020
2016
2019
2014
2011
2014
2012
2010
2003
2001
2010
2004
2017
2016
2009
2015
2018
2018
2011
2000
1988
2013
2011
2017
2003
2016
2007
1995
2011
2008
2017
2004
2005
2007
2010
2010
2019
2020
2019
2007
2017
2015
2015
2017
2012
2005
2007
2019
2016
2018
2007
2014
2012
2004
1989
2019
2012
2015
2016
2018
2013
2019
1997
2010
2014
2017
2014
2016
2020
2012
2013
2013
2019
2020
2017
1997
2016
2016
2017
2009
2013
2016
1994
2009
2007
2006
2020
2011
1900
2013
2006
2008
2010
2011
2015
2019
2019
2011
2005
2018
2015
2019
2013
2014
2015
2015
2006
2019
2017
2019
2008
2018
2011
2009
2008
1900
1900
2010
2017
2019
2020
2019
2016
2009
2016
2015
2008
2007
2008
2018
2017
2011
2011
2015
2014
2012
2017
2012
2013
2018
2018
2018
2020
2018
2018
2018
2015
2011
2009
2014
2018
2019
2006
2009
2002
2006
2005
2010
2016
2015
2015
1999
2006
2005
2012
2012
2008
2011
2020
2017
2011
2016
2020
2016
2011
2017
1900
2008
2010
2010
2018
2009
2009
2016
2008
2012
2018
2016
2015
2012
2003
2010
2013
2020
2009
2014
2013
2015
2014
2018
2017
2017
2015
2015
2014
2014
2012
2008
2015
2014
2021
2006
2017
2011
2018
2014
1900
2019
2010
2015
2020
2015
2012
2018
2019
2017
2015
2004
2017
2014
2018
2017
2009
2016
2012
2006
2019
1996
2013
2020
2019
2019
2018
2018
2019
2017
2013
2017
2012
1900
2015
2005
2017
2017
2019
2012
2014
1994
1993
2009
2011
2017
2002
1995
2018
2019
2011
2019
2005
2013
2011
2013
2010
2011
2020
2012
2011
2019
2014
2019
2013
2012
2018
2015
2011
2005
2009
2018
2011
2014
2016
2019
2016
2015
2019
1997
2015
2019
2020
2019
2009
2012
2009
1900
2019
2008
2010
2018
2014
2004
2014
2019
2019
2012
2012
2016
2008
2010
2012
2017
2013
2009
2018
2014
2018
2018
2010
2018
2016
2014
2011
2010
2012
2008
2017
2018
2009
2017
2017
2018
2016
2016
2008
2010
2006
2020
2018
2019
2019
2019
2006
1900
2016
2001
2016
2018
2015
2014
2003
2013
2010
2013
2016
2016
2013
2018
2011
1996
2016
2012
2017
2011
2017
2017
2020
2018
2014
2016
2016
2016
2017
2018
2014
2009
2019
1900
2018
2016
2007
2010
2012
2017
2009
2007
2012
2011
2020
2018
2001
2012
2017
2019
2013
2013
2009
2012
2014
2016
2013
2010
2014
2004
2014
2018
2018
2019
2020
2018
2017
2018
2007
2012
2014
1900
1900
1900
1900
1900
2009
2019
2019
2017
2012
1998
2009
2008
2011
2014
2017
2010
2015
2018
2016
2012
2016
2006
2009
2002
2017
2009
2018
2017
2019
2017
2019
2018
2016
2016
2012
2020
2011
2018
2019
2018
2017
2017
2004
2014
2014
2016
2012
2010
2018
2011
2009
2004
2020
2019
2016
2019
2008
2010
2005
1900
2005
2014
2014
1900
2017
2008
2009
2011
2010
2018
2020
2016
2013
2012
2009
2017
2016
2011
2020
2002
2013
2013
2005
2006
2018
2017
2012
2015
2020
2017
2017
2015
2009
2014
2013
2020
2018
2013
2019
2014
2018
2011
2008
2018
2017
2018
1999
2019
2017
2017
2011
2018
2009
2012
2020
2015
2007
1900
2017
2019
2014
2018
2019
2014
2016
2018
2012
2020
2011
2019
2019
2019
2009
2018
2017
2017
2016
2007
2011
2019
2016
Number
2015 536
2016 535
2017 537
2018 548
2019 502
2020 168

Clinical Trials in Vaccines

Загружено:

Сведения о документе

Оригинальное название

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

Clinical Trials in Vaccines

Загружено:

Авторское право:

Доступные форматы

Rank NCT NumbTitle Acronym Status Study ResuConditions Interventi

1 NCT04110Nasal and Flu-M3 Active, notNo ResultsInfluenza|Vaccine Virus Shedding Biological:

31-Mar-17 31-May-37 ### ### ### Orchard Investigationahttps://Cl

Вам также может понравиться